Am	O
J	O
Surg	O
Pathol	O
2001	O
May	O
;	O
25	O
(	O
5	O
)	O
:	O
595-601	O
Small	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
pathology	O
study	O
of	O
12	O
cases	O
.	O
Maitra	O
A	O
,	O
Tascilar	O
M	O
,	O
Hruban	O
RH	O
,	O
Offerhaus	O
GJ	O
,	O
Albores-Saavedra	O
J	O
.	O
Departments	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
,	O
Texas	O
,	O
USA	O
.	O
Small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
are	O
unusual	O
neoplasms	O
that	O
have	O
been	O
characterized	O
only	O
recently	O
.	O
The	O
authors	O
describe	O
the	O
clinical	O
,	O
histopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
features	O
of	O
12	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	O
gallbladder	O
.	O
The	O
mean	O
age	O
at	O
diagnosis	O
was	O
69	O
years	O
,	O
and	O
the	O
male	O
-	O
to	O
-	O
female	O
ratio	O
was	O
5	O
:	O
7	O
.	O
The	O
neoplasms	O
had	O
an	O
average	O
size	O
of	O
3	O
cm	O
,	O
and	O
90	O
%	O
showed	O
invasion	O
of	O
the	O
muscularis	O
propria	O
and	O
perimuscular	O
connective	O
tissue	O
.	O
Seventy-five	O
percent	O
of	O
the	O
carcinomas	B-malignancy-type
had	O
metastasized	O
or	O
extended	O
locally	O
beyond	O
the	O
gallbladder	O
at	O
surgery	O
.	O
Survival	O
was	O
uniformly	O
poor	O
,	O
with	O
a	O
mean	O
survival	O
of	O
10.7	O
months	O
(	O
range	O
,	O
3	O
-	O
25	O
months	O
)	O
.	O
Half	O
the	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
combined	O
with	O
other	O
neoplasms	O
.	O
Four	O
had	O
foci	O
of	O
adenocarcinoma	B-malignancy-type
,	O
one	O
contained	O
areas	O
of	O
squamous	O
differentiation	O
,	O
and	O
another	O
had	O
a	O
component	O
of	O
carcinosarcoma	B-malignancy-type
.	O
Immunohistochemical	O
analysis	O
showed	O
focal	O
reactivity	O
for	O
chromogranin	O
(	O
six	O
of	O
six	O
cases	O
)	O
,	O
neuron	O
-	O
specific	O
enolase	O
(	O
six	O
of	O
six	O
cases	O
)	O
,	O
and	O
Leu-7	O
(	O
three	O
of	O
three	O
cases	O
)	O
.	O
The	O
molecular	O
changes	O
in	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
similar	O
to	O
those	O
of	O
adenocarcinomas	B-malignancy-type
occurring	O
at	O
this	O
site	O
,	O
with	O
a	O
high	O
frequency	O
of	O
p53	O
(	O
75	O
%	O
)	O
and	O
p16INK4a	O
(	O
33	O
%	O
)	O
abnormalities	O
,	O
and	O
a	O
low	O
frequency	O
of	O
deleted	O
in	O
pancreatic	O
carcinoma-4	O
inactivation	O
(	O
0	O
%	O
)	O
and	O
K-ras	O
codon	O
12	O
mutations	O
(	O
17	O
%	O
)	O
.	O
In	O
contrast	O
to	O
pulmonary	B-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
p16INK4a	O
function	O
appears	O
to	O
be	O
abrogated	O
more	O
frequently	O
in	O
these	O
carcinomas	B-malignancy-type
.	O
PMID	O
:	O
11342770	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Jpn	O
J	O
Clin	O
Oncol	O
2002	O
Jun	O
;	O
32	O
(	O
6	O
)	O
:	O
219-21	O
Concurrent	O
mutations	O
of	O
K-ras	O
oncogene	O
at	O
codons	O
12	O
and	O
22	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Miyakura	O
Y	O
,	O
Sugano	O
K	O
,	O
Fukayama	O
N	O
,	O
Konishi	O
F	O
,	O
Nagai	O
H	O
.	O
Department	O
of	O
Surgery	O
,	O
Jichi	O
Medical	O
School	O
,	O
Minami	O
Kawachi	O
,	O
Tochigi	O
,	O
Japan	O
.	O
K-ras	O
mutation	O
is	O
the	O
most	O
common	O
oncogenic	O
alteration	O
in	O
various	O
human	O
cancers	O
including	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Point	O
mutations	O
have	O
the	O
potential	O
to	O
activate	O
the	O
K-ras	O
gene	O
if	O
they	O
occur	O
in	O
the	O
critical	O
coding	O
sequences	O
.	O
Almost	O
all	O
of	O
these	O
mutations	O
have	O
been	O
localized	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
We	O
report	O
a	O
case	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
presenting	O
point	O
mutations	O
at	O
both	O
codons	O
12	O
and	O
22	O
of	O
the	O
K-ras	O
gene	O
.	O
PCR	O
-	O
SSCP	O
and	O
subsequent	O
sequencing	O
revealed	O
that	O
GGT	O
(	O
glycine	O
,	O
wild	O
-	O
type	O
)	O
to	O
AGT	O
(	O
serine	O
)	O
substitution	O
at	O
codon	O
12	O
and	O
CAG	O
(	O
glutamine	O
,	O
wild	O
-	O
type	O
)	O
to	O
CGG	O
(	O
arginine	O
)	O
substitution	O
at	O
codon	O
22	O
occurred	O
in	O
the	O
same	O
allele	O
.	O
PMID	O
:	O
12110640	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2002	O
Jul	O
11	O
;	O
21	O
(	O
30	O
)	O
:	O
4646-62	O
Novel	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
leading	O
to	O
better	O
understanding	O
of	O
the	O
diversity	O
of	O
respective	O
primary	O
cancers	O
.	O
Vecsey-Semjen	O
B	O
,	O
Becker	O
KF	O
,	O
Sinski	O
A	O
,	O
Blennow	O
E	O
,	O
Vietor	O
I	O
,	O
Zatloukal	O
K	O
,	O
Beug	O
H	O
,	O
Wagner	O
E	O
,	O
Huber	O
LA	O
.	O
IMP	O
,	O
Research	O
Institute	O
of	O
Molecular	O
Pathology	O
,	O
Vienna	O
,	O
Austria	O
.	O
A	O
major	O
obstacle	O
to	O
obtaining	O
more	O
detailed	O
insights	O
into	O
the	O
diversity	O
of	O
phenotypic	O
and	O
molecular	O
changes	O
occurring	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
cells	O
is	O
the	O
lack	O
of	O
low	O
-	O
passage	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
which	O
would	O
still	O
closely	O
reflect	O
the	O
phenotype	O
of	O
the	O
colon	B-malignancy-type
cancer	I-malignancy-type
cells	O
in	O
vivo	O
.	O
Here	O
,	O
we	O
characterize	O
eight	O
novel	O
,	O
low	O
passage	O
number	O
human	O
colon	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
,	O
originating	O
from	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
extensively	O
characterized	O
in	O
the	O
clinics	O
.	O
All	O
cell	O
lines	O
closely	O
resemble	O
the	O
original	O
tumors	O
with	O
respect	O
to	O
phenotype	O
,	O
markers	O
and	O
detectable	O
genetic	O
changes	O
.	O
Cell	O
morphology	O
and	O
marker	O
expression	O
is	O
highly	O
variable	O
,	O
ranging	O
from	O
fully	O
polarized	O
cells	O
correctly	O
expressing	O
all	O
basolateral	O
epithelial	O
markers	O
,	O
to	O
cells	O
with	O
mesenchymal	O
characteristics	O
and	O
a	O
complete	O
loss	O
of	O
polarity	O
due	O
to	O
delocalization	O
or	O
loss	O
of	O
junction	O
complex	O
proteins	O
.	O
The	O
alterations	O
in	O
phenotype	O
and	O
epithelial	O
marker	O
expression	O
correspond	O
to	O
changes	O
already	O
detectable	O
in	O
the	O
primary	O
tumor	O
in	O
vivo	O
.	O
Seven	O
of	O
the	O
cell	O
lines	O
show	O
chromosomal	O
instability	O
,	O
while	O
one	O
cell	O
line	O
is	O
characterized	O
by	O
microsatellite	O
instability	O
.	O
p53	O
associated	O
with	O
K-ras	O
mutations	O
were	O
detected	O
in	O
three	O
cell	O
lines	O
.	O
Hitherto	O
non	O
-	O
described	O
E-cadherin	O
mutations	O
were	O
found	O
at	O
both	O
alleles	O
in	O
one	O
cell	O
line	O
whereas	O
in	O
another	O
cell	O
line	O
the	O
E-cadherin	O
protein	O
was	O
down	O
-	O
regulated	O
.	O
A	O
stabilizing	O
beta-catenin	O
mutation	O
(	O
S	O
45	O
F	O
)	O
appears	O
in	O
the	O
same	O
cell	O
line	O
that	O
carried	O
the	O
mutated	O
E-cadherin	O
gene	O
.	O
Six	O
cell	O
lines	O
carried	O
APC	O
mutations	O
,	O
which	O
in	O
five	O
of	O
the	O
lines	O
led	O
to	O
an	O
activated	O
beta-catenin	O
/	O
Tcf	O
/	O
LEF	O
signaling	O
pathway	O
.	O
In	O
accordance	O
with	O
beta-catenin	O
/	O
Tcf	O
/	O
LEF	O
activation	O
,	O
the	O
cell	O
lines	O
show	O
increased	O
migration	O
and	O
invasiveness	O
.	O
Our	O
results	O
show	O
that	O
the	O
characterized	O
,	O
low	O
-	O
passage	O
cell	O
lines	O
mirror	O
the	O
diversity	O
of	O
the	O
individual	O
tumors	O
from	O
which	O
they	O
were	O
derived	O
.	O
Through	O
molecular	O
analyses	O
of	O
these	O
cell	O
lines	O
we	O
demonstrate	O
that	O
tumorgenicity	O
events	O
are	O
much	O
more	O
diverse	O
in	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
than	O
expected	O
,	O
despite	O
the	O
common	O
origin	O
of	O
the	O
tumors	O
from	O
a	O
small	O
patient	O
group	O
with	O
similar	O
tumor	O
grading	O
and	O
clinical	O
prognosis	O
.	O
PMID	O
:	O
12096341	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2002	O
Jun	O
20	O
;	O
21	O
(	O
27	O
)	O
:	O
4301-6	O
Common	O
occurrence	O
of	O
multiple	O
K-RAS	O
mutations	O
in	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
with	O
associated	O
precursor	O
lesions	O
and	O
in	O
biliary	B-malignancy-type
cancers	I-malignancy-type
.	O
Laghi	O
L	O
,	O
Orbetegli	O
O	O
,	O
Bianchi	O
P	O
,	O
Zerbi	O
A	O
,	O
Di	O
Carlo	O
V	O
,	O
Boland	O
CR	O
,	O
Malesci	O
A	O
.	O
Division	O
of	O
Gastroenterology	O
,	O
Istituto	O
Clinico	O
Humanitas	O
,	O
Rozzano	O
,	O
Milan	O
,	O
20089	O
Italy	O
.	O
Recent	O
studies	O
on	O
small	O
series	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
(	O
PC	B-malignancy-type
)	O
with	O
foci	O
of	O
pancreatic	O
intraepithelial	O
neoplasia	O
(	O
PanIN	O
)	O
,	O
a	O
putative	O
precursor	O
lesion	O
,	O
have	O
shown	O
that	O
multiple	O
K-RAS	O
mutations	O
may	O
coexist	O
in	O
the	O
same	O
neoplastic	O
pancreas	O
.	O
To	O
see	O
whether	O
mutant	O
-	O
K-RAS	O
polyclonality	O
is	O
a	O
common	O
and	O
specific	O
feature	O
of	O
pancreatic	O
carcinogenesis	O
,	O
we	O
investigated	O
a	O
unselected	O
series	O
of	O
periampullary	B-malignancy-type
cancers	I-malignancy-type
(	O
41	O
pancreatic	B-malignancy-type
,	O
13	O
biliary	B-malignancy-type
and	O
two	O
ampullary	B-malignancy-type
adenocarcinomas	I-malignancy-type
)	O
.	O
After	O
hemi	O
-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
mutations	O
identified	O
with	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
were	O
confirmed	O
by	O
allele	O
-	O
specific	O
PCR	O
and	O
sequencing	O
.	O
K-RAS	O
codon	O
12	O
was	O
mutated	O
in	O
34	O
(	O
83	O
%	O
)	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
and	O
in	O
11	O
(	O
85	O
%	O
)	O
biliary	B-malignancy-type
cancers	I-malignancy-type
.	O
Multiple	O
distinct	O
K-RAS	O
mutations	O
were	O
found	O
in	O
16	O
PC	B-malignancy-type
(	O
39	O
%	O
of	O
all	O
cases	O
,	O
47	O
%	O
of	O
those	O
with	O
mutated	O
K-RAS	O
)	O
and	O
in	O
eight	O
biliary	O
cancers	O
(	O
62	O
and	O
72	O
%	O
,	O
respectively	O
)	O
.	O
In	O
PC	O
,	O
multiple	O
K-RAS	O
mutations	O
were	O
more	O
frequent	O
(	O
P	O
<	O
0.001	O
)	O
in	O
cancers	O
with	O
(	O
nine	O
of	O
12	O
,	O
75	O
%	O
)	O
than	O
in	O
those	O
without	O
detectable	O
PanIN	O
(	O
seven	O
of	O
29	O
,	O
24	O
%	O
)	O
.	O
Individual	O
precursor	O
lesions	O
of	O
the	O
same	O
neoplastic	O
pancreas	O
were	O
found	O
to	O
harbor	O
distinct	O
mutations	O
.	O
Results	O
show	O
that	O
multiple	O
K-RAS	O
mutations	O
are	O
frequent	O
both	O
in	O
PC	B-malignancy-type
with	O
associated	O
PanIN	O
and	O
in	O
biliary	B-malignancy-type
cancers	I-malignancy-type
,	O
and	O
indicate	O
that	O
clonally	O
distinct	O
precursor	O
lesions	O
of	O
PC	B-malignancy-type
might	O
variably	O
contribute	O
to	O
tumor	O
development	O
.	O
PMID	O
:	O
12082617	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Oncol	O
2002	O
Jun	O
1	O
;	O
20	O
(	O
11	O
)	O
:	O
2726-35	O
Phase	O
I	O
clinical	O
and	O
pharmacologic	O
study	O
of	O
chronic	O
oral	O
administration	O
of	O
the	O
farnesyl	O
protein	O
transferase	O
inhibitor	O
R115777	O
in	O
advanced	O
cancer	O
.	O
Crul	O
M	O
,	O
de	O
Klerk	O
GJ	O
,	O
Swart	O
M	O
,	O
van't	O
Veer	O
LJ	O
,	O
de	O
Jong	O
D	O
,	O
Boerrigter	O
L	O
,	O
Palmer	O
PA	O
,	O
Bol	O
CJ	O
,	O
Tan	O
H	O
,	O
de	O
Gast	O
GC	O
,	O
Beijnen	O
JH	O
,	O
Schellens	O
JH	O
.	O
Netherlands	O
Cancer	O
Institute	O
and	O
Academic	O
Medical	O
Centre	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
apmcr@slz.nl	O
PURPOSE	O
:	O
To	O
determine	O
the	O
maximum	O
-	O
tolerated	O
dose	O
,	O
toxicities	O
,	O
and	O
pharmacokinetics	O
of	O
R115777	O
,	O
a	O
farnesyl	O
transferase	O
inhibitor	O
,	O
when	O
administered	O
continuously	O
via	O
the	O
oral	O
route	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
advanced	O
solid	O
malignancies	O
were	O
treated	O
with	O
R115777	O
using	O
an	O
interpatient	O
dose	O
escalation	O
scheme	O
starting	O
at	O
50	O
mg	O
bid	O
.	O
Pharmacokinetics	O
were	O
assessed	O
on	O
days	O
1	O
,	O
28	O
,	O
and	O
56	O
.	O
RESULTS	O
:	O
Twenty-eight	O
patients	O
were	O
entered	O
onto	O
the	O
study	O
and	O
the	O
median	O
duration	O
of	O
treatment	O
was	O
55	O
days	O
.	O
The	O
dose	O
-	O
limiting	O
toxicities	O
were	O
myelosuppression	O
and	O
neurotoxicity	O
.	O
At	O
a	O
dose	O
of	O
400	O
mg	O
bid	O
,	O
grade	O
4	O
leukocytopenia	B-malignancy-type
and	O
neutropenia	B-malignancy-type
were	O
seen	O
in	O
two	O
of	O
four	O
patients	O
.	O
Neurotoxicity	O
grade	O
3	O
developed	O
in	O
one	O
of	O
five	O
patients	O
at	O
500	O
mg	O
bid	O
and	O
in	O
one	O
of	O
13	O
at	O
300	O
mg	O
bid	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O
Common	O
nonhematologic	O
toxicities	O
were	O
nausea	O
,	O
vomiting	O
,	O
and	O
fatigue	O
.	O
The	O
recommended	O
dose	O
for	O
phase	O
II	O
/	O
III	O
testing	O
in	O
this	O
scheme	O
is	O
300	O
mg	O
bid	O
.	O
The	O
pharmacokinetic	O
studies	O
indicated	O
dose	O
proportionality	O
.	O
Little	O
accumulation	O
occurred	O
and	O
steady	O
-	O
state	O
levels	O
were	O
reached	O
within	O
2	O
to	O
3	O
days	O
.	O
Analyses	O
of	O
historic	O
tumor	O
material	O
showed	O
that	O
five	O
of	O
15	O
of	O
patients	O
had	O
a	O
K-ras	O
mutation	O
in	O
codon	O
12	O
.	O
Three	O
patients	O
with	O
pancreatic	B-malignancy-type
,	O
colon	B-malignancy-type
,	O
and	O
cervix	B-malignancy-type
carcinomas	I-malignancy-type
had	O
stable	O
disease	O
and	O
one	O
patient	O
with	O
a	O
colon	O
carcinoma	O
had	O
a	O
minor	O
response	O
accompanied	O
by	O
a	O
more	O
than	O
50	O
%	O
decrease	O
in	O
carcinoembryonic	O
antigen	O
tumor	O
marker	O
.	O
A	O
fifth	O
patient	O
,	O
with	O
platinum	B-malignancy-type
-	I-malignancy-type
refractory	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
,	O
showed	O
a	O
partial	O
response	O
that	O
lasted	O
for	O
5	O
months	O
.	O
CONCLUSION	O
:	O
Continuous	O
dosing	O
of	O
R115777	O
is	O
feasible	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
at	O
a	O
dose	O
of	O
300	O
mg	O
bid	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Clinical	O
Trial	O
,	O
Phase	O
I	O
PMID	O
:	O
12039935	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
2002	O
May	O
;	O
34	O
(	O
1	O
)	O
:9-16	O
APC	O
/	O
CTNNB1	O
(	O
beta-catenin	O
)	O
pathway	O
alterations	O
in	O
human	O
prostate	B-malignancy-type
cancers	I-malignancy-type
.	O
Gerstein	O
AV	O
,	O
Almeida	O
TA	O
,	O
Zhao	O
G	O
,	O
Chess	O
E	O
,	O
Shih	O
IeM	O
,	O
Buhler	O
K	O
,	O
Pienta	O
K	O
,	O
Rubin	O
MA	O
,	O
Vessella	O
R	O
,	O
Papadopoulos	O
N	O
.	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Cancer	O
Genetics	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
New	O
York	O
,	O
USA	O
.	O
Genetic	O
alterations	O
serve	O
as	O
beacons	O
for	O
the	O
involvement	O
of	O
specific	O
pathways	O
in	O
tumorigenesis	O
.	O
It	O
was	O
previously	O
shown	O
that	O
5	O
%	O
of	O
prostate	B-malignancy-type
tumors	I-malignancy-type
harbor	O
CTNNB1	O
mutations	O
,	O
suggesting	O
that	O
this	B-malignancy-type
tumor	I-malignancy-type
type	I-malignancy-type
may	O
involve	O
a	O
deregulated	O
APC	O
/	O
CTNNB1	O
pathway	O
.	O
To	O
explore	O
this	O
possibility	O
further	O
,	O
we	O
searched	O
for	O
mutations	O
in	O
genes	O
implicated	O
in	O
this	O
pathway	O
in	O
22	O
samples	O
that	O
included	O
cell	O
lines	O
,	O
xenografts	O
,	O
and	O
primary	O
tumors	O
.	O
We	O
identified	O
seven	O
alterations	O
:	O
two	O
in	O
CTNNB1	O
,	O
three	O
in	O
APC	O
,	O
and	O
two	O
in	O
hTRCP1	O
(	O
also	O
known	O
as	O
BTRC	O
)	O
which	O
controls	O
the	O
degradation	O
of	O
CTNNB1	O
.	O
Alterations	O
in	O
the	O
CTNNB1	O
regulatory	O
domain	O
,	O
APC	O
,	O
and	O
hTRCP1	O
were	O
mutually	O
exclusive	O
,	O
consistent	O
with	O
their	O
equivalent	O
effects	O
on	O
CTNNB1	O
stability	O
.	O
These	O
results	O
suggest	O
that	O
CTNNB1	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
a	O
significant	O
fraction	O
of	O
prostate	B-malignancy-type
cancers	I-malignancy-type
.	O
Moreover	O
,	O
they	O
provide	O
the	O
first	O
evidence	O
that	O
hTRCP1	O
plays	O
a	O
role	O
in	O
human	O
neoplasia	B-malignancy-type
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O
PMID	O
:	O
11921277	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Histopathology	O
2001	O
Dec	O
;	O
39	O
(	O
6	O
)	O
:	O
629-37	O
Secondary	O
malignant	B-malignancy-type
giant	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
bone	I-malignancy-type
:	O
molecular	O
abnormalities	O
of	O
p53	O
and	O
H-ras	O
gene	O
correlated	O
with	O
malignant	O
transformation	O
.	O
Oda	O
Y	O
,	O
Sakamoto	O
A	O
,	O
Saito	O
T	O
,	O
Matsuda	O
S	O
,	O
Tanaka	O
K	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M	O
.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
3-1-1	O
Maidashi	O
,	O
Higashi-ku	O
,	O
Fukuoka	O
812-8582	O
,	O
Japan	O
.	O
AIMS	O
:	O
We	O
report	O
two	O
cases	O
of	O
secondary	O
malignant	B-malignancy-type
giant	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
occurring	O
without	O
irradiation	O
therapy	O
.	O
To	O
elucidate	O
the	O
mechanism	O
of	O
malignant	O
transformation	O
in	O
this	B-malignancy-type
tumour	I-malignancy-type
,	O
we	O
searched	O
for	O
the	O
molecular	O
abnormalities	O
of	O
p53	O
,	O
MDM2	O
and	O
the	O
H-ras	O
genes	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
These	O
cases	O
were	O
retrieved	O
after	O
a	O
review	O
of	O
103	O
cases	O
of	O
primary	O
giant	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
bone	I-malignancy-type
,	O
registered	O
in	O
our	O
institute	O
.	O
One	O
case	O
occurred	O
in	O
the	O
distal	O
femur	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
female	O
after	O
surgical	O
curettage	O
,	O
while	O
the	O
other	O
arose	O
in	O
the	O
acetabulum	O
of	O
a	O
25	O
-	O
year	O
-	O
old	O
male	O
after	O
en	O
bloc	O
resection	O
.	O
Microscopically	O
,	O
the	O
malignant	B-malignancy-type
tumour	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
distal	I-malignancy-type
femur	I-malignancy-type
was	O
composed	O
of	O
a	O
proliferation	O
of	O
ovoid	O
or	O
fusiform	O
cells	O
arranged	O
in	O
fascicles	O
with	O
high	O
mitotic	O
activities	O
.	O
The	O
malignant	B-malignancy-type
transformed	I-malignancy-type
tumour	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
acetabulum	I-malignancy-type
was	O
made	O
up	O
of	O
pleomorphic	B-malignancy-type
tumour	I-malignancy-type
cells	I-malignancy-type
with	O
atypical	O
mitoses	O
.	O
In	O
the	O
tumour	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
distal	I-malignancy-type
femur	I-malignancy-type
,	O
both	O
p53	O
and	O
H-ras	O
mutations	O
were	O
detected	O
.	O
Abnormal	O
nuclear	O
accumulation	O
of	O
p53	O
protein	O
and	O
c-myc	O
expression	O
were	O
also	O
revealed	O
by	O
immunohistochemistry	O
.	O
In	O
both	O
cases	O
,	O
the	O
recurrent	O
malignant	B-malignancy-type
tumour	I-malignancy-type
over	O
-	O
expressed	O
MMP-9	O
and	O
revealed	O
a	O
higher	O
MIB-1	O
-	O
labelling	O
index	O
compared	O
with	O
the	O
primary	O
conventional	O
giant	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumour	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
multiple	O
oncogene	O
or	O
tumour	O
suppressor	O
gene	O
mutations	O
may	O
play	O
an	O
important	O
role	O
during	O
malignant	O
transformation	O
in	O
conventional	O
giant	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
tumours	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
of	O
Reported	O
Cases	O
PMID	O
:	O
11903582	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Sep	O
15	O
;	O
92	O
(	O
6	O
)	O
:	O
1525-30	O
Cigarette	O
smoking	O
is	O
strongly	O
associated	O
with	O
mutation	O
of	O
the	O
K-ras	O
gene	O
in	O
patients	O
with	O
primary	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
Ahrendt	O
SA	O
,	O
Decker	O
PA	O
,	O
Alawi	O
EA	O
,	O
Zhu	O
Yr	O
YR	O
,	O
Sanchez-Cespedes	O
M	O
,	O
Yang	O
SC	O
,	O
Haasler	O
GB	O
,	O
Kajdacsy-Balla	O
A	O
,	O
Demeure	O
MJ	O
,	O
Sidransky	O
D	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Rochester	O
,	O
Rochester	O
,	O
New	O
York	O
14642	O
,	O
USA	O
.	O
Steven_Ahrendt@urmc.rochester.edu	O
BACKGROUND	O
:	O
The	O
majority	O
of	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
cases	O
occur	O
in	O
current	O
or	O
former	O
smokers	O
.	O
K-ras	O
gene	O
mutations	O
are	O
common	O
in	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
have	O
been	O
associated	O
with	O
cigarette	O
smoking	O
,	O
asbestos	O
exposure	O
,	O
and	O
female	O
gender	O
.	O
METHODS	O
:	O
In	O
the	O
current	O
study	O
,	O
the	O
authors	O
examined	O
the	O
contribution	O
of	O
cigarette	O
smoking	O
to	O
K-ras	O
gene	O
mutations	O
in	O
patients	O
with	O
primary	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Smoking	O
histories	O
were	O
obtained	O
from	O
106	O
prospectively	O
enrolled	O
patients	O
with	O
primary	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
the	O
primary	O
tumor	B-malignancy-type
using	O
an	O
allele	O
-	O
specific	O
ligation	O
assay	O
.	O
Ninety-two	O
of	O
the	O
106	O
patients	O
(	O
87	O
%	O
)	O
with	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
smokers	O
.	O
Nonsmokers	O
with	O
this	B-malignancy-type
tumor	I-malignancy-type
were	O
more	O
likely	O
to	O
be	O
women	O
(	O
11	O
of	O
14	O
;	O
79	O
%	O
)	O
,	O
whereas	O
the	O
majority	O
of	O
smokers	O
(	O
57	O
%	O
)	O
were	O
men	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
40	O
of	O
106	O
tumors	B-malignancy-type
(	O
38	O
%	O
)	O
and	O
were	O
significantly	O
more	O
common	O
in	O
smokers	O
compared	O
with	O
nonsmokers	O
(	O
43	O
%	O
vs.	O
0	O
%	O
;	O
P	O
=	O
0.001	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
the	O
current	O
study	O
confirm	O
and	O
extend	O
previous	O
observations	O
that	O
smokers	O
with	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
are	O
more	O
likely	O
to	O
have	O
K-ras	O
mutant	O
tumors	B-malignancy-type
compared	O
with	O
nonsmokers	O
.	O
The	O
strong	O
link	O
between	O
cigarette	O
smoking	O
and	O
K-ras	O
mutations	O
in	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
supports	O
the	O
role	O
of	O
specific	O
tobacco	O
carcinogens	O
in	O
the	O
etiology	O
of	O
this	B-malignancy-type
malignancy	I-malignancy-type
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11745231	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Dermatol	O
2001	O
Oct	O
;	O
145	O
(	O
4	O
)	O
:	O
576-81	O
beta-catenin	O
expression	O
in	O
pilomatrixomas	B-malignancy-type
.	O
Relationship	O
with	O
beta-catenin	O
gene	O
mutations	O
and	O
comparison	O
with	O
beta-catenin	O
expression	O
in	O
normal	O
hair	O
follicles	O
.	O
Moreno-Bueno	O
G	O
,	O
Gamallo	O
C	O
,	O
Perez-Gallego	O
L	O
,	O
Contreras	O
F	O
,	O
Palacios	O
J	O
.	O
Programa	O
de	O
Patologia	O
Molecular	O
,	O
Centro	O
Nacional	O
de	O
Investigaciones	O
Oncologicas	O
Carlos	O
III	O
,	O
Instituto	O
de	O
Salud	O
Carlos	O
III	O
,	O
Ctra	O
Majadahonda-Pozuelo	O
Km	O
2	O
,	O
280220	O
Majadahonda	O
Madrid	O
,	O
Spain	O
.	O
BACKGROUND	O
:	O
beta-catenin	O
functions	O
in	O
signal	O
transduction	O
in	O
the	O
Wnt	O
signalling	O
pathway	O
,	O
which	O
has	O
recently	O
been	O
implicated	O
in	O
hair	O
follicle	O
(	O
HF	O
)	O
morphogenesis	O
.	O
beta-catenin	O
gene	O
mutations	O
affecting	O
exon	O
3	O
have	O
been	O
reported	O
in	O
a	O
high	O
percentage	O
of	O
human	O
pilomatrixomas	B-malignancy-type
.	O
However	O
,	O
the	O
expression	O
pattern	O
of	O
beta-catenin	O
in	O
human	O
HFs	O
and	O
pilomatrixomas	B-malignancy-type
has	O
not	O
been	O
reported	O
.	O
OBJECTIVES	O
:	O
To	O
analyse	O
immunohistochemically	O
the	O
expression	O
pattern	O
of	O
beta-catenin	O
in	O
normal	O
anagen	O
HFs	O
and	O
in	O
40	O
human	O
pilomatrixomas	B-malignancy-type
.	O
METHODS	O
:	O
In	O
11	O
of	O
these	O
tumours	O
we	O
also	O
studied	O
exon	O
3	O
beta-catenin	O
gene	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
As	O
these	O
mutations	O
have	O
been	O
related	O
to	O
a	O
replication	O
error	O
(	O
RER	O
)	O
phenotype	O
in	O
other	O
tumour	O
types	O
,	O
we	O
explored	O
whether	O
or	O
not	O
this	O
association	O
also	O
occurs	O
in	O
pilomatrixomas	B-malignancy-type
.	O
RESULTS	O
:	O
beta-catenin	O
was	O
expressed	O
in	O
the	O
cell	O
membranes	O
of	O
the	O
outer	O
and	O
inner	O
root	O
sheaths	O
and	O
in	O
matrix	O
cells	O
located	O
at	O
the	O
base	O
and	O
periphery	O
of	O
the	O
HF	O
bulb	O
.	O
However	O
,	O
central	O
matrix	O
cells	O
that	O
differentiate	O
into	O
cortical	O
cells	O
,	O
cortical	O
and	O
cuticular	O
cells	O
expressed	O
beta-catenin	O
in	O
the	O
nucleus	O
,	O
suggesting	O
a	O
role	O
in	O
signal	O
transduction	O
.	O
In	O
addition	O
,	O
some	O
fibroblasts	O
of	O
the	O
dermal	O
papilla	O
also	O
showed	O
nuclear	O
expression	O
of	O
beta-catenin	O
.	O
All	O
40	O
analysed	O
pilomatrixomas	B-malignancy-type
showed	O
intense	O
nuclear	O
and	O
cytoplasmic	O
beta-catenin	O
expression	O
in	O
proliferating	O
matrix	O
(	O
basaloid	O
)	O
cells	O
.	O
In	O
areas	O
of	O
maturation	O
,	O
transitional	O
cells	O
mainly	O
showed	O
cytoplasmic	O
and	O
membranous	O
expression	O
of	O
beta-catenin	O
,	O
while	O
only	O
a	O
few	O
cells	O
retained	O
nuclear	O
expression	O
.	O
Shadow	O
or	O
ghost	O
cells	O
did	O
not	O
show	O
beta-catenin	O
expression	O
.	O
Three	O
of	O
11	O
tumours	O
(	O
26	O
%	O
)	O
had	O
beta-catenin	O
mutations	O
.	O
All	O
three	O
had	O
the	O
same	O
heterozygote	O
mis	O
-	O
sense	O
mutation	O
:	O
a	O
G	O
to	O
T	O
change	O
affecting	O
the	O
first	O
nucleotide	O
at	O
codon	O
32	O
(	O
D	O
32	O
Y	O
)	O
.	O
None	O
of	O
the	O
11	O
tumours	O
studied	O
had	O
a	O
positive	O
RER	O
phenotype	O
.	O
CONCLUSIONS	O
:	O
Present	O
and	O
previous	O
studies	O
suggest	O
that	O
the	O
Wnt	O
/	O
beta-catenin	O
/	O
Tcf-Lef	O
pathway	O
is	O
activated	O
in	O
normal	O
matrix	O
cells	O
of	O
the	O
HF	O
to	O
induce	O
differentiation	O
to	O
the	O
hair	O
shaft	O
.	O
Additionally	O
,	O
the	O
beta-catenin	O
mutation	O
in	O
matrix	O
cells	O
of	O
the	O
HF	O
stabilizes	O
beta-catenin	O
protein	O
,	O
which	O
translocates	O
into	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
of	O
gene	O
transcription	O
together	O
with	O
lymphoid	O
enhancer	O
factor-1	O
producing	O
pilomatrixoma	B-malignancy-type
.	O
These	O
mutations	O
occur	O
without	O
an	O
underlying	O
defect	O
in	O
DNA	O
mismatch	O
repair	O
.	O
PMID	O
:	O
11703283	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncol	O
Rep	O
2001	O
Nov	O
-	O
Dec	O
;	O
8	O
(	O
6	O
)	O
:	O
1301-4	O
Fibroblast	O
growth	O
factor	O
receptor	O
3	O
S	O
249	O
C	O
mutation	O
in	O
virus	O
associated	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Shotelersuk	O
V	O
,	O
Ittiwut	O
C	O
,	O
Shotelersuk	O
K	O
,	O
Triratanachat	O
S	O
,	O
Poovorawan	O
Y	O
,	O
Mutirangura	O
A	O
.	O
Genetics	O
Unit	O
,	O
Department	O
of	O
Pediatrics	O
,	O
King	O
Chulalongkorn	O
Memorial	O
Hospital	O
,	O
Bangkok	O
10330	O
,	O
Thailand	O
.	O
vorasuk.s@chula.ac.th	O
An	O
S	O
249	O
C	O
mutation	O
in	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
gene	O
was	O
recently	O
identified	O
in	O
patients	O
with	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
(	O
CC	B-malignancy-type
)	O
.	O
However	O
,	O
its	O
importance	O
in	O
cervical	O
tumorigenesis	O
is	O
still	O
inconclusive	O
.	O
Apart	O
from	O
CC	B-malignancy-type
,	O
nasopharyngeal	B-malignancy-type
carcinoma	I-malignancy-type
(	O
NPC	B-malignancy-type
)	O
is	O
the	O
other	O
major	O
virus	O
associated	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
sought	O
to	O
clarify	O
the	O
frequency	O
of	O
the	O
FGFR3	O
S	O
249	O
C	O
mutation	O
in	O
75	O
primary	O
CC	B-malignancy-type
in	O
the	O
Thai	O
population	O
and	O
to	O
determine	O
its	O
prevalence	O
in	O
69	O
primary	O
NPC	B-malignancy-type
by	O
PCR	O
and	O
restriction	O
enzyme	O
digestion	O
.	O
None	O
of	O
the	O
patients	O
but	O
one	O
NPC	B-malignancy-type
showed	O
the	O
enzyme	O
digestion	O
pattern	O
consistent	O
with	O
the	O
mutation	O
.	O
This	O
is	O
the	O
first	O
report	O
demonstrating	O
the	O
role	O
of	O
FGFR3	O
in	O
the	O
development	O
of	O
human	O
NPC	B-malignancy-type
.	O
This	O
study	O
confirms	O
the	O
low	O
frequency	O
of	O
the	O
FGFR3	O
S	O
249	O
C	O
mutation	O
in	O
CC	B-malignancy-type
.	O
Nevertheless	O
,	O
the	O
discovery	O
of	O
the	O
mutation	O
,	O
not	O
only	O
in	O
CC	B-malignancy-type
as	O
reported	O
by	O
previous	O
studies	O
,	O
but	O
in	O
NPC	B-malignancy-type
based	O
on	O
this	O
report	O
,	O
suggests	O
that	O
FGFR3	O
may	O
play	O
a	O
significant	O
role	O
in	O
human	O
CC	B-malignancy-type
and	O
NPC	B-malignancy-type
development	O
.	O
PMID	O
:	O
11605053	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Hepatol	O
2001	O
Aug	O
;	O
35	O
(	O
2	O
)	O
:	O
235-44	O
Microsatellite	O
instability	O
and	O
alternative	O
genetic	O
pathway	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
.	O
Momoi	O
H	O
,	O
Itoh	O
T	O
,	O
Nozaki	O
Y	O
,	O
Arima	O
Y	O
,	O
Okabe	O
H	O
,	O
Satoh	O
S	O
,	O
Toda	O
Y	O
,	O
Sakai	O
E	O
,	O
Nakagawara	O
K	O
,	O
Flemming	O
P	O
,	O
Yamamoto	O
M	O
,	O
Shimahara	O
Y	O
,	O
Yamaoka	O
Y	O
,	O
Fukumoto	O
M	O
.	O
Department	O
of	O
Gastroenterological	O
Surgery	O
,	O
Kyoto	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
Intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
(	O
ICC	B-malignancy-type
)	O
arises	O
from	O
intrahepatic	O
bile	O
duct	O
epithelium	O
and	O
is	O
the	O
second	O
most	O
prevalent	O
among	O
primary	O
liver	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
mechanism	O
of	O
cholangiocarcinogenesis	O
.	O
METHODS	O
:	O
We	O
studied	O
the	O
incidence	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
involving	O
eight	O
highly	O
polymorphic	O
microsatellite	O
markers	O
and	O
alternations	O
of	O
the	O
K-ras	O
,	O
p53	O
and	O
mdm-2	O
genes	O
in	O
human	O
ICC	B-malignancy-type
tissues	O
.	O
Overexpression	O
of	O
mdm-2	O
oncoprotein	O
was	O
also	O
immunohistochemically	O
studied	O
.	O
RESULTS	O
:	O
Of	O
all	O
65	O
cases	O
examined	O
,	O
K-ras	O
gene	O
mutation	O
was	O
found	O
in	O
three	O
cases	O
(	O
4.6	O
%	O
)	O
at	O
codon	O
12	O
.	O
Analysis	O
of	O
p53	O
alterations	O
was	O
performed	O
in	O
28	O
cases	O
including	O
22	O
frozen	O
samples	O
and	O
mutations	O
were	O
found	O
in	O
three	O
cases	O
(	O
10.7	O
%	O
)	O
.	O
Overexpression	O
of	O
mdm-2	O
protein	O
was	O
observed	O
in	O
25	O
(	O
41.7	O
%	O
)	O
out	O
of	O
60	O
cases	O
analyzed	O
.	O
In	O
22	O
frozen	O
samples	O
,	O
seven	O
(	O
31.8	O
%	O
)	O
cases	O
showed	O
mdm-2	O
amplification	O
and	O
four	O
(	O
18.2	O
%	O
)	O
cases	O
revealed	O
MSI	O
-	O
positive	O
phenotype	O
.	O
Among	O
the	O
cases	O
analyzed	O
,	O
all	O
the	O
tumors	O
with	O
mdm-2	O
amplification	O
/	O
overexpression	O
harbored	O
the	O
wild	O
-	O
type	O
p53	O
gene	O
and	O
all	O
the	O
microsatellite	O
instability	O
-	O
positive	O
cases	O
were	O
from	O
mass	O
-	O
forming	O
(	O
MF	O
)	O
+	O
periductal	O
-	O
infiltrating	O
(	O
PI	O
)	O
subtype	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
mdm-2	O
plays	O
a	O
role	O
,	O
which	O
might	O
be	O
partially	O
through	O
inhibiting	O
p53	O
activity	O
,	O
in	O
cholangiocarcinogenesis	O
and	O
that	O
M	O
PMID	O
:	O
11580146	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Mol	O
Med	O
2001	O
Oct;8	O
(	O
4	O
)	O
:453-	O
9	O
Molecular	O
analysis	O
of	O
p53	O
and	O
K-ras	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
of	O
coal	O
miners	O
.	O
Sarkar	O
FH	O
,	O
Li	O
Y	O
,	O
Vallyathan	O
V	O
.	O
Department	O
of	O
Pathology	O
,	O
Wayne	O
State	O
University	O
School	O
of	O
Medicine	O
,	O
540	O
E.	O
Canfield	O
Avenue	O
,	O
Detroit	O
,	O
MI	O
48201	O
,	O
USA	O
.	O
fsarkar@med.wayne.edu	O
Thirty-three	O
cases	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
from	O
the	O
archives	O
of	O
National	O
Coal	O
Workers	O
'	O
Autopsy	O
Study	O
were	O
studied	O
for	O
mutational	O
alterations	O
in	O
p53	O
and	O
K-ras	O
using	O
PCR	O
-	O
SSCP	O
,	O
DNA	O
sequencing	O
and	O
PCR	O
-	O
oligonucleotide	O
probe	O
hybridization	O
techniques	O
.	O
Mutations	O
of	O
the	O
p53	O
were	O
observed	O
in	O
4	O
smokers	O
(	O
19	O
%	O
)	O
and	O
one	O
in	O
a	O
never	O
smoker	O
(	O
8	O
%	O
)	O
.	O
Two	O
polymorphisms	O
in	O
smokers	O
were	O
detected	O
at	O
codon	O
213	O
,	O
a	O
common	O
site	O
for	O
sequence	O
variation	O
.	O
Among	O
the	O
smokers	O
the	O
p53	O
mutations	O
were	O
in	O
the	O
heavy	O
smokers	O
.	O
In	O
never	O
smokers	O
there	O
was	O
only	O
a	O
single	O
p53	O
mutation	O
and	O
two	O
K-ras	O
mutations	O
.	O
In	O
never	O
smokers	O
the	O
frequency	O
of	O
K-ras	O
mutations	O
was	O
similar	O
(	O
17	O
%	O
)	O
in	O
smokers	O
,	O
but	O
one	O
never	O
smoker	O
had	O
two	O
K-ras	O
mutations	O
.	O
Mutations	O
of	O
p53	O
were	O
more	O
frequent	O
in	O
adenocarcinomas	B-malignancy-type
(	O
27	O
%	O
)	O
and	O
they	O
were	O
AT	O
-->	O
GC	O
transitions	O
.	O
Four	O
of	O
11	O
(	O
36	O
%	O
)	O
adenocarcinomas	B-malignancy-type
were	O
found	O
to	O
have	O
K-ras	O
codon	O
12	O
mutations	O
,	O
and	O
one	O
adenocarcinoma	B-malignancy-type
had	O
two	O
K-ras	O
mutations	O
.	O
There	O
were	O
two	O
large	B-malignancy-type
cell	I-malignancy-type
undifferentiated	I-malignancy-type
carcinomas	I-malignancy-type
with	O
p53	O
mutation	O
and	O
one	O
with	O
a	O
K-ras	O
mutation	O
.	O
Two	O
of	O
the	O
16	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
positive	O
for	O
p53	O
mutation	O
,	O
while	O
no	O
K-ras	O
mutations	O
were	O
found	O
in	O
this	O
group	O
.	O
The	O
results	O
of	O
these	O
preliminary	O
studies	O
indicate	O
a	O
moderately	O
different	O
mutational	O
spectrum	O
of	O
p53	O
and	O
K-ras	O
in	O
coal	O
miners	O
independent	O
of	O
cigarette	O
smoking	O
.	O
The	O
mutational	O
spectrum	O
observed	O
in	O
this	O
study	O
of	O
coal	O
miners	O
with	O
heavy	O
cigarette	O
smoking	O
history	O
suggest	O
a	O
protective	O
effect	O
of	O
coal	O
mine	O
dust	O
in	O
preventing	O
abnormal	O
mutations	O
induced	O
by	O
chemical	O
carcinogens	O
in	O
cigarette	O
smoke	O
or	O
reactive	O
oxygen	O
species	O
.	O
These	O
limited	O
preliminary	O
studies	O
provide	O
insight	O
into	O
the	O
possibility	O
of	O
accurately	O
measuring	O
changes	O
in	O
etiologic	O
markers	O
to	O
unravel	O
the	O
uncertainties	O
of	O
cancer	O
in	O
coal	O
miners	O
.	O
PMID	O
:	O
11562787	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
2001	O
Sep	O
15	O
;	O
61	O
(	O
18	O
)	O
:	O
6679-81	O
Lung	B-malignancy-type
tumor	I-malignancy-type
KRAS	O
and	O
TP53	O
mutations	O
in	O
nonsmokers	O
reflect	O
exposure	O
to	O
PAH	O
-	O
rich	O
coal	O
combustion	O
emissions	O
.	O
DeMarini	O
DM	O
,	O
Landi	O
S	O
,	O
Tian	O
D	O
,	O
Hanley	O
NM	O
,	O
Li	O
X	O
,	O
Hu	O
F	O
,	O
Roop	O
BC	O
,	O
Mass	O
MJ	O
,	O
Keohavong	O
P	O
,	O
Gao	O
W	O
,	O
Olivier	O
M	O
,	O
Hainaut	O
P	O
,	O
Mumford	O
JL	O
.	O
Environmental	O
Carcinogenesis	O
Division	O
(	O
MD-68	O
)	O
,	O
United	O
States	O
Environmental	O
Protection	O
Agency	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27711	O
,	O
USA	O
.	O
demarini.david@epa.gov	O
We	O
determined	O
the	O
TP53	O
and	O
codon	O
12	O
KRAS	O
mutations	O
in	O
lung	B-malignancy-type
tumors	I-malignancy-type
from	O
24	O
nonsmokers	O
whose	O
tumors	O
were	O
associated	O
with	O
exposure	O
to	O
smoky	O
coal	O
.	O
Among	O
any	O
tumors	O
studied	O
previously	O
,	O
these	O
showed	O
the	O
highest	O
percentage	O
of	O
mutations	O
that	O
(a)	O
were	O
G	O
-->	O
T	O
transversions	O
at	O
either	O
KRAS	O
(	O
86	O
%	O
)	O
or	O
TP53	O
(	O
76	O
%	O
)	O
,	O
(b)	O
clustered	O
at	O
the	O
G	O
-	O
rich	O
codons	O
153	O
-	O
158	O
of	O
TP53	O
(	O
33	O
%	O
)	O
,	O
and	O
(c)	O
had	O
100	O
%	O
of	O
the	O
guanines	O
of	O
the	O
G	O
-->	O
T	O
transversions	O
on	O
the	O
nontranscribed	O
strand	O
.	O
This	O
mutation	O
spectrum	O
is	O
consistent	O
with	O
an	O
exposure	O
to	O
polycyclic	O
aromatic	O
hydrocarbons	O
,	O
which	O
are	O
the	O
primary	O
component	O
of	O
the	O
smoky	O
coal	O
emissions	O
.	O
These	O
results	O
show	O
that	O
mutations	O
in	O
the	O
TP53	O
and	O
KRAS	O
genes	O
can	O
reflect	O
a	O
specific	O
environmental	O
exposure	O
.	O
PMID	O
:	O
11559534	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2001	O
Jul	O
19	O
;	O
20	O
(	O
32	O
)	O
:	O
4416-8	O
Frequency	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
mutations	O
in	O
sporadic	O
tumours	O
.	O
Sibley	O
K	O
,	O
Stern	O
P	O
,	O
Knowles	O
MA	O
.	O
ICRF	O
Clinical	O
Centre	O
,	O
St.	O
James's	O
University	O
Hospital	O
,	O
Leeds	O
,	O
LS9	O
7TF	O
,	O
UK	O
.	O
Mutations	O
in	O
FGFR3	O
have	O
been	O
identified	O
in	O
several	O
tumour	O
types	O
including	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
,	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
In	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
recently	O
identified	O
FGFR3	O
mutations	O
in	O
41	O
%	O
of	O
tumours	O
,	O
making	O
this	O
the	O
most	O
frequently	O
mutated	O
putative	O
oncogene	O
identified	O
in	O
bladder	B-malignancy-type
cancer	I-malignancy-type
to	O
date	O
.	O
We	O
have	O
now	O
investigated	O
the	O
frequency	O
of	O
FGFR3	O
mutation	O
in	O
a	O
panel	O
of	O
125	O
tumours	O
and	O
13	O
cell	O
lines	O
from	O
various	O
other	O
organs	O
.	O
We	O
analysed	O
the	O
mutation	O
hotspots	O
in	O
exons	O
7	O
,	O
10	O
and	O
15	O
by	O
direct	O
DNA	O
sequencing	O
,	O
and	O
found	O
one	O
mutation	O
in	O
exon	O
7	O
(	O
S	O
249	O
C	O
)	O
in	O
1	O
/	O
28	O
(	O
3.5	O
%	O
)	O
cervical	B-malignancy-type
tumours	I-malignancy-type
.	O
Mutations	O
were	O
not	O
detected	O
in	O
stomach	B-malignancy-type
,	O
rectum	B-malignancy-type
,	O
colon	B-malignancy-type
,	O
prostate	B-malignancy-type
,	O
ovarian	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
brain	B-malignancy-type
,	O
or	O
renal	B-malignancy-type
tumours	I-malignancy-type
,	O
nor	O
were	O
they	O
found	O
in	O
any	O
of	O
the	O
cell	O
lines	O
included	O
in	O
this	O
study	O
.	O
We	O
conclude	O
that	O
FGFR3	O
is	O
commonly	O
mutated	O
in	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
and	O
only	O
rarely	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Several	O
tumour	O
types	O
appear	O
not	O
to	O
possess	O
any	O
mutations	O
in	O
FGFR3	O
,	O
suggesting	O
that	O
these	O
mutations	O
are	O
important	O
only	O
in	O
the	O
development	O
of	O
certain	O
types	O
of	O
tumour	O
.	O
PMID	O
:	O
11466624	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2001	O
Aug	O
10	O
;	O
169	O
(	O
1	O
)	O
:	O
59-68	O
Genetic	O
alterations	O
in	O
gallbladder	B-malignancy-type
adenoma	I-malignancy-type
,	O
dysplasia	B-malignancy-type
and	O
carcinoma	B-malignancy-type
.	O
Kim	O
YT	O
,	O
Kim	O
J	O
,	O
Jang	O
YH	O
,	O
Lee	O
WJ	O
,	O
Ryu	O
JK	O
,	O
Park	O
YK	O
,	O
Kim	O
SW	O
,	O
Kim	O
WH	O
,	O
Yoon	O
YB	O
,	O
Kim	O
CY	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
South	O
Korea	O
.	O
yongtkim@plaza.snu.ac.kr	O
Adenoma	B-malignancy-type
and	O
dysplasia	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
(	O
GB	O
)	O
have	O
been	O
reported	O
as	O
precancerous	O
lesions	O
,	O
but	O
the	O
genetic	O
evidence	O
of	O
this	O
is	O
not	O
clearly	O
defined	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
frequencies	O
of	O
K-ras	O
,	O
p53	O
,	O
and	O
p16	O
gene	O
mutations	O
,	O
of	O
microsatellite	O
instability	O
(	O
MI	O
)	O
and	O
of	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
GB	B-malignancy-type
cancer	I-malignancy-type
,	O
dysplasia	B-malignancy-type
,	O
and	O
adenoma	B-malignancy-type
.	O
Tissues	O
from	O
15	O
GB	B-malignancy-type
cancers	I-malignancy-type
,	O
five	O
dysplasias	B-malignancy-type
around	O
cancerous	O
tumors	O
,	O
and	O
three	O
adenomas	B-malignancy-type
were	O
collected	O
prospectively	O
.	O
The	O
mutation	O
rates	O
of	O
K-ras	O
,	O
p53	O
,	O
and	O
p16	O
were	O
20.0	O
,	O
35.7	O
,	O
and	O
30.7	O
%	O
,	O
respectively	O
,	O
in	O
GB	B-malignancy-type
cancers	I-malignancy-type
.	O
However	O
,	O
no	O
mutations	O
were	O
found	O
in	O
dysplasia	B-malignancy-type
or	O
adenoma	B-malignancy-type
.	O
Reduced	O
staining	O
for	O
p16	O
was	O
seen	O
in	O
23	O
%	O
of	O
carcinomas	B-malignancy-type
.	O
All	O
of	O
the	O
GB	B-malignancy-type
carcinomas	I-malignancy-type
and	O
four	O
out	O
of	O
five	O
(	O
80	O
%	O
)	O
of	O
the	O
dysplasias	B-malignancy-type
showed	O
LOH	O
in	O
a	O
minimum	O
of	O
one	O
locus	O
,	O
but	O
one	O
out	O
of	O
three	O
(	O
33	O
%	O
)	O
cases	O
of	O
adenoma	B-malignancy-type
displayed	O
LOH	O
in	O
only	O
one	O
locus	O
.	O
All	O
of	O
the	O
loci	O
of	O
LOH	O
in	O
the	O
dysplasias	B-malignancy-type
,	O
except	O
one	O
,	O
showed	O
the	O
same	O
patterns	O
of	O
allelic	O
loss	O
as	O
the	O
adjacent	O
carcinomas	B-malignancy-type
.	O
Only	O
one	O
dysplasia	B-malignancy-type
showed	O
multiple	O
MI	O
.	O
In	O
conclusion	O
,	O
multiple	O
LOH	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
dysplasia	B-malignancy-type
and	O
the	O
malignant	O
transformation	O
of	O
GB	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Gene	O
alterations	O
of	O
K-ras	O
,	O
p53	O
,	O
and	O
p16	O
are	O
important	O
steps	O
in	O
the	O
malignant	O
changes	O
of	O
dysplasia	B-malignancy-type
.	O
However	O
,	O
MI	O
seems	O
to	O
have	O
only	O
a	O
limited	O
role	O
in	O
GB	B-malignancy-type
cancer	I-malignancy-type
development	O
.	O
PMID	O
:	O
11410326	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Diagn	O
Mol	O
Pathol	O
2001	O
Jun;10(	O
2	O
)	O
:	O
116-22	O
beta-Catenin	O
expression	O
pattern	O
,	O
beta-catenin	O
gene	O
mutations	O
,	O
and	O
microsatellite	O
instability	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
and	O
synchronous	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Moreno-Bueno	O
G	O
,	O
Gamallo	O
C	O
,	O
Perez-Gallego	O
L,	O
de	O
Mora	O
JC	O
,	O
Suarez	O
A	O
,	O
Palacios	O
J.	O
Programa	O
de	O
Patologia	O
Molecular	O
,	O
Centro	O
Nacional	O
de	O
Investigaciones	O
Oncologicas	O
(	O
CNIO	O
)	O
,	O
Madrid	O
,	O
Spain	O
.	O
beta-Catenin	O
gene	O
mutations	O
and	O
microsatellite	O
instability	O
(	O
MI	O
)	O
have	O
been	O
reported	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
In	O
colon	B-malignancy-type
but	O
not	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
,	O
beta-catenin	O
gene	O
mutations	O
are	O
associated	O
with	O
a	O
replication	O
error	O
phenotype	O
and	O
MI	O
.	O
In	O
this	O
study	O
the	O
authors	O
investigate	O
whether	O
beta-catenin	O
mutations	O
and	O
MI	O
are	O
two	O
independent	O
oncogenic	O
pathways	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
They	O
also	O
evaluate	O
the	O
usefulness	O
of	O
these	O
molecular	O
markers	O
in	O
determining	O
the	O
primary	O
origin	O
of	O
simultaneous	O
tumors	O
in	O
the	O
ovary	O
and	O
endometrium	O
.	O
This	O
study	O
was	O
performed	O
on	O
26	O
patients	O
diagnosed	O
with	O
primary	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
,	O
five	O
of	O
whom	O
also	O
had	O
pathologically	O
diagnosed	O
primary	O
synchronous	O
endometrioid	B-malignancy-type
endometrial	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Immunohistochemical	O
and	O
molecular	O
analyses	O
indicated	O
that	O
there	O
were	O
25	O
primary	O
ovarian	B-malignancy-type
tumors	I-malignancy-type
with	O
four	O
primary	O
synchronous	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
and	O
one	O
ovarian	B-malignancy-type
metastasis	I-malignancy-type
of	O
a	O
primary	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
All	O
studies	O
were	O
performed	O
on	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
samples	O
.	O
The	O
beta-catenin	O
expression	O
pattern	O
(	O
nuclear	O
vs.	O
membranous	O
)	O
was	O
analyzed	O
immunohistochemically	O
.	O
Mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
were	O
studied	O
by	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
,	O
and	O
direct	O
sequencing	O
.	O
MI	O
status	O
was	O
established	O
by	O
studying	O
BAT-26	O
and	O
BAT-25	O
mononucleotide	O
repeats	O
.	O
In	O
the	O
group	O
with	O
21	O
single	O
ovarian	B-malignancy-type
tumors	I-malignancy-type
,	O
18	O
(	O
85	O
%	O
)	O
had	O
beta-catenin	O
nuclear	O
expression	O
,	O
eight	O
(	O
38	O
%	O
)	O
had	O
beta-catenin	O
gene	O
mutations	O
(	O
always	O
associated	O
with	O
beta-catenin	O
nuclear	O
expression	O
)	O
,	O
and	O
four	O
(	O
19	O
%	O
)	O
had	O
MI	O
.	O
Only	O
one	O
case	O
(	O
5	O
%	O
)	O
had	O
both	O
beta-catenin	O
gene	O
mutations	O
and	O
MI	O
.	O
The	O
mutations	O
affected	O
one	O
of	O
the	O
serine	O
/	O
threonine	O
residues	O
targeted	O
for	O
phosphorylation	O
by	O
glycogen	O
synthase	O
kinase-3beta	O
or	O
adjacent	O
residues	O
.	O
At	O
codon	O
32	O
,	O
a	O
GAC	O
-	O
to	O
-	O
TAC	O
(	O
D	O
32	O
Y	O
)	O
change	O
was	O
found	O
;	O
at	O
codon	O
33	O
,	O
two	O
TCT	O
-	O
to	O
-	O
TGT	O
(	O
S	O
33	O
C	O
)	O
changes	O
were	O
found	O
;	O
at	O
codon	O
37	O
,	O
three	O
TCT	O
-	O
to	O
-	O
TTT	O
(	O
S	O
37	O
F	O
)	O
changes	O
and	O
one	O
TCT	O
-	O
to	O
-	O
TGT	O
(	O
S	O
37	O
C	O
)	O
change	O
were	O
found	O
;	O
and	O
,	O
lastly	O
,	O
one	O
ACC	O
-	O
to	O
-	O
GCC	O
change	O
at	O
codon	O
41	O
(	O
T	O
41	O
A	O
)	O
was	O
detected	O
.	O
Four	O
of	O
the	O
25	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
(	O
16	O
%	O
)	O
had	O
an	O
associated	O
synchronous	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
There	O
was	O
a	O
higher	O
percentage	O
of	O
beta-catenin	O
mutations	O
(	O
n	O
=	O
3	O
,	O
75	O
%	O
)	O
in	O
synchronous	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
than	O
in	O
single	O
ones	O
,	O
although	O
with	O
a	O
similar	O
percentage	O
of	O
MI	O
(	O
n	O
=	O
1	O
,	O
25	O
%	O
)	O
.	O
beta-catenin	O
mutations	O
were	O
S	O
37	O
C	O
in	O
two	O
cases	O
and	O
D	O
32	O
G	O
in	O
one	O
.	O
One	O
of	O
the	O
four	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
an	O
S	O
33	O
C	O
beta-catenin	O
mutation	O
,	O
and	O
two	O
carcinomas	B-malignancy-type
had	O
MI	O
.	O
None	O
of	O
the	O
four	O
tumors	O
had	O
both	O
beta-catenin	O
gene	O
mutation	O
and	O
MI	O
.	O
beta-catenin	O
gene	O
mutations	O
were	O
always	O
associated	O
with	O
a	O
nuclear	O
beta-catenin	O
expression	O
pattern	O
,	O
whereas	O
MI	O
was	O
associated	O
with	O
a	O
membranous	O
pattern	O
.	O
In	O
one	O
patient	O
both	O
the	O
ovarian	B-malignancy-type
and	O
the	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
had	O
beta-catenin	O
gene	O
mutations	O
,	O
in	O
another	O
patient	O
both	O
tumors	O
showed	O
MI	O
,	O
whereas	O
in	O
the	O
remaining	O
two	O
patients	O
the	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
beta-catenin	O
gene	O
mutations	O
and	O
the	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
MI	O
.	O
To	O
summarize	O
,	O
the	O
results	O
of	O
this	O
study	O
suggest	O
that	O
beta-catenin	O
mutations	O
and	O
MI	O
could	O
represent	O
two	O
independent	O
pathways	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
because	O
they	O
occur	O
simultaneously	O
very	O
infrequently	O
(	O
in	O
5	O
%	O
of	O
these	O
cases	O
)	O
.	O
beta-catenin	O
mutations	O
are	O
always	O
associated	O
with	O
a	O
nuclear	O
beta-catenin	O
expression	O
pattern	O
,	O
whereas	O
cases	O
with	O
a	O
replication	O
error	O
-	O
plus	O
phenotype	O
showed	O
no	O
abnormal	O
beta-catenin	O
subcellular	O
localization	O
.	O
The	O
study	O
of	O
the	O
beta-catenin	O
expression	O
pattern	O
,	O
beta-catenin	O
mutations	O
,	O
and	O
MI	O
,	O
together	O
with	O
conventional	O
clinicopathologic	O
findings	O
,	O
could	O
aid	O
in	O
distinguishing	O
between	O
the	O
metastatic	O
or	O
independent	O
origin	O
of	O
simultaneous	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
and	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Tumors	O
with	O
identical	O
immunohistochemical	O
and	O
molecular	O
features	O
should	O
therefore	O
be	O
considered	O
to	O
have	O
a	O
common	O
origin	O
.	O
PMID	O
:	O
11385321	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
2002	O
Jun	O
28;180(	O
2	O
)	O
:153	O
-	O
8	O
Unique	O
K-ras	O
mutational	O
pattern	O
in	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
from	O
Taiwanese	O
patients	O
.	O
Wang	O
JY	O
,	O
Lian	O
ST	O
,	O
Chen	O
YF	O
,	O
Yang	O
YC	O
,	O
Chen	O
LT	O
,	O
Lee	O
KT	O
,	O
Huang	O
TJ	O
,	O
Lin	O
SR.	O
Department	O
of	O
Surgery	O
,	O
Kaohsiung	O
Medical	O
University	O
,	O
No	O
.	O
100	O
,	O
Shih	O
-Chuan	O
1st	O
Road	O
,	O
Kaohsiung	O
807	O
,	O
Taiwan	O
.	O
To	O
assess	O
the	O
prevalence	O
and	O
spectrum	O
of	O
K-ras	O
mutations	O
in	O
Taiwanese	O
patients	O
with	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
we	O
analyzed	O
20	O
patients	O
of	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
head	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
undergoing	O
pancreaticoduodenectomy	O
.	O
The	O
study	O
included	O
K-ras	O
mutations	O
that	O
were	O
detected	O
using	O
DNA	O
direct	O
sequencing	O
analysis	O
of	O
the	O
polymerase	O
chain	O
reaction	O
products	O
and	O
confirmed	O
by	O
reverse	O
sequencing	O
primers	O
.	O
The	O
results	O
showed	O
that	O
K-ras	O
codon	O
12	O
mutation	O
was	O
detected	O
in	O
90	O
%	O
of	O
the	O
cancer	O
tissues	O
(	O
18	O
/	O
20	O
)	O
.	O
Moreover	O
,	O
the	O
results	O
from	O
direct	O
sequencing	O
indicated	O
that	O
missense	O
mutations	O
were	O
found	O
to	O
be	O
a	O
GGT	O
to	O
GTT	O
in	O
94.5	O
%	O
of	O
the	O
cases	O
(	O
17	O
/	O
18	O
)	O
and	O
a	O
GGT	O
to	O
TTT	O
in	O
5.5	O
%	O
of	O
the	O
cases	O
(	O
1	O
/	O
18	O
)	O
.	O
All	O
cases	O
with	O
K-ras	O
codon	O
12	O
mutations	O
were	O
found	O
to	O
be	O
G	O
to	O
T	O
transversion	O
.	O
However	O
,	O
no	O
alterations	O
were	O
found	O
at	O
codons	O
13	O
and	O
61	O
.	O
From	O
these	O
findings	O
,	O
the	O
high	O
prevalence	O
of	O
K-ras	O
codon	O
12	O
mutation	O
in	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
the	O
predominant	O
G	O
to	O
T	O
transversion	O
with	O
the	O
preferential	O
substitution	O
of	O
glycine	O
with	O
valine	O
might	O
indicate	O
an	O
unusual	O
sensitivity	O
and	O
specificity	O
of	O
this	O
codon	O
in	O
genetic	O
alterations	O
for	O
pancreatic	O
carcinogenesis	O
.	O
The	O
strikingly	O
high	O
mutational	O
rate	O
and	O
the	O
unique	O
mutational	O
spectrum	O
of	O
K-ras	O
codon	O
12	O
in	O
Taiwanese	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
can	O
provide	O
us	O
with	O
more	O
information	O
about	O
the	O
alternative	O
diagnostic	O
and	O
therapeutic	O
strategies	O
in	O
Taiwan	O
.	O
PMID	O
:	O
12175546	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
2001	O
Apr;44(	O
4	O
)	O
:	O
54	O
9-	O
57	O
Prognostic	O
value	O
of	O
K-ras	O
mutations	O
and	O
allelic	O
imbalance	O
on	O
chromosome	O
18q	O
in	O
patients	O
with	O
resected	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Font	O
A	O
,	O
Abad	O
A	O
,	O
Monzo	O
M,	O
Sanchez	O
JJ	O
,	O
Guillot	O
M,	O
Manzano	O
JL	O
,	O
Pinol	O
M,	O
Ojanguren	O
I	O
,	O
Rosell	O
R.	O
Laboratory	O
of	O
Molecular	O
Biology	O
of	O
Cancer	O
,	O
Hospital	O
Germans	O
Trias	O
i	O
Pujol	O
,	O
Badalona	O
,	O
Spain	O
.	O
PURPOSE	O
:	O
We	O
designed	O
this	O
study	O
to	O
assess	O
the	O
frequency	O
of	O
K-ras	O
mutations	O
in	O
patients	O
with	O
resected	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
and	O
their	O
association	O
with	O
survival	O
.	O
A	O
second	O
objective	O
was	O
to	O
analyze	O
the	O
prognostic	O
value	O
of	O
different	O
K-ras	O
genotypes	O
.	O
In	O
a	O
subgroup	O
of	O
patients	O
we	O
also	O
investigated	O
the	O
presence	O
of	O
allelic	O
imbalance	O
on	O
chromosome	O
18q	O
and	O
its	O
relationship	O
to	O
clinical	O
outcome	O
.	O
METHODS	O
:	O
One	O
hundred	O
fourteen	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
resected	O
between	O
1983	O
and	O
1986	O
were	O
analyzed	O
to	O
detect	O
K-ras	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
by	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
allele	O
specific	O
oligonucleotide	O
hybridization	O
.	O
A	O
subgroup	O
of	O
77	O
tumors	B-malignancy-type
was	O
further	O
screened	O
to	O
detect	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	O
18q	O
using	O
three	O
polymorphic	O
microsatellite	O
markers	O
(	O
D18S67	O
,	O
D18S474	O
and	O
D18S58	O
)	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
29	O
percent	O
(	O
33	O
/	O
114	O
)	O
of	O
patients	O
.	O
K-ras	O
mutations	O
correlated	O
with	O
age	O
and	O
preoperative	O
carcinoembryonic	O
antigen	O
levels	O
,	O
and	O
there	O
was	O
some	O
indication	O
that	O
they	O
may	O
be	O
linked	O
to	O
poor	O
survival	O
,	O
especially	O
in	O
Stage	O
II	O
tumors	O
,	O
where	O
a	O
subgroup	O
of	O
patients	O
with	O
aspartic	O
and	O
serine	O
mutations	O
showed	O
significantly	O
reduced	O
survival	O
(	O
P	O
=	O
0.03	O
)	O
compared	O
with	O
K-ras	O
-	O
negative	O
patients	O
.	O
18q	O
loss	O
of	O
heterozygosity	O
was	O
present	O
in	O
39	O
percent	O
(	O
25	O
/	O
63	O
)	O
of	O
tumors	B-malignancy-type
.	O
A	O
multivariate	O
analysis	O
of	O
Stage	O
II	O
tumors	O
showed	O
that	O
18q	O
loss	O
of	O
heterozygosity	O
was	O
significantly	O
associated	O
with	O
a	O
worse	O
prognosis	O
(	O
P	O
=	O
0.006	O
)	O
.	O
A	O
significant	O
decrease	O
in	O
survival	O
was	O
identified	O
in	O
ten	O
patients	O
harboring	O
both	O
genetic	O
alterations	O
(	O
K-i	O
mutations	O
and	O
18q	O
loss	O
of	O
heterozygosity	O
;	O
P	O
=	O
0.02	O
)	O
.	O
CONCLUSIONS	O
:	O
In	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
,	O
K-ras	O
mutations	O
and	O
18q	O
loss	O
of	O
heterozygosity	O
are	O
two	O
genetic	O
markers	O
which	O
may	O
identify	O
patients	O
with	O
more	O
aggressive	O
behavior	O
,	O
mainly	O
in	O
Stage	O
II	O
tumors	O
.	O
These	O
findings	O
warrant	O
further	O
research	O
,	O
because	O
they	O
can	O
be	O
useful	O
in	O
customizing	O
adjuvant	O
chemotherapy	O
.	O
PMID	O
:	O
11330582	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2001	O
Apr;158	O
(	O
4	O
)	O
:1517-24	O
Inverse	O
relationship	O
between	O
microsatellite	O
instability	O
and	O
K-ras	O
and	O
p53	O
gene	O
alterations	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Samowitz	O
WS	O
,	O
Holden	O
JA	O
,	O
Curtin	O
K,	O
Edwards	O
SL	O
,	O
Walker	O
AR	O
,	O
Lin	O
HA	O
,	O
Robertson	O
MA	O
,	O
Nichols	O
MF	O
,	O
Gruenthal	O
KM	O
,	O
Lynch	O
BJ	O
,	O
Leppert	O
MF	O
,	O
Slattery	O
ML	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Utah	O
Health	O
Sciences	O
Center	O
,	O
50	O
North	O
Medical	O
Dr.	O
,	O
Salt	O
Lake	O
City	O
,	O
UT	O
84132	O
,	O
USA	O
.	O
wsamowitz@msscc.med	O
.utah	O
.edu	O
Some	O
studies	O
have	O
shown	O
an	O
inverse	O
relationship	O
between	O
microsatellite	O
instability	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
and	O
mutations	O
in	O
p53	O
and	O
K-ras	O
,	O
whereas	O
others	O
have	O
not	O
.	O
We	O
therefore	O
evaluated	O
these	O
features	O
in	O
a	O
population	O
-	O
based	O
sample	O
of	O
496	O
individuals	O
with	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
Microsatellite	O
instability	O
was	O
determined	O
by	O
a	O
panel	O
of	O
10	O
tetranucleotide	O
repeats	O
,	O
the	O
Bethesda	O
consensus	O
panel	O
of	O
mono	O
-	O
and	O
di	O
nucleotide	O
repeats	O
,	O
and	O
coding	O
mononucleotide	O
repeats	O
in	O
transforming	O
growth	O
factor	O
-	O
beta	O
receptor	O
type	O
II	O
,	O
hMSH3	O
,	O
BAX	O
,	O
hMSH6	O
,	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
receptor	O
type	O
II	O
.	O
Mutations	O
in	O
codons	O
12	O
and	O
13	O
in	O
K-ras	O
were	O
evaluated	O
by	O
sequencing	O
.	O
p53	O
overexpression	O
(	O
as	O
detected	O
by	O
immunohistochemistry	O
)	O
was	O
used	O
as	O
an	O
indicator	O
of	O
p53	O
mutation	O
;	O
this	O
was	O
evaluated	O
in	O
275	O
of	O
the	B-malignancy-type
tumors	I-malignancy-type
.	O
K-ras	O
mutations	O
were	O
present	O
in	O
33.2	O
%	O
of	O
tumors	B-malignancy-type
,	O
p53	O
overexpression	O
in	O
51.5	O
%	O
,	O
and	O
microsatellite	O
instability	O
(	O
as	O
determined	O
by	O
the	O
Bethesda	O
consensus	O
panel	O
)	O
in	O
12.5	O
%	O
.	O
K-ras	O
mutations	O
were	O
significantly	O
less	O
common	O
in	O
unstable	O
tumors	B-malignancy-type
than	O
stable	O
tumors	B-malignancy-type
(	O
11.8	O
%	O
versus	O
36.9	O
%	O
,	O
P	O
:	O
<	O
0.001	O
)	O
.	O
p53	O
overexpression	O
was	O
significantly	O
less	O
common	O
in	O
unstable	O
tumors	B-malignancy-type
than	O
stable	O
tumors	B-malignancy-type
(	O
20.0	O
%	O
versus	O
55.7	O
%	O
,	O
P	O
:	O
<	O
0.001	O
)	O
.	O
These	O
inverse	O
relationships	O
between	O
microsatellite	O
instability	O
and	O
ras	O
gene	O
mutations	O
and	O
p53	O
overexpression	O
were	O
shown	O
to	O
be	O
independent	O
of	O
tumor	B-malignancy-type
site	O
in	O
logistic	O
regression	O
analyses	O
.	O
All	O
other	O
measures	O
of	O
instability	O
also	O
showed	O
statistically	O
significant	O
inverse	O
relationships	O
independent	O
of	O
tumor	B-malignancy-type
site	O
with	O
alterations	O
in	O
ras	O
and	O
p53	O
,	O
and	O
instability	O
results	O
determined	O
by	O
the	O
panel	O
of	O
10	O
tetranucleotide	O
repeats	O
were	O
highly	O
significantly	O
related	O
to	O
those	O
determined	O
by	O
the	O
Bethesda	O
consensus	O
panel	O
.	O
Coding	O
mononucleotide	O
repeat	O
mutations	O
were	O
significantly	O
more	O
common	O
in	O
unstable	O
tumors	B-malignancy-type
than	O
stable	O
tumors	B-malignancy-type
(	O
85.7	O
%	O
versus	O
1.0	O
%	O
,	O
P	O
:	O
<	O
0.001	O
)	O
.	O
We	O
conclude	O
that	O
there	O
is	O
an	O
inverse	O
relationship	O
between	O
microsatellite	O
instability	O
and	O
mutations	O
in	O
p53	O
and	O
K-ras	O
,	O
and	O
that	O
the	O
molecular	O
profile	O
of	O
colon	B-malignancy-type
cancers	I-malignancy-type
with	O
microsatellite	O
instability	O
is	O
characterized	O
by	O
relatively	O
infrequent	O
mutations	O
in	O
K-ras	O
and	O
p53	O
and	O
relatively	O
frequent	O
mutations	O
in	O
coding	O
mononucleotide	O
repeats	O
.	O
PMID	O
:	O
11290569	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Jan;25(	O
1	O
)	O
:	O
26-42	O
Colloid	B-malignancy-type
(	I-malignancy-type
mucinous	I-malignancy-type
noncystic	I-malignancy-type
)	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Adsay	O
NV	O
,	O
Pierson	O
C	O
,	O
Sarkar	O
F	O
,	O
Abrams	O
J,	O
Weaver	O
D	O
,	O
Conlon	O
KC	O
,	O
Brennan	O
MF	O
,	O
Klimstra	O
DS	O
.	O
Department	O
of	O
Pathology	O
,	O
Karmanos	O
Cancer	O
Institute	O
,	O
Harper	O
Hospital	O
,	O
Wayne	O
State	O
University	O
School	O
of	O
Medicine	O
,	O
Detroit	O
,	O
Michigan	O
48201	O
,	O
USA	O
.	O
adsayv@med	O
.wayne	O
.edu	O
In	O
the	O
past	O
,	O
colloid	B-malignancy-type
(	I-malignancy-type
mucinous	I-malignancy-type
noncystic	I-malignancy-type
)	I-malignancy-type
carcinoma	I-malignancy-type
(	O
CC	B-malignancy-type
)	O
of	B-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
had	O
been	O
included	O
under	O
the	O
category	O
of	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
a	O
tumor	O
with	O
a	O
dismal	O
prognosis	O
,	O
or	O
was	O
frequently	O
misdiagnosed	O
as	O
mucinous	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
.	O
The	O
clinicopathologic	O
features	O
of	O
CC	B-malignancy-type
have	O
not	O
yet	O
been	O
well	O
characterized	O
,	O
because	O
most	O
cases	O
on	O
record	O
have	O
been	O
parts	O
of	O
studies	O
on	O
either	O
mucinous	B-malignancy-type
cystic	I-malignancy-type
neoplasms	I-malignancy-type
(	O
MCN	B-malignancy-type
)	O
or	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
neoplasms	I-malignancy-type
(	O
IPMN	B-malignancy-type
)	O
,	O
with	O
which	O
colloid	B-malignancy-type
carcinomas	I-malignancy-type
are	O
frequently	O
associated	O
.	O
To	O
determine	O
the	O
clinicopathologic	O
characteristics	O
of	O
CC	B-malignancy-type
,	O
17	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
composed	O
predominantly	O
(	O
>	O
80	O
%	O
)	O
of	O
CC	B-malignancy-type
(	O
defined	O
as	O
nodular	O
extracellular	O
mucin	O
lakes	O
with	O
scanty	O
malignant	B-malignancy-type
epithelial	I-malignancy-type
cells	I-malignancy-type
)	O
and	O
in	O
which	O
the	O
invasive	O
carcinoma	B-malignancy-type
measured	O
larger	O
than	O
1	O
cm	O
were	O
studied	O
.	O
Ten	O
of	O
these	O
were	O
originally	O
classified	O
as	O
mucinous	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
four	O
as	O
mucinous	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
.	O
The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
61	O
years	O
;	O
9	O
were	O
men	O
and	O
8	O
were	O
women	O
.	O
The	O
mean	O
size	O
of	O
the	O
CC	B-malignancy-type
was	O
5.3	O
cm	O
(	O
range	O
,	O
1.2	O
-	O
16	O
cm	O
)	O
.	O
In	O
more	O
than	O
half	O
of	O
the	O
patients	O
,	O
CC	B-malignancy-type
represented	O
the	O
invasive	O
component	O
of	O
an	O
IPMN	B-malignancy-type
(	O
in	O
nine	O
cases	O
)	O
or	O
MCN	B-malignancy-type
(	O
in	O
one	O
case	O
)	O
.	O
The	O
tumors	O
were	O
composed	O
of	O
well	O
-	O
defined	O
pools	O
of	O
mucin	O
with	O
sparse	O
malignant	O
cells	O
in	O
various	O
patterns	O
of	O
distribution	O
.	O
Signet	B-malignancy-type
-	I-malignancy-type
ring	I-malignancy-type
cells	I-malignancy-type
floating	O
in	O
the	O
mucin	O
(	O
but	O
not	O
as	O
individual	O
cells	O
infiltrating	O
stroma	O
,	O
a	O
characteristic	O
finding	O
of	O
signet	B-malignancy-type
-	I-malignancy-type
ring	I-malignancy-type
cell	I-malignancy-type
adenocarcinomas	I-malignancy-type
)	O
were	O
commonly	O
identified	O
and	O
were	O
prominent	O
in	O
five	O
cases	O
.	O
Perineurial	O
invasion	O
was	O
noted	O
in	O
six	O
cases	O
and	O
regional	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
in	O
eight	O
.	O
Mutation	O
in	O
codon	O
12	O
of	O
the	O
k-ras	O
gene	O
was	O
detected	O
in	O
only	O
4	O
of	O
12	O
cases	O
studied	O
and	O
p53	O
mutation	O
in	O
2	O
of	O
9	O
.	O
Immunohistochemical	O
and	O
histochemical	O
mucin	O
stains	O
suggested	O
luminalization	O
of	O
the	O
basal	O
aspects	O
of	O
the	O
cells	O
.	O
Five	O
-	O
year	O
survival	O
was	O
57	O
%	O
.	O
At	O
an	O
overall	O
mean	O
follow	O
up	O
of	O
57	O
months	O
,	O
10	O
patients	O
were	O
alive	O
with	O
no	O
evidence	O
of	O
disease	O
(	O
median	O
,	O
79	O
mos	O
)	O
,	O
including	O
four	O
with	O
lymph	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
,	O
three	O
others	O
with	O
perineurial	O
invasion	O
,	O
and	O
another	O
with	O
vascular	O
invasion	O
.	O
Four	O
patients	O
died	O
of	O
disease	O
(	O
18	O
,	O
18	O
,	O
25	O
,	O
and	O
26	O
mos	O
)	O
,	O
and	O
three	O
died	O
of	O
thromboembolism	O
(	O
with	O
persistent	O
disease	O
)	O
at	O
2	O
,	O
5	O
,	O
10	O
months	O
.	O
All	O
seven	O
patients	O
who	O
died	O
with	O
or	O
of	O
tumor	B-malignancy-type
had	O
undergone	O
incisional	O
biopsy	O
of	O
the	B-malignancy-type
tumor	I-malignancy-type
either	O
before	O
the	O
operation	O
or	O
intraoperatively	O
,	O
whereas	O
none	O
of	O
the	O
patients	O
who	O
were	O
alive	O
had	O
incisional	O
biopsy	O
.	O
When	O
compared	O
with	O
82	O
cases	O
of	O
resectable	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
on	O
whom	O
follow-up	O
and	O
staging	O
information	O
was	O
complete	O
,	O
it	O
was	O
found	O
that	O
the	O
patients	O
with	O
CC	B-malignancy-type
present	O
with	O
larger	O
tumors	B-malignancy-type
(	O
p	O
=	O
0.03	O
)	O
but	O
lower	O
stage	O
(	O
p	O
=	O
0.01	O
)	O
.	O
The	O
prognosis	O
of	O
CC	B-malignancy-type
is	O
significantly	O
better	O
:	O
2	O
-	O
year	O
and	O
5	O
-	O
year	O
survival	O
are	O
70	O
%	O
versus	O
28	O
%	O
and	O
57	O
%	O
versus	O
12	O
%	O
,	O
respectively	O
(	O
p	O
=	O
0.001	O
)	O
.	O
In	O
conclusion	O
,	O
pancreatic	B-malignancy-type
CC	I-malignancy-type
may	O
occur	O
with	O
or	O
without	O
an	O
identifiable	O
IPMN	B-malignancy-type
and	O
MCN	B-malignancy-type
component	O
,	O
and	O
should	O
be	O
distinguished	O
from	O
mucinous	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
,	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
and	O
signet	B-malignancy-type
-	I-malignancy-type
ring	I-malignancy-type
cell	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
CC	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
is	O
associated	O
with	O
a	O
significantly	O
better	O
prognosis	O
than	O
ordinary	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
In	O
addition	O
to	O
its	O
distinctive	O
morphologic	O
and	O
clinical	O
characteristics	O
,	O
CC	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
also	O
appears	O
to	O
have	O
a	O
low	O
incidence	O
of	O
mutation	O
in	O
codon	O
12	O
of	O
the	O
k-ras	O
gene	O
.	O
In	O
cases	O
with	O
a	O
clinical	O
suspicion	O
of	O
colloid	B-malignancy-type
carcinoma	I-malignancy-type
,	O
the	O
possibility	O
that	O
an	O
incisional	O
biopsy	O
may	O
contribute	O
to	O
thromboembolic	O
complications	O
or	O
even	O
dissemination	O
of	O
the	B-malignancy-type
tumor	I-malignancy-type
may	O
need	O
to	O
be	O
considered	O
.	O
The	O
luminalization	O
of	O
the	O
basal	O
aspects	O
of	O
the	B-malignancy-type
tumor	I-malignancy-type
cells	O
may	O
be	O
the	O
cause	O
of	O
stromal	O
mucin	O
accumulation	O
that	O
characterizes	O
colloid	B-malignancy-type
carcinoma	I-malignancy-type
and	O
may	O
act	O
as	O
a	O
containing	O
factor	O
.	O
PMID	O
:	O
11145249	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2001	O
Jan	O
-	O
Feb	O
;	O
8	O
(	O
1	O
)	O
:	O
89	O
-	O
92	O
Characterization	O
of	O
the	O
mutations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
p16	O
,	O
and	O
SMAD4	O
genes	O
in	O
15	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Sun	O
C	O
,	O
Yamato	O
T	O
,	O
Furukawa	O
T	O
,	O
Ohnishi	O
Y	O
,	O
Kijima	O
H	O
,	O
Horii	O
A	O
.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Aoba-ku	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
Human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
one	O
of	O
the	O
most	O
malignant	O
diseases	O
in	O
the	O
world	O
.	O
In	O
order	O
to	O
save	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
it	O
is	O
necessary	O
to	O
develop	O
novel	O
methods	O
for	O
treatment	O
.	O
For	O
such	O
a	O
purpose	O
,	O
a	O
series	O
of	O
well	O
-	O
characterized	O
cancer	O
cell	O
lines	O
are	O
of	O
great	O
help	O
for	O
in	O
vitro	O
studies	O
that	O
are	O
generally	O
the	O
first	O
step	O
in	O
approaching	O
the	O
invention	O
of	O
novel	O
methods	O
for	O
treatment	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
15	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
for	O
genetic	O
alterations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
p16	O
,	O
and	O
SMAD4	O
genes	O
,	O
which	O
are	O
very	O
frequent	O
targets	O
for	O
mutation	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
;	O
these	O
cell	O
lines	O
are	O
useful	O
resources	O
in	O
cancer	O
research	O
.	O
PMID	O
:	O
11115575	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Hematol	O
2000	O
Dec	O
;	O
65	O
(	O
4	O
)	O
:	O
307-9	O
Mast	B-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
associated	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
:	O
detection	O
of	O
a	O
new	O
c-kit	O
mutation	O
Asp	O
816	O
His	O
.	O
Pullarkat	O
VA	O
,	O
Pullarkat	O
ST	O
,	O
Calverley	O
DC	O
,	O
Brynes	O
RK	O
.	O
Division	O
of	O
Hematology	O
,	O
University	O
of	O
Southern	O
California	O
School	O
of	O
Medicine	O
,	O
Los	O
Angeles	O
,	O
California	O
90033-	O
0804	O
,	O
USA	O
.	O
vinodpullarkat@pol.net	O
Mast	B-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
(	O
MCD	B-malignancy-type
)	O
,	O
a	O
proliferation	O
of	O
mast	O
cells	O
(	O
MC	O
)	O
,	O
is	O
occasionally	O
associated	O
with	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
Neoplastic	O
MC	B-malignancy-type
have	O
activating	O
c-kit	O
mutations	O
.	O
c-kit	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
required	O
for	O
the	O
development	O
,	O
proliferation	O
,	O
and	O
survival	O
of	O
MC	O
.	O
Interaction	O
of	O
c-kit	O
with	O
its	O
ligand	O
stem	O
cell	O
factor	O
induces	O
dimerization	O
,	O
receptor	O
phosphorylation	O
,	O
and	O
signal	O
transduction	O
.	O
The	O
most	O
common	O
c-kit	O
mutation	O
detected	O
in	O
neoplastic	O
MCD	B-malignancy-type
is	O
Asp	O
816	O
Val	O
,	O
which	O
results	O
in	O
ligand	O
-	O
independent	O
autophosphorylation	O
of	O
the	O
receptor	O
leading	O
to	O
MC	O
proliferation	O
.	O
We	O
describe	O
the	O
rare	O
occurrence	O
of	O
MCD	B-malignancy-type
associated	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
report	O
a	O
novel	O
c-kit	O
mutation	O
Asp	O
816	O
His	O
,	O
and	O
discuss	O
the	O
pathogenesis	O
of	O
MCD	B-malignancy-type
associated	O
with	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11074560	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2000	O
Oct	O
;	O
9	O
(	O
10	O
)	O
:	O
1027-35	O
Molecular	O
changes	O
in	O
second	B-malignancy-type
primary	I-malignancy-type
lung	I-malignancy-type
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
after	O
therapy	O
for	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
.	O
Behrens	O
C	O
,	O
Travis	O
LB	O
,	O
Wistuba	O
II	O
,	O
Davis	O
S	O
,	O
Maitra	O
A	O
,	O
Clarke	O
EA	O
,	O
Lynch	O
CF	O
,	O
Glimelius	O
B	O
,	O
Wiklund	O
T	O
,	O
Tarone	O
R	O
,	O
Gazdar	O
AF	O
.	O
Hamon	O
Center	O
for	O
Therapeutic	O
Oncology	O
Research	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75390-8593	O
,	O
USA	O
.	O
The	O
risk	O
of	O
lung	B-malignancy-type
and	O
breast	B-malignancy-type
cancer	I-malignancy-type
is	O
significantly	O
increased	O
after	O
therapy	O
for	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
(	O
HD	B-malignancy-type
)	O
,	O
but	O
there	O
are	O
few	O
data	O
that	O
describe	O
the	O
molecular	O
profiles	O
of	O
these	O
tumors	O
.	O
We	O
investigated	O
the	O
genetic	O
abnormalities	O
in	O
second	O
primary	O
lung	B-malignancy-type
(	O
n	O
=	O
19	O
)	O
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
(	O
n	O
=	O
19	O
)	O
that	O
follow	O
therapy	O
for	O
HD	B-malignancy-type
(	O
"	O
post	B-malignancy-type
-	I-malignancy-type
HD	I-malignancy-type
cancers	I-malignancy-type
"	O
)	O
and	O
compared	O
these	O
with	O
changes	O
observed	O
in	O
corresponding	O
tumor	O
types	O
(	O
57	O
lung	B-malignancy-type
and	O
20	O
breast	B-malignancy-type
cancers	I-malignancy-type
)	O
arising	O
in	O
the	O
general	O
population	O
(	O
"	O
sporadic	O
cancers	O
"	O
)	O
.	O
DNA	O
obtained	O
from	O
archival	O
tissues	O
was	O
examined	O
using	O
PCR	O
-	O
based	O
analyses	O
for	O
loss	O
of	O
heterozygosity	O
and	O
microsatellite	O
alterations	O
(	O
MAs	O
)	O
at	O
several	O
chromosomal	O
regions	O
,	O
TP53	O
and	O
K-ras	O
gene	O
mutations	O
,	O
and	O
frameshift	O
mutations	O
at	O
minisatellite	O
sequences	O
at	O
the	O
coding	O
regions	O
of	O
several	O
genes	O
(	O
TGF-betaRII	O
,	O
IGFIIR	O
,	O
BAX	O
,	O
hMSH6	O
,	O
and	O
hMSH3	O
)	O
.	O
The	O
occurrence	O
of	O
loss	O
of	O
heterozygosity	O
at	O
all	O
chromosomal	O
regions	O
taken	O
together	O
and	O
frequencies	O
at	O
most	O
individual	O
areas	O
were	O
similar	O
for	O
the	O
post	O
-	O
HD	O
and	O
sporadic	O
cancers	O
for	O
both	O
lung	B-malignancy-type
and	O
breast	B-malignancy-type
sites	O
.	O
The	O
overall	O
frequency	O
of	O
MAs	O
in	O
the	O
post	B-malignancy-type
-	I-malignancy-type
HD	I-malignancy-type
tumors	I-malignancy-type
was	O
substantially	O
greater	O
(	O
lung	O
,	O
2.4	O
-	O
fold	O
,	O
P	O
=	O
0.004	O
;	O
breast	O
,	O
4.2	O
-	O
fold	O
,	O
P	O
=	O
0.16	O
)	O
than	O
that	O
in	O
the	O
respective	O
sporadic	O
cancers	O
.	O
No	O
differences	O
in	O
the	O
pattern	O
of	O
TP53	O
and	O
K-ras	O
mutations	O
were	O
detected	O
between	O
post	O
-	O
HD	O
and	O
sporadic	O
cancers	O
.	O
No	O
mutations	O
were	O
detected	O
at	O
the	O
minisatellite	O
sequences	O
examined	O
.	O
MAs	O
,	O
which	O
reflect	O
widespread	O
genomic	O
instability	O
,	O
occur	O
at	O
greatly	O
increased	O
frequency	O
in	O
post	O
-	O
HD	O
lung	B-malignancy-type
and	O
breast	B-malignancy-type
cancers	I-malignancy-type
.	O
Although	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
increased	O
MAs	O
are	O
unknown	O
,	O
they	O
have	O
been	O
associated	O
with	O
immunosuppression	O
and	O
radiation	O
exposure	O
.	O
Future	O
research	O
should	O
address	O
the	O
role	O
that	O
MAs	O
,	O
as	O
well	O
as	O
other	O
influences	O
,	O
may	O
play	O
in	O
the	O
development	O
of	O
neoplasias	O
that	O
occur	O
after	O
therapy	O
for	O
HD	B-malignancy-type
.	O
PMID	O
:	O
11045784	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Pathol	O
2000	O
Aug	O
;	O
53	O
(	O
4	O
)	O
:	O
188	O
-	O
93	O
Detection	O
of	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
in	O
microdissected	O
bone	O
marrow	O
infiltrates	O
in	O
a	O
case	O
of	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
associated	O
with	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukaemia	I-malignancy-type
.	O
Sotlar	O
K	O
,	O
Marafioti	O
T	O
,	O
Griesser	O
H	O
,	O
Theil	O
J	O
,	O
Aepinus	O
C	O
,	O
Jaussi	O
R	O
,	O
Stein	O
H	O
,	O
Valent	O
P	O
,	O
Horny	O
HP	O
.	O
Institute	O
of	O
Pathology	O
,	O
University	O
Hospital	O
Tubingen	O
,	O
Germany	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
The	O
occurrence	O
of	O
myeloid	B-malignancy-type
leukaemia	I-malignancy-type
in	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
is	O
a	O
well	O
recognised	O
phenomenon	O
.	O
However	O
,	O
the	O
pathophysiological	O
basis	O
of	O
such	O
a	O
coevolution	O
has	O
not	O
been	O
clarified	O
.	O
Recent	O
data	O
have	O
shown	O
that	O
the	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
is	O
detectable	O
in	O
neoplastic	O
mast	O
cells	O
in	O
most	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
including	O
those	O
who	O
have	O
associated	O
haematological	O
disorders	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
study	O
clonal	O
disease	O
evolution	O
by	O
analysing	O
bone	O
marrow	O
cells	O
from	O
a	O
patient	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
associated	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukaemia	I-malignancy-type
(	O
CMML	B-malignancy-type
)	O
for	O
the	O
presence	O
of	O
this	O
mutation	O
.	O
METHODS	O
:	O
The	O
DNA	O
of	O
microdissected	O
bone	O
marrow	O
cells	O
from	O
a	O
patient	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
associated	O
CMML	B-malignancy-type
was	O
analysed	O
for	O
the	O
presence	O
of	O
the	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
by	O
means	O
of	O
HinfI	O
digestion	O
and	O
direct	O
sequencing	O
of	O
semi	O
-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
.	O
RESULTS	O
:	O
The	O
two	O
neoplasms	O
could	O
easily	O
be	O
identified	O
and	O
discriminated	O
in	O
paraffin	O
wax	O
embedded	O
bone	O
marrow	O
sections	O
by	O
tryptase	O
and	O
chloroacetate	O
esterase	O
staining	O
.	O
A	O
total	O
number	O
of	O
10	O
tryptase	O
positive	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
infiltrates	O
and	O
10	O
tryptase	O
negative	O
CMML	B-malignancy-type
infiltrates	O
were	O
removed	O
by	O
microdissection	O
.	O
As	O
assessed	O
by	O
HinfI	O
digestion	O
and	O
direct	O
sequencing	O
of	O
semi	O
-	O
nested	O
PCR	O
products	O
,	O
the	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
was	O
detected	O
in	O
five	O
of	O
seven	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
infiltrates	O
and	O
four	O
of	O
six	O
CMML	B-malignancy-type
infiltrates	O
.	O
By	O
contrast	O
,	O
no	O
c-kit	O
mutation	O
Asp	O
816	O
to	O
Val	O
was	O
found	O
in	O
bone	O
marrow	O
infiltrates	O
in	O
patients	O
with	O
CMML	B-malignancy-type
without	O
associated	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
n	O
=	O
20	O
)	O
.	O
CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
monoclonal	O
evolution	O
of	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
concurrent	O
CMML	B-malignancy-type
in	O
the	O
patient	O
studied	O
.	O
PMID	O
:	O
11040941	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2000	O
Oct	O
16	O
;	O
159	O
(	O
1	O
)	O
:	O
73	O
-	O
8	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
as	O
an	O
early	O
event	O
in	O
colorectal	O
tumorigenesis	O
.	O
Murata	O
M	O
,	O
Iwao	O
K	O
,	O
Miyoshi	O
Y	O
,	O
Nagasawa	O
Y	O
,	O
Yabu	O
M	O
,	O
Himeno	O
S	O
,	O
Imanishi	O
K	O
,	O
Ohsawa	O
M	O
,	O
Wada	O
H	O
,	O
Tominaga	O
S	O
,	O
Shimano	O
T	O
,	O
Kobayashi	O
T	O
,	O
Nakamura	O
Y	O
.	O
Department	O
of	O
Surgery	O
,	O
Ikeda	O
Municipal	O
Hospital	O
,	O
3-1-18	O
Jyonan	O
,	O
Ikeda-shi	O
,	O
563-8510	O
,	O
Osaka	O
,	O
Japan	O
.	O
muratamasaru@mth.biglobe.ne.jp	O
beta-Catenin	O
has	O
been	O
identified	O
as	O
an	O
oncogene	O
in	O
several	O
tumors	O
including	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
beta-Catenin	O
gene	O
is	O
activated	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
in	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
of	O
Japanese	O
population	O
,	O
in	O
contrast	O
to	O
amino	O
acid	O
substitutions	O
detected	O
among	O
Caucasian	O
population	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
type	O
and	O
frequency	O
of	O
beta-catenin	O
gene	O
mutation	O
during	O
early	O
stages	O
of	O
colorectal	O
tumorigenesis	O
.	O
We	O
screened	O
100	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
for	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
,	O
as	O
well	O
as	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O
In	O
cases	O
with	O
mutations	O
,	O
sequencing	O
analyses	O
and	O
immunohistochemical	O
staining	O
were	O
also	O
performed	O
.	O
Somatic	O
interstitial	O
deletions	O
of	O
272	O
-	O
413	O
bp	O
,	O
each	O
of	O
which	O
included	O
all	O
parts	O
of	O
exon	O
3	O
,	O
were	O
detected	O
in	O
three	O
tumors	O
.	O
However	O
,	O
no	O
adenoma	B-malignancy-type
carried	O
missense	O
mutations	O
.	O
We	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
cytoplasm	O
and	O
nuclei	O
of	O
adenoma	B-malignancy-type
cells	O
by	O
immunohistochemical	O
analysis	O
.	O
Our	O
results	O
suggested	O
that	O
activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
might	O
be	O
less	O
frequent	O
compared	O
with	O
frequent	O
alterations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
,	O
but	O
could	O
be	O
an	O
early	O
event	O
in	O
colorectal	O
tumorigenesis	O
equivalent	O
to	O
APC	O
gene	O
alterations	O
in	O
the	O
Japanese	O
population	O
.	O
PMID	O
:	O
10974408	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gynecol	O
Oncol	O
2000	O
Apr	O
;	O
77	O
(	O
1	O
)	O
:	O
105-11	O
ras	O
gene	O
activation	O
and	O
infrequent	O
mutation	O
in	O
papillary	B-malignancy-type
serous	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
peritoneum	I-malignancy-type
.	O
.	O
.	O
OBJECTIVE	O
:	O
The	O
ras	O
genes	O
are	O
a	O
well	O
-	O
studied	O
family	O
of	O
proto	O
-	O
oncogenes	O
whose	O
involvement	O
in	O
many	O
cancers	O
has	O
been	O
delineated	O
.	O
However	O
,	O
K-ras	O
mutations	O
have	O
not	O
previously	O
been	O
examined	O
in	O
papillary	B-malignancy-type
serous	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
peritoneum	I-malignancy-type
(	O
PSCP	B-malignancy-type
)	O
,	O
a	O
tumor	B-malignancy-type
which	O
resembles	O
serous	B-malignancy-type
epithelial	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
(	O
SEOC	B-malignancy-type
)	O
both	O
in	O
histology	O
and	O
epidemiology	O
.	O
In	O
this	O
study	O
we	O
examine	O
the	O
role	O
of	O
the	O
K-ras	O
oncogene	O
in	O
PSCP	B-malignancy-type
compared	O
to	O
SEOC	B-malignancy-type
.	O
METHODS	O
:	O
Using	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
cycle	O
sequencing	O
protocols	O
,	O
we	O
evaluated	O
our	O
collection	O
of	O
51	O
cases	O
of	O
PSCP	B-malignancy-type
for	O
K-ras	O
mutations	O
and	O
compared	O
these	O
findings	O
with	O
the	O
experience	O
in	O
SEOC	B-malignancy-type
.	O
We	O
then	O
examined	O
5	O
cases	O
of	O
PSCP	B-malignancy-type
for	O
activation	O
of	O
ras	O
proteins	O
and	O
MAP	O
kinase	O
to	O
evaluate	O
the	O
potential	O
involvement	O
of	O
the	O
ras	O
pathway	O
in	O
PSCP	B-malignancy-type
tumorigenesis	O
.	O
RESULTS	O
:	O
We	O
found	O
only	O
one	O
K-ras	O
mutation	O
in	O
our	O
51	O
cases	O
(	O
2	O
%	O
)	O
of	O
PSCP	B-malignancy-type
compared	O
to	O
three	O
mutations	O
in	O
46	O
cases	O
(	O
6.5	O
%	O
)	O
of	O
high	O
-	O
grade	O
,	O
late	O
-	O
stage	O
SEOC	B-malignancy-type
.	O
This	O
was	O
not	O
significantly	O
different	O
(	O
P	O
>	O
0.10	O
)	O
.	O
In	O
the	O
single	O
PSCP	B-malignancy-type
case	O
with	O
a	O
K-ras	O
mutation	O
,	O
the	O
mutation	O
was	O
found	O
in	O
only	O
one	O
of	O
five	O
tumor	B-malignancy-type
sites	O
tested	O
.	O
All	O
four	O
mutations	O
involved	O
a	O
single	O
nucleotide	O
alteration	O
in	O
codon	O
12	O
(	O
GGT	O
to	O
GTT	O
,	O
Gly	O
to	O
Val	O
)	O
.	O
To	O
evaluate	O
the	O
ras	O
pathway	O
in	O
PSCP	B-malignancy-type
,	O
we	O
used	O
the	O
known	O
activated	O
ras	O
binding	O
domain	O
on	O
Raf-1	O
to	O
perform	O
an	O
assay	O
to	O
test	O
for	O
activated	O
ras	O
.	O
We	O
identified	O
ras	O
activation	O
in	O
4	O
of	O
5	O
PSCP	B-malignancy-type
cases	O
tested	O
and	O
,	O
to	O
confirm	O
that	O
the	O
activation	O
was	O
functional	O
,	O
we	O
tested	O
and	O
found	O
similar	O
activation	O
of	O
MAP	O
kinase	O
,	O
a	O
downstream	O
mediator	O
for	O
K-ras	O
expression	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
mutations	O
occur	O
at	O
low	O
rates	O
in	O
both	O
PSCP	B-malignancy-type
and	O
high	O
-	O
grade	O
,	O
late	O
-	O
stage	O
SEOC	B-malignancy-type
,	O
and	O
therefore	O
K-ras	O
mutations	O
are	O
not	O
involved	O
in	O
the	O
development	O
of	O
these	O
two	O
diseases	O
.	O
Finding	O
the	O
mutation	O
in	O
only	O
one	O
of	O
multiple	O
tumor	B-malignancy-type
sites	O
in	O
the	O
PSCP	B-malignancy-type
case	O
supports	O
growing	O
evidence	O
for	O
a	O
multifocal	O
origin	O
of	O
PSCP	B-malignancy-type
.	O
Our	O
findings	O
of	O
ras	O
activation	O
in	O
four	O
of	O
five	O
cases	O
of	O
PSCP	B-malignancy-type
suggest	O
that	O
ras	O
activation	O
by	O
mechanisms	O
other	O
than	O
genetic	O
mutation	O
is	O
important	O
for	O
PSCP	B-malignancy-type
tumorigenesis	O
.	O
Copyright	O
2000	O
Academic	O
Press	O
.	O

Cancer	O
Res	O
2000	O
Feb	O
1	O
;	O
60	O
(	O
3	O
)	O
:	O
522-4	O
High	O
frequency	O
of	O
K-ras	O
mutations	O
in	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
of	O
cases	O
with	O
a	O
long	O
common	O
channel	O
in	O
the	O
papilla	O
of	O
Vater	O
.	O
Hidaka	O
E	O
,	O
Yanagisawa	O
A	O
,	O
Seki	O
M	O
,	O
Takano	O
K	O
,	O
Setoguchi	O
T	O
,	O
Kato	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Cancer	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
frequency	O
of	O
K-ras	O
mutation	O
in	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
in	O
different	O
locations	O
and	O
the	O
relationship	O
to	O
the	O
form	O
of	O
the	O
junction	O
of	O
the	O
pancreaticobiliary	O
duct	O
(	O
JPBD	O
)	O
are	O
not	O
understood	O
clearly	O
.	O
These	O
points	O
were	O
investigated	O
in	O
the	O
present	O
study	O
.	O
Thirty-seven	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
in	O
patients	O
without	O
anomalous	O
JPBD	O
were	O
investigated	O
for	O
K-ras	O
mutations	O
.	O
Regarding	O
location	O
,	O
12	O
were	O
hilar	O
,	O
4	O
in	O
the	O
upper	O
,	O
11	O
in	O
the	O
middle	O
,	O
and	O
10	O
in	O
the	O
lower	O
portion	O
of	O
the	O
duct	O
.	O
Furthermore	O
,	O
with	O
14	O
cases	O
for	O
which	O
the	O
form	O
of	O
the	O
JPBD	O
could	O
be	O
confirmed	O
by	O
endoscopic	O
retrograde	O
cholangiopancreatography	O
or	O
postoperative	O
cholangiopancreatography	O
,	O
division	O
was	O
made	O
into	O
two	O
types	O
:	O
those	O
with	O
a	O
long	O
common	O
channel	O
(	O
>	O
5	O
mm	O
)	O
in	O
the	O
papilla	O
of	O
Vater	O
(	O
type	O
1	O
,	O
n	O
=	O
4	O
)	O
,	O
and	O
the	O
other	O
with	O
a	O
shorter	O
or	O
nonapparent	O
common	O
channel	O
(	O
type	O
2	O
,	O
n	O
=	O
10	O
)	O
.	O
The	O
overall	O
frequency	O
of	O
K-ras	O
mutation	O
was	O
30	O
%	O
,	O
the	O
incidence	O
gradually	O
increasing	O
from	O
upper	O
to	O
lower	O
regions	O
.	O
K-ras	O
mutations	O
were	O
significantly	O
more	O
frequent	O
in	O
biliary	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
long	O
common	O
channels	O
(	O
P	O
<	O
0.05	O
)	O
.	O
These	O
results	O
suggest	O
that	O
a	O
long	O
common	O
channel	O
may	O
bear	O
a	O
relation	O
to	O
K-ras	O
mutations	O
in	O
biliary	O
duct	O
carcinogenesis	O
,	O
presumably	O
through	O
its	O
influence	O
on	O
pancreatic	O
juice	O
regurgitation	O
.	O
PMID	O
:	O
10676628	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
2000	O
Feb	O
;	O
14	O
2	O
)	O
:	O
312-5	O
Rapid	O
and	O
reliable	O
detection	O
of	O
N-ras	O
mutations	O
in	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
by	O
melting	O
curve	O
analysis	O
using	O
LightCycler	O
technology	O
.	O
Nakao	O
M	O
,	O
Janssen	O
JW	O
,	O
Seriu	O
T	O
,	O
Bartram	O
CR	O
.	O
Institute	O
of	O
Human	O
Genetics	O
,	O
University	O
of	O
Heidelberg	O
,	O
Germany	O
.	O
We	O
applied	O
a	O
new	O
strategy	O
for	O
the	O
detection	O
of	O
N-ras	O
gene	O
mutations	O
based	O
on	O
LightCycler	O
technology	O
.	O
We	O
designed	O
two	O
sets	O
of	O
amplimers	O
and	O
internal	O
hybridization	O
probes	O
representing	O
N-ras	O
codons	O
12	O
/	O
13	O
and	O
codon	O
61	O
,	O
respectively	O
.	O
Genomic	O
DNAs	O
from	O
134	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
patients	O
(	O
83	O
common	O
ALL	B-malignancy-type
,	O
nine	O
pre	B-malignancy-type
-	I-malignancy-type
pre	I-malignancy-type
-	I-malignancy-type
B	I-malignancy-type
ALL	I-malignancy-type
,	O
19	O
pre	B-malignancy-type
-	I-malignancy-type
B	I-malignancy-type
ALL	I-malignancy-type
,	O
23	O
T	B-malignancy-type
-	I-malignancy-type
ALL	I-malignancy-type
)	O
were	O
amplified	O
,	O
followed	O
by	O
the	O
analysis	O
of	O
the	O
melting	O
temperatures	O
of	O
the	O
PCR	O
products	O
on	O
the	O
LightCycler	O
.	O
PCR	O
products	O
exhibiting	O
an	O
abnormal	O
melting	O
characteristic	O
were	O
directly	O
sequenced	O
.	O
Sequence	O
analyses	O
unravelled	O
nucleotide	O
substitutions	O
at	O
codon	O
12	O
in	O
10	O
patients	O
,	O
at	O
codon	O
13	O
in	O
three	O
,	O
and	O
at	O
codon	O
61	O
in	O
one	O
case	O
.	O
The	O
incidence	O
of	O
N-ras	O
mutations	O
(	O
10	O
%	O
)	O
is	O
compatible	O
with	O
previous	O
reports	O
.	O
The	O
LightCycler	O
technology	O
facilitates	O
the	O
rapid	O
analysis	O
of	O
other	O
genes	O
exhibiting	O
hot	O
spot	O
mutations	O
in	O
human	O
malignancies	O
.	O
PMID	O
:	O
10673750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Endocrinol	O
Invest	O
1999	O
Nov	O
;	O
22	O
(	O
10	O
)	O
:	O
781-9	O
Ras	O
mutations	O
are	O
uncommon	O
in	O
sporadic	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
in	O
children	O
and	O
young	O
adults	O
.	O
Fenton	O
C	O
,	O
Anderson	O
J	O
,	O
Lukes	O
Y	O
,	O
Dinauer	O
CA	O
,	O
Tuttle	O
RM	O
,	O
Francis	O
GL	O
.	O
Department	O
of	O
Pediatrics	O
,	O
F	O
.	O
Edward	O
Hebert	O
School	O
of	O
Medicine	O
,	O
Uniformed	O
Services	O
University	O
of	O
the	O
Health	O
Sciences	O
,	O
Bethesda	O
,	O
MD	O
20814	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
ras	O
genes	O
(	O
H-ras	O
,	O
K-ras	O
,	O
and	O
N-ras	O
)	O
occur	O
in	O
10	O
-	O
15	O
%	O
of	O
all	O
human	O
cancers	O
,	O
and	O
commonly	O
arise	O
from	O
single	O
base	O
substitutions	O
at	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
Although	O
ras	O
mutations	O
have	O
been	O
found	O
in	O
adult	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
,	O
they	O
were	O
absent	O
from	O
the	O
two	O
studies	O
which	O
examined	O
childhood	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
.	O
Both	O
studies	O
included	O
only	O
children	O
with	O
radiation	O
induced	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
it	O
remains	O
unclear	O
if	O
ras	O
mutations	O
occur	O
in	O
children	O
without	O
radiation	O
exposure	O
.	O
To	O
answer	O
this	O
question	O
,	O
we	O
examined	O
archival	O
tissue	O
blocks	O
from	O
31	O
children	O
with	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
(	O
PTC	B-malignancy-type
)	O
4	O
with	O
follicular	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
(	O
FTC	B-malignancy-type
)	O
,	O
2	O
with	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
(	O
MTC	B-malignancy-type
)	O
,	O
and	O
1	O
with	O
lymphoma	B-malignancy-type
(	O
LYM	B-malignancy-type
)	O
.	O
Only	O
1	O
patient	O
with	O
PTC	B-malignancy-type
had	O
previous	O
radiation	O
exposure	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
and	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
ras	O
genes	O
.	O
The	O
PCR	O
products	O
were	O
analyzed	O
by	O
oligospecific	O
hybridization	O
for	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
.	O
Two	O
of	O
the	O
PTCs	B-malignancy-type
(	O
6.5	O
%	O
)	O
contained	O
ras	O
mutations	O
.	O
Both	O
patients	O
had	O
class	O
II	O
disease	O
and	O
no	O
history	O
of	O
previous	O
radiation	O
exposure	O
.	O
One	O
patient	O
subsequently	O
developed	O
bone	O
and	O
lung	O
metastases	O
.	O
The	O
patient	O
with	O
lymphoma	B-malignancy-type
also	O
had	O
a	O
ras	O
mutation	O
(	O
N	O
-	O
61	O
)	O
,	O
but	O
ras	O
mutations	O
were	O
absent	O
from	O
all	O
FTC	B-malignancy-type
and	O
MTC	B-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
ras	O
mutations	O
are	O
uncommon	O
in	O
spontaneous	O
childhood	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
occur	O
with	O
a	O
frequency	O
similar	O
to	O
that	O
found	O
in	O
previous	O
reports	O
of	O
adult	O
differentiated	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
number	O
of	O
subjects	O
was	O
too	O
small	O
to	O
determine	O
if	O
ras	O
mutations	O
are	O
more	O
common	O
in	O
patients	O
with	O
aggressive	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10614528	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1999	O
Sep	O
1	O
;	O
59	O
(	O
17	O
)	O
:	O
4297-300	O
Effect	O
of	O
c-kit	O
mutation	O
on	O
prognosis	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Taniguchi	O
M	O
,	O
Nishida	O
T	O
,	O
Hirota	O
S	O
,	O
Isozaki	O
K	O
,	O
Ito	O
T	O
,	O
Nomura	O
T	O
,	O
Matsuda	O
H	O
,	O
Kitamura	O
Y	O
.	O
Department	O
of	O
Surgery	O
I	O
,	O
Osaka	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Suita	O
,	O
Japan	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
is	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
.	O
Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
juxtamembrane	O
domain	O
of	O
the	O
c-kit	O
gene	O
have	O
been	O
found	O
in	O
several	O
GISTs	B-malignancy-type
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
correlation	O
between	O
the	O
presence	O
of	O
c-kit	O
mutation	O
and	O
prognosis	O
in	O
124	O
cases	O
of	O
GIST	B-malignancy-type
.	O
DNA	O
samples	O
were	O
extracted	O
from	O
paraffin	O
sections	O
.	O
Exon	O
11	O
of	O
the	O
c-kit	O
gene	O
encoding	O
the	O
juxtamembrane	O
domain	O
and	O
exon	O
17	O
encoding	O
the	O
kinase	O
domain	O
were	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
.	O
Most	O
GISTs	B-malignancy-type
(	O
89	O
%	O
)	O
express	O
the	O
KIT	O
protein	O
,	O
and	O
missense	O
mutations	O
of	O
exon	O
11	O
were	O
found	O
in	O
71	O
of	O
124	O
GISTs	B-malignancy-type
(	O
57	O
%	O
)	O
.	O
No	O
mutations	O
were	O
detectable	O
in	O
exon	O
17	O
.	O
These	O
71	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
were	O
larger	O
in	O
size	O
and	O
had	O
more	O
frequently	O
invaded	O
adjacent	O
tissues	O
than	O
did	O
the	O
53	O
mutation	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
GISTs	I-malignancy-type
.	O
Histologically	O
,	O
the	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
showed	O
higher	O
mitotic	O
figures	O
and	O
more	O
necrosis	O
and	O
hemorrhage	O
.	O
The	O
patients	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
showed	O
more	O
frequent	O
recurrences	O
(	O
P	O
=	O
0.0005	O
)	O
and	O
higher	O
mortality	O
(	O
P	O
=	O
0.0001	O
)	O
than	O
did	O
those	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
GISTs	I-malignancy-type
.	O
The	O
c-kit	O
mutation	O
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
overall	O
and	O
cause	O
-	O
specific	O
survival	O
of	O
the	O
patients	O
with	O
GISTs	B-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
GISTs	B-malignancy-type
may	O
be	O
divided	O
into	O
mutation	O
-	O
positive	O
and	O
-	O
negative	O
subtypes	O
.	O
The	O
prognosis	O
was	O
worse	O
in	O
patients	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
GISTs	I-malignancy-type
than	O
in	O
those	O
with	O
mutation	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
GISTs	I-malignancy-type
.	O
Thus	O
,	O
mutation	O
of	O
the	O
c-kit	O
gene	O
may	O
be	O
a	O
good	O
prognostic	O
marker	O
of	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
10485475	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
1999	O
Jun;154	O
(	O
6	O
)	O
:1643-7	O
Activating	O
c-kit	O
gene	O
mutations	O
in	O
human	O
germ	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
Tian	O
Q	O
,	O
Frierson	O
HF	O
Jr	O
,	O
Krystal	O
GW	O
,	O
Moskaluk	O
CA.	O
Departments	O
of	O
Pathology	O
,	O
University	O
of	O
Virginia	O
Health	O
Sciences	O
Center	O
,	O
Charlottesville	O
,	O
USA	O
.	O
The	O
c-kit	O
gene	O
encodes	O
a	O
tyrosine	O
kinase	O
receptor	O
(	O
KIT	O
)	O
that	O
is	O
required	O
in	O
normal	O
spermatogenesis	O
and	O
is	O
expressed	O
in	O
seminomas	B-malignancy-type
and	O
dysgerminomas	B-malignancy-type
,	O
a	O
subset	O
of	O
human	O
germ	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
(	O
GCTs	B-malignancy-type
)	O
.	O
To	O
determine	O
whether	O
activating	O
mutations	O
of	O
the	O
c-kit	O
gene	O
occur	O
in	O
GCTs	B-malignancy-type
,	O
primary	O
tissue	O
samples	O
of	O
33	O
testicular	B-malignancy-type
and	O
ovarian	B-malignancy-type
tumors	I-malignancy-type
were	O
examined	O
for	O
mutations	O
in	O
the	O
juxtamembrane	O
and	O
phosphotransferase	O
domains	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
DNA	O
sequencing	O
.	O
A	O
novel	O
missense	O
mutation	O
(	O
D	O
816	O
H	O
)	O
was	O
found	O
in	O
the	O
phosphotransferase	O
domain	O
in	O
tumors	B-malignancy-type
of	I-malignancy-type
seminoma	I-malignancy-type
/	O
dysgerminoma	B-malignancy-type
differentiation	O
.	O
The	O
c-kit	O
alleles	O
in	O
nonneoplastic	O
tissues	O
from	O
these	O
patients	O
were	O
wild	O
type	O
,	O
suggesting	O
that	O
the	O
mutant	O
alleles	O
were	O
acquired	O
and	O
selected	O
for	O
during	O
malignant	O
transformation	O
.	O
In	O
cell	O
transfection	O
experiments	O
,	O
the	O
D	O
816	O
H	O
mutant	O
protein	O
was	O
a	O
constitutively	O
activated	O
kinase	O
and	O
was	O
constitutively	O
phosphorylated	O
on	O
tyrosine	O
residues	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
an	O
activating	O
c-kit	O
mutation	O
in	O
GCTs	B-malignancy-type
and	O
is	O
evidence	O
that	O
the	O
KIT	O
signal	O
transduction	O
pathway	O
is	O
important	O
in	O
the	O
pathogenesis	O
of	O
neoplasms	O
with	O
seminoma	O
differentiation	O
.	O
PMID	O
:	O
10362788	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1999	O
May	O
;12(	O
5	O
)	O
:	O
518	O
-28	O
A	O
clinicopathologic	O
and	O
immunohistochemical	O
study	O
of	O
22	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
neoplasms	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
,	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O
Paal	O
E	O
,	O
Thompson	O
LD	O
,	O
Przygodzki	O
RM	O
,	O
Bratthauer	O
GL	O
,	O
Heffess	O
CS	O
.	O
American	O
Registry	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
,	O
USA	O
.	O
Intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
neoplasms	I-malignancy-type
(	I-malignancy-type
IPMNs	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
are	O
rare	O
lesions	O
.	O
We	O
undertook	O
this	O
study	O
to	O
analyze	O
these	O
tumors	O
by	O
focusing	O
on	O
the	O
diagnostic	O
criteria	O
and	O
correlating	O
the	O
histologic	O
features	O
with	O
clinical	O
prognosis	O
.	O
Twenty-two	O
cases	O
of	O
IPMN	B-malignancy-type
were	O
retrieved	O
from	O
the	O
Endocrine	B-malignancy-type
Tumor	I-malignancy-type
Registry	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
.	O
Blocks	O
or	O
unstained	O
slides	O
were	O
available	O
for	O
histochemical	O
and	O
immunohistochemical	O
studies	O
(	O
including	O
proliferative	O
markers	O
and	O
cell	O
cycle	O
regulators	O
)	O
and	O
K-ras	O
oncogene	O
mutations	O
in	O
15	O
cases	O
.	O
Patient	O
follow	O
-	O
up	O
was	O
obtained	O
in	O
all	O
of	O
the	O
cases	O
.	O
IPMN	B-malignancy-type
occurs	O
in	O
both	O
genders	O
with	O
a	O
slight	O
male	O
predominance	O
,	O
with	O
a	O
mean	O
age	O
at	O
presentation	O
of	O
64.4	O
years	O
(	O
range	O
,	O
48	O
-	O
85	O
yr	O
)	O
.	O
The	O
patients	O
presented	O
with	O
abdominal	O
pain	O
.	O
The	O
neoplasms	B-malignancy-type
were	O
radiologically	O
and	O
grossly	O
cystic	O
,	O
usually	O
(	O
18	O
cases	O
of	O
22	O
)	O
located	O
in	O
the	O
head	O
of	O
the	O
pancreas	O
.	O
Histologically	O
,	O
the	O
tumors	B-malignancy-type
consisted	O
of	O
intraductal	O
papillary	O
proliferations	O
protruding	O
into	O
and	O
expanding	O
the	O
pancreatic	O
ducts	O
.	O
Invasion	O
into	O
the	O
surrounding	O
pancreatic	O
parenchyma	O
was	O
detected	O
in	O
15	O
cases	O
.	O
Chronic	O
pancreatitis	O
was	O
present	O
in	O
all	O
of	O
the	O
cases	O
.	O
p27	O
immunoreactivity	O
always	O
exceeded	O
the	O
immunoreactivity	O
of	O
cyclin	O
E	O
.	O
K-ras	O
oncogene	O
mutations	O
were	O
detected	O
in	O
two	O
cases	O
.	O
Patients	O
were	O
treated	O
with	O
a	O
complete	O
surgical	O
resection	O
(	O
n	O
=	O
7	O
)	O
or	O
a	O
Whipple	O
procedure	O
(	O
n	O
=	O
13	O
)	O
.	O
Only	O
2	O
of	O
22	O
patients	O
died	O
of	O
disease	O
(	O
3	O
died	O
immediately	O
postoperatively	O
and	O
3	O
died	O
of	O
unrelated	O
causes	O
)	O
,	O
whereas	O
the	O
remaining	O
14	O
patients	O
were	O
alive	O
at	O
last	O
follow	O
-	O
up	O
,	O
without	O
evidence	O
of	O
disease	O
,	O
an	O
average	O
of	O
58.2	O
months	O
after	O
initial	O
presentation	O
.	O
IPMNs	B-malignancy-type
are	O
rare	O
,	O
distinctive	O
neoplasms	O
,	O
with	O
complex	O
intraductal	O
papillae	O
,	O
that	O
can	O
be	O
easily	O
separated	O
from	O
in	O
situ	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
mucinous	B-malignancy-type
cystic	I-malignancy-type
neoplasms	I-malignancy-type
.	O
The	O
high	O
ratio	O
of	O
p27	O
protein	O
to	O
cyclin	O
E	O
supports	O
the	O
excellent	O
prognosis	O
of	O
these	O
neoplasms	B-malignancy-type
,	O
despite	O
the	O
presence	O
of	O
invasion	O
and	O
K-ras	O
oncogene	O
mutation	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
Literature	O
PMID	O
:	O
10349991	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1999	O
Feb;17(	O
2	O
)	O
:	O
668	O
-	O
75	O
Prognostic	O
significance	O
of	O
K-ras	O
codon	O
12	O
mutations	O
in	O
patients	O
with	O
resected	O
stage	O
I	O
and	O
II	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
Graziano	O
SL	O
,	O
Gamble	O
GP	O
,	O
Newman	O
NB	O
,	O
Abbott	O
LZ	O
,	O
Rooney	O
M,	O
Mookherjee	O
S	O
,	O
Lamb	O
ML	O
,	O
Kohman	O
LJ	O
,	O
Poiesz	O
BJ.	O
Department	O
of	O
Medicine	O
,	O
State	O
University	O
of	O
New	O
York	O
Health	O
Science	O
Center	O
and	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
Syracuse	O
13210	O
,	O
USA	O
.	O
PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prognostic	O
importance	O
of	O
codon	O
12	O
K-ras	O
mutations	O
in	O
patients	O
with	O
early	O
-	O
stage	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
identified	O
260	O
patients	O
with	O
surgically	O
resected	O
stage	O
I	O
(	O
n	O
=	O
193	O
)	O
and	O
stage	O
II	O
(	O
n	O
=	O
67	O
)	O
NSCLC	B-malignancy-type
with	O
at	O
least	O
a	O
5	O
-	O
year	O
follow	O
-	O
up	O
.	O
We	O
performed	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
DNA	O
obtained	O
from	O
paraffin	O
-	O
embedded	O
NSCLC	B-malignancy-type
tissue	O
,	O
using	O
mutation	O
-	O
specific	O
probes	O
for	O
codon	O
12	O
K-ras	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
35	O
of	O
213	O
assessable	O
specimens	O
(	O
16.4	O
%	O
)	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
27	O
of	O
93	O
adenocarcinomas	B-malignancy-type
(	O
29.0	O
%	O
)	O
,	O
one	O
of	O
61	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
1.6	O
%	O
)	O
,	O
five	O
of	O
39	O
large	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
12.8	O
%	O
)	O
,	O
and	O
two	O
of	O
20	O
adenosquamous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
10	O
%	O
)	O
(	O
P	O
=	O
.001	O
)	O
.	O
G	O
to	O
T	O
transversions	O
accounted	O
for	O
71	O
%	O
of	O
the	O
mutations	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
overall	O
survival	O
for	O
all	O
patients	O
with	O
K-ras	O
mutations	O
(	O
median	O
survival	O
,	O
39	O
months	O
)	O
compared	O
with	O
patients	O
without	O
K-ras	O
mutations	O
(	O
median	O
survival	O
,	O
53	O
months	O
;	O
P	O
=	O
.33	O
)	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
overall	O
or	O
disease	O
-	O
free	O
survival	O
for	O
subgroups	O
with	O
stage	O
I	O
disease	O
,	O
adenocarcinoma	B-malignancy-type
,	O
or	O
non	B-malignancy-type
-	I-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
or	O
for	O
specific	O
amino	O
acid	O
substitutions	O
.	O
The	O
median	O
survival	O
time	O
for	O
stage	O
II	O
patients	O
with	O
K-ras	O
mutations	O
was	O
13	O
months	O
,	O
compared	O
with	O
38	O
months	O
for	O
patients	O
without	O
K-ras	O
mutations	O
(	O
P	O
=	O
.03	O
)	O
.	O
CONCLUSION	O
:	O
Codon	O
12	O
K-ras	O
mutations	O
were	O
more	O
common	O
in	O
adenocarcinomas	B-malignancy-type
than	O
in	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
For	O
the	O
subgroup	O
with	O
stage	O
II	O
NSCLC	B-malignancy-type
,	O
there	O
was	O
a	O
statistically	O
significant	O
adverse	O
effect	O
on	O
survival	O
for	O
the	O
presence	O
of	O
K-ras	O
mutations	O
.	O
However	O
,	O
when	O
the	O
entire	O
group	O
was	O
considered	O
,	O
the	O
presence	O
of	O
K-ras	O
mutations	O
was	O
not	O
of	O
prognostic	O
significance	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
resected	O
early	O
-	O
stage	O
NSCLC	B-malignancy-type
.	O
PMID	O
:	O
10080613	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Feb;154	O
(	O
2	O
)	O
:	O
32	O
5-9	O
Frequent	O
nuclear	O
/	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
without	O
exon	O
3	O
mutations	O
in	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
.	I-malignancy-type
Rimm	O
DL	O
,	O
Caca	O
K,	O
Hu	O
G	O
,	O
Harrison	O
FB	O
,	O
Fearon	O
ER	O
.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06510	O
,	O
USA	O
.	O
david	O
.rimm@yale	O
.edu	O
Beta-Catenin	O
has	O
a	O
critical	O
role	O
in	O
E-cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
,	O
and	O
it	O
also	O
functions	O
as	O
a	O
downstream	O
signaling	O
molecule	O
in	O
the	O
wnt	O
pathway	O
.	O
Mutations	O
in	O
the	O
putative	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
sites	O
near	O
the	O
beta-catenin	O
amino	O
terminus	O
have	O
been	O
found	O
in	O
some	O
cancers	O
and	O
cancer	O
cell	O
lines	O
.	O
The	O
mutations	O
render	O
beta-catenin	O
resistant	O
to	O
regulation	O
by	O
a	O
complex	O
containing	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
,	O
adenomatous	O
polyposis	O
coli	O
,	O
and	O
axin	O
proteins	O
.	O
As	O
a	O
result	O
,	O
beta-catenin	O
accumulates	O
in	O
the	O
cytosol	O
and	O
nucleus	O
and	O
activates	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancing	O
factor	O
transcription	O
factors	O
.	O
Previously	O
,	O
6	O
of	O
27	O
melanoma	B-malignancy-type
cell	O
lines	O
were	O
found	O
to	O
have	O
beta-catenin	O
exon	O
3	O
mutations	O
affecting	O
the	O
N	O
-	O
terminal	O
phosphorylation	O
sites	O
(	O
Rubinfeld	O
B	O
,	O
Robbins	O
P	O
,	O
Elgamil	O
M	O
,	O
Albert	O
I	O
,	O
Porfiri	O
E	O
,	O
Polakis	O
P	O
:	O
Stabilization	O
of	O
beta-catenin	O
by	O
genetic	O
defects	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Science	O
1997	O
,	O
275	O
:	O
1790	O
-	O
1792	O
)	O
.	O
To	O
assess	O
the	O
role	O
of	O
beta-catenin	O
defects	O
in	O
primary	B-malignancy-type
melanomas	I-malignancy-type
,	O
we	O
undertook	O
immunohistochemical	O
and	O
DNA	O
sequencing	O
studies	O
in	O
65	O
melanoma	B-malignancy-type
specimens	O
.	O
Nuclear	O
and/or	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
,	O
a	O
potential	O
indicator	O
of	O
wnt	O
pathway	O
activation	O
,	O
was	O
seen	O
focally	O
within	O
roughly	O
one	O
third	O
of	O
the	O
tumors	O
,	O
though	O
a	O
clonal	O
somatic	O
mutation	O
in	O
beta-catenin	O
was	O
found	O
in	O
only	O
one	O
case	O
(	O
codon	O
45	O
Ser	O
-->	O
Pro	O
)	O
.	O
Our	O
findings	O
demonstrate	O
that	O
beta-catenin	O
mutations	O
are	O
rare	O
in	O
primary	O
melanoma	B-malignancy-type
,	O
in	O
contrast	O
to	O
the	O
situation	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Nonetheless	O
,	O
activation	O
of	O
beta-catenin	O
,	O
as	O
indicated	O
by	O
its	O
nuclear	O
and/or	O
cytoplasmic	O
localization	O
,	O
appears	O
to	O
be	O
frequent	O
in	O
melanoma	B-malignancy-type
,	O
and	O
in	O
some	O
cases	O
,	O
it	O
may	O
reflect	O
focal	O
and	O
transient	O
activation	O
of	O
the	O
wnt	O
pathway	O
within	O
the	O
tumor	O
.	O
PMID	O
:	O
10027390	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Jun	O
15	O
;58	O
(	O
12	O
)	O
:2520-3	O
Beta-catenin	O
mutations	O
in	O
human	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Voeller	O
HJ	O
,	O
Truica	O
CI	O
,	O
Gelmann	O
EP	O
.	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Lombardi	O
Cancer	O
Center	O
,	O
Georgetown	O
University	O
School	O
of	O
Medicine	O
,	O
Washington	O
,	O
DC	O
20007	O
-	O
2197	O
,	O
USA	O
.	O
Beta-catenin	O
plays	O
essential	O
roles	O
in	O
both	O
intercellular	O
adhesion	O
and	O
signal	O
transduction	O
.	O
As	O
a	O
signaling	O
molecule	O
,	O
beta-catenin	O
supplies	O
an	O
activating	O
domain	O
to	O
the	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancer	O
-	O
binding	O
factor	O
family	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
activates	O
gene	O
transcription	O
.	O
Posttranslational	O
stabilization	O
of	O
beta-catenin	O
,	O
leading	O
to	O
elevated	O
protein	O
levels	O
and	O
constitutive	O
gene	O
activation	O
,	O
has	O
been	O
proposed	O
as	O
an	O
important	O
step	O
in	O
oncogenesis	O
.	O
Stabilization	O
of	O
beta-catenin	O
can	O
occur	O
through	O
mutation	O
to	O
highly	O
conserved	O
amino	O
acids	O
encoded	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
.	O
To	O
determine	O
whether	O
this	O
pathway	O
of	O
malignant	O
transformation	O
is	O
important	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
analyzed	O
104	O
prostate	B-malignancy-type
cancer	I-malignancy-type
tissue	O
specimens	O
,	O
4	O
prostate	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
and	O
3	O
prostate	O
tumor	O
xenografts	O
for	O
activating	O
mutations	O
in	O
exon	O
3	O
of	O
CTNNB1	O
.	O
Mutations	O
were	O
detected	O
in	O
5	O
of	O
the	O
104	O
prostate	B-malignancy-type
cancer	I-malignancy-type
tissue	O
samples	O
.	O
Four	O
of	O
the	O
five	O
mutations	O
involved	O
serine	O
or	O
threonine	O
residues	O
implicated	O
in	O
the	O
degradation	O
of	O
beta-catenin	O
.	O
A	O
fifth	O
tumor	B-malignancy-type
had	O
a	O
mutation	O
at	O
codon	O
32	O
,	O
changing	O
a	O
highly	O
conserved	O
aspartic	O
acid	O
to	O
a	O
tyrosine	O
.	O
Mutational	O
analysis	O
of	O
multiple	O
regions	O
from	O
several	O
tumor	O
samples	O
showed	O
that	O
the	O
beta-catenin	O
mutations	O
were	O
present	O
focally	O
and	O
therefore	O
may	O
occur	O
during	O
tumor	O
progression	O
.	O
PMID	O
:	O
9635571	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Apr	O
10	O
;126	O
(	O
1	O
)	O
:	O
59	O
-	O
65	O
K-ras	O
mutations	O
in	O
sinonasal	B-malignancy-type
adenocarcinomas	I-malignancy-type
in	O
patients	O
occupationally	O
exposed	O
to	O
wood	O
or	O
leather	O
dust	O
.	O
Saber	O
AT	O
,	O
Nielsen	O
LR	O
,	O
Dictor	O
M,	O
Hagmar	O
L,	O
Mikoczy	O
Z	O
,	O
Wallin	O
H.	O
National	O
Institute	O
of	O
Occupational	O
Health	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O
Of	O
39	O
males	O
diagnosed	O
with	O
sinonasal	B-malignancy-type
adenocarcinomas	I-malignancy-type
over	O
30	O
years	O
in	O
the	O
Lund	O
University	O
Hospital	O
catchment	O
area	O
(	O
1.5	O
million	O
inhabitants	O
)	O
,	O
archival	O
tumor	O
tissue	O
was	O
available	O
from	O
29	O
.	O
Of	O
these	O
,	O
16	O
had	O
been	O
exposed	O
to	O
wood	O
dust	O
and	O
three	O
had	O
been	O
exposed	O
to	O
leather	O
dust	O
.	O
The	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
and	O
papillary	B-malignancy-type
adenocarcinomas	I-malignancy-type
were	O
more	O
common	O
in	O
the	O
exposed	O
patients	O
(	O
P	O
=	O
0.0002	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
The	O
tumors	O
from	O
all	O
but	O
one	O
of	O
the	O
29	O
sinonasal	B-malignancy-type
adenocarcinomas	I-malignancy-type
could	O
be	O
analyzed	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
K-ras	O
gene	O
.	O
Four	O
mutations	O
were	O
detected	O
in	O
the	O
28	O
tumors	B-malignancy-type
.	O
The	O
three	O
mutations	O
in	O
the	O
patients	O
exposed	O
to	O
wood	O
and	O
leather	O
dust	O
were	O
all	O
G	O
:	O
C	O
-->	O
A	O
:	O
T	O
transitions	O
,	O
with	O
two	O
at	O
position	O
2	O
of	O
codon	O
12	O
and	O
one	O
at	O
position	O
2	O
of	O
codon	O
13	O
.	O
The	O
high	O
proportion	O
of	O
G	O
:	O
C	O
-->	O
A	O
:	O
T	O
mutations	O
in	O
this	O
rare	O
tumor	O
may	O
reflect	O
a	O
genotoxic	O
agent	O
in	O
wood	O
and	O
leather	O
dust	O
.	O
PMID	O
:	O
9563649	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
15	O
;58	O
(	O
6	O
)	O
:	O
1130	O
-4	O
Mutational	O
analysis	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Sparks	O
AB	O
,	O
Morin	O
PJ	O
,	O
Vogelstein	O
B	O
,	O
Kinzler	O
KW	O
.	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
Baltimore	O
,	O
Maryland	O
21231	O
,	O
USA	O
.	O
Mutation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
tumor	O
suppressor	O
gene	O
initiates	O
the	O
majority	O
of	O
colorectal	B-malignancy-type
(	I-malignancy-type
CR	I-malignancy-type
)	I-malignancy-type
cancers	I-malignancy-type
.	O
One	O
consequence	O
of	O
this	O
inactivation	O
is	O
constitutive	O
activation	O
of	O
beta-catenin	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
.	O
To	O
further	O
explore	O
the	O
role	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
CR	B-malignancy-type
tumorigenesis	O
,	O
we	O
searched	O
for	O
mutations	O
in	O
genes	O
implicated	O
in	O
this	O
pathway	O
in	O
CR	B-malignancy-type
tumors	I-malignancy-type
lacking	O
APC	O
mutations	O
.	O
No	O
mutations	O
of	O
the	O
gamma-catenin	O
(	O
CTNNG1	O
)	O
,	O
GSK-3alpha	O
(	O
GSK3A	O
)	O
,	O
or	O
GSK-3beta	O
(	O
GSK3B	O
)	O
genes	O
were	O
detected	O
.	O
In	O
contrast	O
,	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
domain	O
of	O
beta-catenin	O
(	O
CTNNB1	O
)	O
were	O
found	O
in	O
13	O
of	O
27	O
(	O
48	O
%	O
)	O
CR	O
tumors	O
lacking	O
APC	O
mutations	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
regulatory	O
domain	O
and	O
APC	O
were	O
observed	O
to	O
be	O
mutually	O
exclusive	O
,	O
consistent	O
with	O
their	O
equivalent	O
effects	O
on	O
beta-catenin	O
stability	O
and	O
Tcf	O
transactivation	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
CTNNB1	O
mutations	O
can	O
occur	O
in	O
the	O
early	O
,	O
adenomatous	O
stage	O
of	O
CR	B-malignancy-type
neoplasia	O
,	O
as	O
has	O
been	O
observed	O
previously	O
with	O
APC	O
mutations	O
.	O
These	O
results	O
suggest	O
that	O
CTNNB1	O
mutations	O
can	O
uniquely	O
substitute	O
for	O
APC	O
mutations	O
in	O
CR	B-malignancy-type
tumors	O
and	O
that	O
beta-catenin	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
CR	B-malignancy-type
tumorigenesis	O
.	O
PMID	O
:	O
9515795	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1998	O
Mar;77	O
(	O
5	O
)	O
:720-3	O
K-ras	O
point	O
mutation	O
occurs	O
in	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
Sagawa	O
M,	O
Saito	O
Y	O
,	O
Fujimura	O
S	O
,	O
Linnoila	O
RI.	O
Biomarkers	O
and	O
Prevention	O
Research	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Rockville	O
,	O
Maryland	O
20850	O
,	O
USA	O
.	O
In	O
order	O
to	O
determine	O
the	O
topographical	O
distribution	O
of	O
the	O
K-ras	O
codon	O
12	O
mutations	O
in	O
carcinoma	B-malignancy-type
and	O
preneoplastic	B-malignancy-type
lesions	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
,	O
selective	O
ultraviolet	O
radiation	O
fractionation	O
,	O
as	O
well	O
as	O
microdissection	O
followed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RELP	O
)	O
,	O
was	O
performed	O
.	O
Fourteen	O
of	O
61	O
samples	O
amplified	O
(	O
23.0	O
%	O
)	O
had	O
a	O
mutation	O
in	O
the	O
K-ras	O
codon	O
12	O
.	O
Of	O
41	O
adenocarcinoma	B-malignancy-type
,	O
12	O
samples	O
(	O
29.3	O
%	O
)	O
had	O
a	O
mutation	O
,	O
whereas	O
none	O
of	O
the	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
had	O
a	O
mutation	O
.	O
One	O
of	O
six	O
large	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
of	O
three	O
carcinoid	O
tumours	O
and	O
none	O
of	O
three	O
other	O
carcinomas	B-malignancy-type
had	O
a	O
mutation	O
.	O
Direct	O
sequencing	O
revealed	O
that	O
K-ras	O
codon	O
12	O
of	O
six	O
samples	O
were	O
TGT	O
(	O
Cys	O
)	O
,	O
five	O
samples	O
were	O
GTT	O
(	O
Val	O
)	O
,	O
two	O
samples	O
were	O
GCT	O
(	O
Ala	O
)	O
and	O
one	O
sample	O
was	O
TTT	O
(	O
Phe	O
)	O
.	O
A	O
total	O
of	O
113	O
lesions	B-malignancy-type
of	O
13	O
cases	O
covered	O
by	O
dot	O
were	O
amplified	O
after	O
UV	O
radiation	O
.	O
All	O
of	O
74	O
carcinoma	B-malignancy-type
lesions	O
had	O
the	O
mutation	O
,	O
and	O
intratumour	O
heterogeneity	O
was	O
not	O
observed	O
.	O
Of	O
39	O
non	B-malignancy-type
-	I-malignancy-type
malignant	I-malignancy-type
lesions	I-malignancy-type
,	O
one	O
type	O
II	O
cell	O
hyperplasia	O
had	O
the	O
mutation	O
,	O
which	O
suggests	O
that	O
the	O
K-ras	O
mutation	O
occurs	O
in	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
.	O
The	O
lack	O
of	O
intratumour	O
heterogeneity	O
supports	O
the	O
hypothesis	O
.	O
PMID	O
:	O
9514049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1997	O
Nov	O
14;73	O
(	O
4	O
)	O
:	O
492	O
-	O
6	O
Molecular	O
analysis	O
of	O
occupational	O
cancer	O
:	O
infrequent	O
p53	O
and	O
ras	O
mutations	O
in	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
in	O
workers	O
exposed	O
to	O
gasoline	O
.	O
Roth	O
S	O
,	O
Partanen	O
T	O
,	O
Suitiala	O
T	O
,	O
Anttila	O
S	O
,	O
Ojajarvi	O
A	O
,	O
Hemminki	O
K,	O
Vainio	O
H,	O
Husgafvel	O
-	O
Pursiainen	O
K.	O
Department	O
of	O
Epidemiology	O
and	O
Biostatistics	O
,	O
Finnish	O
Institute	O
of	O
Occupational	O
Health	O
,	O
Helsinki	O
.	O
Occupational	O
exposure	O
to	O
gasoline	O
has	O
been	O
identified	O
in	O
several	O
studies	O
as	O
a	O
risk	O
factor	O
for	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
.	O
Cases	O
of	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
with	O
and	O
without	O
work	O
-	O
related	O
exposure	O
to	O
gasoline	O
or	O
gasoline	O
and	O
diesel	O
fuel	O
were	O
studied	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
tumour	O
-	O
suppressor	O
gene	O
p53	O
(	O
n	O
=	O
23	O
exposed	O
and	O
30	O
non	O
-	O
exposed	O
cases	O
studied	O
)	O
and	O
ras	O
oncogene	O
(	O
n	O
=	O
30	O
exposed	O
and	O
36	O
non	O
-	O
exposed	O
cases	O
studied	O
)	O
.	O
An	O
average	O
cumulative	O
exposure	O
was	O
estimated	O
at	O
10	O
ppm	O
-	O
years	O
benzene	O
among	O
the	O
exposed	O
.	O
Three	O
p53	O
mutations	O
were	O
detected	O
by	O
denaturing	O
-	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
among	O
the	O
23	O
exposed	O
cases	O
(	O
3	O
/	O
23	O
,	O
13	O
%	O
)	O
.	O
Of	O
the	O
non	O
-	O
exposed	O
referent	O
cases	O
,	O
4	O
had	O
a	O
mutation	O
(	O
4	O
/	O
30	O
,	O
13	O
%	O
)	O
.	O
All	O
but	O
one	O
of	O
the	O
cases	O
with	O
a	O
p53	O
mutation	O
had	O
smoked	O
.	O
A	O
ras	O
gene	O
(	O
K-ras	O
or	O
N-ras	O
)	O
mutation	O
was	O
found	O
in	O
3	O
(	O
3	O
/	O
66	O
,	O
4.5	O
%	O
)	O
cases	O
,	O
all	O
of	O
whom	O
were	O
smoker	O
referents	O
.	O
We	O
conclude	O
that	O
p53	O
and	O
ras	O
mutations	O
are	O
infrequent	O
in	O
renal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
associated	O
with	O
occupational	O
exposure	O
to	O
gasoline	O
.	O
However	O
,	O
the	O
majority	O
of	O
the	O
mutations	O
(	O
6	O
/	O
7	O
for	O
p53	O
,	O
and	O
3	O
/	O
3	O
for	O
ras	O
genes	O
)	O
were	O
seen	O
in	O
smokers	O
.	O
PMID	O
:	O
9389561	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1997	O
Aug;21(	O
8	O
)	O
:69	O
7	O
-	O
701	O
Mutations	O
of	O
the	O
RAS	O
genes	O
in	O
childhood	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
juvenile	O
chronic	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Sheng	O
XM	O
,	O
Kawamura	O
M,	O
Ohnishi	O
H,	O
Ida	O
K,	O
Hanada	O
R	O
,	O
Kojima	O
S	O
,	O
Kobayashi	O
M,	O
Bessho	O
F	O
,	O
Yanagisawa	O
M,	O
Hayashi	O
Y	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
Using	O
the	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
method	O
and	O
direct	O
sequencing	O
,	O
12	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
cell	O
lines	O
and	O
108	O
fresh	O
childhood	O
myeloid	B-malignancy-type
tumor	I-malignancy-type
specimens	O
,	O
including	O
67	O
AML	O
,	O
29	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
,	O
and	O
12	O
juvenile	O
chronic	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
JCML	O
)	O
were	O
examined	O
for	O
mutation	O
in	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
RAS	O
genes	O
.	O
The	O
mutation	O
was	O
found	O
in	O
eight	O
of	O
the	O
120	O
samples	O
(	O
6.7	O
%	O
)	O
,	O
which	O
consisted	O
of	O
four	O
cell	O
lines	O
(	O
33.3	O
%	O
)	O
and	O
four	O
fresh	O
myeloid	O
tumors	O
(	O
3.7	O
%	O
)	O
.	O
The	O
frequency	O
of	O
the	O
mutation	O
in	O
the	O
cell	O
lines	O
was	O
apparently	O
higher	O
than	O
that	O
in	O
fresh	O
myeloid	B-malignancy-type
tumors	I-malignancy-type
.	O
K-RAS	O
gene	O
mutations	O
were	O
found	O
in	O
two	O
of	O
the	O
67	O
fresh	O
AML	B-malignancy-type
specimens	O
(	O
3	O
%	O
)	O
.	O
Interestingly	O
,	O
these	O
two	O
patients	O
had	O
11q23	O
translocations	O
.	O
The	O
N-RAS	O
gene	O
mutation	O
was	O
found	O
in	O
one	O
of	O
the	O
29	O
specimens	O
(	O
3.4	O
%	O
)	O
of	O
MDS	B-malignancy-type
and	O
in	O
one	O
of	O
the	O
12	O
specimens	O
(	O
8.3	O
%	O
)	O
of	O
JCML	O
.	O
All	O
mutations	O
were	O
found	O
in	O
codon	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
N-RAS	O
and	O
K-RAS	O
genes	O
.	O
Frequency	O
of	O
mutation	O
of	O
RAS	O
genes	O
in	O
fresh	O
myeloid	B-malignancy-type
malignancies	I-malignancy-type
was	O
very	O
low	O
.	O
These	O
findings	O
suggest	O
that	O
mutation	O
of	O
RAS	O
genes	O
does	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
childhood	O
myeloid	B-malignancy-type
malignancies	I-malignancy-type
.	O
PMID	O
:	O
9379676	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1997	O
Sep	O
;	O
88	O
(	O
9	O
)	O
:	O
846	O
-	O
54	O
Frequent	O
somatic	O
mutations	O
of	O
the	O
APC	O
and	O
p53	O
genes	O
in	O
sporadic	B-malignancy-type
ampullary	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Imai	O
Y	O
,	O
Oda	O
H	O
,	O
Tsurutani	O
N	O
,	O
Nakatsuru	O
Y	O
,	O
Inoue	O
T	O
,	O
Ishikawa	O
T	O
.	O
Department	O
of	O
Pathology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
.	O
Although	O
a	O
close	O
relation	O
of	O
somatic	O
mutations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
with	O
ampullary	B-malignancy-type
carcinomas	I-malignancy-type
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
has	O
been	O
reported	O
,	O
the	O
possible	O
association	O
with	O
sporadic	B-malignancy-type
ampullary	I-malignancy-type
neoplasms	I-malignancy-type
has	O
not	O
been	O
fully	O
examined	O
.	O
We	O
have	O
therefore	O
investigated	O
loss	O
of	O
heterozygosity	O
at	O
the	O
adenomatous	O
polyposis	O
coli	O
locus	O
and	O
the	O
mutational	O
status	O
of	O
a	O
portion	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
,	O
including	O
the	O
mutation	O
cluster	O
region	O
,	O
in	O
17	O
ampullary	B-malignancy-type
carcinomas	I-malignancy-type
of	O
non	B-malignancy-type
-	I-malignancy-type
familial	I-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
.	O
Alteration	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
was	O
found	O
in	O
8	O
of	O
17	O
(	O
47.1	O
%	O
)	O
cases	O
,	O
as	O
missense	O
or	O
insertion	O
mutations	O
,	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
.	O
Additional	O
investigation	O
of	O
p53	O
(	O
exons	O
5	O
-	O
8	O
)	O
and	O
K-ras	O
(	O
codons	O
12	O
and	O
13	O
)	O
gene	O
mutations	O
revealed	O
a	O
striking	O
mutational	O
pattern	O
of	O
the	O
p53	O
gene	O
.	O
Nine	O
of	O
the	O
17	O
cases	O
demonstrated	O
a	O
total	O
of	O
12	O
mutations	O
,	O
6	O
clustered	O
at	O
codon	O
189	O
and	O
3	O
at	O
codon	O
166	O
.	O
Furthermore	O
,	O
5	O
of	O
the	O
12	O
mutations	O
were	O
nonsense	O
mutations	O
.	O
Regarding	O
the	O
K-ras	O
gene	O
,	O
4	O
of	O
the	O
17	O
(	O
23.5	O
%	O
)	O
cases	O
had	O
mutations	O
in	O
codon	O
12	O
,	O
3	O
of	O
the	O
4	O
cases	O
being	O
derived	O
from	O
the	O
intraduodenal	O
bile	O
duct	O
.	O
The	O
findings	O
indicate	O
that	O
alterations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
and	O
the	O
p53	O
genes	O
are	O
relatively	O
frequent	O
in	O
sporadic	B-malignancy-type
ampullary	I-malignancy-type
carcinomas	I-malignancy-type
.	O
In	O
particular	O
,	O
the	O
clustering	O
at	O
specific	O
p53	O
codons	O
might	O
offer	O
an	O
etiological	O
clue	O
to	O
clarify	O
ampullary	O
carcinogenesis	O
.	O
Mutations	O
of	O
the	O
K-ras	O
gene	O
,	O
on	O
the	O
other	O
hand	O
,	O
might	O
be	O
characteristic	O
of	O
intraduodenal	O
bile	O
duct	O
origin	O
.	O
PMID	O
:	O
9369932	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Nat	O
Genet	O
1997	O
Jul	O
;	O
16	O
(	O
3	O
)	O
:	O
260	O
-	O
4	O
Frequent	O
translocation	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32.3	O
)	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
is	O
associated	O
with	O
increased	O
expression	O
and	O
activating	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
.	O
Chesi	O
M	O
,	O
Nardini	O
E	O
,	O
Brents	O
LA	O
,	O
Schrock	O
E	O
,	O
Ried	O
T	O
,	O
Kuehl	O
WM	O
,	O
Bergsagel	O
PL	O
.	O
Genetics	O
Department	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20889	O
-	O
5105	O
,	O
USA	O
.	O
Dysregulation	O
of	O
oncogenes	O
by	O
translocation	O
to	O
the	O
IgH	O
locus	O
(	O
14q32	O
)	O
is	O
a	O
seminal	O
event	O
in	O
the	O
pathogenesis	O
of	O
B-cell	B-malignancy-type
tumours	I-malignancy-type
.	O
In	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	B-malignancy-type
MM	I-malignancy-type
)	O
,	O
translocations	O
to	O
the	O
IgH	O
locus	O
have	O
been	O
reported	O
at	O
an	O
incidence	O
of	O
20	O
-	O
60	O
%	O
.	O
For	O
most	O
translocations	O
,	O
the	O
partner	O
chromosome	O
is	O
unknown	O
(	O
14q	O
+	O
)	O
;	O
for	O
the	O
others	O
,	O
a	O
diverse	O
array	O
of	O
chromosomal	O
partners	O
have	O
been	O
identified	O
,	O
with	O
11q13	O
(	O
cyclin	O
D1	O
)	O
the	O
only	O
chromosome	O
that	O
is	O
frequently	O
involved	O
.	O
Recently	O
,	O
we	O
developed	O
a	O
Southern	O
-	O
blot	O
assay	O
that	O
detects	O
translocation	O
breakpoint	O
fragments	O
in	O
most	O
MM	B-malignancy-type
tumours	I-malignancy-type
,	O
including	O
those	O
with	O
no	O
translocation	O
detected	O
by	O
conventional	O
karyotyping	O
.	O
In	O
a	O
continuing	O
analysis	O
of	O
translocation	O
in	O
21	O
myeloma	B-malignancy-type
cell	O
lines	O
and	O
primary	O
tumours	O
,	O
we	O
show	O
that	O
the	O
novel	O
,	O
karyotypically	O
silent	O
translocation	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32.3	O
)	O
is	O
present	O
in	O
five	O
lines	O
and	O
at	O
least	O
three	O
of	O
ten	O
primary	O
tumours	O
.	O
The	O
chromosome	O
-	O
4	O
breakpoints	O
are	O
clustered	O
in	O
a	O
70	O
-	O
kb	O
region	O
centromeric	O
to	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
gene	O
(	O
FGFR3	O
)	O
,	O
the	O
apparent	O
dysregulated	O
oncogene	O
.	O
Two	O
lines	O
and	O
one	O
primary	O
tumour	O
with	O
this	O
translocation	O
selectively	O
express	O
an	O
FGFR3	O
allele	O
containing	O
activating	O
mutations	O
identified	O
previously	O
in	O
thanatophoric	O
dwarfism	O
.	O
We	O
propose	O
that	O
after	O
the	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	O
,	O
somatic	O
mutation	O
during	O
tumour	O
progression	O
frequently	O
generates	O
in	O
FGFR3	O
protein	O
that	O
is	O
active	O
in	O
the	O
absence	O
of	O
ligand	O
.	O
PMID	O
:	O
9207791	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1997	O
Jun	O
;	O
11	O
(	O
6	O
)	O
:	O
863	O
-	O
5	O
No	O
concomitant	O
occurrence	O
of	O
the	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
.	O
Mitani	O
K	O
,	O
Hangaishi	O
A	O
,	O
Imamura	O
N	O
,	O
Miyagawa	O
K	O
,	O
Ogawa	O
S	O
,	O
Kanda	O
Y	O
,	O
Yazaki	O
Y	O
,	O
Hirai	O
H	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Bunkyo-ku	O
,	O
Japan	O
.	O
Mutations	O
of	O
the	O
N-ras	O
oncogene	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
were	O
simultaneously	O
investigated	O
in	O
bone	O
marrow	O
cells	O
from	O
44	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
or	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
followed	O
by	O
direct	O
sequencing	O
.	O
The	O
mutations	O
of	O
the	O
N-ras	O
gene	O
were	O
detected	O
only	O
in	O
two	O
cases	O
with	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
.	O
Three	O
patients	O
with	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
and	O
one	O
with	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
exhibited	O
five	O
mutations	O
of	O
the	O
p53	O
gene	O
.	O
No	O
concomitant	O
mutations	O
of	O
both	O
genes	O
were	O
observed	O
in	O
our	O
study	O
,	O
suggesting	O
that	O
alterations	O
of	O
both	O
genes	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
progression	O
of	O
MDS	B-malignancy-type
in	O
a	O
non	O
-	O
cooperative	O
manner	O
.	O
PMID	O
:	O
9177441	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1997	O
Apr	O
;	O
25	O
(3-4)	O
:	O
281	O
-	O
7	O
c-kit	O
Point	O
mutation	O
in	O
patients	O
with	O
myeloproliferative	B-malignancy-type
disorders	I-malignancy-type
.	O
Kimura	O
A	O
,	O
Nakata	O
Y	O
,	O
Katoh	O
O	O
,	O
Hyodo	O
H	O
.	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Myeloproliferative	B-malignancy-type
disorders	I-malignancy-type
(	O
MPD	B-malignancy-type
)	O
constitute	O
a	O
group	O
of	O
hematopoietic	B-malignancy-type
neoplasms	I-malignancy-type
at	O
the	O
myeloid	O
stem	O
cell	O
level	O
.	O
Myeloid	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
from	O
MPD	B-malignancy-type
have	O
been	O
considered	O
sensitive	O
to	O
hematopoietic	O
growth	O
factors	O
,	O
including	O
erythropoietin	O
,	O
thrombopoietin	O
and	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O
SCF	O
is	O
a	O
ligand	O
for	O
c-kit	O
receptor	O
with	O
tyrosine	O
kinase	O
.	O
We	O
analysed	O
the	O
gene	O
alteration	O
of	O
the	O
c-kit	O
extracellular	O
domain	O
in	O
MPD	O
patients	O
by	O
PCR	O
-	O
SSCP	O
and	O
subsequent	O
nucleotide	O
sequencing	O
.	O
The	O
point	O
mutation	O
in	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
domain	O
,	O
codon	O
52	O
(	O
Asp	O
-->	O
Asn	O
)	O
,	O
was	O
found	O
in	O
two	O
patients	O
with	O
primary	O
myelofibrosis	O
and	O
one	O
with	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
We	O
review	O
the	O
literature	O
regarding	O
the	O
role	O
of	O
SCF	O
/	O
c-kit	O
system	O
in	O
the	O
oncogenesis	O
of	O
leukemia	B-malignancy-type
and	O
MPD	B-malignancy-type
,	O
and	O
then	O
discuss	O
the	O
significance	O
of	O
our	O
finding	O
in	O
the	O
context	O
of	O
growth	O
advantage	O
of	O
the	O
mutated	O
clones	O
over	O
the	O
normal	O
clones	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9168438	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1997	O
Jan	O
;	O
24	O
(	O
3-4	O
)	O
:	O
309	O
-	O
17	O
N-ras	O
gene	O
point	O
mutations	O
in	O
Brazilian	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
patients	O
correlate	O
with	O
a	O
poor	O
prognosis	O
.	O
De	O
Melo	O
MB	O
,	O
Lorand-Metze	O
I	O
,	O
Lima	O
CS	O
,	O
Saad	O
ST	O
,	O
Costa	O
FF	O
.	O
Department	O
of	O
Clinical	O
Medicine-Hemocentro	O
,	O
School	O
of	O
Medical	O
Sciences	O
,	O
State	O
University	O
of	O
Campinas	O
(	O
UNICAMP	O
)	O
,	O
SP-Brazil	O
.	O
The	O
frequency	O
of	O
ras	O
gene	O
mutations	O
varies	O
from	O
11	O
to	O
27	O
%	O
in	O
AML	B-malignancy-type
populations	O
from	O
the	O
United	O
States	O
and	O
Europe	O
but	O
it	O
seems	O
that	O
there	O
is	O
no	O
study	O
regarding	O
the	O
frequency	O
of	O
mutated	O
N-ras	O
gene	O
in	O
patients	O
with	O
AML	B-malignancy-type
in	O
South	O
America	O
.	O
In	O
order	O
to	O
study	O
the	O
frequency	O
of	O
N-ras	O
gene	O
mutations	O
(	O
exons	O
1	O
and	O
2	O
)	O
in	O
Brazilian	O
patients	O
with	O
AML	B-malignancy-type
and	O
to	O
evaluate	O
the	O
possible	O
correlation	O
between	O
the	O
presence	O
of	O
the	O
mutation	O
and	O
clinical	O
features	O
,	O
40	O
patients	O
were	O
analyzed	O
.	O
N-ras	O
mutations	O
were	O
identified	O
in	O
DNA	O
samples	O
from	O
eight	O
of	O
40	O
AML	B-malignancy-type
patients	O
(	O
20	O
%	O
)	O
.	O
No	O
significant	O
correlation	O
was	O
found	O
between	O
N-ras	O
mutation	O
and	O
age	O
,	O
sex	O
,	O
race	O
,	O
response	O
to	O
therapy	O
,	O
FAB	O
subtype	O
or	O
occupational	O
exposure	O
.	O
However	O
,	O
the	O
overall	O
survival	O
and	O
AML	B-malignancy-type
-	O
free	O
survival	O
were	O
significantly	O
shorter	O
in	O
patients	O
with	O
N-ras	O
mutations	O
than	O
in	O
those	O
without	O
these	O
abnormalities	O
.	O
PMID	O
:	O
9156660	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Nat	O
Genet	O
1997	O
May	O
;16	O
(	O
1	O
)	O
:68	O
-	O
73	O
Germline	O
and	O
somatic	O
mutations	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Schmidt	O
L,	O
Duh	O
FM	O
,	O
Chen	O
F	O
,	O
Kishida	O
T	O
,	O
Glenn	O
G	O
,	O
Choyke	O
P,	O
Scherer	O
SW	O
,	O
Zhuang	O
Z	O
,	O
Lubensky	O
I	O
,	O
Dean	O
M,	O
Allikmets	O
R	O
,	O
Chidambaram	O
A	O
,	O
Bergerheim	O
UR	O
,	O
Feltis	O
JT	O
,	O
Casadevall	O
C	O
,	O
Zamarron	O
A	O
,	O
Bernues	O
M,	O
Richard	O
S	O
,	O
Lips	O
CJ	O
,	O
Walther	O
MM	O
,	O
Tsui	O
LC	O
,	O
Geil	O
L,	O
Orcutt	O
ML	O
,	O
Stackhouse	O
T	O
,	O
Zbar	O
B	O
,	O
et	O
al	O
.	O
Intramural	O
Research	O
Support	O
Program	O
,	O
SAIC	O
Frederick	O
,	O
MD	O
,	O
USA	O
.	O
Hereditary	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
(	O
HPRC	O
)	O
is	O
a	O
recently	O
recognized	O
form	O
of	O
inherited	O
kidney	B-malignancy-type
cancer	I-malignancy-type
characterized	O
by	O
a	O
predisposition	O
to	O
develop	O
multiple	O
,	O
bilateral	O
papillary	B-malignancy-type
renal	I-malignancy-type
tumours	I-malignancy-type
.	O
The	O
pattern	O
of	O
inheritance	O
of	O
HPRC	O
is	O
consistent	O
with	O
autosomal	O
dominant	O
transmission	O
with	O
reduced	O
penetrance	O
.	O
HPRC	O
is	O
histologically	O
and	O
genetically	O
distinct	O
from	O
two	O
other	O
causes	O
of	O
inherited	O
renal	B-malignancy-type
carcinoma	I-malignancy-type
,	O
von	B-malignancy-type
Hippel	I-malignancy-type
-	I-malignancy-type
Lindau	I-malignancy-type
disease	I-malignancy-type
(	O
VHL	B-malignancy-type
)	O
and	O
the	O
chromosome	O
translocation	O
(	O
3	O
;	O
8	O
)	O
.	O
Malignant	O
papillary	O
renal	O
carcinomas	O
are	O
characterized	O
by	O
trisomy	O
of	O
chromosomes	O
7	O
,	O
16	O
and	O
17	O
,	O
and	O
in	O
men	O
,	O
by	O
loss	O
of	O
the	O
Y	O
chromosome	O
.	O
Inherited	O
and	O
sporadic	B-malignancy-type
clear	I-malignancy-type
cell	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
are	O
characterized	O
by	O
inactivation	O
of	O
both	O
copies	O
of	O
the	O
VHL	O
gene	O
by	O
mutation	O
,	O
and/or	O
by	O
hypermethylation	O
.	O
We	O
found	O
that	O
the	O
HPRC	O
gene	O
was	O
located	O
at	O
chromosome	O
7q	O
31	O
.	O
1	O
-	O
34	O
in	O
a	O
27	O
-	O
centimorgan	O
(	O
cM	O
)	O
interval	O
between	O
D7S496	O
and	O
D7S1837	O
.	O
We	O
identified	O
missense	O
mutations	O
located	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
in	O
the	O
germline	O
of	O
affected	O
members	O
of	O
HPRC	O
families	O
and	O
in	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Three	O
mutations	O
in	O
the	O
MET	O
gene	O
are	O
located	O
in	O
codons	O
that	O
are	O
homologous	O
to	O
those	O
in	O
c-kit	O
and	O
RET	O
,	O
proto	O
-	O
oncogenes	O
that	O
are	O
targets	O
of	O
naturally	O
-	O
occurring	O
mutations	O
.	O
The	O
results	O
suggest	O
that	O
missense	O
mutations	O
located	O
in	O
the	O
MET	O
proto	O
-	O
oncogene	O
lead	O
to	O
constitutive	O
activation	O
of	O
the	O
MET	O
protein	O
and	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9140397	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
1997	O
Mar	O
21;275	O
(	O
5307	O
)	O
:1790	O
-2	O
Comment	O
in	O
:	O
Science	O
.	O
1997	O
Mar	O
21;275	O
(	O
5307	O
)	O
:1752-3.	O
Stabilization	O
of	O
beta-catenin	O
by	O
genetic	O
defects	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Rubinfeld	O
B	O
,	O
Robbins	O
P,	O
El	O
-Gamil	O
M,	O
Albert	O
I	O
,	O
Porfiri	O
E	O
,	O
Polakis	O
P.	O
Onyx	O
Pharmaceuticals	O
,	O
3031	O
Research	O
Drive	O
,	O
Richmond	O
,	O
CA	O
94806	O
,	O
USA	O
.	O
Signal	O
transduction	O
by	O
beta-catenin	O
involves	O
its	O
posttranslational	O
stabilization	O
and	O
downstream	O
coupling	O
to	O
the	O
Lef	O
and	O
Tcf	O
transcription	O
factors	O
.	O
Abnormally	O
high	O
amounts	O
of	O
beta-catenin	O
were	O
detected	O
in	O
7	O
of	O
26	O
human	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Unusual	O
messenger	O
RNA	O
splicing	O
and	O
missense	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
that	O
result	O
in	O
stabilization	O
of	O
the	O
protein	O
were	O
identified	O
in	O
six	O
of	O
the	O
lines	O
,	O
and	O
the	O
adenomatous	O
polyposis	O
coli	O
tumor	O
suppressor	O
protein	O
(	O
APC	O
)	O
was	O
altered	O
or	O
missing	O
in	O
two	O
others	O
.	O
In	O
the	O
APC	O
-	O
deficient	O
cells	O
,	O
ectopic	O
expression	O
of	O
wild	O
-	O
type	O
APC	O
eliminated	O
the	O
excess	O
beta-catenin	O
.	O
Cells	O
with	O
stabilized	O
beta-catenin	O
contained	O
a	O
constitutive	O
beta-catenin	O
-	O
Lef-1	O
complex	O
.	O
Thus	O
,	O
genetic	O
defects	O
that	O
result	O
in	O
up	O
-	O
regulation	O
of	O
beta-catenin	O
may	O
play	O
a	O
role	O
in	O
melanoma	B-malignancy-type
progression	O
.	O
PMID	O
:	O
9065403	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Thyroid	O
1996	O
Oct;	O
6	O
(	O
5	O
)	O
:	O
409	O
-	O
16	O
Prevalence	O
of	O
activating	O
ras	O
mutations	O
in	O
morphologically	O
characterized	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
Ezzat	O
S	O
,	O
Zheng	O
L,	O
Kolenda	O
J,	O
Safarian	O
A	O
,	O
Freeman	O
JL	O
,	O
Asa	O
SL	O
.	O
Department	O
of	O
Medicine	O
,	O
Wellesley	O
Hospital	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
Ras	O
proteins	O
are	O
signal	O
-	O
transducing	O
proteins	O
that	O
share	O
common	O
properties	O
with	O
membrane	O
-	O
anchored	O
G	O
proteins	O
.	O
Mutations	O
at	O
codon	O
12	O
/	O
13	O
or	O
codon	O
61	O
alter	O
GTP	O
-	O
binding	O
or	O
GTPase	O
activity	O
,	O
respectively	O
.	O
Such	O
activating	O
mutations	O
are	O
present	O
in	O
nearly	O
30	O
-	O
50	O
%	O
of	O
various	O
malignancies	O
including	O
colon	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
and	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
.	O
There	O
are	O
conflicting	O
data	O
regarding	O
the	O
prevalence	O
of	O
ras	O
mutations	O
in	O
the	O
thyroid	O
and	O
their	O
possible	O
pathogenetic	O
role	O
in	O
the	O
different	O
tumor	O
types	O
.	O
To	O
address	O
this	O
question	O
,	O
we	O
examined	O
45	O
morphologically	O
characterized	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
,	O
adenomas	B-malignancy-type
,	O
and	O
hyperplastic	B-malignancy-type
nodules	I-malignancy-type
using	O
a	O
highly	O
sensitive	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
approach	O
combined	O
with	O
DNA	O
-	O
sequencing	O
.	O
DNA	O
from	O
cell	O
lines	O
with	O
known	O
mutations	O
served	O
as	O
controls	O
.	O
A	O
G	O
to	O
A	O
H	O
13	O
codon	O
substitution	O
replacing	O
an	O
Asp	O
for	O
a	O
Gly	O
residue	O
was	O
detected	O
in	O
1	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Although	O
no	O
H	O
12	O
or	O
H	O
61	O
codon	O
substitutions	O
were	O
identified	O
,	O
2	O
discrete	O
alterations	O
were	O
identified	O
in	O
codons	O
H	O
17	O
and	O
22	O
.	O
No	O
N	O
12	O
/	O
13	O
codon	O
substitutions	O
were	O
identified	O
.	O
N	O
61	O
codon	O
substitutions	O
of	O
A	O
to	O
G	O
resulting	O
in	O
a	O
Gly	O
to	O
Arg	O
substitution	O
were	O
detected	O
in	O
2	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
;	O
the	O
same	O
mutation	O
was	O
also	O
found	O
in	O
one	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
.	O
Interestingly	O
,	O
K	O
12	O
/	O
13	O
and	O
K	O
61	O
ras	O
mutations	O
were	O
not	O
present	O
in	O
any	O
of	O
the	O
tumors	O
examined	O
.	O
These	O
data	O
establish	O
a	O
low	O
prevalence	O
of	O
mutations	O
in	O
all	O
ras	O
gene	O
family	O
members	O
in	O
human	O
thyroid	B-malignancy-type
neoplasms	I-malignancy-type
.	O
This	O
difference	O
from	O
neoplasms	O
of	O
other	O
organs	O
may	O
explain	O
the	O
relatively	O
indolent	O
biologic	O
behavior	O
of	O
many	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
and	O
supports	O
an	O
alternate	O
early	O
genetic	O
mutation	O
that	O
is	O
more	O
characteristic	O
of	O
these	O
neoplasms	O
.	O
PMID	O
:	O
8936664	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1996	O
Sep;149(	O
3	O
)	O
:	O
883	O
-	O
93	O
Comment	O
in	O
:	O
Am	O
J	O
Pathol	O
.	O
1996	O
Sep;149(	O
3	O
)	O
:739	O
-	O
44	O
.	O
Relevance	O
of	O
ultraviolet	O
-	O
induced	O
N-ras	O
oncogene	O
point	O
mutations	O
in	O
development	O
of	O
primary	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
van	O
Elsas	O
A	O
,	O
Zerp	O
SF	O
,	O
van	O
der	O
Flier	O
S	O
,	O
Kruse	O
KM	O
,	O
Aarnoudse	O
C	O
,	O
Hayward	O
NK	O
,	O
Ruiter	O
DJ	O
,	O
Schrier	O
PI.	O
Department	O
of	O
Clinical	O
Oncology	O
,	O
University	O
Hospital	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Intermittent	O
or	O
recreational	O
exposure	O
to	O
sunlight	O
is	O
thought	O
to	O
contribute	O
to	O
development	O
of	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
We	O
investigated	O
the	O
incidence	O
of	O
ras	O
oncogene	O
mutation	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
in	O
connection	O
to	O
sun	O
-	O
exposed	O
body	O
sites	O
in	O
the	O
patient	O
,	O
using	O
a	O
large	O
series	O
of	O
DNA	O
samples	O
derived	O
from	O
paraffin	O
-	O
embedded	O
material	O
as	O
well	O
as	O
from	O
fresh	O
tumor	O
samples	O
and	O
cell	O
lines	O
.	O
We	O
first	O
show	O
that	O
,	O
of	O
the	O
ras	O
family	O
,	O
predominantly	O
N-ras	O
is	O
activated	O
(	O
15	O
%	O
)	O
,	O
whereas	O
rarely	O
H-ras	O
or	O
K-ras	O
are	O
mutated	O
.	O
The	O
occurrence	O
of	O
N-ras	O
mutations	O
correlates	O
with	O
continuous	O
exposure	O
to	O
sunlight	O
of	O
the	O
primary	O
tumor	O
site	O
.	O
Of	O
all	O
tumors	O
initiated	O
on	O
chronically	O
sun	O
-	O
exposed	O
body	O
sites	O
,	O
26	O
%	O
contained	O
mutated	O
N-ras	O
,	O
in	O
contrast	O
to	O
0	O
%	O
of	O
sun	O
-	O
protected	O
melanomas	B-malignancy-type
.	O
Melanoma	B-malignancy-type
lesions	I-malignancy-type
obtained	O
from	O
patients	O
from	O
North	O
or	O
Central	O
Europe	O
contained	O
fewer	O
N-ras	O
mutations	O
(	O
12	O
%	O
)	O
as	O
compared	O
with	O
patients	O
from	O
Australia	O
(	O
24	O
%	O
)	O
.	O
Mutations	O
were	O
specifically	O
associated	O
with	O
nodular	B-malignancy-type
melanoma	I-malignancy-type
and	O
to	O
a	O
lesser	O
extent	O
with	O
lentigo	B-malignancy-type
malignant	I-malignancy-type
melanoma	I-malignancy-type
.	O
N-ras	O
mutations	O
did	O
not	O
correlate	O
with	O
metastasis	O
or	O
survival	O
parameters	O
.	O
This	O
study	O
identifies	O
a	O
subset	O
of	O
cutaneous	B-malignancy-type
melanomas	I-malignancy-type
that	O
contain	O
in	O
the	O
primary	O
lesion	O
ultraviolet	O
-	O
induced	O
N-ras	O
mutations	O
,	O
which	O
are	O
maintained	O
through	O
further	O
progression	O
.	O
PMID	O
:	O
8780392	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Hematol	O
1995	O
Aug;	O
62(	O
2	O
)	O
:91-7	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
are	O
very	O
rare	O
events	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
Yasuga	O
Y	O
,	O
Hirosawa	O
S	O
,	O
Yamamoto	O
K,	O
Tomiyama	O
J,	O
Nagata	O
K,	O
Aokia	O
N	O
.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
,	O
Japan	O
.	O
The	O
frequencies	O
of	O
p53	O
and	O
N-ras	O
gene	O
mutations	O
were	O
examined	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
DNA	O
samples	O
of	O
45	O
cases	O
of	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
were	O
obtained	O
from	O
stored	O
bone	O
marrow	O
smears	O
.	O
All	O
samples	O
were	O
analyzed	O
for	O
the	O
N-ras	O
gene	O
at	O
codon	O
12	O
by	O
the	O
allele	O
specific	O
restriction	O
analysis	O
method	O
and	O
at	O
codon	O
61	O
by	O
direct	O
sequencing	O
.	O
DNA	O
was	O
screened	O
for	O
mutations	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
for	O
the	O
p53	O
gene	O
in	O
exons	O
5	O
to	O
8	O
.	O
DNA	O
fragments	O
showing	O
an	O
altered	O
electrophoretic	O
pattern	O
were	O
further	O
studied	O
by	O
direct	O
sequencing	O
to	O
confirm	O
the	O
mutations	O
.	O
Ras	O
mutations	O
were	O
found	O
in	O
two	O
cases	O
at	O
codon	O
61	O
(	O
4.4	O
%	O
)	O
.	O
A	O
point	O
mutation	O
of	O
the	O
p53	O
gene	O
was	O
detected	O
in	O
one	O
of	O
45	O
cases	O
(	O
2.2	O
%	O
)	O
.	O
These	O
3	O
cases	O
with	O
mutations	O
were	O
in	O
an	O
advanced	O
stage	O
.	O
In	O
conclusion	O
,	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
may	O
occur	O
at	O
a	O
late	O
stage	O
of	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
,	O
but	O
the	O
frequencies	O
of	O
the	O
mutations	O
are	O
very	O
low	O
.	O
PMID	O
:	O
8590778	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
1995	O
Nov;30	O
Suppl	O
8	O
:	O
30-2	O
Detection	O
of	O
c-ras	O
gene	O
mutation	O
and	O
expression	O
of	O
p21	O
protein	O
in	O
dysplasias	B-malignancy-type
and	O
carcinomas	B-malignancy-type
complicating	O
ulcerative	O
colitis	O
.	O
Tsuda	O
T	O
,	O
Mochizuki	O
M,	O
Wakasa	O
H.	O
Department	O
of	O
Pathology	O
,	O
Fukushima	O
Medical	O
College	O
,	O
Japan	O
.	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
and	O
the	O
expression	O
of	O
p21	O
protein	O
were	O
analyzed	O
in	O
13	O
patients	O
with	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
complicating	O
ulcerative	O
colitis	O
;	O
in	O
12	O
of	O
the	O
13	O
,	O
there	O
were	O
dysplastic	B-malignancy-type
lesions	I-malignancy-type
close	O
to	O
the	O
carcinomas	B-malignancy-type
.	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
were	O
studied	O
by	O
polymerase	O
chain	O
reaction	O
and	O
dot	O
blot	O
hybridization	O
with	O
32p	O
-	O
labeled	O
oligonucleotide	O
probes	O
.	O
Findings	O
indicated	O
mutations	O
of	O
c-Ki-ras	O
at	O
condons	O
12	O
,	O
13	O
,	O
and	O
61	O
and	O
c-Ha-ras	O
and	O
c-N-ras	O
at	O
condons	O
12	O
and	O
61	O
.	O
The	O
expression	O
of	O
p21	O
protein	O
was	O
analyzed	O
by	O
immunohistochemical	O
staining	O
using	O
a	O
monoclonal	O
antibody	O
.	O
Only	O
1	O
of	O
the	O
13	O
patients	O
with	O
carcinoma	B-malignancy-type
showed	O
a	O
point	O
mutation	O
,	O
this	O
being	O
from	O
G	O
to	O
A	O
transition	O
at	O
the	O
second	O
position	O
of	O
codon	O
12	O
of	O
c-Ki-ras	O
.	O
No	O
point	O
mutations	O
of	O
c-Ki-ras	O
,	O
c-Ha-ras	O
,	O
or	O
c-N-ras	O
were	O
found	O
in	O
other	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
and	O
dysplasias	B-malignancy-type
.	O
In	O
the	O
dysplastic	B-malignancy-type
or	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
of	O
11	O
patients	O
,	O
the	O
increased	O
expression	O
of	O
p21	O
protein	O
was	O
observed	O
.	O
These	O
results	O
suggest	O
that	O
point	O
mutations	O
of	O
c-ras	O
genes	O
are	O
rare	O
in	O
dysplasias	B-malignancy-type
and	O
carcinomas	B-malignancy-type
complicating	O
ulcerative	O
colitis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
p21	O
protein	O
is	O
not	O
always	O
correlated	O
with	O
point	O
mutations	O
of	O
c-ras	O
genes	O
.	O
PMID	O
:	O
8563883	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1993	O
Apr;8	O
4	O
(	O
4	O
)	O
:	O
379	O
-	O
87	O
Clonal	O
analysis	O
of	O
multiple	O
point	O
mutations	O
in	O
the	O
N-ras	O
gene	O
in	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Kubo	O
K,	O
Naoe	O
T	O
,	O
Kiyoi	O
H,	O
Fukutani	O
H,	O
Kato	O
Y	O
,	O
Oguri	O
T	O
,	O
Yamamori	O
S	O
,	O
Akatsuka	O
Y	O
,	O
Kodera	O
Y	O
,	O
Ohno	O
R.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nagoya	O
University	O
Branch	O
Hospital	O
.	O
We	O
have	O
screened	O
mutations	O
of	O
the	O
N-ras	O
gene	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
in	O
leukemia	B-malignancy-type
cells	O
obtained	O
from	O
100	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
and	O
found	O
mutated	O
N-ras	O
alleles	O
in	O
9	O
patients	O
.	O
We	O
further	O
analyzed	O
the	O
polyclonality	O
of	O
multiple	O
N-ras	O
gene	O
mutations	O
in	O
4	O
AML	B-malignancy-type
patients	O
.	O
One	O
patient	O
,	O
who	O
had	O
the	O
monoclonal	O
karyotype	O
,	O
t	O
(	O
11	O
;	O
17	O
)	O
,	O
had	O
two	O
types	O
of	O
double	O
missense	O
mutations	O
at	O
codons	O
13	O
and	O
61	O
in	O
the	O
same	O
allele	O
.	O
Each	O
of	O
the	O
remaining	O
three	O
patients	O
,	O
one	O
of	O
whom	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
with	O
a	O
monoclonal	O
rearrangement	O
of	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
and	O
PML	O
genes	O
,	O
carried	O
two	O
missense	O
mutations	O
in	O
a	O
relatively	O
small	O
population	O
of	O
leukemia	B-malignancy-type
cells	O
.	O
We	O
have	O
demonstrated	O
that	O
multiple	O
clonality	O
of	O
the	O
N-ras	O
gene	O
is	O
occasionally	O
observed	O
in	O
leukemia	B-malignancy-type
with	O
a	O
monoclonal	O
karyotype	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
N-ras	O
mutations	O
may	O
not	O
always	O
be	O
characterized	O
simply	O
by	O
an	O
accumulative	O
process	O
and	O
that	O
the	O
activated	O
N-ras	O
gene	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
leukemia	B-malignancy-type
.	O
PMID	O
:	O
8514604	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1993	O
Apr	O
1;53(	O
7)	O
:1625	O
-	O
9	O
High	O
mutation	O
frequency	O
in	O
ras	O
genes	O
of	O
skin	B-malignancy-type
tumors	I-malignancy-type
isolated	O
from	O
DNA	O
repair	O
deficient	O
xeroderma	B-malignancy-type
pigmentosum	I-malignancy-type
patients	O
.	O
Daya	O
-	O
Grosjean	O
L,	O
Robert	O
C	O
,	O
Drougard	O
C	O
,	O
Suarez	O
H	O
,	O
Sarasin	O
A.	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O
Institut	O
de	O
Recherches	O
Scientifiques	O
sur	O
le	O
Cancer	O
,	O
Villejuif	O
,	O
France	O
.	O
Xeroderma	B-malignancy-type
pigmentosum	I-malignancy-type
(	O
XP	B-malignancy-type
)	O
patients	O
are	O
clinically	O
characterized	O
by	O
a	O
very	O
high	O
incidence	O
of	O
skin	O
cancers	O
on	O
exposed	O
skin	O
,	O
at	O
an	O
early	O
age	O
.	O
XP	O
cells	O
in	O
vitro	O
are	O
strongly	O
deficient	O
in	O
excision	O
-	O
repair	O
and	O
highly	O
mutagenized	O
by	O
UV	O
light	O
.	O
We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
measuring	O
mutation	O
frequency	O
and	O
in	O
determining	O
mutation	O
spectra	O
in	O
patients	O
'	O
tumors	O
exposed	O
to	O
UV	O
lesions	O
.	O
We	O
chose	O
to	O
look	O
at	O
oncogene	O
activation	O
in	O
skin	B-malignancy-type
tumors	I-malignancy-type
with	O
the	O
idea	O
that	O
more	O
mutations	O
,	O
particularly	O
of	O
the	O
ras	O
gene	O
family	O
,	O
would	O
be	O
found	O
in	O
XP	B-malignancy-type
tumors	I-malignancy-type
where	O
lesions	O
remain	O
unrepaired	O
compared	O
to	O
normal	O
individuals	O
.	O
Our	O
results	O
clearly	O
show	O
that	O
more	O
than	O
a	O
2	O
-	O
fold	O
significantly	O
higher	O
mutation	O
frequency	O
(	O
50	O
%	O
)	O
of	O
the	O
ras	O
genes	O
was	O
found	O
in	O
XP	B-malignancy-type
in	O
contrast	O
to	O
control	O
tumors	O
(	O
22	O
%	O
)	O
.	O
The	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
at	O
codon	O
12	O
of	O
all	O
three	O
ras	O
genes	O
with	O
a	O
preponderance	O
for	O
N-ras	O
in	O
XP	B-malignancy-type
samples	O
.	O
The	O
mutation	O
spectra	O
indicate	O
that	O
all	O
mutations	O
found	O
were	O
located	O
opposite	O
pyrimidine	O
-	O
pyrimidine	O
sequences	O
which	O
represent	O
a	O
hot	O
spot	O
for	O
UV	O
-	O
induced	O
DNA	O
lesions	O
.	O
Most	O
of	O
the	O
mutations	O
were	O
of	O
the	O
type	O
expected	O
from	O
studies	O
performed	O
in	O
vitro	O
with	O
model	O
systems	O
.	O
This	O
high	O
mutation	O
frequency	O
in	O
XP	B-malignancy-type
was	O
accompanied	O
by	O
a	O
very	O
high	O
level	O
of	O
Ha-ras	O
and	O
c-myc	O
gene	O
amplification	O
and	O
rearrangement	O
.	O
All	O
these	O
data	O
are	O
consistent	O
with	O
a	O
fundamental	O
role	O
of	O
unrepaired	O
UV	O
-	O
induced	O
DNA	O
lesions	O
as	O
an	O
initiating	O
event	O
in	O
human	O
skin	B-malignancy-type
tumors	I-malignancy-type
on	O
exposed	O
parts	O
of	O
the	O
body	O
.	O
PMID	O
:	O
8453633	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Aug;8(	O
8	O
)	O
:1331	O
-	O
6	O
N-ras	O
mutation	O
and	O
karyotypic	O
evolution	O
are	O
closely	O
associated	O
with	O
leukemic	O
transformation	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Horiike	O
S,	O
Misawa	O
S,	O
Nakai	O
H	O
,	O
Kaneko	O
H	O
,	O
Yokota	O
S,	O
Taniwaki	O
M,	O
Yamane	O
Y	O
,	O
Inazawa	O
J,	O
Abe	O
T	O
,	O
Kashima	O
K.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
III	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
performed	O
a	O
longitudinal	O
analysis	O
of	O
the	O
karyotypes	O
and	O
N-ras	O
gene	O
configuration	O
of	O
bone	O
marrow	O
cells	O
in	O
35	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Karyotypic	O
evolution	O
was	O
found	O
in	O
eight	O
patients	O
,	O
and	O
was	O
associated	O
with	O
disease	O
progression	O
,	O
including	O
leukemic	O
transformation	O
,	O
in	O
all	O
the	O
patients	O
.	O
We	O
identified	O
N-ras	O
mutations	O
in	O
six	O
patients	O
,	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
,	O
in	O
which	O
oligonucleotide	O
primers	O
were	O
constructed	O
with	O
induced	O
mismatches	O
,	O
followed	O
by	O
endonuclease	O
digestion	O
.	O
Direct	O
sequencing	O
confirmed	O
single	O
base	O
substitutions	O
at	O
codon	O
12	O
in	O
two	O
patients	O
and	O
at	O
codon	O
13	O
in	O
four	O
.	O
The	O
incidence	O
of	O
N-ras	O
gene	O
mutations	O
was	O
significantly	O
higher	O
in	O
the	O
karyotypically	O
evolved	O
group	O
(	O
five	O
of	O
eight	O
patients	O
)	O
than	O
in	O
the	O
stable	O
group	O
(	O
one	O
of	O
27	O
patients	O
)	O
.	O
All	O
of	O
five	O
patients	O
harboring	O
both	O
karyotypic	O
evolution	O
and	O
an	O
N-ras	O
mutation	O
showed	O
concomitant	O
disease	O
progression	O
to	O
overt	B-malignancy-type
leukemia	I-malignancy-type
or	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
in	O
transformation	O
(	O
RAEB-T	O
)	O
.	O
Two	O
of	O
four	O
patients	O
with	O
either	O
karyotypic	O
evolution	O
or	O
N-ras	O
mutation	O
and	O
six	O
of	O
26	O
patients	O
without	O
any	O
of	O
these	O
alterations	O
also	O
progressed	O
to	O
overt	B-malignancy-type
leukemia	I-malignancy-type
.	O
Our	O
results	O
indicate	O
that	O
the	O
accumulation	O
of	O
these	O
genetic	O
alterations	O
is	O
closely	O
associated	O
with	O
leukemic	O
transformation	O
of	O
MDS	B-malignancy-type
,	O
although	O
other	O
genetic	O
alterations	O
may	O
also	O
play	O
a	O
key	O
role	O
in	O
the	O
remaining	O
patients	O
.	O
PMID	O
:	O
8057669	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Dermatol	O
1994	O
Jul;131(	O
1	O
)	O
:72	O
-	O
7	O
Point	O
mutations	O
in	O
the	O
N-ras	O
oncogene	O
in	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
and	O
congenital	B-malignancy-type
naevi	I-malignancy-type
.	O
Carr	O
J,	O
Mackie	O
RM	O
.	O
Department	O
of	O
Dermatology	O
,	O
University	O
of	O
Glasgow	O
,	O
U.K.	O
DNA	O
from	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
processed	O
samples	O
from	O
100	O
melanocytic	B-malignancy-type
lesions	I-malignancy-type
(	O
39	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
,	O
18	O
cases	O
of	O
dysplastic	B-malignancy-type
naevi	I-malignancy-type
,	O
and	O
43	O
congenital	B-malignancy-type
naevi	I-malignancy-type
)	O
was	O
extracted	O
,	O
and	O
the	O
sequences	O
around	O
codons	O
12	O
/	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
oncogene	O
were	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
The	O
amplified	O
product	O
was	O
then	O
analysed	O
both	O
by	O
dot	O
-	O
blotting	O
and	O
by	O
direct	O
sequencing	O
for	O
point	O
mutations	O
.	O
By	O
the	O
dot	O
-	O
blotting	O
technique	O
,	O
mutations	O
were	O
seen	O
in	O
18	O
of	O
100	O
lesions	O
.	O
These	O
were	O
in	O
one	O
of	O
five	O
distant	O
metastases	O
(	O
20	O
%	O
)	O
,	O
in	O
one	O
of	O
three	O
nodal	O
metastases	O
(	O
33	O
%	O
)	O
,	O
in	O
four	O
of	O
31	O
(	O
13	O
%	O
)	O
primary	O
melanomas	B-malignancy-type
,	O
in	O
none	O
of	O
18	O
dysplastic	O
naevi	O
,	O
and	O
in	O
12	O
of	O
43	O
(	O
28	O
%	O
)	O
congenital	B-malignancy-type
naevi	I-malignancy-type
,	O
all	O
at	O
codon	O
61	O
.	O
On	O
direct	O
sequencing	O
,	O
nine	O
of	O
18	O
mutations	O
were	O
confirmed	O
,	O
in	O
two	O
of	O
31	O
(	O
6	O
%	O
)	O
primary	O
tumours	O
,	O
one	O
distant	O
metastasis	O
,	O
and	O
six	O
of	O
43	O
(	O
14	O
%	O
)	O
congenital	B-malignancy-type
naevi	I-malignancy-type
.	O
Of	O
the	O
23	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanomas	I-malignancy-type
examined	O
,	O
eight	O
were	O
on	O
sun	O
-	O
exposed	O
skin	O
.	O
A	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanoma	I-malignancy-type
,	O
in	O
which	O
the	O
N-ras	O
mutation	O
at	O
codon	O
61	O
was	O
confirmed	O
,	O
was	O
on	O
non	O
-	O
exposed	O
skin	O
,	O
and	O
an	O
unconfirmed	O
mutation	O
was	O
from	O
an	O
exposed	O
site	O
.	O
One	O
of	O
three	O
nodular	B-malignancy-type
melanomas	I-malignancy-type
with	O
a	O
confirmed	O
mutation	O
was	O
on	O
a	O
light	O
-	O
exposed	O
site	O
,	O
and	O
the	O
other	O
two	O
nodular	B-malignancy-type
melanomas	I-malignancy-type
were	O
from	O
non	O
-	O
exposed	O
areas	O
.	O
All	O
four	O
lentigo	B-malignancy-type
maligna	I-malignancy-type
melanomas	I-malignancy-type
were	O
from	O
exposed	O
sites	O
,	O
and	O
one	O
of	O
these	O
had	O
an	O
unconfirmed	O
mutation	O
.	O
The	O
only	O
acral	B-malignancy-type
lentiginous	I-malignancy-type
melanoma	I-malignancy-type
,	O
which	O
had	O
no	O
mutation	O
,	O
was	O
from	O
a	O
sun	O
-	O
exposed	O
area	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
8043423	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Oct;8(	O
10	O
)	O
:1682	O
-	O
7	O
The	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutations	O
in	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Coghlan	O
DW	O
,	O
Morley	O
AA	O
,	O
Matthews	O
JP	O
,	O
Bishop	O
JF.	O
Department	O
of	O
Haematology	O
,	O
Flinders	O
Medical	O
Centre	O
,	O
Bedford	O
Park	O
,	O
South	O
Australia	O
.	O
To	O
determine	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutation	O
in	O
the	O
N-ras	O
gene	O
in	O
de	O
novo	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
we	O
performed	O
an	O
analysis	O
of	O
bone	O
marrow	O
smears	O
from	O
219	O
patients	O
with	O
de	O
novo	O
AML	B-malignancy-type
treated	O
between	O
1984	O
and	O
1986	O
and	O
followed	O
for	O
at	O
least	O
six	O
years	O
.	O
DNA	O
extracted	O
from	O
bone	O
marrow	O
smears	O
taken	O
at	O
diagnosis	O
was	O
screened	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
exon	O
1	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
to	O
insert	O
an	O
Hph1	O
restriction	O
enzyme	O
site	O
into	O
DNA	O
.	O
Presumptive	O
mutations	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
.	O
Mutations	O
were	O
detected	O
in	O
a	O
total	O
of	O
26	O
patients	O
(	O
12	O
%	O
)	O
;	O
in	O
nine	O
patients	O
(	O
4	O
%	O
)	O
in	O
codon	O
12	O
only	O
,	O
in	O
ten	O
patients	O
(	O
5	O
%	O
)	O
in	O
codon	O
13	O
only	O
,	O
and	O
in	O
seven	O
patients	O
(	O
3	O
%	O
)	O
in	O
both	O
codons	O
.	O
Mutations	O
in	O
codon	O
12	O
or	O
codon	O
13	O
were	O
not	O
associated	O
with	O
any	O
clinical	O
features	O
.	O
Mutations	O
in	O
codon	O
12	O
had	O
no	O
prognostic	O
significance	O
but	O
mutations	O
in	O
codon	O
13	O
were	O
associated	O
with	O
an	O
increased	O
remission	O
rate	O
,	O
a	O
more	O
durable	O
remission	O
,	O
and	O
a	O
significantly	O
prolonged	O
survival	O
which	O
appeared	O
to	O
be	O
independent	O
of	O
other	O
prognostic	O
factors	O
.	O
PMID	O
:	O
7934163	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Oncol	O
1995	O
;34(	O
6)	O
:759	O
-	O
65	O
Glutathione	O
transferase	O
P1-1	O
expression	O
in	O
human	O
melanoma	B-malignancy-type
metastases	O
:	O
correlation	O
to	O
N-RAS	O
mutations	O
and	O
expression	O
.	O
Platz	O
A	O
,	O
Jungnelius	O
U	O
,	O
Grafstrom	O
E	O
,	O
Lagerlof	O
B	O
,	O
Mannervik	O
B	O
,	O
Ringborg	O
U.	O
Department	O
of	O
Oncology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
Expression	O
of	O
the	O
detoxication	O
enzyme	O
glutathione	O
transferase	O
P1-1	O
(	O
GST	O
P1-1	O
)	O
at	O
elevated	O
levels	O
has	O
been	O
noted	O
in	O
many	O
types	O
of	O
human	O
tumors	O
,	O
including	O
melanomas	B-malignancy-type
.	O
The	O
products	O
of	O
the	O
human	O
H-RAS	O
,	O
K-RAS	O
and	O
N-RAS	O
genes	O
play	O
a	O
key	O
role	O
in	O
intracellular	O
signal	O
transduction	O
leading	O
to	O
transcriptional	O
activation	O
of	O
AP-1	O
(	O
Fos	O
/	O
Jun	O
)	O
responsive	O
genes	O
.	O
The	O
oncogenic	O
mutated	O
forms	O
of	O
the	O
ras	O
proteins	O
are	O
constitutively	O
active	O
and	O
interfere	O
with	O
normal	O
signal	O
transduction	O
.	O
Mutated	O
RAS	O
genes	O
as	O
well	O
as	O
increased	O
expression	O
of	O
wild	O
-	O
type	O
ras	O
proteins	O
are	O
common	O
features	O
in	O
human	O
tumors	O
including	O
melanoma	B-malignancy-type
.	O
We	O
have	O
characterized	O
30	O
melanoma	B-malignancy-type
metastases	O
from	O
23	O
melanoma	B-malignancy-type
patients	O
with	O
reference	O
to	O
N-RAS	O
expression	O
and	O
mutation	O
as	O
well	O
as	O
to	O
GST	O
P1	O
expression	O
(	O
immunohistochemistry	O
and	O
genetic	O
analysis	O
)	O
.	O
Twenty-three	O
of	O
30	O
samples	O
(	O
70	O
%	O
)	O
had	O
high	O
N-Ras	O
p21	O
and/or	O
N-RAS	O
codon	O
61	O
mutations	O
and	O
18	O
of	O
these	O
23	O
samples	O
also	O
had	O
high	O
GST	O
P1-1	O
immunoreactivity	O
.	O
Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
samples	O
had	O
low	O
N-Ras	O
p21	O
immunoreactivity	O
and	O
no	O
detectable	O
N-RAS	O
codon	O
61	O
mutations	O
.	O
Six	O
of	O
these	O
7	O
samples	O
(	O
86	O
%	O
)	O
also	O
had	O
low	O
GST	O
P1-1	O
immunoreactivity	O
.	O
The	O
results	O
indicate	O
a	O
statistically	O
significant	O
correlation	O
(	O
Spearman	O
correlation	O
coefficient	O
,	O
r	O
=	O
0.56	O
,	O
p	O
=	O
0.001	O
,	O
2	O
-	O
tailed	O
test	O
)	O
and	O
provide	O
,	O
for	O
the	O
first	O
time	O
,	O
indirect	O
evidence	O
for	O
a	O
possible	O
coregulation	O
of	O
N-RAS	O
and	O
GST	O
P1	O
in	O
human	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
which	O
should	O
be	O
further	O
evaluated	O
.	O
PMID	O
:	O
7576742	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nippon	O
Shokakibyo	O
Gakkai	O
Zasshi	O
1989	O
Nov;86(	O
11	O
)	O
:2566	O
-	O
71	O
[	O
Detection	O
of	O
ras	O
gene	O
mutations	O
of	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
method	O
]	O
[Article	O
in	O
Japanese	O
]	O
Tada	O
M,	O
Yokosuka	O
O	O
,	O
Omata	O
M,	O
Ohto	O
M,	O
Isono	O
K.	O
Ras	O
genes	O
(	O
H	O
-	O
,	O
K	O
-	O
,	O
N	O
-	O
ras	O
)	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	O
mutations	O
occurring	O
in	O
either	O
codon	O
12	O
,	O
13	O
or	O
61	O
.	O
We	O
analyzed	O
19	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
(	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
)	O
of	O
these	O
codons	O
by	O
a	O
method	O
to	O
directly	O
sequence	O
nucleotides	O
around	O
codons	O
12	O
/	O
13	O
and	O
61	O
of	O
the	O
three	O
ras	O
genes	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
method	O
.	O
Of	O
19	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
,	O
all	O
17	O
duct	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
involving	O
2	O
mucous	O
producing	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
had	O
point	O
mutations	O
of	O
the	O
K-ras	O
codon	O
12	O
,	O
but	O
2	O
islet	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
had	O
ano	O
point	O
mutation	O
around	O
codons	O
12	O
,	O
13	O
,	O
61	O
of	O
the	O
three	O
ras	O
genes	O
.	O
Extremely	O
high	O
incidence	O
of	O
ras	O
gene	O
mutation	O
may	O
be	O
relevant	O
to	O
certain	O
pathogenesis	O
of	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
2689731	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1989	O
Jul;3(	O
7)	O
:511	O
-	O
5	O
c-myc	O
amplification	O
coexistent	O
with	O
activating	O
N-ras	O
point	O
mutation	O
in	O
the	O
biphenotypic	O
leukemic	O
cell	O
line	O
RED-3	O
.	O
Mallet	O
MK	O
,	O
Mane	O
SM	O
,	O
Meltzer	O
SJ	O
,	O
Needleman	O
SW.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Maryland	O
Hospital	O
,	O
Baltimore	O
21201	O
.	O
While	O
activation	O
of	O
the	O
protooncogene	O
c-N-ras	O
is	O
observed	O
regularly	O
in	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
,	O
amplification	O
of	O
c-myc	O
in	O
AML	B-malignancy-type
cells	O
or	O
derived	O
lines	O
is	O
uncommon	O
.	O
In	O
particular	O
,	O
concurrent	O
ras	O
/	O
myc	O
activation	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
critical	O
in	O
several	O
elegant	O
models	O
of	O
malignancy	O
,	O
has	O
been	O
demonstrated	O
in	O
a	O
very	O
small	O
number	O
of	O
human	O
tumors	O
or	O
derivative	O
cell	O
lines	O
.	O
A	O
cell	O
line	O
,	O
RED-3	O
,	O
is	O
described	O
which	O
was	O
derived	O
from	O
cells	O
of	O
a	O
patient	O
with	O
aggressive	B-malignancy-type
acute	I-malignancy-type
leukemia	I-malignancy-type
which	O
exhibits	O
many	O
markers	O
of	O
lineage	O
infidelity	O
.	O
DNA	O
from	O
this	O
cell	O
line	O
contains	O
an	O
activating	O
point	O
mutation	O
of	O
c-N-ras	O
as	O
well	O
as	O
20	O
-	O
30	O
-	O
fold	O
amplification	O
of	O
c-myc	O
.	O
After	O
HL-60	O
,	O
this	O
is	O
the	O
second	O
example	O
of	O
ras	O
/	O
myc	O
activation	O
in	O
AML	B-malignancy-type
derived	O
cells	O
and	O
demonstrates	O
that	O
this	O
lesion	O
is	O
not	O
unique	O
to	O
HL-60	O
.	O
Rather	O
,	O
it	O
may	O
be	O
important	O
in	O
leukemogenesis	O
in	O
a	O
small	O
proportion	O
of	O
AML	B-malignancy-type
patients	O
.	O
PMID	O
:	O
2659902	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Feb;4(	O
2	O
)	O
:159	O
-	O
64	O
High	O
frequency	O
of	O
ras	O
oncogene	O
activation	O
in	O
all	O
stages	O
of	O
human	O
thyroid	O
tumorigenesis	O
.	O
Lemoine	O
NR	O
,	O
Mayall	O
ES	O
,	O
Wyllie	O
FS	O
,	O
Williams	O
ED	O
,	O
Goyns	O
M,	O
Stringer	O
B	O
,	O
Wynford	O
-	O
Thomas	O
D.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Health	O
Park	O
,	O
Cardiff	O
,	O
UK.	O
Using	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
oligonucleotide	O
probing	O
,	O
the	O
activation	O
of	O
ras	O
oncogenes	O
in	O
24	O
benign	B-malignancy-type
and	O
20	O
malignant	B-malignancy-type
human	O
thyroid	B-malignancy-type
neoplasms	I-malignancy-type
was	O
examined	O
.	O
The	O
frequency	O
of	O
ras	O
oncogene	O
activation	O
was	O
similar	O
at	O
all	O
stages	O
of	O
tumorigenesis	O
in	O
this	O
system	O
,	O
being	O
found	O
in	O
33	O
%	O
of	O
adenomas	B-malignancy-type
overall	O
(	O
50	O
%	O
of	O
microfollicular	O
tumours	O
)	O
,	O
53	O
%	O
of	O
differentiated	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
and	O
60	O
%	O
of	O
undifferentiated	O
carcinomas	O
.	O
This	O
supports	O
the	O
contention	O
that	O
mutation	O
of	O
these	O
oncogenes	O
occurs	O
at	O
an	O
early	O
step	O
in	O
tumorigenesis	O
.	O
The	O
predominant	O
amino	O
acid	O
substitution	O
in	O
the	O
differentiated	O
tumours	B-malignancy-type
was	O
glutamine	O
to	O
arginine	O
at	O
position	O
61	O
of	O
Ha-ras	O
or	O
N-ras	O
,	O
but	O
this	O
mutation	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
undifferentiated	B-malignancy-type
tumours	I-malignancy-type
.	O
It	O
was	O
noted	O
that	O
while	O
transition	O
mutations	O
predominated	O
in	O
differentiated	B-malignancy-type
tumours	I-malignancy-type
(	O
both	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
)	O
,	O
transversions	O
were	O
more	O
common	O
in	O
the	O
undifferentiated	B-malignancy-type
tumours	I-malignancy-type
.	O
PMID	O
:	O
2648253	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1989	O
Jan	O
15	O
;49(	O
2	O
)	O
:357	O
-	O
60	O
Incidence	O
of	O
activating	O
ras	O
oncogene	O
mutations	O
associated	O
with	O
primary	B-malignancy-type
and	O
metastatic	O
human	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
Rochlitz	O
CF	O
,	O
Scott	O
GK	O
,	O
Dodson	O
JM	O
,	O
Liu	O
E	O
,	O
Dollbaum	O
C	O
,	O
Smith	O
HS	O
,	O
Benz	O
CC.	O
Cancer	O
Research	O
Institute	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
ras	O
activation	O
is	O
involved	O
in	O
the	O
final	O
stages	O
of	O
breast	B-malignancy-type
cancer	I-malignancy-type
progression	O
,	O
we	O
analyzed	O
tumor	O
DNA	O
derived	O
from	O
60	O
different	O
patients	O
and	O
extracted	O
from	O
40	O
invasive	O
primary	O
breast	B-malignancy-type
tumors	I-malignancy-type
,	O
seven	O
lymph	B-malignancy-type
node	I-malignancy-type
and	O
skin	B-malignancy-type
metastases	I-malignancy-type
,	O
nine	O
metastatic	O
effusions	O
,	O
and	O
five	O
established	O
breast	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
The	O
polymerase	O
chain	O
reaction	O
technique	O
was	O
used	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
Kirsten	O
-	O
(	O
Ki	O
-	O
)	O
,	O
Harvey	O
-	O
(	O
Ha	O
-	O
)	O
,	O
and	O
N	O
-	O
ras	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
which	O
were	O
then	O
probed	O
on	O
slot	O
-	O
blots	O
with	O
labeled	O
synthetic	O
oligomers	O
to	O
detect	O
nonconservative	O
single	O
base	O
mutations	O
.	O
Activating	O
mutations	O
were	O
found	O
in	O
one	O
of	O
40	O
primary	O
tumors	O
(	O
Ki-ras	O
codon	O
13	O
)	O
,	O
zero	O
of	O
seven	O
lymph	B-malignancy-type
node	I-malignancy-type
and	O
skin	B-malignancy-type
metastases	I-malignancy-type
,	O
one	O
of	O
nine	O
metastatic	O
effusions	O
(	O
Ki-ras	O
codon	O
12	O
)	O
,	O
and	O
two	O
of	O
five	O
cell	O
lines	O
(	O
Ki-ras	O
codons	O
12	O
and	O
13	O
)	O
.	O
These	O
results	O
indicate	O
that	O
activating	O
ras	O
mutations	O
are	O
rarely	O
involved	O
in	O
either	O
the	O
initiation	O
or	O
metastatic	O
progression	O
of	O
human	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
2642738	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1990	O
Mar;61(	O
3	O
)	O
:365	O
-	O
8	O
Low	O
incidence	O
of	O
ras	O
oncogene	O
activation	O
in	O
human	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Rumsby	O
G	O
,	O
Carter	O
RL	O
,	O
Gusterson	O
BA.	O
Department	O
of	O
Chemical	O
Pathology	O
,	O
Royal	O
Marsden	O
Hospital	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
Activation	O
of	O
the	O
ras	O
gene	O
family	O
by	O
point	O
mutation	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
has	O
been	O
demonstrated	O
in	O
up	O
to	O
20	O
%	O
of	O
unselected	O
series	O
of	O
human	O
tumours	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
assess	O
the	O
incidence	O
of	O
ras	O
activation	O
in	O
37	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
head	I-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
,	O
seven	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
skin	I-malignancy-type
and	O
eight	O
squamous	O
carcinoma	O
cell	O
lines	O
.	O
Oligonucleotide	O
probes	O
and	O
the	O
polymerase	O
chain	O
reaction	O
were	O
used	O
on	O
DNA	O
extracted	O
from	O
achival	O
paraffin	O
embedded	O
material	O
.	O
Mutations	O
in	O
codon	O
12	O
of	O
the	O
Harvey	O
ras	O
gene	O
was	O
found	O
in	O
a	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
larynx	I-malignancy-type
and	O
a	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lip	I-malignancy-type
,	O
both	O
of	O
which	O
had	O
received	O
prior	O
irradiation	O
.	O
A	O
cell	O
line	O
(	O
LICR-LON-HN8	O
)	O
established	O
from	O
the	O
same	O
laryngeal	B-malignancy-type
cancer	I-malignancy-type
showed	O
the	O
same	O
mutation	O
.	O
This	O
study	O
indicates	O
that	O
there	O
is	O
a	O
low	O
incidence	O
of	O
ras	O
mutation	O
in	O
human	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
that	O
activation	O
of	O
this	O
family	O
of	O
genes	O
is	O
probably	O
not	O
a	O
common	O
factor	O
in	O
the	O
development	O
of	O
this	O
group	O
of	O
tumours	B-malignancy-type
.	O
PMID	O
:	O
2183872	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1990	O
Mar;5(	O
3	O
)	O
:411	O
-	O
6	O
RAS	O
mutations	O
in	O
patients	O
following	O
cytotoxic	O
therapy	O
for	O
lymphoma	B-malignancy-type
.	O
Carter	O
G	O
,	O
Hughes	O
DC	O
,	O
Clark	O
RE	O
,	O
McCormick	O
F	O
,	O
Jacobs	O
A	O
,	O
Whittaker	O
JA	O
,	O
Padua	O
RA.	O
Department	O
of	O
Haematology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Cardiff	O
,	O
UK.	O
The	O
occurrence	O
of	O
Myelodysplastic	B-malignancy-type
Syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
Acute	B-malignancy-type
Myeloblastic	I-malignancy-type
Leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
following	O
cytotoxic	O
therapy	O
for	O
neoplastic	O
disease	O
is	O
well	O
recognised	O
.	O
RAS	O
mutations	O
are	O
common	O
in	O
patients	O
with	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
.	O
To	O
determine	O
whether	O
these	O
lesions	O
are	O
found	O
as	O
early	O
markers	O
of	O
secondary	O
disease	O
,	O
we	O
have	O
studied	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
the	O
peripheral	O
blood	O
of	O
70	O
patients	O
in	O
complete	O
remission	O
from	O
lymphoma	B-malignancy-type
.	O
Patients	O
were	O
treated	O
by	O
standard	O
chemotherapy	O
regimes	O
and/or	O
localised	O
radiotherapy	O
.	O
Treatment	O
had	O
been	O
given	O
6	O
months	O
to	O
14	O
1	O
/	O
2	O
years	O
previously	O
and	O
no	O
patient	O
showed	O
any	O
sign	O
of	O
residual	O
disease	O
.	O
Genomic	O
DNA	O
from	O
peripheral	O
blood	O
leukocytes	O
was	O
amplified	O
in	O
vitro	O
at	O
target	O
codons	O
of	O
N	O
,	O
K	O
and	O
H	O
RAS	O
genes	O
,	O
and	O
mutations	O
detected	O
by	O
hybridisation	O
with	O
oligonucleotide	O
probes	O
.	O
RAS	O
mutations	O
were	O
detected	O
in	O
9	O
subjects	O
.	O
One	O
patient	O
with	O
an	O
N	O
12	O
valine	O
(	O
Val	O
)	O
substitution	O
had	O
been	O
in	O
complete	O
remission	O
from	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
(	O
HD	B-malignancy-type
)	O
for	O
9	O
years	O
.	O
DNA	O
from	O
this	O
patient	O
registered	O
in	O
a	O
nude	O
mouse	O
tumorigenicity	O
assay	O
(	O
NMT	O
)	O
.	O
The	O
N	O
12	O
Val	O
mutation	O
was	O
not	O
detected	O
in	O
the	O
original	O
tumour	O
tissue	O
from	O
the	O
same	O
patient	O
.	O
A	O
second	O
patient	O
in	O
remission	O
from	O
HD	B-malignancy-type
showed	O
evidence	O
of	O
co	O
-	O
existent	O
N	O
12	O
cysteine	O
(	O
Cys	O
)	O
and	O
N	O
13	O
valine	O
(	O
Val	O
)	O
substitutions	O
which	O
were	O
not	O
detected	O
in	O
presentation	O
material	O
or	O
unaffected	O
tissues	O
.	O
All	O
patients	O
are	O
currently	O
haematologically	O
normal	O
,	O
indicating	O
that	O
clones	O
of	O
mutant	O
RAS	O
bearing	O
cells	O
may	O
be	O
detected	O
prior	O
to	O
any	O
overt	O
sign	O
of	O
disease	O
.	O
PMID	O
:	O
2179819	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1990	O
Apr;94(	O
4)	O
:423	O
-	O
5	O
Ras	O
oncogene	O
mutations	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
human	I-malignancy-type
skin	I-malignancy-type
.	O
van	O
der	O
Schroeff	O
JG	O
,	O
Evers	O
LM	O
,	O
Boot	O
AJ	O
,	O
Bos	O
JL.	O
Department	O
of	O
Dermatology	O
,	O
University	O
Hospital	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Activated	O
ras	O
oncogenes	O
have	O
been	O
detected	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
.	O
Activation	O
of	O
ras	O
oncogenes	O
usually	O
occurs	O
by	O
point	O
mutations	O
within	O
specific	O
codons	O
of	O
the	O
H-ras	O
,	O
N-ras	O
,	O
and	O
K-ras	O
genes	O
.	O
For	O
the	O
present	O
study	O
,	O
DNA	O
was	O
isolated	O
from	O
30	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
BCC	B-malignancy-type
)	O
and	O
12	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SCC	B-malignancy-type
)	O
.	O
After	O
amplification	O
of	O
genomic	O
DNA	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
the	O
occurrence	O
of	O
point	O
mutations	O
was	O
investigated	O
with	O
32P	O
-	O
labeled	O
synthetic	O
oligonucleotides	O
.	O
These	O
probes	O
are	O
complementary	O
to	O
the	O
known	O
point	O
-	O
mutated	O
nucleotide	O
sequences	O
of	O
the	O
ras	O
genes	O
.	O
In	O
four	O
out	O
of	O
the	O
30	O
BCC	B-malignancy-type
studied	O
,	O
point	O
mutations	O
were	O
detected	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
and	O
at	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
.	O
The	O
K-ras	O
mutations	O
involve	O
glycine	O
to	O
cysteine	O
and	O
glycine	O
to	O
asparagine	O
amino	O
acid	O
changes	O
.	O
The	O
mutation	O
at	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
is	O
consistent	O
with	O
a	O
replacement	O
of	O
glutamine	O
by	O
histidine	O
.	O
In	O
one	O
SCC	B-malignancy-type
,	O
a	O
point	O
mutation	O
was	O
detected	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
,	O
involving	O
a	O
glycine	O
to	O
cysteine	O
substitution	O
in	O
the	O
gene	O
product	O
.	O
These	O
findings	O
demonstrate	O
that	O
mutational	O
activation	O
of	O
ras	O
genes	O
takes	O
place	O
in	O
skin	B-malignancy-type
carcinomas	I-malignancy-type
,	O
but	O
the	O
rate	O
at	O
which	O
these	O
mutations	O
occur	O
seems	O
to	O
be	O
relatively	O
low	O
.	O
PMID	O
:	O
2179417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1991	O
Apr;63(	O
4)	O
:573	O
-	O
8	O
High	O
frequency	O
mutation	O
in	O
codons	O
12	O
and	O
61	O
of	O
H-ras	O
oncogene	O
in	O
chewing	O
tobacco	O
-	O
related	O
human	O
oral	B-malignancy-type
carcinoma	I-malignancy-type
in	O
India	O
.	O
Saranath	O
D	O
,	O
Chang	O
SE	O
,	O
Bhoite	O
LT	O
,	O
Panchal	O
RG	O
,	O
Kerr	O
IB	O
,	O
Mehta	O
AR	O
,	O
Johnson	O
NW	O
,	O
Deo	O
MG.	O
Cell	O
and	O
Developmental	O
Pathology	O
Division	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Bombay	O
,	O
India	O
.	O
57	O
primary	O
tumour	O
samples	O
from	O
Indian	O
oral	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
a	O
5	O
-	O
15	O
year	O
tobacco	O
chewing	O
habit	O
,	O
were	O
examined	O
for	O
mutational	O
activation	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
oncogenes	O
.	O
The	O
highly	O
sensitive	O
assay	O
based	O
on	O
specific	O
oligonucleotide	O
hybridisation	O
following	O
in	O
vitro	O
amplification	O
of	O
unique	O
sequences	O
by	O
polymerase	O
chain	O
reaction	O
was	O
employed	O
.	O
Mutations	O
were	O
detected	O
in	O
twenty	O
(	O
35	O
%	O
)	O
of	O
the	O
samples	O
and	O
were	O
restricted	O
to	O
H-ras	O
,	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
Two	O
cases	O
had	O
concurrent	O
mutations	O
in	O
codons	O
12	O
and	O
61	O
.	O
The	O
majority	O
of	O
the	O
mutations	O
were	O
at	O
H-ras	O
61.2	O
(	O
Glutamine	O
to	O
Arginine	O
)	O
and	O
H-ras	O
12.2	O
(	O
Glycine	O
to	O
Valine	O
)	O
.	O
Three	O
of	O
the	O
less	O
frequent	O
mutations	O
are	O
apparently	O
novel	O
.	O
Interestingly	O
,	O
eight	O
of	O
the	O
samples	O
with	O
H-ras	O
mutations	O
also	O
showed	O
loss	O
of	O
wild	O
-	O
type	O
H-ras	O
,	O
as	O
judged	O
by	O
absence	O
of	O
signals	O
for	O
wild	O
-	O
type	O
codons	O
12	O
or	O
61	O
on	O
dot	O
blots	O
.	O
The	O
specific	O
H-ras	O
mutations	O
in	O
these	O
oral	B-malignancy-type
malignancies	I-malignancy-type
associated	O
with	O
tobacco	O
chewing	O
,	O
may	O
represent	O
an	O
important	O
example	O
of	O
an	O
environmental	O
carcinogen	O
-	O
induced	O
step	O
,	O
in	O
a	O
pathway	O
leading	O
to	O
malignant	O
transformation	O
.	O
PMID	O
:	O
2021541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Jan	O
15;75(	O
2	O
)	O
:453	O
-	O
7	O
Alteration	O
of	O
N-ras	O
gene	O
mutation	O
after	O
relapse	O
in	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Terada	O
N	O
,	O
Miyoshi	O
J,	O
Kawa	O
-	O
Ha	O
K	O
,	O
Sasai	O
H	O
,	O
Orita	O
S,	O
Yumura	O
-	O
Yagi	O
K	O
,	O
Hara	O
J,	O
Fujinami	O
A	O
,	O
Kakunaga	O
T.	O
Department	O
of	O
Oncogene	O
Research	O
,	O
Osaka	O
University	O
,	O
Japan	O
.	O
We	O
investigated	O
N-ras	O
activation	O
in	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
dALL	O
)	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
the	O
oligonucleotide	O
hybridization	O
method	O
.	O
The	O
frequency	O
of	O
point	O
-	O
mutation	O
of	O
the	O
N-ras	O
gene	O
was	O
not	O
high	O
(	O
2	O
of	O
15	O
)	O
,	O
and	O
one	O
positive	O
case	O
who	O
relapsed	O
was	O
analyzed	O
in	O
detail	O
.	O
Although	O
N-ras	O
gene	O
activation	O
was	O
detected	O
at	O
both	O
onset	O
and	O
relapse	O
,	O
the	O
mutation	O
sites	O
were	O
different	O
.	O
At	O
onset	O
,	O
Gly	O
(	O
GGT	O
)	O
was	O
changed	O
to	O
Ser	O
(	O
AGT	O
)	O
at	O
codon	O
12	O
,	O
and	O
at	O
relapse	O
,	O
Gly	O
(	O
GGT	O
)	O
to	O
Asp	O
(	O
GAT	O
)	O
was	O
observed	O
at	O
the	O
same	O
codon	O
.	O
In	O
addition	O
,	O
the	O
DNA	O
at	O
relapse	O
showed	O
a	O
remarkably	O
higher	O
transforming	O
activity	O
than	O
the	O
DNA	O
at	O
onset	O
on	O
two	O
independent	O
recipient	O
cell	O
lines	O
.	O
The	O
identical	O
cell	O
surface	O
phenotype	O
and	O
the	O
same	O
rearrangement	O
patterns	O
of	O
both	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
heavy	O
chain	O
and	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
gamma	O
chain	O
genes	O
indicated	O
that	O
the	O
leukemic	O
cells	O
at	O
onset	O
and	O
those	O
at	O
relapse	O
were	O
derived	O
from	O
the	O
same	O
precursor	O
cell	O
.	O
Therefore	O
,	O
this	O
case	O
supports	O
the	O
concept	O
that	O
ras	O
activation	O
is	O
not	O
the	O
event	O
initiating	O
leukemogenesis	O
,	O
but	O
may	O
be	O
involved	O
in	O
leukemic	O
progression	O
.	O
PMID	O
:	O
1967219	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1991	O
Sep;59(	O
3	O
)	O
:231	O
-	O
5	O
Low	O
incidence	O
of	O
Ha-ras	O
oncogene	O
mutations	O
in	O
human	O
epidermal	B-malignancy-type
tumors	I-malignancy-type
.	O
Lieu	O
FM	O
,	O
Yamanishi	O
K	O
,	O
Konishi	O
K	O
,	O
Kishimoto	O
S,	O
Yasuno	O
H.	O
Department	O
of	O
Dermatology	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
Activation	O
of	O
the	O
Ha-ras	O
oncogene	O
by	O
point	O
mutations	O
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
animal	O
skin	O
carcinogenesis	O
models	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
the	O
Ha-ras	O
mutations	O
in	O
human	O
epidermal	B-malignancy-type
tumors	I-malignancy-type
.	O
DNAs	O
from	O
paraffin	O
-	O
embedded	O
tissues	O
of	O
benign	O
and	O
malignant	O
human	O
epidermal	B-malignancy-type
tumors	I-malignancy-type
(	O
27	O
samples	O
from	O
25	O
patients	O
)	O
were	O
prepared	O
and	O
examined	O
for	O
point	O
mutations	O
of	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
Ha-ras	O
gene	O
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
.	O
Only	O
one	O
sample	O
of	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
and	O
one	O
sample	O
of	O
keratoacanthoma	B-malignancy-type
were	O
found	O
to	O
carry	O
an	O
A	O
to	O
T	O
transversion	O
at	O
the	O
second	O
position	O
of	O
codon	O
61	O
.	O
This	O
low	O
incidence	O
of	O
Ha-ras	O
mutations	O
suggests	O
that	O
the	O
mutational	O
activation	O
of	O
the	O
gene	O
may	O
not	O
be	O
primarily	O
involved	O
in	O
human	O
epidermal	O
tumorigenesis	O
.	O
PMID	O
:	O
1913619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1992	O
Feb	O
1;50(	O
3	O
)	O
:382	O
-	O
5	O
Infrequent	O
mutation	O
of	O
the	O
ras	O
genes	O
in	O
skin	B-malignancy-type
tumors	I-malignancy-type
of	O
xeroderma	O
pigmentosum	O
patients	O
in	O
Japan	O
.	O
Ishizaki	O
K	O
,	O
Tsujimura	O
T	O
,	O
Nakai	O
M,	O
Nishigori	O
C	O
,	O
Sato	O
K	O
,	O
Katayama	O
S,	O
Kurimura	O
O	O
,	O
Yoshikawa	O
K	O
,	O
Imamura	O
S,	O
Ikenaga	O
M.	O
Radiation	O
Biology	O
Center	O
,	O
Kyoto	O
University	O
,	O
Japan	O
.	O
By	O
using	O
PCR	O
amplification	O
and	O
oligonucleotide	O
mismatch	O
hybridization	O
,	O
base	O
-	O
substitution	O
mutations	O
of	O
the	O
ras	O
genes	O
in	O
26	O
skin	B-malignancy-type
tumors	I-malignancy-type
of	O
Japanese	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
patients	O
were	O
studied	O
.	O
Thin	O
sections	O
of	O
tumor	O
tissues	O
which	O
were	O
fixed	O
and	O
embedded	O
in	O
paraffin	O
blocks	O
were	O
used	O
in	O
this	O
study	O
.	O
After	O
analyzing	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
by	O
using	O
66	O
oligomer	O
probes	O
,	O
we	O
detected	O
only	O
one	O
mutation	O
of	O
the	O
K-ras	O
gene	O
at	O
codon	O
61	O
in	O
one	O
tumor	O
sample	O
.	O
All	O
the	O
other	O
tumors	O
were	O
therefore	O
considered	O
not	O
to	O
have	O
a	O
mutation	O
in	O
the	O
ras	O
genes	O
.	O
These	O
results	O
suggest	O
that	O
mutations	O
of	O
the	O
ras	O
genes	O
are	O
not	O
particularly	O
associated	O
with	O
skin	B-malignancy-type
tumors	I-malignancy-type
of	O
Japanese	O
XP	O
patients	O
.	O
PMID	O
:	O
1735606	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Keio	O
J	O
Med	O
1992	O
Jun;41(	O
2	O
)	O
:80	O
-	O
6	O
Detection	O
of	O
H-ras	O
gene	O
point	O
mutations	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
human	O
urinary	B-malignancy-type
bladder	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
.	O
Saito	O
S.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Keio	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
It	O
has	O
been	O
reported	O
that	O
the	O
H-ras	O
gene	O
is	O
activated	O
as	O
oncogene	O
in	O
human	O
bladder	B-malignancy-type
cancer	I-malignancy-type
cases	O
,	O
and	O
that	O
codon	O
12	O
and	O
codon	O
61	O
are	O
the	O
major	O
"	O
hot	O
spots	O
"	O
of	O
its	O
activation	O
.	O
A	O
simple	O
method	O
to	O
detect	O
point	O
mutations	O
in	O
these	O
codons	O
of	O
H-ras	O
gene	O
was	O
established	O
for	O
the	O
use	O
of	O
clinical	O
diagnosis	O
.	O
In	O
this	O
method	O
,	O
the	O
DNA	O
segments	O
including	O
codon	O
12	O
or	O
codon	O
61	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and	O
the	O
reaction	O
products	O
were	O
examined	O
for	O
their	O
susceptibility	O
to	O
the	O
restriction	O
enzyme	O
NaeI	O
or	O
BstNI	O
,	O
and	O
by	O
dot	O
blot	O
hybridization	O
assay	O
with	O
oligonucleotide	O
probes	O
.	O
Point	O
mutations	O
were	O
detectable	O
in	O
small	O
amounts	O
of	O
DNAs	O
isolated	O
from	O
fresh	O
or	O
frozen	O
tumor	O
tissues	O
,	O
urine	O
cells	O
and	O
paraffin	O
sections	O
.	O
The	O
method	O
was	O
applied	O
for	O
a	O
clinical	O
sample	O
and	O
a	O
case	O
that	O
had	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
H-ras	O
gene	O
was	O
detected	O
.	O
The	O
point	O
mutation	O
was	O
existed	O
in	O
DNAs	O
of	O
primary	O
tumor	O
tissue	O
,	O
all	O
recurrent	O
tumor	O
tissues	O
and	O
cells	O
isolated	O
from	O
urine	O
of	O
this	O
case	O
.	O
PMID	O
:	O
1619852	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1992	O
May	O
15;52(	O
10	O
)	O
:2777	O
-	O
81	O
Clinical	O
implications	O
of	O
K-ras	O
mutations	O
in	O
malignant	O
epithelial	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
endometrium	I-malignancy-type
.	O
Mizuuchi	O
H	O
,	O
Nasim	O
S,	O
Kudo	O
R,	O
Silverberg	O
SG	O
,	O
Greenhouse	O
S,	O
Garrett	O
CT.	O
Department	O
of	O
Pathology	O
,	O
George	O
Washington	O
University	O
,	O
Washington	O
,	O
DC	O
20037	O
.	O
Tumorigenesis	O
in	O
humans	O
and	O
experimental	O
animals	O
appears	O
to	O
involve	O
the	O
activation	O
of	O
ras	O
protooncogenes	O
for	O
a	O
number	O
of	O
organ	O
systems	O
and	O
seems	O
to	O
be	O
important	O
to	O
the	O
development	O
of	O
the	O
metastatic	O
phenotype	O
in	O
several	O
model	O
systems	O
.	O
Clinically	O
,	O
the	O
presence	O
of	O
activated	O
ras	O
protooncogenes	O
has	O
been	O
reported	O
to	O
be	O
a	O
negative	O
prognostic	O
factor	O
in	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
in	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
In	O
the	O
present	O
study	O
we	O
examined	O
49	O
cases	O
of	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
for	O
mutations	O
in	O
the	O
first	O
exon	O
of	O
K-ras	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Mutations	O
in	O
codon	O
12	O
or	O
13	O
of	O
K-ras	O
were	O
detected	O
in	O
6	O
of	O
49	O
cases	O
(	O
12.2	O
%	O
)	O
.	O
These	O
six	O
cases	O
consisted	O
of	O
five	O
endometrioid	B-malignancy-type
endometrial	I-malignancy-type
carcinomas	I-malignancy-type
,	O
each	O
of	O
which	O
had	O
a	O
mutation	O
in	O
codon	O
12	O
,	O
and	O
one	O
case	O
of	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
which	O
had	O
a	O
mutation	O
in	O
codon	O
13	O
.	O
In	O
our	O
study	O
the	O
presence	O
of	O
mutations	O
in	O
K-ras	O
appeared	O
to	O
be	O
an	O
unfavorable	O
prognostic	O
factor	O
.	O
Three	O
of	O
six	O
patients	O
with	O
the	O
mutation	O
died	O
during	O
follow	O
-	O
up	O
,	O
while	O
only	O
7	O
%	O
of	O
the	O
43	O
patients	O
without	O
K-ras	O
mutations	O
expired	O
during	O
this	O
same	O
period	O
.	O
In	O
multivariate	O
analysis	O
using	O
the	O
Cox	O
proportional	O
hazard	O
model	O
,	O
K-ras	O
activation	O
appeared	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
when	O
compared	O
with	O
clinical	O
stage	O
,	O
depth	O
of	O
myometrial	O
invasion	O
,	O
and	O
patient	O
age	O
.	O
Thus	O
,	O
our	O
findings	O
support	O
the	O
hypothesis	O
that	O
K-ras	O
protooncogene	O
activation	O
plays	O
an	O
important	O
role	O
in	O
determining	O
the	O
aggressiveness	O
of	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
1581890	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
1992	O
Nov;23(	O
11	O
)	O
:1199	O
-	O
204	O
Concurrent	O
mutations	O
of	O
coding	O
and	O
regulatory	O
sequences	O
of	O
the	O
Ha-ras	O
gene	O
in	O
urinary	B-malignancy-type
bladder	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Czerniak	O
B	O
,	O
Cohen	O
GL	O
,	O
Etkind	O
P	O
,	O
Deitch	O
D	O
,	O
Simmons	O
H	O
,	O
Herz	O
F	O
,	O
Koss	O
LG.	O
Department	O
of	O
Pathology	O
,	O
Montefiore	O
Medical	O
Center	O
,	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
Bronx	O
,	O
NY	O
10467	O
.	O
This	O
report	O
concerns	O
the	O
study	O
of	O
Ha-ras	O
gene	O
mutations	O
and	O
ras	O
p21	O
expression	O
in	O
primary	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
urinary	I-malignancy-type
bladder	I-malignancy-type
.	O
Polymerase	O
chain	O
reaction	O
-	O
based	O
techniques	O
and	O
computerized	O
image	O
analysis	O
were	O
used	O
.	O
The	O
data	O
obtained	O
were	O
related	O
to	O
tumor	O
grade	O
,	O
DNA	O
ploidy	O
,	O
and	O
tumor	O
invasion	O
.	O
A	O
point	O
mutation	O
(	O
G	O
-->	O
T	O
)	O
at	O
Ha-ras	O
codon	O
12	O
was	O
found	O
in	O
30	O
of	O
67	O
tumors	O
.	O
The	O
mutation	O
frequency	O
was	O
greater	O
in	O
grade	O
III	O
(	O
65	O
%	O
)	O
than	O
in	O
grade	O
II	O
(	O
44	O
%	O
)	O
tumors	O
;	O
no	O
mutations	O
were	O
observed	O
in	O
grade	O
I	O
tumors	O
.	O
The	O
mutation	O
was	O
observed	O
more	O
often	O
in	O
aneuploid	O
(	O
58	O
%	O
)	O
than	O
in	O
diploid	O
(	O
28	O
%	O
)	O
tumors	O
.	O
No	O
other	O
substitution	O
at	O
codon	O
12	O
was	O
seen	O
and	O
no	O
codon	O
61	O
mutation	O
was	O
detected	O
.	O
The	O
tumors	O
were	O
also	O
tested	O
for	O
the	O
A	O
-->	O
G	O
mutation	O
at	O
position	O
2719	O
of	O
Ha-ras	O
intron	O
D	O
.	O
Concurrent	O
codon	O
12	O
and	O
intron	O
D	O
mutations	O
were	O
identified	O
in	O
seven	O
high	O
-	O
grade	O
aneuploid	O
tumors	O
;	O
six	O
were	O
invasive	O
.	O
The	O
levels	O
of	O
the	O
ras	O
gene	O
product	O
p21	O
were	O
approximately	O
10	O
times	O
higher	O
in	O
tumors	O
with	O
intron	O
D	O
mutation	O
than	O
in	O
those	O
without	O
.	O
These	O
findings	O
confirm	O
on	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
the	O
observations	O
of	O
the	O
effect	O
of	O
synchronous	O
exon	O
-	O
intron	O
mutations	O
reported	O
on	O
the	O
bladder	B-malignancy-type
cancer	I-malignancy-type
cell	O
line	O
T24	O
.	O
Our	O
results	O
are	O
the	O
first	O
demonstration	O
of	O
Ha-ras	O
intron	O
D	O
alterations	O
in	O
human	O
tumor	O
tissues	O
and	O
suggest	O
that	O
concurrent	O
mutations	O
at	O
codon	O
12	O
and	O
intron	O
D	O
of	O
this	O
gene	O
within	O
the	O
same	O
tumor	O
may	O
contribute	O
to	O
the	O
aggressive	O
behavior	O
of	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
1427748	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1992	O
Sep;5(	O
2	O
)	O
:109	O
-	O
18	O
Detection	O
of	O
RAS	O
mutations	O
in	O
archival	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
.	O
Moul	O
JW	O
,	O
Theune	O
SM	O
,	O
Chang	O
EH.	O
Department	O
of	O
Surgery	O
,	O
Uniformed	O
Services	O
University	O
of	O
the	O
Health	O
Sciences	O
,	O
Bethesda	O
,	O
Maryland	O
20814	O
-	O
4799	O
.	O
Preliminary	O
studies	O
of	O
RAS	O
mutational	O
activation	O
in	O
human	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
neoplasms	I-malignancy-type
have	O
yielded	O
conflicting	O
results	O
.	O
Whereas	O
two	O
studies	O
of	O
clinical	O
material	O
revealed	O
a	O
significant	O
incidence	O
of	O
N	O
-	O
and	O
K	O
RAS	O
mutations	O
,	O
two	O
studies	O
of	O
a	O
variety	O
of	O
germ	O
cell	O
lines	O
failed	O
to	O
document	O
RAS	O
mutations	O
.	O
To	O
clarify	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
these	O
tumors	B-malignancy-type
,	O
we	O
studied	O
archival	O
paraffin	O
-	O
embedded	O
,	O
formalin	O
-	O
fixed	O
orchiectomy	O
specimens	O
from	O
25	O
nonseminomas	B-malignancy-type
(	O
NSGCT	B-malignancy-type
)	O
,	O
18	O
seminomas	B-malignancy-type
(	O
SEM	B-malignancy-type
)	O
,	O
and	O
one	O
Leydig	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
.	O
For	O
14	O
of	O
the	O
44	O
neoplasms	O
,	O
DNA	O
was	O
also	O
available	O
from	O
nonmalignant	O
testis	O
adjacent	O
to	O
the	O
tumor	O
.	O
Six	O
age	O
-	O
matched	O
patients	O
had	O
testes	O
removed	O
because	O
of	O
nonmalignant	O
disease	O
and	O
were	O
studied	O
as	O
controls	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
the	O
K	O
-	O
,	O
N	O
-	O
,	O
and	O
H	O
RAS	O
12	O
,	O
13	O
,	O
and	O
61	O
codons	O
of	O
these	O
specimens	O
,	O
and	O
mutations	O
were	O
detected	O
with	O
mutation	O
-	O
specific	O
oligonucleotide	O
probe	O
hybridization	O
of	O
Southern	O
and	O
slot	O
blots	O
.	O
Four	O
mutations	O
were	O
found	O
in	O
KRAS	O
12	O
(	O
4	O
/	O
44	O
;	O
[	O
9.1	O
%	O
]	O
)	O
.	O
One	O
seminoma	B-malignancy-type
[	O
1	O
/	O
18	O
(	O
5.6	O
%	O
)	O
]	O
contained	O
the	O
mutation	O
GGT	O
(	O
GLY	O
)	O
----	O
CGT	O
(	O
ARG	O
)	O
,	O
and	O
three	O
NSGCT	B-malignancy-type
[	O
3	O
/	O
25	O
(	O
12	O
%	O
)	O
]	O
were	O
found	O
to	O
have	O
GGT	O
(	O
GLY	O
)	O
----	O
GAT	O
(	O
ASP	O
)	O
mutations	O
.	O
One	O
of	O
the	O
NSGCT	B-malignancy-type
mutations	O
was	O
detected	O
in	O
adjacent	O
nonmalignant	O
tissue	O
,	O
but	O
the	O
corresponding	O
tumor	O
did	O
not	O
contain	O
any	O
detectable	O
mutation	O
.	O
No	O
mutations	O
were	O
detected	O
at	O
KRAS	O
13	O
or	O
61	O
,	O
in	O
NRAS	O
or	O
HRAS	O
12	O
,	O
13	O
,	O
or	O
61	O
,	O
or	O
in	O
the	O
control	O
normal	O
testes	O
.	O
PCR	O
,	O
slot	O
blots	O
,	O
and	O
hybridizations	O
were	O
performed	O
twice	O
by	O
two	O
separate	O
investigators	O
for	O
confirmation	O
of	O
results	O
.	O
PCR	O
-	O
generated	O
mutation	O
-	O
specific	O
positive	O
controls	O
were	O
created	O
for	O
all	O
possible	O
RAS	O
mutations	O
,	O
and	O
these	O
along	O
with	O
wild	O
-	O
type	O
DNA	O
controls	O
were	O
integral	O
to	O
interpretation	O
of	O
the	O
oligonucleotide	O
mismatch	O
hybridization	O
assay	O
.	O
By	O
using	O
positive	O
and	O
negative	O
controls	O
,	O
we	O
have	O
detected	O
a	O
relatively	O
low	O
incidence	O
of	O
RAS	O
mutations	O
in	O
archival	O
human	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
1381946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreatology	O
2002	O
;2	O
(	O
1	O
)	O
:17-25	O
Frequent	O
deletions	O
of	O
tumor	O
suppressor	O
genes	O
in	O
pure	O
pancreatic	O
juice	O
from	O
patients	O
with	O
tumoral	O
or	O
nontumoral	O
pancreatic	O
diseases	O
.	O
Costentin	O
L,	O
Pages	O
P,	O
Bouisson	O
M,	O
Berthelemy	O
P,	O
Buscail	O
L,	O
Escourrou	O
J,	O
Pradayrol	O
L,	O
Vaysse	O
N	O
.	O
INSERM	O
,	O
U531	O
Biologie	O
,	O
Pathologie	O
Digestive	O
et	O
Departement	O
de	O
Gastroenterologie	O
,	O
CHU	O
Rangueil	O
,	O
1	O
,	O
avenue	O
J.-Poulhes	O
F-31403	O
Toulouse	O
,	O
France	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
K-ras	O
codon	O
12	O
mutation	O
is	O
the	O
most	O
frequent	O
genetic	O
alteration	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Sensitivity	O
and	O
specificity	O
of	O
K-ras	O
are	O
not	O
high	O
enough	O
to	O
detect	O
all	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
especially	O
at	O
early	O
stage	O
.	O
This	O
study	O
investigated	O
whether	O
detection	O
of	O
p16	O
and/or	O
DPC4	O
deletions	O
along	O
with	O
K-ras	O
mutation	O
in	O
DNA	O
samples	O
could	O
improve	O
the	O
definition	O
of	O
patients	O
at	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
K-ras	O
mutations	O
were	O
investigated	O
by	O
sequencing	O
.	O
p16	O
and	O
DPC4	O
homozygous	O
deletions	O
were	O
studied	O
using	O
comparative	O
multiplex	O
polymerase	O
chain	O
reaction	O
of	O
DNA	O
in	O
pancreatic	O
juice	O
sampled	O
during	O
endoscopic	O
retrograde	O
pancreatography	O
in	O
57	O
patients	O
with	O
either	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
(	O
group	O
I	O
,	O
18	O
patients	O
)	O
,	O
chronic	O
pancreatitis	O
(	O
group	O
II	O
,	O
20	O
patients	O
)	O
,	O
or	O
nontumoral	O
pancreatobiliary	O
disease	O
(	O
group	O
III	O
,	O
19	O
patients	O
)	O
.	O
RESULTS	O
:	O
The	O
frequencies	O
of	O
Ki-ras	O
mutations	O
were	O
61	O
%	O
in	O
group	O
I	O
,	O
10	O
%	O
in	O
group	O
II	O
,	O
and	O
10.5	O
%	O
in	O
group	O
III	O
.	O
The	O
frequencies	O
of	O
p16	O
exon	O
2	O
and	O
DPC4	O
deletions	O
were	O
,	O
respectively	O
,	O
28	O
and	O
36	O
%	O
in	O
group	O
I	O
,	O
50	O
and	O
58	O
%	O
in	O
group	O
II	O
,	O
and	O
24	O
and	O
36	O
%	O
in	O
group	O
III	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
p16	O
and	O
DPC4	O
deletions	O
with	O
K-ras	O
mutation	O
does	O
not	O
improve	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
based	O
on	O
K-ras	O
mutation	O
alone	O
.	O
These	O
data	O
suggest	O
that	O
tumor	O
suppressor	O
gene	O
inactivation	O
can	O
occur	O
with	O
a	O
high	O
frequency	O
during	O
nonmalignant	O
pancreatic	O
diseases	O
.	O
PMID	O
:	O
12120000	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Radiat	O
Oncol	O
Biol	O
Phys	O
1996	O
Jan	O
1;34(	O
1	O
)	O
:161	O
-	O
6	O
C-Ki-ras	O
mutations	O
in	O
peripheral	O
blood	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
patients	O
:	O
a	O
marker	O
for	O
early	O
tumor	O
metastasis	O
.	O
Mohiuddin	O
M,	O
Ahmed	O
MM	O
,	O
Venkatasubbarao	O
K.	O
Department	O
of	O
Radiation	O
Medicine	O
,	O
University	O
of	O
Kentucky	O
,	O
Lexington	O
40536	O
-0084	O
,	O
USA	O
.	O
PURPOSE	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
circulating	O
minimal	O
malignant	O
clone	O
(	O
CMMC	O
)	O
(	O
harboring	O
c-Ki-ras-2	O
mutation	O
)	O
in	O
peripheral	O
blood	O
(	O
PB	O
)	O
samples	O
of	O
untreated	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analysis	O
of	O
c-Ki-ras-2	O
oncogene	O
.	O
METHODS	O
AND	O
MATERIALS	O
:	O
Experiments	O
were	O
carried	O
out	O
in	O
fresh	O
tumor	O
,	O
peritoneal	O
washings	O
(	O
PW	O
)	O
,	O
and	O
PB	O
samples	O
of	O
untreated	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
patients	O
(	O
both	O
resectable	O
and	O
unresectable	O
)	O
.	O
Samples	O
were	O
taken	O
from	O
16	O
patients	O
diagnosed	O
with	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
for	O
the	O
PCR	O
analysis	O
of	O
mutated	O
c-Ki-ras	O
oncogene	O
.	O
Five	O
tumor	O
samples	O
,	O
15	O
PB	O
samples	O
,	O
and	O
3	O
PW	O
samples	O
were	O
analyzed	O
for	O
point	O
mutation	O
of	O
the	O
c-Ki-ras	O
gene	O
at	O
codon	O
12	O
.	O
RESULTS	O
:	O
Out	O
of	O
five	O
tumor	O
samples	O
analyzed	O
for	O
c-Ki-ras	O
mutation	O
,	O
four	O
were	O
positive	O
at	O
the	O
12th	O
codon	O
.	O
Out	O
of	O
total	O
15	O
PB	O
samples	O
,	O
nine	O
were	O
positive	O
for	O
the	O
c-Ki-ras	O
point	O
mutation	O
at	O
the	O
12th	O
codon	O
.	O
All	O
the	O
positive	O
PB	O
samples	O
showed	O
a	O
base	O
substitution	O
from	O
GGT	O
to	O
GAT	O
in	O
the	O
second	O
position	O
of	O
the	O
12th	O
codon	O
.	O
Out	O
of	O
three	O
PW	O
samples	O
,	O
two	O
showed	O
mutation	O
at	O
the	O
second	O
position	O
from	O
GGT	O
to	O
GAT	O
similar	O
to	O
their	O
PB	O
and	O
tumor	O
samples	O
.	O
CONCLUSION	O
:	O
Our	O
study	O
indicated	O
the	O
presence	O
of	O
the	O
tumor	O
cells	O
(	O
CMMC	O
)	O
in	O
PB	O
of	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
that	O
can	O
be	O
identified	O
by	O
PCR	O
analysis	O
of	O
c-Ki-ras	O
oncogene	O
.	O
Patients	O
with	O
presence	O
of	O
CMMC	O
in	O
PB	O
and	O
mutation	O
in	O
PW	O
had	O
aggressive	O
tumors	O
that	O
responded	O
poorly	O
to	O
treatment	O
.	O
PMID	O
:	O
12118546	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2002	O
Mar;9	O
3	O
(	O
3	O
)	O
:	O
267	O
-	O
74	O
Mutations	O
of	O
p53	O
,	O
c-kit	O
,	O
K-ras	O
,	O
and	O
beta-catenin	O
gene	O
in	O
non	B-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
adrenal	I-malignancy-type
gland	I-malignancy-type
.	O
Nakatsuka	O
S	O
,	O
Hongyo	O
T	O
,	O
Syaifudin	O
M,	O
Nomura	O
T	O
,	O
Shingu	O
N	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Suita	O
,	O
Osaka	O
56	O
5	O
-0871	O
,	O
Japan	O
.	O
Malignant	O
lymphoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
adrenal	I-malignancy-type
gland	I-malignancy-type
is	O
a	O
rare	O
disease	O
,	O
usually	O
with	O
diffuse	O
large	O
cell	O
morphology	O
and	O
B-cell	O
immunophenotype	O
,	O
and	O
often	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
.	O
In	O
this	O
study	O
,	O
mutations	O
of	O
p53	O
,	O
c-kit	O
,	O
K-ras	O
,	O
and	O
beta-catenin	O
gene	O
were	O
analyzed	O
in	O
17	O
cases	O
(	O
13	O
males	O
and	O
four	O
females	O
with	O
ages	O
ranging	O
from	O
25	O
to	O
84	O
years	O
)	O
of	O
such	O
lymphomas	B-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
followed	O
by	O
direct	O
sequencing	O
.	O
Selected	O
exons	O
in	O
each	O
gene	O
,	O
representing	O
hot	O
spots	O
,	O
were	O
analyzed	O
.	O
All	O
44	O
mutations	O
detected	O
were	O
single	O
-	O
nucleotide	O
substitutions	O
and	O
33	O
were	O
missense	O
mutations	O
.	O
Nineteen	O
mutations	O
were	O
detected	O
in	O
exon	O
5	O
and	O
/	O
or	O
7	O
of	O
the	O
p53	O
gene	O
in	O
nine	O
of	O
17	O
cases	O
(	O
52.9	O
%	O
)	O
and	O
21	O
in	O
exon	O
11	O
and	O
/	O
or	O
17	O
of	O
the	O
c-kit	O
gene	O
in	O
10	O
of	O
14	O
cases	O
(	O
71.4	O
%	O
)	O
.	O
Bilateral	O
adrenal	B-malignancy-type
lesions	I-malignancy-type
in	O
one	O
case	O
who	O
had	O
not	O
received	O
any	O
adjuvant	O
therapy	O
showed	O
different	O
mutational	O
patterns	O
of	O
the	O
p53	O
and	O
c-kit	O
genes	O
,	O
suggesting	O
different	O
clonal	O
evolution	O
of	O
lymphoma	B-malignancy-type
between	O
the	O
left	O
and	O
right	O
sides	O
.	O
Mutation	O
at	O
codon	O
13	O
of	O
the	O
K-ras	O
gene	O
was	O
detected	O
in	O
one	O
of	O
14	O
cases	O
(	O
7.1	O
%	O
)	O
,	O
and	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
three	O
of	O
12	O
cases	O
(	O
25	O
%	O
)	O
.	O
All	O
but	O
one	O
mutation	O
were	O
transition	O
mutations	O
,	O
indicating	O
that	O
some	O
endogenous	O
mutagens	O
act	O
in	O
lymphomagenesis	O
in	O
the	O
adrenal	O
gland	O
.	O
Our	O
results	O
suggest	O
that	O
p53	O
and	O
c-kit	O
gene	O
mutations	O
might	O
play	O
a	O
role	O
in	O
adrenal	O
lymphomagenesis	O
.	O
PMID	O
:	O
11927008	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
2002	O
Mar;82	O
(	O
3	O
)	O
:257	O
-64	O
Gene	O
mutations	O
in	O
lymphoproliferative	B-malignancy-type
disorders	I-malignancy-type
of	I-malignancy-type
T	I-malignancy-type
and	I-malignancy-type
NK	I-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
cell	I-malignancy-type
phenotypes	I-malignancy-type
developing	O
in	O
renal	O
transplant	O
patients	O
.	O
Hoshida	O
Y	O
,	O
Hongyo	O
T	O
,	O
Nakatsuka	O
S	O
,	O
Nishiu	O
M,	O
Takakuwa	O
T	O
,	O
Tomita	O
Y	O
,	O
Nomura	O
T	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Osaka	O
,	O
Japan	O
.	O
Post	B-malignancy-type
-	I-malignancy-type
transplantation	I-malignancy-type
lymphoproliferative	I-malignancy-type
disorder	I-malignancy-type
(	O
PT-LPD	B-malignancy-type
)	O
is	O
characterized	O
by	O
lymphoid	O
proliferation	O
after	O
organ	O
or	O
bone	O
marrow	O
transplantation	O
.	O
In	O
Western	O
countries	O
,	O
most	O
cases	O
of	O
PT-LPD	O
are	O
B-cell	O
-	O
derived	O
and	O
Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
,	O
in	O
which	O
alterations	O
of	O
c-myc	O
,	O
p53	O
,	O
and	O
N-ras	O
genes	O
might	O
play	O
a	O
role	O
in	O
disease	O
progression	O
.	O
In	O
Japan	O
,	O
PT-LPD	B-malignancy-type
of	I-malignancy-type
T	I-malignancy-type
-	I-malignancy-type
and	I-malignancy-type
NK	I-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
types	I-malignancy-type
are	O
not	O
uncommon	O
in	O
renal	O
transplant	O
patients	O
.	O
Mutations	O
of	O
p53	O
(	O
exons	O
4	O
through	O
8	O
)	O
,	O
K-ras	O
(	O
exons	O
1	O
and	O
2	O
)	O
,	O
c-kit	O
(	O
exons	O
11	O
and	O
17	O
)	O
,	O
and	O
beta-catenin	O
genes	O
(	O
exon	O
3	O
)	O
in	O
12	O
cases	O
of	O
these	O
diseases	O
were	O
analyzed	O
by	O
PCR	O
single	O
strand	O
conformation	O
polymorphism	O
and	O
then	O
by	O
direct	O
sequencing	O
.	O
p53	O
gene	O
mutations	O
were	O
detected	O
in	O
5	O
of	O
5	O
cases	O
of	O
peripheral	B-malignancy-type
T-cell	I-malignancy-type
lymphoma	I-malignancy-type
,	O
3	O
(	O
60	O
%	O
)	O
of	O
5	O
cases	O
of	O
adult	B-malignancy-type
T-cell	I-malignancy-type
leukemia	I-malignancy-type
/	I-malignancy-type
lymphoma	I-malignancy-type
,	O
and	O
1	O
of	O
2	O
cases	O
of	O
NK	B-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Twenty-five	O
percent	O
of	O
T	B-malignancy-type
and	I-malignancy-type
NK	I-malignancy-type
/	I-malignancy-type
T	I-malignancy-type
cell	I-malignancy-type
lymphomas	I-malignancy-type
showed	O
K-ras	O
mutations	O
.	O
Mutations	O
of	O
c-kit	O
and	O
beta-catenin	O
genes	O
were	O
found	O
in	O
33	O
%	O
of	O
cases	O
.	O
Among	O
a	O
total	O
of	O
42	O
substitution	O
mutations	O
,	O
40	O
were	O
transitions	O
with	O
involvement	O
of	O
CpG	O
sites	O
in	O
20	O
to	O
30	O
%	O
of	O
cases	O
.	O
Most	O
cases	O
had	O
at	O
least	O
one	O
mutation	O
that	O
changed	O
an	O
amino	O
acid	O
,	O
which	O
might	O
have	O
provided	O
the	O
selection	O
pressure	O
for	O
expansion	O
.	O
These	O
findings	O
suggested	O
that	O
p53	O
gene	O
mutations	O
might	O
play	O
a	O
central	O
role	O
in	O
development	O
of	O
peripheral	B-malignancy-type
T-cell	I-malignancy-type
lymphoma	I-malignancy-type
including	O
adult	B-malignancy-type
T-cell	I-malignancy-type
leukemia	I-malignancy-type
/	I-malignancy-type
lymphoma	I-malignancy-type
in	O
renal	O
transplant	O
patients	O
.	O
PMID	O
:	O
11896204	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2002	O
Jan	O
1;94	O
(	O
1	O
)	O
:	O
219	O
-	O
27	O
Detection	O
of	O
genetic	O
alterations	O
in	O
the	O
p53	O
suppressor	O
gene	O
and	O
the	O
K-ras	O
oncogene	O
among	O
different	O
grades	O
of	O
dysplasia	O
in	O
patients	O
with	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
Hosaka	O
S	O
,	O
Aoki	O
Y	O
,	O
Akamatsu	O
T	O
,	O
Nakamura	O
N	O
,	O
Hosaka	O
N	O
,	O
Kiyosawa	O
K.	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Shinshu	O
University	O
School	O
of	O
Medicine	O
,	O
Matsumoto	O
,	O
Nagano	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Although	O
it	O
is	O
believed	O
that	O
p53	O
suppressor	O
gene	O
mutations	O
,	O
compared	O
with	O
mutations	O
in	O
the	O
K-ras	O
oncogene	O
,	O
occur	O
at	O
a	O
later	O
stage	O
of	O
colorectal	O
tumorigenesis	O
,	O
the	O
distribution	O
of	O
these	O
genetic	O
alterations	O
at	O
an	O
early	O
stage	O
remains	O
poorly	O
characterized	O
.	O
METHODS	O
:	O
The	O
authors	O
analyzed	O
the	O
immunoreactivity	O
for	O
p53	O
protein	O
(	O
p53	O
protein	O
expression	O
)	O
,	O
which	O
reflects	O
the	O
functionally	O
altered	O
p53	O
gene	O
,	O
and	O
K-ras	O
mutations	O
at	O
codons	O
12	O
in	O
68	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
with	O
both	O
low	O
-	O
grade	O
and	O
high	O
-	O
grade	O
dysplasia	O
obtained	O
from	O
62	O
patients	O
.	O
RESULTS	O
:	O
The	O
prevalence	O
of	O
p53	O
positive	O
immunostaining	O
was	O
significantly	O
greater	O
compared	O
with	O
the	O
prevalence	O
of	O
K-ras	O
mutations	O
both	O
in	O
low	O
-	O
grade	O
dysplasia	O
and	O
in	O
high	O
-	O
grade	O
dysplasia	O
.	O
Twenty-two	O
adenomas	B-malignancy-type
(	O
32.3	O
%	O
)	O
showed	O
positive	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
also	O
were	O
positive	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
20	O
adenomas	B-malignancy-type
(	O
29.4	O
%	O
)	O
showed	O
positive	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
were	O
negative	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
8	O
adenomas	B-malignancy-type
(	O
11.7	O
%	O
)	O
showed	O
negative	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
were	O
positive	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
and	O
18	O
adenomas	B-malignancy-type
(	O
26.4	O
%	O
)	O
showed	O
negative	O
immunostaining	O
for	O
p53	O
protein	O
in	O
both	O
high	O
-	O
grade	O
dysplasia	O
and	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
.	O
On	O
the	O
whole	O
,	O
a	O
significant	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
was	O
seen	O
in	O
the	O
frequency	O
of	O
p53	O
positive	O
immunostaining	O
between	O
low	O
-	O
grade	O
dysplasia	O
and	O
high	O
-	O
grade	O
dysplasia	O
(	O
44.1	O
%	O
and	O
61.8	O
%	O
,	O
respectively	O
)	O
but	O
not	O
in	O
that	O
of	O
K-ras	O
mutations	O
(	O
20.3	O
%	O
and	O
23.4	O
%	O
,	O
respectively	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
mutation	O
of	O
the	O
p53	O
suppressor	O
gene	O
occurs	O
earlier	O
in	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
than	O
K-ras	O
mutation	O
,	O
providing	O
a	O
clue	O
for	O
further	O
understanding	O
of	O
the	O
role	O
of	O
the	O
p53	O
gene	O
in	O
the	O
early	O
stage	O
of	O
colorectal	O
tumorigenesis	O
.	O
Copyright	O
2002	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11815980	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virchows	O
Arch	O
2001	O
Dec;439	O
(	O
6	O
)	O
:	O
798-802	O
Genetic	O
profile	O
of	O
22	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
.	O
Analysis	O
of	O
K-ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
/	O
Smad4	O
.	O
Moore	O
PS	O
,	O
Sipos	O
B	O
,	O
Orlandini	O
S	O
,	O
Sorio	O
C	O
,	O
Real	O
FX	O
,	O
Lemoine	O
NR	O
,	O
Gress	O
T	O
,	O
Bassi	O
C	O
,	O
Kloppel	O
G	O
,	O
Kalthoff	O
H,	O
Ungefroren	O
H,	O
Lohr	O
M,	O
Scarpa	O
A	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Verona	O
,	O
Italy	O
.	O
The	O
K-ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
genes	O
are	O
among	O
those	O
most	O
frequently	O
altered	O
in	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
analyzed	O
22	O
cell	O
lines	O
for	O
alterations	O
in	O
these	O
genes	O
by	O
direct	O
sequence	O
analysis	O
and	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O
These	O
cell	O
lines	O
showed	O
mutations	O
in	O
K-ras	O
and	O
p53	O
at	O
frequencies	O
of	O
91	O
%	O
and	O
95	O
%	O
,	O
respectively	O
.	O
Alterations	O
in	O
p16INK4a	O
were	O
found	O
in	O
all	O
cases	O
and	O
included	O
nine	O
homozygous	O
deletions	O
,	O
seven	O
mutations	O
and	O
promoter	O
methylation	O
in	O
six	O
cases	O
.	O
Eight	O
cell	O
lines	O
(	O
36	O
%	O
)	O
had	O
an	O
alteration	O
of	O
DPC4	O
,	O
including	O
one	O
mutation	O
and	O
seven	O
homozygous	O
deletions	O
.	O
The	O
most	O
typical	O
mutational	O
profile	O
involved	O
K-ras	O
,	O
p53	O
,	O
and	O
p16INK4a	O
,	O
concurrently	O
aberrated	O
in	O
20	O
cases	O
(	O
91	O
%	O
)	O
.	O
Eight	O
cell	O
lines	O
had	O
alterations	O
in	O
all	O
four	O
genes	O
.	O
Inactivation	O
of	O
DPC4	O
was	O
always	O
accompanied	O
by	O
alteration	O
of	O
all	O
of	O
the	O
other	O
three	O
genes	O
.	O
This	O
comprehensive	O
data	O
regarding	O
the	O
cumulative	O
genetic	O
alterations	O
in	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
will	O
be	O
of	O
great	O
value	O
for	O
studies	O
involving	O
drug	O
sensitivity	O
or	O
resistance	O
that	O
may	O
be	O
associated	O
with	O
inactivation	O
of	O
a	O
particular	O
gene	O
or	O
molecular	O
pathway	O
.	O
PMID	O
:	O
11787853	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Lymphoma	O
2001	O
Jul;42(	O
3	O
)	O
:473	O
-	O
9	O
Lack	O
of	O
association	O
between	O
N-ras	O
gene	O
mutations	O
and	O
clinical	O
prognosis	O
in	O
Brazilian	O
children	O
with	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Clementino	O
NC	O
,	O
Yamamoto	O
M,	O
Viana	O
MB	O
,	O
Figueiredo	O
MS	O
,	O
Kerbauy	O
J,	O
Saad	O
ST	O
,	O
Costa	O
FF.	O
Federal	O
University	O
of	O
Sao	O
Paulo	O
,	O
UNIFESP-EPM	O
,	O
Federal	O
University	O
of	O
Minas	O
Gerais	O
,	O
UFMG	O
,	O
S.	O
Paulo	O
,	O
Brazil	O
.	O
Point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
have	O
been	O
detected	O
in	O
several	O
human	O
malignancies	O
.	O
We	O
studied	O
170	O
patients	O
with	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
,	O
treated	O
from	O
1988	O
to	O
1994	O
according	O
to	O
a	O
protocol	O
derived	O
from	O
BFM-83	O
studies	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutations	O
in	O
this	O
gene	O
in	O
childhood	O
ALL	O
.	O
DNA	O
was	O
extracted	O
from	O
bone	O
marrow	O
smears	O
at	O
diagnosis	O
and	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
After	O
screening	O
with	O
SSCP	O
,	O
PCR	O
products	O
were	O
hybridized	O
with	O
allele	O
specific	O
probes	O
and	O
,	O
in	O
some	O
cases	O
,	O
cloned	O
in	O
a	O
pMOS	O
Blue	O
T	O
vector	O
and	O
sequenced	O
.	O
Exon	O
2	O
was	O
also	O
studied	O
in	O
101	O
children	O
.	O
Our	O
results	O
showed	O
4	O
%	O
of	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
and	O
2	O
%	O
in	O
exon	O
2	O
.	O
Similar	O
to	O
a	O
previous	O
report	O
,	O
we	O
identified	O
7	O
%	O
of	O
mutations	O
among	O
children	O
who	O
were	O
studied	O
for	O
both	O
exons	O
.	O
A	O
new	O
mutation	O
in	O
codon	O
64	O
of	O
the	O
N-ras	O
gene	O
was	O
detected	O
in	O
one	O
patient	O
.	O
No	O
significant	O
clinical	O
differences	O
between	O
patients	O
with	O
and	O
without	O
mutations	O
were	O
detected	O
(	O
sex	O
,	O
age	O
,	O
leukocyte	O
counts	O
at	O
diagnosis	O
,	O
nutritional	O
status	O
,	O
and	O
risk	O
factor	O
according	O
to	O
the	O
BFM	O
protocol	O
)	O
.	O
Children	O
with	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
showed	O
significantly	O
higher	O
reactivity	O
to	O
PAS	O
staining	O
on	O
blast	O
cells	O
than	O
children	O
with	O
a	O
wild	O
type	O
N-ras	O
gene	O
configuration	O
.	O
Comparison	O
of	O
overall	O
-	O
and	O
recurrence	O
-	O
free	O
survival	O
did	O
not	O
show	O
significant	O
difference	O
between	O
groups	O
with	O
and	O
without	O
mutations	O
.	O
Our	O
results	O
suggest	O
that	O
mutations	O
in	O
the	O
ras	O
gene	O
are	O
infrequent	O
in	O
children	O
with	O
ALL	B-malignancy-type
at	O
diagnosis	O
and	O
seem	O
to	O
be	O
of	O
low	O
prognostic	O
value	O
.	O
PMID	O
:	O
11699412	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Jul	O
1;9	O
2	O
(	O
1	O
)	O
:	O
136-45	O
beta-Catenin	O
mutation	O
and	O
overexpression	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
:	O
clinicopathologic	O
and	O
prognostic	O
significance	O
.	O
Wong	O
CM	O
,	O
Fan	O
ST	O
,	O
Ng	O
IO	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Hong	O
Kong	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
Pokfulam	O
,	O
Hong	O
Kong	O
.	O
BACKGROUND	O
:	O
beta-Catenin	O
has	O
been	O
recognized	O
as	O
a	O
critical	O
member	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
and	O
inappropriate	O
activation	O
of	O
this	O
pathway	O
has	O
been	O
implicated	O
in	O
carcinogenesis	O
.	O
METHODS	O
:	O
To	O
determine	O
the	O
clinical	O
significance	O
of	O
beta-catenin	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
,	O
we	O
performed	O
mutational	O
analysis	O
at	O
exon	O
3	O
of	O
the	O
gene	O
,	O
investigated	O
the	O
subcellular	O
protein	O
expression	O
,	O
and	O
analyzed	O
their	O
clinicopathologic	O
and	O
prognostic	O
significance	O
in	O
60	O
patients	O
with	O
resected	O
primary	O
HCC	B-malignancy-type
.	O
RESULTS	O
:	O
By	O
direct	O
DNA	O
sequencing	O
,	O
somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
were	O
detected	O
in	O
7	O
(	O
12	O
%	O
)	O
HCCs	O
.	O
All	O
the	O
mutations	O
were	O
found	O
at	O
the	O
region	O
(	O
exon	O
3	O
)	O
responsible	O
for	O
phosphorylation	O
and	O
ubiquitination	O
,	O
therefore	O
likely	O
to	O
result	O
in	O
stabilization	O
of	O
free	O
cytoplasmic	O
beta-catenin	O
.	O
Nuclear	O
accumulation	O
of	O
the	O
beta-catenin	O
protein	O
,	O
similar	O
to	O
the	O
response	O
to	O
the	O
Wnt	O
signal	O
,	O
was	O
found	O
in	O
10	O
(	O
17	O
%	O
)	O
HCCs	B-malignancy-type
and	O
was	O
closely	O
associated	O
with	O
gene	O
mutation	O
(	O
P	O
<	O
0.001	O
)	O
.	O
In	O
the	O
remaining	O
cases	O
,	O
nonnuclear	O
type	O
overexpression	O
,	O
that	O
is	O
,	O
overexpression	O
in	O
the	O
cytoplasm	O
and/or	O
cytoplasmic	O
membrane	O
,	O
was	O
observed	O
in	O
31	O
(	O
62	O
%	O
)	O
HCCs	B-malignancy-type
,	O
thus	O
suggesting	O
that	O
the	O
mechanisms	O
leading	O
to	O
beta-catenin	O
overexpression	O
may	O
be	O
heterogeneous	O
.	O
HCCs	B-malignancy-type
with	O
a	O
nonnuclear	O
type	O
of	O
beta-catenin	O
overexpression	O
were	O
more	O
frequently	O
larger	O
than	O
5	O
cm	O
in	O
diameter	O
(	O
P	O
=	O
0.022	O
)	O
and	O
had	O
poorer	O
cellular	O
differentiation	O
(	O
P	O
=	O
0.037	O
)	O
,	O
and	O
the	O
patients	O
had	O
significantly	O
shorter	O
disease	O
-	O
free	O
survival	O
lengths	O
(	O
P	O
=	O
0.041	O
)	O
.	O
Review	O
of	O
the	O
data	O
from	O
previous	O
studies	O
in	O
HCC	B-malignancy-type
showed	O
that	O
beta-catenin	O
mutations	O
were	O
more	O
frequent	O
in	O
HCV	O
-	O
associated	O
HCC	B-malignancy-type
than	O
in	O
HBV	O
-	O
associated	O
ones	O
.	O
CONCLUSIONS	O
:	O
beta-catenin	O
mutation	O
and	O
deregulation	O
may	O
play	O
an	O
important	O
role	O
in	O
hepatocarcinogenesis	O
.	O
Nonnuclear	O
type	O
beta-catenin	O
overexpression	O
appeared	O
to	O
have	O
pathologic	O
and	O
prognostic	O
significance	O
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11443619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Mol	O
Pathol	O
2001	O
Jun;70	O
(	O
3	O
)	O
:195-200	O
Rapid	O
,	O
efficient	O
genotyping	O
of	O
clinical	O
tumor	O
samples	O
by	O
laser	O
-	O
capture	O
microdissection	O
/	O
PCR	O
/	O
SSCP	O
.	O
Dillon	O
D	O
,	O
Zheng	O
K,	O
Costa	O
J.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06520	O
,	O
USA	O
.	O
Background	O
:	O
Mutation	O
analysis	O
is	O
becoming	O
increasingly	O
important	O
in	O
clinical	O
practice	O
,	O
since	O
sporadic	O
mutations	O
in	O
tumors	O
often	O
correlate	O
with	O
prognosis	O
and/or	O
therapeutic	O
response	O
.	O
However	O
,	O
the	O
labor	O
-	O
intensive	O
nature	O
of	O
the	O
molecular	O
analyses	O
has	O
limited	O
the	O
routine	O
clinical	O
use	O
of	O
tumor	O
genotyping	O
.	O
Laser	O
-	O
capture	O
microdissection	O
(	O
LCM	O
)	O
allows	O
procurement	O
of	O
relatively	O
pure	O
tumor	O
cell	O
populations	O
.	O
We	O
have	O
investigated	O
the	O
possibility	O
that	O
the	O
use	O
of	O
laser	O
-	O
capture	O
microdissection	O
would	O
allow	O
elimination	O
of	O
time	O
-	O
consuming	O
intermediate	O
steps	O
in	O
tumor	O
genotyping	O
.	O
Design	O
.	O
Archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
seven	O
cases	O
of	O
colorectal	B-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
laser	O
-	O
and	O
hand	O
-	O
microdissected	O
and	O
subsequently	O
evaluated	O
by	O
PCR	O
/	O
SSCP	O
/	O
sequencing	O
for	O
Ki-ras	O
exon	O
1	O
and	O
p53	O
exons	O
5	O
,	O
7	O
,	O
and	O
8	O
.	O
Results	O
.	O
Mutations	O
in	O
Ki-ras	O
exon	O
1	O
and/or	O
p53	O
exons	O
5	O
and	O
7	O
were	O
detected	O
in	O
five	O
of	O
the	O
seven	O
samples	O
.	O
In	O
the	O
hand	O
-	O
microdissected	O
samples	O
,	O
confident	O
identification	O
of	O
mutations	O
was	O
possible	O
in	O
several	O
cases	O
only	O
after	O
band	O
excision	O
,	O
DNA	O
elution	O
,	O
reamplification	O
,	O
and	O
verification	O
of	O
mutant	O
enrichment	O
by	O
a	O
second	O
SSCP	O
analysis	O
prior	O
to	O
sequencing	O
.	O
In	O
the	O
laser	O
-	O
microdissected	O
samples	O
,	O
confident	O
mutation	O
identification	O
was	O
possible	O
in	O
all	O
cases	O
with	O
direct	O
sequencing	O
of	O
the	O
original	O
PCR	O
product	O
,	O
reducing	O
the	O
time	O
required	O
for	O
molecular	O
analysis	O
to	O
3	O
days	O
.	O
Conclusion	O
.	O
Using	O
laser	O
-	O
capture	O
microdissection	O
,	O
mutant	O
signals	O
are	O
strong	O
enough	O
to	O
sequence	O
directly	O
from	O
original	O
PCR	O
products	O
.	O
With	O
rapid	O
,	O
efficient	O
genotyping	O
by	O
LCM	O
/	O
PCR	O
/	O
SSCP	O
,	O
results	O
can	O
be	O
incorporated	O
directly	O
into	O
the	O
surgical	O
pathology	O
report	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11417998	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dig	O
Dis	O
Sci	O
2000	O
Nov;45(	O
11	O
)	O
:2187	O
-	O
94	O
No	O
major	O
difference	O
in	O
K-ras	O
and	O
p53	O
abnormalities	O
in	O
sporadic	B-malignancy-type
and	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
.	O
Voskuil	O
DW	O
,	O
Kampman	O
E	O
,	O
van	O
Geloof	O
W	O
,	O
Grubben	O
M,	O
Kok	O
F	O
,	O
van	O
Muijen	O
G	O
,	O
Nagengast	O
F	O
,	O
Vasen	O
H	O
,	O
van't	O
Veer	O
P.	O
Division	O
of	O
Human	O
Nutrition	O
and	O
Epidemiology	O
,	O
Wageningen	O
University	O
,	O
The	O
Netherlands	O
.	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
are	O
known	O
to	O
occur	O
in	O
high	O
frequencies	O
in	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
cancers	I-malignancy-type
,	O
but	O
findings	O
are	O
inconsistent	O
in	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
HNPCC	B-malignancy-type
)	O
.	O
We	O
compared	O
K-ras	O
codon	O
12	O
and	O
13	O
gene	O
mutations	O
and	O
p53	O
protein	O
overexpression	O
in	O
48	O
HNPCC	B-malignancy-type
(	O
positive	O
for	O
Amsterdam	O
criteria	O
)	O
and	O
59	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
,	O
to	O
examine	O
whether	O
they	O
may	O
represent	O
similar	O
or	O
different	O
molecular	O
pathways	O
to	O
cancer	O
.	O
In	O
sporadic	B-malignancy-type
adenomas	I-malignancy-type
K-ras	O
mutations	O
were	O
detected	O
in	O
32	O
%	O
and	O
p53	O
overexpression	O
in	O
31	O
%	O
of	O
the	O
cases	O
.	O
Similarly	O
,	O
K-ras	O
mutations	O
and	O
p53	O
overexpression	O
were	O
both	O
found	O
in	O
25	O
%	O
of	O
HNPCC	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
frequencies	O
of	O
these	O
abnormalities	O
were	O
not	O
significantly	O
different	O
between	O
HNPCC	B-malignancy-type
and	O
sporadic	B-malignancy-type
adenomas	I-malignancy-type
.	O
When	O
taking	O
differences	O
in	O
adenoma	B-malignancy-type
size	O
into	O
account	O
,	O
the	O
frequencies	O
were	O
even	O
more	O
similar	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
suggest	O
a	O
similar	O
molecular	O
pathway	O
to	O
adenomas	B-malignancy-type
in	O
HNPCC	B-malignancy-type
and	O
sporadic	O
carcinogenesis	O
,	O
with	O
respect	O
to	O
involvement	O
of	O
K-ras	O
and	O
p53	O
.	O
PMID	O
:	O
11215737	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dig	O
Dis	O
Sci	O
2000	O
Oct;45(	O
10	O
)	O
:2022	O
-	O
8	O
Combination	O
analysis	O
of	O
genetic	O
alterations	O
and	O
cell	O
proliferation	O
in	O
small	B-malignancy-type
intestinal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Muneyuki	O
T	O
,	O
Watanabe	O
M,	O
Yamanaka	O
M,	O
Isaji	O
S,	O
Kawarada	O
Y	O
,	O
Yatani	O
R.	O
First	O
Department	O
of	O
Surgery	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Tsu	O
-	O
shi	O
,	O
Japan	O
.	O
We	O
analyzed	O
K-ras	O
and	O
p53	O
mutations	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
methods	O
,	O
as	O
well	O
as	O
p53	O
expression	O
and	O
the	O
Ki-67	O
labeling	O
index	O
(	O
LI	O
)	O
using	O
immunohistochemistry	O
in	O
10	O
duodenal	B-malignancy-type
and	O
10	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
two	O
duodenal	B-malignancy-type
(	O
20	O
%	O
)	O
and	O
three	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
30	O
%	O
)	O
carcinomas	B-malignancy-type
and	O
p53	O
mutations	O
in	O
one	O
(	O
10	O
%	O
)	O
and	O
three	O
(	O
30	O
%	O
)	O
,	O
respectively	O
.	O
LOH	O
of	O
17p	O
was	O
detected	O
in	O
two	O
duodenal	B-malignancy-type
(	O
20	O
%	O
)	O
and	O
two	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
20	O
%	O
)	O
carcinomas	B-malignancy-type
and	O
p53	O
expression	O
in	O
four	O
duodenal	B-malignancy-type
(	O
40	O
%	O
)	O
and	O
four	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
40	O
%	O
)	O
.	O
One	O
duodenal	B-malignancy-type
(	O
10	O
%	O
)	O
and	O
two	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
20	O
%	O
)	O
carcinomas	B-malignancy-type
demonstrated	O
MSI	O
.	O
LOH	O
of	O
APC	O
was	O
detected	O
in	O
three	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
(	O
30	O
%	O
)	O
,	O
but	O
none	O
of	O
the	O
duodenal	B-malignancy-type
carcinomas	B-malignancy-type
.	O
The	O
Ki-67	O
LI	O
was	O
44	O
%	O
in	O
duodenal	B-malignancy-type
and	O
52.6	O
%	O
in	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
carcinomas	B-malignancy-type
.	O
A	O
subset	O
of	O
small	B-malignancy-type
intestinal	I-malignancy-type
carcinomas	I-malignancy-type
showed	O
involvement	O
of	O
K-ras	O
and	O
p53	O
mutations	O
,	O
LOH	O
of	O
APC	O
,	O
and	O
MSI	O
.	O
A	O
difference	O
was	O
also	O
apparent	O
for	O
LOH	O
of	O
APC	O
between	O
duodenal	B-malignancy-type
and	O
jejunal	B-malignancy-type
/	O
ileal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
11117578	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Gastroenterol	O
Hepatol	O
2000	O
Oct;15(	O
10	O
)	O
:1151	O
-	O
7	O
Analysis	O
of	O
K-ras	O
codon	O
12	O
mutations	O
and	O
p53	O
overexpression	O
in	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
.	O
Kusaka	O
T	O
,	O
Fukui	O
H	O
,	O
Sano	O
Y	O
,	O
Ueda	O
Y	O
,	O
Chiba	O
T	O
,	O
Fujimori	O
T.	O
Department	O
of	O
Pathology	O
,	O
Dokkyo	O
University	O
School	O
of	O
Medicine	O
,	O
Shimotsuga	O
,	O
Tochigi	O
,	O
Japan	O
.	O
BACKGROUND	O
AND	O
AIMS	O
:	O
Morphologically	O
,	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
are	O
quite	O
different	O
from	O
polypoid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
that	O
develop	O
via	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
.	O
Although	O
polypoid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
are	O
well	O
known	O
to	O
have	O
a	O
high	O
incidence	O
of	O
K-ras	O
gene	O
mutation	O
and	O
p53	O
overexpression	O
,	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
have	O
not	O
been	O
examined	O
in	O
terms	O
of	O
genetic	O
changes	O
and	O
clinicopathological	O
features	O
.	O
In	O
the	O
present	O
study	O
,	O
therefore	O
,	O
we	O
analysed	O
the	O
clinicopathological	O
features	O
,	O
genetic	O
changes	O
in	O
K-ras	O
codon	O
12	O
,	O
and	O
p53	O
overexpression	O
in	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
.	O
METHODS	O
:	O
A	O
total	O
of	O
18	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumors	I-malignancy-type
were	O
surgically	O
resected	O
and	O
then	O
analysed	O
clinicopathologically	O
.	O
Immunohistochemistry	O
and	O
polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
were	O
performed	O
to	O
analyse	O
p53	O
abnormalities	O
in	O
the	O
tumors	O
.	O
K-ras	O
codon	O
12	O
mutations	O
were	O
screened	O
out	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
and	O
analysed	O
by	O
fluorescence	O
direct	O
sequencing	O
.	O
RESULTS	O
:	O
p53	O
overexpression	O
was	O
observed	O
in	O
six	O
lesions	O
(	O
33	O
%	O
)	O
.	O
p53	O
-	O
overexpressing	O
cells	O
were	O
observed	O
in	O
parts	O
of	O
carcinoma	B-malignancy-type
or	O
adenoma	B-malignancy-type
showing	O
high	O
-	O
grade	O
atypia	O
.	O
Four	O
of	O
the	O
10	O
(	O
40	O
%	O
)	O
samples	O
had	O
a	O
p53	O
gene	O
mutation	O
.	O
Nine	O
of	O
the	O
18	O
(	O
50	O
%	O
)	O
samples	O
had	O
a	O
K-ras	O
codon	O
12	O
point	O
mutation	O
.	O
In	O
eight	O
cases	O
(	O
89	O
%	O
)	O
,	O
the	O
mutations	O
of	O
the	O
K-ras	O
codon	O
12	O
were	O
of	O
the	O
same	O
type	O
:	O
GGT	O
(	O
glycine	O
)	O
to	O
GTT	O
(	O
valine	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
colorectal	B-malignancy-type
nodule	I-malignancy-type
-	I-malignancy-type
aggregating	I-malignancy-type
tumor	I-malignancy-type
has	O
distinctive	O
characteristics	O
showing	O
a	O
morphological	O
phenotype	O
of	O
the	O
superficial	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
and	O
genotype	O
of	O
the	O
polypoid	B-malignancy-type
tumors	I-malignancy-type
in	O
terms	O
of	O
K-ras	O
gene	O
mutation	O
and	O
p53	O
overexpression	O
.	O
PMID	O
:	O
11106095	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Gastroenterol	O
2000	O
Oct;95(	O
10	O
)	O
:2953	O
-	O
7	O
Impact	O
of	O
KRAS	O
and	O
TP53	O
mutations	O
on	O
survival	O
in	O
patients	O
with	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
Dukes	I-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
.	O
Bleeker	O
WA	O
,	O
Hayes	O
VM	O
,	O
Karrenbeld	O
A	O
,	O
Hofstra	O
RM	O
,	O
Hermans	O
J,	O
Buys	O
CC	O
,	O
Plukker	O
JT.	O
Department	O
of	O
Surgery	O
,	O
Medical	O
Genetics	O
and	O
Pathology	O
,	O
University	O
Hospital	O
Groningen	O
,	O
The	O
Netherlands	O
.	O
OBJECTIVE	O
:	O
It	O
has	O
been	O
suggested	O
that	O
KRAS	O
and	O
TP53	O
mutated	O
tumors	O
might	O
influence	O
the	O
phenotypic	O
behavior	O
of	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
.	O
We	O
investigated	O
the	O
incidence	O
of	O
these	O
mutations	O
in	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
and	O
their	O
possible	O
influence	O
on	O
survival	O
in	O
a	O
homogeneous	O
group	O
of	O
patients	O
with	O
Dukes	B-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancers	I-malignancy-type
.	O
METHODS	O
:	O
The	O
primary	O
tumors	O
of	O
55	O
patients	O
with	O
a	O
sporadic	B-malignancy-type
Dukes	I-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
,	O
all	O
treated	O
with	O
adjuvant	O
chemotherapy	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
KRAS	O
and	O
TP53	O
mutations	O
.	O
Mutation	O
detection	O
of	O
the	O
KRAS	O
and	O
TP53	O
genes	O
was	O
performed	O
on	O
paraffin	O
-	O
embedded	O
tumor	O
material	O
,	O
using	O
denaturating	O
gradient	O
gel	O
electrophoresis	O
.	O
The	O
5	O
-	O
yr	O
survival	O
rates	O
of	O
KRAS	O
and	O
TP53	O
mutated	O
tumors	O
were	O
analyzed	O
regarding	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
(	O
defined	O
as	O
tumors	B-malignancy-type
up	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
splenic	I-malignancy-type
flexure	I-malignancy-type
)	O
and	O
left	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
(	O
defined	O
as	O
tumors	B-malignancy-type
from	I-malignancy-type
the	I-malignancy-type
splenic	I-malignancy-type
flexure	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
rectosigmoid	I-malignancy-type
peritoneal	I-malignancy-type
reflection	I-malignancy-type
)	O
.	O
RESULTS	O
:	O
KRAS	O
mutations	O
occurred	O
more	O
frequently	O
in	O
the	O
right	O
colon	O
compared	O
to	O
the	O
left	O
colon	O
(	O
R	O
=	O
38	O
%	O
(	O
10	O
/	O
26	O
)	O
;	O
L	O
=	O
10	O
%	O
(	O
3	O
/	O
29	O
)	O
;	O
chi2	O
test	O
:	O
p	O
=	O
0.014	O
)	O
.	O
KRAS	O
mutations	O
did	O
not	O
influence	O
survival	O
in	O
patients	O
with	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
.	O
Patients	O
with	O
KRAS	O
mutation	O
-	O
negative	O
tumors	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
right	I-malignancy-type
colon	I-malignancy-type
,	O
however	O
,	O
had	O
a	O
significantly	O
worse	O
survival	O
than	O
patients	O
with	O
left	O
-	O
sided	O
KRAS	O
mutation	O
-	O
negative	O
tumors	O
(	O
5	O
-	O
yr	O
survival	O
;	O
R	O
:	O
34	O
%	O
vs	O
L	O
:	O
65	O
%	O
,	O
log	O
-	O
rank	O
test	O
:	O
p	O
=	O
0.007	O
)	O
.	O
TP53	O
mutations	O
of	O
a	O
possible	O
causative	O
nature	O
were	O
found	O
in	O
24	O
tumors	O
(	O
44	O
%	O
)	O
.	O
Neither	O
the	O
incidence	O
(	O
R	O
=	O
42	O
%	O
(	O
11	O
/	O
26	O
)	O
;	O
L	O
=	O
45	O
%	O
(	O
13	O
/	O
29	O
)	O
)	O
nor	O
the	O
survival	O
of	O
TP53	O
mutated	O
tumors	O
differed	O
significantly	O
between	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
.	O
Furthermore	O
,	O
survival	O
of	O
patients	O
with	O
TP53	O
mutation	O
-	O
negative	O
tumors	O
did	O
not	O
differ	O
significantly	O
between	O
left	B-malignancy-type
-	I-malignancy-type
and	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
There	O
seems	O
to	O
be	O
no	O
difference	O
in	O
survival	O
rate	O
between	O
patients	O
with	O
KRAS	O
mutated	O
and	O
KRAS	O
negative	O
Dukes	B-malignancy-type
'	I-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
;	O
however	O
,	O
KRAS	O
mutations	O
are	O
more	O
frequently	O
found	O
in	O
the	O
right	O
colon	O
compared	O
to	O
the	O
left	O
colon	O
.	O
TP53	O
mutations	O
do	O
not	O
have	O
predominance	O
for	O
either	O
side	O
of	O
the	O
colon	O
,	O
and	O
there	O
are	O
no	O
differences	O
in	O
survival	O
in	O
patients	O
with	O
left	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
versus	O
right	B-malignancy-type
-	I-malignancy-type
sided	I-malignancy-type
tumors	I-malignancy-type
.	O
Patients	O
with	O
KRAS	O
-	O
nonmutated	O
tumors	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
right	I-malignancy-type
colon	I-malignancy-type
did	O
have	O
a	O
worse	O
survival	O
compared	O
to	O
those	O
with	O
such	O
tumors	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
left	I-malignancy-type
colon	I-malignancy-type
.	O
This	O
suggests	O
that	O
other	O
genetic	O
factors	O
may	O
play	O
a	O
role	O
in	O
tumor	O
genesis	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O
PMID	O
:	O
11051374	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mod	O
Pathol	O
2000	O
Oct;13(	O
10	O
)	O
:1066	O
-	O
71	O
Mutational	O
analysis	O
of	O
the	O
CTNNB1	O
and	O
APC	O
genes	O
in	O
uterine	B-malignancy-type
endometrioid	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Schlosshauer	O
PW	O
,	O
Pirog	O
EC	O
,	O
Levine	O
RL	O
,	O
Ellenson	O
LH.	O
Department	O
of	O
Pathology	O
,	O
Joan	O
and	O
Sanford	O
I	O
.	O
Weill	O
Medical	O
College	O
of	O
Cornell	O
University	O
,	O
New	O
York	O
,	O
USA	O
.	O
Despite	O
recent	O
studies	O
,	O
the	O
molecular	O
genetic	O
events	O
responsible	O
for	O
the	O
development	O
of	O
uterine	B-malignancy-type
endometrioid	I-malignancy-type
carcinoma	I-malignancy-type
(	O
UEC	B-malignancy-type
)	O
remain	O
incompletely	O
characterized	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
(	O
CTNNB1	O
)	O
gene	O
have	O
been	O
recently	O
reported	O
in	O
a	O
small	O
percentage	O
of	O
UECs	B-malignancy-type
and	O
in	O
the	O
endometrioid	B-malignancy-type
variant	I-malignancy-type
of	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
involved	O
in	O
the	O
development	O
of	O
female	B-malignancy-type
genital	I-malignancy-type
tract	I-malignancy-type
tumors	I-malignancy-type
with	O
endometrioid	O
morphology	O
.	O
The	O
Wnt	O
pathway	O
is	O
a	O
critical	O
pathway	O
in	O
the	O
development	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
(	O
CRC	B-malignancy-type
)	O
with	O
mutations	O
occurring	O
in	O
the	O
beta-catenin	O
(	O
CTNNB1	O
)	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
genes	O
in	O
10	O
to	O
15	O
%	O
and	O
85	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
Because	O
UEC	B-malignancy-type
and	O
CRC	B-malignancy-type
share	O
other	O
molecular	O
genetic	O
alterations	O
and	O
histologic	O
features	O
and	O
previous	O
studies	O
of	O
UEC	B-malignancy-type
have	O
not	O
reported	O
an	O
analysis	O
of	O
the	O
APC	O
gene	O
,	O
we	O
chose	O
to	O
further	O
elucidate	O
the	O
role	O
of	O
the	O
Wnt	O
pathway	O
in	O
UEC	B-malignancy-type
.	O
To	O
this	O
end	O
,	O
we	O
analyzed	O
32	O
cases	O
of	O
UEC	B-malignancy-type
for	O
mutations	O
of	O
the	O
CTNNB1	O
and	O
APC	O
genes	O
.	O
Mutations	O
of	O
CTNNB1	O
were	O
present	O
in	O
six	O
of	O
32	O
(	O
18	O
%	O
)	O
cases	O
:	O
four	O
grade	B-malignancy-type
1	I-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
grade	B-malignancy-type
2	I-malignancy-type
,	O
and	O
one	O
grade	B-malignancy-type
3	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Five	O
missense	O
mutations	O
were	O
identified	O
,	O
three	O
involving	O
Ser	O
/	O
Thr	O
phosphorylation	O
sites	O
and	O
two	O
adjacent	O
to	O
a	O
Ser	O
phosphorylation	O
site	O
.	O
One	O
case	O
contained	O
a	O
deletion	O
encompassing	O
codons	O
34	O
to	O
37	O
,	O
which	O
includes	O
a	O
Ser	O
phosphorylation	O
site	O
.	O
No	O
mutations	O
resulting	O
in	O
truncation	O
of	O
the	O
APC	O
protein	O
were	O
found	O
.	O
Our	O
results	O
support	O
a	O
role	O
for	O
the	O
Wnt	O
signaling	O
pathway	O
via	O
mutation	O
of	O
CTNNB1	O
,	O
but	O
not	O
APC	O
,	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
UECs	B-malignancy-type
.	O
PMID	O
:	O
11048799	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pathol	O
Res	O
Pract	O
2000	O
;196(9	O
)	O
:601	O
-	O
5	O
Ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
analysis	O
in	O
cardiac	B-malignancy-type
myxomas	I-malignancy-type
.	O
Karga	O
H	O
,	O
Papaioannou	O
P	O
,	O
Karayianni	O
M,	O
Papadimitriou	O
K	O
,	O
Priftis	O
D	O
,	O
Voujuklakis	O
T	O
,	O
Migdou	O
B	O
,	O
Nanas	O
J,	O
Papapetrou	O
P.	O
Endocrine	O
Unit	O
,	O
Alexandra	O
Hospital	O
,	O
Athens	O
,	O
Greece	O
.	O
Although	O
ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
mutations	O
are	O
implicated	O
in	O
the	O
development	O
of	O
several	O
human	O
tumors	O
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
the	O
pathogenesis	O
of	O
primary	O
cardiac	B-malignancy-type
tumors	I-malignancy-type
.	O
Paraffin	O
-	O
embedded	O
tissue	O
from	O
19	O
cardiac	B-malignancy-type
myxomas	I-malignancy-type
were	O
investigated	O
for	O
the	O
presence	O
of	O
ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
abnormalities	O
.	O
Immunohistochemical	O
analysis	O
was	O
used	O
to	O
identify	O
the	O
accumulation	O
of	O
p21	O
-	O
ras	O
and	O
p53	O
proteins	O
.	O
A	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
amplify	O
exons	O
1	O
and	O
2	O
of	O
the	O
ras	O
genes	O
and	O
exons	O
5	O
to	O
8	O
of	O
the	O
p53	O
gene	O
.	O
The	O
PCR	O
products	O
were	O
analyzed	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
by	O
direct	O
DNA	O
sequencing	O
.	O
Three	O
of	O
19	O
myxomas	B-malignancy-type
showed	O
strong	O
positive	O
staining	O
for	O
the	O
ras	O
p21	O
protein	O
.	O
In	O
contrast	O
,	O
nuclear	O
p53	O
was	O
not	O
detectable	O
in	O
any	O
of	O
the	O
myxomas	B-malignancy-type
.	O
Among	O
the	O
ras	O
p21	O
immunopositive	O
myxomas	B-malignancy-type
,	O
2	O
were	O
heterozygous	O
for	O
a	O
missense	O
point	O
mutation	O
of	O
the	O
K-ras	O
,	O
Gly	O
12	O
Asp	O
.	O
Further	O
screening	O
of	O
the	O
remaining	O
myxomas	B-malignancy-type
showed	O
no	O
mutation	O
or	O
even	O
silent	O
polymorphism	O
in	O
any	O
exon	O
of	O
the	O
ras	O
and	O
p53	O
.	O
The	O
results	O
suggest	O
that	O
although	O
genetic	O
alterations	O
of	O
ras	O
oncogenes	O
and	O
p53	O
are	O
uncommon	O
events	O
in	O
cardiac	B-malignancy-type
myxomas	I-malignancy-type
,	O
ras	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
a	O
subgroup	O
of	O
this	O
type	O
of	O
tumor	B-malignancy-type
.	O
PMID	O
:	O
10997733	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Arch	O
Pathol	O
Lab	O
Med	O
2000	O
Jun;124(	O
6)	O
:836	O
-	O
9	O
ras	O
gene	O
mutations	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
.	O
Yoo	O
J,	O
Robinson	O
RA.	O
Department	O
of	O
Pathology	O
,	O
Catholic	O
University	O
,	O
St	O
Vincent	O
Hospital	O
,	O
Suwon	O
,	O
Republic	O
of	O
Korea	O
.	O
OBJECTIVE	O
:	O
To	O
assess	O
the	O
prevalence	O
of	O
activating	O
mutations	O
in	O
K-ras	O
and	O
H-ras	O
genes	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
with	I-malignancy-type
ductal	I-malignancy-type
or	O
acinar	B-malignancy-type
differentiation	I-malignancy-type
and	O
to	O
evaluate	O
their	O
potential	O
correlation	O
with	O
clinical	O
parameters	O
.	O
DESIGN	O
:	O
Paraffin	O
-	O
embedded	O
tissue	O
samples	O
of	O
salivary	B-malignancy-type
gland	I-malignancy-type
carcinomas	I-malignancy-type
were	O
investigated	O
by	O
the	O
application	O
of	O
a	O
direct	O
sequence	O
analysis	O
procedure	O
with	O
automated	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
ras	O
sequences	O
.	O
SETTING	O
:	O
Tertiary	O
care	O
teaching	O
hospital	O
.	O
PATIENTS	O
:	O
Twenty-four	O
patients	O
with	O
salivary	B-malignancy-type
gland	I-malignancy-type
carcinoma	I-malignancy-type
were	O
surgically	O
treated	O
.	O
Nine	O
had	O
adenocarcinoma	B-malignancy-type
,	O
1	O
had	O
adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
,	O
11	O
had	O
mucoepidermoid	B-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
3	O
had	O
acinic	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
RESULTS	O
:	O
Point	O
mutations	O
were	O
detected	O
in	O
7	O
(	O
29	O
%	O
)	O
of	O
the	O
24	O
carcinomas	B-malignancy-type
examined	O
.	O
The	O
K-ras	O
gene	O
was	O
mutated	O
in	O
only	O
2	O
samples	O
(	O
8	O
%	O
)	O
:	O
a	O
GGC	O
-	O
to	O
-	O
ATC	O
mutation	O
at	O
codon	O
13	O
in	O
an	O
adenocarcinoma	B-malignancy-type
and	O
a	O
GGC	O
-	O
to	O
-	O
GTC	O
transversion	O
mutation	O
at	O
codon	O
13	O
in	O
a	O
mucoepidermoid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Five	O
(	O
21	O
%	O
)	O
harbored	O
H-ras	O
mutations	O
:	O
4	O
contained	O
a	O
GGC	O
-	O
to	O
-	O
GTC	O
transversion	O
mutation	O
at	O
codon	O
12	O
and	O
1	O
had	O
2	O
distinct	O
mutations	O
,	O
the	O
same	O
G	O
-	O
to	O
-	O
T	O
at	O
codon	O
12	O
as	O
was	O
shown	O
in	O
the	O
other	O
cases	O
and	O
a	O
GGT	O
-	O
to	O
-	O
GGA	O
heterozygous	O
mutation	O
at	O
codon	O
13	O
.	O
All	O
the	O
H-ras	O
mutations	O
were	O
in	O
the	O
group	O
of	O
mucoepidermoid	B-malignancy-type
carcinoma	I-malignancy-type
lesions	I-malignancy-type
(	O
45	O
%	O
;	O
5	O
/	O
11	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
K-ras	O
gene	O
alteration	O
is	O
probably	O
not	O
an	O
important	O
factor	O
in	O
the	O
oncogenesis	O
of	O
human	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
.	O
However	O
,	O
mutational	O
activation	O
of	O
the	O
H-ras	O
gene	O
appears	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
salivary	B-malignancy-type
gland	I-malignancy-type
mucoepidermoid	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
10835516	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
Apr	O
1;60(	O
7)	O
:1800	O
-	O
4	O
Relative	O
reciprocity	O
of	O
NRAS	O
and	O
PTEN	O
/	O
MMAC1	O
alterations	O
in	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
cell	O
lines	O
.	O
Tsao	O
H	O
,	O
Zhang	O
X	O
,	O
Fowlkes	O
K	O
,	O
Haluska	O
FG.	O
Department	O
of	O
Dermatology	O
,	O
Massachusetts	O
General	O
Hospital	O
and	O
Dana	O
-	O
Farber	O
/	O
Partners	O
CancerCare	O
,	O
Boston	O
02114	O
,	O
USA	O
.	O
Both	O
inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
and	O
oncogenic	O
activation	O
of	O
RAS	O
have	O
been	O
described	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
In	O
mice	O
,	O
activation	O
of	O
a	O
RAS	O
-	O
containing	O
pathway	O
is	O
a	O
necessary	O
step	O
in	O
the	O
pathogenesis	O
of	O
murine	O
melanomas	B-malignancy-type
.	O
Because	O
PTEN	O
negatively	O
regulates	O
on	O
the	O
downstream	O
effects	O
of	O
phosphatidylinositol-3-kinase	O
(	O
PI3-K	O
)	O
,	O
we	O
hypothesized	O
that	O
the	O
loss	O
of	O
PTEN	O
/	O
MMAC1	O
and	O
the	O
activation	O
of	O
RAS	O
may	O
be	O
largely	O
equivalent	O
because	O
RAS	O
is	O
a	O
known	O
positive	O
upstream	O
regulator	O
of	O
PI3-K	O
.	O
We	O
expanded	O
our	O
previous	O
survey	O
of	O
PTEN	O
/	O
MMAC1	O
mutations	O
and	O
analyzed	O
the	O
RAS	O
status	O
of	O
53	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
cell	O
lines	O
,	O
18	O
glioma	B-malignancy-type
cell	O
lines	O
,	O
and	O
17	O
uncultured	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
metastasis	O
.	O
Overall	O
,	O
51	O
%	O
of	O
the	O
cell	O
lines	O
had	O
alterations	O
in	O
either	O
PTEN	O
/	O
MMAC1	O
or	O
RAS	O
.	O
We	O
found	O
16	O
cell	O
lines	O
(	O
30	O
%	O
)	O
with	O
alterations	O
in	O
PTEN	O
/	O
MMAC1	O
and	O
11	O
cell	O
lines	O
(	O
21	O
%	O
)	O
with	O
activating	O
NRAS	O
mutations	O
;	O
only	O
1	O
cell	O
line	O
had	O
concurrent	O
alterations	O
in	O
both	O
genes	O
.	O
Moreover	O
,	O
glioma	B-malignancy-type
cell	O
lines	O
with	O
a	O
high	O
frequency	O
of	O
PTEN	O
/	O
MMAC1	O
inactivation	O
had	O
no	O
identifiable	O
RAS	O
alterations	O
.	O
Ectopic	O
expression	O
of	O
PTEN	O
in	O
several	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
cell	O
lines	O
suppressed	O
colony	O
formation	O
irrespective	O
of	O
PTEN	O
/	O
MMAC1	O
status	O
;	O
furthermore	O
,	O
PTEN	O
expression	O
in	O
cell	O
lines	O
carrying	O
activated	O
RAS	O
also	O
suppressed	O
colony	O
formation	O
.	O
The	O
relative	O
reciprocity	O
of	O
PTEN	O
/	O
MMAC1	O
abrogation	O
and	O
NRAS	O
activation	O
suggests	O
that	O
the	O
two	O
genetic	O
changes	O
,	O
in	O
a	O
subset	O
of	O
cutaneous	B-malignancy-type
melanomas	I-malignancy-type
,	O
are	O
functionally	O
overlapping	O
.	O
PMID	O
:	O
10766161	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Chem	O
Lab	O
Med	O
1999	O
Jul;37(	O
7)	O
:723	O
-	O
7	O
A	O
relationship	O
between	O
K-ras	O
gene	O
mutations	O
and	O
some	O
clinical	O
and	O
histologic	O
variables	O
in	O
patients	O
with	O
primary	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Beranek	O
M,	O
Bures	O
J,	O
Palicka	O
V	O
,	O
Jandik	O
P	O
,	O
Langr	O
F	O
,	O
Nejedla	O
E.	O
Institute	O
of	O
Clinical	O
Biochemistry	O
and	O
Diagnostics	O
,	O
University	O
Hospital	O
,	O
Hradec	O
Kralove	O
,	O
Czech	O
Republic	O
.	O
Mutations	O
in	O
the	O
Kirsten	O
ras	O
2	O
(	O
K-ras	O
)	O
gene	O
were	O
described	O
as	O
early	O
events	O
in	O
the	O
process	O
of	O
colorectal	O
carcinogenesis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
a	O
possible	O
relationship	O
between	O
the	O
presence	O
of	O
K-ras	O
mutation	O
in	O
samples	O
of	O
primary	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
and	O
the	O
clinico	O
-	O
pathological	O
data	O
of	O
the	O
investigated	O
patients	O
.	O
Mutation	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
was	O
determined	O
in	O
18	O
of	O
53	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
(	O
34	O
%	O
)	O
in	O
our	O
group	O
of	O
patients	O
.	O
The	O
presence	O
of	O
K-ras	O
gene	O
mutations	O
was	O
not	O
related	O
to	O
gender	O
,	O
age	O
of	O
subject	O
at	O
diagnosis	O
,	O
staging	O
or	O
cancer	O
location	O
(	O
p	O
>	O
0.05	O
)	O
.	O
Sixteen	O
of	O
the	O
42	O
(	O
38	O
%	O
)	O
moderately	O
differentiated	O
carcinomas	B-malignancy-type
,	O
and	O
two	O
of	O
the	O
eight	O
(	O
25	O
%	O
)	O
well	O
differentiated	O
carcinomas	B-malignancy-type
contained	O
K-ras	O
mutation	O
in	O
codon	O
12	O
,	O
but	O
none	O
of	O
the	O
three	O
poorly	O
differentiated	O
carcinomas	B-malignancy-type
contained	O
the	O
mutation	O
.	O
Moderately	O
differentiated	O
tumours	O
contained	O
an	O
aspartate	O
code	O
GAT	O
(	O
in	O
eight	O
cases	O
)	O
,	O
a	O
valine	O
code	O
GTT	O
(	O
in	O
six	O
cases	O
)	O
,	O
an	O
alanine	O
code	O
GCT	O
(	O
in	O
one	O
case	O
)	O
and	O
a	O
serine	O
code	O
AGT	O
(	O
in	O
one	O
case	O
)	O
in	O
codon	O
12	O
.	O
Well	O
differentiated	O
tumours	O
contained	O
only	O
the	O
valine	O
code	O
GTT	O
(	O
two	O
cases	O
)	O
.	O
Our	O
results	O
show	O
that	O
the	O
frequency	O
of	O
mutations	O
in	O
the	O
K-ras	O
gene	O
in	O
carcinomas	B-malignancy-type
in	O
Central	O
Europe	O
is	O
not	O
different	O
from	O
the	O
frequencies	O
found	O
in	O
other	O
parts	O
of	O
the	O
world	O
.	O
The	O
homogeneous	O
incidence	O
of	O
K-ras	O
mutation	O
does	O
not	O
seem	O
to	O
be	O
related	O
to	O
ethnic	O
factors	O
,	O
dietary	O
habits	O
,	O
or	O
the	O
composition	O
of	O
the	O
diet	O
.	O
PMID	O
:	O
10510729	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Sep	O
1;59(	O
17	O
)	O
:4257	O
-	O
60	O
Frequent	O
somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
Park	O
WS	O
,	O
Oh	O
RR	O
,	O
Park	O
JY	O
,	O
Lee	O
SH	O
,	O
Shin	O
MS	O
,	O
Kim	O
YS	O
,	O
Kim	O
SY	O
,	O
Lee	O
HK	O
,	O
Kim	O
PJ	O
,	O
Oh	O
ST	O
,	O
Yoo	O
NJ	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Catholic	O
University	O
Medical	O
College	O
,	O
Seoul	O
,	O
Korea	O
.	O
The	O
increased	O
level	O
of	O
cytoplasmic	O
beta-catenin	O
through	O
the	O
mutations	O
to	O
either	O
beta-catenin	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
has	O
been	O
proposed	O
as	O
an	O
important	O
oncogenic	O
step	O
in	O
various	O
tumors	O
.	O
Gastric	B-malignancy-type
cancer	I-malignancy-type
showed	O
frequent	O
genetic	O
alterations	O
of	O
the	O
APC	O
gene	O
,	O
and	O
the	O
risk	O
for	O
gastric	B-malignancy-type
cancer	I-malignancy-type
in	O
familial	B-malignancy-type
adenomatosus	I-malignancy-type
polyposis	I-malignancy-type
patients	O
is	O
10	O
times	O
higher	O
than	O
that	O
in	O
the	O
general	O
population	O
.	O
These	O
findings	O
raise	O
the	O
possibility	O
that	O
mutations	O
of	O
beta-catenin	O
may	O
also	O
be	O
associated	O
with	O
the	O
development	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
.	O
We	O
detected	O
seven	O
somatic	O
mutations	O
in	O
a	O
portion	O
of	O
exon	O
3	O
encoding	O
for	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
consensus	O
region	O
of	O
the	O
beta-catenin	O
gene	O
in	O
43	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
All	O
of	O
these	O
mutations	O
were	O
missense	O
mutations	O
,	O
of	O
which	O
five	O
are	O
in	O
the	O
highly	O
conserved	O
aspartic	O
acid	O
32	O
and	O
two	O
are	O
in	O
serine	O
29	O
;	O
all	O
of	O
these	O
seven	O
mutations	O
were	O
detected	O
exclusively	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
(	O
7	O
of	O
26	O
;	O
26.9	O
%	O
)	O
,	O
but	O
not	O
in	O
the	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
(	O
0	O
of	O
17	O
)	O
.	O
We	O
concluded	O
that	O
disruption	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
T	O
cell	O
factor	O
-	O
lymphoid	O
enhancer	O
binding	O
factor	O
pathway	O
might	O
play	O
an	O
important	O
role	O
especially	O
in	O
the	O
development	O
of	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10485468	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
1999	O
Aug;15(	O
2	O
)	O
:391	O
-	O
8	O
Sampling	O
technique	O
influences	O
the	O
detection	O
of	O
K-ras	O
mutations	O
in	O
normal	O
appearing	O
mucosa	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Schimanski	O
CC	O
,	O
Sutter	O
C	O
,	O
Linnemann	O
U	O
,	O
Berger	O
MR	O
.	O
Unit	O
of	O
Toxicology	O
and	O
Chemotherapy	O
,	O
German	O
Cancer	O
Research	O
Centre	O
,	O
69120	O
Heidelberg	O
,	O
Germany	O
.	O
Based	O
on	O
three	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
with	O
specified	O
K-ras	O
status	O
,	O
a	O
sensitive	O
PCR	O
-	O
RFLP	O
assay	O
was	O
established	O
detecting	O
one	O
K-ras	O
mutant	O
among	O
106	O
wild	O
-	O
type	O
cells	O
.	O
Using	O
this	O
assay	O
for	O
tissues	O
of	O
124	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
59	O
tumor	O
(	O
46	O
%	O
)	O
and	O
11	O
mucosa	O
samples	O
(	O
9	O
%	O
)	O
were	O
found	O
to	O
harbor	O
a	O
K-ras	O
mutation	O
.	O
When	O
using	O
the	O
same	O
scalpel	O
for	O
collecting	O
tumor	O
and	O
mucosa	O
tissues	O
(	O
group	O
A	O
)	O
,	O
18	O
%	O
of	O
the	O
patients	O
had	O
a	O
matching	O
K-ras	O
mutation	O
in	O
both	O
tissues	O
,	O
but	O
this	O
coincidence	O
was	O
seen	O
in	O
3	O
%	O
of	O
patients	O
only	O
,	O
when	O
separate	O
scalpels	O
were	O
used	O
(	O
group	O
B	O
)	O
.	O
Thus	O
we	O
conclude	O
that	O
the	O
sampling	O
technique	O
used	O
for	O
collecting	O
specimens	O
is	O
a	O
major	O
contributor	O
to	O
the	O
detection	O
of	O
K-ras	O
mutations	O
in	O
normal	O
appearing	O
mucosa	O
when	O
a	O
highly	O
sensitive	O
detection	O
technique	O
is	O
used	O
.	O
PMID	O
:	O
10402253	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Apr	O
1;59(	O
7)	O
:1442	O
-	O
4	O
Beta-catenin	O
mutations	O
are	O
more	O
frequent	O
in	O
small	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
than	O
in	O
larger	B-malignancy-type
adenomas	I-malignancy-type
and	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Samowitz	O
WS	O
,	O
Powers	O
MD	O
,	O
Spirio	O
LN	O
,	O
Nollet	O
F	O
,	O
van	O
Roy	O
F	O
,	O
Slattery	O
ML.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Utah	O
Health	O
Sciences	O
Center	O
,	O
Salt	O
Lake	O
City	O
84132	O
,	O
USA	O
.	O
Loss	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
from	O
exon	O
3	O
of	O
beta-catenin	O
has	O
been	O
identified	O
in	O
approximately	O
half	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
which	O
lack	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
,	O
but	O
the	O
overall	O
contribution	O
of	O
beta-catenin	O
mutations	O
to	O
sporadic	O
colorectal	O
tumorigenesis	O
is	O
unclear	O
.	O
We	O
therefore	O
used	O
PCR	O
to	O
amplify	O
and	O
sequence	O
exon	O
3	O
of	O
beta-catenin	O
from	O
202	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Exon	O
3	O
beta-catenin	O
mutations	O
were	O
identified	O
in	O
6	O
of	O
48	O
small	B-malignancy-type
(	O
<	O
1	O
cm	O
)	O
adenomas	B-malignancy-type
,	O
2	O
of	O
82	O
large	B-malignancy-type
(	O
>	O
or	O
=	O
1	O
cm	O
)	O
adenomas	B-malignancy-type
,	O
and	O
1	O
of	O
72	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Eight	O
of	O
the	O
nine	O
mutations	O
,	O
including	O
all	O
of	O
those	O
in	O
the	O
small	B-malignancy-type
adenomas	I-malignancy-type
and	O
the	O
invasive	O
cancer	O
,	O
involved	O
loss	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
.	O
The	O
percentage	O
of	O
beta-catenin	O
mutations	O
in	O
small	B-malignancy-type
adenomas	I-malignancy-type
(	O
12.5	O
%	O
)	O
was	O
significantly	O
greater	O
than	O
that	O
in	O
large	B-malignancy-type
adenomas	I-malignancy-type
(	O
2.4	O
%	O
)	O
and	O
invasive	O
cancers	O
(	O
1.4	O
%	O
;	O
P	O
=	O
0.05	O
and	O
P	O
=	O
0.02	O
,	O
respectively	O
)	O
.	O
We	O
conclude	O
that	O
mutation	O
of	O
beta-catenin	O
can	O
be	O
an	O
early	O
,	O
perhaps	O
initiating	O
,	O
event	O
in	O
colorectal	O
tumorigenesis	O
.	O
Small	B-malignancy-type
adenomas	I-malignancy-type
with	O
beta-catenin	O
mutations	O
do	O
not	O
appear	O
to	O
be	O
as	O
likely	O
to	O
progress	O
to	O
larger	B-malignancy-type
adenomas	I-malignancy-type
and	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
as	O
other	O
adenomas	B-malignancy-type
,	O
however	O
,	O
with	O
the	O
result	O
that	O
beta-catenin	O
mutations	O
are	O
only	O
rarely	O
seen	O
in	O
invasive	O
cancers	O
.	O
This	O
suggests	O
that	O
APC	O
and	O
beta-catenin	O
mutations	O
are	O
not	O
functionally	O
equivalent	O
,	O
and	O
that	O
the	O
APC	O
gene	O
may	O
have	O
other	O
tumor	O
suppressor	O
functions	O
besides	O
the	O
degradation	O
of	O
beta-catenin	O
.	O
PMID	O
:	O
10197610	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1999	O
Apr;21(	O
4)	O
:410	O
-	O
3	O
A	O
common	O
human	O
skin	B-malignancy-type
tumour	I-malignancy-type
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta-catenin	O
.	O
Chan	O
EF	O
,	O
Gat	O
U	O
,	O
McNiff	O
JM	O
,	O
Fuchs	O
E.	O
Howard	O
Hughes	O
Medical	O
Institute	O
,	O
Department	O
of	O
Molecular	O
Genetics	O
and	O
Cell	O
Biology	O
,	O
The	O
University	O
of	O
Chicago	O
,	O
Illinois	O
60637	O
,	O
USA	O
.	O
WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs	O
.	O
In	O
response	O
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta-catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF	O
/	O
TCF	O
family	O
.	O
One	O
of	O
the	O
target	O
genes	O
for	O
beta-catenin	O
/	O
TCF	O
encodes	O
c-MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	B-malignancy-type
,	O
particularly	O
in	B-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
Most	O
colon	B-malignancy-type
cancers	I-malignancy-type
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
,	O
a	O
protein	O
required	O
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta-catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	B-malignancy-type
and	O
some	O
other	O
cancers	B-malignancy-type
harbour	O
beta-catenin	O
-	O
stabilizing	O
mutations	O
.	O
Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta-catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-malignancy-type
tumours	I-malignancy-type
resembling	O
pilomatricomas	B-malignancy-type
.	O
Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	B-malignancy-type
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta-catenin	O
-	O
stabilizing	O
mutations	O
.	O
Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B-malignancy-type
tumour	I-malignancy-type
.	O
We	O
found	O
nuclear	O
LEF-1	O
in	O
the	O
dividing	O
tumour	O
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	B-malignancy-type
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O
At	O
least	O
75	O
%	O
of	O
these	O
tumours	O
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O
This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	O
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta-catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
PMID	O
:	O
10192393	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
1998	O
Jun;33(	O
3	O
)	O
:390	O
-	O
6	O
Detection	O
of	O
Ki-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
tissue	O
and	O
pancreatic	O
juice	O
from	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Kondoh	O
S,	O
Kaino	O
M,	O
Okita	O
S,	O
Ryozawa	O
S,	O
Akiyama	O
T	O
,	O
Okita	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Yamaguchi	O
University	O
School	O
of	O
Medicine	O
,	O
Ube	O
,	O
Japan	O
.	O
Pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
have	O
a	O
high	O
incidence	O
of	O
Ki-ras	O
mutations	O
,	O
and	O
the	O
genetic	O
change	O
is	O
thought	O
to	O
occur	O
at	O
an	O
early	O
stage	O
in	O
the	O
carcinogenesis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
usefulness	O
of	O
detecting	O
genetic	O
mutations	O
in	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
.	O
DNA	O
was	O
extracted	O
from	O
tissue	O
specimens	O
of	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
and	O
from	O
cells	O
in	O
PPJ	O
,	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
Two	O
types	O
of	O
mobility	O
shifts	O
that	O
indicate	O
Ki-ras	O
mutations	O
were	O
observed	O
in	O
13	O
of	O
the	O
20	O
(	O
65	O
%	O
)	O
tissue	O
specimens	O
obtained	O
by	O
operation	O
or	O
autopsy	O
.	O
Ten	O
of	O
15	O
specimens	O
(	O
67	O
%	O
)	O
of	O
PPJ	O
collected	O
from	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
showed	O
two	O
types	O
of	O
mobility	O
shifts	O
.	O
Conventional	O
imaging	O
techniques	O
did	O
not	O
show	O
two	O
in	O
10	O
of	O
these	O
patients	O
.	O
PPJ	O
from	O
patients	O
with	O
non	O
-	O
cancerous	O
pancreatic	O
diseases	O
showed	O
no	O
Ki-ras	O
mutations	O
.	O
The	O
p53	O
tumor	O
suppressor	O
gene	O
,	O
examined	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
,	O
was	O
mutated	O
in	O
8	O
of	O
the	O
20	O
tissue	O
specimens	O
obtained	O
by	O
operation	O
or	O
autopsy	O
(	O
40	O
%	O
)	O
.	O
The	O
detection	O
of	O
Ki-ras	O
and	O
p53	O
mutations	O
in	O
PPJ	O
could	O
be	O
useful	O
for	O
the	O
early	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
,	O
especially	O
for	O
neoplastic	B-malignancy-type
lesions	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
intraductal	I-malignancy-type
type	I-malignancy-type
.	O
PMID	O
:	O
9658319	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1998	O
Jul	O
1;83(	O
1	O
)	O
:122	O
-	O
9	O
A	O
c-rasHa	O
mutation	O
in	O
the	O
metastasis	O
of	O
a	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-	O
18	O
positive	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
suggests	O
a	O
cooperative	O
effect	O
between	O
HPV-18	O
and	O
c-rasHa	O
activation	O
in	O
malignant	O
progression	O
.	O
Leis	O
PF	O
,	O
Stevens	O
KR	O
,	O
Baer	O
SC	O
,	O
Kadmon	O
D	O
,	O
Goldberg	O
LH	O
,	O
Wang	O
XJ	O
.	O
Department	O
of	O
Dermatology	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Houston	O
,	O
Texas	O
77030	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Human	O
papillomaviruses	O
(	O
HPV	O
)	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
anogenital	B-malignancy-type
squamous	I-malignancy-type
epithelial	I-malignancy-type
tumors	I-malignancy-type
.	O
Of	O
the	O
65	O
HPV	O
strains	O
,	O
subtypes	O
HPV-16	O
and	O
HPV-18	O
frequently	O
are	O
associated	O
with	O
malignant	O
conditions	O
and	O
are	O
capable	O
of	O
transforming	O
keratinocytes	O
in	O
vitro	O
.	O
However	O
,	O
additional	O
cellular	O
changes	O
are	O
necessary	O
to	O
confer	O
tumorigenicity	O
to	O
HPV	O
-	O
infected	O
cells	O
.	O
Secondary	O
events	O
implicated	O
in	O
the	O
progression	O
to	O
malignancy	O
include	O
loss	O
of	O
tumor	O
suppressor	O
genes	O
such	O
as	O
p53	O
and/or	O
activation	O
of	O
cellular	O
oncogenes	O
such	O
as	O
c-rasHa	O
.	O
METHODS	O
:	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
identify	O
HPV-16	O
or	O
HPV-18	O
genetic	O
sequence	O
in	O
primary	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
and	O
two	O
inguinal	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
.	O
p53	O
and	O
c-rasHa	O
loci	O
were	O
analyzed	O
by	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O
RESULTS	O
:	O
HPV-18	O
but	O
not	O
HPV-16	O
infection	O
was	O
found	O
in	O
the	O
primary	O
carcinoma	B-malignancy-type
and	O
in	O
inguinal	O
metastases	O
occurring	O
5	O
and	O
7	O
years	O
after	O
the	O
initial	O
lesion	O
.	O
Sequence	O
analysis	O
did	O
not	O
identify	O
any	O
p53	O
mutations	O
in	O
the	O
primary	O
carcinoma	B-malignancy-type
or	O
its	O
metastases	O
.	O
However	O
,	O
although	O
the	O
primary	O
lesion	O
and	O
the	O
5	O
-	O
year	O
metastasis	O
encoded	O
wild	O
-	O
type	O
c-rasHa	O
,	O
the	O
7	O
-	O
year	O
metastasis	O
had	O
a	O
missense	O
mutation	O
within	O
c-rasHa	O
codon	O
61	O
.	O
CONCLUSIONS	O
:	O
To	O
the	O
authors	O
'	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
activating	O
c-rasHa	O
mutation	O
associated	O
with	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
penis	I-malignancy-type
.	O
The	O
presence	O
of	O
activated	O
c-rasHa	O
in	O
the	O
second	O
metastasis	O
but	O
not	O
in	O
the	O
first	O
metastasis	O
or	O
the	O
primary	O
lesion	O
suggests	O
that	O
activation	O
of	O
c-rasHa	O
may	O
be	O
a	O
late	O
event	O
in	O
the	O
malignant	O
progression	O
of	O
HPV-18	O
-	O
associated	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Analysis	O
of	O
additional	O
samples	O
from	O
primary	O
lesions	O
and	O
their	O
resultant	O
metastases	O
is	O
necessary	O
to	O
elucidate	O
the	O
incidence	O
and	O
significance	O
of	O
c-rasHa	O
activation	O
in	O
penile	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9655301	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Apr	O
24;126(	O
2	O
)	O
:179	O
-	O
85	O
Role	O
of	O
K-ras	O
mutations	O
in	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Chiang	O
JM	O
.	O
Division	O
of	O
Colon	O
and	O
Rectal	O
Surgery	O
,	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
In	O
order	O
to	O
investigate	O
whether	O
two	O
common	O
types	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
with	O
different	O
gross	O
appearances	O
share	O
the	O
same	O
incidence	O
of	O
K-ras	O
mutation	O
,	O
the	O
occurrence	O
of	O
a	O
point	O
mutation	O
in	O
codon	O
12	O
or	O
codon	O
13	O
of	O
the	O
K-ras	O
oncogene	O
was	O
determined	O
in	O
50	O
cases	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
PCR	O
technique	O
was	O
employed	O
,	O
followed	O
by	O
RFLP	O
analysis	O
and	O
sequencing	O
to	O
identify	O
specific	O
point	O
mutations	O
.	O
No	O
correlation	O
was	O
found	O
between	O
the	O
presence	O
of	O
a	O
K-ras	O
gene	O
mutation	O
and	O
histological	O
parameters	O
.	O
A	O
strong	O
association	O
was	O
found	O
between	O
K-ras	O
mutations	O
and	O
the	O
gross	O
polypoid	O
appearance	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
(	O
polypoid	O
73	O
%	O
versus	O
ulcerative	O
8	O
%	O
)	O
.	O
The	O
results	O
indicate	O
a	O
preferential	O
association	O
with	O
the	O
K-ras	O
oncogene	O
involved	O
in	O
polypoid	B-malignancy-type
type	I-malignancy-type
colorectal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9585064	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
1;58(	O
5	O
)	O
:1021	O
-	O
6	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
in	O
primary	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
without	O
adenomatous	O
polyposis	O
coli	O
mutations	O
.	O
Iwao	O
K	O
,	O
Nakamori	O
S,	O
Kameyama	O
M,	O
Imaoka	O
S,	O
Kinoshita	O
M,	O
Fukui	O
T	O
,	O
Ishiguro	O
S,	O
Nakamura	O
Y	O
,	O
Miyoshi	O
Y.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Biomedical	O
Research	O
Center	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
City	O
,	O
Japan	O
.	O
Among	O
222	O
primary	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
we	O
examined	O
,	O
58	O
showed	O
no	O
detectable	O
APC	O
mutations	O
by	O
the	O
protein	O
truncation	O
test	O
.	O
We	O
screened	O
those	O
58	O
tumors	O
for	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
Although	O
amino	O
acid	O
substitutions	O
in	O
serine	O
or	O
threonine	O
residues	O
in	O
exon	O
3	O
had	O
been	O
reported	O
,	O
we	O
found	O
no	O
such	O
mutations	O
;	O
however	O
,	O
in	O
seven	O
tumors	O
,	O
we	O
detected	O
somatic	O
interstitial	O
deletions	O
of	O
234	O
-	O
760	O
bp	O
,	O
each	O
of	O
which	O
included	O
all	O
or	O
part	O
of	O
exon	O
3	O
.	O
Short	O
nucleotide	O
sequences	O
at	O
both	O
ends	O
of	O
each	O
deletion	O
were	O
either	O
identical	O
or	O
complementary	O
,	O
indicating	O
that	O
repeated	O
or	O
inversely	O
repeated	O
sequences	O
were	O
involved	O
in	O
the	O
somatic	O
rearrangements	O
.	O
Reverse	O
transcription	O
-	O
PCR	O
experiments	O
using	O
RNAs	O
isolated	O
from	O
three	O
of	O
these	O
seven	O
tumors	O
detected	O
transcripts	O
that	O
lacked	O
exon	O
3	O
,	O
in	O
addition	O
to	O
the	O
normal	O
transcript	O
.	O
In	O
one	O
of	O
these	O
cases	O
,	O
we	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
cytoplasm	O
and	O
nuclei	O
of	O
cancer	O
cells	O
by	O
Western	O
and	O
immunohistochemical	O
analyses	O
.	O
This	O
result	O
suggested	O
that	O
,	O
in	O
the	O
absence	O
of	O
a	O
peptide	O
encoded	O
by	O
exon	O
3	O
,	O
beta-catenin	O
is	O
stabilized	O
and	O
has	O
a	O
dominant	O
oncogenic	O
effect	O
on	O
colorectal	O
tumorigenesis	O
.	O
PMID	O
:	O
9500465	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1997	O
Sep;11(	O
9	O
)	O
:1442	O
-	O
6	O
Tandem	O
duplications	O
of	O
the	O
FLT3	O
receptor	O
gene	O
are	O
associated	O
with	O
leukemic	O
transformation	O
of	O
myelodysplasia	B-malignancy-type
.	O
Horiike	O
S,	O
Yokota	O
S,	O
Nakao	O
M,	O
Iwai	O
T	O
,	O
Sasai	O
Y	O
,	O
Kaneko	O
H	O
,	O
Taniwaki	O
M,	O
Kashima	O
K	O
,	O
Fujii	O
H	O
,	O
Abe	O
T	O
,	O
Misawa	O
S.	O
Department	O
of	O
Internal	O
Medicine	O
III	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
recently	O
reported	O
an	O
internal	O
tandem	O
duplication	O
of	O
the	O
human	O
flt3	O
receptor	O
gene	O
(	O
FLT3	O
)	O
as	O
a	O
somatic	O
mutation	O
in	O
17	O
%	O
of	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
The	O
present	O
study	O
revealed	O
the	O
duplication	O
at	O
the	O
juxtamembrane	O
and	O
the	O
first	O
tyrosine	O
kinase	O
domains	O
of	O
FLT3	O
in	O
seven	O
of	O
92	O
(	O
8	O
%	O
)	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
AML	B-malignancy-type
with	O
trilineage	B-malignancy-type
myelodysplasia	I-malignancy-type
(	O
AML	B-malignancy-type
/	O
TMDS	B-malignancy-type
)	O
,	O
the	O
diseases	O
which	O
may	O
represent	O
neoplastic	O
changes	O
of	O
pluripotent	O
stem	O
cells	O
.	O
A	O
tandem	O
duplication	O
of	O
exon	O
11	O
of	O
FLT3	O
was	O
harbored	O
by	O
two	O
of	O
58	O
(	O
3	O
%	O
)	O
patients	O
with	O
MDS	B-malignancy-type
and	O
five	O
of	O
34	O
(	O
15	O
%	O
)	O
with	O
overt	B-malignancy-type
leukemia	I-malignancy-type
,	O
including	O
MDS	B-malignancy-type
-	I-malignancy-type
derived	I-malignancy-type
leukemia	I-malignancy-type
,	O
AML	B-malignancy-type
/	O
TMDS	B-malignancy-type
and	O
therapy	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
leukemia	I-malignancy-type
.	O
Although	O
the	O
duplicated	O
regions	O
varied	O
within	O
exon	O
11	O
in	O
each	O
case	O
,	O
they	O
occurred	O
in	O
-	O
frame	O
,	O
and	O
altered	O
mRNA	O
expressions	O
were	O
demonstrated	O
by	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
Two	O
cases	O
of	O
MDS	B-malignancy-type
with	O
a	O
FLT3	O
duplication	O
transformed	O
to	O
overt	B-malignancy-type
leukemia	I-malignancy-type
within	O
a	O
few	O
months	O
.	O
Longitudinal	O
analyses	O
in	O
two	O
other	O
patients	O
with	O
leukemia	B-malignancy-type
revealed	O
that	O
the	O
duplication	O
was	O
a	O
late	O
genetic	O
event	O
during	O
the	O
disease	O
course	O
;	O
one	O
of	O
whom	O
showed	O
two	O
independent	O
duplications	O
of	O
FLT3	O
at	O
the	O
terminal	O
therapy	O
-	O
resistant	O
phase	O
.	O
Of	O
seven	O
patients	O
with	O
the	O
FLT3	O
duplication	O
,	O
six	O
had	O
abnormal	O
karyotypes	O
,	O
and	O
four	O
harbored	O
a	O
point	O
mutation	O
of	O
the	O
N-RAS	O
and/or	O
TP53	O
genes	O
.	O
Patients	O
with	O
FLT3	O
mutations	O
have	O
poor	O
prognoses	O
.	O
This	O
study	O
uncovered	O
the	O
fact	O
that	O
the	O
accumulation	O
of	O
genetic	O
events	O
,	O
including	O
FLT3	O
duplication	O
,	O
correlates	O
with	O
leukemic	O
transformation	O
from	O
antecedent	O
myelodysplasia	B-malignancy-type
and	O
with	O
subsequent	O
disease	O
progression	O
.	O
PMID	O
:	O
9305595	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
Arch	O
Allergy	O
Immunol	O
1997	O
May	O
-	O
Jul;113(	O
1	O
-	O
3	O
)	O
:184	O
-	O
6	O
c-kit	O
mutation	O
in	O
a	O
population	O
of	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
Nagata	O
H	O
,	O
Okada	O
T	O
,	O
Worobec	O
AS	O
,	O
Semere	O
T	O
,	O
Metcalfe	O
DD.	O
Department	O
of	O
Otolaryngology	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
The	O
c-kit	O
Asp	O
816	O
Val	O
activating	O
mutation	O
is	O
found	O
in	O
all	O
patients	O
with	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
,	O
and	O
at	O
least	O
in	O
a	O
subset	O
of	O
patients	O
with	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
The	O
case	O
of	O
an	O
11	O
-	O
month	O
-	O
old	O
child	O
is	O
presented	O
who	O
was	O
categorized	O
as	O
having	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
and	O
where	O
the	O
Asp	O
816	O
Val	O
mutation	O
was	O
identified	O
in	O
lesional	O
skin	O
,	O
but	O
not	O
in	O
bone	O
marrow	O
or	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
populations	O
.	O
The	O
significance	O
of	O
these	O
findings	O
is	O
discussed	O
.	O
PMID	O
:	O
9130517	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
1997	O
Feb;40(	O
2	O
)	O
:161	O
-	O
7	O
Ki-ras	O
point	O
mutation	O
in	O
different	O
types	O
of	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
in	O
early	O
stages	O
.	O
Kojima	O
M,	O
Konishi	O
F	O
,	O
Tsukamoto	O
T	O
,	O
Yamashita	O
K	O
,	O
Kanazawa	O
K.	O
Department	O
of	O
Surgery	O
,	O
Jichi	O
Medical	O
School	O
,	O
Tochigi	O
,	O
Japan	O
.	O
PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
pathways	O
of	O
carcinogenesis	O
in	O
the	O
colon	O
and	O
rectum	O
by	O
investigating	O
Ki-ras	O
point	O
mutation	O
in	O
different	O
types	O
of	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
in	O
the	O
early	O
stage	O
.	O
METHODS	O
:	O
We	O
analyzed	O
rates	O
of	O
Ki-ras	O
codon	O
12	O
mutations	O
in	O
34	O
small	B-malignancy-type
,	I-malignancy-type
polypoid	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
carcinomas	I-malignancy-type
(	O
Tis	B-malignancy-type
or	O
T1	B-malignancy-type
)	O
,	O
21	O
superficial	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
carcinomas	I-malignancy-type
(	O
Tis	B-malignancy-type
or	O
T1	B-malignancy-type
)	O
,	O
and	O
42	O
advanced	B-malignancy-type
carcinomas	I-malignancy-type
(	O
T2	B-malignancy-type
,	O
T3	B-malignancy-type
,	O
and	O
T4	O
)	O
.	O
RESULTS	O
:	O
Frequency	O
of	O
Ki-ras	O
mutations	O
in	O
superficial	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
carcinomas	I-malignancy-type
was	O
14.3	O
percent	O
(	O
3	O
/	O
21	O
)	O
,	O
which	O
was	O
significantly	O
lower	O
than	O
50	O
percent	O
(	O
17	O
/	O
34	O
)	O
in	O
small	B-malignancy-type
polypoid	I-malignancy-type
carcinomas	I-malignancy-type
and	O
40.5	O
percent	O
(	O
17	O
/	O
42	O
)	O
in	O
advanced	O
carcinomas	B-malignancy-type
.	O
These	O
data	O
suggest	O
that	O
another	O
pathway	O
of	O
colorectal	O
carcinogenesis	O
that	O
does	O
not	O
involve	O
Ki-ras	O
point	O
mutation	O
might	O
exist	O
.	O
Among	O
the	O
17	O
small	B-malignancy-type
polypoid	I-malignancy-type
carcinomas	I-malignancy-type
with	O
Ki-ras	O
point	O
mutation	O
in	O
which	O
both	O
adenomatous	B-malignancy-type
and	O
carcinomatous	B-malignancy-type
tissue	I-malignancy-type
were	O
examined	O
,	O
12	O
showed	O
a	O
mutation	O
of	O
the	O
same	O
type	O
in	O
both	O
carcinomatous	B-malignancy-type
and	O
adenomatous	B-malignancy-type
tissues	I-malignancy-type
.	O
In	O
two	O
cases	O
,	O
mutation	O
was	O
present	O
only	O
in	O
carcinomatous	B-malignancy-type
tissue	I-malignancy-type
and	O
not	O
in	O
adenomatous	B-malignancy-type
tissue	I-malignancy-type
;	O
in	O
the	O
other	O
three	O
cases	O
,	O
Ki-ras	O
point	O
mutation	O
was	O
present	O
only	O
in	O
adenomatous	B-malignancy-type
tissue	I-malignancy-type
but	O
not	O
in	O
carcinomatous	B-malignancy-type
tissue	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
carcinoma	B-malignancy-type
in	O
a	O
small	O
polypoid	O
lesion	O
does	O
not	O
always	O
develop	O
from	O
pre	O
-	O
existing	O
adenoma	B-malignancy-type
with	O
Ki-ras	O
point	O
mutation	O
;	O
in	O
a	O
small	O
number	O
of	O
the	O
polypoid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
early	I-malignancy-type
carcinomas	I-malignancy-type
,	O
polyclonal	O
composition	O
concerning	O
the	O
Ki-ras	O
gene	O
may	O
exist	O
.	O
PMID	O
:	O
9075750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Yonsei	O
Med	O
J	O
1996	O
Dec;37(	O
6)	O
:371	O
-	O
9	O
A	O
PCR	O
-	O
RFLP	O
method	O
for	O
the	O
detection	O
of	O
activated	O
H-ras	O
oncogene	O
with	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
and	O
61	O
.	O
Hong	O
SJ	O
,	O
Lee	O
T	O
,	O
Park	O
YS	O
,	O
Lee	O
KO	O
,	O
Chung	O
BH	O
,	O
Lee	O
SH.	O
Department	O
of	O
Urology	O
,	O
Yonsei	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
To	O
investigate	O
the	O
incidence	O
of	O
the	O
H-ras	O
gene	O
activation	O
in	O
bladder	B-malignancy-type
tumor	I-malignancy-type
and	O
the	O
feasibility	O
of	O
using	O
urinary	O
washout	O
samples	O
for	O
screening	O
,	O
a	O
series	O
of	O
33	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
and	O
their	O
preoperatively	O
collected	O
urinary	O
washout	O
samples	O
were	O
screened	O
using	O
a	O
mutant	O
specific	O
PCR	O
-	O
RFLP	O
(	O
polymerase	O
chain	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
)	O
to	O
detect	O
a	O
point	O
mutation	O
of	O
the	O
H-ras	O
gene	O
.	O
Five	O
tumors	B-malignancy-type
were	O
found	O
to	O
harbor	O
H-ras	O
mutations	O
where	O
two	O
tumors	B-malignancy-type
had	O
a	O
glycine	O
to	O
valine	O
(	O
G	O
-->	O
T	O
)	O
change	O
in	O
codon	O
12	O
and	O
three	O
tumors	B-malignancy-type
had	O
a	O
glutamine	O
to	O
lysine	O
(	O
C	O
-->	O
A	O
)	O
change	O
in	O
codon	O
61	O
,	O
respectively	O
.	O
Moreover	O
,	O
we	O
could	O
also	O
detect	O
the	O
same	O
point	O
mutations	O
of	O
the	O
H-ras	O
gene	O
in	O
corresponding	O
urine	O
washout	O
samples	O
.	O
The	O
incidence	O
of	O
H-ras	O
mutation	O
in	O
Korean	O
bladder	B-malignancy-type
cancer	I-malignancy-type
was	O
estimated	O
at	O
approximately	O
15.2	O
%	O
.	O
In	O
conclusion	O
,	O
a	O
mutant	O
specific	O
PCR	O
-	O
RFLP	O
method	O
for	O
the	O
detection	O
of	O
H-ras	O
gene	O
mutation	O
is	O
useful	O
for	O
screening	O
or	O
postoperative	O
follow	O
-	O
up	O
of	O
bladder	B-malignancy-type
tumor	I-malignancy-type
due	O
to	O
its	O
simplicity	O
and	O
high	O
specificity	O
even	O
in	O
urinary	O
samples	O
.	O
PMID	O
:	O
9048488	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
1997	O
Jan;76(	O
1	O
)	O
:153	O
-	O
9	O
Sporadic	O
and	O
Thorotrast	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
angiosarcomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
manifest	O
frequent	O
and	O
multiple	O
point	O
mutations	O
in	O
K-ras-2	O
.	O
Przygodzki	O
RM	O
,	O
Finkelstein	O
SD	O
,	O
Keohavong	O
P	O
,	O
Zhu	O
D	O
,	O
Bakker	O
A	O
,	O
Swalsky	O
PA	O
,	O
Soini	O
Y	O
,	O
Ishak	O
KG	O
,	O
Bennett	O
WP	O
.	O
Laboratory	O
of	O
Human	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
,	O
USA	O
.	O
Hepatic	B-malignancy-type
angiosarcoma	I-malignancy-type
(	O
HA	B-malignancy-type
)	O
is	O
an	O
uncommon	O
neoplasm	O
associated	O
with	O
known	O
etiologic	O
factors	O
in	O
25	O
%	O
to	O
42	O
%	O
of	O
cases	O
.	O
It	O
is	O
,	O
however	O
,	O
one	O
of	O
the	O
most	O
common	O
sarcomas	B-malignancy-type
found	O
in	O
the	O
liver	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
was	O
to	O
find	O
mutations	O
in	O
the	O
K-ras-2	O
oncogene	O
in	O
sporadic	B-malignancy-type
and	O
Thorotrast	B-malignancy-type
(	I-malignancy-type
TT	I-malignancy-type
)	I-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
.	O
Point	O
mutations	O
in	O
K-ras-2	O
were	O
sought	O
in	O
archival	O
,	O
formalin	O
-	O
fixed	O
tissue	O
blocks	O
from	O
24	O
patients	O
with	O
angiosarcoma	B-malignancy-type
.	O
Of	O
these	O
,	O
19	O
cases	O
were	O
sporadic	B-malignancy-type
and	O
5	O
were	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
.	O
Mutational	O
analysis	O
was	O
performed	O
by	O
topographic	O
microdissection	O
with	O
PCR	O
amplification	O
followed	O
by	O
genotyping	O
.	O
Specific	O
mutations	O
were	O
determined	O
by	O
two	O
independent	O
methods	O
:	O
(a)	O
direct	O
sequencing	O
of	O
the	O
PCR	O
product	O
confirmed	O
by	O
rePCR	O
and	O
by	O
using	O
a	O
different	O
sequencing	O
primer	O
,	O
and	O
(b)	O
PCR	O
-	O
based	O
selective	O
enrichment	O
of	O
mutant	O
DNA	O
by	O
endonuclease	O
digestion	O
followed	O
by	O
heteroduplex	O
DNA	O
analysis	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Eleven	O
K-ras-2	O
point	O
mutations	O
were	O
detected	O
in	O
7	O
of	O
24	O
(	O
29	O
%	O
)	O
tumors	O
,	O
including	O
5	O
of	O
19	O
(	O
26	O
%	O
)	O
sporadic	B-malignancy-type
HA	I-malignancy-type
and	O
2	O
of	O
5	O
(	O
40	O
%	O
)	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
.	O
There	O
were	O
seven	O
G:C	O
>	O
A:T	O
and	O
four	O
G:C	O
>	O
T:A	O
mutations	O
.	O
All	O
seven	O
mutated	O
tumors	O
contained	O
a	O
codon	O
12	O
-	O
aspartate	O
amino	O
acid	O
substitution	O
.	O
In	O
addition	O
,	O
a	O
second	O
codon	O
12	O
-	O
cysteine	O
mutant	O
cell	O
population	O
was	O
present	O
in	O
one	O
of	O
two	O
codon	O
12	O
-	O
aspartate	O
mutated	O
TT	O
-	O
induced	O
HA	O
and	O
in	O
three	O
of	O
five	O
codon	O
12	O
-	O
aspartate	O
sporadic	O
tumors	O
.	O
Of	O
these	O
four	O
tumors	O
,	O
three	O
contained	O
both	O
aspartate	O
and	O
cysteine	O
mutations	O
and	O
were	O
composed	O
of	O
multiple	O
nodules	O
;	O
the	O
fourth	O
was	O
a	O
single	O
mass	O
.	O
Seventeen	O
tumors	O
had	O
multiple	O
nodules	O
;	O
whereas	O
5	O
had	O
a	O
K-ras-2	O
mutation	O
,	O
12	O
were	O
wild	O
-	O
type	O
.	O
The	O
molecular	O
pathology	O
of	O
both	O
sporadic	B-malignancy-type
and	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
is	O
characterized	O
by	O
a	O
high	O
rate	O
of	O
K-ras-2	O
mutations	O
characteristic	O
of	O
oxidative	O
damage	O
(	O
ie	O
,	O
G:C	O
>	O
A:T	O
and	O
G:C	O
>	O
T:A	O
mutations	O
)	O
resulting	O
in	O
two	O
mutated	O
population	O
sets	O
:	O
codon	O
12	O
GGT	O
>	O
GAT	O
and	O
GGT	O
>	O
TGT	O
(	O
glycine	O
to	O
aspartic	O
acid	O
and	O
cysteine	O
)	O
.	O
This	O
is	O
,	O
to	O
date	O
,	O
the	O
first	O
study	O
to	O
characterize	O
the	O
K-ras-2	O
gene	O
mutations	O
within	O
human	O
sporadic	B-malignancy-type
and	O
TT	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
HA	I-malignancy-type
by	O
direct	O
sequence	O
analysis	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
These	O
data	O
further	O
support	O
the	O
hypothesis	O
linking	O
adduct	O
-	O
forming	O
vinyl	O
chloride	O
exposure	O
to	O
HA	B-malignancy-type
containing	O
a	O
much	O
higher	O
frequency	O
of	O
K-ras-2	O
mutations	O
and	O
a	O
mutational	O
spectrum	O
characteristic	O
of	O
chloroethylene	O
oxide	O
,	O
a	O
carcinogenic	O
metabolite	O
of	O
vinyl	O
chloride	O
.	O
PMID	O
:	O
9010458	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1996	O
Nov-	O
Dec;20(	O
11	O
-	O
12	O
)	O
:901	O
-	O
3	O
RAS	O
gene	O
mutations	O
in	O
Chinese	O
leukaemia	B-malignancy-type
patients	O
and	O
members	O
of	O
a	O
family	O
with	O
high	O
incidence	O
of	O
leukaemia	B-malignancy-type
.	O
He	O
LZ	O
,	O
Stephenson	O
J,	O
He	O
GY	O
,	O
Mufti	O
GJ.	O
Department	O
of	O
Haematological	O
Medicine	O
,	O
King	O
's	O
College	O
School	O
of	O
Medicine	O
and	O
Dentistry	O
,	O
London	O
,	O
UK.	O
We	O
investigated	O
mutations	O
of	O
N-RAS	O
and	O
K-RAS	O
by	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
oligonucleotide	O
hybridization	O
techniques	O
in	O
40	O
cases	O
of	O
Chinese	O
leukaemia	B-malignancy-type
patients	O
and	O
17	O
presently	O
healthy	O
members	O
of	O
a	O
family	O
with	O
high	O
incidence	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
.	O
The	O
results	O
showed	O
only	O
two	O
patients	O
carried	O
the	O
mutation	O
in	O
codon	O
12	O
of	O
N-RAS	O
.	O
Strikingly	O
,	O
however	O
,	O
in	O
both	O
cases	O
the	O
malignancies	O
involved	O
lymphoid	O
lineage	O
.	O
There	O
was	O
no	O
hereditary	O
RAS	O
mutation	O
in	O
the	O
members	O
of	O
the	O
remarkable	O
family	O
.	O
PMID	O
:	O
9009246	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1996	O
Mar;12(	O
3	O
)	O
:312	O
-	O
4	O
Somatic	O
c-KIT	O
activating	O
mutation	O
in	O
urticaria	O
pigmentosa	O
and	O
aggressive	B-malignancy-type
mastocytosis	I-malignancy-type
:	O
establishment	O
of	O
clonality	O
in	O
a	O
human	O
mast	B-malignancy-type
cell	I-malignancy-type
neoplasm	I-malignancy-type
.	O
Longley	O
BJ	O
,	O
Tyrrell	O
L,	O
Lu	O
SZ	O
,	O
Ma	O
YS	O
,	O
Langley	O
K	O
,	O
Ding	O
TG	O
,	O
Duffy	O
T	O
,	O
Jacobs	O
P	O
,	O
Tang	O
LH	O
,	O
Modlin	O
I.	O
Department	O
of	O
Dermatology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
Connecticut	O
06510	O
,	O
USA	O
.	O
Mastocytosis	B-malignancy-type
is	O
characterized	O
by	O
accumulations	O
of	O
mast	O
cells	O
in	O
various	O
organs	O
(	O
1	O
)	O
.	O
Most	O
cases	O
are	O
indolent	O
and	O
confined	O
to	O
the	O
skin	O
,	O
where	O
discrete	O
mast	O
cell	O
infiltrates	O
are	O
associated	O
increased	O
epidermal	O
melanin	O
,	O
a	O
clinical	O
picture	O
known	O
as	O
urticaria	O
pigmentosa	O
(	O
UP	O
)	O
.	O
Other	O
forms	O
of	O
mastocytosis	B-malignancy-type
combine	O
UP	O
with	O
aggressive	O
involvement	O
of	O
other	O
organs	O
or	O
with	O
haemotologic	O
abnormalities	O
(	O
1	O
-	O
4	O
)	O
.	O
It	O
is	O
not	O
known	O
whether	O
all	O
forms	O
of	O
mastocytosis	B-malignancy-type
are	O
true	O
neoplasms	B-malignancy-type
or	O
whether	O
some	O
might	O
represent	O
reactive	B-malignancy-type
hyperplasias	I-malignancy-type
(	O
5	O
-	O
7	O
)	O
.	O
The	O
c-KIT	O
proto	O
-	O
oncogene	O
encodes	O
a	O
type	O
III	O
receptor	O
tyrosine	O
kinase	O
(	O
KIT	O
)	O
that	O
is	O
critical	O
to	O
the	O
development	O
and	O
survival	O
of	O
mast	O
cells	O
and	O
melanocytes	O
(	O
8	O
-	O
11	O
)	O
.	O
The	O
ligand	O
for	O
KIT	O
(	O
KL	O
)	O
can	O
stimulate	O
mast	O
cell	O
development	O
,	O
proliferation	O
,	O
and	O
mediator	O
release	O
(	O
9	O
,	O
12	O
-	O
17	O
)	O
,	O
as	O
well	O
as	O
melanocyte	O
proliferation	O
and	O
pigment	O
production	O
(	O
18	O
-	O
20	O
)	O
.	O
To	O
determine	O
the	O
role	O
of	O
c-KIT	O
in	O
the	O
pathogenesis	O
of	O
mastocytosis	B-malignancy-type
,	O
we	O
examined	O
tissue	O
and	O
cells	O
isolated	O
from	O
a	O
patient	O
with	O
UP	O
and	O
aggressive	B-malignancy-type
systemic	I-malignancy-type
mastocytosis	I-malignancy-type
with	O
massive	O
splenic	O
involvement	O
.	O
We	O
found	O
a	O
mutation	O
that	O
results	O
in	O
constitutive	O
activation	O
and	O
expression	O
of	O
c-KIT	O
in	O
mast	O
cells	O
of	O
both	O
skin	O
and	O
spleen	O
.	O
This	O
is	O
the	O
first	O
in	O
situ	O
demonstration	O
of	O
an	O
activation	O
c-KIT	O
mutation	O
in	O
neoplastic	O
cells	O
.	O
It	O
also	O
demonstrates	O
the	O
clonal	O
and	O
neoplastic	O
nature	O
of	O
this	O
form	O
of	O
mastocytes	O
.	O
PMID	O
:	O
8589724	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1993	O
Mar;6(	O
2	O
)	O
:129	O
-	O
32	O
H-ras-1	O
point	O
mutations	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
Wilke	O
W	O
,	O
Maillet	O
M,	O
Robinson	O
R.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
.	O
The	O
H-ras-1	O
protooncogene	O
is	O
activated	O
by	O
single	O
base	O
substitutions	O
occurring	O
in	O
either	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
These	O
mutations	O
have	O
been	O
described	O
with	O
varying	O
frequencies	O
in	O
several	O
human	O
tumor	O
types	O
.	O
Since	O
ras	O
oncogenes	O
were	O
first	O
discovered	O
as	O
the	O
transforming	O
sequences	O
of	O
Harvey	O
and	O
Kirsten	O
murine	O
sarcoma	O
viruses	O
(	O
which	O
also	O
contain	O
activating	O
point	O
mutations	O
compared	O
to	O
the	O
homologous	O
cellular	O
sequences	O
)	O
,	O
we	O
wished	O
to	O
investigate	O
the	O
possibility	O
that	O
ras	O
mutations	O
might	O
also	O
occur	O
in	O
human	O
sarcomas	B-malignancy-type
.	O
We	O
extracted	O
DNA	O
from	O
six	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFH	B-malignancy-type
)	O
,	O
three	O
embryonal	B-malignancy-type
rhabdomyosarcomas	I-malignancy-type
(	O
ER	B-malignancy-type
)	O
,	O
one	O
alveolar	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
,	O
one	O
pleomorphic	B-malignancy-type
rhabdomyosarcoma	I-malignancy-type
,	O
and	O
one	O
leiomyosarcoma	B-malignancy-type
.	O
The	O
DNA	O
from	O
regions	O
flanking	O
codons	O
12	O
/	O
13	O
and	O
codon	O
61	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
sequenced	O
with	O
an	O
automated	O
DNA	O
sequencer	O
.	O
As	O
controls	O
,	O
we	O
amplified	O
and	O
sequenced	O
normal	O
DNA	O
(	O
placenta	O
)	O
and	O
DNA	O
with	O
known	O
point	O
mutations	O
(	O
T24	B-malignancy-type
bladder	I-malignancy-type
carcinoma	I-malignancy-type
cells	I-malignancy-type
)	O
.	O
We	O
found	O
three	O
cases	O
with	O
mutations	O
,	O
all	O
occurring	O
in	O
codon	O
12	O
.	O
One	O
ER	B-malignancy-type
showed	O
a	O
G	O
-	O
to	O
-	O
T	O
mutation	O
in	O
the	O
second	O
position	O
of	O
codon	O
12	O
(	O
coding	O
for	O
valine	O
instead	O
of	O
glycine	O
)	O
.	O
Two	O
MFHs	B-malignancy-type
showed	O
G	O
-	O
to	O
-	O
A	O
mutations	O
in	O
the	O
second	O
position	O
of	O
codon	O
12	O
(	O
coding	O
for	O
aspartic	O
acid	O
instead	O
of	O
glycine	O
)	O
.	O
Although	O
a	O
limited	O
number	O
of	O
cases	O
were	O
sampled	O
,	O
we	O
conclude	O
that	O
study	O
of	O
H-ras-1	O
mutations	O
may	O
be	O
relevant	O
to	O
MFH	B-malignancy-type
and	O
ER	B-malignancy-type
.	O
Additional	O
studies	O
of	O
N	O
and	O
K	O
-	O
ras	O
mutations	O
as	O
well	O
as	O
more	O
cases	O
investigating	O
H-ras	O
will	O
be	O
required	O
before	O
we	O
can	O
ascertain	O
the	O
significance	O
of	O
ras	O
mutations	O
in	O
the	O
oncogenesis	O
of	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
PMID	O
:	O
8483882	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1993	O
Mar;7(	O
3	O
)	O
:469	O
-	O
71	O
Amplification	O
of	O
c-MYC	O
oncogene	O
and	O
point	O
mutation	O
of	O
N-RAS	O
oncogene	O
point	O
mutation	O
in	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemias	I-malignancy-type
with	O
double	O
minute	O
chromosomes	O
.	O
Tanaka	O
K	O
,	O
Takechi	O
M,	O
Nishimura	O
S,	O
Oguma	O
N	O
,	O
Kamada	O
N.	O
Department	O
of	O
Hematology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Two	O
patients	O
with	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
showing	O
double	O
minute	O
(	O
dmin	O
)	O
chromosomes	O
were	O
analysed	O
to	O
identify	O
oncogene	O
activation	O
.	O
Cytogenetic	O
analysis	O
showed	O
1	O
-	O
53	O
dmin	O
chromosomes	O
with	O
the	O
normal	O
karyotype	O
in	O
the	O
first	O
patient	O
and	O
1	O
-	O
84	O
dmin	O
chromosomes	O
with	O
complex	O
chromosome	O
aberrations	O
.	O
Analysis	O
of	O
DNA	O
from	O
two	O
patients	O
revealed	O
five	O
-	O
to	O
ten	O
fold	O
amplification	O
of	O
c-MYC	O
oncogene	O
in	O
the	O
leukemic	O
cells	O
.	O
The	O
other	O
sixteen	O
oncogenes	O
studied	O
showed	O
no	O
increase	O
in	O
the	O
gene	O
content	O
.	O
Furthermore	O
,	O
a	O
transforming	O
gene	O
,	O
N-RAS	O
was	O
detected	O
in	O
the	O
first	O
patient	O
by	O
nude	O
mouse	O
tumorigenicity	O
assay	O
(	O
in	O
vivo	O
selection	O
assay	O
)	O
.	O
These	O
results	O
suggest	O
that	O
the	O
amplification	O
of	O
c-MYC	O
gene	O
is	O
common	O
in	O
dmin	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
AML	I-malignancy-type
patients	O
and	O
co	O
-	O
ordination	O
of	O
c-MYC	O
and	O
N-RAS	O
oncogene	O
might	O
also	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
AML	B-malignancy-type
patients	O
.	O
PMID	O
:	O
8445953	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
1994	O
May;74(	O
1	O
)	O
:40	O
-	O
9	O
Cytogenetic	O
studies	O
,	O
ras	O
mutation	O
,	O
and	O
clinical	O
characteristics	O
in	O
primary	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
A	O
study	O
on	O
68	O
Chinese	O
patients	O
in	O
Taiwan	O
.	O
Tien	O
HF	O
,	O
Wang	O
CH	O
,	O
Chuang	O
SM	O
,	O
Chow	O
JM	O
,	O
Lee	O
FY	O
,	O
Liu	O
MC	O
,	O
Chen	O
YC	O
,	O
Shen	O
MC	O
,	O
Lin	O
DT	O
,	O
Lin	O
KH.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
R.O.C.	O
Cytogenetics	O
and	O
clinical	O
features	O
were	O
studied	O
for	O
68	O
Chinese	O
patients	O
with	O
primary	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Ras	O
mutation	O
was	O
analyzed	O
in	O
25	O
of	O
them	O
.	O
Thirty-four	O
patients	O
(	O
50	O
%	O
)	O
had	O
clonal	O
chromosomal	O
abnormalities	O
at	O
initial	O
analysis	O
.	O
The	O
most	O
common	O
cytogenetic	O
aberrations	O
were	O
-	O
7	O
,	O
+	O
8	O
,	O
5q	O
-	O
,	O
and	O
20q	O
-	O
,	O
which	O
occurred	O
in	O
11	O
(	O
16.2	O
%	O
)	O
,	O
seven	O
(	O
10.3	O
%	O
)	O
,	O
five	O
(	O
7.4	O
%	O
)	O
and	O
three	O
patients	O
,	O
respectively	O
.	O
The	O
incidence	O
of	O
-	O
7	O
was	O
higher	O
and	O
that	O
of	O
5q	O
-	O
lower	O
in	O
our	O
patients	O
than	O
in	O
patients	O
from	O
most	O
other	O
geographic	O
areas	O
.	O
The	O
17	O
patients	O
with	O
multiple	O
chromosomal	O
abnormalities	O
had	O
a	O
significantly	O
shorter	O
median	O
survival	O
(	O
9	O
months	O
)	O
than	O
the	O
34	O
patients	O
with	O
normal	O
karyotype	O
(	O
33	O
months	O
)	O
and	O
the	O
17	O
patients	O
with	O
patients	O
with	O
single	O
anomalies	O
(	O
26	O
months	O
)	O
.	O
Evolution	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
occurred	O
in	O
20	O
patients	O
(	O
29	O
%	O
)	O
after	O
a	O
median	O
interval	O
of	O
8	O
months	O
following	O
the	O
diagnosis	O
.	O
Patients	O
with	O
multiple	O
cytogenetic	O
changes	O
at	O
initial	O
analysis	O
or	O
in	O
subsequent	O
studies	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
acute	O
transformation	O
than	O
others	O
(	O
55	O
%	O
vs.	O
18.6	O
%	O
,	O
p	O
=	O
0.007	O
)	O
;	O
the	O
same	O
was	O
not	O
true	O
if	O
only	O
the	O
data	O
of	O
initial	O
study	O
were	O
considered	O
.	O
Serial	O
cytogenetic	O
studies	O
are	O
important	O
in	O
patient	O
follow	O
-	O
up	O
.	O
N-ras	O
mutation	O
was	O
detected	O
in	O
5	O
(	O
20	O
%	O
)	O
of	O
25	O
patients	O
within	O
the	O
study	O
.	O
There	O
was	O
no	O
correlation	O
between	O
the	O
gene	O
mutation	O
and	O
acute	O
transformation	O
.	O
But	O
combing	O
the	O
data	O
of	O
N-ras	O
mutation	O
and	O
cytogenetics	O
,	O
patients	O
with	O
either	O
the	O
N-ras	O
mutation	O
or	O
clonal	O
chromosomal	O
abnormalities	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
developing	O
acute	B-malignancy-type
leukemia	I-malignancy-type
than	O
those	O
with	O
neither	O
of	O
the	O
changes	O
(	O
77	O
%	O
vs.	O
25	O
%	O
)	O
.	O
PMID	O
:	O
8194046	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1994	O
Apr	O
15	O
;83(	O
8	O
)	O
:2248	O
-	O
54	O
Mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
juvenile	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Miyauchi	O
J,	O
Asada	O
M,	O
Sasaki	O
M,	O
Tsunematsu	O
Y	O
,	O
Kojima	O
S,	O
Mizutani	O
S.	O
Department	O
of	O
Virology	O
,	O
National	O
Children	O
's	O
Medical	O
Research	O
Center	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Juvenile	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
JCML	B-malignancy-type
)	O
,	O
a	O
myeloproliferative	O
disorder	O
of	O
childhood	O
,	O
is	O
distinct	O
from	O
adult	O
-	O
type	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
and	O
bears	O
resemblance	O
to	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
CMMoL	B-malignancy-type
)	O
.	O
Since	O
mutations	O
in	O
the	O
N-ras	O
gene	O
have	O
been	O
found	O
at	O
high	O
frequencies	O
in	O
CMMoL	B-malignancy-type
,	O
but	O
only	O
rarely	O
in	O
CML	B-malignancy-type
,	O
we	O
analyzed	O
mutations	O
activating	O
the	O
N-ras	O
gene	O
in	O
20	O
patients	O
with	O
JCML	B-malignancy-type
.	O
We	O
used	O
the	O
strategy	O
for	O
analysis	O
of	O
gene	O
mutations	O
based	O
on	O
in	O
vitro	O
DNA	O
amplification	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
followed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and/or	O
direct	O
sequence	O
analysis	O
.	O
Nucleotide	O
sequence	O
analysis	O
showed	O
single	O
nucleotide	O
substitutions	O
involving	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
in	O
six	O
of	O
20	O
patients	O
(	O
30	O
%	O
)	O
.	O
Four	O
of	O
six	O
patients	O
with	O
mutations	O
were	O
in	O
chronic	O
phase	O
and	O
the	O
other	O
two	O
in	O
blast	O
crisis	O
,	O
indicating	O
no	O
apparent	O
correlation	O
with	O
disease	O
stage	O
.	O
Most	O
of	O
the	O
patients	O
with	O
mutations	O
were	O
in	O
the	O
older	O
age	O
group	O
with	O
poor	O
prognosis	O
,	O
although	O
one	O
patient	O
in	O
the	O
younger	O
age	O
group	O
also	O
harbored	O
the	O
mutation	O
.	O
These	O
data	O
suggest	O
that	O
N-ras	O
gene	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
and/or	O
prognosis	O
of	O
JCML	B-malignancy-type
and	O
provide	O
further	O
evidence	O
that	O
JCML	B-malignancy-type
is	O
an	O
entity	O
distinct	O
from	O
CML	B-malignancy-type
.	O
PMID	O
:	O
8161790	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1994	O
Jun;87(	O
2	O
)	O
:235	O
-	O
42	O
Establishment	O
and	O
characterization	O
of	O
a	O
novel	O
myeloid	O
cell	O
line	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Tohyama	O
K	O
,	O
Tsutani	O
H	O
,	O
Ueda	O
T	O
,	O
Nakamura	O
T	O
,	O
Yoshida	O
Y.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Fukui	O
Medical	O
School	O
,	O
Japan	O
.	O
A	O
novel	O
long	O
-	O
term	O
cultured	O
myeloid	O
cell	O
line	O
was	O
established	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
This	O
cell	O
line	O
,	O
designated	O
MDS92	O
,	O
proliferated	O
in	O
the	O
presence	O
of	O
interleukin-3	O
or	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
transiently	O
in	O
the	O
presence	O
of	O
Steel	O
factor	O
,	O
with	O
a	O
tendency	O
for	O
gradual	O
maturation	O
,	O
and	O
formed	O
myeloid	O
colonies	O
in	O
the	O
semi	O
-	O
solid	O
culture	O
condition	O
.	O
In	O
addition	O
,	O
the	O
MDS92	O
cell	O
line	O
represented	O
rather	O
complicated	O
karyotypic	O
abnormalities	O
including	O
the	O
deletion	O
of	O
fifth	O
and	O
seventh	O
chromosomes	O
and	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
N-ras	O
oncogene	O
.	O
These	O
characteristics	O
of	O
the	O
MDS92	O
cell	O
line	O
are	O
exclusively	O
compatible	O
with	O
the	O
property	O
of	O
preleukaemia	B-malignancy-type
.	O
PMID	O
:	O
7947263	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1994	O
Aug;85(	O
8	O
)	O
:847	O
-	O
52	O
State	O
of	O
adenomatous	B-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
gene	O
and	O
ras	O
oncogenes	O
in	O
Japanese	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Suzuki	O
H	O
,	O
Aida	O
S,	O
Akimoto	O
S,	O
Igarashi	O
T	O
,	O
Yatani	O
R,	O
Shimazaki	O
J.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Chiba	O
University	O
.	O
Genetic	O
alterations	O
of	O
ras	O
oncogenes	O
(	O
K	O
-	O
,	O
H	O
-	O
and	O
N	O
-	O
ras	O
)	O
and	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
in	O
tissues	O
of	O
prostate	B-malignancy-type
cancer	I-malignancy-type
from	O
Japanese	O
patients	O
were	O
examined	O
using	O
PCR	O
-	O
SSCP	O
(	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Tissues	O
from	O
8	O
cases	O
of	O
untreated	O
stage	O
B	O
prostate	B-malignancy-type
cancer	I-malignancy-type
surgically	O
removed	O
and	O
from	O
10	O
cases	O
of	O
endocrine	O
therapy	O
-	O
resistant	O
metastatic	O
disease	O
obtained	O
at	O
autopsy	O
were	O
used	O
in	O
the	O
present	O
study	O
.	O
In	O
four	O
out	O
of	O
18	O
cases	O
(	O
22	O
%	O
)	O
,	O
ras	O
point	O
mutations	O
were	O
found	O
,	O
two	O
in	O
either	O
codon	O
12	O
or	O
61	O
of	O
K-ras	O
and	O
two	O
in	O
either	O
13	O
or	O
61	O
of	O
H-ras	O
.	O
These	O
point	O
mutations	O
were	O
detected	O
in	O
one	O
of	O
the	O
stage	O
B	O
cases	O
(	O
13	O
%	O
)	O
and	O
in	O
three	O
of	O
the	O
autopsy	O
cases	O
(	O
30	O
%	O
)	O
.	O
All	O
these	O
cases	O
were	O
poorly	O
differentiated	O
adenocarcinoma	B-malignancy-type
.	O
In	O
autopsy	O
cases	O
showing	O
ras	O
mutation	O
in	O
cancerous	B-malignancy-type
prostate	I-malignancy-type
,	O
the	O
same	O
alteration	O
was	O
observed	O
in	O
metastatic	O
tissues	O
.	O
No	O
APC	O
gene	O
mutation	O
was	O
detected	O
in	O
any	O
sample	O
,	O
although	O
polymorphism	O
was	O
found	O
in	O
some	O
cases	O
.	O
These	O
results	O
indicate	O
that	O
ras	O
oncogene	O
mutations	O
are	O
related	O
to	O
the	O
progression	O
of	O
prostate	B-malignancy-type
cancer	I-malignancy-type
,	O
whereas	O
APC	O
gene	O
alteration	O
is	O
not	O
involved	O
in	O
tumorigenesis	O
and	O
development	O
of	O
this	O
cancer	B-malignancy-type
.	O
PMID	O
:	O
7928631	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
1995	O
;121(	O
1	O
)	O
:23	O
-	O
30	O
Analysis	O
of	O
ras	O
mutations	O
in	O
human	O
melanocytic	O
lesions	O
:	O
activation	O
of	O
the	O
ras	O
gene	O
seems	O
to	O
be	O
associated	O
with	O
the	O
nodular	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
human	I-malignancy-type
malignant	I-malignancy-type
melanoma	I-malignancy-type
.	O
Jafari	O
M,	O
Papp	O
T	O
,	O
Kirchner	O
S,	O
Diener	O
U	O
,	O
Henschler	O
D	O
,	O
Burg	O
G	O
,	O
Schiffmann	O
D.	O
Institute	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Wurzburg	O
,	O
Germany	O
.	O
We	O
have	O
analyzed	O
the	O
Ha-ras	O
,	O
Ki-ras	O
and	O
N-ras	O
gene	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
via	O
restriction	O
fragment	O
length	O
polymorphism	O
/	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
subsequent	O
direct	O
sequencing	O
in	O
non	O
-	O
cultured	O
fresh	O
-	O
frozen	O
tissues	O
of	O
16	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanomas	I-malignancy-type
(	O
SSM	B-malignancy-type
)	O
,	O
13	O
nodular	B-malignancy-type
malignant	I-malignancy-type
melanomas	I-malignancy-type
(	O
NMM	B-malignancy-type
)	O
,	O
2	O
lentigo	B-malignancy-type
malignant	I-malignancy-type
melanomas	I-malignancy-type
(	O
LMM	B-malignancy-type
)	O
,	O
1	O
dysplastic	B-malignancy-type
nevus	I-malignancy-type
,	O
1	O
congenital	B-malignancy-type
nevus	I-malignancy-type
and	O
5	O
normal	B-malignancy-type
nevi	I-malignancy-type
from	O
38	O
patients	O
.	O
Mutations	O
were	O
found	O
in	O
4	O
melanoma	B-malignancy-type
samples	O
,	O
all	O
belonging	O
to	O
the	O
nodular	B-malignancy-type
malignant	I-malignancy-type
type	I-malignancy-type
.	O
Three	O
of	O
them	O
were	O
mutated	O
in	O
N-ras	O
and	O
one	O
in	O
the	O
Ha-ras	O
gene	O
.	O
Mutation	O
in	O
N-ras	O
was	O
also	O
detected	O
in	O
the	O
congenital	B-malignancy-type
nevus	I-malignancy-type
.	O
All	O
mutations	O
were	O
exclusively	O
located	O
at	O
the	O
first	O
two	O
base	O
pairs	O
of	O
codon	O
61	O
.	O
No	O
Ki-ras	O
mutation	O
was	O
detected	O
in	O
any	O
lesion	O
.	O
No	O
mutation	O
could	O
be	O
found	O
in	O
SSM	B-malignancy-type
and	O
LMM	B-malignancy-type
in	O
addition	O
to	O
dysplastic	B-malignancy-type
and	O
normal	B-malignancy-type
nevi	B-malignancy-type
.	O
The	O
frequency	O
of	O
ras	O
mutation	O
in	O
NMM	B-malignancy-type
was	O
31	O
%	O
,	O
whereas	O
in	O
SSM	B-malignancy-type
it	O
was	O
0	O
%	O
.	O
Our	O
study	O
suggests	O
(a)	O
an	O
association	O
between	O
ras	O
mutations	O
(	O
mainly	O
N-ras	O
)	O
and	O
the	O
NMM	B-malignancy-type
as	O
a	O
subgroup	O
of	O
human	O
melanoma	B-malignancy-type
;	O
(b)	O
that	O
activation	O
of	O
Ki-ras	O
is	O
not	O
involved	O
in	O
the	O
pathogenesis	O
of	O
melanoma	B-malignancy-type
.	O
The	O
role	O
of	O
UV	O
radiation	O
in	O
point	O
mutations	O
of	O
ras	O
genes	O
in	O
human	O
melanoma	B-malignancy-type
is	O
discussed	O
.	O
PMID	O
:	O
7860615	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1995	O
May	O
;104(	O
5	O
)	O
:868	O
-	O
71	O
Ras	O
gene	O
mutations	O
:	O
a	O
rare	O
event	O
in	O
nonmetastatic	O
primary	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
.	O
Wagner	O
SN	O
,	O
Ockenfels	O
HM	O
,	O
Wagner	O
C	O
,	O
Hofler	O
H	O
,	O
Goos	O
M.	O
Department	O
of	O
Dermatology	O
,	O
University	O
Essen	O
,	O
Germany	O
.	O
Ras	O
gene	O
mutations	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
a	O
variety	O
of	O
human	O
tumors	O
.	O
Mutated	O
ras	O
genes	O
have	O
been	O
isolated	O
from	O
human	O
melanoma	B-malignancy-type
cell	O
lines	O
,	O
but	O
subsequent	O
studies	O
indicated	O
that	O
ras	O
gene	O
mutations	O
may	O
be	O
a	O
rare	O
event	O
in	O
melanocytic	O
lesions	O
.	O
Recently	O
,	O
a	O
study	O
reported	O
a	O
high	O
frequency	O
of	O
ras	O
mutations	O
correlated	O
with	O
increasing	O
invasion	O
level	O
.	O
To	O
address	O
this	O
inconsistency	O
in	O
the	O
published	O
data	O
,	O
we	O
analyzed	O
50	O
primary	O
melanomas	B-malignancy-type
to	O
correlate	O
invasion	O
level	O
,	O
tumor	O
thickness	O
,	O
histologic	O
typing	O
,	O
and	O
body	O
localization	O
with	O
point	O
mutations	O
around	O
codons	O
12	O
/	O
13	O
/	O
61	O
of	O
the	O
three	O
ras	O
genes	O
.	O
After	O
micro	O
-	O
dissection	O
of	O
paraffin	O
-	O
embedded	O
tumor	O
tissue	O
,	O
ras	O
gene	O
mutations	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
of	O
tumor	O
DNA	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
Only	O
two	O
melanomas	B-malignancy-type
exhibited	O
ras	O
gene	O
mutations	O
,	O
one	O
sample	O
containing	O
a	O
transition	O
from	O
A	O
to	O
G	O
at	O
position	O
2	O
of	O
N-ras	O
codon	O
61	O
and	O
the	O
other	O
exhibiting	O
a	O
transversion	O
from	O
C	O
to	O
A	O
at	O
position	O
1	O
and	O
a	O
transition	O
from	O
A	O
to	O
G	O
at	O
position	O
2	O
of	O
N-ras	O
codon	O
61	O
.	O
Both	O
tumors	O
were	O
classified	O
as	O
Clark	O
level	O
IV	O
,	O
with	O
a	O
tumor	O
thickness	O
of	O
2.5	O
and	O
1.2	O
mm	O
,	O
respectively	O
.	O
Both	O
were	O
typed	O
as	O
superficial	B-malignancy-type
spreading	I-malignancy-type
melanoma	I-malignancy-type
and	O
localized	O
to	O
intermittently	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
The	O
low	O
frequency	O
of	O
ras	O
mutations	O
in	O
malignant	O
melanoma	B-malignancy-type
and	O
the	O
lack	O
of	O
ras	O
mutations	O
in	O
melanoma	B-malignancy-type
samples	O
from	O
constantly	O
sun	O
-	O
exposed	O
body	O
sites	O
argue	O
against	O
the	O
hypothesis	O
of	O
ras	O
mutations	O
as	O
a	O
marker	O
of	O
progression	O
in	O
malignant	O
melanoma	B-malignancy-type
and	O
the	O
suggestion	O
that	O
ras	O
mutations	O
occur	O
predominantly	O
in	O
melanomas	B-malignancy-type
from	O
constantly	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
PMID	O
:	O
7738369	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1984	O
Jun;81(	O
12	O
)	O
:3670	O
-	O
4	O
Mechanism	O
of	O
activation	O
of	O
an	O
N-ras	O
oncogene	O
of	O
SW-1271	O
human	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
cells	O
.	O
Yuasa	O
Y	O
,	O
Gol	O
RA	O
,	O
Chang	O
A	O
,	O
Chiu	O
IM	O
,	O
Reddy	O
EP	O
,	O
Tronick	O
SR	O
,	O
Aaronson	O
SA	O
.	O
An	O
N-ras	O
-	O
related	O
transforming	O
gene	O
was	O
detected	O
in	O
the	O
human	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
line	O
SW-1271	O
and	O
molecularly	O
cloned	O
.	O
The	O
lesion	O
responsible	O
for	O
its	O
acquisition	O
of	O
transforming	O
activity	O
was	O
localized	O
to	O
a	O
single	O
nucleotide	O
transition	O
from	O
A	O
to	O
G	O
in	O
codon	O
61	O
of	O
the	O
predicted	O
protein	O
.	O
This	O
lesion	O
in	O
the	O
second	O
exon	O
results	O
in	O
the	O
substitution	O
of	O
arginine	O
for	O
glutamine	O
at	O
this	O
position	O
.	O
These	O
findings	O
,	O
together	O
with	O
previous	O
studies	O
,	O
indicate	O
that	O
the	O
activation	O
of	O
ras	O
oncogenes	O
in	O
human	O
tumors	O
is	O
most	O
commonly	O
due	O
to	O
point	O
mutations	O
at	O
one	O
of	O
two	O
major	O
"	O
hot	O
spots	O
"	O
in	O
the	O
ras	O
coding	O
sequence	O
.	O
PMID	O
:	O
6587382	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
1987	O
Jul	O
15	O
;146(	O
1	O
)	O
:247	O
-	O
52	O
A	O
point	O
mutation	O
at	O
codon	O
13	O
of	O
the	O
N-ras	O
oncogene	O
in	O
a	O
human	O
stomach	B-malignancy-type
cancer	I-malignancy-type
.	O
Nishida	O
J,	O
Kobayashi	O
Y	O
,	O
Hirai	O
H	O
,	O
Takaku	O
F.	O
A	O
surgically	O
removed	O
human	O
stomach	B-malignancy-type
cancer	I-malignancy-type
with	O
the	O
histological	O
diagnosis	O
of	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
adenocarcinoma	I-malignancy-type
contained	O
an	O
activated	O
N-ras	O
oncogene	O
detected	O
by	O
an	O
in	O
vivo	O
selection	O
assay	O
in	O
nude	O
mice	O
using	O
transfected	O
NIH3T3	O
cells	O
.	O
Analysis	O
using	O
synthetic	O
20	O
-	O
mer	O
oligonucleotide	O
probes	O
revealed	O
a	O
point	O
mutation	O
from	O
G	O
to	O
C	O
at	O
the	O
first	O
letter	O
of	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
arginine	O
for	O
glycine	O
.	O
This	O
is	O
the	O
first	O
observation	O
of	O
an	O
activated	O
N-ras	O
oncogene	O
in	O
human	O
stomach	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
3038106	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1989	O
Dec;74(	O
8	O
)	O
:2629	O
-	O
33	O
Mutations	O
of	O
the	O
ras	O
protooncogenes	O
in	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
:	O
a	O
high	O
frequency	O
of	O
ras	O
mutations	O
in	O
bcr	O
/	O
abl	O
rearrangement	O
-	O
negative	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Cogswell	O
PC	O
,	O
Morgan	O
R,	O
Dunn	O
M,	O
Neubauer	O
A	O
,	O
Nelson	O
P	O
,	O
Poland	O
-	O
Johnston	O
NK	O
,	O
Sandberg	O
AA	O
,	O
Liu	O
E.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
27599	O
.	O
Seventy	O
cases	O
of	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
oligonucleotide	O
hybridization	O
,	O
and	O
direct	O
PCR	O
sequencing	O
.	O
All	O
cases	O
had	O
preceding	O
cytogenetic	O
and	O
bcr	O
rearrangement	O
studies	O
.	O
Aberrant	O
ras	O
genes	O
were	O
detected	O
in	O
none	O
of	O
39	O
patients	O
with	O
Philadelphia	O
(	O
Ph	O
)	O
chromosome	O
or	O
bcr	O
/	O
abl	O
rearrangement	O
positive	O
chronic	O
-	O
phase	O
CML	B-malignancy-type
and	O
in	O
only	O
1	O
of	O
18	O
patients	O
in	O
blast	O
crisis	O
,	O
suggesting	O
that	O
ras	O
mutations	O
have	O
little	O
or	O
no	O
role	O
in	O
initiation	O
or	O
progression	O
of	O
common	O
CML	B-malignancy-type
.	O
Seven	O
of	O
13	O
,	O
or	O
54	O
%	O
of	O
patients	O
with	O
bcr	O
/	O
abl	O
rearrangement	O
negative	O
chronic	O
phase	O
CML	B-malignancy-type
(	O
atypical	O
CML	B-malignancy-type
)	O
harbored	O
mutations	O
in	O
ras	O
,	O
however	O
.	O
This	O
high	O
incidence	O
of	O
ras	O
mutations	O
,	O
together	O
with	O
the	O
absence	O
of	O
bcr	O
/	O
abl	O
rearrangement	O
,	O
provides	O
evidence	O
that	O
atypical	O
CML	B-malignancy-type
is	O
an	O
entity	O
that	O
is	O
molecularly	O
distinct	O
from	O
common	B-malignancy-type
CML	I-malignancy-type
.	O
Moreover	O
,	O
the	O
clinical	O
characteristics	O
and	O
the	O
high	O
frequency	O
of	O
ras	O
mutations	O
suggest	O
that	O
atypical	O
CML	B-malignancy-type
may	O
constitute	O
a	O
subset	O
of	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
may	O
be	O
best	O
classified	O
as	O
a	O
variant	O
of	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
CMML	B-malignancy-type
)	O
.	O
PMID	O
:	O
2684296	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1989	O
Aug;86(	O
16	O
)	O
:6372	O
-	O
6	O
Oncogene	O
activation	O
in	O
human	O
benign	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
skin	I-malignancy-type
(	O
keratoacanthomas	B-malignancy-type
)	O
:	O
is	O
HRAS	O
involved	O
in	O
differentiation	O
as	O
well	O
as	O
proliferation	O
?	O
Corominas	O
M,	O
Kamino	O
H	O
,	O
Leon	O
J,	O
Pellicer	O
A.	O
Department	O
of	O
Pathology	O
,	O
New	O
York	O
University	O
Medical	O
Center	O
,	O
NY	O
10016	O
.	O
In	O
vitro	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
mismatch	O
hybridization	O
was	O
used	O
to	O
study	O
the	O
frequency	O
of	O
HRAS	O
mutations	O
in	O
the	O
benign	O
self	O
-	O
regressing	O
skin	B-malignancy-type
tumors	I-malignancy-type
keratoacanthomas	B-malignancy-type
and	O
in	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
We	O
used	O
freshly	O
obtained	O
keratoacanthomas	B-malignancy-type
as	O
well	O
as	O
Formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
both	O
types	O
of	O
tumors	O
.	O
DNA	O
from	O
50	O
samples	O
of	O
each	O
tumor	O
type	O
was	O
analyzed	O
for	O
activating	O
mutations	O
involving	O
codons	O
12	O
and	O
61	O
.	O
A	O
relatively	O
high	O
percentage	O
(	O
30	O
%	O
)	O
of	O
HRAS	O
mutations	O
was	O
found	O
in	O
the	O
keratoacanthomas	B-malignancy-type
compared	O
with	O
13	O
%	O
in	O
the	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
most	O
frequent	O
mutation	O
identified	O
is	O
the	O
A-T	O
-	O
to	O
-	O
T.A	O
transversion	O
in	O
the	O
second	O
position	O
of	O
codon	O
61	O
.	O
The	O
present	O
findings	O
demonstrate	O
the	O
involvement	O
of	O
the	O
HRAS	O
oncogene	O
in	O
human	O
benign	B-malignancy-type
tumors	I-malignancy-type
.	O
Moreover	O
,	O
they	O
indicate	O
that	O
an	O
activated	O
HRAS	O
oncogene	O
is	O
not	O
sufficient	O
to	O
maintain	O
a	O
neoplastic	O
phenotype	O
and	O
argue	O
against	O
a	O
role	O
of	O
HRAS	O
in	O
the	O
progression	O
of	O
skin	O
tumorigenesis	O
.	O
PMID	O
:	O
2668964	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
May	O
;4(	O
5	O
)	O
:609	O
-	O
14	O
Mechanisms	O
of	O
ras	O
mutation	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Yunis	O
JJ	O
,	O
Boot	O
AJ	O
,	O
Mayer	O
MG	O
,	O
Bos	O
JL.	O
Department	O
of	O
Laboratory	O
Medicine	O
and	O
Pathology	O
,	O
University	O
of	O
Minnesota	O
Medical	O
School	O
,	O
Minneapolis	O
.	O
Using	O
synthetic	O
oligonucleotide	O
hybridization	O
,	O
we	O
have	O
found	O
a	O
ras	O
mutation	O
in	O
11	O
of	O
27	O
patients	O
(	O
41	O
%	O
)	O
with	O
primary	O
or	O
non	O
-	O
therapy	O
related	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
This	O
high	O
incidence	O
of	O
mutation	O
,	O
mainly	O
of	O
the	O
N-ras	O
oncogene	O
,	O
was	O
generally	O
found	O
in	O
patients	O
with	O
disease	O
progression	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
(	O
8	O
of	O
11	O
patients	O
=	O
73	O
%	O
)	O
.	O
Two	O
general	O
mechanisms	O
of	O
ras	O
mutation	O
were	O
found	O
.	O
In	O
five	O
patients	O
the	O
ras	O
mutation	O
was	O
present	O
in	O
only	O
a	O
fraction	O
of	O
the	O
cells	O
;	O
sometimes	O
appearing	O
in	O
late	O
stages	O
of	O
the	O
disease	O
,	O
suggesting	O
that	O
it	O
can	O
occur	O
in	O
a	O
differentiated	O
cell	O
clone	O
.	O
In	O
six	O
other	O
patients	O
,	O
the	O
ras	O
mutation	O
was	O
present	O
in	O
the	O
great	O
majority	O
of	O
bone	O
marrow	O
or	O
blood	O
cells	O
.	O
The	O
mutation	O
was	O
detected	O
in	O
mature	O
normal	O
lymphocytes	O
and	O
persisted	O
following	O
a	O
complete	O
clinical	O
remission	O
in	O
two	O
of	O
these	O
patients	O
,	O
implying	O
that	O
the	O
ras	O
mutation	O
can	O
occur	O
in	O
an	O
early	O
stage	O
of	O
cell	O
differentiation	O
or	O
stem	O
cell	O
.	O
Patients	O
with	O
a	O
ras	O
mutation	O
had	O
a	O
median	O
survival	O
of	O
nine	O
months	O
(	O
all	O
patients	O
dead	O
)	O
compared	O
to	O
16	O
patients	O
without	O
a	O
ras	O
mutation	O
that	O
had	O
a	O
median	O
follow	O
-	O
up	O
of	O
16	O
months	O
(	O
10	O
patients	O
alive	O
;	O
P	O
less	O
than	O
0.005	O
)	O
.	O
Since	O
9	O
of	O
the	O
11	O
patients	O
(	O
82	O
%	O
)	O
with	O
a	O
ras	O
mutation	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
monocytic	O
component	O
at	O
diagnosis	O
or	O
during	O
disease	O
evolution	O
,	O
it	O
is	O
possible	O
that	O
in	O
myeloid	O
disorders	O
a	O
ras	O
mutation	O
is	O
preferentially	O
associated	O
with	O
myelomonocytic	O
cell	O
differentiation	O
.	O
PMID	O
:	O
2657575	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Apr	O
15;75(	O
8	O
)	O
:1684	O
-	O
90	O
The	O
pattern	O
of	O
mutational	O
involvement	O
of	O
RAS	O
genes	O
in	O
human	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
determined	O
by	O
DNA	O
amplification	O
and	O
direct	O
sequencing	O
.	O
Ahuja	O
HG	O
,	O
Foti	O
A	O
,	O
Bar	O
-	O
Eli	O
M,	O
Cline	O
MJ.	O
Department	O
of	O
Medicine	O
,	O
Jonsson	O
Cancer	O
Center	O
,	O
UCLA	O
School	O
of	O
Medicine	O
90024	O
-	O
1678	O
.	O
DNA	O
from	O
161	O
patients	O
with	O
various	O
forms	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
were	O
investigated	O
for	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
N-RAS	O
,	O
K-RAS	O
and	O
Ha-RAS	O
gene	O
by	O
direct	O
sequencing	O
of	O
DNA	O
amplified	O
in	O
vitro	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
involving	O
either	O
codons	O
11	O
,	O
12	O
,	O
or	O
13	O
of	O
the	O
N-RAS	O
gene	O
were	O
identified	O
in	O
18	O
of	O
the	O
161	O
patients	O
.	O
The	O
relative	O
frequencies	O
of	O
N-RAS	O
gene	O
mutations	O
in	O
these	O
hematologic	O
disorders	O
was	O
as	O
follows	O
:	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	O
)	O
,	O
15	O
%	O
;	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	O
)	O
,	O
14	O
%	O
;	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
,	O
24	O
%	O
;	O
and	O
myeloid	O
and	O
lymphoid	O
blast	O
crisis	O
of	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
,	O
3	O
%	O
.	O
No	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
of	O
mutations	O
and	O
cytologic	O
features	O
or	O
immunophenotype	O
of	O
these	O
malignancies	O
.	O
Mutations	O
involving	O
codons	O
12	O
or	O
13	O
were	O
equally	O
prevalent	O
,	O
with	O
a	O
glycine	O
to	O
aspartic	O
acid	O
substitution	O
being	O
the	O
most	O
frequently	O
encountered	O
change	O
.	O
A	O
single	O
T-ALL	B-malignancy-type
case	O
had	O
a	O
codon	O
11	O
mutation	O
resulting	O
in	O
substitution	O
of	O
alanine	O
with	O
threonine	O
.	O
We	O
failed	O
to	O
find	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
K-RAS	O
or	O
Ha-RAS	O
genes	O
in	O
any	O
case	O
except	O
a	O
single	O
AML	B-malignancy-type
with	O
a	O
mutation	O
in	O
codon	O
61	O
of	O
the	O
K-RAS	O
gene	O
.	O
Also	O
,	O
no	O
mutations	O
were	O
identified	O
in	O
chronic	O
phase	O
of	O
CML	B-malignancy-type
,	O
chronic	B-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Ph1	O
positive	O
ALL	B-malignancy-type
,	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
,	O
Hodgkin	B-malignancy-type
's	I-malignancy-type
disease	I-malignancy-type
,	O
or	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
These	O
results	O
indicate	O
that	O
RAS	O
mutations	O
,	O
especially	O
those	O
involving	O
exon	O
1	O
of	O
the	O
N-RAS	O
gene	O
,	O
are	O
frequent	O
only	O
in	O
a	O
subset	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
PMID	O
:	O
2183888	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1991	O
May	O
15;51(	O
10	O
)	O
:2690	O
-	O
3	O
High	O
rates	O
of	O
ras	O
codon	O
61	O
mutation	O
in	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
in	O
an	O
iodide	O
-	O
deficient	O
area	O
.	O
Shi	O
YF	O
,	O
Zou	O
MJ	O
,	O
Schmidt	O
H	O
,	O
Juhasz	O
F	O
,	O
Stensky	O
V	O
,	O
Robb	O
D	O
,	O
Farid	O
NR	O
.	O
Thyroid	O
Research	O
Laboratory	O
,	O
Health	O
Sciences	O
Centre	O
,	O
St.	O
John	O
's	O
,	O
Newfoundland	O
,	O
Canada	O
.	O
Using	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
,	O
the	O
frequency	O
of	O
three	O
ras	O
oncogene	O
mutations	O
(	O
N-ras	O
,	O
Ha-ras	O
,	O
and	O
K-ras	O
)	O
in	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
(	O
25	O
adenomas	B-malignancy-type
,	O
16	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
22	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
)	O
was	O
investigated	O
in	O
both	O
iodide	O
-	O
deficient	O
and	O
iodide	O
-	O
sufficient	O
areas	O
.	O
The	O
ras	O
oncogene	O
mutation	O
rate	O
was	O
significantly	O
higher	O
in	O
the	O
iodide	O
-	O
deficient	O
area	O
,	O
being	O
85	O
versus	O
17	O
%	O
in	O
the	O
adenomas	B-malignancy-type
,	O
and	O
50	O
versus	O
10	O
%	O
in	O
the	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
No	O
mutations	O
were	O
found	O
in	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
most	O
common	O
mutation	O
site	O
was	O
Ha-ras	O
codon	O
61	O
with	O
Gln	O
----	O
Arg	O
substitution	O
.	O
Two	O
ras	O
mutations	O
at	O
codon	O
61	O
(	O
Gln	O
----	O
Lys	O
in	O
N-ras	O
and	O
Gln	O
----	O
Arg	O
in	O
Ha-ras	O
)	O
were	O
found	O
in	O
a	O
microfollicular	B-malignancy-type
adenoma	I-malignancy-type
specimen	O
from	O
Eastern	O
Hungary	O
.	O
We	O
conclude	O
that	O
dietary	O
iodine	O
may	O
modulate	O
ras	O
oncogene	O
mutations	O
,	O
and	O
that	O
in	O
the	O
iodide	O
-	O
deficient	O
area	O
,	O
ras	O
oncogene	O
activation	O
may	O
play	O
a	O
more	O
important	O
role	O
in	O
the	O
initiation	O
and/or	O
maintenance	O
of	O
follicular	B-malignancy-type
tumors	I-malignancy-type
.	O
Additional	O
factors	O
are	O
,	O
however	O
,	O
necessary	O
to	O
initiate	O
carcinogenesis	O
.	O
PMID	O
:	O
2021946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1992	O
Apr;74(	O
4)	O
:914	O
-	O
9	O
Ras	O
mutations	O
in	O
human	O
pituitary	B-malignancy-type
tumors	I-malignancy-type
.	O
Karga	O
HJ	O
,	O
Alexander	O
JM	O
,	O
Hedley	O
-	O
Whyte	O
ET	O
,	O
Klibanski	O
A	O
,	O
Jameson	O
JL.	O
Department	O
of	O
Medicine	O
,	O
Massachusetts	O
General	O
General	O
Hospital	O
,	O
Boston	O
02114	O
.	O
The	O
cellular	O
basis	O
for	O
pituitary	B-malignancy-type
neoplasia	I-malignancy-type
is	O
poorly	O
understood	O
.	O
Mutations	O
that	O
activate	O
the	O
ras	O
protooncogenes	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
different	O
types	O
of	O
human	O
cancers	O
and	O
potentially	O
represent	O
one	O
of	O
the	O
genetic	O
alterations	O
that	O
occur	O
in	O
pituitary	B-malignancy-type
tumors	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
examined	O
19	O
pituitary	B-malignancy-type
tumors	I-malignancy-type
for	O
the	O
occurrence	O
of	O
ras	O
mutations	O
.	O
The	O
tumor	O
types	O
included	O
11	O
nonfunctioning	B-malignancy-type
adenomas	I-malignancy-type
,	O
6	O
somatotroph	B-malignancy-type
adenomas	I-malignancy-type
,	O
and	O
2	O
prolactinomas	B-malignancy-type
.	O
Each	O
of	O
the	O
three	O
ras	O
genes	O
(	O
K-ras	O
,	O
N-ras	O
,	O
and	O
H-ras	O
)	O
was	O
amplified	O
from	O
pituitary	B-malignancy-type
tumor	I-malignancy-type
DNA	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Oligonucleotide	O
-	O
specific	O
hybridization	O
was	O
used	O
to	O
screen	O
for	O
mutations	O
that	O
inhibit	O
GTPase	O
activity	O
and	O
cause	O
activation	O
of	O
the	O
ras	O
oncogene	O
.	O
No	O
ras	O
mutations	O
were	O
observed	O
in	O
18	O
of	O
the	O
pituitary	B-malignancy-type
adenomas	I-malignancy-type
.	O
However	O
,	O
a	O
mutation	O
was	O
identified	O
in	O
codon	O
12	O
of	O
the	O
H-ras	O
gene	O
(	O
Gly	O
to	O
Val	O
)	O
in	O
a	O
recurrent	O
prolactinoma	B-malignancy-type
that	O
was	O
highly	O
invasive	O
and	O
ultimately	O
proved	O
to	O
be	O
fatal	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
are	O
uncommon	O
in	O
pituitary	B-malignancy-type
adenomas	I-malignancy-type
,	O
but	O
may	O
provide	O
a	O
marker	O
for	O
highly	O
invasive	O
tumors	O
.	O
PMID	O
:	O
1312542	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2001	O
Nov;32	O
(	O
11	O
)	O
:	O
1203	O
-	O
8	O
Heterogeneous	O
genetic	O
alterations	O
in	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
:	O
application	O
and	O
usefulness	O
of	O
laser	O
capture	O
microdissection	O
.	O
Takeshima	O
Y	O
,	O
Amatya	O
VJ	O
,	O
Daimaru	O
Y	O
,	O
Nakayori	O
F	O
,	O
Nakano	O
T	O
,	O
Inai	O
K.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
.	O
Histologic	O
observation	O
of	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
suggests	O
that	O
there	O
is	O
a	O
multistep	O
transition	O
through	O
the	O
accumulation	O
of	O
genetic	O
alterations	O
.	O
We	O
analyzed	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
and	O
replication	O
error	O
(	O
RER	O
)	O
on	O
TP53	O
and	O
D17S855	O
as	O
well	O
as	O
K-ras	O
point	O
mutations	O
of	O
the	O
heterogeneous	O
histologic	O
areas	O
of	O
the	O
same	O
tumor	O
in	O
26	O
cases	O
of	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumor	I-malignancy-type
.	O
The	O
laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
technique	O
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
K-ras	O
point	O
mutation	O
in	O
10	O
cases	O
.	O
As	O
for	O
genetic	O
alterations	O
for	O
LOH	O
or	O
RER	O
on	O
TP53	O
and	O
D17S855	O
,	O
2	O
(	O
1	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
1	O
carcinoma	B-malignancy-type
)	O
of	O
14	O
cases	O
and	O
4	O
(	O
1	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
3	O
carcinomas	B-malignancy-type
)	O
of	O
12	O
cases	O
,	O
respectively	O
,	O
showed	O
genetic	O
heterogeneities	O
in	O
different	O
histologic	O
areas	O
.	O
Six	O
(	O
2	O
borderline	B-malignancy-type
tumors	I-malignancy-type
and	O
4	O
carcinomas	O
)	O
of	O
18	O
cases	O
showed	O
heterogeneity	O
of	O
K-ras	O
point	O
mutation	O
in	O
the	O
different	O
histologic	O
areas	O
of	O
the	O
same	O
tumor	O
,	O
and	O
5	O
(	O
1	O
cystadenoma	B-malignancy-type
with	I-malignancy-type
Brenner	I-malignancy-type
tumor	I-malignancy-type
component	I-malignancy-type
,	O
2	O
borderline	B-malignancy-type
tumors	I-malignancy-type
,	O
and	O
2	O
carcinomas	B-malignancy-type
)	O
of	O
10	O
cases	O
showed	O
heterogeneous	O
K-ras	O
mutation	O
pattern	O
in	O
the	O
same	O
tumor	O
when	O
the	O
LCM	O
technique	O
was	O
used	O
.	O
Atypical	O
areas	O
tended	O
to	O
show	O
K-ras	O
point	O
mutations	O
frequently	O
.	O
Out	O
of	O
3	O
cases	O
of	O
mixed	B-malignancy-type
mucinous	I-malignancy-type
cystadenoma	I-malignancy-type
and	I-malignancy-type
Brenner	I-malignancy-type
tumor	I-malignancy-type
,	O
1	O
case	O
showed	O
K-ras	O
point	O
mutation	O
in	O
the	O
Brenner	B-malignancy-type
tumor	I-malignancy-type
area	O
but	O
not	O
in	O
the	O
area	O
of	O
mucinous	B-malignancy-type
cystadenoma	I-malignancy-type
.	O
These	O
preliminary	O
results	O
suggest	O
that	O
a	O
subset	O
of	O
ovarian	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
occur	O
through	O
multistep	O
carcinogenesis	O
and	O
show	O
that	O
LCM	O
is	O
useful	O
for	O
molecular	O
pathologic	O
studies	O
.	O
Copyright	O
2001	O
by	O
W.B.	O
Saunders	O
Company	O
Publication	O
Types	O
:	O
Evaluation	O
Studies	O
PMID	O
:	O
11727259	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Electron	O
Microsc	O
2002	O
Mar;35	O
(	O
1	O
)	O
:	O
9-15	O
Mutation	O
of	O
beta-catenin	O
gene	O
in	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
but	O
not	O
in	O
associated	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
Ashihara	O
K,	O
Saito	O
T	O
,	O
Mizumoto	O
H,	O
Nishimura	O
M,	O
Tanaka	O
R	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Sapporo	O
Medical	O
University	O
,	O
S-1	O
,	O
W-16	O
,	O
Chuo-ku	O
,	O
Sapporo	O
060	O
-0061	O
,	O
Japan	O
.	O
Endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
is	O
a	O
recognized	O
effect	O
of	O
excessive	O
or	O
unopposed	O
estrogen	O
stimulation	O
and	O
is	O
considered	O
to	O
be	O
a	O
precancerous	O
condition	O
of	O
endometrial	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
in	O
the	O
human	O
endometrium	O
is	O
changed	O
according	O
to	O
cell	O
proliferation	O
,	O
suggesting	O
a	O
role	O
of	O
intercellular	O
transduction	O
in	O
cell	O
-	O
growth	O
control	O
in	O
human	O
endometrium	O
,	O
not	O
only	O
in	O
the	O
physiological	O
condition	O
but	O
also	O
in	O
the	O
carcinogenic	O
endometrium	O
.	O
In	O
the	O
present	O
study	O
,	O
to	O
clarify	O
at	O
which	O
stage	O
of	O
endometrial	O
carcinogenesis	O
molecular	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
occurs	O
,	O
we	O
analyzed	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
by	O
immunohistochemistry	O
,	O
and	O
we	O
analyzed	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
in	O
25	O
patients	O
-	O
with	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
and	O
20	O
patients	O
with	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
associated	O
with	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
,	O
digesting	O
DNA	O
from	O
the	O
cancer	O
and	O
hyperplasia	O
parts	O
,	O
separately	O
.	O
Fourteen	O
of	O
the	O
25	O
(	O
56.0	O
%	O
)	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
samples	O
,	O
12	O
(	O
60.0	O
%	O
)	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
,	O
and	O
11	O
(	O
55.0	O
%	O
)	O
associated	B-malignancy-type
hyperplasias	I-malignancy-type
of	O
the	O
20	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
associated	O
with	O
hyperplasia	B-malignancy-type
showed	O
nuclear	O
localization	O
of	O
beta-catenin	O
.	O
Mutation	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
found	O
in	O
2	O
of	O
the	O
20	O
endometrial	O
cancer	O
samples	O
;	O
however	O
,	O
it	O
was	O
not	O
found	O
in	O
the	O
25	O
endometrial	B-malignancy-type
hyperplasias	I-malignancy-type
or	O
the	O
20	O
associated	O
hyperplasias	B-malignancy-type
.	O
The	O
results	O
suggest	O
that	O
molecular	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
occurs	O
in	O
atypical	B-malignancy-type
hyperplasia	I-malignancy-type
or	O
cancer	O
,	O
rather	O
than	O
in	O
simple	B-malignancy-type
or	O
complex	B-malignancy-type
hyperplasia	I-malignancy-type
without	I-malignancy-type
atypia	I-malignancy-type
,	O
during	O
endometrial	O
carcinogenesis	O
.	O
PMID	O
:	O
12111402	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
2002	O
Jun;20	O
(	O
6	O
)	O
:	O
1263	O
-	O
8	O
Frequent	O
detection	O
of	O
K-ras	O
mutation	O
in	O
stool	O
samples	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
patients	O
after	O
improved	O
DNA	O
extraction	O
:	O
comparison	O
with	O
tissue	O
samples	O
.	O
Ito	O
Y	O
,	O
Kobayashi	O
S	O
,	O
Taniguchi	O
T	O
,	O
Kainuma	O
O	O
,	O
Hara	O
T	O
,	O
Ochiai	O
T.	O
Department	O
of	O
Surgery	O
,	O
Shimizu	O
Kosei	O
General	O
Hospital	O
,	O
Chiba	O
,	O
Japan	O
.	O
Fecal	O
occult	O
blood	O
testing	O
is	O
widely	O
used	O
in	O
the	O
clinical	O
screening	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
.	O
However	O
,	O
this	O
method	O
has	O
so	O
frequent	O
false	O
-	O
positive	O
results	O
that	O
more	O
accurate	O
screening	O
-	O
strategy	O
should	O
be	O
established	O
.	O
Although	O
the	O
molecular	O
screening	O
using	O
K-ras	O
gene	O
mutation	O
in	O
stools	O
has	O
been	O
attempted	O
to	O
improve	O
the	O
results	O
,	O
the	O
low	O
rate	O
of	O
DNA	O
extraction	O
from	O
stools	O
leaves	O
this	O
measurement	O
under	O
utility	O
value	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
or	O
not	O
our	O
applied	O
DNA	O
extraction	O
method	O
from	O
stools	O
could	O
produce	O
enough	O
DNA	O
for	O
the	O
molecular	O
screening	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
by	O
K-ras	O
gene	O
mutations	O
in	O
stools	O
.	O
We	O
applied	O
cetyltrimethylammonium	O
bromide	O
(	O
CTAB	O
)	O
solution	O
to	O
improve	O
human	O
DNA	O
extraction	O
from	O
stools	O
and	O
a	O
mutant	O
-	O
allele	O
-	O
sensitive	O
amplification	O
(	O
MASA	O
)	O
method	O
to	O
detect	O
K-ras	O
mutation	O
within	O
codon	O
12	O
.	O
We	O
were	O
able	O
to	O
confirm	O
the	O
stool	O
DNA	O
by	O
identifying	O
K-ras	O
fragments	O
in	O
all	O
the	O
20	O
patients	O
.	O
Tissue	O
K-ras	O
mutation	O
was	O
identified	O
in	O
4	O
(	O
2	O
cancers	B-malignancy-type
and	O
2	O
adenomas	B-malignancy-type
)	O
of	O
20	O
patients	O
.	O
Stool	O
K-ras	O
mutations	O
were	O
found	O
in	O
6	O
patients	O
,	O
3	O
tissue	O
K-ras	O
mutation	O
positive	O
patients	O
(	O
2	O
cancers	B-malignancy-type
and	O
an	O
adenoma	B-malignancy-type
)	O
and	O
3	O
tissue	O
K-ras	O
mutation	O
negative	O
patients	O
.	O
These	O
results	O
indicate	O
that	O
it	O
is	O
possible	O
to	O
extract	O
enough	O
DNA	O
from	O
human	O
stool	O
samples	O
of	O
all	O
patients	O
with	O
colorectal	O
tumors	O
for	O
K-ras	O
mutation	O
studies	O
.	O
K-ras	O
mutations	O
are	O
more	O
frequently	O
detected	O
in	O
stools	O
than	O
in	O
resected	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
.	O
This	O
study	O
indicates	O
that	O
K-ras	O
mutation	O
screening	O
in	O
stools	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
may	O
include	O
not	O
only	O
a	O
primary	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
but	O
also	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
in	O
all	O
parts	O
of	O
a	O
gastrointestinal	O
tract	O
.	O
PMID	O
:	O
12012008	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2002	O
May	O
;160	O
(	O
5	O
)	O
:1567	O
-72	O
KIT	O
mutations	O
are	O
common	O
in	O
incidental	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
one	O
centimeter	O
or	O
less	O
in	O
size	O
.	O
Corless	O
CL	O
,	O
McGreevey	O
L,	O
Haley	O
A	O
,	O
Town	O
A	O
,	O
Heinrich	O
MC	O
.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Oregon	O
Health	O
and	O
Science	O
University	O
,	O
Portland	O
,	O
97201	O
,	O
USA	O
.	O
corrlessc@ohsu.edu	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
mesenchymal	B-malignancy-type
neoplasms	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gut	I-malignancy-type
wall	I-malignancy-type
that	O
express	O
the	O
receptor	O
tyrosine	O
kinase	O
KIT	O
.	O
Somatic	O
mutations	O
that	O
result	O
in	O
constitutive	O
activation	O
of	O
KIT	O
kinase	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
studies	O
of	O
GISTs	O
,	O
although	O
the	O
reported	O
frequency	O
of	O
these	O
mutations	O
has	O
varied	O
over	O
a	O
wide	O
range	O
(	O
20	O
to	O
92	O
%	O
)	O
.	O
Several	O
reports	O
have	O
suggested	O
that	O
KIT	O
gene	O
mutations	O
are	O
more	O
common	O
in	O
malignant	O
GISTs	B-malignancy-type
than	O
in	O
benign	O
lesions	O
,	O
and	O
it	O
has	O
been	O
proposed	O
that	O
mutations	O
in	O
exon	O
11	O
of	O
KIT	O
are	O
a	O
negative	O
prognostic	O
factor	O
.	O
To	O
maximize	O
sensitivity	O
for	O
KIT	O
mutations	O
we	O
have	O
adapted	O
denaturing	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
as	O
a	O
method	O
for	O
screening	O
polymerase	O
chain	O
reaction	O
amplimers	O
of	O
exons	O
9	O
,	O
11	O
,	O
13	O
,	O
and	O
17	O
from	O
GIST	B-malignancy-type
genomic	O
DNA	O
.	O
This	O
approach	O
was	O
used	O
to	O
assess	O
the	O
frequency	O
of	O
KIT	O
mutations	O
in	O
13	O
morphologically	O
benign	O
,	O
incidentally	O
discovered	O
,	O
GISTs	B-malignancy-type
identified	O
at	O
autopsy	O
,	O
endoscopy	O
,	O
or	O
laparotomy	O
for	O
unrelated	O
disease	O
.	O
Representing	O
the	O
smallest	O
pathologically	O
recognizable	O
GISTs	B-malignancy-type
,	O
these	O
lesions	O
ranged	O
in	O
size	O
from	O
4	O
to	O
10	O
mm	O
in	O
diameter	O
and	O
were	O
all	O
immunohistochemically	O
positive	O
for	O
KIT	O
.	O
Eleven	O
of	O
the	O
13	O
tumors	O
had	O
sequence	O
-	O
confirmed	O
mutations	O
in	O
KIT	O
,	O
including	O
10	O
mutations	O
in	O
exon	O
11	O
(	O
77	O
%	O
)	O
and	O
one	O
mutation	O
in	O
exon	O
9	O
(	O
7.7	O
%	O
)	O
.	O
The	O
remaining	O
two	O
tumors	O
were	O
wild	O
type	O
for	O
exons	O
9	O
,	O
11	O
,	O
and	O
17	O
;	O
one	O
of	O
these	O
was	O
also	O
analyzed	O
for	O
exon	O
13	O
and	O
was	O
wild	O
type	O
in	O
this	O
exon	O
as	O
well	O
.	O
The	O
mutations	O
found	O
in	O
the	O
incidental	O
GISTs	B-malignancy-type
were	O
identical	O
to	O
those	O
that	O
have	O
been	O
documented	O
in	O
larger	O
GISTs	B-malignancy-type
.	O
In	O
addition	O
,	O
the	O
overall	O
frequency	O
of	O
mutations	O
in	O
the	O
incidental	O
tumors	O
(	O
85	O
%	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
we	O
previously	O
reported	O
in	O
a	O
series	O
of	O
72	O
advanced	O
/	O
metastatic	O
GISTs	B-malignancy-type
(	O
86	O
%	O
)	O
,	O
strongly	O
supporting	O
the	O
view	O
that	O
activating	O
mutations	O
in	O
KIT	O
are	O
acquired	O
very	O
early	O
in	O
the	O
development	O
of	O
most	O
GISTs	B-malignancy-type
.	O
The	O
findings	O
suggest	O
that	O
KIT	O
mutations	O
per	O
se	O
are	O
of	O
little	O
prognostic	O
importance	O
in	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
12000708	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Gastroenterol	O
Hepatol	O
2002	O
Apr;14(	O
4	O
)	O
:	O
445-	O
8	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
oesophagus	I-malignancy-type
:	O
significance	O
of	O
immunohistochemical	O
and	O
genetic	O
analyses	O
of	O
the	O
c-kit	O
gene	O
.	O
Iijima	O
S	O
,	O
Maesawa	O
C	O
,	O
Sato	O
N	O
,	O
Ikeda	O
K,	O
Inaba	O
T	O
,	O
Akiyama	O
Y	O
,	O
Ishida	O
K,	O
Saito	O
K,	O
Masuda	O
T.	O
Departments	O
of	O
Pathology	O
,	O
Iwate	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Uchimaru	O
19-1	O
,	O
020	O
-	O
8505	O
Morioka	O
,	O
Japan	O
.	O
Oesophageal	B-malignancy-type
gastrointestinal	I-malignancy-type
stromal	I-malignancy-type
tumours	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
rare	O
in	O
comparison	O
to	O
those	O
of	O
the	O
stomach	B-malignancy-type
and	O
intestines	B-malignancy-type
.	O
Recently	O
,	O
it	O
has	O
been	O
clarified	O
that	O
mutations	O
of	O
the	O
c-kit	O
gene	O
resulting	O
in	O
gain	O
of	O
function	O
might	O
be	O
associated	O
with	O
histogenesis	O
of	O
this	O
type	O
of	O
tumour	B-malignancy-type
arising	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
stomach	I-malignancy-type
and	I-malignancy-type
intestines	I-malignancy-type
.	O
We	O
describe	O
an	O
oesophageal	B-malignancy-type
GIST	I-malignancy-type
on	O
immunohistochemical	O
and	O
genetic	O
analyses	O
of	O
the	O
gene	O
.	O
A	O
71	O
-	O
year	O
-	O
old	O
man	O
had	O
an	O
intramural	B-malignancy-type
tumour	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
middle	I-malignancy-type
third	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
oesophagus	I-malignancy-type
.	O
Tumour	O
cells	O
were	O
composed	O
predominantly	O
of	O
spindle	O
-	O
shaped	O
and	O
partially	O
epithelioid	O
cells	O
.	O
They	O
were	O
diffusely	O
positive	O
for	O
CD117	O
.	O
Six	O
base	O
deletion	O
resulting	O
in	O
in	O
-	O
frame	O
mutation	O
of	O
the	O
c-kit	O
gene	O
was	O
confirmed	O
at	O
codon	O
556	O
-	O
558	O
(	O
cag	O
tgg	O
aag	O
to	O
cag	O
)	O
of	O
exon	O
11	O
.	O
Patients	O
with	O
mutations	O
of	O
the	O
c-kit	O
gene	O
revealed	O
worse	O
prognoses	O
in	O
GISTs	B-malignancy-type
arising	I-malignancy-type
from	I-malignancy-type
other	I-malignancy-type
locations	I-malignancy-type
.	O
A	O
long	O
-	O
term	O
follow	O
-	O
up	O
observation	O
is	O
needed	O
for	O
the	O
case	O
.	O
PMID	O
:	O
11943962	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2002	O
Mar;160	O
(	O
3	O
)	O
:953	O
-	O
62	O
Genetic	O
and	O
immunohistochemical	O
analysis	O
of	O
pancreatic	B-malignancy-type
acinar	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
:	O
frequent	O
allelic	O
loss	O
on	O
chromosome	O
11p	O
and	O
alterations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
.	O
Abraham	O
SC	O
,	O
Wu	O
TT	O
,	O
Hruban	O
RH	O
,	O
Lee	O
JH	O
,	O
Yeo	O
CJ	O
,	O
Conlon	O
K,	O
Brennan	O
M,	O
Cameron	O
JL	O
,	O
Klimstra	O
DS	O
.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
GI	O
/	O
LiverPathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
-2196	O
,	O
USA	O
.	O
sabraham@jhmi.edu	O
Acinar	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
ACCs	B-malignancy-type
)	O
are	O
rare	O
malignant	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
exocrine	I-malignancy-type
pancreas	I-malignancy-type
.	O
The	O
specific	O
molecular	O
alterations	O
that	O
characterize	O
ACCs	B-malignancy-type
have	O
not	O
yet	O
been	O
elucidated	O
.	O
ACCs	B-malignancy-type
are	O
morphologically	O
and	O
genetically	O
distinct	O
from	O
the	O
more	O
common	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Instead	O
,	O
the	O
morphological	O
,	O
immunohistochemical	O
,	O
and	O
clinical	O
features	O
of	O
ACCs	B-malignancy-type
overlap	O
with	O
those	O
of	O
another	O
rare	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
,	O
pancreatoblastoma	B-malignancy-type
.	O
We	O
have	O
recently	O
demonstrated	O
a	O
high	O
frequency	O
of	O
allelic	O
loss	O
on	O
chromosome	O
arm	O
11p	O
and	O
mutations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
in	O
pancreatoblastomas	B-malignancy-type
,	O
suggesting	O
that	O
similar	O
alterations	O
might	O
also	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
ACCs	B-malignancy-type
.	O
We	O
analyzed	O
a	O
series	O
of	O
21	O
ACCs	O
for	O
somatic	O
alterations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
and	O
for	O
allelic	O
loss	O
on	O
chromosome	O
11p	O
.	O
In	O
addition	O
,	O
we	O
evaluated	O
the	O
ACCs	B-malignancy-type
for	O
alterations	O
in	O
p53	O
and	O
Dpc4	O
expression	O
using	O
immunohistochemistry	O
,	O
and	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
using	O
polymerase	O
chain	O
amplification	O
of	O
a	O
panel	O
of	O
microsatellite	O
markers	O
.	O
Allelic	O
loss	O
on	O
chromosome	O
11p	O
was	O
the	O
most	O
common	O
genetic	O
alteration	O
in	O
ACCs	B-malignancy-type
,	O
present	O
in	O
50	O
%	O
(	O
6	O
of	O
12	O
informative	O
cases	O
)	O
.	O
Molecular	O
alterations	O
in	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
were	O
detected	O
in	O
23.5	O
%	O
(	O
4	O
of	O
17	O
)	O
of	O
the	O
carcinomas	B-malignancy-type
,	O
including	O
one	O
ACC	B-malignancy-type
with	O
an	O
activating	O
mutation	O
of	O
the	O
beta-catenin	O
oncogene	O
and	O
three	O
ACCs	B-malignancy-type
with	O
truncating	O
APC	O
mutations	O
.	O
One	O
ACC	B-malignancy-type
(	O
1	O
of	O
13	O
,	O
7.6	O
%	O
)	O
showed	O
allelic	O
shifts	O
in	O
four	O
of	O
the	O
five	O
markers	O
tested	O
(	O
MSI	O
-	O
high	O
)	O
,	O
two	O
(	O
15.4	O
%	O
)	O
showed	O
an	O
allelic	O
shift	O
in	O
only	O
one	O
of	O
the	O
five	O
markers	O
tested	O
(	O
MSI	O
-	O
low	O
)	O
,	O
and	O
no	O
shifts	O
were	O
detected	O
in	O
the	O
remaining	O
10	O
cases	O
.	O
The	O
MSI	O
-	O
high	O
ACC	B-malignancy-type
showed	O
medullary	O
histological	O
features	O
.	O
In	O
contrast	O
,	O
no	O
loss	O
of	O
Dpc4	O
protein	O
expression	O
or	O
p53	O
accumulation	O
was	O
detected	O
.	O
These	O
results	O
indicate	O
that	O
ACCs	O
are	O
genetically	O
distinct	O
from	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
but	O
some	O
cases	O
contain	O
genetic	O
alterations	O
common	O
to	O
histologically	O
similar	O
pancreatoblastomas	B-malignancy-type
.	O
PMID	O
:	O
11891193	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Carcinogenesis	O
2002	O
Jan;23(	O
1	O
)	O
:	O
87	O
-	O
91	O
Increased	O
beta-catenin	O
mRNA	O
levels	O
and	O
mutational	O
alterations	O
of	O
the	O
APC	O
and	O
beta-catenin	O
gene	O
are	O
present	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
Ebert	O
MP	O
,	O
Fei	O
G	O
,	O
Kahmann	O
S	O
,	O
Muller	O
O	O
,	O
Yu	O
J,	O
Sung	O
JJ	O
,	O
Malfertheiner	O
P.	O
Department	O
of	O
Gastroenterology	O
,	O
Hepatology	O
and	O
Infectious	O
Diseases	O
,	O
Otto-von	O
-	O
Guericke	O
University	O
,	O
D-	O
39120	O
Magdeburg	O
,	O
Germany	O
.	O
Beta-catenin	O
is	O
critical	O
for	O
intercellular	O
adhesion	O
and	O
also	O
plays	O
a	O
role	O
as	O
a	O
transcription	O
activating	O
protein	O
in	O
the	O
Wnt	O
signalling	O
pathway	O
.	O
Increased	O
protein	O
levels	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
have	O
been	O
demonstrated	O
in	O
various	O
cancers	O
;	O
however	O
,	O
the	O
role	O
of	O
beta-catenin	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
remains	O
largely	O
unknown	O
.	O
Using	O
gastric	B-malignancy-type
cancer	I-malignancy-type
tissues	O
and	O
normal	O
adjacent	O
gastric	O
mucosa	O
obtained	O
from	O
20	O
patients	O
with	O
gastric	B-malignancy-type
cancer	I-malignancy-type
(	O
eight	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
,	O
12	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
)	O
undergoing	O
gastric	O
resection	O
or	O
endoscopy	O
,	O
we	O
assessed	O
the	O
expression	O
of	O
beta-catenin	O
by	O
immunohistochemistry	O
and	O
quantitative	O
PCR	O
analysis	O
.	O
Furthermore	O
,	O
the	O
tumour	O
suppressor	O
gene	O
APC	O
,	O
which	O
down	O
-	O
regulates	O
the	O
beta-catenin	O
levels	O
was	O
analysed	O
for	O
mutations	O
.	O
Overall	O
mRNA	O
levels	O
of	O
beta-catenin	O
were	O
significantly	O
increased	O
in	O
the	O
tumour	O
samples	O
compared	O
with	O
the	O
matched	O
normal	O
gastric	O
mucosa	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Increased	O
beta-catenin	O
mRNA	O
levels	O
were	O
significantly	O
more	O
frequent	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
as	O
compared	O
to	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
(	O
P	O
<	O
0.01	O
)	O
.	O
Six	O
out	O
of	O
20	O
tumours	O
exhibited	O
>	O
6	O
-	O
fold	O
increased	O
beta-catenin	O
mRNA	O
levels	O
as	O
compared	O
with	O
normal	O
mucosa	O
.	O
APC	O
gene	O
mutations	O
were	O
found	O
in	O
four	O
cases	O
.	O
A	O
beta-catenin	O
gene	O
mutation	O
was	O
identified	O
only	O
in	O
one	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
exhibiting	O
a	O
massive	O
overexpression	O
of	O
beta-catenin	O
mRNA	O
in	O
the	O
tumour	O
.	O
In	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
beta-catenin	O
mRNA	O
levels	O
are	O
greatly	O
enhanced	O
.	O
APC	O
and	O
beta-catenin	O
gene	O
mutations	O
are	O
also	O
present	O
primarily	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
.	O
These	O
findings	O
support	O
the	O
hypothesis	O
that	O
in	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
the	O
accumulation	O
of	O
beta-catenin	O
protein	O
may	O
result	O
from	O
impaired	O
degradation	O
of	O
the	O
beta-catenin	O
protein	O
due	O
to	O
alterations	O
of	O
the	O
beta-catenin	O
and	O
APC	O
genes	O
,	O
as	O
well	O
as	O
from	O
enhanced	O
beta-catenin	O
transcription	O
which	O
is	O
present	O
in	O
the	O
great	O
majority	O
of	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
11756228	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Dec	O
1;61	O
(	O
23	O
)	O
:	O
8401-4	O
Frequent	O
beta-catenin	O
mutation	O
and	O
cytoplasmic	O
/	O
nuclear	O
accumulation	O
in	O
pancreatic	B-malignancy-type
solid	I-malignancy-type
-	I-malignancy-type
pseudopapillary	I-malignancy-type
neoplasm	I-malignancy-type
.	O
Tanaka	O
Y	O
,	O
Kato	O
K,	O
Notohara	O
K,	O
Hojo	O
H,	O
Ijiri	O
R	O
,	O
Miyake	O
T	O
,	O
Nagahara	O
N	O
,	O
Sasaki	O
F	O
,	O
Kitagawa	O
N	O
,	O
Nakatani	O
Y	O
,	O
Kobayashi	O
Y	O
.	O
Division	O
of	O
Pathology	O
,	O
Kanagawa	O
Children	O
's	O
Medical	O
Center	O
,	O
Yokohama	O
,	O
Japan	O
.	O
Significance	O
of	O
Wnt	O
signaling	O
with	O
beta-catenin	O
mutations	O
on	O
solid	B-malignancy-type
-	I-malignancy-type
pseudopapillary	I-malignancy-type
neoplasm	I-malignancy-type
(	I-malignancy-type
SPN	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
was	O
studied	O
by	O
immunohistochemistry	O
and	O
molecular	O
analysis	O
.	O
On	O
immunohistochemistry	O
,	O
all	O
18	O
SPNs	B-malignancy-type
tested	O
showed	O
diffuse	O
cytoplasmic	O
/	O
nuclear	O
positivity	O
for	O
beta-catenin	O
.	O
Upon	O
direct	O
DNA	O
sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
15	O
(	O
83	O
%	O
)	O
of	O
the	O
18	O
SPNs	B-malignancy-type
showed	O
1	O
-	O
bp	O
missense	O
mutation	O
in	O
codons	O
32	O
(	O
5	O
cases	O
)	O
,	O
33	O
(	O
3	O
cases	O
)	O
,	O
34	O
(	O
3	O
cases	O
)	O
,	O
37	O
(	O
3	O
cases	O
)	O
,	O
and	O
41	O
(	O
1	O
case	O
)	O
.	O
Immunoreactivity	O
for	O
cyclin	O
D1	O
,	O
one	O
of	O
the	O
intranuclear	O
targets	O
of	O
beta-catenin	O
complexes	O
,	O
was	O
found	O
in	O
tumor	O
cells	O
of	O
more	O
than	O
half	O
the	O
tumor	O
cells	O
of	O
all	O
of	O
the	O
18	O
SPNs	B-malignancy-type
.	O
The	O
present	O
study	O
strongly	O
suggested	O
a	O
significant	O
role	O
of	O
Wnt	O
signaling	O
,	O
mostly	O
associated	O
with	O
beta-catenin	O
mutations	O
in	O
the	O
tumorigenesis	O
of	O
SPN	B-malignancy-type
.	O
PMID	O
:	O
11731417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2002	O
Aug	O
27;87	O
(	O
5	O
)	O
:	O
551	O
-4	O
Differential	O
diagnosis	O
between	O
chronic	O
pancreatitis	O
and	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
:	O
value	O
of	O
the	O
detection	O
of	O
KRAS2	O
mutations	O
in	O
circulating	O
DNA	O
.	O
Maire	O
F	O
,	O
Micard	O
S	O
,	O
Hammel	O
P,	O
Voitot	O
H,	O
Levy	O
P,	O
Cugnenc	O
PH	O
,	O
Ruszniewski	O
P,	O
Puig	O
PL.	O
Federation	O
Medico-Chirurgicale	O
d'Hepato-Gastroenterologie	O
,	O
Hopital	O
Beaujon	O
,	O
AP-HP	O
,	O
92110	O
Clichy	O
,	O
France	O
.	O
frederique	O
.maire@bjn	O
.ap-hop	O
-	O
paris	O
.fr	O
KRAS2	O
mutations	O
in	O
codon	O
12	O
have	O
been	O
detected	O
in	O
about	O
80	O
%	O
of	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
value	O
of	O
KRAS2	O
mutations	O
detection	O
in	O
circulating	O
deoxyribo	O
nucleic	O
acid	O
to	O
differentiate	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
from	O
chronic	O
pancreatitis	O
.	O
Circulating	O
deoxyribonucleic	O
acid	O
was	O
isolated	O
from	O
serum	O
in	O
47	O
patients	O
with	O
histologically	O
proven	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
(	O
26	O
males	O
,	O
median	O
age	O
65	O
years	O
)	O
and	O
31	O
controls	O
with	O
chronic	O
pancreatitis	O
(	O
26	O
males	O
,	O
median	O
age	O
48	O
years	O
)	O
.	O
Mutations	O
at	O
codon	O
12	O
of	O
KRAS2	O
gene	O
were	O
searched	O
for	O
using	O
polymerase	O
chain	O
reaction	O
and	O
allele	O
specific	O
amplification	O
.	O
Serum	O
carbohydrate	O
antigen	O
19.9	O
levels	O
were	O
also	O
determined	O
.	O
KRAS2	O
mutations	O
were	O
found	O
in	O
22	O
patients	O
(	O
47	O
%	O
)	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
and	O
in	O
four	O
controls	O
with	O
chronic	O
pancreatitis	O
(	O
13	O
%	O
)	O
(	O
P	O
<	O
0.002	O
)	O
.	O
None	O
of	O
the	O
latter	O
developed	O
a	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
within	O
the	O
36	O
months	O
of	O
median	O
follow	O
-	O
up	O
.	O
The	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
serum	O
serum	O
KRAS2	O
mutations	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
were	O
47	O
,	O
87	O
,	O
85	O
and	O
52	O
%	O
,	O
respectively	O
.	O
KRAS2	O
mutations	O
were	O
not	O
related	O
to	O
age	O
,	O
gender	O
,	O
smoking	O
habit	O
,	O
tumour	O
stage	O
,	O
or	O
survival	O
.	O
Among	O
the	O
26	O
patients	O
with	O
normal	O
or	O
non	O
-	O
contributive	O
(	O
due	O
to	O
cholestasis	O
)	O
serum	O
carbohydrate	O
antigen	O
19.9	O
levels	O
,	O
14	O
(	O
54	O
%	O
)	O
had	O
KRAS2	O
mutations	O
.	O
The	O
combination	O
of	O
KRAS2	O
and	O
carbohydrate	O
antigen	O
19.9	O
gave	O
a	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
and	O
negative	O
predictive	O
values	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
of	O
98	O
,	O
77	O
,	O
87	O
and	O
96	O
%	O
,	O
respectively	O
.	O
Detection	O
of	O
KRAS2	O
mutations	O
in	O
circulating	O
deoxyribo	O
nucleic	O
acid	O
has	O
a	O
low	O
sensitivity	O
but	O
a	O
specificity	O
about	O
90	O
%	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
It	O
seems	O
particularly	O
useful	O
when	O
serum	O
carbohydrate	O
antigen	O
19.9	O
levels	O
are	O
normal	O
or	O
inconclusive	O
.	O
A	O
combined	O
normal	O
serum	O
carbohydrate	O
antigen	O
19.9	O
and	O
absence	O
of	O
circulating	O
KRAS2	O
mutations	O
makes	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
extremely	O
unlikely	O
.	O
PMID	O
:	O
12189555	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreas	O
2001	O
Nov;23(	O
4	O
)	O
:	O
356-63	O
Usefulness	O
of	O
supernatant	O
of	O
pancreatic	O
juice	O
for	O
genetic	O
analysis	O
of	O
K-ras	O
in	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Ha	O
A	O
,	O
Watanabe	O
H,	O
Yamaguchi	O
Y	O
,	O
Ohtsubo	O
K,	O
Wang	O
Y	O
,	O
Motoo	O
Y	O
,	O
Okai	O
T	O
,	O
Wakabayahi	O
T	O
,	O
Sawabu	O
N	O
.	O
Department	O
of	O
Internal	O
Medicine	O
and	O
Medical	O
Oncology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Kanazawa	O
University	O
,	O
4-86	O
,	O
Yoneizumi	O
,	O
Kanazawa	O
921	O
-8044	O
,	O
Japan	O
.	O
AIMS	O
:	O
To	O
ascertain	O
whether	O
analysis	O
of	O
K-ras	O
mutations	O
at	O
codon	O
12	O
(	O
KRM	O
)	O
in	O
the	O
supernatant	O
of	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
is	O
more	O
useful	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
(	O
PCa	B-malignancy-type
)	O
than	O
that	O
in	O
sediment	O
,	O
the	O
authors	O
analyzed	O
KRM	O
in	O
DNA	O
extract	O
from	O
not	O
only	O
the	O
sediment	O
but	O
also	O
the	O
supernatant	O
of	O
PPJ	O
and	O
compared	O
the	O
results	O
.	O
METHODOLOGY	O
:	O
PPJ	O
was	O
collected	O
endoscopically	O
from	O
19	O
patients	O
with	O
PCa	B-malignancy-type
and	O
25	O
patients	O
with	O
chronic	O
pancreatitis	O
(	O
CP	O
)	O
.	O
DNA	O
was	O
extracted	O
from	O
the	O
supernatant	O
and	O
the	O
sediment	O
of	O
PPJ	O
.	O
Mutant	O
allele	O
-	O
specific	O
amplification	O
(	O
MASA	O
)	O
was	O
performed	O
for	O
KRM	O
analysis	O
with	O
the	O
DNA	O
extracts	O
from	O
these	O
samples	O
.	O
RESULTS	O
:	O
The	O
incidence	O
of	O
KRM	O
in	O
the	O
supernatant	O
of	O
PPJ	O
was	O
89	O
%	O
(	O
17	O
of	O
19	O
)	O
in	O
patients	O
with	O
PCa	B-malignancy-type
and	O
28	O
%	O
(	O
7	O
of	O
25	O
)	O
in	O
patients	O
with	O
CP	O
,	O
whereas	O
that	O
in	O
the	O
sediment	O
was	O
79	O
%	O
(	O
15	O
of	O
19	O
)	O
in	O
patients	O
with	O
PCa	B-malignancy-type
and	O
20	O
%	O
(	O
5	O
of	O
25	O
)	O
in	O
patients	O
with	O
CP	O
.	O
Although	O
there	O
was	O
no	O
significant	O
difference	O
in	O
KRM	O
incidence	O
between	O
supernatant	O
and	O
sediment	O
,	O
the	O
positive	O
rate	O
of	O
KRM	O
was	O
higher	O
in	O
the	O
former	O
.	O
Additionally	O
,	O
with	O
regard	O
to	O
the	O
PCa	B-malignancy-type
cases	O
,	O
KRM	O
were	O
found	O
in	O
the	O
supernatant	O
alone	O
in	O
four	O
cases	O
and	O
in	O
the	O
sediment	O
alone	O
in	O
two	O
cases	O
.	O
Consequently	O
,	O
by	O
a	O
combination	O
assay	O
,	O
all	O
of	O
the	O
patients	O
with	O
PCa	B-malignancy-type
showed	O
KRM	O
in	O
either	O
the	O
supernatant	O
or	O
sediment	O
of	O
PPJ	O
.	O
Although	O
there	O
was	O
no	O
relation	O
between	O
the	O
incidence	O
of	O
KRM	O
in	O
PPJ	O
and	O
the	O
location	O
and	O
size	O
of	O
tumor	O
,	O
and	O
clinical	O
stage	O
of	O
carcinoma	B-malignancy-type
in	O
the	O
patients	O
with	O
PCa	B-malignancy-type
,	O
two	O
patients	O
with	O
clinical	O
stage	O
I	O
disease	O
showed	O
KRM	O
in	O
the	O
supernatant	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
the	O
positive	O
rate	O
of	O
KRM	O
in	O
the	O
supernatant	O
is	O
not	O
lower	O
than	O
that	O
in	O
the	O
sediment	O
,	O
and	O
simultaneous	O
analysis	O
of	O
KRM	O
in	O
the	O
supernatant	O
and	O
sediment	O
of	O
PPJ	O
enhances	O
the	O
genetic	O
diagnosis	O
of	O
PCa	B-malignancy-type
.	O
PMID	O
:	O
11668203	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
2001	O
Sep;127	O
(	O
9	O
)	O
:	O
577	O
-	O
81	O
Mutation	O
and	O
overexpression	O
of	O
the	O
beta-catenin	O
gene	O
may	O
play	O
an	O
important	O
role	O
in	O
primary	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
among	O
Chinese	O
people	O
.	O
Cui	O
J,	O
Zhou	O
X	O
,	O
Liu	O
Y	O
,	O
Tang	O
Z	O
.	O
Department	O
of	O
Food	O
Science	O
and	O
Human	O
Nutrition	O
,	O
Michigan	O
State	O
University	O
,	O
East	O
Lansing	O
48824	O
,	O
USA	O
.	O
cuij@msu.edu	O
AIM	O
:	O
To	O
study	O
the	O
role	O
of	O
beta-catenin	O
gene	O
mutation	O
and	O
expression	O
in	O
hepatocellular	O
carcinogenesis	O
.	O
METHOD	O
:	O
Thirty-four	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
specimens	O
and	O
adjacent	O
para	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
tissues	I-malignancy-type
,	O
and	O
four	O
normal	O
liver	O
tissues	O
were	O
analyzed	O
.	O
Subcellular	O
distribution	O
of	O
beta-catenin	O
was	O
examined	O
by	O
immunohistochemistry	O
staining	O
.	O
Mutation	O
and	O
semiquantitative	O
expression	O
of	O
beta-catenin	O
gene	O
exon	O
3	O
mRNA	O
were	O
detected	O
by	O
RT	O
-	O
PCR	O
-	O
SSCP	O
and	O
in	O
situ	O
hybridization	O
.	O
RESULT	O
:	O
Immunohistochemistry	O
showed	O
that	O
all	O
normal	O
liver	O
tissues	O
and	O
para	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
tissues	I-malignancy-type
examined	O
showed	O
membranous	O
-	O
type	O
staining	O
for	O
beta-catenin	O
protein	O
,	O
frequently	O
with	O
weak	O
expression	O
in	O
the	O
cytoplasm	O
,	O
but	O
no	O
beta-catenin	O
accumulation	O
in	O
nuclei	O
was	O
found	O
;	O
while	O
in	O
liver	B-malignancy-type
cancer	I-malignancy-type
,	O
21	O
cases	O
(	O
61.8	O
%	O
)	O
of	O
HCC	B-malignancy-type
examined	O
showed	O
accumulated	O
type	O
in	O
cytoplasms	O
or	O
nuclei	O
.	O
On	O
SSCP	O
,	O
15	O
cases	O
(	O
44.1	O
%	O
)	O
of	O
HCC	B-malignancy-type
altogether	O
displayed	O
three	O
kinds	O
of	O
characteristic	O
mutational	O
mobility	O
shifts	O
.	O
No	O
abnormal	O
shifting	O
bands	O
were	O
found	O
in	O
tissues	O
from	O
normal	O
liver	O
or	O
para	O
-	O
cancerous	O
area	O
.	O
The	O
beta-catenin	O
gene	O
exon	O
3	O
mRNA	O
expression	O
index	O
of	O
34	O
HCCs	B-malignancy-type
was	O
higher	O
than	O
that	O
of	O
para	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
tissue	I-malignancy-type
and	O
normal	O
liver	O
tissue	O
.	O
Using	O
in	O
situ	O
hybridization	O
,	O
the	O
signal	O
corresponding	O
to	O
beta-catenin	O
gene	O
exon	O
3	O
mRNA	O
was	O
particularly	O
strong	O
in	O
cytoplasm	O
of	O
HCC	B-malignancy-type
when	O
compared	O
with	O
those	O
of	O
paracancerous	B-malignancy-type
tissues	I-malignancy-type
and	O
normal	O
liver	O
tissues	O
.	O
CONCLUSION	O
:	O
beta-catenin	O
gene	O
mutation	O
and	O
overexpression	O
may	O
have	O
a	O
critical	O
role	O
in	O
malignant	O
progression	O
of	O
hepatic	O
carcinogenesis	O
among	O
Chinese	O
people	O
.	O
PMID	O
:	O
11570580	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
2001	O
Aug;114(	O
2	O
)	O
:	O
362-4	O
Analysis	O
of	O
FGFR3	O
gene	O
mutations	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
patients	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
Intini	O
D	O
,	O
Baldini	O
L,	O
Fabris	O
S	O
,	O
Lombardi	O
L,	O
Ciceri	O
G	O
,	O
Maiolo	O
AT	O
,	O
Neri	O
A	O
.	O
Servizio	O
Ematologia	O
,	O
Dipartimento	O
di	O
Scienze	O
Mediche	O
,	O
Universita	O
di	O
Milano	O
,	O
Ospedale	O
Maggiore	O
di	O
Milano	O
,	O
IRCCS	O
,	O
Milano	O
,	O
Italy	O
.	O
The	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
leads	O
to	O
an	O
apparent	O
deregulation	O
of	O
the	O
FGFR3	O
and	O
WHSC1	O
/	O
MMSET	O
genes	O
.	O
FGFR3	O
mutations	O
,	O
known	O
to	O
be	O
associated	O
with	O
genetic	O
skeletal	O
disorders	O
,	O
have	O
also	O
been	O
identified	O
in	O
a	O
few	O
cases	O
of	O
MM	B-malignancy-type
(	O
mainly	O
cell	O
lines	O
)	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
We	O
investigated	O
FGFR3	O
mutations	O
in	O
a	O
series	O
of	O
53	O
MM	B-malignancy-type
cases	O
;	O
11	O
cases	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
and	O
FGFR3	O
overexpression	O
were	O
analysed	O
using	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
while	O
the	O
remaining	O
cases	O
were	O
studied	O
at	O
DNA	O
level	O
.	O
The	O
Arg	O
248	O
Cys	O
mutation	O
,	O
which	O
is	O
associated	O
with	O
some	O
lethal	O
forms	O
of	O
skeletal	O
disorders	O
,	O
was	O
found	O
in	O
one	O
case	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
FGFR3	O
mutations	O
occur	O
in	O
only	O
a	O
small	O
fraction	O
of	O
MM	B-malignancy-type
cases	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
PMID	O
:	O
11529856	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
2001	O
Sep	O
1;98(	O
5	O
)	O
:1555	O
-60	O
Detection	O
of	O
N-Ras	O
codon	O
61	O
mutations	O
in	O
subpopulations	O
of	O
tumor	O
cells	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
at	O
presentation	O
.	O
Kalakonda	O
N	O
,	O
Rothwell	O
DG	O
,	O
Scarffe	O
JH	O
,	O
Norton	O
JD.	O
CRC	O
Gene	O
Regulation	O
Group	O
,	O
Paterson	O
Institute	O
for	O
Cancer	O
Research	O
,	O
and	O
CRC	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Christie	O
Hospital	O
NHS	O
Trust	O
,	O
Manchester	O
,	O
United	O
Kingdom	O
.	O
Activating	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
of	O
the	O
K-ras	O
and	O
N-ras	O
genes	O
have	O
been	O
reported	O
to	O
occur	O
in	O
up	O
to	O
40	O
%	O
of	O
patients	O
with	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
at	O
presentation	O
.	O
In	O
a	O
study	O
of	O
34	O
presentation	O
myeloma	B-malignancy-type
cases	O
using	O
a	O
sensitive	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
strategy	O
on	O
enriched	O
tumor	O
cell	O
populations	O
,	O
the	O
present	O
study	O
detected	O
N-ras	O
codon	O
61	O
mutation	O
-	O
positive	O
cells	O
in	O
all	O
patients	O
.	O
Quantitative	O
plaque	O
hybridization	O
using	O
allele	O
-	O
specific	O
oligonucleotide	O
probes	O
showed	O
that	O
in	O
the	O
majority	O
of	O
patients	O
,	O
ras	O
mutation	O
-	O
positive	O
cells	O
comprise	O
only	O
a	O
subpopulation	O
of	O
the	O
total	O
malignant	O
plasma	O
cell	O
compartment	O
(	O
range	O
,	O
12	O
%	O
-	O
100	O
%	O
)	O
.	O
Using	O
clonospecific	O
point	O
mutations	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
BCL6	O
gene	O
to	O
quantitate	O
clonal	O
B	O
cells	O
in	O
FACS	O
-	O
sorted	O
bone	O
marrow	O
populations	O
from	O
2	O
patients	O
,	O
the	O
representation	O
of	O
ras	O
mutation	O
-	O
positive	O
cells	O
was	O
independent	O
of	O
immunophenotype	O
.	O
These	O
observations	O
imply	O
that	O
mutational	O
activation	O
of	O
N-ras	O
codon	O
61	O
is	O
a	O
mandatory	O
event	O
in	O
the	O
pathogenesis	O
of	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
;	O
such	O
mutations	O
provide	O
a	O
marker	O
of	O
intraclonal	O
heterogeneity	O
that	O
may	O
originate	O
at	O
an	O
earlier	O
ontologic	O
stage	O
than	O
immunophenotypic	O
diversification	O
of	O
the	O
malignant	O
B	O
cell	O
clone	O
.	O
PMID	O
:	O
11520807	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
2001	O
Sep;82	O
(	O
3	O
)	O
:	O
563-7	O
Carcinosarcoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
:	O
immunohistochemical	O
and	O
genetic	O
analysis	O
of	O
clonality	O
of	O
one	O
case	O
.	O
Watanabe	O
M,	O
Shimizu	O
K,	O
Kato	O
H,	O
Imai	O
H,	O
Nakano	O
H,	O
Sugawa	O
M,	O
Shiraishi	O
T.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
2-174	O
Edobashi	O
,	O
Tsu	O
,	O
Mie	O
514	O
-8507	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Carcinosarcomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
are	O
characterized	O
by	O
admixtures	O
of	O
malignant	O
epithelial	O
and	O
stromal	O
cells	O
,	O
and	O
their	O
histogenesis	O
remains	O
controversial	O
.	O
CASE	O
:	O
An	O
operated	O
case	O
of	O
carcinosarcoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
in	O
a	O
49	O
-	O
year	O
-	O
old	O
woman	O
is	O
reported	O
with	O
clonal	O
analysis	O
.	O
The	O
tumor	O
was	O
composed	O
of	O
carcinomatous	O
,	O
sarcomatous	O
,	O
and	O
transitional	O
elements	O
in	O
the	O
frontal	O
wall	O
of	O
the	O
uterine	O
body	O
and	O
therefore	O
was	O
diagnosed	O
as	O
a	O
carcinosarcoma	B-malignancy-type
.	O
On	O
immunohistochemical	O
analysis	O
,	O
the	O
sarcomatous	O
component	O
proved	O
negative	O
for	O
epithelial	O
membrane	O
antigen	O
and	O
keratin	O
while	O
both	O
components	O
were	O
positive	O
for	O
vimentin	O
.	O
Analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
showed	O
the	O
same	O
pattern	O
throughout	O
and	O
additionally	O
,	O
the	O
same	O
K-ras	O
and	O
p53	O
mutations	O
were	O
homogeneously	O
detected	O
.	O
Microsatellite	O
instability	O
analysis	O
showed	O
loss	O
of	O
heterozygosity	O
at	O
D5S346	O
in	O
the	O
sarcomatous	O
but	O
not	O
the	O
carcinomatous	O
component	O
.	O
CONCLUSIONS	O
:	O
This	O
tumor	O
appears	O
monoclonal	O
in	O
line	O
with	O
the	O
combination	O
tumor	O
theory	O
,	O
with	O
late	O
divergence	O
in	O
genetic	O
alteration	O
in	O
the	O
sarcomatous	O
elements	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11520156	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Aug	O
25;9	O
3	O
(	O
4	O
)	O
:	O
269	O
-	O
75	O
Fine	O
-	O
needle	O
aspiration	O
biopsy	O
diagnosis	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
using	O
morphology	O
,	O
immunocytochemistry	O
,	O
and	O
mutational	O
analysis	O
of	O
c-kit	O
.	O
Rader	O
AE	O
,	O
Avery	O
A	O
,	O
Wait	O
CL	O
,	O
McGreevey	O
LS	O
,	O
Faigel	O
D	O
,	O
Heinrich	O
MC	O
.	O
Department	O
of	O
Pathology	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
Oregon	O
97201-3098	O
,	O
USA	O
.	O
radera@ohsu.edu	O
BACKGROUND	O
:	O
Differentiating	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
from	O
other	O
intramural	B-malignancy-type
mesenchymal	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
GI	I-malignancy-type
tract	I-malignancy-type
on	O
fine	O
-	O
needle	O
aspiration	O
biopsies	O
(	O
FNABs	O
)	O
is	O
difficult	O
.	O
Recent	O
studies	O
have	O
shown	O
that	O
GISTs	B-malignancy-type
are	O
immunophenotypically	O
and	O
genetically	O
distinct	O
.	O
GISTs	B-malignancy-type
exhibit	O
consistent	O
immunohistochemical	O
expression	O
of	O
CD-117	O
(	O
KIT	O
)	O
and	O
often	O
express	O
activating	O
mutations	O
of	O
this	O
protooncogene	O
.	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
employ	O
immunocytochemistry	O
and	O
mutational	O
analysis	O
of	O
the	O
c-kit	O
gene	O
to	O
aid	O
in	O
the	O
diagnosis	O
of	O
GISTs	B-malignancy-type
on	O
FNAB	O
.	O
METHODS	O
:	O
Five	O
endoscopic	O
ultrasound	O
-	O
guided	O
FNABs	O
of	O
gastrointestinal	B-malignancy-type
spindle	I-malignancy-type
cell	I-malignancy-type
neoplasms	I-malignancy-type
performed	O
at	O
the	O
Veterans	O
Affairs	O
Medical	O
Center	O
(	O
VAMC	O
)	O
in	O
Portland	O
,	O
Oregon	O
,	O
from	O
1998	O
-	O
1999	O
were	O
reviewed	O
.	O
A	O
panel	O
of	O
immunocytochemical	O
stains	O
was	O
performed	O
on	O
each	O
cellblock	O
including	O
CD-117	O
(	O
KIT	O
)	O
,	O
smooth	O
muscle	O
actin	O
(	O
SMA	O
)	O
,	O
desmin	O
,	O
S-100	O
,	O
and	O
CD34	O
.	O
Genomic	O
DNA	O
(	O
gDNA	O
)	O
was	O
extracted	O
,	O
and	O
amplification	O
of	O
exons	O
9	O
,	O
11	O
,	O
13	O
and	O
17	O
of	O
c-kit	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
on	O
CD-117	O
(	O
KIT	O
)	O
and	O
CD34	O
positive	O
cases	O
.	O
Direct	O
sequencing	O
of	O
amplicons	O
identified	O
the	O
mutations	O
.	O
RESULTS	O
:	O
Five	O
patients	O
were	O
diagnosed	O
with	O
GISTs	B-malignancy-type
based	O
on	O
morphology	O
and	O
immunocytochemical	O
positivity	O
for	O
CD-117	O
and	O
CD34	O
.	O
PCR	O
analysis	O
of	O
c-kit	O
exon	O
11	O
revealed	O
three	O
cases	O
with	O
novel	O
-	O
sized	O
PCR	O
bands	O
in	O
addition	O
to	O
the	O
expected	O
wild	O
-	O
type	O
-	O
sized	O
PCR	O
product	O
.	O
Amplicons	O
from	O
these	O
cases	O
contained	O
an	O
in	O
-	O
frame	O
deletion	O
mutation	O
.	O
One	O
of	O
the	O
two	O
cases	O
with	O
wild	O
-	O
type	O
-	O
;	O
sized	O
exon	O
11	O
amplicons	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
point	O
mutation	O
producing	O
an	O
amino	O
acid	O
substitution	O
(	O
W	O
557	O
R	O
)	O
.	O
No	O
mutations	O
in	O
exon	O
9	O
,	O
11	O
,	O
13	O
,	O
or	O
17	O
of	O
c-kit	O
were	O
found	O
in	O
the	O
remaining	O
case	O
.	O
CONCLUSIONS	O
:	O
Ancillary	O
techniques	O
such	O
as	O
immunocytochemistry	O
and	O
c-kit	O
gene	O
mutational	O
analysis	O
may	O
aid	O
in	O
the	O
diagnosis	O
of	O
GISTs	B-malignancy-type
on	O
FNABs	O
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11507701	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Carcinogenesis	O
2001	O
Aug;22(	O
8	O
)	O
:	O
1327	O
-	O
30	O
Glutathione	O
S-transferase	O
mu1	O
null	O
genotype	O
is	O
associated	O
with	O
K-ras	O
gene	O
mutation	O
in	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
among	O
smokers	O
.	O
Matsuzoe	O
D	O
,	O
Hideshima	O
T	O
,	O
Iwasaki	O
A	O
,	O
Yoneda	O
S	O
,	O
Kawahara	O
K,	O
Shirakusa	O
T	O
,	O
Kimura	O
A	O
.	O
Second	O
Department	O
of	O
Surgery	O
,	O
School	O
of	O
Medicine	O
,	O
Fukuoka	O
University	O
,	O
7-45-1	O
Nanakuma	O
,	O
Jonanku	O
,	O
Fukuoka	O
814	O
-0180	O
,	O
Japan	O
.	O
Glutathione	O
S-transferase	O
mu1	O
(	O
GSTM1	O
)	O
plays	O
a	O
role	O
in	O
the	O
detoxification	O
of	O
benzo[a]pyrene	O
(	O
BP	O
)	O
diol	O
epoxide	O
in	O
tobacco	O
smoke	O
.	O
Individuals	O
who	O
genetically	O
lack	O
the	O
GSTM1	O
gene	O
are	O
likely	O
to	O
have	O
an	O
increased	O
risk	O
of	O
smoking	O
-	O
related	O
lung	B-malignancy-type
cancers	I-malignancy-type
,	O
however	O
,	O
the	O
target	O
oncogenes	O
for	O
mutation	O
are	O
unknown	O
.	O
To	O
investigate	O
the	O
relation	O
between	O
GSTM1	O
genotype	O
and	O
K-ras	O
gene	O
mutation	O
we	O
examined	O
193	O
adenocarcinomas	B-malignancy-type
and	O
119	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
lung	I-malignancy-type
.	O
The	O
GSTM1	O
genotype	O
was	O
determined	O
by	O
PCR	O
and	O
K-ras	O
gene	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
were	O
detected	O
by	O
dot	O
-	O
blot	O
hybridization	O
analysis	O
using	O
sequence	O
-	O
specific	O
oligonucleotide	O
probes	O
.	O
K-ras	O
gene	O
mutations	O
were	O
found	O
in	O
29	O
of	O
312	O
(	O
9.3	O
%	O
)	O
tumors	O
.	O
All	O
of	O
them	O
arose	O
in	O
patients	O
who	O
were	O
habitual	O
smokers	O
.	O
Mutations	O
of	O
the	O
K-ras	O
gene	O
were	O
detected	O
in	O
6	O
of	O
100	O
(	O
6	O
%	O
)	O
and	O
15	O
of	O
93	O
(	O
16.1	O
%	O
)	O
adenocarcinoma	B-malignancy-type
cases	O
with	O
the	O
GSTM1	O
(	O
+	O
)	O
and	O
GSTM1	O
(	O
-	O
)	O
genotypes	O
,	O
respectively	O
,	O
and	O
the	O
difference	O
was	O
statistically	O
significant	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
cause	O
of	O
K-ras	O
gene	O
mutation	O
in	O
smokers	O
with	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
may	O
be	O
in	O
part	O
an	O
accumulation	O
of	O
BP	O
diol	O
epoxide	O
which	O
is	O
not	O
well	O
detoxified	O
in	O
individuals	O
with	O
the	O
GSTM1	O
null	O
genotype	O
.	O
PMID	O
:	O
11470766	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2001	O
Jul	O
6;8	O
5	O
(	O
1	O
)	O
:64	O
-	O
8	O
Mutations	O
of	O
the	O
beta	O
-	O
and	O
gamma	O
-	O
catenin	O
genes	O
are	O
uncommon	O
in	O
human	O
lung	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
kidney	B-malignancy-type
,	O
cervical	B-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Ueda	O
M,	O
Gemmill	O
RM	O
,	O
West	O
J,	O
Winn	O
R	O
,	O
Sugita	O
M,	O
Tanaka	O
N	O
,	O
Ueki	O
M,	O
Drabkin	O
HA	O
.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Osaka	O
Medical	O
College	O
,	O
2-7	O
Daigakumachi	O
,	O
Takatsuki	O
,	O
Osaka	O
569	O
-	O
8686	O
,	O
Japan	O
.	O
Beta-catenin	O
forms	O
complexes	O
with	O
Tcf	O
and	O
Lef-1	O
and	O
functions	O
as	O
a	O
transcriptional	O
activator	O
in	O
the	O
Wnt	O
signalling	O
pathway	O
.	O
Although	O
recent	O
investigations	O
have	O
been	O
focused	O
on	O
the	O
role	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
human	O
tumorigenesis	O
,	O
there	O
have	O
been	O
very	O
few	O
reports	O
on	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
a	O
variety	O
of	O
tumour	O
types	O
.	O
Using	O
PCR	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
,	O
we	O
examined	O
93	O
lung	B-malignancy-type
,	O
9	O
breast	B-malignancy-type
,	O
6	O
kidney	B-malignancy-type
,	O
19	O
cervical	B-malignancy-type
and	O
7	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
for	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
.	O
In	O
addition	O
,	O
we	O
tested	O
these	O
same	O
samples	O
for	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
region	O
of	O
the	O
gamma-catenin	O
gene	O
.	O
Mutational	O
analysis	O
for	O
the	O
entire	O
coding	O
region	O
of	O
beta-catenin	O
cDNA	O
was	O
also	O
undertaken	O
in	O
20	O
lung	B-malignancy-type
,	O
9	O
breast	B-malignancy-type
,	O
5	O
kidney	B-malignancy-type
and	O
6	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
.	O
Deletion	O
of	O
most	O
beta-catenin	O
coding	O
exons	O
was	O
confirmed	O
in	O
line	O
NCI-H28	O
(	O
lung	B-malignancy-type
mesothelioma	I-malignancy-type
)	O
and	O
a	O
silent	O
mutation	O
at	O
codon	O
214	O
in	O
exon	O
5	O
was	O
found	O
in	O
HeLa	O
(	O
cervical	B-malignancy-type
adenocarcinoma	I-malignancy-type
)	O
.	O
A	O
missense	O
mutation	O
at	O
codon	O
19	O
and	O
a	O
silent	O
mutation	O
at	O
codon	O
28	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
region	O
of	O
the	O
gamma-catenin	O
gene	O
were	O
found	O
in	O
H1726	O
(	O
squamous	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
)	O
and	O
H1048	O
(	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
)	O
,	O
respectively	O
.	O
Neither	O
deletions	O
nor	O
mutations	O
of	O
these	O
genes	O
were	O
detected	O
in	O
the	O
other	O
cell	O
lines	O
examined	O
.	O
These	O
results	O
suggest	O
that	O
beta	O
-	O
and	O
gamma	O
-	O
catenins	O
are	O
infrequent	O
mutational	O
targets	O
during	O
development	O
of	O
human	O
lung	B-malignancy-type
,	O
breast	B-malignancy-type
,	O
kidney	B-malignancy-type
,	O
cervical	B-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11437403	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2001	O
Jun	O
14;20(	O
27	O
)	O
:	O
3553	O
-	O
62	O
Deregulated	O
FGFR3	O
mutants	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
cell	O
lines	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
:	O
comparative	O
analysis	O
of	O
Y	O
373	O
C	O
,	O
K	O
650	O
E	O
and	O
the	O
novel	O
G	O
384	O
D	O
mutations	O
.	O
Ronchetti	O
D	O
,	O
Greco	O
A	O
,	O
Compasso	O
S	O
,	O
Colombo	O
G	O
,	O
Dell'Era	O
P,	O
Otsuki	O
T	O
,	O
Lombardi	O
L,	O
Neri	O
A	O
.	O
Hematology	O
Service	O
,	O
Department	O
of	O
Medical	O
Sciences	O
,	O
Universita	O
degli	O
Studi	O
,	O
Ospedale	O
Maggiore	O
IRCCS	O
,	O
Milan	O
,	O
Italy	O
.	O
The	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
chromosomal	O
translocation	O
occurs	O
in	O
approximately	O
20	O
%	O
of	O
multiple	B-malignancy-type
myelomas	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
and	O
leads	O
to	O
the	O
apparent	O
deregulation	O
of	O
two	O
genes	O
located	O
on	O
4p16.3	O
:	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
and	O
the	O
putative	O
transcription	O
factor	O
WHSC1	O
/	O
MMSET	O
.	O
Interestingly	O
,	O
FGFR3	O
mutations	O
known	O
to	O
be	O
associated	O
with	O
autosomal	O
dominant	O
human	O
skeletal	O
disorders	O
have	O
also	O
been	O
found	O
in	O
some	O
MM	B-malignancy-type
cell	O
lines	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
but	O
their	O
pathogenetic	O
role	O
in	O
MM	B-malignancy-type
is	O
still	O
controversial	O
.	O
Since	O
cell	O
lines	O
may	O
represent	O
useful	O
models	O
for	O
investigating	O
the	O
effects	O
of	O
deregulated	O
FGFR3	O
mutants	O
in	O
MM	B-malignancy-type
,	O
we	O
analysed	O
the	O
expression	O
,	O
activation	O
,	O
signaling	O
pathways	O
and	O
oncogenic	O
potential	O
of	O
three	O
mutants	O
identified	O
so	O
far	O
:	O
the	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
in	O
the	O
KMS-11	O
and	O
OPM-2	O
cell	O
lines	O
respectively	O
,	O
and	O
the	O
novel	O
G	O
384	O
D	O
mutation	O
here	O
identified	O
in	O
the	O
KMS-18	O
cell	O
line	O
.	O
All	O
of	O
the	O
cell	O
lines	O
present	O
a	O
heterozygous	O
FGFR3	O
gene	O
mutation	O
and	O
transcribe	O
the	O
mutated	O
allele	O
;	O
unlike	O
KMS-11	O
and	O
OPM-2	O
(	O
which	O
express	O
the	O
IIIc	O
isoform	O
)	O
,	O
the	O
KMS-18	O
cell	O
line	O
expresses	O
prevalently	O
the	O
isoform	O
IIIb	O
.	O
We	O
demonstrated	O
that	O
,	O
under	O
serum	O
-	O
starved	O
conditions	O
,	O
KMS-11	O
and	O
OPM-2	O
cells	O
express	O
appreciable	O
levels	O
of	O
phosphorylated	O
FGFR3	O
mutants	O
indicating	O
a	O
constitutive	O
activation	O
of	O
the	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
receptors	O
;	O
the	O
addition	O
of	O
the	O
aFGF	O
ligand	O
further	O
increased	O
the	O
level	O
of	O
receptor	O
phosphorylation	O
.	O
Conversely	O
,	O
the	O
FGFR3	O
mutant	O
in	O
KMS-18	O
does	O
not	O
seem	O
to	O
be	O
constitutively	O
activated	O
since	O
it	O
was	O
phosphorylated	O
only	O
in	O
the	O
presence	O
of	O
the	O
ligand	O
.	O
In	O
all	O
three	O
MM	B-malignancy-type
cell	O
lines	O
,	O
ligand	O
-	O
stimulated	O
FGFR3	O
mutants	O
activated	O
the	O
MAP	O
kinase	O
signaling	O
pathway	O
but	O
did	O
not	O
apparently	O
involve	O
either	O
the	O
STAT1	O
or	O
STAT3	O
cascades	O
.	O
However	O
,	O
when	O
transfected	O
in	O
293T	O
cells	O
,	O
G	O
384	O
D	O
,	O
like	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
,	O
was	O
capable	O
of	O
activating	O
MAPK	O
,	O
STAT1	O
and	O
STAT3	O
under	O
serum	O
-	O
starved	O
condition	O
.	O
Finally	O
,	O
a	O
focus	O
formation	O
assay	O
of	O
NIH3T3	O
cells	O
transfected	O
with	O
FGFR3	O
-	O
expressing	O
plasmid	O
vectors	O
showed	O
that	O
Y	O
373	O
C	O
and	O
K	O
650	O
E	O
(	O
albeit	O
at	O
different	O
levels	O
)	O
but	O
not	O
G	O
384	O
D	O
or	O
the	O
wild	O
-	O
type	O
receptor	O
,	O
can	O
induce	O
transformed	O
foci	O
.	O
Overall	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
FGFR3	O
mutations	O
are	O
graded	O
in	O
terms	O
of	O
their	O
activation	O
capability	O
,	O
thus	O
suggesting	O
that	O
they	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
tumor	O
progression	O
of	O
MM	B-malignancy-type
patients	O
with	O
t	O
(	O
4	O
;	O
14	O
)	O
.	O
PMID	O
:	O
11429702	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
2001	O
May	O
;113(	O
2	O
)	O
:	O
357	O
-64	O
Mutation	O
analysis	O
of	O
C-KIT	O
in	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
without	I-malignancy-type
mastocytosis	I-malignancy-type
and	O
cases	O
of	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
Fritsche-	O
Polanz	O
R	O
,	O
Jordan	O
JH	O
,	O
Feix	O
A	O
,	O
Sperr	O
WR	O
,	O
Sunder	O
-	O
Plassmann	O
G	O
,	O
Valent	O
P,	O
Fodinger	O
M.	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
Division	O
of	O
Endocrinology	O
and	O
Metabolism	O
,	O
University	O
of	O
Vienna	O
,	O
Vienna	O
,	O
Austria	O
.	O
The	O
proto	O
-	O
oncogene	O
C-KIT	O
encodes	O
a	O
tyrosine	O
kinase	O
receptor	O
that	O
is	O
expressed	O
on	O
mast	O
cells	O
and	O
haematopoietic	O
stem	O
cells	O
and	O
can	O
show	O
somatic	O
mutations	O
in	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
Only	O
scattered	O
information	O
is	O
available	O
about	O
mutations	O
in	O
C-KIT	O
in	O
patients	O
with	O
other	O
myeloid	B-malignancy-type
neoplasms	I-malignancy-type
.	O
Moreover	O
,	O
the	O
prevalence	O
of	O
mutations	O
in	O
C-KIT	O
in	O
bone	O
marrow	O
specimens	O
of	O
individuals	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
is	O
largely	O
unknown	O
.	O
Using	O
sequence	O
analysis	O
,	O
we	O
have	O
screened	O
cDNAs	O
of	O
the	O
C-KIT	O
domain	O
encompassing	O
codon	O
510	O
-	O
626	O
and	O
codon	O
763	O
-	O
858	O
in	O
bone	O
marrow	O
(	O
BM	O
)	O
mononuclear	O
cells	O
(	O
MNCs	O
)	O
of	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
n	O
=	O
28	O
)	O
and	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
n	O
=	O
12	O
)	O
for	O
the	O
presence	O
of	O
mutations	O
.	O
Furthermore	O
,	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
was	O
applied	O
for	O
identification	O
of	O
the	O
C-KIT	O
2468	O
A	O
-->	O
T	O
and	O
the	O
C-KIT	O
1700	O
T	O
-->	O
G	O
mutation	O
,	O
as	O
well	O
as	O
the	O
C-KIT	O
1642	O
A	O
-->	O
C	O
polymorphism	O
.	O
All	O
11	O
patients	O
with	O
systemic	B-malignancy-type
indolent	I-malignancy-type
mastocytosis	I-malignancy-type
tested	O
positive	O
for	O
C-KIT	O
2468	O
A	O
-->	O
T	O
.	O
In	O
contrast	O
,	O
no	O
mutation	O
was	O
identified	O
in	O
the	O
case	O
of	O
aggressive	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
Among	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
,	O
no	O
patient	O
showed	O
a	O
somatic	O
mutation	O
in	O
C-KIT	O
.	O
The	O
allele	O
frequency	O
for	O
C-KIT	O
1642	O
A	O
-->	O
C	O
among	O
the	O
entire	O
patient	O
population	O
was	O
0.038	O
and	O
was	O
0.125	O
among	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
.	O
Our	O
data	O
demonstrate	O
that	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
without	O
histological	O
or	O
cytological	O
evidence	O
of	O
mastocytosis	B-malignancy-type
do	O
not	O
exhibit	O
somatic	O
mutations	O
in	O
exons	O
10	O
,	O
11	O
,	O
12	O
,	O
16	O
,	O
17	O
and	O
18	O
of	O
C-KIT	O
.	O
In	O
contrast	O
,	O
BM	O
MNCs	O
of	O
patients	O
with	O
systemic	B-malignancy-type
indolent	I-malignancy-type
mastocytosis	I-malignancy-type
were	O
all	O
positive	O
for	O
C-KIT	O
2468	O
A	O
-->	O
T	O
and	O
negative	O
for	O
additional	O
mutations	O
in	O
these	O
exons	O
.	O
The	O
C-KIT	O
1642	O
A	O
-->	O
C	O
polymorphism	O
is	O
not	O
associated	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
or	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
PMID	O
:	O
11380399	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2001	O
Jun	O
15;9	O
2	O
(	O
6	O
)	O
:839	O
-	O
42	O
Cytoplasmic	O
and	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
is	O
rarely	O
caused	O
by	O
CTNNB1	O
exon	O
3	O
mutations	O
in	O
cutaneous	B-malignancy-type
malignant	I-malignancy-type
melanoma	I-malignancy-type
.	O
Omholt	O
K,	O
Platz	O
A	O
,	O
Ringborg	O
U	O
,	O
Hansson	O
J.	O
Cancer	O
Centre	O
Karolinska	O
,	O
Department	O
of	O
Oncology-Pathology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
Beta-catenin	O
plays	O
an	O
important	O
role	O
in	O
the	O
Wnt	O
signaling	O
pathway	O
by	O
activating	O
T-cell	O
factor	O
(	O
Tcf	O
)	O
/	O
lymphoid	O
enhancer	O
factor	O
(	O
Lef	O
)	O
-	O
regulated	O
gene	O
transcription	O
.	O
The	O
level	O
of	O
beta-catenin	O
is	O
regulated	O
through	O
GSK-3beta	O
phosphorylation	O
of	O
specific	O
serine	O
and	O
threonine	O
residues	O
,	O
all	O
of	O
which	O
are	O
encoded	O
for	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
.	O
Mutations	O
altering	O
the	O
GSK-3beta	O
phosphorylation	O
sites	O
lead	O
to	O
cellular	O
accumulation	O
of	O
beta-catenin	O
and	O
constitutive	O
transcription	O
of	O
Tcf	O
/	O
Lef	O
target	O
genes	O
.	O
Such	O
mutations	O
have	O
previously	O
been	O
found	O
in	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
In	O
our	O
study	O
,	O
primary	O
melanomas	B-malignancy-type
and	O
their	O
corresponding	O
metastases	O
were	O
screened	O
for	O
CTNNB1	O
exon	O
3	O
mutations	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequence	O
analysis	O
.	O
One	O
of	O
31	O
primary	O
tumors	O
and	O
1	O
of	O
37	O
metastases	O
,	O
both	O
originating	O
from	O
the	O
same	O
patient	O
,	O
had	O
a	O
TCT	O
to	O
TTT	O
mutation	O
at	O
codon	O
45	O
,	O
changing	O
serine	O
to	O
phenylalanine	O
.	O
Immunohistochemical	O
analysis	O
revealed	O
membranous	O
localization	O
of	O
beta-catenin	O
in	O
a	O
majority	O
of	O
the	O
samples	O
.	O
The	O
mutated	O
primary	O
tumor	O
and	O
metastasis	O
,	O
however	O
,	O
displayed	O
widespread	O
cytoplasmic	O
and	O
nuclear	O
expression	O
of	O
beta-catenin	O
.	O
An	O
additional	O
30	O
%	O
of	O
the	O
primary	O
tumors	O
showed	O
focal	O
cytoplasmic	O
and	O
nuclear	O
staining	O
.	O
Thus	O
,	O
beta-catenin	O
exon	O
3	O
mutations	O
are	O
rare	O
in	O
primary	O
as	O
well	O
as	O
metastatic	O
melanomas	B-malignancy-type
and	O
do	O
not	O
explain	O
the	O
abnormal	O
cytoplasmic	O
and	O
nuclear	O
localization	O
of	O
beta-catenin	O
found	O
in	O
a	O
relatively	O
large	O
fraction	O
of	O
primary	O
melanomas	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11351304	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
2001	O
Apr;	O
7(	O
4	O
)	O
:	O
901	O
-	O
8	O
Frequent	O
deletions	O
and	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
associated	O
with	O
overexpression	O
of	O
cyclin	O
D1	O
and	O
fibronectin	O
and	O
poorly	O
differentiated	O
histology	O
in	O
childhood	O
hepatoblastoma	B-malignancy-type
.	O
Takayasu	O
H,	O
Horie	O
H,	O
Hiyama	O
E	O
,	O
Matsunaga	O
T	O
,	O
Hayashi	O
Y	O
,	O
Watanabe	O
Y	O
,	O
Suita	O
S	O
,	O
Kaneko	O
M,	O
Sasaki	O
F	O
,	O
Hashizume	O
K,	O
Ozaki	O
T	O
,	O
Furuuchi	O
K,	O
Tada	O
M,	O
Ohnuma	O
N	O
,	O
Nakagawara	O
A	O
.	O
Division	O
of	O
Biochemistry	O
,	O
Chiba	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Chiba	O
260	O
-	O
8717	O
,	O
Japan	O
.	O
Hepatoblastoma	B-malignancy-type
(	O
HBL	B-malignancy-type
)	O
is	O
the	O
most	O
common	O
malignant	O
liver	B-malignancy-type
tumor	I-malignancy-type
in	O
young	O
children	O
.	O
Recent	O
reports	O
have	O
shown	O
that	O
the	O
beta-catenin	O
gene	O
was	O
frequently	O
mutated	O
or	O
deleted	O
in	O
HBLS	B-malignancy-type
:	O
To	O
elucidate	O
the	O
role	O
of	O
beta-catenin	O
abnormalities	O
in	O
HBLs	B-malignancy-type
,	O
we	O
searched	O
for	O
mutations	O
of	O
beta-catenin	O
and	O
APC	O
as	O
well	O
as	O
expression	O
of	O
the	O
target	O
genes	O
,	O
cyclin	O
D1	O
,	O
c-myc	O
,	O
and	O
fibronectin	O
,	O
in	O
68	O
primary	O
HBLS	B-malignancy-type
:	O
The	O
mutation	O
analysis	O
revealed	O
that	O
44	O
(	O
65	O
%	O
)	O
tumors	O
carried	O
missense	O
mutations	O
or	O
deletions	O
of	O
beta-catenin	O
,	O
all	O
of	O
which	O
were	O
somatic	O
and	O
targeted	O
to	O
the	O
exon	O
3	O
encoding	O
the	O
amino	O
acid	O
residues	O
involved	O
in	O
its	O
degradation	O
.	O
However	O
,	O
no	O
loss	O
of	O
function	O
mutation	O
of	O
the	O
APC	O
gene	O
was	O
detected	O
by	O
the	O
yeast	O
functional	O
assay	O
.	O
Of	O
interest	O
,	O
beta-catenin	O
mutation	O
was	O
significantly	O
correlated	O
with	O
overexpression	O
of	O
the	O
target	O
genes	O
,	O
cyclin	O
D1	O
and	O
fibronectin	O
,	O
but	O
not	O
with	O
that	O
of	O
c-myc	O
in	O
HBLs	B-malignancy-type
as	O
measured	O
by	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
.	O
The	O
immunohistochemical	O
studies	O
in	O
15	O
HBLs	B-malignancy-type
demonstrated	O
that	O
the	O
nuclear	O
/	O
cytoplasmic	O
accumulation	O
of	O
beta-catenin	O
was	O
positive	O
in	O
13	O
tumors	O
,	O
9	O
of	O
which	O
had	O
the	O
deletion	O
or	O
mutation	O
of	O
the	O
gene	O
.	O
The	O
significant	O
correlation	O
between	O
the	O
beta-catenin	O
gene	O
abnormality	O
and	O
the	O
positive	O
staining	O
of	O
cyclin	O
D1	O
was	O
also	O
confirmed	O
.	O
Furthermore	O
,	O
the	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
strongly	O
associated	O
with	O
the	O
poorly	O
differentiated	O
tumor	O
cell	O
components	O
as	O
well	O
as	O
with	O
the	O
positive	O
staining	O
of	O
cyclin	O
D1	O
within	O
the	O
tumor	O
.	O
Thus	O
,	O
our	O
present	O
results	O
suggested	O
that	O
the	O
gain	O
of	O
function	O
mutation	O
of	O
beta-catenin	O
played	O
a	O
crucial	O
role	O
in	O
the	O
malignant	O
progression	O
of	O
HBL	B-malignancy-type
in	O
vivo	O
.	O
PMID	O
:	O
11309340	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2001	O
May	O
20;95	O
(	O
3	O
)	O
:162-7	O
Determination	O
of	O
microsatellite	O
instability	O
,	O
p53	O
and	O
K-RAS	O
mutations	O
in	O
hepatic	O
metastases	O
from	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
:	O
relationship	O
with	O
response	O
to	O
5-fluorouracil	O
and	O
survival	O
.	O
Rosty	O
C	O
,	O
Chazal	O
M,	O
Etienne	O
MC	O
,	O
Letoublon	O
C	O
,	O
Bourgeon	O
A	O
,	O
Delpero	O
JR	O
,	O
Pezet	O
D	O
,	O
Beaune	O
P,	O
Laurent	O
-	O
Puig	O
P,	O
Milano	O
G.	O
Laboratoire	O
de	O
Toxicologie	O
Moleculaire	O
,	O
INSERM	O
U490	O
,	O
Faculte	O
de	O
Medecine	O
des	O
Saints	O
-	O
Peres	O
,	O
45	O
Rue	O
des	O
Saints	O
-	O
Peres	O
,	O
75270	O
Paris	O
Cedex	O
06	O
,	O
France	O
.	O
In	O
vitro	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
high	O
-	O
frequency	O
microsatellite	O
instability	O
(	O
MSI-H	O
)	O
phenotype	O
,	O
p53	O
and	O
K-ras	O
mutations	O
might	O
influence	O
the	O
response	O
to	O
chemotherapy	O
in	O
a	O
variety	O
of	O
tumors	O
,	O
including	O
primary	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
(	O
CRC	B-malignancy-type
)	O
.	O
Unresectable	O
hepatic	O
metastases	O
from	O
CRC	B-malignancy-type
are	O
commonly	O
treated	O
with	O
5-fluorouracil	O
(	O
5FU	O
)	O
and	O
folinic	O
acid	O
.	O
Since	O
several	O
new	O
active	O
drugs	O
are	O
now	O
used	O
for	O
treating	O
CRC	B-malignancy-type
,	O
molecular	O
determinants	O
predictive	O
to	O
response	O
to	O
5FU	O
would	O
thus	O
be	O
crucial	O
for	O
optimizing	O
indications	O
of	O
chemotherapy	O
to	O
those	O
patients	O
.	O
MSI-H	O
phenotype	O
,	O
p53	O
and	O
K-ras	O
status	O
were	O
characterized	O
in	O
a	O
prospective	O
study	O
of	O
56	O
patients	O
with	O
CRC	B-malignancy-type
metastatic	O
to	O
the	O
liver	O
and	O
treated	O
with	O
5FU	O
-	O
based	O
chemotherapy	O
.	O
The	O
objective	O
response	O
rate	O
after	O
a	O
3	O
-	O
month	O
treatment	O
was	O
32.1	O
%	O
.	O
The	O
prevalence	O
of	O
p53	O
mutations	O
,	O
K-ras	O
mutations	O
and	O
MSI-H	O
phenotype	O
was	O
62.5	O
%	O
,	O
30.3	O
%	O
and	O
1.8	O
%	O
,	O
respectively	O
.	O
No	O
significant	O
association	O
was	O
found	O
between	O
response	O
to	O
chemotherapy	O
and	O
p53	O
mutations	O
(	O
78	O
%	O
mutated	O
tumors	O
in	O
responders	O
vs.	O
55	O
%	O
in	O
nonresponders	O
;	O
p	O
=	O
0.10	O
)	O
and	O
K-ras	O
mutations	O
(	O
39	O
%	O
mutated	O
tumors	O
in	O
responders	O
vs.	O
26	O
%	O
in	O
nonresponders	O
;	O
p	O
=	O
0.34	O
)	O
.	O
Survival	O
was	O
longer	O
for	O
patients	O
with	O
p53	O
-	O
mutated	O
metastases	O
than	O
for	O
patients	O
with	O
unresected	O
wild	O
-	O
type	O
p53	O
metastases	O
(	O
median	O
survival	O
15	O
months	O
vs.	O
17	O
months	O
;	O
p	O
=	O
0.06	O
)	O
.	O
The	O
determination	O
of	O
the	O
MSI-H	O
phenotype	O
,	O
p53	O
and	O
K-ras	O
status	O
in	O
hepatic	O
metastases	O
from	O
CRC	B-malignancy-type
does	O
not	O
discriminate	O
a	O
group	O
of	O
patients	O
that	O
should	O
preferentially	O
benefit	O
from	O
5FU	O
-	O
based	O
chemotherapy	O
.	O
The	O
prognosis	O
of	O
patients	O
with	O
treated	O
liver	O
metastases	O
is	O
better	O
when	O
p53	O
is	O
mutated	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11307149	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Mar	O
15	O
;61	O
(	O
6	O
)	O
:	O
267	O
6-83	O
Genetic	O
pathways	O
in	O
the	O
evolution	O
of	O
morphologically	O
distinct	O
colorectal	O
neoplasms	O
.	O
Yashiro	O
M,	O
Carethers	O
JM	O
,	O
Laghi	O
L,	O
Saito	O
K,	O
Slezak	O
P,	O
Jaramillo	O
E	O
,	O
Rubio	O
C	O
,	O
Koizumi	O
K,	O
Hirakawa	O
K,	O
Boland	O
CR	O
.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
California	O
,	O
San	O
Diego	O
,	O
La	O
Jolla	O
92093	O
-0688	O
,	O
USA	O
.	O
Colorectal	B-malignancy-type
adenomas	I-malignancy-type
can	O
be	O
morphologically	O
classified	O
as	O
exophytic	O
or	O
flat	O
.	O
Polypoid	B-malignancy-type
cancers	I-malignancy-type
and	O
cancers	O
arising	O
de	O
novo	O
(	O
ie.	O
,	O
without	O
any	O
adenomatous	O
component	O
)	O
might	O
be	O
the	O
results	O
of	O
genetic	O
progression	O
from	O
exophytic	O
and	O
flat	O
adenomas	B-malignancy-type
,	O
respectively	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
94	O
morphologically	O
distinct	O
neoplastic	O
specimens	O
for	O
mutations	O
in	O
K-RAS	O
and	O
analyzed	O
10	O
microsatellite	O
loci	O
tightly	O
linked	O
to	O
the	O
tumor	O
suppressor	O
genes	O
APC	O
,	O
p53	O
,	O
DCC	O
/	O
SMAD4	O
,	O
hMSH2	O
,	O
and	O
hMLH1	O
.	O
K-RAS	O
mutations	O
were	O
significantly	O
associated	O
with	O
exophytic	B-malignancy-type
adenomas	I-malignancy-type
[	O
11	O
of	O
21	O
(	O
52	O
%	O
)	O
]	O
compared	O
to	O
flat	B-malignancy-type
adenomas	I-malignancy-type
[	O
2	O
of	O
13	O
(	O
15	O
%	O
)	O
,	O
P	O
<	O
0.03	O
]	O
and	O
polypoid	B-malignancy-type
cancers	I-malignancy-type
[	O
17	O
of	O
25	O
(	O
68	O
%	O
)	O
]	O
compared	O
to	O
cancers	O
arising	O
de	O
novo	O
[	O
7	O
of	O
25	O
(	O
28	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O
Two	O
polypoid	B-malignancy-type
cancer	I-malignancy-type
cases	O
demonstrated	O
three	O
and	O
four	O
different	O
K-RAS	O
mutations	O
,	O
respectively	O
,	O
suggesting	O
multiple	O
areas	O
of	O
clonal	O
expansion	O
.	O
Cancers	O
arising	O
de	O
novo	O
were	O
significantly	O
associated	O
with	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
chromosome	O
3p	O
compared	O
to	O
pol	B-malignancy-type
ypoid	I-malignancy-type
cancers	I-malignancy-type
[	O
6	O
of	O
18	O
(	O
33	O
%	O
)	O
versus	O
1	O
of	O
20	O
(	O
5	O
%	O
)	O
,	O
P	O
<	O
0.03	O
]	O
,	O
whereas	O
the	O
prevalence	O
of	O
LOH	O
at	O
chromosomes	O
2p	O
,	O
5q	O
,	O
17p	O
,	O
and	O
18q	O
and	O
microsatellite	O
instability	O
were	O
not	O
different	O
between	O
the	O
groups	O
.	O
For	O
all	O
cancers	O
,	O
LOH	O
at	O
chromosomes	O
17p	O
and	O
18q	O
occurred	O
in	O
47	O
and	O
51	O
%	O
,	O
respectively	O
.	O
However	O
,	O
LOH	O
at	O
17p	O
and	O
18q	O
occurred	O
in	O
0	O
and	O
16	O
%	O
of	O
benign	O
lesions	O
,	O
respectively	O
,	O
suggesting	O
their	O
role	O
in	O
malignant	O
transformation	O
.	O
There	O
was	O
no	O
difference	O
in	O
LOH	O
at	O
chromosomes	O
17p	O
and	O
18q	O
between	O
exophytic	O
and	O
flat	O
lesions	O
.	O
These	O
findings	O
suggest	O
that	O
(a)	O
mutant	O
K-RAS	O
is	O
associated	O
with	O
the	O
exophytic	O
growth	O
of	O
colonic	B-malignancy-type
neoplasms	I-malignancy-type
,	O
and	O
that	O
(b)	O
some	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
arising	O
de	O
novo	O
lose	O
chromosome	O
3p	O
during	O
their	O
evolution	O
,	O
which	O
is	O
not	O
seen	O
in	O
polypoid	B-malignancy-type
cancers	I-malignancy-type
.	O
Half	O
of	O
all	O
cancers	O
lose	O
chromosomes	O
17p	O
and	O
18q	O
at	O
or	O
near	O
the	O
malignant	O
transition	O
of	O
benign	O
lesions	O
as	O
reported	O
previously	O
,	O
irrespective	O
of	O
morphology	O
.	O
There	O
may	O
be	O
more	O
than	O
one	O
genetic	O
avenue	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
formation	O
,	O
and	O
this	O
correlates	O
with	O
the	O
morphological	O
characteristics	O
.	O
PMID	O
:	O
11289147	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hepatol	O
Res	O
2001	O
May	O
1;20(	O
1	O
)	O
:	O
39	O
-	O
51	O
Frequent	O
beta-catenin	O
aberration	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Fujie	O
H,	O
Moriya	O
K,	O
Shintani	O
Y	O
,	O
Tsutsumi	O
T	O
,	O
Takayama	O
T	O
,	O
Makuuchi	O
M,	O
Kimura	O
S	O
,	O
Koike	O
K.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Graduate	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
7-	O
3-1	O
Hongo	O
,	O
Bunkyo-ku	O
,	O
113-8655	O
,	O
Tokyo	O
,	O
Japan	O
Recently	O
,	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
have	O
been	O
reported	O
:	O
approximately	O
20	O
%	O
of	O
HCCs	B-malignancy-type
had	O
activating	O
mutations	O
at	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
sites	O
within	O
the	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
.	O
However	O
,	O
changes	O
in	O
the	O
level	O
of	O
the	O
beta-catenin	O
protein	O
in	O
HCC	B-malignancy-type
have	O
not	O
been	O
well	O
studied	O
.	O
We	O
examined	O
,	O
by	O
Western	O
blotting	O
,	O
the	O
expression	O
level	O
of	O
the	O
beta-catenin	O
protein	O
in	O
cancerous	O
tissues	O
in	O
comparison	O
with	O
that	O
in	O
adjacent	O
non	O
-	O
cancerous	O
tissues	O
obtained	O
from	O
32	O
cases	O
of	O
HCC	B-malignancy-type
with	O
hepatitis	O
C	O
.	O
An	O
increase	O
in	O
the	O
beta-catenin	O
protein	O
level	O
in	O
cancerous	O
tissue	O
compared	O
to	O
that	O
in	O
adjacent	O
non	O
-	O
cancerous	O
tissue	O
was	O
found	O
in	O
15	O
(	O
46.9	O
%	O
)	O
of	O
32	O
cases	O
of	O
HCC	B-malignancy-type
.	O
Mutation	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
found	O
in	O
six	O
(	O
18.8	O
%	O
)	O
of	O
the	O
32	O
cases	O
,	O
in	O
five	O
of	O
which	O
the	O
beta-catenin	O
protein	O
level	O
was	O
increased	O
.	O
In	O
total	O
,	O
beta-catenin	O
aberration	O
was	O
found	O
in	O
16	O
(	O
50.0	O
%	O
)	O
of	O
32	O
cases	O
of	O
HCC	B-malignancy-type
.	O
It	O
should	O
be	O
noted	O
that	O
beta-catenin	O
aberration	O
was	O
also	O
found	O
in	O
early	O
HCC	B-malignancy-type
although	O
it	O
was	O
observed	O
chiefly	O
in	O
advanced	O
HCCs	B-malignancy-type
.	O
These	O
results	O
indicate	O
that	O
beta-catenin	O
aberration	O
is	O
a	O
frequent	O
event	O
in	O
the	O
development	O
of	O
HCC	B-malignancy-type
and	O
may	O
facilitate	O
the	O
development	O
of	O
HCC	B-malignancy-type
in	O
the	O
course	O
of	O
chronic	O
hepatitis	O
.	O
PMID	O
:	O
11282485	O
[	O
PubMed	O
-	O
as	O
supplied	O
by	O
publisher	O
]	O

J	O
Pathol	O
2001	O
Apr;19	O
3	O
(	O
4	O
)	O
:	O
483	O
-	O
90	O
Nuclear	O
localization	O
of	O
beta-catenin	O
is	O
an	O
important	O
prognostic	O
factor	O
in	O
hepatoblastoma	B-malignancy-type
.	O
Park	O
WS	O
,	O
Oh	O
RR	O
,	O
Park	O
JY	O
,	O
Kim	O
PJ	O
,	O
Shin	O
MS	O
,	O
Lee	O
JH	O
,	O
Kim	O
HS	O
,	O
Lee	O
SH	O
,	O
Kim	O
SY	O
,	O
Park	O
YG	O
,	O
An	O
WG	O
,	O
Kim	O
HS	O
,	O
Jang	O
JJ	O
,	O
Yoo	O
NJ	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
College	O
of	O
Medicine	O
,	O
The	O
Catholic	O
University	O
of	O
Korea	O
,	O
505	O
Banpo	O
-dong	O
,	O
Sacho-	O
gu	O
,	O
Seoul	O
137	O
-	O
701	O
,	O
Korea	O
.	O
In	O
this	O
study	O
,	O
mutational	O
and	O
immunohistochemical	O
analyses	O
of	O
beta-catenin	O
were	O
performed	O
in	O
30	O
hepatoblastomas	B-malignancy-type
,	O
to	O
assess	O
the	O
prevalence	O
of	O
alterations	O
of	O
the	O
Wnt	O
pathway	O
with	O
respect	O
to	O
clinicopathological	O
parameters	O
and	O
survival	O
.	O
Four	O
missense	O
mutations	O
of	O
beta-catenin	O
(	O
13.3	O
%	O
)	O
were	O
detected	O
and	O
there	O
was	O
strong	O
immunoreactivity	O
for	O
beta-catenin	O
in	O
the	O
cytoplasm	O
and/or	O
the	O
nucleus	O
in	O
97	O
%	O
of	O
hepatoblastomas	O
.	O
Nuclear	O
and	O
cytoplasmic	O
staining	O
was	O
demonstrated	O
in	O
19	O
of	O
30	O
tumours	O
(	O
63	O
%	O
)	O
,	O
while	O
ten	O
revealed	O
only	O
cytoplasmic	O
staining	O
.	O
Statistically	O
,	O
this	O
nuclear	O
beta-catenin	O
staining	O
was	O
significantly	O
higher	O
in	O
the	O
embryonal	O
(	O
Fisher	O
exact	O
test	O
;	O
p	O
=	O
0.00393	O
)	O
or	O
undifferentiated	O
type	O
(	O
p	O
=	O
0.00156	O
)	O
of	O
hepatoblastoma	B-malignancy-type
than	O
in	O
the	O
fetal	O
type	O
,	O
but	O
there	O
was	O
no	O
difference	O
between	O
clinical	O
stages	O
I	O
and	O
II	O
and	O
clinical	O
stages	O
III	O
and	O
IV	O
(	O
p	O
=	O
0.175	O
)	O
.	O
Cumulative	O
survival	O
curves	O
showed	O
that	O
nuclear	O
beta-catenin	O
staining	O
(	O
generalized	O
Wilcoxon	O
test	O
;	O
p	O
=	O
0.0088	O
)	O
,	O
undifferentiated	O
histological	O
type	O
(	O
p	O
=	O
0.0305	O
)	O
,	O
and	O
clinical	O
stages	O
III	O
and	O
IV	O
(	O
p	O
=	O
0.0107	O
)	O
were	O
significantly	O
correlated	O
with	O
shorter	O
survival	O
time	O
in	O
these	O
patients	O
.	O
Moreover	O
,	O
Cox	O
multivariate	O
analysis	O
provides	O
evidence	O
that	O
nuclear	O
beta-catenin	O
staining	O
is	O
the	O
most	O
important	O
prognostic	O
factor	O
for	O
survival	O
(	O
p	O
=	O
0.0090	O
)	O
.	O
It	O
is	O
therefore	O
concluded	O
that	O
immunohistochemical	O
analysis	O
of	O
beta-catenin	O
might	O
be	O
a	O
useful	O
clinical	O
tool	O
for	O
estimating	O
the	O
prognosis	O
for	O
patients	O
with	O
hepatoblastoma	B-malignancy-type
.	O
Copyright	O
2000	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O
PMID	O
:	O
11276007	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arch	O
Pathol	O
Lab	O
Med	O
2001	O
Mar;125(	O
3	O
)	O
:	O
347	O
-52	O
Novel	O
method	O
for	O
simultaneous	O
analysis	O
of	O
p53	O
and	O
K-ras	O
mutations	O
and	O
p53	O
protein	O
expression	O
in	O
single	O
histologic	O
sections	O
.	O
Yamashita	O
K,	O
Yoshida	O
T	O
,	O
Shinoda	O
H,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
East	O
Hospital	O
,	O
Sagamihara	O
,	O
Kanagawa	O
,	O
Japan	O
.	O
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Abnormal	O
protein	O
expression	O
and	O
gene	O
mutation	O
should	O
be	O
examined	O
on	O
exactly	O
identified	O
lesions	O
.	O
To	O
perform	O
simultaneous	O
analyses	O
of	O
oncogene	O
or	O
tumor	O
suppressor	O
gene	O
mutations	O
and	O
related	O
protein	O
expression	O
in	O
single	O
histologic	O
sections	O
,	O
we	O
have	O
developed	O
a	O
novel	O
method	O
using	O
an	O
antigen	O
-	O
retrieval	O
solution	O
for	O
a	O
polymerase	O
chain	O
reaction	O
template	O
before	O
immunohistochemical	O
staining	O
.	O
METHODS	O
:	O
Using	O
20	O
cases	O
of	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
carcinoma	I-malignancy-type
,	O
several	O
kinds	O
of	O
antigen	O
-	O
retrieval	O
solutions	O
were	O
tested	O
after	O
heating	O
rehydrated	O
,	O
4	O
-	O
microm	O
-	O
thick	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
histologic	O
sections	O
at	O
96	O
degrees	O
C	O
for	O
20	O
minutes	O
.	O
Polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
was	O
conducted	O
for	O
p53	O
(	O
exons	O
5	O
through	O
9	O
)	O
and	O
K-ras	O
(	O
exons	O
1	O
and	O
2	O
)	O
,	O
and	O
the	O
histologic	O
sections	O
were	O
then	O
immunostained	O
with	O
monoclonal	O
antibody	O
against	O
p53	O
.	O
RESULTS	O
:	O
DNA	O
analysis	O
of	O
antigen	O
-	O
retrieval	O
solutions	O
was	O
possible	O
in	O
all	O
20	O
cases	O
and	O
revealed	O
completely	O
consistent	O
results	O
(	O
100	O
%	O
)	O
with	O
fresh	O
cancer	O
tissue	O
and	O
microdissected	O
cancer	O
tissue	O
of	O
paraffin	O
-	O
embedded	O
histologic	O
sections	O
.	O
With	O
this	O
method	O
,	O
K-ras	O
mutations	O
were	O
positive	O
in	O
10	O
of	O
20	O
cases	O
(	O
exon	O
1	O
in	O
9	O
cases	O
and	O
exon	O
2	O
in	O
1	O
case	O
)	O
and	O
p53	O
mutations	O
were	O
positive	O
in	O
9	O
of	O
20	O
cases	O
(	O
exon	O
5	O
in	O
4	O
cases	O
,	O
exon	O
6	O
in	O
1	O
,	O
exon	O
7	O
in	O
3	O
,	O
and	O
exon	O
8	O
in	O
1	O
case	O
)	O
,	O
with	O
8	O
of	O
the	O
9	O
p53	O
mutation	O
cases	O
showing	O
diffuse	O
p53	O
protein	O
expression	O
on	O
immunostaining	O
.	O
Base	O
alterations	O
of	O
all	O
abnormal	O
conformers	O
were	O
confirmed	O
with	O
direct	O
sequencing	O
.	O
For	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
sodium	O
citrate	O
buffer	O
(	O
pH	O
6.0	O
)	O
was	O
found	O
to	O
be	O
the	O
optimal	O
antigen	O
-	O
retrieval	O
solution	O
.	O
CONCLUSIONS	O
:	O
This	O
newly	O
developed	O
method	O
can	O
be	O
used	O
for	O
routine	O
immunostaining	O
and	O
genetic	O
analysis	O
with	O
single	O
histologic	O
sections	O
.	O
PMID	O
:	O
11231481	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Jan	O
1;61	O
(	O
1	O
)	O
:19	O
-22	O
More	O
frequent	O
beta-catenin	O
exon	O
3	O
mutations	O
in	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
than	O
in	O
carcinomas	B-malignancy-type
indicate	O
different	O
lineages	O
.	O
Yanagisawa	O
N	O
,	O
Mikami	O
T	O
,	O
Saegusa	O
M,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
Sagamihara	O
,	O
Kanagawa	O
,	O
Japan	O
.	O
To	O
clarify	O
the	O
contribution	O
of	O
beta-catenin	O
,	O
which	O
is	O
related	O
to	O
cell	O
adhesion	O
and	O
intranuclear	O
transcription	O
,	O
to	O
gallbladder	O
carcinogenesis	O
,	O
we	O
investigated	O
its	O
expression	O
using	O
immunohistochemistry	O
,	O
and	O
beta-catenin	O
exon	O
3	O
mutations	O
by	O
DNA	O
direct	O
sequencing	O
,	O
in	O
18	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
and	O
82	O
adenocarcinomas	B-malignancy-type
.	O
Membranous	O
expression	O
was	O
significantly	O
lower	O
in	O
moderately	O
and	O
poorly	O
differentiated	O
than	O
in	O
well	O
-	O
differentiated	O
adenocarcinoma	B-malignancy-type
cases	O
(	O
P	O
<	O
0.001	O
)	O
.	O
The	O
gallbladder	O
adenomas	O
showed	O
significantly	O
stronger	O
expression	O
in	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
than	O
carcinomas	B-malignancy-type
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
,	O
and	O
exon	O
3	O
mutations	O
were	O
observed	O
in	O
62.5	O
%	O
(	O
10	O
of	O
16	O
)	O
of	O
adenomas	B-malignancy-type
,	O
but	O
only	O
4.8	O
%	O
(	O
1	O
of	O
21	O
)	O
of	O
carcinomas	B-malignancy-type
.	O
With	O
beta-catenin	O
as	O
a	O
molecular	O
marker	O
,	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
can	O
be	O
considered	O
to	O
be	O
a	O
minor	O
pathway	O
in	O
gallbladder	O
carcinogenesis	O
.	O
PMID	O
:	O
11196159	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatobiliary	O
Pancreat	O
Surg	O
2000	O
;	O
7	O
(	O
4	O
)	O
:	O
426-31	O
p53	O
overexpression	O
and	O
K-ras	O
gene	O
mutations	O
in	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
-	O
associated	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
.	O
Ahrendt	O
SA	O
,	O
Rashid	O
A	O
,	O
Chow	O
JT	O
,	O
Eisenberger	O
CF	O
,	O
Pitt	O
HA	O
,	O
Sidransky	O
D	O
.	O
Department	O
of	O
Surgery	O
,	O
Medical	O
College	O
of	O
Wisconsin	O
,	O
9200	O
West	O
Wisconsin	O
Avenue	O
,	O
Milwaukee	O
,	O
WI	O
53226	O
,	O
USA	O
.	O
Cholangiocarcinoma	B-malignancy-type
occurs	O
frequently	O
in	O
patients	O
with	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
(	O
PSC	B-malignancy-type
)	O
.	O
We	O
evaluated	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
p53	O
protein	O
overexpression	O
and	O
K-ras	O
gene	O
mutations	O
in	O
patients	O
with	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
and	O
PSC	B-malignancy-type
.	O
p53	O
protein	O
expression	O
was	O
determined	O
in	O
specimens	O
from	O
12	O
patients	O
with	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
,	O
using	O
the	O
antibody	O
,	O
D07	O
.	O
K-ras	O
mutations	O
were	O
detected	O
using	O
DNA	O
sequencing	O
and	O
a	O
mutation	O
ligation	O
assay	O
.	O
Accumulation	O
of	O
p53	O
protein	O
was	O
detected	O
in	O
6	O
of	O
12	O
tumors	O
(	O
50	O
%	O
)	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
4	O
of	O
12	O
tumors	O
(	O
33	O
%	O
)	O
.	O
Overall	O
survival	O
in	O
patients	O
with	O
p53	O
-	O
negative	O
tumors	O
was	O
significantly	O
longer	O
(	O
P	O
<	O
0.05	O
)	O
than	O
that	O
in	O
patients	O
with	O
p53	O
-	O
positive	O
(	O
mutant	O
)	O
tumors	O
.	O
Similarly	O
,	O
overall	O
survival	O
was	O
significantly	O
longer	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
absence	O
of	O
a	O
K-ras	O
mutation	O
than	O
in	O
patients	O
with	O
a	O
tumor	O
containing	O
a	O
K-ras	O
mutation	O
.	O
Mean	O
interval	O
from	O
the	O
time	O
of	O
diagnosis	O
of	O
PSC	O
until	O
the	O
diagnosis	O
of	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
was	O
significantly	O
shorter	O
(	O
P	O
<	O
0.05	O
)	O
in	O
patients	O
with	O
p53	O
overexpression	O
than	O
in	O
those	O
patients	O
without	O
p53	O
overexpression	O
(	O
2	O
versus	O
47	O
months	O
)	O
.	O
p53	O
overexpression	O
and	O
K-ras	O
mutations	O
occur	O
commonly	O
in	O
patients	O
with	O
PSC	B-malignancy-type
and	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
and	O
are	O
associated	O
with	O
a	O
shortened	O
survival	O
.	O
Patients	O
with	O
longstanding	O
PSC	B-malignancy-type
are	O
less	O
likely	O
to	O
have	O
these	O
genetic	O
alterations	O
and	O
may	O
have	O
a	O
better	O
prognosis	O
.	O
PMID	O
:	O
11180865	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
2001	O
Mar	O
;	O
30	O
(	O
3	O
)	O
:	O
316-21	O
Constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
by	O
CTNNB1	O
(	O
beta-catenin	O
)	O
mutations	O
in	O
a	O
subset	O
of	O
human	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Sunaga	O
N	O
,	O
Kohno	O
T	O
,	O
Kolligs	O
FT	O
,	O
Fearon	O
ER	O
,	O
Saito	O
R	O
,	O
Yokota	O
J	O
.	O
Biology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
as	O
a	O
result	O
of	O
genetic	O
alterations	O
of	O
APC	O
,	O
AXIN1	O
,	O
and	O
CTNNB1	O
has	O
been	O
found	O
in	O
various	O
human	O
cancers	O
,	O
including	O
those	O
of	O
the	O
colon	B-malignancy-type
,	O
liver	B-malignancy-type
,	O
endometrium	B-malignancy-type
,	O
ovary	B-malignancy-type
,	O
prostate	B-malignancy-type
,	O
and	O
stomach	B-malignancy-type
.	O
To	O
investigate	O
the	O
pathogenetic	O
significance	O
of	O
constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
in	O
human	O
lung	O
carcinogenesis	O
,	O
CTNNB1	O
alterations	O
in	O
exon	O
3	O
,	O
a	O
region	O
known	O
to	O
represent	O
a	O
mutation	O
hot	O
spot	O
,	O
were	O
screened	O
in	O
46	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
and	O
47	O
primary	O
lung	B-malignancy-type
cancers	I-malignancy-type
.	O
Missense	O
mutations	O
causing	O
substitutions	O
of	O
Ser	O
/	O
Thr	O
residues	O
critical	O
for	O
regulation	O
by	O
GSK	O
-	O
3beta	O
were	O
detected	O
in	O
one	O
(	O
2	O
%	O
)	O
of	O
the	O
cell	O
lines	O
,	O
A427	O
,	O
and	O
two	O
(	O
4	O
%	O
)	O
of	O
the	O
surgical	O
specimens	O
.	O
The	O
three	O
lung	B-malignancy-type
cancers	I-malignancy-type
with	O
CTNNB1	O
mutations	O
were	O
adenocarcinomas	B-malignancy-type
.	O
To	O
explore	O
the	O
prevalence	O
of	O
constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
assessed	O
15	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
representing	O
major	O
histological	O
subtypes	O
of	O
lung	B-malignancy-type
cancers	I-malignancy-type
for	O
constitutive	O
Tcf	O
transcriptional	O
activity	O
(	O
CTTA	O
)	O
.	O
CTTA	O
was	O
observed	O
only	O
in	O
the	O
A427	O
adenocarcinoma	B-malignancy-type
cell	O
line	O
,	O
but	O
not	O
in	O
the	O
remaining	O
14	O
cell	O
lines	O
.	O
The	O
data	O
indicate	O
that	O
constitutive	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
caused	O
by	O
CTNNB1	O
mutation	O
is	O
involved	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
a	O
subset	O
of	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
,	O
preferentially	O
in	O
adenocarcinoma	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O
PMID	O
:	O
11170292	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gynecol	O
Oncol	O
2001	O
Feb	O
;	O
80	O
(	O
2	O
)	O
:	O
201	O
-	O
6	O
K-ras	O
mutations	O
in	O
Mullerian	B-malignancy-type
inclusion	I-malignancy-type
cysts	I-malignancy-type
associated	O
with	O
serous	B-malignancy-type
borderline	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ovary	I-malignancy-type
.	O
Alvarez	O
AA	O
,	O
Moore	O
WF	O
,	O
Robboy	O
SJ	O
,	O
Bentley	O
RC	O
,	O
Gumbs	O
C	O
,	O
Futreal	O
PA	O
,	O
Berchuck	O
A	O
.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
/	O
Division	O
of	O
Gynecologic	O
Oncology	O
,	O
Duke	O
University	O
Medical	O
Center	O
,	O
Durham	O
,	O
North	O
Carolina	O
27710	O
,	O
USA	O
.	O
OBJECTIVE	O
:	O
Mullerian	B-malignancy-type
inclusion	I-malignancy-type
cysts	I-malignancy-type
(	O
MIC	B-malignancy-type
)	O
are	O
small	O
benign	O
appearing	O
glands	O
that	O
are	O
occasionally	O
noted	O
in	O
lymph	O
nodes	O
and	O
peritoneal	O
biopsies	O
.	O
They	O
occur	O
most	O
frequently	O
in	O
women	O
with	O
serous	B-malignancy-type
ovarian	I-malignancy-type
tumors	I-malignancy-type
,	O
with	O
borderline	O
tumors	O
(	O
SBOT	B-malignancy-type
)	O
having	O
a	O
higher	O
incidence	O
than	O
invasive	O
cancers	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
MIC	B-malignancy-type
and	O
SBOT	B-malignancy-type
have	O
identical	O
K-ras	O
mutations	O
,	O
which	O
would	O
suggest	O
that	O
they	O
are	O
related	O
.	O
Methods	O
.	O
Six	O
patients	O
in	O
whom	O
adequate	O
tissue	O
was	O
available	O
from	O
SBOT	B-malignancy-type
,	O
MIC	B-malignancy-type
,	O
and	O
normal	O
tissue	O
were	O
identified	O
from	O
a	O
consecutive	O
series	O
of	O
patients	O
with	O
SBOT	B-malignancy-type
who	O
underwent	O
lymph	O
node	O
sampling	O
from	O
1992	O
to	O
1997	O
at	O
Duke	O
University	O
Medical	O
Center	O
.	O
DNA	O
extraction	O
was	O
performed	O
using	O
laser	O
capture	O
microdissection	O
.	O
Exon	O
1	O
of	O
the	O
K-ras	O
gene	O
was	O
amplified	O
using	O
PCR	O
and	O
subjected	O
to	O
single	O
-	O
strand	O
conformation	O
analysis	O
to	O
screen	O
for	O
mutations	O
.	O
Shifted	O
bands	O
were	O
sequenced	O
to	O
confirm	O
the	O
presence	O
of	O
mutations	O
.	O
RESULTS	O
:	O
Mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
were	O
found	O
in	O
three	O
of	O
six	O
(	O
50	O
%	O
)	O
SBOT	B-malignancy-type
.	O
In	O
two	O
of	O
these	O
three	O
cases	O
,	O
the	O
identical	O
mutation	O
was	O
found	O
in	O
the	O
SBOT	B-malignancy-type
and	O
the	O
MIC	B-malignancy-type
(	O
gly	O
to	O
val	O
in	O
both	O
cases	O
)	O
,	O
but	O
not	O
in	O
the	O
corresponding	O
normal	O
DNA	O
.	O
In	O
one	O
case	O
,	O
a	O
mutation	O
was	O
seen	O
in	O
the	O
ovarian	B-malignancy-type
tumor	I-malignancy-type
(	O
gly	O
to	O
asp	O
)	O
,	O
but	O
not	O
in	O
the	O
corresponding	O
MIC	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
Mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
are	O
a	O
hallmark	O
of	O
serous	B-malignancy-type
borderline	I-malignancy-type
tumors	I-malignancy-type
.	O
The	O
presence	O
of	O
identical	O
K-ras	O
mutations	O
in	O
some	O
SBOT	B-malignancy-type
and	O
their	O
associated	O
MIC	B-malignancy-type
suggests	O
that	O
they	O
are	O
related	O
processes	O
.	O
Both	O
may	O
arise	O
due	O
to	O
a	O
field	O
effect	O
,	O
or	O
alternatively	O
some	O
MIC	B-malignancy-type
may	O
represent	O
metastases	O
from	O
the	O
primary	O
ovarian	B-malignancy-type
tumor	I-malignancy-type
.	O
PMID	O
:	O
11161860	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Arch	O
Surg	O
2000	O
Dec	O
;	O
135	O
(	O
12	O
)	O
:	O
1450	O
-	O
5	O
K-ras	O
point	O
mutation	O
in	O
the	O
nerve	O
plexuses	O
around	O
the	O
superior	O
mesenteric	O
artery	O
in	O
resectable	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
head	I-malignancy-type
:	O
distribution	O
pattern	O
and	O
related	O
factors	O
.	O
Ohigashi	O
H	O
,	O
Ishikawa	O
O	O
,	O
Sasaki	O
Y	O
,	O
Yamada	O
T	O
,	O
Furukawa	O
H	O
,	O
Imaoka	O
S	O
,	O
Kasugai	O
T	O
,	O
Ishiguro	O
S	O
,	O
Ueda	O
K	O
,	O
Miyoshi	O
Y	O
,	O
Nakamura	O
Y	O
.	O
MD	O
,	O
Department	O
of	O
Surgery	O
,	O
Osaka	O
Medical	O
Center	O
for	O
Cancer	O
and	O
Cardiovascular	O
Diseases	O
,	O
3-Nakamichi	O
,	O
1-chome	O
,	O
Higashinari-ku	O
,	O
Osaka	O
,	O
537	O
-	O
8511	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
is	O
likely	O
to	O
spread	O
into	O
the	O
nerve	O
plexuses	O
around	O
the	O
superior	O
mesenteric	O
artery	O
(	O
SMA	O
)	O
at	O
a	O
microscopic	O
level	O
.	O
Since	O
there	O
has	O
been	O
no	O
detailed	O
report	O
on	O
how	O
minute	O
cancer	O
invasion	O
is	O
distributed	O
among	O
the	O
peri	O
-	O
SMA	O
plexuses	O
or	O
which	O
cases	O
are	O
more	O
vulnerable	O
to	O
such	O
an	O
event	O
,	O
it	O
has	O
long	O
been	O
controversial	O
how	O
to	O
treat	O
this	O
area	O
when	O
resecting	O
the	O
pancreatic	B-malignancy-type
head	I-malignancy-type
cancer	I-malignancy-type
.	O
HYPOTHESIS	O
:	O
The	O
K-ras	O
mutation	O
assay	O
is	O
more	O
sensitive	O
than	O
the	O
conventional	O
histologic	O
diagnosis	O
in	O
detecting	O
minute	O
cancer	O
invasion	O
around	O
the	O
SMA	O
.	O
DESIGN	O
:	O
Prospective	O
consecutive	O
series	O
.	O
SETTING	O
:	O
Cancer	O
center	O
hospital	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
entire	O
circle	O
of	O
the	O
peri	O
-	O
SMA	O
tissues	O
was	O
obtained	O
from	O
24	O
patients	O
who	O
had	O
received	O
an	O
extended	O
pancreatectomy	O
for	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
head	I-malignancy-type
.	O
They	O
were	O
divided	O
into	O
right	O
and	O
left	O
hemicircular	O
samples	O
(	O
48	O
samples	O
)	O
,	O
and	O
each	O
sample	O
was	O
used	O
for	O
both	O
histologic	O
and	O
genetic	O
diagnoses	O
.	O
Since	O
all	O
patients	O
'	O
primary	O
tumors	O
were	O
positive	O
for	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
,	O
the	O
presence	O
or	O
absence	O
of	O
the	O
mutation	O
was	O
determined	O
for	O
the	O
peri	O
-	O
SMA	O
plexuses	O
using	O
the	O
mutant	O
allele	O
specific	O
amplification	O
method	O
.	O
RESULTS	O
:	O
Compared	O
with	O
results	O
of	O
the	O
histologic	O
examination	O
,	O
the	O
K-ras	O
mutation	O
assay	O
was	O
more	O
sensitive	O
in	O
detecting	O
positive	O
findings	O
in	O
the	O
peri	O
-	O
SMA	O
plexuses	O
(	O
12	O
samples	O
from	O
9	O
patients	O
)	O
.	O
According	O
to	O
the	O
distribution	O
of	O
the	O
K-ras	O
mutation	O
into	O
the	O
right	O
-	O
and	O
left	O
-	O
half	O
samples	O
,	O
24	O
patients	O
were	O
classified	O
into	O
the	O
following	O
4	O
patterns	O
(	O
right	O
/	O
left	O
)	O
:	O
negative	O
/	O
negative	O
in	O
15	O
patients	O
;	O
positive	O
/	O
negative	O
in	O
6	O
patients	O
;	O
positive	O
/	O
positive	O
in	O
3	O
patients	O
;	O
and	O
negative	O
/	O
positive	O
in	O
0	O
patients	O
.	O
In	O
3	O
patients	O
who	O
showed	O
a	O
positive	O
/	O
positive	O
pattern	O
in	O
the	O
genetic	O
diagnosis	O
,	O
their	O
right	O
-	O
half	O
samples	O
included	O
more	O
cancer	O
cells	O
that	O
were	O
detectable	O
by	O
routine	O
microscopy	O
.	O
There	O
was	O
no	O
relation	O
between	O
K-ras	O
mutation	O
and	O
lymphatic	O
invasion	O
,	O
while	O
K-ras	O
mutation	O
was	O
particularly	O
related	O
with	O
the	O
invasion	O
of	O
portal	O
vein	O
(	O
P	O
=	O
.04	O
)	O
and	O
posterior	O
peripancreatic	O
tissues	O
(	O
P	O
=	O
.002	O
)	O
.	O
All	O
3	O
patients	O
with	O
K-ras	O
mutation	O
in	O
bilateral	O
plexuses	O
were	O
classified	O
by	O
the	O
TNM	O
staging	O
system	O
as	O
T4	O
using	O
Union	O
Internationale	O
Contre	O
le	O
Cancer	O
classification	O
.	O
CONCLUSIONS	O
:	O
The	O
K-ras	O
mutation	O
(	O
at	O
codon	O
12	O
)	O
assay	O
indicated	O
a	O
simple	O
and	O
regular	O
pattern	O
of	O
cancer	O
extension	O
into	O
the	O
nerve	O
plexuses	O
around	O
the	O
SMA	O
from	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
head	I-malignancy-type
:	O
(1)	O
The	O
left	O
half	O
of	O
the	O
plexus	O
was	O
unlikely	O
to	O
be	O
involved	O
by	O
cancer	O
in	O
cases	O
in	O
which	O
the	O
right	O
half	O
was	O
intact	O
.	O
(2)	O
Cancer	O
extension	O
into	O
the	O
peri	O
-	O
SMA	O
plexuses	O
occurred	O
after	O
the	O
posterior	O
confine	O
of	O
the	O
pancreas	O
had	O
been	O
involved	O
by	O
direct	O
invasion	O
from	O
the	O
primary	O
pancreatic	B-malignancy-type
tumor	I-malignancy-type
.	O
(3)	O
The	O
left	O
half	O
was	O
not	O
involved	O
in	O
cancerous	B-malignancy-type
tumors	I-malignancy-type
classified	I-malignancy-type
as	I-malignancy-type
T1	I-malignancy-type
to	I-malignancy-type
T3	I-malignancy-type
but	O
was	O
occasionally	O
involved	O
in	O
those	O
classified	O
as	O
T4	B-malignancy-type
tumors	I-malignancy-type
.	O
These	O
data	O
seem	O
to	O
provide	O
a	O
useful	O
indicator	O
of	O
some	O
additional	O
treatments	O
(	O
resection	O
,	O
irradiation	O
,	O
etc	O
)	O
for	O
the	O
peri	O
-	O
SMA	O
region	O
when	O
a	O
locally	O
advanced	O
pancreatic	B-malignancy-type
head	I-malignancy-type
cancer	I-malignancy-type
is	O
treated	O
with	O
a	O
curative	O
intent	O
.	O
PMID	O
:	O
11115351	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2000	O
Nov	O
16	O
;	O
19	O
(	O
48	O
)	O
:	O
5543	O
-	O
6	O
Somatic	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
are	O
uncommon	O
in	O
carcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterine	I-malignancy-type
cervix	I-malignancy-type
.	O
Wu	O
R	O
,	O
Connolly	O
D	O
,	O
Ngelangel	O
C	O
,	O
Bosch	O
FX	O
,	O
Munoz	O
N	O
,	O
Cho	O
KR	O
.	O
Department	O
of	O
Pathology	O
,	O
The	O
University	O
of	O
Michigan	O
Medical	O
School	O
,	O
Ann	O
Arbor	O
48109	O
,	O
USA	O
.	O
Germline	O
mutations	O
of	O
the	O
gene	O
encoding	O
human	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
have	O
been	O
shown	O
to	O
be	O
responsible	O
for	O
several	O
related	O
autosomal	O
dominant	O
forms	O
of	O
syndromic	O
craniosynostosis	O
and	O
short	O
limb	O
dwarfism	O
.	O
Somatic	O
activating	O
mutations	O
of	O
FGFR3	O
were	O
recently	O
reported	O
to	O
occur	O
in	O
three	O
of	O
12	O
(	O
25	O
%	O
)	O
uterine	B-malignancy-type
cervical	I-malignancy-type
carcinomas	I-malignancy-type
and	O
nine	O
of	O
26	O
(	O
35	O
%	O
)	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
that	O
constitutive	O
activation	O
of	O
FGFR3	O
may	O
be	O
an	O
important	O
mechanism	O
underlying	O
the	O
development	O
and/or	O
progression	O
of	O
these	O
common	O
epithelial	B-malignancy-type
malignancies	I-malignancy-type
.	O
In	O
order	O
to	O
investigate	O
further	O
a	O
possible	O
role	O
for	O
FGFR3	O
mutations	O
in	O
cervical	O
carcinogenesis	O
,	O
we	O
performed	O
sequence	O
-	O
based	O
mutational	O
analysis	O
of	O
FGFR3	O
in	O
51	O
primary	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
and	O
seven	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
-	O
derived	O
cell	O
lines	O
.	O
The	O
regions	O
analysed	O
(	O
exons	O
7	O
,	O
10	O
,	O
13	O
,	O
15	O
,	O
and	O
19	O
)	O
encompassed	O
all	O
previously	O
described	O
FGFR3	O
mutations	O
.	O
A	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
249	O
,	O
predicting	O
a	O
serine	O
to	O
cysteine	O
amino	O
acid	O
substitution	O
(	O
S	O
249	O
C	O
)	O
in	O
the	O
FGFR3	O
extracellular	O
domain	O
,	O
was	O
identified	O
in	O
one	O
primary	O
tumor	O
.	O
Only	O
wild	O
type	O
FGFR3	O
alleles	O
were	O
identified	O
in	O
the	O
remaining	O
tumors	O
and	O
cell	O
lines	O
.	O
The	O
S	O
249	O
C	O
mutation	O
is	O
the	O
only	O
FGFR3	O
mutation	O
described	O
to	O
date	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
.	O
These	O
findings	O
suggest	O
that	O
while	O
activating	O
mutations	O
of	O
FGFR3	O
occur	O
in	O
cervical	B-malignancy-type
cancer	I-malignancy-type
,	O
they	O
may	O
not	O
be	O
as	O
common	O
as	O
initially	O
reported	O
.	O
PMID	O
:	O
11114733	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
2001	O
Jan;30	O
(	O
1	O
)	O
:	O
32-7	O
Frequent	O
activation	O
of	O
the	O
beta-catenin	O
-	O
Tcf	O
signaling	O
pathway	O
in	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
with	O
microsatellite	O
instability	O
.	O
Shitoh	O
K,	O
Furukawa	O
T	O
,	O
Kojima	O
M,	O
Konishi	O
F	O
,	O
Miyaki	O
M,	O
Tsukamoto	O
T	O
,	O
Nagai	O
H.	O
Department	O
of	O
Surgery	O
,	O
Jichi	O
Medical	O
School	O
,	O
Tochigi	O
,	O
Japan	O
.	O
kshitoh@jichi.ac.jp	O
It	O
has	O
been	O
reported	O
that	O
wild	O
-	O
type	O
APC	O
protein	O
forms	O
a	O
complex	O
with	O
beta-Catenin	O
and	O
GSK3beta	O
,	O
inducing	O
degradation	O
of	O
beta-Catenin	O
in	O
normal	O
cells	O
.	O
Both	O
beta-Catenin	O
and	O
APC	O
gene	O
mutations	O
have	O
recently	O
been	O
shown	O
to	O
activate	O
the	O
same	O
signaling	O
pathway	O
.	O
Frequent	O
mutations	O
of	O
beta-Catenin	O
in	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
have	O
also	O
been	O
reported	O
.	O
It	O
was	O
,	O
however	O
,	O
controversial	O
whether	O
the	O
mutation	O
of	O
the	O
beta-Catenin	O
gene	O
was	O
frequent	O
in	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
with	O
high	O
-	O
frequency	O
microsatellite	O
instability	O
(	O
MSI-H	O
)	O
.	O
We	O
analyzed	O
the	O
mutations	O
of	O
the	O
APC	O
and	O
beta-Catenin	O
genes	O
in	O
56	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
stratified	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
APC	O
mutations	O
were	O
identified	O
in	O
11	O
of	O
22	O
(	O
50	O
%	O
)	O
cases	O
of	O
MSI-H	O
and	O
14	O
of	O
34	O
(	O
41	O
%	O
)	O
cases	O
of	O
microsatellite	O
-	O
stable	O
(	O
MSS	O
)	O
/	O
low	O
-	O
frequency	O
microsatellite	O
instability	O
(	O
MSI-L	O
)	O
.	O
In	O
contrast	O
,	O
the	O
frequency	O
of	O
beta-Catenin	O
mutations	O
was	O
significantly	O
higher	O
in	O
MSI-H	O
(	O
6	O
/	O
22	O
;	O
27	O
%	O
)	O
than	O
in	O
MSS	O
/	O
MSI-L	O
(	O
1	O
/	O
34	O
;	O
3	O
%	O
)	O
(	O
P	O
=	O
0.01	O
)	O
.	O
beta-Catenin	O
mutations	O
were	O
not	O
detected	O
in	O
carcinomas	B-malignancy-type
with	O
APC	O
mutation	O
.	O
APC	O
mutation	O
occurred	O
irrespective	O
of	O
MSI	O
status	O
.	O
beta-Catenin	O
mutation	O
,	O
however	O
,	O
occurred	O
frequently	O
in	O
MSI-H	O
carcinomas	B-malignancy-type
.	O
Our	O
data	O
suggest	O
that	O
activation	O
of	O
the	O
beta-Catenin	O
-	O
Tcf	O
signaling	O
pathway	O
,	O
through	O
either	O
beta-Catenin	O
or	O
APC	O
mutation	O
,	O
frequently	O
contributes	O
to	O
MSI-H	O
nonfamilial	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
(	O
17	O
/	O
22	O
;	O
77	O
%	O
)	O
.	O
PMID	O
:	O
11107173	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
Nov	O
15	O
;60	O
(22	O
)	O
:	O
6311-3	O
Somatic	O
mutations	O
of	O
LKB1	O
and	O
beta-catenin	O
genes	O
in	O
gastrointestinal	B-malignancy-type
polyps	I-malignancy-type
from	O
patients	O
with	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
syndrome	I-malignancy-type
.	O
Miyaki	O
M,	O
Iijima	O
T	O
,	O
Hosono	O
K,	O
Ishii	O
R	O
,	O
Yasuno	O
M,	O
Mori	O
T	O
,	O
Toi	O
M,	O
Hishima	O
T	O
,	O
Shitara	O
N	O
,	O
Tamura	O
K,	O
Utsunomiya	O
J,	O
Kobayashi	O
N	O
,	O
Kuroki	O
T	O
,	O
Iwama	O
T.	O
Hereditary	O
Tumor	O
Research	O
Project	O
,	O
Tokyo	O
Metropolitan	O
Komagome	O
Hospital	O
,	O
Japan	O
.	O
mmiyaki@opal	O
.famille	O
.ne	O
.jp	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
syndrome	I-malignancy-type
(	O
PJS	B-malignancy-type
)	O
is	O
characterized	O
by	O
multiple	B-malignancy-type
gastrointestinal	I-malignancy-type
hamartomatous	I-malignancy-type
polyps	I-malignancy-type
,	O
mucocutaneous	O
melanin	O
deposition	O
,	O
and	O
increased	O
risk	O
of	O
cancer	B-malignancy-type
,	O
mainly	O
in	B-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
.	O
We	O
examined	O
mutations	O
of	O
the	O
LKB1	O
,	O
beta-catenin	O
,	O
APC	O
,	O
K-ras	O
,	O
and	O
p53	O
genes	O
in	O
27	O
gastrointestinal	B-malignancy-type
hamartomatous	I-malignancy-type
polyps	I-malignancy-type
from	O
10	O
patients	O
in	O
nine	O
PJS	B-malignancy-type
families	O
.	O
Of	O
these	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
,	O
one	O
intestinal	B-malignancy-type
polyp	I-malignancy-type
had	O
an	O
adenomatous	B-malignancy-type
lesion	I-malignancy-type
,	O
and	O
one	O
gastric	B-malignancy-type
polyp	I-malignancy-type
contained	O
adenomatous	B-malignancy-type
and	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
.	O
Germ	O
-	O
line	O
mutations	O
of	O
the	O
LKB1	O
gene	O
were	O
detected	O
in	O
six	O
PJS	B-malignancy-type
families	O
.	O
Somatic	O
mutations	O
of	O
the	O
LKB1	O
gene	O
were	O
found	O
in	O
5	O
polyps	B-malignancy-type
,	O
whereas	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
LKB1	O
locus	O
at	O
19p	O
was	O
seen	O
in	O
14	O
other	O
polyps	B-malignancy-type
.	O
In	O
adenomatous	B-malignancy-type
lesions	I-malignancy-type
microdissected	O
from	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
,	O
both	O
beta-catenin	O
mutation	O
and	O
19p	O
LOH	O
were	O
detected	O
.	O
Furthermore	O
,	O
a	O
carcinomatous	B-malignancy-type
lesion	I-malignancy-type
in	O
a	O
gastric	B-malignancy-type
hamartomatous	I-malignancy-type
polyp	I-malignancy-type
was	O
found	O
to	O
contain	O
a	O
mutation	O
of	O
the	O
p53	O
gene	O
and	O
LOH	O
at	O
the	O
p53	O
locus	O
in	O
addition	O
to	O
LOH	O
at	O
the	O
LKB1	O
locus	O
and	O
a	O
beta-catenin	O
mutation	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
a	O
few	O
polyps	B-malignancy-type
,	O
whereas	O
no	O
APC	O
mutation	O
or	O
5q	O
LOH	O
was	O
detected	O
in	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
.	O
These	O
results	O
suggest	O
that	O
gastrointestinal	B-malignancy-type
hamartomatous	I-malignancy-type
polyps	I-malignancy-type
in	O
PJS	B-malignancy-type
patients	O
develop	O
through	O
inactivation	O
of	O
the	O
LKB1	O
gene	O
by	O
germ	O
-	O
line	O
mutation	O
plus	O
somatic	O
mutation	O
or	O
LOH	O
of	O
the	O
unaffected	O
LKB1	O
allele	O
,	O
and	O
that	O
additional	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
and	O
p53	O
gene	O
convert	O
hamartomatous	B-malignancy-type
polyps	I-malignancy-type
into	O
adenomatous	B-malignancy-type
and	O
carcinomatous	B-malignancy-type
lesions	I-malignancy-type
.	O
PMID	O
:	O
11103790	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
Nov	O
15	O
;60	O
(22	O
)	O
:	O
6288	O
-	O
92	O
Frequent	O
association	O
of	O
beta-catenin	O
and	O
WT1	O
mutations	O
in	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
Maiti	O
S	O
,	O
Alam	O
R	O
,	O
Amos	O
CI	O
,	O
Huff	O
V	O
.	O
Department	O
of	O
Biochemistry	O
and	O
Molecular	O
Biology	O
,	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
,	O
Texas	O
77030	O
,	O
USA	O
.	O
The	O
etiology	O
of	O
Wilms	B-malignancy-type
tumor	I-malignancy-type
,	O
an	O
embryonic	O
kidney	B-malignancy-type
tumor	I-malignancy-type
,	O
is	O
genetically	O
heterogeneous	O
.	O
One	O
Wilms	B-malignancy-type
tumor	I-malignancy-type
gene	O
,	O
WT1	O
,	O
which	O
encodes	O
a	O
zinc	O
finger	O
transcription	O
factor	O
,	O
is	O
mutated	O
in	O
10	O
-	O
20	O
%	O
of	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
,	O
but	O
it	O
is	O
still	O
not	O
clear	O
what	O
critical	O
cellular	O
pathway(s)	O
is	O
affected	O
by	O
these	O
mutations	O
.	O
Recently	O
beta-catenin	O
mutations	O
have	O
been	O
reported	O
in	O
6	O
of	O
40	O
(	O
15	O
%	O
)	O
of	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
Beta-catenin	O
is	O
the	O
central	O
effector	O
in	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
,	O
and	O
deregulation	O
of	O
beta-catenin	O
signaling	O
is	O
critical	O
in	O
the	O
development	O
of	O
a	O
number	O
of	O
malignancies	O
.	O
The	O
observation	O
of	O
beta-catenin	O
mutations	O
in	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
suggests	O
that	O
abrogation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
also	O
plays	O
a	O
role	O
in	O
some	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
To	O
assess	O
the	O
relationship	O
of	O
WT1	O
mutations	O
vis-a-vis	O
beta-catenin	O
mutations	O
in	O
Wilms	B-malignancy-type
tumor	I-malignancy-type
,	O
we	O
analyzed	O
153	O
primary	O
tumors	O
,	O
and	O
21	O
of	O
153	O
(	O
14	O
%	O
)	O
carried	O
beta-catenin	O
mutations	O
.	O
Surprisingly	O
,	O
we	O
observed	O
a	O
highly	O
significant	O
(	O
P	O
=	O
3.6	O
x	O
10(-13)	O
)	O
association	O
between	O
WT1	O
and	O
beta-catenin	O
mutations	O
;	O
19	O
of	O
20	O
beta-catenin	O
-	O
mutant	O
tumors	O
had	O
also	O
sustained	O
WT1	O
mutations	O
.	O
By	O
analogy	O
to	O
the	O
patterns	O
of	O
concordant	O
and	O
discordant	O
gene	O
mutations	O
observed	O
in	O
other	O
tumors	O
,	O
our	O
data	O
suggest	O
that	O
mutation	O
of	O
WT1	O
and	O
beta-catenin	O
affects	O
two	O
different	O
cellular	O
pathways	O
,	O
both	O
of	O
which	O
are	O
critically	O
altered	O
in	O
at	O
least	O
a	O
subset	O
of	O
Wilms	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
11103785	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2000	O
Nov	O
20;89	O
(	O
6	O
)	O
:469	O
-	O
74	O
K-ras	O
oncogene	O
subtype	O
mutations	O
are	O
associated	O
with	O
survival	O
but	O
not	O
expression	O
of	O
p53	O
,	O
p16	O
(	O
INK4A	O
)	O
,	O
p21	O
(	O
WAF-1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
in	O
resected	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Kawesha	O
A	O
,	O
Ghaneh	O
P,	O
Andren-Sandberg	O
A	O
,	O
Ograed	O
D	O
,	O
Skar	O
R	O
,	O
Dawiskiba	O
S	O
,	O
Evans	O
JD	O
,	O
Campbell	O
F	O
,	O
Lemoine	O
N	O
,	O
Neoptolemos	O
JP	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Liverpool	O
,	O
Liverpool	O
,	O
UK.	O
Previous	O
studies	O
of	O
molecular	O
prognostic	O
markers	O
following	O
resection	O
for	O
exocrine	B-malignancy-type
pancreatic	I-malignancy-type
cancer	I-malignancy-type
have	O
produced	O
conflicting	O
results	O
.	O
Our	O
aim	O
was	O
to	O
undertake	O
a	O
comprehensive	O
analysis	O
of	O
potentially	O
useful	O
molecular	O
markers	O
in	O
a	O
large	O
,	O
multicentre	O
patient	O
population	O
and	O
to	O
compare	O
these	O
markers	O
with	O
standard	O
pathological	O
prognostic	O
variables	O
.	O
Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
specimens	O
of	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
analysed	O
from	O
157	O
patients	O
[	O
100	O
men	O
and	O
57	O
women	O
with	O
a	O
median	O
(	O
range	O
)	O
age	O
of	O
60	O
(	O
33	O
-	O
77	O
)	O
years	O
]	O
who	O
had	O
undergone	O
pancreatectomy	O
.	O
Immunohistochemistry	O
was	O
used	O
to	O
detect	O
expression	O
of	O
p16	O
(	O
INK4	O
)	O
,	O
p53	O
,	O
p21	O
(	O
WAF1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
.	O
Mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
oncogene	O
were	O
detected	O
by	O
SSCP	O
and	O
sequencing	O
following	O
DNA	O
extraction	O
and	O
amplification	O
by	O
PCR	O
.	O
The	O
median	O
(	O
range	O
)	O
survival	O
post	O
-	O
resection	O
was	O
12.5	O
(	O
3	O
-	O
83	O
)	O
months	O
.	O
Abnormalities	O
of	O
p16	O
(	O
INK4	O
)	O
,	O
p53	O
,	O
p21	O
(	O
WAF1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
expression	O
were	O
found	O
in	O
87	O
%	O
,	O
41	O
%	O
,	O
75	O
%	O
,	O
72	O
%	O
,	O
33	O
%	O
and	O
57	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
There	O
was	O
no	O
significant	O
correlation	O
between	O
expression	O
of	O
any	O
of	O
these	O
markers	O
and	O
patient	O
survival	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
73	O
(	O
75	O
%	O
)	O
of	O
97	O
cases	O
with	O
amplifiable	O
DNA	O
.	O
The	O
presence	O
of	O
K-ras	O
mutation	O
alone	O
did	O
not	O
correlate	O
with	O
survival	O
,	O
but	O
there	O
were	O
significant	O
differences	O
in	O
survival	O
according	O
to	O
the	O
type	O
of	O
K-ras	O
mutation	O
(	O
p	O
=	O
0.0007	O
)	O
.	O
Reduced	O
survival	O
was	O
found	O
in	O
patients	O
with	O
GaT	O
,	O
cGT	O
and	O
GcT	O
K-ras	O
mutations	O
compared	O
to	O
GtT	O
,	O
aGT	O
and	O
GaC	O
mutations	O
.	O
In	O
conclusion	O
,	O
survival	O
was	O
associated	O
with	O
type	O
of	O
K-ras	O
mutation	O
but	O
not	O
expression	O
of	O
p16	O
(	O
INK4	O
)	O
,	O
p53	O
,	O
p21	O
(	O
WAF1	O
)	O
,	O
cyclin	O
D1	O
,	O
erbB-2	O
and	O
erbB-3	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
Publication	O
Types	O
:	O
Multicenter	O
Study	O
PMID	O
:	O
11102889	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
2000	O
;35	O
(	O
10	O
)	O
:779	O
-83	O
Specific	O
mutation	O
in	O
exon	O
11	O
of	O
c-kit	O
proto	O
-	O
oncogene	O
in	O
a	O
malignant	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
.	O
Yamaguchi	O
M,	O
Miyaki	O
M,	O
Iijima	O
T	O
,	O
Matsumoto	O
T	O
,	O
Kuzume	O
M,	O
Matsumiya	O
A	O
,	O
Endo	O
Y	O
,	O
Sanada	O
Y	O
,	O
Kumada	O
K.	O
Department	O
of	O
Surgery	O
,	O
Showa	O
University	O
Fujigaoka	O
Hospital	O
,	O
Yokohama	O
,	O
Japan	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
in	B-malignancy-type
the	I-malignancy-type
distal	I-malignancy-type
third	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
was	O
detected	O
in	O
a	O
57	O
-	O
year	O
-	O
old	O
man	O
who	O
underwent	O
an	O
abdominoperineal	O
resection	O
of	O
the	O
rectum	O
.	O
Because	O
the	O
tumor	O
expressed	O
CD34	O
and	O
c-kit	O
gene	O
product	O
,	O
but	O
did	O
not	O
express	O
smooth	O
muscle	O
actin	O
or	O
S-100	O
protein	O
,	O
it	O
was	O
diagnosed	O
as	O
an	O
uncommitted	O
type	O
of	O
GIST	B-malignancy-type
.	O
Moreover	O
,	O
a	O
specific	O
mutation	O
in	O
the	O
sequence	O
coding	O
the	O
juxtamembrane	O
domain	O
in	O
exon	O
11	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
was	O
revealed	O
by	O
a	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
.	O
One	O
year	O
after	O
resection	O
,	O
the	O
patient	O
developed	O
multiple	O
liver	O
metastases	O
.	O
It	O
is	O
suggested	O
that	O
a	O
specific	O
mutation	O
in	O
exon	O
11	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
may	O
have	O
played	O
an	O
essential	O
role	O
in	O
the	O
development	O
of	O
the	O
liver	O
metastases	O
.	O
PMID	O
:	O
11063223	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2000	O
Oct;13(	O
10	O
)	O
:	O
1055-9	O
Mutations	O
in	O
beta-catenin	O
and	O
APC	O
genes	O
are	O
uncommon	O
in	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Choi	O
YW	O
,	O
Heath	O
EI	O
,	O
Heitmiller	O
R	O
,	O
Forastiere	O
AA	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
-2196	O
,	O
USA	O
.	O
Beta-catenin	O
plays	O
important	O
roles	O
in	O
both	O
intercellular	O
adhesion	O
and	O
signal	O
transduction	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
can	O
alter	O
the	O
degradation	O
of	O
beta-catenin	O
and	O
cause	O
aberrant	O
accumulation	O
of	O
beta-catenin	O
result	O
in	O
increased	O
transcription	O
of	O
target	O
genes	O
.	O
The	O
dysregulated	O
APC	O
/	O
beta-catenin	O
pathway	O
has	O
been	O
recently	O
discovered	O
as	O
an	O
important	O
mechanism	O
of	O
tumorigenesis	O
in	O
various	O
cancers	O
,	O
but	O
its	O
role	O
in	O
esophageal	B-malignancy-type
adenocarcinomas	I-malignancy-type
is	O
not	O
clear	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
beta-catenin	O
gene	O
mutation	O
,	O
allelic	O
loss	O
of	O
chromosome	O
5q	O
,	O
and	O
APC	O
gene	O
mutation	O
in	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Two	O
(	O
2	O
%	O
)	O
somatic	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
encompassing	O
the	O
region	O
for	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
phosphorylation	O
,	O
were	O
detected	O
from	O
109	O
adenocarcinomas	B-malignancy-type
.	O
Chromosomal	O
allelic	O
loss	O
on	O
5q	O
was	O
frequent	O
in	O
45.3	O
%	O
(	O
44	O
/	O
97	O
)	O
of	O
tumors	O
.	O
Only	O
one	O
missense	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
was	O
detected	O
from	O
38	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinomas	I-malignancy-type
with	O
the	O
5q	O
allelic	O
loss	O
.	O
Our	O
results	O
based	O
on	O
partial	O
screening	O
mutational	O
analyses	O
indicate	O
that	O
mutations	O
of	O
APC	O
/	O
beta-catenin	O
pathway	O
,	O
unlike	O
in	O
colorectal	O
carcinoma	O
,	O
involve	O
only	O
a	O
small	O
subset	O
of	O
esophageal	B-malignancy-type
and	O
esophagogastric	B-malignancy-type
junction	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
11048797	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
2000	O
Nov;47	O
(	O
5	O
)	O
:721-7	O
Frequency	O
of	O
p16	O
(	O
INK4A	O
)	O
alterations	O
and	O
K-ras	O
mutations	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
.	O
Tannapfel	O
A	O
,	O
Benicke	O
M,	O
Katalinic	O
A	O
,	O
Uhlmann	O
D	O
,	O
Kockerling	O
F	O
,	O
Hauss	O
J,	O
Wittekind	O
C.	O
Institute	O
of	O
Pathology	O
,	O
University	O
of	O
Leipzig	O
,	O
Liebigstr	O
26	O
,	O
04103	O
Leipzig	O
,	O
Germany	O
.	O
tana@medizin	O
.uni-	O
leipzig.de	O
BACKGROUND	O
:	O
Inactivation	O
of	O
the	O
tumour	O
suppressor	O
gene	O
p16	O
(	O
CDKN2	O
/	O
MTS-1	O
/	O
INK4A	O
)	O
and	O
K-ras	O
mutations	O
are	O
among	O
the	O
most	O
frequent	O
genetic	O
alterations	O
in	O
human	O
malignancies	O
.	O
AIMS	O
:	O
To	O
investigate	O
the	O
tumour	O
suppressor	O
gene	O
p16	O
and	O
its	O
possible	O
association	O
with	O
K-ras	O
mutations	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
.	O
METHODS	O
:	O
The	O
status	O
of	O
p16	O
was	O
evaluated	O
in	O
41	O
cholangiocarcinomas	B-malignancy-type
by	O
methylation	O
specific	O
polymerase	O
chain	O
reaction	O
,	O
microsatellite	O
analysis	O
,	O
DNA	O
sequencing	O
,	O
and	O
immunohistochemical	O
staining	O
.	O
K-ras	O
mutations	O
were	O
determined	O
by	O
direct	O
DNA	O
sequencing	O
analyses	O
after	O
microdissection	O
.	O
The	O
results	O
obtained	O
were	O
correlated	O
with	O
histopathological	O
variables	O
and	O
patient	O
survival	O
.	O
RESULTS	O
:	O
Hypermethylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
the	O
p16	O
gene	O
was	O
found	O
in	O
34	O
of	O
41	O
(	O
83	O
%	O
)	O
carcinomas	B-malignancy-type
.	O
Homozygous	O
deletion	O
at	O
the	O
p16	O
region	O
was	O
present	O
in	O
two	O
(	O
5	O
%	O
)	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
eight	O
cases	O
(	O
20	O
%	O
)	O
.	O
We	O
failed	O
to	O
detect	O
p16	O
gene	O
missense	O
mutations	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
22	O
of	O
41	O
(	O
54	O
%	O
)	O
cholangiocarcinomas	B-malignancy-type
and	O
in	O
two	O
cases	O
of	O
tumour	O
surrounding	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
.	O
All	O
22	O
cancers	O
with	O
K-ras	O
mutations	O
also	O
exhibited	O
methylated	O
p16	O
.	O
We	O
failed	O
to	O
observe	O
a	O
correlation	O
between	O
K-ras	O
or	O
p16	O
status	O
and	O
histopathological	O
factors	O
or	O
prognosis	O
of	O
patients	O
.	O
CONCLUSION	O
:	O
These	O
data	O
suggest	O
that	O
inactivation	O
of	O
the	O
p16	O
gene	O
is	O
a	O
frequent	O
event	O
in	O
cholangiocarcinoma	B-malignancy-type
.	O
The	O
most	O
common	O
somatic	O
alteration	O
is	O
promotor	O
methylation	O
of	O
the	O
p16	O
gene	O
which	O
is	O
closely	O
associated	O
with	O
K-ras	O
mutations	O
.	O
We	O
failed	O
to	O
establish	O
p16	O
or	O
K-ras	O
status	O
as	O
independent	O
prognostic	O
factors	O
in	O
these	O
tumours	O
.	O
PMID	O
:	O
11034592	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2000	O
Oct;2	O
4(	O
10	O
)	O
:	O
1339	O
-52	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
genetic	O
study	O
of	O
44	O
cases	O
.	O
Miettinen	O
M,	O
Sarlomo-Rikala	O
M,	O
Sobin	O
LH	O
,	O
Lasota	O
J.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-6000	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
,	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
largely	O
specific	O
for	O
the	O
gastrointestinal	O
tract	O
,	O
have	O
been	O
well	O
defined	O
in	O
the	O
stomach	O
and	O
small	O
intestine	O
,	O
but	O
have	O
not	O
been	O
extensively	O
documented	O
or	O
contrasted	O
with	O
true	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
clinicopathologic	O
features	O
of	O
GISTs	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
,	O
excluding	O
the	O
rectum	O
,	O
and	O
to	O
compare	O
them	O
with	O
leiomyosarcomas	B-malignancy-type
(	O
LMSs	B-malignancy-type
)	O
of	O
the	O
same	O
location	O
.	O
A	O
total	O
of	O
37	O
colonic	B-malignancy-type
GISTs	I-malignancy-type
and	O
seven	O
LMSs	B-malignancy-type
from	O
the	O
files	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
and	O
the	O
Haartman	O
Institute	O
of	O
the	O
University	O
of	O
Helsinki	O
were	O
analyzed	O
.	O
The	O
GISTs	B-malignancy-type
occurred	O
predominantly	O
in	O
adults	O
older	O
than	O
50	O
years	O
of	O
age	O
(	O
median	O
,	O
67	O
yrs	O
)	O
,	O
and	O
most	O
were	O
histologically	O
malignant	O
;	O
four	O
small	O
benign	O
tumors	O
(	O
<	O
or	O
=	O
1	O
cm	O
)	O
were	O
incidentally	O
detected	O
,	O
and	O
10	O
others	O
had	O
minimal	O
mitotic	O
activity	O
(	O
five	O
or	O
fewer	O
mitoses	O
per	O
50	O
high	O
-	O
power	O
fields	O
)	O
.	O
The	O
colonic	B-malignancy-type
GISTs	I-malignancy-type
were	O
typically	O
transmural	B-malignancy-type
tumors	I-malignancy-type
with	O
frequent	O
intraluminal	O
and	O
outward	O
bulging	O
components	O
.	O
Histologically	O
,	O
they	O
usually	O
showed	O
a	O
spindle	O
cell	O
pattern	O
(	O
92	O
%	O
)	O
,	O
whereas	O
8	O
%	O
were	O
epithelioid	O
.	O
Most	O
tumors	O
(	O
19	O
of	O
25	O
)	O
were	O
positive	O
for	O
CD117	O
(	O
KIT	O
)	O
and	O
for	O
CD34	O
(	O
16	O
of	O
27	O
)	O
;	O
six	O
tumors	O
coexpressed	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
and	O
CD117	O
;	O
none	O
showed	O
desmin	O
or	O
S-100	O
protein	O
.	O
C-kit	O
mutations	O
in	O
exon	O
11	O
were	O
seen	O
in	O
5	O
(	O
36	O
%	O
)	O
of	O
14	O
colonic	B-malignancy-type
GISTs	I-malignancy-type
.	O
None	O
of	O
the	O
patients	O
with	O
incidental	O
small	O
tumors	O
had	O
a	O
recurrence	O
,	O
whereas	O
2	O
of	O
10	O
patients	O
with	O
tumors	O
larger	O
than	O
1	O
cm	O
but	O
minimal	O
mitotic	O
activity	O
died	O
of	O
the	O
disease	O
with	O
liver	O
metastasis	O
.	O
Nearly	O
all	O
patients	O
whose	O
tumor	O
was	O
larger	O
than	O
1	O
cm	O
and	O
showed	O
more	O
than	O
five	O
mitoses	O
per	O
50	O
high	O
-	O
power	O
fields	O
died	O
of	O
disease	O
;	O
half	O
had	O
evidence	O
of	O
metastasis	O
.	O
LMSs	B-malignancy-type
were	O
typically	O
intraluminally	O
bulging	O
,	O
polypoid	O
masses	O
that	O
showed	O
a	O
histologic	O
likeness	O
to	O
differentiated	O
smooth	O
muscle	O
cells	O
.	O
They	O
occurred	O
in	O
five	O
men	O
and	O
two	O
women	O
with	O
a	O
median	O
age	O
of	O
61	O
years	O
.	O
Most	O
LMSs	B-malignancy-type
were	O
high	O
-	O
grade	O
histologically	O
and	O
showed	O
smooth	O
muscle	O
actin	O
,	O
desmin	O
,	O
or	O
both	O
.	O
All	O
were	O
negative	O
for	O
CD34	O
and	O
CD117	O
and	O
lacked	O
c-kit	O
mutations	O
.	O
Five	O
of	O
the	O
seven	O
patients	O
died	O
of	O
disease	O
,	O
and	O
two	O
had	O
a	O
long	O
-	O
term	O
survival	O
,	O
despite	O
high	O
mitotic	O
activity	O
.	O
These	O
results	O
show	O
that	O
KIT	O
-	O
positive	O
GISTs	B-malignancy-type
are	O
more	O
common	O
than	O
LMSs	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
,	O
and	O
these	O
tumor	O
groups	O
have	O
clinicopathologic	O
differences	O
that	O
warrant	O
their	O
separation	O
.	O
PMID	O
:	O
11023095	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2000	O
Jul	O
20;89	O
(	O
4	O
)	O
:	O
33	O
7-44	O
Detection	O
of	O
tumor	O
cells	O
in	O
blood	O
using	O
CD45	O
magnetic	O
cell	O
separation	O
followed	O
by	O
nested	O
mutant	O
allele	O
-	O
specific	O
amplification	O
of	O
p53	O
and	O
K-ras	O
genes	O
in	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Iinuma	O
H,	O
Okinaga	O
K,	O
Adachi	O
M,	O
Suda	O
K,	O
Sekine	O
T	O
,	O
Sakagawa	O
K,	O
Baba	O
Y	O
,	O
Tamura	O
J,	O
Kumagai	O
H,	O
Ida	O
A	O
.	O
Second	O
Department	O
of	O
Surgery	O
,	O
Teikyo	O
University	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
iinuma@med	O
.teikyo	O
-u.ac.jp	O
A	O
new	O
method	O
for	O
detecting	O
circulating	O
tumor	O
cells	O
that	O
is	O
based	O
on	O
magnetic	O
-	O
activated	O
cell	O
separation	O
(	O
MACS	O
)	O
and	O
nested	O
mutant	O
allele	O
-	O
specific	O
amplification	O
(	O
nested	O
MASA	O
)	O
was	O
evaluated	O
in	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
using	O
the	O
p53	O
and	O
K-ras	O
genes	O
as	O
genetic	O
markers	O
.	O
By	O
negative	O
selection	O
with	O
anti	O
-	O
CD45	O
monoclonal	O
antibody	O
-	O
conjugated	O
supermagnetic	O
microbeads	O
,	O
the	O
proportion	O
of	O
tumor	O
cells	O
was	O
enriched	O
9	O
-	O
fold	O
.	O
By	O
the	O
combination	O
of	O
MACS	O
and	O
nested	O
MASA	O
,	O
10	O
tumor	O
cells	O
in	O
10(7)	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
could	O
be	O
detected	O
without	O
false	O
-	O
positives	O
.	O
Using	O
this	O
method	O
,	O
we	O
examined	O
blood	O
taken	O
from	O
the	O
tumor	O
drainage	O
veins	O
of	O
23	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Eighty-seven	O
percent	O
(	O
20	O
/	O
23	O
)	O
of	O
primary	O
tumor	O
tissues	O
showed	O
p53	O
and/or	O
K-ras	O
gene	O
mutations	O
.	O
Forty-five	O
percent	O
(	O
9	O
/	O
20	O
)	O
of	O
patients	O
with	O
p53	O
and/or	O
K-ras	O
mutations	O
in	O
the	O
primary	O
tumor	O
showed	O
the	O
same	O
mutated	O
genes	O
in	O
the	O
blood	O
samples	O
.	O
There	O
was	O
a	O
significant	O
association	O
between	O
the	O
presence	O
of	O
p53	O
and	O
K-ras	O
gene	O
mutation	O
in	O
the	O
blood	O
and	O
tumor	O
size	O
,	O
depth	O
of	O
invasion	O
,	O
and	O
venous	O
invasion	O
.	O
Blood	O
gene	O
mutation	O
was	O
detected	O
in	O
80	O
%	O
(	O
4	O
/	O
5	O
)	O
of	O
samples	O
from	O
patients	O
with	O
synchronous	O
liver	O
metastases	O
.	O
Sixty	O
percent	O
(	O
3	O
/	O
5	O
)	O
of	O
patients	O
with	O
mutant	O
genes	O
in	O
the	O
blood	O
developed	O
asynchronous	O
liver	O
metastases	O
after	O
surgery	O
.	O
The	O
overall	O
survival	O
of	O
patients	O
with	O
p53	O
and/or	O
K-ras	O
gene	O
mutation	O
-	O
positive	O
findings	O
in	O
blood	O
was	O
significantly	O
shorter	O
than	O
that	O
of	O
patients	O
testing	O
negative	O
on	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
method	O
may	O
be	O
useful	O
for	O
reliable	O
detection	O
of	O
tumor	O
cells	O
circulating	O
in	O
the	O
blood	O
and	O
may	O
help	O
to	O
identify	O
patients	O
at	O
high	O
risk	O
for	O
relapse	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
10956407	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2000	O
Jul;31(	O
7	O
)	O
:	O
795-803	O
K-ras	O
gene	O
mutations	O
and	O
loss	O
of	O
heterozygosity	O
at	O
the	O
p53	O
gene	O
locus	O
relative	O
to	O
histological	O
characteristics	O
of	O
mucin	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Sakai	O
Y	O
,	O
Yanagisawa	O
A	O
,	O
Shimada	O
M,	O
Hidaka	O
E	O
,	O
Seki	O
M,	O
Tada	O
Y	O
,	O
Harada	O
T	O
,	O
Saisho	O
H,	O
Kato	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Cancer	O
Institute	O
Hospital	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Mucin	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
tumors	I-malignancy-type
(	I-malignancy-type
MPTs	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
accompanied	O
by	O
carcinomas	B-malignancy-type
usually	O
include	O
various	O
grades	O
of	O
dysplasia	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
ductal	I-malignancy-type
epithelium	I-malignancy-type
,	O
and	O
invasive	O
areas	O
are	O
histologically	O
similar	O
to	O
those	O
of	O
common	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
that	O
MPTs	O
provide	O
a	O
good	O
tool	O
to	O
investigate	O
early	O
stages	O
of	O
pancreatic	O
carcinogenesis	O
.	O
Thus	O
,	O
to	O
clarify	O
genetic	O
alterations	O
in	O
the	O
early	O
stage	O
of	O
pancreatic	O
carcinogenesis	O
,	O
we	O
analyzed	O
K-ras	O
gene	O
mutations	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
p53	O
gene	O
locus	O
using	O
37	O
cases	O
of	O
MPTs	B-malignancy-type
harboring	O
dysplastic	B-malignancy-type
epithelium	I-malignancy-type
.	O
Further	O
,	O
we	O
conducted	O
an	O
extended	O
,	O
multifocal	O
microdissection	O
analysis	O
focusing	O
on	O
the	O
histological	O
features	O
of	O
ductal	O
epithelium	O
and	O
the	O
distribution	O
of	O
genetic	O
alterations	O
for	O
3	O
cases	O
of	O
MPT	B-malignancy-type
positive	O
for	O
LOH	O
of	O
the	O
p53	O
gene	O
to	O
determine	O
the	O
relation	O
to	O
tumor	O
progression	O
.	O
K-ras	O
gene	O
mutations	O
were	O
detected	O
with	O
high	O
frequency	O
in	O
50	O
%	O
or	O
more	O
cases	O
of	O
the	O
adenomas	B-malignancy-type
(	O
14	O
of	O
19	O
)	O
,	O
borderline	B-malignancy-type
tumors	I-malignancy-type
(	O
4	O
of	O
7	O
)	O
,	O
and	O
carcinomas	B-malignancy-type
(	O
8	O
of	O
11	O
)	O
,	O
whereas	O
LOH	O
of	O
the	O
p53	O
gene	O
was	O
limited	O
to	O
carcinomas	B-malignancy-type
(	O
3	O
of	O
5	O
informative	O
cases	O
,	O
60	O
%	O
)	O
and	O
always	O
accompanied	O
by	O
K-ras	O
gene	O
mutation	O
.	O
Investigation	O
of	O
a	O
total	O
of	O
126	O
microdissection	O
sites	O
from	O
3	O
cases	O
showed	O
the	O
presence	O
of	O
K-ras	O
gene	O
mutations	O
in	O
mild	B-malignancy-type
dysplasia	I-malignancy-type
and	O
all	O
(	O
100	O
%	O
)	O
regions	O
of	O
moderate	O
or	O
more	O
marked	O
dysplasia	B-malignancy-type
,	O
whereas	O
LOH	O
of	O
the	O
p53	O
gene	O
showed	O
more	O
gradual	O
tendency	O
to	O
increase	O
with	O
grade	O
from	O
moderate	B-malignancy-type
dysplasia	I-malignancy-type
.	O
In	O
addition	O
,	O
the	O
multifocal	O
genetic	O
analysis	O
showed	O
K-ras	O
gene	O
mutations	O
to	O
be	O
widely	O
distributed	O
throughout	O
tumors	O
,	O
whereas	O
LOH	O
of	O
the	O
p53	O
gene	O
was	O
localized	O
to	O
1	O
or	O
a	O
few	O
areas	O
.	O
Further	O
,	O
topographically	O
delimited	O
areas	O
with	O
the	O
same	O
histology	O
in	O
the	O
same	O
tumor	O
did	O
not	O
always	O
show	O
the	O
same	O
genetic	O
alteration	O
.	O
In	O
conclusion	O
,	O
we	O
could	O
confirm	O
that	O
both	O
the	O
K-ras	O
and	O
p53	O
gene	O
alterations	O
occur	O
in	O
the	O
intraductal	O
stage	O
of	O
MPT	B-malignancy-type
,	O
and	O
the	O
latter	O
is	O
superimposed	O
on	O
the	O
former	O
during	O
the	O
course	O
of	O
tumor	O
progression	O
.	O
However	O
,	O
the	O
pattern	O
of	O
association	O
of	O
histological	O
features	O
with	O
genetic	O
alteration	O
differs	O
from	O
tumor	O
to	O
tumor	O
.	O
PMID	O
:	O
10923915	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
May	O
1;60	O
(	O
9	O
)	O
:	O
2345-7	O
Specific	O
c-kit	O
mutations	O
in	O
sinonasal	B-malignancy-type
natural	I-malignancy-type
killer	I-malignancy-type
/	O
T-cell	B-malignancy-type
lymphoma	I-malignancy-type
in	O
China	O
and	O
Japan	O
.	O
Hongyo	O
T	O
,	O
Li	O
T	O
,	O
Syaifudin	O
M	O
,	O
Baskar	O
R	O
,	O
Ikeda	O
H	O
,	O
Kanakura	O
Y	O
,	O
Aozasa	O
K	O
,	O
Nomura	O
T	O
.	O
Department	O
of	O
Radiation	O
Biology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Osaka	O
University	O
,	O
Japan	O
.	O
Sinonasal	B-malignancy-type
lymphoma	I-malignancy-type
is	O
one	O
of	O
the	O
constituents	O
of	O
lethal	B-malignancy-type
midline	I-malignancy-type
granuloma	I-malignancy-type
,	O
which	O
is	O
a	O
clinical	O
term	O
for	O
progressive	O
,	O
destructive	O
lesions	B-malignancy-type
affecting	I-malignancy-type
the	I-malignancy-type
midline	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
face	I-malignancy-type
.	O
The	O
majority	O
of	O
sinonasal	B-malignancy-type
lymphomas	I-malignancy-type
,	O
especially	O
those	O
showing	O
polymorphous	O
patterns	O
of	O
proliferation	O
and	O
thus	O
termed	O
polymorphic	B-malignancy-type
reticulosis	I-malignancy-type
,	O
recently	O
were	O
categorized	O
as	O
sinonasal	B-malignancy-type
natural	I-malignancy-type
killer	I-malignancy-type
/	O
T-cell	B-malignancy-type
lymphomas	I-malignancy-type
.	O
They	O
are	O
more	O
prevalent	O
in	O
Asia	O
than	O
Europe	O
or	O
North	O
America	O
and	O
are	O
associated	O
with	O
EBV	O
infection	O
.	O
Twenty-three	O
cases	O
with	O
sinonasal	B-malignancy-type
natural	I-malignancy-type
killer	I-malignancy-type
/	O
T-cell	B-malignancy-type
lymphomas	I-malignancy-type
were	O
collected	O
from	O
two	O
high	O
-	O
incidence	O
regions	O
:	O
Beijing	O
,	O
China	O
(	O
14	O
cases	O
)	O
and	O
Osaka	O
,	O
Japan	O
(	O
9	O
cases	O
)	O
.	O
c-kit	O
mutations	O
were	O
analyzed	O
on	O
paraffin	O
-	O
embedded	O
specimens	O
by	O
PCR	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
followed	O
by	O
direct	O
sequencing	O
;	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
encodes	O
a	O
receptor	O
of	O
tyrosine	O
kinase	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
and	O
neoplastic	O
hematopoiesis	O
by	O
the	O
interaction	O
with	O
its	O
specific	O
ligand	O
,	O
termed	O
stem	O
cell	O
factor	O
.	O
Twelve	O
single	O
nucleotide	O
substitution	O
mutations	O
were	O
seen	O
in	O
23	O
cases	O
.	O
Ten	O
of	O
14	O
Chinese	O
cases	O
(	O
71.4	O
%	O
)	O
had	O
mutations	O
at	O
exon	O
11	O
or	O
exon	O
17	O
,	O
whereas	O
only	O
two	O
of	O
nine	O
Japanese	O
cases	O
(	O
22.2	O
%	O
)	O
had	O
mutations	O
,	O
showing	O
a	O
significant	O
difference	O
in	O
frequency	O
between	O
Chinese	O
and	O
Japanese	O
cases	O
.	O
Furthermore	O
,	O
seven	O
of	O
eight	O
mutations	O
(	O
92	O
%	O
)	O
in	O
exon	O
17	O
occurred	O
at	O
codon	O
825	O
and	O
three	O
of	O
four	O
mutations	O
(	O
75	O
%	O
)	O
in	O
exon	O
11	O
occurred	O
at	O
codon	O
561	O
.	O
Such	O
a	O
specificity	O
has	O
not	O
been	O
reported	O
before	O
,	O
and	O
these	O
results	O
,	O
taken	O
together	O
,	O
suggest	O
that	O
location	O
-	O
specific	O
differences	O
in	O
etiological	O
factors	O
cause	O
specific	O
mutations	O
in	O
c-kit	O
gene	O
.	O
PMID	O
:	O
10811105	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncol	O
Rep	O
2000	O
May	O
-	O
Jun	O
;	O
7	O
(	O
3	O
)	O
:	O
567	O
-	O
70	O
Anticorresponding	O
mutations	O
of	O
the	O
KRAS	O
and	O
PTEN	O
genes	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
Ikeda	O
T	O
,	O
Yoshinaga	O
K	O
,	O
Suzuki	O
A	O
,	O
Sakurada	O
A	O
,	O
Ohmori	O
H	O
,	O
Horii	O
A	O
.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
PTEN	O
is	O
a	O
newly	O
isolated	O
candidate	O
tumor	O
suppressor	O
gene	O
and	O
its	O
mutation	O
is	O
the	O
most	O
frequently	O
found	O
in	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
(	O
EC	B-malignancy-type
)	O
,	O
a	O
very	O
common	O
female	O
pelvic	B-malignancy-type
malignant	I-malignancy-type
disease	I-malignancy-type
.	O
Mutations	O
of	O
the	O
KRAS	O
gene	O
are	O
also	O
reported	O
in	O
this	O
disease	O
.	O
Recent	O
analysis	O
of	O
the	O
PTEN	O
protein	O
suggested	O
the	O
possibility	O
that	O
this	O
protein	O
acts	O
in	O
the	O
same	O
pathway	O
as	O
does	O
the	O
RAS	O
protein	O
.	O
To	O
elucidate	O
this	O
possibility	O
further	O
,	O
we	O
performed	O
a	O
mutation	O
analysis	O
of	O
these	O
two	O
genes	O
in	O
44	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
specimens	O
(	O
38	O
primary	O
tumors	O
and	O
6	O
cell	O
lines	O
)	O
.	O
Altogether	O
23	O
(	O
52	O
%	O
)	O
of	O
44	O
tumors	O
had	O
mutations	O
in	O
either	O
PTEN	O
or	O
KRAS	O
,	O
but	O
none	O
of	O
them	O
had	O
mutations	O
in	O
both	O
of	O
these	O
genes	O
.	O
These	O
results	O
support	O
the	O
idea	O
that	O
the	O
protein	O
products	O
of	O
these	O
two	O
genes	O
act	O
in	O
the	O
same	O
growth	O
regulatory	O
pathway	O
in	O
the	O
endometrium	O
.	O
PMID	O
:	O
10767369	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2000	O
Mar	O
;	O
9	O
(	O
3	O
)	O
:	O
279	O
-	O
84	O
Ki-ras	O
point	O
mutation	O
and	O
p53	O
expression	O
in	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
:	O
a	O
comparative	O
study	O
among	O
Chinese	O
,	O
Japanese	O
,	O
and	O
Western	O
patients	O
.	O
Dong	O
M	O
,	O
Nio	O
Y	O
,	O
Tamura	O
K	O
,	O
Song	O
MM	O
,	O
Guo	O
KJ	O
,	O
Guo	O
RX	O
,	O
Dong	O
YT	O
.	O
First	O
Department	O
of	O
Surgery	O
,	O
Shimane	O
Medical	O
University	O
,	O
Izumo	O
,	O
Japan	O
.	O
mingdong@shimane-med.ac.jp	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
features	O
of	O
Ki-ras	O
point	O
mutation	O
(	O
PM	O
)	O
and	O
p53	O
expression	O
in	O
Chinese	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
and	O
to	O
compare	O
those	O
with	O
that	O
in	O
other	O
countries	O
.	O
Dot	O
blot	O
hybridization	O
and	O
immunohistochemical	O
methods	O
were	O
performed	O
in	O
59	O
Chinese	O
patients	O
.	O
The	O
results	O
showed	O
that	O
Ki-ras	O
PMs	O
at	O
codon	O
12	O
and	O
p53	O
expression	O
were	O
frequent	O
in	O
this	O
group	O
.	O
No	O
relationships	O
were	O
found	O
between	O
Ki-ras	O
PM	O
alone	O
and	O
p53	O
expression	O
alone	O
,	O
and	O
clinicopathological	O
parameters	O
,	O
including	O
age	O
,	O
gender	O
,	O
clinical	O
stage	O
,	O
and	O
histological	O
grade	O
and	O
classification	O
in	O
Chinese	O
patients	O
.	O
However	O
,	O
their	O
cooperation	O
was	O
significantly	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
this	O
group	O
.	O
Comparison	O
showed	O
that	O
there	O
were	O
significant	O
differences	O
in	O
the	O
overall	O
frequency	O
and	O
substitution	O
of	O
Ki-ras	O
PM	O
and	O
in	O
the	O
ratio	O
of	O
transition	O
:	O
transversion	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
among	O
various	O
countries	O
.	O
In	O
addition	O
,	O
the	O
effect	O
of	O
Ki-ras	O
PM	O
and	O
p53	O
expression	O
on	O
a	O
poor	O
prognosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
different	O
among	O
various	O
countries	O
.	O
These	O
findings	O
suggested	O
that	O
not	O
only	O
Ki-ras	O
PM	O
and	O
p53	O
expression	O
are	O
frequent	O
in	O
Chinese	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
also	O
a	O
gene	O
component	O
to	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
different	O
between	O
Asian	O
and	O
Western	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
addition	O
,	O
it	O
seems	O
that	O
cooperation	O
of	O
Ki-ras	O
PM	O
and	O
p53	O
expression	O
may	O
predict	O
a	O
poor	O
prognosis	O
in	O
Chinese	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10750666	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
2000	O
Mar	O
;	O
82	O
(	O
6	O
)	O
:	O
1183	O
-	O
5	O
Mutational	O
status	O
of	O
K-ras	O
and	O
TP53	O
genes	O
in	O
primary	B-malignancy-type
sarcomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
heart	I-malignancy-type
.	O
Garcia	O
JM	O
,	O
Gonzalez	O
R	O
,	O
Silva	O
JM	O
,	O
Dominguez	O
G	O
,	O
Vegazo	O
IS	O
,	O
Gamallo	O
C	O
,	O
Provencio	O
M	O
,	O
Espana	O
P	O
,	O
Bonilla	O
F	O
.	O
Department	O
of	O
Medical	O
Oncology	O
,	O
Clinica	O
Puerta	O
de	O
Hierro	O
,	O
Madrid	O
,	O
Spain	O
.	O
We	O
investigated	O
three	O
patients	O
with	O
cardiac	B-malignancy-type
angiosarcomas	I-malignancy-type
and	O
two	O
with	O
cardiac	B-malignancy-type
rhabdomyosarcomas	I-malignancy-type
,	O
all	O
for	O
mutations	O
at	O
exons	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
of	O
the	O
p53	O
gene	O
and	O
at	O
exon	O
1	O
of	O
K-ras	O
.	O
No	O
point	O
mutations	O
were	O
observed	O
in	O
the	O
p53	O
gene	O
in	O
any	O
of	O
the	O
five	O
cases	O
;	O
however	O
,	O
at	O
exon	O
1	O
of	O
K-ras	O
,	O
three	O
patients	O
(	O
60	O
%	O
)	O
presented	O
the	O
same	O
mutation	O
at	O
the	O
first	O
base	O
of	O
codon	O
13	O
(	O
G	O
to	O
A	O
transition	O
)	O
.	O
Interestingly	O
,	O
this	O
mutation	O
was	O
detected	O
in	O
both	O
rhabdomyosarcoma	B-malignancy-type
and	O
angiosarcoma	B-malignancy-type
histologic	O
sarcoma	B-malignancy-type
types	O
.	O
PMID	O
:	O
10735503	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Exp	O
Hematol	O
2000	O
Feb	O
;	O
28	O
(	O
2	O
)	O
:	O
140	O
-	O
7	O
Analysis	O
of	O
the	O
surface	O
expression	O
of	O
c-kit	O
and	O
occurrence	O
of	O
the	O
c-kit	O
Asp	O
816	O
Val	O
activating	O
mutation	O
in	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
myelomonocytic	O
cells	O
in	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
Akin	O
C	O
,	O
Kirshenbaum	O
AS	O
,	O
Semere	O
T	O
,	O
Worobec	O
AS	O
,	O
Scott	O
LM	O
,	O
Metcalfe	O
DD	O
.	O
Laboratory	O
of	O
Allergic	O
Diseases	O
,	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
-	O
1881	O
,	O
USA	O
.	O
cakin@atlas.niaid.nih.gov	O
OBJECTIVE	O
:	O
The	O
Asp	O
816	O
Val	O
c-kit	O
activating	O
mutation	O
is	O
detectable	O
in	O
the	O
peripheral	O
blood	O
cells	O
of	O
some	O
patients	O
with	O
mastocytosis	B-malignancy-type
and	O
in	O
lesional	B-malignancy-type
skin	I-malignancy-type
biopsies	O
obtained	O
from	O
adult	O
patients	O
with	O
urticaria	B-malignancy-type
pigmentosa	I-malignancy-type
.	O
These	O
observations	O
led	O
to	O
the	O
conclusion	O
that	O
this	O
mutation	O
is	O
present	O
in	O
mast	O
cells	O
and	O
mast	O
cell	O
precursors	O
that	O
express	O
c-kit	O
.	O
However	O
,	O
the	O
distribution	O
of	O
the	O
Asp	O
816	O
Val	O
mutation	O
among	O
hematopoietic	O
lineages	O
is	O
unknown	O
.	O
To	O
determine	O
the	O
distribution	O
of	O
the	O
Asp	O
816	O
Val	O
mutation	O
among	O
hematopoietic	O
lineages	O
and	O
to	O
explore	O
its	O
relationship	O
to	O
clinical	O
disease	O
,	O
we	O
examined	O
cells	O
bearing	O
differentiation	O
markers	O
for	O
myelomonocytic	O
cells	O
as	O
well	O
as	O
T	O
and	O
B	O
lymphocytes	O
,	O
in	O
both	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
obtained	O
from	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
presence	O
of	O
Asp	O
816	O
Val	O
c-kit	O
mutation	O
in	O
cells	O
magnetically	O
sorted	O
from	O
peripheral	O
blood	O
or	O
bone	O
marrow	O
according	O
to	O
surface	O
differentiation	O
markers	O
was	O
studied	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
The	O
surface	O
expression	O
of	O
c-kit	O
was	O
determined	O
by	O
flow	O
cytometry	O
.	O
RESULTS	O
:	O
The	O
mutation	O
was	O
detectable	O
by	O
RT	O
-	O
PCR	O
in	O
at	O
least	O
one	O
cell	O
lineage	O
in	O
the	O
bone	O
marrow	O
in	O
7	O
of	O
7	O
patients	O
examined	O
and	O
in	O
the	O
peripheral	O
blood	O
of	O
11	O
of	O
11	O
adult	O
patients	O
with	O
urticaria	B-malignancy-type
pigmentosa	I-malignancy-type
and	O
indolent	O
disease	O
.	O
The	O
mutation	O
was	O
identified	O
most	O
frequently	O
in	O
B	O
cells	O
and	O
myeloid	O
cells	O
.	O
Flow	O
cytometric	O
analysis	O
demonstrated	O
that	O
the	O
differentiated	O
cells	O
expressing	O
mutated	O
c-kit	O
were	O
negative	O
for	O
surface	O
KIT	O
.	O
CONCLUSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
the	O
conclusion	O
that	O
the	O
c-kit	O
Asp	O
816	O
Val	O
mutation	O
occurs	O
in	O
an	O
early	O
progenitor	O
cell	O
and	O
is	O
carried	O
by	O
myelomonocytic	O
cells	O
,	O
T	O
cells	O
,	O
and	O
B	O
cells	O
in	O
addition	O
to	O
mast	O
cells	O
.	O
However	O
,	O
unlike	O
mast	O
cells	O
,	O
these	O
myelomonocytic	O
cells	O
,	O
T	O
cells	O
,	O
and	O
B	O
cells	O
do	O
not	O
concomitantly	O
express	O
surface	O
c-kit	O
and	O
thus	O
may	O
be	O
less	O
susceptible	O
to	O
the	O
effects	O
of	O
this	O
mutation	O
.	O
PMID	O
:	O
10706069	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Oncol	O
2000	O
Mar;16	O
(	O
3	O
)	O
:	O
501-11	O
The	O
K-ras	O
gene	O
regulates	O
vascular	O
endothelial	O
growth	O
factor	O
gene	O
expression	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Konishi	O
T	O
,	O
Huang	O
CL	O
,	O
Adachi	O
M,	O
Taki	O
T	O
,	O
Inufusa	O
H,	O
Kodama	O
K,	O
Kohno	O
N	O
,	O
Miyake	O
M.	O
Department	O
of	O
Thoracic	O
Surgery	O
,	O
Kitano	O
Hospital	O
,	O
Tazuke	O
Kofukai	O
Medical	O
Research	O
Institute	O
,	O
Kamiyama-cho	O
,	O
Osaka	O
530	O
-	O
8480	O
,	O
Japan	O
.	O
Tumor	O
angiogenesis	O
is	O
an	O
essential	O
step	O
for	O
tumor	O
cell	O
growth	O
,	O
progression	O
and	O
metastasis	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
mitogen	O
specific	O
for	O
endothelial	O
cells	O
,	O
and	O
therefore	O
is	O
believed	O
to	O
play	O
a	O
key	O
role	O
in	O
tumor	O
angiogenesis	O
.	O
However	O
,	O
the	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
VEGF	O
expression	O
remain	O
virtually	O
unknown	O
and	O
the	O
only	O
major	O
regulator	O
of	O
VEGF	O
expression	O
has	O
been	O
reported	O
to	O
be	O
hypoxia	O
.	O
Recently	O
,	O
it	O
was	O
reported	O
that	O
a	O
mutant	O
p53	O
in#duced	O
the	O
expression	O
of	O
VEGF	O
mRNA	O
,	O
and	O
that	O
wild	O
-	O
type	O
p53	O
down	O
-	O
regulated	O
endogenous	O
VEGF	O
mRNA	O
levels	O
.	O
In	O
contrast	O
,	O
it	O
has	O
also	O
been	O
reported	O
that	O
mutant	O
ras	O
oncogenes	O
were	O
associated	O
with	O
the	O
marked	O
up	O
-	O
regulation	O
of	O
VEGF	O
in	O
transformed	O
epithelial	O
cells	O
.	O
Based	O
on	O
these	O
results	O
,	O
we	O
performed	O
a	O
retrospective	O
study	O
of	O
the	O
p53	O
and	O
K-ras	O
genes	O
status	O
and	O
VEGF	O
gene	O
expression	O
in	O
the	O
tumor	O
tissues	O
from	O
181	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
using	O
SSCP	O
,	O
sequencing	O
,	O
RT	O
-	O
PCR	O
and	O
immunohistochemical	O
techniques	O
.	O
Forty-six	O
carcinomas	B-malignancy-type
(	O
25.4	O
%	O
)	O
were	O
evaluated	O
as	O
having	O
high	O
VEGF	O
expression	O
,	O
and	O
135	O
tumors	O
(	O
74.6	O
%	O
)	O
had	O
low	O
VEGF	O
expression	O
.	O
Of	O
the	O
181	O
primary	O
NSCLC	B-malignancy-type
studied	O
,	O
63	O
carcinomas	B-malignancy-type
(	O
34.8	O
%	O
)	O
contained	O
mutations	O
of	O
p53	O
,	O
whereas	O
only	O
14	O
carcinomas	B-malignancy-type
(	O
7.7	O
%	O
)	O
had	O
mutations	O
of	O
K-ras	O
.	O
There	O
were	O
no	O
significant	O
relationships	O
between	O
VEGF	O
expression	O
and	O
p53	O
status	O
or	O
each	O
mutant	O
exon	O
of	O
p53	O
.	O
In	O
contrast	O
,	O
a	O
significant	O
difference	O
was	O
found	O
between	O
VEGF	O
expression	O
and	O
K-ras	O
status	O
.	O
Of	O
the	O
14	O
tumors	O
with	O
mutant	O
K-ras	O
genes	O
,	O
7	O
cases	O
(	O
50.0	O
%	O
)	O
had	O
high	O
VEGF	O
expression	O
whereas	O
only	O
39	O
of	O
the	O
167	O
tumors	O
with	O
wild	O
-	O
type	O
K-ras	O
(	O
23.4	O
%	O
)	O
had	O
high	O
VEGF	O
expression	O
(	O
p	O
=	O
0.0278	O
)	O
.	O
The	O
mean	O
VEGF	O
conservation	O
rate	O
for	O
the	O
14	O
tumors	O
with	O
mutant	O
K-ras	O
genes	O
was	O
0.77	O
+/-	O
0.58	O
and	O
the	O
rate	O
of	O
the	O
167	O
tumors	O
with	O
wild	O
-	O
type	O
K-ras	O
genes	O
was	O
0.49	O
+/-	O
0.46	O
(	O
p	O
=	O
0.	O
0350	O
)	O
.	O
Moreover	O
,	O
the	O
overall	O
survival	O
rate	O
of	O
patients	O
with	O
high	O
VEGF	O
expression	O
was	O
lower	O
than	O
patients	O
with	O
low	O
VEGF	O
expression	O
(	O
45.7	O
%	O
vs	O
60.7	O
%	O
,	O
p	O
=	O
0.0419	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
overall	O
survival	O
rate	O
between	O
patients	O
with	O
a	O
mutant	O
p53	O
and	O
those	O
with	O
a	O
wild	O
-	O
type	O
p53	O
;	O
there	O
was	O
also	O
no	O
difference	O
in	O
the	O
overall	O
survival	O
between	O
patients	O
with	O
a	O
mutant	O
K-ras	O
and	O
those	O
with	O
a	O
wild	O
-	O
type	O
K-ras	O
.	O
The	O
Cox	O
regression	O
model	O
analysis	O
indicated	O
that	O
three	O
variables	O
,	O
VEGF	O
status	O
,	O
K-ras	O
status	O
and	O
nodal	O
status	O
,	O
were	O
found	O
to	O
be	O
significant	O
indicators	O
for	O
prognosis	O
(	O
p	O
=	O
0.0236	O
,	O
p	O
=	O
0.0172	O
and	O
p	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O
Our	O
data	O
suggest	O
that	O
a	O
high	O
expression	O
of	O
VEGF	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
This	O
may	O
be	O
a	O
clue	O
to	O
improving	O
lung	B-malignancy-type
cancer	I-malignancy-type
diagnoses	O
and	O
therapies	O
aimed	O
at	O
inhibiting	O
tumor	O
angiogenesis	O
due	O
to	O
VEGF	O
.	O
PMID	O
:	O
10675482	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2000	O
Feb;156	O
(	O
2	O
)	O
:433	O
-7	O
APC	O
mutations	O
in	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
.	O
Huang	O
H,	O
Mahler	O
-	O
Araujo	O
BM	O
,	O
Sankila	O
A	O
,	O
Chimelli	O
L,	O
Yonekawa	O
Y	O
,	O
Kleihues	O
P,	O
Ohgaki	O
H.	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
,	O
Lyon	O
,	O
France	O
.	O
The	O
cerebellar	B-malignancy-type
medulloblastoma	I-malignancy-type
(	O
WHO	O
Grade	O
IV	O
)	O
is	O
a	O
highly	O
malignant	O
,	O
invasive	O
embryonal	O
tumor	O
with	O
preferential	O
manifestation	O
in	O
children	O
.	O
Several	O
molecular	O
alterations	O
appear	O
to	O
be	O
involved	O
,	O
including	O
isochromosome	O
17q	O
and	O
the	O
p53	O
,	O
PTCH	O
,	O
and	O
beta-catenin	O
gene	O
mutations	O
.	O
In	O
this	O
study	O
,	O
46	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
were	O
screened	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
genes	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
(	O
APC	O
and	O
beta-catenin	O
)	O
.	O
Single	O
-	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
revealed	O
3	O
miscoding	O
APC	O
mutations	O
in	O
2	O
(	O
4.3	O
%	O
)	O
medulloblastomas	B-malignancy-type
.	O
One	O
case	O
contained	O
a	O
GCA	O
-->	O
GTA	O
mutation	O
at	O
codon	O
1296	O
(	O
Ala	O
-->	O
Val	O
)	O
,	O
and	O
another	O
case	O
had	O
double	O
point	O
mutations	O
at	O
codons	O
1472	O
(	O
GTA	O
-->	O
ATA	O
,	O
Val	O
-->	O
Ile	O
)	O
and	O
1495	O
(	O
AGT	O
-->	O
GGT	O
,	O
Ser	O
-->	O
Gly	O
)	O
.	O
Miscoding	O
beta-catenin	O
mutations	O
were	O
detected	O
in	O
4	O
tumors	O
(	O
8.7	O
%	O
)	O
.	O
Three	O
of	O
these	O
were	O
located	O
at	O
codon	O
33	O
(	O
TCT	O
-->	O
TTT	O
,	O
Ser	O
-->	O
Phe	O
)	O
and	O
another	O
at	O
codon	O
37	O
(	O
TCT	O
-->	O
GCT	O
,	O
Ser	O
-->	O
Ala	O
)	O
.	O
Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
and	O
beta-catenin	O
mutations	O
were	O
mutually	O
exclusive	O
and	O
occurred	O
in	O
a	O
total	O
of	O
6	O
of	O
46	O
cases	O
(	O
13	O
%	O
)	O
.	O
Although	O
germline	O
APC	O
mutations	O
are	O
a	O
well	O
established	O
cause	O
of	O
familial	B-malignancy-type
colon	I-malignancy-type
and	O
brain	B-malignancy-type
tumors	I-malignancy-type
(	O
Turcot	B-malignancy-type
syndrome	I-malignancy-type
)	O
,	O
this	O
study	O
provides	O
the	O
first	O
evidence	O
that	O
APC	O
mutations	O
are	O
also	O
operative	O
in	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
.	O
PMID	O
:	O
10666372	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Natl	O
Cancer	O
Inst	O
1999	O
Dec	O
1;91(	O
23	O
)	O
:	O
2032	O
-	O
8	O
Implications	O
and	O
prognostic	O
value	O
of	O
K-ras	O
mutation	O
for	O
early	O
-	O
stage	O
lung	B-malignancy-type
cancer	I-malignancy-type
in	O
women	O
.	O
Nelson	O
HH	O
,	O
Christiani	O
DC	O
,	O
Mark	O
EJ	O
,	O
Wiencke	O
JK	O
,	O
Wain	O
JC	O
,	O
Kelsey	O
KT.	O
Department	O
of	O
Cancer	O
Cell	O
Biology	O
,	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
Boston	O
,	O
MA	O
02115-6021	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Because	O
there	O
is	O
no	O
clear	O
consensus	O
as	O
to	O
the	O
predictive	O
value	O
of	O
K-ras	O
gene	O
mutation	O
for	O
survival	O
in	O
patients	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
examined	O
the	O
occurrence	O
of	O
K-ras	O
mutations	O
in	O
a	O
large	O
,	O
prospective	O
case	O
series	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
.	O
Our	O
goals	O
were	O
to	O
define	O
the	O
patient	O
characteristics	O
associated	O
with	O
K-ras	O
mutation	O
and	O
to	O
determine	O
whether	O
mutation	O
of	O
this	O
gene	O
might	O
be	O
a	O
biomarker	O
of	O
patient	O
prognosis	O
.	O
METHODS	O
:	O
Consecutive	O
,	O
newly	O
diagnosed	O
patients	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
treated	O
with	O
potentially	O
curative	O
resection	O
over	O
a	O
4	O
-	O
year	O
period	O
were	O
recruited	O
for	O
study	O
.	O
The	O
mutation	O
status	O
of	O
K-ras	O
codon	O
12	O
in	O
each	O
patient	O
's	O
tumor	O
DNA	O
was	O
determined	O
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
archived	O
pathology	O
specimens	O
.	O
Analyses	O
were	O
restricted	O
to	O
adenocarcinoma	B-malignancy-type
.	O
RESULTS	O
:	O
There	O
was	O
a	O
statistically	O
significant	O
association	O
between	O
female	O
sex	O
and	O
K-ras	O
mutation	O
after	O
adjustment	O
for	O
carcinogen	O
exposures	O
(	O
odds	O
ratio	O
=	O
3.3	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1.3	O
-	O
7.9	O
)	O
;	O
mutations	O
were	O
found	O
only	O
in	O
smokers	O
.	O
Comparison	O
of	O
Kaplan	O
-	O
Meier	O
curves	O
indicated	O
a	O
strong	O
association	O
between	O
K-ras	O
mutation	O
and	O
decreased	O
patient	O
survival	O
(	O
two	O
-	O
sided	O
P	O
=	O
.009	O
)	O
;	O
analysis	O
stratified	O
by	O
pathologic	O
staging	O
groups	O
revealed	O
that	O
this	O
association	O
was	O
statistically	O
significant	O
only	O
for	O
stage	O
I	O
tumors	O
(	O
two	O
-	O
sided	O
P	O
=	O
.002	O
)	O
.	O
Cox	O
proportional	O
hazards	O
modeling	O
indicated	O
that	O
K-ras	O
codon	O
12	O
mutation	O
was	O
a	O
statistically	O
significant	O
predictor	O
of	O
patient	O
survival	O
,	O
after	O
adjustment	O
for	O
the	O
effects	O
of	O
age	O
,	O
sex	O
,	O
and	O
stage	O
(	O
risk	O
ratio	O
=	O
1.8	O
;	O
95	O
%	O
CI	O
=	O
1.1	O
-	O
3.1	O
)	O
.	O
CONCLUSIONS	O
:	O
After	O
adjustment	O
for	O
environmental	O
exposures	O
,	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
tumors	I-malignancy-type
in	O
women	O
appear	O
to	O
be	O
more	O
likely	O
than	O
those	O
in	O
men	O
to	O
harbor	O
K-ras	O
mutations	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
estrogen	O
exposure	O
in	O
either	O
the	O
initiation	O
or	O
the	O
selection	O
of	O
K-ras	O
mutant	O
clones	O
in	O
adenocarcinoma	B-malignancy-type
.	O
In	O
addition	O
,	O
our	O
data	O
suggest	O
that	O
K-ras	O
codon	O
12	O
mutation	O
is	O
a	O
marker	O
of	O
aggressive	B-malignancy-type
NSCLC	I-malignancy-type
,	O
as	O
evidenced	O
by	O
its	O
association	O
with	O
decreased	O
patient	O
survival	O
,	O
particularly	O
for	O
early	O
-	O
stage	O
disease	O
.	O
PMID	O
:	O
10580029	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Radiat	O
Res	O
1999	O
Dec;152(	O
6	O
Suppl	O
)	O
:S118	O
-24	O
Analysis	O
of	O
genetic	O
changes	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
induced	O
by	O
thorotrast	O
.	O
Kamikawa	O
T	O
,	O
Amenomori	O
M,	O
Itoh	O
T	O
,	O
Momoi	O
H,	O
Hiai	O
H,	O
Machinami	O
R	O
,	O
Ishikawa	O
Y	O
,	O
Mori	O
T	O
,	O
Shimahara	O
Y	O
,	O
Yamaoka	O
Y	O
,	O
Fukumoto	O
M.	O
Department	O
of	O
Pathology	O
,	O
Kyoto	O
University	O
,	O
Kyoto	O
,	O
Japan	O
.	O
Thorotrast	O
,	O
a	O
colloidal	O
suspension	O
of	O
radioactive	O
(232)ThO(2)	O
that	O
emits	O
alpha	O
particles	O
,	O
was	O
used	O
as	O
a	O
radiographic	O
contrast	O
agent	O
in	O
the	O
1930s	O
-	O
1950s	O
.	O
Several	O
decades	O
after	O
injection	O
,	O
Thorotrast	O
causes	O
liver	B-malignancy-type
cancers	I-malignancy-type
,	O
among	O
which	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
(	O
ICC	B-malignancy-type
)	O
is	O
prominent	O
.	O
We	O
investigated	O
mutations	O
of	O
the	O
RAS	O
and	O
the	O
TP53	O
genes	O
in	O
archival	O
sections	O
of	O
ICC	B-malignancy-type
induced	O
by	O
Thorotrast	O
.	O
Compared	O
to	O
ICC	O
that	O
was	O
not	O
associated	O
with	O
Thorotrast	O
,	O
the	O
frequency	O
of	O
mutation	O
of	O
the	O
KRAS	O
gene	O
was	O
lower	O
,	O
while	O
that	O
of	O
the	O
TP53	O
gene	O
was	O
more	O
than	O
two	O
times	O
higher	O
.	O
The	O
most	O
common	O
mutation	O
of	O
the	O
TP53	O
gene	O
was	O
A	O
-	O
G	O
transitions	O
.	O
Interestingly	O
,	O
TP53	O
mutations	O
were	O
also	O
found	O
in	O
noncancerous	O
areas	O
of	O
livers	O
in	O
which	O
Thorotrast	O
had	O
been	O
deposited	O
.	O
Furthermore	O
,	O
mutations	O
tended	O
to	O
accumulate	O
in	O
tissues	O
from	O
more	O
advanced	O
tumors	O
.	O
These	O
results	O
suggest	O
that	O
deposited	O
Thorotrast	O
continuously	O
damages	O
DNA	O
in	O
liver	O
cells	O
in	O
some	O
way	O
,	O
resulting	O
in	O
A	O
-	O
G	O
transitions	O
of	O
the	O
TP53	O
gene	O
.	O
However	O
,	O
we	O
have	O
not	O
been	O
able	O
to	O
rule	O
out	O
the	O
possibility	O
that	O
genetic	O
insults	O
occur	O
indirectly	O
in	O
the	O
proliferating	O
cells	O
adjacent	O
to	O
the	O
necrosis	O
rather	O
than	O
being	O
a	O
direct	O
effect	O
of	O
alpha	O
particles	O
.	O
PMID	O
:	O
10564951	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Med	O
Genet	O
1999	O
Aug;36	O
(	O
8	O
)	O
:	O
610-4	O
Mutational	O
analysis	O
of	O
the	O
N-ras	O
,	O
p53	O
,	O
p16INK4a	O
,	O
CDK4	O
,	O
and	O
MC1R	O
genes	O
in	O
human	O
congenital	B-malignancy-type
melanocytic	I-malignancy-type
naevi	I-malignancy-type
.	O
Papp	O
T	O
,	O
Pemsel	O
H,	O
Zimmermann	O
R	O
,	O
Bastrop	O
R	O
,	O
Weiss	O
DG	O
,	O
Schiffmann	O
D.	O
University	O
of	O
Rostock	O
,	O
Department	O
of	O
Biology	O
,	O
Germany	O
.	O
Eighteen	O
human	O
congenital	B-malignancy-type
melanocytic	I-malignancy-type
naevi	I-malignancy-type
(	O
CMN	B-malignancy-type
)	O
from	O
17	O
patients	O
were	O
screened	O
for	O
activating	O
point	O
mutations	O
in	O
the	O
oncogenes	O
N-ras	O
and	O
CDK4	O
and	O
for	O
sequence	O
variants	O
in	O
the	O
MC1R	O
gene	O
by	O
combined	O
RFLP	O
-	O
PCR	O
/	O
SSCP	O
analysis	O
.	O
In	O
addition	O
,	O
all	O
lesions	O
were	O
screened	O
for	O
deletions	O
and	O
point	O
mutations	O
in	O
the	O
tumour	O
suppressor	O
genes	O
p53	O
and	O
p16INK4a	O
(	O
CDKN2A	O
)	O
by	O
combined	O
multiplex	O
PCR	O
/	O
SSCP	O
analysis	O
.	O
Positive	O
screening	O
data	O
were	O
specified	O
by	O
sequencing	O
of	O
the	O
corresponding	O
PCR	O
product	O
.	O
Activating	O
point	O
mutations	O
in	O
the	O
N-ras	O
gene	O
(	O
nine	O
CAA	O
(	O
Gln	O
)	O
to	O
AAA	O
(	O
Lys	O
)	O
transversions	O
and	O
one	O
CAA	O
(	O
Gln	O
)	O
to	O
CGA	O
(	O
Arg	O
)	O
transition	O
at	O
codon	O
61	O
)	O
were	O
detected	O
at	O
high	O
frequency	O
(	O
56	O
%	O
)	O
.	O
Furthermore	O
,	O
three	O
missense	O
mutations	O
(	O
V	O
92	O
M	O
)	O
and	O
two	O
silent	O
mutations	O
(	O
CGA	O
(	O
Arg	O
)	O
to	O
CGG	O
(	O
Arg	O
)	O
,	O
codon	O
213	O
,	O
exon	O
6	O
)	O
were	O
found	O
in	O
the	O
MC1R	O
and	O
p53	O
genes	O
,	O
respectively	O
.	O
No	O
mutations	O
were	O
found	O
in	O
p16	O
or	O
CDK4	O
.	O
The	O
activated	O
N-ras	O
oncogene	O
,	O
which	O
is	O
also	O
found	O
in	O
human	O
cutaneous	B-malignancy-type
melanomas	I-malignancy-type
,	O
may	O
constitute	O
a	O
potential	O
risk	O
factor	O
for	O
melanoma	B-malignancy-type
formation	O
within	O
CMN	B-malignancy-type
.	O
PMID	O
:	O
10465111	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1999	O
Aug;12(	O
8	O
)	O
:775	O
-80	O
H-ras	O
and	O
K-ras	O
gene	O
mutations	O
in	O
primary	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcoma	I-malignancy-type
:	O
concomitant	O
mutations	O
of	O
the	O
ras	O
genes	O
.	O
Yoo	O
J,	O
Robinson	O
RA	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
,	O
Catholic	O
University	O
,	O
St.	O
Vincent	O
Hospital	O
,	O
Suwon	O
,	O
South	O
Korea	O
.	O
ras	O
gene	O
mutations	O
have	O
been	O
described	O
with	O
varying	O
frequency	O
in	O
several	O
types	O
of	O
human	O
malignancies	O
.	O
To	O
determine	O
the	O
incidence	O
and	O
type	O
of	O
ras	O
mutations	O
in	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
tumors	I-malignancy-type
,	O
we	O
studied	O
45	O
sarcomas	B-malignancy-type
,	O
including	O
27	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFHs	B-malignancy-type
)	O
,	O
10	O
liposarcomas	B-malignancy-type
,	O
2	O
rhabdomyosarcomas	B-malignancy-type
,	O
and	O
6	O
leiomyosarcomas	B-malignancy-type
.	O
Al	O
of	O
the	O
tumors	O
were	O
investigated	O
by	O
direct	O
sequence	O
analysis	O
with	O
the	O
automated	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
ras	O
sequences	O
.	O
Twenty	O
(	O
44	O
%	O
)	O
of	O
the	O
sarcomas	B-malignancy-type
examined	O
harbored	O
K-ras	O
mutations	O
,	O
18	O
(	O
90	O
%	O
)	O
of	O
which	O
were	O
MFHs	B-malignancy-type
.	O
All	O
of	O
the	O
K-ras	O
mutations	O
were	O
G	O
-	O
to	O
-	O
A	O
transition	O
mutations	O
in	O
the	O
second	O
position	O
of	O
codon	O
13	O
(	O
glycine	O
-->	O
aspartic	O
acid	O
)	O
.	O
Of	O
the	O
samples	O
with	O
K-ras	O
activation	O
,	O
7	O
(	O
16	O
%	O
of	O
the	O
total	O
of	O
45	O
tumors	O
)	O
,	O
including	O
6	O
MFHs	B-malignancy-type
and	O
1	O
leiomyosarcoma	B-malignancy-type
,	O
also	O
contained	O
H-ras	O
mutation	O
.	O
All	O
of	O
the	O
tumors	O
that	O
showed	O
H-ras	O
alteration	O
had	O
G	O
-	O
to	O
-	O
T	O
transversion	O
mutations	O
in	O
the	O
second	O
base	O
of	O
codon	O
12	O
(	O
glycine	O
-->	O
valine	O
)	O
.	O
These	O
data	O
possibly	O
implicate	O
that	O
ras	O
gene	O
activation	O
may	O
be	O
a	O
relatively	O
uncommon	O
event	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
tumors	I-malignancy-type
,	O
with	O
the	O
exception	O
of	O
MFH	B-malignancy-type
.	O
It	O
is	O
suggested	O
that	O
the	O
oncogenic	O
process	O
underlying	O
the	O
development	O
of	O
tumors	O
between	O
these	O
groups	O
may	O
be	O
different	O
and	O
that	O
ras	O
gene	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
etiology	O
and/or	O
progression	O
of	O
MFH	B-malignancy-type
.	O
It	O
is	O
noteworthy	O
that	O
when	O
ras	O
gene	O
activation	O
occurs	O
in	O
sarcoma	B-malignancy-type
,	O
it	O
predominantly	O
affects	O
the	O
K-ras	O
gene	O
,	O
particularly	O
codon	O
13	O
.	O
Moreover	O
,	O
H-ras	O
mutations	O
in	O
our	O
samples	O
were	O
detected	O
only	O
in	O
association	O
with	O
tumors	O
that	O
also	O
displayed	O
K-ras	O
-	O
mutated	O
genes	O
.	O
This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
concomitant	O
mutations	O
in	O
two	O
different	O
members	O
of	O
the	O
ras	O
gene	O
family	O
in	O
sarcoma	B-malignancy-type
PMID	O
:	O
10463479	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
May;90	O
(	O
5	O
)	O
:	O
510	O
-	O
5	O
Mutational	O
analysis	O
of	O
beta-catenin	O
gene	O
in	O
Japanese	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
:	O
frequent	O
mutations	O
in	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Sagae	O
S	O
,	O
Kobayashi	O
K,	O
Nishioka	O
Y	O
,	O
Sugimura	O
M,	O
Ishioka	O
S	O
,	O
Nagata	O
M,	O
Terasawa	O
K,	O
Tokino	O
T	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Hokkaido	O
.	O
sagaes@sapmed	O
.ac.jp	O
To	O
investigate	O
the	O
contribution	O
of	O
the	O
beta-catenin	O
gene	O
to	O
the	O
development	O
of	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
mutational	O
analysis	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
conducted	O
.	O
We	O
analyzed	O
61	O
primary	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
consisting	O
of	O
49	O
non	B-malignancy-type
-	I-malignancy-type
endometrioid	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
and	O
12	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
,	O
for	O
genetic	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Five	O
carcinomas	B-malignancy-type
showed	O
beta-catenin	O
mutations	O
(	O
S	O
37	O
C	O
,	O
T	O
41	O
I	O
,	O
T	O
41	O
A	O
)	O
,	O
including	O
4	O
(	O
33	O
%	O
)	O
of	O
12	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
and	O
1	O
(	O
14	O
%	O
)	O
of	O
7	O
mucinous	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
.	O
All	O
of	O
these	O
mutations	O
altered	O
at	O
the	O
serine	O
/	O
threonine	O
residues	O
that	O
are	O
potential	O
sites	O
of	O
GSK	O
3-beta	O
phosphorylation	O
.	O
We	O
detected	O
no	O
carcinomas	B-malignancy-type
with	O
interstitial	O
deletion	O
involving	O
exon	O
3	O
of	O
beta-catenin	O
.	O
Furthermore	O
,	O
we	O
immunohistochemically	O
studied	O
27	O
of	O
the	O
61	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Both	O
nuclear	O
and	O
cytoplasmic	O
beta-catenin	O
expressions	O
were	O
demonstrated	O
in	O
4	O
of	O
the	O
27	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
for	O
which	O
tissue	O
samples	O
were	O
available	O
for	O
examination	O
.	O
All	O
4	O
cases	O
exhibited	O
mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
,	O
including	O
a	O
mucinous	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Our	O
results	O
suggested	O
that	O
beta-catenin	O
gene	O
mutation	O
at	O
potential	O
GSK	O
3-beta	O
phosphorylation	O
sites	O
results	O
in	O
accumulation	O
of	O
beta-catenin	O
protein	O
within	O
the	O
cells	O
and	O
its	O
translocation	O
to	O
nuclei	O
.	O
Accumulated	O
beta-catenin	O
protein	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
some	O
mucinous	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10391090	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Chin	O
Med	O
J	O
(	O
Engl	O
)	O
1998	O
Apr;111(	O
4	O
)	O
:	O
343	O
-	O
5	O
N-ras	O
mutations	O
in	O
43	O
Chinese	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Guo	O
W	O
,	O
Tang	O
B	O
,	O
Xu	O
S	O
,	O
Yao	O
Y	O
,	O
Ye	O
D.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Post	O
and	O
Telecommunications	O
General	O
Hospital	O
,	O
Beijing	O
,	O
China	O
.	O
OBJECTIVE	O
:	O
To	O
detect	O
3	O
kinds	O
of	O
N-ras	O
mutations	O
in	O
Chinese	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
METHODS	O
:	O
In	O
vitro	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
dot	O
analysis	O
were	O
used	O
to	O
study	O
N-ras	O
gene	O
mutations	O
in	O
43	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
25	O
healthy	O
people	O
were	O
used	O
as	O
controls	O
.	O
Patients	O
were	O
selected	O
in	O
the	O
Beijing	O
district	O
and	O
consisted	O
of	O
19	O
males	O
and	O
24	O
females	O
.	O
The	O
average	O
age	O
was	O
37	O
.	O
The	O
controls	O
were	O
healthy	O
individuals	O
with	O
the	O
average	O
age	O
of	O
36.5	O
from	O
the	O
same	O
region	O
.	O
3	O
oligonucleotide	O
probes	O
were	O
artificially	O
synthesized	O
to	O
detect	O
mutations	O
in	O
codon	O
12	O
and	O
13	O
of	O
N-ras	O
.	O
RESULTS	O
:	O
Five	O
out	O
of	O
43	O
AML	B-malignancy-type
samples	O
have	O
been	O
found	O
contain	O
G	O
-->	O
A	O
mutation	O
in	O
codon	O
12.2	O
have	O
G	O
-->	O
T	O
mutation	O
in	O
codon	O
12	O
.	O
One	O
has	O
G	O
-->	O
A	O
mutation	O
in	O
codon	O
13	O
.	O
The	O
mutation	O
rate	O
was	O
18.6	O
%	O
.	O
None	O
of	O
the	O
controls	O
presented	O
these	O
mutations	O
.	O
The	O
frequency	O
of	O
mutation	O
of	O
N-ras	O
in	O
the	O
AML	B-malignancy-type
samples	O
showed	O
statistical	O
differences	O
with	O
that	O
of	O
the	O
controls	O
.	O
CONCLUSION	O
:	O
Analysis	O
of	O
the	O
results	O
suggests	O
the	O
N-ras	O
mutations	O
may	O
have	O
some	O
relationship	O
with	O
the	O
etiology	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
PMID	O
:	O
10374400	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
1999	O
Jun;94	O
(	O
6	O
)	O
:1638-42	O
Gene	O
mutations	O
of	O
K-ras	O
in	O
gallbladder	O
mucosae	O
and	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
with	O
an	O
anomalous	O
junction	O
of	O
the	O
pancreaticobiliary	O
duct	O
.	O
Hanada	O
K,	O
Tsuchida	O
A	O
,	O
Iwao	O
T	O
,	O
Eguchi	O
N	O
,	O
Sasaki	O
T	O
,	O
Morinaka	O
K,	O
Matsubara	O
K,	O
Kawasaki	O
Y	O
,	O
Yamamoto	O
S	O
,	O
Kajiyama	O
G.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Onomichi	O
General	O
Hospital	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
OBJECTIVE	O
:	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
mutational	O
spectrum	O
of	O
K-ras	O
in	O
cases	O
of	O
gallbladder	O
and	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
with	O
an	O
anomalous	O
junction	O
of	O
the	O
pancreaticobiliary	O
duct	O
(	O
AJPBD	O
)	O
.	O
METHODS	O
:	O
We	O
examined	O
35	O
gallbladders	O
with	O
AJPBD	O
(	O
20	O
with	O
hyperplasia	B-malignancy-type
,	O
15	O
with	O
carcinoma	B-malignancy-type
)	O
and	O
38	O
gallbladders	O
without	O
AJPBD	O
(	O
four	O
normal	O
gallbladders	O
,	O
four	O
with	O
hyperplasia	B-malignancy-type
,	O
six	O
with	O
adenoma	B-malignancy-type
,	O
24	O
with	O
carcinoma	B-malignancy-type
)	O
.	O
Polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
were	O
performed	O
to	O
detect	O
mutations	O
in	O
codon	O
12	O
or	O
13	O
of	O
K-ras	O
.	O
RESULTS	O
:	O
In	O
the	O
cases	O
with	O
AJPBD	O
,	O
the	O
prevalences	O
of	O
K-ras	O
mutation	O
were	O
15	O
%	O
(	O
3	O
/	O
20	O
)	O
in	O
hyperplasia	B-malignancy-type
,	O
60	O
%	O
(	O
6	O
/	O
10	O
)	O
in	O
stage	O
I	O
carcinoma	B-malignancy-type
,	O
and	O
100	O
%	O
(	O
5	O
/	O
5	O
)	O
in	O
stage	O
II	O
-	O
IV	O
carcinoma	B-malignancy-type
.	O
In	O
the	O
cases	O
without	O
AJPBD	O
,	O
the	O
prevalences	O
of	O
K-ras	O
mutation	O
were	O
0	O
%	O
(	O
0	O
/	O
4	O
)	O
in	O
normal	O
gallbladder	O
,	O
0	O
%	O
(	O
0	O
/	O
4	O
)	O
in	O
hyperplasia	B-malignancy-type
,	O
17	O
%	O
(	O
1	O
/	O
6	O
)	O
in	O
adenoma	B-malignancy-type
,	O
7	O
%	O
(	O
1	O
/	O
16	O
)	O
in	O
stage	O
I	O
carcinoma	B-malignancy-type
,	O
and	O
38	O
%	O
(	O
3	O
/	O
8	O
)	O
in	O
stage	O
II	O
-	O
IV	O
carcinoma	B-malignancy-type
.	O
Prevalences	O
of	O
K-ras	O
mutation	O
in	O
hyperplasia	B-malignancy-type
and	O
carcinoma	B-malignancy-type
with	O
AJPBD	O
were	O
greater	O
than	O
those	O
without	O
AJPBD	O
(	O
p	O
<	O
0.05	O
)	O
.	O
The	O
point	O
mutation	O
of	O
GGT	O
to	O
GAT	O
in	O
codon	O
12	O
was	O
frequently	O
observed	O
in	O
the	O
cases	O
with	O
AJPBD	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
the	O
specific	O
K-ras	O
mutation	O
in	O
codon	O
12	O
(	O
GGT	O
to	O
GAT	O
)	O
may	O
contribute	O
to	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
in	O
the	O
gallbladder	O
with	O
AJPBD	O
.	O
PMID	O
:	O
10364037	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Lymphoma	O
1993	O
;11	O
Suppl	O
1	O
:25-	O
8	O
Molecular	O
defects	O
associated	O
with	O
the	O
acute	O
phase	O
CML	B-malignancy-type
.	O
Serra	O
A	O
,	O
Guerrasio	O
A	O
,	O
Gaidano	O
G	O
,	O
Rosso	O
C	O
,	O
Rege	O
-	O
Cambrin	O
G	O
,	O
Petroni	O
D	O
,	O
Mazza	O
U	O
,	O
Saglio	O
G.	O
Dipartimento	O
di	O
Scienze	O
Biomediche	O
e	O
Oncologia	O
Umana	O
,	O
Universita	O
di	O
Torino	O
,	O
Italy	O
.	O
Parts	O
of	O
the	O
Bcr	O
/	O
Abl	O
hybrid	O
transcript	O
supposed	O
to	O
be	O
important	O
for	O
its	O
transforming	O
ability	O
were	O
sequenced	O
in	O
a	O
series	O
of	O
CML	B-malignancy-type
blast	O
crises	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
possible	O
presence	O
of	O
alterations	O
responsible	O
for	O
the	O
disease	O
transition	O
from	O
the	O
chronic	O
to	O
the	O
acute	O
phase	O
.	O
In	O
addition	O
,	O
the	O
N	O
-	O
and	O
Ki	O
-	O
ras	O
as	O
well	O
as	O
the	O
p53	O
involvement	O
was	O
investigated	O
by	O
exploring	O
their	O
structure	O
and	O
expression	O
in	O
the	O
same	O
patients	O
.	O
We	O
used	O
traditional	O
types	O
of	O
molecular	O
analysis	O
including	O
Southern	O
and	O
Northern	O
blot	O
,	O
together	O
with	O
methods	O
that	O
allow	O
a	O
rapid	O
detection	O
of	O
point	O
mutations	O
and	O
microdeletions	O
,	O
such	O
as	O
SSCP	O
,	O
single	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
.	O
The	O
results	O
obtained	O
may	O
be	O
summarized	O
as	O
follows	O
:	O
no	O
alterations	O
were	O
found	O
in	O
the	O
parts	O
of	O
the	O
Bcr	O
/	O
Abl	O
transcripts	O
investigated	O
in	O
the	O
present	O
study	O
(	O
SH2	O
,	O
SH3	O
and	O
the	O
region	O
surrounding	O
codon	O
832	O
)	O
;	O
p53	O
alterations	O
were	O
observed	O
in	O
5	O
%	O
and	O
N	O
-	O
and	O
Ki	O
-	O
RAS	O
mutations	O
in	O
5	O
%	O
of	O
the	O
cases	O
examined	O
.	O
These	O
molecular	O
defects	O
are	O
therefore	O
responsible	O
for	O
the	O
clinical	O
progression	O
of	O
the	O
Ph1	O
-	O
positive	O
CML	B-malignancy-type
only	O
in	O
a	O
minority	O
of	O
cases	O
.	O
PMID	O
:	O
8251905	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1993	O
Jul;8	O
4	O
(	O
3	O
)	O
:	O
443	O
-50	O
Occurrence	O
of	O
point	O
mutations	O
in	O
p53	O
gene	O
is	O
not	O
increased	O
in	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
carrying	O
an	O
activating	O
N-ras	O
mutation	O
.	O
Buhler	O
-	O
Leclerc	O
M,	O
Gratwohl	O
A	O
,	O
Senn	O
HP	O
.	O
Institut	O
fur	O
Medizinische	O
Mikrobiologie	O
,	O
Universitat	O
Basel	O
,	O
Switzerland	O
.	O
The	O
frequency	O
of	O
simultaneously	O
detecting	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
was	O
studied	O
in	O
leukaemia	B-malignancy-type
cells	O
of	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
or	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Using	O
in	O
vitro	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
hybridization	O
analysis	O
,	O
45	O
AML	B-malignancy-type
and	O
six	O
MDS	B-malignancy-type
patients	O
were	O
screened	O
for	O
activating	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N-ras	O
.	O
Ten	O
of	O
them	O
(	O
eight	O
AML	B-malignancy-type
and	O
two	O
MDS	B-malignancy-type
)	O
were	O
found	O
positive	O
.	O
These	O
10	O
patients	O
and	O
10	O
others	O
without	O
activating	O
N-ras	O
mutation	O
were	O
further	O
analysed	O
by	O
direct	O
sequencing	O
of	O
the	O
amplified	O
exons	O
for	O
p53	O
mutations	O
and	O
for	O
atypical	O
N-ras	O
mutations	O
.	O
Beside	O
the	O
activating	O
mutations	O
in	O
the	O
N-ras	O
gene	O
,	O
no	O
additional	O
transforming	O
or	O
nontransforming	O
mutations	O
could	O
be	O
detected	O
in	O
the	O
N-ras	O
.	O
However	O
,	O
exon	O
7	O
of	O
p53	O
was	O
mutated	O
in	O
two	O
AML	B-malignancy-type
patients	O
without	O
activating	O
N-ras	O
mutation	O
.	O
These	O
data	O
show	O
that	O
p53	O
mutations	O
occurred	O
with	O
half	O
the	O
frequency	O
of	O
N-ras	O
mutations	O
in	O
AML	B-malignancy-type
and	O
that	O
no	O
positive	O
correlation	O
could	O
be	O
found	O
between	O
the	O
onset	O
of	O
mutations	O
in	O
N-ras	O
and	O
p53	O
genes	O
.	O
PMID	O
:	O
8217795	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surgery	O
1993	O
Oct;114(	O
4	O
)	O
:758-63	O
;	O
discussion	O
763-4	O
Comparison	O
of	O
mutations	O
of	O
ras	O
oncogene	O
in	O
human	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
and	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
.	O
Yashiro	O
T	O
,	O
Fulton	O
N	O
,	O
Hara	O
H,	O
Yasuda	O
K,	O
Montag	O
A	O
,	O
Yashiro	O
N	O
,	O
Straus	O
F	O
2nd	O
,	O
Ito	O
K,	O
Aiyoshi	O
Y	O
,	O
Kaplan	O
EL	O
.	O
Department	O
of	O
Surgery	O
,	O
Howard	O
Hughes	O
Medical	O
Institute	O
,	O
University	O
of	O
Chicago	O
Pritzker	O
School	O
of	O
Medicine	O
,	O
IL	O
60637	O
.	O
BACKGROUND	O
.	O
Ras	O
oncogene	O
mutations	O
have	O
been	O
found	O
in	O
many	O
human	O
cancers	O
;	O
however	O
,	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
have	O
rarely	O
been	O
studied	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
ras	O
mutations	O
in	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
and	O
to	O
compare	O
these	O
results	O
with	O
the	O
incidence	O
of	O
ras	O
mutations	O
in	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
cancers	I-malignancy-type
studied	O
in	O
our	O
laboratory	O
.	O
METHODS	O
.	O
Ras	O
oncogene	O
mutations	O
were	O
studied	O
in	O
33	O
foregut	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
(	O
pancreatic	B-malignancy-type
31	O
,	O
duodenal	B-malignancy-type
submucosa	I-malignancy-type
2	O
)	O
.	O
Eleven	O
were	O
insulinomas	B-malignancy-type
,	O
12	O
gastrinomas	B-malignancy-type
,	O
2	O
glucagonomas	B-malignancy-type
,	O
and	O
11	O
others	O
were	O
nonfunctioning	B-malignancy-type
islet	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Thirteen	O
were	O
benign	O
and	O
20	O
were	O
malignant	O
.	O
These	O
were	O
compared	O
with	O
65	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
cancers	I-malignancy-type
.	O
Tumors	O
were	O
microdissected	O
from	O
paraffin	O
-	O
embedded	O
sections	O
.	O
DNA	O
was	O
extracted	O
and	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
were	O
detected	O
by	O
a	O
oligonucleotide	O
hybridization	O
method	O
with	O
sequence	O
-	O
specific	O
phosphorus	O
32	O
-	O
radiolabeled	O
probes	O
.	O
RESULTS	O
.	O
No	O
ras	O
mutations	O
were	O
identified	O
among	O
the	O
33	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
.	O
In	O
contrast	O
,	O
51	O
of	O
65	O
(	O
78.5	O
%	O
)	O
pancreatic	B-malignancy-type
exocrine	I-malignancy-type
cancers	I-malignancy-type
exhibited	O
a	O
ras	O
mutation	O
.	O
Fifty	O
were	O
K-ras	O
mutations	O
and	O
one	O
unusual	O
tumor	O
exhibited	O
a	O
N-	O
61	O
ras	O
mutation	O
.	O
CONCLUSIONS	O
.	O
Ras	O
oncogene	O
mutations	O
do	O
not	O
play	O
a	O
role	O
in	O
the	O
tumorigenesis	O
of	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
8211691	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
May	O
1;	O
57	O
(	O
3	O
)	O
:	O
362-4	O
Association	O
of	O
H-ras	O
mutations	O
with	O
adenocarcinomas	B-malignancy-type
of	O
the	O
parotid	O
gland	O
.	O
van	O
Halteren	O
HK	O
,	O
Top	O
B	O
,	O
Mooi	O
WJ	O
,	O
Balm	O
AJ	O
,	O
Rodenhuis	O
S.	O
Department	O
of	O
Surgery	O
,	O
The	O
Netherlands	O
Cancer	O
Institute	O
,	O
Amsterdam	O
.	O
We	O
have	O
examined	O
17	O
adenocarcinomas	B-malignancy-type
and	O
2	O
mixed	O
tumors	O
of	O
the	O
salivary	O
glands	O
for	O
mutational	O
activation	O
of	O
the	O
oncogenes	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
.	O
The	O
presence	O
of	O
mutations	O
was	O
determined	O
by	O
in	O
vitro	O
amplification	O
of	O
gene	O
fragments	O
spanning	O
codons	O
12	O
,	O
13	O
and	O
61	O
and	O
the	O
use	O
of	O
mutation	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
ras	O
mutations	O
were	O
present	O
in	O
3	O
of	O
13	O
adenocarcinomas	B-malignancy-type
(	O
23	O
%	O
)	O
of	O
the	O
parotid	O
gland	O
.	O
The	O
mutations	O
were	O
confirmed	O
and	O
characterized	O
by	O
means	O
of	O
cycle	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
fragments	O
.	O
In	O
all	O
3	O
cases	O
,	O
the	O
mutation	O
was	O
an	O
A	O
:	O
T	O
to	O
G	O
:	O
C	O
transition	O
at	O
the	O
second	O
position	O
of	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
.	O
This	O
rather	O
unusual	O
ras	O
mutation	O
could	O
provide	O
a	O
clue	O
to	O
identify	O
one	O
or	O
more	O
carcinogens	O
involved	O
in	O
the	O
pathogenesis	O
of	O
parotid	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
8168996	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
Jul	O
15	O
;58(	O
2	O
)	O
:174	O
-	O
8	O
International	O
comparison	O
on	O
ras	O
gene	O
mutations	O
in	O
latent	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Watanabe	O
M,	O
Shiraishi	O
T	O
,	O
Yatani	O
R	O
,	O
Nomura	O
AM	O
,	O
Stemmermann	O
GN	O
.	O
Department	O
of	O
Pathology	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Tsu	O
,	O
Japan	O
.	O
Latent	O
carcinomas	B-malignancy-type
of	O
the	O
prostate	O
,	O
discovered	O
at	O
autopsy	O
in	O
men	O
with	O
no	O
prior	O
treatment	O
for	O
prostatic	B-malignancy-type
disease	I-malignancy-type
,	O
were	O
studied	O
for	O
ras	O
proto	O
-	O
oncogene	O
mutations	O
.	O
Subjects	O
included	O
21	O
Japanese	O
,	O
15	O
U.S.	O
whites	O
,	O
15	O
U.S.	O
blacks	O
,	O
20	O
Hawaiian	O
Japanese	O
and	O
10	O
Colombians	O
.	O
PCR	O
and	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
identified	O
mutations	O
in	O
5	O
Japanese	O
,	O
in	O
1	O
Hawaiian	O
Japanese	O
,	O
in	O
1	O
U.S.	O
black	O
,	O
in	O
1	O
U.S.	O
white	O
and	O
in	O
3	O
Colombians	O
.	O
The	O
5	O
Japanese	O
tumor	O
samples	O
contained	O
3	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
and	O
2	O
mutations	O
in	O
codon	O
12	O
of	O
N-ras	O
respectively	O
.	O
One	O
tumor	O
in	O
a	O
Hawaiian	O
Japanese	O
man	O
also	O
showed	O
a	O
K-ras	O
point	O
mutation	O
at	O
codon	O
12	O
.	O
Two	O
Colombians	O
and	O
one	O
U.S.	O
black	O
man	O
had	O
tumors	O
with	O
mutations	O
at	O
codon	O
61	O
of	O
H-ras	O
,	O
while	O
1	O
Colombian	O
showed	O
an	O
N-ras	O
mutation	O
at	O
this	O
codon	O
.	O
The	O
overall	O
frequency	O
of	O
ras	O
gene	O
mutations	O
was	O
low	O
,	O
but	O
point	O
mutations	O
in	O
codon	O
12	O
were	O
most	O
common	O
in	O
latent	O
tumors	O
of	O
Japanese	O
,	O
who	O
experienced	O
the	O
lowest	O
incidence	O
and	O
mortality	O
from	O
this	O
tumor	O
.	O
Latent	O
tumors	O
in	O
men	O
from	O
ethnic	O
groups	O
with	O
high	O
mortality	O
and	O
incidence	O
rates	O
showed	O
fewer	O
ras	O
mutations	O
than	O
the	O
Japanese	O
,	O
and	O
these	O
were	O
more	O
likely	O
to	O
involve	O
codon	O
61	O
.	O
This	O
finding	O
is	O
consistent	O
with	O
prior	O
studies	O
of	O
more	O
aggressive	O
clinical	O
cancers	O
in	O
Japanese	O
men	O
that	O
indicated	O
a	O
higher	O
frequency	O
of	O
mutations	O
at	O
codon	O
61	O
.	O
PMID	O
:	O
8026877	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Oral	O
Pathol	O
Med	O
1994	O
Aug;23(	O
7	O
)	O
:	O
298-301	O
High	O
incidence	O
of	O
H-ras	O
oncogene	O
mutations	O
in	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
lip	O
vermilion	O
.	O
Milasin	O
J,	O
Pujic	O
N	O
,	O
Dedovic	O
N	O
,	O
Nikolic	O
Z	O
,	O
Petrovic	O
V	O
,	O
Dimitrijevic	O
B.	O
Nine	O
specimens	O
of	O
well	O
-	O
differentiated	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
lip	O
vermilion	O
have	O
been	O
analyzed	O
for	O
the	O
presence	O
of	O
H-ras	O
oncogene	O
mutations	O
,	O
using	O
the	O
technique	O
of	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
on	O
in	O
vitro	O
amplified	O
tumour	O
DNA	O
.	O
Five	O
specimens	O
harbored	O
mutations	O
:	O
four	O
in	O
codon	O
12	O
and	O
one	O
in	O
codon	O
13	O
.	O
This	O
high	O
incidence	O
(	O
55	O
%	O
)	O
of	O
mutated	O
H-ras	O
genes	O
suggests	O
that	O
their	O
activation	O
may	O
play	O
an	O
important	O
role	O
in	O
lip	B-malignancy-type
tumour	I-malignancy-type
development	O
and	O
may	O
be	O
connected	O
to	O
the	O
exposure	O
to	O
chemical	O
and/or	O
physical	O
carcinogens	O
.	O
PMID	O
:	O
7965884	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1994;30A(	O
7	O
)	O
:987	O
-	O
93	O
Selective	O
activation	O
of	O
ras	O
oncogenes	O
in	O
follicular	B-malignancy-type
and	O
undifferentiated	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Manenti	O
G	O
,	O
Pilotti	O
S	O
,	O
Re	O
FC	O
,	O
Della	O
Porta	O
G	O
,	O
Pierotti	O
MA.	O
Divisione	O
di	O
Oncologia	O
Sperimentale	O
A	O
,	O
Istituto	O
Nazionale	O
Tumori	O
,	O
Milan	O
,	O
Italy	O
.	O
A	O
total	O
of	O
96	O
tumour	O
samples	O
(	O
88	O
primary	O
tumours	O
and	O
8	O
nodal	O
metastases	O
)	O
from	O
88	O
patients	O
with	O
thyroid	B-malignancy-type
adenomas	B-malignancy-type
and	O
carcinomas	B-malignancy-type
were	O
investigated	O
for	O
ras	O
gene	O
mutations	O
using	O
polymerase	O
chain	O
reaction	O
,	O
oligonucleotide	O
probing	O
and	O
sequencing	O
.	O
Neither	O
the	O
19	O
adenomas	B-malignancy-type
nor	O
the	O
31	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
analysed	O
harboured	O
point	O
mutations	O
.	O
In	O
our	O
cases	O
,	O
mutations	O
in	O
all	O
three	O
ras	O
oncogenes	O
were	O
found	O
in	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
five	O
out	O
of	O
21	O
)	O
and	O
in	O
the	O
less	O
differentiated	O
thyroid	B-malignancy-type
tumour	I-malignancy-type
:	O
poorly	O
differentiated	O
carcinomas	B-malignancy-type
(	O
three	O
out	O
of	O
11	O
)	O
and	O
undifferentiated	O
carcinomas	B-malignancy-type
(	O
one	O
out	O
of	O
five	O
)	O
.	O
Finally	O
,	O
mutated	O
ras	O
oncogenes	O
had	O
a	O
significant	O
association	O
with	O
the	O
appearance	O
of	O
haematogenous	O
(	O
particularly	O
bone	O
)	O
metastases	O
,	O
suggesting	O
a	O
role	O
of	O
ras	O
genes	O
activation	O
in	O
the	O
metastatic	O
capability	O
of	O
these	O
tumours	O
.	O
PMID	O
:	O
7946598	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1995	O
Jun	O
15	O
;55	O
(	O
12	O
)	O
:2511	O
-5	O
Allele	O
-	O
specific	O
mutations	O
involved	O
in	O
the	O
pathogenesis	O
of	O
endemic	B-malignancy-type
gallbladder	I-malignancy-type
carcinoma	I-malignancy-type
in	O
Chile	O
.	O
Wistuba	O
II	O
,	O
Sugio	O
K,	O
Hung	O
J,	O
Kishimoto	O
Y	O
,	O
Virmani	O
AK	O
,	O
Roa	O
I	O
,	O
Albores-Saavedra	O
J,	O
Gazdar	O
AF.	O
Simmons	O
Cancer	O
Center	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
,	O
USA	O
.	O
Although	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
is	O
one	O
of	O
the	O
most	O
frequent	O
neoplasms	B-malignancy-type
in	O
Chile	O
,	O
there	O
is	O
limited	O
information	O
about	O
the	O
molecular	O
changes	O
involved	O
in	O
its	O
pathogenesis	O
.	O
We	O
investigated	O
the	O
incidence	O
of	O
ras	O
gene	O
mutations	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
following	O
genes	O
/	O
loci	O
:	O
p53	O
,	O
DCC	O
,	O
rb	O
,	O
5q	O
3p	O
,	O
8p	O
,	O
and	O
9p	O
.	O
We	O
precisely	O
microdissected	O
194	O
relevant	O
areas	O
from	O
paraffin	O
-	O
embedded	O
microslides	O
from	O
25	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
and	O
their	O
accompanying	O
nonneoplastic	O
lesions	O
(	O
which	O
were	O
present	O
in	O
15	O
cases	O
)	O
from	O
patients	O
in	O
Chile	O
.	O
The	O
specimens	O
were	O
analyzed	O
by	O
PCR	O
-	O
based	O
assays	O
for	O
LOH	O
,	O
and	O
we	O
designed	O
a	O
RFLP	O
method	O
for	O
ras	O
mutations	O
and	O
immunohistochemistry	O
for	O
p53	O
protein	O
overexpression	O
.	O
We	O
determined	O
that	O
LOH	O
at	O
p53	O
(	O
91	O
%	O
)	O
,	O
9p	O
(	O
50	O
%	O
)	O
,	O
8p	O
(	O
44	O
%	O
)	O
and	O
DCC	O
(	O
31	O
%	O
)	O
are	O
frequent	O
events	O
and	O
that	O
LOH	O
at	O
p53	O
,	O
9p	O
,	O
and	O
DCC	O
are	O
early	O
events	O
,	O
while	O
ras	O
mutations	O
and	O
LOH	O
at	O
3p	O
,	O
rb	O
,	O
and	O
5q	O
occurred	O
occasionally	O
.	O
LOH	O
at	O
p53	O
occurred	O
more	O
frequently	O
and	O
earlier	O
than	O
protein	O
overexpression	O
.	O
The	O
mean	O
number	O
of	O
mutations	O
present	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
was	O
2.1	O
,	O
and	O
in	O
six	O
cases	O
,	O
LOH	O
at	O
the	O
p53	O
gene	O
was	O
the	O
sole	O
mutation	O
detected	O
.	O
The	O
same	O
allele	O
was	O
lost	O
in	O
61	O
(	O
93	O
%	O
)	O
of	O
71	O
nonneoplastic	O
foci	O
as	O
in	O
the	O
corresponding	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
for	O
all	O
four	O
mutations	O
studied	O
.	O
The	O
odds	O
of	O
this	O
occurring	O
by	O
chance	O
are	O
approximately	O
4	O
x	O
10(-15)	O
.	O
Although	O
clonality	O
cannot	O
be	O
excluded	O
,	O
allelic	O
loss	O
appears	O
to	O
be	O
highly	O
directed	O
,	O
but	O
the	O
mechanism	O
for	O
allele	O
-	O
specific	O
mutations	O
remains	O
to	O
be	O
determined	O
.	O
PMID	O
:	O
7780959	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1995	O
May	O
1;8	O
5	O
(	O
9	O
)	O
:2546-52	O
Mutations	O
of	O
the	O
p53	O
and	O
ras	O
genes	O
in	O
childhood	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Kawamura	O
M,	O
Kikuchi	O
A	O
,	O
Kobayashi	O
S	O
,	O
Hanada	O
R	O
,	O
Yamamoto	O
K,	O
Horibe	O
K,	O
Shikano	O
T	O
,	O
Ueda	O
K,	O
Hayashi	O
K,	O
Sekiya	O
T	O
,	O
et	O
al	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
We	O
have	O
investigated	O
the	O
alterations	O
of	O
p53	O
and	O
ras	O
genes	O
including	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
in	O
22	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
cases	O
and	O
five	O
cell	O
lines	O
carrying	O
t	O
(	O
1	O
;	O
19	O
)	O
by	O
use	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
The	O
mutations	O
of	O
the	O
p53	O
gene	O
were	O
found	O
in	O
2	O
of	O
20	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
cases	O
at	O
diagnosis	O
(	O
10	O
%	O
)	O
,	O
all	O
of	O
4	O
cases	O
at	O
relapse	O
(	O
100	O
%	O
)	O
,	O
and	O
4	O
of	O
the	O
5	O
cell	O
lines	O
(	O
80	O
%	O
)	O
.	O
Four	O
of	O
the	O
five	O
patients	O
who	O
died	O
had	O
missense	O
mutations	O
at	O
codons	O
49	O
,	O
177	O
,	O
179	O
,	O
and	O
248	O
.	O
In	O
cases	O
examined	O
sequentially	O
,	O
one	O
had	O
the	O
same	O
point	O
mutation	O
at	O
codon	O
179	O
at	O
both	O
diagnosis	O
and	O
relapse	O
,	O
and	O
another	O
had	O
the	O
same	O
p53	O
gene	O
mutation	O
at	O
codon	O
240	O
both	O
in	O
leukemic	O
cells	O
at	O
relapse	O
and	O
in	O
a	O
cell	O
line	O
derived	O
at	O
that	O
time	O
.	O
The	O
other	O
case	O
had	O
no	O
mutation	O
at	O
diagnosis	O
but	O
had	O
the	O
mutation	O
at	O
codon	O
177	O
at	O
relapse	O
and	O
cell	O
lines	O
derived	O
from	O
blast	O
cells	O
at	O
diagnosis	O
,	O
suggesting	O
that	O
a	O
small	O
number	O
of	O
leukemic	O
cells	O
with	O
the	O
p53	O
gene	O
mutation	O
at	O
diagnosis	O
might	O
have	O
escaped	O
PCR	O
-	O
SSCP	O
analysis	O
.	O
In	O
cell	O
lines	O
,	O
SCMC	O
-	O
L9	O
had	O
three	O
point	O
mutations	O
in	O
the	O
p53	O
gene	O
at	O
codons	O
175	O
,	O
248	O
,	O
and	O
358	O
,	O
whereas	O
SCMC	O
-	O
L10	O
had	O
frame	O
shift	O
at	O
codons	O
209	O
-	O
211	O
.	O
One	O
case	O
had	O
a	O
rare	O
polymorphism	O
at	O
codon	O
11	O
.	O
We	O
found	O
only	O
one	O
mutation	O
of	O
the	O
N-ras	O
gene	O
that	O
was	O
a	O
2	O
-	O
bp	O
substitution	O
of	O
GGT	O
(	O
Gly	O
)	O
to	O
GTC	O
(	O
Val	O
)	O
at	O
codon	O
13	O
among	O
22	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
cases	O
and	O
five	O
cell	O
lines	O
.	O
This	O
case	O
showed	O
no	O
mutation	O
of	O
the	O
p53	O
gene	O
and	O
has	O
had	O
a	O
good	O
course	O
.	O
These	O
results	O
suggest	O
that	O
in	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
,	O
mutations	O
of	O
the	O
p53	O
and	O
ras	O
genes	O
are	O
infrequent	O
at	O
diagnosis	O
and	O
that	O
p53	O
gene	O
alterations	O
may	O
be	O
associated	O
with	O
relapse	O
phase	O
or	O
progression	O
of	O
t	O
(	O
1	O
;	O
19	O
)	O
-	O
ALL	B-malignancy-type
.	O
PMID	O
:	O
7727782	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Invest	O
1993	O
;11(	O
1	O
)	O
:25-32	O
Comment	O
in	O
:	O
Cancer	O
Invest	O
.	O
1993	O
;11(	O
1	O
)	O
:92	O
-3.	O
Mutational	O
status	O
of	O
codons	O
12	O
and	O
13	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
genes	O
in	O
tissue	O
and	O
cell	O
lines	O
derived	O
from	O
primary	O
and	O
metastatic	O
prostate	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Pergolizzi	O
RG	O
,	O
Kreis	O
W	O
,	O
Rottach	O
C	O
,	O
Susin	O
M,	O
Broome	O
JD.	O
Department	O
of	O
Research	O
,	O
North	O
Shore	O
University	O
Hospital	O
-Cornell	O
University	O
Medical	O
College	O
,	O
Manhasset	O
,	O
New	O
York	O
11030	O
.	O
N	O
-	O
and	O
K	O
-	O
ras	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
were	O
investigated	O
using	O
oligonucleotide	O
hybridization	O
analysis	O
after	O
PCR	O
amplification	O
and	O
subsequent	O
sequence	O
analysis	O
of	O
the	O
amplified	O
DNA	O
from	O
the	O
region	O
of	O
interest	O
in	O
the	O
following	O
prostatic	B-malignancy-type
primary	O
and	O
metastatic	O
(	O
met	O
)	O
carcinoma	B-malignancy-type
-	O
derived	O
cell	O
lines	O
:	O
1013L	O
(	O
primary	O
)	O
,	O
PC3	O
(	O
bone	O
met	O
)	O
,	O
DU145	O
(	O
brain	O
met	O
)	O
,	O
and	O
LNCaP	O
(	O
lymph	O
node	O
met	O
)	O
.	O
We	O
also	O
examined	O
fresh	O
and	O
archival	O
primary	O
and	O
metastatic	O
prostate	B-malignancy-type
tumor	I-malignancy-type
tissue	O
and	O
benign	O
prostatic	O
hypertrophy	O
specimens	O
.	O
All	O
prostatic	O
cells	O
and	O
tissues	O
examined	O
contain	O
at	O
least	O
one	O
wild	O
-	O
type	O
N	O
-	O
and	O
K	O
-	O
ras	O
allele	O
with	O
respect	O
to	O
codons	O
12	O
and	O
13	O
.	O
No	O
mutations	O
were	O
found	O
at	O
N-ras	O
codon	O
13	O
.	O
The	O
only	O
mutation	O
seen	O
in	O
the	O
prostatic	O
cell	O
lines	O
and	O
tissues	O
was	O
a	O
K-ras	O
codon	O
12	O
position	O
II	O
G	O
-	O
to	O
-	O
T	O
transversion	O
.	O
Since	O
these	O
are	O
established	O
nonclonal	O
cell	O
lines	O
that	O
have	O
adapted	O
to	O
tissue	O
culture	O
,	O
it	O
is	O
possible	O
that	O
this	O
mutation	O
does	O
not	O
represent	O
the	O
mutational	O
state	O
of	O
prostatic	B-malignancy-type
carcinoma	I-malignancy-type
in	O
vivo	O
.	O
However	O
,	O
the	O
lack	O
of	O
consistent	O
mutation	O
in	O
the	O
ras	O
genes	O
amplified	O
directly	O
from	O
tumors	O
suggests	O
that	O
when	O
ras	O
mutations	O
occur	O
during	O
the	O
progression	O
of	O
prostatic	B-malignancy-type
carcinoma	I-malignancy-type
,	O
they	O
are	O
late	O
-	O
stage	O
events	O
not	O
directly	O
involved	O
in	O
the	O
initial	O
development	O
of	O
disease	O
.	O
Immunoprecipitation	O
studies	O
using	O
pan	O
-	O
ras	O
antibodies	O
revealed	O
no	O
evidence	O
of	O
altered	O
expression	O
of	O
Ras	O
proteins	O
.	O
PMID	O
:	O
7678540	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1995	O
Aug	O
3;11(	O
3	O
)	O
:601-3	O
Pattern	O
of	O
ras	O
and	O
gsp	O
oncogene	O
mutations	O
in	O
radiation	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
human	I-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
.	O
Challeton	O
C	O
,	O
Bounacer	O
A	O
,	O
Du	O
Villard	O
JA	O
,	O
Caillou	O
B	O
,	O
De	O
Vathaire	O
F	O
,	O
Monier	O
R	O
,	O
Schlumberger	O
M,	O
Suarez	O
HG.	O
IFC	O
HO1	O
,	O
Laboratoire	O
de	O
Genetique	O
Moleculaire	O
,	O
Villejuif	O
,	O
France	O
.	O
The	O
preferential	O
activation	O
of	O
the	O
Ki-ras	O
oncogene	O
in	O
follicular	B-malignancy-type
radiation	I-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
human	I-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
,	O
has	O
been	O
suggested	O
by	O
Wright	O
et	O
al.	O
(	O
1991	O
)	O
.	O
However	O
,	O
only	O
12	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
were	O
analysed	O
in	O
this	O
study	O
.	O
In	O
order	O
to	O
confirm	O
if	O
radiation	O
favours	O
,	O
in	O
human	O
thyroid	O
tumorigenesis	O
,	O
the	O
appearance	O
of	O
a	O
particular	O
molecular	O
lesion	O
,	O
we	O
studied	O
33	O
benign	O
and	O
malignant	O
human	O
radiation	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
.	O
We	O
used	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
allele	O
-	O
specific	O
hybridization	O
with	O
mutant	O
-	O
specific	O
probes	O
for	O
the	O
three	O
ras	O
genes	O
and	O
the	O
gsp	O
oncogene	O
.	O
Compared	O
to	O
85	O
'	B-malignancy-type
spontaneous	I-malignancy-type
'	I-malignancy-type
human	I-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
,	O
the	O
radiation	O
-	O
associated	O
cases	O
:	O
(1)	O
show	O
a	O
similar	O
overall	O
frequency	O
of	O
ras	O
and	O
gsp	O
mutations	O
(	O
about	O
30	O
%	O
and	O
6	O
%	O
respectively	O
)	O
;	O
(2)	O
present	O
a	O
similar	O
frequency	O
of	O
mutation	O
of	O
the	O
three	O
ras	O
genes	O
without	O
any	O
predominance	O
in	O
adenomas	B-malignancy-type
and	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
and	O
(3)	O
all	O
Ki-ras	O
mutations	O
were	O
found	O
in	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
(	O
4	O
/	O
15	O
)	O
.	O
ras	O
and	O
gsp	O
genes	O
were	O
never	O
found	O
mutated	O
simultaneously	O
,	O
suggesting	O
an	O
alternative	O
role	O
for	O
both	O
oncogenes	O
in	O
the	O
thyroid	O
tumorigenic	O
radiation	O
-	O
associated	O
process	O
.	O
PMID	O
:	O
7630645	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1995	O
Oct;147	O
(	O
4	O
)	O
:	O
1112-22	O
Intratumor	O
cellular	O
heterogeneity	O
and	O
alterations	O
in	O
ras	O
oncogene	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
in	O
human	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Konishi	O
N	O
,	O
Hiasa	O
Y	O
,	O
Matsuda	O
H,	O
Tao	O
M,	O
Tsuzuki	O
T	O
,	O
Hayashi	O
I	O
,	O
Kitahori	O
Y	O
,	O
Shiraishi	O
T	O
,	O
Yatani	O
R	O
,	O
Shimazaki	O
J,	O
et	O
al	O
.	O
Department	O
of	O
Pathology	O
,	O
Nara	O
Medical	O
University	O
,	O
Japan	O
.	O
To	O
assess	O
the	O
potential	O
role	O
of	O
ras	O
oncogene	O
activation	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
mutations	O
in	O
the	O
development	O
of	O
human	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
,	O
nine	O
cases	O
of	O
histologically	O
heterogeneous	O
prostate	B-malignancy-type
tumors	I-malignancy-type
obtained	O
from	O
total	O
prostatectomies	O
were	O
probed	O
for	O
these	O
specific	O
events	O
.	O
Each	O
tumor	O
was	O
divided	O
into	O
5	O
to	O
10	O
areas	O
according	O
to	O
different	O
growth	O
or	O
histological	O
patterns	O
.	O
Targeted	O
DNA	O
sequences	O
coding	O
for	O
ras	O
and	O
p53	O
were	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
analyzed	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphisms	O
,	O
and	O
confirmed	O
by	O
direct	O
DNA	O
sequencing	O
.	O
Point	O
mutations	O
of	O
the	O
ras	O
gene	O
were	O
found	O
in	O
three	O
of	O
the	O
nine	O
tumors	O
.	O
Two	O
contained	O
K-ras	O
codon	O
13	O
and	O
H-ras	O
codon	O
61	O
mutations	O
,	O
found	O
in	O
only	O
one	O
and	O
three	O
areas	O
of	O
each	O
lesion	O
,	O
respectively	O
.	O
The	O
third	O
tumor	O
contained	O
two	O
different	O
point	O
mutations	O
in	O
K-ras	O
codons	O
13	O
and	O
61	O
in	O
different	O
foci	O
of	O
the	O
sample	O
.	O
Loss	O
of	O
heterozygosity	O
at	O
the	O
polymorphic	O
codon	O
72	O
in	O
the	O
p53	O
gene	O
was	O
detected	O
in	O
two	O
of	O
four	O
informative	O
cases	O
(	O
50	O
%	O
)	O
showing	O
fragment	O
cleavage	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O
Mutations	O
in	O
p53	O
,	O
missense	O
transversions	O
,	O
single	O
base	O
insertions	O
,	O
and	O
two	O
base	O
deletions	O
were	O
also	O
detected	O
in	O
three	O
tumors	O
.	O
The	O
present	O
results	O
reveal	O
mutated	O
ras	O
and	O
p53	O
occasionally	O
occurring	O
in	O
small	O
foci	O
of	O
the	O
tumor	O
and	O
that	O
genetic	O
mutations	O
in	O
p53	O
,	O
as	O
opposed	O
to	O
those	O
in	O
ras	O
,	O
are	O
more	O
closely	O
associated	O
with	O
invasive	O
growth	O
of	O
heterogeneous	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
7573356	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1995	O
Feb;12(	O
2	O
)	O
:	O
110	O
-	O
6	O
N	O
-	O
and	O
K	O
RAS	O
mutations	O
in	O
primary	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
:	O
incidence	O
and	O
possible	O
biological	O
implications	O
.	O
Olie	O
RA	O
,	O
Looijenga	O
LH	O
,	O
Boerrigter	O
L,	O
Top	O
B	O
,	O
Rodenhuis	O
S	O
,	O
Langeveld	O
A	O
,	O
Mulder	O
MP	O
,	O
Oosterhuis	O
JW	O
.	O
Laboratory	O
of	O
Experimental	O
Patho-Oncology	O
,	O
Dr	O
.	O
Daniel	O
den	O
Hoed	O
Cancer	O
Center	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
.	O
Recently	O
,	O
conflicting	O
results	O
have	O
been	O
reported	O
on	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
primary	O
testicular	B-malignancy-type
germ	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	O
adults	O
(	O
TGCTs	B-malignancy-type
)	O
.	O
In	O
four	O
studies	O
a	O
low	O
incidence	O
of	O
mutations	O
(	O
less	O
than	O
15	O
%	O
)	O
in	O
a	O
variety	O
of	O
TGCTs	B-malignancy-type
or	O
derived	O
cell	O
lines	O
was	O
found	O
,	O
whereas	O
in	O
two	O
other	O
studies	O
a	O
high	O
incidence	O
of	O
N	O
-	O
or	O
K	O
RAS	O
mutations	O
(	O
over	O
40	O
%	O
)	O
was	O
shown	O
.	O
A	O
total	O
of	O
62	O
testicular	B-malignancy-type
seminomas	I-malignancy-type
(	O
SE	B-malignancy-type
)	O
and	O
34	O
nonseminomatous	B-malignancy-type
TGCTs	I-malignancy-type
(	O
NS	B-malignancy-type
)	O
were	O
studied	O
thus	O
far	O
.	O
The	O
largest	O
series	O
consisted	O
of	O
42	O
TGCTs	B-malignancy-type
,	O
studied	O
on	O
paraffin	O
embedded	O
tissue	O
.	O
We	O
present	O
the	O
results	O
of	O
analysis	O
for	O
the	O
presence	O
of	O
N	O
-	O
and	O
K	O
RAS	O
mutations	O
,	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
,	O
in	O
snap	O
frozen	O
samples	O
of	O
100	O
primary	O
TGCTs	B-malignancy-type
,	O
comprising	O
40	O
SE	B-malignancy-type
and	O
60	O
NS	B-malignancy-type
.	O
Using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
allele	O
specific	O
oligonucleotide	O
hybridization	O
(	O
ASO	O
)	O
,	O
mutations	O
were	O
found	O
in	O
five	O
SE	O
(	O
three	O
in	O
NRAS	O
and	O
two	O
in	O
KRAS	O
,	O
all	O
codon	O
12	O
)	O
,	O
and	O
in	O
one	O
NS	B-malignancy-type
(	O
KRAS	O
,	O
codon	O
12	O
)	O
.	O
To	O
exclude	O
underestimation	O
of	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
TGCTs	B-malignancy-type
due	O
to	O
the	O
presence	O
of	O
an	O
excess	O
of	O
wild	O
type	O
alleles	O
in	O
the	O
analyzed	O
sample	O
,	O
a	O
PCR	O
technique	O
preferentially	O
amplifying	O
KRAS	O
alleles	O
with	O
a	O
mutation	O
in	O
codon	O
12	O
was	O
applied	O
to	O
all	O
SE	B-malignancy-type
.	O
This	O
approach	O
,	O
allowing	O
a	O
250	O
times	O
more	O
sensitive	O
assay	O
,	O
resulted	O
in	O
the	O
detection	O
of	O
only	O
one	O
additional	O
SE	B-malignancy-type
with	O
a	O
mutation	O
.	O
Based	O
on	O
a	O
critical	O
analysis	O
of	O
published	O
data	O
and	O
on	O
our	O
results	O
from	O
the	O
largest	O
series	O
of	O
frozen	O
samples	O
investigated	O
thus	O
far	O
,	O
we	O
conclude	O
that	O
N	O
-	O
or	O
K	O
RAS	O
mutations	O
are	O
rare	O
and	O
apparently	O
not	O
essential	O
for	O
initiation	O
or	O
progression	O
of	O
TGCTs	B-malignancy-type
.	O
PMID	O
:	O
7535083	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
1995	O
Oct	O
1;8	O
4	O
(	O
1	O
)	O
:60	O
-	O
8	O
Correlation	O
of	O
cytogenetic	O
results	O
with	O
immunophenotype	O
,	O
genotype	O
,	O
clinical	O
features	O
,	O
and	O
ras	O
mutation	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
A	O
study	O
of	O
235	O
Chinese	O
patients	O
in	O
Taiwan	O
.	O
Tien	O
HF	O
,	O
Wang	O
CH	O
,	O
Lin	O
MT	O
,	O
Lee	O
FY	O
,	O
Liu	O
MC	O
,	O
Chuang	O
SM	O
,	O
Chen	O
YC	O
,	O
Shen	O
MC	O
,	O
Lin	O
KH	O
,	O
Lin	O
DT.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
Republic	O
of	O
China	O
.	O
Of	O
235	O
consecutive	O
patients	O
with	O
de	O
novo	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
clonal	O
chromosomal	O
abnormalities	O
were	O
detected	O
in	O
151	O
(	O
64	O
%	O
)	O
of	O
them	O
.	O
Twenty-four	O
of	O
the	O
71	O
patients	O
with	O
M2	O
AML	B-malignancy-type
had	O
t	O
(	O
8	O
;	O
21	O
)	O
,	O
35	O
of	O
the	O
36	O
M3	O
patients	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
and	O
11	O
of	O
the	O
45	O
M4	O
leukemia	B-malignancy-type
disclosed	O
inv	O
(	O
16	O
)	O
.	O
Six	O
of	O
the	O
eight	O
patients	O
with	O
11	O
q	O
23	O
abnormality	O
had	O
M4	O
or	O
M5	O
subtype	O
of	O
leukemia	B-malignancy-type
.	O
The	O
incidence	O
of	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
t	O
(	O
8	O
;	O
21	O
)	O
was	O
higher	O
in	O
our	O
patients	O
than	O
in	O
patients	O
from	O
most	O
Western	O
countries	O
.	O
Immunophenotyping	O
was	O
performed	O
on	O
197	O
patients	O
.	O
Patients	O
with	O
t	O
(	O
15	O
;	O
17	O
)	O
were	O
associated	O
with	O
negativity	O
to	O
HLA	O
-	O
DR	O
,	O
CD11b	O
,	O
and	O
CD34	O
.	O
Patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
expressed	O
CD13	O
and	O
CD33	O
less	O
frequently	O
than	O
other	O
patients	O
,	O
but	O
all	O
showed	O
CD15	O
positivity	O
.	O
Coexpression	O
of	O
lymphoid	O
-	O
associated	O
antigens	O
on	O
the	O
leukemic	O
blasts	O
was	O
detected	O
in	O
52	O
patients	O
(	O
26	O
%	O
)	O
,	O
including	O
all	O
7	O
patients	O
with	O
t	O
(	O
9	O
;	O
22	O
)	O
,	O
3	O
of	O
the	O
8	O
patients	O
with	O
t	O
/	O
del	O
(	O
11	O
)	O
(	O
q23	O
)	O
,	O
2	O
of	O
the	O
25	O
patients	O
with	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
and	O
2	O
of	O
the	O
22	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
.	O
Seven	O
(	O
35	O
%	O
)	O
of	O
the	O
20	O
patients	O
coexpressing	O
lymphoid	O
markers	O
showed	O
immunoglobulin	O
heavy	O
chain	O
or	O
T-cell	O
receptor	O
beta	O
-	O
chain	O
gene	O
rearrangements	O
,	O
while	O
only	O
2	O
(	O
4	O
%	O
)	O
of	O
the	O
53	O
patients	O
without	O
lymphoid	O
antigen	O
expression	O
did	O
so	O
.	O
Patients	O
with	O
inv	O
(	O
16	O
)	O
,	O
t	O
(	O
8	O
;	O
21	O
)	O
,	O
and	O
t	O
(	O
15	O
;	O
17	O
)	O
had	O
a	O
better	O
prognosis	O
than	O
other	O
patients	O
.	O
Of	O
all	O
surface	O
antigens	O
tested	O
,	O
only	O
CD15	O
,	O
CD11b	O
,	O
and	O
HLA	O
-	O
DR	O
were	O
of	O
prognostic	O
value	O
:	O
CD15	O
with	O
a	O
higher	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
and	O
CD11b	O
or	O
HLA	O
-	O
DR	O
with	O
a	O
shorter	O
CR	O
duration	O
.	O
N-ras	O
mutations	O
were	O
detected	O
in	O
7	O
(	O
18	O
%	O
)	O
of	O
the	O
40	O
patients	O
in	O
the	O
study	O
,	O
including	O
two	O
of	O
the	O
three	O
patients	O
with	O
inv	O
(	O
16	O
)	O
.	O
This	O
study	O
demonstrated	O
differences	O
in	O
clinical	O
features	O
,	O
immunophenotypes	O
,	O
and	O
genotypes	O
among	O
different	O
cytogenetic	O
subgroups	O
.	O
PMID	O
:	O
7497445	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Nov;4(	O
11	O
)	O
:	O
1363	O
-	O
74	O
Analysis	O
of	O
ras	O
oncogenes	O
in	O
malignant	O
melanoma	B-malignancy-type
and	O
precursor	B-malignancy-type
lesions	I-malignancy-type
:	O
correlation	O
of	O
point	O
mutations	O
with	O
differentiation	O
phenotype	O
.	O
Albino	O
AP	O
,	O
Nanus	O
DM	O
,	O
Mentle	O
IR	O
,	O
Cordon	O
-	O
Cardo	O
C	O
,	O
McNutt	O
NS	O
,	O
Bressler	O
J,	O
Andreeff	O
M.	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
New	O
York	O
10021	O
.	O
This	O
study	O
examined	O
noncultured	O
and	O
cultured	O
melanomas	B-malignancy-type
and	O
related	O
precursor	O
specimens	O
for	O
(i)	O
mutated	O
ras	O
genes	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
methodology	O
,	O
(ii)	O
correlation	O
of	O
mutated	O
ras	O
genes	O
with	O
differentiation	O
related	O
phenotypic	O
characteristics	O
,	O
(iii)	O
expression	O
of	O
ras	O
-	O
encoded	O
p21	O
proteins	O
in	O
tissues	O
by	O
immunoperoxidase	O
analysis	O
,	O
(iv)	O
quantitative	O
expression	O
of	O
mutated	O
and	O
wild	O
-	O
type	O
ras	O
encoded	O
p21	O
proteins	O
by	O
flow	O
cytometry	O
,	O
and	O
(v)	O
correlation	O
between	O
p21	O
expression	O
,	O
the	O
occurrence	O
of	O
ras	O
mutations	O
,	O
and	O
cell	O
cycle	O
kinetics	O
.	O
The	O
results	O
of	O
these	O
studies	O
are	O
(1)	O
24	O
%	O
of	O
cultured	O
malignant	O
melanomas	B-malignancy-type
have	O
activated	O
ras	O
genes	O
,	O
with	O
N-ras	O
being	O
activated	O
ten	O
times	O
as	O
frequently	O
as	O
Harvey	O
(	O
Ha	O
)	O
-	O
ras	O
.	O
Each	O
example	O
of	O
an	O
activated	O
ras	O
gene	O
showed	O
a	O
mutation	O
at	O
the	O
61st	O
codon	O
of	O
the	O
protein	O
,	O
with	O
the	O
exception	O
of	O
one	O
melanoma	B-malignancy-type
which	O
showed	O
a	O
mutation	O
at	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
;	O
(2)	O
all	O
the	O
melanomas	B-malignancy-type
displaying	O
an	O
activated	O
ras	O
gene	O
had	O
a	O
similar	O
cell	O
surface	O
phenotype	O
and	O
appear	O
to	O
come	O
from	O
a	O
similar	O
phase	O
of	O
differentiation	O
;	O
(3)	O
5	O
-	O
6	O
%	O
of	O
noncultured	O
primary	O
and	O
metastatic	O
melanomas	B-malignancy-type
have	O
mutated	O
ras	O
genes	O
;	O
(4)	O
no	O
ras	O
gene	O
mutations	O
were	O
found	O
in	O
any	O
precursor	B-malignancy-type
lesion	I-malignancy-type
,	O
specifically	O
normal	B-malignancy-type
nevi	I-malignancy-type
and	O
dysplastic	B-malignancy-type
nevi	I-malignancy-type
;	O
(5)	O
immunoperoxidase	O
analysis	O
of	O
paraffin	O
-	O
embedded	O
specimens	O
indicated	O
no	O
quantitative	O
or	O
qualitative	O
alterations	O
in	O
p21	O
expression	O
that	O
correlate	O
with	O
tumor	O
progression	O
;	O
(6)	O
there	O
were	O
no	O
observable	O
differences	O
in	O
p21	O
expression	O
between	O
melanoma	B-malignancy-type
cells	O
growing	O
exponentially	O
or	O
in	O
plateau	O
phase	O
,	O
or	O
between	O
melanoma	B-malignancy-type
cells	O
with	O
or	O
without	O
ras	O
mutations	O
;	O
nor	O
were	O
any	O
cell	O
kinetic	O
differences	O
found	O
between	O
cells	O
with	O
and	O
without	O
mutated	O
ras	O
genes	O
.	O
These	O
studies	O
suggest	O
that	O
the	O
role	O
of	O
ras	O
mutations	O
may	O
be	O
limited	O
to	O
an	O
indirect	O
involvement	O
in	O
the	O
transformation	O
of	O
a	O
subset	O
of	O
melanomas	B-malignancy-type
.	O
PMID	O
:	O
2682463	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Nov;4(	O
11	O
)	O
:	O
1345-51	O
Activated	O
ras	O
genes	O
in	O
human	O
seminoma	B-malignancy-type
:	O
evidence	O
for	O
tumor	O
heterogeneity	O
.	O
Mulder	O
MP	O
,	O
Keijzer	O
W	O
,	O
Verkerk	O
A	O
,	O
Boot	O
AJ	O
,	O
Prins	O
ME	O
,	O
Splinter	O
TA	O
,	O
Bos	O
JL.	O
Department	O
of	O
Cell	O
Biology	O
and	O
Genetics	O
,	O
Erasmus	O
University	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
.	O
The	O
incidence	O
of	O
mutations	O
in	O
cellular	O
ras	O
genes	O
was	O
determined	O
in	O
human	O
seminoma	B-malignancy-type
,	O
a	O
germ	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
testis	I-malignancy-type
,	O
with	O
the	O
aid	O
of	O
specific	O
oligonucleotide	O
probe	O
hybridization	O
.	O
To	O
eliminate	O
the	O
large	O
number	O
of	O
nonneoplastic	O
cells	O
present	O
in	O
seminomas	B-malignancy-type
,	O
aneuploid	O
tumor	O
cell	O
nuclei	O
were	O
isolated	O
from	O
the	O
tumor	O
tissue	O
by	O
flow	O
sorting	O
.	O
Mutations	O
were	O
detected	O
in	O
40	O
%	O
of	O
the	O
seminomas	B-malignancy-type
at	O
codons	O
12	O
or	O
61	O
of	O
either	O
the	O
Ki-ras	O
or	O
the	O
N-ras	O
gene	O
.	O
No	O
correlation	O
was	O
found	O
with	O
histopathological	O
or	O
clinical	O
features	O
.	O
In	O
some	O
seminomas	B-malignancy-type
the	O
mutant	O
gene	O
was	O
present	O
in	O
only	O
a	O
fraction	O
of	O
the	O
tumor	O
cell	O
population	O
,	O
suggesting	O
tumor	O
heterogeneity	O
for	O
ras	O
gene	O
mutations	O
.	O
Yet	O
,	O
flow	O
cytometric	O
measurement	O
of	O
nuclear	O
DNA	O
contents	O
and	O
histological	O
examination	O
of	O
tumor	O
tissue	O
did	O
not	O
reveal	O
two	O
different	O
tumor	O
cell	O
populations	O
.	O
We	O
conclude	O
from	O
these	O
observations	O
that	O
ras	O
mutation	O
is	O
probably	O
not	O
the	O
initial	O
genetic	O
event	O
in	O
the	O
development	O
of	O
seminoma	B-malignancy-type
.	O
PMID	O
:	O
2682461	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Aug;	O
4(	O
8	O
)	O
:	O
1029-	O
36	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
and	O
methylation	O
state	O
in	O
human	O
leukemias	B-malignancy-type
.	O
Browett	O
PJ	O
,	O
Norton	O
JD.	O
Department	O
of	O
Hematology	O
,	O
Royal	O
Free	O
Hospital	O
School	O
of	O
Medicine	O
,	O
Hampstead	O
,	O
London	O
,	O
UK.	O
We	O
have	O
screened	O
a	O
large	O
series	O
of	O
primary	O
human	O
leukemias	B-malignancy-type
for	O
activating	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
and	O
K-ras	O
proto	O
-	O
oncogenes	O
and	O
at	O
codons	O
12	O
and	O
61	O
of	O
the	O
H-ras	O
proto	O
-	O
oncogene	O
by	O
using	O
panels	O
of	O
oligonucleotide	O
probes	O
in	O
conjunction	O
with	O
polymerase	O
chain	O
reaction	O
gene	O
amplification	O
.	O
13	O
of	O
64	O
(	O
20	O
%	O
)	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
cases	O
had	O
ras	O
gene	O
mutations	O
mostly	O
involving	O
N-ras	O
codon	O
12	O
/	O
13	O
,	O
G	O
-	O
A	O
(	O
gly	O
-	O
asp	O
)	O
transitions	O
.	O
Consistent	O
with	O
previous	O
studies	O
,	O
a	O
comparable	O
pattern	O
and	O
frequency	O
of	O
ras	O
mutation	O
was	O
found	O
amongst	O
45	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
and	O
myelodysplasia	B-malignancy-type
.	O
By	O
contrast	O
,	O
of	O
30	O
cases	O
of	O
mature	B-malignancy-type
B	I-malignancy-type
cell	I-malignancy-type
chronic	I-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
,	O
only	O
one	O
in	O
terminal	O
prolymphocytoid	O
transformation	O
harboured	O
an	O
activated	O
ras	O
gene	O
.	O
These	O
patterns	O
of	O
mutation	O
did	O
not	O
correlate	O
with	O
ras	O
gene	O
methylation	O
state	O
,	O
a	O
finding	O
not	O
obviously	O
compatible	O
with	O
differential	O
gene	O
accessibility	O
being	O
an	O
important	O
determinant	O
of	O
ras	O
gene	O
mutation	O
patterns	O
in	O
leukemogenesis	O
.	O
Our	O
data	O
suggest	O
that	O
activated	O
ras	O
is	O
more	O
important	O
in	O
tumourigenesis	O
of	O
immature	O
than	O
mature	O
lymphocyte	O
progenitors	O
whilst	O
similar	O
mechanisms	O
associated	O
with	O
aetiology	O
and/or	O
target	O
cell	O
susceptibility	O
probably	O
underlie	O
the	O
similar	O
patterns	O
of	O
ras	O
gene	O
mutations	O
seen	O
in	O
acute	B-malignancy-type
leukemias	I-malignancy-type
of	I-malignancy-type
both	I-malignancy-type
myeloid	I-malignancy-type
and	I-malignancy-type
lymphoid	I-malignancy-type
cell	I-malignancy-type
lineages	I-malignancy-type
.	O
PMID	O
:	O
2668844	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1989	O
Mar;73	O
(	O
4	O
)	O
:	O
889	O
-	O
91	O
Ras	O
oncogene	O
mutations	O
are	O
rare	O
late	O
stage	O
events	O
in	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
LeMaistre	O
A	O
,	O
Lee	O
MS	O
,	O
Talpaz	O
M,	O
Kantarjian	O
HM	O
,	O
Freireich	O
EJ	O
,	O
Deisseroth	O
AB	O
,	O
Trujillo	O
JM	O
,	O
Stass	O
SA	O
.	O
Division	O
of	O
Laboratory	O
Medicine	O
,	O
University	O
of	O
Texas	O
,	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
77030	O
.	O
DNA	O
from	O
bone	O
marrow	O
and	O
peripheral	O
blood	O
samples	O
of	O
44	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
patients	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
mutations	O
of	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
N-ras	O
,	O
H-ras	O
,	O
or	O
K-ras	O
genes	O
.	O
In	O
seven	O
patients	O
,	O
samples	O
were	O
available	O
from	O
both	O
their	O
chronic	O
phase	O
and	O
blast	O
crisis	O
.	O
A	O
total	O
of	O
29	O
samples	O
examined	O
were	O
at	O
chronic	O
phase	O
and	O
22	O
were	O
at	O
blast	O
crisis	O
(	O
eight	O
lymphoid	O
,	O
eight	O
myeloid	O
,	O
and	O
six	O
undifferentiated	O
)	O
.	O
No	O
mutations	O
were	O
identified	O
in	O
N-ras	O
or	O
H-ras	O
.	O
Two	O
patients	O
in	O
myeloid	O
blast	O
crisis	O
had	O
K-ras	O
mutations	O
,	O
one	O
patient	O
at	O
codon	O
12	O
,	O
the	O
other	O
at	O
codon	O
13	O
.	O
In	O
the	O
former	O
patient	O
the	O
mutation	O
was	O
not	O
present	O
and	O
the	O
latter	O
patient	O
was	O
not	O
tested	O
in	O
chronic	O
phase	O
.	O
Our	O
findings	O
indicate	O
ras	O
mutations	O
are	O
an	O
infrequent	O
late	O
stage	O
event	O
in	O
CML	B-malignancy-type
that	O
occur	O
in	O
myeloid	O
blast	O
crisis	O
.	O
PMID	O
:	O
2645949	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Henry	O
Ford	O
Hosp	O
Med	O
J	O
1989	O
;37	O
(	O
3-	O
4)	O
:	O
112-5	O
Allele	O
loss	O
on	O
chromosome	O
10	O
and	O
point	O
mutation	O
of	O
ras	O
oncogenes	O
are	O
infrequent	O
in	O
tumors	O
of	O
MEN	O
2A	O
.	O
Okazaki	O
M,	O
Miya	O
A	O
,	O
Tanaka	O
N	O
,	O
Miki	O
T	O
,	O
Yamamoto	O
M,	O
Motomura	O
K,	O
Miyauchi	O
A	O
,	O
Mori	O
T	O
,	O
Takai	O
S.	O
The	O
multiple	O
endocrine	O
neoplasia	O
type	O
2A	O
(	O
MEN	O
2A	O
)	O
gene	O
has	O
been	O
mapped	O
to	O
the	O
centromeric	O
region	O
of	O
chromosome	O
10	O
by	O
linkage	O
analysis	O
.	O
We	O
examined	O
36	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
(	O
MTCs	B-malignancy-type
)	O
(	O
16	O
hereditary	B-malignancy-type
and	O
20	O
sporadic	B-malignancy-type
)	O
and	O
ten	O
pheochromocytomas	B-malignancy-type
(	O
eight	O
hereditary	B-malignancy-type
and	O
two	O
sporadic	B-malignancy-type
)	O
to	O
detect	O
loss	O
of	O
alleles	O
on	O
chromosome	O
10	O
using	O
seven	O
polymorphic	O
DNA	O
markers	O
mapped	O
to	O
this	O
chromosome	O
.	O
Of	O
20	O
informative	O
cases	O
,	O
only	O
one	O
(	O
5	O
%	O
)	O
sporadic	B-malignancy-type
MTC	I-malignancy-type
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
locus	O
RBP3	O
.	O
Allele	O
loss	O
at	O
the	O
RBP3	O
locus	O
was	O
not	O
found	O
in	O
pheochromocytomas	B-malignancy-type
from	O
six	O
heterozygotes	O
.	O
All	O
tumors	O
retained	O
constitutional	O
heterozygosity	O
at	O
six	O
other	O
loci	O
on	O
chromosome	O
10	O
(	O
D10S17	O
,	O
D10S34	O
,	O
D10S24	O
on	O
the	O
short	O
arm	O
,	O
D10S15	O
in	O
the	O
pericentromeric	O
region	O
,	O
D10S20	O
,	O
and	O
D10S4	O
on	O
the	O
long	O
arm	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
second	O
hit	O
for	O
tumorigenesis	O
in	O
MEN	O
2A	O
may	O
not	O
be	O
loss	O
of	O
function	O
of	O
the	O
normal	O
allele	O
at	O
the	O
homologous	O
locus	O
on	O
the	O
other	O
copy	O
of	O
chromosome	O
10	O
.	O
Mutated	O
ras	O
oncogene	O
was	O
found	O
only	O
in	O
one	O
of	O
18	O
MTCs	B-malignancy-type
at	O
the	O
codon	O
61	O
of	O
H-ras	O
.	O
PMID	O
:	O
2576939	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1989	O
Mar;80	O
(	O
3	O
)	O
:196-9	O
Low	O
incidence	O
of	O
point	O
mutation	O
of	O
c-Ki-ras	O
and	O
N-ras	O
oncogenes	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Tsuda	O
H,	O
Hirohashi	O
S	O
,	O
Shimosato	O
Y	O
,	O
Ino	O
Y	O
,	O
Yoshida	O
T	O
,	O
Terada	O
M.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
.	O
We	O
examined	O
the	O
incidence	O
of	O
point	O
mutation	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
c-Ki-ras	O
and	O
N-ras	O
genes	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
techniques	O
.	O
Among	O
34	O
tissues	O
specimens	O
surgically	O
resected	O
from	O
30	O
patients	O
and	O
5	O
cell	O
lines	O
of	O
human	O
HCC	B-malignancy-type
,	O
only	O
two	O
had	O
ras	O
point	O
mutations	O
;	O
in	O
one	O
case	O
,	O
codon	O
12	O
of	O
c-Ki-ras	O
was	O
altered	O
from	O
GGT	O
,	O
coding	O
glycine	O
,	O
to	O
GTT	O
,	O
coding	O
valine	O
;	O
in	O
the	O
other	O
case	O
,	O
codon	O
61	O
of	O
N-ras	O
was	O
altered	O
from	O
CAA	O
,	O
coding	O
glutamine	O
,	O
to	O
AAA	O
,	O
coding	O
lysine	O
.	O
Thus	O
,	O
point	O
-	O
mutational	O
activation	O
of	O
ras	O
oncogenes	O
is	O
an	O
uncommon	O
event	O
in	O
human	O
HCC	B-malignancy-type
.	O
PMID	O
:	O
2542205	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hematol	O
Pathol	O
1990	O
;4(	O
3	O
)	O
:	O
149-	O
55	O
Hypereosinophilic	O
syndrome	O
with	O
evolution	O
to	O
myeloproliferative	B-malignancy-type
disorder	I-malignancy-type
:	O
temporal	O
relationship	O
to	O
loss	O
of	O
Y	O
chromosome	O
and	O
c-N-ras	O
activation	O
.	O
Needleman	O
SW	O
,	O
Mane	O
SM	O
,	O
Gutheil	O
JC	O
,	O
Kapil	O
V	O
,	O
Heyman	O
MR	O
,	O
Testa	O
JR.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Maryland	O
Hospital	O
,	O
Baltimore	O
21201	O
.	O
A	O
case	O
of	O
hypereosinophilic	O
syndrome	O
is	O
presented	O
in	O
which	O
the	O
patient	O
was	O
serially	O
observed	O
for	O
4	O
years	O
.	O
Transformation	O
to	O
a	O
disorder	O
resembling	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemic	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
occurred	O
36	O
months	O
after	O
diagnosis	O
;	O
at	O
42	O
months	O
,	O
blastic	O
transformation	O
and	O
marrow	O
failure	O
ensued	O
,	O
leading	O
to	O
death	O
.	O
Marrow	O
examination	O
for	O
histopathologic	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
biologic	O
analyses	O
were	O
performed	O
during	O
the	O
eosinophilic	O
,	O
myeloproliferative	O
,	O
and	O
blastic	O
stages	O
.	O
These	O
demonstrated	O
ras	O
activation	O
by	O
virtue	O
of	O
a	O
codon	O
12	O
G	O
to	O
C	O
transversion	O
mutation	O
,	O
predicting	O
for	O
substitution	O
of	O
glycine	O
by	O
alanine	O
;	O
in	O
addition	O
,	O
we	O
observed	O
Y	O
chromosome	O
loss	O
late	O
in	O
the	O
natural	O
history	O
of	O
this	O
illness	O
,	O
suggesting	O
that	O
these	O
genetic	O
lesions	O
can	O
play	O
a	O
role	O
in	O
the	O
profound	O
loss	O
of	O
myeloid	O
differentiation	O
characteristic	O
of	O
the	O
accelerated	O
phase	O
commonly	O
observed	O
in	O
myeloproliferative	B-malignancy-type
syndromes	I-malignancy-type
.	O
PMID	O
:	O
2258361	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Aug	O
15	O
;76	O
(	O
4	O
)	O
:	O
801-7	O
N-ras	O
mutations	O
in	O
adult	O
de	O
novo	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
:	O
prevalence	O
and	O
clinical	O
significance	O
.	O
Radich	O
JP	O
,	O
Kopecky	O
KJ	O
,	O
Willman	O
CL	O
,	O
Weick	O
J,	O
Head	O
D	O
,	O
Appelbaum	O
F	O
,	O
Collins	O
SJ.	O
Molecular	O
Medicine	O
Program	O
,	O
Fred	O
Hutchinson	O
Cancer	O
Research	O
Center	O
,	O
Seattle	O
,	O
WA	O
98104	O
.	O
Point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogenes	O
have	O
been	O
previously	O
detected	O
in	O
20	O
%	O
to	O
60	O
%	O
of	O
samples	O
of	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
but	O
the	O
clinical	O
significance	O
of	O
these	O
mutations	O
is	O
presently	O
unclear	O
.	O
We	O
directly	O
sequenced	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
N-ras	O
fragments	O
to	O
determine	O
the	O
frequency	O
of	O
N-ras	O
point	O
mutations	O
in	O
55	O
adult	O
patients	O
with	O
de	O
novo	O
AML	B-malignancy-type
.	O
Mutations	O
were	O
present	O
in	O
8	O
of	O
55	O
(	O
15	O
%	O
)	O
patients	O
.	O
These	O
mutations	O
were	O
usually	O
in	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
,	O
but	O
one	O
patient	O
had	O
mutations	O
in	O
both	O
codons	O
13	O
and	O
61	O
,	O
and	O
another	O
had	O
an	O
unusual	O
point	O
mutation	O
in	O
N-ras	O
codon	O
60	O
.	O
A	O
comparison	O
of	O
patients	O
with	O
and	O
without	O
N-ras	O
mutations	O
showed	O
no	O
statistically	O
significant	O
differences	O
in	O
pretreatment	O
clinical	O
variables	O
,	O
response	O
to	O
induction	O
therapy	O
,	O
or	O
survival	O
,	O
except	O
for	O
a	O
possibly	O
higher	O
percentage	O
of	O
FAB	O
M4	O
subtypes	O
in	O
patients	O
with	O
the	O
N-ras	O
mutation	O
.	O
These	O
data	O
together	O
with	O
previous	O
reports	O
suggest	O
that	O
the	O
presence	O
of	O
N-ras	O
point	O
mutations	O
do	O
not	O
clearly	O
define	O
a	O
unique	O
clinical	O
or	O
biologic	O
subset	O
of	O
AML	B-malignancy-type
patients	O
.	O
PMID	O
:	O
2200539	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1990	O
Apr;98(	O
4	O
)	O
:955	O
-60	O
Infrequent	O
point	O
mutations	O
of	O
ras	O
oncogenes	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
Nanus	O
DM	O
,	O
Kelsen	O
DP	O
,	O
Mentle	O
IR	O
,	O
Altorki	O
N	O
,	O
Albino	O
AP	O
.	O
Laboratory	O
of	O
Mammalian	O
Cell	O
Transformation	O
,	O
Sloan	O
Kettering	O
Institute	O
,	O
New	O
York	O
,	O
New	O
York	O
.	O
Adenocarcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
proximal	I-malignancy-type
and	I-malignancy-type
distal	I-malignancy-type
stomach	I-malignancy-type
have	O
significant	O
clinical	O
and	O
biological	O
differences	O
.	O
A	O
study	O
was	O
undertaken	O
to	O
determine	O
if	O
a	O
difference	O
in	O
the	O
incidence	O
of	O
mutated	O
ras	O
oncogenes	O
exists	O
between	O
proximal	B-malignancy-type
(	O
gastroesophageal	B-malignancy-type
junction	I-malignancy-type
or	O
cardia	B-malignancy-type
)	O
and	O
distal	B-malignancy-type
(	O
body	B-malignancy-type
or	O
antrum	B-malignancy-type
)	O
gastric	B-malignancy-type
tumors	I-malignancy-type
,	O
and	O
to	O
assess	O
the	O
overall	O
incidence	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
from	O
non	O
-	O
Asian	O
patients	O
.	O
Deoxyribonucleic	O
acid	O
from	O
28	O
primary	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
were	O
analyzed	O
for	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
protooncogenes	O
using	O
polymerase	O
-	O
catalyzed	O
chain	O
reaction	O
methodology	O
.	O
Twelve	O
tumors	O
were	O
located	O
at	O
the	O
gastroesophageal	O
junction	O
or	O
cardia	O
,	O
and	O
16	O
in	O
the	O
body	O
or	O
antrum	O
.	O
Mutated	O
ras	O
genes	O
were	O
detected	O
in	O
2	O
of	O
28	O
tumors	O
for	O
an	O
overall	O
incidence	O
of	O
7	O
%	O
.	O
The	O
mutations	O
occurred	O
in	O
codon	O
61	O
of	O
the	O
N-ras	O
gene	O
in	O
a	O
proximal	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
and	O
in	O
codon	O
12	O
of	O
the	O
Ki-ras	O
gene	O
in	O
a	O
distal	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
.	O
These	O
data	O
indicate	O
that	O
mutations	O
in	O
ras	O
genes	O
are	O
an	O
uncommon	O
event	O
in	O
primary	O
gastric	O
cancers	O
and	O
that	O
there	O
is	O
no	O
meaningful	O
difference	O
in	O
the	O
incidence	O
of	O
ras	O
mutations	O
in	O
proximal	B-malignancy-type
and	O
distal	B-malignancy-type
stomach	I-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
2179035	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1990	O
Mar	O
1;50(	O
5	O
)	O
:1521-7	O
Characterization	O
of	O
a	O
transforming	O
N-ras	O
gene	O
in	O
the	O
human	O
hepatoma	B-malignancy-type
cell	O
line	O
Hep	O
G2	O
:	O
additional	O
evidence	O
for	O
the	O
importance	O
of	O
c-myc	O
and	O
ras	O
cooperation	O
in	O
hepatocarcinogenesis	O
.	O
Richards	O
CA	O
,	O
Short	O
SA	O
,	O
Thorgeirsson	O
SS	O
,	O
Huber	O
BE.	O
Wellcome	O
Research	O
Laboratories	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
.	O
The	O
expression	O
of	O
the	O
c-myc	O
gene	O
has	O
previously	O
been	O
shown	O
to	O
be	O
elevated	O
and	O
deregulated	O
in	O
the	O
human	O
hepatoma	B-malignancy-type
cell	O
line	O
Hep	O
G2	O
(	O
B.	O
E.	O
Huber	O
and	O
S.	O
S.	O
Thorgeirsson	O
,	O
Cancer	O
Res.	O
,	O
47	O
:	O
3414	O
-	O
3420	O
,	O
1987	O
)	O
.	O
We	O
now	O
report	O
that	O
the	O
Hep	O
G2	O
N-ras	O
gene	O
is	O
activated	O
to	O
a	O
dominant	O
-	O
acting	O
,	O
transforming	O
gene	O
by	O
a	O
missense	O
mutation	O
in	O
codon	O
61	O
.	O
Hep	O
G2	O
DNA	O
produced	O
transformed	O
foci	O
when	O
transfected	O
into	O
NIH	O
3T3	O
cells	O
.	O
Subsequent	O
to	O
a	O
secondary	O
round	O
of	O
transfection	O
,	O
Southern	O
blot	O
analysis	O
of	O
tumorigenic	O
NIH	O
3T3	O
foci	O
demonstrated	O
the	O
presence	O
of	O
human	O
N-ras	O
sequences	O
.	O
Nucleotide	O
sequence	O
analysis	O
of	O
one	O
Hep	O
G2	O
N-ras	O
allele	O
demonstrated	O
that	O
codons	O
12	O
,	O
13	O
,	O
and	O
59	O
were	O
normal	O
and	O
that	O
codon	O
61	O
had	O
a	O
missense	O
mutation	O
(	O
CAA	O
to	O
CTA	O
)	O
.	O
This	O
mutation	O
results	O
in	O
the	O
incorporation	O
of	O
leucine	O
instead	O
of	O
glutamine	O
at	O
residue	O
61	O
of	O
the	O
N-ras	O
gene	O
product	O
,	O
p21	O
.	O
N-ras	O
sequences	O
were	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
from	O
both	O
Hep	O
G2	O
genomic	O
DNA	O
and	O
Hep	O
G2	O
complementary	O
DNA	O
.	O
Analysis	O
of	O
the	O
amplified	O
sequences	O
demonstrated	O
that	O
only	O
one	O
Hep	O
G2	O
N-ras	O
allele	O
exhibited	O
the	O
codon	O
61	O
mutation	O
and	O
that	O
both	O
the	O
mutant	O
and	O
normal	O
alleles	O
were	O
transcribed	O
.	O
Northern	O
blot	O
analysis	O
demonstrated	O
equivalent	O
steady	O
-	O
state	O
levels	O
of	O
N-ras	O
transcripts	O
in	O
Hep	O
G2	O
cells	O
and	O
normal	O
human	O
liver	O
.	O
The	O
steady	O
-	O
state	O
levels	O
of	O
N-ras	O
and	O
ornithine	O
decarboxylase	O
transcripts	O
were	O
positively	O
correlated	O
suggesting	O
a	O
positive	O
relationship	O
between	O
N-ras	O
expression	O
and	O
the	O
replication	O
rate	O
of	O
Hep	O
G2	O
cells	O
.	O
c-Ki-ras	O
and	O
c-Ha-ras	O
transcripts	O
were	O
not	O
detected	O
in	O
either	O
Hep	O
G2	O
cells	O
or	O
normal	O
human	O
liver	O
.	O
Immunoprecipitation	O
experiments	O
using	O
the	O
monoclonal	O
antibody	O
Y13-259	O
demonstrated	O
the	O
presence	O
of	O
p21	O
in	O
Hep	O
G2	O
cells	O
.	O
Expression	O
of	O
a	O
dominant	O
-	O
acting	O
,	O
transforming	O
N-ras	O
gene	O
,	O
in	O
conjunction	O
with	O
the	O
altered	O
regulation	O
of	O
the	O
c-myc	O
gene	O
,	O
documents	O
two	O
important	O
genetic	O
lesions	O
that	O
could	O
be	O
responsible	O
for	O
the	O
transformed	O
phenotype	O
of	O
Hep	O
G2	O
cells	O
.	O
PMID	O
:	O
2154325	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1991	O
Mar;77	O
(	O
3	O
)	O
:	O
323-7	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
in	O
childhood	O
myeloid	B-malignancy-type
leukaemia	I-malignancy-type
.	O
Farr	O
C	O
,	O
Gill	O
R	O
,	O
Katz	O
F	O
,	O
Gibbons	O
B	O
,	O
Marshall	O
CJ.	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
London	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
approximately	O
30	O
%	O
of	O
adult	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemias	I-malignancy-type
and	O
20	O
%	O
of	O
adult	O
acute	B-malignancy-type
lymphoid	I-malignancy-type
leukaemias	I-malignancy-type
contain	O
point	O
mutated	O
ras	O
oncogenes	O
.	O
In	O
order	O
to	O
assess	O
whether	O
ras	O
oncogenes	O
are	O
also	O
involved	O
in	O
childhood	O
leukaemias	B-malignancy-type
,	O
we	O
have	O
used	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
synthetic	O
oligonucleotide	O
probes	O
to	O
study	O
the	O
nature	O
and	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
childhood	O
leukaemias	B-malignancy-type
,	O
concentrating	O
largely	O
on	O
the	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemias	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
Thirty-four	O
childhood	O
presentation	O
AML	B-malignancy-type
DNAs	O
were	O
screened	O
for	O
mutations	O
in	O
and	O
around	O
codons	O
12	O
,	O
61	O
and	O
117	O
of	O
N	O
-	O
,	O
K	O
-	O
and	O
H	O
-	O
ras	O
.	O
Eight	O
of	O
these	O
samples	O
(	O
24	O
%	O
)	O
contained	O
ras	O
mutations	O
.	O
As	O
in	O
the	O
adult	O
disease	O
,	O
the	O
gene	O
predominantly	O
involved	O
was	O
N-ras	O
(	O
6	O
/	O
8	O
)	O
,	O
with	O
occasional	O
activation	O
of	O
K-ras	O
(	O
2	O
/	O
6	O
)	O
.	O
The	O
most	O
common	O
base	O
change	O
was	O
a	O
G	O
----	O
A	O
transition	O
at	O
codon	O
12	O
or	O
13	O
(	O
4	O
/	O
8	O
)	O
.	O
Of	O
the	O
patients	O
with	O
mutant	O
ras	O
,	O
4	O
/	O
8	O
were	O
diagnosed	O
as	O
AML	B-malignancy-type
FAB	I-malignancy-type
subtype	I-malignancy-type
M5	I-malignancy-type
.	O
Five	O
of	O
the	O
34	O
childhood	O
AMLs	B-malignancy-type
analysed	O
displayed	O
abnormalities	O
of	O
chromosome	O
7	O
.	O
However	O
,	O
none	O
of	O
these	O
cases	O
contained	O
a	O
mutant	O
ras	O
gene	O
.	O
One	O
AML	B-malignancy-type
patient	O
was	O
studied	O
at	O
relapse	O
,	O
14	O
months	O
after	O
initial	O
presentation	O
.	O
The	O
presentation	O
mutation	O
(	O
N	O
61	O
p3	O
)	O
was	O
not	O
detectable	O
,	O
although	O
a	O
new	O
mutation	O
(	O
N	O
13	O
Cys	O
)	O
was	O
readily	O
identified	O
.	O
This	O
observation	O
extends	O
our	O
original	O
finding	O
with	O
presentation	O
and	O
relapse	O
samples	O
of	O
adult	O
AML	B-malignancy-type
,	O
in	O
which	O
it	O
was	O
uncommon	O
for	O
the	O
relapse	O
sample	O
to	O
contain	O
the	O
same	O
ras	O
mutation	O
as	O
the	O
presentation	O
DNA	O
.	O
In	O
addition	O
,	O
two	O
out	O
of	O
five	O
patients	O
diagnosed	O
as	O
juvenile	O
CML	B-malignancy-type
,	O
were	O
found	O
to	O
harbour	O
mutant	O
ras	O
.	O
PMID	O
:	O
2012756	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1991	O
Mar;	O
6	O
(	O
3	O
)	O
:471-3	O
Radiation	O
-	O
associated	O
and	O
'	O
spontaneous	O
'	O
human	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
show	O
a	O
different	O
pattern	O
of	O
ras	O
oncogene	O
mutation	O
.	O
Wright	O
PA	O
,	O
Williams	O
ED	O
,	O
Lemoine	O
NR	O
,	O
Wynford	O
-	O
Thomas	O
D.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Heath	O
Park	O
,	O
Cardiff	O
,	O
UK.	O
Activated	O
ras	O
oncogenes	O
in	O
experimentally	O
induced	O
rodent	O
tumours	O
have	O
been	O
demonstrated	O
to	O
show	O
specific	O
patterns	O
of	O
oncogene	O
activation	O
which	O
depend	O
on	O
the	O
inducing	O
agent	O
,	O
with	O
H-ras	O
activation	O
in	O
nitrosomethylurea	O
(	O
NMU	O
)	O
induced	O
tumours	O
,	O
and	O
K-ras	O
activation	O
in	O
tumours	O
induced	O
by	O
ionising	O
radiation	O
.	O
We	O
report	O
a	O
study	O
of	O
12	O
radiation	O
-	O
associated	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
,	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
paraffin	O
-	O
embedded	O
material	O
and	O
allele	O
-	O
specific	O
hybridisation	O
with	O
mutant	O
-	O
specific	O
probes	O
for	O
the	O
3	O
ras	O
oncogenes	O
.	O
Compared	O
to	O
68	O
'	O
spontaneous	O
'	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
,	O
the	O
radiation	O
-	O
associated	O
cases	O
show	O
the	O
same	O
overall	O
prevalence	O
of	O
ras	O
mutation	O
.	O
However	O
there	O
is	O
a	O
significantly	O
higher	O
rate	O
of	O
K-ras	O
mutation	O
in	O
radiation	O
-	O
associated	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
than	O
in	O
'	O
spontaneous	O
'	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
60	O
%	O
compared	O
to	O
6	O
%	O
,	O
P	O
less	O
than	O
0.05	O
)	O
,	O
suggesting	O
that	O
radiation	O
may	O
preferentially	O
activate	O
K-ras	O
in	O
human	O
as	O
well	O
as	O
rodent	O
tumours	O
.	O
PMID	O
:	O
2011403	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1991	O
Mar	O
15;51(	O
6)	O
:1596	O
-	O
9	O
Low	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
cancers	I-malignancy-type
.	O
Moley	O
JF	O
,	O
Brother	O
MB	O
,	O
Wells	O
SA	O
,	O
Spengler	O
BA	O
,	O
Biedler	O
JL	O
,	O
Brodeur	O
GM	O
.	O
Department	O
of	O
Surgery	O
,	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St.	O
Louis	O
,	O
Missouri	O
63110	O
.	O
Little	O
is	O
known	O
about	O
the	O
prevalence	O
and	O
significance	O
of	O
ras	O
gene	O
activation	O
in	O
neural	B-malignancy-type
crest	I-malignancy-type
tumors	I-malignancy-type
such	O
as	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
medullary	B-malignancy-type
thyroid	I-malignancy-type
cancers	I-malignancy-type
(	O
MTCs	O
)	O
.	O
Therefore	O
,	O
we	O
analyzed	O
DNA	O
from	O
10	O
human	O
neuroblastoma	B-malignancy-type
cell	O
lines	O
and	O
10	O
primary	O
human	O
pheochromocytomas	B-malignancy-type
for	O
activating	O
mutations	O
in	O
N-ras	O
,	O
H-ras	O
,	O
and	O
K-ras	O
.	O
We	O
also	O
studied	O
DNA	O
from	O
24	O
primary	O
neuroblastomas	B-malignancy-type
and	O
10	O
MTCs	B-malignancy-type
for	O
N-ras	O
mutations	O
.	O
ras	O
genes	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
of	O
specific	O
DNA	O
fragments	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
With	O
the	O
exception	O
of	O
the	O
SK-N-SH	O
cell	O
line	O
,	O
the	O
examined	O
ras	O
gene	O
sequences	O
were	O
normal	O
in	O
all	O
the	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
MTCs	B-malignancy-type
tested	O
.	O
A	O
single	O
point	O
mutation	O
was	O
identified	O
at	O
codon	O
59	O
(	O
GCT	O
(	O
ala	O
)	O
----	O
ACT	O
(	O
thr	O
)	O
)	O
in	O
one	O
N-ras	O
allele	O
in	O
an	O
SK-N-SH	O
subline	O
.	O
Interestingly	O
,	O
this	O
mutation	O
is	O
different	O
from	O
the	O
activating	O
codon	O
61	O
mutation	O
which	O
resulted	O
in	O
the	O
initial	O
identification	O
of	O
N-ras	O
from	O
SK-N-SH	O
DNA	O
.	O
Therefore	O
,	O
we	O
analyzed	O
the	O
sequences	O
of	O
earlier	O
passages	O
and	O
sublines	O
of	O
the	O
SK-N-SH	O
cell	O
line	O
,	O
but	O
mutations	O
at	O
codon	O
59	O
or	O
61	O
were	O
not	O
detected	O
,	O
suggesting	O
that	O
neither	O
mutation	O
was	O
present	O
in	O
the	O
primary	O
tumor	O
.	O
Our	O
results	O
indicate	O
that	O
N-ras	O
mutations	O
may	O
occur	O
spontaneously	O
during	O
in	O
vitro	O
passage	O
of	O
cell	O
lines	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
occur	O
in	O
primary	O
neuroblastomas	B-malignancy-type
,	O
pheochromocytomas	B-malignancy-type
,	O
and	O
MTCs	B-malignancy-type
.	O
In	O
addition	O
,	O
we	O
have	O
not	O
found	O
H-ras	O
or	O
K-ras	O
mutations	O
in	O
any	O
neuroblastoma	B-malignancy-type
cell	O
line	O
or	O
primary	O
pheochromocytoma	B-malignancy-type
.	O
PMID	O
:	O
1998949	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1991	O
Sep;6(9	O
)	O
:1651	O
-	O
6	O
Detection	O
of	O
transforming	O
genes	O
by	O
transfection	O
of	O
DNA	O
from	O
primary	O
soft	B-malignancy-type
-	I-malignancy-type
tissue	I-malignancy-type
tumours	I-malignancy-type
.	O
Gill	O
S,	O
Stratton	O
MR	O
,	O
Patterson	O
H	O
,	O
Spurr	O
NK	O
,	O
Fisher	O
C	O
,	O
Gusterson	O
BA	O
,	O
Cooper	O
CS	O
.	O
Section	O
of	O
Molecular	O
Carcinogenesis	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Sutton	O
,	O
Surrey	O
,	O
UK.	O
A	O
series	O
of	O
adult	O
soft	B-malignancy-type
-	I-malignancy-type
tissue	I-malignancy-type
tumours	I-malignancy-type
were	O
screened	O
for	O
the	O
presence	O
of	O
activated	O
oncogenes	O
by	O
transfecting	O
tumour	O
DNA	O
into	O
NIH3T3	O
mouse	O
fibroblasts	O
.	O
In	O
these	O
studies	O
an	O
activated	O
K-ras	O
gene	O
that	O
contained	O
a	O
mutation	O
at	O
the	O
second	O
position	O
of	O
codon	O
12	O
(	O
GGT	O
----	O
GAT	O
)	O
was	O
found	O
in	O
a	O
leiomyosarcoma	B-malignancy-type
.	O
In	O
addition	O
,	O
following	O
transfection	O
of	O
DNA	O
from	O
a	O
liposarcoma	B-malignancy-type
,	O
we	O
identified	O
an	O
activated	O
gene	O
that	O
failed	O
to	O
hybridize	O
to	O
probes	O
prepared	O
from	O
10	O
known	O
human	O
oncogenes	O
(	O
K-ras	O
,	O
H-ras	O
,	O
N-ras	O
,	O
ret	O
,	O
met	O
,	O
trk	O
,	O
mas	O
,	O
dbl	O
,	O
raf	O
and	O
hst	O
)	O
that	O
have	O
previously	O
been	O
detected	O
in	O
DNA	O
transfection	O
experiments	O
.	O
BamHI	O
-	O
BamHI	O
fragments	O
of	O
this	O
activated	O
gene	O
of	O
3.5	O
and	O
8.5	O
kb	O
were	O
cloned	O
from	O
NIH3T3	O
secondary	O
transfectants	O
using	O
a	O
probe	O
that	O
detects	O
the	O
human	O
alu	O
family	O
of	O
highly	O
repetitive	O
DNA	O
sequences	O
.	O
Repeat	O
-	O
free	O
subclones	O
of	O
these	O
BamHI	O
fragments	O
were	O
used	O
to	O
map	O
this	O
gene	O
to	O
human	O
chromosome	O
19	O
(	O
p13.2	O
-	O
q13.3	O
)	O
.	O
Our	O
studies	O
also	O
demonstrate	O
that	O
a	O
subclone	O
from	O
one	O
of	O
the	O
BamHI	O
fragments	O
detects	O
a	O
3.0	O
kb	O
transcript	O
in	O
primary	O
and	O
secondary	O
transfectants	O
.	O
PMID	O
:	O
1923531	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1991	O
;15(	O
10	O
)	O
:935	O
-	O
41	O
N-ras	O
gene	O
mutations	O
in	O
childhood	O
acute	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Terada	O
N	O
,	O
Smith	O
TJ	O
,	O
Stork	O
LC	O
,	O
Odom	O
LF	O
,	O
Gelfand	O
EW.	O
Division	O
of	O
Basic	O
Sciences	O
,	O
National	O
Jewish	O
Center	O
for	O
Immunology	O
and	O
Respiratory	O
Medicine	O
,	O
Denver	O
,	O
CO	O
80206	O
.	O
In	O
view	O
of	O
the	O
potential	O
role	O
for	O
ras	O
activation	O
in	O
leukemogenesis	O
,	O
we	O
have	O
screened	O
a	O
number	O
of	O
children	O
with	O
acute	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ANLL	B-malignancy-type
)	O
for	O
activating	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
using	O
panels	O
of	O
oligonucleotide	O
probes	O
in	O
conjunction	O
with	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
gene	O
amplification	O
.	O
In	O
contrast	O
to	O
the	O
frequent	O
occurrence	O
(	O
approximately	O
30	O
%	O
)	O
of	O
N-ras	O
mutation	O
reported	O
in	O
adult	O
ANLL	B-malignancy-type
,	O
6	O
of	O
46	O
cases	O
(	O
13	O
%	O
)	O
at	O
the	O
time	O
of	O
diagnosis	O
had	O
N-ras	O
mutations	O
involving	O
codons	O
12	O
and	O
13	O
.	O
In	O
these	O
patients	O
we	O
also	O
determine	O
whether	O
presenting	O
clinical	O
symptoms	O
,	O
cellular	O
pathology	O
,	O
karyotype	O
,	O
or	O
eventual	O
outcome	O
distinguished	O
them	O
from	O
the	O
ras	O
-	O
negative	O
group	O
.	O
N-ras	O
activation	O
tended	O
to	O
be	O
associated	O
with	O
a	O
higher	O
white	O
blood	O
cell	O
count	O
at	O
diagnosis	O
(	O
mean	O
of	O
225,000	O
/	O
microliters	O
vs	O
91,000	O
/	O
microliters	O
)	O
and	O
fewer	O
remissions	O
obtained	O
after	O
28	O
days	O
of	O
therapy	O
(	O
3	O
/	O
6	O
,	O
50	O
%	O
vs	O
24	O
/	O
32	O
,	O
75	O
%	O
)	O
.	O
It	O
is	O
possible	O
that	O
activation	O
of	O
N-ras	O
oncogene	O
may	O
be	O
involved	O
in	O
the	O
progression	O
of	O
some	O
cases	O
of	O
childhood	O
ANLL	B-malignancy-type
.	O
PMID	O
:	O
1921453	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncology	O
1992	O
;49(	O
2	O
)	O
:114	O
-	O
22	O
Multiple	O
point	O
mutation	O
of	O
N-ras	O
and	O
K-ras	O
oncogenes	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
and	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Nakagawa	O
T	O
,	O
Saitoh	O
S,	O
Imoto	O
S,	O
Itoh	O
M,	O
Tsutsumi	O
M,	O
Hikiji	O
K	O
,	O
Nakamura	O
H	O
,	O
Matozaki	O
S,	O
Ogawa	O
R,	O
Nakao	O
Y	O
,	O
et	O
al	O
.	O
Department	O
of	O
Medicine	O
,	O
Hyogo	O
Medical	O
Center	O
for	O
Adults	O
,	O
Akashi	O
,	O
Japan	O
.	O
We	O
analyzed	O
activating	O
mutations	O
of	O
N-ras	O
and	O
K-ras	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
in	O
hematological	O
disorders	O
.	O
Activating	O
mutations	O
of	O
these	O
codons	O
were	O
detected	O
in	O
4	O
of	O
20	O
cases	O
of	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
15	O
of	O
77	O
cases	O
of	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
Our	O
of	O
19	O
cases	O
of	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
who	O
carried	O
active	O
mutations	O
,	O
7	O
cases	O
were	O
found	O
to	O
have	O
two	O
or	O
more	O
distinct	O
mutations	O
in	O
activating	O
codons	O
of	O
N-ras	O
and	O
K-ras	O
.	O
Ras	O
mutation	O
was	O
found	O
preferentially	O
in	O
progressive	O
disease	O
such	O
as	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
(	O
RAEB	O
)	O
of	O
RAEB	O
in	O
transformation	O
(	O
RAEB-t	O
)	O
.	O
A	O
relatively	O
high	O
incidence	O
of	O
ras	O
mutation	O
was	O
found	O
in	O
M5	O
AML	B-malignancy-type
(	O
40	O
%	O
)	O
.	O
No	O
ras	O
mutations	O
were	O
found	O
in	O
other	O
hematological	O
disorders	O
,	O
such	O
as	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
and	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
-	I-malignancy-type
leukemia	I-malignancy-type
.	O
The	O
most	O
frequent	O
amino	O
acid	O
substitution	O
was	O
that	O
of	O
an	O
aspartate	O
for	O
glycine	O
at	O
codon	O
12	O
of	O
N-ras	O
resulting	O
from	O
G	O
to	O
A	O
mutation	O
(	O
11	O
/	O
35	O
)	O
.	O
The	O
survival	O
of	O
AML	B-malignancy-type
patients	O
who	O
carried	O
ras	O
mutations	O
showed	O
no	O
significant	O
differences	O
from	O
those	O
without	O
ras	O
mutations	O
calculated	O
by	O
Kaplan	O
-	O
Meier	O
.	O
Seven	O
cases	O
of	O
MDS	B-malignancy-type
and	O
7	O
cases	O
of	O
AML	B-malignancy-type
patients	O
could	O
be	O
investigated	O
at	O
various	O
points	O
during	O
their	O
clinical	O
course	O
.	O
Among	O
these	O
14	O
cases	O
,	O
we	O
found	O
2	O
interesting	O
cases	O
of	O
MDS	B-malignancy-type
.	O
The	O
first	O
case	O
lost	O
multiple	O
clones	O
carrying	O
ras	O
mutations	O
during	O
disease	O
progression	O
,	O
the	O
second	O
case	O
acquired	O
mutation	O
of	O
the	O
ras	O
gene	O
during	O
disease	O
progression	O
.	O
These	O
results	O
suggested	O
that	O
multiple	O
point	O
mutations	O
of	O
ras	O
genes	O
may	O
not	O
be	O
initiating	O
events	O
but	O
may	O
contribute	O
to	O
a	O
clonal	O
evolution	O
of	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
.	O
PMID	O
:	O
1574246	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Korean	O
Med	O
Sci	O
1992	O
Jun;7(	O
2	O
)	O
:110	O
-	O
5	O
Point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
c-Ha-ras	O
gene	O
in	O
human	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
Koh	O
EH	O
,	O
Chung	O
HC	O
,	O
Lee	O
KB	O
,	O
Han	O
EK	O
,	O
Oh	O
SH	O
,	O
Min	O
JS	O
,	O
Choi	O
EM	O
,	O
Youn	O
JK	O
,	O
Kim	O
BS	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Yonsei	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
The	O
molecular	O
mechanisms	O
of	O
the	O
carcinogenic	O
process	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
have	O
not	O
been	O
fully	O
understood	O
yet	O
.	O
In	O
order	O
to	O
know	O
whether	O
c-Ha-ras	O
gene	O
is	O
being	O
involved	O
in	O
the	O
process	O
of	O
gastric	O
carcinogenesis	O
,	O
8	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
,	O
8	O
cases	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
and	O
same	O
number	O
of	O
adjacent	O
dysplasia	B-malignancy-type
were	O
analyzed	O
for	O
the	O
presence	O
of	O
mutation	O
at	O
codon	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
c-Ha-ras	O
gene	O
by	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
mutant	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Point	O
mutations	O
at	O
codon	O
12	O
of	O
the	O
c-Ha-ras	O
gene	O
were	O
found	O
in	O
2	O
out	O
of	O
8	O
gastric	B-malignancy-type
cancer	I-malignancy-type
and	O
dysplasia	B-malignancy-type
samples	O
in	O
one	O
case	O
,	O
but	O
we	O
found	O
no	O
mutation	O
at	O
codon	O
13	O
or	O
61	O
of	O
the	O
c-Ha-ras	O
gene	O
.	O
These	O
results	O
suggest	O
that	O
the	O
frequency	O
of	O
mutation	O
of	O
the	O
c-Ha-ras	O
gene	O
detected	O
by	O
sensitive	O
PCR	O
technique	O
is	O
low	O
indeed	O
,	O
however	O
it	O
would	O
be	O
notable	O
that	O
such	O
a	O
genetic	O
change	O
has	O
been	O
detected	O
in	O
the	O
dysplastic	B-malignancy-type
lesion	I-malignancy-type
of	O
the	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patient	O
.	O
PMID	O
:	O
1524724	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1992	O
Dec	O
2;52(	O
6)	O
:867	O
-	O
72	O
The	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
and	O
ras	O
oncogene	O
mutations	O
in	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Sakai	O
E	O
,	O
Rikimaru	O
K	O
,	O
Ueda	O
M,	O
Matsumoto	O
Y	O
,	O
Ishii	O
N	O
,	O
Enomoto	O
S,	O
Yamamoto	O
H	O
,	O
Tsuchida	O
N.	O
Department	O
of	O
Molecular	O
Cellular	O
Oncology	O
and	O
Microbiology	O
,	O
Faculty	O
of	O
Dentistry	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
,	O
Japan	O
.	O
The	O
frequencies	O
of	O
mutations	O
in	O
the	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
and	O
ras	O
proto	O
-	O
oncogenes	O
were	O
investigated	O
systematically	O
in	O
surgically	O
resected	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SCCs	B-malignancy-type
)	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and/or	O
dot	O
-	O
blot	O
hybridization	O
analysis	O
of	O
DNA	O
fragments	O
which	O
had	O
been	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
p53	O
gene	O
mutations	O
,	O
within	O
the	O
region	O
of	O
exons	O
5	O
to	O
8	O
,	O
were	O
detected	O
in	O
17	O
out	O
of	O
27	O
(	O
63	O
%	O
)	O
tumor	O
specimens	O
.	O
The	O
role	O
of	O
p53	O
mutations	O
in	O
cell	O
-	O
line	O
establishment	O
was	O
investigated	O
.	O
p53	O
gene	O
mutations	O
were	O
detected	O
in	O
5	O
out	O
of	O
6	O
tissue	O
samples	O
from	O
which	O
cell	O
lines	O
were	O
established	O
and	O
in	O
4	O
out	O
of	O
5	O
specimens	O
from	O
which	O
cell	O
lines	O
could	O
not	O
be	O
established	O
,	O
suggesting	O
that	O
the	O
presence	O
of	O
p53	O
gene	O
mutations	O
is	O
not	O
by	O
itself	O
sufficient	O
for	O
cell	O
-	O
line	O
establishment	O
.	O
Tumor	O
samples	O
were	O
also	O
analyzed	O
for	O
point	O
mutational	O
activation	O
of	O
the	O
ras	O
proto	O
-	O
oncogenes	O
.	O
One	O
out	O
of	O
30	O
(	O
3	O
%	O
)	O
tumors	O
showed	O
an	O
activating	O
point	O
mutation	O
in	O
codon	O
12	O
of	O
H-ras	O
,	O
this	O
being	O
consistent	O
with	O
reports	O
from	O
Europe	O
and	O
USA	O
but	O
not	O
with	O
any	O
from	O
India	O
.	O
Compared	O
to	O
frequencies	O
of	O
the	O
other	O
genetic	O
changes	O
so	O
far	O
reported	O
for	O
oral	B-malignancy-type
SCC	I-malignancy-type
,	O
the	O
p53	O
mutations	O
have	O
been	O
observed	O
most	O
often	O
to	O
undergo	O
genetic	O
change	O
.	O
p53	O
gene	O
mutation	O
is	O
thus	O
intimately	O
involved	O
in	O
the	O
genesis	O
of	O
oral	B-malignancy-type
SCC	I-malignancy-type
and	O
consequently	O
should	O
be	O
useful	O
as	O
a	O
marker	O
for	O
the	O
diagnosis	O
of	O
this	O
neoplasm	B-malignancy-type
.	O
PMID	O
:	O
1459726	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Thorac	O
Cardiovasc	O
Surg	O
1992	O
Nov;104(	O
5	O
)	O
:1465	O
-	O
9	O
Ras	O
oncogene	O
point	O
mutation	O
:	O
an	O
infrequent	O
event	O
in	O
bronchioloalveolar	B-malignancy-type
cancer	I-malignancy-type
.	O
Rusch	O
VW	O
,	O
Reuter	O
VE	O
,	O
Kris	O
MG	O
,	O
Kurie	O
J,	O
Miller	O
WH	O
Jr	O
,	O
Nanus	O
DM	O
,	O
Albino	O
AP	O
,	O
Dmitrovsky	O
E.	O
Laboratory	O
of	O
Molecular	O
Medicine	O
,	O
Memorial	O
Sloan	O
-	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
N.Y	O
.	O
Ras	O
oncogene	O
point	O
mutation	O
,	O
primarily	O
activating	O
the	O
K-ras	O
gene	O
,	O
has	O
been	O
reported	O
in	O
approximately	O
one	O
third	O
of	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
This	O
identifies	O
a	O
subset	O
of	O
early	O
stage	O
tumors	O
clinically	O
associated	O
with	O
smoking	O
and	O
an	O
aggressive	O
clinical	O
course	O
.	O
Because	O
of	O
these	O
findings	O
,	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
occurrence	O
of	O
ras	O
point	O
mutations	O
in	O
bronchioloalveolar	B-malignancy-type
carcinoma	I-malignancy-type
.	O
This	O
uncommon	O
form	O
of	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
is	O
usually	O
indolent	O
but	O
can	O
sometimes	O
present	O
as	O
a	O
rapidly	O
growing	O
,	O
multifocal	B-malignancy-type
tumor	I-malignancy-type
.	O
Twenty	O
tumor	O
samples	O
obtained	O
at	O
thoracotomy	O
were	O
examined	O
for	O
H-ras	O
,	O
K-ras	O
,	O
and	O
N-ras	O
oncogene	O
mutational	O
activation	O
involving	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
This	O
was	O
performed	O
by	O
an	O
oligonucleotide	O
hybridization	O
technique	O
following	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
these	O
specific	O
sequences	O
.	O
K-ras	O
point	O
mutation	O
involving	O
codon	O
12	O
was	O
observed	O
in	O
two	O
tumors	O
,	O
but	O
not	O
in	O
the	O
adjacent	O
histologically	O
benign	O
lung	O
tissue	O
.	O
These	O
mutations	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
of	O
these	O
polymerase	O
chain	O
reaction	O
products	O
.	O
Both	O
patients	O
were	O
smokers	O
,	O
had	O
stage	O
I	O
tumors	O
,	O
and	O
remain	O
disease	O
-	O
free	O
at	O
27	O
and	O
40	O
months	O
postoperatively	O
.	O
No	O
H-ras	O
or	O
N-ras	O
point	O
mutations	O
were	O
found	O
.	O
These	O
findings	O
suggest	O
that	O
ras	O
activation	O
is	O
an	O
infrequent	O
event	O
in	O
bronchioloalveolar	B-malignancy-type
carcinoma	I-malignancy-type
.	O
We	O
speculate	O
that	O
ras	O
activation	O
is	O
not	O
a	O
common	O
transformational	O
event	O
in	O
this	O
form	O
of	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
1331621	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1992	O
Aug	O
15;70(	O
4)	O
:760	O
-	O
3	O
Incidence	O
of	O
ras	O
oncogene	O
activation	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
in	O
Hong	O
Kong	O
.	O
Lung	O
ML	O
,	O
Wong	O
M,	O
Lam	O
WK	O
,	O
Lau	O
KS	O
,	O
Kwan	O
S,	O
Fu	O
KH	O
,	O
Cheung	O
H	O
,	O
Yew	O
WW.	O
Department	O
of	O
Microbiology	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
University	O
of	O
Hong	O
Kong	O
.	O
BACKGROUND	O
.	O
In	O
Hong	O
Kong	O
,	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
contribute	O
to	O
the	O
majority	O
of	O
cancer	O
deaths	O
among	O
Chinese	O
.	O
Point	O
mutational	O
activation	O
of	O
ras	O
oncogenes	O
has	O
been	O
observed	O
in	O
several	O
populations	O
.	O
The	O
incidence	O
of	O
these	O
mutations	O
in	O
Hong	O
Kong	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
was	O
investigated	O
.	O
METHODS	O
.	O
Lung	O
resections	O
obtained	O
from	O
52	O
Chinese	O
patients	O
whose	O
conditions	O
were	O
newly	O
diagnosed	O
as	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
,	O
paraffin	O
sections	O
from	O
29	O
Chinese	O
patients	O
with	O
previously	O
diagnosed	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
,	O
and	O
paraffin	O
sections	O
from	O
49	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
were	O
examined	O
for	O
the	O
presence	O
of	O
point	O
mutations	O
in	O
Ki-ras	O
codon	O
12	O
,	O
N-ras	O
codon	O
61	O
,	O
and	O
Ha-ras	O
codon	O
12	O
oncogenes	O
by	O
allele	O
-	O
specific	O
hybridization	O
after	O
specific	O
amplification	O
of	O
appropriate	O
regions	O
of	O
the	O
DNA	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
RESULTS	O
.	O
Among	O
the	O
130	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
investigated	O
,	O
Ki-ras	O
point	O
mutations	O
were	O
detected	O
in	O
seven	O
cases	O
,	O
of	O
which	O
six	O
were	O
adenocarcinomas	B-malignancy-type
and	O
one	O
a	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
No	O
mutations	O
were	O
detected	O
in	O
the	O
N-ras	O
and	O
Ha-ras	O
codons	O
.	O
CONCLUSIONS	O
.	O
The	O
incidence	O
of	O
Ki-ras	O
codon	O
12	O
point	O
mutational	O
activation	O
in	O
Chinese	O
patients	O
with	O
adenocarcinomas	B-malignancy-type
was	O
6	O
of	O
63	O
(	O
9.5	O
%	O
)	O
.	O
The	O
incidence	O
of	O
Ki-ras	O
12	O
point	O
mutational	O
activation	O
among	O
men	O
with	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
in	O
Hong	O
Kong	O
(	O
6	O
of	O
32	O
patients	O
,	O
18.8	O
%	O
)	O
is	O
significantly	O
different	O
from	O
that	O
in	O
women	O
in	O
Hong	O
Kong	O
(	O
0	O
of	O
31	O
patients	O
,	O
0	O
%	O
)	O
.	O
Although	O
ras	O
oncogenes	O
are	O
implicated	O
as	O
having	O
a	O
role	O
in	O
the	O
development	O
of	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
especially	O
among	O
smokers	O
,	O
it	O
is	O
clear	O
from	O
these	O
data	O
that	O
they	O
are	O
not	O
associated	O
with	O
the	O
unusually	O
high	O
incidence	O
of	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
among	O
women	O
in	O
Hong	O
Kong	O
.	O
PMID	O
:	O
1322782	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2002	O
Jul	O
18;21(	O
31	O
)	O
:4863	O
-	O
71	O
Mutational	O
spectrum	O
of	O
beta-catenin	O
,	O
AXIN1	O
,	O
and	O
AXIN2	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
and	O
hepatoblastomas	B-malignancy-type
.	O
Taniguchi	O
K	O
,	O
Roberts	O
LR	O
,	O
Aderca	O
IN	O
,	O
Dong	O
X	O
,	O
Qian	O
C	O
,	O
Murphy	O
LM	O
,	O
Nagorney	O
DM	O
,	O
Burgart	O
LJ	O
,	O
Roche	O
PC	O
,	O
Smith	O
DI	O
,	O
Ross	O
JA	O
,	O
Liu	O
W.	O
Division	O
of	O
Experimental	O
Pathology	O
,	O
Mayo	O
Clinic	O
,	O
Rochester	O
,	O
Minnesota	O
,	O
MN	O
55905	O
,	O
USA	O
.	O
Activation	O
of	O
Wnt	O
signaling	O
through	O
beta-catenin	O
mutations	O
contributes	O
to	O
the	O
development	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
and	O
hepatoblastoma	B-malignancy-type
(	O
HB	B-malignancy-type
)	O
.	O
To	O
explore	O
the	O
contribution	O
of	O
additional	O
Wnt	O
pathway	O
molecules	O
to	O
hepatocarcinogenesis	O
,	O
we	O
examined	O
beta-catenin	O
,	O
AXIN1	O
and	O
AXIN2	O
mutations	O
in	O
73	O
HCCs	B-malignancy-type
and	O
27	O
HBs	B-malignancy-type
.	O
beta-catenin	O
mutations	O
were	O
detected	O
in	O
19.2	O
%	O
(	O
14	O
out	O
of	O
73	O
)	O
HCCs	B-malignancy-type
and	O
70.4	O
%	O
(	O
19	O
out	O
of	O
27	O
)	O
HBs	B-malignancy-type
.	O
beta-catenin	O
mutations	O
in	O
HCCs	B-malignancy-type
were	O
primarily	O
point	O
mutations	O
,	O
whereas	O
more	O
than	O
half	O
of	O
the	O
HBs	B-malignancy-type
had	O
deletions	O
.	O
AXIN1	O
mutations	O
occurred	O
in	O
seven	O
(	O
9.6	O
%	O
)	O
HCCs	B-malignancy-type
and	O
two	O
(	O
7.4	O
%	O
)	O
HBs	B-malignancy-type
.	O
The	O
AXIN1	O
mutations	O
included	O
seven	O
missense	O
mutations	O
,	O
a	O
1	O
bp	O
deletion	O
,	O
and	O
a	O
12	O
bp	O
insertion	O
.	O
The	O
predominance	O
of	O
missense	O
mutations	O
found	O
in	O
the	O
AXIN1	O
gene	O
is	O
different	O
from	O
the	O
small	O
deletions	O
or	O
nonsense	O
mutations	O
described	O
previously	O
.	O
Loss	O
of	O
heterozygosity	O
at	O
the	O
AXIN1	O
locus	O
was	O
present	O
in	O
four	O
of	O
five	O
informative	O
HCCs	B-malignancy-type
with	O
AXIN1	O
mutations	O
,	O
suggesting	O
a	O
tumor	O
suppressor	O
function	O
of	O
this	O
gene	O
.	O
AXIN2	O
mutations	O
were	O
found	O
in	O
two	O
(	O
2.7	O
%	O
)	O
HCCs	B-malignancy-type
but	O
not	O
in	O
HBs	B-malignancy-type
.	O
Two	O
HCCs	B-malignancy-type
had	O
both	O
AXIN1	O
and	O
beta-catenin	O
mutations	O
,	O
and	O
one	O
HCC	B-malignancy-type
had	O
both	O
AXIN2	O
and	O
beta-catenin	O
mutations	O
.	O
About	O
half	O
the	O
HCCs	B-malignancy-type
with	O
AXIN1	O
or	O
AXIN2	O
mutations	O
showed	O
beta-catenin	O
accumulation	O
in	O
the	O
nucleus	O
,	O
cytoplasm	O
or	O
membrane	O
.	O
Overall	O
,	O
these	O
data	O
indicate	O
that	O
besides	O
the	O
approximately	O
20	O
%	O
of	O
HCCs	B-malignancy-type
and	O
80	O
%	O
of	O
HBs	B-malignancy-type
with	O
beta-catenin	O
mutations	O
contributing	O
to	O
hepatocarcinogenesis	O
,	O
AXIN1	O
and	O
AXIN2	O
mutations	O
appear	O
to	O
be	O
important	O
in	O
an	O
additional	O
10	O
%	O
of	O
HCCs	B-malignancy-type
and	O
HBs	B-malignancy-type
.	O
PMID	O
:	O
12101426	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
2001	O
Dec;7(	O
12	O
)	O
:4000	O
-	O
7	O
Molecular	O
analysis	O
of	O
sulindac	B-malignancy-type
-	I-malignancy-type
resistant	I-malignancy-type
adenomas	I-malignancy-type
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
.	O
Keller	O
JJ	O
,	O
Offerhaus	O
GJ	O
,	O
Drillenburg	O
P	O
,	O
Caspers	O
E	O
,	O
Musler	O
A	O
,	O
Ristimaki	O
A	O
,	O
Giardiello	O
FM	O
.	O
Department	O
of	O
Pathology	O
,	O
Academic	O
Medical	O
Center	O
,	O
1100	O
DD	O
Amsterdam	O
,	O
the	O
Netherlands	O
.	O
j.j.keller@amc.uva.nl	O
PURPOSE	O
:	O
Sulindac	O
causes	O
the	O
reduction	O
of	O
adenomas	B-malignancy-type
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
patients	O
,	O
but	O
complete	O
regression	O
is	O
unusual	O
,	O
and	O
breakthrough	O
of	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
during	O
sulindac	O
treatment	O
has	O
been	O
described	O
.	O
The	O
molecular	O
features	O
related	O
to	O
sulindac	O
resistance	O
are	O
unknown	O
.	O
Therefore	O
,	O
we	O
investigated	O
molecular	O
alterations	O
in	O
adenomas	B-malignancy-type
from	O
FAP	B-malignancy-type
patients	O
with	O
complete	O
adenoma	B-malignancy-type
regression	O
on	O
sulindac	O
(	O
responsive	O
patients	O
)	O
and	O
from	O
FAP	B-malignancy-type
patients	O
with	O
sulindac	B-malignancy-type
-	I-malignancy-type
resistant	I-malignancy-type
adenomas	I-malignancy-type
(	O
resistant	O
patients	O
)	O
.	O
DESIGN	O
:	O
Fourteen	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
(	O
removed	O
before	O
sulindac	O
treatment	O
)	O
from	O
six	O
responsive	O
patients	O
were	O
studied	O
.	O
Also	O
,	O
9	O
baseline	O
adenomas	O
and	O
34	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
(	O
removed	O
during	O
sulindac	O
treatment	O
)	O
from	O
three	O
resistant	O
patients	O
were	O
analyzed	O
.	O
Using	O
immunohistochemistry	O
,	O
we	O
evaluated	O
the	O
expression	O
of	O
beta-catenin	O
,	O
cyclooxygenase-2	O
(	O
Cox-2	O
)	O
,	O
p53	O
,	O
Bcl-2	O
,	O
and	O
Bax	O
.	O
K-ras	O
codon	O
12	O
mutations	O
,	O
loss	O
of	O
heterozygosity	O
at	O
5q	O
(	O
APC	O
locus	O
)	O
,	O
and	O
microsatellite	O
instability	O
were	O
studied	O
with	O
PCR	O
-	O
based	O
techniques	O
.	O
RESULTS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
between	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
sulindac	O
-	O
responsive	O
and	O
-	O
resistant	O
patients	O
(	O
P	O
>	O
0.05	O
)	O
.	O
There	O
was	O
less	O
loss	O
of	O
membranous	O
beta-catenin	O
staining	O
and	O
less	O
nuclear	O
beta-catenin	O
accumulation	O
in	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
compared	O
with	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
the	O
same	O
(	O
sulindac	O
-	O
resistant	O
)	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
or	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
responsive	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
.	O
Epithelial	O
Cox-2	O
expression	O
was	O
less	O
,	O
though	O
not	O
significant	O
,	O
in	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
compared	O
with	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
resistant	O
patients	O
,	O
but	O
was	O
significantly	O
less	O
in	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
from	O
responsive	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
8	O
of	O
34	O
resistant	B-malignancy-type
adenomas	I-malignancy-type
(	O
24	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
baseline	B-malignancy-type
adenomas	I-malignancy-type
(	O
P	O
<	O
0.05	O
)	O
.	O
Stromal	O
Cox-2	O
expression	O
,	O
staining	O
of	O
p53	O
and	O
Bcl-2	O
,	O
and	O
loss	O
of	O
heterozygosity	O
at	O
5q	O
were	O
comparable	O
in	O
both	O
groups	O
.	O
Loss	O
of	O
Bax	O
staining	O
and	O
microsatellite	O
instability	O
were	O
not	O
found	O
in	O
any	O
adenoma	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
Sulindac	B-malignancy-type
-	I-malignancy-type
resistant	I-malignancy-type
adenomas	I-malignancy-type
display	O
less	O
alteration	O
in	O
beta-catenin	O
staining	O
and	O
less	O
epithelial	O
Cox-2	O
expression	O
when	O
compared	O
with	O
adenomas	B-malignancy-type
removed	O
before	O
sulindac	O
treatment	O
.	O
K-ras	O
mutations	O
may	O
contribute	O
to	O
sulindac	O
-	O
resistance	O
.	O
Continued	O
research	O
is	O
needed	O
to	O
investigate	O
molecular	O
alterations	O
related	O
to	O
sulindac	O
resistance	O
.	O
PMID	O
:	O
11751493	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2001	O
Nov;32(	O
11	O
)	O
:1225	O
-	O
31	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
gene	O
mutation	O
in	O
atypical	B-malignancy-type
fibroxanthoma	I-malignancy-type
and	O
malignant	O
fibrous	B-malignancy-type
histiocytoma	I-malignancy-type
.	O
Sakamoto	O
A	O
,	O
Oda	O
Y	O
,	O
Itakura	O
E	O
,	O
Oshiro	O
Y	O
,	O
Tamiya	O
S,	O
Honda	O
Y	O
,	O
Ishihara	O
A	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Atypical	B-malignancy-type
fibroxanthoma	I-malignancy-type
(	O
AFX	B-malignancy-type
)	O
which	O
is	O
histologically	O
similar	O
to	O
malignant	O
fibrous	B-malignancy-type
histiocytoma	I-malignancy-type
(	O
MFH	B-malignancy-type
)	O
,	O
occurs	O
in	O
the	O
sun	O
-	O
exposed	O
skin	O
.	O
The	O
presence	O
of	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
H	O
-	O
and	O
K	O
-	O
ras	O
genes	O
and	O
in	O
exons	O
1	O
and	O
2	O
,	O
which	O
include	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
,	O
of	O
the	O
N-ras	O
gene	O
was	O
studied	O
in	O
8	O
cases	O
of	O
AFX	O
and	O
8	O
cases	O
of	O
storiform	B-malignancy-type
-	I-malignancy-type
pleomorphic	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
MFH	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
PCR	O
-	O
single	O
-	O
conformation	O
polymorphism	O
.	O
Two	O
of	O
the	O
8	O
cases	O
of	O
MFH	B-malignancy-type
showed	O
ras	O
mutations	O
in	O
the	O
H-ras	O
gene	O
at	O
codon	O
12	O
(	O
GGC	O
-	O
AGC	O
)	O
and	O
in	O
the	O
K-ras	O
gene	O
at	O
codon	O
13	O
(	O
GGC	O
-	O
GAC	O
)	O
.	O
H	O
-	O
and	O
K	O
-	O
ras	O
gene	O
mutations	O
were	O
not	O
seen	O
in	O
any	O
of	O
the	O
cases	O
of	O
AFX	B-malignancy-type
(	O
0	O
of	O
8	O
)	O
.	O
N-ras	O
gene	O
mutation	O
was	O
not	O
detected	O
in	O
either	O
the	O
AFX	B-malignancy-type
(	O
0	O
of	O
8	O
)	O
or	O
MFH	B-malignancy-type
(	O
0	O
of	O
8	O
)	O
cases	O
.	O
In	O
conclusion	O
,	O
although	O
the	O
number	O
of	O
cases	O
in	O
this	O
study	O
was	O
small	O
,	O
H	O
-	O
and	O
K	O
-	O
ras	O
genes	O
were	O
present	O
in	O
some	O
of	O
the	O
MFH	B-malignancy-type
cases	O
and	O
accordingly	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
MFH	B-malignancy-type
.	O
In	O
addition	O
,	O
the	O
finding	O
that	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
gene	O
mutations	O
are	O
not	O
present	O
in	O
AFX	B-malignancy-type
may	O
indicate	O
why	O
AFX	B-malignancy-type
has	O
a	O
more	O
favorable	O
behavior	O
than	O
MFH	B-malignancy-type
.	O
Copyright	O
2001	O
by	O
W.B.	O
Saunders	O
Company	O
PMID	O
:	O
11727262	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Pediatr	O
Surg	O
Int	O
2001	O
Sep;17(	O
7)	O
:508	O
-	O
12	O
High	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
hepatoblastoma	B-malignancy-type
.	O
Udatsu	O
Y	O
,	O
Kusafuka	O
T	O
,	O
Kuroda	O
S,	O
Miao	O
J,	O
Okada	O
A.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Japan	O
.	O
Hepatoblastoma	B-malignancy-type
(	O
HB	B-malignancy-type
)	O
is	O
an	O
embryonic	B-malignancy-type
neoplasm	I-malignancy-type
representing	O
the	O
most	O
frequent	O
malignant	O
liver	B-malignancy-type
tumour	I-malignancy-type
in	O
childhood	O
.	O
Its	O
tumourigenesis	O
at	O
the	O
molecular	O
level	O
is	O
still	O
poorly	O
understood	O
,	O
and	O
candidate	O
genes	O
are	O
yet	O
to	O
be	O
identified	O
.	O
According	O
to	O
recent	O
reports	O
describing	O
beta-catenin	O
mutations	O
(	O
BCM	O
)	O
at	O
hot	O
-	O
spot	O
regions	O
involving	O
exon	O
3	O
in	O
several	O
types	O
of	O
malignancies	O
including	O
HB	B-malignancy-type
,	O
we	O
investigated	O
BCM	O
in	O
16	O
HBs	B-malignancy-type
classified	O
into	O
different	O
histological	O
types	O
.	O
One	O
tumour	O
had	O
been	O
previously	O
confirmed	O
to	O
harbour	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
that	O
exhibit	O
a	O
similar	O
oncogenic	O
effect	O
to	O
that	O
of	O
BCM	O
.	O
Mutations	O
in	O
both	O
exon	O
3	O
and	O
its	O
flanking	O
region	O
of	O
the	O
beta-catenin	O
gene	O
were	O
investigated	O
and	O
determined	O
.	O
Twelve	O
tumours	O
(	O
75	O
%	O
)	O
revealed	O
pathogenic	O
BCM	O
,	O
including	O
5	O
with	O
missense	O
mutations	O
at	O
codons	O
32	O
,	O
34	O
,	O
or	O
37	O
and	O
7	O
with	O
interstitial	O
deletions	O
that	O
partially	O
or	O
totally	O
affected	O
exon	O
3	O
.	O
All	O
7	O
deletions	O
were	O
in	O
-	O
frame	O
deletions	O
without	O
frameshift	O
.	O
A	O
single	O
nucleotide	O
change	O
at	O
codon	O
31	O
regarded	O
as	O
non	O
-	O
pathogenic	O
polymorphism	O
was	O
detected	O
in	O
the	O
tumour	O
possessing	O
APC	O
mutations	O
.	O
Therefore	O
,	O
a	O
total	O
of	O
13	O
tumours	O
(	O
81	O
%	O
)	O
were	O
compromised	O
by	O
an	O
enhanced	O
beta-catenin	O
-	O
mediated	O
transcription	O
pathway	O
.	O
Mutations	O
were	O
observed	O
in	O
every	O
histological	O
type	O
of	O
HB	B-malignancy-type
.	O
The	O
very	O
high	O
frequency	O
without	O
correlation	O
to	O
histological	O
type	O
indicates	O
that	O
BCM	O
are	O
crucial	O
events	O
in	O
the	O
tumourigenesis	O
of	O
HB	B-malignancy-type
.	O
PMID	O
:	O
11666046	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Tumour	O
Biol	O
2001	O
Sep	O
-	O
Oct;22(	O
5	O
)	O
:299	O
-	O
309	O
Oncogenic	O
potential	O
of	O
c-erbB-2	O
and	O
its	O
association	O
with	O
c-K-ras	O
in	O
premalignant	O
and	O
malignant	O
lesions	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
uterine	I-malignancy-type
endometrium	I-malignancy-type
.	O
Manavi	O
M,	O
Bauer	O
M,	O
Baghestanian	O
M,	O
Berger	O
A	O
,	O
Kucera	O
E	O
,	O
Pischinger	O
K	O
,	O
Battistutti	O
W	O
,	O
Czerwenka	O
K.	O
Department	O
of	O
Gynecology	O
and	O
Obstetrics	O
,	O
Division	O
of	O
Special	O
Gynecology	O
,	O
University	O
Hospital	O
of	O
Vienna	O
,	O
Austria	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
detect	O
activated	O
c-K-ras	O
by	O
gene	O
point	O
mutation	O
and	O
to	O
find	O
c-erbB-2	O
gene	O
amplification	O
with	O
p185	O
expression	O
in	O
association	O
with	O
the	O
c-K-ras	O
gene	O
product	O
p21	O
in	O
the	O
human	O
endometrium	O
.	O
Specimens	O
obtained	O
from	O
25	O
normal	O
,	O
31	O
hyperplastic	B-malignancy-type
and	O
72	O
malignant	B-malignancy-type
samples	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
endometrium	I-malignancy-type
were	O
examined	O
for	O
point	O
mutation	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
c-K-ras	O
by	O
direct	O
sequencing	O
and	O
c-erbB-2	O
gene	O
amplification	O
with	O
p185	O
and	O
p21	O
expression	O
by	O
differential	O
polymerase	O
chain	O
reaction	O
(	O
DPCR	O
)	O
and	O
immunohistochemistry	O
.	O
Neither	O
the	O
normal	O
endometrium	O
nor	O
endometrial	B-malignancy-type
hyperplasias	I-malignancy-type
were	O
found	O
to	O
have	O
mutations	O
in	O
the	O
c-K-ras	O
gene	O
,	O
although	O
a	O
double	O
mutation	O
of	O
codons	O
12	O
and	O
13	O
as	O
a	O
single	O
-	O
point	O
mutation	O
was	O
observed	O
in	O
one	O
case	O
of	O
endometrioid	B-malignancy-type
carcinoma	I-malignancy-type
(	O
2.8	O
%	O
)	O
.	O
In	O
each	O
of	O
two	O
other	O
cases	O
of	O
endometrioid	B-malignancy-type
carcinoma	I-malignancy-type
(	O
2	O
/	O
72	O
)	O
,	O
two	O
single	O
-	O
point	O
mutations	O
of	O
codon	O
13	O
(	O
5.6	O
%	O
)	O
were	O
shown	O
.	O
Using	O
DPCR	O
,	O
we	O
found	O
c-erbB-2	O
to	O
be	O
amplified	O
in	O
15	O
premalignant	O
(	O
48	O
%	O
)	O
and	O
45	O
malignant	O
(	O
63	O
%	O
)	O
samples	O
.	O
We	O
noticed	O
that	O
nonamplification	O
of	O
the	O
c-erbB-2	O
gene	O
was	O
associated	O
with	O
the	O
absence	O
of	O
immunoreactivity	O
.	O
Our	O
data	O
indicate	O
that	O
,	O
while	O
c-erbB-2	O
plays	O
a	O
role	O
in	O
the	O
early	O
development	O
of	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
,	O
c-K-ras	O
gene	O
activation	O
by	O
point	O
mutation	O
does	O
not	O
.	O
Copyright	O
2001	O
S	O
.	O
Karger	O
AG	O
,	O
Basel	O
PMID	O
:	O
11553860	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gastroenterology	O
2001	O
Aug;121(	O
2	O
)	O
:302	O
-	O
9	O
Ki-ras	O
proto	O
-	O
oncogene	O
mutations	O
in	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
:	O
relationship	O
to	O
histologic	O
and	O
clinical	O
characteristics	O
.	O
Maltzman	O
T	O
,	O
Knoll	O
K	O
,	O
Martinez	O
ME	O
,	O
Byers	O
T	O
,	O
Stevens	O
BR	O
,	O
Marshall	O
JR	O
,	O
Reid	O
ME	O
,	O
Einspahr	O
J,	O
Hart	O
N	O
,	O
Bhattacharyya	O
AK	O
,	O
Kramer	O
CB	O
,	O
Sampliner	O
R,	O
Alberts	O
DS	O
,	O
Ahnen	O
DJ.	O
Department	O
of	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
111E	O
,	O
1055	O
Clermont	O
Street	O
,	O
Denver	O
,	O
Colorado	O
80220	O
,	O
USA	O
.	O
BACXKGROUND	O
&	O
AIMS	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
Ki-ras	O
mutations	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
characteristics	O
of	O
both	O
the	O
subject	O
(	O
age	O
,	O
gender	O
,	O
and	O
family	O
/	O
personal	O
history	O
of	O
colonic	B-malignancy-type
neoplasia	I-malignancy-type
)	O
and	O
the	O
adenoma	B-malignancy-type
(	O
multiplicity	O
,	O
size	O
,	O
location	O
,	O
and	O
histologic	O
features	O
)	O
.	O
METHODS	O
:	O
Ki-ras	O
mutations	O
were	O
detected	O
by	O
direct	O
sequencing	O
in	O
738	O
adenomatous	B-malignancy-type
polyps	I-malignancy-type
removed	O
at	O
baseline	O
from	O
639	O
participants	O
in	O
a	O
nutritional	O
trial	O
of	O
adenoma	B-malignancy-type
recurrence	O
.	O
RESULTS	O
:	O
Ki-ras	O
mutations	O
were	O
detected	O
in	O
17.2	O
%	O
of	O
the	O
adenomas	B-malignancy-type
.	O
Ki-ras	O
mutations	O
were	O
unrelated	O
to	O
gender	O
,	O
family	O
,	O
or	O
personal	O
history	O
of	O
colonic	B-malignancy-type
neoplasia	I-malignancy-type
,	O
location	O
within	O
the	O
colorectum	O
,	O
or	O
adenoma	B-malignancy-type
multiplicity	O
,	O
but	O
were	O
more	O
common	O
in	O
older	O
subjects	O
(	O
P	O
=	O
0.01	O
for	O
trend	O
)	O
,	O
in	O
larger	B-malignancy-type
adenomas	I-malignancy-type
(	O
P	O
<	O
0.0001	O
for	O
trend	O
)	O
,	O
in	O
adenomas	B-malignancy-type
with	I-malignancy-type
villous	I-malignancy-type
histology	I-malignancy-type
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
3.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
2.1	O
-	O
4.9	O
vs.	O
tubular	B-malignancy-type
)	O
,	O
and	O
in	O
adenomas	B-malignancy-type
with	I-malignancy-type
high	I-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
(	O
32.0	O
%	O
vs.	O
13.6	O
%	O
;	O
OR	O
,	O
3.0	O
;	O
95	O
%	O
CI	O
,	O
1.9	O
-	O
4.6	O
vs.	O
low	B-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
)	O
.	O
Multivariate	O
analysis	O
showed	O
Ki-ras	O
mutations	O
to	O
be	O
independently	O
associated	O
with	O
subject	O
age	O
(	O
P	O
=	O
0.01	O
for	O
trend	O
)	O
,	O
tubulovillous	O
/	O
villous	O
histology	O
(	O
OR	O
,	O
2.3	O
;	O
95	O
%	O
CI	O
,	O
1.5	O
-	O
3.7	O
)	O
,	O
and	O
high	B-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
(	O
OR	O
,	O
1.9	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
3.1	O
)	O
.	O
Adenoma	B-malignancy-type
size	O
was	O
not	O
independently	O
related	O
to	O
Ki-ras	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Ki-ras	O
mutations	O
are	O
associated	O
with	O
the	O
histologic	O
features	O
of	O
adenoma	B-malignancy-type
progression	O
(	O
villous	O
histology	O
and	O
high	B-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
)	O
rather	O
than	O
with	O
adenoma	B-malignancy-type
growth	O
.	O
PMID	O
:	O
11487539	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O
	O

Am	O
J	O
Pathol	O
2001	O
Jun;158(	O
6)	O
:1955	O
-	O
9	O
Frequent	O
FGFR3	O
mutations	O
in	O
papillary	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
invasive	I-malignancy-type
bladder	I-malignancy-type
(	I-malignancy-type
pTa	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
.	O
Billerey	O
C	O
,	O
Chopin	O
D	O
,	O
Aubriot	O
-	O
Lorton	O
MH	O
,	O
Ricol	O
D	O
,	O
Gil	O
Diez	O
de	O
Medina	O
S,	O
Van	O
Rhijn	O
B	O
,	O
Bralet	O
MP	O
,	O
Lefrere	O
-	O
Belda	O
MA	O
,	O
Lahaye	O
JB	O
,	O
Abbou	O
CC	O
,	O
Bonaventure	O
J,	O
Zafrani	O
ES	O
,	O
van	O
der	O
Kwast	O
T	O
,	O
Thiery	O
JP	O
,	O
Radvanyi	O
F.	O
Service	O
d'Anatomie	O
et	O
de	O
Cytologie	O
Pathologiques	O
,	O
Centre	O
Hospitalo	O
-	O
Universitaire	O
de	O
Rouen	O
,	O
Hopital	O
Charles	O
Nicolle	O
,	O
Rouen	O
,	O
France	O
.	O
We	O
recently	O
identified	O
activating	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
in	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
assessed	O
the	O
incidence	O
of	O
FGFR3	O
mutations	O
in	O
a	O
series	O
of	O
132	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
:	O
20	O
carcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
(	O
CIS	B-malignancy-type
)	O
,	O
50	O
pTa	O
,	O
19	O
pT1	O
,	O
and	O
43	O
pT2-4	O
.	O
All	O
48	O
mutations	O
identified	O
were	O
identical	O
to	O
the	O
germinal	O
activating	O
mutations	O
that	O
cause	O
thanatophoric	B-malignancy-type
dysplasia	I-malignancy-type
,	O
a	O
lethal	O
form	O
of	O
dwarfism	O
.	O
The	O
S	O
249	O
C	O
mutation	O
,	O
found	O
in	O
33	O
of	O
the	O
48	O
mutated	O
tumors	O
,	O
was	O
the	O
most	O
common	O
.	O
The	O
frequency	O
of	O
mutations	O
was	O
higher	O
in	O
pTa	B-malignancy-type
tumors	I-malignancy-type
(	O
37	O
of	O
50	O
,	O
74	O
%	O
)	O
than	O
in	O
CIS	B-malignancy-type
(	O
0	O
of	O
20	O
,	O
0	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
pT1	B-malignancy-type
(	O
4	O
of	O
19	O
,	O
21	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
pT2-4	B-malignancy-type
tumors	I-malignancy-type
(	O
7	O
of	O
43	O
,	O
16	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O
FGFR3	O
mutations	O
were	O
detected	O
in	O
27	O
of	O
32	O
(	O
84	O
%	O
)	O
G1	B-malignancy-type
,	O
16	O
of	O
29	O
(	O
55	O
%	O
)	O
G2	B-malignancy-type
,	O
and	O
5	O
of	O
71	O
(	O
7	O
%	O
)	O
G3	B-malignancy-type
tumors	I-malignancy-type
.	O
This	O
association	O
between	O
FGFR3	O
mutations	O
and	O
low	O
grade	O
was	O
highly	O
significant	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
FGFR3	O
is	O
the	O
first	O
gene	O
found	O
to	O
be	O
mutated	O
at	O
a	O
high	O
frequency	O
in	O
pTa	B-malignancy-type
tumors	I-malignancy-type
.	O
The	O
absence	O
of	O
FGFR3	O
mutations	O
in	O
CIS	B-malignancy-type
and	O
the	O
low	O
frequency	O
of	O
FGFR3	O
mutations	O
in	O
pT1	B-malignancy-type
and	O
pT2-4	B-malignancy-type
tumors	I-malignancy-type
are	O
consistent	O
with	O
the	O
model	O
of	O
bladder	B-malignancy-type
tumor	I-malignancy-type
progression	O
in	O
which	O
the	O
most	O
common	O
precursor	O
of	O
pT1	B-malignancy-type
and	O
pT2-4	B-malignancy-type
tumors	I-malignancy-type
is	O
CIS	B-malignancy-type
.	O
PMID	O
:	O
11395371	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Cancer	O
Res	O
2001	O
Feb	O
15;61(	O
4)	O
:1265	O
-	O
8	O
The	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
mutation	O
is	O
a	O
strong	O
indicator	O
of	O
superficial	B-malignancy-type
bladder	I-malignancy-type
cancer	I-malignancy-type
with	O
low	O
recurrence	O
rate	O
.	O
van	O
Rhijn	O
BW	O
,	O
Lurkin	O
I	O
,	O
Radvanyi	O
F	O
,	O
Kirkels	O
WJ	O
,	O
van	O
der	O
Kwast	O
TH	O
,	O
Zwarthoff	O
EC	O
.	O
Department	O
of	O
Pathology	O
,	O
Josephine	O
Nefkens	O
Institute	O
,	O
Erasmus	O
University	O
,	O
Rotterdam	O
,	O
The	O
Netherlands	O
.	O
We	O
analyzed	O
the	O
possible	O
prognostic	O
value	O
of	O
the	O
recently	O
discovered	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
mutations	O
in	O
bladder	B-malignancy-type
cancer	O
.	O
A	O
FGFR3	O
mutation	O
was	O
found	O
in	O
34	O
of	O
53	O
pTaG	B-malignancy-type
1	I-malignancy-type
-	I-malignancy-type
2	I-malignancy-type
bladder	I-malignancy-type
cancers	I-malignancy-type
,	O
whereas	O
none	O
of	O
the	O
19	O
higher	O
-	O
staged	O
tumors	O
had	O
a	O
mutation	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
In	O
57	O
patients	O
with	O
superficial	O
disease	O
followed	O
prospectively	O
by	O
cystoscopy	O
for	O
12	O
months	O
,	O
14	O
of	O
23	O
patients	O
in	O
the	O
wild	O
-	O
type	O
FGFR3	O
group	O
developed	O
recurrent	B-malignancy-type
bladder	I-malignancy-type
cancer	I-malignancy-type
compared	O
with	O
only	O
7	O
of	O
34	O
patients	O
in	O
the	O
mutant	O
group	O
(	O
P	O
=	O
0.004	O
)	O
.	O
The	O
recurrence	O
rate	O
per	O
year	O
was	O
0.24	O
for	O
the	O
FGFR3	O
mutant	O
tumors	O
and	O
1.12	O
for	O
tumors	O
with	O
a	O
wild	O
-	O
type	O
FGFR3	O
gene	O
.	O
In	O
addition	O
,	O
FGFR3	O
mutation	O
status	O
was	O
the	O
strongest	O
predictor	O
of	O
recurrence	O
when	O
compared	O
with	O
stage	O
and	O
grade	O
(	O
P	O
=	O
0.008	O
)	O
.	O
This	O
is	O
the	O
first	O
mutation	O
in	O
bladder	B-malignancy-type
cancer	I-malignancy-type
that	O
selectively	O
identifies	O
patients	O
with	O
favorable	O
disease	O
characteristics	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
frequency	O
of	O
cystoscopic	O
examinations	O
can	O
be	O
reduced	O
considerably	O
in	O
patients	O
with	O
FGFR3	O
-	O
positive	O
tumors	O
.	O
PMID	O
:	O
11245416	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Cytol	O
2000	O
Nov-	O
Dec;44(	O
6)	O
:981	O
-	O
6	O
Analysis	O
of	O
KIT	O
mutation	O
and	O
protein	O
expression	O
in	O
fine	O
needle	O
aspirates	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
/	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
.	O
Li	O
SQ	O
,	O
O'Leary	O
TJ	O
,	O
Sobin	O
LH	O
,	O
Erozan	O
YS	O
,	O
Rosenthal	O
DL	O
,	O
Przygodzki	O
RM	O
.	O
Department	O
of	O
Pathology	O
,	O
Columbia	O
University	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
,	O
VC	O
14	O
-	O
215	O
,	O
630	O
West	O
168th	O
Street	O
,	O
New	O
York	O
,	O
New	O
York	O
100	O
32	O
,	O
USA	O
.	O
sl828@columbia	O
.edu	O
OBJECTIVE	O
:	O
To	O
determine	O
if	O
sequencing	O
the	O
KIT	O
gene	O
could	O
facilitate	O
more	O
definitive	O
FNA	O
diagnosis	O
.	O
STUDY	O
DESIGN	O
:	O
Sixteen	O
cases	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
/	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
in	O
which	O
fine	O
needle	O
aspiration	O
(	O
FNA	O
)	O
was	O
performed	O
(	O
mean	O
age	O
,	O
67	O
;	O
M	O
/	O
F	O
=	O
12	O
/	O
4	O
)	O
were	O
studied	O
.	O
DNA	O
was	O
extracted	O
from	O
cytologic	O
preparations	O
from	O
all	O
patients	O
(	O
15	O
cell	O
blocks	O
,	O
1	O
alcohol	O
-	O
fixed	O
smear	O
)	O
and	O
seven	O
subsequent	O
resection	O
specimens	O
.	O
DNA	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
,	O
using	O
primers	O
designed	O
to	O
amplify	O
a	O
segment	O
of	O
the	O
KIT	O
gene	O
exon	O
11	O
and	O
sequenced	O
on	O
an	O
ABI	O
Prism	O
377	O
DNA	O
sequence	O
analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Indianapolis	O
,	O
Indiana	O
,	O
U.S.A.	O
)	O
.	O
Immunocytochemical	O
staining	O
for	O
CD	O
117	O
(	O
the	O
KIT	O
gene	O
product	O
)	O
was	O
performed	O
on	O
sections	O
from	O
12	O
cell	O
blocks	O
and	O
7	O
surgical	O
resections	O
.	O
RESULTS	O
:	O
In	O
-	O
frame	O
deletion	O
of	O
exon	O
11	O
was	O
detected	O
in	O
eight	O
cases	O
(	O
7	O
monoalleic	O
,	O
1	O
bialleic	O
)	O
;	O
a	O
point	O
mutation	O
was	O
found	O
in	O
one	O
case	O
.	O
Mutation	O
was	O
found	O
only	O
in	O
histologically	O
malignant	O
(	O
6	O
of	O
10	O
cases	O
)	O
and	O
borderline	B-malignancy-type
GISTs	I-malignancy-type
(	O
3	O
of	O
4	O
cases	O
)	O
.	O
No	O
mutation	O
was	O
identified	O
in	O
benign	O
tumors	O
.	O
In	O
three	O
cases	O
,	O
scant	O
cellularity	O
or	O
blood	O
precluded	O
sequencing	O
.	O
CD	O
117	O
was	O
expressed	O
in	O
12	O
of	O
15	O
cases	O
.	O
CONCLUSION	O
:	O
Immunocytochemical	O
staining	O
for	O
CD	O
117	O
is	O
useful	O
in	O
confirming	O
a	O
cytologic	O
diagnosis	O
of	O
GIST	B-malignancy-type
but	O
does	O
not	O
facilitate	O
diagnosis	O
of	O
malignancy	O
.	O
FNA	O
biopsy	O
specimens	O
are	O
suitable	O
for	O
KIT	O
gene	O
sequencing	O
;	O
detection	O
of	O
a	O
KIT	O
mutation	O
favors	O
a	O
malignant	O
diagnosis	O
,	O
though	O
absence	O
of	O
mutation	O
does	O
not	O
preclude	O
malignancy	O
.	O
PMID	O
:	O
11127756	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Hematol	O
2000	O
Nov;65(	O
3	O
)	O
:234	O
-	O
8	O
Epstein	O
-	O
Barr	O
virus	O
associated	O
B-cell	O
lymphoma	O
of	O
brain	O
developing	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
with	O
c-kit	O
mutation	O
(	O
Try	O
-	O
557	O
-->	O
stop	O
)	O
.	O
Kuwahara	O
Y	O
,	O
Hirata	O
A	O
,	O
Miwa	O
H	O
,	O
Munakata	O
S,	O
Ueda	O
S,	O
Kanakura	O
Y	O
,	O
Maruno	O
M,	O
Hongyo	O
T	O
,	O
Nomura	O
T	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Japan	O
.	O
The	O
first	O
case	O
of	O
B-cell	B-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
brain	I-malignancy-type
in	O
a	O
patient	O
with	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
was	O
reported	O
.	O
A	O
68	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
because	O
of	O
anemia	O
,	O
fever	O
,	O
and	O
thrombocytopenia	O
and	O
was	O
diagnosed	O
as	O
having	O
MDS	O
(	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
)	O
on	O
the	O
basis	O
of	O
the	O
findings	O
of	O
bone	O
marrow	O
aspiration	O
and	O
chromosomal	O
analysis	O
.	O
The	O
patient	O
was	O
followed	O
up	O
without	O
chemotherapy	O
,	O
but	O
a	O
brain	B-malignancy-type
tumor	I-malignancy-type
appeared	O
after	O
3	O
years	O
.	O
Histologic	O
and	O
immunohistologic	O
examinations	O
revealed	O
diffuse	B-malignancy-type
large	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Mutations	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
(	O
stem	O
cell	O
factor	O
receptor	O
)	O
and	O
the	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
were	O
examined	O
in	O
the	O
MDS	B-malignancy-type
lesion	I-malignancy-type
and	O
malignant	B-malignancy-type
lymphoma	I-malignancy-type
(	O
ML	B-malignancy-type
)	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
method	O
followed	O
by	O
direct	O
sequencing	O
.	O
The	O
p53	O
mutation	O
was	O
not	O
found	O
in	O
either	O
MDS	B-malignancy-type
or	O
ML	B-malignancy-type
,	O
but	O
a	O
nonsense	O
mutation	O
(	O
Try	O
-	O
557	O
-->	O
stop	O
)	O
in	O
exon	O
11	O
of	O
the	O
c-kit	O
,	O
which	O
might	O
lead	O
to	O
dysfunction	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
was	O
detected	O
in	O
MDS	B-malignancy-type
.	O
This	O
is	O
the	O
first	O
report	O
of	O
c-kit	O
mutation	O
in	O
MDS	B-malignancy-type
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
was	O
demonstrated	O
in	O
the	O
nucleus	O
of	O
brain	B-malignancy-type
ML	I-malignancy-type
cells	O
by	O
in	O
situ	O
hybridization	O
with	O
EBV	O
-	O
encoded	O
RNA-1	O
probe	O
.	O
Immunohistochemistry	O
showed	O
that	O
the	O
tumor	O
cells	O
expressed	O
latent	O
infection	O
gene	O
products	O
,	O
including	O
EBV	O
nuclear	O
antigen-2	O
and	O
latent	O
membrane	O
protein-1	O
.	O
This	O
pattern	O
of	O
latent	O
gene	O
expression	O
was	O
Lat	O
III	O
,	O
which	O
is	O
usually	O
found	O
in	O
malignant	B-malignancy-type
lymphomas	I-malignancy-type
developing	O
in	O
immunocompromised	O
hosts	O
.	O
These	O
findings	O
suggest	O
that	O
a	O
profound	O
pancytopenia	O
in	O
MDS	B-malignancy-type
resulted	O
in	O
an	O
immunodeficient	O
condition	O
,	O
after	O
which	O
EBV	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
brain	I-malignancy-type
developed	O
.	O
PMID	O
:	O
11074541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
2000	O
Sep;157(	O
3	O
)	O
:763	O
-	O
70	O
Beta-catenin	O
mutations	O
are	O
associated	O
with	O
a	O
subset	O
of	O
low	O
-	O
stage	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
negative	O
for	O
hepatitis	O
B	O
virus	O
and	O
with	O
favorable	O
prognosis	O
.	O
Hsu	O
HC	O
,	O
Jeng	O
YM	O
,	O
Mao	O
TL	O
,	O
Chu	O
JS	O
,	O
Lai	O
PL	O
,	O
Peng	O
SY	O
.	O
Department	O
of	O
Pathology	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
heychi@ha.mc.ntu.edu.tw	O
To	O
better	O
understand	O
the	O
role	O
of	O
beta-catenin	O
mutation	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
,	O
we	O
correlated	O
the	O
gene	O
mutation	O
with	O
hepatitis	O
virus	O
B	O
(	O
HBV	O
)	O
and	O
hepatitis	O
virus	O
C	O
(	O
HCV	O
)	O
status	O
and	O
the	O
clinicopathological	O
features	O
in	O
366	O
patients	O
with	O
resected	O
primary	O
unifocal	B-malignancy-type
HCC	I-malignancy-type
.	O
beta-Catenin	O
mutations	O
were	O
also	O
analyzed	O
in	O
55	O
patients	O
with	O
multifocal	B-malignancy-type
HCC	I-malignancy-type
(	O
68	O
tumors	O
)	O
.	O
Of	O
the	O
whole	O
series	O
,	O
57	O
(	O
13.1	O
%	O
)	O
of	O
434	O
tumors	O
examined	O
had	O
beta-catenin	O
mutations	O
,	O
34	O
occurred	O
at	O
the	O
serine	O
/	O
threonine	O
residues	O
of	O
the	O
GSK-3beta	O
region	O
of	O
beta-catenin	O
.	O
Outside	O
the	O
GSK-3beta	O
phosphorylation	O
site	O
,	O
codons	O
32	O
and	O
34	O
were	O
two	O
mutational	O
hot	O
spots	O
(	O
17	O
tumors	O
)	O
.	O
The	O
non	B-malignancy-type
-	I-malignancy-type
HBV	I-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCC	I-malignancy-type
that	O
was	O
predominantly	O
HCV	O
related	O
had	O
a	O
higher	O
frequency	O
of	O
mutation	O
(	O
P	O
:	O
<	O
0.00001	O
)	O
and	O
more	O
frequent	O
mutations	O
at	O
codon	O
45	O
than	O
HBV	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCC	I-malignancy-type
.	O
HBV	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCC	I-malignancy-type
had	O
a	O
younger	O
mean	O
age	O
(	O
P	O
:	O
<	O
0.00001	O
)	O
,	O
and	O
higher	O
male	O
-	O
to	O
-	O
female	O
ratio	O
(	O
P	O
:	O
<	O
0.003	O
)	O
and	O
positive	O
familial	O
history	O
of	O
HCC	O
(	O
P	O
:	O
<	O
0.014	O
)	O
.	O
Among	O
366	O
unifocal	B-malignancy-type
HCCs	I-malignancy-type
selected	O
for	O
clinicopathological	O
analysis	O
,	O
beta-catenin	O
mutations	O
were	O
associated	O
with	O
grade	O
I	O
(	O
P	O
:	O
=	O
0.005	O
)	O
and	O
stage	O
I	O
and	O
II	O
HCC	B-malignancy-type
(	O
P	O
:	O
<	O
0.0001	O
)	O
,	O
and	O
a	O
better	O
5	O
-	O
year	O
survival	O
rate	O
(	O
P	O
:	O
=	O
0.	O
00003	O
)	O
.	O
These	O
findings	O
suggest	O
mechanisms	O
for	O
beta-catenin	O
mutations	O
differ	O
between	O
HBV	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
and	O
non	B-malignancy-type
-	I-malignancy-type
HBV	I-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
HCCs	I-malignancy-type
,	O
and	O
that	O
beta-catenin	O
mutation	O
is	O
a	O
favorable	O
prognostic	O
factor	O
related	O
to	O
low	O
stage	O
.	O
beta-Catenin	O
mutation	O
was	O
associated	O
with	O
nuclear	O
expression	O
of	O
the	O
protein	O
(	O
P	O
:	O
<	O
0.00001	O
)	O
,	O
but	O
we	O
failed	O
to	O
detect	O
point	O
or	O
large	O
fragment	O
deletion	O
mutation	O
in	O
39	O
HCCs	B-malignancy-type
with	O
nuclear	O
beta-catenin	O
expression	O
,	O
presumably	O
wild	O
-	O
type	O
protein	O
.	O
HCCs	B-malignancy-type
expressing	O
mutant	O
nuclear	O
beta-catenin	O
had	O
a	O
better	O
5	O
-	O
year	O
survival	O
rate	O
(	O
P	O
:	O
<	O
0.007	O
)	O
,	O
suggesting	O
that	O
mutant	O
and	O
wild	O
-	O
type	O
nuclear	O
beta-catenin	O
proteins	O
are	O
not	O
functionally	O
equivalent	O
and	O
deserve	O
more	O
studies	O
for	O
further	O
clarification	O
.	O
PMID	O
:	O
10980116	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
2000	O
Aug	O
25;90(	O
4)	O
:258	O
-	O
63	O
Application	O
of	O
the	O
p53	O
and	O
K-ras	O
gene	O
mutation	O
patterns	O
for	O
cytologic	O
diagnosis	O
of	O
recurrent	B-malignancy-type
lung	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Dai	O
Y	O
,	O
Morishita	O
Y	O
,	O
Mase	O
K	O
,	O
Sato	O
N	O
,	O
Akaogi	O
E	O
,	O
Mitsui	O
T	O
,	O
Noguchi	O
M.	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Basic	O
Medical	O
Sciences	O
,	O
University	O
of	O
Tsukuba	O
,	O
Tennodai	O
,	O
Tsukuba	O
-	O
shi	O
,	O
Ibaraki	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Cytologic	O
specimens	O
are	O
one	O
of	O
the	O
most	O
important	O
materials	O
for	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
diagnosis	O
,	O
because	O
they	O
can	O
be	O
used	O
in	O
mass	O
screening	O
for	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
and	O
early	O
detection	O
of	O
cancer	O
recurrence	O
by	O
examination	O
of	O
sputum	O
and	O
pleural	O
fluid	O
.	O
METHODS	O
:	O
To	O
prove	O
the	O
potentiality	O
of	O
the	O
cytologic	O
specimens	O
to	O
be	O
subjected	O
to	O
molecular	O
detection	O
of	O
recurrent	B-malignancy-type
lung	I-malignancy-type
carcinomas	I-malignancy-type
,	O
the	O
authors	O
enrolled	O
16	O
patients	O
who	O
had	O
undergone	O
surgical	O
treatment	O
for	O
lung	B-malignancy-type
carcinoma	I-malignancy-type
with	I-malignancy-type
recurrence	I-malignancy-type
detected	O
by	O
malignant	O
pleural	O
fluid	O
.	O
First	O
,	O
they	O
examined	O
K-ras	O
gene	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
abnormalities	O
in	O
resected	O
tumors	O
by	O
polymerase	O
chain	O
reaction	O
-	O
based	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
.	O
Next	O
,	O
using	O
a	O
microdissection	O
method	O
,	O
they	O
investigated	O
the	O
use	O
of	O
cytologic	O
specimens	O
such	O
as	O
pleural	O
fluid	O
for	O
the	O
detection	O
of	O
recurrence	O
by	O
finding	O
the	O
same	O
mutations	O
observed	O
in	O
the	O
initially	O
resected	O
tumor	O
.	O
RESULTS	O
:	O
Seven	O
abnormally	O
shifted	O
bands	O
were	O
detected	O
among	O
six	O
patients	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
of	O
surgical	O
materials	O
.	O
Five	O
of	O
7	O
abnormally	O
shifted	O
bands	O
(	O
71.4	O
%	O
)	O
also	O
were	O
detected	O
from	O
microdissected	O
malignant	O
cells	O
in	O
cytologic	O
smears	O
.	O
In	O
two	O
cases	O
,	O
they	O
detected	O
mutations	O
by	O
using	O
single	O
malignant	O
cells	O
in	O
pleural	O
fluid	O
.	O
CONCLUSIONS	O
:	O
The	O
authors	O
successfully	O
detected	O
the	O
same	O
mutations	O
in	O
recurrent	O
cytologic	O
specimens	O
as	O
those	O
in	O
the	O
initially	O
resected	O
tumors	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
p53	O
and	O
K-ras	O
gene	O
mutation	O
patterns	O
are	O
effective	O
markers	O
for	O
the	O
detection	O
of	O
recurrent	B-malignancy-type
lung	I-malignancy-type
carcinoma	I-malignancy-type
in	O
cytologic	O
specimens	O
.	O
Cancer	O
(	O
Cancer	O
Cytopathol	O
)	O
Copyright	O
2000	O
American	O
Cancer	O
Society	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10966568	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2000	O
Sep	O
1;157(	O
2	O
)	O
:185	O
-	O
91	O
Beta-catenin	O
and	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
in	O
adenomas	B-malignancy-type
from	O
hereditary	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
polyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Akiyama	O
Y	O
,	O
Nagasaki	O
H	O
,	O
Yagi	O
KO	O
,	O
Nomizu	O
T	O
,	O
Yuasa	O
Y.	O
Department	O
of	O
Hygiene	O
and	O
Oncology	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
School	O
of	O
Medicine	O
,	O
1	O
-	O
5	O
-	O
45	O
Yushima	O
,	O
Bunkyo	O
-	O
ku	O
,	O
113	O
-	O
8519	O
,	O
Tokyo	O
,	O
Japan	O
.	O
To	O
clarify	O
the	O
roles	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
beta-catenin	O
genes	O
in	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
HNPCC	B-malignancy-type
)	O
tumorigenesis	O
,	O
we	O
searched	O
for	O
their	O
mutations	O
in	O
14	O
HNPCC	B-malignancy-type
adenomas	I-malignancy-type
with	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
Seven	O
(	O
50	O
%	O
)	O
adenomas	B-malignancy-type
exhibited	O
somatic	O
APC	O
mutations	O
,	O
five	O
of	O
which	O
were	O
frameshift	O
mutations	O
and	O
the	O
other	O
two	O
nonsense	O
ones	O
.	O
However	O
,	O
the	O
APC	O
mutational	O
spectrum	O
of	O
these	O
adenomas	B-malignancy-type
was	O
similar	O
to	O
that	O
of	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Two	O
adenomas	B-malignancy-type
(	O
14.3	O
%	O
)	O
with	O
undetectable	O
APC	O
alterations	O
showed	O
missense	O
mutations	O
at	O
codon	O
45	O
(	O
TCT	O
to	O
TTT	O
or	O
to	O
CCT	O
)	O
in	O
beta-catenin	O
.	O
The	O
MSI	O
frequency	O
in	O
adenomas	B-malignancy-type
with	O
beta-catenin	O
mutations	O
was	O
significantly	O
higher	O
than	O
that	O
with	O
APC	O
ones	O
(	O
P	O
<	O
0.001	O
)	O
,	O
indicating	O
that	O
mutations	O
of	O
beta-catenin	O
rather	O
than	O
APC	O
are	O
strongly	O
associated	O
with	O
MSI	O
.	O
These	O
data	O
suggest	O
that	O
adenomas	B-malignancy-type
with	O
beta-catenin	O
activating	O
mutations	O
and	O
some	O
with	O
APC	O
inactivating	O
mutations	O
may	O
be	O
precursors	O
of	O
HNPCC	B-malignancy-type
colorectal	I-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
10936679	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
2000	O
Apr	O
28;152(	O
1	O
)	O
:45	O
-	O
51	O
Somatic	O
mutations	O
of	O
beta-catenin	O
play	O
a	O
crucial	O
role	O
in	O
the	O
tumorigenesis	O
of	O
sporadic	B-malignancy-type
hepatoblastoma	I-malignancy-type
.	O
Jeng	O
YM	O
,	O
Wu	O
MZ	O
,	O
Mao	O
TL	O
,	O
Chang	O
MH	O
,	O
Hsu	O
HC.	O
Department	O
of	O
Pathology	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
7	O
Chung	O
-	O
Shan	O
South	O
Road	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
Hepatoblastoma	B-malignancy-type
(	O
HB	B-malignancy-type
)	O
is	O
the	O
most	O
common	O
malignant	B-malignancy-type
hepatic	I-malignancy-type
tumor	I-malignancy-type
during	O
early	O
childhood	O
.	O
Its	O
molecular	O
pathogenesis	O
is	O
still	O
poorly	O
understood	O
.	O
Mutations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
have	O
been	O
identified	O
in	O
sporadic	O
cases	O
and	O
in	O
individuals	O
associated	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
syndrome	I-malignancy-type
.	O
beta-catenin	O
is	O
a	O
key	O
element	O
in	O
the	O
cadherin	O
-	O
mediated	O
cell	O
adhesion	O
system	O
and	O
Wnt	O
/	O
wingless	O
pathway	O
,	O
and	O
is	O
controlled	O
by	O
APC	O
.	O
APC	O
affects	O
the	O
degradation	O
of	O
beta-catenin	O
by	O
its	O
NH(2)	O
-	O
terminal	O
phosphorylation	O
on	O
the	O
serine	O
/	O
threonine	O
residues	O
of	O
exon	O
3	O
.	O
Mutations	O
of	O
these	O
phosphorylation	O
sites	O
are	O
primary	O
targets	O
for	O
activating	O
mutations	O
in	O
several	O
types	O
of	O
human	O
cancer	O
and	O
lead	O
to	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
protein	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
nine	O
patients	O
with	O
HB	O
using	O
immunohistochemistry	O
and	O
direct	O
DNA	O
sequencing	O
.	O
All	O
nine	O
cases	O
showed	O
predominant	O
nuclear	O
expression	O
of	O
beta-catenin	O
.	O
Eight	O
cases	O
(	O
89	O
%	O
)	O
showed	O
mutations	O
involving	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
including	O
five	O
with	O
deletions	O
and	O
three	O
with	O
missense	O
mutations	O
.	O
All	O
five	O
deletions	O
were	O
in	O
-	O
frame	O
deletions	O
without	O
frameshift	O
.	O
The	O
very	O
high	O
frequency	O
of	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
suggests	O
that	O
beta-catenin	O
mutations	O
are	O
crucial	O
in	O
the	O
tumorigenesis	O
of	O
HB	B-malignancy-type
.	O
PMID	O
:	O
10754205	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
2000	O
Mar;24(	O
3	O
)	O
:245	O
-	O
50	O
AXIN1	O
mutations	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
growth	O
suppression	O
in	O
cancer	O
cells	O
by	O
virus	O
-	O
mediated	O
transfer	O
of	O
AXIN1	O
.	O
Satoh	O
S,	O
Daigo	O
Y	O
,	O
Furukawa	O
Y	O
,	O
Kato	O
T	O
,	O
Miwa	O
N	O
,	O
Nishiwaki	O
T	O
,	O
Kawasoe	O
T	O
,	O
Ishiguro	O
H	O
,	O
Fujita	O
M,	O
Tokino	O
T	O
,	O
Sasaki	O
Y	O
,	O
Imaoka	O
S,	O
Murata	O
M,	O
Shimano	O
T	O
,	O
Yamaoka	O
Y	O
,	O
Nakamura	O
Y.	O
Laboratory	O
of	O
Molecular	O
Medicine	O
,	O
Human	O
Genome	O
Center	O
,	O
Institute	O
of	O
Medical	O
Science	O
,	O
The	O
University	O
of	O
Tokyo	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
Wnt	O
signaling	O
pathway	O
is	O
essential	O
for	O
development	O
and	O
organogenesis	O
.	O
Wnt	O
signaling	O
stabilizes	O
beta-catenin	O
,	O
which	O
accumulates	O
in	O
the	O
cytoplasm	O
,	O
binds	O
to	O
1-cell	O
factor	O
(	O
TCF	O
;	O
also	O
known	O
as	O
lymphocyte	O
enhancer	O
-	O
binding	O
factor	O
,	O
LEF	O
)	O
and	O
then	O
upregulates	O
downstream	O
genes	O
.	O
Mutations	O
in	O
CTNNB1	O
(	O
encoding	O
beta-catenin	O
)	O
or	O
APC	O
(	O
adenomatous	O
polyposis	O
coli	O
)	O
have	O
been	O
reported	O
in	O
human	O
neoplasms	B-malignancy-type
including	O
colon	B-malignancy-type
cancers	I-malignancy-type
and	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
.	O
Because	O
HCC5	B-malignancy-type
tend	O
to	O
show	O
accumulation	O
of	O
beta-catenin	O
more	O
often	O
than	O
mutations	O
in	O
CTNNB1	O
,	O
we	O
looked	O
for	O
mutations	O
in	O
AXIN1	O
,	O
encoding	O
a	O
key	O
factor	O
for	O
Wnt	O
signaling	O
,	O
in	O
6	O
HCC	B-malignancy-type
cell	O
lines	O
and	O
100	O
primary	O
HCC5	B-malignancy-type
.	O
Among	O
the	O
4	O
cell	O
lines	O
and	O
87	O
HCC5	B-malignancy-type
in	O
which	O
we	O
did	O
not	O
detect	O
CTNNB1	O
mutations	O
,	O
we	O
identified	O
AXIN1	O
mutations	O
in	O
3	O
cell	O
lines	O
and	O
6	O
mutations	O
in	O
5	O
of	O
the	O
primary	O
HCCs	B-malignancy-type
.	O
In	O
cell	O
lines	O
containing	O
mutations	O
in	O
either	O
gene	O
,	O
we	O
observed	O
increased	O
DNA	O
binding	O
of	O
TCF	O
associated	O
with	O
beta-catenin	O
in	O
nuclei	O
.	O
Adenovirus	O
mediated	O
gene	O
transfer	O
of	O
wild	O
-	O
type	O
AXINI	O
induced	O
apoptosis	O
in	O
hepatocellular	B-malignancy-type
and	O
colorectal	B-malignancy-type
cancer	B-malignancy-type
cells	O
that	O
had	O
accumulated	O
beta-catenin	O
as	O
a	O
consequence	O
of	O
either	O
APC	O
,	O
CTNNB1	O
or	O
AXIN1	O
mutation	O
,	O
suggesting	O
that	O
axin	O
may	O
be	O
an	O
effective	O
therapeutic	O
molecule	O
for	O
suppressing	O
growth	O
of	O
hepatocellular	B-malignancy-type
and	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
10700176	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Dec;90(	O
12	O
)	O
:1301	O
-	O
9	O
Erratum	O
in	O
:	O
Jpn	O
J	O
Cancer	O
Res	O
2000	O
Feb;91(	O
2	O
)	O
:270	O
Comment	O
in	O
:	O
Jpn	O
J	O
Cancer	O
Res	O
.	O
1999	O
Dec;90(	O
12	O
)	O
:inside	O
front	O
cover	O
.	O
Beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Kondo	O
Y	O
,	O
Kanai	O
Y	O
,	O
Sakamoto	O
M,	O
Genda	O
T	O
,	O
Mizokami	O
M,	O
Ueda	O
R,	O
Hirohashi	O
S.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
.	O
A	O
study	O
was	O
conducted	O
to	O
clarify	O
the	O
contribution	O
of	O
beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
to	O
hepatocarcinogenesis	O
.	O
Beta-catenin	O
accumulation	O
was	O
examined	O
immunohistochemically	O
in	O
38	O
paired	O
samples	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
and	O
corresponding	O
non	O
-	O
cancerous	O
liver	O
tissue	O
.	O
Gene	O
mutation	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
using	O
intronic	O
primers	O
encompassing	O
exon	O
3	O
.	O
Neither	O
accumulation	O
nor	O
mutation	O
was	O
detected	O
in	O
non	O
-	O
cancerous	O
liver	O
tissues	O
that	O
showed	O
no	O
remarkable	O
histological	O
features	O
,	O
chronic	O
hepatitis	O
or	O
liver	O
cirrhosis	O
.	O
Accumulation	O
of	O
beta-catenin	O
was	O
seen	O
in	O
the	O
nucleus	O
,	O
cytoplasm	O
or	O
cell	O
membrane	O
in	O
15	O
of	O
38	O
(	O
39	O
%	O
)	O
HCC	B-malignancy-type
samples	O
,	O
and	O
gene	O
mutation	O
was	O
seen	O
in	O
9	O
of	O
38	O
(	O
24	O
%	O
)	O
HCC	B-malignancy-type
samples	O
.	O
Although	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
accumulation	O
and	O
mutation	O
(	O
P	O
<	O
0.01	O
)	O
,	O
six	O
HCCs	B-malignancy-type
without	O
mutation	O
also	O
showed	O
accumulation	O
.	O
Samples	O
of	O
early	O
HCC	B-malignancy-type
showed	O
neither	O
accumulation	O
nor	O
mutation	O
,	O
and	O
accumulation	O
and	O
mutation	O
were	O
each	O
correlated	O
significantly	O
with	O
portal	B-malignancy-type
vein	I-malignancy-type
tumor	I-malignancy-type
involvement	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
present	O
results	O
indicate	O
that	O
(1)	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
can	O
lead	O
to	O
beta-catenin	O
accumulation	O
,	O
although	O
other	O
mechanisms	O
of	O
accumulation	O
may	O
also	O
operate	O
in	O
HCC	B-malignancy-type
,	O
and	O
(2)	O
beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
are	O
not	O
early	O
events	O
in	O
hepatocarcinogenesis	O
,	O
and	O
may	O
be	O
associated	O
with	O
the	O
malignant	O
progression	O
of	O
HCC	B-malignancy-type
.	O
PMID	O
:	O
10665646	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anal	O
Cell	O
Pathol	O
1999;19(	O
1	O
)	O
:39	O
-	O
46	O
K-ras2	O
activation	O
and	O
genome	O
instability	O
increase	O
proliferation	O
and	O
size	O
of	O
FAP	B-malignancy-type
adenomas	I-malignancy-type
.	O
Rapallo	O
A	O
,	O
Sciutto	O
A	O
,	O
Geido	O
E	O
,	O
Orecchia	O
R,	O
Infusini	O
E	O
,	O
Pujic	O
N	O
,	O
d'Amore	O
ES	O
,	O
Monaco	O
R,	O
Risio	O
M,	O
Rossini	O
FP	O
,	O
Giaretti	O
W.	O
Laboratory	O
of	O
Biophysics	O
and	O
Cytometry	O
,	O
National	O
Cancer	O
Institute	O
,	O
Genoa	O
,	O
Italy	O
.	O
The	O
possible	O
role	O
of	O
K-ras2	O
mutations	O
and	O
aneuploidy	O
toward	O
increase	O
of	O
proliferation	O
and	O
adenoma	B-malignancy-type
size	O
in	O
Familial	B-malignancy-type
Adenomatous	I-malignancy-type
Polyposis	I-malignancy-type
(	I-malignancy-type
FAP	I-malignancy-type
)	I-malignancy-type
adenomas	I-malignancy-type
is	O
not	O
known	O
.	O
The	O
present	O
study	O
addresses	O
these	O
issues	O
by	O
investigating	O
147	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
obtained	O
from	O
four	O
FAP	B-malignancy-type
patients	O
.	O
The	O
majority	O
of	O
adenomas	B-malignancy-type
had	O
size	O
lower	O
than	O
or	O
equal	O
to	O
10	O
mm	O
(	O
86	O
%	O
)	O
,	O
low	B-malignancy-type
grade	I-malignancy-type
dysplasia	I-malignancy-type
(	O
63	O
%	O
)	O
,	O
and	O
were	O
preferentially	O
located	O
in	O
the	O
right	O
colon	O
(	O
60	O
%	O
)	O
.	O
Normal	O
mucosa	O
samples	O
were	O
obtained	O
from	O
19	O
healthy	O
donors	O
.	O
Three	O
synchronous	O
adenocarcinomas	B-malignancy-type
were	O
also	O
investigated	O
.	O
K-ras2	O
mutation	O
spectrum	O
was	O
analysed	O
by	O
PCR	O
and	O
Sequence	O
Specific	O
Oligonucleotide	O
(	O
SSO	O
)	O
hybridization	O
,	O
while	O
flow	O
cytometry	O
(	O
FCM	O
)	O
was	O
used	O
for	O
evaluating	O
degree	O
of	O
DNA	O
ploidy	O
and	O
S-phase	O
fraction	O
.	O
Overall	O
,	O
incidences	O
of	O
K-ras2	O
mutations	O
,	O
DNA	O
aneuploidy	O
and	O
high	O
S-phase	O
values	O
(	O
>	O
7.2	O
%	O
)	O
were	O
6.6	O
%	O
,	O
5.4	O
%	O
and	O
10.5	O
%	O
,	O
respectively	O
.	O
In	O
particular	O
,	O
among	O
the	O
adenomas	B-malignancy-type
with	O
size	O
lower	O
than	O
5	O
mm	O
,	O
K-ras2	O
mutation	O
and	O
DNA	O
aneuploidy	O
frequencies	O
were	O
only	O
slightly	O
above	O
1	O
%	O
.	O
Statistically	O
significant	O
correlations	O
were	O
found	O
between	O
K-ras2	O
and	O
size	O
,	O
DNA	O
ploidy	O
and	O
size	O
and	O
K-ras2	O
and	O
S-phase	O
(	O
p	O
<	O
0.001	O
)	O
.	O
In	O
particular	O
,	O
among	O
the	O
wild	O
type	O
K-ras2	O
adenomas	B-malignancy-type
,	O
high	O
S-phase	O
values	O
were	O
detected	O
in	O
8	O
%	O
of	O
the	O
cases	O
versus	O
57	O
%	O
among	O
the	O
K-ras2	O
mutated	O
adenomas	B-malignancy-type
(	O
p	O
=	O
0.0005	O
)	O
.	O
The	O
present	O
series	O
of	O
FAP	B-malignancy-type
adenomas	I-malignancy-type
indicates	O
that	O
K-ras2	O
activation	O
and	O
gross	O
genomic	O
changes	O
play	O
a	O
role	O
toward	O
a	O
proliferative	O
gain	O
and	O
tumour	O
growth	O
in	O
size	O
.	O
PMID	O
:	O
10661623	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1999	O
Feb;17(	O
2	O
)	O
:578	O
-	O
84	O
K-ras	O
mutations	O
in	O
DNA	O
extracted	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
:	O
diagnostic	O
utility	O
and	O
prognostic	O
significance	O
.	O
Castells	O
A	O
,	O
Puig	O
P	O
,	O
Mora	O
J,	O
Boadas	O
J,	O
Boix	O
L,	O
Urgell	O
E	O
,	O
Sole	O
M,	O
Capella	O
G	O
,	O
Lluis	O
F	O
,	O
Fernandez	O
-	O
Cruz	O
L,	O
Navarro	O
S,	O
Farre	O
A.	O
Institut	O
Clinic	O
de	O
Malalties	O
Digestives	O
and	O
Department	O
of	O
Pathology	O
,	O
Hospital	O
Clinic	O
i	O
Provincial	O
,	O
University	O
of	O
Barcelona	O
,	O
Catalonia	O
,	O
Spain	O
.	O
castells	O
@helix	O
.mgh	O
.harvard	O
.edu	O
PURPOSE	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
the	O
presence	O
of	O
K-ras	O
mutations	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
However	O
,	O
the	O
diagnostic	O
utility	O
and	O
the	O
prognostic	O
significance	O
of	O
this	O
finding	O
have	O
never	O
been	O
addressed	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Forty-four	O
consecutive	O
patients	O
with	O
histologically	O
confirmed	O
primary	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
included	O
.	O
A	O
control	O
group	O
of	O
37	O
patients	O
with	O
chronic	O
pancreatitis	O
,	O
10	O
patients	O
with	O
other	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreatic	I-malignancy-type
area	I-malignancy-type
,	O
nine	O
patients	O
with	O
acute	O
pancreatitis	O
,	O
and	O
four	O
healthy	O
volunteers	O
was	O
also	O
included	O
.	O
Plasma	O
DNA	O
was	O
isolated	O
and	O
K-ras	O
codon	O
-	O
12	O
mutations	O
were	O
analyzed	O
by	O
means	O
of	O
restriction	O
fragment	O
length	O
polymorphism	O
-	O
polymerase	O
chain	O
reaction	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
techniques	O
.	O
Patients	O
were	O
followed	O
up	O
to	O
establish	O
their	O
clinical	O
outcome	O
.	O
RESULTS	O
:	O
The	O
mutant	O
-	O
type	O
K-ras	O
gene	O
was	O
found	O
in	O
plasma	O
DNA	O
samples	O
of	O
12	O
(	O
27	O
%	O
)	O
of	O
44	O
patients	O
with	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
;	O
this	O
finding	O
was	O
related	O
to	O
the	O
tumor	O
stage	O
(	O
P	O
=	O
.05	O
)	O
,	O
mainly	O
in	O
the	O
presence	O
of	O
distant	O
metastases	O
(	O
P	O
=	O
.02	O
)	O
.	O
In	O
addition	O
,	O
K-ras	O
mutations	O
were	O
detected	O
in	O
the	O
plasma	O
DNA	O
of	O
two	O
(	O
5	O
%	O
)	O
of	O
37	O
patients	O
with	O
chronic	O
pancreatitis	O
.	O
In	O
the	O
subset	O
of	O
patients	O
with	O
pancreatic	B-malignancy-type
masses	I-malignancy-type
,	O
the	O
sensitivity	O
and	O
specificity	O
of	O
plasma	O
K-ras	O
analysis	O
for	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
were	O
27	O
%	O
and	O
100	O
%	O
,	O
respectively	O
.	O
Finally	O
,	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
patients	O
with	O
the	O
mutant	O
-	O
type	O
K-ras	O
gene	O
in	O
plasma	O
DNA	O
exhibited	O
a	O
shorter	O
survival	O
time	O
than	O
patients	O
with	O
the	O
wild	O
-	O
type	O
gene	O
(	O
P	O
<	O
.005	O
)	O
,	O
and	O
plasma	O
K-ras	O
mutations	O
were	O
identified	O
as	O
the	O
only	O
independent	O
prognostic	O
factor	O
(	O
odds	O
ratio	O
,	O
1.51	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.02	O
to	O
2.23	O
)	O
.	O
CONCLUSION	O
:	O
Plasma	O
K-ras	O
analysis	O
is	O
a	O
highly	O
specific	O
,	O
low	O
-	O
sensitivity	O
approach	O
that	O
has	O
diagnostic	O
and	O
prognostic	O
clinical	O
implications	O
in	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
10080602	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1999	O
Feb;23(	O
2	O
)	O
:115	O
-	O
26	O
Alterations	O
of	O
the	O
p53	O
,	O
p21	O
,	O
p16	O
,	O
p15	O
and	O
RAS	O
genes	O
in	O
childhood	O
T-cell	B-malignancy-type
acute	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Kawamura	O
M,	O
Ohnishi	O
H	O
,	O
Guo	O
SX	O
,	O
Sheng	O
XM	O
,	O
Minegishi	O
M,	O
Hanada	O
R,	O
Horibe	O
K	O
,	O
Hongo	O
T	O
,	O
Kaneko	O
Y	O
,	O
Bessho	O
F	O
,	O
Yanagisawa	O
M,	O
Sekiya	O
T	O
,	O
Hayashi	O
Y.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
We	O
investigated	O
the	O
alterations	O
of	O
the	O
p53	O
,	O
p21	O
,	O
p16	O
,	O
p15	O
and	O
RAS	O
genes	O
in	O
childhood	O
T-cell	B-malignancy-type
acute	I-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
T-ALL	B-malignancy-type
)	O
and	O
T-ALL	B-malignancy-type
cell	O
lines	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Mutations	O
of	O
the	O
p53	O
gene	O
were	O
found	O
in	O
three	O
of	O
57	O
(	O
5	O
%	O
)	O
patients	O
at	O
diagnosis	O
,	O
one	O
of	O
14	O
(	O
7	O
%	O
)	O
patients	O
at	O
relapse	O
and	O
in	O
12	O
of	O
18	O
(	O
67	O
%	O
)	O
cell	O
lines	O
.	O
In	O
these	O
12	O
cell	O
lines	O
,	O
four	O
had	O
more	O
than	O
two	O
mutations	O
of	O
the	O
p53	O
gene	O
.	O
The	O
p53	O
mutations	O
were	O
found	O
in	O
four	O
of	O
five	O
cell	O
lines	O
whose	O
original	O
fresh	O
leukemic	O
cells	O
were	O
simultaneously	O
examined	O
original	O
fresh	O
leukemic	O
cells	O
.	O
However	O
,	O
only	O
one	O
of	O
the	O
four	O
fresh	O
leukemic	O
cells	O
had	O
the	O
same	O
mutation	O
.	O
All	O
patients	O
with	O
p53	O
mutations	O
in	O
the	O
course	O
of	O
disease	O
died	O
.	O
Mutations	O
of	O
the	O
p21	O
gene	O
were	O
not	O
identified	O
in	O
71	O
fresh	O
samples	O
and	O
in	O
18	O
cell	O
lines	O
.	O
N-RAS	O
mutations	O
were	O
found	O
in	O
two	O
of	O
57	O
(	O
4	O
%	O
)	O
fresh	O
T-ALL	B-malignancy-type
patients	O
at	O
diagnosis	O
,	O
and	O
four	O
of	O
18	O
cell	O
lines	O
(	O
22	O
%	O
)	O
,	O
whereas	O
no	O
mutations	O
were	O
detected	O
in	O
any	O
samples	O
at	O
relapse	O
.	O
Alterations	O
of	O
the	O
p16	O
gene	O
were	O
found	O
in	O
18	O
of	O
47	O
(	O
38	O
%	O
)	O
patients	O
at	O
diagnosis	O
and	O
in	O
seven	O
of	O
14	O
(	O
50	O
%	O
)	O
at	O
relapse	O
.	O
These	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
There	O
were	O
no	O
differences	O
in	O
the	O
frequency	O
of	O
alteration	O
of	O
the	O
p16	O
and	O
p15	O
genes	O
between	O
event	O
-	O
free	O
patients	O
and	O
the	O
remaining	O
patients	O
.	O
Furthermore	O
,	O
we	O
found	O
the	O
methylation	O
of	O
p16	O
gene	O
in	O
three	O
of	O
seven	O
patients	O
lacking	O
homozygous	O
deletions	O
,	O
suggesting	O
higher	O
frequency	O
of	O
p16	O
inactivation	O
than	O
previous	O
reports	O
in	O
T-ALL	B-malignancy-type
.	O
Interestingly	O
,	O
we	O
found	O
that	O
one	O
allele	O
is	O
inactivated	O
by	O
methylation	O
and	O
another	O
allele	O
had	O
nonsense	O
mutation	O
in	O
one	O
cell	O
line	O
(	O
KOPT-KI	O
)	O
,	O
resulting	O
in	O
loss	O
of	O
protein	O
expression	O
of	O
p16	O
.	O
This	O
type	O
of	O
p16	O
inactivation	O
has	O
not	O
been	O
so	O
far	O
reported	O
in	O
leukemia	B-malignancy-type
.	O
We	O
conclude	O
that	O
,	O
(1)	O
p53	O
mutations	O
are	O
infrequent	O
at	O
diagnosis	O
but	O
tend	O
to	O
be	O
associated	O
with	O
poor	O
clinical	O
outcome	O
;	O
(2)	O
RAS	O
and	O
p21	O
mutations	O
may	O
not	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
T-ALL	B-malignancy-type
;	O
(3)	O
not	O
only	O
frequent	O
alterations	O
of	O
p16	O
and	O
p15	O
genes	O
but	O
also	O
methylation	O
of	O
p16	O
gene	O
are	O
involved	O
in	O
initiating	O
the	O
leukemogenesis	O
of	O
T-ALLs	B-malignancy-type
,	O
and	O
(4)	O
these	O
5	O
genes	O
are	O
independently	O
involved	O
in	O
T-ALL	B-malignancy-type
.	O
PMID	O
:	O
10071127	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Dec	O
25	O
;134(	O
2	O
)	O
:169	O
-	O
76	O
Ki-ras	O
codon	O
12	O
point	O
mutational	O
activation	O
in	O
Hong	O
Kong	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
patients	O
.	O
Ko	O
JM	O
,	O
Cheung	O
MH	O
,	O
Wong	O
CM	O
,	O
Lau	O
KW	O
,	O
Tang	O
CM	O
,	O
Kwan	O
MW	O
,	O
Lung	O
ML.	O
Department	O
of	O
Biology	O
,	O
Hong	O
Kong	O
University	O
of	O
Science	O
and	O
Technology	O
,	O
Clear	O
Water	O
Bay	O
,	O
Kowloon	O
.	O
This	O
study	O
investigated	O
the	O
frequency	O
and	O
importance	O
of	O
Ki-ras	O
codon	O
12	O
mutations	O
in	O
99	O
Hong	O
Kong	O
Chinese	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
specimens	O
by	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
The	O
frequency	O
of	O
mutations	O
detected	O
was	O
30	O
%	O
and	O
the	O
most	O
common	O
mutation	O
observed	O
resulted	O
in	O
aspartic	O
acid	O
substitutions	O
.	O
Previous	O
studies	O
showed	O
that	O
specific	O
Ki-ras	O
mutations	O
have	O
been	O
significantly	O
associated	O
with	O
prognosis	O
.	O
Ki-ras	O
codon	O
12	O
point	O
mutational	O
activation	O
in	O
CRC	B-malignancy-type
was	O
significantly	O
associated	O
with	O
the	O
differentiation	O
status	O
of	O
tumors	O
in	O
this	O
study	O
.	O
Ethnic	O
differences	O
in	O
the	O
patterns	O
of	O
Ki-ras	O
codon	O
12	O
point	O
mutations	O
were	O
observed	O
.	O
PMID	O
:	O
10025877	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1999	O
Feb	O
16;96(	O
4)	O
:1609	O
-	O
14	O
Activating	O
and	O
dominant	O
inactivating	O
c-KIT	O
catalytic	O
domain	O
mutations	O
in	O
distinct	O
clinical	O
forms	O
of	O
human	O
mastocytosis	B-malignancy-type
.	O
Longley	O
BJ	O
Jr	O
,	O
Metcalfe	O
DD	O
,	O
Tharp	O
M,	O
Wang	O
X	O
,	O
Tyrrell	O
L,	O
Lu	O
SZ	O
,	O
Heitjan	O
D	O
,	O
Ma	O
Y.	O
Departments	O
of	O
Dermatology	O
and	O
Pathology	O
,	O
Section	O
of	O
Dermatopathology	O
,	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
of	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
100	O
32	O
,	O
USA	O
.	O
jack	O
.longley	O
@columbia	O
.edu	O
Human	O
mastocytosis	B-malignancy-type
is	O
characterized	O
by	O
increased	O
mast	O
cells	O
.	O
It	O
usually	O
occurs	O
as	O
a	O
sporadic	O
disease	O
that	O
is	O
often	O
transient	O
and	O
limited	O
in	O
children	O
and	O
persistent	O
or	O
progressive	O
in	O
adults	O
.	O
The	O
c-KIT	O
protooncogene	O
encodes	O
KIT	O
,	O
a	O
tyrosine	O
kinase	O
that	O
is	O
the	O
receptor	O
for	O
mast	O
cell	O
growth	O
factor	O
.	O
Because	O
mutated	O
KIT	O
can	O
transform	O
cells	O
,	O
we	O
examined	O
c-KIT	O
in	O
skin	B-malignancy-type
lesions	I-malignancy-type
of	O
22	O
patients	O
with	O
sporadic	B-malignancy-type
mastocytosis	I-malignancy-type
and	O
3	O
patients	O
with	O
familial	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
All	O
patients	O
with	O
adult	O
sporadic	B-malignancy-type
mastocytosis	I-malignancy-type
had	O
somatic	O
c-KIT	O
mutations	O
in	O
codon	O
816	O
causing	O
substitution	O
of	O
valine	O
for	O
aspartate	O
and	O
spontaneous	O
activation	O
of	O
mast	O
cell	O
growth	O
factor	O
receptor	O
(	O
P	O
=	O
0.0001	O
)	O
.	O
A	O
subset	O
of	O
four	O
pediatric	O
onset	O
cases	O
with	O
clinically	O
unusual	O
disease	O
also	O
had	O
codon	O
816	O
activating	O
mutations	O
substituting	O
valine	O
,	O
tyrosine	O
,	O
or	O
phenylalanine	O
for	O
aspartate	O
.	O
Typical	O
pediatric	O
patients	O
lacked	O
816	O
mutations	O
,	O
but	O
limited	O
sequencing	O
showed	O
three	O
of	O
six	O
had	O
a	O
novel	O
dominant	O
inactivating	O
mutation	O
substituting	O
lysine	O
for	O
glutamic	O
acid	O
in	O
position	O
839	O
,	O
the	O
site	O
of	O
a	O
potential	O
salt	O
bridge	O
that	O
is	O
highly	O
conserved	O
in	O
receptor	O
tyrosine	O
kinases	O
.	O
No	O
c-KIT	O
mutations	O
were	O
found	O
in	O
the	O
entire	O
coding	O
region	O
of	O
three	O
patients	O
with	O
familial	B-malignancy-type
mastocytosis	I-malignancy-type
.	O
We	O
conclude	O
that	O
c-KIT	O
somatic	O
mutations	O
substituting	O
valine	O
in	O
position	O
816	O
of	O
KIT	O
are	O
characteristic	O
of	O
sporadic	B-malignancy-type
adult	I-malignancy-type
mastocytosis	I-malignancy-type
and	O
may	O
cause	O
this	O
disease	O
.	O
Similar	O
mutations	O
causing	O
activation	O
of	O
the	O
mast	O
cell	O
growth	O
factor	O
receptor	O
are	O
found	O
in	O
children	O
apparently	O
at	O
risk	O
for	O
extensive	O
or	O
persistent	O
disease	O
.	O
In	O
contrast	O
,	O
typical	O
pediatric	B-malignancy-type
mastocytosis	I-malignancy-type
patients	O
lack	O
these	O
mutations	O
and	O
may	O
express	O
inactivating	O
c-KIT	O
mutations	O
.	O
Familial	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
however	O
,	O
may	O
occur	O
in	O
the	O
absence	O
of	O
c-KIT	O
coding	O
mutations	O
.	O
PMID	O
:	O
9990072	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1999	O
Feb;21(	O
2	O
)	O
:187	O
-	O
90	O
Activating	O
SRC	O
mutation	O
in	O
a	O
subset	O
of	O
advanced	O
human	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
Irby	O
RB	O
,	O
Mao	O
W	O
,	O
Coppola	O
D	O
,	O
Kang	O
J,	O
Loubeau	O
JM	O
,	O
Trudeau	O
W	O
,	O
Karl	O
R,	O
Fujita	O
DJ	O
,	O
Jove	O
R,	O
Yeatman	O
TJ.	O
Department	O
of	O
Surgery	O
,	O
H.	O
Lee	O
Moffitt	O
Cancer	O
Center	O
&	O
Research	O
Institute	O
,	O
University	O
of	O
South	O
Florida	O
College	O
of	O
Medicine	O
,	O
Tampa	O
33612	O
,	O
USA	O
.	O
The	O
discovery	O
of	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
led	O
to	O
the	O
identification	O
of	O
cellular	O
Src	O
(	O
c-Src	O
)	O
,	O
a	O
non	O
-	O
receptor	O
tyrosine	O
kinase	O
,	O
which	O
has	O
since	O
been	O
implicated	O
in	O
the	O
development	O
of	O
numerous	O
human	O
cancers	O
.	O
c-Src	O
has	O
been	O
found	O
to	O
be	O
highly	O
activated	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
,	O
particularly	O
in	O
those	O
metastatic	O
to	O
the	O
liver	O
.	O
Studies	O
of	O
the	O
mechanism	O
of	O
c-Src	O
regulation	O
have	O
suggested	O
that	O
c-Src	O
kinase	O
activity	O
is	O
downregulated	O
by	O
phosphorylation	O
of	O
a	O
critical	O
carboxy	O
-	O
terminal	O
tyrosine	O
(	O
Tyr	O
530	O
in	O
human	O
c-Src	O
,	O
equivalent	O
to	O
Tyr	O
527	O
in	O
chicken	O
Src	O
)	O
and	O
have	O
implied	O
the	O
existence	O
of	O
activating	O
mutations	O
in	O
this	O
C-terminal	O
regulatory	O
region	O
.	O
We	O
report	O
here	O
the	O
identification	O
of	O
a	O
truncating	O
mutation	O
in	O
SRC	O
at	O
codon	O
531	O
in	O
12	O
%	O
of	O
cases	O
of	O
advanced	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
tested	O
and	O
demonstrate	O
that	O
the	O
mutation	O
is	O
activating	O
,	O
transforming	O
,	O
tumorigenic	O
and	O
promotes	O
metastasis	O
.	O
These	O
results	O
provide	O
,	O
for	O
the	O
first	O
time	O
,	O
genetic	O
evidence	O
that	O
activating	O
SRC	O
mutations	O
may	O
have	O
a	O
role	O
in	O
the	O
malignant	O
progression	O
of	O
human	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9988270	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Jan	O
15;59(	O
2	O
)	O
:307	O
-	O
10	O
Somatic	O
mutations	O
in	O
the	O
kinase	O
domain	O
of	O
the	O
Met	O
/	O
hepatocyte	O
growth	O
factor	O
receptor	O
gene	O
in	O
childhood	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Park	O
WS	O
,	O
Dong	O
SM	O
,	O
Kim	O
SY	O
,	O
Na	O
EY	O
,	O
Shin	O
MS	O
,	O
Pi	O
JH	O
,	O
Kim	O
BJ	O
,	O
Bae	O
JH	O
,	O
Hong	O
YK	O
,	O
Lee	O
KS	O
,	O
Lee	O
SH	O
,	O
Yoo	O
NJ	O
,	O
Jang	O
JJ	O
,	O
Pack	O
S,	O
Zhuang	O
Z	O
,	O
Schmidt	O
L,	O
Zbar	O
B	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Catholic	O
University	O
Medical	O
College	O
,	O
Seoul	O
,	O
Korea	O
.	O
The	O
MET	O
protooncogene	O
encodes	O
a	O
transmembrane	O
tyrosine	O
kinase	O
identified	O
as	O
the	O
receptor	O
of	O
a	O
polypeptide	O
known	O
as	O
hepatocyte	O
growth	O
factor	O
/	O
scatter	O
factor	O
.	O
We	O
performed	O
PCR	O
-	O
based	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
and	O
sequencing	O
analysis	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
(	O
exon	O
15	O
-	O
19	O
)	O
in	O
75	O
primary	O
liver	B-malignancy-type
cancers	I-malignancy-type
.	O
Three	O
missense	O
mutations	O
were	O
detected	O
exclusively	O
in	O
10	O
childhood	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
,	O
while	O
no	O
mutations	O
were	O
detected	O
in	O
16	O
adult	O
HCCs	B-malignancy-type
,	O
21	O
cholangiocarcinomas	B-malignancy-type
,	O
or	O
28	O
hepatoblastomas	B-malignancy-type
.	O
The	O
extremely	O
short	O
incubation	O
period	O
from	O
hepatitis	O
B	O
virus	O
infection	O
to	O
the	O
genesis	O
of	O
childhood	O
HCC	B-malignancy-type
as	O
compared	O
with	O
the	O
adult	O
HCC	B-malignancy-type
suggests	O
that	O
there	O
may	O
be	O
an	O
additional	O
mechanism	O
that	O
accelerates	O
the	O
carcinogenesis	O
of	O
childhood	O
HCC	B-malignancy-type
.	O
Our	O
results	O
indicate	O
that	O
mutations	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
may	O
be	O
involved	O
in	O
the	O
acceleration	O
of	O
the	O
carcinogenesis	O
in	O
childhood	O
HCC	B-malignancy-type
.	O
PMID	O
:	O
9927037	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1999	O
Jan	O
15;59(	O
2	O
)	O
:269	O
-	O
73	O
Childhood	O
hepatoblastomas	O
frequently	O
carry	O
a	O
mutated	O
degradation	O
targeting	O
box	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Koch	O
A	O
,	O
Denkhaus	O
D	O
,	O
Albrecht	O
S,	O
Leuschner	O
I	O
,	O
von	O
Schweinitz	O
D	O
,	O
Pietsch	O
T.	O
Department	O
of	O
Neuropathology	O
,	O
University	O
of	O
Bonn	O
Medical	O
Center	O
,	O
Germany	O
.	O
Hepatoblastomas	B-malignancy-type
(	O
HBs	B-malignancy-type
)	O
are	O
embryonal	B-malignancy-type
tumors	I-malignancy-type
affecting	O
young	O
children	O
and	O
representing	O
the	O
most	O
frequent	O
malignant	O
liver	B-malignancy-type
tumors	I-malignancy-type
in	O
childhood	O
.	O
The	O
molecular	O
pathogenesis	O
of	O
HB	B-malignancy-type
is	O
poorly	O
understood	O
.	O
Although	O
most	O
cases	O
are	O
sporadic	O
,	O
the	O
incidence	O
is	O
highly	O
elevated	O
in	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
.	O
These	O
patients	O
carry	O
germline	O
mutations	O
of	O
the	O
APC	O
tumor	O
suppressor	O
gene	O
.	O
APC	O
controls	O
the	O
degradation	O
of	O
the	O
oncogene	O
product	O
beta-catenin	O
after	O
its	O
NH2	O
-	O
terminal	O
phosphorylation	O
on	O
serine	O
/	O
threonine	O
residues	O
.	O
APC	O
,	O
as	O
well	O
as	O
beta-catenin	O
,	O
has	O
been	O
found	O
to	O
be	O
a	O
central	O
effector	O
of	O
the	O
growth	O
promoting	O
wingless	O
signaling	O
pathway	O
in	O
development	O
.	O
To	O
find	O
out	O
if	O
this	O
pathway	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
HBs	I-malignancy-type
,	O
we	O
examined	O
52	O
biopsies	O
and	O
three	O
cell	O
lines	O
from	O
sporadic	B-malignancy-type
HBs	I-malignancy-type
for	O
mutations	O
in	O
the	O
APC	O
and	O
beta-catenin	O
genes	O
.	O
Using	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
,	O
deletion	O
screening	O
by	O
PCR	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
sporadic	B-malignancy-type
HBs	I-malignancy-type
(	O
48	O
%	O
)	O
.	O
The	O
mutations	O
affected	O
exon	O
3	O
encoding	O
the	O
degradation	O
targeting	O
box	O
of	O
beta-catenin	O
leading	O
to	O
accumulation	O
of	O
intracytoplasmic	O
and	O
nuclear	O
beta-catenin	O
protein	O
.	O
The	O
high	O
frequency	O
of	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
indicates	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HB	B-malignancy-type
.	O
PMID	O
:	O
9927029	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Hum	O
Pathol	O
1999	O
Jan;30(	O
1	O
)	O
:21	O
-	O
5	O
Gallbladder	B-malignancy-type
adenomas	I-malignancy-type
have	O
molecular	O
abnormalities	O
different	O
from	O
those	O
present	O
in	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Wistuba	O
II	O
,	O
Miquel	O
JF	O
,	O
Gazdar	O
AF	O
,	O
Albores	O
-	O
Saavedra	O
J.	O
Hamon	O
Center	O
for	O
Therapeutic	O
and	O
Oncology	O
Research	O
,	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
-	O
9072	O
,	O
USA	O
.	O
Although	O
most	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
evolve	O
from	O
dysplasia	B-malignancy-type
and	O
carcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
,	O
the	O
role	O
of	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
in	O
the	O
pathogenesis	O
of	O
gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
is	O
still	O
controversial	O
.	O
A	O
series	O
of	O
molecular	O
changes	O
including	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
17p	O
(	O
TP53	O
gene	O
)	O
,	O
13q	O
(	O
RB	O
gene	O
)	O
,	O
18q	O
(	O
DCC	O
gene	O
)	O
,	O
and	O
9p21	O
(	O
CDKN2a	O
gene	O
)	O
chromosomal	O
regions	O
have	O
been	O
identified	O
in	O
dysplasias	B-malignancy-type
,	O
carcinomas	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
,	O
and	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
,	O
whereas	O
mutations	O
in	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
are	O
rare	O
.	O
To	O
determine	O
whether	O
the	O
molecular	O
abnormalities	O
of	O
adenomas	B-malignancy-type
are	O
similar	O
to	O
those	O
found	O
in	O
carcinomas	B-malignancy-type
,	O
we	O
obtained	O
extracted	O
DNA	O
from	O
precisely	O
microdissected	O
tissue	O
from	O
16	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
(	O
14	O
pyloric	B-malignancy-type
and	O
2	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
)	O
.	O
We	O
determined	O
the	O
presence	O
of	O
mutations	O
in	O
TP53	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
,	O
and	O
LOH	O
at	O
five	O
chromosomal	O
regions	O
(	O
5q22	O
APC	O
-	O
MCC	O
region	O
,	O
RB	O
,	O
TP53	O
,	O
DCC	O
and	O
9p21	O
-	O
CDKN2a	O
)	O
.	O
For	O
the	O
TP53	O
mutation	O
study	O
,	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
in	O
exons	O
4	O
to	O
8	O
were	O
performed	O
.	O
K	O
-	O
and	O
N	O
-	O
ras	O
mutations	O
detection	O
was	O
performed	O
by	O
designed	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
method	O
and	O
sequencing	O
.	O
Only	O
a	O
single	O
LOH	O
(	O
at	O
5q22	O
)	O
was	O
detected	O
in	O
a	O
gallbladder	B-malignancy-type
adenoma	I-malignancy-type
of	I-malignancy-type
intestinal	I-malignancy-type
type	I-malignancy-type
.	O
No	O
mutations	O
at	O
the	O
TP53	O
were	O
detected	O
.	O
Four	O
adenomas	B-malignancy-type
(	O
25	O
%	O
)	O
showed	O
K-ras	O
mutations	O
(	O
two	O
in	O
codon	O
12	O
and	O
two	O
in	O
codon	O
61	O
)	O
.	O
We	O
conclude	O
that	O
gallbladder	B-malignancy-type
adenoma	I-malignancy-type
lacks	O
the	O
molecular	O
changes	O
frequently	O
detected	O
in	O
dysplasia	B-malignancy-type
,	O
carcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
,	O
and	O
invasive	B-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gallbladder	I-malignancy-type
.	O
Likewise	O
the	O
occurrence	O
of	O
K-ras	O
mutations	O
at	O
codon	O
12	O
and	O
61	O
in	O
25	O
%	O
of	O
adenomas	B-malignancy-type
strongly	O
suggests	O
that	O
these	O
lesions	B-malignancy-type
are	O
not	O
precursors	O
of	O
invasive	B-malignancy-type
gallbladder	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9923922	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Am	O
J	O
Pathol	O
1999	O
Jan;154(	O
1	O
)	O
:53	O
-	O
60	O
Mutations	O
in	O
exon	O
11	O
of	O
c-Kit	O
occur	O
preferentially	O
in	O
malignant	O
versus	O
benign	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
and	O
do	O
not	O
occur	O
in	O
leiomyomas	B-malignancy-type
or	O
leiomyosarcomas	B-malignancy-type
.	O
Lasota	O
J,	O
Jasinski	O
M,	O
Sarlomo	O
-	O
Rikala	O
M,	O
Miettinen	O
M.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-	O
6000	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
comprise	O
the	O
largest	O
subset	O
of	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
.	O
These	O
neoplasms	B-malignancy-type
differ	O
histologically	O
and	O
immunohistochemically	O
from	O
typical	O
leiomyomas	B-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
.	O
Most	O
GISTs	B-malignancy-type
express	O
CD34	O
and	O
CD117	O
(	O
c-kit	O
protein	O
)	O
but	O
not	O
desmin	O
.	O
Recently	O
,	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
c-kit	O
proto	O
-	O
oncogene	O
have	O
been	O
shown	O
in	O
five	O
solitary	B-malignancy-type
GISTs	I-malignancy-type
and	O
in	O
tumors	O
and	O
leukocytes	O
from	O
a	O
family	O
with	O
multiple	B-malignancy-type
GISTs	I-malignancy-type
.	O
An	O
in-frame	O
deletion	O
or	O
a	O
point	O
mutation	O
in	O
exon	O
11	O
of	O
c-kit	O
was	O
detected	O
in	O
these	O
cases	O
.	O
Stable	O
transfection	O
of	O
the	O
mutant	O
c-kit	O
complementary	O
DNA	O
was	O
also	O
shown	O
to	O
induce	O
malignant	O
transformation	O
of	O
murine	O
lymphoid	O
cells	O
,	O
suggesting	O
that	O
the	O
c-kit	O
mutations	O
contribute	O
to	O
tumor	O
development	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
43	O
GISTs	B-malignancy-type
and	O
14	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
for	O
mutations	O
in	O
the	O
exon	O
11	O
of	O
c-kit	O
by	O
a	O
PCR	O
-	O
assay	O
.	O
Half	O
of	O
the	O
malignant	O
GISTs	B-malignancy-type
(	O
12	O
/	O
24	O
)	O
and	O
only	O
one	O
benign	O
GIST	B-malignancy-type
(	O
1	O
/	O
19	O
)	O
revealed	O
mutant	O
bands	O
.	O
No	O
mutant	O
bands	O
were	O
found	O
in	O
3	O
leiomyomas	B-malignancy-type
and	O
11	O
leiomyosarcomas	B-malignancy-type
.	O
Sequence	O
analysis	O
confirmed	O
the	O
presence	O
of	O
an	O
in-frame	O
deletion	O
of	O
3	O
-	O
21	O
bp	O
in	O
all	O
13	O
GISTs	B-malignancy-type
with	O
mutant	O
bands	O
.	O
Wild	O
-	O
type	O
bands	O
from	O
8	O
malignant	O
and	O
11	O
benign	O
GISTs	B-malignancy-type
and	O
7	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
without	O
mutant	O
bands	O
were	O
cloned	O
and	O
sequenced	O
.	O
Additional	O
mutations	O
were	O
found	O
in	O
3	O
malignant	O
and	O
2	O
benign	O
GISTs	B-malignancy-type
.	O
There	O
were	O
no	O
mutations	O
in	O
3	O
leiomyomas	B-malignancy-type
and	O
4	O
leiomyosarcomas	B-malignancy-type
.	O
The	O
mutation	O
status	O
of	O
exon	O
11	O
did	O
not	O
correlate	O
with	O
immunohistochemically	O
detectable	O
expression	O
of	O
the	O
CD117	O
,	O
as	O
virtually	O
all	O
GISTs	B-malignancy-type
with	O
or	O
without	O
such	O
mutations	O
showed	O
CD117	O
immunoreactivity	O
.	O
The	O
c-kit	O
mutations	O
occur	O
preferentially	O
in	O
malignant	O
GISTs	B-malignancy-type
and	O
might	O
be	O
a	O
clinically	O
useful	O
adjunct	O
marker	O
in	O
the	O
evaluation	O
of	O
GISTs	B-malignancy-type
.	O
The	O
conservation	O
of	O
the	O
c-kit	O
mutation	O
pattern	O
,	O
observed	O
in	O
consecutive	O
lesions	B-malignancy-type
from	O
the	O
same	O
patients	O
,	O
suggests	O
that	O
these	O
mutations	O
might	O
be	O
useful	O
tumor	O
markers	O
in	O
monitoring	O
recurrence	O
or	O
minimal	O
residual	O
disease	O
.	O
PMID	O
:	O
9916918	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Eur	O
J	O
Gastroenterol	O
Hepatol	O
1998	O
Dec;10(	O
12	O
)	O
:1025	O
-	O
9	O
Analysis	O
of	O
K-ras	O
gene	O
mutations	O
in	O
rare	O
pancreatic	B-malignancy-type
and	O
ampullary	B-malignancy-type
tumours	I-malignancy-type
.	O
Ebert	O
MP	O
,	O
Hoffmann	O
J,	O
Schneider	O
-	O
Stock	O
R,	O
Kasper	O
HU	O
,	O
Schulz	O
HU	O
,	O
Lippert	O
H	O
,	O
Roessner	O
A	O
,	O
Malfertheiner	O
P.	O
Department	O
of	O
Gastroenterology	O
,	O
Otto	O
-	O
von	O
-	O
Guericke	O
Universitat	O
Magdeburg	O
,	O
Germany	O
.	O
OBJECTIVE	O
:	O
Mutation	O
of	O
the	O
K-ras	O
oncogene	O
is	O
a	O
frequent	O
event	O
in	O
pancreatic	O
ductal	O
carcinogenesis	O
and	O
it	O
is	O
believed	O
to	O
occur	O
at	O
an	O
early	O
stage	O
in	O
the	O
development	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
However	O
,	O
little	O
is	O
known	O
of	O
the	O
role	O
of	O
K-ras	O
mutations	O
in	O
rare	O
pancreatic	B-malignancy-type
epithelial	I-malignancy-type
neoplasms	I-malignancy-type
,	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
or	O
other	O
non	B-malignancy-type
-	I-malignancy-type
epithelial	I-malignancy-type
tumours	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Furthermore	O
,	O
limited	O
data	O
are	O
available	O
regarding	O
the	O
role	O
of	O
K-ras	O
mutations	O
in	O
the	O
pathogenesis	O
of	O
ampullary	O
tumours	O
.	O
DESIGN	O
AND	O
METHODS	O
:	O
Using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
amplified	O
fragments	O
,	O
we	O
analysed	O
codons	O
12	O
and	O
13	O
for	O
the	O
presence	O
of	O
oncogenic	O
mutations	O
of	O
the	O
K-ras	O
oncogene	O
.	O
Tissues	O
were	O
obtained	O
from	O
patients	O
undergoing	O
tumour	O
resection	O
for	O
various	O
rare	O
pancreatic	B-malignancy-type
or	O
ampullary	B-malignancy-type
neoplasms	I-malignancy-type
(	O
number	O
of	O
cases	O
in	O
brackets	O
)	O
:	O
ampullary	B-malignancy-type
adenoma	I-malignancy-type
(	O
1	O
)	O
,	O
neuro	B-malignancy-type
-	I-malignancy-type
endocrine	I-malignancy-type
tumour	I-malignancy-type
(	O
3	O
)	O
,	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
(	O
1	O
)	O
,	O
pancreatic	B-malignancy-type
cystadenocarcinoma	I-malignancy-type
(	O
1	O
)	O
,	O
serous	B-malignancy-type
cystadenoma	I-malignancy-type
(	O
1	O
)	O
,	O
and	O
primary	B-malignancy-type
and	O
metastatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ampulla	I-malignancy-type
(	I-malignancy-type
5	I-malignancy-type
)	I-malignancy-type
and	I-malignancy-type
pancreas	I-malignancy-type
(	O
3	O
)	O
.	O
RESULTS	O
:	O
K-ras	O
gene	O
mutations	O
at	O
codon	O
12	O
were	O
detected	O
in	O
both	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
in	O
the	O
metastatic	B-malignancy-type
lesion	I-malignancy-type
,	O
whereas	O
two	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
harboured	O
a	O
point	O
mutation	O
at	O
codon	O
13	O
:	O
GGC	O
-->	O
GGG	O
and	O
GGC	O
-->	O
GGT	O
.	O
None	O
of	O
the	O
other	O
tumours	O
exhibited	O
a	O
K-ras	O
gene	O
mutation	O
at	O
codons	O
12	O
or	O
13	O
.	O
CONCLUSION	O
:	O
Pancreatic	B-malignancy-type
tumours	I-malignancy-type
other	O
than	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
do	O
not	O
harbour	O
mutations	O
of	O
the	O
K-ras	O
oncogene	O
.	O
In	O
addition	O
,	O
ampullary	B-malignancy-type
adenocarcinomas	I-malignancy-type
may	O
present	O
with	O
codon	O
13	O
mutations	O
;	O
however	O
,	O
these	O
mutations	O
were	O
not	O
associated	O
with	O
amino	O
acid	O
substitution	O
.	O
Therefore	O
,	O
K-ras	O
gene	O
mutations	O
seem	O
to	O
be	O
a	O
specific	O
genetic	O
alteration	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
9895049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
	O

Oncol	O
Rep	O
2002	O
No	O
v-Dec;	O
9	O
(	O
6	O
)	O
:	O
119	O
7-203	O
Beta-catenin	O
and	O
cyclin	O
D1	O
expression	O
in	O
human	O
hepatocellular	O
carcinoma	O
.	O
Ueta	O
T	O
,	O
Ikeguchi	O
M,	O
Hirooka	O
Y	O
,	O
Kaibara	O
N	O
,	O
Terada	O
T.	O
The	O
Second	O
Department	O
of	O
Pathology	O
and	O
the	O
First	O
Department	O
of	O
Surgery	O
,	O
Tottori	O
University	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Yonago	O
68	O
3-8504	O
,	O
Tottori	O
,	O
Japan	O
.	O
bug1@grape	O
.med	O
tottor	O
i-u	O
.ac.jp	O
To	O
understand	O
the	O
nature	O
and	O
roles	O
of	O
mutated	O
beta-catenin	O
in	O
human	O
hepatocellular	O
carcinomas	O
(	O
HCCs	O
)	O
,	O
57	O
cases	O
of	O
surgically	O
resected	O
HCCs	O
were	O
studied	O
.	O
DNAs	O
extracted	O
from	O
each	O
tumor	O
were	O
examined	O
for	O
somatic	O
mutations	O
of	O
exon	O
3	O
,	O
and	O
the	O
protein	O
expressions	O
of	O
beta-catenin	O
,	O
cyclin	O
D1	O
,	O
and	O
Ki-67	O
were	O
observed	O
by	O
immunohistochemical	O
staining	O
.	O
beta-catenin	O
mutations	O
in	O
exon	O
3	O
were	O
detected	O
in	O
10	O
(	O
17.5	O
%	O
)	O
out	O
of	O
57	O
HCCs	O
,	O
including	O
nine	O
missense	O
mutations	O
and	O
one	O
deletion	O
mutation	O
.	O
All	O
of	O
the	O
cases	O
with	O
gene	O
alterations	O
had	O
the	O
anti	O
-	O
HCV	O
antibody	O
,	O
and	O
tested	O
negative	O
for	O
the	O
HBs	O
antigen	O
in	O
the	O
sera	O
.	O
All	O
of	O
the	O
mutations	O
occurred	O
at	O
the	O
serine	O
/	O
threonine	O
phosphorylation	O
sites	O
of	O
glycogen	O
synthase	O
kinase-3beta	O
(	O
GSK-3beta	O
)	O
or	O
their	O
neighboring	O
residues	O
.	O
Significant	O
correlation	O
with	O
intracellular	O
expression	O
(	O
p	O
=	O
0.00055	O
)	O
was	O
shown	O
in	O
the	O
HCCs	O
harboring	O
beta-catenin	O
mutations	O
.	O
The	O
intracellular	O
accumulation	O
of	O
beta-catenin	O
showed	O
significant	O
correlation	O
with	O
the	O
cyclin	O
D1	O
expression	O
(	O
p	O
=	O
0.00858	O
)	O
,	O
and	O
with	O
a	O
higher	O
proliferation	O
index	O
(	O
p	O
=	O
0.00072	O
)	O
.	O
In	O
addition	O
,	O
the	O
beta-catenin	O
mutations	O
showed	O
significant	O
association	O
with	O
the	O
cyclin	O
D1	O
expression	O
(	O
p	O
=	O
0.0424	O
)	O
.	O
These	O
results	O
suggest	O
that	O
accumulated	O
beta-catenin	O
proteins	O
may	O
bind	O
to	O
the	O
lymphocyte	O
enhancer	O
binding	O
factor-1	O
(	O
LEF-1	O
)	O
,	O
form	O
the	O
beta-catenin	O
/	O
LEF-1	O
complex	O
,	O
and	O
stimulate	O
such	O
promoters	O
regulating	O
the	O
cell	O
cycle	O
as	O
the	O
cyclin	O
D1	O
gene	O
.	O
This	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
a	O
significant	O
correlation	O
between	O
beta-catenin	O
and	O
the	O
cyclin	O
D1	O
expression	O
in	O
human	O
HCCs	O
.	O
PMID	O
:	O
12375019	O
[	O
PubMed	O
-	O
in	O
process	O
]	O

Cancer	O
1992	O
May	O
1;6	O
9	O
(	O
9	O
)	O
:	O
238	O
5-92	O
Primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
after	O
prophylactic	O
central	O
nervous	O
system	O
irradiation	O
in	O
children	O
.	O
Association	O
with	O
an	O
activated	O
K-ras	O
gene	O
.	O
Brustle	O
O,	O
Ohgaki	O
H,	O
Schmitt	O
HP	O
,	O
Walter	O
GF	O
,	O
Ostertag	O
H,	O
Kleihues	O
P.	O
Laboratory	O
of	O
Neuropathology	O
,	O
Institute	O
of	O
Pathology	O
,	O
University	O
of	O
Zurich	O
,	O
Switzerland	O
.	O
Three	O
patients	O
had	O
supratentorial	B-malignancy-type
malignant	I-malignancy-type
brain	I-malignancy-type
tumors	I-malignancy-type
7	O
to	O
9	O
years	O
after	O
prophylactic	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
treatment	O
for	O
acute	B-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
or	O
malignant	B-malignancy-type
T-cell	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Therapy	O
was	O
administered	O
at	O
the	O
age	O
of	O
3	O
to	O
8	O
years	O
and	O
included	O
cranial	O
irradiation	O
(	O
total	O
dose	O
,	O
1800	O
to	O
2400	O
cGy	O
)	O
and	O
intrathecal	O
methotrexate	O
.	O
The	O
brain	B-malignancy-type
tumors	I-malignancy-type
had	O
histologic	O
and	O
immunohistochemical	O
features	O
of	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
(	O
PNET	B-malignancy-type
)	O
,	O
including	O
neuroblastic	O
rosettes	O
,	O
rhythmic	O
arrangement	O
of	O
tumor	O
cells	O
,	O
and	O
immunohistochemical	O
expression	O
of	O
glial	O
,	O
and	O
in	O
one	O
patient	O
neuronal	O
,	O
marker	O
proteins	O
.	O
Using	O
polymerase	O
chain	O
reaction	O
-	O
mediated	O
DNA	O
amplification	O
from	O
paraffin	O
-	O
embedded	O
tissues	O
and	O
subsequent	O
DNA	O
sequence	O
analysis	O
,	O
an	O
activating	O
point	O
mutation	O
was	O
detected	O
in	O
the	O
K-ras	O
protooncogene	O
in	O
one	O
tumor	O
.	O
This	O
mutation	O
was	O
a	O
G	O
to	O
A	O
transition	O
in	O
position	O
2	O
of	O
codon	O
12	O
,	O
substituting	O
aspartate	O
(	O
GAT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
.	O
This	O
type	O
of	O
mutation	O
has	O
not	O
been	O
observed	O
before	O
in	O
human	O
brain	B-malignancy-type
tumors	I-malignancy-type
,	O
but	O
it	O
is	O
frequent	O
in	O
radiation	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
murine	I-malignancy-type
lymphomas	I-malignancy-type
.	O
These	O
observations	O
suggest	O
that	O
PNET	B-malignancy-type
can	O
be	O
induced	O
after	O
completion	O
of	O
the	O
embryonal	O
and	O
fetal	O
development	O
of	O
the	O
human	O
CNS	O
.	O
Oncogene	O
-	O
activating	O
point	O
mutations	O
may	O
represent	O
a	O
pathogenetic	O
mechanism	O
involved	O
in	O
the	O
genesis	O
of	O
radiation	B-malignancy-type
-	I-malignancy-type
induced	I-malignancy-type
brain	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
1314130	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatol	O
1992	O
Mar;1	O
4	O
(	O
2-3	O
)	O
:	O
34	O
2-6	O
Infrequent	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
61	O
of	O
ras	O
oncogenes	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Challen	O
C,	O
Guo	O
K,	O
Collier	O
JD	O
,	O
Cavanagh	O
D	O
,	O
Bassendine	O
MF.	O
University	O
of	O
Newcastle	O
upon	O
Tyne	O
,	O
Department	O
of	O
Medicine	O
,	O
Medical	O
School	O
,	O
United	O
Kingdom	O
.	O
DNA	O
from	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
codons	O
12	O
and	O
61	O
of	O
the	O
K-ras	O
,	O
H-ras	O
and	O
N-ras	O
genes	O
.	O
The	O
relevant	O
ras	O
sequences	O
were	O
amplified	O
in	O
vitro	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
point	O
mutations	O
detected	O
by	O
selective	O
hybridisation	O
using	O
mutation	O
-	O
specific	O
synthetic	O
oligonucleotides	O
.	O
In	O
one	O
of	O
the	O
19	O
HCCs	B-malignancy-type
a	O
mutation	O
in	O
codon	O
61	O
of	O
the	O
K-ras	O
gene	O
was	O
detected	O
,	O
whilst	O
in	O
3	O
/	O
19	O
HCCs	B-malignancy-type
a	O
mutation	O
was	O
found	O
in	O
codon	O
61	O
of	O
the	O
N-ras	O
gene	O
.	O
The	O
mutations	O
were	O
all	O
heterozygous	O
A	O
-	O
T	O
transversions	O
and	O
were	O
found	O
in	O
HCCs	B-malignancy-type
arising	O
in	O
patients	O
with	O
underlying	O
cirrhosis	O
.	O
In	O
two	O
of	O
these	O
patients	O
where	O
the	O
corresponding	O
normal	O
tissue	O
was	O
available	O
only	O
the	O
wild	O
-	O
type	O
ras	O
gene	O
was	O
detected	O
,	O
indicating	O
that	O
oncogenic	O
activation	O
of	O
the	O
ras	O
gene	O
was	O
a	O
consequence	O
of	O
somatic	O
mutation	O
.	O
In	O
another	O
patient	O
the	O
same	O
mutation	O
in	O
codon	O
61	O
of	O
the	O
N-ras	O
gene	O
was	O
found	O
in	O
cirrhotic	O
liver	O
tissue	O
and	O
in	O
all	O
four	O
patients	O
the	O
same	O
mutation	O
was	O
also	O
detected	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
liver	O
biopsy	O
HCC	B-malignancy-type
tissue	O
obtained	O
at	O
diagnosis	O
.	O
These	O
results	O
indicate	O
that	O
mutational	O
activation	O
of	O
the	O
ras	O
genes	O
at	O
codon	O
61	O
is	O
an	O
infrequent	O
but	O
possibly	O
early	O
event	O
in	O
the	O
development	O
of	O
HCC	B-malignancy-type
in	O
Britain	O
.	O
PMID	O
:	O
1323601	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surg	O
Oncol	O
1992	O
Dec;	O
1	O
(	O
6	O
)	O
:	O
40	O
5-11	O
Analysis	O
of	O
ras	O
oncogene	O
mutations	O
in	O
human	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
head	I-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
.	O
Nunez	O
F	O
,	O
Dominguez	O
O,	O
Coto	O
E	O
,	O
Suare	O
z-Nieto	O
C,	O
Perez	O
P,	O
Lope	O
z-Larrea	O
C.	O
Department	O
of	O
Otolaryngology	O
,	O
Hospital	O
Central	O
de	O
Asturias	O
,	O
Oviedo	O
,	O
Spain	O
.	O
The	O
presence	O
of	O
proto	O
-	O
oncogene	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
Ha	O
-	O
,	O
Ki	O
-	O
,	O
and	O
N-ras	O
in	O
primary	B-malignancy-type
head	I-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
are	O
analysed	O
in	O
this	O
study	O
.	O
Oncogene	O
ras	O
-	O
specific	O
sequences	O
were	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
probed	O
with	O
mutation	O
specific	O
oligonucleotide	O
probes	O
.	O
Mutations	O
were	O
detected	O
in	O
8	O
of	O
22	O
samples	O
(	O
36.3	O
%	O
)	O
.	O
No	O
mutations	O
were	O
detected	O
on	O
patients	O
'	O
peripheral	O
blood	O
DNA	O
.	O
We	O
found	O
that	O
histologically	O
and	O
clinically	O
,	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
with	O
or	O
without	O
a	O
ras	O
mutation	O
do	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
.	O
PMID	O
:	O
1341278	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1992	O
Nov	O
1;5	O
2	O
(	O
21	O
)	O
:	O
599	O
1-6	O
Presence	O
of	O
ras	O
oncogene	O
mutations	O
and	O
human	O
papillomavirus	O
DNA	O
in	O
human	O
prostate	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Anwar	O
K,	O
Nakakuki	O
K,	O
Shiraishi	O
T	O
,	O
Naiki	O
H,	O
Yatani	O
R	O
,	O
Inuzuka	O
M.	O
Department	O
of	O
Pathology	O
,	O
Fukui	O
Medical	O
School	O
,	O
Matsuoka	O
,	O
Japan	O
.	O
The	O
frequency	O
of	O
H-ras	O
,	O
K-ras	O
,	O
and	O
N-ras	O
mutations	O
and	O
the	O
presence	O
of	O
high	O
-	O
risk	O
human	O
papillomavirus	O
(	O
HPV	O
16	O
,	O
18	O
,	O
and	O
33	O
)	O
DNA	O
were	O
studied	O
in	O
75	O
paraffin	O
-	O
embedded	O
specimens	O
obtained	O
from	O
68	O
Japanese	O
patients	O
with	O
a	O
variety	O
of	O
prostate	B-malignancy-type
carcinomas	I-malignancy-type
by	O
using	O
polymerase	O
chain	O
reaction	O
and	O
DNA	O
hybridization	O
with	O
sequence	O
-	O
specific	O
oligonucleotides	O
.	O
Ten	O
specimens	O
each	O
of	O
normal	O
and	O
benign	B-malignancy-type
hyperplastic	I-malignancy-type
prostatic	I-malignancy-type
tissues	I-malignancy-type
from	O
the	O
same	O
number	O
of	O
patients	O
were	O
also	O
examined	O
for	O
this	O
analysis	O
.	O
Of	O
68	O
carcinoma	B-malignancy-type
cases	O
,	O
ras	O
gene	O
mutations	O
were	O
present	O
in	O
16	O
cases	O
(	O
24	O
%	O
)	O
and	O
HPV	O
DNAs	O
in	O
28	O
cases	O
(	O
41	O
%	O
)	O
.	O
Eleven	O
mutations	O
were	O
detected	O
in	O
codon	O
61	O
of	O
H-ras	O
,	O
4	O
in	O
codon	O
12	O
of	O
N-ras	O
,	O
and	O
2	O
in	O
codon	O
61	O
of	O
K-ras	O
.	O
HPV	O
16	O
,	O
18	O
,	O
and	O
33	O
DNAs	O
were	O
found	O
in	O
11	O
,	O
17	O
,	O
and	O
5	O
cases	O
,	O
respectively	O
.	O
Eight	O
of	O
the	O
16	O
cases	O
with	O
ras	O
mutation	O
also	O
harbored	O
HPV	O
DNAs	O
.	O
The	O
frequency	O
of	O
ras	O
mutations	O
and	O
the	O
HPV	O
infection	O
increased	O
in	O
patients	O
with	O
advanced	O
stages	O
of	O
the	O
tumor	O
and	O
with	O
the	O
higher	O
Gleason	O
score	O
.	O
There	O
was	O
the	O
predominant	O
presence	O
of	O
H-ras	O
codon	O
61.2	O
(	O
CAG	O
-->	O
CTG	O
)	O
mutation	O
and	O
HPV	O
18	O
DNA	O
in	O
prostatic	B-malignancy-type
carcinomas	I-malignancy-type
metastasizing	O
to	O
the	O
bone	O
.	O
None	O
of	O
the	O
normal	O
or	O
benign	B-malignancy-type
hyperplastic	I-malignancy-type
prostatic	I-malignancy-type
specimens	I-malignancy-type
contained	O
either	O
ras	O
mutation	O
or	O
HPV	O
DNA	O
.	O
Our	O
results	O
suggest	O
that	O
ras	O
gene	O
mutations	O
and	O
HPV	O
infections	O
are	O
relatively	O
frequent	O
,	O
at	O
least	O
in	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
of	O
Japanese	O
patients	O
.	O
These	O
two	O
factors	O
appear	O
to	O
be	O
related	O
to	O
the	O
progression	O
of	O
the	O
tumor	O
.	O
Moreover	O
,	O
H-ras	O
codon	O
61.2	O
mutation	O
and	O
HPV	O
18	O
infection	O
may	O
have	O
some	O
predictive	O
roles	O
for	O
bone	O
metastasis	O
in	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
1382850	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1992	O
Oct;8	O
3	O
(	O
10	O
)	O
:	O
105	O
7-62	O
ras	O
mutations	O
in	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
:	O
mutation	O
detection	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
.	O
Yoshimoto	O
K,	O
Iwahana	O
H,	O
Fukuda	O
A	O
,	O
Sano	O
T	O
,	O
Katsuragi	O
K,	O
Kinoshita	O
M,	O
Saito	O
S	O
,	O
Itakura	O
M.	O
Otsuka	O
Department	O
of	O
Clinical	O
and	O
Molecular	O
Nutrition	O
,	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Tokushima	O
.	O
To	O
elucidate	O
the	O
molecular	O
basis	O
for	O
endocrine	O
tumorigenesis	O
,	O
ras	O
mutations	O
in	O
human	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
were	O
analyzed	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
analysis	O
.	O
Mutations	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
,	O
N-ras	O
genes	O
were	O
examined	O
in	O
genomic	O
DNAs	O
from	O
169	O
successfully	O
amplified	O
primary	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
out	O
of	O
189	O
samples	O
.	O
Four	O
out	O
of	O
24	O
thyroid	B-malignancy-type
follicular	I-malignancy-type
adenomas	I-malignancy-type
analyzed	O
contained	O
mutated	O
N-ras	O
codon	O
61	O
,	O
and	O
one	O
contained	O
the	O
mutated	O
H-ras	O
codon	O
61	O
.	O
One	O
of	O
the	O
19	O
pheochromocytomas	B-malignancy-type
revealed	O
mutation	O
of	O
the	O
H-ras	O
codon	O
13	O
.	O
No	O
mutations	O
of	O
the	O
ras	O
gene	O
were	O
detected	O
in	O
pituitary	B-malignancy-type
adenomas	I-malignancy-type
,	O
parathyroid	B-malignancy-type
tumors	I-malignancy-type
,	O
thyroid	B-malignancy-type
cancers	I-malignancy-type
,	O
endocrine	B-malignancy-type
pancreatic	I-malignancy-type
tumors	I-malignancy-type
,	O
and	O
adrenocortical	B-malignancy-type
tumors	I-malignancy-type
.	O
Based	O
on	O
these	O
findings	O
we	O
conclude	O
that	O
activation	O
of	O
the	O
ras	O
gene	O
may	O
play	O
a	O
role	O
in	O
the	O
tumorigenesis	O
of	O
a	O
limited	O
number	O
of	O
thyroid	B-malignancy-type
follicular	I-malignancy-type
adenomas	I-malignancy-type
and	O
pheochromocytomas	B-malignancy-type
,	O
and	O
that	O
mutation	O
of	O
the	O
ras	O
gene	O
is	O
not	O
frequent	O
in	O
other	O
human	O
endocrine	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
1452458	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1992	O
May	O
15	O
;5	O
2	O
(	O
10	O
)	O
:	O
290	O
3-6	O
ras	O
gene	O
mutations	O
as	O
a	O
prognostic	O
marker	O
in	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
lung	I-malignancy-type
without	O
lymph	O
node	O
metastasis	O
.	O
Sugio	O
K,	O
Ishida	O
T	O
,	O
Yokoyama	O
H,	O
Inoue	O
T	O
,	O
Sugimachi	O
K,	O
Sasazuki	O
T.	O
Department	O
of	O
Surgery	O
II	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
obtained	O
at	O
surgical	O
resection	O
was	O
examined	O
for	O
mutation	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
oncogenes	O
K-ras	O
,	O
H-ras	O
,	O
and	O
N-ras	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
techniques	O
.	O
The	O
mutation	O
was	O
detected	O
in	O
18	O
of	O
the	O
115	O
cases	O
(	O
15.7	O
%	O
)	O
,	O
and	O
15	O
of	O
18	O
were	O
at	O
codon	O
12	O
,	O
2	O
were	O
at	O
codon	O
13	O
of	O
K-ras	O
,	O
and	O
1	O
was	O
at	O
codon	O
61	O
of	O
N-ras	O
.	O
G	O
to	O
T	O
transversions	O
were	O
most	O
common	O
.	O
The	O
ras	O
gene	O
mutations	O
were	O
more	O
frequent	O
in	O
the	O
male	O
patients	O
(	O
P	O
=	O
0.0048	O
)	O
.	O
No	O
significant	O
differences	O
were	O
found	O
to	O
be	O
related	O
to	O
stage	O
of	O
the	O
disease	O
or	O
tumor	O
-	O
nodes	O
-	O
metastases	O
classification	O
between	O
positive	O
and	O
negative	O
groups	O
of	O
the	O
ras	O
gene	O
mutations	O
.	O
A	O
history	O
of	O
tobacco	O
use	O
was	O
not	O
always	O
a	O
factor	O
contributing	O
to	O
mutation	O
.	O
Of	O
the	O
completely	O
resected	O
group	O
without	O
lymph	O
node	O
metastasis	O
,	O
the	O
5	O
-	O
year	O
survival	O
rate	O
in	O
the	O
ras	O
-	O
positive	O
group	O
was	O
53.3	O
%	O
,	O
which	O
was	O
significantly	O
poorer	O
than	O
the	O
83.6	O
%	O
survival	O
rate	O
in	O
the	O
ras	O
-	O
negative	O
group	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
ras	O
gene	O
mutations	O
may	O
be	O
prognostic	O
,	O
especially	O
in	O
the	O
early	O
stage	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
PMID	O
:	O
1581907	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1992	O
;2	O
8	O
(	O
2-3	O
)	O
:	O
33	O
3-6	O
Mutations	O
in	O
the	O
ras	O
protooncogenes	O
are	O
rare	O
events	O
in	O
renal	B-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
.	O
Rochlitz	O
CF	O
,	O
Peter	O
S	O
,	O
Willroth	O
G,	O
de	O
Kant	O
E	O
,	O
Lobeck	O
H,	O
Huhn	O
D	O
,	O
Herrmann	O
R.	O
Abt	O
.	O
Hamatologi	O
e/Onkologie	O
,	O
Klinikums	O
Charlottenburg	O
,	O
Freien	O
Universitat	O
Berlin	O
,	O
F.R.G.	O
Mutations	O
in	O
codon	O
12	O
,	O
13	O
or	O
61	O
of	O
one	O
of	O
the	O
three	O
ras	O
genes	O
,	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
,	O
convert	O
these	O
genes	O
into	O
active	O
oncogenes	O
.	O
To	O
determine	O
the	O
role	O
mutated	O
ras	O
genes	O
play	O
in	O
the	O
carcinogenesis	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
analysed	O
tumour	O
DNA	O
and	O
unaffected	O
renal	O
tissue	O
derived	O
from	O
55	O
patients	O
.	O
The	O
polymerase	O
chain	O
reaction	O
technique	O
was	O
used	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
Ki	O
-	O
,	O
Ha	O
-	O
,	O
and	O
N-ras	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
.	O
The	O
amplified	O
fragments	O
were	O
then	O
probed	O
on	O
slot	O
-	O
blots	O
with	O
labeled	O
mutation	O
-	O
specific	O
oligomers	O
.	O
A	O
single	O
Ki-ras	O
mutation	O
(	O
codon	O
12	O
,	O
gly	O
-_greater_than	O
val	O
)	O
was	O
detected	O
in	O
a	O
patient	O
with	O
a	O
pT2N2M1	B-malignancy-type
tumour	I-malignancy-type
.	O
We	O
concluded	O
that	O
ras	O
oncogene	O
mutations	O
do	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
initiation	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
1591047	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Singapore	O
Med	O
J	O
1992	O
Feb	O
;	O
33	O
(	O
1	O
)	O
:	O
48	O
-	O
50	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
probes	O
.	O
Chin	O
Y	O
M	O
,	O
Bosco	O
J	O
J	O
,	O
Koh	O
C	O
L	O
.	O
Haematology	O
Division	O
,	O
Institute	O
for	O
Medical	O
Research	O
,	O
Jalan	O
Pahang	O
,	O
Kuala	O
Lumpur	O
,	O
Malaysia	O
.	O
In	O
vitro	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
amplification	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
followed	O
by	O
hybridization	O
with	O
oligonucleotide	O
probes	O
were	O
used	O
to	O
study	O
ras	O
gene	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
The	O
DNA	O
of	O
30	O
AML	B-malignancy-type
patients	O
at	O
presentation	O
of	O
the	O
disease	O
at	O
the	O
University	O
of	O
Malaya	O
Hospital	O
,	O
Kuala	O
Lumpur	O
were	O
screened	O
for	O
ras	O
gene	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
,	O
K-ras	O
and	O
H-ras	O
genes	O
.	O
Four	O
patients	O
(	O
13.3	O
%	O
)	O
had	O
ras	O
gene	O
mutations	O
.	O
They	O
were	O
all	O
below	O
their	O
early	O
thirties	O
in	O
age	O
.	O
Of	O
the	O
four	O
patients	O
with	O
ras	O
gene	O
mutations	O
,	O
three	O
were	O
M3	B-malignancy-type
and	O
one	O
was	O
M4	B-malignancy-type
according	O
to	O
the	O
French	O
American	O
British	O
(	O
FAB	O
)	O
classification	O
of	O
AML	B-malignancy-type
.	O
PMID	O
:	O
1598607	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
1991	O
Aug	O
;	O
6	O
(	O
8	O
)	O
:	O
1353	O
-	O
62	O
Mutations	O
of	O
ras	O
genes	O
distinguish	O
a	O
subset	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
from	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Mitsudomi	O
T	O
,	O
Viallet	O
J	O
,	O
Mulshine	O
JL	O
,	O
Linnoila	O
RI	O
,	O
Minna	O
JD	O
,	O
Gazdar	O
AF.	O
NCI	O
-	O
Navy	O
Medical	O
Oncology	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
20889	O
-	O
5105	O
.	O
We	O
screened	O
a	O
panel	O
of	O
103	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
for	O
the	O
presence	O
of	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
human	O
K	O
-	O
,	O
H	O
-	O
and	O
N-ras	O
genes	O
,	O
using	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLP	O
)	O
,	O
created	O
through	O
mismatched	O
primers	O
during	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
of	O
genomic	O
DNA	O
.	O
We	O
found	O
ras	O
mutations	O
in	O
22	O
/	O
61	O
(	O
36	O
%	O
)	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
cell	O
lines	O
,	O
predominantly	O
in	O
K-ras	O
codon	O
12	O
.	O
Identical	O
mutations	O
were	O
present	O
in	O
uncultured	O
tumor	O
materials	O
corresponding	O
to	O
11	O
cell	O
lines	O
containing	O
mutated	O
ras	O
genes	O
.	O
ras	O
mutations	O
were	O
found	O
not	O
only	O
in	O
adenocarcinoma	B-malignancy-type
cell	O
lines	O
(	O
9	O
/	O
32	O
,	O
28	O
%	O
)	O
,	O
but	O
also	O
in	O
cell	O
lines	O
derived	O
from	O
other	O
types	O
of	O
NSCLC	B-malignancy-type
(	O
13	O
/	O
29	O
,	O
45	O
%	O
)	O
.	O
In	O
contrast	O
,	O
none	O
of	O
37	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
SCLC	B-malignancy-type
)	O
cell	O
lines	O
and	O
five	O
extra	B-malignancy-type
-	I-malignancy-type
pulmonary	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
had	O
ras	O
mutations	O
.	O
ras	O
mutations	O
were	O
not	O
correlated	O
with	O
sex	O
of	O
the	O
patients	O
,	O
tumor	O
extent	O
,	O
prior	O
therapy	O
status	O
or	O
in	O
vitro	O
culture	O
time	O
.	O
G	O
to	O
T	O
or	O
A	O
to	O
T	O
transversions	O
were	O
the	O
most	O
common	O
base	O
substitutions	O
,	O
occurring	O
in	O
codons	O
12	O
and	O
61	O
respectively	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
a	O
subset	O
of	O
NSCLC	B-malignancy-type
but	O
are	O
not	O
involved	O
in	O
SCLC	B-malignancy-type
.	O
PMID	O
:	O
1679529	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
1992	O
Mar	O
1	O
;	O
69	O
(	O
5	O
)	O
:	O
1115	O
-	O
8	O
High	O
incidence	O
of	O
ras	O
gene	O
mutation	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
.	O
Tada	O
M,	O
Omata	O
M,	O
Ohto	O
M.	O
First	O
Department	O
of	O
Medicine	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
The	O
DNA	O
sequences	O
around	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
ras	O
gene	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
in	O
18	O
intrahepatic	B-malignancy-type
cholangiocarcinomas	I-malignancy-type
.	O
The	O
ras	O
gene	O
mutations	O
were	O
found	O
in	O
9	O
of	O
18	O
(	O
50	O
%	O
)	O
:	O
6	O
in	O
K-ras	O
codon	O
12	O
,	O
1	O
in	O
K-ras	O
codon	O
13	O
,	O
1	O
in	O
K-ras	O
codon	O
61	O
,	O
and	O
1	O
in	O
N-ras	O
codon	O
12	O
.	O
The	O
incidence	O
of	O
mutations	O
was	O
higher	O
in	O
the	O
hilar	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
intrahepatic	I-malignancy-type
cholangiocarcinomas	I-malignancy-type
,	O
especially	O
when	O
these	O
tumors	O
were	O
large	O
.	O
The	O
incidence	O
and	O
spectrum	O
of	O
the	O
mutations	O
were	O
almost	O
the	O
same	O
as	O
those	O
reported	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
,	O
possibly	O
indicating	O
similar	O
etiologic	O
agent	O
(	O
s	O
)	O
in	O
the	O
carcinogenesis	O
of	O
both	O
cancers	O
.	O
PMID	O
:	O
1739910	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

therapy-related_leukemia	B-malignancy-type
myelodysplastic_syndrome	B-malignancy-type
therapy-related_leukemia	B-malignancy-type
therapy-related_myelodysplastic_syndrome	B-malignancy-type
N-ras	O
K-ras	O
N-ras	O
K-ras	O
mutations	O
codons_12	O
13	O
61	O
N-ras	O
K-ras	O
N-ras	O
mutation	O
aspartic_acid	O
GAT	O
glycine	O
GGT	O
N-ras	O
codon_13	O
mutation	O
valine	O
GTT	O
glycine	O
K-ras	O
codon_12	O
mutations	O
aspartic_acid	O
GAT	O
cysteine	O
TGT	O
glycine	O
GGT	O
K-ras	O
codon_61	O
mutation	O
lysine	O
AAA	O
glutamic_acid	O
CAA	O
loss	O
chromosome_7	O
N-ras	O
K-ras	O
loss_of_heterozygosity	O
chromosome_7	O
herapy-related_leukemia	B-malignancy-type
myelodysplastic_syndrome	B-malignancy-type

Blood	O
1991	O
Feb	O
1	O
;	O
77	O
(	O
3	O
)	O
:	O
594	O
-	O
8	O
Mutations	O
of	O
the	O
ras	O
proto	O
-	O
oncogenes	O
in	O
childhood	O
monosomy	O
7	O
.	O
Neubauer	O
A	O
,	O
Shannon	O
K	O
,	O
Liu	O
E	O
.	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
27599-7295	O
.	O
ras	O
gene	O
mutations	O
are	O
the	O
most	O
frequent	O
molecular	O
changes	O
found	O
in	O
the	O
preleukemic	B-malignancy-type
syndromes	I-malignancy-type
of	O
adults	O
and	O
may	O
play	O
a	O
role	O
in	O
initiating	O
these	O
diseases	O
and	O
in	O
their	O
progression	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
incidence	O
or	O
importance	O
of	O
these	O
genetic	O
mutations	O
in	O
childhood	B-malignancy-type
myeloproliferative	I-malignancy-type
states	I-malignancy-type
(	B-malignancy-type
MPS	I-malignancy-type
)	O
.	O
The	O
bone	O
marrow	O
(	O
BM	O
)	O
monosomy	O
7	O
syndrome	O
accounts	O
for	O
a	O
large	O
percentage	O
of	O
childhood	O
MPS	B-malignancy-type
.	O
Although	O
the	O
duration	O
of	O
the	O
MPS	B-malignancy-type
is	O
quite	O
variable	O
,	O
children	O
with	O
monosomy	O
7	O
eventually	O
develop	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
We	O
investigated	O
20	O
children	O
(	O
13	O
with	O
MPS	B-malignancy-type
,	O
7	O
with	O
AML	B-malignancy-type
)	O
with	O
BM	O
monosomy	O
7	O
or	O
7q-	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
hybridization	O
with	O
mutation	O
-	O
specific	O
oligonucleotides	O
.	O
Mutations	O
of	O
N-ras	O
and	O
K-ras	O
were	O
detected	O
in	O
three	O
children	O
.	O
Two	O
patients	O
carrying	O
a	O
ras	O
mutation	O
were	O
in	O
the	O
myeloproliferative	O
phase	O
,	O
and	O
one	O
had	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
All	O
three	O
patients	O
with	O
ras	O
mutations	O
either	O
died	O
of	O
their	O
disease	O
or	O
relapsed	O
after	O
BM	O
transplantation	O
as	O
compared	O
with	O
8	O
of	O
17	O
without	O
ras	O
mutations	O
.	O
However	O
,	O
this	O
difference	O
is	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
.14	O
,	O
not	O
significant	O
)	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
are	O
observed	O
in	O
childhood	O
monosomy	O
7	O
,	O
though	O
less	O
frequently	O
than	O
in	O
adult	O
MDS	B-malignancy-type
,	O
and	O
may	O
play	O
a	O
limited	O
role	O
in	O
the	O
progression	O
of	O
this	O
disease	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
More	O
patients	O
are	O
needed	O
to	O
address	O
the	O
prognostic	O
role	O
of	O
ras	O
mutations	O
in	O
this	O
rare	O
disease	O
.	O
PMID	O
:	O
1991170	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
1991	O
Apr	O
15	O
;	O
67	O
(	O
8	O
)	O
:	O
2103	O
-	O
10	O
A	O
T-cell	B-malignancy-type
neoplasia	I-malignancy-type
showing	O
clinicopathologic	O
features	O
of	O
malignant	B-malignancy-type
histiocytosis	I-malignancy-type
with	O
novel	O
chromosomal	O
abnormalities	O
and	O
N-ras	O
mutation	O
.	O
Itoyama	O
T	O
,	O
Sadamori	O
N	O
,	O
Sasagawa	O
I	O
,	O
Nakamura	O
H	O
,	O
Tokunaga	O
S	O
,	O
Yamada	O
Y	O
,	O
Ichimaru	O
M	O
,	O
Yoshida	O
T	O
,	O
Kikuchi	O
M	O
,	O
Takeshima	O
F	O
,	O
et	O
al	O
.	O
Department	O
of	O
Hematology	O
,	O
Atomic	O
Disease	O
Institute	O
,	O
Nagasaki	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Malignant	B-malignancy-type
histiocytosis	I-malignancy-type
(	O
MH	B-malignancy-type
)	O
is	O
a	O
distinct	O
disease	O
entity	O
defined	O
clinically	O
and	O
morphologically	O
.	O
However	O
,	O
the	O
neoplastic	O
origin	O
of	O
MH	B-malignancy-type
is	O
not	O
well	O
established	O
.	O
The	O
authors	O
report	O
a	O
26-year-old	O
woman	O
who	O
showed	O
the	O
typical	O
clinicopathologic	O
features	O
of	O
so-called	O
MH	B-malignancy-type
.	O
Cytogenetic	O
and	O
molecular	O
genetic	O
examinations	O
were	O
performed	O
in	O
addition	O
to	O
the	O
morphologic	O
and	O
immunologic	O
approach	O
.	O
The	O
expression	O
of	O
CD2	O
and	O
T-cell	O
receptor	O
gene	O
rearrangements	O
indicated	O
the	O
T-cell	O
origin	O
of	O
this	O
case	O
.	O
CD30	O
,	O
which	O
is	O
positive	O
for	O
anaplastic	B-malignancy-type
large	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
Ki-1	B-malignancy-type
lymphoma	I-malignancy-type
)	O
,	O
was	O
not	O
expressed	O
.	O
The	O
cytogenetic	O
study	O
revealed	O
a	O
clonal	O
chromosome	O
abnormality	O
involving	O
3q25	O
,	O
6p21	O
,	O
11p15	O
,	O
and	O
11q21	O
.	O
An	O
N-ras	O
point	O
mutation	O
within	O
codon	O
12	O
(	O
GGT	O
----	O
GCT	O
)	O
was	O
also	O
detected	O
.	O
These	O
finding	O
indicate	O
that	O
MH	B-malignancy-type
defined	O
clinically	O
and	O
morphologically	O
is	O
not	O
a	O
tumor	O
of	O
true	O
histiocytic	O
origin	O
and	O
that	O
it	O
should	O
be	O
reclassified	O
on	O
the	O
basis	O
of	O
immunologic	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
genetic	O
data	O
.	O
PMID	O
:	O
2004329	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
1991	O
May	O
30	O
;	O
48	O
(	O
3	O
)	O
:	O
409	O
-	O
12	O
Ras	O
mutations	O
in	O
United	O
Kingdom	O
examples	O
of	O
oral	B-malignancy-type
malignancies	I-malignancy-type
are	O
infrequent	O
.	O
Chang	O
SE	O
,	O
Bhatia	O
P	O
,	O
Johnson	O
NW	O
Morgan	O
PR	O
,	O
McCormick	O
F	O
,	O
Young	O
B	O
,	O
Hiorns	O
L	O
.	O
Department	O
of	O
Dental	O
Sciences	O
,	O
Royal	O
College	O
of	O
Surgeons	O
of	O
England	O
,	O
London	O
,	O
UK	O
.	O
Point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
the	O
oncogenes	O
Ha-ras	O
,	O
Ki-ras	O
or	O
N-ras	O
have	O
been	O
identified	O
in	O
human	O
malignancies	O
of	O
many	O
types	O
.	O
Using	O
the	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
technique	O
for	O
DNA	O
amplification	O
in	O
vitro	O
and	O
stringent	O
probing	O
of	O
the	O
amplified	O
DNA	O
on	O
dot	O
blots	O
with	O
a	O
library	O
of	O
specific	O
oligonucleotides	O
,	O
we	O
have	O
screened	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
in	O
oral	B-malignancy-type
and	O
para	B-malignancy-type
-	I-malignancy-type
oral	I-malignancy-type
malignancies	I-malignancy-type
and	O
some	O
associated	O
lesions	B-malignancy-type
.	O
The	O
material	O
,	O
from	O
UK	O
patients	O
,	O
consisted	O
of	O
22	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
including	O
5	O
neck	B-malignancy-type
metastases	I-malignancy-type
,	O
1	O
oral	B-malignancy-type
mucosal	I-malignancy-type
dysplasia	I-malignancy-type
,	O
1	O
proliferative	B-malignancy-type
verrucous	I-malignancy-type
leukoplakia	I-malignancy-type
,	O
1	O
antral	B-malignancy-type
and	O
1	O
tonsillar	B-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
basal	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
salivary	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
1	O
salivary	B-malignancy-type
adenoid	I-malignancy-type
cystic	I-malignancy-type
carcinoma	I-malignancy-type
and	O
1	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
metastatic	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
gingiva	I-malignancy-type
.	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
tissues	O
which	O
were	O
fresh	O
or	O
preserved	O
in	O
liquid	O
nitrogen	O
.	O
Two	O
DNA	O
samples	O
contained	O
point	O
mutations	O
in	O
codon	O
61	O
of	O
Ki-ras	O
.	O
One	O
of	O
these	O
mutations	O
was	O
in	O
the	O
lymphocytes	O
infiltrating	O
a	O
retromolar	B-malignancy-type
SCC	I-malignancy-type
.	O
The	O
other	O
mutation	O
(	O
CAA	O
to	O
CAU	O
;	O
substitution	O
of	O
glutamine	O
by	O
histidine	O
)	O
was	O
in	O
the	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
metastasis	O
.	O
The	O
absence	O
of	O
ras	O
mutations	O
in	O
the	O
epithelium	O
of	O
primary	O
oral	B-malignancy-type
squamous	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
is	O
of	O
considerable	O
interest	O
as	O
other	O
work	O
in	O
our	O
Department	O
on	O
Indian	O
cases	O
of	O
oral	B-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
chewing	O
tobacco	O
(	O
quid	O
)	O
revealed	O
that	O
35	O
%	O
of	O
these	O
had	O
a	O
codon	O
12	O
,	O
13	O
or	O
61	O
mutation	O
in	O
Ha-ras	O
.	O
While	O
ras	O
activations	O
arising	O
from	O
point	O
mutations	O
may	O
occur	O
in	O
a	O
high	O
proportion	O
of	O
oral	B-malignancy-type
malignancies	I-malignancy-type
associated	O
with	O
chewing	O
tobacco	O
(	O
quid	O
)	O
,	O
this	O
was	O
not	O
the	O
case	O
in	O
UK	O
oral	B-malignancy-type
malignancies	I-malignancy-type
,	O
even	O
where	O
tobacco	O
was	O
smoked	O
.	O
PMID	O
:	O
2040536	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1990	O
Nov	O
1	O
;	O
50	O
(	O
21	O
)	O
:	O
6830	O
-	O
2	O
ras	O
gene	O
mutations	O
in	O
human	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Carter	O
BS	O
,	O
Epstein	O
JI	O
,	O
Isaacs	O
WB.	O
Brady	O
Urological	O
Research	O
Institute	O
,	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
and	O
Hospital	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
.	O
Point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
of	O
the	O
Ha	O
-	O
,	O
Ki	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
are	O
able	O
to	O
convert	O
these	O
normal	O
cellular	O
genes	O
into	O
activated	O
oncogenes	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
ras	O
gene	O
mutations	O
occur	O
in	O
a	O
variety	O
of	O
human	O
solid	B-malignancy-type
tumors	I-malignancy-type
and	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
some	O
of	O
these	O
tumors	O
.	O
In	O
order	O
to	O
test	O
the	O
hypothesis	O
that	O
ras	O
gene	O
mutations	O
may	O
be	O
associated	O
with	O
prostate	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
have	O
used	O
an	O
oligodeoxynucleotide	O
hybridization	O
assay	O
to	O
detect	O
wild-type	O
and	O
mutant	O
alleles	O
in	O
genomic	O
DNA	O
from	O
prostate	B-malignancy-type
tumors	I-malignancy-type
and	O
prostate	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Twenty-four	O
primary	O
prostate	B-malignancy-type
tumors	I-malignancy-type
(	O
23	O
acinar	B-malignancy-type
tumors	I-malignancy-type
and	O
one	O
ductal	B-malignancy-type
tumor	I-malignancy-type
)	O
and	O
five	O
prostate	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
were	O
examined	O
for	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
Ki-ras	O
,	O
Ha-ras	O
,	O
and	O
N-ras	O
genes	O
.	O
Two	O
mutations	O
were	O
detected	O
:	O
an	O
A	O
----	O
G	O
transition	O
causing	O
a	O
glutamine	O
to	O
arginine	O
amino	O
acid	O
substitution	O
at	O
codon	O
61	O
of	O
the	O
Ha-ras	O
gene	O
in	O
a	O
primary	O
prostatic	B-malignancy-type
duct	I-malignancy-type
adenocarcinoma	I-malignancy-type
and	O
a	O
G	O
----	O
T	O
transversion	O
causing	O
a	O
glycine	O
to	O
valine	O
amino	O
acid	O
substitution	O
at	O
codon	O
12	O
of	O
the	O
Ha-ras	O
gene	O
in	O
a	O
prostate	B-malignancy-type
tumor	I-malignancy-type
cell	O
line	O
(	O
TSU-PR1	O
)	O
derived	O
from	O
a	O
lymph	O
node	O
metastasis	O
.	O
While	O
the	O
overall	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
prostate	B-malignancy-type
tumors	I-malignancy-type
is	O
low	O
,	O
when	O
these	O
mutations	O
do	O
occur	O
they	O
may	O
have	O
a	O
role	O
in	O
the	O
progression	O
of	O
disease	O
or	O
the	O
development	O
of	O
the	O
unusual	O
ductal	O
variant	O
of	O
prostatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
2208148	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Surgery	O
1990	O
Dec	O
;	O
108	O
(	O
6	O
)	O
:	O
994	O
-	O
9	O
;	O
discussion	O
999	O
-	O
1000	O
N-ras	O
61	O
oncogene	O
mutations	O
in	O
Hurthle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
.	O
Schark	O
C	O
,	O
Fulton	O
N	O
,	O
Jacoby	O
RF	O
,	O
Westbrook	O
CA	O
,	O
Straus	O
FH	O
2nd	O
,	O
Kaplan	O
EL	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Chicago	O
,	O
Pritzker	O
School	O
of	O
Medicine	O
,	O
IL	O
60637	O
.	O
Mutations	O
of	O
ras	O
oncogenes	O
are	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
initiation	O
or	O
progression	O
of	O
human	O
tumors	O
.	O
In	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
the	O
incidence	O
of	O
ras	O
activation	O
by	O
specific	O
point	O
mutations	O
has	O
been	O
reported	O
to	O
range	O
from	O
33	O
%	O
in	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
up	O
to	O
60	O
%	O
in	O
anaplastic	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Because	O
of	O
our	O
long	O
-	O
standing	O
interest	O
in	O
Hurthle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
,	O
we	O
began	O
a	O
study	O
of	O
70	O
such	O
cases	O
to	O
determine	O
the	O
incidence	O
of	O
ras	O
mutations	O
and	O
their	O
clinical	O
correlates	O
.	O
Analysis	O
of	O
N-ras	O
sequences	O
at	O
codon	O
position	O
61	O
,	O
with	O
the	O
polymerase	O
chain	O
reaction	O
method	O
and	O
oligonucleotide	O
probe	O
hybridization	O
,	O
showed	O
point	O
mutations	O
of	O
the	O
normal	O
codon	O
CAA	O
*	O
in	O
eight	O
tumor	O
samples	O
.	O
One	O
was	O
a	O
mutation	O
from	O
CAA	O
to	O
AAA	O
,	O
one	O
from	O
CAA	O
to	O
CTA	O
,	O
*	O
and	O
six	O
from	O
CAA	O
to	O
CGA	O
.	O
These	O
mutations	O
would	O
result	O
in	O
amino	O
acid	O
substitutions	O
of	O
lysine	O
,	O
leucine	O
,	O
or	O
arginine	O
for	O
the	O
normal	O
glutamine	O
at	O
position	O
61	O
in	O
the	O
N-ras	O
protein	O
.	O
Identical	O
ras	O
mutations	O
in	O
two	O
tumors	O
and	O
some	O
of	O
their	O
surrounding	O
thyroid	O
tissue	O
may	O
indicate	O
that	O
activating	O
ras	O
point	O
mutations	O
are	O
an	O
early	O
event	O
in	O
carcinogenesis	O
.	O
The	O
incidence	O
of	O
mutations	O
was	O
1	O
of	O
24	O
(	O
4	O
%	O
)	O
of	O
the	O
histologically	O
benign	O
tumors	O
,	O
5	O
of	O
34	O
(	O
15	O
%	O
)	O
of	O
the	O
intermediate	O
tumors	O
(	O
with	O
vascular	O
or	O
capsular	O
permeation	O
)	O
,	O
and	O
2	O
of	O
12	O
(	O
17	O
%	O
)	O
in	O
the	O
malignant	O
group	O
.	O
Four	O
of	O
these	O
eight	O
patients	O
died	O
of	O
metastatic	O
thyroid	B-malignancy-type
disease	I-malignancy-type
and	O
four	O
are	O
alive	O
without	O
evidence	O
of	O
recurrence	O
.	O
PMID	O
:	O
2247846	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Endocrinol	O
1990	O
Oct;	O
4	O
(	O
10	O
)	O
:	O
147	O
4-9	O
Point	O
mutations	O
of	O
ras	O
oncogenes	O
are	O
an	O
early	O
event	O
in	O
thyroid	O
tumorigenesis	O
.	O
Namba	O
H,	O
Rubin	O
SA	O
,	O
Fagin	O
JA.	O
Department	O
of	O
Medicine	O
,	O
Cedar	O
s-Sinai	O
Medical	O
Center	O
,	O
UCLA	O
School	O
of	O
Medicine	O
90048	O
.	O
Identifying	O
the	O
nature	O
of	O
the	O
genetic	O
mutations	O
in	O
thyroid	B-malignancy-type
neoplasms	I-malignancy-type
and	O
their	O
prevalence	O
in	O
the	O
various	O
tumor	O
phenotypes	O
is	O
critical	O
to	O
understanding	O
their	O
pathogenesis	O
.	O
Mutational	O
activation	O
of	O
ras	O
oncogenes	O
in	O
human	O
tumors	O
occurs	O
predominantly	O
through	O
point	O
mutations	O
in	O
two	O
functional	O
regions	O
of	O
the	O
molecules	O
,	O
codons	O
12	O
,	O
13	O
(	O
GTP	O
-	O
binding	O
domain	O
)	O
or	O
codon	O
61	O
(	O
GTPase	O
domain	O
)	O
.	O
We	O
examined	O
the	O
prevalence	O
of	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
oncogenes	O
K-ras	O
,	O
N-ras	O
,	O
and	O
H-ras	O
in	O
benign	O
and	O
malignant	O
human	O
thyroid	B-malignancy-type
tumors	I-malignancy-type
by	O
hybridization	O
of	O
PCR	O
-	O
amplified	O
tumor	O
DNA	O
with	O
synthetic	O
oligodeoxynucleotide	O
probes	O
.	O
None	O
of	O
the	O
eight	O
normal	O
thyroid	O
tissues	O
harbored	O
point	O
mutations	O
.	O
Four	O
of	O
nineteen	O
nodules	O
from	O
multinodular	O
goiters	O
(	O
21	O
%	O
)	O
,	O
6	O
/	O
24	O
microfollicular	B-malignancy-type
adenomas	I-malignancy-type
(	O
25	O
%	O
)	O
,	O
3	O
/	O
14	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
(	O
21	O
%	O
)	O
,	O
and	O
0	O
/	O
3	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
contained	O
ras	O
point	O
mutations	O
.	O
The	O
predominant	O
mutation	O
was	O
a	O
valine	O
for	O
glycine	O
substitution	O
in	O
codon	O
12	O
of	O
H-ras	O
.	O
None	O
of	O
the	O
multinodular	B-malignancy-type
goiter	I-malignancy-type
tumors	I-malignancy-type
known	O
to	O
be	O
polyclonal	O
(	O
and	O
thus	O
due	O
to	O
hyperplasia	B-malignancy-type
)	O
had	O
point	O
mutations	O
,	O
whereas	O
one	O
of	O
the	O
two	O
monoclonal	B-malignancy-type
adenomas	I-malignancy-type
arising	I-malignancy-type
in	I-malignancy-type
nodular	I-malignancy-type
glands	I-malignancy-type
contained	O
in	O
H-ras	O
codon	O
12	O
valine	O
substitution	O
,	O
which	O
was	O
confirmed	O
by	O
sequencing	O
the	O
tumor	O
DNA	O
.	O
These	O
data	O
show	O
that	O
ras	O
activation	O
is	O
about	O
equally	O
prevalent	O
in	O
benign	O
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
,	O
and	O
thus	O
may	O
be	O
an	O
early	O
event	O
in	O
the	O
tumorigenic	O
process	O
.	O
PMID	O
:	O
2283998	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Urol	O
1990	O
Jan;14	O
3	O
(	O
1	O
)	O
:	O
17	O
5-8	O
Infrequent	O
ras	O
oncogene	O
point	O
mutations	O
in	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Nanus	O
DM	O
,	O
Mentle	O
IR	O
,	O
Motzer	O
RJ	O
,	O
Bander	O
NH	O
,	O
Albino	O
AP	O
.	O
Department	O
of	O
Medicine	O
,	O
Memorial	O
Sloan	O
Kettering	O
Cancer	O
Center	O
,	O
New	O
York	O
,	O
NY	O
10021	O
.	O
The	O
role	O
of	O
ras	O
oncogenes	O
in	O
the	O
pathogenesis	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
is	O
unclear	O
.	O
We	O
have	O
previously	O
shown	O
that	O
insertion	O
of	O
a	O
mutated	O
ras	O
oncogene	O
into	O
cultured	O
human	O
proximal	O
tubular	O
cells	O
,	O
the	O
normal	O
counterpart	O
of	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
initiates	O
a	O
series	O
of	O
transformation	O
events	O
which	O
results	O
in	O
cells	O
possessing	O
a	O
renal	B-malignancy-type
cancer	I-malignancy-type
phenotype	O
.	O
These	O
data	O
suggested	O
a	O
role	O
for	O
mutated	O
ras	O
genes	O
in	O
the	O
initiation	O
and	O
maintenance	O
of	O
this	O
disease	O
.	O
Therefore	O
,	O
to	O
assess	O
the	O
involvement	O
of	O
ras	O
genes	O
in	O
renal	O
carcinogenesis	O
,	O
51	O
primary	O
and	O
metastatic	O
renal	B-malignancy-type
carcinomas	I-malignancy-type
,	O
including	O
three	O
oncocytomas	B-malignancy-type
,	O
were	O
analyzed	O
for	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
Ha-ras	O
,	O
Ki-ras	O
and	O
N-ras	O
proto	O
-	O
oncogenes	O
using	O
polymerase	O
-	O
catalyzed	O
chain	O
reaction	O
methodology	O
.	O
A	O
mutated	O
Ha-ras	O
gene	O
was	O
found	O
in	O
one	O
renal	B-malignancy-type
cancer	I-malignancy-type
metastatic	O
to	O
lung	O
for	O
an	O
overall	O
incidence	O
of	O
2	O
%	O
.	O
These	O
data	O
indicate	O
that	O
ras	O
oncogenes	O
,	O
activated	O
by	O
point	O
mutations	O
,	O
do	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
initiation	O
,	O
maintenance	O
or	O
metastases	O
of	O
renal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
2403598	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1989	O
Jan;7	O
3	O
(	O
1	O
)	O
:	O
28	O
1-3	O
Analysis	O
of	O
N-RAS	O
exon-1	O
mutations	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Ba	O
r-Eli	O
M,	O
Ahuja	O
H,	O
Gonzale	O
z-Cadavid	O
N	O
,	O
Foti	O
A	O
,	O
Cline	O
MJ.	O
Division	O
of	O
Hematolog	O
y/Oncology	O
,	O
University	O
of	O
California	O
,	O
Los	O
Angeles	O
9002	O
4-1678	O
.	O
Mutations	O
in	O
codons	O
12	O
or	O
13	O
of	O
the	O
first	O
exon	O
of	O
the	O
N-RAS	O
gene	O
have	O
been	O
reported	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
in	O
frequencies	O
that	O
vary	O
between	O
9	O
%	O
and	O
40	O
%	O
depending	O
on	O
the	O
techniques	O
used	O
in	O
analysis	O
.	O
Gene	O
amplification	O
and	O
direct	O
sequencing	O
provides	O
the	O
only	O
unambiguous	O
method	O
of	O
detecting	O
those	O
mutations	O
that	O
induce	O
amino	O
acid	O
alterations	O
.	O
Using	O
this	O
technique	O
,	O
we	O
analyzed	O
21	O
MDS	B-malignancy-type
patients	O
for	O
mutations	O
in	O
exon-1	O
of	O
N-RAS	O
.	O
Codon	O
12	O
mutations	O
substituting	O
aspartic	O
acid	O
(	O
GAT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
were	O
found	O
in	O
four	O
cases	O
,	O
and	O
a	O
codon	O
13	O
mutation	O
substituting	O
alanine	O
(	O
GCT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
was	O
detected	O
in	O
one	O
patient	O
.	O
We	O
conclude	O
that	O
N-RAS	O
exon-1	O
mutations	O
in	O
one	O
patient	O
.	O
We	O
conclude	O
that	O
N-RAS	O
exon-1	O
mutations	O
producing	O
amino	O
acid	O
changes	O
occur	O
in	O
about	O
20	O
%	O
to	O
25	O
%	O
of	O
MDS	B-malignancy-type
cases	O
.	O
PMID	O
:	O
2642713	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1989	O
May;7	O
2	O
(	O
1	O
)	O
:	O
3	O
6-9	O
N-RAS	O
mutations	O
in	O
T-cell	B-malignancy-type
acute	I-malignancy-type
lymphocytic	I-malignancy-type
leukaemia	I-malignancy-type
:	O
analysis	O
by	O
direct	O
sequencing	O
detects	O
a	O
novel	O
mutation	O
.	O
Ba	O
r-Eli	O
M,	O
Ahuja	O
H,	O
Foti	O
A	O
,	O
Cline	O
MJ.	O
Division	O
of	O
Hematolog	O
y/Oncology	O
,	O
University	O
of	O
California	O
,	O
Los	O
Angeles	O
9002	O
4-1678	O
.	O
A	O
novel	O
mutation	O
of	O
the	O
N-RAS	O
gene	O
of	O
T-ALL	B-malignancy-type
blast	O
cells	O
was	O
detected	O
by	O
a	O
direct	O
sequencing	O
of	O
in	O
vitro	O
amplified	O
exon-1	O
of	O
the	O
N-RAS	O
gene	O
.	O
Threonine	O
(	O
ACA	O
)	O
was	O
substituted	O
for	O
alanine	O
(	O
GCA	O
)	O
at	O
codon	O
11	O
.	O
This	O
mutation	O
would	O
have	O
been	O
overlooked	O
by	O
conventional	O
probe	O
hybridization	O
techniques	O
.	O
A	O
search	O
for	O
other	O
mutations	O
in	O
N-RAS	O
exon-1	O
in	O
T-ALL	B-malignancy-type
revealed	O
a	O
codon	O
13	O
mutation	O
substituting	O
aspartic	O
acid	O
(	O
GAT	O
)	O
for	O
glycine	O
(	O
GGT	O
)	O
in	O
one	O
of	O
18	O
patients	O
.	O
No	O
mutations	O
at	O
codon	O
12	O
were	O
detected	O
.	O
PMID	O
:	O
2660900	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Tumori	O
1989	O
Aug	O
31;75	O
(	O
4	O
)	O
:	O
33	O
7-40	O
N-ras	O
mutations	O
in	O
myeloid	B-malignancy-type
leukemias	I-malignancy-type
.	O
Saglio	O
G,	O
Serra	O
A	O
,	O
Novarino	O
A	O
,	O
Falda	O
M,	O
Gavosto	O
F.	O
Dipartimento	O
di	O
Scienze	O
Biomediche	O
e	O
Universita	O
di	O
Torino	O
,	O
Italy	O
.	O
The	O
presence	O
of	O
mutations	O
activating	O
the	O
N-ras	O
gene	O
was	O
investigated	O
by	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
in	O
twenty	O
patients	O
with	O
acute	B-malignancy-type
myeloblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
at	O
onset	O
and	O
in	O
four	O
patients	O
with	O
Ph1	B-malignancy-type
positive	I-malignancy-type
chronic	I-malignancy-type
myelogeneous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
either	O
in	O
chronic	O
phase	O
or	O
in	O
blast	O
crisis	O
.	O
Four	O
remission	O
samples	O
and	O
four	O
relapses	O
from	O
the	O
AML	B-malignancy-type
cases	O
were	O
also	O
studied	O
.	O
Mutations	O
were	O
found	O
in	O
five	O
out	O
of	O
twenty	O
(	O
25	O
%	O
)	O
untreated	O
AML	B-malignancy-type
cases	O
at	O
onset	O
.	O
No	O
mutations	O
were	O
detected	O
in	O
the	O
complete	O
remission	O
samples	O
,	O
two	O
of	O
them	O
with	O
N-ras	O
mutations	O
during	O
the	O
leukemic	O
phase	O
.	O
Two	O
out	O
of	O
the	O
four	O
leukemia	B-malignancy-type
relapses	O
were	O
positive	O
for	O
the	O
same	O
N-ras	O
mutation	O
shown	O
at	O
presentation	O
,	O
whereas	O
no	O
new	O
mutations	O
were	O
found	O
in	O
the	O
other	O
two	O
initially	O
negative	O
cases	O
.	O
An	O
N-ras	O
mutation	O
appeared	O
during	O
the	O
blast	O
crisis	O
of	O
one	O
of	O
the	O
four	O
CML	B-malignancy-type
,	O
which	O
were	O
all	O
negative	O
during	O
the	O
chronic	O
phase	O
.	O
In	O
conclusion	O
,	O
whereas	O
some	O
data	O
appear	O
to	O
be	O
consistent	O
with	O
a	O
role	O
of	O
the	O
N-ras	O
mutations	O
as	O
initiating	O
events	O
in	O
myeloid	B-malignancy-type
leukemias	I-malignancy-type
,	O
in	O
other	O
cases	O
N-ras	O
activation	O
seems	O
to	O
represent	O
a	O
factor	O
involved	O
in	O
progression	O
.	O
These	O
data	O
suggest	O
that	O
a	O
partial	O
overlapping	O
between	O
initiation	O
and	O
progression	O
factors	O
could	O
exist	O
in	O
naturally	O
occurring	O
tumors	O
.	O
PMID	O
:	O
2683276	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
Res	O
1989	O
;	O
5	O
(	O
2	O
)	O
:	O
121	O
-	O
7	O
ras	O
mutations	O
in	O
human	O
melanotic	B-malignancy-type
lesions	I-malignancy-type
:	O
K-ras	O
activation	O
is	O
a	O
frequent	O
and	O
early	O
event	O
in	O
melanoma	B-malignancy-type
development	O
.	O
Shukla	O
VK	O
,	O
Hughes	O
DC	O
,	O
Hughes	O
LE	O
,	O
McCormick	O
F	O
,	O
Padua	O
RA	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Heath	O
Park	O
,	O
Cardiff	O
,	O
United	O
Kingdom	O
.	O
We	O
have	O
used	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
an	O
amplification	O
procedure	O
,	O
and	O
oligonucleotide	O
hybridization	O
to	O
detect	O
ras	O
gene	O
point	O
mutations	O
in	O
DNA	O
from	O
melanoma	B-malignancy-type
tumor	O
samples	O
.	O
Genomic	O
DNA	O
was	O
examined	O
from	O
40	O
specimens	O
of	O
melanotic	B-malignancy-type
lesions	I-malignancy-type
,	O
including	O
benign	B-malignancy-type
nevi	I-malignancy-type
,	O
primary	O
melanomas	B-malignancy-type
,	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
,	O
and	O
systemic	B-malignancy-type
metastases	I-malignancy-type
.	O
Adjacent	O
normal	O
skin	O
or	O
peripheral	O
blood	O
was	O
analyzed	O
as	O
control	O
material	O
in	O
28	O
cases	O
.	O
ras	O
mutations	O
were	O
detected	O
overall	O
in	O
25	O
%	O
of	O
malignant	O
tumors	O
.	O
In	O
addition	O
,	O
mutations	O
of	O
all	O
three	O
ras	O
genes	O
were	O
detected	O
.	O
We	O
observed	O
ras	O
mutations	O
in	O
2	O
of	O
4	O
benign	B-malignancy-type
atypical	I-malignancy-type
nevi	I-malignancy-type
(	O
2	O
X	O
K	O
12	O
)	O
,	O
4	O
of	O
22	O
primary	O
melanomas	B-malignancy-type
(	O
3	O
X	O
K	O
12	O
,	O
1	O
X	O
H	O
12	O
,	O
1	O
X	O
N	O
61	O
)	O
,	O
and	O
4	O
of	O
14	O
secondary	O
(	O
5	O
X	O
K	O
12	O
,	O
1	O
X	O
N	O
61	O
)	O
tumors	O
.	O
One	O
with	O
a	O
primary	O
melanoma	B-malignancy-type
had	O
concurrent	O
K	O
12	O
and	O
H	O
12	O
,	O
and	O
two	O
patients	O
with	O
secondary	O
tumors	O
had	O
concurrent	O
K	O
12	O
/	O
N	O
61	O
and	O
K	O
12	O
Asp	O
/	O
K	O
12	O
Val	O
mutations	O
,	O
respectively	O
,	O
making	O
a	O
total	O
of	O
10	O
of	O
40	O
(	O
25	O
%	O
)	O
patients	O
with	O
ras	O
mutations	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
K-ras	O
mutations	O
in	O
human	O
melanoma	B-malignancy-type
.	O
The	O
presence	O
of	O
K-ras	O
mutations	O
in	O
nevi	O
,	O
putative	O
melanoma	B-malignancy-type
precursors	O
,	O
suggests	O
that	O
ras	O
activation	O
may	O
be	O
an	O
early	O
event	O
in	O
melanoma	B-malignancy-type
development	O
.	O
No	O
correlation	O
between	O
tumor	O
thickness	O
and	O
the	O
presence	O
of	O
a	O
ras	O
mutation	O
was	O
observed	O
.	O
PMID	O
:	O
2691957	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Res	O
1995	O
Oct;19	O
(	O
10	O
)	O
:	O
74	O
1-8	O
Possible	O
co-existence	O
of	O
RAS	O
activation	O
and	O
monosomy	O
7	O
in	O
the	O
leukaemic	O
transformation	O
of	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
.	O
Stephenson	O
J,	O
Lizhen	O
H,	O
Mufti	O
GJ.	O
Department	O
of	O
Haematological	O
Medicine	O
,	O
Kings	O
College	O
School	O
of	O
Medicine	O
and	O
Dentistry	O
,	O
London	O
,	O
UK.	O
The	O
frequency	O
of	O
RAS	O
activation	O
was	O
studied	O
in	O
48	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
or	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
,	O
in	O
order	O
to	O
address	O
the	O
question	O
of	O
whether	O
patients	O
possessing	O
monosomy	O
7	O
or	O
other	O
alterations	O
of	O
chromosome	O
7	O
have	O
a	O
higher	O
incidence	O
of	O
RAS	O
activation	O
than	O
those	O
lacking	O
chromosome	O
7	O
abnormalities	O
.	O
Samples	O
were	O
screened	O
for	O
oncogenic	O
point	O
mutation	O
by	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
hybridization	O
analysis	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N-RAS	O
and	O
codons	O
12	O
and	O
13	O
of	O
K-RAS	O
.	O
Two	O
additional	O
samples	O
were	O
considered	O
to	O
have	O
activated	O
RAS	O
due	O
to	O
additional	O
karyotypic	O
abnormalities	O
t	O
(	O
5	O
;	O
12	O
)	O
or	O
loss	O
of	O
both	O
copies	O
of	O
chromosome	O
17	O
and	O
hence	O
,	O
the	O
neurofibromatosis	O
(	O
NF1	O
)	O
loci	O
.	O
The	O
group	O
of	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukaemia	I-malignancy-type
(	O
CMML	B-malignancy-type
)	O
patients	O
had	O
activated	O
RAS	O
in	O
4	O
/	O
11	O
cases	O
and	O
inclusion	O
of	O
two	O
CMMLt	B-malignancy-type
patients	O
(	O
with	O
monosomy	O
7	O
)	O
brings	O
this	O
incidence	O
to	O
5	O
/	O
13	O
.	O
No	O
change	O
in	O
frequency	O
of	O
RAS	O
activation	O
was	O
seen	O
between	O
groups	O
containing	O
de	B-malignancy-type
novo	I-malignancy-type
AML	I-malignancy-type
samples	I-malignancy-type
with	O
or	O
without	O
chromosome	O
7	O
abnormalities	O
(	O
1	O
/	O
5	O
and	O
2	O
/	O
12	O
,	O
respectively	O
)	O
.	O
However	O
,	O
assessment	O
of	O
MDS	O
samples	O
in	O
the	O
process	O
of	O
,	O
or	O
subsequent	O
to	O
,	O
leukaemic	O
progression	O
showed	O
a	O
difference	O
between	O
the	O
two	O
groups	O
.	O
The	O
frequency	O
of	O
RAS	O
activation	O
in	O
samples	O
with	O
monosomy	O
7	O
was	O
4	O
/	O
9	O
samples	O
while	O
none	O
of	O
the	O
seven	O
samples	O
without	O
chromosome	O
7	O
changes	O
showed	O
RAS	O
activation	O
.	O
The	O
co-existence	O
of	O
RAS	O
activation	O
and	O
monosomy	O
7	O
in	O
MDS	B-malignancy-type
indicates	O
that	O
these	O
lesions	O
can	O
co-operate	O
in	O
the	O
multistep	O
process	O
of	O
leukemogenesis	O
.	O
PMID	O
:	O
7500652	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1995	O
Sep;19	O
(	O
9	O
)	O
:	O
59	O
5-603	O
Acute	O
leukemic	O
transformation	O
of	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
--	O
immunophenotypic	O
,	O
genotypic	O
,	O
and	O
cytogenetic	O
studies	O
.	O
Tien	O
HF	O
,	O
Wang	O
CH,	O
Chuang	O
SM	O
,	O
Lee	O
FY	O
,	O
Liu	O
MC	O
,	O
Chen	O
YC	O
,	O
Shen	O
MC	O
,	O
Lin	O
KH,	O
Lin	O
DT	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
Republic	O
of	O
China	O
.	O
The	O
clinical	O
and	O
biological	O
characteristics	O
of	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
in	O
acute	O
leukemic	O
transformation	O
were	O
studied	O
in	O
23	O
patients	O
.	O
All	O
had	O
myeloid	O
transformation	O
according	O
to	O
FAB	O
criteria	O
,	O
but	O
coexpression	O
of	O
lymphoid	O
-	O
associated	O
antigens	O
was	O
detected	O
in	O
five	O
of	O
the	O
20	O
patients	O
who	O
underwent	O
an	O
immunophenotypic	O
study	O
.	O
Rearrangement	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
was	O
also	O
observed	O
in	O
one	O
of	O
the	O
five	O
patients	O
who	O
coexpressed	O
lymphoid	O
markers	O
and	O
that	O
of	O
the	O
T-cell	O
receptor	O
beta	O
chain	O
gene	O
in	O
another	O
one	O
.	O
None	O
had	O
pure	O
lymphoid	O
transformation	O
.	O
Clonal	O
chromosomal	O
abnormalities	O
were	O
noted	O
in	O
12	O
(	O
63	O
%	O
)	O
of	O
the	O
19	O
patients	O
who	O
underwent	O
cytogenetic	O
study	O
,	O
most	O
commonly	O
-	O
7	O
(	O
six	O
patients	O
or	O
32	O
%	O
)	O
.	O
In	O
the	O
18	O
patients	O
who	O
underwent	O
serial	O
analyses	O
both	O
at	O
MDS	B-malignancy-type
diagnosis	O
and	O
at	O
acute	O
transformation	O
,	O
seven	O
(	O
39	O
%	O
)	O
underwent	O
karyotypic	O
evolution	O
.	O
The	O
most	O
common	O
new	O
or	O
additional	O
aberrations	O
were	O
+	O
8	O
and	O
+	O
21	O
.	O
N-ras	O
gene	O
mutation	O
was	O
detected	O
in	O
two	O
of	O
the	O
nine	O
patients	O
at	O
acute	O
leukemic	O
transformation	O
.	O
The	O
median	O
interval	O
from	O
diagnosis	O
of	O
MDS	B-malignancy-type
to	O
onset	O
of	O
acute	O
transformation	O
was	O
10	O
months	O
(	O
1	O
-	O
36	O
months	O
)	O
.	O
Patients	O
with	O
a	O
normal	O
karyotype	O
at	O
diagnosis	O
had	O
a	O
significantly	O
longer	O
chronic	O
phase	O
duration	O
than	O
those	O
with	O
chromosomal	O
abnormalities	O
(	O
median	O
of	O
20	O
months	O
vs.	O
5	O
months	O
)	O
.	O
However	O
,	O
all	O
had	O
a	O
short	O
survival	O
time	O
after	O
diagnosis	O
of	O
acute	B-malignancy-type
leukemia	I-malignancy-type
,	O
whether	O
chromosomal	O
anomalies	O
were	O
present	O
or	O
not	O
.	O
PMID	O
:	O
7564469	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Recent	O
Results	O
Cancer	O
Res	O
1995	O
;	O
139	O
:	O
57	O
-	O
67	O
Analysis	O
of	O
N-ras	O
mutations	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
:	O
tumor	O
heterogeneity	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
analysis	O
.	O
van	O
Elsas	O
A	O
,	O
Zerp	O
S	O
,	O
van	O
der	O
Flier	O
S	O
,	O
Kruse-Wolters	O
M	O
,	O
Vacca	O
A	O
,	O
Ruiter	O
DJ	O
,	O
Schrier	O
P	O
.	O
Department	O
of	O
Clinical	O
Oncology	O
,	O
University	O
Hospital	O
,	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Determination	O
of	O
the	O
activation	O
state	O
of	O
oncogenes	O
as	O
well	O
as	O
tumor	O
suppressor	O
genes	O
is	O
a	O
main	O
subject	O
of	O
interest	O
in	O
the	O
analysis	O
of	O
the	O
mechanism	O
of	O
tumor	O
initiation	O
.	O
In	O
human	O
melanoma	B-malignancy-type
,	O
the	O
c-myc	O
and	O
N-ras	O
oncogenes	O
have	O
been	O
found	O
to	O
be	O
activated	O
in	O
approximately	O
50	O
%	O
and	O
15	O
%	O
of	O
the	O
analyzed	O
material	O
,	O
respectively	O
.	O
These	O
studies	O
have	O
mostly	O
been	O
done	O
on	O
fresh	O
tumor	O
material	O
or	O
cell	O
lines	O
.	O
Only	O
in	O
a	O
few	O
cases	O
has	O
an	O
attempt	O
been	O
made	O
to	O
look	O
at	O
tumor	O
heterogeneity	O
or	O
clonality	O
with	O
respect	O
to	O
the	O
activation	O
of	O
oncogenes	O
.	O
We	O
have	O
adjusted	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
technique	O
to	O
screen	O
paraffin	O
-	O
embedded	O
melanoma	B-malignancy-type
material	O
for	O
the	O
presence	O
of	O
N-ras	O
mutations	O
and	O
found	O
genetic	O
defects	O
at	O
particular	O
progression	O
stages	O
.	O
In	O
one	O
melanoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
skin	I-malignancy-type
,	O
we	O
were	O
able	O
to	O
sublocalize	O
an	O
N-ras	O
mutation	O
in	O
the	O
intraepidermal	B-malignancy-type
tumor	I-malignancy-type
part	O
,	O
that	O
was	O
absent	O
in	O
the	O
part	O
deeply	O
invading	O
the	O
dermal	O
layer	O
.	O
We	O
conclude	O
that	O
a	O
thorough	O
investigation	O
of	O
N-ras	O
activation	O
in	O
human	O
melanoma	B-malignancy-type
should	O
include	O
analysis	O
of	O
histologically	O
different	O
parts	O
of	O
the	O
tumor	O
.	O
PMID	O
:	O
7597312	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1995	O
Apr;80	O
(	O
4	O
)	O
:	O
134	O
7-51	O
Genetic	O
alterations	O
in	O
thyroid	B-malignancy-type
hyperfunctioning	I-malignancy-type
adenomas	I-malignancy-type
.	O
Russo	O
D	O
,	O
Arturi	O
F	O
,	O
Wicker	O
R	O
,	O
Chazenbalk	O
GD	O
,	O
Schlumberger	O
M,	O
DuVillard	O
JA	O
,	O
Caillou	O
B	O
,	O
Monier	O
R	O
,	O
Rapoport	O
B	O
,	O
Filetti	O
S	O
,	O
et	O
al	O
.	O
Dipartimento	O
di	O
Medicina	O
Sperimentale	O
e	O
Clinica	O
,	O
Facolta	O
di	O
Farmacia	O
,	O
Universita	O
di	O
Reggio	O
Calabria	O
,	O
Catanzaro	O
,	O
Italy	O
.	O
Thirty-seven	O
thyroid	B-malignancy-type
autonomously	I-malignancy-type
hyperfunctioning	I-malignancy-type
adenomas	I-malignancy-type
were	O
screened	O
for	O
mutations	O
in	O
the	O
TSH	O
receptor	O
(	O
TSHR	O
)	O
,	O
G	O
alpha	O
s	O
(	O
gsp	O
)	O
,	O
and	O
ras	O
genes	O
.	O
Polymerase	O
chain	O
reaction	O
-	O
amplified	O
fragments	O
of	O
the	O
TSHR	O
C	O
-	O
terminal	O
part	O
(	O
exon	O
10	O
)	O
,	O
the	O
G	O
alpha	O
s	O
(	O
exons	O
8	O
and	O
9	O
)	O
,	O
and	O
the	O
three	O
ras	O
genes	O
were	O
obtained	O
from	O
the	O
genomic	O
DNA	O
extracted	O
from	O
37	O
tumors	O
and	O
their	O
adjacent	O
normal	O
tissues	O
and	O
were	O
studied	O
by	O
direct	O
nucleotide	O
sequencing	O
and	O
hybridization	O
with	O
synthetic	O
probes	O
.	O
A	O
point	O
mutation	O
in	O
the	O
third	O
intracellular	O
loop	O
(	O
codon	O
623	O
)	O
of	O
the	O
TSHR	O
was	O
found	O
in	O
3	O
of	O
37	O
adenomas	B-malignancy-type
studied	O
.	O
This	O
mutation	O
codes	O
for	O
a	O
change	O
(	O
Ala	O
to	O
Ser	O
)	O
in	O
the	O
TSHR	O
structure	O
and	O
is	O
somatic	O
and	O
heterozygotic	O
.	O
Constitutive	O
activation	O
of	O
the	O
TSHR	O
was	O
demonstrated	O
by	O
an	O
increase	O
in	O
basal	O
cAMP	O
levels	O
after	O
transfection	O
of	O
Chinese	O
hamster	O
ovary	O
cells	O
with	O
a	O
mutated	O
Ser	O
623	O
-	O
TSHR	O
complementary	O
DNA	O
.	O
Nine	O
gsp	O
[00ae]	O
MDRV	O
[00af]	O
-	O
and	O
one	O
ras	O
-	O
activating	O
mutations	O
were	O
also	O
detected	O
.	O
No	O
simultaneous	O
alteration	O
of	O
the	O
studied	O
genes	O
was	O
present	O
.	O
Thus	O
,	O
in	O
hyperfunctioning	B-malignancy-type
thyroid	I-malignancy-type
adenomas	I-malignancy-type
,	O
our	O
data	O
suggest	O
that	O
a	O
mutational	O
activation	O
of	O
the	O
TSHR	O
and	O
gsp	O
genes	O
may	O
play	O
a	O
tumorigenic	O
role	O
through	O
constitutive	O
activation	O
of	O
the	O
cAMP	O
pathway	O
.	O
PMID	O
:	O
7714109	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

World	O
J	O
Surg	O
1994	O
Jul	O
-	O
Aug	O
;	O
18	O
(	O
4	O
)	O
:	O
455	O
-	O
60	O
;	O
discussion	O
460	O
-	O
1	O
Point	O
mutations	O
of	O
ras	O
genes	O
in	O
human	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
tumors	I-malignancy-type
:	O
absence	O
in	O
adrenocortical	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
Yashiro	O
T	O
,	O
Hara	O
H	O
,	O
Fulton	O
NC	O
,	O
Obara	O
T	O
,	O
Kaplan	O
EL	O
.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Chicago	O
Pritzker	O
School	O
of	O
Medicine	O
,	O
Illinois	O
60637	O
,	O
USA	O
.	O
Point	O
mutations	O
of	O
ras	O
genes	O
(	O
K-	O
,	O
H-	O
,	O
and	O
N-ras	O
)	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
and	O
of	O
the	O
Gi2	O
alpha	O
gene	O
at	O
codons	O
179	O
and	O
205	O
,	O
were	O
studied	O
in	O
56	O
primary	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
tumors	I-malignancy-type
and	O
6	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
hyperplasias	I-malignancy-type
.	O
Of	O
56	O
tumors	O
,	O
24	O
were	O
carcinomas	B-malignancy-type
and	O
32	O
were	O
benign	O
.	O
The	O
24	O
carcinomas	B-malignancy-type
and	O
20	O
of	O
the	O
benign	O
tumors	O
were	O
from	O
American	O
patients	O
;	O
the	O
12	O
remaining	O
adenomas	B-malignancy-type
were	O
from	O
Japanese	O
patients	O
.	O
Of	O
the	O
benign	O
tumors	O
12	O
were	O
cortisol	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
adenomas	I-malignancy-type
,	O
15	O
were	O
aldosterone	B-malignancy-type
-	I-malignancy-type
producing	I-malignancy-type
adenomas	I-malignancy-type
,	O
3	O
were	O
nonfunctioning	B-malignancy-type
adenomas	I-malignancy-type
,	O
and	O
2	O
were	O
adenomas	B-malignancy-type
that	I-malignancy-type
produced	I-malignancy-type
a	I-malignancy-type
virilizing	I-malignancy-type
syndrome	I-malignancy-type
.	O
Tumor	O
DNA	O
obtained	O
from	O
archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
or	O
fresh	O
frozen	O
tissue	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
;	O
and	O
point	O
mutations	O
were	O
detected	O
by	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Activating	O
ras	O
mutations	O
were	O
found	O
in	O
7	O
of	O
56	O
(	O
12.5	O
%	O
)	O
of	O
all	O
tumors	O
:	O
3	O
of	O
24	O
(	O
12.5	O
%	O
)	O
carcinomas	O
and	O
4	O
of	O
32	O
(	O
12.5	O
%	O
)	O
adenomas	B-malignancy-type
.	O
Of	O
adenomas	B-malignancy-type
from	O
an	O
American	O
population	O
,	O
4	O
of	O
20	O
(	O
20	O
%	O
)	O
exhibited	O
positive	O
ras	O
mutations	O
,	O
whereas	O
none	O
was	O
present	O
in	O
the	O
Japanese	O
tumors	O
.	O
All	O
mutations	O
detected	O
were	O
adenine	O
to	O
guanine	O
transitions	O
at	O
the	O
second	O
position	O
of	O
N-ras	O
codon	O
61	O
,	O
resulting	O
in	O
a	O
conversion	O
from	O
glutamine	O
to	O
arginine	O
.	O
No	O
mutations	O
were	O
found	O
in	O
K-ras	O
or	O
H-ras	O
genes	O
.	O
Furthermore	O
,	O
no	O
mutations	O
of	O
the	O
Gi2	O
alpha	O
gene	O
were	O
identified	O
.	O
These	O
findings	O
demonstrate	O
that	O
N-ras	O
mutations	O
at	O
codon	O
61	O
may	O
contribute	O
to	O
the	O
genesis	O
of	O
both	O
benign	O
and	O
malignant	O
human	O
adrenal	B-malignancy-type
cortical	I-malignancy-type
tumors	I-malignancy-type
.	O
Finally	O
,	O
no	O
mutations	O
of	O
the	O
ras	O
or	O
Gi2	O
alpha	O
genes	O
were	O
identified	O
in	O
hyperplastic	B-malignancy-type
adrenocortical	I-malignancy-type
tissues	I-malignancy-type
.	O
PMID	O
:	O
7725728	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Haematol	O
1994	O
Nov	O
;	O
88	O
(	O
3	O
)	O
:	O
575	O
-	O
81	O
Karyotypic	O
and	O
ras	O
gene	O
mutational	O
analysis	O
in	O
idiopathic	B-malignancy-type
myelofibrosis	I-malignancy-type
.	O
Reilly	O
JT	O
,	O
Wilson	O
G	O
,	O
Barnett	O
D	O
,	O
Watmore	O
A	O
,	O
Potter	O
A	O
.	O
Department	O
of	O
Haematology	O
,	O
Northern	O
General	O
Hospital	O
,	O
Sheffield	O
.	O
Karyotypic	O
analysis	O
was	O
performed	O
in	O
a	O
total	O
of	O
69	O
patients	O
with	O
well	O
-	O
characterized	O
idiopathic	B-malignancy-type
myelofibrosis	I-malignancy-type
.	O
Karyotypic	O
abnormalities	O
were	O
detected	O
in	O
46	O
%	O
of	O
cases	O
examined	O
during	O
the	O
chronic	O
phase	O
(	O
29	O
/	O
63	O
)	O
;	O
with	O
three	O
abnormalities	O
,	O
del	O
(	O
13q	O
)	O
,	O
del	O
(	O
20q	O
)	O
and	O
partial	O
trisomy	O
1q	O
,	O
accounting	O
for	O
75	O
%	O
of	O
all	O
abnormalities	O
at	O
diagnosis	O
.	O
The	O
absence	O
of	O
del	O
(	O
5q	O
)	O
,	O
trisomy	O
8	O
and	O
21	O
,	O
as	O
well	O
as	O
the	O
rarity	O
of	O
monosomy	O
7	O
,	O
contrasts	O
with	O
pooled	O
published	O
data	O
and	O
may	O
reflect	O
our	O
exclusion	O
of	O
closely	O
related	O
disorders	O
,	O
in	O
particular	O
MDS	B-malignancy-type
with	I-malignancy-type
fibrosis	I-malignancy-type
.	O
Chromosomal	O
aberrations	O
increased	O
to	O
approximately	O
90	O
%	O
(	O
8	O
/	O
9	O
)	O
in	O
patients	O
analysed	O
during	O
acute	O
transformation	O
.	O
Mutational	O
activation	O
of	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N	O
-	O
,	O
Ha	O
-	O
and	O
Ki-ras	O
genes	O
were	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
and	O
hybridization	O
with	O
synthetic	O
non	O
-	O
radioactive	O
digoxigenin	O
-	O
labelled	O
probes	O
.	O
Three	O
mutations	O
were	O
detected	O
in	O
samples	O
of	O
peripheral	O
blood	O
DNA	O
taken	O
from	O
50	O
patients	O
during	O
the	O
chronic	O
phase	O
of	O
their	O
disease	O
:	O
one	O
N	O
12	O
Asp	O
(	O
GGT	O
-->	O
GAT	O
)	O
and	O
two	O
N	O
12	O
Ser	O
(	O
GGT	O
-->	O
AGT	O
)	O
mutations	O
.	O
The	O
results	O
from	O
this	O
study	O
indicate	O
that	O
karyotypic	O
abnormalities	O
are	O
present	O
in	O
at	O
least	O
29	O
%	O
of	O
cases	O
at	O
diagnosis	O
and	O
that	O
del	O
(	O
13q	O
)	O
,	O
del	O
(	O
20q	O
)	O
and	O
partial	O
trisomy	O
1q	O
are	O
the	O
most	O
frequent	O
findings	O
.	O
Ras	O
mutations	O
were	O
relatively	O
infrequent	O
(	O
6	O
%	O
)	O
and	O
appeared	O
restricted	O
to	O
the	O
N-ras	O
gene	O
.	O
Karyotypic	O
analysis	O
at	O
diagnosis	O
was	O
found	O
to	O
be	O
of	O
prognostic	O
significance	O
.	O
PMID	O
:	O
7819070	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Acta	O
Haematol	O
1994	O
;	O
92	O
(	O
3	O
)	O
:	O
123	O
-	O
5	O
High	O
incidence	O
of	O
conservative	O
RAS	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Aurer	O
I	O
,	O
Labar	O
B	O
,	O
Nemet	O
D	O
,	O
Ajdukovic	O
R	O
,	O
Bogdanic	O
V	O
,	O
Gale	O
RP	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Medical	O
School	O
and	O
University	O
Hospital	O
Rebro	O
,	O
Zagreb	O
,	O
Croatia	O
.	O
RAS	O
mutations	O
are	O
found	O
in	O
about	O
25	O
%	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
cases	O
.	O
The	O
importance	O
of	O
these	O
changes	O
is	O
unknown	O
.	O
If	O
RAS	O
mutations	O
confer	O
growth	O
advantage	O
to	O
leukemia	B-malignancy-type
subclones	O
in	O
which	O
they	O
emerge	O
,	O
substantially	O
more	O
nonconservative	O
than	O
conservative	O
mutations	O
should	O
be	O
found	O
.	O
The	O
incidence	O
of	O
conservative	O
mutations	O
was	O
not	O
reported	O
previously	O
.	O
We	O
sequenced	O
N-RAS	O
and	O
K-RAS	O
codons	O
12	O
and	O
13	O
and	O
N-RAS	O
codon	O
61	O
in	O
20	O
subjects	O
with	O
newly	O
diagnosed	O
AML	B-malignancy-type
.	O
Four	O
nonconservative	O
N-RAS	O
mutations	O
and	O
4	O
conservative	O
K-RAS	O
mutations	O
were	O
found	O
.	O
There	O
were	O
no	O
differences	O
between	O
subjects	O
with	O
AML	B-malignancy-type
and	O
nonconservative	O
RAS	O
mutations	O
and	O
those	O
with	O
conservative	O
or	O
without	O
RAS	O
mutations	O
.	O
Additional	O
studies	O
are	O
needed	O
to	O
examine	O
the	O
incidence	O
of	O
conservative	O
RAS	O
mutations	O
in	O
subjects	O
with	O
AML	B-malignancy-type
.	O
PMID	O
:	O
7871950	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1995	O
Mar	O
;	O
9	O
(	O
3	O
)	O
:	O
466	O
-	O
70	O
Comment	O
in	O
:	O
Leukemia	O
.	O
1995	O
Oct	O
;	O
9	O
(	O
10	O
)	O
:	O
1790	O
-	O
1	O
.	O
RAS	O
and	O
FMS	O
mutations	O
following	O
cytotoxic	O
therapy	O
for	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukaemia	I-malignancy-type
.	O
Taylor	O
C	O
,	O
McGlynn	O
H	O
,	O
Carter	O
G	O
,	O
Baker	O
AH	O
,	O
Warren	O
N	O
,	O
Ridge	O
SA	O
,	O
Owen	O
G	O
,	O
Thompson	O
E	O
,	O
Thompson	O
PW	O
,	O
Jacobs	O
A	O
,	O
et	O
al	O
.	O
Haematology	O
Department	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Health	O
Park	O
,	O
Cardiff	O
,	O
UK	O
.	O
Patients	O
who	O
have	O
received	O
cytotoxic	O
therapy	O
for	O
primary	O
neoplastic	B-malignancy-type
disease	I-malignancy-type
are	O
at	O
an	O
increased	O
risk	O
of	O
developing	O
secondary	O
(	O
therapy	O
-	O
related	O
)	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
or	O
myelodysplasia	B-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
RAS	O
and	O
FMS	O
mutations	O
have	O
been	O
observed	O
in	O
patients	O
with	O
AML	B-malignancy-type
and	O
MDS	B-malignancy-type
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
mutational	O
status	O
within	O
these	O
genes	O
may	O
be	O
predictive	O
of	O
early	O
secondary	O
leukaemic	B-malignancy-type
disease	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
have	O
screened	O
50	O
haematologically	O
normal	O
patients	O
in	O
complete	O
remission	O
from	O
childhood	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukaemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
for	O
activating	O
point	O
mutations	O
in	O
the	O
RAS	O
and	O
FMS	O
proto	O
-	O
oncogenes	O
.	O
Such	O
patients	O
may	O
be	O
considered	O
at	O
risk	O
of	O
therapy	O
-	O
related	O
disease	O
.	O
Codons	O
12	O
,	O
13	O
and	O
61	O
were	O
screened	O
in	O
RAS	O
and	O
codon	O
969	O
in	O
FMS	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
followed	O
by	O
oligonucleotide	O
hybridization	O
(	O
ONH	O
)	O
.	O
Three	O
of	O
the	O
50	O
patients	O
(	O
6	O
%	O
)	O
were	O
found	O
to	O
harbour	O
N12	O
RAS	O
mutations	O
.	O
One	O
of	O
these	O
three	O
patients	O
(	O
2	O
%	O
)	O
had	O
both	O
a	O
N12	O
RAS	O
and	O
FMS	O
969	O
mutation	O
.	O
Upon	O
sequencing	O
the	O
RAS	O
mutations	O
,	O
substitutions	O
of	O
serine	O
,	O
cysteine	O
and	O
aspartic	O
acid	O
for	O
glycine	O
were	O
identified	O
.	O
The	O
FMS	O
969	O
mutation	O
was	O
also	O
confirmed	O
,	O
by	O
sequencing	O
,	O
as	O
a	O
histidine	O
substitution	O
.	O
RAS	O
mutations	O
were	O
not	O
detected	O
in	O
presentation	O
samples	O
indicating	O
that	O
these	O
lesions	O
have	O
been	O
somatically	O
acquired	O
presumably	O
subsequent	O
to	O
cytotoxic	O
therapy	O
for	O
the	O
primary	O
disease	O
.	O
Continued	O
follow-up	O
of	O
these	O
patients	O
may	O
indicate	O
a	O
role	O
for	O
these	O
mutations	O
in	O
the	O
development	O
of	O
secondary	O
malignancies	O
.	O
PMID	O
:	O
7885045	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Hokkaido	O
Igaku	O
Zasshi	O
1994	O
May;6	O
9	O
(	O
3	O
)	O
:	O
54	O
3-54	O
[	O
Molecular	O
study	O
on	O
minute	O
alterations	O
of	O
the	O
p53	O
and	O
the	O
N-ras	O
genes	O
in	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
]	O
[Article	O
in	O
Japanese	O
]	O
Kurosawa	O
M.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Hokkaido	O
University	O
School	O
of	O
Medicine	O
,	O
Sapporo	O
,	O
Japan	O
.	O
Minute	O
alterations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
N-ras	O
oncogene	O
were	O
investigated	O
in	O
106	O
samples	O
for	O
the	O
p53	O
gene	O
and	O
23	O
samples	O
for	O
the	O
N-ras	O
gene	O
obtained	O
from	O
patients	O
with	O
various	O
types	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
and	O
direct	O
nucleotide	O
sequencing	O
.	O
Mobility	O
shifts	O
suggesting	O
sequence	O
alteration	O
were	O
observed	O
in	O
9	O
cases	O
(	O
8.5	O
%	O
)	O
in	O
exons	O
5	O
through	O
8	O
containing	O
evolutionarily	O
highly	O
conserved	O
regions	O
of	O
the	O
p53	O
gene	O
by	O
PCR-SSCP	O
;	O
missense	O
point	O
mutations	O
in	O
3	O
cases	O
(	O
1	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
1	O
chronic	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
in	O
the	O
accelerated	O
phase	O
,	O
and	O
1	O
CML	B-malignancy-type
in	O
the	O
blast	O
crisis	O
)	O
,	O
silent	O
point	O
mutation	O
in	O
1	O
case	O
(	O
malignant	B-malignancy-type
lymphoma	I-malignancy-type
)	O
,	O
and	O
frame	O
shift	O
mutations	O
due	O
to	O
insertions	O
and	O
deletions	O
causing	O
stop	O
codons	O
in	O
3	O
cases	O
(	O
1	O
AML	B-malignancy-type
,	O
1	O
CML	B-malignancy-type
in	O
the	O
chronic	O
phase	O
and	O
1	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
)	O
.	O
p53	O
gene	O
alterations	O
did	O
not	O
always	O
cluster	O
within	O
evolutionarily	O
highly	O
conserved	O
regions	O
,	O
and	O
there	O
were	O
various	O
base	O
change	O
forms	O
in	O
cases	O
with	O
p53	O
point	O
mutations	O
.	O
p53	O
mutations	O
were	O
detected	O
in	O
2	O
cases	O
out	O
of	O
4	O
cases	O
with	O
17	O
monosomy	O
.	O
There	O
was	O
no	O
case	O
with	O
p53	O
gene	O
alteration	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
cases	O
.	O
Mobility	O
shifts	O
suggesting	O
sequence	O
alteration	O
were	O
observed	O
in	O
5	O
cases	O
(	O
22	O
%	O
)	O
in	O
exon	O
1	O
and	O
2	O
of	O
the	O
N-ras	O
gene	O
by	O
PCR-SSCP	O
.	O
3	O
cases	O
(	O
1	O
MDS	B-malignancy-type
,	O
1	O
MDS	B-malignancy-type
overt	B-malignancy-type
AML	I-malignancy-type
and	O
1	O
ALL	B-malignancy-type
)	O
were	O
detected	O
to	O
contain	O
missense	O
point	O
mutations	O
.	O
However	O
,	O
simultaneous	O
mutations	O
in	O
both	O
the	O
genes	O
were	O
detected	O
in	O
only	O
2	O
cases	O
out	O
of	O
23	O
,	O
thereby	O
indicating	O
infrequent	O
occurrence	O
of	O
concomitant	O
mutation	O
of	O
both	O
the	O
genes	O
in	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
.	O
Alterations	O
of	O
the	O
p53	O
and	O
the	O
N-ras	O
genes	O
are	O
involved	O
in	O
the	O
tumorigenesis	O
,	O
progression	O
and	O
prognosis	O
of	O
at	O
least	O
some	O
cases	O
of	O
hematologic	B-malignancy-type
malignancies	I-malignancy-type
,	O
in	O
spite	O
that	O
they	O
are	O
relatively	O
infrequent	O
.	O
PMID	O
:	O
7927179	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surg	O
Oncol	O
1994	O
Jun;	O
3	O
(	O
3	O
)	O
:	O
15	O
3-9	O
Analysis	O
of	O
multiple	O
molecular	O
changes	O
in	O
human	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
.	O
Arany	O
I	O
,	O
Rady	O
P,	O
Evers	O
BM	O
,	O
Tyring	O
SK	O
,	O
Townsend	O
CM	O
Jr.	O
Department	O
of	O
Microbiology	O
,	O
University	O
of	O
Texas	O
Medical	O
Branch	O
,	O
Galveston	O
77555	O
.	O
To	O
define	O
the	O
molecular	O
changes	O
occurring	O
in	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
,	O
we	O
have	O
analysed	O
three	O
human	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
established	O
in	O
our	O
laboratory	O
:	O
BON	B-malignancy-type
,	O
a	O
functioning	O
carcinoid	B-malignancy-type
tumour	I-malignancy-type
from	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
;	O
SIM	B-malignancy-type
,	O
a	O
nonfunctioning	B-malignancy-type
carcinoid	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ileum	I-malignancy-type
;	O
and	O
STAN	B-malignancy-type
,	O
a	O
pheochromocytoma	B-malignancy-type
.	O
A	O
homozygous	O
point	O
mutation	O
of	O
the	O
N-ras	O
gene	O
was	O
identified	O
at	O
codon	O
61	O
in	O
BON	B-malignancy-type
cells	O
in	O
conjunction	O
with	O
overexpression	O
of	O
N-ras	O
mRNA	O
and	O
protein	O
.	O
BON	B-malignancy-type
cells	O
also	O
exhibited	O
increased	O
expression	O
of	O
c-myc	O
and	O
cdc2	O
kinase	O
mRNA	O
and	O
protein	O
;	O
TGF-beta	O
1	O
,	O
p53	O
and	O
retinoblastoma	O
(	O
RB	O
)	O
mRNA	O
and	O
protein	O
levels	O
were	O
decreased	O
.	O
In	O
addition	O
,	O
increased	O
expression	O
of	O
the	O
mdm2	O
oncogene	O
and	O
both	O
the	O
truncated	O
and	O
the	O
wild-type	O
RB	O
protein	O
were	O
noted	O
in	O
BON	B-malignancy-type
.	O
SIM	B-malignancy-type
cells	O
exhibited	O
moderately	O
increased	O
N-ras	O
and	O
c-myc	O
mRNA	O
levels	O
along	O
with	O
decreased	O
levels	O
of	O
RB	O
mRNA	O
and	O
protein	O
.	O
Similar	O
to	O
BON	B-malignancy-type
and	O
SIM	B-malignancy-type
,	O
analysis	O
of	O
STAN	B-malignancy-type
showed	O
increased	O
N-ras	O
and	O
c-myc	O
levels	O
.	O
Our	O
data	O
show	O
multiple	O
molecular	O
changes	O
in	O
the	O
three	O
human	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
with	O
the	O
BON	B-malignancy-type
cell	O
line	O
exhibiting	O
the	O
most	O
dramatic	O
changes	O
.	O
Furthermore	O
,	O
our	O
data	O
suggest	O
the	O
existence	O
of	O
different	O
molecular	O
pathways	O
in	O
the	O
pathogenesis	O
of	O
endocrine	B-malignancy-type
tumours	I-malignancy-type
.	O
These	O
cell	O
lines	O
will	O
provide	O
unique	O
in	O
vitro	O
models	O
to	O
further	O
analyse	O
the	O
significance	O
of	O
these	O
molecular	O
alterations	O
.	O
PMID	O
:	O
7952399	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Melanoma	O
Res	O
1994	O
Feb;	O
4	O
(	O
1	O
)	O
:	O
1	O
1-9	O
N-RAS	O
mutations	O
and	O
susceptibility	O
to	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
cells	O
in	O
human	O
melanoma	B-malignancy-type
.	O
Lupetti	O
R	O
,	O
Sensi	O
M,	O
Mortarini	O
R	O
,	O
Anichini	O
A	O
,	O
Clemente	O
C,	O
Parmiani	O
G.	O
Division	O
of	O
Experimental	O
Oncology	O
D	O
,	O
Istituto	O
Nazionale	O
Tumori	O
,	O
Milan	O
,	O
Italy	O
.	O
RAS	O
oncogene	O
expression	O
has	O
been	O
reported	O
to	O
affect	O
several	O
biological	O
features	O
of	O
rodent	O
tumours	O
cells	O
,	O
including	O
lysability	O
by	O
activated	O
natural	O
killer	O
cells	O
.	O
In	O
order	O
to	O
examine	O
whether	O
expression	O
of	O
mutated	O
RAS	O
genes	O
in	O
human	O
melanoma	B-malignancy-type
cells	O
alters	O
their	O
susceptibility	O
to	O
lysis	O
by	O
LAK	O
cells	O
,	O
seven	O
melanoma	B-malignancy-type
lines	O
were	O
assessed	O
for	O
the	O
presence	O
of	O
Ki	O
-	O
and	O
N-RAS	O
genes	O
bearing	O
all	O
possible	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
A	O
panel	O
of	O
21	O
clones	O
deriving	O
from	O
the	O
metastatic	B-malignancy-type
lesion	I-malignancy-type
Me665	I-malignancy-type
/	I-malignancy-type
2	I-malignancy-type
,	O
which	O
had	O
a	O
Gln	O
-->	O
Arg	O
substitution	O
at	O
codon	O
61	O
of	O
N-RAS	O
(	O
N-RAS	O
/	O
61	O
+	O
)	O
,	O
were	O
also	O
examined	O
.	O
Melanoma	B-malignancy-type
cells	O
and	O
clones	O
were	O
used	O
as	O
targets	O
of	O
allogeneic	O
LAK	O
in	O
a	O
4	O
-	O
h	O
51Cr	O
-	O
release	O
assay	O
.	O
LAK	O
showed	O
a	O
higher	O
lysis	O
on	O
melanoma	B-malignancy-type
lines	O
and	O
clones	O
harbouring	O
a	O
mutated	O
RAS	O
compared	O
with	O
counterparts	O
bearing	O
no	O
RAS	O
mutations	O
.	O
In	O
addition	O
,	O
LAK	O
-	O
mediated	O
lysis	O
drastically	O
decreased	O
on	O
Me665	O
/	O
2	O
sublines	O
progressively	O
selected	O
by	O
exposure	O
to	O
LAK	O
.	O
This	O
loss	O
was	O
paralleled	O
by	O
a	O
reduction	O
or	O
even	O
disappearance	O
of	O
N-RAS	O
/	O
61	O
+	O
mRNA	O
signal	O
in	O
Me665	O
/	O
2	O
sublines	O
.	O
To	O
evaluate	O
whether	O
N-RAS	O
could	O
directly	O
modulate	O
LAK	O
susceptibility	O
to	O
lysis	O
,	O
N-RAS	O
/	O
61	O
+	O
gene	O
was	O
transfected	O
in	O
two	O
N-RAS	O
wild	O
type	O
(	O
N-RAS	O
/	O
61	O
-	O
)	O
665	O
/	O
2	O
melanoma	B-malignancy-type
clones	O
by	O
a	O
cosmid	O
vector	O
.	O
In	O
contrast	O
to	O
the	O
high	O
lysability	O
of	O
melanoma	B-malignancy-type
cells	O
constitutively	O
expressing	O
the	O
mutationally	O
active	O
N-RAS	O
oncogene	O
,	O
N-RAS	O
/	O
61	O
+	O
transfectants	O
did	O
not	O
show	O
a	O
consistent	O
high	O
lysability	O
by	O
LAK	O
,	O
compared	O
with	O
some	O
control	O
pSV2neo	O
transfectants	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
8032213	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1993	O
Jan	O
1	O
;	O
53	O
(	O
1	O
)	O
:	O
133	O
-	O
9	O
Mutation	O
of	O
H-ras	O
is	O
infrequent	O
in	O
bladder	B-malignancy-type
cancer	I-malignancy-type
:	O
confirmation	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
designed	O
restriction	O
fragment	O
length	O
polymorphisms	O
,	O
and	O
direct	O
sequencing	O
.	O
Knowles	O
MA	O
,	O
Williamson	O
M	O
.	O
Epithelial	O
Carcinogenesis	O
Laboratory	O
,	O
Marie	O
Curie	O
Research	O
Institute	O
,	O
Oxted	O
,	O
Surrey	O
,	O
England	O
.	O
A	O
series	O
of	O
152	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
,	O
14	O
bladder	B-malignancy-type
tumor	I-malignancy-type
cell	O
lines	O
,	O
and	O
1	O
immortal	O
urothelial	O
cell	O
line	O
were	O
examined	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
designed	O
restriction	O
fragment	O
.	O
length	O
polymorphism	O
analyses	O
for	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
H-ras	O
gene	O
.	O
Nine	O
tumors	O
(	O
6	O
%	O
)	O
contained	O
mutations	O
.	O
There	O
was	O
complete	O
concordance	O
between	O
SSCP	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
analyses	O
.	O
Six	O
mutations	O
in	O
exon	O
1	O
and	O
three	O
in	O
exon	O
2	O
were	O
identified	O
by	O
SSCP	O
analysis	O
.	O
Subsequent	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
showed	O
that	O
of	O
the	O
exon	O
1	O
mutations	O
,	O
four	O
were	O
in	O
codon	O
12	O
and	O
two	O
in	O
codon	O
13	O
,	O
and	O
all	O
three	O
exon	O
2	O
mutations	O
were	O
in	O
codon	O
61	O
.	O
Eight	O
mutations	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
.	O
One	O
codon	O
13	O
mutation	O
could	O
not	O
be	O
identified	O
by	O
direct	O
sequencing	O
.	O
Distinct	O
strand	O
mobility	O
shifts	O
detected	O
by	O
SSCP	O
analysis	O
identified	O
specific	O
point	O
mutations	O
,	O
and	O
in	O
all	O
cases	O
,	O
strands	O
containing	O
different	O
mutations	O
migrated	O
differently	O
.	O
The	O
base	O
substitutions	O
identified	O
in	O
these	O
bladder	B-malignancy-type
tumors	I-malignancy-type
were	O
diverse	O
and	O
included	O
four	O
transversions	O
(	O
three	O
G	O
-->	O
T	O
and	O
one	O
A	O
-->	O
T	O
)	O
and	O
four	O
transitions	O
(	O
two	O
G	O
-->	O
A	O
and	O
two	O
A	O
-->	O
G	O
)	O
.	O
This	O
pattern	O
of	O
base	O
substitutions	O
is	O
compatible	O
with	O
interactions	O
of	O
the	O
urothelium	O
with	O
more	O
than	O
one	O
class	O
of	O
environmental	O
agent	O
during	O
bladder	B-malignancy-type
tumor	I-malignancy-type
development	O
.	O
No	O
correlation	O
was	O
found	O
between	O
tumor	O
grade	O
and/or	O
stage	O
and	O
the	O
presence	O
of	O
H-ras	O
mutation	O
.	O
We	O
conclude	O
that	O
H-ras	O
mutation	O
does	O
not	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
the	O
majority	O
of	O
transitional	O
cell	O
tumors	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
.	O
PMID	O
:	O
8093230	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1993	O
Nov	O
;	O
11	O
(	O
5	O
-	O
6	O
)	O
:	O
405	O
-	O
10	O
Frequency	O
of	O
RAS	O
and	O
p53	O
mutations	O
in	O
acute	B-malignancy-type
promyelocytic	I-malignancy-type
leukemias	I-malignancy-type
.	O
Longo	O
L	O
,	O
Trecca	O
D	O
,	O
Biondi	O
A	O
,	O
Lo	O
Coco	O
F	O
,	O
Grignani	O
F	O
,	O
Maiolo	O
AT	O
,	O
Pelicci	O
PG	O
,	O
Neri	O
A	O
.	O
Istituto	O
Clinica	O
Medica	O
I	O
,	O
University	O
of	O
Perugia	O
,	O
Italy	O
.	O
The	O
frequency	O
of	O
RAS	O
and	O
p53	O
mutations	O
was	O
investigated	O
in	O
30	O
acute	B-malignancy-type
promyelocytic	I-malignancy-type
leukemias	I-malignancy-type
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O
Only	O
two	O
cases	O
bore	O
N-RAS	O
codon	O
12	O
mutations	O
and	O
none	O
had	O
p53	O
mutations	O
responsible	O
for	O
aminoacid	O
substitutions	O
.	O
It	O
would	O
,	O
therefore	O
,	O
seem	O
that	O
neither	O
RAS	O
nor	O
p53	O
are	O
involved	O
in	O
acute	O
promyelocytic	O
leukemogenesis	O
.	O
PMID	O
:	O
8124213	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Eur	O
J	O
Cancer	O
B	O
Oral	O
Oncol	O
1993	O
Jan	O
;	O
29B	O
(	O
1	O
)	O
:	O
63	O
-	O
7	O
Ras	O
gene	O
point	O
mutation	O
is	O
a	O
rare	O
event	O
in	O
premalignant	O
tissues	O
and	O
malignant	O
cells	O
and	O
tissues	O
from	O
oral	B-malignancy-type
mucosal	I-malignancy-type
lesions	I-malignancy-type
.	O
Yeudall	O
WA	O
,	O
Torrance	O
LK	O
,	O
Elsegood	O
KA	O
,	O
Speight	O
P	O
,	O
Scully	O
C	O
,	O
Prime	O
SS	O
.	O
Department	O
of	O
Oral	O
Medicine	O
,	O
Pathology	O
and	O
Microbiology	O
,	O
University	O
of	O
Bristol	O
Dental	O
School	O
,	O
U.K.	O
Three	O
series	O
of	O
biopsy	O
specimens	O
of	O
premalignant	O
and	O
malignant	O
oral	B-malignancy-type
lesions	I-malignancy-type
,	O
together	O
with	O
seven	O
human	O
keratinocyte	O
cultures	O
,	O
previously	O
established	O
from	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
analysed	O
for	O
point	O
mutation	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
c-Ha-ras	O
,	O
c-Ki-ras	O
and	O
N-ras	O
genes	O
by	O
direct	O
nucleotide	O
sequencing	O
of	O
DNAs	O
amplified	O
in	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
Only	O
one	O
out	O
of	O
12	O
biopsy	O
samples	O
(	O
8.3	O
%	O
)	O
,	O
a	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
carcinoma	I-malignancy-type
which	O
was	O
the	O
latest	O
in	O
a	O
series	O
of	O
floor	O
of	O
mouth	B-malignancy-type
lesions	I-malignancy-type
from	O
1	O
of	O
the	O
3	O
patients	O
studied	O
,	O
harboured	O
a	O
mutant	O
c-Ha-ras	O
gene	O
,	O
being	O
heterozygous	O
at	O
codon	O
12	O
for	O
a	O
GGA	O
-	O
GTA	O
change	O
.	O
One	O
cell	O
line	O
(	O
H357	O
)	O
showed	O
heterozygosity	O
in	O
both	O
exons	O
1	O
and	O
2	O
of	O
c-Ha-ras	O
,	O
harbouring	O
a	O
GGT	O
to	O
AGT	O
mutation	O
over	O
codon	O
13	O
and	O
a	O
CAG	O
to	O
CAA	O
mutation	O
over	O
codon	O
61	O
.	O
The	O
remaining	O
six	O
oral	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
(	O
85.7	O
%	O
)	O
were	O
homozygous	O
normal	O
at	O
both	O
exons	O
1	O
and	O
2	O
of	O
c-Ha-ras	O
.	O
All	O
cell	O
lines	O
showed	O
normal	O
c-Ki-ras	O
and	O
N-ras	O
loci	O
.	O
We	O
conclude	O
that	O
ras	O
gene	O
mutation	O
is	O
an	O
infrequent	O
occurrence	O
in	O
the	O
malignant	O
progression	O
of	O
oral	O
epithelial	O
cells	O
,	O
despite	O
the	O
probable	O
importance	O
of	O
chemical	O
carcinogens	O
in	O
the	O
aetiology	O
of	O
the	O
disease	O
.	O
We	O
emphasise	O
the	O
need	O
to	O
search	O
for	O
other	O
cellular	O
sequences	O
which	O
may	O
be	O
targets	O
for	O
chemical	O
or	O
viral	O
carcinogens	O
.	O
PMID	O
:	O
8180579	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Haematol	O
1994	O
Feb	O
;	O
86	O
(	O
2	O
)	O
:	O
298	O
-	O
302	O
Persistence	O
of	O
an	O
activating	O
N-RAS	O
oncogene	O
mutation	O
in	O
clonogenic	O
progenitor	O
cells	O
from	O
an	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
patient	O
in	O
remission	O
.	O
Zaheer	O
HA	O
,	O
Bagnara	O
M	O
,	O
Gibson	O
FM	O
,	O
Robinson	O
G	O
,	O
Rutherford	O
TR	O
,	O
Gordon-Smith	O
EC	O
.	O
Department	O
of	O
Cellular	O
and	O
Molecular	O
Sciences	O
,	O
St	O
George	O
's	O
Hospital	O
Medical	O
School	O
,	O
London	O
.	O
A	O
patient	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
with	O
an	O
activating	O
N-RAS	O
oncogene	O
mutation	O
was	O
studied	O
in	O
a	O
haemopoietic	O
clonogenic	O
progenitor	O
cell	O
assay	O
.	O
Individual	O
colonies	O
and	O
clusters	O
were	O
analysed	O
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
for	O
the	O
original	O
mutation	O
.	O
The	O
mutation	O
was	O
detected	O
in	O
a	O
majority	O
of	O
leukaemic	O
clusters	O
,	O
but	O
also	O
in	O
almost	O
half	O
of	O
the	O
differentiated	O
colonies	O
.	O
After	O
chemotherapy	O
the	O
patient	O
entered	O
clinical	O
remission	O
.	O
However	O
,	O
the	O
mutation	O
could	O
still	O
be	O
detected	O
in	O
the	O
bone	O
marrow	O
.	O
Only	O
differentiated	O
colonies	O
and	O
no	O
leukaemic	O
clusters	O
were	O
grown	O
from	O
the	O
remission	O
bone	O
marrow	O
,	O
but	O
the	O
original	O
mutation	O
was	O
still	O
detectable	O
in	O
almost	O
half	O
of	O
the	O
colonies	O
.	O
PMID	O
:	O
8199018	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
1993	O
Dec	O
2	O
;	O
55	O
(	O
6	O
)	O
:	O
915	O
-	O
20	O
Low	O
incidence	O
of	O
c-Ha-ras	O
gene	O
mutations	O
in	O
benign	O
and	O
malignant	O
cutaneous	B-malignancy-type
lesions	I-malignancy-type
from	O
transplant	O
recipients	O
.	O
Pelisson	O
I	O
,	O
Chardonnet	O
Y	O
,	O
Euvrard	O
S	O
,	O
Schmitt	O
D	O
.	O
INSERM	O
U	O
346	O
affiliee	O
CNRS	O
,	O
Hopital	O
Edouard	O
Herriot	O
,	O
Lyon	O
,	O
France	O
.	O
Transplant	O
recipients	O
successively	O
develop	O
benign	O
,	O
premalignant	O
and	O
malignant	O
skin	B-malignancy-type
lesions	I-malignancy-type
on	I-malignancy-type
sun	I-malignancy-type
-	I-malignancy-type
exposed	I-malignancy-type
areas	I-malignancy-type
.	O
It	O
has	O
been	O
suggested	O
that	O
UV	O
radiations	O
might	O
induce	O
mutations	O
in	O
ras	O
oncogenes	O
and	O
p53	O
tumour	O
-	O
suppressor	O
gene	O
,	O
responsible	O
for	O
skin	B-malignancy-type
cancers	I-malignancy-type
.	O
With	O
PCR	O
and	O
oligoprobe	O
hybridization	O
,	O
we	O
investigated	O
c-Ha-ras	O
gene	O
mutations	O
at	O
codons	O
12	O
and	O
61	O
in	O
120	O
cutaneous	B-malignancy-type
lesions	I-malignancy-type
from	O
grafted	O
patients	O
,	O
since	O
they	O
could	O
represent	O
a	O
marker	O
of	O
the	O
evolution	O
of	O
benign	O
skin	B-malignancy-type
lesions	I-malignancy-type
towards	O
malignancy	O
in	O
this	O
population	O
;	O
29	O
similar	O
skin	O
biopsies	O
from	O
non	O
-	O
immunosuppressed	O
patients	O
were	O
also	O
analyzed	O
.	O
In	O
transplant	O
recipients	O
,	O
we	O
detected	O
mutations	O
at	O
codon	O
12	O
only	O
in	O
1	O
/	O
42	O
non	B-malignancy-type
-	I-malignancy-type
melanoma	I-malignancy-type
skin	I-malignancy-type
cancers	I-malignancy-type
and	O
2	O
/	O
29	O
pre	B-malignancy-type
-	I-malignancy-type
cancerous	I-malignancy-type
keratoses	I-malignancy-type
.	O
No	O
mutation	O
was	O
detected	O
in	O
11	O
cases	O
of	O
cutaneous	O
Bowen	O
's	O
disease	O
from	O
grafted	O
patients	O
and	O
in	O
pre	O
-	O
malignant	O
and	O
malignant	O
skin	O
samples	O
from	O
control	O
patients	O
.	O
Benign	O
warts	O
exhibited	O
an	O
overall	O
incidence	O
of	O
18	O
%	O
and	O
15	O
%	O
of	O
mutations	O
at	O
codon	O
12	O
of	O
c-Ha-ras	O
gene	O
in	O
grafted	O
and	O
control	O
patients	O
respectively	O
.	O
We	O
detected	O
only	O
one	O
mutation	O
at	O
codon	O
61	O
in	O
a	O
plantar	O
wart	O
.	O
Human	O
papillomaviruses	O
(	O
HPV	O
)	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
malignant	O
evolution	O
of	O
cutaneous	O
disorders	O
in	O
transplant	O
recipients	O
and	O
cooperate	O
with	O
a	O
ras	O
oncogene	O
to	O
induce	O
malignancy	O
in	O
vitro	O
.	O
The	O
presence	O
of	O
HPV	O
DNA	O
in	O
our	O
series	O
of	O
skin	O
samples	O
from	O
grafted	O
patients	O
showed	O
no	O
correlation	O
with	O
the	O
occurrence	O
of	O
c-Ha-ras	O
mutations	O
.	O
Our	O
findings	O
indicate	O
that	O
c-Ha-ras	O
-	O
gene	O
activation	O
by	O
mutations	O
is	O
rare	O
in	O
cutaneous	B-malignancy-type
lesions	I-malignancy-type
from	O
transplant	O
recipients	O
,	O
and	O
is	O
unlikely	O
to	O
play	O
a	O
crucial	O
role	O
in	O
transformation	O
towards	O
malignancy	O
in	O
skin	O
carcinogenesis	O
among	O
grafted	O
patients	O
.	O
PMID	O
:	O
8253528	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
1994	O
;	O
120	O
(	O
3	O
)	O
:	O
143	O
-	O
8	O
Gene	O
analysis	O
of	O
K	O
-	O
,	O
H-ras	O
,	O
p53	O
,	O
and	O
retinoblastoma	O
susceptibility	O
genes	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
by	O
the	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
.	O
Kashii	O
T	O
,	O
Mizushima	O
Y	O
,	O
Monno	O
S	O
,	O
Nakagawa	O
K	O
,	O
Kobayashi	O
M	O
.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Toyama	O
Medical	O
and	O
Pharmaceutical	O
University	O
,	O
Japan	O
.	O
In	O
order	O
to	O
know	O
the	O
involvement	O
of	O
multiple	O
gene	O
alterations	O
in	O
the	O
pathogenesis	O
of	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
examined	O
the	O
genes	O
of	O
K	O
-	O
,	O
H-ras	O
(	O
codons	O
12	O
,	O
13	O
,	O
61	O
)	O
,	O
p53	O
(	O
exons	O
5	O
-	O
9	O
)	O
and	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
(	O
RB	O
)	O
(	O
exons	O
20	O
-	O
22	O
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
in	O
32	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
(	O
5	O
squamous	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
10	O
adenocarcinomas	B-malignancy-type
,	O
3	O
large	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
14	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
)	O
.	O
In	O
18	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
lines	O
,	O
gene	O
alterations	O
were	O
found	O
in	O
4	O
for	O
K-ras	O
(	O
22	O
%	O
)	O
,	O
none	O
for	O
H-ras	O
(	O
0	O
%	O
)	O
,	O
4	O
for	O
p53	O
(	O
22	O
%	O
)	O
and	O
none	O
for	O
the	O
RB	O
(	O
0	O
%	O
)	O
gene	O
.	O
In	O
14	O
small	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
SCLC	B-malignancy-type
)	O
lines	O
,	O
no	O
gene	O
alterations	O
were	O
found	O
in	O
K-ras	O
(	O
0	O
%	O
)	O
,	O
or	O
H-ras	O
(	O
0	O
%	O
)	O
,	O
but	O
6	O
were	O
found	O
for	O
p53	O
(	O
43	O
%	O
)	O
and	O
3	O
for	O
the	O
RB	O
(	O
21	O
%	O
)	O
gene	O
.	O
Coincident	O
abnormalities	O
of	O
K-ras	O
and	O
p53	O
,	O
or	O
K-ras	O
and	O
RB	O
genes	O
were	O
not	O
found	O
in	O
any	O
cell	O
lines	O
,	O
and	O
those	O
of	O
the	O
p53	O
and	O
RB	O
genes	O
were	O
found	O
in	O
only	O
2	O
SCLC	B-malignancy-type
lines	O
.	O
No	O
association	O
was	O
observed	O
between	O
these	O
three	O
gene	O
alterations	O
and	O
N-myc	O
amplification	O
.	O
Although	O
the	O
above	O
three	O
genes	O
may	O
be	O
involved	O
to	O
some	O
extent	O
in	O
the	O
pathogenesis	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
more	O
factors	O
are	O
required	O
for	O
its	O
development	O
.	O
PMID	O
:	O
8263009	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Carcinog	O
1993	O
;	O
8	O
(	O
4	O
)	O
:	O
312	O
-	O
8	O
Mutations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
the	O
ras	O
gene	O
family	O
in	O
intrahepatic	B-malignancy-type
cholangiocellular	I-malignancy-type
carcinomas	I-malignancy-type
in	O
Japan	O
and	O
Thailand	O
.	O
Kiba	O
T	O
,	O
Tsuda	O
H	O
,	O
Pairojkul	O
C	O
,	O
Inoue	O
S	O
,	O
Sugimura	O
T	O
,	O
Hirohashi	O
S	O
.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
incidence	O
and	O
pattern	O
of	O
mutations	O
of	O
the	O
ras	O
oncogenes	O
and	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
have	O
been	O
shown	O
to	O
differ	O
among	O
different	O
cancer	O
types	O
and	O
even	O
among	O
the	O
same	O
cancer	O
types	O
with	O
different	O
etiological	O
backgrounds	O
.	O
For	O
example	O
,	O
in	O
a	O
previous	O
study	O
we	O
showed	O
that	O
not	O
only	O
the	O
etiology	O
but	O
also	O
the	O
incidence	O
of	O
point	O
mutation	O
of	O
the	O
c-Ki-ras	O
oncogene	O
in	O
cholangiocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
CCCs	B-malignancy-type
)	O
differ	O
between	O
Japanese	O
and	O
Thai	O
patients	O
.	O
In	O
the	O
study	O
presented	O
here	O
,	O
we	O
examined	O
the	O
incidence	O
of	O
mutations	O
in	O
the	O
ras	O
gene	O
family	O
and	O
the	O
p53	O
gene	O
in	O
CCCs	B-malignancy-type
of	O
both	O
Japanese	O
and	O
Thai	O
patients	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
analyses	O
and	O
compared	O
the	O
pattern	O
of	O
p53	O
mutation	O
between	O
these	O
two	O
CCC	B-malignancy-type
groups	O
.	O
Although	O
the	O
incidence	O
of	O
ras	O
mutation	O
differed	O
markedly	O
between	O
Japanese	O
(	O
seven	O
of	O
12	O
,	O
58	O
%	O
)	O
and	O
Thai	O
(	O
two	O
of	O
26	O
,	O
8	O
%	O
)	O
cases	O
,	O
the	O
incidence	O
of	O
p53	O
mutation	O
was	O
similar	O
:	O
four	O
of	O
12	O
(	O
33	O
%	O
)	O
and	O
nine	O
of	O
26	O
(	O
35	O
%	O
)	O
,	O
respectively	O
.	O
Except	O
for	O
one	O
case	O
in	O
which	O
deletion	O
-	O
insertion	O
was	O
detected	O
in	O
the	O
second	O
exon	O
of	O
the	O
N-ras	O
gene	O
,	O
all	O
ras	O
mutations	O
occurred	O
at	O
codon	O
12	O
or	O
13	O
of	O
the	O
c-Ki-ras	O
gene	O
.	O
All	O
p53	O
mutations	O
but	O
one	O
were	O
detected	O
in	O
a	O
highly	O
conserved	O
region	O
,	O
and	O
the	O
predominant	O
form	O
of	O
the	O
mutations	O
was	O
G	O
:	O
C	O
-->	O
A	O
:	O
T	O
transition	O
at	O
CpG	O
sites	O
in	O
both	O
Japanese	O
and	O
Thai	O
cases	O
,	O
similar	O
to	O
that	O
reported	O
for	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
Therefore	O
,	O
in	O
contrast	O
to	O
the	O
ras	O
oncogenes	O
,	O
mutation	O
of	O
the	O
p53	O
gene	O
was	O
frequently	O
involved	O
in	O
the	O
development	O
of	O
CCCs	B-malignancy-type
in	O
both	O
Japanese	O
and	O
Thai	O
patients	O
,	O
irrespective	O
of	O
any	O
difference	O
in	O
etiology	O
.	O
PMID	O
:	O
8280380	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1993	O
Jul	O
;	O
7	O
(	O
7	O
)	O
:	O
946	O
-	O
53	O
Mutations	O
in	O
the	O
P53	O
and	O
RAS	O
family	O
genes	O
are	O
associated	O
with	O
tumor	O
progression	O
of	O
BCR	O
/	O
ABL	O
negative	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
.	O
Gaidano	O
G	O
,	O
Guerrasio	O
A	O
,	O
Serra	O
A	O
,	O
Carozzi	O
F	O
,	O
Cambrin	O
GR	O
,	O
Petroni	O
D	O
,	O
Saglio	O
G	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
&	O
Surgeons	O
of	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
10032	O
.	O
We	O
have	O
investigated	O
the	O
involvement	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
RAS	O
family	O
proto	O
-	O
oncogenes	O
in	O
BCR	O
/	O
ABL	O
-	O
negative	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
(	O
CMPD	O
)	O
,	O
including	O
nine	O
cases	O
of	O
myelosclerosis	O
with	O
myeloid	B-malignancy-type
metaplasia	I-malignancy-type
,	O
four	O
polycythemia	O
vera	O
,	O
10	O
essential	O
thrombocythemia	O
,	O
one	O
juvenile	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
and	O
eight	O
BCR	O
/	O
ABL	O
-	O
negative	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Twenty-five	O
samples	O
were	O
studied	O
in	O
the	O
chronic	O
phase	O
,	O
while	O
seven	O
samples	O
were	O
analyzed	O
in	O
the	O
acute	O
accelerated	O
or	O
blastic	O
phase	O
.	O
The	O
presence	O
of	O
mutations	O
in	O
p53	O
exons	O
5	O
-	O
9	O
,	O
as	O
well	O
as	O
in	O
N	O
-	O
,	O
K	O
-	O
,	O
H	O
-	O
Ras	O
exons	O
1	O
and	O
2	O
(	O
containing	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
was	O
tested	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
single	O
strand	O
conformation	O
polymorphism	O
technique	O
and	O
by	O
PCR	O
direct	O
sequencing	O
.	O
In	O
addition	O
,	O
restriction	O
analysis	O
was	O
performed	O
to	O
screen	O
for	O
gross	O
rearrangements	O
within	O
the	O
p53	O
locus	O
.	O
Alterations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
Ras	O
family	O
proto	O
-	O
oncogenes	O
were	O
detected	O
in	O
2	O
/	O
7	O
and	O
3	O
/	O
7	O
cases	O
of	O
acute	O
phase	O
BCR	O
/	O
ABL	O
-	O
negative	O
CMPD	B-malignancy-type
,	O
respectively	O
,	O
while	O
consistently	O
negative	O
in	O
all	O
the	O
chronic	O
phase	O
samples	O
analyzed	O
.	O
These	O
results	O
suggest	O
that	O
p53	O
inactivation	O
and/or	O
Ras	O
activation	O
might	O
play	O
a	O
role	O
in	O
acute	O
transformation	O
of	O
BCR	O
/	O
ABL	O
-	O
negative	O
CMPD	B-malignancy-type
.	O
PMID	O
:	O
8321046	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
1993	O
Jan	O
2;5	O
3	O
(	O
1	O
)	O
:	O
2	O
2-8	O
ras	O
gene	O
mutations	O
and	O
HPV	O
infection	O
are	O
common	O
in	O
human	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Anwar	O
K,	O
Nakakuki	O
K,	O
Naiki	O
H,	O
Inuzuka	O
M.	O
Department	O
of	O
Pathology	O
,	O
Fukui	O
Medical	O
School	O
,	O
Japan	O
.	O
To	O
evaluate	O
the	O
role	O
of	O
ras	O
activation	O
and	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
infection	O
in	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
analyzed	O
tumor	O
DNA	O
from	O
43	O
cases	O
,	O
including	O
25	O
primary	O
laryngeal	B-malignancy-type
tumors	I-malignancy-type
,	O
12	O
lymph	B-malignancy-type
-	I-malignancy-type
node	I-malignancy-type
and	O
one	O
skin	B-malignancy-type
metastases	I-malignancy-type
,	O
and	O
5	O
recurrent	B-malignancy-type
laryngeal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Thirteen	O
normal	O
laryngeal	O
tissues	O
and	O
7	O
benign	O
laryngeal	O
nodule	O
biopsy	O
specimens	O
along	O
with	O
normal	O
tissue	O
surrounding	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
in	O
2	O
cases	O
were	O
also	O
included	O
.	O
The	O
polymerase	O
-	O
chain	O
-	O
reaction	O
technique	O
was	O
used	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
codon	O
12	O
and	O
61	O
of	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
,	O
also	O
HPV	O
16	O
,	O
18	O
and	O
33	O
DNA	O
,	O
subsequently	O
hybridized	O
with	O
sequence	O
-	O
specific	O
oligonucleotides	O
.	O
DNA	O
samples	O
from	O
22	O
patients	O
with	O
laryngeal	B-malignancy-type
carcinoma	I-malignancy-type
revealed	O
ras	O
mutations	O
(	O
18	O
in	O
N-ras	O
codon	O
12	O
,	O
6	O
in	O
H-ras	O
codon	O
61	O
,	O
and	O
3	O
in	O
K-ras	O
codon	O
61	O
)	O
.	O
Likewise	O
,	O
HPV	O
DNA	O
was	O
found	O
in	O
16	O
cases	O
(	O
HPV	O
16	O
,	O
18	O
and	O
33	O
in	O
3	O
cases	O
,	O
14	O
cases	O
and	O
1	O
case	O
respectively	O
)	O
.	O
ras	O
mutations	O
were	O
significantly	O
higher	O
in	O
metastatic	B-malignancy-type
tumors	I-malignancy-type
(	O
10	O
of	O
13	O
cases	O
)	O
than	O
in	O
primary	O
(	O
11	O
of	O
25	O
cases	O
)	O
and	O
recurrent	B-malignancy-type
laryngeal	I-malignancy-type
carcinomas	I-malignancy-type
(	O
1	O
of	O
5	O
cases	O
)	O
.	O
HPV	O
DNA	O
was	O
detected	O
in	O
60	O
%	O
of	O
recurrent	O
,	O
44	O
%	O
of	O
primary	O
and	O
15	O
%	O
of	O
metastatic	O
tumors	O
.	O
Only	O
2	O
of	O
the	O
13	O
normal	O
laryngeal	O
tissues	O
and	O
1	O
out	O
of	O
7	O
laryngeal	O
nodule	O
specimens	O
were	O
found	O
to	O
contain	O
HPV	O
DNA	O
.	O
These	O
results	O
suggest	O
that	O
ras	O
activation	O
,	O
especially	O
in	O
N-ras	O
codon	O
12.1	O
(	O
GGT	O
-->	O
AGT	O
)	O
and	O
HPV	O
infection	O
are	O
2	O
important	O
factors	O
in	O
(	O
multistage	O
)	O
laryngeal	O
carcinogenesis	O
.	O
The	O
ras	O
mutation	O
may	O
be	O
associated	O
with	O
metastatic	O
ability	O
of	O
the	O
tumor	O
.	O
PMID	O
:	O
8380055	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1993	O
Jan	O
1;8	O
1	O
(	O
1	O
)	O
:	O
16	O
6-76	O
Multiple	O
genetic	O
lesions	O
in	O
acquired	B-malignancy-type
immunodeficiency	I-malignancy-type
syndrome	I-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Ballerini	O
P,	O
Gaidano	O
G,	O
Gong	O
JZ	O
,	O
Tassi	O
V	O
,	O
Saglio	O
G,	O
Knowles	O
DM	O
,	O
Dall	O
a	O
-Favera	O
R.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
&	O
Surgeons	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
10032	O
.	O
Non	B-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
(	O
NHL	B-malignancy-type
)	O
develops	O
in	O
about	O
5	O
%	O
to	O
10	O
%	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
patients	O
.	O
The	O
vast	O
majority	O
of	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
are	O
clinically	O
aggressive	B-malignancy-type
B-cell	I-malignancy-type
NHL	I-malignancy-type
that	O
are	O
histologically	O
classified	O
as	O
small	B-malignancy-type
noncleaved	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
SNCCL	B-malignancy-type
)	O
,	O
large	B-malignancy-type
cell	I-malignancy-type
immunoblastic	I-malignancy-type
plasmacytoid	I-malignancy-type
lymphoma	I-malignancy-type
(	O
LC-IBPL	B-malignancy-type
)	O
,	O
and	O
large	B-malignancy-type
noncleaved	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
LNCCL	B-malignancy-type
)	O
.	O
In	O
an	O
attempt	O
to	O
understand	O
the	O
molecular	O
pathogenesis	O
of	O
these	O
tumors	O
,	O
we	O
have	O
investigated	O
the	O
involvement	O
of	O
dominantly	O
acting	O
oncogenes	O
(	O
c-myc	O
,	O
N	O
-	O
,	O
K	O
-	O
,	O
H	O
-	O
Ras	O
)	O
,	O
tumor	O
suppressor	O
genes	O
(	O
p53	O
,	O
RB1	O
)	O
,	O
and	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
in	O
27	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
samples	O
(	O
16	O
SNCCL	B-malignancy-type
,	O
5	O
LC-IBP	B-malignancy-type
,	O
and	O
6	O
LNCCL	B-malignancy-type
)	O
.	O
The	O
following	O
lesions	O
were	O
detected	O
in	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
:	O
EBV	O
infection	O
(	O
10	O
/	O
24	O
;	O
41.6	O
%	O
)	O
,	O
c-myc	O
rearrangement	O
(	O
19	O
/	O
24	O
;	O
79.1	O
%	O
)	O
,	O
Ras	O
mutation	O
(	O
4	O
/	O
27	O
;	O
14.8	O
%	O
)	O
,	O
and	O
p53	O
loss	O
/	O
mutation	O
(	O
10	O
/	O
27	O
;	O
37.0	O
%	O
)	O
.	O
These	O
lesions	O
are	O
not	O
uniformly	O
distributed	O
,	O
but	O
,	O
rather	O
,	O
cluster	O
with	O
specific	O
types	O
of	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
:	O
EBV	O
infection	O
is	O
preferentially	O
associated	O
with	O
LC-IBPL	B-malignancy-type
(	O
4	O
/	O
4	O
;	O
100	O
%	O
)	O
,	O
while	O
it	O
is	O
present	O
in	O
only	O
a	O
fraction	O
of	O
SNCCL	B-malignancy-type
(	O
5	O
/	O
16	O
;	O
31.2	O
%	O
)	O
and	O
LNCCL	B-malignancy-type
(	O
1	O
/	O
4	O
;	O
25	O
%	O
)	O
;	O
c-myc	O
oncogene	O
activation	O
clusters	O
with	O
SNCCL	B-malignancy-type
(	O
16	O
/	O
16	O
;	O
100	O
%	O
)	O
,	O
whereas	O
it	O
is	O
less	O
frequent	O
in	O
LC-IBPL	B-malignancy-type
(	O
1	O
/	O
4	O
;	O
25	O
%	O
)	O
and	O
LNCCL	B-malignancy-type
(	O
2	O
/	O
4	O
;	O
50	O
%	O
)	O
;	O
p53	O
inactivation	O
is	O
restricted	O
to	O
SNCCL	B-malignancy-type
(	O
10	O
/	O
16	O
;	O
62.5	O
%	O
)	O
and	O
consistently	O
associated	O
with	O
c-myc	O
activation	O
.	O
These	O
data	O
show	O
that	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
are	O
associated	O
with	O
multiple	O
genetic	O
lesions	O
that	O
involve	O
both	O
proto	O
-	O
oncogenes	O
and	O
tumor	O
suppressor	O
genes	O
and	O
may	O
accumulate	O
in	O
the	O
relatively	O
short	O
period	O
of	O
time	O
(	O
4	O
to	O
6	O
years	O
)	O
between	O
human	O
immunodeficiency	O
virus	O
infection	O
and	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
development	O
.	O
These	O
genetic	O
lesions	O
differ	O
in	O
the	O
various	O
AIDS	B-malignancy-type
-	I-malignancy-type
NHL	I-malignancy-type
subtypes	O
,	O
suggesting	O
the	O
involvement	O
of	O
distinct	O
molecular	O
pathway	O
.	O
PMID	O
:	O
8380252	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
1993	O
Jan;6	O
5	O
(	O
1	O
)	O
:	O
1	O
2-20	O
Analysis	O
of	O
karyotype	O
,	O
SCE	O
,	O
and	O
point	O
mutation	O
of	O
RAS	O
oncogene	O
in	O
Indian	O
MDS	B-malignancy-type
patients	O
.	O
Mansoor	O
AM	O
,	O
Bharadwaj	O
TP	O
,	O
Sethuraman	O
S	O
,	O
Chandy	O
M,	O
Pushpa	O
V	O
,	O
Kamada	O
N	O
,	O
Murthy	O
PB.	O
Department	O
of	O
Hematology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Thirty	O
Indian	O
patients	O
diagnosed	O
as	O
having	O
primary	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
as	O
per	O
the	O
French	O
-	O
American	O
-	O
British	O
classification	O
were	O
investigated	O
,	O
on	O
admission	O
,	O
for	O
the	O
frequencies	O
of	O
nonrandom	O
karyotype	O
abnormalities	O
,	O
sister	O
chromatid	O
exchange	O
,	O
and	O
point	O
mutations	O
of	O
the	O
RAS	O
oncogene	O
.	O
Successful	O
karyotype	O
analysis	O
was	O
possible	O
in	O
24	O
patients	O
,	O
of	O
whom	O
9	O
(	O
37.5	O
%	O
)	O
showed	O
nonrandom	O
karyotypic	O
changes	O
.	O
Anomalies	O
of	O
chromosomes	O
5	O
,	O
7	O
,	O
and	O
8	O
were	O
detected	O
in	O
their	O
bone	O
marrow	O
(	O
BM	O
)	O
.	O
In	O
addition	O
,	O
two	O
new	O
anomalies	O
,	O
del	O
(	O
8	O
)	O
(	O
q22	O
)	O
and	O
+	O
19	O
,	O
were	O
observed	O
for	O
the	O
first	O
time	O
in	O
our	O
series	O
.	O
Six	O
MDS	B-malignancy-type
patients	O
were	O
studied	O
for	O
SCE	O
in	O
either	O
BM	O
or	O
peripheral	O
blood	O
.	O
These	O
data	O
revealed	O
a	O
normal	O
SCE	O
incidence	O
.	O
Of	O
the	O
10	O
MDS	B-malignancy-type
patients	O
studied	O
for	O
point	O
mutations	O
of	O
NRAS	O
12	O
and	O
61	O
and	O
KRAS	O
12	O
and	O
61	O
,	O
one	O
patient	O
exhibited	O
a	O
base	O
substitution	O
at	O
position	O
1	O
of	O
the	O
12th	O
codon	O
of	O
the	O
KRAS	O
gene	O
.	O
These	O
data	O
,	O
gathered	O
for	O
the	O
first	O
time	O
on	O
the	O
Indian	O
patients	O
,	O
throw	O
some	O
light	O
on	O
the	O
nature	O
of	O
genetic	O
changes	O
in	O
MDS	B-malignancy-type
of	O
our	O
country	O
.	O
PMID	O
:	O
8431911	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1993	O
Feb;8	O
4	O
(	O
2	O
)	O
:	O
16	O
3-7	O
Infrequent	O
ras	O
mutation	O
in	O
human	O
stomach	B-malignancy-type
cancers	I-malignancy-type
.	O
Koshiba	O
M,	O
Ogawa	O
O,	O
Habuchi	O
T	O
,	O
Hamazaki	O
S	O
,	O
Shimada	O
T	O
,	O
Takahashi	O
R	O
,	O
Sugiyama	O
T.	O
Department	O
of	O
Geriatric	O
Medicine	O
,	O
Kyoto	O
University	O
.	O
Mutations	O
of	O
ras	O
oncogenes	O
in	O
37	O
human	O
stomach	B-malignancy-type
cancers	I-malignancy-type
and	O
13	O
adenomas	B-malignancy-type
were	O
investigated	O
with	O
regard	O
to	O
the	O
histological	O
phenotypes	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
and/or	O
direct	O
sequencing	O
of	O
the	O
PCR	O
products	O
.	O
The	O
ras	O
mutation	O
was	O
found	O
only	O
in	O
one	O
case	O
(	O
2.7	O
%	O
)	O
,	O
the	O
histology	O
of	O
which	O
was	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
found	O
no	O
mutation	O
in	O
stomach	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
mutation	O
consisted	O
of	O
a	O
guanine	O
-	O
to	O
-	O
adenine	O
transition	O
in	O
the	O
first	O
base	O
of	O
codon	O
13	O
of	O
c-Ki-ras	O
which	O
replaced	O
wild-type	O
glycine	O
with	O
serine	O
,	O
indicating	O
that	O
a	O
putative	O
glycine	O
-	O
to	O
-	O
aspartic	O
acid	O
change	O
is	O
not	O
necessarily	O
the	O
critical	O
event	O
for	O
c-Ki-ras	O
gene	O
activation	O
in	O
codon	O
13	O
.	O
These	O
results	O
further	O
confirm	O
the	O
infrequency	O
of	O
ras	O
mutation	O
in	O
stomach	B-malignancy-type
tumors	I-malignancy-type
and	O
also	O
suggest	O
that	O
ras	O
mutations	O
are	O
not	O
specific	O
to	O
the	O
differentiated	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
stomach	I-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
8463133	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Stem	O
Cells	O
1995	O
Sep;1	O
3	O
(	O
5	O
)	O
:	O
55	O
6-63	O
Analysis	O
of	O
mutations	O
of	O
neurofibromatosis	O
type	O
1	O
gene	O
and	O
N-ras	O
gene	O
in	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
.	O
Lee	O
YY	O
,	O
Kim	O
WS	O
,	O
Bang	O
YJ	O
,	O
Jung	O
CW,	O
Park	O
S	O
,	O
Yoon	O
WJ	O
,	O
Cho	O
KS	O
,	O
Kim	O
IS	O
,	O
Jung	O
TJ	O
,	O
Choi	O
IY	O
,	O
et	O
al	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Han	O
Yang	O
University	O
Hospital	O
,	O
Seoul	O
,	O
Korea	O
.	O
Neurofibromatosis	O
type	O
1	O
(	O
NF1	O
)	O
gene	O
is	O
a	O
tumor	O
suppressor	O
gene	O
,	O
and	O
the	O
NF1	O
gene	O
product	O
,	O
neurofibromin	O
,	O
can	O
downregulate	O
the	O
N-ras	O
gene	O
.	O
Because	O
the	O
N-ras	O
gene	O
is	O
often	O
mutated	O
in	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
we	O
wondered	O
if	O
the	O
NF1	O
gene	O
might	O
be	O
mutated	O
in	O
those	O
AML	B-malignancy-type
samples	O
not	O
having	O
N-ras	O
mutations	O
.	O
We	O
investigated	O
the	O
mutational	O
status	O
of	O
the	O
N-ras	O
gene	O
and	O
the	O
FLR	O
exon	O
of	O
codons	O
1371	O
-	O
1423	O
of	O
the	O
open	O
reading	O
frame	O
of	O
the	O
full-length	O
NF1	O
cDNA	O
,	O
which	O
has	O
a	O
strong	O
homology	O
with	O
the	O
mammalian	O
ras	O
GTPase	O
-	O
activating	O
protein	O
(	O
GAP	O
)	O
,	O
especially	O
for	O
a	O
stretch	O
of	O
three	O
consecutive	O
amino	O
acids	O
(	O
F	O
,	O
L	O
,	O
R	O
)	O
,	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
in	O
samples	O
from	O
patients	O
with	O
AML	B-malignancy-type
.	O
Of	O
48	O
AML	B-malignancy-type
patients	O
,	O
10	O
(	O
21	O
%	O
)	O
had	O
point	O
(	O
missense	O
)	O
mutations	O
of	O
the	O
N-ras	O
gene	O
involving	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
However	O
,	O
mutations	O
in	O
the	O
FLR	O
exon	O
of	O
the	O
NF1	O
gene	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
AML	B-malignancy-type
samples	O
.	O
We	O
also	O
examined	O
the	O
difference	O
of	O
clinical	O
response	O
to	O
induction	O
therapy	O
between	O
AML	B-malignancy-type
patients	O
with	O
and	O
without	O
N-ras	O
mutation	O
.	O
A	O
significantly	O
lower	O
rate	O
of	O
complete	O
remission	O
was	O
noted	O
in	O
individuals	O
with	O
N-ras	O
gene	O
mutations	O
.	O
These	O
results	O
suggest	O
that	O
mutation	O
of	O
the	O
NF1	O
gene	O
,	O
at	O
least	O
in	O
the	O
FLR	O
exon	O
,	O
is	O
very	O
rare	O
in	O
AML	B-malignancy-type
and	O
the	O
NF1	O
gene	O
probably	O
is	O
not	O
a	O
functional	O
complement	O
of	O
the	O
N-ras	O
gene	O
mutation	O
.	O
The	O
presence	O
of	O
N-ras	O
gene	O
mutation	O
may	O
be	O
associated	O
with	O
a	O
lower	O
clinical	O
response	O
to	O
antileukemic	O
therapy	O
.	O
PMID	O
:	O
8528106	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1996	O
May	O
;87(	O
5	O
)	O
:466	O
-	O
74	O
Detection	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
pancreatic	O
juice	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
by	O
hybridization	O
protection	O
assay	O
:	O
a	O
simple	O
method	O
for	O
the	O
determination	O
of	O
the	O
types	O
of	O
point	O
mutation	O
.	O
Watanabe	O
H	O
,	O
Miyagi	O
C	O
,	O
Yamaguchi	O
Y	O
,	O
Satomura	O
Y	O
,	O
Ohta	O
H	O
,	O
Motoo	O
Y	O
,	O
Okai	O
T	O
,	O
Yoshimura	O
T	O
,	O
Tsuji	O
Y	O
,	O
Sawabu	O
N.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
detect	O
K-ras	O
oncogene	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
by	O
the	O
hybridization	O
protection	O
assay	O
(	O
HPA	O
)	O
method	O
for	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
(	O
PC	B-malignancy-type
)	O
.	O
This	O
assay	O
can	O
be	O
carried	O
out	O
within	O
30	O
min	O
and	O
can	O
determine	O
not	O
only	O
the	O
presence	O
of	O
a	O
mutation	O
,	O
but	O
also	O
the	O
mutational	O
type	O
of	O
K-ras	O
at	O
codon	O
12	O
.	O
The	O
minimal	O
ratio	O
of	O
mutant	O
DNA	O
detectable	O
by	O
the	O
HPA	O
was	O
5	O
-	O
10	O
%	O
of	O
the	O
total	O
DNA	O
.	O
PPJ	O
was	O
collected	O
through	O
a	O
cannula	O
under	O
duodenal	O
fiberscope	O
control	O
from	O
20	O
patients	O
with	O
PC	B-malignancy-type
and	O
20	O
patients	O
with	O
chronic	O
pancreatitis	O
(	O
CP	O
)	O
.	O
Analysis	O
of	O
PPJ	O
by	O
the	O
HPA	O
revealed	O
that	O
the	O
incidence	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
was	O
55	O
%	O
(	O
11	O
/	O
20	O
)	O
in	O
patients	O
with	O
PC	B-malignancy-type
and	O
0	O
%	O
(	O
0	O
/	O
20	O
)	O
in	O
those	O
with	O
CP	O
.	O
Mutational	O
types	O
of	O
K-ras	O
at	O
codon	O
12	O
in	O
PC	B-malignancy-type
were	O
aspartic	O
acid	O
(	O
Asp	O
)	O
in	O
nine	O
cases	O
,	O
both	O
Asp	O
and	O
cysteine	O
in	O
one	O
case	O
,	O
and	O
arginine	O
in	O
one	O
case	O
.	O
Analysis	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
PPJ	O
using	O
the	O
HPA	O
method	O
seems	O
promising	O
as	O
a	O
new	O
genetic	O
test	O
for	O
the	O
diagnosis	O
of	O
PC	B-malignancy-type
,	O
because	O
the	O
HPA	O
method	O
is	O
simple	O
,	O
and	O
can	O
easily	O
determine	O
the	O
mutational	O
type	O
.	O
PMID	O
:	O
8641983	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Tongji	O
Med	O
Univ	O
1996;16(	O
1	O
)	O
:58	O
-	O
60	O
C-Ha-ras	O
oncogene	O
in	O
oral	B-malignancy-type
leukoplakia	I-malignancy-type
tissues	O
.	O
Cheng	O
P	O
,	O
Li	O
H	O
,	O
Yang	O
P	O
,	O
Tan	O
Y.	O
Department	O
of	O
Stomatology	O
,	O
Tongji	O
Hospital	O
,	O
Tongji	O
Medical	O
University	O
,	O
Wuhan	O
.	O
The	O
amplification	O
and	O
the	O
G	O
-	O
T	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
C-Ha-ras	O
oncogene	O
in	O
oral	B-malignancy-type
leukoplakia	I-malignancy-type
tissues	O
were	O
analyzed	O
by	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
molecular	O
biologic	O
technique	O
.	O
The	O
results	O
showed	O
that	O
these	O
tissues	O
had	O
no	O
amplification	O
of	O
Ha-ras	O
oncogene	O
.	O
Only	O
one	O
case	O
harbored	O
G	O
-	O
T	O
mutation	O
in	O
11	O
oral	B-malignancy-type
leukoplakias	I-malignancy-type
,	O
but	O
this	O
mutation	O
was	O
absent	O
in	O
10	O
normal	O
oral	O
mucosal	O
tissues	O
.	O
The	O
possible	O
role	O
and	O
significance	O
of	O
C-Ha-ras	O
oncogene	O
in	O
oral	B-malignancy-type
precancerous	I-malignancy-type
lesions	I-malignancy-type
were	O
also	O
discussed	O
.	O
PMID	O
:	O
8758750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1996	O
Mar;148(	O
3	O
)	O
:731	O
-	O
8	O
Single	O
somatic	O
ras	O
gene	O
point	O
mutation	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
.	O
Bohle	O
RM	O
,	O
Brettreich	O
S,	O
Repp	O
R,	O
Borkhardt	O
A	O
,	O
Kosmehl	O
H	O
,	O
Altmannsberger	O
HM	O
.	O
Institut	O
fur	O
Pathologie	O
,	O
Justus	O
-	O
Liebig	O
-	O
Universitat	O
Giessen	O
,	O
Germany	O
.	O
The	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
human	O
soft	B-malignancy-type
tissue	I-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
within	O
and	O
around	O
the	O
hot	O
spot	O
codons	O
(	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
of	O
all	O
ras	O
genes	O
,	O
(	O
H-ras-1	O
,	O
K-ras-2	O
,	O
and	O
N-ras	O
)	O
was	O
studied	O
by	O
nested	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
DNA	O
sequencing	O
from	O
archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
Light	O
microscopy	O
and	O
immunohistochemistry	O
served	O
to	O
define	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytoma	I-malignancy-type
.	O
All	O
of	O
the	O
four	O
differentiation	O
subtypes	O
(	O
storiform	B-malignancy-type
-	I-malignancy-type
pleomorphic	I-malignancy-type
,	O
inflammatory	B-malignancy-type
,	O
myxoid	B-malignancy-type
,	O
and	O
giant	B-malignancy-type
cell	I-malignancy-type
)	O
were	O
investigated	O
.	O
Nine	O
of	O
thirty-two	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
28	O
%	O
)	O
contained	O
ras	O
gene	O
point	O
mutations	O
.	O
The	O
highest	O
incidence	O
was	O
found	O
in	O
the	O
myxoid	B-malignancy-type
subtype	O
(	O
four	O
of	O
nine	O
)	O
.	O
H-ras-1	O
gene	O
codon	O
12.2	O
was	O
the	O
only	O
codon	O
affected	O
and	O
contained	O
in	O
all	O
mutated	O
cases	O
a	O
GGC	O
-->	O
GTC	O
exchange	O
.	O
Seven	O
of	O
the	O
nine	O
mutations	O
were	O
homozygous	O
and	O
probably	O
affected	O
more	O
than	O
80	O
%	O
of	O
the	O
tumor	O
DNA	O
.	O
The	O
flanking	O
regions	O
of	O
all	O
hotspot	O
codons	O
did	O
not	O
contain	O
any	O
point	O
mutation	O
.	O
The	O
presence	O
of	O
a	O
single	O
and	O
often	O
homozygous	O
point	O
mutation	O
of	O
the	O
H-ras-1	O
gene	O
,	O
especially	O
in	O
myxoid	B-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytoma	I-malignancy-type
could	O
serve	O
as	O
a	O
basis	O
for	O
further	O
genomic	O
discrimination	O
of	O
myxoid	B-malignancy-type
sarcomas	I-malignancy-type
.	O
PMID	O
:	O
8774129	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
1996	O
Nov-	O
Dec;16(	O
6B)	O
:3761	O
-	O
6	O
Concomitant	O
point	O
mutation	O
of	O
tumor	O
suppressor	O
gene	O
p53	O
and	O
oncogene	O
c-N-ras	O
in	O
malignant	B-malignancy-type
neuroendocrine	I-malignancy-type
pancreatic	I-malignancy-type
tumor	I-malignancy-type
.	O
Hrascan	O
R,	O
Pavelic	O
K	O
,	O
Pavicic	O
D	O
,	O
Krizanac	O
S,	O
Stajcer	O
-	O
Sittic	O
V	O
,	O
Pecur	O
L,	O
Spaventi	O
S,	O
Klimpfinger	O
M,	O
Pavelic	O
J.	O
Division	O
of	O
Molecular	O
Medicine	O
,	O
Ruder	O
Boskovic	O
Institute	O
,	O
Zagreb	O
,	O
Croatia	O
.	O
Activation	O
by	O
point	O
mutation	O
of	O
ras	O
family	O
genes	O
as	O
well	O
as	O
point	O
mutations	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
are	O
found	O
in	O
many	O
tumors	O
.	O
Here	O
we	O
describe	O
a	O
rare	O
case	O
of	O
malignant	B-malignancy-type
neuroendocrine	I-malignancy-type
pancreatic	I-malignancy-type
tumor	I-malignancy-type
with	O
multiple	O
metastases	O
in	O
different	O
organs	O
showing	O
strong	O
positivity	O
for	O
synaptophysin	O
,	O
glucagon	O
-	O
like	O
peptide	O
1	O
,	O
pan-cytokeratin	O
,	O
moderate	O
positivity	O
for	O
chromogranin	O
,	O
Phe-5	O
and	O
calcitonin	O
and	O
weak	O
positivity	O
for	O
vasointestinal	O
peptide	O
.	O
We	O
found	O
a	O
point	O
mutation	O
at	O
codon	O
61	O
of	O
the	O
c-N-ras	O
oncogene	O
,	O
and	O
point	O
mutations	O
in	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
in	O
the	O
primary	O
tumor	O
as	O
well	O
as	O
in	O
its	O
metastases	B-malignancy-type
in	I-malignancy-type
liver	I-malignancy-type
.	O
The	O
mutation	O
in	O
the	O
c-N-ras	O
gene	O
was	O
a	O
cytosine	O
to	O
adenine	O
transversion	O
,	O
resulting	O
in	O
the	O
amino	O
-	O
acid	O
lysine	O
.	O
Allele	O
specific	O
hybridization	O
showed	O
that	O
the	O
mutation	O
involved	O
one	O
of	O
two	O
c-N-ras	O
alleles	O
as	O
the	O
oligonucleotide	O
for	O
the	O
normal	O
codon	O
also	O
hybridized	O
to	O
amplified	O
tumor	O
DNA	O
.	O
Concomitant	O
mutation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
at	O
codons	O
248	O
and	O
249	O
was	O
found	O
.	O
The	O
mutation	O
in	O
codon	O
248	O
was	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
resulting	O
in	O
the	O
amino	O
-	O
acid	O
glycine	O
.	O
The	O
mutation	O
in	O
codon	O
249	O
was	O
a	O
third	O
base	O
,	O
G	O
-	O
>	O
T	O
,	O
transversion	O
leading	O
to	O
a	O
change	O
from	O
arginine	O
to	O
serine	O
.	O
This	O
is	O
the	O
first	O
time	O
that	O
concomitant	O
point	O
mutations	O
in	O
c-N-ras	O
and	O
p53	O
have	O
been	O
found	O
in	O
a	O
neuroendocrine	B-malignancy-type
pancreatic	I-malignancy-type
tumor	I-malignancy-type
.	O
Based	O
upon	O
these	O
and	O
our	O
previous	O
results	O
,	O
we	O
concluded	O
that	O
these	O
genetic	O
changes	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
this	O
particular	O
pancreatic	B-malignancy-type
tumor	I-malignancy-type
.	O
PMID	O
:	O
9042254	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
1997	O
Mar	O
21	O
;275(5307	O
)	O
:1787	O
-	O
90	O
Comment	O
in	O
:	O
Science	O
.	O
1997	O
Mar	O
21	O
;275(5307	O
)	O
:1752	O
-	O
3	O
.	O
Activation	O
of	O
beta-catenin	O
-	O
Tcf	O
signaling	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
by	O
mutations	O
in	O
beta-catenin	O
or	O
APC	O
.	O
Morin	O
PJ	O
,	O
Sparks	O
AB	O
,	O
Korinek	O
V	O
,	O
Barker	O
N	O
,	O
Clevers	O
H	O
,	O
Vogelstein	O
B	O
,	O
Kinzler	O
KW.	O
Howard	O
Hughes	O
Medical	O
Institute	O
and	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
424	O
North	O
Bond	O
Street	O
,	O
Baltimore	O
,	O
MD	O
21231	O
,	O
USA	O
.	O
Inactivation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
tumor	O
suppressor	O
gene	O
initiates	O
colorectal	B-malignancy-type
neoplasia	I-malignancy-type
.	O
One	O
of	O
the	O
biochemical	O
activities	O
associated	O
with	O
the	O
APC	O
protein	O
is	O
down	O
-	O
regulation	O
of	O
transcriptional	O
activation	O
mediated	O
by	O
beta-catenin	O
and	O
T	O
cell	O
transcription	O
factor	O
4	O
(	O
Tcf-4	O
)	O
.	O
The	O
protein	O
products	O
of	O
mutant	O
APC	O
genes	O
present	O
in	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
were	O
found	O
to	O
be	O
defective	O
in	O
this	O
activity	O
.	O
Furthermore	O
,	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
with	O
intact	O
APC	O
genes	O
were	O
found	O
to	O
contain	O
activating	O
mutations	O
of	O
beta-catenin	O
that	O
altered	O
functionally	O
significant	O
phosphorylation	O
sites	O
.	O
These	O
results	O
indicate	O
that	O
regulation	O
of	O
beta-catenin	O
is	O
critical	O
to	O
APC	O
's	O
tumor	O
suppressive	O
effect	O
and	O
that	O
this	O
regulation	O
can	O
be	O
circumvented	O
by	O
mutations	O
in	O
either	O
APC	O
or	O
beta-catenin	O
.	O
PMID	O
:	O
9065402	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
1997	O
Apr;11	O
2	O
(	O
4	O
)	O
:	O
111	O
4-20	O
K-ras	O
mutations	O
are	O
found	O
in	O
DNA	O
extracted	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Anker	O
P,	O
Lefort	O
F	O
,	O
Vasioukhin	O
V	O
,	O
Lyautey	O
J,	O
Lederrey	O
C,	O
Chen	O
XQ	O
,	O
Stroun	O
M,	O
Mulcahy	O
HE	O
,	O
Farthing	O
MJ.	O
Departement	O
de	O
Biochimie	O
et	O
de	O
Physiologie	O
Vegetale	O
,	O
Universite	O
de	O
Geneve	O
,	O
Switzerland	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Circulating	O
DNA	O
can	O
be	O
isolated	O
from	O
the	O
plasma	O
of	O
healthy	O
subjects	O
and	O
from	O
patients	O
with	O
cancer	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
detect	O
K-ras	O
mutations	O
in	O
DNA	O
extracted	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
Tumor	O
and	O
plasma	O
DNA	O
were	O
extracted	O
from	O
14	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
(	O
stages	O
A	O
-	O
D	O
)	O
,	O
and	O
K-ras	O
alterations	O
were	O
detected	O
using	O
a	O
polymerase	O
chain	O
reaction	O
assay	O
that	O
uses	O
sequence	O
-	O
specific	O
primers	O
to	O
amplify	O
mutant	O
DNA	O
.	O
These	O
results	O
were	O
confirmed	O
with	O
another	O
polymerase	O
chain	O
reaction	O
assay	O
that	O
creates	O
an	O
enzyme	O
restriction	O
site	O
in	O
the	O
absence	O
of	O
a	O
K-ras	O
mutation	O
followed	O
by	O
direct	O
sequencing	O
and	O
additional	O
cloning	O
techniques	O
.	O
RESULTS	O
:	O
Seven	O
patients	O
(	O
50	O
%	O
)	O
had	O
a	O
codon	O
12	O
K-ras	O
mutation	O
within	O
their	O
primary	O
tumor	O
,	O
and	O
identical	O
mutations	O
were	O
found	O
in	O
the	O
plasma	O
DNA	O
of	O
6	O
patients	O
(	O
86	O
%	O
)	O
.	O
Mutant	O
DNA	O
was	O
not	O
detected	O
in	O
the	O
plasma	O
specimens	O
of	O
7	O
patients	O
whose	O
tumors	O
tested	O
negative	O
for	O
K-ras	O
alterations	O
or	O
in	O
healthy	O
control	O
subjects	O
.	O
Similar	O
results	O
were	O
obtained	O
using	O
all	O
three	O
molecular	O
biological	O
techniques	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
abnormalities	O
can	O
be	O
detected	O
in	O
circulating	O
DNA	O
extracted	O
from	O
the	O
plasma	O
specimens	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
If	O
these	O
results	O
are	O
confirmed	O
in	O
larger	O
studies	O
,	O
genetic	O
analysis	O
of	O
plasma	O
DNA	O
may	O
have	O
clinical	O
applications	O
in	O
the	O
future	O
.	O
PMID	O
:	O
9097993	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hua	O
Xi	O
Yi	O
Ke	O
Da	O
Xue	O
Xue	O
Bao	O
1996	O
Mar;2	O
7	O
(	O
1	O
)	O
:	O
5-9	O
[	O
Carcinogenic	O
mechanisms	O
of	O
multiple	O
genes	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
]	O
[Article	O
in	O
Chinese	O
]	O
Huang	O
G,	O
Xiao	O
X	O
,	O
Huang	O
Y	O
,	O
Huang	O
R.	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Chengdu	O
.	O
The	O
alterations	O
of	O
multiple	O
genes	O
and	O
their	O
carcinogenic	O
mechanism	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
were	O
studies	O
by	O
molecular	O
hybridisation	O
,	O
PCR	O
and	O
PCR	O
-	O
ASO	O
techniques	O
.	O
The	O
G	O
-	O
T	O
point	O
mutation	O
in	O
the	O
12th	O
coden	O
of	O
Ha-ras	O
was	O
detected	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
with	O
mutation	O
frequency	O
of	O
18.2	O
%	O
(	O
8	O
/	O
44	O
)	O
,	O
and	O
the	O
amplification	O
rate	O
of	O
Ha-ras	O
gene	O
was	O
45	O
%	O
(	O
9	O
/	O
20	O
)	O
.	O
The	O
c-erb	O
B2	O
was	O
amplified	O
3	O
-	O
30	O
fold	O
with	O
an	O
amplification	O
rate	O
of	O
73.3	O
%	O
(	O
11	O
/	O
15	O
)	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
and	O
5	O
cancerous	O
samples	O
showed	O
gene	O
rearrangement	O
.	O
The	O
elevated	O
copies	O
of	O
c-myc	O
gene	O
with	O
amplification	O
rate	O
of	O
91.7	O
%	O
(	O
11	O
/	O
12	O
)	O
were	O
observed	O
in	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
study	O
of	O
HPV16	O
viral	O
gene	O
showed	O
that	O
the	O
existence	O
of	O
HPV16	O
DNA	O
sequence	O
was	O
positively	O
associated	O
with	O
c-myc	O
gene	O
amplification	O
in	O
cervical	B-malignancy-type
cancerous	I-malignancy-type
samples	O
.	O
The	O
p53	O
and	O
Rb	O
tumor	O
suppressor	O
genes	O
absence	O
of	O
deletion	O
were	O
observed	O
in	O
the	O
12	O
specimens	O
of	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
investigated	O
.	O
As	O
mentioned	O
above	O
,	O
the	O
study	O
on	O
alteration	O
and	O
carcinogenic	O
mechanism	O
of	O
multiple	O
genes	O
indicated	O
that	O
3	O
oncogenes	O
and	O
HPV16	O
viral	O
gene	O
were	O
activated	O
or	O
integrated	O
throygh	O
different	O
mechanisms	O
and	O
they	O
played	O
roles	O
in	O
co	O
-	O
carcinogenesis	O
.	O
The	O
integration	O
of	O
HPV16	O
gene	O
might	O
promote	O
the	O
c-myc	O
gene	O
at	O
the	O
early	O
stage	O
in	O
carcinogenesis	O
of	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
,	O
while	O
the	O
alteration	O
of	O
Ha-ras	O
and	O
c-erb	O
B2	O
gene	O
might	O
be	O
middle	O
-	O
late	O
event	O
.	O
As	O
for	O
the	O
roles	O
of	O
the	O
p53	O
and	O
Rb	O
tumor	O
suppresor	O
gene	O
in	O
cervical	O
carcinogenesis	O
need	O
further	O
researches	O
.	O
PMID	O
:	O
9208611	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1997	O
Sep	O
16;94	O
(	O
19	O
)	O
:	O
1033	O
0-4	O
Beta-catenin	O
mutations	O
in	O
cell	O
lines	O
established	O
from	O
human	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
Ilyas	O
M,	O
Tomlinson	O
IP	O
,	O
Rowan	O
A	O
,	O
Pignatelli	O
M,	O
Bodmer	O
WF.	O
Cancer	O
Genetics	O
and	O
Immunology	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
Institute	O
of	O
Molecular	O
Medicine	O
,	O
John	O
Radcliffe	O
Hospital	O
,	O
Oxford	O
,	O
OX3	O
9DU	O
,	O
United	O
Kingdom	O
.	O
ilyas@europa.lif.icnet	O
.uk	O
beta-catenin	O
has	O
functions	O
as	O
both	O
an	O
adhesion	O
and	O
a	O
signaling	O
molecule	O
.	O
Disruption	O
of	O
these	O
functions	O
through	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
may	O
be	O
important	O
in	O
the	O
development	O
of	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
.	O
We	O
examined	O
the	O
entire	O
coding	O
sequence	O
of	O
beta-catenin	O
by	O
reverse	O
transcriptase	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
direct	O
sequencing	O
of	O
23	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
from	O
21	O
patients	O
.	O
In	O
two	O
cell	O
lines	O
,	O
there	O
was	O
apparent	O
instability	O
of	O
the	O
beta-catenin	O
mRNA	O
.	O
Five	O
different	O
mutations	O
(	O
26	O
%	O
)	O
were	O
found	O
in	O
the	O
remaining	O
21	O
cell	O
lines	O
(	O
from	O
19	O
patients	O
)	O
.	O
A	O
three	O
-	O
base	O
deletion	O
(	O
codon	O
45	O
)	O
was	O
identified	O
in	O
the	O
cell	O
line	O
HCT	O
116	O
,	O
whereas	O
cell	O
lines	O
SW	O
48	O
,	O
HCA	O
46	O
,	O
CACO	O
2	O
,	O
and	O
Colo	O
201	O
each	O
contained	O
single	O
-	O
base	O
missense	O
mutations	O
(	O
codons	O
33	O
,	O
183	O
,	O
245	O
,	O
and	O
287	O
,	O
respectively	O
)	O
.	O
All	O
23	O
cell	O
lines	O
had	O
full-length	O
beta-catenin	O
protein	O
that	O
was	O
detectable	O
by	O
Western	O
blotting	O
and	O
that	O
coprecipitated	O
with	O
E-cadherin	O
.	O
In	O
three	O
of	O
the	O
cell	O
lines	O
with	O
CTNNB1	O
mutations	O
,	O
complexes	O
of	O
beta-catenin	O
with	O
alpha-catenin	O
and	O
APC	O
were	O
detectable	O
.	O
In	O
SW48	O
and	O
HCA	O
46	O
,	O
however	O
,	O
we	O
did	O
not	O
detect	O
complexes	O
of	O
beta-catenin	O
protein	O
with	O
alpha-catenin	O
and	O
APC	O
,	O
respectively	O
.	O
These	O
results	O
show	O
that	O
selection	O
of	O
CTNNB1	O
mutations	O
occurs	O
in	O
up	O
to	O
26	O
%	O
of	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
from	O
which	O
cell	O
lines	O
are	O
derived	O
.	O
In	O
these	O
cases	O
,	O
mutation	O
selection	O
is	O
probably	O
for	O
altered	O
beta-catenin	O
function	O
,	O
which	O
may	O
significantly	O
alter	O
intracellular	O
signaling	O
and	O
intercellular	O
adhesion	O
and	O
may	O
serve	O
as	O
a	O
complement	O
to	O
APC	O
mutations	O
in	O
the	O
early	O
stages	O
of	O
tumorigenesis	O
.	O
PMID	O
:	O
9294210	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
1997	O
Oct;	O
6	O
(	O
10	O
)	O
:	O
84	O
1-7	O
Prognostic	O
value	O
of	O
specific	O
KRAS	O
mutations	O
in	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Siegfried	O
JM	O
,	O
Gillespie	O
AT	O
,	O
Mera	O
R	O
,	O
Casey	O
TJ	O
,	O
Keohavong	O
P,	O
Testa	O
JR	O
,	O
Hunt	O
JD.	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Pittsburgh	O
School	O
of	O
Medicine	O
,	O
University	O
of	O
Pittsburgh	O
Cancer	O
Institute	O
,	O
Pennsylvania	O
15261	O
,	O
USA	O
.	O
Adenocarcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
remain	O
a	O
significant	O
public	O
health	O
problem	O
.	O
Locally	O
defined	O
(	O
stage	O
I	O
)	O
tumors	O
are	O
considered	O
amenable	O
to	O
resection	O
with	O
curative	O
intent	O
.	O
However	O
,	O
only	O
about	O
45	O
%	O
of	O
these	O
patients	O
survive	O
for	O
5	O
years	O
.	O
The	O
median	O
survival	O
for	O
more	O
advanced	O
tumors	O
is	O
drastically	O
lower	O
.	O
Much	O
research	O
has	O
been	O
focused	O
on	O
identifying	O
a	O
valid	O
genetic	O
biomarker	O
of	O
prognosis	O
.	O
Mutations	O
of	O
the	O
proto	O
-	O
oncogene	O
KRAS	O
have	O
been	O
identified	O
by	O
some	O
groups	O
as	O
being	O
a	O
valid	O
prognostic	O
indicator	O
for	O
adenocarcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
lung	I-malignancy-type
.	O
To	O
evaluate	O
the	O
effect	O
of	O
KRAS	O
gene	O
mutation	O
on	O
the	O
survival	O
of	O
patients	O
with	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
181	O
archival	B-malignancy-type
tumors	I-malignancy-type
were	O
examined	O
by	O
PCR	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Mutations	O
in	O
either	O
codon	O
12	O
or	O
13	O
were	O
found	O
in	O
31.5	O
%	O
of	O
the	O
samples	O
.	O
The	O
most	O
common	O
mutation	O
was	O
a	O
G	O
-->	O
T	O
transversion	O
in	O
codon	O
12	O
,	O
representing	O
66.7	O
%	O
of	O
the	O
mutations	O
.	O
No	O
difference	O
was	O
observed	O
in	O
the	O
survival	O
of	O
patients	O
with	O
a	O
KRAS	O
mutation	O
versus	O
those	O
whose	O
tumors	O
contained	O
wild-type	O
KRAS	O
.	O
This	O
lack	O
of	O
difference	O
was	O
also	O
observed	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
those	O
with	O
stage	O
I	O
tumors	O
or	O
when	O
patients	O
with	O
stage	O
I	O
or	O
II	O
disease	O
were	O
grouped	O
together	O
.	O
However	O
,	O
certain	O
amino	O
acid	O
substitutions	O
,	O
including	O
cysteine	O
,	O
arginine	O
,	O
and	O
aspartate	O
,	O
indicated	O
a	O
significantly	O
poorer	O
prognosis	O
,	O
whereas	O
hydrophobic	O
amino	O
acid	O
substitutions	O
showed	O
a	O
significantly	O
better	O
prognosis	O
than	O
wild-type	O
(	O
P	O
=	O
0.04	O
)	O
.	O
Sample	O
sizes	O
were	O
small	O
for	O
this	O
analysis	O
due	O
to	O
the	O
number	O
of	O
possible	O
mutations	O
.	O
As	O
expected	O
,	O
the	O
stage	O
of	O
tumor	O
at	O
resection	O
was	O
the	O
most	O
significant	O
predictor	O
of	O
outcome	O
.	O
Based	O
on	O
this	O
study	O
of	O
181	O
patients	O
from	O
two	O
major	O
medical	O
centers	O
located	O
in	O
different	O
cities	O
,	O
we	O
conclude	O
that	O
KRAS	O
mutation	O
status	O
is	O
not	O
a	O
satisfactory	O
predictor	O
of	O
prognosis	O
in	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
but	O
the	O
substitution	O
of	O
a	O
polar	O
or	O
charged	O
amino	O
acid	O
for	O
the	O
wild-type	O
glycine	O
residue	O
may	O
be	O
a	O
negative	O
prognostic	O
indicator	O
.	O
PMID	O
:	O
9332768	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1997	O
Oct	O
15	O
;5	O
7	O
(20	O
)	O
:	O
447	O
8-81	O
Mutations	O
in	O
beta-catenin	O
are	O
uncommon	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
occurring	O
in	O
occasional	O
replication	O
error	O
-	O
positive	O
tumors	O
.	O
Kitaeva	O
MN	O
,	O
Grogan	O
L,	O
Williams	O
JP	O
,	O
Dimond	O
E	O
,	O
Nakahara	O
K,	O
Hausner	O
P,	O
DeNobile	O
JW,	O
Soballe	O
PW,	O
Kirsch	O
IR.	O
Genetics	O
Department	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Maryland	O
2088	O
9-5101	O
,	O
USA	O
.	O
Beta-catenin	O
has	O
been	O
identified	O
as	O
an	O
oncogene	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
and	O
melanoma	B-malignancy-type
.	O
Phosphorylation	O
of	O
sites	O
in	O
exon	O
3	O
of	O
beta-catenin	O
leads	O
to	O
degradation	O
of	O
this	O
protein	O
.	O
These	O
sites	O
are	O
primary	O
targets	O
for	O
activating	O
mutations	O
.	O
The	O
frequency	O
with	O
which	O
oncogenic	O
mutations	O
at	O
these	O
sites	O
are	O
found	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
is	O
unknown	O
,	O
as	O
is	O
the	O
frequency	O
of	O
their	O
occurrence	O
in	O
other	O
malignancies	O
.	O
We	O
analyzed	O
92	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
(	O
CRCs	B-malignancy-type
)	O
and	O
57	O
cancer	O
cell	O
lines	O
(	O
representing	O
a	O
diversity	O
of	O
tumor	O
types	O
)	O
to	O
determine	O
the	O
frequency	O
of	O
activating	O
mutations	O
in	O
this	O
gene	O
.	O
Mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
were	O
found	O
in	O
2	O
of	O
92	O
CRCs	O
and	O
in	O
the	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
line	O
HCT	O
116	O
.	O
Both	O
tumors	O
with	O
beta-catenin	O
mutations	O
exhibited	O
widespread	O
microsatellite	O
instability	O
,	O
which	O
is	O
indicative	O
of	O
a	O
replication	O
error	O
phenotype	O
,	O
a	O
phenotype	O
known	O
to	O
be	O
present	O
in	O
HCT	O
116	O
.	O
This	O
suggests	O
that	O
mutations	O
in	O
beta-catenin	O
are	O
infrequent	O
in	O
CRC	B-malignancy-type
and	O
miscellaneous	O
cancer	O
cell	O
lines	O
and	O
may	O
occur	O
in	O
association	O
with	O
a	O
replication	O
error	O
phenotype	O
.	O
PMID	O
:	O
9377556	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
1997	O
Sep;4	O
1	O
(	O
3	O
)	O
:	O
32	O
0-2	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
polyps	I-malignancy-type
,	O
dysplasia	B-malignancy-type
,	O
and	O
K-ras	O
codon	O
12	O
mutations	O
.	O
Entius	O
MM	O
,	O
Westerman	O
AM	O
,	O
Giardiello	O
FM	O
,	O
van	O
Velthuysen	O
ML	O
,	O
Polak	O
MM	O
,	O
Slebos	O
RJ	O
,	O
Wilson	O
JH,	O
Hamilton	O
SR	O
,	O
Offerhaus	O
GJ.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
BACKGROUND	O
:	O
Peutz	B-malignancy-type
-	I-malignancy-type
Jeghers	I-malignancy-type
syndrome	I-malignancy-type
(	O
PJS	B-malignancy-type
)	O
is	O
a	O
rare	O
,	O
autosomal	O
dominant	O
,	O
polyposis	B-malignancy-type
syndrome	I-malignancy-type
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
gastrointestinal	B-malignancy-type
and	O
extragastrointestinal	B-malignancy-type
malignancy	I-malignancy-type
.	O
Occasionally	O
dysplasia	B-malignancy-type
occurs	O
in	O
PJS	B-malignancy-type
polyps	I-malignancy-type
.	O
AIMS	O
:	O
In	O
colorectal	O
carcinomas	O
,	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
are	O
common	O
and	O
are	O
found	O
at	O
similar	O
frequency	O
in	O
precursor	B-malignancy-type
adenomas	I-malignancy-type
.	O
Therefore	O
,	O
K-ras	O
codon	O
12	O
point	O
mutations	O
in	O
PJS	B-malignancy-type
polyps	I-malignancy-type
,	O
were	O
evaluated	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Fifty	O
two	O
PJS	B-malignancy-type
polyps	I-malignancy-type
,	O
including	O
four	O
with	O
dysplasia	B-malignancy-type
,	O
collected	O
from	O
19	O
patients	O
with	O
PJS	B-malignancy-type
,	O
were	O
analysed	O
for	O
mutations	O
in	O
the	O
K-ras	O
codon	O
12	O
by	O
a	O
mutant	O
enriched	O
polymerase	O
chain	O
reaction	O
procedure	O
,	O
followed	O
by	O
allele	O
specific	O
oligodeoxynucleotide	O
hybridisation	O
.	O
RESULTS	O
:	O
A	O
K-ras	O
codon	O
12	O
mutation	O
was	O
identified	O
,	O
in	O
one	O
colonic	B-malignancy-type
polyp	I-malignancy-type
with	I-malignancy-type
dysplasia	I-malignancy-type
.	O
The	O
mutation	O
was	O
found	O
in	O
the	O
non	O
-	O
neoplasmic	O
epithelial	O
cells	O
and	O
not	O
in	O
the	O
dysplastic	O
component	O
of	O
the	O
polyp	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
K-ras	O
codon	O
12	O
point	O
mutations	O
are	O
very	O
rare	O
in	O
PJS	B-malignancy-type
polyps	I-malignancy-type
,	O
by	O
contrast	O
with	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
findings	O
support	O
previous	O
evidence	O
that	O
there	O
seems	O
to	O
be	O
no	O
intrinsic	O
relation	O
between	O
K-ras	O
codon	O
12	O
mutation	O
and	O
dysplasia	B-malignancy-type
.	O
PMID	O
:	O
9378385	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
1997	O
Dec;9	O
2	O
(	O
12	O
)	O
:	O
216	O
6-70	O
Comment	O
in	O
:	O
Am	O
J	O
Gastroenterol	O
.	O
1997	O
Dec;9	O
2	O
(	O
12	O
)	O
:	O
214	O
4-6	O
.	O
Detection	O
of	O
Ki-ras	O
mutations	O
by	O
PCR	O
and	O
differential	O
hybridization	O
and	O
of	O
p53	O
mutations	O
by	O
SSCP	O
analysis	O
in	O
endoscopically	O
obtained	O
lavage	O
solution	O
from	O
patients	O
with	O
long	B-malignancy-type
-	I-malignancy-type
standing	I-malignancy-type
ulcerative	I-malignancy-type
colitis	I-malignancy-type
.	O
Lang	O
SM	O
,	O
Heinzlmann	O
M,	O
Stratakis	O
DF	O
,	O
Teschauer	O
W	O
,	O
Loeschke	O
K.	O
Department	O
of	O
Gastroenterology	O
,	O
Medizinische	O
Klinik	O
,	O
Ludwi	O
g-Maximilians	O
Universitat	O
Munchen	O
,	O
Germany	O
.	O
OBJECTIVES	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
the	O
early	O
detection	O
of	O
malignant	O
transformation	O
in	O
patients	O
with	O
long	B-malignancy-type
-	I-malignancy-type
standing	I-malignancy-type
ulcerative	I-malignancy-type
colitis	I-malignancy-type
;	O
therefore	O
,	O
mutations	O
of	O
the	O
Ki-ras	O
and	O
p53	O
gene	O
were	O
analyzed	O
in	O
lavage	O
solution	O
and	O
biopsies	O
obtained	O
at	O
surveillance	O
colonoscopy	O
.	O
METHODS	O
:	O
DNA	O
was	O
isolated	O
from	O
14	O
patients	O
(	O
nine	O
female	O
,	O
five	O
male	O
)	O
with	O
a	O
history	O
of	O
pancolitis	O
for	O
more	O
than	O
10	O
yr	O
.	O
Exon	O
1	O
of	O
the	O
Ki-ras	O
gene	O
and	O
exons	O
5	O
-	O
8	O
of	O
the	O
p53	O
gene	O
were	O
amplified	O
via	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
of	O
the	O
p53	O
gene	O
were	O
detected	O
via	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
;	O
point	O
mutations	O
of	O
the	O
Ki-ras	O
gene	O
were	O
hybridized	O
on	O
dot	O
blots	O
with	O
oligonucleotides	O
marked	O
with	O
digoxigenin	O
.	O
RESULTS	O
:	O
Wild-type	O
Ki-ras	O
and	O
wild-type	O
p53	O
were	O
detected	O
in	O
all	O
cases	O
of	O
ulcerative	B-malignancy-type
colitis	I-malignancy-type
and	O
in	O
four	O
of	O
seven	O
control	O
patients	O
.	O
In	O
two	O
ulcerative	B-malignancy-type
colitis	I-malignancy-type
patients	O
,	O
a	O
mutation	O
was	O
found	O
in	O
the	O
Ki-ras	O
gene	O
(	O
Gly	O
-->	O
Asp	O
12	O
and	O
Gly	O
-->	O
Val	O
12	O
)	O
,	O
and	O
in	O
one	O
patient	O
,	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
the	O
p53	O
gene	O
.	O
Mutations	O
were	O
found	O
only	O
in	O
the	O
lavage	O
fluid	O
,	O
whereas	O
random	O
biopsies	O
were	O
negative	O
.	O
CONCLUSIONS	O
:	O
From	O
colonic	O
lavage	O
fluid	O
,	O
it	O
is	O
possible	O
to	O
extract	O
DNA	O
of	O
sufficient	O
quantity	O
and	O
quality	O
for	O
polymerase	O
chain	O
reaction	O
-	O
based	O
amplification	O
and	O
subsequent	O
analysis	O
via	O
single-strand	O
conformation	O
polymorphism	O
or	O
hybridization	O
.	O
Mutations	O
were	O
found	O
in	O
three	O
of	O
14	O
patients	O
with	O
long	B-malignancy-type
-	I-malignancy-type
standing	I-malignancy-type
ulcerative	I-malignancy-type
colitis	I-malignancy-type
but	O
were	O
not	O
found	O
in	O
controls	O
.	O
The	O
method	O
may	O
be	O
useful	O
for	O
the	O
screening	O
of	O
such	O
patients	O
.	O
PMID	O
:	O
9399746	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
1998	O
Jan	O
23;27	O
9	O
(5350	O
)	O
:	O
57	O
7-80	O
Gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
c-kit	O
in	O
human	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	I-malignancy-type
Hirota	O
S	O
,	O
Isozaki	O
K,	O
Moriyama	O
Y	O
,	O
Hashimoto	O
K,	O
Nishida	O
T	O
,	O
Ishiguro	O
S	O
,	O
Kawano	O
K,	O
Hanada	O
M,	O
Kurata	O
A	O
,	O
Takeda	O
M,	O
Muhammad	O
Tunio	O
G,	O
Matsuzawa	O
Y	O
,	O
Kanakura	O
Y	O
,	O
Shinomura	O
Y	O
,	O
Kitamura	O
Y	O
.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Yamad	O
a	O
-oka	O
2-2	O
,	O
Suita	O
565	O
,	O
Japan	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
in	O
the	O
human	O
digestive	O
tract	O
,	O
but	O
their	O
molecular	O
etiology	O
and	O
cellular	O
origin	O
are	O
unknown	O
.	O
Sequencing	O
of	O
c-kit	O
complementary	O
DNA	O
,	O
which	O
encodes	O
a	O
proto	O
-	O
oncogenic	O
receptor	O
tyrosine	O
kinase	O
(	O
KIT	O
)	O
,	O
from	O
five	O
GISTs	B-malignancy-type
revealed	O
mutations	O
in	O
the	O
region	O
between	O
the	O
transmembrane	O
and	O
tyrosine	O
kinase	O
domains	O
.	O
All	O
of	O
the	O
corresponding	O
mutant	O
KIT	O
proteins	O
were	O
constitutively	O
activated	O
without	O
the	O
KIT	O
ligand	O
,	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O
Stable	O
transfection	O
of	O
the	O
mutant	O
c-kit	O
complementary	O
DNAs	O
induced	O
malignant	O
transformation	O
of	O
Ba	O
/	O
F3	O
murine	O
lymphoid	O
cells	O
,	O
suggesting	O
that	O
the	O
mutations	O
contribute	O
to	O
tumor	O
development	O
.	O
GISTs	B-malignancy-type
may	O
originate	O
from	O
the	O
interstitial	O
cells	O
of	O
Cajal	O
(	O
ICCs	O
)	O
because	O
the	O
development	O
of	O
ICCs	O
is	O
dependent	O
on	O
the	O
SCF	O
-	O
KIT	O
interaction	O
and	O
because	O
,	O
like	O
GISTs	B-malignancy-type
,	O
these	O
cells	O
express	O
both	O
KIT	O
and	O
CD34	O
.	O
PMID	O
:	O
9438854	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
1	O
;	O
58	O
(	O
5	O
)	O
:	O
896	O
-	O
9	O
Sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
contain	O
oncogenic	O
beta-catenin	O
mutations	O
.	O
Zurawel	O
RH	O
,	O
Chiappa	O
SA	O
,	O
Allen	O
C	O
,	O
Raffel	O
C.	O
Department	O
of	O
Neurosurgery	O
,	O
Mayo	O
Clinic	O
and	O
Foundation	O
,	O
Rochester	O
,	O
Minnesota	O
55905	O
,	O
USA	O
.	O
The	O
beta-catenin	O
,	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK-3beta	O
)	O
,	O
and	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
products	O
interact	O
to	O
form	O
a	O
network	O
that	O
influences	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O
Medulloblastoma	B-malignancy-type
occurs	O
as	O
part	O
of	O
Turcot	O
's	O
syndrome	O
,	O
and	O
patients	O
with	O
Turcot	O
's	O
who	O
develop	O
medulloblastomas	B-malignancy-type
have	O
been	O
shown	O
to	O
harbor	O
germ	O
-	O
line	O
APC	O
mutations	O
.	O
Although	O
APC	O
mutations	O
have	O
been	O
investigated	O
and	O
not	O
identified	O
in	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
,	O
the	O
status	O
of	O
the	O
beta-catenin	O
and	O
GSK-3beta	O
genes	O
has	O
not	O
been	O
evaluated	O
in	O
this	O
tumor	O
.	O
Here	O
we	O
show	O
that	O
3	O
of	O
67	O
medulloblastomas	B-malignancy-type
harbor	O
beta-catenin	O
mutations	O
,	O
each	O
of	O
which	O
converts	O
a	O
GSK-3beta	O
phosphorylation	O
site	O
from	O
serine	O
to	O
cysteine	O
.	O
The	O
beta-catenin	O
mutation	O
seen	O
in	O
the	O
tumors	O
was	O
not	O
present	O
in	O
matched	O
constitutional	O
DNA	O
in	O
the	O
two	O
cases	O
where	O
matched	O
DNA	O
was	O
available	O
.	O
A	O
loss	O
of	O
heterozygosity	O
analysis	O
of	O
32	O
medulloblastomas	B-malignancy-type
with	O
paired	O
normal	O
DNA	O
samples	O
was	O
performed	O
with	O
four	O
microsatellite	O
markers	O
flanking	O
the	O
GSK-3beta	O
locus	O
;	O
loss	O
of	O
heterozygosity	O
with	O
at	O
least	O
one	O
marker	O
was	O
identified	O
in	O
7	O
tumors	O
.	O
Sequencing	O
of	O
the	O
remaining	O
GSK-3beta	O
allele	O
in	O
these	O
cases	O
failed	O
to	O
identify	O
any	O
mutations	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
medulloblastomas	B-malignancy-type
.	O
The	O
GSK-3beta	O
gene	O
does	O
not	O
appear	O
to	O
be	O
a	O
target	O
for	O
inactivation	O
in	O
this	O
tumor	O
.	O
PMID	O
:	O
9500446	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Histopathology	O
1998	O
Mar;	O
32	O
(	O
3	O
)	O
:	O
199	O
-	O
208	O
Immunoperoxidase	O
staining	O
for	O
cytokeratins	O
8	O
and	O
18	O
is	O
very	O
sensitive	O
for	O
detection	O
of	O
occult	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
of	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
:	O
a	O
comparison	O
with	O
genetic	O
analysis	O
of	O
K-ras	O
.	O
Sasaki	O
M	O
,	O
Watanabe	O
H	O
,	O
Jass	O
JR	O
,	O
Ajioka	O
Y	O
,	O
Kobayashi	O
M	O
,	O
Hatakeyama	O
K.	O
First	O
Department	O
of	O
Pathology	O
,	O
Niigata	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
AIMS	O
:	O
Recent	O
reports	O
suggest	O
that	O
genetic	O
examination	O
of	O
K-ras	O
or	O
p53	O
mutation	O
is	O
more	O
sensitive	O
for	O
the	O
detection	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
in	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
than	O
conventional	O
examination	O
by	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
staining	O
or	O
immunohistochemistry	O
for	O
gene	O
products	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
,	O
first	O
,	O
to	O
define	O
the	O
microscopic	O
characteristics	O
of	O
metastatic	O
cancer	O
cells	O
in	O
lymph	O
nodes	O
stained	O
by	O
the	O
anti	O
-	O
cytokeratin	O
antibody	O
CAM5.2	O
for	O
cytokeratins	O
8	O
and	O
18	O
,	O
and	O
,	O
second	O
,	O
to	O
compare	O
the	O
detection	O
rate	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
for	O
immunohistochemical	O
vs	O
genetic	O
methods	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
first	O
examined	O
in	O
primary	O
tumours	O
of	O
seven	O
cases	O
which	O
showed	O
distant	B-malignancy-type
metastasis	I-malignancy-type
or	O
local	O
recurrence	O
within	O
5	O
years	O
of	O
the	O
initial	O
surgery	O
in	O
spite	O
of	O
the	O
original	O
reporting	O
of	O
no	O
lymph	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
by	O
routine	O
H	O
&	O
E	O
staining	O
.	O
K-ras	O
mutations	O
were	O
positive	O
in	O
three	O
cases	O
in	O
primary	O
tumours	O
and	O
lymph	O
nodes	O
,	O
and	O
the	O
remaining	O
four	O
primary	O
tumours	O
were	O
negative	O
for	O
p53	O
mutation	O
as	O
well	O
as	O
K-ras	O
mutation	O
.	O
Therefore	O
,	O
genetic	O
analysis	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
was	O
uninformative	O
,	O
but	O
occult	B-malignancy-type
metastasis	I-malignancy-type
was	O
detected	O
by	O
cytokeratin	O
staining	O
in	O
two	O
of	O
these	O
four	O
cases	O
.	O
Comparative	O
study	O
of	O
cytokeratin	O
-	O
positive	O
cells	O
was	O
performed	O
on	O
each	O
of	O
the	O
43	O
lymph	O
nodes	O
from	O
three	O
cases	O
with	O
K-ras	O
mutations	O
.	O
Cancer	O
cells	O
were	O
detected	O
in	O
28	O
of	O
the	O
43	O
lymph	O
nodes	O
(	O
65.1	O
%	O
)	O
by	O
cytokeratin	O
staining	O
and	O
in	O
10	O
of	O
the	O
43	O
corresponding	O
lymph	O
nodes	O
(	O
23.3	O
%	O
)	O
by	O
genetic	O
analysis	O
.	O
Artefactual	O
contamination	O
by	O
cancer	O
cells	O
was	O
present	O
in	O
eight	O
of	O
the	O
28	O
cytokeratin	O
positive	O
lymph	O
nodes	O
,	O
and	O
three	O
of	O
the	O
eight	O
nodes	O
were	O
genetically	O
positive	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
cytokeratin	O
immunohistochemistry	O
is	O
more	O
sensitive	O
and	O
specific	O
for	O
the	O
detection	O
of	O
occult	B-malignancy-type
lymph	I-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
than	O
genetic	O
diagnosis	O
by	O
K-ras	O
mutation	O
in	O
cases	O
with	O
genetic	O
alterations	O
as	O
well	O
as	O
in	O
cases	O
without	O
them	O
.	O
PMID	O
:	O
9568504	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Genes	O
Chromosomes	O
Cancer	O
1998	O
May	O
;	O
22	O
(	O
1	O
)	O
:	O
37	O
-	O
41	O
A	O
beta-catenin	O
mutation	O
in	O
a	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumor	I-malignancy-type
of	O
the	O
RER	O
phenotype	O
and	O
absence	O
of	O
beta-catenin	O
germline	O
mutations	O
in	O
FAP	B-malignancy-type
patients	O
.	O
Muller	O
O	O
,	O
Nimmrich	O
I	O
,	O
Finke	O
U	O
,	O
Friedl	O
W	O
,	O
Hoffmann	O
I	O
.	O
Arbeitsgruppe	O
Tumorgenetik	O
,	O
Abteilung	O
fur	O
Strukturelle	O
Biologie	O
,	O
Max	O
-	O
Planck	O
-	O
Institut	O
fur	O
molekulare	O
Physiologie	O
,	O
Dortmund	O
,	O
Germany	O
.	O
As	O
a	O
signaling	O
protein	O
in	O
the	O
Wnt	O
pathway	O
beta-catenin	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
proliferation	O
.	O
Recently	O
,	O
oncogenic	O
beta-catenin	O
mutations	O
were	O
described	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
and	O
melanoma	B-malignancy-type
cell	O
lines	O
.	O
Since	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
have	O
similar	O
effects	O
on	O
the	O
biochemical	O
level	O
as	O
inactivating	O
mutations	O
in	O
the	O
tumor	O
suppressor	O
gene	O
APC	O
,	O
it	O
is	O
speculated	O
that	O
beta-catenin	O
mutations	O
may	O
substitute	O
APC	O
gene	O
inactivation	O
in	O
carcinogenesis	O
.	O
To	O
address	O
this	O
question	O
we	O
analyzed	O
twenty-three	O
sporadic	O
colorectal	O
tumors	O
of	O
different	O
progression	O
states	O
for	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
Eighteen	O
of	O
these	O
tumors	O
showed	O
the	O
wildtype	O
APC	O
gene	O
sequence	O
.	O
In	O
only	O
one	O
of	O
the	O
tumors	O
with	O
wildtype	O
APC	O
a	O
beta-catenin	O
gene	O
mutation	O
was	O
found	O
.	O
This	O
tumor	O
was	O
of	O
the	O
RER	O
(	O
replication	O
error	O
)	O
phenotype	O
which	O
may	O
explain	O
the	O
finding	O
that	O
the	O
mutation	O
occurred	O
in	O
a	O
sequential	O
repeat	O
motif	O
of	O
the	O
beta-catenin	O
gene	O
.	O
The	O
second	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
differences	O
in	O
the	O
phenotypic	O
variability	O
in	O
FAP	B-malignancy-type
(	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
)	O
might	O
be	O
due	O
to	O
inherited	O
alterations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
For	O
this	O
we	O
analyzed	O
DNA	O
from	O
fourteen	O
FAP	B-malignancy-type
patients	O
from	O
eight	O
different	O
families	O
for	O
germline	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
We	O
did	O
not	O
find	O
any	O
beta-catenin	O
gene	O
alteration	O
in	O
these	O
samples	O
.	O
Our	O
results	O
indicate	O
that	O
somatic	O
beta-catenin	O
activating	O
mutations	O
contribute	O
only	O
to	O
a	O
minor	O
part	O
of	O
human	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
and	O
that	O
germline	O
beta-catenin	O
mutations	O
do	O
not	O
play	O
a	O
role	O
in	O
the	O
variability	O
of	O
symptoms	O
in	O
FAP	B-malignancy-type
.	O
PMID	O
:	O
9591632	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
1998	O
May;	O
77	O
(	O
10	O
)	O
:	O
1573	O
-	O
9	O
Analysis	O
of	O
p53	O
,	O
p16MTS	O
,	O
p21WAF1	O
and	O
H-ras	O
in	O
archived	B-malignancy-type
bladder	I-malignancy-type
tumours	I-malignancy-type
from	O
workers	O
exposed	O
to	O
aromatic	O
amines	O
.	O
Sorlie	O
T	O
,	O
Marte	O
l-Planche	O
G,	O
Hainaut	O
P,	O
Lewalter	O
J,	O
Holm	O
R	O
,	O
Borrese	O
n-Dale	O
AL	O
,	O
Montesano	O
R.	O
Department	O
of	O
Genetics	O
,	O
Institute	O
for	O
Cancer	O
Research	O
,	O
The	O
Norwegian	O
Radium	O
Hospital	O
,	O
Oslo	O
.	O
Exposure	O
to	O
aromatic	O
amines	O
is	O
considered	O
a	O
major	O
risk	O
factor	O
for	O
the	O
development	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
pattern	O
of	O
point	O
mutations	O
in	O
several	O
tumour	O
genes	O
in	O
21	O
cases	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
arising	O
among	O
western	O
European	O
workers	O
exposed	O
to	O
aromatic	O
amines	O
in	O
an	O
attempt	O
to	O
determine	O
whether	O
this	O
exposure	O
may	O
be	O
associated	O
with	O
a	O
unique	O
spectrum	O
of	O
mutations	O
.	O
Of	O
the	O
four	O
genes	O
analysed	O
(	O
p53	O
,	O
p16MTS1	O
,	O
p21WAF1	O
and	O
H-ras	O
)	O
,	O
only	O
p53	O
showed	O
a	O
high	O
frequency	O
of	O
mutations	O
(	O
in	O
8	O
out	O
of	O
21	O
cases	O
,	O
38	O
%	O
)	O
.	O
Two	O
mutations	O
were	O
found	O
in	O
p16	O
,	O
one	O
in	O
H-ras	O
and	O
none	O
in	O
p21	O
exon	O
3	O
.	O
All	O
mutations	O
were	O
at	O
G	O
:	O
C	O
base	O
pairs	O
,	O
mostly	O
at	O
non	O
-	O
CpG	O
residues	O
.	O
This	O
spectrum	O
of	O
mutations	O
,	O
which	O
is	O
highly	O
suggestive	O
of	O
an	O
involvement	O
of	O
exogenous	O
carcinogens	O
,	O
is	O
however	O
identical	O
to	O
the	O
spectrum	O
of	O
p53	O
mutations	O
detected	O
in	O
bladder	B-malignancy-type
cancers	I-malignancy-type
of	O
the	O
general	O
population	O
.	O
In	O
exposed	O
workers	O
,	O
p53	O
mutations	O
were	O
associated	O
with	O
tumour	O
grade	O
and	O
with	O
high	O
occupational	O
and	O
tobacco	O
exposure	O
.	O
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
the	O
same	O
carcinogens	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
bladder	B-malignancy-type
cancers	I-malignancy-type
in	O
workers	O
exposed	O
to	O
aromatic	O
amines	O
and	O
in	O
the	O
general	O
population	O
.	O
PMID	O
:	O
9635831	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Histopathology	O
1998	O
May;	O
32	O
(	O
5	O
)	O
:	O
444	O
-	O
8	O
Clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
:	O
an	O
adenocarcinoma	B-malignancy-type
with	I-malignancy-type
ductal	I-malignancy-type
phenotype	I-malignancy-type
.	O
Luttges	O
J,	O
Vogel	O
I	O
,	O
Menke	O
M,	O
Henn	O
e-Bruns	O
D	O
,	O
Kremer	O
B	O
,	O
Kloppel	O
G.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Kiel	O
,	O
Germany	O
.	O
AIMS	O
:	O
Primary	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
resembling	O
metastatic	B-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
has	O
only	O
rarely	O
been	O
described	O
.	O
To	O
date	O
it	O
has	O
been	O
poorly	O
characterized	O
as	O
a	O
distinct	O
tumour	O
entity	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
report	O
a	O
case	O
of	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
in	O
a	O
53	O
-	O
year	O
-	O
old	O
man	O
involving	O
the	O
head	O
of	O
the	O
pancreas	O
and	O
which	O
had	O
a	O
small	O
intraductal	O
papillary	O
component	O
.	O
The	O
clear	O
cell	O
portion	O
comprised	O
about	O
90	O
%	O
of	O
the	O
tumour	O
mass	O
.	O
It	O
showed	O
predominantly	O
a	O
solid	O
growth	O
pattern	O
with	O
a	O
few	O
scattered	O
tubular	O
structures	O
.	O
Immunocytochemically	O
the	O
tumour	O
cells	O
stained	O
positively	O
for	O
cytokeratins	O
7	O
,	O
8	O
,	O
18	O
and	O
19	O
,	O
whereas	O
the	O
reaction	O
for	O
vimentin	O
and	O
neuroendocrine	O
markers	O
was	O
negative	O
.	O
K-ras	O
analysis	O
revealed	O
a	O
point	O
mutation	O
at	O
codon	O
12	O
with	O
mutation	O
of	O
GGT	O
to	O
GAT	O
.	O
CONCLUSION	O
:	O
The	O
intraductal	O
tumour	O
component	O
of	O
this	O
clear	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
as	O
well	O
as	O
the	O
cytokeratin	O
pattern	O
and	O
the	O
K-ras	O
mutation	O
suggest	O
that	O
this	O
rare	O
type	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
has	O
a	O
ductal	O
phenotype	O
.	O
PMID	O
:	O
9639120	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Gastroenterol	O
1998	O
Jun;3	O
3	O
(	O
3	O
)	O
:	O
39	O
7-401	O
Primary	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
small	I-malignancy-type
intestine	I-malignancy-type
and	O
mutational	O
analysis	O
of	O
the	O
K-ras	O
and	O
p53	O
genes	O
.	O
Amano	O
M,	O
Imai	O
Y	O
,	O
Hashimoto	O
T	O
,	O
Saito	O
Y	O
,	O
Miyaoka	O
M,	O
Kawaguchi	O
M,	O
Saito	O
T.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Hokuso	O
Shiroi	O
Hospital	O
,	O
Chiba	O
,	O
Japan	O
.	O
A	O
69	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
Hokuso	O
Shiroi	O
Hospital	O
because	O
of	O
recurrent	O
pain	O
in	O
the	O
lower	O
right	O
side	O
of	O
the	O
abdomen	O
.	O
Small	B-malignancy-type
-	I-malignancy-type
intestinal	I-malignancy-type
cancer	I-malignancy-type
was	O
strongly	O
suspected	O
after	O
fluoroscopy	O
of	O
the	O
small	O
intestine	O
.	O
Laparotomy	O
showed	O
advanced	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
ileum	I-malignancy-type
,	I-malignancy-type
of	I-malignancy-type
complete	I-malignancy-type
annular	I-malignancy-type
constrictive	I-malignancy-type
type	I-malignancy-type
,	O
9.5	O
x	O
5	O
cm	O
in	O
size	O
.	O
Histologically	O
it	O
was	O
moderately	B-malignancy-type
differentiated	I-malignancy-type
tubular	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Neither	O
visceral	O
nor	O
nodal	O
metastases	O
were	O
found	O
,	O
and	O
the	O
patient	O
has	O
been	O
well	O
for	O
the	O
20	O
months	O
since	O
surgery	O
.	O
The	O
strong	O
resemblance	O
between	O
the	O
epidemiological	O
characteristics	O
of	O
small	B-malignancy-type
-	I-malignancy-type
intestinal	I-malignancy-type
cancers	I-malignancy-type
and	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
prompted	O
us	O
to	O
investigate	O
the	O
carcinogenetic	O
mechanisms	O
at	O
the	O
molecular	O
level	O
.	O
A	O
point	O
mutation	O
at	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
was	O
found	O
,	O
while	O
no	O
alterations	O
were	O
noted	O
in	O
the	O
p53	O
gene	O
,	O
whose	O
mutations	O
are	O
frequent	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
carcinogenetic	O
mechanisms	O
of	O
the	O
small	B-malignancy-type
-	I-malignancy-type
intestinal	I-malignancy-type
cancer	I-malignancy-type
we	O
experienced	O
may	O
thus	O
differ	O
from	O
those	O
of	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
9658320	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1998	O
Jul	O
21;95	O
(	O
15	O
)	O
:	O
884	O
7-51	O
Somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
frequent	O
in	O
mouse	O
and	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
de	O
La	O
Coste	O
A	O
,	O
Romagnolo	O
B	O
,	O
Billuart	O
P,	O
Renard	O
CA	O
,	O
Buendia	O
MA	O
,	O
Soubrane	O
O,	O
Fabre	O
M,	O
Chelly	O
J,	O
Beldjord	O
C,	O
Kahn	O
A	O
,	O
Perret	O
C.	O
Institut	O
National	O
de	O
la	O
Sante	O
et	O
de	O
la	O
Recherche	O
Medicale	O
U129	O
,	O
Institut	O
Cochin	O
de	O
Genetique	O
Moleculaire	O
,	O
Universite	O
Paris	O
V	O
Rene	O
Descartes	O
,	O
24	O
rue	O
du	O
Faubourg	O
Sain	O
t-Jacques	O
,	O
75014	O
Paris	O
,	O
France	O
.	O
Hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
is	O
the	O
major	O
primary	O
malignant	O
tumor	B-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
human	I-malignancy-type
liver	I-malignancy-type
,	O
but	O
the	O
molecular	O
changes	O
leading	O
to	O
liver	O
cell	O
transformation	O
remain	O
largely	O
unknown	O
.	O
The	O
Wnt	O
-	O
beta-catenin	O
pathway	O
is	O
activated	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
and	O
some	O
melanoma	B-malignancy-type
cell	O
lines	O
,	O
but	O
has	O
not	O
yet	O
been	O
investigated	O
in	O
HCC	B-malignancy-type
.	O
We	O
have	O
examined	O
the	O
status	O
of	O
the	O
beta-catenin	O
gene	O
in	O
different	O
transgenic	O
mouse	O
lines	O
of	O
HCC	B-malignancy-type
obtained	O
with	O
the	O
oncogenes	O
c-myc	O
or	O
H-ras	O
.	O
Fifty	O
percent	O
of	O
the	O
hepatic	B-malignancy-type
tumors	I-malignancy-type
in	O
these	O
transgenic	O
mice	O
had	O
activating	O
somatic	O
mutations	O
within	O
the	O
beta-catenin	O
gene	O
similar	O
to	O
those	O
found	O
in	O
colon	B-malignancy-type
cancers	I-malignancy-type
and	O
melanomas	B-malignancy-type
.	O
These	O
alterations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
point	O
mutations	O
or	O
deletions	O
)	O
lead	O
to	O
a	O
disregulation	O
of	O
the	O
signaling	O
function	O
of	O
beta-catenin	O
and	O
thus	O
to	O
carcinogenesis	O
.	O
We	O
then	O
analyzed	O
human	O
HCCs	B-malignancy-type
and	O
found	O
similar	O
mutations	O
in	O
eight	O
of	O
31	O
(	O
26	O
%	O
)	O
human	O
liver	B-malignancy-type
tumors	I-malignancy-type
tested	O
and	O
in	O
HepG2	O
and	O
HuH6	O
hepatoma	B-malignancy-type
cells	O
.	O
The	O
mutations	O
led	O
to	O
the	O
accumulation	O
of	O
beta-catenin	O
in	O
the	O
nucleus	O
.	O
Thus	O
alterations	O
in	O
the	O
beta-catenin	O
gene	O
frequently	O
are	O
selected	O
for	O
during	O
liver	O
tumorigenesis	O
and	O
suggest	O
that	O
disregulation	O
of	O
the	O
Wnt	O
-	O
beta-catenin	O
pathway	O
is	O
a	O
major	O
event	O
in	O
the	O
development	O
of	O
HCC	B-malignancy-type
in	O
humans	O
and	O
mice	O
.	O
PMID	O
:	O
9671767	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1998	O
Jul;2	O
2	O
(	O
7	O
)	O
:	O
63	O
1-7	O
Significance	O
of	O
chromosomal	O
alterations	O
and	O
mutations	O
of	O
the	O
N-RAS	O
and	O
TP53	O
genes	O
in	O
relation	O
to	O
leukemogenesis	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Misawa	O
S	O
,	O
Horiike	O
S	O
,	O
Kaneko	O
H,	O
Sasai	O
Y	O
,	O
Ueda	O
Y	O
,	O
Nakao	O
M,	O
Yokota	O
S	O
,	O
Taniwaki	O
M,	O
Fujii	O
H,	O
Nakagawa	O
H,	O
Tsuda	O
S	O
,	O
Kashima	O
K.	O
Division	O
of	O
Hematology	O
,	O
Kyoto	O
Prefectural	O
Yosanoumi	O
Hospital	O
,	O
Japan	O
.	O
We	O
examined	O
chromosomes	O
and	O
mutations	O
of	O
the	O
N-RAS	O
and	O
TP53	O
genes	O
in	O
73	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
Twenty-six	O
patients	O
showed	O
a	O
reciprocal	O
chromosomal	O
translocation	O
or	O
an	O
inversion	O
,	O
and	O
34	O
patients	O
showed	O
only	O
unbalanced	O
aberrations	O
.	O
Balanced	O
aberrations	O
were	O
predominantly	O
detected	O
in	O
the	O
AML	B-malignancy-type
patients	O
who	O
did	O
not	O
have	O
myelodysplasia	B-malignancy-type
,	O
preceding	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
,	O
and	O
a	O
history	O
of	O
chemotherapy	O
or	O
radiation	O
therapy	O
.	O
In	O
contrast	O
,	O
unbalanced	O
aberrations	O
were	O
more	O
frequently	O
seen	O
in	O
the	O
patients	O
with	O
AML	B-malignancy-type
with	O
trilineage	B-malignancy-type
myelodysplasia	I-malignancy-type
,	O
AML	B-malignancy-type
transformed	O
from	O
MDS	B-malignancy-type
,	O
and	O
therapy	O
-	O
related	O
AML	B-malignancy-type
.	O
Twenty-two	O
mutations	O
of	O
the	O
N-RAS	O
and	O
TP53	O
genes	O
were	O
detected	O
,	O
and	O
these	O
mutations	O
were	O
frequently	O
associated	O
with	O
unbalanced	O
chromosomal	O
aberrations	O
.	O
Furthermore	O
,	O
the	O
spectrum	O
of	O
mutations	O
was	O
suggestive	O
of	O
an	O
exposure	O
to	O
alkylating	O
chemicals	O
.	O
PMID	O
:	O
9680114	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
1998	O
Ju	O
l-Aug;1	O
8	O
(4A)	O
:	O
267	O
5-8	O
Low-frequency	O
mutation	O
of	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
.	O
Olderoy	O
G,	O
Daehlin	O
L,	O
Ogreid	O
D.	O
Center	O
for	O
Molecular	O
Medicine	O
,	O
Haukeland	O
Hospital	O
,	O
Bergen	O
,	O
Norway	O
.	O
BACKGROUND	O
,	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
objective	O
was	O
to	O
study	O
the	O
frequency	O
of	O
mutations	O
of	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
in	O
bladder	B-malignancy-type
tumours	I-malignancy-type
.	O
Transitional	B-malignancy-type
cell	I-malignancy-type
tumours	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
from	O
55	O
patients	O
were	O
subjected	O
to	O
analyses	O
of	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
using	O
a	O
variety	O
of	O
techniques	O
including	O
sequencing	O
to	O
detect	O
mutations	O
.	O
RESULTS	O
:	O
Two	O
tumours	O
(	O
4	O
%	O
)	O
exhibited	O
mutation	O
of	O
the	O
Ki-ras	O
oncogene	O
,	O
both	O
tumours	O
were	O
fast	O
growing	O
and	O
invasive	O
.	O
We	O
did	O
not	O
detect	O
Ha-ras	O
mutation	O
in	O
any	O
of	O
the	O
samples	O
.	O
Nineteen	O
tumours	O
(	O
35	O
%	O
)	O
with	O
established	O
invasion	O
of	O
the	O
detrusor	O
muscle	O
,	O
did	O
not	O
reveal	O
any	O
mutation	O
.	O
CONCLUSION	O
:	O
Analyses	O
of	O
ras	O
oncogenes	O
seem	O
to	O
be	O
of	O
limited	O
value	O
for	O
the	O
biological	O
assessment	O
of	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9703927	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Feb;9	O
0	O
(	O
2	O
)	O
:	O
20	O
5-9	O
Frequent	O
beta-catenin	O
abnormalities	O
in	O
bone	B-malignancy-type
and	O
soft-tissue	B-malignancy-type
tumors	I-malignancy-type
.	O
Iwao	O
K,	O
Miyoshi	O
Y	O
,	O
Nawa	O
G,	O
Yoshikawa	O
H,	O
Ochi	O
T	O
,	O
Nakamura	O
Y	O
.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Biomedical	O
Research	O
Center	O
,	O
Osaka	O
.	O
We	O
have	O
screened	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
method	O
in	O
62	O
malignant	O
bone	B-malignancy-type
and	O
soft-tissue	B-malignancy-type
tumors	I-malignancy-type
,	O
including	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFHs	B-malignancy-type
)	O
,	O
osteosarcomas	O
,	O
synovial	O
sarcomas	O
,	O
liposarcomas	B-malignancy-type
,	O
malignant	B-malignancy-type
schwannomas	I-malignancy-type
,	O
and	O
other	O
types	O
of	O
tumors	O
,	O
as	O
well	O
as	O
11	O
benign	O
tumors	O
.	O
beta-Catenin	O
-	O
activating	O
missense	O
mutations	O
were	O
found	O
in	O
two	O
malignant	O
tumors	O
.	O
One	O
found	O
in	O
MFH	B-malignancy-type
occurred	O
at	O
codon	O
45	O
and	O
caused	O
an	O
amino	O
acid	O
substitution	O
from	O
serine	O
(	O
one	O
of	O
the	O
GSK3	O
beta	O
-	O
targeted	O
phosphorylation	O
sites	O
)	O
to	O
phenylalanine	O
.	O
The	O
other	O
,	O
detected	O
in	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
at	O
codon	O
32	O
,	O
resulted	O
in	O
an	O
amino	O
acid	O
change	O
from	O
aspartic	O
acid	O
(	O
located	O
adjacent	O
to	O
the	O
phosphorylation	O
target	O
,	O
serine	O
,	O
encoded	O
by	O
codon	O
33	O
)	O
to	O
tyrosine	O
.	O
Furthermore	O
,	O
we	O
found	O
accumulation	O
of	O
beta-catenin	O
by	O
western	O
-	O
blotting	O
analysis	O
in	O
12	O
of	O
19	O
malignant	O
tumors	O
in	O
which	O
we	O
found	O
no	O
mutation	O
involving	O
exon	O
3	O
.	O
Our	O
results	O
suggested	O
the	O
possible	O
involvement	O
of	O
beta-catenin	O
activation	O
,	O
by	O
beta-catenin	O
gene	O
mutation	O
or	O
alteration	O
of	O
other	O
factor(s)	O
,	O
in	O
the	O
formation	O
and/or	O
progression	O
of	O
various	O
types	O
of	O
bone	B-malignancy-type
and	O
soft-tissue	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
10189891	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Feb;9	O
0	O
(	O
2	O
)	O
:	O
24	O
0-8	O
K-ras	O
point	O
mutations	O
in	O
the	O
supernatants	O
of	O
pancreatic	O
juice	O
and	O
bile	O
are	O
reliable	O
for	O
diagnosis	O
of	O
pancreas	B-malignancy-type
and	O
biliary	B-malignancy-type
tract	I-malignancy-type
carcinomas	I-malignancy-type
complementary	O
to	O
cytologic	O
examination	O
.	O
Yamashita	O
K,	O
Kida	O
Y	O
,	O
Shinoda	O
H,	O
Kida	O
M,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
East	O
Hospital	O
,	O
Kanagawa	O
.	O
In	O
order	O
to	O
clarify	O
whether	O
DNA	O
analysis	O
for	O
K-ras	O
mutation	O
can	O
be	O
used	O
to	O
diagnose	O
cancers	O
in	O
supernatants	O
of	O
pancreatic	O
juice	O
and	O
bile	O
,	O
samples	O
from	O
29	O
cases	O
of	O
pancreatic	B-malignancy-type
,	O
biliary	B-malignancy-type
tract	I-malignancy-type
,	O
gastric	B-malignancy-type
,	O
and	O
neuroendocrine	B-malignancy-type
carcinomas	I-malignancy-type
,	O
1	O
malignant	B-malignancy-type
lymphoma	I-malignancy-type
case	O
,	O
2	O
cases	O
of	O
pancreatic	B-malignancy-type
adenoma	I-malignancy-type
,	O
9	O
cases	O
of	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
21	O
other	O
non	O
-	O
cancer	O
cases	O
were	O
examined	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
for	O
K-ras	O
gene	O
codons	O
2	O
to	O
97	O
of	O
exons	O
1	O
and	O
2	O
were	O
generated	O
with	O
33	O
/	O
33	O
(	O
100	O
%	O
)	O
pancreatic	O
juice	O
and	O
41	O
/	O
41	O
(	O
100	O
%	O
)	O
bile	O
samples	O
.	O
By	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
method	O
,	O
point	O
mutations	O
were	O
detected	O
in	O
the	O
pancreatic	O
juice	O
or	O
bile	O
supernatants	O
of	O
13	O
/	O
13	O
(	O
100	O
%	O
)	O
pancreas	B-malignancy-type
cancer	I-malignancy-type
cases	O
,	O
5	O
/	O
14	O
(	O
35.7	O
%	O
)	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
cases	O
,	O
1	O
/	O
2	O
(	O
50.0	O
%	O
)	O
pancreatic	B-malignancy-type
adenoma	I-malignancy-type
cases	O
and	O
3	O
/	O
9	O
(	O
33.3	O
%	O
)	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
cases	O
.	O
Direct	O
sequencing	O
confirmed	O
identical	O
point	O
mutations	O
in	O
the	O
supernatants	O
,	O
malignant	O
cells	O
of	O
cytologic	O
smears	O
of	O
pancreatic	O
juice	O
or	O
bile	O
and	O
cancer	O
tissues	O
.	O
The	O
DNA	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
K-ras	O
point	O
mutations	O
in	O
3	O
cases	O
of	O
pancreatic	B-malignancy-type
carcinomas	I-malignancy-type
with	O
false-negative	O
cytologic	O
diagnoses	O
.	O
This	O
novel	O
method	O
allows	O
simultaneous	O
testing	O
for	O
genetic	O
abnormalities	O
in	O
supernatants	O
of	O
pancreatic	O
juice	O
and	O
bile	O
,	O
after	O
removing	O
cells	O
for	O
cytologic	O
diagnosis	O
and	O
screening	O
for	O
pancreatic	B-malignancy-type
and	O
biliary	B-malignancy-type
tract	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
10189896	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
1999	O
Apr;	O
8	O
(	O
4	O
Pt	O
1	O
)	O
:	O
29	O
7-302	O
Erratum	O
in	O
:	O
Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2001	O
Dec;1	O
0	O
(	O
12	O
)	O
:	O
1309	O
Comparison	O
of	O
mutations	O
in	O
the	O
p53	O
and	O
K-ras	O
genes	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
smoking	O
and	O
nonsmoking	O
women	O
.	O
Gealy	O
R	O
,	O
Zhang	O
L,	O
Siegfried	O
JM	O
,	O
Luketich	O
JD	O
,	O
Keohavong	O
P.	O
Department	O
of	O
Environmental	O
and	O
Occupational	O
Health	O
,	O
University	O
of	O
Pittsburgh	O
,	O
Pennsylvania	O
,	O
USA	O
.	O
Lung	B-malignancy-type
cancer	I-malignancy-type
incidence	O
is	O
increasing	O
in	O
women	O
with	O
little	O
or	O
no	O
tobacco	O
exposure	O
,	O
and	O
the	O
cause	O
of	O
this	O
trend	O
is	O
not	O
known	O
.	O
One	O
possibility	O
is	O
increased	O
sensitivity	O
to	O
environmental	O
tobacco	O
smoke	O
in	O
women	O
nonsmokers	O
diagnosed	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
To	O
determine	O
whether	O
mutations	O
associated	O
with	O
tobacco	O
exposure	O
are	O
found	O
in	O
the	O
lung	B-malignancy-type
tumors	I-malignancy-type
of	O
women	O
who	O
are	O
lifetime	O
nonsmokers	O
or	O
occasional	O
smokers	O
,	O
we	O
compared	O
the	O
p53	O
and	O
K-ras	O
mutational	O
spectra	O
in	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
23	O
female	O
nonsmokers	O
,	O
2	O
female	O
occasional	O
smokers	O
(	O
<	O
10	O
pack	O
-	O
years	O
)	O
,	O
and	O
30	O
female	O
long-term	O
smokers	O
(	O
20	O
-	O
100	O
pack	O
-	O
years	O
)	O
.	O
We	O
also	O
looked	O
for	O
p53	O
and	O
K-ras	O
mutations	O
in	O
three	O
carcinoid	B-malignancy-type
lung	I-malignancy-type
tumors	I-malignancy-type
,	O
two	O
from	O
female	O
nonsmokers	O
and	O
one	O
from	O
a	O
female	O
occasional	O
smoker	O
.	O
For	O
the	O
p53	O
gene	O
,	O
exons	O
4	O
-	O
8	O
were	O
examined	O
for	O
mutations	O
;	O
for	O
the	O
K-ras	O
gene	O
,	O
exon	O
1	O
was	O
examined	O
.	O
No	O
mutations	O
were	O
found	O
in	O
the	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
.	O
In	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
,	O
p53	O
mutations	O
were	O
identified	O
in	O
six	O
(	O
26.1	O
%	O
)	O
of	O
the	O
cases	O
from	O
lifetime	O
nonsmokers	O
and	O
consisted	O
of	O
five	O
transitions	O
(	O
including	O
three	O
C	O
to	O
T	O
,	O
one	O
G	O
to	O
A	O
,	O
and	O
one	O
T	O
to	O
C	O
)	O
and	O
one	O
T	O
to	O
A	O
transversion	O
.	O
In	O
comparison	O
,	O
p53	O
mutations	O
were	O
identified	O
in	O
10	O
(	O
31.3	O
%	O
)	O
of	O
the	O
32	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
short-term	O
and	O
long-term	O
smokers	O
and	O
consisted	O
of	O
six	O
transversions	O
(	O
four	O
G	O
to	O
T	O
,	O
one	O
A	O
to	O
T	O
,	O
and	O
one	O
G	O
to	O
C	O
)	O
,	O
one	O
A	O
to	O
G	O
transition	O
,	O
one	O
C	O
to	O
T	O
transition	O
,	O
and	O
two	O
deletions	O
of	O
one	O
to	O
four	O
bp	O
.	O
Mutations	O
in	O
the	O
p53	O
gene	O
found	O
in	O
nonsmokers	O
also	O
occurred	O
in	O
either	O
different	O
codons	O
or	O
different	O
positions	O
within	O
a	O
codon	O
compared	O
with	O
those	O
seen	O
in	O
long-term	O
smokers	O
.	O
K-ras	O
mutations	O
in	O
codon	O
12	O
were	O
identified	O
in	O
two	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
(	O
8.7	O
%	O
)	O
from	O
lifetime	O
nonsmokers	O
.	O
The	O
K-ras	O
mutations	O
found	O
were	O
a	O
G	O
to	O
T	O
transversion	O
and	O
a	O
G	O
to	O
A	O
transition	O
.	O
Eight	O
(	O
25	O
%	O
)	O
of	O
the	O
32	O
lung	B-malignancy-type
carcinomas	I-malignancy-type
from	O
smokers	O
contained	O
K-ras	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
(	O
four	O
G	O
to	O
T	O
transversions	O
and	O
four	O
G	O
to	O
A	O
transitions	O
)	O
.	O
In	O
addition	O
,	O
six	O
silent	O
mutations	O
that	O
are	O
most	O
likely	O
polymorphisms	O
were	O
found	O
in	O
both	O
smokers	O
and	O
nonsmokers	O
.	O
These	O
results	O
confirm	O
that	O
K-ras	O
mutations	O
are	O
more	O
frequent	O
in	O
smokers	O
than	O
in	O
nonsmokers	O
,	O
but	O
that	O
the	O
same	O
type	O
of	O
mutation	O
in	O
the	O
K-ras	O
gene	O
is	O
found	O
in	O
both	O
groups	O
.	O
In	O
contrast	O
,	O
although	O
the	O
frequency	O
of	O
mutation	O
in	O
the	O
p53	O
gene	O
was	O
similar	O
in	O
lifetime	O
nonsmokers	O
compared	O
with	O
long-term	O
smokers	O
,	O
the	O
types	O
and	O
spectra	O
of	O
mutation	O
are	O
significantly	O
different	O
.	O
Two	O
of	O
the	O
C	O
to	O
T	O
transitions	O
found	O
in	O
nonsmokers	O
,	O
but	O
none	O
of	O
those	O
found	O
in	O
smokers	O
,	O
occur	O
at	O
the	O
C	O
of	O
a	O
CpG	O
site	O
.	O
These	O
results	O
suggest	O
the	O
mutagen(s)	O
and/or	O
mechanisms	O
of	O
p53	O
mutations	O
in	O
women	O
nonsmokers	O
are	O
different	O
from	O
those	O
responsible	O
for	O
p53	O
mutations	O
in	O
women	O
smokers	O
,	O
which	O
are	O
probably	O
largely	O
induced	O
by	O
tobacco	O
mutagens	O
.	O
PMID	O
:	O
10207632	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
1999	O
Jun;44	O
(	O
6	O
)	O
:	O
82	O
2-5	O
Molecular	O
screening	O
of	O
patients	O
with	O
long	O
standing	O
extensive	O
ulcerative	O
colitis	O
:	O
detection	O
of	O
p53	O
and	O
Ki-ras	O
mutations	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
differential	O
hybridisation	O
in	O
colonic	O
lavage	O
fluid	O
.	O
Lang	O
SM	O
,	O
Stratakis	O
DF	O
,	O
Heinzlmann	O
M,	O
Heldwein	O
W	O
,	O
Wiebecke	O
B	O
,	O
Loeschke	O
K.	O
Medizinische	O
Klinik	O
,	O
Klinikum	O
Innenstadt	O
der	O
Universitat	O
Munchen	O
,	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Ziemssenstrasse	O
1	O
,	O
D-80336	O
Munchen	O
,	O
Germany	O
.	O
BACKGROUND	O
:	O
In	O
patients	O
with	O
long	O
standing	O
ulcerative	O
colitis	O
at	O
risk	O
of	O
developing	O
malignancy	O
,	O
mutations	O
of	O
the	O
p53	O
and	O
Ki-ras	O
gene	O
were	O
investigated	O
in	O
lavage	O
solution	O
obtained	O
at	O
surveillance	O
colonoscopy	O
.	O
METHODS	O
:	O
DNA	O
was	O
isolated	O
from	O
31	O
consecutive	O
patients	O
with	O
total	O
or	O
subtotal	O
ulcerative	O
colitis	O
and	O
a	O
disease	O
duration	O
of	O
between	O
seven	O
and	O
26	O
years	O
.	O
Twenty	O
seven	O
control	O
patients	O
showed	O
no	O
macroscopic	O
or	O
microscopic	O
inflammation	O
on	O
colonoscopy	O
.	O
Exons	O
5	O
-	O
8	O
of	O
the	O
p53	O
gene	O
and	O
exon	O
1	O
of	O
the	O
Ki-ras	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	O
of	O
the	O
p53	O
gene	O
were	O
detected	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
Point	O
mutations	O
of	O
the	O
Ki-ras	O
gene	O
were	O
hybridised	O
on	O
dot	O
blots	O
with	O
oligonucleotides	O
marked	O
with	O
digoxigenin	O
.	O
RESULTS	O
:	O
In	O
all	O
cases	O
of	O
ulcerative	O
colitis	O
and	O
in	O
all	O
of	O
the	O
27	O
control	O
patients	O
,	O
wild	O
type	O
p53	O
and	O
wild	O
type	O
Ki-ras	O
could	O
be	O
detected	O
.	O
In	O
four	O
patients	O
with	O
ulcerative	O
colitis	O
,	O
a	O
mutation	O
in	O
exon	O
5	O
to	O
7	O
of	O
the	O
p53	O
gene	O
was	O
found	O
,	O
and	O
two	O
patients	O
had	O
a	O
mutation	O
of	O
the	O
Ki-ras	O
gene	O
(	O
Gly	O
to	O
Asp	O
-	O
12	O
,	O
Gly	O
to	O
Val	O
-	O
12	O
)	O
.	O
None	O
of	O
these	O
patients	O
had	O
dysplasia	B-malignancy-type
in	O
serial	O
biopsy	O
specimens	O
,	O
and	O
all	O
but	O
one	O
had	O
had	O
the	O
disease	O
for	O
more	O
than	O
10	O
years	O
.	O
One	O
control	O
patient	O
had	O
a	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Mutations	O
were	O
more	O
frequent	O
in	O
patients	O
with	O
long	O
standing	O
ulcerative	O
colitis	O
(	O
19	O
%	O
)	O
than	O
in	O
control	O
patients	O
(	O
3	O
%	O
,	O
p	O
=	O
0.07	O
)	O
.	O
The	O
technique	O
may	O
be	O
useful	O
for	O
screening	O
for	O
early	O
malignancy	O
in	O
ulcerative	B-malignancy-type
colitis	I-malignancy-type
.	O
PMID	O
:	O
10323884	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
1999	O
Jun;44	O
(	O
6	O
)	O
:	O
82	O
6-33	O
Genetic	O
epidemiology	O
of	O
mutated	O
K-ras	O
proto	O
-	O
oncogene	O
,	O
altered	O
suppressor	O
genes	O
,	O
and	O
microsatellite	O
instability	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
Rashid	O
A	O
,	O
Zahurak	O
M,	O
Goodman	O
SN	O
,	O
Hamilton	O
SR.	O
Division	O
of	O
Gastrointestina	O
l/	O
Liver	O
Pathology	O
,	O
Department	O
of	O
Pathology	O
,	O
Ross	O
Building	O
Room	O
632	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
720	O
Rutland	O
Avenue	O
,	O
Baltimore	O
,	O
MD	O
2120	O
5-2196	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
The	O
genetic	O
epidemiology	O
of	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
has	O
not	O
been	O
studied	O
prospectively	O
in	O
colonoscopy	O
patients	O
without	O
cancer	O
.	O
AIMS	O
:	O
To	O
study	O
genetic	O
alterations	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
correlate	O
these	O
with	O
patient	O
demographics	O
and	O
adenoma	O
characteristics	O
.	O
METHODS	O
:	O
Mutations	O
and	O
allelic	O
deletions	O
in	O
201	O
adenomas	B-malignancy-type
from	O
60	O
patients	O
were	O
compared	O
with	O
demographic	O
features	O
,	O
adenoma	O
characteristics	O
,	O
and	O
family	O
history	O
.	O
RESULTS	O
:	O
The	O
most	O
common	O
alteration	O
was	O
K-ras	O
proto	O
-	O
oncogene	O
mutation	O
,	O
present	O
in	O
35	O
%	O
of	O
adenomas	B-malignancy-type
and	O
65	O
%	O
of	O
patients	O
.	O
Patients	O
65	O
years	O
of	O
age	O
and	O
older	O
had	O
a	O
decreased	O
probability	O
of	O
K-ras	O
mutations	O
(	O
26	O
%	O
versus	O
45	O
%	O
)	O
.	O
Overexpression	O
of	O
p53	O
gene	O
product	O
was	O
present	O
in	O
only	O
6	O
%	O
of	O
adenomas	B-malignancy-type
but	O
was	O
more	O
frequent	O
in	O
villous	B-malignancy-type
or	O
tubulovillous	B-malignancy-type
adenomas	I-malignancy-type
(	O
19	O
%	O
versus	O
3	O
%	O
)	O
.	O
Allelic	O
loss	O
of	O
chromosome	O
18q	O
was	O
present	O
in	O
only	O
2	O
%	O
of	O
adenomas	O
and	O
was	O
significantly	O
less	O
frequent	O
than	O
p53	O
overexpression	O
.	O
DNA	O
replication	O
errors	O
(	O
RER	O
)	O
were	O
present	O
in	O
7	O
%	O
of	O
adenomas	B-malignancy-type
and	O
15	O
%	O
of	O
patients	O
,	O
including	O
multiple	O
adenomas	B-malignancy-type
in	O
four	O
patients	O
(	O
two	O
with	O
hereditary	B-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
polyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
syndrome	O
)	O
.	O
Only	O
36	O
%	O
of	O
RER	B-malignancy-type
positive	I-malignancy-type
adenomas	I-malignancy-type
had	O
alteration	O
of	O
BAT-26	O
alleles	O
,	O
none	O
had	O
alteration	O
of	O
BAT-25	O
,	O
and	O
only	O
one	O
(	O
8	O
%	O
)	O
had	O
mutation	O
in	O
the	O
transforming	O
growth	O
factor	O
beta	O
type	O
II	O
receptor	O
gene	O
.	O
RER	B-malignancy-type
positive	I-malignancy-type
adenomas	I-malignancy-type
were	O
more	O
likely	O
to	O
have	O
a	O
K-ras	O
mutation	O
.	O
In	O
patients	O
with	O
multiple	O
adenomas	B-malignancy-type
,	O
there	O
was	O
concordance	O
of	O
p53	O
overexpression	O
and	O
RER	O
but	O
not	O
of	O
K-ras	O
mutations	O
.	O
CONCLUSIONS	O
:	O
Genetic	O
progression	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
is	O
heterogeneous	O
,	O
involving	O
factors	O
related	O
to	O
patient	O
age	O
and	O
the	O
presence	O
of	O
RER	O
for	O
the	O
occurrence	O
of	O
ras	O
mutations	O
,	O
but	O
different	O
intraindividual	O
characteristics	O
for	O
the	O
occurrence	O
of	O
p53	O
alterations	O
and	O
RER	O
.	O
PMID	O
:	O
10323885	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Res	O
1998;1	O
0	O
(	O
1	O
1-12	O
)	O
:	O
59	O
1-4	O
Frequent	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
in	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
from	O
patients	O
without	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
.	O
Miyoshi	O
Y	O
,	O
Iwao	O
K,	O
Nawa	O
G,	O
Yoshikawa	O
H,	O
Ochi	O
T	O
,	O
Nakamura	O
Y	O
.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suit	O
a	O
-shi	O
,	O
Japan	O
.	O
Mutations	O
in	O
the	O
APC	O
gene	O
contribute	O
to	O
development	O
of	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
as	O
well	O
as	O
to	O
the	O
hereditary	O
tumors	O
that	O
usually	O
accompany	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
.	O
Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
cause	O
an	O
intracellular	O
accumulation	O
of	O
beta-catenin	O
that	O
results	O
in	O
abnormal	O
signaling	O
in	O
the	O
wnt	O
/	O
wingless	O
pathway	O
.	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
itself	O
have	O
also	O
been	O
noted	O
in	O
several	O
types	O
of	O
tumors	O
.	O
In	O
this	O
study	O
we	O
screened	O
the	O
beta-catenin	O
gene	O
in	O
13	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
for	O
alterations	O
in	O
exon	O
3	O
,	O
which	O
encodes	O
several	O
serine	O
/	O
threonine	O
residues	O
that	O
are	O
targets	O
for	O
phosphorylation	O
by	O
GSK-3beta	O
.	O
Somatic	O
substitutions	O
at	O
codons	O
41	O
(	O
threonine	O
)	O
and	O
45	O
(	O
serine	O
)	O
were	O
identified	O
in	O
seven	O
independent	O
tumors	O
,	O
respectively	O
.	O
Although	O
no	O
APC	O
mutations	O
were	O
detected	O
among	O
the	O
remaining	O
six	O
tumors	O
,	O
we	O
found	O
accumulation	O
of	O
beta-catenin	O
by	O
Western	O
blotting	O
analysis	O
in	O
one	O
such	O
tumor	O
for	O
which	O
frozen	O
tissues	O
were	O
available	O
.	O
Our	O
results	O
have	O
suggested	O
that	O
possible	O
involvement	O
of	O
beta-catenin	O
activation	O
by	O
beta-catenin	O
gene	O
mutation	O
or	O
alteration	O
of	O
other	O
factor(s)	O
can	O
contribute	O
to	O
desmoid	O
tumorigenesis	O
.	O
PMID	O
:	O
10367940	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1999	O
Jul	O
1;8	O
6	O
(	O
1	O
)	O
:	O
5	O
8-63	O
H-ras	O
and	O
K-ras	O
mutations	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcoma	I-malignancy-type
:	O
comparative	O
studies	O
of	O
sarcomas	B-malignancy-type
from	O
Korean	O
and	O
American	O
patients	O
.	O
Yoo	O
J,	O
Robinson	O
RA.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
The	O
authors	O
'	O
recent	O
investigation	O
of	O
Korean	O
patients	O
with	O
sarcoma	B-malignancy-type
has	O
suggested	O
that	O
ras	O
gene	O
activation	O
may	O
play	O
a	O
role	O
in	O
oncogenesis	O
.	O
The	O
authors	O
attempted	O
to	O
extend	O
the	O
mutation	O
analysis	O
to	O
sarcomas	B-malignancy-type
in	O
American	O
patients	O
to	O
determine	O
whether	O
there	O
were	O
racial	O
or	O
geographic	O
factors	O
relevant	O
to	O
the	O
initiation	O
or	O
progression	O
of	O
sarcoma	B-malignancy-type
.	O
METHODS	O
:	O
H-ras	O
and	O
K-ras	O
genes	O
were	O
examined	O
in	O
sarcomas	B-malignancy-type
obtained	O
from	O
patients	O
in	O
the	O
midwestern	O
U.	O
S.	O
using	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
and	O
direct	O
automated	O
sequencing	O
analysis	O
.	O
Tumors	O
studied	O
included	O
29	O
malignant	B-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
,	O
7	O
liposarcomas	B-malignancy-type
,	O
5	O
rhabdomyosarcomas	B-malignancy-type
,	O
and	O
9	O
leiomyosarcomas	B-malignancy-type
.	O
RESULTS	O
:	O
Of	O
the	O
50	O
sarcomas	B-malignancy-type
evaluated	O
,	O
only	O
1	O
(	O
2	O
%	O
)	O
definable	O
mutation	O
was	O
found	O
;	O
a	O
GGC	O
to	O
AGC	O
transition	O
at	O
codon	O
12	O
of	O
H-ras	O
was	O
found	O
in	O
a	O
rhabdomyosarcoma	B-malignancy-type
.	O
None	O
of	O
the	O
patients	O
had	O
a	O
K-ras	O
mutation	O
.	O
The	O
rates	O
of	O
incidence	O
of	O
ras	O
point	O
mutations	O
in	O
these	O
samples	O
were	O
much	O
lower	O
(	O
H-ras	O
:	O
2	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
0	O
-	O
11.5	O
%	O
and	O
K-ras	O
:	O
0	O
%	O
)	O
than	O
described	O
for	O
both	O
genes	O
in	O
Korean	O
studies	O
(	O
H-ras	O
:	O
16	O
%	O
;	O
95	O
%	O
CI	O
,	O
5.2	O
-	O
26.8	O
%	O
and	O
K-ras	O
:	O
44	O
%	O
;	O
95	O
%	O
CI	O
,	O
29.5	O
-	O
58.5	O
%	O
)	O
.	O
CONCLUSIONS	O
:	O
Although	O
the	O
reason	O
for	O
this	O
discrepancy	O
is	O
not	O
clear	O
,	O
there	O
were	O
no	O
major	O
differences	O
found	O
in	O
histology	O
or	O
clinical	O
stages	O
.	O
Based	O
on	O
this	O
study	O
of	O
50	O
sarcoma	B-malignancy-type
samples	O
from	O
American	O
patients	O
and	O
the	O
authors	O
'	O
previous	O
study	O
of	O
45	O
Korean	O
tumor	O
samples	O
,	O
the	O
authors	O
conclude	O
that	O
differing	O
genetic	O
and/or	O
environmental	O
mechanisms	O
can	O
affect	O
sarcoma	B-malignancy-type
development	O
or	O
progression	O
.	O
Mutation	O
of	O
the	O
H-ras	O
and	O
K-ras	O
genes	O
appears	O
to	O
be	O
uncommon	O
in	O
sarcomas	B-malignancy-type
occurring	O
in	O
American	O
patients	O
,	O
suggesting	O
that	O
the	O
activation	O
by	O
point	O
mutations	O
of	O
the	O
H-ras	O
and	O
K-ras	O
genes	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
or	O
progression	O
of	O
sarcoma	B-malignancy-type
in	O
these	O
patients	O
.	O
PMID	O
:	O
10391564	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1999	O
Aug;2	O
5	O
(	O
4	O
)	O
:	O
39	O
9-402	O
Beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	B-malignancy-type
.	O
Blaker	O
H,	O
Hofmann	O
WJ	O
,	O
Rieker	O
RJ	O
,	O
Penzel	O
R	O
,	O
Graf	O
M,	O
Otto	O
HF.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Heidelberg	O
,	O
Heidelberg	O
,	O
Germany	O
.	O
hendrik_blaeker@ukl	O
.un	O
i-heidelberg.de	O
Hepatoblastoma	B-malignancy-type
is	O
a	O
rare	O
malignant	O
tumor	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
liver	I-malignancy-type
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years	O
.	O
Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	O
type	O
in	O
families	O
affected	O
by	O
adenomatous	B-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
.	O
In	O
addition	O
to	O
the	O
epidemiologic	O
data	O
,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
APC	O
tumor	O
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	O
tumorigenesis	O
.	O
A	O
major	O
function	O
of	O
APC	O
is	O
the	O
downregulation	O
of	O
beta-catenin	O
,	O
a	O
transcription	O
-	O
activating	O
protein	O
with	O
oncogenic	O
potential	O
.	O
In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta-catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	O
types	O
that	O
are	O
associated	O
with	O
adenomatous	B-malignancy-type
polyposis	I-malignancy-type
coli	I-malignancy-type
,	O
we	O
observed	O
increased	O
beta-catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B-malignancy-type
.	O
Sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	O
samples	O
.	O
Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta-catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B-malignancy-type
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	O
type	O
.	O
Genes	O
Chromosomes	O
Cancer	O
25	O
:	O
399	O
-	O
402	O
,	O
1999	O
.	O
Copyright	O
1999	O
Wiley-Liss	O
,	O
Inc.	O
PMID	O
:	O
10398436	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Jul	O
15	O
;5	O
9	O
(	O
14	O
)	O
:	O
334	O
6-51	O
Beta-catenin	O
mutations	O
are	O
specific	O
for	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
with	O
microsatellite	O
instability	O
but	O
occur	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
irrespective	O
of	O
mutator	O
pathway	O
.	O
Mirabell	O
i-Primdahl	O
L,	O
Gryfe	O
R	O
,	O
Kim	O
H,	O
Millar	O
A	O
,	O
Luceri	O
C,	O
Dale	O
D	O
,	O
Holowaty	O
E	O
,	O
Bapat	O
B	O
,	O
Gallinger	O
S	O
,	O
Redston	O
M.	O
Centre	O
for	O
Cancer	O
Genetics	O
,	O
Samuel	O
Lunenfeld	O
Research	O
Institute	O
,	O
Mount	O
Sinai	O
Hospital	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
Some	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
with	O
wild-type	O
adenomatous	O
polyposis	O
coli	O
gene	O
have	O
activating	O
mutations	O
in	O
beta-catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
that	O
result	O
in	O
decreased	O
phosphorylation	O
by	O
GSK-3beta	O
and	O
increased	O
signaling	O
through	O
the	O
Tcf	O
/	O
Lef	O
transcription	O
factors	O
.	O
To	O
investigate	O
the	O
relationship	O
between	O
CTNNB1	O
mutations	O
and	O
underlying	O
pathways	O
of	O
genomic	O
instability	O
,	O
we	O
examined	O
80	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
stratified	O
by	O
the	O
presence	O
or	O
absence	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
CTNNB1	O
mutations	O
were	O
identified	O
in	O
13	O
(	O
25	O
%	O
)	O
of	O
53	O
cancers	O
with	O
high	O
frequency	O
MSI	O
(	O
MSI-H	O
)	O
,	O
including	O
12	O
point	O
mutations	O
at	O
exon	O
3	O
phosphorylation	O
sites	O
(	O
codons	O
41	O
and	O
45	O
)	O
and	O
one	O
deletion	O
of	O
the	O
entire	O
exon	O
3	O
degradation	O
box	O
.	O
No	O
CTNNB1	O
mutations	O
were	O
identified	O
in	O
27	O
microsatellite	O
stable	O
or	O
low	O
frequency	O
MSI	O
(	O
MSI-L	O
)	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
(	O
P	O
<	O
0.01	O
)	O
.	O
In	O
contrast	O
,	O
CTNNB1	O
mutations	O
were	O
identified	O
in	O
3	O
of	O
9	O
(	O
33	O
%	O
)	O
MSI-H	O
and	O
10	O
of	O
20	O
(	O
50	O
%	O
)	O
MSS	O
/	O
MSI-L	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
a	O
more	O
generalized	O
involvement	O
in	O
these	O
tumors	O
.	O
Only	O
six	O
(	O
46	O
%	O
)	O
of	O
the	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
CTNNB1	O
mutations	O
occurred	O
at	O
residues	O
directly	O
phosphorylated	O
by	O
GSK-3beta	O
,	O
and	O
only	O
one	O
of	O
these	O
was	O
at	O
either	O
codon	O
41	O
or	O
45	O
.	O
All	O
point	O
mutations	O
in	O
MSI-H	O
cancers	O
were	O
transitions	O
,	O
whereas	O
64	O
%	O
of	O
those	O
in	O
MSS	O
/	O
MSI-L	O
cancers	O
were	O
transversions	O
(	O
P	O
<	O
0.01	O
)	O
.	O
The	O
differences	O
in	O
the	O
mutation	O
profiles	O
suggest	O
that	O
there	O
may	O
be	O
molecular	O
fingerprints	O
of	O
CTNNB1	O
mutations	O
,	O
determined	O
by	O
biological	O
factors	O
related	O
to	O
both	O
tumor	O
type	O
and	O
underlying	O
pathways	O
of	O
genomic	O
instability	O
.	O
PMID	O
:	O
10416591	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1999	O
Aug	O
27;8	O
2	O
(	O
5	O
)	O
:	O
62	O
5-9	O
beta-catenin	O
mutation	O
and	O
expression	O
analysis	O
in	O
ovarian	B-malignancy-type
cancer	I-malignancy-type
:	O
exon	O
3	O
mutations	O
and	O
nuclear	O
translocation	O
in	O
16	O
%	O
of	O
endometrioid	B-malignancy-type
tumours	I-malignancy-type
.	O
Wright	O
K,	O
Wilson	O
P,	O
Morland	O
S	O
,	O
Campbell	O
I	O
,	O
Walsh	O
M,	O
Hurst	O
T	O
,	O
Ward	O
B	O
,	O
Cummings	O
M,	O
Chenevi	O
x-Trench	O
G.	O
Joint	O
Experimental	O
Oncology	O
Program	O
,	O
Queensland	O
Institute	O
of	O
Medical	O
Research	O
and	O
University	O
of	O
Queensland	O
,	O
Brisbane	O
,	O
Australia	O
.	O
The	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
generation	O
of	O
epithelial	B-malignancy-type
ovarian	I-malignancy-type
cancers	I-malignancy-type
are	O
poorly	O
understood	O
,	O
but	O
evidence	O
suggests	O
that	O
the	O
different	O
histological	O
subtypes	O
may	O
arise	O
from	O
independent	O
tumorigenic	O
events	O
.	O
beta-Catenin	O
is	O
emerging	O
as	O
an	O
important	O
oncogene	O
in	O
the	O
transformation	O
of	O
a	O
number	O
of	O
epithelial	B-malignancy-type
cancers	I-malignancy-type
,	O
and	O
mutations	O
have	O
been	O
reported	O
in	O
a	O
small	O
study	O
of	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Mutations	O
in	O
the	O
NH(2)	O
-	O
regulatory	O
domain	O
of	O
beta-catenin	O
stabilise	O
the	O
cytoplasmic	O
levels	O
of	O
this	O
protein	O
,	O
which	O
promotes	O
up	O
-	O
regulation	O
of	O
the	O
beta-catenin	O
-	O
T-cell	O
factor	O
-	O
lymphoid	O
enhancer	O
factor	O
transcriptional	O
complex	O
.	O
We	O
report	O
here	O
beta-catenin	O
(	O
CTNNB1	O
)	O
exon	O
3	O
mutation	O
analysis	O
in	O
149	O
epithelial	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
This	O
revealed	O
10	O
/	O
63	O
(	O
16	O
%	O
)	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
tumours	I-malignancy-type
with	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
.	O
All	O
mutations	O
were	O
missense	O
changes	O
within	O
the	O
GSK3beta	O
consensus	O
site	O
,	O
affecting	O
serine	O
residues	O
at	O
codons	O
33	O
and	O
37	O
and	O
glycine	O
at	O
codon	O
34	O
.	O
Immuno	O
-	O
histochemical	O
analysis	O
identified	O
cytoplasmic	O
stabilisation	O
and	O
nuclear	O
translocation	O
in	O
those	O
endometrioid	B-malignancy-type
tumours	I-malignancy-type
with	O
mutations	O
.	O
This	O
phenotypic	O
change	O
was	O
also	O
identified	O
in	O
3	O
other	O
endometrioid	B-malignancy-type
tumours	I-malignancy-type
that	O
did	O
not	O
have	O
somatic	O
mutations	O
within	O
exon	O
3	O
of	O
CTNNB1	O
.	O
Stabilisation	O
of	O
the	O
free	O
,	O
monomeric	O
pool	O
of	O
beta-catenin	O
and	O
the	O
probable	O
resulting	O
constitutive	O
activation	O
of	O
its	O
Tcf	O
-	O
associated	O
transcriptional	O
complex	O
appears	O
to	O
be	O
a	O
specific	O
oncogenic	O
event	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
Copyright	O
1999	O
Wiley-Liss	O
,	O
Inc.	O
PMID	O
:	O
10417756	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hepatogastroenterology	O
1999	O
Ma	O
y-Jun;46	O
(27	O
)	O
:	O
206	O
3-8	O
K-ras	O
mutations	O
in	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
and	O
in	O
carcinomas	B-malignancy-type
from	O
the	O
non	O
-	O
operated	O
stomach	O
.	O
van	O
Rees	O
BP	O
,	O
Musler	O
A	O
,	O
Caspers	O
E	O
,	O
Drillenburg	O
P,	O
Craanen	O
ME	O
,	O
Polkowski	O
W	O
,	O
Chibowski	O
D	O
,	O
Offerhaus	O
GJ.	O
Department	O
of	O
Pathology	O
,	O
Academic	O
Medical	O
Center	O
,	O
University	O
of	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
b.p.vanrees@amc.uva.nl	O
BACKGROUND	O
/	O
AIMS	O
:	O
Partial	O
gastrectomy	O
is	O
a	O
well	O
-	O
established	O
pre	O
-	O
malignant	O
condition	O
.	O
It	O
is	O
postulated	O
that	O
in	O
the	O
gastric	O
stump	O
an	O
accelerated	O
neoplastic	O
process	O
takes	O
place	O
,	O
similar	O
to	O
that	O
of	O
(	B-malignancy-type
intestinal	I-malignancy-type
type	I-malignancy-type
)	I-malignancy-type
adenocarcinoma	I-malignancy-type
from	O
the	O
non	O
-	O
operated	O
stomach	O
.	O
K-ras	O
codon	O
12	O
mutation	O
is	O
one	O
of	O
the	O
most	O
frequent	O
oncogenic	O
alterations	O
in	O
human	O
solid	B-malignancy-type
neoplasms	I-malignancy-type
.	O
It	O
is	O
rare	O
in	O
conventional	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
and	O
has	O
not	O
been	O
studied	O
in	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
prevalence	O
of	O
K-ras	O
codon	O
12	O
point	O
mutations	O
in	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
with	O
those	O
in	O
conventional	O
carcinomas	B-malignancy-type
from	O
the	O
non	O
-	O
operated	O
stomach	O
.	O
METHODOLOGY	O
:	O
Twenty-four	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
were	O
compared	O
with	O
26	O
conventional	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Stage	O
,	O
histology	O
,	O
and	O
demographics	O
were	O
comparable	O
in	O
both	O
groups	O
.	O
Mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
gene	O
were	O
examined	O
with	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
based	O
method	O
and	O
subsequent	O
dot	O
blot	O
hybridization	O
with	O
mutation	O
-	O
specific	O
probes	O
.	O
The	O
results	O
of	O
Helicobacter	O
pylori	O
infection	O
,	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
and	O
p53	O
immunohistochemistry	O
were	O
partially	O
known	O
from	O
a	O
previous	O
study	O
.	O
RESULTS	O
:	O
In	O
one	O
of	O
the	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
as	O
well	O
as	O
in	O
one	O
of	O
the	O
conventional	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
a	O
K-ras	O
codon	O
12	O
point	O
mutation	O
was	O
found	O
.	O
p53	O
immunohistochemistry	O
results	O
were	O
comparable	O
in	O
both	O
groups	O
.	O
Interestingly	O
,	O
Helicobacter	O
pylori	O
infection	O
rate	O
and	O
Epstein	O
-	O
Barr	O
virus	O
in	O
situ	O
hybridization	O
for	O
EBER1	O
,	O
as	O
previously	O
studied	O
,	O
appeared	O
were	O
significantly	O
different	O
in	O
the	O
two	O
groups	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
codon	O
12	O
point	O
mutations	O
are	O
rare	O
in	O
both	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinomas	I-malignancy-type
and	O
conventional	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
This	O
supports	O
the	O
postulated	O
hypothesis	O
that	O
the	O
pathways	O
of	O
carcinogenesis	O
in	O
both	O
gastric	B-malignancy-type
stump	I-malignancy-type
carcinoma	I-malignancy-type
and	O
conventional	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
share	O
common	O
features	O
.	O
However	O
,	O
these	O
groups	O
differ	O
in	O
infection	O
rate	O
of	O
Helicobacter	O
pylori	O
and	O
of	O
Epstein	O
-	O
Barr	O
virus	O
,	O
which	O
suggests	O
that	O
some	O
neoplastic	O
stimuli	O
differ	O
as	O
well	O
.	O
PMID	O
:	O
10430398	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Aug	O
15	O
;5	O
9	O
(	O
16	O
)	O
:	O
388	O
0-2	O
Mutational	O
activation	O
of	O
the	O
beta-catenin	O
proto	O
-	O
oncogene	O
is	O
a	O
common	O
event	O
in	O
the	O
development	O
of	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumors	I-malignancy-type
.	O
Koesters	O
R	O
,	O
Ridder	O
R	O
,	O
Kop	O
p-Schneider	O
A	O
,	O
Betts	O
D	O
,	O
Adams	O
V	O
,	O
Niggli	O
F	O
,	O
Briner	O
J,	O
von	O
Knebel	O
Doeberitz	O
M.	O
Department	O
of	O
Surgery	O
,	O
University	O
of	O
Heidelberg	O
,	O
Germany	O
.	O
R.Koesters@DKF	O
Z-Heidelberg.de	O
Activation	O
of	O
beta-catenin	O
-	O
mediated	O
transcription	O
is	O
the	O
nuclear	O
end	O
point	O
of	O
organ	O
-	O
specific	O
Wnt	O
signaling	O
.	O
In	O
the	O
developing	O
kidney	O
,	O
Wnt-4	O
,	O
a	O
secreted	O
glycoprotein	O
,	O
acts	O
as	O
an	O
autoinducer	O
of	O
the	O
mesenchymal	O
to	O
epithelial	O
transition	O
that	O
underlies	O
normal	O
nephron	O
development	O
.	O
Dysregulation	O
of	O
this	O
epithelial	O
transformation	O
process	O
may	O
lead	O
to	O
Wilms	B-malignancy-type
'	I-malignancy-type
tumors	I-malignancy-type
(	O
WTs	B-malignancy-type
)	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
the	O
beta-catenin	O
proto	O
-	O
oncogene	O
,	O
a	O
candidate	O
downstream	O
target	O
molecule	O
of	O
Wnt-4	O
signaling	O
,	O
in	O
the	O
development	O
of	O
WTs	B-malignancy-type
.	O
In	O
6	O
of	O
40	O
tumors	O
(	O
15	O
%	O
)	O
,	O
mutation	O
analysis	O
revealed	O
heterozygous	O
missense	O
mutations	O
or	O
small	O
deletions	O
that	O
result	O
in	O
the	O
loss	O
of	O
important	O
regulatory	O
phosphorylation	O
sites	O
within	O
the	O
beta-catenin	O
protein	O
.	O
These	O
findings	O
indicate	O
that	O
activating	O
beta-catenin	O
mutations	O
may	O
play	O
a	O
significant	O
role	O
in	O
the	O
development	O
of	O
WTs	B-malignancy-type
and	O
establish	O
a	O
direct	O
link	O
between	O
Wilms	O
'	O
tumorigenesis	O
and	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
governing	O
normal	O
kidney	O
development	O
.	O
PMID	O
:	O
10463574	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Endocrinol	O
(	O
Oxf	O
)	O
1999	O
Apr;50	O
(	O
4	O
)	O
:	O
52	O
9-35	O
Prevalence	O
of	O
Ras	O
mutations	O
in	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
.	O
Esapa	O
CT	O
,	O
Johnson	O
SJ	O
,	O
Kendal	O
l-Taylor	O
P,	O
Lennard	O
TW	O
,	O
Harris	O
PE.	O
Department	O
of	O
Diabetes	O
,	O
Endocrinology	O
and	O
Internal	O
Medicine	O
,	O
Guys'	O
,	O
King	O
's	O
and	O
St	O
Thomas	O
'	O
School	O
of	O
Medicine	O
,	O
London	O
,	O
UK.	O
OBJECTIVE	O
:	O
Mutations	O
at	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
ras	O
which	O
result	O
in	O
constitutive	O
activation	O
occur	O
frequently	O
in	O
human	O
malignancies	O
.	O
There	O
have	O
been	O
varied	O
reports	O
on	O
their	O
prevalence	O
and	O
hence	O
their	O
likely	O
significance	O
in	O
the	O
pathogenesis	O
of	O
primary	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
.	O
To	O
address	O
this	O
,	O
we	O
have	O
examined	O
a	O
large	O
series	O
of	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
tumours	I-malignancy-type
for	O
ras	O
mutations	O
.	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
the	O
presence	O
of	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
by	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Direct	O
DNA	O
sequencing	O
was	O
used	O
to	O
confirm	O
the	O
mutations	O
.	O
PATIENTS	O
:	O
A	O
total	O
of	O
90	O
samples	O
with	O
benign	B-malignancy-type
(	O
66	O
)	O
and	O
malignant	B-malignancy-type
(	I-malignancy-type
24	I-malignancy-type
)	I-malignancy-type
thyroid	I-malignancy-type
disease	I-malignancy-type
were	O
investigated	O
.	O
RESULTS	O
:	O
A	O
total	O
of	O
14	O
/	O
90	O
(	O
15.5	O
%	O
)	O
samples	O
had	O
a	O
ras	O
mutation	O
.	O
All	O
mutations	O
were	O
at	O
codon	O
61	O
of	O
either	O
N-ras	O
or	O
K-ras	O
.	O
The	O
positive	O
cases	O
were	O
1	O
/	O
25	O
(	O
4	O
%	O
)	O
nodular	B-malignancy-type
goitre	I-malignancy-type
,	O
7	O
/	O
38	O
(	O
18	O
%	O
)	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
4	O
/	O
9	O
(	O
44	O
%	O
)	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
/	O
1	O
anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
,	O
1	O
/	O
1	O
follicular	B-malignancy-type
variant	I-malignancy-type
of	I-malignancy-type
papillary	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
1	O
metastatic	B-malignancy-type
follicular	I-malignancy-type
carcinoma	I-malignancy-type
in	O
which	O
the	O
primary	O
tumour	O
had	O
the	O
same	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Our	O
data	O
demonstrate	O
a	O
relatively	O
low	O
overall	O
prevalence	O
of	O
ras	O
mutations	O
in	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
,	O
with	O
a	O
predominance	O
in	O
follicular	B-malignancy-type
neoplasms	I-malignancy-type
.	O
Their	O
presence	O
in	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
suggests	O
that	O
they	O
may	O
have	O
an	O
early	O
aetiological	O
role	O
in	O
the	O
development	O
of	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
.	O
PMID	O
:	O
10468914	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Diagn	O
Mol	O
Pathol	O
1999	O
Jun;	O
8	O
(	O
2	O
)	O
:	O
7	O
1-9	O
Analysis	O
of	O
K-ras	O
,	O
N-ras	O
,	O
H-ras	O
,	O
and	O
p53	O
in	O
lung	B-malignancy-type
neuroendocrine	I-malignancy-type
neoplasms	I-malignancy-type
.	O
Couce	O
ME	O
,	O
Bautista	O
D	O
,	O
Costa	O
J,	O
Carter	O
D.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
,	O
USA	O
.	O
This	O
study	O
screened	O
11	O
samples	O
of	O
typical	B-malignancy-type
carcinoid	I-malignancy-type
(	O
TC	B-malignancy-type
)	O
,	O
4	O
samples	O
of	O
atypical	B-malignancy-type
carcinoid	I-malignancy-type
(	O
AC	B-malignancy-type
)	O
,	O
1	O
sample	O
of	O
large	B-malignancy-type
cell	I-malignancy-type
neuroendocrine	I-malignancy-type
carcinoma	I-malignancy-type
(	O
LCNEC	B-malignancy-type
)	O
,	O
and	O
four	O
metastases	O
for	O
point	O
mutations	O
in	O
exons	O
5	O
to	O
8	O
of	O
the	O
p53	O
gene	O
,	O
and	O
exons	O
1	O
and	O
2	O
of	O
the	O
K-ras	O
.	O
H-ras	O
,	O
and	O
N-ras	O
genes	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
single-strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
and	O
by	O
immunohistochemistry	O
for	O
p53	O
.	O
Exon	O
1	O
of	O
K-ras	O
was	O
mutated	O
in	O
two	O
samples	O
of	O
low-grade	B-malignancy-type
AC	I-malignancy-type
and	O
a	O
metastasis	O
from	O
one	O
of	O
these	O
tumors	O
(	O
GAT12	O
and	O
AGT12	O
,	O
respectively	O
)	O
.	O
No	O
mutations	O
in	O
N-ras	O
or	O
H-ras	O
were	O
found	O
.	O
Mutations	O
in	O
exons	O
5	O
and	O
8	O
of	O
the	O
p53	O
gene	O
were	O
identified	O
in	O
a	O
high-grade	B-malignancy-type
AC	I-malignancy-type
and	O
a	O
LCNEC	B-malignancy-type
.	O
Positive	O
immunostaining	O
for	O
p53	O
was	O
present	O
in	O
three	O
samples	O
,	O
with	O
only	O
one	O
genotypic	O
mutation	O
shown	O
(	O
LCNEC	B-malignancy-type
)	O
.	O
In	O
conclusion	O
,	O
point	O
mutations	O
of	O
the	O
p53	O
gene	O
were	O
infrequent	O
in	O
these	O
pulmonary	B-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
,	O
did	O
not	O
correlate	O
in	O
all	O
samples	O
with	O
immunostaining	O
,	O
and	O
were	O
associated	O
with	O
the	O
higher-grade	O
tumors	O
.	O
Second	O
,	O
the	O
presence	O
of	O
K-ras	O
mutations	O
seems	O
to	O
be	O
associated	O
with	O
the	O
higher-grade	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Third	O
,	O
N-ras	O
and	O
H-ras	O
mutations	O
were	O
not	O
found	O
with	O
these	O
pulmonary	B-malignancy-type
neuroendocrine	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
10475381	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Sep;155(	O
3	O
)	O
:703	O
-	O
10	O
Nuclear	O
accumulation	O
of	O
mutated	O
beta-catenin	O
in	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
is	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O
Nhieu	O
JT	O
,	O
Renard	O
CA	O
,	O
Wei	O
Y	O
,	O
Cherqui	O
D	O
,	O
Zafrani	O
ES	O
,	O
Buendia	O
MA.	O
Departement	O
de	O
Pathologie	O
,	O
Service	O
de	O
Chirurgie	O
,	O
Hopital	O
Henri	O
Mondor	O
-	O
AP	O
-	O
HP	O
,	O
Creteil	O
,	O
Paris	O
,	O
France	O
.	O
Inappropriate	O
activation	O
of	O
the	O
Wnt	O
pathway	O
resulting	O
from	O
beta-catenin	O
gene	O
alterations	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
development	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	O
)	O
.	O
To	O
explore	O
the	O
in	O
vivo	O
effects	O
of	O
mutated	O
beta-catenin	O
,	O
HCC	B-malignancy-type
specimens	O
from	O
32	O
patients	O
carrying	O
one	O
or	O
several	O
tumors	O
were	O
screened	O
for	O
somatic	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
and	O
the	O
expression	O
and	O
subcellular	O
localization	O
of	O
beta-catenin	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O
Missense	O
mutations	O
or	O
interstitial	O
deletions	O
in	O
beta-catenin	O
exon	O
3	O
were	O
detected	O
in	O
12	O
of	O
35	O
(	O
34	O
%	O
)	O
HCC	B-malignancy-type
samples	O
.	O
After	O
immunostaining	O
,	O
most	O
tumors	O
exhibited	O
increased	O
membranous	O
and/or	O
cytoplasmic	O
expression	O
of	O
beta-catenin	O
compared	O
with	O
adjacent	O
nontumoral	O
liver	O
.	O
Strong	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
observed	O
either	O
focally	O
or	O
uniformly	O
in	O
15	O
of	O
35	O
(	O
43	O
%	O
)	O
tumor	O
specimens	O
,	O
but	O
not	O
in	O
cirrhotic	O
nodules	O
or	O
dysplastic	B-malignancy-type
liver	I-malignancy-type
cells	O
in	O
adjacent	O
liver	O
.	O
Aberrant	O
nuclear	O
expression	O
of	O
beta-catenin	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
P	O
<	O
0.005	O
)	O
.	O
Moreover	O
,	O
nuclear	O
beta-catenin	O
staining	O
correlated	O
significantly	O
with	O
increased	O
Ki-67	O
proliferative	O
index	O
in	O
tumor	O
(	O
P	O
<	O
0.001	O
)	O
and	O
seemed	O
to	O
be	O
associated	O
with	O
poor	O
outcome	O
in	O
patients	O
with	O
HCC	B-malignancy-type
.	O
In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
activation	O
of	O
the	O
Wnt	O
/	O
beta-catenin	O
pathway	O
in	O
HCC	B-malignancy-type
results	O
mainly	O
from	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
and	O
may	O
promote	O
tumor	O
progression	O
by	O
stimulating	O
tumor	O
cell	O
proliferation	O
.	O
PMID	O
:	O
10487827	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Cancer	O
Res	O
1999	O
Sep;5(	O
9	O
)	O
:2450	O
-	O
4	O
Molecular	O
detection	O
of	O
neoplastic	B-malignancy-type
cells	I-malignancy-type
in	I-malignancy-type
lymph	I-malignancy-type
nodes	I-malignancy-type
of	O
metastatic	B-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
patients	O
predicts	O
recurrence	O
.	O
Sanchez	O
-	O
Cespedes	O
M,	O
Esteller	O
M,	O
Hibi	O
K	O
,	O
Cope	O
FO	O
,	O
Westra	O
WH	O
,	O
Piantadosi	O
S,	O
Herman	O
JG	O
,	O
Jen	O
J,	O
Sidransky	O
D.	O
Department	O
of	O
Otolaryngology	O
-	O
Head	O
and	O
Neck	O
Surgery	O
,	O
The	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
Baltimore	O
,	O
Maryland	O
21205	O
,	O
USA	O
.	O
Disseminated	O
disease	O
,	O
especially	O
to	O
the	O
liver	O
,	O
constitutes	O
the	O
major	O
risk	O
of	O
recurrence	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
However	O
,	O
successful	O
resection	O
can	O
still	O
be	O
achieved	O
in	O
25	O
-	O
35	O
%	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
isolated	O
metastases	O
.	O
To	O
evaluate	O
the	O
clinical	O
value	O
of	O
occult	O
micrometastatic	O
disease	O
detection	O
in	O
lymph	O
nodes	O
,	O
we	O
tested	O
genetic	O
(	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
)	O
and	O
epigenetic	O
(	O
p16	O
promoter	O
hypermethylation	O
)	O
molecular	O
markers	O
in	O
the	O
perihepatic	O
lymph	O
nodes	O
from	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
isolated	O
liver	B-malignancy-type
metastases	I-malignancy-type
.	O
DNA	O
was	O
extracted	O
from	O
21	O
paraffin	O
-	O
embedded	O
liver	B-malignancy-type
metastases	I-malignancy-type
and	O
80	O
lymph	O
nodes	O
from	O
21	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
were	O
identified	O
in	O
DNA	O
from	O
liver	B-malignancy-type
metastases	I-malignancy-type
by	O
PCR	O
amplification	O
followed	O
by	O
cycle	O
sequencing	O
.	O
A	O
sensitive	O
oligonucleotide	O
-	O
mediated	O
mismatch	O
ligation	O
assay	O
was	O
used	O
to	O
search	O
for	O
the	O
presence	O
of	O
K-ras	O
and	O
p53	O
mutations	O
to	O
detect	O
occult	O
disease	O
in	O
68	O
lymph	O
nodes	O
from	O
tumors	O
positive	O
for	O
these	O
gene	O
mutations	O
.	O
Promoter	O
hypermethylation	O
at	O
the	O
p16	O
tumor	O
suppressor	O
gene	O
was	O
examined	O
in	O
both	O
liver	B-malignancy-type
lesions	I-malignancy-type
and	O
lymph	O
nodes	O
by	O
methylation	O
-	O
specific	O
PCR	O
.	O
Sixteen	O
of	O
the	O
21	O
(	O
76	O
%	O
)	O
liver	B-malignancy-type
metastases	I-malignancy-type
harbored	O
either	O
gene	O
point	O
mutations	O
or	O
p16	O
promoter	O
hypermethylation	O
.	O
Twelve	O
of	O
the	O
68	O
lymph	O
nodes	O
were	O
positive	O
for	O
tumor	O
cells	O
by	O
molecular	O
evaluation	O
and	O
negative	O
for	O
tumor	O
cells	O
by	O
histopathology	O
and	O
cytokeratin	O
immunohistochemistry	O
,	O
whereas	O
none	O
were	O
positive	O
for	O
tumor	O
cells	O
by	O
histopathology	O
or	O
negative	O
for	O
tumor	O
cells	O
by	O
molecular	O
analysis	O
(	O
P	O
=	O
0.0005	O
,	O
McNemar	O
's	O
test	O
)	O
.	O
Moreover	O
,	O
in	O
three	O
patients	O
with	O
lymph	O
nodes	O
that	O
were	O
histologically	O
negative	O
at	O
all	O
sites	O
,	O
molecular	O
screening	O
detected	O
tumor	O
DNA	O
at	O
one	O
or	O
more	O
lymph	O
nodes	O
.	O
Survival	O
analysis	O
showed	O
a	O
median	O
survival	O
of	O
1056	O
days	O
for	O
patients	O
without	O
evidence	O
of	O
lymph	O
node	O
involvement	O
by	O
molecular	O
analysis	O
and	O
165	O
days	O
for	O
patients	O
with	O
positive	O
lymph	O
nodes	O
by	O
this	O
approach	O
(	O
P	O
=	O
0.0005	O
)	O
.	O
These	O
results	O
indicate	O
that	O
lymph	B-malignancy-type
node	I-malignancy-type
metastasis	I-malignancy-type
screening	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
by	O
molecular	O
-	O
based	O
techniques	O
increases	O
the	O
sensitivity	O
of	O
tumor	O
cell	O
detection	O
and	O
can	O
be	O
a	O
good	O
predictor	O
of	O
recurrence	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
with	O
resectable	O
liver	B-malignancy-type
metastases	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Multicenter	O
Study	O
PMID	O
:	O
10499618	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1999	O
Jun;105(	O
4)	O
:894	O
-	O
900	O
c-kit	O
proto	O
-	O
oncogene	O
exon	O
8	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
.	O
Gari	O
M,	O
Goodeve	O
A	O
,	O
Wilson	O
G	O
,	O
Winship	O
P	O
,	O
Langabeer	O
S,	O
Linch	O
D	O
,	O
Vandenberghe	O
E	O
,	O
Peake	O
I	O
,	O
Reilly	O
J.	O
Molecular	O
Haematology	O
Unit	O
,	O
Division	O
of	O
Molecular	O
and	O
Genetic	O
Medicine	O
,	O
Royal	O
Hallamshire	O
Hospital	O
,	O
Sheffield	O
,	O
London	O
.	O
Genomic	O
DNA	O
from	O
60	O
cases	O
of	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
was	O
screened	O
for	O
mutations	O
in	O
the	O
c-kit	O
gene	O
.	O
DNA	O
from	O
all	O
21	O
exons	O
was	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
analysis	O
by	O
conformation	O
sensitive	O
gel	O
electrophoresis	O
(	O
CSGE	O
)	O
;	O
exons	O
showing	O
altered	O
CSGE	O
patterns	O
were	O
then	O
sequenced	O
.	O
Mutations	O
were	O
identified	O
only	O
in	O
those	O
patients	O
with	O
inv	O
(	O
16	O
)	O
(	O
3	O
/	O
7	O
cases	O
)	O
or	O
t	O
(	O
8	O
;	O
21	O
)	O
(	O
1	O
/	O
2	O
cases	O
)	O
and	O
comprised	O
three	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
(	O
exon	O
8	O
)	O
and	O
one	O
point	O
mutation	O
(	O
exon	O
10	O
,	O
GTA	O
-->	O
ATA	O
,	O
Val	O
530	O
Ile	O
)	O
.	O
Exons	O
8	O
and	O
10	O
were	O
then	O
analysed	O
in	O
31	O
further	O
cases	O
of	O
inv	O
(	O
16	O
)	O
(	O
n	O
=	O
14	O
)	O
and	O
t	O
(	O
8	O
;	O
21	O
)	O
(	O
n	O
=	O
17	O
)	O
,	O
revealing	O
four	O
additional	O
exon	O
8	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
,	O
all	O
of	O
which	O
were	O
in	O
cases	O
of	O
inv	O
(	O
16	O
)	O
.	O
All	O
exon	O
8	O
in	O
-	O
frame	O
deletion	O
plus	O
insertion	O
mutations	O
(	O
n	O
=	O
7	O
)	O
involved	O
the	O
loss	O
or	O
replacement	O
of	O
the	O
codon	O
for	O
Asp	O
419	O
which	O
is	O
highly	O
conserved	O
cross	O
species	O
and	O
is	O
located	O
in	O
the	O
receptor	O
's	O
extracellular	O
domain	O
.	O
The	O
high	O
frequency	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
exon	O
8	O
deletion	O
plus	O
insertion	O
mutations	O
in	O
AML	B-malignancy-type
suggests	O
an	O
essential	O
role	O
for	O
this	O
region	O
of	O
the	O
receptor	O
's	O
extracellular	O
domain	O
.	O
The	O
association	O
with	O
inv	O
(	O
16	O
)	O
invites	O
speculation	O
as	O
to	O
the	O
link	O
between	O
these	O
two	O
changes	O
in	O
the	O
pathogenesis	O
of	O
AML	B-malignancy-type
.	O
PMID	O
:	O
10554798	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1999	O
Nov;12(	O
11	O
)	O
:1001	O
-	O
9	O
Comparative	O
immunohistochemical	O
and	O
molecular	O
analysis	O
of	O
uterine	B-malignancy-type
and	O
extrauterine	B-malignancy-type
leiomyosarcomas	I-malignancy-type
.	O
Rao	O
UN	O
,	O
Finkelstein	O
SD	O
,	O
Jones	O
MW.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Pittsburgh	O
Medical	O
Center	O
,	O
Presbyterian	O
University	O
Hospital	O
,	O
Pennsylvania	O
15213	O
-	O
2582	O
,	O
USA	O
.	O
Histologic	O
criteria	O
defining	O
malignancy	O
in	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
are	O
currently	O
site	O
specific	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
,	O
in	O
leiomyosarcomas	B-malignancy-type
(	O
LMS	B-malignancy-type
)	O
occurring	O
in	O
different	O
anatomic	O
locations	O
,	O
there	O
were	O
differences	O
in	O
patterns	O
of	O
expression	O
of	O
molecules	O
that	O
have	O
been	O
demonstrated	O
to	O
be	O
associated	O
with	O
biologically	O
aggressive	O
behavior	O
in	O
malignant	B-malignancy-type
neoplasms	I-malignancy-type
,	O
and	O
also	O
to	O
determine	O
their	O
diagnostic	O
utility	O
.	O
Formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
blocks	O
were	O
selected	O
from	O
16	O
extrauterine	B-malignancy-type
leiomyosarcomas	I-malignancy-type
(	O
EULMS	B-malignancy-type
)	O
,	O
14	O
cases	O
of	O
uterine	B-malignancy-type
leiomyosarcomas	I-malignancy-type
(	O
ULMS	B-malignancy-type
)	O
and	O
from	O
five	O
cases	O
each	O
of	O
uterine	B-malignancy-type
and	O
extrauterine	B-malignancy-type
leiomyomas	I-malignancy-type
(	O
LM	B-malignancy-type
)	O
.	O
Utilizing	O
immunohistochemical	O
(	O
ABC	O
)	O
techniques	O
with	O
antigen	O
retrieval	O
,	O
we	O
assessed	O
serial	O
sections	O
of	O
each	O
tumor	O
for	O
immunoreactivity	O
with	O
Glut1	O
,	O
CD44s	O
,	O
bcl2	O
,	O
cyclin	O
D1	O
,	O
and	O
estrogen	O
receptor	O
.	O
Molecular	O
genotyping	O
for	O
detecting	O
k-ras-2	O
point	O
mutation	O
,	O
p53	O
gene	O
loss	O
,	O
and	O
mdm2	O
gene	O
amplification	O
was	O
performed	O
on	O
microdissected	O
tumor	O
samples	O
from	O
the	O
same	O
histologic	O
sections	O
.	O
All	O
of	O
the	O
uterine	B-malignancy-type
and	O
extrauterine	B-malignancy-type
LM	I-malignancy-type
were	O
diffusely	O
positive	O
for	O
CD44s	O
,	O
bcl2	O
,	O
and	O
cyclin	O
D1	O
,	O
and	O
uniformly	O
negative	O
for	O
Glut1	O
.	O
In	O
contrast	O
,	O
50	O
%	O
of	O
the	O
ULMS	B-malignancy-type
and	O
25	O
%	O
of	O
EULMS	B-malignancy-type
were	O
Glutl	O
positive	O
.	O
Moreover	O
,	O
Glut1	O
positivity	O
closely	O
correlated	O
with	O
aggressive	O
biologic	O
behavior	O
reflected	O
by	O
distant	O
metastatic	O
spread	O
.	O
Eighty	O
-	O
percent	O
of	O
LM	B-malignancy-type
and	O
70	O
%	O
of	O
the	O
ULMS	B-malignancy-type
were	O
estrogen	O
receptor	O
positive	O
,	O
whereas	O
only	O
one	O
retroperitoneal	B-malignancy-type
tumor	I-malignancy-type
had	O
focal	O
weak	O
positivity	O
.	O
Over	O
80	O
%	O
of	O
the	O
extrauterine	B-malignancy-type
and	O
50	O
%	O
of	O
the	O
uterine	B-malignancy-type
sarcomas	I-malignancy-type
showed	O
absence	O
of	O
CD44s	O
immunoreactivity	O
.	O
Percentage	O
of	O
cyclin	O
D1	O
immunoreactivity	O
was	O
independent	O
of	O
tumor	O
grade	O
and	O
inversely	O
proportional	O
to	O
the	O
percent	O
of	O
bcl2	O
positivity	O
.	O
An	O
LMS	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
male	I-malignancy-type
breast	I-malignancy-type
contained	O
k-ras-2	O
exon	O
1	O
point	O
mutation	O
(	O
codon	O
12	O
aspartate	O
substitution	O
of	O
glycine	O
)	O
.	O
P53	O
allelic	O
imbalance	O
was	O
present	O
in	O
29	O
%	O
of	O
ULMS	B-malignancy-type
and	O
57	O
%	O
EULMS	B-malignancy-type
.	O
Mdm2	O
amplification	O
was	O
present	O
in	O
three	O
of	O
six	O
EULMS	B-malignancy-type
but	O
not	O
in	O
ULMS	B-malignancy-type
.	O
In	O
addition	O
to	O
clinical	O
staging	O
,	O
Glut1	O
positivity	O
together	O
with	O
patterns	O
of	O
immunoreactivity	O
of	O
CD44	O
and	O
bcl2	O
may	O
be	O
helpful	O
in	O
identifying	O
aggressive	B-malignancy-type
smooth	I-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterus	I-malignancy-type
and	O
some	O
EULMS	B-malignancy-type
.	O
The	O
presence	O
of	O
estrogen	O
receptor	O
staining	O
may	O
be	O
helpful	O
in	O
identifying	O
uterine	B-malignancy-type
versus	O
nonuterine	B-malignancy-type
LMS	I-malignancy-type
.	O
Although	O
sample	O
numbers	O
are	O
too	O
small	O
for	O
definite	O
conclusions	O
,	O
this	O
study	O
suggests	O
that	O
there	O
are	O
differences	O
in	O
glucose	O
transport	O
,	O
expression	O
of	O
adhesion	O
molecules	O
,	O
and	O
estrogen	O
receptors	O
in	O
ULMS	B-malignancy-type
and	O
EULMS	B-malignancy-type
,	O
which	O
in	O
part	O
may	O
be	O
due	O
to	O
the	O
estrogen	O
dependency	O
of	O
the	O
ULMS	B-malignancy-type
.	O
P53	O
mutations	O
and	O
mdm2	O
amplifications	O
appear	O
to	O
be	O
more	O
frequent	O
in	O
EULMS	B-malignancy-type
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
Randomized	O
Controlled	O
Trial	O
PMID	O
:	O
10574596	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Rinsho	O
Byori	O
1999	O
Nov;47(	O
11	O
)	O
:1059	O
-	O
63	O
[	O
Detection	O
of	O
K-ras	O
mutations	O
in	O
colon	B-malignancy-type
cancer	I-malignancy-type
by	O
PHA	O
-	O
PHFA	O
(	O
preferential	O
homoduplex	O
formation	O
assay	O
)	O
]	O
[	O
Article	O
in	O
Japanese	O
]	O
Funato	O
T	O
,	O
Zeng	O
Z	O
,	O
Satoh	O
J,	O
Fujiwara	O
J,	O
Kaku	O
M,	O
Sasaki	O
T.	O
Department	O
of	O
Molecular	O
Diagnostics	O
,	O
Tohoku	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Sendai	O
.	O
The	O
mutations	O
of	O
K-ras	O
gene	O
have	O
been	O
demonstrated	O
at	O
frequencies	O
of	O
about	O
40	O
%	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
We	O
applied	O
a	O
developed	O
PCR	O
-	O
preferential	O
homoduplex	O
formation	O
assay	O
(	O
PCR	O
-	O
PHFA	O
)	O
to	O
detect	O
a	O
point	O
mutation	O
of	O
K-ras	O
gene	O
in	O
the	O
surgical	O
specimens	O
from	O
thirty	O
patients	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
This	O
method	O
is	O
based	O
on	O
the	O
strand	O
competition	O
during	O
hybridization	O
between	O
a	O
double	O
labeled	O
amplicon	O
,	O
prepared	O
from	O
biotin	O
and	O
DNP	O
labeled	O
primers	O
,	O
and	O
an	O
unlabeled	O
amplicon	O
.	O
The	O
procedure	O
of	O
this	O
method	O
is	O
simple	O
and	O
speedy	O
,	O
and	O
suitable	O
to	O
detect	O
mutations	O
in	O
a	O
small	O
number	O
of	O
samples	O
.	O
By	O
using	O
this	O
method	O
,	O
the	O
mutations	O
were	O
found	O
in	O
37	O
%	O
(	O
11	O
/	O
30	O
)	O
and	O
confirmed	O
by	O
sequencing	O
analysis	O
.	O
The	O
results	O
suggest	O
that	O
the	O
PCR	O
-	O
PHFA	O
system	O
may	O
be	O
useful	O
for	O
detecting	O
low	O
frequent	O
mutation	O
of	O
K-ras	O
gene	O
even	O
in	O
the	O
case	O
of	O
an	O
early	O
cancer	O
.	O
PMID	O
:	O
10590684	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Dec;155(	O
6)	O
:1795	O
-	O
801	O
Beta-catenin	O
mutations	O
are	O
frequent	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
associated	I-malignancy-type
with	I-malignancy-type
hepatitis	I-malignancy-type
C	I-malignancy-type
virus	I-malignancy-type
infection	I-malignancy-type
.	O
Huang	O
H	O
,	O
Fujii	O
H	O
,	O
Sankila	O
A	O
,	O
Mahler	O
-	O
Araujo	O
BM	O
,	O
Matsuda	O
M,	O
Cathomas	O
G	O
,	O
Ohgaki	O
H.	O
Unit	O
of	O
Molecular	O
Pathology	O
,	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
(	O
IARC	O
)	O
,	O
Lyon	O
,	O
France	O
.	O
Hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
is	O
one	O
of	O
the	O
most	O
common	O
fatal	O
cancers	O
worldwide	O
.	O
Hepatitis	O
B	O
virus	O
and	O
hepatitis	O
C	O
virus	O
infections	O
,	O
exposure	O
to	O
aflatoxin	O
,	O
and	O
excessive	O
intake	O
of	O
alcohol	O
have	O
been	O
identified	O
as	O
major	O
risk	O
factors	O
.	O
However	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
their	O
development	O
are	O
still	O
poorly	O
understood	O
.	O
Recently	O
,	O
beta-catenin	O
,	O
one	O
of	O
the	O
key	O
components	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
has	O
been	O
found	O
to	O
be	O
mutated	O
in	O
about	O
20	O
%	O
of	O
HCCs	B-malignancy-type
,	O
suggesting	O
a	O
role	O
of	O
the	O
Wnt	O
pathway	O
in	O
their	O
development	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
beta-catenin	O
and	O
APC	O
mutations	O
in	O
22	O
HCCs	B-malignancy-type
associated	I-malignancy-type
with	I-malignancy-type
HCV	I-malignancy-type
infection	I-malignancy-type
,	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
.	O
beta-Catenin	O
mutations	O
were	O
found	O
in	O
nine	O
(	O
41	O
%	O
)	O
cases	O
,	O
but	O
no	O
APC	O
mutations	O
were	O
found	O
.	O
beta-Catenin	O
immunohistochemistry	O
revealed	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
all	O
nine	O
tumors	O
with	O
a	O
beta-catenin	O
mutation	O
and	O
two	O
additional	O
tumors	O
without	O
a	O
mutation	O
.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
by	O
beta-catenin	O
mutation	O
contributes	O
significantly	O
to	O
the	O
hepatocellular	O
carcinogenesis	O
associated	O
with	O
HCV	O
infection	O
.	O
PMID	O
:	O
10595907	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Nov	O
11;1	O
8	O
(	O
47	O
)	O
:	O
658	O
3-8	O
Close	O
correlation	O
between	O
beta-catenin	O
gene	O
alterations	O
and	O
nuclear	O
accumulation	O
of	O
the	O
protein	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Terris	O
B	O
,	O
Pineau	O
P,	O
Bregeaud	O
L,	O
Valla	O
D	O
,	O
Belghiti	O
J,	O
Tiollais	O
P,	O
Degott	O
C,	O
Dejean	O
A.	O
Service	O
d'Anatomie	O
Pathologique	O
,	O
Hopital	O
Beaujon	O
,	O
Clichy	O
,	O
France	O
.	O
Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
beta-catenin	O
acquires	O
oncogenic	O
activity	O
when	O
its	O
intracellular	O
concentration	O
increases	O
as	O
a	O
result	O
of	O
either	O
mutation	O
in	O
the	O
beta-catenin	O
gene	O
itself	O
or	O
inactivation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
.	O
In	O
an	O
attempt	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
underlying	O
hepatocellular	O
carcinogenesis	O
,	O
we	O
have	O
studied	O
the	O
frequency	O
of	O
beta-catenin	O
gene	O
alterations	O
in	O
exon	O
3	O
,	O
a	O
region	O
known	O
to	O
represent	O
a	O
mutation	O
hot	O
spot	O
,	O
and	O
its	O
inappropriate	O
protein	O
expression	O
by	O
immunohistochemistry	O
in	O
73	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
.	O
The	O
results	O
were	O
correlated	O
with	O
different	O
clinical	O
and	O
pathological	O
data	O
,	O
particularly	O
with	O
the	O
presence	O
or	O
not	O
of	O
an	O
associated	O
cirrhosis	O
.	O
Fourteen	O
(	O
19	O
%	O
)	O
HCCs	B-malignancy-type
showed	O
beta-catenin	O
gene	O
alterations	O
with	O
missense	O
mutations	O
in	O
nine	O
cases	O
and	O
interstitial	O
deletions	O
in	O
five	O
cases	O
.	O
These	O
genetic	O
alterations	O
were	O
present	O
in	O
both	O
cirrhotic	O
and	O
non	O
-	O
cirrhotic	O
groups	O
.	O
By	O
contrast	O
,	O
we	O
did	O
not	O
find	O
any	O
beta-catenin	O
gene	O
alterations	O
in	O
the	O
nine	O
fibromellar	B-malignancy-type
carcinomas	I-malignancy-type
we	O
examined	O
.	O
Nuclear	O
accumulation	O
of	O
the	O
protein	O
was	O
observed	O
in	O
18	O
of	O
them	O
(	O
25	O
%	O
)	O
.	O
Remarkably	O
,	O
these	O
included	O
ten	O
of	O
the	O
14	O
tumors	O
harboring	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
accumulation	O
of	O
beta-catenin	O
resulting	O
from	O
genetic	O
mutations	O
is	O
a	O
frequent	O
event	O
in	O
non	B-malignancy-type
-	I-malignancy-type
fibrolamellar	I-malignancy-type
type	I-malignancy-type
hepatocellular	I-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
close	O
association	O
between	O
increased	O
beta-catenin	O
protein	O
stability	O
and	O
mutation	O
indicates	O
that	O
immunohistochemistry	O
may	O
be	O
a	O
powerful	O
method	O
for	O
the	O
detection	O
of	O
the	O
mutated	O
protein	O
in	O
future	O
clinical	O
practice	O
.	O
PMID	O
:	O
10597262	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Pathol	O
1999	O
Sep;5	O
2	O
(	O
9	O
)	O
:	O
69	O
5-6	O
A	O
novel	O
case	O
of	O
a	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumour	I-malignancy-type
with	O
mutation	O
of	O
the	O
beta	O
catenin	O
gene	O
.	O
Shitoh	O
K,	O
Konishi	O
F	O
,	O
Iijima	O
T	O
,	O
Ohdaira	O
T	O
,	O
Sakai	O
K,	O
Kanazawa	O
K,	O
Miyaki	O
M.	O
Hereditary	O
Tumour	O
Research	O
Project	O
,	O
Tokyo	O
Metropolitan	O
Komagome	O
Hospital	O
,	O
Japan	O
.	O
A	O
42	O
year	O
old	O
man	O
without	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
had	O
recurrent	O
desmoid	B-malignancy-type
tumours	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
left	I-malignancy-type
subclavicular	I-malignancy-type
site	I-malignancy-type
.	O
Histological	O
examination	O
showed	O
a	O
typical	O
desmoid	B-malignancy-type
tumour	I-malignancy-type
.	O
Molecular	O
analysis	O
was	O
performed	O
in	O
genomic	O
DNA	O
from	O
this	O
tumour	O
,	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
methods	O
.	O
No	O
mutation	O
could	O
be	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
APC	O
gene	O
,	O
nor	O
in	O
H-ras	O
,	O
K-ras	O
,	O
N-ras	O
,	O
or	O
p53	O
genes	O
.	O
On	O
seeking	O
a	O
mutation	O
of	O
the	O
beta	O
catenin	O
gene	O
(	O
CTNNB1	O
)	O
,	O
an	O
activating	O
mutation	O
from	O
ACC	O
(	O
Thr	O
)	O
to	O
GCC	O
(	O
Ala	O
)	O
at	O
codon	O
41	O
was	O
found	O
.	O
Immunohistochemical	O
staining	O
showed	O
that	O
accumulated	O
beta	O
catenin	O
protein	O
was	O
predominantly	O
localised	O
in	O
the	O
nuclei	O
of	O
desmoid	O
cells	O
.	O
This	O
is	O
the	O
first	O
example	O
of	O
a	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumour	I-malignancy-type
in	O
which	O
a	O
mutation	O
of	O
the	O
beta	O
catenin	O
gene	O
was	O
revealed	O
.	O
PMID	O
:	O
10655994	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2000	O
Feb;24(	O
2	O
)	O
:211	O
-	O
22	O
Esophageal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
genetic	O
study	O
of	O
17	O
cases	O
and	O
comparison	O
with	O
esophageal	B-malignancy-type
leiomyomas	I-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
.	O
Miettinen	O
M,	O
Sarlomo	O
-	O
Rikala	O
M,	O
Sobin	O
LH	O
,	O
Lasota	O
J.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-	O
6000	O
,	O
USA	O
.	O
Although	O
rare	O
elsewhere	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
leiomyomas	B-malignancy-type
(	O
LMs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
esophageal	B-malignancy-type
mesenchymal	I-malignancy-type
neoplasms	I-malignancy-type
.	O
In	O
contrast	O
,	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	O
)	O
predominate	O
in	O
the	O
stomach	O
and	O
intestines	O
but	O
have	O
not	O
been	O
documented	O
in	O
the	O
esophagus	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
clinicopathologic	O
features	O
and	O
frequency	O
of	O
esophageal	B-malignancy-type
GISTs	I-malignancy-type
compared	O
with	O
LMs	B-malignancy-type
and	O
leiomyosarcomas	B-malignancy-type
(	O
LMSs	B-malignancy-type
)	O
of	B-malignancy-type
the	I-malignancy-type
esophagus	I-malignancy-type
.	O
A	O
total	O
of	O
68	O
stromal	B-malignancy-type
/	O
smooth	B-malignancy-type
muscle	I-malignancy-type
tumors	I-malignancy-type
from	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
and	O
the	O
Haartman	O
Institute	O
of	O
University	O
of	O
Helsinki	O
were	O
reclassified	O
by	O
current	O
histologic	O
and	O
immunohistochemical	O
criteria	O
.	O
There	O
were	O
17	O
GISTs	B-malignancy-type
,	O
48	O
LMs	B-malignancy-type
,	O
and	O
three	O
LMSs	B-malignancy-type
.	O
The	O
esophageal	B-malignancy-type
GISTs	I-malignancy-type
occurred	O
in	O
12	O
men	O
and	O
five	O
women	O
with	O
a	O
median	O
age	O
of	O
63	O
years	O
(	O
range	O
,	O
49	O
-	O
75	O
years	O
)	O
.	O
All	O
tumors	B-malignancy-type
were	O
from	O
the	O
lowest	O
third	O
of	B-malignancy-type
the	I-malignancy-type
esophagus	I-malignancy-type
,	O
and	O
the	O
most	O
common	O
complaint	O
was	O
dysphagia	O
,	O
whereas	O
two	O
tumors	O
were	O
detected	O
incidentally	O
.	O
Histologically	O
the	O
tumors	O
had	O
an	O
overall	O
basophilic	O
appearance	O
and	O
showed	O
combinations	O
of	O
solid	O
,	O
myxoid	O
,	O
and	O
perivascular	O
collarlike	O
patterns	O
with	O
a	O
spindle	O
cell	O
histology	O
in	O
13	O
patients	O
and	O
epithelioid	O
histology	O
in	O
four	O
patients	O
.	O
All	O
tumors	O
were	O
positive	O
for	O
CD117	O
and	O
for	O
CD34	O
,	O
whereas	O
two	O
patients	O
were	O
also	O
positive	O
for	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
SMA	O
)	O
and	O
three	O
patients	O
were	O
positive	O
for	O
desmin	O
.	O
One	O
patient	O
showed	O
a	O
unique	O
immunophenotype	O
with	O
coexpression	O
of	O
CD117	O
,	O
CD34	O
,	O
SMA	O
,	O
and	O
desmin	O
.	O
Nine	O
patients	O
died	O
of	O
disease	O
,	O
including	O
all	O
who	O
had	O
a	O
tumor	O
larger	O
than	O
10	O
cm	O
,	O
and	O
also	O
one	O
patient	O
whose	O
tumor	O
showed	O
five	O
mitoses	O
per	O
50	O
high	O
-	O
power	O
fields	O
.	O
In	O
comparison	O
,	O
esophageal	B-malignancy-type
LMs	I-malignancy-type
(	O
n	O
=	O
48	O
)	O
occurred	O
in	O
a	O
younger	O
population	O
(	O
median	O
age	O
,	O
35	O
years	O
)	O
but	O
,	O
similar	O
to	O
the	O
GIST	O
group	O
,	O
men	O
predominated	O
(	O
67	O
%	O
)	O
.	O
All	O
LMs	B-malignancy-type
were	O
clinically	B-malignancy-type
indolent	I-malignancy-type
tumors	O
with	O
no	O
tumor	O
-	O
related	O
mortality	O
.	O
The	O
LMs	B-malignancy-type
showed	O
eosinophilic	O
cytoplasm	O
,	O
and	O
were	O
positive	O
for	O
desmin	O
and	O
SMA	O
,	O
and	O
negative	O
for	O
CD117	O
and	O
CD34	O
.	O
All	O
three	O
LMSs	B-malignancy-type
were	O
large	B-malignancy-type
high	I-malignancy-type
-	I-malignancy-type
grade	I-malignancy-type
tumors	O
that	O
showed	O
muscle	O
cell	O
markers	O
but	O
no	O
CD117	O
.	O
All	O
patients	O
died	O
of	O
disease	O
.	O
Esophageal	B-malignancy-type
GISTs	I-malignancy-type
showed	O
mutations	O
in	O
exon	O
11	O
of	O
c-kit	O
as	O
described	O
previously	O
in	O
gastric	B-malignancy-type
and	O
intestinal	B-malignancy-type
GISTs	B-malignancy-type
.	O
The	O
separation	O
of	O
GISTs	B-malignancy-type
from	O
esophageal	B-malignancy-type
LMs	I-malignancy-type
is	O
important	O
diagnostically	O
because	O
the	O
former	O
group	O
has	O
a	O
high	O
risk	O
of	O
malignant	O
behavior	O
.	O
PMID	O
:	O
10680889	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
2000	O
Feb	O
29;97(	O
5	O
)	O
:2225	O
-	O
8	O
APC	O
mutations	O
are	O
sufficient	O
for	O
the	O
growth	O
of	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
.	O
Lamlum	O
H	O
,	O
Papadopoulou	O
A	O
,	O
Ilyas	O
M,	O
Rowan	O
A	O
,	O
Gillet	O
C	O
,	O
Hanby	O
A	O
,	O
Talbot	O
I	O
,	O
Bodmer	O
W	O
,	O
Tomlinson	O
I.	O
Molecular	O
and	O
Population	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
44	O
,	O
Lincoln	O
's	O
Inn	O
Fields	O
,	O
London	O
WC2A	O
3PX	O
,	O
United	O
Kingdom	O
.	O
It	O
is	O
not	O
clear	O
whether	O
APC	O
mutations	O
are	O
sufficient	O
for	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
to	O
grow	O
or	O
whether	O
additional	O
mutations	O
at	O
other	O
loci	O
are	O
required	O
.	O
We	O
previously	O
have	O
screened	O
210	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
from	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
for	O
mutations	O
and	O
allelic	O
loss	O
at	O
APC	O
.	O
Here	O
,	O
we	O
determined	O
whether	O
allelic	O
loss	O
at	O
APC	O
had	O
any	O
effect	O
on	O
the	O
nearby	O
alpha	O
-	O
catenin	O
gene	O
.	O
However	O
,	O
loss	O
on	O
5q	O
in	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
adenomas	I-malignancy-type
rarely	O
extended	O
as	O
far	O
as	O
alpha	O
-	O
catenin	O
,	O
and	O
no	O
differences	O
in	O
alpha-catenin	O
protein	O
expression	O
were	O
found	O
in	O
tumors	O
that	O
showed	O
loss	O
encompassing	O
both	O
APC	O
and	O
alpha-catenin	O
.	O
We	O
then	O
screened	O
all	O
210	O
tumors	O
for	O
mutations	O
at	O
candidate	O
loci	O
other	O
than	O
APC	O
(	O
K-ras	O
,	O
beta-catenin	O
,	O
and	O
allelic	O
loss	O
at	O
1p33	O
-	O
p35	O
and	O
1p36	O
)	O
and	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
Each	O
of	O
these	O
loci	O
has	O
been	O
implicated	O
previously	O
in	O
early	O
colorectal	O
tumorigenesis	O
.	O
One	O
tumor	O
harbored	O
a	O
beta-catenin	O
mutation	O
and	O
another	O
MSI	O
,	O
but	O
none	O
showed	O
K-ras	O
mutation	O
or	O
allelic	O
loss	O
at	O
1p33	O
-	O
p35	O
or	O
1p36	O
.	O
These	O
data	O
support	O
the	O
following	O
hypotheses	O
derived	O
from	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
:	O
beta-catenin	O
mutations	O
are	O
generally	O
an	O
alternative	O
to	O
mutations	O
at	O
APC	O
,	O
MSI	O
is	O
not	O
usually	O
an	O
early	O
phenomenon	O
in	O
colorectal	O
tumorigenesis	O
,	O
and	O
K-ras	O
mutations	O
are	O
more	O
typical	O
of	O
large	B-malignancy-type
-	I-malignancy-type
and	O
moderate	B-malignancy-type
-	I-malignancy-type
sized	I-malignancy-type
adenomas	I-malignancy-type
.	O
Contrary	O
to	O
some	O
previous	O
reports	O
,	O
chromosome	O
1p	O
allelic	O
loss	O
is	O
infrequent	O
in	O
very	O
early	O
adenomas	B-malignancy-type
.	O
APC	O
mutations	O
are	O
generally	O
sufficient	O
for	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
to	O
grow	O
to	O
about	O
1	O
-	O
cm	O
diameter	O
,	O
although	O
chance	O
mutations	O
at	O
other	O
loci	O
can	O
provide	O
these	O
early	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
with	O
a	O
selective	O
advantage	O
,	O
and	O
some	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
may	O
develop	O
along	O
a	O
pathway	O
not	O
involving	O
APC	O
.	O
PMID	O
:	O
10681434	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Surg	O
Oncol	O
2000	O
Mar;73(	O
3	O
)	O
:158	O
-	O
63	O
Aberrations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
and	O
APC	O
genes	O
in	O
extrahepatic	B-malignancy-type
bile	I-malignancy-type
duct	I-malignancy-type
cancer	I-malignancy-type
.	O
Suto	O
T	O
,	O
Habano	O
W	O
,	O
Sugai	O
T	O
,	O
Uesugi	O
N	O
,	O
Funato	O
O	O
,	O
Kanno	O
S,	O
Saito	O
K	O
,	O
Nakamura	O
S.	O
Department	O
of	O
Surgery	O
I	O
,	O
School	O
of	O
Medicine	O
,	O
Iwate	O
Medical	O
University	O
,	O
Morioka	O
,	O
Iwate	O
,	O
Japan	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
genetic	O
alterations	O
involved	O
in	O
extrahepatic	B-malignancy-type
bile	I-malignancy-type
duct	I-malignancy-type
(	I-malignancy-type
EHBD	I-malignancy-type
)	I-malignancy-type
cancer	I-malignancy-type
are	O
poorly	O
understood	O
.	O
Our	O
aim	O
was	O
to	O
identify	O
aberrations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
and	O
APC	O
genes	O
in	O
EHBD	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
We	O
investigated	O
aberrations	O
of	O
these	O
genes	O
in	O
52	O
EHBD	B-malignancy-type
cancers	I-malignancy-type
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
followed	O
by	O
direct	O
sequence	O
determination	O
and	O
a	O
PCR	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O
RESULTS	O
:	O
The	O
K-ras	O
,	O
p53	O
,	O
and	O
APC	O
genes	O
were	O
mutated	O
in	O
9.6	O
%	O
,	O
32.7	O
%	O
,	O
and	O
0	O
%	O
of	O
EHBD	B-malignancy-type
cancers	I-malignancy-type
,	O
respectively	O
.	O
Loss	O
of	O
heterozygosity	O
at	O
the	O
p53	O
and	O
APC	O
gene	O
loci	O
was	O
identified	O
in	O
15.6	O
%	O
and	O
38.5	O
%	O
of	O
EHBD	B-malignancy-type
cancers	I-malignancy-type
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
an	O
unknown	O
suppressor	O
gene	O
on	O
5q	O
other	O
than	O
the	O
APC	O
gene	O
may	O
be	O
responsible	O
for	O
EHBD	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10738270	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Neuropathol	O
Exp	O
Neurol	O
2000	O
Apr;5	O
9	O
(	O
4	O
)	O
:	O
33	O
3-7	O
Nuclear	O
localization	O
and	O
mutation	O
of	O
beta-catenin	O
in	O
medulloblastomas	B-malignancy-type
.	O
Eberhart	O
CG	O
,	O
Tihan	O
T	O
,	O
Burger	O
PC	O
.	O
Department	O
of	O
Pathology	O
,	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
,	O
USA	O
.	O
The	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
,	O
a	O
member	O
of	O
the	O
Wingless	O
/	O
Wnt	O
signal	O
transduction	O
pathway	O
,	O
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
medulloblastomas	B-malignancy-type
in	O
Turcot	B-malignancy-type
's	I-malignancy-type
syndrome	I-malignancy-type
.	O
beta-catenin	O
also	O
functions	O
in	O
this	O
highly	O
conserved	O
signaling	O
pathway	O
and	O
is	O
instrumental	O
in	O
growth	O
and	O
development	O
.	O
Mutations	O
in	O
either	O
APC	O
or	O
beta-catenin	O
can	O
stabilize	O
beta-catenin	O
protein	O
.	O
Stabilized	O
beta-catenin	O
complexes	O
with	O
Tcf	O
/	O
Lef	O
transcription	O
factors	O
and	O
moves	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
where	O
it	O
regulates	O
the	O
transcription	O
of	O
c-Myc	O
and	O
other	O
genes	O
.	O
Nuclear	O
localization	O
of	O
beta-catenin	O
therefore	O
implies	O
activation	O
of	O
the	O
signaling	O
pathway	O
.	O
We	O
have	O
analyzed	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
in	O
51	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
and	O
in	O
1	O
medulloblastoma	B-malignancy-type
arising	O
in	O
a	O
patient	O
with	O
Turcot	B-malignancy-type
's	I-malignancy-type
syndrome	I-malignancy-type
.	O
Nuclear	O
beta-catenin	O
staining	O
was	O
present	O
in	O
9	O
of	O
the	O
sporadic	O
tumors	O
(	O
18	O
%	O
)	O
and	O
in	O
the	O
1	O
medulloblastoma	B-malignancy-type
from	O
a	O
Turcot	B-malignancy-type
's	I-malignancy-type
patient	O
.	O
The	O
remaining	O
41	O
cases	O
did	O
not	O
show	O
nuclear	O
staining	O
.	O
This	O
confirms	O
earlier	O
observations	O
that	O
Wingless	O
/	O
Wnt	O
signaling	O
is	O
involved	O
in	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
.	O
We	O
also	O
examined	O
48	O
glial	B-malignancy-type
and	O
meningeal	B-malignancy-type
CNS	I-malignancy-type
tumors	I-malignancy-type
,	O
all	O
of	O
which	O
were	O
negative	O
for	O
nuclear	O
beta-catenin	O
.	O
Exon	O
3	O
of	O
beta-catenin	O
was	O
sequenced	O
in	O
6	O
of	O
the	O
9	O
sporadic	B-malignancy-type
medulloblastomas	I-malignancy-type
with	O
nuclear	O
beta-catenin	O
staining	O
.	O
Five	O
of	O
the	O
6	O
tumors	O
sequenced	O
had	O
mutations	O
affecting	O
highly	O
conserved	O
beta-catenin	O
phosphorylation	O
sites	O
involved	O
in	O
protein	O
stability	O
.	O
These	O
data	O
suggest	O
a	O
simple	O
immunohistochemical	O
method	O
to	O
screen	O
for	O
beta-catenin	O
mutations	O
in	O
medulloblastomas	B-malignancy-type
.	O
PMID	O
:	O
10759189	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2000	O
Ma	O
y-Jun;	O
7	O
(	O
3	O
)	O
:	O
49	O
7-500	O
Screening	O
of	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
for	O
the	O
presence	O
of	O
Ha-ras	O
codon	O
12	O
mutation	O
.	O
Cattan	O
N	O
,	O
Saiso	O
n-Behmoaras	O
T	O
,	O
Mari	O
B	O
,	O
Mazeau	O
C,	O
Amiel	O
JL	O
,	O
Rossi	O
B	O
,	O
Gioanni	O
J.	O
Laboratoire	O
de	O
Cancerologie	O
du	O
Centre	O
Antoine	O
Lacassagne	O
,	O
06107	O
Nice	O
Cedex	O
02	O
,	O
France	O
.	O
Contradictory	O
results	O
were	O
obtained	O
from	O
previous	O
studies	O
aiming	O
at	O
defining	O
the	O
frequency	O
of	O
Ha-ras	O
codon	O
12	O
mutations	O
in	O
bladder	B-malignancy-type
tumors	I-malignancy-type
.	O
Differences	O
in	O
the	O
sensitivities	O
of	O
the	O
methods	O
used	O
could	O
account	O
for	O
this	O
discrepancy	O
.	O
In	O
this	O
study	O
,	O
we	O
reevaluated	O
the	O
frequency	O
of	O
Ha-ras	O
codon	O
12	O
mutations	O
in	O
a	O
series	O
of	O
87	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
using	O
a	O
combination	O
of	O
two	O
different	O
methods	O
.	O
The	O
first	O
was	O
derived	O
from	O
the	O
protocol	O
of	O
Ooi	O
et	O
al	O
and	O
consisted	O
in	O
a	O
one	O
-	O
step	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
using	O
mismatched	O
primers	O
in	O
two	O
separate	O
PCR	O
.	O
This	O
method	O
is	O
very	O
rapid	O
and	O
highly	O
sensitive	O
,	O
detecting	O
the	O
presence	O
of	O
minor	O
populations	O
(	O
less	O
than	O
10	O
%	O
)	O
of	O
mutant	O
alleles	O
.	O
The	O
second	O
strategy	O
consisted	O
in	O
screening	O
all	O
tumors	O
using	O
natural	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
The	O
two	O
methods	O
were	O
in	O
complete	O
concordance	O
and	O
enabled	O
us	O
to	O
show	O
that	O
only	O
one	O
out	O
of	O
87	O
primary	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
(	O
1	O
%	O
)	O
exhibited	O
the	O
mutation	O
,	O
in	O
accordance	O
with	O
previous	O
studies	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
,	O
even	O
if	O
minor	O
cell	O
populations	O
overexpress	O
codon	O
12	O
Ha-ras	O
mutation	O
,	O
the	O
analysis	O
of	O
this	O
mutation	O
cannot	O
be	O
used	O
to	O
screen	O
potentially	B-malignancy-type
invasive	I-malignancy-type
transitional	I-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
bladder	I-malignancy-type
.	O
PMID	O
:	O
10767358	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2000	O
May;156	O
(	O
5	O
)	O
:	O
164	O
1-51	O
Genetic	O
,	O
immunohistochemical	O
,	O
and	O
clinical	O
features	O
of	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
:	O
A	O
newly	O
described	O
and	O
characterized	O
entity	O
.	O
Wilentz	O
RE	O
,	O
Goggins	O
M,	O
Redston	O
M,	O
Marcus	O
VA	O
,	O
Adsay	O
NV	O
,	O
Sohn	O
TA	O
,	O
Kadkol	O
SS	O
,	O
Yeo	O
CJ	O
,	O
Choti	O
M,	O
Zahurak	O
M,	O
Johnson	O
K,	O
Tascilar	O
M,	O
Offerhaus	O
GJ	O
,	O
Hruban	O
RH	O
,	O
Kern	O
SE.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
21231	O
,	O
USA	O
.	O
Medullary	B-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
are	O
a	O
recently	O
described	O
,	O
histologically	O
distinct	O
subset	O
of	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
adenocarcinomas	I-malignancy-type
that	O
may	O
have	O
a	O
unique	O
pathogenesis	O
and	O
clinical	O
course	O
.	O
To	O
further	O
evaluate	O
these	O
neoplasms	B-malignancy-type
,	O
we	O
studied	O
genetic	O
,	O
pathological	O
,	O
and	O
clinical	O
features	O
of	O
13	O
newly	O
identified	O
medullary	B-malignancy-type
carcinomas	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
Nine	O
(	O
69	O
%	O
)	O
of	O
these	O
had	O
wild-type	O
K-ras	O
genes	O
,	O
and	O
one	O
had	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
This	O
MSI	B-malignancy-type
medullary	I-malignancy-type
carcinoma	I-malignancy-type
,	O
along	O
with	O
three	O
previously	O
reported	O
MSI	B-malignancy-type
medullary	I-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
examined	O
immunohistochemically	O
for	O
Mlh1	O
and	O
Msh2	O
expression	O
,	O
and	O
all	O
four	O
expressed	O
Msh2	O
but	O
did	O
not	O
express	O
Mlh1	O
.	O
In	O
contrast	O
,	O
all	O
of	O
the	O
medullary	B-malignancy-type
carcinomas	I-malignancy-type
without	I-malignancy-type
MSI	I-malignancy-type
expressed	O
both	O
Msh2	O
and	O
Mlh1	O
.	O
Remarkably	O
,	O
the	O
MSI	B-malignancy-type
medullary	I-malignancy-type
carcinoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
in	O
the	O
present	O
series	O
arose	O
in	O
a	O
patient	O
with	O
a	O
synchronous	O
but	O
histologically	O
distinct	O
cecal	B-malignancy-type
carcinoma	I-malignancy-type
that	I-malignancy-type
also	I-malignancy-type
had	I-malignancy-type
MSI	I-malignancy-type
and	O
did	O
not	O
express	O
Mlh1	O
.	O
The	O
synchronous	O
occurrence	O
of	O
two	O
MSI	B-malignancy-type
carcinomas	I-malignancy-type
suggests	O
an	O
inherited	O
basis	O
for	O
the	O
development	O
of	O
these	O
carcinomas	B-malignancy-type
.	O
Indeed	O
,	O
the	O
medullary	O
phenotype	O
,	O
irrespective	O
of	O
MSI	O
,	O
was	O
highly	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	O
in	O
first-degree	O
relatives	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Finally	O
,	O
one	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
with	I-malignancy-type
lymphoepithelioma	I-malignancy-type
-	I-malignancy-type
like	I-malignancy-type
features	I-malignancy-type
contained	O
Epstein	O
-	O
Barr	O
virus	O
-	O
encoded	O
RNA-1	O
by	O
in	O
situ	O
hybridization	O
.	O
Therefore	O
,	O
because	O
of	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
's	O
special	O
genetic	O
,	O
immunohistochemical	O
,	O
and	O
clinical	O
features	O
,	O
recognition	O
of	O
the	O
medullary	B-malignancy-type
variant	I-malignancy-type
of	I-malignancy-type
pancreatic	I-malignancy-type
adenocarcinoma	I-malignancy-type
is	O
important	O
.	O
Only	O
by	O
classifying	O
medullary	B-malignancy-type
carcinoma	I-malignancy-type
as	O
special	O
subset	O
of	O
adenocarcinoma	B-malignancy-type
can	O
we	O
hope	O
to	O
further	O
elucidate	O
its	O
unique	O
pathogenesis	O
.	O
PMID	O
:	O
10793075	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arch	O
Pathol	O
Lab	O
Med	O
2000	O
Jun;12	O
4	O
(	O
6	O
)	O
:	O
89	O
4-7	O
Spindle	B-malignancy-type
cell	I-malignancy-type
tumor	I-malignancy-type
of	I-malignancy-type
urinary	I-malignancy-type
bladder	I-malignancy-type
serosa	I-malignancy-type
with	O
phenotypic	O
and	O
genotypic	O
features	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
.	O
Lasota	O
J,	O
Carlson	O
JA	O
,	O
Miettinen	O
M.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
2030	O
6-6000	O
,	O
USA	O
.	O
Most	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
are	O
now	O
referred	O
to	O
as	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
.	O
The	O
tumors	O
differ	O
from	O
ordinary	O
leiomyomas	B-malignancy-type
and	O
schwannomas	B-malignancy-type
in	O
several	O
respects	O
:	O
the	O
GISTs	B-malignancy-type
typically	O
express	O
c-kit	O
protein	O
(	O
CD117	O
)	O
and	O
CD34	O
,	O
30	O
%	O
to	O
50	O
%	O
of	O
them	O
are	O
(	O
often	O
focally	O
)	O
positive	O
for	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
,	O
and	O
all	O
are	O
negative	O
for	O
desmin	O
and	O
S100	O
protein	O
.	O
Recently	O
,	O
mutations	O
in	O
the	O
exon	O
11	O
of	O
the	O
c-kit	O
gene	O
have	O
been	O
identified	O
and	O
confirmed	O
as	O
a	O
molecular	O
genetic	O
marker	O
for	O
the	O
subset	O
of	O
GISTs	B-malignancy-type
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
mesenchymal	B-malignancy-type
tumor	I-malignancy-type
removed	O
from	O
the	O
pelvic	O
cavity	O
of	O
a	O
52	O
-	O
year	O
-	O
old	O
woman	O
,	O
who	O
is	O
alive	O
without	O
disease	O
36	O
months	O
after	O
the	O
surgery	O
.	O
The	O
5	O
-	O
cm	O
tumor	O
was	O
densely	O
attached	O
to	O
the	O
external	O
aspect	O
of	O
the	O
urinary	O
bladder	O
but	O
was	O
attached	O
to	O
small	O
intestine	O
by	O
only	O
filmy	O
adhesions	O
.	O
The	O
tumor	O
grossly	O
resembled	O
a	O
leiomyoma	B-malignancy-type
and	O
was	O
histologically	O
composed	O
of	O
sheets	O
of	O
spindle	O
cells	O
with	O
a	O
dense	O
collagenous	O
background	O
.	O
The	O
mitotic	O
activity	O
was	O
low	O
,	O
less	O
then	O
1	O
per	O
50	O
high	O
-	O
power	O
fields	O
.	O
Immunohistochemically	O
,	O
the	O
tumor	O
cells	O
were	O
negative	O
for	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
and	O
desmin	O
and	O
positive	O
for	O
CD117	O
and	O
CD34	O
.	O
Molecular	O
genetic	O
analysis	O
of	O
the	O
exon	O
11	O
of	O
the	O
c-kit	O
gene	O
revealed	O
a	O
point	O
mutation	O
in	O
the	O
region	O
commonly	O
mutated	O
in	O
GISTs	B-malignancy-type
.	O
This	O
mutation	O
substituted	O
T	O
for	O
A	O
in	O
the	O
codon	O
557	O
,	O
leading	O
to	O
the	O
change	O
of	O
amino	O
acid	O
sequence	O
(	O
tryptophan	O
for	O
arginine	O
)	O
of	O
the	O
KIT	O
protein	O
.	O
This	O
case	O
illustrates	O
that	O
tumors	O
phenotypically	O
and	O
genotypically	O
similar	O
to	O
GISTs	B-malignancy-type
may	O
present	O
in	O
sites	O
other	O
than	O
the	O
tubular	O
gastrointestinal	O
tract	O
.	O
PMID	O
:	O
10835530	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Pathol	O
2000	O
Feb;5	O
3	O
(	O
1	O
)	O
:	O
2	O
4-30	O
p53	O
and	O
K-ras	O
gene	O
mutations	O
in	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
among	O
Finnish	O
women	O
.	O
Servomaa	O
K,	O
Kiuru	O
A	O
,	O
Kosma	O
VM	O
,	O
Hirvikoski	O
P,	O
Rytomaa	O
T.	O
North	O
Savo	O
Regional	O
Environment	O
Centre	O
,	O
Kuopio	O
,	O
Finland	O
.	O
kristina	O
.servomaa@vyh	O
.fi	O
AIMS	O
/	O
BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
p53	O
and	O
K-ras	O
gene	O
mutations	O
in	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
among	O
Finnish	O
women	O
.	O
Mutation	O
patterns	O
might	O
give	O
clues	O
to	O
aetiological	O
factors	O
when	O
comparisons	O
are	O
made	O
with	O
other	O
human	O
tumours	O
.	O
METHODS	O
:	O
Of	O
134	O
women	O
with	O
carcinoma	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
rectum	I-malignancy-type
,	O
paraffin	O
wax	O
embedded	O
specimens	O
of	O
the	O
tumour	O
tissue	O
were	O
obtained	O
from	O
118	O
patients	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
,	O
and	O
exons	O
4	O
-	O
8	O
of	O
the	O
p53	O
gene	O
and	O
codons	O
12	O
/	O
13	O
and	O
61	O
of	O
the	O
K-ras	O
gene	O
were	O
amplified	O
,	O
and	O
analysed	O
for	O
mutations	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
.	O
The	O
production	O
of	O
p53	O
and	O
K-ras	O
proteins	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
The	O
overall	O
crude	O
frequency	O
for	O
mutations	O
in	O
the	O
p53	O
gene	O
was	O
35	O
%	O
but	O
the	O
true	O
frequency	O
appears	O
to	O
be	O
higher	O
(	O
up	O
to	O
56	O
%	O
)	O
.	O
In	O
the	O
K-ras	O
gene	O
,	O
the	O
mutation	O
frequency	O
(	O
15	O
%	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
reported	O
for	O
colon	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
the	O
p53	O
gene	O
,	O
the	O
mutation	O
frequency	O
increased	O
significantly	O
with	O
patient	O
age	O
.	O
In	O
a	O
high	O
proportion	O
of	O
patients	O
(	O
14	O
%	O
)	O
the	O
rectal	B-malignancy-type
tumours	I-malignancy-type
contained	O
small	O
subclones	O
of	O
tumour	O
cells	O
that	O
displayed	O
extremely	O
rare	O
mutations	O
at	O
codons	O
110	O
and	O
232	O
of	O
the	O
p53	O
gene	O
.	O
Hot	O
spot	O
codon	O
175	O
mutations	O
were	O
significantly	O
less	O
common	O
in	O
rectal	B-malignancy-type
cancer	I-malignancy-type
than	O
in	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Rectal	B-malignancy-type
cancer	I-malignancy-type
among	O
Finnish	O
women	O
has	O
characteristics	O
in	O
the	O
mutations	O
of	O
the	O
p53	O
and	O
K-ras	O
genes	O
that	O
are	O
uncommon	O
in	O
other	O
human	O
tumours	O
,	O
including	O
cancer	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
.	O
A	O
biological	O
explanation	O
of	O
these	O
findings	O
is	O
not	O
clear	O
at	O
present	O
,	O
but	O
might	O
be	O
associated	O
with	O
an	O
unidentified	O
genetic	O
factor	O
in	O
Finland	O
.	O
PMID	O
:	O
10884918	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2000	O
Aug;83(	O
4)	O
:473	O
-	O
9	O
Multiple	O
molecular	O
marker	O
testing	O
(	O
p53	O
,	O
C-Ki-ras	O
,	O
c-erbB-2	O
)	O
improves	O
estimation	O
of	O
prognosis	O
in	O
potentially	O
curative	O
resected	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
Schneider	O
PM	O
,	O
Praeuer	O
HW	O
,	O
Stoeltzing	O
O	O
,	O
Boehm	O
J,	O
Manning	O
J,	O
Metzger	O
R,	O
Fink	O
U	O
,	O
Wegerer	O
S,	O
Hoelscher	O
AH	O
,	O
Roth	O
JA.	O
Department	O
of	O
Visceral	O
and	O
Vascular	O
Surgery	O
,	O
University	O
of	O
Cologne	O
,	O
Germany	O
.	O
Paul.Schneider@Medizin.Uni-Koeln.de	O
A	O
prospective	O
study	O
was	O
performed	O
in	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
to	O
evaluate	O
the	O
prognostic	O
importance	O
of	O
multiple	O
molecular	O
marker	O
(	O
p53	O
,	O
c-Ki-ras	O
,	O
c-erbB-2	O
)	O
testing	O
.	O
103	O
patients	O
with	O
potentially	O
curative	O
resections	O
(	O
RO	O
resection	O
)	O
for	O
NSCLC	B-malignancy-type
in	O
histopathological	O
stages	O
I	O
-	O
IIIA	O
were	O
included	O
.	O
SSCP	O
analysis	O
and	O
DNA	O
sequencing	O
for	O
p53	O
and	O
c-Ki-ras	O
genes	O
were	O
performed	O
on	O
paired	O
tumour	O
and	O
normal	O
lung	O
tissue	O
samples	O
and	O
immunohistochemistry	O
(	O
c-erbB-2	O
)	O
was	O
done	O
on	O
frozen	O
tissue	O
sections	O
with	O
a	O
specific	O
anti	O
-	O
c-erbB-2	O
monoclonal	O
antibody	O
.	O
46	O
/	O
103	O
(	O
44.6	O
%	O
)	O
NSCLC	B-malignancy-type
showed	O
p53	O
mutations	O
and	O
17	O
/	O
103	O
(	O
16.5	O
%	O
)	O
c-Ki-ras	O
mutations	O
including	O
12	O
/	O
37	O
(	O
32.4	O
%	O
)	O
adenocarcinomas	B-malignancy-type
.	O
Overexpression	O
of	O
c-erbB-2	O
(	O
p185	O
)	O
was	O
detected	O
in	O
56	O
/	O
103	O
(	O
54.4	O
%	O
)	O
tumours	O
.	O
24	O
/	O
103	O
(	O
23.3	O
%	O
)	O
NSCLC	B-malignancy-type
were	O
negative	O
for	O
alterations	O
in	O
all	O
3	O
parameters	O
(	O
c-Ki-ras	O
,	O
p53	O
and	O
p185	O
)	O
whereas	O
79	O
/	O
103	O
(	O
76.7	O
%	O
)	O
were	O
positive	O
for	O
at	O
least	O
one	O
of	O
the	O
3	O
parameters	O
.	O
In	O
a	O
regression	O
model	O
including	O
a	O
multiple	O
molecular	O
marker	O
parameter	O
(	O
negative	O
for	O
all	O
3	O
markers	O
versus	O
positive	O
for	O
at	O
least	O
one	O
marker	O
)	O
,	O
histopathological	O
stage	O
(	O
P	O
<	O
0.00001	O
)	O
,	O
respectively	O
the	O
pT	O
(	O
P	O
<	O
0.01	O
)	O
and	O
pN	O
(	O
P	O
<	O
0.00001	O
)	O
categories	O
and	O
the	O
multiple	O
molecular	O
marker	O
parameter	O
(	O
P	O
<	O
0.01	O
)	O
were	O
of	O
significant	O
prognostic	O
importance	O
.	O
This	O
study	O
demonstrates	O
that	O
testing	O
3	O
molecular	O
markers	O
(	O
c-Ki-ras	O
,	O
p53	O
and	O
c-erbB-2	O
)	O
improves	O
estimation	O
of	O
prognosis	O
compared	O
to	O
single	O
marker	O
testing	O
and	O
appears	O
to	O
define	O
low	O
(	O
82.6	O
%	O
+/-	O
7.9	O
%	O
5	O
-	O
year	O
survival	O
)	O
and	O
high	O
risk	O
(	O
40.2	O
%	O
+/-	O
5.5	O
%	O
5	O
-	O
year	O
survival	O
)	O
groups	O
for	O
treatment	O
failure	O
in	O
potentially	O
curative	O
(	O
RO	O
)	O
resected	O
NSCLC	B-malignancy-type
.	O
PMID	O
:	O
10945494	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2000	O
Sep;13(	O
9	O
)	O
:973	O
-	O
7	O
Missense	O
mutation	O
of	O
the	O
MET	O
gene	O
detected	O
in	O
human	O
glioma	B-malignancy-type
.	O
Moon	O
YW	O
,	O
Weil	O
RJ	O
,	O
Pack	O
SD	O
,	O
Park	O
WS	O
,	O
Pak	O
E	O
,	O
Pham	O
T	O
,	O
Karkera	O
JD	O
,	O
Kim	O
HK	O
,	O
Vortmeyer	O
AO	O
,	O
Fuller	O
BG	O
,	O
Zhuang	O
Z	O
.	O
Radiation	O
Oncology	O
Branch	O
,	O
National	O
Institute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
Multiple	O
mechanisms	O
,	O
such	O
as	O
gene	O
mutations	O
,	O
amplifications	O
,	O
and	O
rearrangements	O
,	O
as	O
well	O
as	O
perturbed	O
mitogen	O
and	O
receptor	O
function	O
,	O
are	O
likely	O
to	O
contribute	O
to	O
glioma	B-malignancy-type
formation	O
.	O
The	O
MET	O
(	O
also	O
known	O
as	O
c-met	O
proto	O
-	O
oncogene	O
located	O
at	O
7q31	O
-	O
34	O
has	O
been	O
shown	O
to	O
be	O
amplified	O
in	O
human	O
gliomas	B-malignancy-type
,	O
and	O
activating	O
mutations	O
within	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
MET	O
have	O
been	O
causally	O
related	O
to	O
tumorigenesis	O
in	O
hereditary	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
To	O
elucidate	O
the	O
role	O
of	O
MET	O
gene	O
in	O
glioma	B-malignancy-type
formation	O
,	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
from	O
11	O
patients	O
were	O
examined	O
for	O
MET	O
gene	O
mutations	O
and	O
allelic	O
duplications	O
or	O
deletions	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
Three	O
of	O
11	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
showed	O
a	O
deletion	O
of	O
one	O
copy	O
of	O
the	O
MET	O
gene	O
,	O
and	O
a	O
specific	O
MET	O
gene	O
missense	O
mutation	O
in	O
the	O
remaining	O
gene	O
copy	O
was	O
detected	O
in	O
one	O
of	O
those	O
tumors	O
.	O
The	O
corresponding	O
sequence	O
in	O
non	O
-	O
tumor	O
DNA	O
was	O
normal	O
in	O
all	O
cases	O
.	O
Three	O
of	O
11	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
showed	O
duplication	O
of	O
one	O
copy	O
of	O
the	O
MET	O
gene	O
,	O
but	O
none	O
of	O
them	O
contained	O
mutations	O
.	O
One	O
tumor	O
showed	O
MET	O
amplification	O
without	O
mutation	O
.	O
Three	O
showed	O
neither	O
allelic	O
change	O
nor	O
mutation	O
.	O
These	O
data	O
suggest	O
that	O
somatic	O
MET	O
gene	O
mutation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
a	O
subgroup	O
of	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
.	O
However	O
,	O
MET	O
mutations	O
appear	O
to	O
be	O
absent	O
in	O
the	O
majority	O
of	O
sporadic	B-malignancy-type
gliomas	I-malignancy-type
.	O
PMID	O
:	O
11007037	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Int	O
2000	O
Sep;50(	O
9	O
)	O
:725	O
-	O
30	O
beta-catenin	O
expression	O
and	O
mutational	O
analysis	O
in	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Kim	O
YS	O
,	O
Kang	O
YK	O
,	O
Kim	O
JB	O
,	O
Han	O
SA	O
,	O
Kim	O
KI	O
,	O
Paik	O
SR	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Medicine	O
,	O
Korea	O
University	O
,	O
Gojan	O
-	O
Dong	O
,	O
Ansan	O
,	O
Korea	O
.	O
apysk@yahoo.com	O
beta-Catenin	O
acts	O
as	O
a	O
downstream	O
transcriptional	O
activator	O
of	O
the	O
Wingless	O
-	O
Wnt	O
signaling	O
pathway	O
.	O
The	O
beta-catenin	O
-	O
Tcf	O
complex	O
transactivates	O
the	O
downstream	O
genes	O
that	O
regulate	O
cell	O
proliferation	O
or	O
inhibit	O
apoptosis	O
.	O
The	O
activation	O
of	O
this	O
pathway	O
through	O
stabilization	O
of	O
beta-catenin	O
is	O
caused	O
either	O
by	O
inactivating	O
mutations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
tumor	O
suppressor	O
gene	O
or	O
by	O
activating	O
mutations	O
in	O
beta-catenin	O
exon	O
3	O
.	O
To	O
determine	O
whether	O
the	O
abnormal	O
expression	O
and	O
activating	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
are	O
implicated	O
in	O
renal	O
cell	O
carcinogenesis	O
,	O
52	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
RCC	B-malignancy-type
)	O
were	O
analyzed	O
by	O
immunohistochemistry	O
,	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
PCR	O
-	O
SSCP	O
)	O
,	O
and	O
direct	O
DNA	O
sequencing	O
.	O
Immunohistochemically	O
,	O
all	O
cases	O
,	O
as	O
well	O
as	O
normal	O
kidneys	O
,	O
showed	O
membranous	O
and	O
/	O
or	O
cytoplasmic	O
staining	O
patterns	O
without	O
nuclear	O
localization	O
.	O
However	O
,	O
the	O
cytoplasmic	O
accumulations	O
of	O
beta-catenin	O
were	O
observed	O
in	O
five	O
(	O
22.7	O
%	O
)	O
of	O
22	O
cases	O
of	O
conventional	B-malignancy-type
(	I-malignancy-type
clear	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
,	O
but	O
not	O
in	O
papillary	B-malignancy-type
or	O
chromophobe	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
beta	O
-	O
catenin	O
mutation	O
was	O
identified	O
in	O
only	O
one	O
case	O
of	O
conventional	B-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
and	O
was	O
a	O
single	O
-	O
base	O
missense	O
mutation	O
on	O
codon	O
61	O
,	O
leading	O
to	O
substitution	O
of	O
glutamine	O
by	O
arginine	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
demonstrates	O
that	O
beta-catenin	O
mutations	O
are	O
a	O
relatively	O
rare	O
event	O
in	O
RCC	B-malignancy-type
and	O
that	O
cytoplasmic	O
accumulations	O
of	O
beta-catenin	O
protein	O
are	O
found	O
only	O
in	O
conventional	B-malignancy-type
(	I-malignancy-type
clear	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
These	O
data	O
suggest	O
that	O
the	O
activation	O
of	O
the	O
beta-catenin	O
signaling	O
pathway	O
may	O
partly	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
conventional	B-malignancy-type
RCC	I-malignancy-type
.	O
PMID	O
:	O
11012986	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Carcinogenesis	O
2000	O
Oct;21(	O
10	O
)	O
:1813	O
-	O
9	O
NAD(P)H:quinone	O
oxidoreductase	O
-	O
dependent	O
risk	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
and	O
its	O
association	O
with	O
the	O
presence	O
of	O
K-ras	O
mutations	O
in	O
tumors	O
.	O
Lafuente	O
MJ	O
,	O
Casterad	O
X	O
,	O
Trias	O
M,	O
Ascaso	O
C	O
,	O
Molina	O
R,	O
Ballesta	O
A	O
,	O
Zheng	O
S,	O
Wiencke	O
JK	O
,	O
Lafuente	O
A.	O
Department	O
of	O
Surgery	O
,	O
Hospital	O
Clinic	O
,	O
Department	O
of	O
Pharmacology	O
,	O
School	O
of	O
Medicine	O
,	O
Casanova	O
143	O
,	O
E-08036	O
,	O
Barcelona	O
,	O
Spain	O
.	O
alafuente@med	O
.ub.es	O
NAD(P)H:quinone	O
oxidoreductase	O
(	O
NQO1	O
)	O
is	O
a	O
polymorphic	O
enzyme	O
involved	O
in	O
the	O
detoxification	O
of	O
potentially	O
mutagenic	O
and	O
carcinogenic	O
quinones	O
.	O
The	O
homozygous	O
C609T	O
NQO1	O
genotype	O
resulting	O
in	O
loss	O
of	O
reductase	O
activity	O
is	O
found	O
in	O
2	O
-	O
20	O
%	O
of	O
individuals	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
NQO1	O
-	O
dependent	O
risk	O
for	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
CRC	B-malignancy-type
)	O
was	O
studied	O
in	O
247	O
incident	O
CRC	B-malignancy-type
cases	O
and	O
296	O
hospital	O
-	O
based	O
controls	O
recruited	O
during	O
1996	O
-	O
1997	O
.	O
Four	O
subgroups	O
of	O
cases	O
were	O
studied	O
:	O
(i)	O
all	O
CRCs	B-malignancy-type
;	O
(ii)	O
a	O
molecular	O
CRC	B-malignancy-type
subgroup	O
(	O
n	O
=	O
117	O
,	O
cases	O
with	O
molecular	O
tumor	O
analyses	O
)	O
;	O
(iii)	O
within	O
the	O
molecular	O
subgroup	O
those	O
tumors	O
with	O
K-ras	O
mutations	O
in	O
codon	O
12	O
(	O
CRC	B-malignancy-type
K	O
12	O
)	O
;	O
(iv)	O
within	O
the	O
molecular	O
subgroup	O
those	O
tumors	O
with	O
K-ras	O
mutations	O
in	O
codon	O
13	O
(	O
CRC	B-malignancy-type
K	O
13	O
)	O
.	O
The	O
C609T	O
NQO1	O
genotype	O
was	O
found	O
to	O
be	O
twice	O
as	O
prevalent	O
in	O
all	O
CRC	B-malignancy-type
patients	O
(	O
6.8	O
%	O
)	O
compared	O
with	O
controls	O
(	O
3	O
%	O
)	O
and	O
six	O
times	O
more	O
common	O
in	O
the	O
subset	O
CRC	B-malignancy-type
K	O
12	O
(	O
20	O
%	O
)	O
.	O
Multivariant	O
analyses	O
in	O
the	O
overall	O
population	O
of	O
247	O
cases	O
and	O
296	O
controls	O
showed	O
a	O
significant	O
age	O
and	O
gender	O
adjusted	O
risk	O
for	O
CRC	B-malignancy-type
associated	O
with	O
the	O
C609T	O
NQO1	O
genotype	O
(	O
OR	O
2.9	O
,	O
95	O
%	O
CI	O
1.19	O
-	O
6.97	O
;	O
P	O
=	O
0.01	O
)	O
or	O
with	O
any	O
variant	O
genotype	O
(	O
the	O
low	O
activity	O
allele	O
frequency	O
,	O
i.e.	O
heterozygotes	O
plus	O
homozygotes	O
)	O
(	O
OR	O
1.41	O
,	O
95	O
%	O
CI	O
1.02	O
-	O
1.92	O
;	O
P	O
=	O
0.03	O
)	O
.	O
Within	O
cases	O
of	O
the	O
molecular	O
subgroup	O
(	O
n	O
=	O
117	O
)	O
the	O
C609T	O
NQO1	O
genotype	O
was	O
associated	O
with	O
the	O
presence	O
of	O
K-ras	O
codon	O
12	O
mutation	O
(	O
OR	O
6.5	O
95	O
%	O
,	O
CI	O
1.39	O
-	O
34.9	O
;	O
P	O
=	O
0.003	O
)	O
.	O
Logistic	O
regression	O
showed	O
an	O
age	O
and	O
gender	O
adjusted	O
risk	O
for	O
K-ras	O
codon	O
12	O
mutant	O
CRC	B-malignancy-type
associated	O
with	O
the	O
C609T	O
NQO1	O
genotype	O
(	O
OR	O
10.5	O
,	O
95	O
%	O
CI	O
2.99	O
-	O
36.7	O
;	O
P	O
:	O
=	O
0.0002	O
)	O
or	O
with	O
any	O
variant	O
NQO1	O
genotype	O
(	O
OR	O
2.23	O
,	O
95	O
%	O
CI	O
1.23	O
-	O
4.00	O
;	O
P	O
=	O
0.007	O
)	O
compared	O
with	O
the	O
control	O
group	O
.	O
Genetically	O
determined	O
variations	O
in	O
NQO1	O
may	O
modify	O
the	O
risk	O
for	O
CRC	B-malignancy-type
and	O
these	O
risks	O
may	O
be	O
greatest	O
for	O
tumors	O
containing	O
K-ras	O
codon	O
12	O
mutations	O
.	O
CRC	B-malignancy-type
with	O
K-ras	O
codon	O
12	O
mutations	O
may	O
represent	O
a	O
distinct	O
and	O
etiologically	O
more	O
homogeneous	O
subtype	O
of	O
the	O
disease	O
,	O
which	O
may	O
be	O
associated	O
with	O
toxicants	O
that	O
are	O
metabolized	O
via	O
a	O
NQO1	O
-	O
dependent	O
pathway	O
.	O
PMID	O
:	O
11023538	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Surg	O
Oncol	O
2000	O
Nov;75	O
(	O
3	O
)	O
:	O
17	O
6-85	O
Comparison	O
of	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
and	O
p21	O
expression	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
between	O
Japanese	O
and	O
Chinese	O
patients	O
.	O
Song	O
MM	O
,	O
Nio	O
Y	O
,	O
Dong	O
M,	O
Tamura	O
K,	O
Furuse	O
K,	O
Tian	O
YL	O
,	O
He	O
SG	O
,	O
Shen	O
K.	O
First	O
Department	O
of	O
Surgery	O
,	O
Shimane	O
Medical	O
University	O
,	O
Izumo	O
,	O
Shimane	O
,	O
Japan	O
.	O
BACKGROUND	O
ANF	O
OBJECTIVES	O
:	O
K-ras	O
(	O
Kirsten-ras	O
)	O
point	O
mutation	O
(	O
PM	O
)	O
in	O
codon	O
12	O
are	O
suggested	O
to	O
be	O
significantly	O
associated	O
with	O
the	O
tumorigenesis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
incidences	O
of	O
K-ras	O
PMs	O
in	O
human	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
are	O
reported	O
to	O
be	O
different	O
between	O
Europeans	O
and	O
Japanese	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
compare	O
the	O
incidences	O
and	O
profile	O
of	O
K-ras	O
PMs	O
and	O
ras	O
-	O
p21	O
expression	O
in	O
primary	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinoma	I-malignancy-type
(	I-malignancy-type
IDC	I-malignancy-type
)	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
between	O
Japanese	O
and	O
Chinese	O
.	O
METHODS	O
:	O
The	O
specimens	O
included	O
51	O
Japanese	O
and	O
34	O
Chinese	O
patients	O
with	O
the	O
primary	O
IDC	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
pancreas	I-malignancy-type
.	O
K-ras	O
PMs	O
were	O
tested	O
by	O
allele	O
specific	O
oligonucleotide	O
dot	O
blot	O
hybridization	O
methods	O
and	O
ras	O
-	O
p21	O
expression	O
was	O
stained	O
by	O
the	O
immunohistochemical	O
method	O
.	O
RESULTS	O
:	O
K-ras	O
PMs	O
were	O
detected	O
in	O
48	O
Japanese	O
IDCs	B-malignancy-type
(	O
94	O
%	O
)	O
and	O
in	O
24	O
Chinese	O
ones	O
(	O
71	O
%	O
)	O
.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O
The	O
GAT	O
mutation	O
was	O
more	O
frequent	O
both	O
in	O
Japanese	O
(	O
61	O
%	O
,	O
33	O
/	O
54	O
)	O
and	O
in	O
Chinese	O
(	O
60	O
%	O
,	O
18	O
/	O
30	O
)	O
IDCs	B-malignancy-type
.	O
The	O
transitions	O
/	O
transversions	O
ratio	O
in	O
the	O
Japanese	O
group	O
was	O
2.4	O
in	O
this	O
study	O
.	O
By	O
contrast	O
,	O
that	O
in	O
the	O
Chinese	O
group	O
was	O
1.5	O
.	O
The	O
expression	O
of	O
p21	O
was	O
detected	O
in	O
24	O
Japanese	O
IDCs	B-malignancy-type
(	O
47	O
%	O
)	O
and	O
in	O
24	O
Chinese	O
IDCs	B-malignancy-type
(	O
71	O
%	O
)	O
.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O
The	O
expression	O
of	O
p21	O
and	O
the	O
patterns	O
of	O
K-ras	O
PMs	O
did	O
not	O
show	O
any	O
significant	O
influence	O
on	O
the	O
survival	O
of	O
the	O
patients	O
both	O
in	O
Japanese	O
and	O
Chinese	O
.	O
In	O
the	O
present	O
study	O
,	O
Chinese	O
IDC	B-malignancy-type
had	O
a	O
lower	O
frequency	O
of	O
K-ras	O
PMs	O
in	O
codon	O
12	O
than	O
Japanese	O
IDC	B-malignancy-type
.	O
The	O
pattern	O
of	O
K-ras	O
PMs	O
in	O
Chinese	O
IDC	B-malignancy-type
was	O
different	O
from	O
that	O
in	O
Japanese	O
and	O
European	O
IDC	B-malignancy-type
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
Ki-ras	O
PM	O
and	O
p21	O
expression	O
were	O
frequently	O
seen	O
both	O
in	O
Japanese	O
and	O
Chinese	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Factors	O
such	O
as	O
lifestyle	O
and	O
environment	O
may	O
have	O
influences	O
on	O
pancreatic	O
carcinogenesis	O
in	O
various	O
populations	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11088049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Int	O
2000	O
Dec;50	O
(	O
12	O
)	O
:	O
94	O
5-52	O
Aberrant	O
expression	O
of	O
beta-catenin	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
renal	B-malignancy-type
and	O
urothelial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Zhu	O
X	O
,	O
Kanai	O
Y	O
,	O
Saito	O
A	O
,	O
Kondo	O
Y	O
,	O
Hirohashi	O
S.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
present	O
study	O
attempted	O
to	O
clarify	O
the	O
significance	O
of	O
aberrant	O
expression	O
of	O
beta-catenin	O
protein	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
renal	O
and	O
urothelial	O
carcinogenesis	O
.	O
beta-Catenin	O
expression	O
was	O
examined	O
immunohistochemically	O
and	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
.	O
beta-Catenin	O
immunoreactivity	O
was	O
observed	O
at	O
the	O
cell	O
membrane	O
in	O
all	O
30	O
renal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
RCC	B-malignancy-type
)	O
examined	O
,	O
and	O
no	O
RCC	B-malignancy-type
showed	O
a	O
mobility	O
-	O
shifted	O
SSCP	O
band	O
.	O
Of	O
46	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
TCC	B-malignancy-type
)	O
examined	O
,	O
there	O
was	O
reduced	O
expression	O
of	O
beta-catenin	O
,	O
as	O
compared	O
with	O
its	O
expression	O
in	O
non	O
-	O
cancerous	O
transitional	O
epithelium	O
,	O
in	O
22	O
cases	O
(	O
48	O
%	O
)	O
and	O
beta-catenin	O
accumulation	O
in	O
the	O
nucleus	O
in	O
five	O
cases	O
(	O
11	O
%	O
)	O
.	O
Of	O
four	O
renal	B-malignancy-type
pelvis	I-malignancy-type
TCC	I-malignancy-type
examined	O
,	O
point	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
at	O
codon	O
45	O
resulting	O
in	O
amino	O
acid	O
substitution	O
(	O
Ser	O
to	O
Phe	O
)	O
was	O
detected	O
in	O
one	O
(	O
25	O
%	O
)	O
.	O
The	O
incidence	O
of	O
reduced	O
expression	O
of	O
beta-catenin	O
correlated	O
significantly	O
with	O
the	O
growth	O
pattern	O
(	O
superficial	B-malignancy-type
type	I-malignancy-type
vs	O
invasive	B-malignancy-type
type	I-malignancy-type
)	O
of	O
TCC	B-malignancy-type
(	O
P	O
<	O
0.05	O
)	O
.	O
These	O
data	O
indicate	O
that	O
:	O
(1)	O
aberrant	O
beta-catenin	O
expression	O
may	O
be	O
at	O
least	O
partly	O
involved	O
in	O
urothelial	O
carcinogenesis	O
,	O
but	O
less	O
significantly	O
so	O
in	O
renal	O
carcinogenesis	O
,	O
and	O
(2)	O
it	O
may	O
be	O
associated	O
with	O
the	O
progression	O
of	O
TCC	B-malignancy-type
showing	O
invasive	O
growth	O
.	O
PMID	O
:	O
11123760	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Tumour	O
Biol	O
2001	O
Ma	O
r-Apr;2	O
2	O
(	O
2	O
)	O
:	O
12	O
3-30	O
Mutational	O
analysis	O
of	O
the	O
beta-catenin	O
gene	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Sasaki	O
Y	O
,	O
Morimoto	O
I	O
,	O
Kusano	O
M,	O
Hosokawa	O
M,	O
Itoh	O
F	O
,	O
Yanagihara	O
K,	O
Imai	O
K,	O
Tokino	O
T.	O
Department	O
of	O
Molecular	O
Biology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Sapporo	O
,	O
Japan	O
.	O
Previous	O
studies	O
reported	O
that	O
mutation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
was	O
not	O
observed	O
in	O
the	O
majority	O
of	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
To	O
evaluate	O
the	O
role	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
,	O
we	O
analyzed	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
and	O
the	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
.	O
An	O
interstitial	O
deletion	O
spanning	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
observed	O
in	O
1	O
of	O
13	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
No	O
missense	O
mutation	O
was	O
found	O
in	O
these	O
13	O
cell	O
lines	O
.	O
Nuclear	O
and/or	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
was	O
observed	O
in	O
16	O
of	O
70	O
primary	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
by	O
immunohistochemistry	O
,	O
while	O
we	O
found	O
no	O
mutations	O
in	O
exon	O
3	O
in	O
35	O
carcinoma	B-malignancy-type
tissues	O
available	O
for	O
PCR	O
amplification	O
.	O
Our	O
findings	O
suggest	O
that	O
somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
rare	O
in	O
human	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
and	O
that	O
accumulation	O
of	O
normal	O
beta-catenin	O
protein	O
in	O
a	O
subset	B-malignancy-type
of	I-malignancy-type
gastric	I-malignancy-type
cancers	I-malignancy-type
may	O
be	O
due	O
to	O
other	O
mechanisms	O
of	O
its	O
activation	O
.	O
Copyright	O
2001	O
S.	O
Karger	O
AG	O
,	O
Basel	O
PMID	O
:	O
11125285	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2001	O
Jan;8	O
4	O
(	O
2	O
)	O
:	O
20	O
9-17	O
beta	O
-	O
Catenin	O
mutations	O
and	O
aberrant	O
nuclear	O
expression	O
during	O
endometrial	O
tumorigenesis	O
.	O
Saegusa	O
M,	O
Hashimura	O
M,	O
Yoshida	O
T	O
,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
1-1	O
5-1	O
Kitasato	O
,	O
Sagamihara	O
,	O
Kanagawa	O
,	O
22	O
8-8555	O
,	O
Japan	O
.	O
msaegusa@med.kitasat	O
o-u.ac.jp	O
To	O
clarify	O
the	O
possible	O
role	O
of	O
aberrant	O
beta-catenin	O
expression	O
during	O
endometrial	O
tumorigenesis	O
,	O
a	O
total	O
of	O
199	O
cases	O
of	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
(	I-malignancy-type
endometrioid	I-malignancy-type
type	I-malignancy-type
)	I-malignancy-type
,	O
as	O
well	O
as	O
37	O
cases	O
of	O
simple	O
/	O
complex	O
and	O
32	O
of	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
,	O
was	O
consecutively	O
investigated	O
for	O
immunohistochemistry	O
,	O
along	O
with	O
141	O
normal	O
endometrial	O
samples	O
distant	O
from	O
carcinomas	B-malignancy-type
.	O
Of	O
199	O
carcinoma	B-malignancy-type
cases	O
,	O
73	O
tumours	O
as	O
well	O
as	O
44	O
normal	O
samples	O
were	O
also	O
analysed	O
using	O
a	O
combination	O
of	O
RT-PCR	O
and	O
Southern	O
blot	O
hybridization	O
,	O
Western	O
blot	O
,	O
and	O
mutation	O
gene	O
assays	O
.	O
Cell	O
membrane	O
beta-catenin	O
immunoreactivity	O
showed	O
a	O
stepwise	O
decrease	O
from	O
normal	O
,	O
through	O
atypical	B-malignancy-type
hyperplasia	I-malignancy-type
,	O
to	O
grade	O
3	O
carcinomas	B-malignancy-type
.	O
In	O
contrast	O
,	O
the	O
nuclear	O
accumulation	O
in	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
and	O
grade	O
1	O
or	O
2	O
tumours	O
was	O
higher	O
than	O
in	O
simple	B-malignancy-type
/	O
complex	B-malignancy-type
hyperplasias	I-malignancy-type
.	O
Mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
involving	O
codons	O
33	O
,	O
34	O
,	O
37	O
,	O
41	O
,	O
and	O
45	O
were	O
observed	O
in	O
16	O
(	O
22.9	O
%	O
)	O
of	O
70	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
as	O
well	O
as	O
3	O
(	O
12.5	O
%	O
)	O
of	O
24	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
,	O
the	O
results	O
being	O
significantly	O
related	O
to	O
low	O
membrane	O
and	O
high	O
nuclear	O
immunoreactivity	O
but	O
not	O
relative	O
mRNA	O
expression	O
levels	O
,	O
suggesting	O
that	O
the	O
gene	O
mutations	O
may	O
be	O
closely	O
associated	O
with	O
changes	O
in	O
subcellular	O
distribution	O
.	O
In	O
addition	O
to	O
significant	O
association	O
between	O
beta-catenin	O
mutation	O
and	O
low	O
grade	O
histological	O
malignancy	O
(	O
P	O
=	O
0.048	O
)	O
,	O
the	O
mutations	O
were	O
detected	O
in	O
none	O
of	O
15	O
and	O
13	O
(	O
26	O
%	O
)	O
of	O
50	O
tumours	O
with	O
or	O
without	O
lymph	O
node	O
metastasis	O
,	O
the	O
difference	O
being	O
significant	O
(	O
P	O
=	O
0.027	O
)	O
.	O
These	O
findings	O
suggest	O
that	O
beta-catenin	O
abnormalities	O
may	O
play	O
an	O
important	O
role	O
in	O
a	O
relatively	O
early	O
event	O
during	O
the	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
sequence	O
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11161379	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
2001	O
Mar	O
26;16	O
4	O
(	O
2	O
)	O
:	O
20	O
7-12	O
K-ras	O
exon	O
2	O
point	O
mutations	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
Semczuk	O
A	O
,	O
Schneide	O
r-Stock	O
R	O
,	O
Berbec	O
H,	O
Marzec	O
B	O
,	O
Jakowicki	O
JA	O
,	O
Roessner	O
A.	O
Second	O
Department	O
of	O
Gynecological	O
Surgery	O
,	O
Lublin	O
School	O
of	O
Medicine	O
,	O
Jaczewski	O
street	O
8	O
,	O
2	O
0-954	O
,	O
Lublin	O
,	O
Poland	O
.	O
tomek@asklepios	O
.am.lublin.pl	O
In	O
the	O
present	O
study	O
,	O
we	O
screened	O
for	O
the	O
K-ras	O
exon	O
2	O
point	O
mutations	O
in	O
a	O
group	O
of	O
87	O
gynecological	B-malignancy-type
neoplasms	I-malignancy-type
(	O
82	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
four	O
carcinomas	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
uterine	I-malignancy-type
cervix	I-malignancy-type
and	O
one	O
uterine	O
carcinosarcoma	O
)	O
using	O
the	O
non	O
-	O
isotopic	O
PCR-SSCP	O
-	O
direct	O
sequencing	O
techniques	O
.	O
Direct	O
sequencing	O
analysis	O
revealed	O
CAA	O
-->	O
CAC	O
(	O
Gln	O
-->	O
His	O
)	O
K-ras	O
codon	O
61	O
point	O
mutations	O
in	O
two	O
(	O
2.4	O
%	O
)	O
of	O
the	O
82	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
mentioned	O
above	O
.	O
These	O
two	O
cases	O
were	O
endometrial	B-malignancy-type
endometrioid	I-malignancy-type
carcinomas	I-malignancy-type
at	O
an	O
early	O
clinical	O
stage	O
of	O
disease	O
(	O
stage	O
IB	O
and	O
IC	O
due	O
to	O
FIGO	O
)	O
.	O
Those	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
that	O
showed	O
K-ras	O
exon	O
2	O
point	O
mutations	O
revealed	O
a	O
strong	O
positivity	O
for	O
heterogeneous	O
nuclear	O
retinoblastoma	O
protein	O
staining	O
;	O
none	O
of	O
these	O
,	O
however	O
,	O
have	O
had	O
the	O
K-ras	O
codon	O
12	O
point	O
mutation	O
.	O
In	O
addition	O
,	O
there	O
were	O
no	O
K-ras	O
gene	O
point	O
mutations	O
in	O
three	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
lacking	O
the	O
Rb	O
protein	O
immunohistochemically	O
.	O
None	O
of	O
the	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
tested	O
had	O
K-ras	O
gene	O
point	O
mutations	O
,	O
whereas	O
one	O
carcinosarcoma	B-malignancy-type
harbored	O
K-ras	O
codon	O
61	O
point	O
mutation	O
(	O
CAA	O
-->	O
CAC	O
)	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
support	O
the	O
view	O
that	O
K-ras	O
exon	O
2	O
point	O
mutations	O
are	O
rare	O
events	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
Rb	O
and	O
K-ras	O
gene	O
abnormalities	O
may	O
occur	O
independently	O
of	O
each	O
other	O
during	O
endometrial	O
carcinogenesis	O
in	O
humans	O
.	O
PMID	O
:	O
11179836	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Clin	O
Pathol	O
2001	O
Feb;11	O
5	O
(	O
2	O
)	O
:	O
23	O
5-42	O
H-ras	O
oncogene	O
mutation	O
in	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
.	O
Polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O
Sakamoto	O
A	O
,	O
Oda	O
Y	O
,	O
Adachi	O
T	O
,	O
Tamiya	O
S	O
,	O
Matsuda	O
S	O
,	O
Tanaka	O
K,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Departments	O
of	O
Anatomic	O
Pathology	O
,	O
Pathological	O
Sciences	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Point	O
mutations	O
of	O
the	O
ras	O
gene	O
family	O
(	O
K-ras	O
,	O
H-ras	O
,	O
and	O
N-ras	O
)	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
variety	O
of	O
human	O
tumors	O
.	O
Dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
is	O
characterized	O
by	O
the	O
coexistence	O
of	O
well	O
-	O
differentiated	O
(	O
WD	O
)	O
and	O
high-grade	O
anaplastic	O
(	O
HG	O
)	O
components	O
.	O
The	O
presence	O
of	O
point	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
H-ras	O
gene	O
was	O
studied	O
in	O
34	O
liposarcomas	B-malignancy-type
,	O
comprising	O
15	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
liposarcomas	I-malignancy-type
and	O
19	O
dedifferentiated	B-malignancy-type
liposarcomas	I-malignancy-type
,	O
and	O
in	O
8	O
storiform	B-malignancy-type
-	I-malignancy-type
pleomorphic	I-malignancy-type
type	I-malignancy-type
malignant	I-malignancy-type
fibrous	I-malignancy-type
histiocytomas	I-malignancy-type
(	O
MFHs	B-malignancy-type
)	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
direct	O
sequencing	O
analysis	O
.	O
The	O
2	O
components	O
of	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
were	O
analyzed	O
independently	O
.	O
H-ras	O
mutations	O
were	O
seen	O
only	O
in	O
dedifferentiated	B-malignancy-type
liposarcomas	I-malignancy-type
(	O
4	O
/	O
19	O
[	O
21	O
%	O
]	O
)	O
,	O
1	O
in	O
WD	O
components	O
and	O
3	O
in	O
HG	O
components	O
.	O
The	O
mutation	O
was	O
not	O
seen	O
in	O
any	O
of	O
15	O
cases	O
of	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
liposarcoma	I-malignancy-type
.	O
MFHs	B-malignancy-type
showed	O
an	O
H-ras	O
mutation	O
in	O
1	O
(	O
12	O
%	O
)	O
of	O
8	O
cases	O
.	O
Our	O
results	O
seem	O
to	O
suggest	O
that	O
the	O
H-ras	O
mutation	O
is	O
a	O
relatively	O
uncommon	O
event	O
in	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
,	O
which	O
may	O
demonstrate	O
an	O
epiphenomenon	O
of	O
dedifferentiation	O
in	O
dedifferentiated	B-malignancy-type
liposarcoma	I-malignancy-type
.	O
PMID	O
:	O
11211612	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Surg	O
Oncol	O
2001	O
Feb;2	O
7	O
(	O
1	O
)	O
:	O
8	O
0-7	O
Relevance	O
of	O
Ki-67	O
antigen	O
expression	O
and	O
K-ras	O
mutation	O
in	O
colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
.	O
Petrowsky	O
H,	O
Sturm	O
I	O
,	O
Graubitz	O
O,	O
Kooby	O
DA	O
,	O
Stai	O
b-Sebler	O
E	O
,	O
Gog	O
C,	O
Kohne	O
CH,	O
Hillebrand	O
T	O
,	O
Daniel	O
PT	O
,	O
Fong	O
Y	O
,	O
Lorenz	O
M.	O
Department	O
of	O
General	O
and	O
Vascular	O
Surgery	O
,	O
Johann	O
Wolfgang	O
Goeth	O
e-University	O
,	O
60590	O
Frankfurt	O
am	O
Main	O
,	O
Germany	O
.	O
AIMS	O
:	O
The	O
liver	O
is	O
a	O
frequent	O
site	O
of	O
metastases	B-malignancy-type
from	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
.	O
While	O
these	O
lesions	O
are	O
potentially	O
amenable	O
to	O
surgical	O
resection	O
,	O
they	O
are	O
usually	O
very	O
aggressive	O
,	O
and	O
recurrence	O
is	O
frequent	O
.	O
Mutations	O
of	O
the	O
proto	O
-	O
oncogene	O
K	O
-	O
ras	O
are	O
thought	O
to	O
impart	O
a	O
strong	O
growth	O
signal	O
to	O
tumour	O
cells	O
and	O
are	O
closely	O
associated	O
with	O
the	O
development	O
of	O
malignancies	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
colon	I-malignancy-type
and	I-malignancy-type
rectum	I-malignancy-type
.	O
Hepatic	B-malignancy-type
metastases	I-malignancy-type
from	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
have	O
notably	O
elevated	O
proliferative	O
rates	O
.	O
The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
relationship	O
between	O
proliferation	O
K	O
-	O
ras	O
mutation	O
and	O
prognosis	O
following	O
curative	O
resection	O
of	O
colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
.	O
METHODS	O
:	O
Colorectal	B-malignancy-type
liver	I-malignancy-type
metastases	I-malignancy-type
from	O
41	O
patients	O
undergoing	O
curative	O
hepatic	O
resection	O
were	O
examined	O
for	O
proliferation	O
status	O
and	O
presence	O
of	O
K	O
-	O
ras	O
mutations	O
.	O
The	O
proliferative	O
activity	O
was	O
assessed	O
by	O
Ki-67	O
immunohistochemistry	O
.	O
DNA	O
from	O
the	O
same	O
tissue	O
samples	O
was	O
screened	O
for	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
K	O
-	O
ras	O
gene	O
using	O
a	O
novel	O
microplate	O
-	O
based	O
allelic	O
-	O
specific	O
hybridization	O
assay	O
.	O
Ki-67	O
scores	O
and	O
K	O
-	O
ras	O
status	O
were	O
then	O
related	O
with	O
patient	O
survival	O
as	O
determined	O
through	O
retrospective	O
analysis	O
.	O
RESULTS	O
:	O
Median	O
survival	O
was	O
40	O
months	O
.	O
Patients	O
with	O
high	O
Ki-67	O
scores	O
(	O
>	O
or	O
=	O
50	O
%	O
)	O
had	O
significantly	O
shorter	O
median	O
survival	O
compared	O
with	O
those	O
with	O
low	O
scores	O
(	O
30	O
vs	O
44	O
months	O
,	O
log	O
-	O
rank	O
P	O
=	O
0.02	O
)	O
.	O
A	O
high	O
Ki-67	O
score	O
was	O
an	O
independent	O
negative	O
prognostic	O
factor	O
by	O
multivariate	O
regression	O
analysis	O
(	O
relative	O
risk	O
=	O
3.04	O
,	O
P	O
=	O
0.036	O
)	O
.	O
K	O
-	O
ras	O
point	O
mutations	O
were	O
detected	O
in	O
6	O
/	O
41	O
patients	O
(	O
15	O
%	O
)	O
,	O
but	O
mutational	O
status	O
did	O
not	O
correlate	O
with	O
Ki-67	O
score	O
or	O
survival	O
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
tumour	O
proliferative	O
index	O
is	O
a	O
useful	O
predictor	O
of	O
aggressive	O
tumour	O
behaviour	O
and	O
an	O
indicator	O
of	O
patient	O
survival	O
.	O
The	O
presence	O
of	O
K	O
-	O
ras	O
mutations	O
does	O
not	O
appear	O
to	O
correlate	O
with	O
tumour	O
proliferation	O
status	O
or	O
patient	O
survival	O
.	O
Copyright	O
Harcourt	O
Publishers	O
Limited	O
.	O
PMID	O
:	O
11237496	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2001	O
Mar;15	O
8	O
(	O
3	O
)	O
:	O
100	O
5-10	O
Sporadic	B-malignancy-type
fundic	I-malignancy-type
gland	I-malignancy-type
polyps	I-malignancy-type
:	O
common	B-malignancy-type
gastric	I-malignancy-type
polyps	I-malignancy-type
arising	O
through	O
activating	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
Abraham	O
SC	O
,	O
Nobukawa	O
B	O
,	O
Giardiello	O
FM	O
,	O
Hamilton	O
SR	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
Gastroenterology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Ross	O
Building	O
,	O
Room	O
632	O
,	O
720	O
Rutland	O
Ave	O
.	O
,	O
Baltimore	O
,	O
MD	O
2120	O
5-2196	O
,	O
USA	O
.	O
sabraham@jhmi	O
.edu	O
Fundic	B-malignancy-type
gland	I-malignancy-type
polyps	I-malignancy-type
(	O
FGPs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
gastric	B-malignancy-type
polyps	I-malignancy-type
.	O
FGPs	B-malignancy-type
traditionally	O
have	O
been	O
regarded	O
as	O
nondysplastic	B-malignancy-type
hamartomatous	I-malignancy-type
or	O
hyperplastic	B-malignancy-type
lesions	I-malignancy-type
,	O
but	O
their	O
pathogenesis	O
remains	O
unclear	O
.	O
We	O
have	O
recently	O
shown	O
that	O
somatic	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
alterations	O
are	O
frequently	O
present	O
in	O
FGPs	O
associated	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
,	O
raising	O
the	O
possibility	O
that	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
affecting	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
might	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
We	O
analyzed	O
somatic	O
beta-catenin	O
gene	O
mutations	O
in	O
57	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
from	O
40	O
patients	O
without	O
FAP	B-malignancy-type
and	O
in	O
19	O
FGPs	B-malignancy-type
from	O
13	O
FAP	B-malignancy-type
patients	O
.	O
Direct	O
DNA	O
sequencing	O
of	O
exon	O
3	O
encompassing	O
the	O
glycogen	O
synthase	O
kinase-3beta	O
phosphorylation	O
region	O
for	O
beta-catenin	O
was	O
used	O
with	O
confirmation	O
by	O
HIN:fI	O
restriction	O
endonuclease	O
digestion	O
.	O
The	O
foveolar	B-malignancy-type
epithelium	I-malignancy-type
and	O
dilated	B-malignancy-type
fundic	I-malignancy-type
glands	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
polyps	I-malignancy-type
were	O
separately	O
microdissected	O
and	O
analyzed	O
in	O
22	O
of	O
57	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
Activating	O
beta-catenin	O
gene	O
mutations	O
were	O
present	O
in	O
91	O
%	O
(	O
52	O
of	O
57	O
)	O
of	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
Both	O
the	O
foveolar	O
epithelium	O
and	O
the	O
dilated	O
fundic	O
gland	O
epithelium	O
comprising	O
the	O
polyps	B-malignancy-type
were	O
shown	O
to	O
have	O
the	O
same	O
somatic	O
beta-catenin	O
mutation	O
in	O
21	O
of	O
22	O
(	O
95	O
%	O
)	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
.	O
In	O
contrast	O
,	O
beta-catenin	O
gene	O
mutations	O
were	O
not	O
present	O
in	O
any	O
of	O
the	O
19	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
FGPs	I-malignancy-type
(	O
P	O
:	O
<	O
0.000001	O
)	O
.	O
The	O
high	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
sporadic	B-malignancy-type
FGPs	I-malignancy-type
indicates	O
that	O
these	O
lesions	O
arise	O
through	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Beta-catenin	O
mutations	O
in	O
gastrointestinal	B-malignancy-type
tract	I-malignancy-type
polyps	I-malignancy-type
have	O
previously	O
only	O
been	O
demonstrated	O
in	O
a	O
subset	O
of	O
adenomatous	B-malignancy-type
(	I-malignancy-type
dysplastic	I-malignancy-type
)	O
or	O
neoplastic	B-malignancy-type
polyps	I-malignancy-type
.	O
Sporadic	B-malignancy-type
FGPs	I-malignancy-type
are	O
therefore	O
the	O
only	O
lesions	B-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
gastrointestinal	I-malignancy-type
tract	I-malignancy-type
to	O
demonstrate	O
beta-catenin	O
mutations	O
while	O
lacking	O
dysplastic	O
morphology	O
.	O
PMID	O
:	O
11238048	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
2001	O
Apr	O
6;8	O
4	O
(	O
7	O
)	O
:	O
98	O
2-9	O
Frequent	O
k	O
-	O
ras	O
-	O
2	O
mutations	O
and	O
p16	O
(	O
INK4A	O
)	O
methylation	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
in	O
workers	O
exposed	O
to	O
vinyl	O
chloride	O
.	O
Weihrauch	O
M,	O
Benicke	O
M,	O
Lehnert	O
G,	O
Wittekind	O
C,	O
Wrbitzky	O
R	O
,	O
Tannapfel	O
A.	O
Institute	O
of	O
Occupational	O
and	O
Environmental	O
Medicine	O
,	O
University	O
of	O
Hannover	O
,	O
Germany	O
.	O
Vinyl	O
chloride	O
(	O
VC	O
)	O
is	O
a	O
know	O
animal	O
and	O
human	O
carcinogen	O
associated	O
with	O
liver	B-malignancy-type
angiosarcomas	I-malignancy-type
(	O
LAS	B-malignancy-type
)	O
and	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCC	B-malignancy-type
)	O
.	O
In	O
VC	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
LAS	I-malignancy-type
mutations	O
of	O
the	O
K	O
-	O
ras	O
-	O
2	O
gene	O
have	O
been	O
reported	O
;	O
however	O
,	O
no	O
data	O
about	O
the	O
prevalence	O
of	O
such	O
mutations	O
in	O
VC	B-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
are	O
available	O
.	O
Recent	O
data	O
indicate	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
induce	O
P16	O
methylation	O
accompanied	O
by	O
inactivation	O
of	O
the	O
p16	O
gene	O
.	O
The	O
presence	O
of	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
was	O
analysed	O
in	O
tissue	O
from	O
18	O
patients	O
with	O
VC	B-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
.	O
As	O
a	O
control	O
group	O
,	O
20	O
patients	O
with	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
due	I-malignancy-type
to	I-malignancy-type
hepatitis	I-malignancy-type
B	I-malignancy-type
(	O
n	O
=	O
7	O
)	O
,	O
hepatitis	O
C	O
(	O
n	O
=	O
5	O
)	O
and	O
alcoholic	O
liver	O
cirrhosis	O
(	O
n	O
=	O
8	O
)	O
was	O
used	O
.	O
The	O
specific	O
mutations	O
were	O
determined	O
by	O
direct	O
sequencing	O
of	O
codon	O
12	O
and	O
13	O
of	O
the	O
K	O
-	O
ras	O
-	O
2	O
gene	O
in	O
carcinomatous	O
and	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
after	O
microdissection	O
.	O
The	O
status	O
of	O
p16	O
was	O
evaluated	O
by	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
,	O
microsatellite	O
analysis	O
,	O
DNA	O
sequencing	O
and	O
immunohistochemical	O
staining	O
.	O
All	O
patients	O
had	O
a	O
documented	O
chronic	O
quantitated	O
exposure	O
to	O
VC	O
(	O
average	O
8883	O
ppmy	O
,	O
average	O
duration	O
:	O
245	O
months	O
)	O
.	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
were	O
found	O
in	O
6	O
of	O
18	O
(	O
33	O
%	O
)	O
examined	O
VC	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
and	O
in	O
3	O
cases	O
of	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
.	O
There	O
were	O
3	O
G	O
-->	O
A	O
point	O
mutations	O
in	O
the	O
tumour	O
tissue	O
.	O
All	O
3	O
mutations	O
found	O
in	O
non	O
-	O
neoplastic	O
liver	O
from	O
VC	O
-	O
exposed	O
patients	O
were	O
also	O
G	O
-->	O
A	O
point	O
mutations	O
(	O
codon	O
12	O
-	O
and	O
codon	O
13	O
-	O
aspartate	O
mutations	O
)	O
.	O
Hypermethylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
the	O
p16	O
gene	O
was	O
found	O
in	O
13	O
of	O
18	O
examined	O
carcinomas	B-malignancy-type
(	O
72	O
%	O
)	O
.	O
Of	O
6	O
cancers	O
with	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
,	O
5	O
specimens	O
also	O
showed	O
methylated	O
p16	O
.	O
Within	O
the	O
control	O
group	O
,	O
K	O
-	O
ras	O
-	O
2	O
mutation	O
were	O
found	O
in	O
3	O
of	O
20	O
(	O
15	O
%	O
)	O
examined	O
HCC	B-malignancy-type
.	O
p16	O
methylation	O
occurred	O
in	O
11	O
out	O
of	O
20	O
(	O
55	O
%	O
)	O
patients	O
.	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
and	O
p16	O
methylation	O
are	O
frequent	O
events	O
in	O
VC	B-malignancy-type
associated	I-malignancy-type
HCCs	I-malignancy-type
.	O
We	O
observed	O
a	O
K	O
-	O
ras	O
-	O
2	O
mutation	O
pattern	O
characteristic	O
of	O
chloroethylene	O
oxide	O
,	O
a	O
carcinogenic	O
metabolite	O
of	O
VC	O
.	O
Our	O
results	O
strongly	O
suggest	O
that	O
K	O
-	O
ras	O
-	O
2	O
mutations	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
VC	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
HCC	I-malignancy-type
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11286481	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Apr	O
15;6	O
1	O
(	O
8	O
)	O
:	O
340	O
6-9	O
Beta-catenin	O
mutations	O
in	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
:	O
a	O
population	O
-	O
based	O
study	O
in	O
China	O
.	O
Rashid	O
A	O
,	O
Gao	O
YT	O
,	O
Bhakta	O
S	O
,	O
Shen	O
MC	O
,	O
Wang	O
BS	O
,	O
Deng	O
J,	O
Fraumeni	O
JF	O
Jr	O
,	O
Hsing	O
AW.	O
Department	O
of	O
Pathology	O
,	O
M.D.	O
Anderson	O
Cancer	O
Center	O
,	O
1515	O
Holcombe	O
Boulevard	O
,	O
Houston	O
,	O
TX	O
7703	O
0-4095	O
,	O
USA	O
.	O
beta-Catenin	O
is	O
an	O
ubiquitously	O
expressed	O
cytoplasmic	O
protein	O
that	O
has	O
a	O
crucial	O
role	O
in	O
both	O
cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
and	O
as	O
a	O
downstream	O
signaling	O
molecule	O
in	O
the	O
wingless	O
/	O
Wnt	O
pathway	O
.	O
Activating	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
at	O
the	O
phosphorylation	O
sites	O
for	O
ubiquitination	O
and	O
degradation	O
of	O
beta-catenin	O
,	O
are	O
present	O
in	O
a	O
variety	O
of	O
cancers	O
.	O
Because	O
alterations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
are	O
present	O
in	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
and	O
the	O
APC	O
protein	O
modulates	O
levels	O
of	O
beta-catenin	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
beta-catenin	O
in	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancer	I-malignancy-type
by	O
sequencing	O
the	O
third	O
exon	O
of	O
the	O
beta-catenin	O
gene	O
among	O
107	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
and	O
7	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
from	O
a	O
population	O
-	O
based	O
study	O
in	O
CHINA	O
:	O
Point	O
mutations	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
in	O
exon	O
3	O
of	O
beta-catenin	O
were	O
present	O
in	O
8	O
of	O
107	O
(	O
7.5	O
%	O
)	O
biliary	B-malignancy-type
tract	I-malignancy-type
cancers	I-malignancy-type
and	O
4	O
of	O
7	O
(	O
57.1	O
%	O
)	O
gallbladder	B-malignancy-type
adenomas	I-malignancy-type
.	O
Mutations	O
of	O
beta-catenin	O
were	O
more	O
frequent	O
in	O
ampullary	B-malignancy-type
and	O
gallbladder	B-malignancy-type
carcinomas	I-malignancy-type
than	O
in	O
bile	B-malignancy-type
duct	I-malignancy-type
carcinomas	I-malignancy-type
(	O
P	O
=	O
0.04	O
)	O
and	O
in	O
papillary	B-malignancy-type
adenocarcinomas	I-malignancy-type
than	O
other	O
histological	O
types	O
of	O
carcinomas	B-malignancy-type
(	O
P	O
=	O
0.02	O
)	O
.	O
These	O
results	O
suggest	O
that	O
the	O
molecular	O
pathways	O
of	O
biliary	B-malignancy-type
tract	I-malignancy-type
neoplasms	I-malignancy-type
vary	O
by	O
anatomical	O
subsite	O
and	O
histological	O
subtype	O
.	O
PMID	O
:	O
11309300	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anal	O
Cell	O
Pathol	O
2000	O
;2	O
1	O
(	O
2	O
)	O
:	O
4	O
9-57	O
Erratum	O
in	O
:	O
Anal	O
Cell	O
Pathol	O
2001;2	O
2	O
(	O
3	O
)	O
:	O
181	O
Intratumor	O
heterogeneity	O
of	O
k-ras	O
and	O
p53	O
mutations	O
among	O
human	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
containing	O
early	O
cancer	O
.	O
Giaretti	O
W	O
,	O
Rapallo	O
A	O
,	O
Sciutto	O
A	O
,	O
Macciocu	O
B	O
,	O
Geido	O
E	O
,	O
Hermsen	O
MA	O
,	O
Postma	O
C,	O
Baak	O
JP	O
,	O
Williams	O
RA	O
,	O
Meijer	O
GA.	O
Laboratory	O
of	O
Biophysics	O
and	O
Cytometry	O
,	O
National	O
Cancer	O
Institute	O
(	O
IST	O
)	O
,	O
Genova	O
,	O
Italy	O
.	O
giaretti@hp380.ist	O
.unige	O
.it	O
The	O
molecular	O
pathways	O
and	O
the	O
timing	O
of	O
genetic	O
events	O
during	O
human	O
colorectal	O
carcinogenesis	O
are	O
still	O
not	O
fully	O
understood	O
.	O
We	O
have	O
addressed	O
the	O
intratumor	O
heterogeneity	O
of	O
the	O
mutational	O
status	O
of	O
the	O
k-ras	O
oncogene	O
and	O
of	O
the	O
p53	O
oncosuppressor	O
gene	O
during	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
by	O
investigating	O
26	O
human	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
containing	O
early	O
cancer	O
.	O
An	O
intratumor	O
comparative	O
analysis	O
was	O
obtained	O
among	O
the	O
adenomatous	O
and	O
carcinomatous	O
component	O
pairs	O
.	O
Additionally	O
,	O
we	O
have	O
analyzed	O
17	O
adenomas	B-malignancy-type
having	O
cancer	O
in	O
the	O
near	O
vicinity	O
.	O
The	O
adenomatous	O
components	O
of	O
the	O
adenomas	B-malignancy-type
containing	O
early	O
cancer	O
and	O
the	O
adenomas	B-malignancy-type
having	O
cancer	O
in	O
the	O
near	O
vicinity	O
had	O
comparable	O
frequencies	O
for	O
k-ras	O
mutations	O
(	O
28	O
and	O
47	O
%	O
)	O
but	O
different	O
for	O
p53	O
mutations	O
(	O
52	O
and	O
7	O
%	O
,	O
p	O
-	O
value	O
=	O
0.01	O
)	O
.	O
Interestingly	O
,	O
the	O
adenomatous	O
and	O
carcinomatous	O
components	O
of	O
the	O
adenomas	B-malignancy-type
containing	O
early	O
cancer	O
were	O
rarely	O
heterogeneous	O
for	O
the	O
k-ras	O
mutational	O
status	O
(	O
only	O
in	O
13	O
%	O
of	O
the	O
cases	O
)	O
but	O
were	O
characterized	O
by	O
heterogeneity	O
of	O
the	O
p53	O
status	O
in	O
59	O
%	O
of	O
the	O
cases	O
(	O
p	O
-	O
value	O
<	O
0.01	O
)	O
.	O
In	O
addition	O
,	O
the	O
mutations	O
of	O
p53	O
for	O
the	O
adenomatous	O
components	O
of	O
the	O
adenomas	B-malignancy-type
containing	O
early	O
cancer	O
were	O
statistically	O
significantly	O
associated	O
with	O
severe	B-malignancy-type
dysplasia	I-malignancy-type
(	O
p	O
-	O
value	O
=	O
0.01	O
)	O
.	O
Intratumor	O
homogeneity	O
of	O
k-ras	O
status	O
during	O
the	O
human	O
colorectal	B-malignancy-type
adenoma	I-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
suggests	O
that	O
the	O
role	O
of	O
k-ras	O
is	O
more	O
related	O
to	O
tumor	O
initiation	O
than	O
to	O
tumor	O
progression	O
.	O
On	O
the	O
contrary	O
,	O
intratumor	O
heterogeneity	O
of	O
p53	O
mutations	O
indicates	O
that	O
the	O
type	O
of	O
the	O
p53	O
mutations	O
may	O
also	O
be	O
relevant	O
for	O
selection	O
and	O
expansion	O
of	O
new	O
subclones	O
leading	O
to	O
tumor	O
progression	O
.	O
PMID	O
:	O
11310641	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2001	O
Feb	O
8;2	O
0	O
(	O
6	O
)	O
:	O
68	O
6-91	O
Loss	O
of	O
heterozygosity	O
at	O
4p16.3	O
and	O
mutation	O
of	O
FGFR3	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Sibley	O
K,	O
Cuthber	O
t-Heavens	O
D	O
,	O
Knowles	O
MA.	O
ICRF	O
Clinical	O
Centre	O
,	O
St	O
James	O
's	O
University	O
Hospital	O
,	O
Beckett	O
Street	O
,	O
Leeds	O
LS9	O
7TF	O
,	O
UK.	O
4p16.3	O
has	O
previously	O
been	O
identified	O
as	O
a	O
region	O
of	O
non	O
-	O
random	O
LOH	O
in	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
suggesting	O
the	O
presence	O
of	O
a	O
tumour	O
suppressor	O
gene	O
.	O
One	O
candidate	O
within	O
this	O
region	O
is	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
.	O
Germline	O
mutations	O
in	O
FGFR3	O
are	O
known	O
to	O
cause	O
several	O
autosomal	O
dominant	O
skeletal	B-malignancy-type
dysplasias	I-malignancy-type
,	O
the	O
severity	O
of	O
which	O
depends	O
on	O
the	O
position	O
and	O
nature	O
of	O
the	O
mutation	O
in	O
the	O
protein	O
.	O
We	O
investigated	O
the	O
frequency	O
and	O
nature	O
of	O
FGFR3	O
mutations	O
in	O
a	O
panel	O
of	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
cell	O
lines	O
and	O
studied	O
the	O
possible	O
link	O
between	O
mutation	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
on	O
4p16.3	O
.	O
FGFR3	O
coding	O
sequence	O
from	O
63	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
TCC	B-malignancy-type
)	O
of	O
various	O
stages	O
and	O
grades	O
,	O
and	O
18	O
cell	O
lines	O
was	O
analysed	O
by	O
fluorescent	O
SSCP	O
.	O
Samples	O
with	O
abnormal	O
migration	O
patterns	O
were	O
sequenced	O
to	O
identify	O
the	O
mutation	O
or	O
polymorphism	O
.	O
Thirty-one	O
of	O
the	O
63	O
tumours	O
had	O
previously	O
been	O
assessed	O
to	O
have	O
LOH	O
at	O
4p16.3	O
.	O
Twenty-six	O
of	O
the	O
63	O
tumours	O
(	O
41	O
%	O
)	O
and	O
4	O
/	O
18	O
(	O
22	O
%	O
)	O
of	O
the	O
cell	O
lines	O
had	O
missense	O
mutations	O
in	O
FGFR3	O
.	O
All	O
mutations	O
detected	O
in	O
our	O
panel	O
have	O
been	O
reported	O
in	O
the	O
germline	O
where	O
all	O
apart	O
from	O
one	O
cause	O
lethal	O
conditions	O
.	O
One	O
tumour	O
contained	O
K	O
652	O
Q	O
which	O
has	O
recently	O
been	O
identified	O
in	O
less	O
severe	O
cases	O
of	O
skeletal	B-malignancy-type
dysplasia	I-malignancy-type
.	O
Tumours	O
with	O
and	O
without	O
LOH	O
at	O
4p16.3	O
had	O
mutations	O
in	O
FGFR3	O
suggesting	O
that	O
these	O
two	O
events	O
are	O
not	O
causally	O
linked	O
.	O
The	O
frequency	O
of	O
FGFR3	O
mutation	O
indicates	O
that	O
this	O
protein	O
plays	O
an	O
important	O
role	O
in	O
TCC	B-malignancy-type
.	O
PMID	O
:	O
11314002	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
May	O
1;6	O
1	O
(	O
9	O
)	O
:	O
354	O
1-3	O
Mutations	O
in	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
and	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
genes	O
associated	O
with	O
human	O
gastric	B-malignancy-type
and	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
Jang	O
JH,	O
Shin	O
KH,	O
Park	O
JG.	O
Laboratory	O
of	O
Cell	O
Biology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
11	O
0-744	O
,	O
Korea	O
.	O
Autosomal	O
dominant	O
disorders	O
of	O
skeletal	O
and	O
cranial	O
development	O
have	O
been	O
linked	O
to	O
fibroblast	O
growth	O
factor	O
receptor	O
(	O
FGFR	O
)	O
2	O
and	O
FGFR3	O
.	O
Here	O
we	O
report	O
two	O
identical	O
mutations	O
in	O
FGFR2	O
that	O
cause	O
craniosynostosis	O
syndromes	O
,	O
Crouzon	O
,	O
Apert	O
,	O
and	O
Pfeiffer	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
.	O
A	O
missense	O
mutation	O
(	O
Ser	O
267	O
Pro	O
)	O
in	O
exon	O
IIIa	O
and	O
a	O
splice	O
site	O
mutation	O
(	O
940	O
-	O
2	O
A	O
-->	O
G	O
)	O
in	O
exon	O
IIIc	O
were	O
detected	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Interestingly	O
,	O
these	O
heterozygous	O
somatic	O
mutations	O
are	O
identical	O
to	O
the	O
germinal	O
activating	O
mutations	O
in	O
FGFR2	O
reported	O
previously	O
in	O
craniosynostosis	O
syndromes	O
.	O
In	O
addition	O
,	O
the	O
two	O
novel	O
mutations	O
of	O
FGFR3	O
in	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
were	O
identified	O
.	O
All	O
identified	O
mutations	O
occurred	O
at	O
highly	O
conserved	O
sequences	O
,	O
not	O
only	O
in	O
the	O
FGFR	O
family	O
of	O
molecules	O
,	O
but	O
also	O
throughout	O
evolution	O
and	O
clustered	O
in	O
the	O
immunoglobulin	O
-	O
like	O
loop	O
-	O
III	O
domain	O
,	O
highlighting	O
the	O
functional	O
importance	O
of	O
this	O
domain	O
.	O
Our	O
results	O
indicate	O
that	O
FGFR2	O
and	O
FGFR3	O
,	O
in	O
addition	O
to	O
their	O
potential	O
role	O
in	O
skeletal	B-malignancy-type
dysplasias	I-malignancy-type
,	O
play	O
an	O
important	O
role	O
in	O
tumorigenesis	O
.	O
PMID	O
:	O
11325814	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
2001	O
May;194	O
(	O
1	O
)	O
:	O
5	O
9-67	O
Frequent	O
nuclear	O
beta-catenin	O
accumulation	O
and	O
associated	O
mutations	O
in	O
endometrioid	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
endometrial	I-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
with	I-malignancy-type
squamous	I-malignancy-type
differentiation	I-malignancy-type
.	O
Saegusa	O
M,	O
Okayasu	O
I.	O
Department	O
of	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
1-1	O
5-1	O
Kitasato	O
,	O
Sagamihara	O
,	O
Kanagawa	O
22	O
8-8555	O
,	O
Japan	O
.	O
msaegusa@med.kitasat	O
o-u.ac.jp	O
Focal	O
squamous	O
differentiation	O
is	O
a	O
common	O
feature	O
of	O
endometrioid	B-malignancy-type
endometrial	I-malignancy-type
and	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
(	O
E-Em	B-malignancy-type
and	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
)	O
.	O
A	O
close	O
association	O
between	O
mutated	O
beta-catenin	O
accumulation	O
and	O
alteration	O
in	O
cellular	O
morphology	O
has	O
recently	O
been	O
demonstrated	O
in	O
murine	O
L	O
cell	O
lines	O
.	O
To	O
clarify	O
the	O
possible	O
role	O
of	O
beta-catenin	O
abnormalities	O
and	O
changes	O
in	O
tumour	O
morphology	O
,	O
60	O
grade	O
(	O
G	O
)	O
1	O
or	O
G2	B-malignancy-type
E-Em	I-malignancy-type
Cas	I-malignancy-type
with	I-malignancy-type
areas	I-malignancy-type
of	I-malignancy-type
squamous	I-malignancy-type
differentiation	I-malignancy-type
(	O
SqD	O
)	O
,	O
including	O
morules	O
and	O
squamous	O
metaplastic	O
(	O
SqM	O
)	O
foci	O
,	O
as	O
well	O
as	O
32	O
G1	O
or	O
G2	O
tumours	O
without	O
such	O
lesions	B-malignancy-type
,	O
were	O
investigated	O
and	O
the	O
results	O
compared	O
with	O
findings	O
for	O
c-jun	O
and	O
wnt-1	O
expression	O
.	O
Twenty-three	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
,	O
with	O
and	O
without	O
SqD	O
lesions	O
,	O
were	O
also	O
examined	O
.	O
In	O
E-Em	B-malignancy-type
Cas	I-malignancy-type
,	O
frequent	O
nuclear	O
beta-catenin	O
accumulation	O
was	O
observed	O
in	O
22	O
(	O
84.6	O
%	O
)	O
of	O
26	O
tumours	O
with	O
morules	O
and	O
15	O
(	O
45.5	O
%	O
)	O
of	O
33	O
with	O
SqM	O
foci	O
,	O
in	O
contrast	O
to	O
4	O
(	O
12.5	O
%	O
)	O
of	O
32	O
without	O
such	O
lesions	B-malignancy-type
.	O
Similar	O
findings	O
were	O
also	O
noted	O
for	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
involving	O
codons	O
32	O
,	O
33	O
,	O
34	O
,	O
37	O
,	O
41	O
,	O
and	O
45	O
,	O
the	O
single	O
nucleotide	O
substitutions	O
being	O
identical	O
between	O
SqD	O
and	O
the	O
surrounding	O
carcinoma	B-malignancy-type
tissue	O
in	O
most	O
informative	O
cases	O
.	O
The	O
mutations	O
were	O
positively	O
related	O
to	O
nuclear	O
immunopositivity	O
,	O
but	O
inversely	O
to	O
membrane	O
expression	O
,	O
while	O
there	O
was	O
no	O
association	O
with	O
the	O
status	O
of	O
c-jun	O
or	O
wnt-1	O
.	O
These	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
,	O
nuclear	O
beta-catenin	O
accumulation	O
and	O
mutations	O
were	O
limited	O
to	O
tumours	B-malignancy-type
with	I-malignancy-type
SqD	I-malignancy-type
features	O
,	O
independent	O
of	O
c-jun	O
and	O
wnt-1	O
status	O
.	O
These	O
data	O
indicate	O
that	O
beta-catenin	O
abnormalities	O
are	O
relatively	O
common	O
in	O
E-Em	B-malignancy-type
and	O
E-Ova	B-malignancy-type
Cas	I-malignancy-type
with	I-malignancy-type
SqD	I-malignancy-type
features	O
,	O
implying	O
a	O
role	O
in	O
the	O
squamous	O
differentiation	O
of	O
tumour	O
cells	O
,	O
not	O
necessarily	O
related	O
to	O
c-jun	O
and/or	O
wnt-1	O
status	O
.	O
Copyright	O
2001	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
PMID	O
:	O
11329142	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2001	O
May;1	O
4	O
(	O
5	O
)	O
:	O
44	O
3-51	O
Adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
:	O
a	O
clinicopathologic	O
series	O
of	O
25	O
cases	O
.	O
Kardon	O
DE	O
,	O
Thompson	O
LD	O
,	O
Przygodzki	O
RM	O
,	O
Heffess	O
CS.	O
Department	O
of	O
Endocrine	O
and	O
Otorhinolaryngi	O
c-Head	O
&	O
Neck	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC.	O
2030	O
6-6000	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
is	O
a	O
rare	O
aggressive	O
subtype	O
of	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
describe	O
the	O
clinical	O
,	O
pathologic	O
,	O
and	O
molecular	O
characteristics	O
of	O
25	O
of	O
these	O
lesions	B-malignancy-type
,	O
the	O
largest	O
series	O
to	O
date	O
.	O
METHODS	O
:	O
Twenty-five	O
cases	O
of	O
adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
diagnosed	O
between	O
1961	O
and	O
1994	O
were	O
retrieved	O
from	O
the	O
files	O
of	O
the	O
Endocrine	O
Registry	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
.	O
Histologic	O
features	O
were	O
reviewed	O
,	O
histochemical	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
(	O
k-ras	O
)	O
studies	O
were	O
performed	O
,	O
and	O
patient	O
follow-up	O
was	O
obtained	O
.	O
RESULTS	O
:	O
The	O
patients	O
included	O
17	O
men	O
and	O
eight	O
women	O
,	O
aged	O
28	O
to	O
82	O
years	O
(	O
mean	O
,	O
65.4	O
y	O
)	O
.	O
The	O
patients	O
usually	O
experienced	O
weight	O
loss	O
(	O
n	O
=	O
17	O
)	O
or	O
painless	O
jaundice	O
(	O
n	O
=	O
11	O
)	O
,	O
while	O
also	O
presenting	O
with	O
other	O
abdominal	O
symptoms	O
.	O
The	O
tumors	O
affected	O
the	O
head	O
most	O
frequently	O
(	O
n	O
=	O
17	O
)	O
,	O
followed	O
by	O
the	O
tail	O
(	O
n	O
=	O
9	O
)	O
or	O
body	O
(	O
n	O
=	O
4	O
)	O
.	O
Five	O
cases	O
involved	O
more	O
than	O
one	O
anatomic	O
region	O
of	O
the	O
pancreas	O
.	O
Microscopically	O
,	O
all	O
tumors	O
demonstrated	O
dual	O
differentiation	O
toward	O
adenocarcinoma	B-malignancy-type
and	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
.	O
All	O
cases	O
tested	O
were	O
immunoreactive	O
with	O
keratin	O
(	O
AE1	O
:	O
AE3	O
and	O
CK1	O
)	O
,	O
whereas	O
other	O
keratin	O
markers	O
were	O
variably	O
expressed	O
:	O
CK5	O
/	O
6	O
(	O
88	O
%	O
)	O
,	O
CK7	O
(	O
68	O
%	O
)	O
,	O
Cam5.2	O
(	O
41	O
%	O
)	O
,	O
and	O
CK20	O
(	O
26	O
%	O
)	O
.	O
CA-19-9	O
(	O
84	O
%	O
)	O
and	O
CEA	O
(	O
74	O
%	O
)	O
were	O
positive	O
in	O
the	O
majority	O
of	O
the	O
cases	O
.	O
K-ras	O
oncogene	O
mutations	O
were	O
identified	O
in	O
seven	O
of	O
13	O
cases	O
.	O
All	O
patients	O
died	O
from	O
their	O
disease	O
an	O
average	O
of	O
5.8	O
months	O
after	O
diagnosis	O
(	O
range	O
,	O
1	O
to	O
33	O
months	O
)	O
.	O
CONCLUSIONS	O
:	O
Adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
represents	O
a	O
distinct	O
clinical	O
and	O
pathologic	O
entity	O
,	O
demonstrating	O
the	O
expected	O
immunoprofile	O
and	O
k-ras	O
oncogene	O
mutation	O
of	O
a	O
ductal	O
origin	O
,	O
with	O
a	O
worse	O
prognosis	O
than	O
ductal	B-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
PMID	O
:	O
11353055	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gastroenterology	O
2001	O
Jun;120	O
(	O
7	O
)	O
:	O
176	O
3-73	O
Genetic	O
alterations	O
associated	O
with	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
define	O
distinct	O
pathways	O
of	O
hepatocarcinogenesis	O
.	O
Lauren	O
t-Puig	O
P,	O
Legoix	O
P,	O
Bluteau	O
O,	O
Belghiti	O
J,	O
Franco	O
D	O
,	O
Binot	O
F	O
,	O
Monges	O
G,	O
Thomas	O
G,	O
Bioula	O
c-Sage	O
P,	O
Zucma	O
n-Rossi	O
J.	O
INSERM	O
U434	O
,	O
CEPH,	O
Paris	O
;	O
Assistance	O
Publique	O
Hopitaux	O
de	O
Paris	O
,	O
France	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
To	O
evaluate	O
how	O
characterization	O
of	O
genetic	O
alterations	O
can	O
help	O
in	O
the	O
elucidation	O
of	O
liver	O
carcinogenesis	O
pathways	O
,	O
137	O
tumors	O
were	O
analyzed	O
.	O
METHODS	O
:	O
High-density	O
allelotype	O
,	O
p53	O
,	O
Axin1	O
,	O
and	O
beta-catenin	O
gene	O
mutations	O
were	O
determined	O
.	O
Alterations	O
were	O
analyzed	O
according	O
to	O
clinical	O
parameters	O
.	O
RESULTS	O
:	O
Tumors	O
could	O
be	O
divided	O
into	O
2	O
groups	O
according	O
to	O
chromosome	O
stability	O
status	O
.	O
In	O
the	O
first	O
group	O
,	O
demonstrating	O
a	O
chromosome	O
stability	O
,	O
beta-catenin	O
mutation	O
associated	O
with	O
chromosome	O
8p	O
losses	O
were	O
frequently	O
found	O
as	O
the	O
single	O
genetic	O
alterations	O
.	O
beta-catenin	O
mutations	O
were	O
associated	O
with	O
large	O
tumor	O
size	O
and	O
with	O
negative	O
hepatitis	O
B	O
virus	O
status	O
.	O
In	O
the	O
second	O
group	O
,	O
demonstrating	O
a	O
chromosome	O
instability	O
,	O
the	O
most	O
frequent	O
allelic	O
losses	O
were	O
on	O
chromosome	O
1p	O
,	O
4q	O
,	O
6q	O
,	O
9p	O
,	O
13q	O
,	O
16p	O
,	O
16q	O
,	O
and	O
17p	O
;	O
Axin1	O
and	O
p53	O
were	O
frequently	O
mutated	O
.	O
All	O
of	O
these	O
alterations	O
,	O
except	O
losses	O
on	O
6q	O
and	O
9p	O
,	O
were	O
associated	O
with	O
hepatitis	O
B	O
virus	O
infection	O
.	O
P53	O
mutations	O
,	O
17p	O
,	O
13q	O
losses	O
,	O
and	O
a	O
high	O
value	O
of	O
the	O
fractional	O
allelic	O
loss	O
index	O
were	O
associated	O
with	O
poor	B-malignancy-type
differentiated	I-malignancy-type
tumors	I-malignancy-type
,	O
independently	O
of	O
risk	O
factors	O
.	O
Finally	O
,	O
in	O
the	O
whole	O
series	O
,	O
chromosome	O
9p	O
and	O
6q	O
losses	O
were	O
associated	O
with	O
poor	O
prognosis	O
.	O
CONCLUSIONS	O
:	O
Two	O
main	O
pathways	O
defined	O
by	O
genetic	O
alterations	O
show	O
different	O
risk	O
factors	O
and	O
clinical	O
characteristics	O
.	O
Furthermore	O
,	O
loss	O
of	O
chromosome	O
9p	O
or	O
6q	O
is	O
an	O
independent	O
prognostic	O
indicator	O
.	O
PMID	O
:	O
11375957	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
2001	O
Jun	O
1;19	O
(	O
11	O
)	O
:	O
283	O
7-43	O
Discordance	O
between	O
K-ras	O
mutations	O
in	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
and	O
the	O
primary	O
tumor	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Tortola	O
S	O
,	O
Steinert	O
R	O
,	O
Hantschick	O
M,	O
Peinado	O
MA	O
,	O
Gastinger	O
I	O
,	O
Stosiek	O
P,	O
Lippert	O
H,	O
Schlegel	O
W	O
,	O
Reymond	O
MA.	O
Fondation	O
Pour	O
Recherches	O
Medicales	O
,	O
Geneva	O
,	O
Switzerland	O
.	O
PURPOSE	O
:	O
To	O
study	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
from	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
for	O
the	O
presence	O
of	O
K-ras	O
mutations	O
and	O
to	O
compare	O
their	O
genotype	O
with	O
that	O
of	O
the	O
corresponding	O
primary	O
tumor	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Bilateral	O
iliac	O
crest	O
aspiration	O
was	O
performed	O
in	O
51	O
patients	O
undergoing	O
surgery	O
for	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
were	O
detected	O
by	O
immunohistochemistry	O
.	O
The	O
presence	O
of	O
K-ras	O
mutations	O
was	O
determined	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
on	O
both	O
primary	O
tumors	O
and	O
paired	O
bone	O
marrow	O
samples	O
and	O
was	O
confirmed	O
by	O
sequencing	O
.	O
RESULTS	O
:	O
In	O
six	O
patients	O
with	O
primary	O
tumor	O
mutations	O
,	O
it	O
was	O
possible	O
to	O
amplify	O
a	O
mutated	O
K-ras	O
gene	O
also	O
from	O
the	O
bone	O
marrow	O
sample	O
.	O
In	O
three	O
of	O
those	O
patients	O
the	O
pattern	O
of	O
K-ras	O
mutations	O
differed	O
between	O
both	O
samples	O
,	O
in	O
two	O
patients	O
the	O
mutation	O
was	O
identical	O
between	O
the	O
bone	O
marrow	O
and	O
its	O
primary	O
tumor	O
,	O
and	O
in	O
one	O
patient	O
the	O
same	O
mutation	O
plus	O
a	O
different	O
one	O
were	O
found	O
.	O
Fifteen	O
of	O
17	O
K-ras	O
mutations	O
found	O
in	O
primary	O
tumors	O
were	O
located	O
in	O
codon	O
12	O
,	O
whereas	O
in	O
bone	O
marrow	O
,	O
five	O
of	O
seven	O
mutations	O
were	O
found	O
in	O
codon	O
13	O
(	O
P	O
=	O
.003	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
demonstrate	O
that	O
,	O
at	O
least	O
for	O
K-ras	O
mutations	O
,	O
disseminated	O
epithelial	O
cells	O
are	O
not	O
always	O
clonal	O
with	O
the	O
primary	O
tumor	O
and	O
they	O
question	O
the	O
malignant	O
genotype	O
of	O
bone	B-malignancy-type
marrow	I-malignancy-type
micrometastases	I-malignancy-type
.	O
They	O
also	O
indicate	O
that	O
different	O
tumoral	O
clones	O
may	O
be	O
circulating	O
simultaneously	O
or	O
sequentially	O
in	O
the	O
same	O
patient	O
.	O
Analysis	O
of	O
the	O
type	O
of	O
mutations	O
suggests	O
that	O
cell	O
dissemination	O
might	O
be	O
an	O
early	O
event	O
in	O
colorectal	O
carcinogenesis	O
.	O
PMID	O
:	O
11387355	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Natl	O
Cancer	O
Inst	O
2001	O
Jun	O
6;9	O
3	O
(	O
11	O
)	O
:	O
85	O
8-65	O
Comment	O
in	O
:	O
J	O
Natl	O
Cancer	O
Inst	O
.	O
2001	O
Jun	O
6;9	O
3	O
(	O
11	O
)	O
:	O
79	O
8-9	O
.	O
Detecting	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
in	O
stool	O
with	O
the	O
use	O
of	O
multiple	O
genetic	O
targets	O
.	O
Dong	O
SM	O
,	O
Traverso	O
G,	O
Johnson	O
C,	O
Geng	O
L,	O
Favis	O
R	O
,	O
Boynton	O
K,	O
Hibi	O
K,	O
Goodman	O
SN	O
,	O
D'Allessio	O
M,	O
Paty	O
P,	O
Hamilton	O
SR	O
,	O
Sidransky	O
D	O
,	O
Barany	O
F	O
,	O
Levin	O
B	O
,	O
Shuber	O
A	O
,	O
Kinzler	O
KW,	O
Vogelstein	O
B	O
,	O
Jen	O
J.	O
Division	O
of	O
Head	O
and	O
Neck	O
Cancer	O
Research	O
,	O
Department	O
of	O
Otolaryngolog	O
y-Head	O
and	O
Neck	O
Surgery	O
,	O
The	O
Johns	O
Hopkins	O
Medical	O
School	O
,	O
The	O
Johns	O
Hopkins	O
University	O
,	O
Baltimore	O
,	O
MD	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Colorectal	B-malignancy-type
cancer	I-malignancy-type
cells	O
are	O
shed	O
into	O
the	O
stool	O
,	O
providing	O
a	O
potential	O
means	O
for	O
the	O
early	O
detection	O
of	O
the	O
disease	O
using	O
noninvasive	O
approaches	O
.	O
Our	O
goal	O
was	O
to	O
develop	O
reliable	O
,	O
specific	O
molecular	O
genetic	O
tests	O
for	O
the	O
detection	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
in	O
stool	O
samples	O
.	O
METHODS	O
:	O
Stool	O
DNA	O
was	O
isolated	O
from	O
paired	O
stools	O
and	O
primary	O
tumor	O
samples	O
from	O
51	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Three	O
genetic	O
targets	O
-	O
TP53	O
,	O
BAT26	O
,	O
and	O
K-RAS	O
-	O
were	O
used	O
to	O
detect	O
tumor	O
-	O
associated	O
mutations	O
in	O
the	O
stool	O
prior	O
to	O
or	O
without	O
regard	O
to	O
the	O
molecular	O
analyses	O
of	O
the	O
paired	O
tumors	O
.	O
TP53	O
gene	O
mutations	O
were	O
detected	O
with	O
a	O
mismatch	O
-	O
ligation	O
assay	O
that	O
detects	O
nine	O
common	O
p53	O
gene	O
mutations	O
.	O
Deletions	O
within	O
the	O
BAT26	O
locus	O
were	O
detected	O
by	O
a	O
modified	O
solid-phase	O
minisequencing	O
method	O
.	O
Mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
K-RAS	O
were	O
detected	O
with	O
a	O
digital	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
.	O
RESULTS	O
:	O
TP53	O
gene	O
mutations	O
were	O
detected	O
in	O
the	O
tumor	O
DNA	O
of	O
30	O
patients	O
,	O
all	O
of	O
whom	O
had	O
the	O
identical	O
TP53	O
mutation	O
in	O
their	O
stools	O
.	O
Tumors	O
from	O
three	O
patients	O
contained	O
a	O
noninherited	O
deletion	O
at	O
the	O
BAT26	O
locus	O
,	O
and	O
the	O
same	O
alterations	O
were	O
identified	O
in	O
these	O
patients	O
'	O
stool	O
specimens	O
.	O
Nineteen	O
of	O
50	O
tumors	O
tested	O
had	O
a	O
K-RAS	O
mutation	O
;	O
identical	O
mutations	O
were	O
detected	O
in	O
the	O
paired	O
stool	O
DNA	O
samples	O
from	O
eight	O
patients	O
.	O
In	O
no	O
case	O
was	O
a	O
mutation	O
found	O
in	O
stool	O
that	O
was	O
not	O
also	O
present	O
in	O
the	O
primary	O
tumor	O
.	O
Thus	O
,	O
the	O
three	O
genetic	O
markers	O
together	O
detected	O
36	O
(	O
71	O
%	O
)	O
of	O
51	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
56	O
%	O
to	O
83	O
%	O
)	O
with	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
and	O
36	O
(	O
92	O
%	O
)	O
of	O
39	O
patients	O
(	O
95	O
%	O
CI	O
=	O
79	O
%	O
to	O
98	O
%	O
)	O
whose	O
tumors	O
had	O
an	O
alteration	O
.	O
CONCLUSION	O
:	O
We	O
were	O
able	O
to	O
detect	O
the	O
majority	O
of	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
by	O
analyzing	O
stool	O
DNA	O
for	O
just	O
three	O
genetic	O
markers	O
.	O
Additional	O
work	O
is	O
needed	O
to	O
determine	O
the	O
specificity	O
of	O
these	O
genetic	O
tests	O
for	O
detecting	O
colorectal	B-malignancy-type
neoplasia	I-malignancy-type
in	O
asymptomatic	O
patients	O
and	O
to	O
more	O
precisely	O
estimate	O
the	O
prevalence	O
of	O
the	O
mutations	O
and	O
sensitivity	O
of	O
the	O
assay	O
.	O
PMID	O
:	O
11390535	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Carcinog	O
2001	O
Jun	O
;	O
31	O
(	O
2	O
)	O
:	O
68	O
-	O
73	O
CTNNB1	O
mutations	O
and	O
beta-catenin	O
protein	O
accumulation	O
in	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
high	O
exposure	O
to	O
aflatoxin	O
B1	O
.	O
Devereux	O
TR	O
,	O
Stern	O
MC	O
,	O
Flake	O
GP	O
,	O
Yu	O
MC	O
,	O
Zhang	O
ZQ	O
,	O
London	O
SJ	O
,	O
Taylor	O
JA	O
Laboratory	O
of	O
Molecular	O
Carcinogenesis	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
NIH	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
,	O
USA	O
.	O
beta-Catenin	O
plays	O
a	O
key	O
role	O
in	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
and	O
mutations	O
of	O
CTNNB1	O
,	O
the	O
gene	O
that	O
encodes	O
beta-catenin	O
,	O
have	O
been	O
identified	O
in	O
about	O
one-fourth	O
of	O
human	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
from	O
regions	O
of	O
low	O
aflatoxin	O
B1	O
exposure	O
.	O
In	O
this	O
study	O
62	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
from	O
people	O
highly	O
exposed	O
to	O
aflatoxin	O
B1	O
in	O
Guangxi	O
,	O
People	O
's	O
Republic	O
of	O
China	O
,	O
were	O
laser	O
-	O
capture	O
microdissected	O
and	O
examined	O
for	O
CTNNB1	O
mutations	O
.	O
In	O
addition	O
,	O
41	O
of	O
the	O
HCCs	O
were	O
evaluated	O
for	O
the	O
presence	O
of	O
the	O
beta-catenin	O
protein	O
by	O
immunohistochemical	O
methods	O
.	O
Twenty	O
of	O
the	O
HCCs	B-malignancy-type
showed	O
positive	O
results	O
for	O
beta-catenin	O
,	O
with	O
strong	O
membrane	O
staining	O
,	O
while	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
lacked	O
or	O
showed	O
only	O
weak	O
membrane	O
staining	O
.	O
One	O
HCC	B-malignancy-type
,	O
in	O
which	O
a	O
CTNNB1	O
mutation	O
was	O
not	O
detected	O
,	O
showed	O
nuclear	O
staining	O
for	O
the	O
beta-catenin	O
protein	O
.	O
Mutations	O
of	O
CTNNB1	O
were	O
identified	O
in	O
five	O
HCCs	B-malignancy-type
.	O
These	O
consisted	O
of	O
four	O
point	O
mutations	O
in	O
the	O
glycogen	O
serine	O
kinase-3beta	O
phosphorylation	O
region	O
of	O
codons	O
32	O
-	O
45	O
and	O
one	O
deletion	O
of	O
codons	O
32	O
-	O
38	O
.	O
These	O
mutations	O
were	O
similar	O
to	O
those	O
previously	O
reported	O
for	O
human	O
HCC	B-malignancy-type
,	O
although	O
at	O
a	O
lower	O
frequency	O
.	O
A	O
signature	O
mutation	O
profile	O
associated	O
with	O
aflatoxin	O
B1	O
exposure	O
could	O
not	O
be	O
identified	O
.	O
The	O
immunohistochemical	O
findings	O
indicate	O
a	O
role	O
for	O
accumulation	O
of	O
beta-catenin	O
and	O
possibly	O
increased	O
Wnt	O
signaling	O
in	O
aflatoxin	O
B1	O
-	O
associated	O
HCC	B-malignancy-type
.	O
The	O
low	O
frequency	O
of	O
CTNNB1	O
mutations	O
,	O
however	O
,	O
suggests	O
that	O
mutation	O
of	O
another	O
Wnt	O
signaling	O
component	O
,	O
such	O
as	O
the	O
Wnt	O
scaffolding	O
protein	O
axin	O
or	O
the	O
adenomatous	O
polyposis	O
coli	O
protein	O
,	O
both	O
of	O
which	O
modulate	O
beta-catenin	O
stability	O
,	O
also	O
may	O
be	O
involved	O
in	O
aflatoxin	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
HCC	I-malignancy-type
.	O
Published	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
PMID	O
:	O
11429783	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
2001	O
Aug	O
1	O
;	O
93	O
(	O
3	O
)	O
:	O
445	O
-	O
9	O
Somatic	O
mutations	O
of	O
WNT	O
/	O
wingless	O
signaling	O
pathway	O
components	O
in	O
primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
.	O
Koch	O
A	O
,	O
Waha	O
A	O
,	O
Tonn	O
JC	O
,	O
Sorensen	O
N	O
,	O
Berthold	O
F	O
,	O
Wolter	O
M,	O
Reifenberger	O
J,	O
Hartmann	O
W	O
,	O
Friedl	O
W	O
,	O
Reifenberger	O
G,	O
Wiestler	O
OD	O
,	O
Pietsch	O
T.	O
Department	O
of	O
Neuropathology	O
,	O
University	O
of	O
Bonn	O
Medical	O
Center	O
;	O
Bonn	O
,	O
Germany	O
.	O
Primitive	B-malignancy-type
neuroectodermal	I-malignancy-type
tumors	I-malignancy-type
(	O
PNETs	B-malignancy-type
)	O
represent	O
the	O
most	O
frequent	O
malignant	O
brain	B-malignancy-type
tumors	I-malignancy-type
in	O
childhood	O
.	O
The	O
majority	O
of	O
these	O
neoplasms	B-malignancy-type
occur	O
in	O
the	O
cerebellum	O
and	O
are	O
classified	O
as	O
medulloblastomas	B-malignancy-type
(	O
MB	B-malignancy-type
)	O
.	O
Most	O
PNETs	B-malignancy-type
develop	O
sporadically	O
;	O
however	O
,	O
their	O
incidence	O
is	O
highly	O
elevated	O
in	O
patients	O
carrying	O
germline	O
APC	O
gene	O
mutations	O
.	O
The	O
APC	O
gene	O
encodes	O
a	O
central	O
component	O
of	O
the	O
WNT	O
/	O
wingless	O
developmental	O
signaling	O
pathway	O
.	O
It	O
regulates	O
the	O
levels	O
of	O
cytoplasmic	O
beta-catenin	O
protein	O
that	O
plays	O
a	O
central	O
role	O
in	O
neural	O
development	O
and	O
cell	O
proliferation	O
.	O
We	O
analyzed	O
87	O
sporadic	B-malignancy-type
PNETs	I-malignancy-type
and	O
10	O
PNET	B-malignancy-type
cell	O
lines	O
for	O
mutations	O
of	O
the	O
APC	O
gene	O
and	O
beta-catenin	O
(	O
CTNNB1	O
)	O
gene	O
using	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
sequencing	O
analysis	O
.	O
We	O
examined	O
the	O
mutation	O
cluster	O
region	O
of	O
APC	O
(	O
codons	O
1255	O
--	O
1641	O
)	O
for	O
germline	O
variants	O
and	O
somatic	O
mutations	O
.	O
The	O
medulloblastoma	B-malignancy-type
cell	O
line	O
MHH-MED-2	O
carried	O
a	O
Glu	O
1317	O
Gln	O
missense	O
germline	O
variant	O
and	O
a	O
sporadic	B-malignancy-type
MB	I-malignancy-type
sample	O
showed	O
a	O
somatic	O
Pro	O
1319	O
Leu	O
substitution	O
.	O
Mutational	O
analysis	O
of	O
exon	O
3	O
of	O
CTNNB1	O
uncovered	O
4	O
PNETs	B-malignancy-type
(	O
4.8	O
%	O
)	O
with	O
somatic	O
missense	O
mutations	O
.	O
These	O
mutations	O
caused	O
amino	O
acid	O
substitutions	O
in	O
3	O
of	O
80	O
medulloblastomas	B-malignancy-type
(	O
Ser	O
33	O
Phe	O
,	O
Ser	O
33	O
Cys	O
and	O
Ser	O
37	O
Cys	O
)	O
and	O
1	O
of	O
4	O
supratentorial	B-malignancy-type
PNETs	I-malignancy-type
(	O
Gly	O
34	O
Val	O
)	O
.	O
All	O
mutations	O
affected	O
GSK-3	O
beta	O
phosphorylation	O
sites	O
of	O
the	O
degradation	O
targeting	O
box	O
of	O
beta-catenin	O
and	O
resulted	O
in	O
nuclear	O
beta-catenin	O
protein	O
accumulation	O
.	O
Deletions	O
of	O
CTNNB1	O
were	O
not	O
detected	O
by	O
PCR	O
amplification	O
with	O
primers	O
spanning	O
exons	O
1	O
--	O
5	O
.	O
Our	O
data	O
indicate	O
that	O
inappropriate	O
activation	O
of	O
the	O
WNT	O
/	O
wingless	O
signaling	O
pathway	O
by	O
mutations	O
of	O
its	O
components	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
subset	O
of	O
PNETs	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11433413	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Ann	O
Diagn	O
Pathol	O
2001	O
Jun;	O
5	O
(	O
3	O
)	O
:	O
129	O
-	O
40	O
A	O
clinicopathologic	O
and	O
immunohistochemical	O
study	O
of	O
35	O
anaplastic	B-malignancy-type
carcinomas	I-malignancy-type
of	O
the	O
pancreas	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O
Paal	O
E	O
,	O
Thompson	O
LD	O
,	O
Frommelt	O
RA	O
,	O
Przygodzki	O
RM	O
,	O
Heffess	O
CS.	O
Department	O
of	O
Endocrine	O
and	O
Otorhinolaryngic	O
-	O
Head	O
&	O
Neck	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
2030	O
6-6000	O
,	O
USA	O
.	O
Anaplastic	B-malignancy-type
pancreatic	I-malignancy-type
carcinomas	I-malignancy-type
are	O
rare	O
tumors	O
,	O
frequently	O
displaying	O
a	O
variety	O
of	O
growth	O
patterns	O
.	O
The	O
literature	O
lacks	O
a	O
comprehensive	O
study	O
of	O
this	O
tumor	O
.	O
Thirty-five	O
cases	O
of	O
anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
diagnosed	O
between	O
1955	O
and	O
1997	O
were	O
retrieved	O
from	O
the	O
Endocrine	O
Registry	O
at	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
.	O
Histology	O
,	O
immunophenotype	O
,	O
molecular	O
analysis	O
,	O
and	O
patient	O
follow-up	O
were	O
analyzed	O
.	O
The	O
tumors	O
of	O
10	O
women	O
and	O
25	O
men	O
,	O
aged	O
34	O
to	O
85	O
years	O
(	O
mean	O
age	O
at	O
presentation	O
,	O
62.5	O
years	O
)	O
,	O
were	O
studied	O
.	O
Patients	O
had	O
vague	O
symptoms	O
(	O
weight	O
loss	O
,	O
pain	O
,	O
and	O
fatigue	O
,	O
nausea	O
,	O
or	O
vomiting	O
)	O
,	O
lasting	O
an	O
average	O
of	O
13.2	O
weeks	O
.	O
The	O
tumors	O
,	O
of	O
an	O
average	O
size	O
of	O
9.2	O
cm	O
,	O
were	O
usually	O
in	O
the	O
head	O
or	O
tail	O
of	O
the	O
pancreas	O
.	O
The	O
tumors	O
were	O
widely	O
infiltrative	O
,	O
histomorphologically	O
separated	O
into	O
predominantly	O
large	O
,	O
pleomorphic	O
cell	O
,	O
or	O
spindle	O
cell	O
groups	O
.	O
Tumor	O
phagocytosis	O
and	O
necrosis	O
were	O
noted	O
.	O
Immunohistochemical	O
studies	O
confirmed	O
an	O
epithelial	O
origin	O
with	O
at	O
least	O
one	O
epithelial	O
marker	O
in	O
78	O
%	O
of	O
the	O
tumors	O
.	O
K-ras	O
mutations	O
by	O
sequence	O
analysis	O
were	O
found	O
in	O
eight	O
of	O
12	O
cases	O
tested	O
.	O
Surgical	O
biopsy	O
/	O
excision	O
was	O
used	O
in	O
all	O
patients	O
.	O
Twenty-nine	O
of	O
35	O
patients	O
died	O
of	O
disease	O
(	O
average	O
,	O
5.2	O
months	O
)	O
,	O
three	O
died	O
with	O
no	O
evidence	O
of	O
disease	O
(	O
average	O
,	O
56.9	O
months	O
)	O
,	O
and	O
three	O
patients	O
were	O
alive	O
at	O
last	O
follow-up	O
(	O
average	O
,	O
94.0	O
months	O
)	O
,	O
one	O
with	O
residual	O
disease	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
survival	O
between	O
patients	O
with	O
and	O
without	O
a	O
K-ras	O
mutation	O
.	O
Anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
usually	O
occurs	O
in	O
the	O
head	O
of	O
the	O
pancreas	O
in	O
older	O
men	O
.	O
The	O
epithelial	O
nature	O
of	O
the	O
pleomorphic	O
cells	O
(	O
giant	O
or	O
spindled	O
)	O
can	O
usually	O
be	O
documented	O
.	O
Patients	O
with	O
K-ras	O
mutations	O
have	O
a	O
shorter	O
survival	O
time	O
,	O
even	O
though	O
the	O
overall	O
prognosis	O
for	O
all	O
anaplastic	B-malignancy-type
carcinomas	I-malignancy-type
is	O
fatal	O
(	O
93	O
%	O
fatality	O
;	O
average	O
survival	O
,	O
448	O
days	O
)	O
.	O
Ann	O
Diagn	O
Pathol	O
5	O
:	O
129	O
-	O
140	O
,	O
2001	O
.	O
This	O
is	O
a	O
US	O
government	O
work	O
.	O
There	O
are	O
no	O
restriction	O
on	O
its	O
use	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
11436166	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncogene	O
2001	O
Jul	O
12;2	O
0	O
(	O
31	O
)	O
:	O
424	O
9-57	O
Genetic	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
in	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
malignant	O
mesothelioma	B-malignancy-type
and	O
identification	O
of	O
a	O
new	O
3p21.3	O
homozygous	O
deletion	O
.	O
Shigemitsu	O
K,	O
Sekido	O
Y	O
,	O
Usami	O
N	O
,	O
Mori	O
S	O
,	O
Sato	O
M,	O
Horio	O
Y	O
,	O
Hasegawa	O
Y	O
,	O
Bader	O
SA	O
,	O
Gazdar	O
AF	O
,	O
Minna	O
JD	O
,	O
Hida	O
T	O
,	O
Yoshioka	O
H,	O
Imaizumi	O
M,	O
Ueda	O
Y	O
,	O
Takahashi	O
M,	O
Shimokata	O
K.	O
Department	O
of	O
Thoracic	O
Surgery	O
,	O
Nagoya	O
University	O
School	O
of	O
Medicine	O
,	O
Nagoya	O
46	O
6-8550	O
,	O
Japan	O
.	O
The	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
has	O
been	O
shown	O
to	O
be	O
genetically	O
mutated	O
in	O
various	O
human	O
malignancies	O
.	O
To	O
determine	O
whether	O
the	O
beta-catenin	O
gene	O
is	O
responsible	O
for	O
oncogenesis	O
in	O
thoracic	B-malignancy-type
malignancies	I-malignancy-type
,	O
we	O
searched	O
for	O
the	O
mutation	O
in	O
166	O
lung	B-malignancy-type
cancers	I-malignancy-type
(	O
90	O
primary	O
tumors	O
and	O
76	O
cell	O
lines	O
)	O
,	O
one	O
blastoma	B-malignancy-type
and	O
10	O
malignant	O
mesotheliomas	B-malignancy-type
(	O
two	O
primary	O
tumors	O
and	O
eight	O
cell	O
lines	O
)	O
.	O
Among	O
the	O
lung	B-malignancy-type
cancers	I-malignancy-type
,	O
including	O
43	O
small	B-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
(	O
SCLCs	B-malignancy-type
)	O
and	O
123	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
(	O
NSCLCs	B-malignancy-type
)	O
,	O
we	O
identified	O
four	O
alterations	O
in	O
exon	O
3	O
,	O
which	O
is	O
the	O
target	O
region	O
of	O
mutation	O
for	O
stabilizing	O
beta-catenin	O
.	O
One	O
primary	O
adenocarcinoma	B-malignancy-type
had	O
a	O
somatic	O
mutation	O
from	O
C	O
to	O
G	O
,	O
leading	O
to	O
an	O
amino	O
acid	O
substitution	O
from	O
Ser	O
to	O
Cys	O
at	O
codon	O
37	O
.	O
Among	O
the	O
cell	O
lines	O
,	O
SCLC	B-malignancy-type
NCI-H1092	O
had	O
a	O
mutation	O
from	O
A	O
to	O
G	O
,	O
leading	O
to	O
an	O
Asp	O
to	O
Gly	O
substitution	O
at	O
codon	O
6	O
,	O
NSCLC	B-malignancy-type
HCC15	O
had	O
a	O
mutation	O
from	O
C	O
to	O
T	O
,	O
leading	O
to	O
a	O
Ser	O
to	O
Phe	O
substitution	O
at	O
codon	O
45	O
,	O
and	O
NSCLC	B-malignancy-type
NCI-H358	O
had	O
a	O
mutation	O
from	O
A	O
to	O
G	O
,	O
leading	O
to	O
a	O
Thr	O
to	O
Ala	O
substitution	O
at	O
codon	O
75	O
.	O
One	O
blastoma	B-malignancy-type
also	O
had	O
a	O
somatic	O
mutation	O
from	O
C	O
to	O
G	O
,	O
leading	O
to	O
a	O
Ser	O
to	O
Cys	O
substitution	O
at	O
codon	O
37	O
.	O
Among	O
the	O
10	O
malignant	O
mesotheliomas	B-malignancy-type
,	O
we	O
identified	O
a	O
homozygous	O
deletion	O
in	O
the	O
NCI-H28	O
cell	O
line	O
.	O
Cloning	O
of	O
the	O
rearranged	O
fragment	O
from	O
NCI-H28	O
indicated	O
that	O
all	O
the	O
exons	O
except	O
exon	O
1	O
of	O
the	O
beta-catenin	O
gene	O
are	O
deleted	O
and	O
that	O
the	O
deletion	O
junction	O
is	O
13	O
kb	O
downstream	O
from	O
exon	O
1	O
.	O
Furthermore	O
,	O
Northern	O
blot	O
analysis	O
of	O
26	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
eight	O
mesothelioma	B-malignancy-type
cell	O
line	O
RNAs	O
detected	O
ubiquitous	O
expression	O
of	O
the	O
beta-catenin	O
messages	O
except	O
NCI-H28	O
,	O
although	O
Western	O
blot	O
analysis	O
showed	O
that	O
relatively	O
less	O
amounts	O
of	O
protein	O
products	O
were	O
expressed	O
in	O
some	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
beta-catenin	O
gene	O
is	O
infrequently	O
mutated	O
in	O
lung	O
cancer	O
and	O
that	O
the	O
NCI-H28	O
homozygous	O
deletion	O
of	O
the	O
beta-catenin	O
gene	O
might	O
indicate	O
the	O
possibility	O
of	O
a	O
new	O
tumor	O
suppressor	O
gene	O
residing	O
in	O
this	O
region	O
at	O
3p21.3	O
,	O
where	O
various	O
types	O
of	O
human	O
cancers	O
show	O
frequent	O
allelic	O
loss	O
.	O
PMID	O
:	O
11464291	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pathol	O
Int	O
2001	O
Jul;5	O
1	O
(	O
7	O
)	O
:	O
54	O
9-54	O
Adenocarcinoma	B-malignancy-type
arising	O
in	O
gastric	O
heterotopic	O
pancreas	O
:	O
clinicopathological	O
and	O
immunohistochemical	O
study	O
with	O
genetic	O
analysis	O
of	O
a	O
case	O
.	O
Osanai	O
M	O
,	O
Miyokawa	O
N	O
,	O
Tamaki	O
T	O
,	O
Yonekawa	O
M	O
,	O
Kawamura	O
A	O
,	O
Sawada	O
N	O
.	O
Department	O
of	O
Pathology	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Sapporo	O
,	O
Japan	O
.	O
osanaim@post.queensu.ca	O
Heterotopic	O
pancreas	O
in	O
the	O
stomach	O
is	O
a	O
relatively	O
common	O
congenital	O
condition	O
,	O
but	O
the	O
risk	O
of	O
malignant	O
transformation	O
is	O
extremely	O
low	O
.	O
In	O
this	O
study	O
,	O
we	O
describe	O
a	O
case	O
of	O
adenocarcinoma	B-malignancy-type
arising	O
from	O
a	O
gastric	O
heterotopic	O
pancreas	O
and	O
we	O
consider	O
its	O
morphological	O
and	O
immunohistochemical	O
features	O
and	O
genetic	O
analysis	O
,	O
in	O
order	O
to	O
examine	O
its	O
histogenesis	O
.	O
This	O
unusual	O
sequela	O
was	O
seen	O
in	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
.	O
Image	O
studies	O
showed	O
a	O
protruding	O
lesion	B-malignancy-type
with	O
a	O
central	O
ulcer	O
located	O
in	O
the	O
lesser	O
curvature	O
from	O
the	O
angle	O
to	O
the	O
body	O
of	O
the	O
stomach	O
.	O
A	O
biopsy	O
specimen	O
confirmed	O
this	O
lesion	B-malignancy-type
as	O
adenocarcinoma	B-malignancy-type
before	O
total	O
gastrectomy	O
.	O
The	O
tumor	O
showed	O
mixed	O
patterns	O
of	O
solid	O
neoplastic	O
-	O
cell	O
proliferation	O
and	O
moderately	O
differentiated	O
glandular	O
structures	O
,	O
and	O
also	O
showed	O
transitional	B-malignancy-type
lesions	I-malignancy-type
to	O
obvious	O
malignancy	O
,	O
that	O
is	O
,	O
dysplasia	B-malignancy-type
,	O
or	O
adenocarcinoma	B-malignancy-type
in	I-malignancy-type
situ	I-malignancy-type
.	O
Neoplastic	O
cells	O
had	O
positive	O
immunoreactivity	O
for	O
carbohydrate	O
antigen	O
(	O
CA	O
)	O
19	O
-	O
9	O
,	O
mucin	O
(	O
MUC	O
)	O
1	O
,	O
and	O
insulin	O
,	O
and	O
the	O
mutant	O
allele	O
-	O
specific	O
amplification	O
method	O
revealed	O
a	O
point	O
mutation	O
at	O
K-ras	O
codon	O
12	O
(	O
GGT	O
[	O
Gly	O
]	O
-->	O
GAT	O
[	O
Asp	O
]	O
)	O
,	O
which	O
is	O
the	O
most	O
common	O
mutational	O
change	O
observed	O
in	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
features	O
of	O
the	O
present	O
case	O
provide	O
clear	O
evidence	O
that	O
this	O
tumor	O
originated	O
from	O
heterotopic	O
pancreatic	O
tissue	O
rather	O
than	O
from	O
gastric	O
epithelium	O
.	O
PMID	O
:	O
11472568	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Aug;2	O
5	O
(	O
8	O
)	O
:	O
97	O
9-87	O
Comment	O
in	O
:	O
Am	O
J	O
Surg	O
Pathol	O
.	O
2002	O
Mar;2	O
6	O
(	O
3	O
)	O
:	O
396	O
,	O
discussion	O
396	O
.	O
Am	O
J	O
Surg	O
Pathol	O
.	O
2002	O
Mar;2	O
6	O
(	O
3	O
)	O
:	O
39	O
6-7	O
;	O
discussion	O
39	O
7-8	O
.	O
Gastrointestinal	B-malignancy-type
autonomic	I-malignancy-type
nerve	I-malignancy-type
tumor	I-malignancy-type
:	O
immunohistochemical	O
and	O
molecular	O
identity	O
with	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
.	O
Lee	O
JR	O
,	O
Joshi	O
V	O
,	O
Griffin	O
JW	O
Jr	O
,	O
Lasota	O
J	O
,	O
Miettinen	O
M	O
.	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Molecular	O
Medicine	O
and	O
Genetics	O
,	O
Medical	O
College	O
of	O
Georgia	O
,	O
Augusta	O
,	O
Georgia	O
30904	O
,	O
USA	O
.	O
JLEE@mail.mcg.edu	O
Gastrointestinal	B-malignancy-type
autonomic	I-malignancy-type
nerve	I-malignancy-type
tumor	I-malignancy-type
(	O
GANT	B-malignancy-type
)	O
is	O
a	O
gastrointestinal	B-malignancy-type
neoplasm	I-malignancy-type
that	O
ultrastructurally	O
recapitulates	O
the	O
enteric	O
neural	O
plexus	O
.	O
This	O
study	O
identifies	O
and	O
defines	O
the	O
features	O
of	O
10	O
cases	O
of	O
this	O
rare	O
mesenchymal	B-malignancy-type
tumor	I-malignancy-type
and	O
compares	O
its	O
clinicopathologic	O
and	O
molecular	O
genetic	O
features	O
with	O
the	O
data	O
on	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
.	O
The	O
majority	O
of	O
patients	O
in	O
this	O
series	O
presented	O
at	O
an	O
older	O
age	O
(	O
mean	O
64	O
years	O
)	O
.	O
Tumors	O
arose	O
from	O
the	O
stomach	O
(	O
6	O
)	O
,	O
small	O
intestine	O
(	O
2	O
)	O
,	O
and	O
retroperitoneum	O
(	O
2	O
)	O
.	O
Mean	O
tumor	O
size	O
was	O
14	O
cm	O
;	O
however	O
,	O
four	O
neoplasms	O
were	O
<	O
6	O
cm	O
.	O
Histologically	O
,	O
tumors	O
were	O
spindled	O
or	O
epithelioid	O
;	O
one	O
epithelioid	B-malignancy-type
tumor	I-malignancy-type
demonstrated	O
a	O
previously	O
undescribed	O
rhabdoid	O
histologic	O
phenotype	O
.	O
All	O
tumors	O
were	O
positive	O
for	O
CD117	O
(	O
KIT	O
)	O
,	O
while	O
eight	O
of	O
10	O
were	O
positive	O
for	O
CD34	O
.	O
In	O
contrast	O
,	O
only	O
two	O
were	O
positive	O
for	O
S-100	O
,	O
and	O
all	O
were	O
negative	O
for	O
actin	O
and	O
desmin	O
.	O
Five	O
GANTs	B-malignancy-type
demonstrated	O
GIST	B-malignancy-type
-	O
specific	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
juxtamembrane	O
domain	O
of	O
the	O
c-kit	O
gene	O
(	O
50	O
%	O
)	O
.	O
Three	O
of	O
10	O
patients	O
died	O
of	O
disease	O
in	O
22	O
-	O
30	O
months	O
,	O
one	O
patient	O
died	O
in	O
the	O
postoperative	O
period	O
,	O
and	O
one	O
patient	O
died	O
of	O
complications	O
of	O
CML	B-malignancy-type
.	O
The	O
clinicopathologic	O
,	O
histologic	O
,	O
immunohistologic	O
,	O
and	O
molecular	O
features	O
of	O
GANT	B-malignancy-type
are	O
similar	O
to	O
GIST	B-malignancy-type
,	O
indicating	O
that	O
GANT	B-malignancy-type
merely	O
represents	O
a	O
phenotypic	O
variant	O
of	O
GIST	B-malignancy-type
.	O
PMID	O
:	O
11474281	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Aug;2	O
5	O
(	O
8	O
)	O
:	O
109	O
5-9	O
Molecular	O
genetic	O
analysis	O
of	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
adenomas	I-malignancy-type
in	O
identical	O
twins	O
,	O
including	O
one	O
with	O
pseudomyxoma	B-malignancy-type
peritonei	I-malignancy-type
.	O
Shih	O
IM	O
,	O
Yan	O
H	O
,	O
Speyrer	O
D	O
,	O
Shmookler	O
BM	O
,	O
Sugarbaker	O
PH	O
,	O
Ronnett	O
BM	O
.	O
Department	O
of	O
Pathology	O
,	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
Maryland	O
,	O
USA	O
.	O
Pseudomyxoma	B-malignancy-type
peritonei	I-malignancy-type
(	O
PMP	B-malignancy-type
)	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
mucinous	O
ascites	O
and	O
peritoneal	B-malignancy-type
lesions	I-malignancy-type
composed	O
of	O
histologically	O
bland	O
to	O
low-grade	O
adenomatous	O
mucinous	O
epithelium	O
within	O
pools	O
of	O
extracellular	O
mucin	O
,	O
often	O
with	O
an	O
associated	O
mucinous	B-malignancy-type
adenoma	I-malignancy-type
of	O
the	O
appendix	O
.	O
There	O
is	O
evidence	O
that	O
the	O
peritoneal	B-malignancy-type
lesions	I-malignancy-type
in	O
PMP	B-malignancy-type
are	O
clonally	O
derived	O
from	O
the	O
associated	O
appendiceal	B-malignancy-type
adenoma	I-malignancy-type
.	O
Little	O
is	O
known	O
about	O
the	O
molecular	O
genetic	O
alterations	O
or	O
hereditary	O
factors	O
involved	O
in	O
the	O
development	O
of	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
and	O
PMP	B-malignancy-type
.	O
We	O
report	O
the	O
only	O
known	O
example	O
of	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
adenomas	I-malignancy-type
in	O
identical	O
twin	O
brothers	O
,	O
one	O
of	O
whom	O
developed	O
PMP	B-malignancy-type
.	O
We	O
analyzed	O
the	O
status	O
of	O
the	O
K-RAS	O
and	O
APC	O
genes	O
in	O
these	O
tumors	O
using	O
digital	O
polymerase	O
chain	O
reaction	O
and	O
digital	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
assay	O
.	O
Identical	O
K-RAS	O
mutations	O
were	O
detected	O
in	O
the	O
appendiceal	B-malignancy-type
adenoma	I-malignancy-type
and	O
peritoneal	O
tumor	O
from	O
the	O
twin	O
with	O
PMP	O
,	O
whereas	O
the	O
adenoma	B-malignancy-type
from	O
the	O
other	O
twin	O
harbored	O
a	O
different	O
mutation	O
.	O
Digital	O
SNP	O
analysis	O
demonstrated	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
only	O
in	O
the	O
adenoma	B-malignancy-type
from	O
the	O
twin	O
without	O
PMP	B-malignancy-type
but	O
not	O
from	O
the	O
appendiceal	B-malignancy-type
or	O
peritoneal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
twin	O
with	O
PMP	B-malignancy-type
.	O
The	O
adjacent	O
normal	O
tissue	O
in	O
each	O
case	O
retained	O
both	O
APC	O
alleles	O
.	O
The	O
K-RAS	O
mutational	O
analysis	O
supports	O
the	O
view	O
that	O
PMP	O
is	O
clonally	O
derived	O
from	O
the	O
associated	O
appendiceal	B-malignancy-type
mucinous	I-malignancy-type
adenoma	I-malignancy-type
.	O
The	O
lack	O
of	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
in	O
the	O
adenoma	B-malignancy-type
and	O
peritoneal	B-malignancy-type
tumor	I-malignancy-type
from	O
the	O
twin	O
with	O
PMP	B-malignancy-type
suggests	O
that	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
is	O
not	O
necessarily	O
involved	O
in	O
the	O
development	O
of	O
all	O
appendiceal	B-malignancy-type
adenomas	I-malignancy-type
or	O
PMP	B-malignancy-type
.	O
The	O
different	O
types	O
of	O
mutations	O
in	O
K-RAS	O
and	O
the	O
different	O
allelic	O
status	O
of	O
the	O
APC	O
locus	O
in	O
the	O
tumors	O
from	O
both	O
twins	O
suggest	O
that	O
mutation	O
in	O
K-RAS	O
and	O
loss	O
of	O
heterozygosity	O
of	O
APC	O
occurs	O
somatically	O
in	O
adenomas	B-malignancy-type
and	O
is	O
independent	O
of	O
the	O
identical	O
genetic	O
background	O
of	O
the	O
twins	O
.	O
PMID	O
:	O
11474297	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2001	O
Aug	O
15;9	O
3	O
(	O
4	O
)	O
:	O
46	O
8-74	O
Tumor	O
heterogeneity	O
in	O
small	B-malignancy-type
hepatocellular	I-malignancy-type
carcinoma	I-malignancy-type
:	O
analysis	O
of	O
tumor	O
cell	O
proliferation	O
,	O
expression	O
and	O
mutation	O
of	O
p53	O
AND	O
beta-catenin	O
.	O
An	O
FQ	O
,	O
Matsuda	O
M	O
,	O
Fujii	O
H	O
,	O
Tang	O
RF	O
,	O
Amemiya	O
H	O
,	O
Dai	O
YM	O
,	O
Matsumoto	O
Y	O
.	O
First	O
Department	O
of	O
Surgery	O
,	O
Yamanashi	O
Medical	O
University	O
,	O
Tamaho	O
,	O
Yamanashi	O
,	O
Japan	O
.	O
Most	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
first	O
occur	O
as	O
well-differentiated	B-malignancy-type
HCCs	I-malignancy-type
,	O
from	O
which	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
HCC	I-malignancy-type
cells	O
develop	O
because	O
of	O
dedifferentiation	O
.	O
In	O
this	O
study	O
,	O
we	O
try	O
to	O
clarify	O
the	O
changes	O
of	O
dedifferentiation	O
and	O
cell	O
proliferative	O
activity	O
and	O
their	O
relationship	O
in	O
small	B-malignancy-type
HCCs	I-malignancy-type
(	O
less	O
than	O
3.0	O
cm	O
in	O
diameter	O
)	O
and	O
try	O
to	O
learn	O
the	O
mechanism	O
of	O
these	O
changes	O
by	O
analysing	O
the	O
expressions	O
and	O
genetic	O
changes	O
of	O
proliferation	O
-	O
related	O
genes	O
p53	O
and	O
beta-catenin	O
.	O
Of	O
41	O
surgically	O
resected	O
small	B-malignancy-type
HCCs	I-malignancy-type
,	O
11	O
were	O
identified	O
to	O
have	O
tumor	O
heterogeneity	O
.	O
DNA	O
from	O
the	O
11	O
small	B-malignancy-type
HCCs	I-malignancy-type
,	O
consisting	O
of	O
29	O
intratumoral	B-malignancy-type
lesions	I-malignancy-type
and	O
11	O
noncancerous	O
liver	O
tissues	O
adjacent	O
to	O
HCCs	B-malignancy-type
,	O
was	O
extracted	O
from	O
paraffin	O
embedded	O
tissue	O
sections	O
.	O
Exons	O
5	O
-	O
8	O
of	O
p53	O
gene	O
and	O
exon	O
3	O
of	O
beta-catenin	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
by	O
direct	O
sequence	O
.	O
The	O
serial	O
sections	O
were	O
also	O
immunostained	O
by	O
anti	O
-	O
Ki-67	O
,	O
p53	O
and	O
beta-catenin	O
antibody	O
.	O
Immunohistochemistry	O
showed	O
that	O
the	O
p53	O
overexpression	O
was	O
significantly	O
related	O
to	O
the	O
proliferative	O
activities	O
as	O
evaluated	O
by	O
Ki-67	O
immunostaining	O
and	O
to	O
the	O
histological	O
differentiation	O
.	O
The	O
expression	O
of	O
beta-catenin	O
was	O
found	O
to	O
be	O
heterogeneously	O
distributed	O
not	O
only	O
in	O
various	O
histological	O
grades	O
of	O
the	O
same	O
tumor	O
but	O
also	O
in	O
areas	O
of	O
the	O
same	O
histological	O
grade	O
.	O
p53	O
and	O
beta-catenin	O
gene	O
mutations	O
were	O
detected	O
in	O
1	O
tumor	O
respectively	O
,	O
both	O
of	O
which	O
were	O
second	O
primary	O
HCCs	B-malignancy-type
and	O
also	O
recurred	O
later	O
.	O
The	O
p53	O
mutation	O
showed	O
the	O
same	O
mutation	O
pattern	O
in	O
heterogeneous	O
subpopulations	O
.	O
beta-catenin	O
mutation	O
was	O
detected	O
only	O
in	O
the	O
less	B-malignancy-type
differentiated	I-malignancy-type
lesion	I-malignancy-type
but	O
not	O
in	O
the	O
well-differentiated	B-malignancy-type
lesion	I-malignancy-type
of	O
tumor	O
.	O
In	O
conclusion	O
,	O
our	O
findings	O
suggest	O
that	O
there	O
was	O
histological	O
heterogeneity	O
in	O
small	B-malignancy-type
but	O
established	O
HCC	B-malignancy-type
,	O
which	O
was	O
accompanied	O
by	O
increased	O
proliferative	O
activity	O
and	O
p53	O
overexpression	O
.	O
The	O
overexpression	O
of	O
beta-catenin	O
may	O
be	O
related	O
to	O
the	O
proliferative	O
activity	O
and	O
dedifferentiation	O
of	O
HCC	B-malignancy-type
.	O
Copyright	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O
PMID	O
:	O
11477549	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Aug	O
1;92(	O
3	O
)	O
:488	O
-	O
99	O
The	O
association	O
of	O
K-ras	O
gene	O
mutation	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
gene	O
expression	O
in	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Ikeda	O
N	O
,	O
Nakajima	O
Y	O
,	O
Sho	O
M,	O
Adachi	O
M,	O
Huang	O
CL	O
,	O
Iki	O
K	O
,	O
Kanehiro	O
H	O
,	O
Hisanaga	O
M,	O
Nakano	O
H	O
,	O
Miyake	O
M.	O
Department	O
of	O
Thoracic	O
Surgery	O
and	O
Department	O
V	O
of	O
Oncology	O
,	O
Kitano	O
Hospital	O
,	O
Tazuke	O
Kofukai	O
Medical	O
Research	O
Institute	O
,	O
13	O
-	O
3	O
,	O
Kamiyama	O
-	O
cho	O
,	O
Kita	O
-	O
ku	O
,	O
Osaka	O
530	O
-	O
8480	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Previously	O
,	O
the	O
authors	O
reported	O
the	O
role	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
as	O
an	O
angiogenic	O
factor	O
in	O
40	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
In	O
this	O
study	O
,	O
they	O
investigated	O
the	O
mechanism	O
underlying	O
the	O
regulation	O
of	O
VEGF	O
gene	O
expression	O
and	O
evaluated	O
VEGF	O
expression	O
and	O
K-ras	O
gene	O
status	O
in	O
48	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
METHODS	O
:	O
The	O
authors	O
used	O
quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
direct	O
sequencing	O
techniques	O
for	O
a	O
retrospective	O
study	O
of	O
VEGF	O
gene	O
expression	O
and	O
K-ras	O
gene	O
status	O
in	O
tumor	O
tissue	O
samples	O
from	O
48	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Immunohistochemistry	O
also	O
was	O
used	O
to	O
investigate	O
VEGF	O
protein	O
expression	O
.	O
RESULTS	O
:	O
Thirty-one	O
tumors	O
(	O
64.6	O
%	O
)	O
were	O
evaluated	O
with	O
high	O
VEGF	O
expression	O
,	O
and	O
17	O
tumors	O
(	O
35.4	O
%	O
)	O
were	O
evaluated	O
with	O
low	O
VEGF	O
expression	O
.	O
Of	O
the	O
48	O
primary	O
pancreatic	B-malignancy-type
tumors	I-malignancy-type
studied	O
,	O
33	O
tumors	O
(	O
68.8	O
%	O
)	O
contained	O
mutations	O
of	O
the	O
K-ras	O
gene	O
.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
VEGF	O
expression	O
and	O
K-ras	O
status	O
.	O
Twenty-five	O
of	O
33	O
tumors	O
(	O
75.8	O
%	O
)	O
with	O
mutant	O
K-ras	O
genes	O
showed	O
high	O
VEGF	O
expression	O
,	O
whereas	O
only	O
6	O
of	O
15	O
tumors	O
with	O
the	O
wild	O
type	O
K-ras	O
(	O
40.0	O
%	O
)	O
showed	O
high	O
VEGF	O
expression	O
(	O
P	O
=	O
0.038	O
)	O
.	O
The	O
mean	O
(	O
+/-	O
standard	O
error	O
)	O
VEGF	O
conservation	O
rate	O
for	O
the	O
33	O
tumors	O
with	O
mutant	O
K-ras	O
was	O
1.839	O
+/-	O
1.241	O
,	O
and	O
that	O
for	O
the	O
15	O
tumors	O
with	O
wild	O
type	O
K-ras	O
was	O
1.057	O
+/-	O
0.983	O
(	O
P	O
=	O
0.037	O
)	O
.	O
Furthermore	O
,	O
the	O
median	O
survival	O
for	O
patients	O
with	O
mutant	O
K-ras	O
was	O
shorter	O
than	O
for	O
those	O
with	O
wild	O
type	O
K-ras	O
(	O
10.6	O
months	O
vs.	O
27.6	O
months	O
,	O
respectively	O
;	O
P	O
=	O
0.026	O
)	O
,	O
whereas	O
the	O
median	O
survival	O
for	O
patients	O
with	O
high	O
VEGF	O
expression	O
was	O
shorter	O
compared	O
with	O
that	O
for	O
patients	O
with	O
low	O
VEGF	O
expression	O
(	O
9.5	O
months	O
vs.	O
26.4	O
months	O
,	O
respectively	O
;	O
P	O
=	O
0.002	O
)	O
.	O
Cox	O
regression	O
model	O
analysis	O
indicated	O
that	O
only	O
the	O
VEGF	O
status	O
was	O
a	O
significant	O
factor	O
for	O
prognosis	O
(	O
P	O
=	O
0.024	O
)	O
.	O
Other	O
variables	O
,	O
i.e.	O
,	O
K-ras	O
status	O
,	O
histopathologic	O
tumor	O
grade	O
,	O
tumor	O
status	O
,	O
lymph	O
node	O
status	O
,	O
metastatic	O
status	O
,	O
gender	O
,	O
and	O
age	O
at	O
surgery	O
,	O
were	O
not	O
significant	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
K-ras	O
oncogene	O
mutation	O
may	O
be	O
associated	O
with	O
VEGF	O
expression	O
and	O
that	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
who	O
have	O
high	O
VEGF	O
expression	O
are	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11505392	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Sep	O
15;6	O
1	O
(	O
18	O
)	O
:	O
665	O
6-9	O
Accumulation	O
of	O
beta-catenin	O
protein	O
and	O
mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
gene	O
in	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumor	I-malignancy-type
.	O
Fujimori	O
M,	O
Ikeda	O
S	O
,	O
Shimizu	O
Y	O
,	O
Okajima	O
M,	O
Asahara	O
T.	O
Second	O
Department	O
of	O
Surgery	O
,	O
Hiroshima	O
University	O
Faculty	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
73	O
4-8551	O
.	O
The	O
molecular	O
basis	O
of	O
carcinogenesis	O
in	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumors	I-malignancy-type
is	O
not	O
well	O
understood	O
.	O
To	O
clarify	O
the	O
contribution	O
of	O
the	O
Wnt	O
/	O
beta-catenin	O
signaling	O
to	O
this	O
type	O
of	O
carcinogenesis	O
,	O
we	O
investigated	O
72	O
cases	O
of	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumor	I-malignancy-type
both	O
immunohistochemically	O
and	O
by	O
direct	O
sequencing	O
of	O
beta-catenin	O
.	O
Accumulation	O
of	O
beta-catenin	O
in	O
the	O
cytoplasm	O
and/or	O
nucleus	O
was	O
observed	O
in	O
57	O
cases	O
(	O
79.2	O
%	O
)	O
.	O
We	O
also	O
detected	O
mutations	O
in	O
exon	O
3	O
of	O
beta-catenin	O
in	O
27	O
cases	O
(	O
37.5	O
%	O
)	O
and	O
one	O
mutation	O
in	O
APC	O
(	O
1.4	O
%	O
)	O
.	O
Our	O
results	O
suggest	O
that	O
alterations	O
in	O
the	O
Wnt	O
/	O
beta-catenin	O
signaling	O
pathway	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
gastrointestinal	B-malignancy-type
carcinoid	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
11559529	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
Arch	O
Occup	O
Environ	O
Health	O
2001	O
Aug	O
;	O
74	O
(	O
6	O
)	O
:	O
405	O
-	O
10	O
High	O
prevalence	O
of	O
K-ras-2	O
mutations	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
in	O
workers	O
exposed	O
to	O
vinyl	O
chloride	O
.	O
Weihrauch	O
M	O
,	O
Benick	O
M	O
,	O
Lehner	O
G	O
,	O
Wittekind	O
M	O
,	O
Bader	O
M	O
,	O
Wrbitzk	O
R	O
,	O
Tannapfel	O
A	O
.	O
Abteilung	O
Arbeitsmedizin	O
,	O
Medizinische	O
Hochschule	O
Hannover	O
,	O
Germany	O
.	O
Weihrauch	O
,	O
Markus@mh-hannover.de	O
OBJECTIVES	O
:	O
Vinyl	O
chloride	O
(	O
VC	O
)	O
and	O
its	O
metabolites	O
are	O
human	O
carcinogens	O
associated	O
with	O
liver	B-malignancy-type
angiosarcomas	I-malignancy-type
(	O
LAS	B-malignancy-type
)	O
and	O
also	O
with	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
HCCs	B-malignancy-type
)	O
.	O
In	O
VC	O
associated	O
LAS	B-malignancy-type
mutations	O
of	O
the	O
K-ras-2	O
gene	O
have	O
been	O
reported	O
,	O
however	O
,	O
no	O
data	O
about	O
the	O
prevalence	O
of	O
such	O
mutations	O
in	O
VC	O
-	O
associated	O
HCCs	B-malignancy-type
are	O
available	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
possible	O
specific	O
K-ras-2	O
oncogene	O
mutations	O
in	O
the	O
case	O
of	O
HCCs	B-malignancy-type
due	O
to	O
VC	O
.	O
METHODS	O
:	O
The	O
presence	O
of	O
K-ras-2	O
mutations	O
was	O
analysed	O
in	O
tissue	O
from	O
12	O
patients	O
with	O
VC	O
-	O
associated	O
HCCs	B-malignancy-type
.	O
All	O
patients	O
had	O
known	O
long-term	O
exposure	O
to	O
VC	O
(	O
average	O
exposure	O
amount	O
:	O
9,942	O
ppm	O
-	O
years	O
)	O
.	O
Twenty	O
patients	O
with	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
due	O
to	O
hepatitis	O
B	O
(	O
n	O
=	O
7	O
)	O
,	O
hepatitis	O
C	O
(	O
n	O
=	O
5	O
)	O
and	O
alcoholic	O
liver	O
cirrhosis	O
(	O
n	O
=	O
8	O
)	O
served	O
as	O
a	O
control	O
group	O
.	O
The	O
specific	O
mutations	O
were	O
determined	O
by	O
direct	O
sequencing	O
of	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras-2	O
gene	O
in	O
carcinomatous	O
and	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
after	O
microdissection	O
.	O
Immunohistochemical	O
analysis	O
was	O
performed	O
to	O
detect	O
p21ras	O
protein	O
.	O
RESULTS	O
:	O
K-ras-2	O
mutations	O
were	O
found	O
in	O
five	O
of	O
12	O
(	O
42	O
%	O
)	O
examined	O
HCCs	B-malignancy-type
and	O
in	O
three	O
cases	O
of	O
adjacent	O
non	O
-	O
neoplastic	O
liver	O
tissue	O
(	O
25	O
%	O
)	O
.	O
There	O
were	O
three	O
guanine	O
to	O
adenine	O
(	O
G	O
-->	O
A	O
)	O
point	O
mutations	O
in	O
the	O
tumour	O
tissue	O
.	O
All	O
three	O
mutations	O
found	O
in	O
non	O
-	O
neoplastic	O
liver	O
from	O
VC	O
-	O
exposed	O
patients	O
were	O
also	O
G	O
-->	O
A	O
point	O
mutations	O
(	O
codon	O
12	O
-	O
and	O
codon	O
13	O
-	O
aspartate	O
mutations	O
)	O
.	O
Within	O
the	O
control	O
group	O
,	O
K-ras-2	O
mutations	O
were	O
found	O
in	O
three	O
of	O
20	O
(	O
15	O
%	O
)	O
examined	O
HCCs	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
Mutations	O
of	O
the	O
K-ras-2	O
gene	O
in	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
associated	O
with	O
VC	O
exposure	O
are	O
frequent	O
events	O
.	O
We	O
observed	O
a	O
K-ras-2	O
mutation	O
pattern	O
characteristic	O
of	O
chloroethylene	O
oxide	O
,	O
one	O
of	O
the	O
carcinogenic	O
metabolites	O
of	O
VC	O
analysed	O
in	O
animal	O
models	O
.	O
Our	O
results	O
suggest	O
that	O
VC	O
had	O
direct	O
toxic	O
effects	O
not	O
only	O
on	O
endothelial	O
cells	O
but	O
also	O
on	O
hepatocytes	O
,	O
as	O
it	O
was	O
previously	O
only	O
described	O
in	O
animal	O
models	O
.	O
PMID	O
:	O
11563603	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
2001	O
Nov	O
15;9	O
2	O
(	O
10	O
)	O
:	O
255	O
5-61	O
Erratum	O
in	O
:	O
Cancer	O
2002	O
Apr	O
1;94	O
(	O
7	O
)	O
:	O
2117	O
The	O
incidence	O
of	O
thanatophoric	O
dysplasia	O
mutations	O
in	O
FGFR3	O
gene	O
is	O
higher	O
in	O
low-grade	O
or	O
superficial	B-malignancy-type
bladder	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Kimura	O
T	O
,	O
Suzuki	O
H,	O
Ohashi	O
T	O
,	O
Asano	O
K,	O
Kiyota	O
H,	O
Eto	O
Y	O
.	O
Department	O
of	O
Urology	O
,	O
Institute	O
of	O
DNA	O
Medicine	O
,	O
Jikei	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Tokyo	O
,	O
Japan	O
.	O
tkimura@jikei	O
.ac.jp	O
BACKGROUND	O
:	O
The	O
point	O
mutations	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
are	O
associated	O
with	O
autosomal	O
dominant	O
human	O
skeletal	O
disorders	O
such	O
as	O
thanatophoric	O
dysplasia	O
(	O
TD	O
)	O
.	O
However	O
,	O
point	O
mutations	O
were	O
reported	O
in	O
a	O
small	O
series	O
of	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
,	O
suggesting	O
their	O
oncogenic	O
role	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
authors	O
investigated	O
the	O
incidence	O
of	O
TD	O
mutations	O
in	O
the	O
FGFR3	O
gene	O
in	O
a	O
large	O
series	O
of	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
to	O
clarify	O
their	O
role	O
in	O
the	O
progression	O
of	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
METHODS	O
:	O
Specimens	O
of	O
transitional	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
urinary	O
bladder	O
from	O
81	O
patients	O
were	O
screened	O
for	O
the	O
FGFR3	O
mutations	O
(	O
codons	O
248	O
,	O
249	O
,	O
372	O
,	O
373	O
,	O
375	O
,	O
652	O
,	O
809	O
)	O
that	O
have	O
been	O
reported	O
in	O
TD	O
,	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
,	O
single-strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O
RESULTS	O
:	O
Point	O
mutations	O
were	O
detected	O
in	O
25	O
of	O
81	O
carcinomas	B-malignancy-type
(	O
2	O
at	O
codon	O
248	O
,	O
11	O
at	O
codon	O
249	O
,	O
1	O
at	O
codon	O
372	O
,	O
9	O
at	O
codon	O
375	O
,	O
2	O
at	O
codon	O
652	O
)	O
.	O
Although	O
no	O
significant	O
relation	O
was	O
found	O
between	O
the	O
occurrence	O
of	O
TD	O
mutations	O
and	O
patient	O
age	O
and	O
clinical	O
status	O
,	O
the	O
incidence	O
of	O
TD	O
mutations	O
was	O
significantly	O
higher	O
in	O
low-grade	O
or	O
superficial	B-malignancy-type
tumors	I-malignancy-type
than	O
high-grade	O
or	O
muscle	B-malignancy-type
invasive	I-malignancy-type
tumors	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
TD	O
mutations	O
in	O
the	O
FGFR3	O
gene	O
do	O
not	O
cause	O
disease	O
progression	O
of	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11745189	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Dec	O
15	O
;	O
61	O
(	O
24	O
)	O
:	O
8624	O
-	O
8	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
with	O
KIT	O
mutations	O
exhibit	O
a	O
remarkably	O
homogeneous	O
gene	O
expression	O
profile	O
.	O
Allander	O
SV	O
,	O
Nupponen	O
NN	O
,	O
Ringner	O
M	O
,	O
,	O
Hostetter	O
G	O
,	O
Maher	O
GW	O
,	O
Goldberger	O
N	O
,	O
Chen	O
Y	O
,	O
Carpten	O
J	O
,	O
Elkahloun	O
AG	O
,	O
Meltzer	O
PS	O
.	O
Cancer	O
Genetics	O
Branch	O
,	O
National	O
Human	O
Genome	O
Research	O
Institute	O
,	O
NIH	O
,	O
Bethesda	O
,	O
Maryland	O
20892	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
,	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
digestive	O
tract	O
,	O
are	O
believed	O
to	O
arise	O
from	O
the	O
interstitial	O
cells	O
of	O
Cajal	O
.	O
GISTs	B-malignancy-type
are	O
characterized	O
by	O
mutations	O
in	O
the	O
proto	O
-	O
oncogene	O
KIT	O
that	O
lead	O
to	O
constitutive	O
activation	O
of	O
its	O
tyrosine	O
kinase	O
activity	O
.	O
The	O
tyrosine	O
kinase	O
inhibitor	O
STI571	O
,	O
active	O
against	O
the	O
BCR	O
-	O
ABL	O
fusion	O
protein	O
in	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
,	O
was	O
recently	O
shown	O
to	O
be	O
highly	O
effective	O
in	O
GISTs	B-malignancy-type
.	O
We	O
used	O
13,826	O
-	O
element	O
cDNA	O
microarrays	O
to	O
define	O
the	O
expression	O
patterns	O
of	O
13	O
KIT	O
mutation	O
-	O
positive	O
GISTs	B-malignancy-type
and	O
compared	O
them	O
with	O
the	O
expression	O
profiles	O
of	O
a	O
group	O
of	O
spindle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
from	O
locations	O
outside	O
the	O
gastrointestinal	O
tract	O
.	O
Our	O
results	O
showed	O
a	O
remarkably	O
distinct	O
and	O
uniform	O
expression	O
profile	O
for	O
all	O
of	O
the	O
GISTs	B-malignancy-type
.	O
In	O
particular	O
,	O
hierarchical	O
clustering	O
of	O
a	O
subset	O
of	O
113	O
cDNAs	O
placed	O
all	O
of	O
the	O
GIST	B-malignancy-type
samples	O
into	O
one	O
branch	O
,	O
with	O
a	O
Pearson	O
correlation	O
>	O
0.91	O
.	O
This	O
homogeneity	O
suggests	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
GIST	B-malignancy-type
results	O
from	O
expansion	O
of	O
a	O
clone	O
that	O
has	O
acquired	O
an	O
activating	O
mutation	O
in	O
KIT	O
without	O
the	O
extreme	O
genetic	O
instability	O
found	O
in	O
the	O
common	O
epithelial	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
results	O
provide	O
insight	O
into	O
the	O
histogenesis	O
of	O
GIST	B-malignancy-type
and	O
the	O
clinical	O
behavior	O
of	O
this	O
therapeutically	O
responsive	O
tumor	O
.	O
PMID	O
:	O
11751374	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
2002	O
Jan;16	O
0	O
(	O
1	O
)	O
:	O
1	O
5-22	O
The	O
complexity	O
of	O
KIT	O
gene	O
mutations	O
and	O
chromosome	O
rearrangements	O
and	O
their	O
clinical	O
correlation	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
(	I-malignancy-type
pacemaker	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
.	O
Andersson	O
J,	O
Sjogren	O
H,	O
Mei	O
s-Kindblom	O
JM	O
,	O
Stenman	O
G,	O
Aman	O
P,	O
Kindblom	O
LG.	O
Department	O
of	O
Pathology	O
,	O
Lundberg	O
Laboratory	O
for	O
Cancer	O
Research	O
,	O
Sahlgrenska	O
University	O
Hospital	O
,	O
Goteborg	O
University	O
,	O
Goteborg	O
,	O
Sweden	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
(	I-malignancy-type
pacemaker	I-malignancy-type
cell	I-malignancy-type
)	I-malignancy-type
tumors	I-malignancy-type
(	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
)	O
are	O
frequently	O
associated	O
with	O
activating	O
KIT	O
mutations	O
,	O
primarily	O
of	O
exon	O
11	O
and	O
rarely	O
of	O
exons	O
9	O
and	O
13	O
,	O
as	O
well	O
as	O
certain	O
chromosome	O
rearrangements	O
.	O
Reports	O
regarding	O
the	O
frequency	O
and	O
prognostic	O
significance	O
of	O
KIT	O
mutations	O
are	O
conflicting	O
and	O
few	O
cases	O
have	O
been	O
completely	O
sequenced	O
.	O
Furthermore	O
,	O
there	O
are	O
few	O
detailed	O
analyses	O
of	O
chromosome	O
alterations	O
in	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
.	O
In	O
a	O
detailed	O
analysis	O
of	O
14	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
from	O
12	O
patients	O
,	O
we	O
found	O
a	O
wider	O
spectrum	O
of	O
KIT	O
mutations	O
than	O
previously	O
reported	O
,	O
including	O
11	O
different	O
in-frame	O
mutations	O
involving	O
exons	O
11	O
,	O
14	O
,	O
and	O
15	O
.	O
No	O
mutations	O
were	O
detected	O
in	O
four	O
malignant	O
tumors	O
.	O
The	O
shorter	O
(	O
GNNK	O
-	O
)	O
KIT	O
isoform	O
was	O
preferentially	O
expressed	O
.	O
Cytogenetic	O
and	O
spectral	O
karyotype	O
analyses	O
of	O
10	O
tumors	O
revealed	O
clonal	O
abnormalities	O
in	O
eight	O
tumors	O
;	O
the	O
most	O
common	O
were	O
terminal	O
1p	O
deletions	O
and	O
losses	O
of	O
chromosomes	O
14	O
and/o	O
22	O
.	O
Neither	O
KIT	O
mutation	O
status	O
nor	O
chromosome	O
aberrations	O
correlated	O
with	O
tumor	O
phenotype	O
or	O
clinical	O
behavior	O
in	O
our	O
series	O
.	O
Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
role	O
of	O
KIT	O
mutations	O
and	O
chromosomal	O
rearrangements	O
in	O
the	O
pathogenesis	O
of	O
GIST	B-malignancy-type
/	O
GIPACTs	B-malignancy-type
are	O
more	O
complex	O
than	O
previously	O
recognized	O
.	O
PMID	O
:	O
11786393	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
2002	O
Jan;8	O
2	O
(	O
1	O
)	O
:	O
9	O
7-103	O
Possible	O
association	O
between	O
higher	O
beta-catenin	O
mRNA	O
expression	O
and	O
mutated	O
beta-catenin	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
:	O
real-time	O
semiquantitative	O
assay	O
by	O
TaqMan	O
polymerase	O
chain	O
reaction	O
.	O
Saito	O
T	O
,	O
Oda	O
Y	O
,	O
Kawaguchi	O
K,	O
Tanaka	O
K,	O
Matsuda	O
S	O
,	O
Tamiya	O
S	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Maidashi	O
3-	O
1-1	O
,	O
Higash	O
i-ku	O
,	O
Fukuoka	O
81	O
2-8582	O
,	O
Japan	O
.	O
We	O
screened	O
for	O
genetic	O
alterations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
beta-catenin	O
genes	O
in	O
17	O
frozen	O
specimens	O
from	O
12	O
cases	O
of	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
and	O
then	O
subdivided	O
these	O
cases	O
into	O
two	O
groups	O
according	O
to	O
the	O
results	O
of	O
mutational	O
analysis	O
.	O
We	O
further	O
examined	O
mRNA	O
expression	O
of	O
beta-catenin	O
and	O
cyclin	O
D1	O
by	O
TaqMan	O
PCR	O
and	O
compared	O
the	O
mRNA	O
expression	O
within	O
both	O
groups	O
.	O
Single-strand	O
conformation	O
polymorphism	O
analysis	O
followed	O
by	O
DNA	O
direct	O
sequencing	O
revealed	O
beta-catenin	O
mutation	O
in	O
3	O
of	O
12	O
cases	O
(	O
6	O
of	O
17	O
specimens	O
)	O
,	O
whereas	O
no	O
APC	O
missense	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
were	O
found	O
.	O
TaqMan	O
PCR	O
revealed	O
extremely	O
higher	O
mRNA	O
expression	O
of	O
beta-catenin	O
and	O
cyclin	O
D1	O
in	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
,	O
compared	O
with	O
those	O
of	O
normal	O
skeletal	O
muscles	O
.	O
In	O
the	O
beta-catenin	O
mutated	O
group	O
,	O
cyclin	O
D1	O
mRNA	O
expression	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
beta-catenin	O
wild-type	O
group	O
(	O
p	O
=	O
0.0120	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
)	O
.	O
In	O
addition	O
,	O
in	O
the	O
beta-catenin	O
mutated	O
group	O
,	O
beta-catenin	O
mRNA	O
expression	O
was	O
also	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
beta-catenin	O
wild-type	O
group	O
(	O
p	O
=	O
0.0036	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
)	O
.	O
All	O
cases	O
of	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
showed	O
detectable	O
beta-catenin	O
nuclear	O
expression	O
immunohistochemically	O
.	O
These	O
results	O
suggest	O
that	O
a	O
continuously	O
elevated	O
beta-catenin	O
protein	O
level	O
caused	O
by	O
the	O
beta-catenin	O
mutation	O
itself	O
may	O
have	O
a	O
stronger	O
power	O
that	O
can	O
transactivate	O
transcription	O
in	O
vivo	O
.	O
Furthermore	O
,	O
the	O
results	O
provide	O
a	O
possible	O
association	O
between	O
higher	O
beta-catenin	O
mRNA	O
expression	O
and	O
mutated	O
beta-catenin	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumors	I-malignancy-type
.	O
This	O
may	O
suggest	O
that	O
the	O
beta-catenin	O
gene	O
may	O
be	O
up	O
-	O
regulated	O
by	O
mutated	O
or	O
continuously	O
elevated	O
beta-catenin	O
protein	O
,	O
that	O
is	O
,	O
the	O
beta-catenin	O
gene	O
may	O
also	O
be	O
one	O
of	O
the	O
targeted	O
genes	O
in	O
the	O
APC	O
-	O
beta-catenin	O
-	O
Tcf	O
pathway	O
.	O
PMID	O
:	O
11796830	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2002	O
Feb	O
10;9	O
7	O
(	O
5	O
)	O
:	O
56	O
2-6	O
K-ras	O
mutation	O
in	O
helicobacter	O
pylori	O
-	O
associated	O
chronic	O
gastritis	O
in	O
patients	O
with	O
and	O
without	O
gastric	B-malignancy-type
cancer	I-malignancy-type
.	O
Hiyama	O
T	O
,	O
Haruma	O
K,	O
Kitadai	O
Y	O
,	O
Masuda	O
H,	O
Miyamoto	O
M,	O
Tanaka	O
S	O
,	O
Yoshihara	O
M,	O
Shimamoto	O
F	O
,	O
Chayama	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
.	O
Mutations	O
of	O
an	O
oncogene	O
,	O
K-ras	O
,	O
are	O
associated	O
with	O
the	O
development	O
and	O
progression	O
of	O
many	O
types	O
of	O
human	O
cancer	O
.	O
To	O
elucidate	O
the	O
significance	O
of	O
K-ras	O
mutations	O
in	O
gastric	O
carcinogenesis	O
,	O
we	O
examined	O
K-ras	O
mutations	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
and	O
in	O
Helicobacter	O
pylori	O
-	O
associated	O
chronic	O
gastritis	O
(	O
H.	O
pylori	O
-	O
CG	O
)	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
the	O
gastric	B-malignancy-type
cancer	I-malignancy-type
development	O
.	O
Specimens	O
of	O
gastric	B-malignancy-type
cancer	I-malignancy-type
and	O
H.	O
pylori	O
-	O
CG	O
were	O
obtained	O
from	O
64	O
gastric	O
cancer	O
patients	O
with	O
H.	O
pylori	O
-	O
CG	O
,	O
99	O
cancer	O
-	O
free	O
H.	O
pylori	O
-	O
CG	O
patients	O
and	O
30	O
H.	O
pylori	O
-	O
negative	O
healthy	O
subjects	O
.	O
K-ras	O
mutations	O
were	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
,	O
followed	O
by	O
DNA	O
sequencing	O
analysis	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
4	O
of	O
48	O
(	O
8.3	O
%	O
)	O
gastric	B-malignancy-type
cancers	I-malignancy-type
,	O
in	O
10	O
of	O
163	O
(	O
6.1	O
%	O
)	O
H.	O
pylori	O
-	O
CG	O
and	O
none	O
of	O
the	O
30	O
H.	O
pylori	O
-	O
negative	O
healthy	O
subjects	O
.	O
In	O
the	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
mutated	O
K-ras	O
was	O
detected	O
in	O
differentiated	B-malignancy-type
type	I-malignancy-type
cancers	I-malignancy-type
but	O
not	O
in	O
any	O
of	O
the	O
undifferentiated	B-malignancy-type
type	I-malignancy-type
cancers	I-malignancy-type
.	O
K-ras	O
mutations	O
in	O
H.	O
pylori	O
-	O
CG	O
were	O
significantly	O
more	O
frequent	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
patients	O
than	O
in	O
cancer	O
-	O
free	O
patients	O
(	O
10.9	O
%	O
vs.	O
3.0	O
%	O
,	O
p	O
=	O
0.044	O
)	O
.	O
In	O
addition	O
,	O
K-ras	O
mutations	O
in	O
H.	O
pylori	O
-	O
CG	O
were	O
significantly	O
more	O
frequent	O
in	O
patients	O
with	O
K-ras	O
mutated	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
than	O
in	O
patients	O
with	O
K-ras	O
unmutated	B-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
(	O
50.0	O
%	O
vs.	O
3.7	O
%	O
,	O
p	O
=	O
0.037	O
)	O
.	O
These	O
data	O
suggest	O
that	O
the	O
genetic	O
mechanism(s)	O
of	O
carcinogenesis	O
differs	O
between	O
the	O
differentiated	B-malignancy-type
type	I-malignancy-type
and	O
the	O
undifferentiated	B-malignancy-type
type	I-malignancy-type
of	I-malignancy-type
gastric	I-malignancy-type
cancer	I-malignancy-type
and	O
that	O
K-ras	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
early	O
stages	O
of	O
gastric	O
carcinogenesis	O
of	O
the	O
differentiated	O
type	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11807778	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2002	O
Feb;1	O
5	O
(	O
2	O
)	O
:	O
12	O
5-36	O
c-kit	O
mutations	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
occur	O
preferentially	O
in	O
the	O
spindle	O
rather	O
than	O
in	O
the	O
epithelioid	O
cell	O
variant	O
.	O
Wardelmann	O
E	O
,	O
Neidt	O
I	O
,	O
Bierhoff	O
E	O
,	O
Speidel	O
N	O
,	O
Manegold	O
C,	O
Fischer	O
HP	O
,	O
Pfeifer	O
U	O
,	O
Pietsch	O
T.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Bonn	O
Medical	O
Center	O
,	O
Bonn	O
,	O
Germany	O
.	O
eva.wardelmann@ukb.un	O
i-bonn.de	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
coexpress	O
CD34	O
and	O
the	O
Kit	O
tyrosine	O
-	O
kinase	O
receptor	O
(	O
CD117	O
)	O
.	O
A	O
subset	O
of	O
GISTs	B-malignancy-type
carry	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
in	O
its	O
juxtamembrane	O
domain	O
.	O
The	O
relationship	O
between	O
the	O
mutational	O
status	O
and	O
histological	O
as	O
well	O
as	O
immunohistochemical	O
features	O
has	O
not	O
been	O
assessed	O
in	O
detail	O
.	O
36	O
GISTs	B-malignancy-type
and	O
14	O
other	O
gastrointestinal	B-malignancy-type
mesenchymal	I-malignancy-type
tumors	I-malignancy-type
were	O
investigated	O
for	O
their	O
morphology	O
and	O
immunophenotype	O
as	O
well	O
as	O
for	O
the	O
presence	O
of	O
c-kit	O
mutations	O
.	O
DNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
Exons	O
9	O
,	O
11	O
,	O
13	O
,	O
and	O
17	O
of	O
c-kit	O
were	O
analyzed	O
by	O
SSCP	O
.	O
Bands	O
with	O
altered	O
mobility	O
were	O
excised	O
,	O
reamplified	O
,	O
and	O
sequenced	O
.	O
C-kit	O
mutations	O
in	O
Exon	O
11	O
encoding	O
the	O
juxtamembrane	O
domain	O
were	O
identified	O
in	O
19	O
cases	O
(	O
52.8	O
%	O
)	O
,	O
with	O
deletions	O
in	O
12	O
cases	O
,	O
insertions	O
in	O
3	O
cases	O
(	O
2	O
of	O
these	O
as	O
duplications	O
)	O
,	O
and	O
point	O
mutations	O
in	O
4	O
cases	O
.	O
The	O
mutations	O
clustered	O
between	O
Codons	O
553	O
and	O
561	O
,	O
pinpointing	O
the	O
critical	O
region	O
for	O
deregulated	O
Kit	O
receptor	O
activation	O
.	O
In	O
both	O
Exons	O
9	O
and	O
13	O
,	O
single	O
mutations	O
could	O
be	O
identified	O
,	O
whereas	O
no	O
mutations	O
were	O
found	O
in	O
Exon	O
17	O
.	O
There	O
were	O
c-kit	O
mutations	O
in	O
66.6	O
%	O
of	O
benign	B-malignancy-type
GISTs	I-malignancy-type
(	O
14	O
/	O
21	O
)	O
,	O
83.3	O
%	O
of	O
the	O
malignant	O
(	O
5	O
/	O
6	O
)	O
,	O
and	O
40	O
%	O
of	O
the	O
cases	O
of	O
intermediate	O
malignancy	O
(	O
2	O
/	O
5	O
)	O
.	O
A	O
low	O
frequency	O
of	O
mutations	O
in	O
benign	B-malignancy-type
GISTs	I-malignancy-type
,	O
as	O
reported	O
previously	O
by	O
other	O
researchers	O
,	O
could	O
not	O
be	O
observed	O
in	O
our	O
panel	O
.	O
Interestingly	O
,	O
all	O
GISTs	B-malignancy-type
with	O
c-kit	O
mutations	O
displayed	O
a	O
spindle	O
cell	O
phenotype	O
,	O
whereas	O
mutations	O
were	O
absent	O
in	O
all	O
7	O
tumors	O
with	O
an	O
epithelioid	O
component	O
(	O
P	O
=	O
.03	O
)	O
.	O
This	O
finding	O
suggests	O
a	O
relationship	O
between	O
c-kit	O
mutation	O
and	O
histological	O
subtype	O
in	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
11850541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Chem	O
2002	O
Mar	O
;	O
48	O
(	O
3	O
)	O
:	O
428	O
-	O
35	O
Diagnostic	O
biochip	O
array	O
for	O
fast	O
and	O
sensitive	O
detection	O
of	O
K-ras	O
mutations	O
in	O
stool	O
.	O
Prix	O
L	O
,	O
Uciechowski	O
P	O
,	O
Bockmann	O
B	O
,	O
Giesing	O
M	O
,	O
Schuetz	O
AJ	O
.	O
Institut	O
fur	O
Molekulare	O
NanoTechnologie	O
,	O
Berghauser	O
Strasse	O
295	O
,	O
45659	O
Recklinghausen	O
,	O
Germany	O
.	O
BACKGROUND	O
:	O
Tumor	O
cells	O
that	O
shed	O
into	O
stool	O
are	O
attractive	O
targets	O
for	O
molecular	O
screening	O
and	O
early	O
detection	O
of	O
colon	B-malignancy-type
or	O
pancreatic	B-malignancy-type
malignancies	I-malignancy-type
.	O
We	O
developed	O
a	O
diagnostic	O
test	O
to	O
screen	O
for	O
10	O
of	O
the	O
most	O
common	O
mutations	O
of	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
gene	O
by	O
hybridization	O
to	O
a	O
new	O
biochip	O
array	O
.	O
METHODS	O
:	O
DNA	O
was	O
isolated	O
from	O
26	O
stool	O
samples	O
by	O
column	O
-	O
based	O
extraction	O
from	O
9	O
cell	O
lines	O
.	O
Peptide	O
nucleic	O
acid	O
(	O
PNA	O
)	O
-	O
mediated	O
PCR	O
clamping	O
was	O
used	O
for	O
mutant	O
-	O
specific	O
amplification	O
.	O
We	O
used	O
a	O
biochip	O
,	O
consisting	O
of	O
a	O
small	O
plastic	O
support	O
with	O
covalently	O
immobilized	O
13mer	O
oligonucleotides	O
.	O
The	O
read	O
out	O
of	O
the	O
biochip	O
was	O
done	O
by	O
confocal	O
time	O
-	O
resolved	O
laser	O
scanning	O
.	O
Hybridization	O
,	O
scanning	O
,	O
and	O
data	O
evaluation	O
could	O
be	O
performed	O
in	O
<	O
2	O
h	O
.	O
RESULTS	O
:	O
Approximately	O
80	O
ng	O
of	O
DNA	O
was	O
obtained	O
from	O
200	O
-	O
mg	O
stool	O
samples	O
.	O
No	O
inhibition	O
of	O
the	O
PCR	O
by	O
remaining	O
impurities	O
from	O
stool	O
was	O
observed	O
.	O
Mutation	O
detection	O
was	O
possible	O
in	O
1000	O
-	O
fold	O
excess	O
of	O
wild-type	O
sequence	O
.	O
Discrimination	O
ratios	O
between	O
the	O
mutations	O
were	O
>	O
19	O
as	O
demonstrated	O
by	O
hybridization	O
with	O
tumor	O
cell	O
line	O
DNA	O
.	O
Stool	O
samples	O
(	O
n	O
=	O
26	O
)	O
were	O
analyzed	O
in	O
parallel	O
with	O
PNA-PCR	O
,	O
restriction	O
assay	O
for	O
K-ras	O
codon	O
12	O
mutations	O
,	O
sequencing	O
,	O
and	O
hybridization	O
to	O
the	O
biochip	O
.	O
Nine	O
mutations	O
were	O
found	O
by	O
hybridization	O
,	O
all	O
confirmed	O
by	O
sequencing	O
.	O
PNA-PCR	O
alone	O
leads	O
to	O
an	O
overestimation	O
of	O
mutations	O
because	O
suppression	O
of	O
the	O
wild	O
type	O
is	O
not	O
effective	O
enough	O
with	O
high	O
concentrations	O
of	O
wild-type	O
DNA	O
.	O
The	O
restriction	O
assay	O
found	O
only	O
four	O
mutations	O
.	O
CONCLUSIONS	O
:	O
The	O
K-ras	O
biochip	O
is	O
well	O
suited	O
for	O
fast	O
mutation	O
detection	O
from	O
stool	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
screening	O
.	O
PMID	O
:	O
11861435	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Invest	O
Dermatol	O
2001	O
Dec	O
;	O
117	O
(	O
6	O
)	O
:	O
1483	O
-	O
9	O
Analysis	O
of	O
N	O
-	O
and	O
K-ras	O
mutations	O
in	O
the	O
distinctive	O
tumor	O
progression	O
phases	O
of	O
melanoma	B-malignancy-type
.	O
Demunter	O
A	O
,	O
Stas	O
M	O
,	O
Degreef	O
H	O
,	O
De	O
Wolf-Peeters	O
C	O
,	O
van	O
den	O
Oord	O
JJ	O
.	O
Department	O
of	O
Pathology	O
,	O
Laboratory	O
of	O
Morphology	O
and	O
Molecular	O
Pathology	O
,	O
University	O
Hospitals	O
,	O
Katholieke	O
Universiteit	O
Leuven	O
,	O
Leuven	O
,	O
Belgium	O
.	O
anouk.demunter@uz.kuleuven.ac.be	O
Mutations	O
in	O
the	O
ras	O
genes	O
are	O
key	O
events	O
in	O
the	O
process	O
of	O
carcinogenesis	O
;	O
in	O
particular	O
,	O
point	O
mutations	O
in	O
codon	O
61	O
of	O
exon	O
2	O
of	O
the	O
N-ras	O
gene	O
occur	O
frequently	O
in	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
To	O
investigate	O
whether	O
these	O
mutations	O
occur	O
in	O
early	O
or	O
late	O
tumor	O
progression	O
phases	O
,	O
we	O
searched	O
for	O
point	O
mutations	O
in	O
the	O
N	O
-	O
and	O
K-ras	O
genes	O
in	O
69	O
primary	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
,	O
35	O
metastases	B-malignancy-type
,	O
and	O
seven	O
nevocellular	B-malignancy-type
nevi	I-malignancy-type
in	O
association	O
with	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
Lesions	B-malignancy-type
were	O
microdissected	O
in	O
order	O
to	O
procure	O
pure	O
tumor	O
samples	O
from	O
the	O
distinctive	O
growth	O
phases	O
of	O
the	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
;	O
the	O
very	O
sensitive	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
technique	O
was	O
used	O
to	O
visualize	O
the	O
mutations	O
,	O
and	O
was	O
followed	O
by	O
sequencing	O
.	O
Point	O
mutations	O
in	O
the	O
N-ras	O
gene	O
but	O
not	O
in	O
the	O
K-ras	O
gene	O
were	O
detected	O
on	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Twenty-three	O
primary	O
(	O
33	O
%	O
)	O
and	O
nine	O
metastatic	O
(	O
26	O
%	O
)	O
melanomas	B-malignancy-type
showed	O
bandshifts	O
for	O
N-ras	O
.	O
In	O
the	O
majority	O
of	O
cases	O
,	O
mutations	O
occurring	O
in	O
early	O
growth	O
phases	O
(	O
i.e.	O
,	O
the	O
"	O
intraepidermal	O
"	O
radial	O
growth	O
phase	O
)	O
,	O
were	O
preserved	O
in	O
later	O
growth	O
phases	O
(	O
i.e.	O
,	O
the	O
invasive	O
radial	O
growth	O
phase	O
,	O
vertical	O
growth	O
phase	O
,	O
and	O
metastatic	O
phase	O
)	O
,	O
which	O
proves	O
the	O
clonal	O
relationship	O
between	O
the	O
successive	O
growth	O
phases	O
.	O
In	O
three	O
cases	O
,	O
however	O
,	O
the	O
mutations	O
differed	O
between	O
the	O
distinctive	O
growth	O
phases	O
within	O
the	O
same	O
cutaneous	O
melanoma	O
,	O
due	O
to	O
the	O
occurrence	O
of	O
an	O
additional	O
mutation	O
(	O
especially	O
in	O
codon	O
61	O
)	O
in	O
a	O
later	O
tumor	O
progression	O
phase	O
.	O
Our	O
approach	O
also	O
permitted	O
us	O
to	O
analyze	O
the	O
mutational	O
status	O
of	O
nevi	O
,	O
associated	O
with	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
Six	O
out	O
of	O
seven	O
associated	O
nevi	O
carried	O
the	O
same	O
sequence	O
(	O
mutated	O
or	O
wild-type	O
)	O
as	O
the	O
primary	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
,	O
whereas	O
in	O
one	O
case	O
the	O
sequence	O
for	O
N-ras	O
differed	O
between	O
the	O
primary	O
melanoma	B-malignancy-type
and	O
the	O
associated	O
nevus	B-malignancy-type
.	O
In	O
conclusion	O
,	O
this	O
approach	O
allowed	O
us	O
to	O
demonstrate	O
the	O
clonal	O
relationship	O
between	O
subsequent	O
growth	O
phases	O
of	O
melanoma	B-malignancy-type
and	O
associated	O
nevi	B-malignancy-type
;	O
our	O
results	O
suggest	O
that	O
N-ras	O
exon	O
1	O
mutations	O
preferentially	O
occur	O
during	O
early	O
stages	O
of	O
tumor	O
progression	O
and	O
hence	O
may	O
be	O
involved	O
in	O
melanoma	B-malignancy-type
initiation	O
,	O
whereas	O
those	O
in	O
N-ras	O
exon	O
2	O
are	O
found	O
preferentially	O
during	O
later	O
stages	O
and	O
hence	O
are	O
more	O
probably	O
involved	O
in	O
metastatic	O
spread	O
of	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
.	O
PMID	O
:	O
11886512	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Pathol	O
2002	O
May	O
;	O
55	O
(	O
5	O
)	O
:	O
340	O
-	O
5	O
Pancreatic	B-malignancy-type
cancer	I-malignancy-type
after	O
remote	O
peptic	O
ulcer	O
surgery	O
.	O
Tascilar	O
M	O
,	O
van	O
Rees	O
BP	O
,	O
Sturm	O
PD	O
,	O
Tytgat	O
GN	O
,	O
Hruban	O
RH	O
,	O
Goodman	O
SN	O
,	O
Giardiello	O
FM	O
,	O
Offerhaus	O
GJ	O
,	O
Tersmette	O
AC	O
.	O
Department	O
of	O
Pathology	O
,	O
Academic	O
Medical	O
Center	O
,	O
University	O
of	O
Amsterdam	O
,	O
1105	O
AZ	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
BACKGROUND	O
:	O
Peptic	O
ulcer	O
surgery	O
may	O
carry	O
an	O
increased	O
risk	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
development	O
.	O
Molecular	O
analysis	O
of	O
K-ras	O
codon	O
12	O
,	O
frequently	O
mutated	O
in	O
conventional	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
might	O
provide	O
insight	O
into	O
the	O
aetiological	O
mechanisms	O
.	O
METHODS	O
:	O
The	O
relative	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
was	O
computed	O
by	O
multivariate	O
and	O
person	O
-	O
year	O
analysis	O
in	O
a	O
cohort	O
of	O
2633	O
patients	O
who	O
had	O
undergone	O
gastrectomy	O
.	O
Lung	B-malignancy-type
cancer	I-malignancy-type
risk	O
was	O
analysed	O
as	O
an	O
indirect	O
means	O
of	O
assessing	O
smoking	O
behaviour	O
.	O
K-ras	O
codon	O
12	O
mutational	O
analysis	O
was	O
performed	O
on	O
15	O
postgastrectomy	B-malignancy-type
pancreatic	I-malignancy-type
cancers	I-malignancy-type
.	O
RESULTS	O
:	O
There	O
was	O
an	O
overall	O
increased	O
risk	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
of	O
1.8	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.3	O
to	O
2.6	O
)	O
five	O
to	O
59	O
years	O
postoperatively	O
,	O
which	O
gradually	O
increased	O
to	O
3.6	O
at	O
35	O
years	O
or	O
more	O
after	O
surgery	O
(	O
chi(2)	O
test	O
for	O
trend	O
,	O
p	O
<	O
0.05	O
)	O
.	O
Multivariate	O
analysis	O
indicated	O
that	O
parameters	O
other	O
than	O
postoperative	O
interval	O
did	O
not	O
influence	O
the	O
risk	O
.	O
Lung	B-malignancy-type
cancer	I-malignancy-type
risk	O
was	O
significantly	O
increased	O
after	O
surgery	O
,	O
but	O
no	O
time	O
trend	O
was	O
observed	O
.	O
The	O
spectrum	O
and	O
prevalence	O
of	O
K-ras	O
codon	O
12	O
mutations	O
were	O
comparable	O
to	O
conventional	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Remote	O
partial	O
gastrectomy	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Postgastrectomy	B-malignancy-type
and	O
non	B-malignancy-type
-	I-malignancy-type
postgastrectomy	I-malignancy-type
pancreatic	I-malignancy-type
cancers	I-malignancy-type
may	O
share	O
similar	O
aetiological	O
factors	O
,	O
such	O
as	O
smoking	O
.	O
However	O
,	O
the	O
neoplastic	O
process	O
in	O
patients	O
who	O
have	O
undergone	O
gastrectomy	O
appears	O
to	O
be	O
accelerated	O
by	O
factors	O
related	O
to	O
the	O
surgery	O
itself	O
.	O
PMID	O
:	O
11986336	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Surg	O
Pathol	O
2002	O
Jun	O
;	O
26	O
(	O
6	O
)	O
:	O
758	O
-	O
66	O
Mutation	O
and	O
altered	O
expression	O
of	O
beta-catenin	O
during	O
gallbladder	O
carcinogenesis	O
.	O
Chang	O
HJ	O
,	O
Jee	O
CD	O
,	O
Kim	O
WH	O
.	O
Department	O
of	O
Pathology	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Korea	O
.	O
Gallbladder	B-malignancy-type
carcinoma	I-malignancy-type
has	O
two	O
main	O
morphologic	O
developmental	O
pathways	O
:	O
a	O
dysplasia	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
and	O
an	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
.	O
beta-Catenin	O
is	O
a	O
key	O
regulator	O
of	O
the	O
cadherin	O
-	O
mediated	O
cell	O
adhesion	O
system	O
,	O
and	O
altered	O
expression	O
and	O
mutation	O
of	O
beta-catenin	O
have	O
been	O
identified	O
in	O
many	O
human	O
malignancies	O
.	O
To	O
clarify	O
its	O
role	O
in	O
gallbladder	O
carcinogenesis	O
,	O
we	O
investigated	O
mutation	O
and	O
immunohistochemical	O
expression	O
of	O
beta-catenin	O
in	O
adenomas	B-malignancy-type
,	O
dysplasias	B-malignancy-type
,	O
and	O
carcinomas	B-malignancy-type
.	O
We	O
classified	O
adenomas	B-malignancy-type
according	O
to	O
the	O
expression	O
of	O
apomucins	O
and	O
cytokeratin	O
and	O
compared	O
the	O
mutational	O
and	O
expression	O
pattern	O
among	O
each	O
type	O
.	O
beta-Catenin	O
mutations	O
were	O
identified	O
in	O
58	O
%	O
(	O
14	O
of	O
24	O
)	O
of	O
the	O
adenomas	B-malignancy-type
,	O
and	O
they	O
were	O
absent	O
from	O
all	O
carcinomas	B-malignancy-type
(	O
37	O
cases	O
)	O
and	O
dysplasias	B-malignancy-type
(	O
13	O
cases	O
)	O
.	O
Altered	O
expression	O
of	O
beta-catenin	O
,	O
such	O
as	O
nuclear	O
or	O
cytoplasmic	O
expression	O
and	O
loss	O
of	O
membranous	O
expression	O
,	O
was	O
also	O
significantly	O
higher	O
in	O
adenomas	B-malignancy-type
than	O
in	O
dysplasias	B-malignancy-type
or	O
carcinomas	B-malignancy-type
(	O
p	O
<	O
0.001	O
)	O
.	O
Of	O
the	O
adenomas	B-malignancy-type
,	O
papillary	B-malignancy-type
adenomas	I-malignancy-type
and	O
tubular	B-malignancy-type
adenomas	I-malignancy-type
of	O
intestinal	O
type	O
showed	O
infrequent	O
beta-catenin	O
abnormality	O
,	O
which	O
was	O
similar	O
to	O
the	O
carcinomas	B-malignancy-type
.	O
The	O
cytoplasmic	O
and	O
nuclear	O
expression	O
of	O
beta-catenin	O
in	O
carcinomas	B-malignancy-type
was	O
correlated	O
with	O
less	O
aggressive	O
tumor	O
behavior	O
;	O
in	O
particular	O
,	O
cytoplasmic	O
expression	O
was	O
associated	O
with	O
improved	O
patient	O
outcome	O
(	O
p	O
=	O
0.028	O
)	O
.	O
Gallbladder	B-malignancy-type
adenoma	I-malignancy-type
may	O
be	O
a	O
heterogeneous	O
entity	O
,	O
and	O
the	O
majority	O
of	O
adenomas	B-malignancy-type
are	O
not	O
responsible	O
for	O
carcinoma	B-malignancy-type
progression	O
.	O
PMID	O
:	O
12023580	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mod	O
Pathol	O
2002	O
Jun;1	O
5	O
(	O
6	O
)	O
:	O
59	O
9-605	O
Mucinous	B-malignancy-type
and	O
nonmucinous	B-malignancy-type
appendiceal	I-malignancy-type
adenocarcinomas	I-malignancy-type
:	O
different	O
clinicopathological	O
features	O
but	O
similar	O
genetic	O
alterations	O
.	O
Kabbani	O
W	O
,	O
Houlihan	O
PS	O
,	O
Luthra	O
R	O
,	O
Hamilton	O
SR	O
,	O
Rashid	O
A.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
,	O
USA	O
.	O
The	O
genetic	O
alterations	O
of	O
appendiceal	B-malignancy-type
carcinomas	I-malignancy-type
have	O
not	O
been	O
reported	O
in	O
detail	O
.	O
We	O
studied	O
the	O
clinicopathological	O
factors	O
and	O
genetic	O
alterations	O
including	O
microsatellite	O
instability	O
,	O
p53	O
overexpression	O
,	O
and	O
mutations	O
of	O
the	O
K-ras	O
proto	O
-	O
oncogene	O
of	O
30	O
appendiceal	B-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
consisting	O
of	O
23	O
mucinous	B-malignancy-type
and	O
7	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Sixteen	O
(	O
70	O
%	O
)	O
mucinous	B-malignancy-type
carcinomas	I-malignancy-type
presented	O
with	O
pseudomyxoma	B-malignancy-type
peritonei	I-malignancy-type
,	O
but	O
6	O
of	O
7	O
(	O
86	O
%	O
)	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
presented	O
with	O
appendicitis	O
(	O
P	O
=	O
.002	O
)	O
.	O
All	O
carcinomas	B-malignancy-type
were	O
microsatellite	O
stable	O
,	O
and	O
p53	O
overexpression	O
was	O
present	O
in	O
only	O
1	O
of	O
30	O
(	O
3	O
%	O
)	O
carcinomas	B-malignancy-type
.	O
K-ras	O
mutation	O
was	O
present	O
in	O
11	O
of	O
20	O
(	O
55	O
%	O
)	O
carcinomas	B-malignancy-type
,	O
including	O
8	O
of	O
16	O
(	O
50	O
%	O
)	O
mucinous	B-malignancy-type
and	O
3	O
of	O
4	O
(	O
75	O
%	O
)	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
mean	O
survival	O
of	O
patients	O
with	O
mucinous	B-malignancy-type
carcinomas	I-malignancy-type
was	O
26	O
+/-	O
19	O
months	O
compared	O
with	O
13	O
+/-	O
9	O
months	O
for	O
patients	O
with	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
P	O
=	O
.0002	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
mucinous	B-malignancy-type
and	O
nonmucinous	B-malignancy-type
carcinomas	I-malignancy-type
of	O
appendix	O
have	O
similar	O
genetic	O
alterations	O
,	O
but	O
different	O
clinical	O
presentation	O
and	O
prognosis	O
.	O
PMID	O
:	O
12065772	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2002	O
Aug;3	O
3	O
(	O
8	O
)	O
:	O
85	O
2-5	O
Two	O
case	O
reports	O
of	O
childhood	O
liver	B-malignancy-type
cell	I-malignancy-type
adenomas	I-malignancy-type
harboring	O
beta-catenin	O
abnormalities	O
.	O
Takayasu	O
H,	O
Motoi	O
T	O
,	O
Kanamori	O
Y	O
,	O
Kitano	O
Y	O
,	O
Nakanishi	O
H,	O
Tange	O
T	O
,	O
Nakagawara	O
A	O
,	O
Hashizume	O
K.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
Tokyo	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
benign	B-malignancy-type
epithelial	I-malignancy-type
neoplasm	I-malignancy-type
liver	I-malignancy-type
cell	I-malignancy-type
adenoma	I-malignancy-type
is	O
rare	O
,	O
especially	O
in	O
childhood	O
.	O
We	O
report	O
2	O
such	O
cases	O
,	O
1	O
of	O
which	O
was	O
associated	O
with	O
Prader	O
-	O
Willi	O
syndrome	O
.	O
Differential	O
diagnosis	O
of	O
the	O
liver	B-malignancy-type
cell	I-malignancy-type
adenomas	I-malignancy-type
on	O
the	O
basis	O
of	O
histopathologic	O
findings	O
proved	O
difficult	O
and	O
was	O
based	O
on	O
the	O
absence	O
of	O
cellular	O
and	O
nuclear	O
atypia	O
,	O
mitotic	O
activity	O
,	O
and	O
invasive	O
growth	O
.	O
In	O
both	O
cases	O
,	O
immunohistochemical	O
staining	O
demonstrated	O
the	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
,	O
and	O
in	O
1	O
case	O
,	O
the	O
tumor	O
cells	O
carried	O
a	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Recently	O
,	O
disregulation	O
of	O
the	O
Wnt	O
/	O
beta-catenin	O
pathway	O
,	O
attributable	O
to	O
abnormalities	O
of	O
the	O
beta-catenin	O
gene	O
,	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
event	O
in	O
the	O
development	O
of	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
and	O
hepatoblastomas	B-malignancy-type
.	O
Our	O
report	O
may	O
be	O
the	O
first	O
to	O
describe	O
the	O
beta-catenin	O
abnormalities	O
in	O
childhood	O
liver	B-malignancy-type
cell	I-malignancy-type
adenoma	I-malignancy-type
.	O
These	O
findings	O
imply	O
that	O
abnormalities	O
of	O
beta-catenin	O
can	O
be	O
an	O
early	O
initiating	O
event	O
in	O
human	O
liver	O
tumorigenesis	O
.	O
Copyright	O
2002	O
,	O
Elsevier	O
Science	O
(	O
USA	O
)	O
.	O
All	O
rights	O
reserved	O
.	O
PMID	O
:	O
12203220	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Urol	O
1997	O
Mar;4(	O
2	O
)	O
:178	O
-	O
85	O
Screening	O
of	O
H-ras	O
gene	O
point	O
mutations	O
in	O
50	O
cases	O
of	O
bladder	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Saito	O
S,	O
Hata	O
M,	O
Fukuyama	O
R,	O
Sakai	O
K	O
,	O
Kudoh	O
J,	O
Tazaki	O
H	O
,	O
Shimizu	O
N.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Keio	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Mutation	O
converts	O
the	O
H-ras	O
gene	O
into	O
an	O
activated	O
oncogene	O
in	O
about	O
10	O
%	O
of	O
human	O
bladder	B-malignancy-type
cancers	I-malignancy-type
.	O
Codons	O
12	O
and	O
61	O
are	O
the	O
major	O
"	O
hot	O
spots	O
"	O
for	O
activation	O
.	O
A	O
simple	O
and	O
accurate	O
method	O
to	O
detect	O
point	O
mutations	O
in	O
these	O
codons	O
may	O
be	O
clinically	O
useful	O
for	O
early	O
diagnosis	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
Bladder	B-malignancy-type
cancer	I-malignancy-type
samples	O
from	O
50	O
patients	O
,	O
plus	O
10	O
samples	O
of	O
normal	O
bladder	O
mucosa	O
,	O
were	O
analyzed	O
for	O
possible	O
point	O
mutation	O
of	O
the	O
H-ras	O
gene	O
at	O
either	O
codon	O
12	O
or	O
codon	O
61	O
.	O
The	O
H-ras	O
gene	O
DNA	O
segments	O
that	O
include	O
these	O
2	O
codons	O
were	O
amplified	O
by	O
PCR	O
methods	O
,	O
then	O
the	O
possible	O
presence	O
of	O
a	O
point	O
mutation	O
was	O
evaluated	O
at	O
each	O
codon	O
by	O
susceptibility	O
of	O
the	O
respective	O
DNA	O
segments	O
to	O
digestion	O
with	O
the	O
restriction	O
enzyme	O
and	O
by	O
dot	O
blot	O
hybridization	O
assay	O
.	O
A	O
bladder	B-malignancy-type
cancer	I-malignancy-type
patient	O
who	O
had	O
an	O
H-ras	O
gene	O
mutation	O
was	O
examined	O
to	O
see	O
whether	O
the	O
mutation	O
was	O
also	O
detectable	O
in	O
the	O
cells	O
released	O
in	O
the	O
urine	O
.	O
RESULTS	O
:	O
Definite	O
or	O
possible	O
point	O
mutations	O
were	O
found	O
in	O
6	O
(	O
12	O
%	O
)	O
out	O
of	O
50	O
bladder	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
while	O
no	O
mutation	O
was	O
detected	O
in	O
normal	O
mucosa	O
.	O
A	O
point	O
mutation	O
could	O
also	O
be	O
detected	O
in	O
cells	O
isolated	O
from	O
the	O
patient	O
's	O
urine	O
sample	O
.	O
CONCLUSION	O
:	O
The	O
prevalence	O
of	O
point	O
mutations	O
at	O
codon	O
12	O
or	O
codon	O
61	O
of	O
the	O
H-ras	O
gene	O
found	O
in	O
this	O
study	O
was	O
similar	O
to	O
that	O
previously	O
estimated	O
for	O
human	O
bladder	B-malignancy-type
cancer	I-malignancy-type
by	O
DNA	O
transfection	O
assay	O
.	O
The	O
method	O
we	O
have	O
used	O
for	O
detecting	O
point	O
mutations	O
of	O
the	O
H-ras	O
gene	O
provides	O
a	O
simple	O
and	O
highly	O
accurate	O
way	O
to	O
detect	O
mutated	O
cancer	O
cells	O
even	O
in	O
the	O
urine	O
.	O
It	O
may	O
be	O
clinically	O
usable	O
for	O
early	O
diagnosis	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9179693	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2001	O
Sep;25(	O
9	O
)	O
:1121	O
-	O
33	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
,	O
intramural	B-malignancy-type
leiomyomas	I-malignancy-type
,	O
and	O
leiomyosarcomas	B-malignancy-type
in	O
the	O
rectum	O
and	O
anus	O
:	O
a	O
clinicopathologic	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
genetic	O
study	O
of	O
144	O
cases	O
.	O
Miettinen	O
M,	O
Furlong	O
M,	O
Sarlomo	O
-	O
Rikala	O
M,	O
Burke	O
A	O
,	O
Sobin	O
LH	O
,	O
Lasota	O
J.	O
Department	O
of	O
Soft	O
Tissue	O
Pathology	O
,	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
20306	O
-	O
6000	O
,	O
USA	O
.	O
miettinen@afip.osd	O
.mil	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
,	O
the	O
specific	O
KIT	O
-	O
positive	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
gastrointestinal	O
tract	O
,	O
have	O
been	O
sporadically	O
reported	O
in	O
the	O
rectum	O
,	O
but	O
there	O
are	O
few	O
clinicopathologic	O
series	O
.	O
In	O
this	O
study	O
we	O
analyzed	O
the	O
clinicopathologic	O
features	O
of	O
133	O
anorectal	B-malignancy-type
GISTs	I-malignancy-type
,	O
3	O
intramural	B-malignancy-type
leiomyomas	I-malignancy-type
(	O
LMs	B-malignancy-type
)	O
,	O
and	O
8	O
leiomyosarcomas	B-malignancy-type
(	O
LMSs	B-malignancy-type
)	O
from	O
the	O
files	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
and	O
the	O
Haartman	O
Institute	O
of	O
the	O
University	O
of	O
Helsinki	O
.	O
Ninety-six	O
GISTs	B-malignancy-type
were	O
documented	O
as	O
KIT	O
-	O
positive	O
and	O
three	O
additional	O
ones	O
as	O
CD34	O
-	O
positive	O
.	O
Thirty-four	O
tumors	O
were	O
included	O
by	O
their	O
histologic	O
similarity	O
to	O
KIT	O
-	O
or	O
CD34	O
-	O
positive	O
cases	O
.	O
GIST	B-malignancy-type
-	O
specific	O
c-kit	O
gene	O
mutations	O
,	O
mostly	O
in	O
exon	O
11	O
,	O
were	O
documented	O
in	O
18	O
of	O
29	O
cases	O
(	O
62	O
%	O
)	O
.	O
The	O
GISTs	B-malignancy-type
occurred	O
in	O
adults	O
with	O
the	O
age	O
range	O
of	O
17	O
-	O
90	O
years	O
(	O
median	O
60	O
years	O
)	O
with	O
a	O
significant	O
male	O
predominance	O
(	O
71	O
%	O
)	O
.	O
The	O
tumors	O
ranged	O
from	O
small	B-malignancy-type
asymptomatic	I-malignancy-type
intramural	I-malignancy-type
nodules	I-malignancy-type
to	O
large	O
masses	O
that	O
bulged	O
into	O
pelvis	O
causing	O
pain	O
,	O
rectal	O
bleeding	O
,	O
or	O
obstruction	O
.	O
They	O
were	O
mostly	O
highly	O
cellular	O
spindle	B-malignancy-type
cell	I-malignancy-type
tumors	I-malignancy-type
;	O
four	O
tumors	O
had	O
an	O
epithelioid	O
morphology	O
.	O
The	O
tumors	O
coexpressed	O
CD34	O
and	O
KIT	O
and	O
were	O
rarely	O
positive	O
for	O
smooth	O
muscle	O
actin	O
or	O
desmin	O
and	O
never	O
for	O
S-100	O
protein	O
.	O
Seventy	O
percent	O
of	O
patients	O
with	O
tumors	O
>	O
5	O
cm	O
with	O
more	O
than	O
5	O
mitoses	O
/	O
50	O
high	O
power	O
fields	O
(	O
HPF	O
)	O
(	O
n	O
=	O
31	O
)	O
died	O
of	O
disease	O
,	O
whereas	O
only	O
one	O
tumor	O
<	O
2	O
cm	O
with	O
<	O
5	O
mitoses	O
/	O
50	O
HPF	O
(	O
n	O
=	O
21	O
)	O
recurred	O
and	O
none	O
caused	O
death	O
.	O
Long	O
latency	O
was	O
common	O
between	O
primary	O
operation	O
and	O
recurrences	O
and	O
metastases	B-malignancy-type
;	O
either	O
one	O
occurred	O
in	O
60	O
of	O
111	O
patients	O
with	O
follow	O
-	O
up	O
(	O
54	O
%	O
)	O
.	O
Distant	O
metastases	B-malignancy-type
were	O
in	O
the	O
liver	B-malignancy-type
,	O
bones	O
,	O
and	O
lungs	O
.	O
Three	O
benign	O
actin	O
-	O
and	O
desmin	O
-	O
positive	O
and	O
KIT	O
-	O
negative	O
intramural	B-malignancy-type
LMs	I-malignancy-type
,	O
similar	O
to	O
those	O
seen	O
in	O
the	O
esophagus	O
,	O
were	O
identified	O
.	O
There	O
were	O
eight	O
LMSs	B-malignancy-type
,	O
six	O
of	O
which	O
formed	O
a	O
polypoid	B-malignancy-type
intraluminal	I-malignancy-type
mass	I-malignancy-type
and	O
were	O
actin	O
-	O
positive	O
and	O
KIT	O
-	O
negative	O
.	O
Despite	O
high	O
mitotic	O
counts	O
,	O
only	O
one	O
LMS	O
patient	O
died	O
of	O
disease	O
.	O
A	O
great	O
majority	O
of	O
rectal	B-malignancy-type
smooth	I-malignancy-type
muscle	I-malignancy-type
and	O
stromal	B-malignancy-type
tumors	I-malignancy-type
are	O
GISTs	B-malignancy-type
,	O
which	O
have	O
a	O
spectrum	O
from	O
minimal	O
indolent	B-malignancy-type
tumors	I-malignancy-type
to	O
overt	O
sarcomas	B-malignancy-type
.	O
Intramural	B-malignancy-type
LMs	I-malignancy-type
are	O
exceptional	O
,	O
and	O
true	O
LMSs	B-malignancy-type
are	O
rare	O
,	O
and	O
similar	O
to	O
colonic	O
ones	O
,	O
often	O
present	O
as	O
intraluminal	B-malignancy-type
polypoid	I-malignancy-type
masses	I-malignancy-type
that	O
appear	O
to	O
have	O
a	O
better	O
prognosis	O
than	O
GISTs	B-malignancy-type
with	O
similar	O
mitotic	O
rates	O
.	O
PMID	O
:	O
11688571	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2001	O
Aug	O
16;20(	O
36	O
)	O
:5025	O
-	O
32	O
Extensive	O
characterization	O
of	O
genetic	O
alterations	O
in	O
a	O
series	O
of	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Gayet	O
J,	O
Zhou	O
XP	O
,	O
Duval	O
A	O
,	O
Rolland	O
S,	O
Hoang	O
JM	O
,	O
Cottu	O
P	O
,	O
Hamelin	O
R.	O
INSERM	O
U434	O
-	O
CEPH	O
,	O
Paris	O
,	O
France	O
.	O
A	O
number	O
of	O
genetic	O
alterations	O
have	O
been	O
described	O
in	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
.	O
They	O
include	O
allelic	O
losses	O
on	O
specific	O
chromosomal	O
arms	O
,	O
mutations	O
of	O
oncogenes	O
,	O
tumor	O
suppressor	O
genes	O
and	O
mismatch	O
repair	O
genes	O
,	O
microsatellite	O
instability	O
in	O
coding	O
repeat	O
sequences	O
of	O
target	O
genes	O
and	O
methylation	O
defects	O
in	O
gene	O
promoters	O
.	O
Since	O
these	O
alterations	O
have	O
been	O
reported	O
by	O
different	O
groups	O
on	O
different	O
tumors	O
and	O
cell	O
lines	O
,	O
the	O
complete	O
repertoire	O
of	O
genetic	O
alterations	O
for	O
any	O
given	O
tumor	O
sample	O
remains	O
unknown	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
analysed	O
a	O
series	O
of	O
22	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
for	O
31	O
different	O
genetic	O
alterations	O
.	O
We	O
found	O
significant	O
correlations	O
between	O
mutational	O
profiles	O
in	O
these	O
colorectal	O
cell	O
lines	O
associated	O
with	O
differences	O
in	O
mismatch	O
repair	O
status	O
.	O
This	O
panel	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
is	O
representative	O
of	O
the	O
genetic	O
heterogeneity	O
occurring	O
in	O
sporadic	B-malignancy-type
colorectal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Our	O
results	O
may	O
prove	O
to	O
be	O
very	O
useful	O
for	O
understanding	O
the	O
different	O
biological	O
pathways	O
involved	O
in	O
the	O
development	O
of	O
colon	B-malignancy-type
cancer	I-malignancy-type
,	O
and	O
for	O
groups	O
studying	O
cellular	O
biology	O
and	O
pharmacology	O
on	O
the	O
same	O
cell	O
lines	O
.	O
PMID	O
:	O
11526487	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
2001	O
Jul	O
20	O
;85(	O
2	O
)	O
:235	O
-	O
41	O
Topographic	O
analysis	O
of	O
K	O
-	O
ras	O
mutations	O
in	O
histologically	O
normal	O
lung	O
tissues	O
and	O
tumours	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
Keohavong	O
P	O
,	O
Mady	O
HH	O
,	O
Gao	O
WM	O
,	O
Siegfried	O
JM	O
,	O
Luketich	O
JD	O
,	O
Melhem	O
MF.	O
Departments	O
of	O
Environmental	O
and	O
Occupational	O
Health	O
,	O
University	O
of	O
Pittsburgh	O
,	O
Pittsburgh	O
,	O
PA	O
15213	O
,	O
USA	O
.	O
Mutations	O
in	O
the	O
K	O
-	O
ras	O
gene	O
are	O
very	O
common	O
in	O
lung	B-malignancy-type
tumours	I-malignancy-type
and	O
are	O
implicated	O
in	O
the	O
development	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
the	O
timing	O
of	O
their	O
occurrence	O
remains	O
poorly	O
understood	O
.	O
We	O
investigated	O
K	O
-	O
ras	O
mutations	O
in	O
cell	O
samples	O
microdissected	O
by	O
laser	O
capture	O
microscopy	O
at	O
multiple	O
sites	O
from	O
lung	O
tissue	O
sections	O
representing	O
tumour	O
tissue	O
and	O
matched	O
histologically	O
normal	O
tissue	O
obtained	O
from	O
48	O
lung	B-malignancy-type
cancer	I-malignancy-type
patients	O
.	O
K	O
-	O
ras	O
mutations	O
were	O
detected	O
in	O
cell	O
samples	O
from	O
10	O
of	O
38	O
(	O
26.3	O
%	O
)	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
in	O
none	O
of	O
the	O
histologically	O
normal	O
or	O
tumour	O
cell	O
samples	O
taken	O
from	O
10	O
lung	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Of	O
the	O
K	O
-	O
ras	O
mutation	O
-	O
positive	O
adenocarcinomas	B-malignancy-type
,	O
in	O
4	O
cases	O
a	O
mutation	O
was	O
found	O
in	O
only	O
the	O
tumour	O
tissue	O
,	O
in	O
1	O
case	O
a	O
mutation	O
was	O
found	O
only	O
in	O
the	O
histologically	O
normal	O
tissue	O
,	O
and	O
in	O
5	O
cases	O
mutations	O
were	O
found	O
in	O
both	O
the	O
tumour	O
tissue	O
and	O
histologically	O
normal	O
tissue	O
.	O
Among	O
these	O
5	O
cases	O
,	O
2	O
had	O
identical	O
mutations	O
in	O
both	O
the	O
tumour	O
tissue	O
and	O
histologically	O
normal	O
tissue	O
,	O
2	O
had	O
1	O
mutation	O
in	O
the	O
tumour	O
tissue	O
and	O
2	O
mutations	O
in	O
the	O
histologically	O
normal	O
tissue	O
,	O
1	O
of	O
which	O
was	O
identical	O
to	O
the	O
mutation	O
found	O
in	O
the	O
tumour	O
,	O
and	O
1	O
case	O
had	O
2	O
codon	O
12	O
mutations	O
in	O
tumour	O
tissue	O
and	O
2	O
mutations	O
,	O
in	O
codons	O
9	O
and	O
11	O
,	O
in	O
histologically	O
normal	O
tissue	O
.	O
These	O
results	O
showed	O
that	O
K	O
-	O
ras	O
mutations	O
are	O
frequent	O
in	O
histologically	O
normal	O
cells	O
taken	O
from	O
outside	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
suggest	O
that	O
some	O
of	O
these	O
mutations	O
may	O
represent	O
early	O
events	O
which	O
could	O
pave	O
the	O
way	O
of	O
lung	O
carcinogenesis	O
.	O
PMID	O
:	O
11461083	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Cancer	O
2001	O
Mar	O
20;95(	O
2	O
)	O
:108	O
-	O
13	O
Altered	O
expression	O
and	O
mutation	O
of	O
beta-catenin	O
gene	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
and	O
cell	O
lines	O
.	O
Woo	O
DK	O
,	O
Kim	O
HS	O
,	O
Lee	O
HS	O
,	O
Kang	O
YH	O
,	O
Yang	O
HK	O
,	O
Kim	O
WH.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
beta-catenin	O
serves	O
not	O
only	O
as	O
a	O
structural	O
component	O
of	O
the	O
E-cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
system	O
,	O
but	O
also	O
as	O
a	O
signaling	O
molecule	O
of	O
the	O
Wnt	O
/	O
wingless	O
pathway	O
.	O
Deregulated	O
expression	O
of	O
beta-catenin	O
and	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
human	O
malignancies	O
.	O
To	O
determine	O
the	O
role	O
of	O
beta-catenin	O
defects	O
in	O
stomach	B-malignancy-type
cancer	I-malignancy-type
,	O
we	O
investigated	O
beta-catenin	O
exon	O
3	O
mutations	O
and	O
altered	O
protein	O
expression	O
in	O
77	O
primary	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
and	O
11	O
cell	O
lines	O
.	O
In	O
addition	O
,	O
the	O
immunohistochemical	O
expression	O
pattern	O
of	O
beta-catenin	O
in	O
303	O
consecutive	O
gastric	B-malignancy-type
cancers	I-malignancy-type
was	O
determined	O
and	O
their	O
relationships	O
with	O
clinicopathologic	O
features	O
and	O
patient	O
outcome	O
were	O
investigated	O
.	O
This	O
study	O
revealed	O
5	O
%	O
(	O
4	O
of	O
77	O
)	O
tumors	O
and	O
27	O
%	O
(	O
3	O
of	O
11	O
)	O
cell	O
lines	O
with	O
beta-catenin	O
gene	O
alteration	O
,	O
6	O
missense	O
mutations	O
,	O
and	O
1	O
interstitial	O
deletion	O
.	O
These	O
genetic	O
changes	O
were	O
shown	O
to	O
correlate	O
closely	O
with	O
nuclear	O
localization	O
of	O
the	O
protein	O
(	O
p	O
=	O
0.001	O
)	O
.	O
In	O
an	O
immunohistochemical	O
analysis	O
,	O
abnormal	O
expressions	O
of	O
beta-catenin	O
,	O
such	O
as	O
nuclear	O
accumulation	O
and	O
loss	O
of	O
membranous	O
distribution	O
,	O
were	O
detected	O
in	O
27	O
%	O
(	O
81	O
of	O
303	O
)	O
of	O
tumors	O
overall	O
.	O
These	O
altered	O
beta-catenin	O
expressions	O
were	O
more	O
commonly	O
observed	O
in	O
37	O
%	O
(	O
58	O
of	O
158	O
)	O
diffuse	O
type	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
(	O
p	O
<	O
0.001	O
)	O
.	O
Loss	O
of	O
membranous	O
beta-catenin	O
staining	O
was	O
associated	O
with	O
poor	O
survival	O
(	O
p	O
=	O
0.045	O
)	O
.	O
In	O
conclusion	O
,	O
our	O
results	O
demonstrate	O
that	O
beta-catenin	O
mutations	O
are	O
common	O
in	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
but	O
occur	O
infrequently	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
tissues	O
.	O
These	O
mutations	O
are	O
one	O
of	O
the	O
causes	O
of	O
the	O
nuclear	O
accumulation	O
of	O
beta-catenin	O
.	O
Frequent	O
abnormalities	O
of	O
beta-catenin	O
expression	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
support	O
the	O
idea	O
that	O
both	O
structural	O
and	O
signaling	O
functions	O
of	O
the	O
protein	O
play	O
a	O
critical	O
role	O
in	O
gastric	O
carcinogenesis	O
.	O
Copyright	O
2001	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11241321	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Pathol	O
2001	O
Feb;193(	O
2	O
)	O
:193	O
-	O
9	O
K-ras	O
mutations	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
with	O
microsatellite	O
instability	O
.	O
Lagarda	O
H	O
,	O
Catasus	O
L,	O
Arguelles	O
R,	O
Matias	O
-	O
Guiu	O
X	O
,	O
Prat	O
J.	O
Department	O
of	O
Pathology	O
,	O
Hospital	O
Santa	O
Creu	O
i	O
Sant	O
Pau	O
,	O
Autonomous	O
University	O
of	O
Barcelona	O
,	O
Spain	O
.	O
K-ras	O
mutations	O
are	O
known	O
to	O
occur	O
in	O
hyperplasias	B-malignancy-type
and	O
carcinomas	B-malignancy-type
of	O
the	O
endometrium	O
.	O
No	O
clear	O
correlation	O
has	O
been	O
found	O
yet	O
between	O
K-ras	O
mutations	O
and	O
microsatellite	O
instability	O
(	O
MI	O
)	O
in	O
these	O
lesions	B-malignancy-type
.	O
Fifty-eight	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
(	O
ECs	B-malignancy-type
)	O
and	O
22	O
endometrial	B-malignancy-type
hyperplasias	I-malignancy-type
(	O
EHs	B-malignancy-type
)	O
were	O
analysed	O
for	O
K-ras	O
mutation	O
by	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
,	O
restriction	O
analysis	O
,	O
and	O
DNA	O
sequencing	O
.	O
MI	O
status	O
had	O
been	O
established	O
previously	O
at	O
five	O
dinucleotide	O
loci	O
and	O
was	O
reconfirmed	O
with	O
markers	O
BAT-25	O
and	O
BAT-26	O
by	O
SSCP	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
11	O
ECs	B-malignancy-type
(	O
18.9	O
%	O
)	O
.	O
All	O
11	O
tumours	O
were	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
K-ras	O
mutations	O
were	O
more	O
frequent	O
in	O
MI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
(	O
6	O
/	O
14	O
,	O
42.8	O
%	O
)	O
than	O
in	O
MI	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
tumours	I-malignancy-type
(	O
5	O
/	O
44	O
,	O
11.3	O
%	O
)	O
(	O
p	O
=	O
0.017	O
)	O
.	O
Methylation	O
-	O
related	O
transitions	O
were	O
detected	O
in	O
five	O
of	O
the	O
six	O
MI	B-malignancy-type
-	I-malignancy-type
positive	I-malignancy-type
tumours	I-malignancy-type
but	O
in	O
only	O
one	O
of	O
the	O
five	O
MI	B-malignancy-type
-	I-malignancy-type
negative	I-malignancy-type
carcinomas	I-malignancy-type
.	O
K-ras	O
mutation	O
was	O
identified	O
in	O
only	O
one	O
atypical	B-malignancy-type
EH	I-malignancy-type
(	O
1	O
/	O
22	O
,	O
4.5	O
%	O
)	O
;	O
in	O
this	O
case	O
,	O
the	O
EH	B-malignancy-type
co	O
-	O
existed	O
with	O
EC	B-malignancy-type
and	O
both	O
lesions	B-malignancy-type
exhibited	O
MI	O
.	O
The	O
results	O
support	O
a	O
close	O
relationship	O
between	O
K-ras	O
mutations	O
and	O
the	O
phenomenon	O
of	O
MI	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
frequent	O
occurrence	O
of	O
methylation	O
-	O
related	O
transitions	O
in	O
these	O
tumours	O
may	O
indicate	O
a	O
cause	O
-	O
effect	O
relationship	O
with	O
the	O
altered	O
methylation	O
status	O
which	O
has	O
been	O
described	O
in	O
association	O
with	O
MI	O
.	O
PMID	O
:	O
11180166	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Oncology	O
2001;60(	O
1	O
)	O
:81	O
-	O
7	O
Genetic	O
changes	O
in	O
contralateral	B-malignancy-type
bronchioloalveolar	I-malignancy-type
carcinomas	I-malignancy-type
of	O
the	O
lung	O
.	O
Shin	O
SW	O
,	O
Breathnach	O
OS	O
,	O
Linnoila	O
RI	O
,	O
Williams	O
J,	O
Gillespie	O
JW	O
,	O
Kelley	O
MJ	O
,	O
Johnson	O
BE.	O
Medicine	O
Branch	O
,	O
Division	O
of	O
Clinical	O
Sciences	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
Md.	O
,	O
USA	O
.	O
OBJECTIVE	O
:	O
The	O
pattern	O
of	O
metastases	B-malignancy-type
and	O
recurrence	O
of	O
bronchioloalveolar	B-malignancy-type
carcinoma	I-malignancy-type
(	O
BAC	B-malignancy-type
)	O
differs	O
from	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
,	O
occurring	O
more	O
frequently	O
within	O
the	O
lung	O
without	O
extrapulmonary	O
involvement	O
.	O
Analyses	O
of	O
genetic	O
differences	O
of	O
contralateral	B-malignancy-type
BACs	I-malignancy-type
may	O
help	O
to	O
explain	O
these	O
clinical	O
differences	O
.	O
METHODS	O
:	O
We	O
compared	O
paired	O
tumors	O
from	O
5	O
patients	O
with	O
contralateral	B-malignancy-type
metachronous	I-malignancy-type
BACs	I-malignancy-type
for	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
on	O
6	O
chromosomal	O
arms	O
(	O
2q	O
,	O
3p	O
,	O
5q	O
,	O
9p	O
,	O
13q	O
and	O
17p	O
)	O
and	O
mutational	O
analysis	O
of	O
p53	O
and	O
K-ras	O
.	O
RESULTS	O
:	O
Two	O
patients	O
,	O
patients	O
1	O
and	O
2	O
,	O
had	O
discordant	O
patterns	O
of	O
LOH	O
on	O
2	O
and	O
3	O
of	O
the	O
chromosome	O
arms	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
patient	O
2	O
had	O
a	O
detectable	O
K-ras	O
mutation	O
in	O
his	O
initial	O
tumor	O
but	O
not	O
in	O
his	O
second	O
.	O
These	O
results	O
suggest	O
that	O
in	O
patients	O
1	O
and	O
2	O
,	O
the	O
contralateral	B-malignancy-type
tumors	I-malignancy-type
were	O
clonally	O
unrelated	O
.	O
Patient	O
3	O
had	O
no	O
mutations	O
in	O
the	O
K-ras	O
or	O
p53	O
gene	O
and	O
no	O
LOH	O
on	O
any	O
of	O
the	O
5	O
informative	O
chromosome	O
arms	O
.	O
Patient	O
4	O
had	O
LOH	O
of	O
9p	O
and	O
mutated	O
K-ras	O
in	O
both	O
the	O
first	O
and	O
the	O
second	O
tumor	O
,	O
with	O
a	O
mutation	O
in	O
the	O
p53	O
gene	O
in	O
the	O
first	O
but	O
not	O
in	O
the	O
second	O
tumor	O
.	O
Patient	O
5	O
had	O
LOH	O
of	O
17p	O
and	O
the	O
same	O
p53	O
mutations	O
in	O
both	O
the	O
first	O
and	O
the	O
second	O
tumor	O
,	O
with	O
a	O
mutation	O
of	O
K-ras	O
in	O
the	O
first	O
tumor	O
but	O
not	O
in	O
the	O
second	O
.	O
CONCLUSIONS	O
:	O
The	O
preponderance	O
of	O
evidence	O
suggests	O
that	O
in	O
patients	O
3	O
,	O
4	O
and	O
5	O
,	O
the	O
paired	O
tumors	O
were	O
clonally	O
related	O
.	O
The	O
different	O
patterns	O
of	O
LOH	O
and	O
mutations	O
in	O
clinically	O
similar	O
contralateral	B-malignancy-type
metachronous	I-malignancy-type
BACs	I-malignancy-type
provide	O
evidence	O
of	O
genetic	O
heterogeneity	O
in	O
the	O
tumors	O
of	O
this	O
patient	O
group	O
.	O
PMID	O
:	O
11150913	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Surg	O
Pathol	O
2000	O
Nov;24(	O
11	O
)	O
:1501	O
-	O
10	O
Carcinoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
extrahepatic	O
bile	O
ducts	O
:	O
a	O
study	O
of	O
seven	O
cases	O
.	O
Maitra	O
A	O
,	O
Krueger	O
JE	O
,	O
Tascilar	O
M,	O
Offerhaus	O
GJ	O
,	O
Angeles	O
-	O
Angeles	O
A	O
,	O
Klimstra	O
DS	O
,	O
Hruban	O
RH	O
,	O
Albores	O
-	O
Saavedra	O
J.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75235	O
,	O
USA	O
.	O
The	O
authors	O
report	O
seven	O
patients	O
with	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
extrahepatic	O
bile	O
ducts	O
(	O
EHBDs	B-malignancy-type
)	O
.	O
All	O
patients	O
were	O
women	O
,	O
with	O
an	O
average	O
age	O
at	O
diagnosis	O
of	O
49.8	O
years	O
(	O
range	O
,	O
37	O
-	O
67	O
yrs	O
)	O
.	O
The	O
most	O
common	O
presenting	O
symptom	O
was	O
painless	O
jaundice	O
with	O
or	O
without	O
pruritus	O
.	O
Although	O
one	O
patient	O
had	O
peptic	O
ulcer	O
disease	O
before	O
the	O
onset	O
of	O
obstructive	O
jaundice	O
,	O
none	O
had	O
systemic	O
endocrine	O
manifestations	O
.	O
These	O
neoplasms	B-malignancy-type
were	O
most	O
often	O
located	O
in	O
the	O
common	O
bile	O
duct	O
.	O
Grossly	O
,	O
the	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
were	O
usually	O
nodular	O
and	O
poorly	O
demarcated	O
,	O
and	O
ranged	O
from	O
1.1	O
to	O
2.7	O
cm	O
in	O
size	O
.	O
Only	O
one	O
of	O
the	O
neoplasms	B-malignancy-type
was	O
polypoid	O
.	O
Microscopically	O
,	O
the	O
tumors	O
had	O
a	O
trabecular	O
or	O
nesting	O
pattern	O
with	O
occasional	O
tubule	O
formation	O
,	O
and	O
were	O
composed	O
of	O
relatively	O
small	O
cells	O
with	O
granular	O
chromatin	O
.	O
All	O
of	O
the	O
neoplasms	B-malignancy-type
expressed	O
chromogranin	O
and	O
two	O
expressed	O
synaptophysin	O
.	O
Three	O
expressed	O
serotonin	O
and	O
two	O
of	O
the	O
three	O
were	O
also	O
immunoreactive	O
for	O
pancreatic	O
polypeptide	O
or	O
somatostatin	O
.	O
Two	O
tumors	O
were	O
focally	O
positive	O
for	O
gastrin	O
and	O
one	O
of	O
these	O
two	O
tumors	O
was	O
also	O
positive	O
for	O
serotonin	O
and	O
pancreatic	O
polypeptide	O
.	O
All	O
seven	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
showed	O
no	O
immunoreactivity	O
for	O
p53	O
,	O
and	O
assays	O
for	O
p53	O
loss	O
of	O
heterozygosity	O
analysis	O
were	O
negative	O
in	O
two	O
,	O
suggesting	O
that	O
p53	O
mutations	O
do	O
not	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
EHBD	B-malignancy-type
carcinoids	I-malignancy-type
.	O
A	O
mutation	O
in	O
codon	O
12	O
of	O
K-ras	O
was	O
found	O
in	O
one	O
carcinoid	B-malignancy-type
tumor	I-malignancy-type
whereas	O
two	O
of	O
two	O
showed	O
immunoreactivity	O
for	O
Dpc4	O
protein	O
.	O
In	O
view	O
of	O
the	O
small	O
number	O
of	O
carcinoids	B-malignancy-type
studied	O
,	O
the	O
importance	O
of	O
these	O
findings	O
in	O
the	O
pathogenesis	O
of	O
these	O
tumors	O
is	O
unclear	O
.	O
Ultrastructural	O
examination	O
of	O
three	O
of	O
the	O
tumors	O
revealed	O
numerous	O
membrane	O
-	O
bound	O
,	O
round	O
neurosecretory	O
granules	O
.	O
Clinically	O
,	O
these	O
lesions	B-malignancy-type
had	O
an	O
indolent	O
course	O
.	O
Even	O
in	O
the	O
presence	O
of	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
(	O
noted	O
in	O
two	O
patients	O
)	O
,	O
all	O
of	O
the	O
patients	O
remained	O
disease	O
free	O
2	O
to	O
11	O
years	O
(	O
average	O
follow	O
up	O
,	O
6.6	O
yrs	O
)	O
after	O
segmental	O
resection	O
or	O
pancreaticoduodenectomy	O
(	O
Whipple	O
's	O
procedure	O
)	O
.	O
Because	O
carcinoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
EHBD	O
are	O
of	O
low	O
malignant	O
potential	O
,	O
they	O
should	O
be	O
separated	O
from	O
the	O
more	O
common	O
adenocarcinomas	B-malignancy-type
in	O
this	O
location	O
.	O
PMID	O
:	O
11075851	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2000	O
Mar;91(	O
3	O
)	O
:280	O
-	O
6	O
Microsatellite	O
instability	O
and	O
k-ras	O
,	O
p53	O
mutations	O
in	O
thyroid	B-malignancy-type
lymphoma	I-malignancy-type
.	O
Takakuwa	O
T	O
,	O
Hongyo	O
T	O
,	O
Syaifudin	O
M,	O
Kanno	O
H	O
,	O
Matsuzuka	O
F	O
,	O
Narabayashi	O
I	O
,	O
Nomura	O
T	O
,	O
Aozasa	O
K.	O
Departments	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Osaka	O
565	O
-0871	O
,	O
Japan	O
.	O
Patho	O
-	O
epidemiological	O
studies	O
showed	O
that	O
thyroid	B-malignancy-type
lymphoma	I-malignancy-type
(	O
TL	B-malignancy-type
)	O
arises	O
in	O
inflammatory	O
lesions	O
of	O
chronic	O
lymphocytic	O
thyroiditis	O
(	O
CLTH	O
)	O
.	O
Replication	O
error	O
(	O
RER	O
)	O
is	O
found	O
in	O
inflammatory	O
lesions	O
and	O
associated	O
cancer	O
,	O
suggesting	O
that	O
chronic	O
inflammation	O
could	O
be	O
a	O
risk	O
factor	O
for	O
neoplastic	O
development	O
through	O
causing	O
RER	O
.	O
To	O
clarify	O
whether	O
RER	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
TL	O
,	O
we	O
examined	O
the	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
in	O
9	O
cases	O
with	O
CLTH	O
and	O
19	O
with	O
TL	O
,	O
including	O
10	O
diffuse	B-malignancy-type
large	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
(	O
DLBL	B-malignancy-type
)	O
,	O
4	O
follicle	B-malignancy-type
center	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
,	O
3	O
marginal	B-malignancy-type
zone	I-malignancy-type
B-cell	I-malignancy-type
lymphoma	I-malignancy-type
of	I-malignancy-type
extranodal	I-malignancy-type
(	O
MALT	B-malignancy-type
)	O
type	B-malignancy-type
,	O
and	O
2	O
lymphoplasmacytic	B-malignancy-type
type	I-malignancy-type
.	O
Sixteen	O
distinct	O
microsatellite	O
repeats	O
were	O
analyzed	O
.	O
Mutations	O
of	O
p53	O
and	O
k-ras	O
genes	O
were	O
also	O
examined	O
.	O
When	O
alterations	O
at	O
2	O
or	O
more	O
microsatellite	O
loci	O
were	O
judged	O
as	O
positive	O
,	O
only	O
5	O
DLBL	B-malignancy-type
cases	O
exhibited	O
MSI	O
.	O
The	O
frequency	O
of	O
MSI	O
in	O
DLBL	B-malignancy-type
was	O
significantly	O
higher	O
than	O
that	O
in	O
other	O
types	O
of	O
TL	O
and	O
CLTH	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Four	O
of	O
19	O
cases	O
(	O
21.1	O
%	O
)	O
showed	O
point	O
mutation	O
of	O
the	O
k-ras	O
gene	O
.	O
The	O
k-ras	O
mutations	O
occurred	O
in	O
the	O
cases	O
with	O
DLBL	B-malignancy-type
with	O
RER	O
,	O
and	O
four	O
of	O
five	O
cases	O
with	O
RER	O
had	O
a	O
k-ras	O
mutation	O
,	O
indicating	O
a	O
close	O
association	O
between	O
RER	O
and	O
k-ras	O
mutation	O
.	O
p53	O
mutations	O
were	O
not	O
found	O
in	O
the	O
CLTH	O
.	O
Two	O
of	O
19	O
TL	O
cases	O
showed	O
mutations	O
of	O
p53	O
gene	O
.	O
There	O
was	O
no	O
significant	O
association	O
between	O
RER	O
and	O
p53	O
mutation	O
.	O
These	O
findings	O
indicate	O
that	O
genomic	O
instability	O
contributes	O
to	O
the	O
progression	O
of	O
TL	B-malignancy-type
from	O
low	O
grade	O
to	O
high	O
grade	O
,	O
but	O
not	O
to	O
the	O
development	O
of	O
low	O
grade	O
lymphoma	B-malignancy-type
in	O
CLTH	O
lesions	O
.	O
PMID	O
:	O
10760686	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
2000	O
Jan	O
15;95(	O
2	O
)	O
:646	O
-	O
50	O
N-RAS	O
gene	O
mutation	O
in	O
patients	O
with	O
aplastic	O
anemia	O
and	O
aplastic	O
anemia	O
/	O
paroxysmal	O
nocturnal	O
hemoglobinuria	O
during	O
evolution	O
to	O
clonal	O
disease	O
.	O
Mortazavi	O
Y	O
,	O
Tooze	O
JA	O
,	O
Gordon	O
-	O
Smith	O
EC	O
,	O
Rutherford	O
TR.	O
Department	O
of	O
Haematology	O
,	O
St.	O
George	O
's	O
Hospital	O
Medical	O
School	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
Long	O
-	O
term	O
survivors	O
of	O
aplastic	O
anemia	O
(	O
AA	O
)	O
have	O
a	O
high	O
incidence	O
of	O
clonal	O
disorders	O
,	O
in	O
particular	O
paroxysmal	O
nocturnal	O
hemoglobinuria	O
(	O
PNH	O
)	O
,	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
,	O
and	O
acute	B-malignancy-type
nonlymphocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
To	O
investigate	O
the	O
potential	O
involvement	O
of	O
N-RAS	O
gene	O
mutations	O
in	O
the	O
predisposition	O
to	O
leukemic	O
evolution	O
,	O
a	O
subset	O
of	O
patients	O
at	O
potentially	O
increased	O
risk	O
for	O
clonal	O
disease	O
was	O
selected	O
based	O
on	O
evidence	O
of	O
existing	O
clonal	O
evolution	O
.	O
Nine	O
patients	O
showed	O
a	O
monoclonal	O
pattern	O
of	O
X-chromosome	O
inactivation	O
,	O
18	O
demonstrated	O
a	O
PNH	O
clone	O
,	O
and	O
in	O
3	O
MDS	B-malignancy-type
developed	O
during	O
the	O
course	O
of	O
this	O
study	O
.	O
No	O
mutations	O
were	O
detected	O
during	O
the	O
aplastic	O
phase	O
of	O
disease	O
;	O
2	O
of	O
3	O
patients	O
with	O
MDS	B-malignancy-type
after	O
AA	O
also	O
showed	O
no	O
mutations	O
.	O
However	O
,	O
in	O
1	O
patient	O
in	O
whom	O
the	O
disease	O
transformed	O
from	O
AA	O
/	O
PNH	O
to	O
MDS	B-malignancy-type
,	O
a	O
mutation	O
of	O
GGT	O
-->	O
GAT	O
at	O
N-RAS	O
codon	O
13	O
became	O
detectable	O
,	O
whereas	O
the	O
PNH	O
mutation	O
disappeared	O
.	O
The	O
authors	O
conclude	O
that	O
N-RAS	O
mutations	O
are	O
not	O
an	O
early	O
event	O
preceding	O
transformation	O
of	O
AA	O
or	O
AA	O
/	O
PNH	O
to	O
leukemia	B-malignancy-type
.	O
In	O
a	O
subset	O
of	O
patients	O
,	O
RAS	O
mutations	O
may	O
occur	O
at	O
the	O
time	O
of	O
evolution	O
to	O
MDS	B-malignancy-type
,	O
but	O
preexisting	O
RAS	O
mutations	O
do	O
not	O
explain	O
the	O
propensity	O
of	O
AA	O
to	O
leukemogenesis	O
.	O
Although	O
PNH	O
is	O
also	O
associated	O
with	O
leukemia	B-malignancy-type
,	O
this	O
may	O
arise	O
in	O
the	O
non	O
-	O
PNH	O
cells	O
,	O
indicating	O
that	O
PIG-A	O
gene	O
mutation	O
is	O
not	O
per	O
se	O
oncogenic	O
.	O
(	O
Blood.	O
2000	O
;	O
95	O
:	O
646	O
-	O
650	O
)	O
PMID	O
:	O
10627475	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
2000	O
Feb;27(	O
2	O
)	O
:202	O
-	O
8	O
Somatic	O
mutations	O
of	O
the	O
APC	O
,	O
KRAS	O
,	O
and	O
TP53	O
genes	O
in	O
nonpolypoid	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
.	O
van	O
Wyk	O
R,	O
Slezak	O
P	O
,	O
Hayes	O
VM	O
,	O
Buys	O
CH	O
,	O
Kotze	O
MJ	O
,	O
de	O
Jong	O
G	O
,	O
Rubio	O
C	O
,	O
Dolk	O
A	O
,	O
Jaramillo	O
E	O
,	O
Koizumi	O
K	O
,	O
Grobbelaar	O
JJ.	O
Division	O
of	O
Human	O
Genetics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Stellenbosch	O
,	O
South	O
Africa	O
.	O
Colorectal	B-malignancy-type
adenomas	I-malignancy-type
are	O
macroscopically	O
visible	O
morphological	O
changes	O
of	O
the	O
mucosa	O
that	O
can	O
develop	O
focal	B-malignancy-type
carcinoma	I-malignancy-type
in	O
the	O
absence	O
of	O
surgical	O
intervention	O
.	O
The	O
successive	O
molecular	O
changes	O
proposed	O
to	O
occur	O
at	O
different	O
stages	O
in	O
the	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
were	O
primarily	O
based	O
on	O
DNA	O
studies	O
of	O
exophytic	B-malignancy-type
,	I-malignancy-type
polypoid	I-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
adenomas	I-malignancy-type
.	O
Not	O
all	O
colorectal	B-malignancy-type
lesions	I-malignancy-type
,	O
however	O
,	O
display	O
an	O
exophytic	O
phenotype	O
and	O
a	O
presumed	O
distinct	O
colorectal	B-malignancy-type
neoplasm	I-malignancy-type
,	O
the	O
nonpolypoid	B-malignancy-type
adenoma	I-malignancy-type
,	O
was	O
subsequently	O
described	O
as	O
a	O
precursor	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
The	O
low	O
incidence	O
of	O
KRAS	O
mutations	O
in	O
nonpolypoid	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
reported	O
previously	O
suggested	O
a	O
different	O
genetic	O
basis	O
for	O
the	O
transformation	O
process	O
in	O
these	O
lesions	O
.	O
We	O
have	O
pursued	O
the	O
identification	O
of	O
genetic	O
changes	O
in	O
benign	B-malignancy-type
sporadic	I-malignancy-type
nonpolypoid	I-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
in	O
a	O
selected	O
Swedish	O
patient	O
group	O
with	O
no	O
family	O
history	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Mutation	O
screening	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
,	O
KRAS	O
,	O
and	O
TP53	O
genes	O
was	O
conducted	O
using	O
the	O
protein	O
truncation	O
test	O
,	O
heteroduplex	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
on	O
PCR	O
-	O
amplified	O
fragments	O
.	O
Fourteen	O
mutations	O
in	O
the	O
APC	O
gene	O
were	O
characterized	O
in	O
10	O
/	O
20	O
samples	O
.	O
Mutations	O
in	O
the	O
KRAS	O
and	O
TP53	O
genes	O
were	O
identified	O
in	O
3	O
/	O
57	O
and	O
4	O
/	O
51	O
adenomas	B-malignancy-type
,	O
respectively	O
.	O
The	O
mutation	O
frequencies	O
and	O
distribution	O
of	O
mutations	O
in	O
APC	O
correlate	O
with	O
published	O
data	O
on	O
exophytic	B-malignancy-type
adenomas	I-malignancy-type
.	O
The	O
low	O
mutation	O
frequency	O
of	O
the	O
TP53	O
gene	O
is	O
consistent	O
with	O
the	O
benign	O
nature	O
of	O
the	O
research	O
material	O
.	O
KRAS	O
activation	O
(	O
an	O
early	O
event	O
in	O
polypoid	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
)	O
apparently	O
does	O
not	O
play	O
a	O
significant	O
role	O
in	O
nonpolypoid	B-malignancy-type
adenoma	I-malignancy-type
development	O
but	O
may	O
result	O
in	O
the	O
development	O
of	O
a	O
polypoid	O
configuration	O
.	O
Genes	O
Chromosomes	O
Cancer	O
27	O
:	O
202	O
-	O
208	O
,	O
2000	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
10612810	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cell	O
Growth	O
Differ	O
1999	O
Jun;10(	O
6)	O
:369	O
-	O
76	O
Beta	O
-	O
and	O
gamma	O
-	O
catenin	O
mutations	O
,	O
but	O
not	O
E-cadherin	O
inactivation	O
,	O
underlie	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancer	O
factor	O
transcriptional	O
deregulation	O
in	O
gastric	O
and	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Caca	O
K	O
,	O
Kolligs	O
FT	O
,	O
Ji	O
X	O
,	O
Hayes	O
M,	O
Qian	O
J,	O
Yahanda	O
A	O
,	O
Rimm	O
DL	O
,	O
Costa	O
J,	O
Fearon	O
ER	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
The	O
Cancer	O
Center	O
,	O
University	O
of	O
Michigan	O
Medical	O
School	O
,	O
Ann	O
Arbor	O
48109	O
,	O
USA	O
.	O
Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
are	O
present	O
in	O
>	O
70	O
%	O
of	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
APC	O
protein	O
binds	O
to	O
beta-catenin	O
(	O
beta-cat	O
)	O
,	O
a	O
protein	O
first	O
identified	O
because	O
of	O
its	O
role	O
in	O
E-cadherin	O
(	O
E-cad	O
)	O
cell	O
adhesion	O
.	O
In	O
some	O
colon	B-malignancy-type
cancers	I-malignancy-type
lacking	O
APC	O
defects	O
,	O
mutations	O
in	O
presumptive	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
sites	O
near	O
the	O
beta-cat	O
NH2	O
terminus	O
appear	O
to	O
render	O
beta-cat	O
resistant	O
to	O
regulation	O
by	O
APC	O
and	O
glycogen	O
synthase	O
kinase	O
3beta	O
.	O
In	O
cells	O
with	O
APC	O
or	O
beta-cat	O
defects	O
,	O
beta-cat	O
is	O
stabilized	O
and	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
activates	O
T-cell	O
factor	O
(	O
Tcf	O
)	O
/	O
lymphoid	O
enhancer	O
factor	O
(	O
Lef	O
)	O
transcription	O
factors	O
.	O
To	O
further	O
explore	O
the	O
role	O
of	O
APC	O
,	O
beta-cat	O
,	O
Tcf	O
,	O
and	O
E-cad	O
defects	O
in	O
gastrointestinal	B-malignancy-type
cancers	I-malignancy-type
,	O
we	O
assessed	O
gastric	B-malignancy-type
and	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
for	O
constitutive	O
Tcf	O
transcriptional	O
activity	O
(	O
CTTA	O
)	O
.	O
Two	O
of	O
four	O
gastric	B-malignancy-type
and	O
two	O
of	O
eight	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
lines	O
showed	O
CTTA	O
.	O
One	O
gastric	B-malignancy-type
and	O
one	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
had	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
phosphorylation	O
sites	O
of	O
beta-cat	O
.	O
The	O
other	O
gastric	B-malignancy-type
cancer	I-malignancy-type
with	O
CTTA	O
had	O
a	O
missense	O
mutation	O
at	O
serine	O
28	O
of	O
gamma-cat	O
,	O
a	O
potential	O
phosphorylation	O
site	O
in	O
this	O
beta-cat	O
-	O
related	O
protein	O
.	O
Although	O
E-cad	O
is	O
an	O
important	O
binding	O
partner	O
for	O
beta-cat	O
and	O
gamma-cat	O
,	O
E-cad	O
inactivation	O
did	O
not	O
result	O
in	O
CTTA	O
.	O
The	O
beta-cat	O
and	O
gamma-cat	O
mutant	O
proteins	O
identified	O
in	O
our	O
studies	O
strongly	O
activated	O
Tcf	O
transcription	O
in	O
vitro	O
,	O
whereas	O
beta-cat	O
mutant	O
proteins	O
with	O
large	O
NH2	O
-	O
terminal	O
deletions	O
had	O
only	O
modest	O
effects	O
on	O
Tcf	O
.	O
Our	O
results	O
suggest	O
a	O
role	O
for	O
Tcf	O
deregulation	O
in	O
gastric	B-malignancy-type
and	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
resulting	O
from	O
beta-cat	O
and	O
gamma-cat	O
mutations	O
in	O
some	O
cases	O
and	O
,	O
in	O
others	O
,	O
from	O
yet	O
to	O
be	O
defined	O
defects	O
.	O
Furthermore	O
,	O
these	O
data	O
imply	O
that	O
the	O
consequences	O
of	O
APC	O
and	O
beta-cat	O
mutations	O
are	O
distinct	O
from	O
the	O
effects	O
of	O
E-cad	O
inactivation	O
.	O
PMID	O
:	O
10392898	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Mar	O
11	O
;18(	O
10	O
)	O
:1897	O
-	O
902	O
Mutations	O
of	O
c-kit	O
JM	O
domain	O
are	O
found	O
in	O
a	O
minority	O
of	O
human	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Moskaluk	O
CA	O
,	O
Tian	O
Q	O
,	O
Marshall	O
CR	O
,	O
Rumpel	O
CA	O
,	O
Franquemont	O
DW	O
,	O
Frierson	O
HF	O
Jr.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Virginia	O
,	O
Charlottesville	O
22908	O
,	O
USA	O
.	O
The	O
c-kit	O
gene	O
encodes	O
a	O
transmembrane	O
receptor	O
kinase	O
(	O
KIT	O
)	O
which	O
is	O
expressed	O
in	O
the	O
majority	O
of	O
human	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	I-malignancy-type
GISTs	B-malignancy-type
)	O
,	O
a	O
subtype	O
of	O
gastrointestinal	B-malignancy-type
mesenchymal	I-malignancy-type
neoplasms	I-malignancy-type
.	O
A	O
previous	O
study	O
identified	O
mutations	O
in	O
the	O
juxtamembrane	O
(	O
JM	O
)	O
domain	O
of	O
c-kit	O
in	O
five	O
of	O
six	O
GISTs	B-malignancy-type
(	O
Science	O
279	O
:	O
577	O
,	O
1998	O
)	O
.	O
To	O
better	O
define	O
the	O
frequency	O
and	O
spectrum	O
of	O
c-kit	O
gene	O
mutations	O
in	O
mesenchymal	B-malignancy-type
neoplasms	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
GI	I-malignancy-type
tract	I-malignancy-type
that	O
had	O
been	O
characterized	O
for	O
KIT	O
protein	O
expression	O
,	O
we	O
examined	O
archived	O
tissue	O
samples	O
for	O
mutations	O
in	O
the	O
JM	O
domain	O
by	O
PCR	O
amplification	O
and	O
DNA	O
sequencing	O
.	O
c-kit	O
JM	O
domain	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
56	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
(	O
46	O
GISTs	B-malignancy-type
,	O
eight	O
leiomyomas	B-malignancy-type
,	O
two	O
leiomyosarcomas	B-malignancy-type
)	O
and	O
occurred	O
exclusively	O
in	O
GISTs	B-malignancy-type
(	O
21	O
%	O
)	O
.	O
Seven	O
of	O
the	O
nine	O
mutations	O
consisted	O
of	O
intragenic	O
deletions	O
of	O
one	O
to	O
19	O
codons	O
.	O
There	O
was	O
one	O
insertion	O
mutation	O
that	O
added	O
12	O
codons	O
and	O
one	O
missense	O
mutation	O
(	O
Val	O
560	O
Asp	O
)	O
.	O
None	O
of	O
the	O
mutations	O
disrupted	O
the	O
downstream	O
reading	O
frame	O
of	O
the	O
gene	O
.	O
The	O
single	O
missense	O
mutation	O
(	O
Val	O
560	O
Asp	O
)	O
is	O
very	O
similar	O
to	O
the	O
only	O
other	O
missense	O
mutation	O
reported	O
in	O
GISTs	B-malignancy-type
(	O
Val	O
599	O
Asp	O
)	O
.	O
Of	O
the	O
46	O
GISTs	B-malignancy-type
,	O
43	O
were	O
strongly	O
positive	O
for	O
KIT	O
protein	O
expression	O
and	O
negative	O
for	O
diffuse	O
expression	O
of	O
desmin	O
.	O
Neither	O
KIT	O
expression	O
nor	O
gene	O
mutations	O
were	O
found	O
in	O
gastrointestinal	B-malignancy-type
leiomyomas	I-malignancy-type
or	O
leiomyosarcomas	B-malignancy-type
.	O
We	O
conclude	O
that	O
mutation	O
of	O
the	O
c-kit	O
JM	O
domain	O
does	O
not	O
occur	O
in	O
gastrointestinal	B-malignancy-type
mesenchymal	I-malignancy-type
neoplasms	I-malignancy-type
with	O
well	O
developed	O
-	O
smooth	O
muscle	O
differentiation	O
,	O
and	O
is	O
restricted	O
to	O
GISTs	B-malignancy-type
.	O
However	O
,	O
since	O
these	O
mutations	O
are	O
only	O
found	O
in	O
a	O
minority	O
of	O
GISTs	B-malignancy-type
,	O
further	O
investigation	O
into	O
the	O
mechanisms	O
of	O
c-kit	O
gene	O
activation	O
in	O
this	O
group	O
of	O
neoplasms	B-malignancy-type
is	O
warranted	O
.	O
PMID	O
:	O
10086344	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1998	O
Mar;89(	O
3	O
)	O
:299	O
-	O
306	O
Genetic	O
alterations	O
of	O
mixed	B-malignancy-type
hyperplastic	I-malignancy-type
adenomatous	I-malignancy-type
polyps	I-malignancy-type
in	O
the	O
colon	O
and	O
rectum	O
.	O
Uchida	O
H	O
,	O
Ando	O
H	O
,	O
Maruyama	O
K	O
,	O
Kobayashi	O
H	O
,	O
Toda	O
H	O
,	O
Ogawa	O
H	O
,	O
Ozawa	O
T	O
,	O
Matsuda	O
Y	O
,	O
Sugimura	O
H	O
,	O
Kanno	O
T	O
,	O
Baba	O
S.	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
Hamamatsu	O
University	O
School	O
of	O
Medicine	O
.	O
Some	O
mixed	B-malignancy-type
hyperplastic	I-malignancy-type
adenomatous	I-malignancy-type
polyps	I-malignancy-type
(	O
MHAPs	B-malignancy-type
)	O
contain	O
dysplastic	B-malignancy-type
lesions	I-malignancy-type
or	O
even	O
carcinomas	B-malignancy-type
.	O
These	O
polyps	B-malignancy-type
are	O
considered	O
to	O
be	O
different	O
from	O
ordinary	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
and	O
may	O
have	O
a	O
preneoplastic	O
potential	O
.	O
We	O
investigated	O
APC	O
and	O
K-ras	O
mutations	O
in	O
MHAPs	B-malignancy-type
of	O
the	O
colon	O
and	O
rectum	O
,	O
and	O
also	O
in	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
to	O
identify	O
molecular	O
differences	O
between	O
MHAPs	B-malignancy-type
,	O
adenomas	B-malignancy-type
and	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
,	O
using	O
direct	O
sequencing	O
of	O
mutation	O
cluster	O
regions	O
(	O
MCR	O
)	O
in	O
APC	O
and	O
K-ras	O
.	O
No	O
APC	O
mutations	O
were	O
identified	O
in	O
12	O
MHAPs	B-malignancy-type
and	O
8	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
,	O
whereas	O
10	O
of	O
27	O
(	O
37.0	O
%	O
)	O
adenomas	B-malignancy-type
showed	O
somatic	O
mutations	O
.	O
K-ras	O
mutations	O
were	O
identified	O
in	O
one	O
of	O
12	O
(	O
8.3	O
%	O
)	O
MHAPs	B-malignancy-type
,	O
one	O
of	O
8	O
(	O
12.5	O
%	O
)	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
,	O
and	O
10	O
of	O
27	O
(	O
37.0	O
%	O
)	O
adenomas	B-malignancy-type
.	O
p53	O
mutation	O
was	O
found	O
in	O
a	O
carcinoma	B-malignancy-type
arising	O
in	O
an	O
MHAP	B-malignancy-type
.	O
Mutations	O
other	O
than	O
APC	O
mutations	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
MHAPs	B-malignancy-type
.	O
PMID	O
:	O
9600124	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2002	O
Aug;161(	O
2	O
)	O
:611	O
-	O
8	O
Inverse	O
relationship	O
between	O
APC	O
gene	O
mutation	O
in	O
gastric	B-malignancy-type
adenomas	I-malignancy-type
and	O
development	O
of	O
adenocarcinoma	B-malignancy-type
.	O
Lee	O
JH	O
,	O
Abraham	O
SC	O
,	O
Kim	O
HS	O
,	O
Nam	O
JH	O
,	O
Choi	O
C	O
,	O
Lee	O
MC	O
,	O
Park	O
CS	O
,	O
Juhng	O
SW	O
,	O
Rashid	O
A	O
,	O
Hamilton	O
SR	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
MD	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
,	O
Texas	O
77030	O
,	O
USA	O
.	O
Gastric	B-malignancy-type
cancer	I-malignancy-type
is	O
common	O
among	O
the	O
world	O
,	O
but	O
genetic	O
mechanisms	O
of	O
gastric	O
carcinogenesis	O
are	O
not	O
well	O
understood	O
.	O
Gastric	B-malignancy-type
polypoid	I-malignancy-type
adenomas	I-malignancy-type
and	O
flat	B-malignancy-type
dysplasias	I-malignancy-type
are	O
regarded	O
as	O
precursor	O
lesions	O
.	O
However	O
,	O
a	O
detailed	O
molecular	O
study	O
of	O
these	O
lesions	B-malignancy-type
has	O
not	O
been	O
done	O
to	O
determine	O
their	O
role	O
as	O
precancerous	O
lesions	O
.	O
We	O
investigated	O
mutations	O
of	O
the	O
APC	O
,	O
beta-catenin	O
,	O
and	O
K-ras	O
genes	O
,	O
and	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
status	O
in	O
35	O
adenomas	B-malignancy-type
and	O
47	O
flat	B-malignancy-type
dysplasias	I-malignancy-type
without	I-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
35	O
adenomas	B-malignancy-type
/	O
dysplasias	B-malignancy-type
associated	O
with	O
adenocarcinomas	B-malignancy-type
,	O
and	O
39	O
adenocarcinomas	B-malignancy-type
(	O
20	O
diffuse	B-malignancy-type
type	I-malignancy-type
and	O
19	O
intestinal	B-malignancy-type
type	I-malignancy-type
)	O
.	O
Somatic	O
APC	O
gene	O
mutations	O
were	O
identified	O
in	O
76	O
%	O
(	O
59	O
of	O
78	O
)	O
of	O
adenomas	O
or	O
flat	B-malignancy-type
dysplasias	I-malignancy-type
without	O
associated	O
adenocarcinoma	B-malignancy-type
,	O
but	O
in	O
only	O
3	O
%	O
(	O
1	O
of	O
30	O
)	O
of	O
adenomas	B-malignancy-type
/	O
dysplasias	B-malignancy-type
associated	B-malignancy-type
with	I-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
and	O
in	O
only	O
4	O
%	O
(	O
3	O
of	O
69	O
)	O
of	O
adenocarcinomas	B-malignancy-type
(	O
P	O
<	O
0.000001	O
)	O
.	O
No	O
mutations	O
of	O
beta-catenin	O
were	O
found	O
in	O
adenocarcinomas	B-malignancy-type
,	O
or	O
adenomas	B-malignancy-type
/	O
dysplasia	B-malignancy-type
without	O
APC	O
mutation	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
5	O
%	O
(	O
4	O
of	O
82	O
)	O
of	O
gastric	B-malignancy-type
adenomas	I-malignancy-type
/	O
dysplasia	B-malignancy-type
without	O
carcinoma	B-malignancy-type
,	O
3	O
%	O
(	O
1	O
of	O
39	O
)	O
of	O
adenocarcinomas	B-malignancy-type
without	O
associated	O
adenoma	B-malignancy-type
/	O
dysplasia	B-malignancy-type
,	O
and	O
not	O
in	O
32	O
adenocarcinomas	B-malignancy-type
with	O
associated	O
adenoma	B-malignancy-type
/	O
dysplasia	B-malignancy-type
.	O
High	O
level	O
of	O
MSI	O
(	O
MSI-H	O
)	O
was	O
more	O
frequent	O
in	O
gastric	B-malignancy-type
adenoma	I-malignancy-type
/	O
dysplasia	B-malignancy-type
associated	O
with	O
carcinoma	B-malignancy-type
(	O
17	O
%	O
,	O
6	O
of	O
35	O
)	O
than	O
in	O
adenomas	B-malignancy-type
/	O
dysplasia	B-malignancy-type
without	O
carcinoma	B-malignancy-type
(	O
3	O
%	O
,	O
2	O
of	O
75	O
;	O
P	O
=	O
0.01	O
)	O
.	O
MSI-H	O
was	O
also	O
more	O
frequent	O
in	O
intestinal	B-malignancy-type
type	I-malignancy-type
adenocarcinoma	I-malignancy-type
(	O
20	O
%	O
,	O
11	O
of	O
54	O
)	O
than	O
in	O
diffuse	B-malignancy-type
type	I-malignancy-type
(	O
0	O
%	O
,	O
0	O
of	O
20	O
;	O
P	O
=	O
0.03	O
)	O
.	O
APC	O
gene	O
mutations	O
were	O
present	O
in	O
six	O
of	O
nine	O
(	O
67	O
%	O
)	O
of	O
gastric	B-malignancy-type
adenomas	I-malignancy-type
/	O
dysplasias	B-malignancy-type
with	O
low	O
level	O
of	O
MSI	O
,	O
but	O
in	O
none	O
of	O
the	O
eight	O
adenomas	B-malignancy-type
/	O
dysplasia	B-malignancy-type
with	O
MSI-H	O
phenotype	O
(	O
P	O
=	O
0.009	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
somatic	O
mutation	O
of	O
the	O
APC	O
gene	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gastric	B-malignancy-type
adenoma	I-malignancy-type
and	O
dysplasia	B-malignancy-type
but	O
has	O
a	O
limited	O
role	O
in	O
neoplastic	O
progression	O
to	O
adenocarcinoma	B-malignancy-type
.	O
Gastric	B-malignancy-type
adenomas	I-malignancy-type
or	O
dysplasias	B-malignancy-type
without	O
APC	O
mutations	O
but	O
with	O
or	O
without	O
MSI	O
may	O
have	O
a	O
different	O
biological	O
behavior	O
,	O
and	O
are	O
precursors	O
of	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
of	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
PMID	O
:	O
12163385	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Prostate	O
1997	O
Jan	O
1;30(	O
1	O
)	O
:53	O
-	O
7	O
Comparison	O
of	O
ras	O
activation	O
in	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
in	O
Japanese	O
and	O
American	O
men	O
.	O
Konishi	O
N	O
,	O
Hiasa	O
Y	O
,	O
Tsuzuki	O
T	O
,	O
Tao	O
M,	O
Enomoto	O
T	O
,	O
Miller	O
GJ.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Nara	O
Medical	O
University	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Comparative	O
studies	O
of	O
point	O
mutations	O
in	O
K	O
-	O
,	O
N	O
-	O
,	O
and	O
H	O
-	O
ras	O
oncogenes	O
were	O
performed	O
on	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
from	O
Japanese	O
and	O
American	O
patients	O
to	O
clarify	O
the	O
racial	O
difference	O
.	O
METHODS	O
:	O
We	O
probed	O
for	O
mutations	O
in	O
70	O
Japanese	O
and	O
31	O
American	O
specimens	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
immunohistochemistry	O
for	O
ras	O
p21	O
.	O
RESULTS	O
:	O
Within	O
the	O
70	O
Japanese	O
specimens	O
,	O
eight	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
(	O
five	O
GGT	O
-->	O
GTT	O
transversions	O
and	O
three	O
CGT	O
-->	O
GAT	O
transitions	O
)	O
and	O
one	O
mutation	O
in	O
codon	O
12	O
of	O
the	O
N-ras	O
gene	O
(	O
a	O
GGT	O
-->	O
GTT	O
transversion	O
)	O
were	O
confirmed	O
,	O
whereas	O
the	O
American	O
samples	O
yielded	O
only	O
one	O
definable	O
mutation	O
,	O
a	O
GGT	O
-->	O
GAT	O
transition	O
,	O
in	O
codon	O
12	O
of	O
K-ras	O
.	O
CONCLUSIONS	O
:	O
The	O
frequency	O
of	O
ras	O
gene	O
mutations	O
in	O
clinical	O
carcinoma	B-malignancy-type
in	O
Japanese	O
men	O
was	O
higher	O
than	O
that	O
in	O
American	O
men	O
.	O
It	O
is	O
suggested	O
that	O
there	O
may	O
be	O
fundamental	O
differences	O
in	O
the	O
etiology	O
of	O
prostate	B-malignancy-type
carcinoma	I-malignancy-type
in	O
Japan	O
and	O
the	O
United	O
States	O
,	O
perhaps	O
based	O
on	O
genetics	O
and/or	O
environmental	O
factors	O
.	O
PMID	O
:	O
9018336	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1997	O
Jan;15(	O
1	O
)	O
:285	O
-	O
91	O
Mutational	O
activation	O
of	O
the	O
K-ras	O
oncogene	O
and	O
the	O
effect	O
of	O
chemotherapy	O
in	O
advanced	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
:	O
a	O
prospective	O
study	O
.	O
Rodenhuis	O
S,	O
Boerrigter	O
L,	O
Top	O
B	O
,	O
Slebos	O
RJ	O
,	O
Mooi	O
WJ	O
,	O
van't	O
Veer	O
L,	O
van	O
Zandwijk	O
N.	O
Division	O
of	O
Medical	O
Oncology	O
,	O
The	O
Netherlands	O
Cancer	O
Institute	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
.	O
sroden@nki	O
.nl	O
PURPOSE	O
:	O
To	O
determine	O
whether	O
the	O
clinical	O
course	O
and	O
the	O
response	O
to	O
chemotherapy	O
of	O
patients	O
with	O
advanced	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
depends	O
on	O
the	O
presence	O
or	O
absence	O
of	O
a	O
ras	O
mutation	O
in	O
the	O
tumor	O
.	O
Mutational	O
activation	O
of	O
K-ras	O
is	O
a	O
strong	O
adverse	O
prognostic	O
factor	O
in	O
stage	O
I	O
or	O
II	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
laboratory	O
studies	O
have	O
suggested	O
that	O
ras	O
mutations	O
lead	O
to	O
resistance	O
against	O
ionizing	O
radiation	O
and	O
chemotherapy	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Patients	O
with	O
advanced	O
adenocarcinoma	B-malignancy-type
of	O
the	O
lung	O
with	O
measurable	O
or	O
assessable	O
disease	O
received	O
chemotherapy	O
with	O
mesna	O
,	O
ifosfamide	O
,	O
carboplatin	O
,	O
and	O
etoposide	O
(	O
MICE	O
)	O
.	O
Archival	O
biopsies	O
,	O
fresh	O
biopsies	O
,	O
or	O
fine	O
-	O
needle	O
aspirations	O
were	O
tested	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
.	O
Associations	O
of	O
ras	O
mutations	O
with	O
clinical	O
characteristics	O
,	O
response	O
to	O
chemotherapy	O
,	O
and	O
survival	O
were	O
studied	O
.	O
RESULTS	O
:	O
The	O
presence	O
or	O
absence	O
of	O
ras	O
gene	O
mutations	O
could	O
be	O
established	O
in	O
69	O
of	O
83	O
patients	O
(	O
83	O
%	O
)	O
.	O
A	O
total	O
of	O
261	O
courses	O
of	O
MICE	O
were	O
administered	O
to	O
62	O
informative	O
patients	O
,	O
16	O
of	O
whom	O
were	O
shown	O
to	O
have	O
a	O
K-ras	O
mutation	O
-	O
positive	O
tumor	O
.	O
The	O
frequency	O
of	O
mutations	O
(	O
26	O
%	O
)	O
and	O
the	O
type	O
of	O
mutations	O
closely	O
matched	O
the	O
pattern	O
we	O
have	O
previously	O
reported	O
in	O
operable	O
disease	O
.	O
Patients	O
with	O
a	O
ras	O
mutation	O
in	O
their	O
tumor	O
were	O
more	O
likely	O
to	O
have	O
a	O
close	O
relative	O
with	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
other	O
clinical	O
characteristics	O
,	O
such	O
as	O
pattern	O
of	O
metastases	B-malignancy-type
,	O
response	O
,	O
and	O
survival	O
,	O
were	O
similar	O
between	O
the	O
ras	O
mutation	O
-	O
positive	O
and	O
ras	O
mutation	O
-	O
negative	O
groups	O
.	O
CONCLUSION	O
:	O
Patients	O
with	O
advanced	O
lung	B-malignancy-type
adenocarcinoma	I-malignancy-type
who	O
harbor	O
a	O
ras	O
mutation	O
may	O
have	O
major	O
responses	O
to	O
chemotherapy	O
and	O
have	O
similar	O
progression	O
-	O
free	O
and	O
overall	O
survival	O
as	O
patients	O
with	O
ras	O
mutation	O
-	O
negative	O
tumors	O
.	O
K-ras	O
mutations	O
may	O
represent	O
one	O
of	O
several	O
ways	O
in	O
which	O
early	O
tumors	O
are	O
enabled	O
to	O
metastasize	O
to	O
distant	O
sites	O
.	O
PMID	O
:	O
8996154	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Biol	O
Chem	O
1996	O
Dec	O
20	O
;271(	O
51	O
)	O
:32491	O
-	O
4	O
Biochemical	O
characterization	O
of	O
a	O
novel	O
KRAS	O
insertion	O
mutation	O
from	O
a	O
human	O
leukemia	B-malignancy-type
.	O
Bollag	O
G	O
,	O
Adler	O
F	O
,	O
elMasry	O
N	O
,	O
McCabe	O
PC	O
,	O
Conner	O
E	O
Jr	O
,	O
Thompson	O
P	O
,	O
McCormick	O
F	O
,	O
Shannon	O
K.	O
ONYX	O
Pharmaceuticals	O
,	O
Richmond	O
,	O
California	O
94806	O
,	O
USA	O
.	O
bollag@macgate	O
.onyx	O
-	O
pharm	O
.com	O
A	O
novel	O
alteration	O
in	O
exon	O
1	O
of	O
KRAS	O
was	O
detected	O
by	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
of	O
DNA	O
amplified	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
4	O
-	O
year	O
-	O
old	O
child	O
with	O
myeloid	B-malignancy-type
leukemia	I-malignancy-type
.	O
Sequencing	O
of	O
this	O
mutant	O
allele	O
revealed	O
an	O
insertion	O
of	O
three	O
nucleotides	O
between	O
codons	O
10	O
and	O
11	O
resulting	O
in	O
an	O
in	O
-	O
frame	O
insertion	O
of	O
glycine	O
.	O
Expression	O
of	O
the	O
mutant	O
protein	O
in	O
NIH	O
3T3	O
cells	O
caused	O
cellular	O
transformation	O
,	O
and	O
expression	O
in	O
COS	O
cells	O
activated	O
the	O
Ras	O
-	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O
Surprisingly	O
,	O
Ras	O
.	O
GTP	O
levels	O
measured	O
in	O
COS	O
cells	O
established	O
that	O
this	O
novel	O
mutant	O
accumulates	O
to	O
90	O
%	O
in	O
the	O
GTP	O
state	O
,	O
considerably	O
higher	O
than	O
a	O
residue	O
12	O
mutant	O
.	O
Biochemical	O
analysis	O
confirmed	O
that	O
the	O
higher	O
Ras	O
.	O
GTP	O
levels	O
correspond	O
to	O
a	O
dramatic	O
decrease	O
in	O
intrinsic	O
GTP	O
hydrolysis	O
as	O
well	O
as	O
resistance	O
to	O
GTPase	O
-	O
activating	O
proteins	O
.	O
This	O
mutation	O
is	O
the	O
first	O
dominant	O
Ras	O
mutation	O
found	O
in	O
human	O
cancer	O
that	O
does	O
not	O
involve	O
residues	O
12	O
,	O
13	O
,	O
or	O
61	O
,	O
and	O
its	O
biochemical	O
properties	O
should	O
help	O
elucidate	O
the	O
mechanism	O
of	O
oncogenic	O
activation	O
.	O
PMID	O
:	O
8955068	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Oral	O
Pathol	O
Med	O
1996	O
May	O
;25(	O
5	O
)	O
:232	O
-	O
8	O
Alterations	O
of	O
p16	O
/	O
CDKN2	O
,	O
p53	O
and	O
ras	O
genes	O
in	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
premalignant	B-malignancy-type
lesions	I-malignancy-type
.	O
Matsuda	O
H	O
,	O
Konishi	O
N	O
,	O
Hiasa	O
Y	O
,	O
Hayashi	O
I	O
,	O
Tsuzuki	O
T	O
,	O
Tao	O
M,	O
Kitahori	O
Y	O
,	O
Yoshioka	O
N	O
,	O
Kirita	O
T	O
,	O
Sugimura	O
M.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Nara	O
Medical	O
University	O
,	O
Japan	O
.	O
Exons	O
1	O
-	O
3	O
of	O
the	O
p16	O
/	O
CDKN2	O
gene	O
,	O
exons	O
4	O
-	O
9	O
of	O
the	O
p53	O
gene	O
and	O
exons	O
1	O
and	O
2	O
of	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
were	O
screened	O
for	O
mutations	O
by	O
a	O
combination	O
of	O
immunohistochemistry	O
and	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analyses	O
of	O
polymerase	O
chain	O
reaction	O
products	O
from	O
human	O
surgical	O
samples	O
of	O
both	O
frank	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
premalignant	B-malignancy-type
lesions	I-malignancy-type
.	O
The	O
samples	O
included	O
20	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
10	O
epithelial	B-malignancy-type
dysplasias	I-malignancy-type
and	O
10	O
epithelial	B-malignancy-type
hyperplasias	I-malignancy-type
.	O
No	O
identifiable	O
gene	O
mutations	O
were	O
detected	O
in	O
any	O
of	O
the	O
dysplasias	B-malignancy-type
or	O
hyperplasias	B-malignancy-type
,	O
while	O
2	O
(	O
10	O
%	O
)	O
deletions	O
and	O
2	O
(	O
10	O
%	O
)	O
mutations	O
of	O
p16	O
/	O
CDKN2	O
,	O
along	O
with	O
5	O
(	O
25	O
%	O
)	O
p53	O
mutations	O
were	O
found	O
in	O
the	O
advanced	O
carcinomas	B-malignancy-type
,	O
yielding	O
characteristic	O
p16	O
/	O
CDKN2	O
and	O
p53	O
changes	O
.	O
A	O
mutation	O
in	O
the	O
K-ras	O
gene	O
was	O
found	O
in	O
single	O
carcinoma	B-malignancy-type
and	O
dysplastic	B-malignancy-type
samples	O
.	O
From	O
the	O
data	O
,	O
it	O
can	O
be	O
argued	O
that	O
p16	O
/	O
CDKN2	O
and	O
p53	O
mutations	O
are	O
relatively	O
late	O
occurrences	O
in	O
human	O
oral	O
tumorigenesis	O
and	O
that	O
genetic	O
alterations	O
of	O
the	O
ras	O
genes	O
may	O
not	O
play	O
a	O
significant	O
role	O
in	O
squamous	B-malignancy-type
neoplasia	I-malignancy-type
.	O
PMID	O
:	O
8835820	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
1996	O
Jul;62(	O
1	O
)	O
:49	O
-	O
54	O
Expression	O
and	O
mutation	O
of	O
H-ras	O
in	O
uterine	B-malignancy-type
cervical	I-malignancy-type
cancer	I-malignancy-type
.	O
Lee	O
JH	O
,	O
Lee	O
SK	O
,	O
Yang	O
MH	O
,	O
Ahmed	O
MM	O
,	O
Mohiuddin	O
M,	O
Lee	O
EY	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Medicine	O
,	O
Kyang	O
Hee	O
University	O
,	O
Seoul	O
,	O
Korea	O
.	O
In	O
cervical	B-malignancy-type
cancer	I-malignancy-type
,	O
abnormalities	O
of	O
ras	O
genes	O
have	O
not	O
been	O
fully	O
investigated	O
.	O
We	O
studied	O
the	O
expression	O
and	O
mutation	O
of	O
H-ras	O
oncogene	O
in	O
cervical	B-malignancy-type
cancer	I-malignancy-type
to	O
investigate	O
their	O
relationship	O
and	O
usefulness	O
as	O
an	O
independent	O
prognostic	O
indicator	O
.	O
Twenty-seven	O
paraffin	O
-	O
embedded	O
resection	O
specimens	O
of	O
cervical	B-malignancy-type
cancer	I-malignancy-type
(	O
21	O
squamous	B-malignancy-type
,	O
3	O
adeno	B-malignancy-type
,	O
2	O
adenosquamous	B-malignancy-type
,	O
and	O
1	O
small	B-malignancy-type
cell	I-malignancy-type
)	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
a	O
mAb	O
H-ras	O
p21	O
and	O
by	O
PCR	O
and	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
using	O
H-ras	O
codon	O
12	O
and	O
61	O
amplimers	O
and	O
oligonucleotide	O
probes	O
.	O
A	O
strong	O
immunoreaction	O
was	O
noted	O
in	O
10	O
cases	O
(	O
37	O
%	O
)	O
and	O
weak	O
immunoreaction	O
in	O
an	O
additional	O
6	O
cases	O
(	O
22	O
%	O
)	O
.	O
H-ras	O
codon	O
12	O
mutations	O
were	O
detected	O
in	O
6	O
of	O
27	O
cases	O
(	O
22	O
%	O
)	O
and	O
all	O
of	O
the	O
mutations	O
were	O
guanine	O
to	O
adenine	O
transitions	O
.	O
There	O
was	O
no	O
mutation	O
in	O
codon	O
61	O
.	O
Cases	O
with	O
codon	O
12	O
mutations	O
included	O
all	O
3	O
squamous	B-malignancy-type
,	O
2	O
adeno	B-malignancy-type
,	O
and	O
I	O
adenosquamous	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Only	O
3	O
of	O
16	O
(	O
19	O
%	O
)	O
cases	O
with	O
positive	O
staining	O
and	O
3	O
of	O
11	O
(	O
27	O
%	O
)	O
cases	O
with	O
negative	O
staining	O
showed	O
mutations	O
.	O
No	O
correlation	O
was	O
found	O
between	O
ras	O
gene	O
alterations	O
and	O
patient	O
survival	O
time	O
.	O
Our	O
findings	O
indicate	O
that	O
expression	O
and	O
mutation	O
of	O
H-ras	O
oncogene	O
occur	O
in	O
cervical	B-malignancy-type
cancer	I-malignancy-type
but	O
their	O
determination	O
adds	O
no	O
useful	O
prognostic	O
information	O
.	O
PMID	O
:	O
8690291	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Endocrinol	O
1996	O
Feb;134(	O
2	O
)	O
:177	O
-	O
83	O
Low	O
frequency	O
of	O
p53	O
mutations	O
in	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
;	O
p53	O
and	O
Ras	O
mutation	O
in	O
two	O
out	O
of	O
fifty-six	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
.	O
Salvatore	O
D	O
,	O
Celetti	O
A	O
,	O
Fabien	O
N	O
,	O
Paulin	O
C	O
,	O
Martelli	O
ML	O
,	O
Battaglia	O
C	O
,	O
Califano	O
D	O
,	O
Monaco	O
C	O
,	O
Viglietto	O
G	O
,	O
Santoro	O
M,	O
Fusco	O
A.	O
Cetro	O
di	O
Endocrinologia	O
ed	O
Oncologia	O
Sperimentale	O
del	O
CNR	O
,	O
Facolta	O
di	O
Medicina	O
e	O
Chirurgia	O
,	O
Universita	O
di	O
Napoli	O
,	O
Naples	O
,	O
Italy	O
.	O
OBJECTIVE	O
:	O
p53	O
is	O
a	O
well	O
-	O
known	O
nuclear	O
phosphoprotein	O
encoded	O
by	O
a	O
suppressor	O
gene	O
know	O
to	O
be	O
mutated	O
in	O
various	O
kinds	O
of	O
human	O
tumours	O
.	O
A	O
relationship	O
between	O
p53	O
gene	O
mutation	O
and	O
tumour	O
progression	O
seems	O
to	O
be	O
a	O
common	O
feature	O
of	O
several	O
neoplasias	B-malignancy-type
.	O
DESIGN	O
:	O
In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
p53	O
mutations	O
in	O
human	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
,	O
DNA	O
samples	O
derived	O
from	O
fifty-six	O
neoplastic	O
tissues	O
,	O
ranging	O
from	O
benign	B-malignancy-type
adenomas	I-malignancy-type
to	O
undifferentiated	B-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
examined	O
for	O
the	O
presence	O
of	O
p53	O
gene	O
mutations	O
.	O
METHODS	O
:	O
The	O
analysis	O
has	O
been	O
conducted	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
the	O
exons	O
5	O
-	O
9	O
of	O
the	O
p53	O
gene	O
followed	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
sequence	O
analyses	O
.	O
RESULTS	O
:	O
One	O
anaplastic	B-malignancy-type
carcinoma	I-malignancy-type
and	O
one	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
showed	O
p53	O
gene	O
mutations	O
in	O
exons	O
5	O
and	O
8	O
,	O
respectively	O
.	O
A	O
cell	O
line	O
established	O
from	O
the	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
showed	O
the	O
same	O
mutation	O
present	O
in	O
the	O
original	O
tumour	O
.	O
Both	O
p53	O
mutations	O
were	O
heterozygous	O
.	O
The	O
p53	O
positive	O
samples	O
were	O
analysed	O
for	O
other	O
genetic	O
alterations	O
frequently	O
detected	O
in	O
human	O
thyroid	B-malignancy-type
carcinomas	I-malignancy-type
(	O
mutations	O
of	O
the	O
RET	O
,	O
TRK	O
,	O
and	O
ras	O
oncogenes	O
)	O
:	O
both	O
p53	O
-	O
mutated	O
samples	O
proved	O
to	O
be	O
mutated	O
at	O
level	O
of	O
codon	O
13	O
of	O
the	O
c-Ki-ras	O
gene	O
.	O
CONCLUSIONS	O
:	O
Our	O
data	O
confirm	O
that	O
p53	O
gene	O
alterations	O
are	O
rare	O
in	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
thyroid	I-malignancy-type
tumours	I-malignancy-type
,	O
that	O
they	O
are	O
an	O
important	O
requirement	O
for	O
the	O
establishment	O
in	O
culture	O
of	O
human	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
,	O
and	O
that	O
they	O
can	O
be	O
associated	O
with	O
other	O
genetic	O
alterations	O
,	O
namely	O
ras	O
mutations	O
,	O
in	O
the	O
malignant	O
progression	O
of	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
.	O
PMID	O
:	O
8630516	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Apr;8	O
Suppl	O
1:S27	O
-	O
9	O
Molecular	O
mechanisms	O
of	O
tumor	O
progression	O
in	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
.	O
Gaidano	O
G	O
,	O
Guerrasio	O
A	O
,	O
Serra	O
A	O
,	O
Rege	O
-	O
Cambrin	O
G	O
,	O
Saglio	O
G.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
&	O
Surgeons	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
NY	O
10032	O
.	O
We	O
have	O
investigated	O
the	O
involvement	O
of	O
tumor	O
suppressor	O
genes	O
(	O
p53	O
and	O
RB1	O
)	O
and	O
dominantly	O
acting	O
oncogenes	O
(	O
Ras	O
family	O
genes	O
)	O
in	O
BCR	O
/	O
ABL	O
positive	O
and	O
negative	O
chronic	B-malignancy-type
myeloproliferative	I-malignancy-type
disorders	I-malignancy-type
(	O
CMPD	B-malignancy-type
)	O
at	O
different	O
stages	O
of	O
the	O
disease	O
,	O
including	O
26	O
cases	O
of	O
BCR	O
/	O
ABL	O
+	O
chronic	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
blast	O
crisis	O
,	O
9	O
myelosclerosis	O
with	O
myeloid	B-malignancy-type
metaplasia	I-malignancy-type
,	O
4	O
polycythemia	B-malignancy-type
vera	I-malignancy-type
,	O
10	O
essential	B-malignancy-type
thrombocythemia	I-malignancy-type
,	O
1	O
juvenile	O
CML	B-malignancy-type
,	O
and	O
8	O
BCR	O
/	O
ABL	O
-	O
CML	B-malignancy-type
.	O
The	O
presence	O
of	O
mutations	O
in	O
p53	O
exons	O
5	O
through	O
9	O
,	O
as	O
well	O
as	O
in	O
RB1	O
exons	O
10	O
-	O
27	O
and	O
in	O
N	O
-	O
,	O
K	O
-	O
,	O
H	O
-	O
Ras	O
exons	O
1	O
and	O
2	O
was	O
tested	O
by	O
the	O
PCR	O
-	O
Single	O
Strand	O
Conformation	O
Polymorphism	O
technique	O
and	O
by	O
PCR	O
-	O
Direct	O
Sequencing	O
.	O
In	O
addition	O
,	O
Southern	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
the	O
occurrence	O
of	O
gross	O
rearrangements	O
in	O
the	O
p53	O
gene	O
as	O
well	O
as	O
loss	O
of	O
heterozygosity	O
at	O
17p13	O
,	O
the	O
site	O
of	O
p53	O
.	O
Acute	O
phase	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
cases	O
displayed	O
a	O
high	O
frequency	O
of	O
p53	O
(	O
2	O
/	O
7	O
)	O
and	O
Ras	O
(	O
3	O
/	O
7	O
)	O
lesions	O
,	O
whereas	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
in	O
chronic	O
phase	O
displayed	O
only	O
germline	O
p53	O
and	O
Ras	O
sequences	O
.	O
Conversely	O
,	O
p53	O
inactivation	O
was	O
restricted	O
to	O
only	O
1	O
/	O
26	O
cases	O
of	O
BCR	O
/	O
ABL	O
+	O
CML	B-malignancy-type
blast	O
crisis	O
.	O
No	O
alterations	O
in	O
the	O
RB1	O
gene	O
were	O
detected	O
in	O
any	O
of	O
the	O
cases	O
analyzed	O
.	O
These	O
data	O
indicate	O
that	O
p53	O
inactivation	O
and/or	O
Ras	O
activation	O
might	O
play	O
a	O
role	O
in	O
acute	O
transformation	O
of	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
and	O
that	O
the	O
molecular	O
mechanisms	O
of	O
tumor	O
progression	O
may	O
be	O
different	O
in	O
BCR	O
/	O
ABL	O
+	O
versus	O
BCR	O
/	O
ABL	O
-	O
CMPD	B-malignancy-type
.	O
PMID	O
:	O
8152300	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1993	O
Nov	O
11;55(	O
5	O
)	O
:785	O
-	O
90	O
Screening	O
of	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
and	O
urine	O
sediments	O
for	O
the	O
presence	O
of	O
H-ras	O
mutations	O
.	O
Levesque	O
P	O
,	O
Ramchurren	O
N	O
,	O
Saini	O
K	O
,	O
Joyce	O
A	O
,	O
Libertino	O
J,	O
Summerhayes	O
IC	O
.	O
Department	O
of	O
Surgery	O
,	O
New	O
England	O
Deaconess	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
,	O
MA	O
02215	O
.	O
A	O
series	O
of	O
111	O
human	O
bladder	B-malignancy-type
tumors	I-malignancy-type
were	O
screened	O
using	O
oligonucleotide	O
mutant	O
specific	O
probes	O
,	O
restriction	O
enzyme	O
analysis	O
and	O
single	O
-	O
stranded	O
confirmation	O
polymorphism	O
(	O
SSCP	O
)	O
for	O
the	O
presence	O
of	O
H-ras	O
activation	O
events	O
.	O
Thirty-three	O
tumors	O
were	O
found	O
to	O
harbor	O
H-ras	O
mutations	O
where	O
a	O
glycine	O
to	O
valine	O
(	O
G	O
-->	O
T	O
)	O
change	O
in	O
codon	O
12	O
was	O
the	O
most	O
common	O
point	O
mutation	O
recorded	O
(	O
26	O
tumors	O
)	O
.	O
Additional	O
mutations	O
involved	O
glycine	O
to	O
cysteine	O
at	O
codon	O
13	O
(	O
2	O
tumors	O
)	O
and	O
glutamine	O
to	O
arginine	O
/	O
lysine	O
/	O
leucine	O
at	O
codon	O
61	O
(	O
3	O
/	O
1	O
/	O
1	O
tumors	O
,	O
respectively	O
)	O
.	O
Ambiguous	O
signals	O
recorded	O
with	O
oligonucleotide	O
probes	O
were	O
further	O
analyzed	O
using	O
SSCP	O
analysis	O
revealing	O
the	O
presence	O
of	O
H-ras	O
mutations	O
in	O
restricted	O
regions	O
of	O
some	O
tumors	O
.	O
The	O
apparent	O
sensitivity	O
of	O
SSCP	O
enabled	O
us	O
to	O
extend	O
this	O
study	O
to	O
DNA	O
isolated	O
from	O
urine	O
sediments	O
where	O
4	O
of	O
the	O
9	O
patients	O
studied	O
showed	O
representation	O
of	O
mutant	O
H-ras	O
.	O
Our	O
study	O
demonstrates	O
a	O
sensitive	O
,	O
non	O
-	O
invasive	O
assay	O
for	O
the	O
screening	O
of	O
urine	O
-	O
borne	O
cells	O
,	O
with	O
no	O
requirement	O
for	O
prior	O
knowledge	O
of	O
the	O
mutational	O
change	O
at	O
the	O
H-ras	O
locus	O
.	O
PMID	O
:	O
7902340	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Nov	O
7;92(	O
23	O
)	O
:10560	O
-	O
4	O
Identification	O
of	O
a	O
point	O
mutation	O
in	O
the	O
catalytic	O
domain	O
of	O
the	O
protooncogene	O
c-kit	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
who	O
have	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
.	O
Nagata	O
H	O
,	O
Worobec	O
AS	O
,	O
Oh	O
CK	O
,	O
Chowdhury	O
BA	O
,	O
Tannenbaum	O
S,	O
Suzuki	O
Y	O
,	O
Metcalfe	O
DD.	O
Allergic	O
Diseases	O
Section	O
,	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
.	O
Both	O
stem	O
cells	O
and	O
mast	O
cells	O
express	O
c-kit	O
and	O
proliferate	O
after	O
exposure	O
to	O
c-kit	O
ligand	O
.	O
Mutations	O
in	O
c-kit	O
may	O
enhance	O
or	O
interfere	O
with	O
the	O
ability	O
of	O
c-kit	O
receptor	O
to	O
initiate	O
the	O
intracellular	O
pathways	O
resulting	O
in	O
cell	O
proliferation	O
.	O
These	O
observations	O
suggested	O
to	O
us	O
that	O
mastocytosis	B-malignancy-type
might	O
in	O
some	O
patients	O
result	O
from	O
mutations	O
in	O
c-kit	O
.	O
cDNA	O
synthesized	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
indolent	B-malignancy-type
mastocytosis	I-malignancy-type
,	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
,	O
aggressive	O
mastocytosis	B-malignancy-type
,	O
solitary	B-malignancy-type
mastocytoma	I-malignancy-type
,	O
and	O
chronic	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
unassociated	O
with	O
mastocytosis	B-malignancy-type
was	O
thus	O
screened	O
for	O
a	O
mutation	O
of	O
c-kit	O
.	O
This	O
analysis	O
revealed	O
that	O
four	O
of	O
four	O
mastocytosis	B-malignancy-type
patients	O
with	O
an	O
associated	O
hematologic	O
disorder	O
with	O
predominantly	O
myelodysplastic	O
features	O
had	O
an	O
A	O
-->	O
T	O
substitution	O
at	O
nt	O
2468	O
of	O
c-kit	O
mRNA	O
that	O
causes	O
an	O
Asp	O
-	O
816	O
-->	O
Val	O
substitution	O
.	O
One	O
of	O
one	O
patient	O
examined	O
who	O
had	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
had	O
the	O
corresponding	O
mutation	O
in	O
genomic	O
DNA	O
.	O
Identical	O
or	O
similar	O
amino	O
acid	O
substitutions	O
in	O
mast	O
cell	O
lines	O
result	O
in	O
ligand	O
-	O
independent	O
autophosphorylation	O
of	O
the	O
c-kit	O
receptor	O
.	O
This	O
mutation	O
was	O
not	O
identified	O
in	O
the	O
patients	O
within	O
the	O
other	O
disease	O
categories	O
or	O
in	O
67	O
of	O
67	O
controls	O
.	O
The	O
identification	O
of	O
the	O
point	O
mutation	O
Asp	O
816	O
Val	O
in	O
c-kit	O
in	O
patients	O
with	O
mastocytosis	B-malignancy-type
with	O
an	O
associated	O
hematologic	O
disorder	O
provides	O
insight	O
not	O
only	O
into	O
the	O
pathogenesis	O
of	O
this	O
form	O
of	O
mastocytosis	B-malignancy-type
but	O
also	O
into	O
how	O
hematopoiesis	O
may	O
become	O
dysregulated	O
and	O
may	O
serve	O
to	O
provide	O
a	O
means	O
of	O
confirming	O
the	O
diagnosis	O
,	O
assessing	O
prognosis	O
,	O
and	O
developing	O
intervention	O
strategies	O
.	O
PMID	O
:	O
7479840	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1989	O
Nov	O
15	O
;49(	O
22	O
)	O
:6324	O
-	O
7	O
Detection	O
of	O
point	O
mutations	O
in	O
N-ras	O
and	O
K-ras	O
genes	O
of	O
human	O
embryonal	O
rhabdomyosarcomas	B-malignancy-type
using	O
oligonucleotide	O
probes	O
and	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Stratton	O
MR	O
,	O
Fisher	O
C	O
,	O
Gusterson	O
BA	O
,	O
Cooper	O
CS	O
.	O
Section	O
of	O
Chemical	O
Carcinogenesis	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
genes	O
of	O
the	O
ras	O
family	O
(	O
H	O
,	O
K	O
,	O
and	O
N	O
)	O
can	O
be	O
activated	O
by	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
used	O
oligonucleotide	O
probes	O
corresponding	O
to	O
these	O
regions	O
to	O
assess	O
the	O
role	O
of	O
ras	O
gene	O
mutations	O
in	O
the	O
genesis	O
of	O
human	O
rhabdomyosarcoma	B-malignancy-type
.	O
To	O
increase	O
the	O
sensitivity	O
of	O
this	O
method	O
the	O
appropriate	O
regions	O
of	O
the	O
three	O
ras	O
genes	O
were	O
first	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
The	O
results	O
show	O
that	O
35	O
%	O
(	O
5	O
/	O
14	O
)	O
embryonal	O
rhabdomyosarcomas	B-malignancy-type
investigated	O
contain	O
mutations	O
in	O
the	O
N-ras	O
or	O
K-ras	O
genes	O
.	O
Thus	O
ras	O
gene	O
mutation	O
is	O
implicated	O
in	O
the	O
development	O
of	O
mesenchymal	B-malignancy-type
and	O
embryonal	O
tumors	B-malignancy-type
in	O
addition	O
to	O
its	O
previously	O
documented	O
role	O
in	O
epithelial	B-malignancy-type
and	O
hematological	B-malignancy-type
neoplasia	I-malignancy-type
.	O
PMID	O
:	O
2680062	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1991	O
Oct;73(	O
4)	O
:832	O
-	O
6	O
Ras	O
oncogene	O
mutations	O
in	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
.	O
Karga	O
H	O
,	O
Lee	O
JK	O
,	O
Vickery	O
AL	O
Jr	O
,	O
Thor	O
A	O
,	O
Gaz	O
RD	O
,	O
Jameson	O
JL.	O
Department	O
of	O
Pathology	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
,	O
Boston	O
02114	O
.	O
Current	O
models	O
for	O
tumorigenesis	O
propose	O
that	O
a	O
series	O
of	O
genetic	O
alterations	O
occur	O
during	O
the	O
progression	O
from	O
the	O
normal	O
cell	O
to	O
the	O
malignant	O
phenotype	O
.	O
Mutations	O
in	O
each	O
of	O
the	O
three	O
ras	O
genes	O
(	O
K-ras	O
,	O
H-ras	O
,	O
and	O
N-ras	O
)	O
have	O
been	O
identified	O
in	O
many	O
human	O
neoplasms	O
,	O
including	O
thyroid	B-malignancy-type
cancer	I-malignancy-type
.	O
In	O
this	O
study	O
we	O
examined	O
genomic	O
DNA	O
from	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
for	O
mutations	O
that	O
are	O
known	O
to	O
activate	O
the	O
ras	O
oncogenes	O
(	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
.	O
DNA	O
from	O
frozen	O
surgically	O
excised	O
tissue	O
(	O
n	O
=	O
8	O
)	O
and	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
(	O
n	O
=	O
30	O
)	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
screened	O
for	O
mutations	O
using	O
oligonucleotide	O
-	O
specific	O
hybridization	O
.	O
No	O
mutations	O
were	O
identified	O
in	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
(	O
n	O
=	O
9	O
)	O
.	O
In	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
2	O
of	O
14	O
tumors	O
contained	O
mutations	O
(	O
N-ras	O
61	O
,	O
Gln	O
to	O
Arg	O
)	O
,	O
and	O
both	O
of	O
these	O
patients	O
had	O
bone	B-malignancy-type
metastases	I-malignancy-type
.	O
One	O
of	O
15	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
had	O
a	O
ras	O
mutation	O
(	O
H-ras	O
12	O
,	O
Gly	O
to	O
Ser	O
)	O
.	O
In	O
contrast	O
to	O
other	O
studies	O
,	O
we	O
found	O
that	O
ras	O
mutations	O
are	O
relatively	O
uncommon	O
in	O
both	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
neoplasms	I-malignancy-type
.	O
Studies	O
of	O
larger	O
numbers	O
of	O
tumors	O
and	O
comparisons	O
of	O
different	O
patient	O
populations	O
will	O
be	O
required	O
to	O
assess	O
a	O
possible	O
association	O
of	O
mutations	O
in	O
N-ras	O
61	O
with	O
clinically	O
aggressive	O
follicular	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
1890154	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Oral	O
Pathol	O
Med	O
1992	O
May	O
;21(	O
5	O
)	O
:225	O
-	O
9	O
Point	O
mutations	O
in	O
the	O
Ha-ras	O
oncogene	O
are	O
detectable	O
in	O
formalin	O
-	O
fixed	O
tissues	O
of	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
but	O
are	O
infrequent	O
in	O
British	O
cases	O
.	O
Warnakulasuriya	O
KA	O
,	O
Chang	O
SE	O
,	O
Johnson	O
NW.	O
Department	O
of	O
Dental	O
Sciences	O
,	O
Hunterian	O
Institute	O
,	O
Royal	O
College	O
of	O
Surgeons	O
,	O
London	O
,	O
England	O
.	O
Oncogene	O
expression	O
in	O
human	O
neoplasia	O
has	O
been	O
examined	O
extensively	O
in	O
the	O
past	O
decade	O
.	O
More	O
recently	O
the	O
advent	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
has	O
facilitated	O
studies	O
of	O
oncogenes	O
and	O
other	O
DNA	O
structures	O
.	O
Those	O
few	O
studies	O
which	O
have	O
so	O
far	O
searched	O
for	O
oncogene	O
changes	O
in	O
oral	B-malignancy-type
cancer	I-malignancy-type
have	O
utilized	O
frozen	O
specimens	O
.	O
We	O
report	O
here	O
an	O
adaptation	O
of	O
the	O
PCR	O
technique	O
applicable	O
to	O
DNA	O
extracted	O
from	O
archival	O
specimens	O
.	O
Our	O
data	O
complement	O
recent	O
findings	O
that	O
Ha-ras	O
mutations	O
are	O
infrequent	O
in	O
oral	B-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
among	O
white	O
caucasoid	O
populations	O
.	O
PMID	O
:	O
1403838	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Environ	O
Mol	O
Mutagen	O
2002	O
;40(	O
1	O
)	O
:36	O
-	O
40	O
Mutation	O
analysis	O
of	O
K-ras-2	O
in	O
liver	B-malignancy-type
angiosarcoma	I-malignancy-type
and	O
adjacent	O
nonneoplastic	O
liver	O
tissue	O
from	O
patients	O
occupationally	O
exposed	O
to	O
vinyl	O
chloride	O
.	O
Weihrauch	O
M,	O
Bader	O
M,	O
Lehnert	O
G	O
,	O
Koch	O
B	O
,	O
Wittekind	O
C	O
,	O
Wrbitzky	O
R,	O
Tannapfel	O
A.	O
Institute	O
of	O
Occupational	O
Medicine	O
,	O
University	O
of	O
Hannover	O
,	O
Germany	O
.	O
Vinyl	O
chloride	O
(	O
VC	O
)	O
is	O
a	O
potent	O
liver	O
carcinogen	O
that	O
induces	O
angiosarcomas	B-malignancy-type
in	O
humans	O
and	O
animals	O
.	O
Recent	O
evidence	O
shows	O
that	O
liver	B-malignancy-type
tumors	I-malignancy-type
from	O
patients	O
with	O
VC	O
exposure	O
may	O
have	O
a	O
specific	O
K-ras	O
mutation	O
pattern	O
.	O
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
status	O
of	O
K-ras-2	O
in	O
liver	B-malignancy-type
angiosarcomas	I-malignancy-type
(	O
LAS	B-malignancy-type
)	O
from	O
workers	O
occupationally	O
exposed	O
to	O
VC	O
.	O
We	O
examined	O
the	O
presence	O
of	O
K-ras-2	O
mutations	O
in	O
15	O
LAS	B-malignancy-type
from	O
patients	O
with	O
known	O
exposure	O
to	O
VC	O
(	O
median	O
exposure	O
:	O
8,260	O
ppm	O
[	O
range	O
3,900	O
-	O
21,000	O
ppm	O
]	O
]	O
.	O
In	O
all	O
cases	O
,	O
other	O
risk	O
factors	O
for	O
the	O
development	O
of	O
LAS	B-malignancy-type
were	O
excluded	O
.	O
Direct	O
DNA	O
sequencing	O
after	O
microdissection	O
of	O
the	O
tumor	O
cells	O
was	O
used	O
for	O
the	O
analysis	O
.	O
Heterozygous	O
mutations	O
of	O
K-ras-2	O
were	O
detected	O
in	O
8	O
/	O
15	O
LAS	B-malignancy-type
(	O
53	O
%	O
)	O
.	O
Five	O
patients	O
(	O
33	O
%	O
)	O
had	O
a	O
mutation	O
of	O
codon	O
12	O
and	O
three	O
of	O
codon	O
13	O
(	O
20	O
%	O
)	O
.	O
The	O
most	O
common	O
changes	O
were	O
G	O
-->	O
A	O
transitions	O
in	O
five	O
LAS	B-malignancy-type
which	O
lead	O
to	O
the	O
substitution	O
of	O
aspartic	O
acid	O
for	O
glycine	O
in	O
the	O
resulting	O
p21	O
protein	O
.	O
In	O
two	O
patients	O
(	O
13	O
%	O
)	O
,	O
mutations	O
of	O
the	O
K-ras-2	O
gene	O
were	O
identified	O
in	O
the	O
adjacent	O
nonneoplastic	O
liver	O
tissue	O
.	O
These	O
data	O
indicate	O
that	O
VC	O
induces	O
a	O
high	O
frequency	O
of	O
G	O
-->	O
A	O
transitions	O
in	O
human	O
LAS	B-malignancy-type
.	I-malignancy-type
This	O
mutation	O
pattern	O
is	O
likely	O
a	O
consequence	O
of	O
VC	O
-	O
DNA	O
-	O
adduct	O
formation	O
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12211074	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Arch	O
Pathol	O
Lab	O
Med	O
2002	O
Sep;126(9	O
)	O
:1096	O
-	O
100	O
ras	O
Gene	O
mutations	O
and	O
expression	O
of	O
Ras	O
signal	O
transduction	O
mediators	O
in	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Yoo	O
J,	O
Park	O
SY	O
,	O
Robinson	O
RA	O
,	O
Kang	O
SJ	O
,	O
Ahn	O
WS	O
,	O
Kang	O
CS	O
.	O
Department	O
of	O
Pathology	O
,	O
St	O
Vincent	O
's	O
Hospital	O
,	O
Catholic	O
University	O
,	O
Suwon	O
,	O
Kyungkido	O
,	O
South	O
Korea	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
ras	O
gene	O
alteration	O
in	O
human	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
its	O
potential	O
relationship	O
to	O
ras	O
signal	O
transduction	O
mediators	O
.	O
DESIGN	O
:	O
Genomic	O
DNA	O
from	O
104	O
gastric	O
tumors	O
were	O
analyzed	O
by	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
products	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
.	O
All	O
the	O
samples	O
were	O
further	O
investigated	O
with	O
the	O
use	O
of	O
immunohistochemical	O
analysis	O
for	O
ERK1	O
and	O
ERK2	O
.	O
SETTING	O
:	O
Tertiary	O
care	O
teaching	O
hospital	O
.	O
PATIENTS	O
:	O
Seventy	O
patients	O
from	O
a	O
Korean	O
population	O
and	O
34	O
from	O
a	O
Midwestern	O
US	O
population	O
composed	O
of	O
white	O
Americans	O
and	O
African	O
Americans	O
.	O
RESULTS	O
:	O
Fifteen	O
tumors	O
(	O
14	O
%	O
)	O
were	O
positive	O
for	O
either	O
H-ras	O
or	O
K-ras	O
mutation	O
:	O
9	O
(	O
13	O
%	O
)	O
of	O
70	O
Korean	O
patients	O
and	O
6	O
(	O
18	O
%	O
)	O
of	O
34	O
US	O
patients	O
.	O
Seven	O
(	O
78	O
%	O
)	O
of	O
the	O
9	O
mutated	O
tumors	O
from	O
Korean	O
patients	O
and	O
all	O
6	O
(	O
100	O
%	O
)	O
from	O
the	O
US	O
patients	O
were	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
lesions	I-malignancy-type
.	O
Either	O
ERK1	O
and/or	O
ERK2	O
was	O
overexpressed	O
in	O
68	O
samples	O
(	O
65	O
%	O
)	O
.	O
No	O
association	O
was	O
established	O
between	O
ras	O
mutations	O
and	O
overexpression	O
of	O
ERK	O
1	O
/	O
2	O
.	O
However	O
,	O
the	O
correlation	O
between	O
ERK	O
1	O
/	O
2	O
and	O
progression	O
(	O
early	O
vs	O
late	O
)	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
.007	O
)	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
ras	O
mutations	O
are	O
uncommon	O
in	O
gastric	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
that	O
differing	O
racial	O
and/or	O
geographic	O
mechanisms	O
may	O
not	O
underlie	O
ras	O
gene	O
alteration	O
.	O
Most	O
ras	O
mutations	O
were	O
,	O
however	O
,	O
observed	O
in	O
the	O
group	O
of	O
intestinal	O
-	O
type	O
samples	O
,	O
supporting	O
the	O
different	O
genetic	O
mechanisms	O
of	O
carcinogenesis	O
between	O
the	O
intestinal	B-malignancy-type
-	I-malignancy-type
and	O
diffuse	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
tumors	I-malignancy-type
.	O
It	O
is	O
noteworthy	O
that	O
enhanced	O
ERK	O
1	O
/	O
2	O
activity	O
could	O
be	O
one	O
of	O
the	O
characteristics	O
of	O
tumor	O
invasiveness	O
in	O
gastric	B-malignancy-type
cancers	I-malignancy-type
.	O
PMID	O
:	O
12204060	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
2002	O
Aug	O
10;100(	O
5	O
)	O
:549	O
-	O
56	O
Molecular	O
genetic	O
analysis	O
of	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
for	O
aberrations	O
of	O
the	O
WNT	O
signaling	O
pathway	O
genes	O
CTNNB1	O
,	O
APC	O
,	O
ICAT	O
and	O
BTRC	O
.	O
Reifenberger	O
J,	O
Knobbe	O
CB	O
,	O
Wolter	O
M,	O
Blaschke	O
B	O
,	O
Schulte	O
KW	O
,	O
Pietsch	O
T	O
,	O
Ruzicka	O
T	O
,	O
Reifenberger	O
G.	O
Department	O
of	O
Dermatology	O
,	O
Heinrich	O
-	O
Heine	O
-	O
University	O
,	O
Dusseldorf	O
,	O
Germany	O
.	O
reifenbergerj@med	O
.uni	O
-	O
duesseldorf	O
.de	O
Aberrant	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
has	O
been	O
reported	O
in	O
different	O
human	O
tumor	O
types	O
,	O
including	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
.	O
We	O
investigated	O
37	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
(	O
15	O
primary	O
tumors	O
and	O
22	O
metastases	B-malignancy-type
)	O
for	O
alterations	O
of	O
4	O
genes	O
encoding	O
members	O
of	O
this	O
pathway	O
,	O
i.e.	O
,	O
CTNNB1	O
(	O
beta-catenin	O
gene	O
,	O
3p22.1	O
)	O
,	O
APC	O
(	O
adenomatous	O
polyposis	O
coli	O
gene	O
,	O
5q22.2	O
)	O
,	O
BTRC	O
(	O
beta-transducin	O
repeat	O
-	O
containing	O
protein	O
gene	O
,	O
10q24.3	O
)	O
and	O
ICAT	O
(	O
inhibitor	O
of	O
beta-catenin	O
and	O
Tcf-4	O
,	O
1p36.2	O
)	O
.	O
Mutational	O
analysis	O
of	O
CTNNB1	O
identified	O
somatic	O
mutations	O
in	O
1	O
primary	O
melanoma	B-malignancy-type
and	O
1	O
melanoma	B-malignancy-type
metastasis	I-malignancy-type
from	O
2	O
different	O
patients	O
(	O
5	O
%	O
)	O
.	O
Both	O
mutations	O
affected	O
the	O
N	O
-	O
terminal	O
degradation	O
box	O
of	O
beta-catenin	O
,	O
which	O
is	O
important	O
for	O
the	O
regulation	O
of	O
beta-catenin	O
homeostasis	O
.	O
Another	O
primary	O
melanoma	B-malignancy-type
carried	O
a	O
somatic	O
APC	O
missense	O
mutation	O
within	O
the	O
known	O
mutation	O
cluster	O
region	O
in	O
exon	O
15	O
.	O
Fourteen	O
tumors	O
(	O
40	O
%	O
)	O
showed	O
LOH	O
at	O
microsatellite	O
markers	O
on	O
1p36	O
.	O
None	O
of	O
the	O
tumors	O
had	O
lost	O
both	O
copies	O
of	O
the	O
ICAT	O
gene	O
,	O
but	O
1	O
melanoma	B-malignancy-type
metastasis	O
carried	O
a	O
somatic	O
point	O
mutation	O
altering	O
the	O
translation	O
start	O
codon	O
of	O
ICAT	O
.	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
showed	O
markedly	O
reduced	O
ICAT	O
transcript	O
levels	O
(	O
<	O
or	O
=	O
20	O
%	O
relative	O
to	O
normal	O
skin	O
and	O
benign	B-malignancy-type
melanocytic	I-malignancy-type
nevi	I-malignancy-type
)	O
in	O
28	O
/	O
36	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
(	O
78	O
%	O
)	O
,	O
including	O
13	O
/	O
14	O
tumors	O
with	O
LOH	O
on	O
1p36	O
.	O
Allelic	O
loss	O
on	O
10q	O
was	O
detected	O
in	O
15	O
tumors	O
(	O
44	O
%	O
)	O
.	O
We	O
found	O
neither	O
mutations	O
nor	O
complete	O
loss	O
of	O
expression	O
of	O
the	O
BTRC	O
gene	O
in	O
our	O
melanoma	B-malignancy-type
series	O
.	O
Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
Wnt	O
pathway	O
may	O
be	O
altered	O
in	O
malignant	B-malignancy-type
melanomas	I-malignancy-type
by	O
different	O
mechanisms	O
,	O
including	O
rare	O
somatic	O
mutations	O
in	O
CTNNB1	O
,	O
APC	O
or	O
ICAT	O
,	O
as	O
well	O
as	O
low	O
or	O
absent	O
expression	O
of	O
ICAT	O
transcripts	O
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
12124804	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gut	O
2002	O
Aug;51(	O
2	O
)	O
:200	O
-	O
6	O
Molecular	O
characteristics	O
of	O
serrated	B-malignancy-type
adenomas	I-malignancy-type
of	O
the	O
colorectum	O
.	O
Sawyer	O
EJ	O
,	O
Cerar	O
A	O
,	O
Hanby	O
AM	O
,	O
Gorman	O
P	O
,	O
Arends	O
M,	O
Talbot	O
IC	O
,	O
Tomlinson	O
IP	O
.	O
Molecular	O
and	O
Population	O
Genetics	O
Laboratory	O
,	O
Imperial	O
Cancer	O
Research	O
Fund	O
,	O
London	O
WC2A	O
3PX	O
,	O
UK.	O
e	O
.sawyer@icrf	O
.icnet	O
.uk	O
BACKGROUND	O
:	O
Serrated	B-malignancy-type
adenomas	I-malignancy-type
(	O
SAs	B-malignancy-type
)	O
of	O
the	O
colorectum	O
combine	O
architectural	O
features	O
of	O
hyperplastic	B-malignancy-type
polyps	I-malignancy-type
and	O
cytological	O
features	O
of	O
classical	B-malignancy-type
adenomas	I-malignancy-type
.	O
Molecular	O
studies	O
comparing	O
SAs	B-malignancy-type
and	O
classical	B-malignancy-type
adenomas	I-malignancy-type
suggest	O
that	O
each	O
may	O
be	O
a	O
distinct	O
entity	O
;	O
in	O
particular	O
,	O
it	O
has	O
been	O
proposed	O
that	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
distinguishes	O
SAs	B-malignancy-type
from	O
classical	B-malignancy-type
adenomas	I-malignancy-type
and	O
that	O
SAs	B-malignancy-type
and	O
the	O
colorectal	B-malignancy-type
cancers	I-malignancy-type
arising	O
from	O
them	O
develop	O
along	O
a	O
pathway	O
driven	O
by	O
low	O
level	O
microsatellite	O
instability	O
(	O
MSI-L	O
)	O
.	O
AIMS	O
:	O
To	O
define	O
the	O
molecular	O
characteristics	O
of	O
SAs	B-malignancy-type
of	O
the	O
colorectum	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
analysed	O
39	O
SAs	O
from	O
27	O
patients	O
,	O
including	O
eight	O
SAs	B-malignancy-type
from	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
.	O
We	O
screened	O
these	O
polyps	B-malignancy-type
for	O
selected	O
molecular	O
changes	O
,	O
including	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
close	O
to	O
APC	O
(	O
5q21	O
)	O
and	O
CRAC1	O
(	O
15q13	O
-	O
q22	O
)	O
,	O
MSI	O
,	O
and	O
mutations	O
of	O
K-ras	O
,	O
APC	O
,	O
p53	O
,	O
and	O
beta-catenin	O
.	O
Expression	O
patterns	O
of	O
beta-catenin	O
,	O
p53	O
,	O
MLH1	O
,	O
MSH2	O
,	O
E-cadherin	O
,	O
and	O
O(6)-methylguanine	O
DNA	O
methyltransferase	O
(	O
MGMT	O
)	O
were	O
assessed	O
by	O
immunohistochemistry	O
.	O
Comparative	O
genomic	O
hybridisation	O
was	O
performed	O
on	O
several	O
polyps	B-malignancy-type
.	O
RESULTS	O
:	O
MSI	O
was	O
rare	O
(	O
<	O
5	O
%	O
cases	O
)	O
and	O
there	O
was	O
no	O
loss	O
of	O
expression	O
of	O
mismatch	O
repair	O
proteins	O
.	O
Wnt	O
pathway	O
abnormalities	O
(	O
APC	O
mutation	O
/	O
LOH	O
,	O
beta-catenin	O
mutation	O
/	O
nuclear	O
expression	O
)	O
occurred	O
in	O
11	O
SAs	B-malignancy-type
,	O
including	O
6	O
/	O
31	O
(	O
19	O
%	O
)	O
non	B-malignancy-type
-	I-malignancy-type
FAP	I-malignancy-type
tumours	I-malignancy-type
.	O
CRAC1	O
LOH	O
occurred	O
in	O
23	O
%	O
of	O
tumours	O
.	O
K-ras	O
mutations	O
and	O
p53	O
mutations	O
/	O
overexpression	O
were	O
found	O
in	O
15	O
%	O
and	O
8	O
%	O
of	O
SAs	B-malignancy-type
,	O
respectively	O
.	O
Loss	O
of	O
MGMT	O
expression	O
occurred	O
in	O
18	O
%	O
of	O
polyps	B-malignancy-type
and	O
showed	O
a	O
borderline	O
association	O
with	O
K-ras	O
mutations	O
.	O
Aberrant	O
E-cadherin	O
expression	O
was	O
found	O
in	O
seven	O
polyps	B-malignancy-type
.	O
Comparative	O
genomic	O
hybridisation	O
detected	O
no	O
gains	O
or	O
deletions	O
of	O
chromosomal	O
material	O
.	O
CONCLUSIONS	O
:	O
The	O
serrated	O
pathway	O
of	O
colorectal	O
tumorigenesis	O
appears	O
to	O
be	O
heterogeneous	O
.	O
In	O
common	O
with	O
classical	B-malignancy-type
adenomas	I-malignancy-type
,	O
some	O
SAs	B-malignancy-type
develop	O
along	O
pathways	O
involving	O
changes	O
in	O
APC	O
/	O
beta-catenin	O
.	O
SAs	B-malignancy-type
rarely	O
show	O
MSI	O
or	O
any	O
evidence	O
of	O
chromosomal	O
-	O
scale	O
genetic	O
instability	O
.	O
K-ras	O
mutations	O
may	O
however	O
be	O
less	O
common	O
in	O
SAs	B-malignancy-type
than	O
in	O
classical	B-malignancy-type
adenomas	I-malignancy-type
.	O
Some	O
SAs	B-malignancy-type
may	O
harbour	O
changes	O
in	O
the	O
CRAC1	O
gene	O
.	O
Changes	O
in	O
known	O
genes	O
do	O
not	O
account	O
for	O
the	O
growth	O
of	O
the	O
majority	O
of	O
SAs	B-malignancy-type
.	O
PMID	O
:	O
12117880	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Clin	O
Oncol	O
2002	O
Apr;32(	O
4)	O
:146	O
-	O
51	O
Invasive	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
of	O
the	O
remnant	O
pancreatic	O
body	O
9	O
years	O
after	O
resection	O
of	O
an	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreatic	O
head	O
:	O
a	O
case	O
report	O
and	O
comparison	O
of	O
DNA	O
sequence	O
in	O
K-ras	O
gene	O
mutation	O
.	O
Komori	O
T	O
,	O
Ishikawa	O
O	O
,	O
Ohigashi	O
H	O
,	O
Yamada	O
T	O
,	O
Sasaki	O
Y	O
,	O
Imaoka	O
S,	O
Nakaizumi	O
A	O
,	O
Uehara	O
H	O
,	O
Tanaka	O
S,	O
Mano	O
Y	O
,	O
Kasugai	O
T.	O
Department	O
of	O
Surgery	O
,	O
Osaka	O
Medical	O
Center	O
for	O
Cancer	O
and	O
Cardiovascular	O
Diseases	O
,	O
Osaka	O
,	O
Japan	O
.	O
Recently	O
,	O
there	O
have	O
been	O
a	O
few	O
case	O
reports	O
of	O
invasive	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
(	O
IDC	B-malignancy-type
)	O
developed	O
in	O
the	O
remnant	O
pancreas	O
after	O
partial	O
pancreatectomy	O
for	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
neoplasm	I-malignancy-type
(	O
IPMN	B-malignancy-type
)	O
.	O
It	O
is	O
necessary	O
to	O
clarify	O
their	O
histogenetic	O
relationships	O
among	O
two	O
sporadic	B-malignancy-type
tumors	I-malignancy-type
and	O
their	O
surrounding	O
duct	O
epithelium	O
and	O
it	O
would	O
be	O
more	O
reliable	O
if	O
genetic	O
analysis	O
is	O
added	O
to	O
the	O
conventional	O
histology	O
.	O
We	O
report	O
a	O
76	O
-	O
year	O
-	O
old	O
woman	O
who	O
received	O
pancreaticoduodenectomy	O
for	O
IPMN	B-malignancy-type
with	O
a	O
focal	O
in	O
situ	O
carcinoma	B-malignancy-type
(	O
IPMC	B-malignancy-type
)	O
,	O
which	O
was	O
transitional	O
to	O
the	O
surrounding	O
duct	O
epithelium	O
with	O
papillary	O
proliferation	O
and	O
a	O
wide	O
variety	O
of	O
dysplasia	B-malignancy-type
.	O
Nine	O
years	O
after	O
the	O
operation	O
,	O
she	O
died	O
of	O
IDC	B-malignancy-type
in	O
the	O
remnant	O
pancreatic	O
body	O
and	O
its	O
surrounding	O
duct	O
epithelium	O
consisted	O
of	O
hyperplastic	O
mucous	O
cells	O
with	O
slight	B-malignancy-type
-	I-malignancy-type
mild	I-malignancy-type
dysplasia	I-malignancy-type
.	O
Analysis	O
of	O
K-ras	O
mutation	O
at	O
codon	O
12	O
(	O
wild	O
-	O
GGT	O
)	O
by	O
direct	O
sequencing	O
after	O
polymerase	O
chain	O
reaction	O
indicated	O
that	O
their	O
transitioning	O
patterns	O
differed	O
from	O
each	O
other	O
:	O
CGT	O
in	O
IPMC	B-malignancy-type
;	O
no	O
mutation	O
in	O
the	O
mildly	B-malignancy-type
dysplastic	I-malignancy-type
duct	I-malignancy-type
epithelium	I-malignancy-type
around	O
IPMC	B-malignancy-type
;	O
GAT	O
in	O
IDC	B-malignancy-type
of	O
the	O
remnant	O
pancreas	O
;	O
and	O
AGT	O
in	O
mucous	B-malignancy-type
cell	I-malignancy-type
hyperplasia	I-malignancy-type
with	O
mild	B-malignancy-type
dysplasia	I-malignancy-type
close	O
to	O
the	O
IDC	B-malignancy-type
.	O
This	O
is	O
the	O
first	O
report	O
in	O
which	O
the	O
DNA	O
sequence	O
of	O
K-ras	O
mutation	O
was	O
determined	O
for	O
the	O
two	O
sporadic	B-malignancy-type
pancreatic	I-malignancy-type
cancers	I-malignancy-type
and	O
surrounding	O
duct	O
changes	O
.	O
The	O
following	O
two	O
suggestions	O
are	O
made	O
:	O
(1)	O
the	O
cell	O
-	O
origin	O
might	O
have	O
differed	O
between	O
the	O
two	O
types	O
of	O
cancer	O
(	O
IDC	B-malignancy-type
and	O
IPMC	B-malignancy-type
)	O
;	O
and	O
(2)	O
no	O
precursor	O
lesion	O
toward	O
IDC	B-malignancy-type
or	O
IPMC	B-malignancy-type
was	O
identified	O
in	O
their	O
surrounding	O
duct	O
epithelium	O
.	O
PMID	O
:	O
12072425	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatobiliary	O
Pancreat	O
Surg	O
2002;9(	O
1	O
)	O
:76	O
-	O
85	O
p16	O
and	O
p53	O
gene	O
alterations	O
and	O
accumulations	O
in	O
the	O
malignant	O
evolution	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
of	O
the	O
pancreas	O
.	O
Wada	O
K.	O
Department	O
of	O
Surgery	O
,	O
Teikyo	O
University	O
School	O
of	O
Medicine	O
,	O
2	O
-	O
11	O
-	O
1	O
Kaga	O
,	O
Itabashi	O
-	O
ku	O
,	O
Tokyo	O
173	O
-	O
8605	O
,	O
Japan	O
.	O
BACKGROUND	O
/	O
PURPOSE	O
:	O
In	O
general	O
,	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
of	O
the	O
pancreas	O
have	O
a	O
favorable	O
prognosis	O
.	O
However	O
,	O
some	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
show	O
a	O
rapid	O
progression	O
and	O
a	O
poor	O
prognosis	O
,	O
such	O
as	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
of	O
the	O
pancreas	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
genetic	O
backgrounds	O
underlying	O
the	O
evolution	O
necessary	O
for	O
these	O
tumors	O
to	O
become	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
METHODS	O
:	O
Twenty-three	O
patients	O
with	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
,	O
including	O
9	O
adenomas	B-malignancy-type
,	O
5	O
borderline	B-malignancy-type
tumors	I-malignancy-type
,	O
3	O
noninvasive	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
6	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
,	O
along	O
with	O
24	O
patients	O
with	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
were	O
studied	O
.	O
After	O
microdissection	O
,	O
K	O
-	O
ras	O
mutation	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
the	O
p16	O
and	O
p53	O
genes	O
were	O
investigated	O
.	O
RESULTS	O
:	O
In	O
the	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
,	O
K	O
-	O
ras	O
mutations	O
were	O
frequently	O
seen	O
,	O
without	O
a	O
relationship	O
to	O
histological	O
grade	O
.	O
LOH	O
of	O
the	O
p16	O
gene	O
was	O
observed	O
increasingly	O
with	O
increasing	O
degrees	O
of	O
histological	O
atypia	O
.	O
LOH	O
of	O
the	O
p53	O
gene	O
was	O
seen	O
only	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
frequency	O
of	O
each	O
genetic	O
alteration	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
was	O
the	O
same	O
as	O
that	O
in	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
The	O
accumulation	O
of	O
genetic	O
alterations	O
was	O
as	O
common	O
in	O
invasive	B-malignancy-type
carcinomas	I-malignancy-type
,	O
as	O
they	O
were	O
in	O
invasive	B-malignancy-type
ductal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
The	O
p16	O
and	O
p53	O
gene	O
alterations	O
and	O
accumulations	O
observed	O
are	O
crucial	O
events	O
during	O
the	O
carcinogenesis	O
and	O
malignant	O
progression	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
of	O
the	O
pancreas	O
.	O
PMID	O
:	O
12021900	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
2002	O
Jun;26(	O
6)	O
:601	O
-	O
6	O
A	O
case	O
of	O
smouldering	B-malignancy-type
mastocytosis	I-malignancy-type
with	O
peripheral	O
blood	O
eosinophilia	O
and	O
lymphadenopathy	O
.	O
Hauswirth	O
AW	O
,	O
Sperr	O
WR	O
,	O
Ghannadan	O
M,	O
Schernthaner	O
GH	O
,	O
Jordan	O
JH	O
,	O
Fritsche	O
-	O
Polanz	O
R,	O
Simonitsch	O
-	O
Klupp	O
I	O
,	O
Fodinger	O
M,	O
Lechner	O
K	O
,	O
Valent	O
P.	O
Department	O
of	O
Internal	O
Medicine	O
I	O
,	O
Division	O
of	O
Hematology	O
and	O
Hemostaseology	O
,	O
University	O
of	O
Vienna	O
,	O
Vienna	O
,	O
Austria	O
.	O
Systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
SM	B-malignancy-type
)	O
is	O
a	O
clonal	O
hematologic	O
disease	O
showing	O
abnormal	O
growth	O
and	O
accumulation	O
of	O
mast	O
cells	O
(	O
MC	O
)	O
in	O
visceral	O
organs	O
with	O
or	O
without	O
skin	O
involvement	O
.	O
The	O
clinical	O
course	O
in	O
SM	B-malignancy-type
is	O
variable	O
.	O
In	O
fact	O
,	O
indolent	O
and	O
aggressive	O
variants	O
have	O
been	O
described	O
.	O
In	O
addition	O
,	O
SM	B-malignancy-type
patients	O
may	O
acquire	O
an	O
associated	O
hematologic	O
clonal	O
non	B-malignancy-type
-	I-malignancy-type
MC	I-malignancy-type
lineage	I-malignancy-type
disease	I-malignancy-type
(	O
AHNMD	B-malignancy-type
)	O
.	O
In	O
some	O
cases	O
,	O
hematologic	O
parameters	O
are	O
indicative	O
of	O
slowly	O
progressing	O
SM	B-malignancy-type
although	O
the	O
clinical	O
course	O
remains	O
indolent	O
over	O
years	O
.	O
These	O
cases	O
have	O
been	O
referred	O
to	O
as	O
smouldering	B-malignancy-type
SM	I-malignancy-type
.	O
We	O
report	O
on	O
a	O
smouldering	B-malignancy-type
patient	O
presenting	O
with	O
typical	O
skin	B-malignancy-type
lesions	I-malignancy-type
,	O
hypercellular	O
marrow	O
with	O
focal	O
MC	O
aggregates	O
,	O
persistent	O
leukocytosis	O
(	O
20,000	O
-	O
30,000	O
/	O
microl	O
)	O
with	O
eosinophilia	O
(	O
5	O
-	O
10	O
%	O
)	O
,	O
marked	O
lymphadenopathy	O
,	O
and	O
splenomegaly	O
.	O
The	O
C-KIT	O
mutation	O
Asp	O
-	O
816	O
-	O
Val	O
confirmed	O
the	O
diagnosis	O
of	O
SM	B-malignancy-type
.	O
The	O
clinical	O
picture	O
remained	O
stable	O
during	O
an	O
observation	O
period	O
of	O
10	O
years	O
without	O
signs	O
of	O
progression	O
to	O
an	O
AHNMD	B-malignancy-type
or	O
a	O
high	O
grade	O
MC	B-malignancy-type
disease	I-malignancy-type
.	O
These	O
data	O
show	O
that	O
some	O
patients	O
with	O
SM	B-malignancy-type
can	O
remain	O
in	O
a	O
clinically	O
indolent	O
smouldering	O
state	O
over	O
years	O
even	O
when	O
presenting	O
with	O
marked	O
eosinophilia	O
and	O
lymphadenopathy	O
.	O
PMID	O
:	O
12007509	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2002	O
Jan;33(	O
1	O
)	O
:39	O
-	O
46	O
Erratum	O
in	O
:	O
Hum	O
Pathol	O
2002	O
Mar;33(	O
3	O
)	O
:379	O
Fibromatosis	B-malignancy-type
of	O
the	O
breast	O
and	O
mutations	O
involving	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
.	O
Abraham	O
SC	O
,	O
Reynolds	O
C	O
,	O
Lee	O
JH	O
,	O
Montgomery	O
EA	O
,	O
Baisden	O
BL	O
,	O
Krasinskas	O
AM	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
Baltimore	O
,	O
MD	O
21205	O
-	O
2196	O
,	O
USA	O
.	O
Fibromatoses	B-malignancy-type
of	O
the	O
breast	O
are	O
nonmetastasizing	B-malignancy-type
tumors	I-malignancy-type
,	O
but	O
can	O
be	O
infiltrative	O
and	O
locally	O
recurrent	O
.	O
Breast	B-malignancy-type
fibromatoses	I-malignancy-type
are	O
rare	O
,	O
and	O
their	O
specific	O
genetic	O
alterations	O
have	O
not	O
been	O
elucidated	O
.	O
However	O
,	O
their	O
occasional	O
occurrence	O
in	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
and	O
their	O
morphologic	O
identification	O
with	O
other	O
deep	O
fibromatoses	B-malignancy-type
(	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
)	O
suggest	O
that	O
alterations	O
of	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
might	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
and	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
breast	I-malignancy-type
fibromatoses	I-malignancy-type
.	O
We	O
analyzed	O
somatic	O
beta-catenin	O
and	O
APC	O
gene	O
mutations	O
in	O
33	O
breast	B-malignancy-type
fibromatoses	I-malignancy-type
(	O
32	O
sporadic	B-malignancy-type
and	O
1	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
)	O
using	O
immunohistochemistry	O
for	O
beta-catenin	O
,	O
5q	O
allelic	O
loss	O
assays	O
,	O
and	O
direct	O
DNA	O
sequencing	O
for	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
and	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
.	O
Nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
present	O
in	O
the	O
stromal	B-malignancy-type
tumor	I-malignancy-type
cells	O
in	O
most	O
(	O
82	O
%	O
)	O
cases	O
but	O
not	O
in	O
normal	O
stroma	O
or	O
mammary	O
epithelial	O
cells	O
.	O
Somatic	O
alterations	O
of	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
were	O
detected	O
in	O
79	O
%	O
of	O
breast	B-malignancy-type
fibromatoses	I-malignancy-type
,	O
including	O
activating	O
beta-catenin	O
gene	O
mutations	O
in	O
15	O
cases	O
and	O
somatic	O
APC	O
alterations	O
(	O
mutation	O
or	O
5q	O
allelic	O
loss	O
or	O
both	O
)	O
in	O
11	O
.	O
These	O
findings	O
indicate	O
that	O
alterations	O
of	O
the	O
APC	O
/	O
beta-catenin	O
pathway	O
with	O
resultant	O
nuclear	O
translocation	O
of	O
beta-catenin	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
both	O
sporadic	B-malignancy-type
and	O
FAP	B-malignancy-type
-	I-malignancy-type
associated	I-malignancy-type
breast	I-malignancy-type
fibromatosis	I-malignancy-type
.	O
The	O
spectrum	O
of	O
beta-catenin	O
and	O
APC	O
alterations	O
is	O
similar	O
to	O
that	O
described	O
for	O
desmoid	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
abdomen	O
,	O
paraspinal	O
region	O
,	O
and	O
extremities	O
.	O
Copyright	O
2002	O
by	O
W.B.	O
Saunders	O
Company	O
PMID	O
:	O
11823972	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

World	O
J	O
Gastroenterol	O
2001	O
Jun;7(	O
3	O
)	O
:352	O
-	O
6	O
APC	O
and	O
K-ras	O
gene	O
mutation	O
in	O
aberrant	B-malignancy-type
crypt	I-malignancy-type
foci	I-malignancy-type
of	O
human	O
colon	O
.	O
Yuan	O
P	O
,	O
Sun	O
MH	O
,	O
Zhang	O
JS	O
,	O
Zhu	O
XZ	O
,	O
Shi	O
DR.	O
Department	O
of	O
Pathology	O
,	O
Medical	O
College	O
of	O
Fudan	O
University	O
,	O
Shanghai	O
2000	O
32	O
,	O
China	O
.	O
AIM	O
:	O
To	O
study	O
the	O
genetic	O
alteration	O
in	O
ACF	B-malignancy-type
and	O
to	O
define	O
the	O
possibility	O
that	O
ACF	O
may	O
be	O
a	O
very	O
early	O
morphological	O
lesion	O
with	O
molecular	O
changes	O
,	O
and	O
to	O
explore	O
the	O
relationship	O
between	O
ACF	B-malignancy-type
and	O
colorectal	B-malignancy-type
adenoma	I-malignancy-type
even	O
carcinoma	B-malignancy-type
.	O
METHODS	O
:	O
DNA	O
from	O
35	O
CRC	B-malignancy-type
,	O
15	O
adenomas	B-malignancy-type
,	O
34	O
ACF	B-malignancy-type
and	O
10	O
normal	O
mucus	O
was	O
isolated	O
by	O
means	O
of	O
microdissection	O
.	O
Direct	O
gene	O
sequencing	O
of	O
K-ras	O
gene	O
including	O
codon	O
12	O
,	O
13	O
and	O
61	O
as	O
well	O
as	O
the	O
mutation	O
cluster	O
region	O
(	O
MCR	O
)	O
of	O
APC	O
gene	O
was	O
performed	O
.	O
RESULTS	O
:	O
K-ras	O
gene	O
mutation	O
frequency	O
in	O
ACF	B-malignancy-type
,	O
adenoma	B-malignancy-type
and	O
carcinoma	B-malignancy-type
was	O
17.6	O
%	O
(	O
6	O
/	O
34	O
)	O
,	O
13.3	O
%	O
(	O
2	O
/	O
15	O
)	O
,	O
and	O
14.3	O
%	O
(	O
5	O
/	O
35	O
)	O
respectively	O
,	O
showing	O
no	O
difference	O
(	O
P	O
>	O
0.05	O
)	O
in	O
K-ras	O
gene	O
mutation	O
among	O
three	O
pathologic	O
procedures	O
.	O
The	O
K-ras	O
gene	O
mutation	O
in	O
adenoma	B-malignancy-type
,	O
carcinoma	B-malignancy-type
and	O
4	O
ACF	B-malignancy-type
restricted	O
in	O
codon	O
12	O
(	O
GGT	O
GAT	O
)	O
,	O
but	O
the	O
other	O
2	O
mutations	O
from	O
ACF	B-malignancy-type
located	O
in	O
codon	O
13	O
(	O
GGC	O
GAC	O
)	O
.	O
K-ras	O
gene	O
mutation	O
was	O
found	O
more	O
frequently	O
in	O
older	O
patients	O
and	O
patients	O
with	O
polypoid	B-malignancy-type
cancer	I-malignancy-type
.	O
No	O
mutation	O
in	O
codon	O
61	O
was	O
found	O
in	O
the	O
three	O
tissue	O
types	O
.	O
Mutation	O
rate	O
of	O
APC	O
gene	O
in	O
adenoma	B-malignancy-type
and	O
carcinoma	B-malignancy-type
was	O
22.9	O
%	O
(	O
8	O
/	O
35	O
)	O
and	O
26.7	O
%	O
(	O
4	O
/	O
15	O
)	O
,	O
which	O
was	O
higher	O
than	O
ACF	B-malignancy-type
(	O
2.9	O
%	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O
APC	O
gene	O
mutation	O
in	O
carcinoma	B-malignancy-type
was	O
not	O
correlated	O
with	O
age	O
of	O
patients	O
,	O
location	O
,	O
size	O
and	O
differentiation	O
of	O
tumor	O
.	O
CONCLUSION	O
:	O
ACF	B-malignancy-type
might	O
be	O
a	O
very	O
early	O
morphological	O
lesion	O
in	O
the	O
tumorogenesis	O
of	O
colorectal	B-malignancy-type
tumor	I-malignancy-type
.	O
The	O
morphological	O
feature	O
and	O
gene	O
mutation	O
status	O
was	O
different	O
in	O
ACF	B-malignancy-type
and	O
adenoma	B-malignancy-type
.	O
ACF	B-malignancy-type
is	O
possibly	O
putative	O
microadenoma	B-malignancy-type
that	O
might	O
be	O
the	O
precursor	O
of	O
adenoma	B-malignancy-type
.	O
In	O
addition	O
,	O
the	O
development	O
of	O
a	O
subgroup	O
of	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
might	O
undergo	O
a	O
way	O
of	O
normal	B-malignancy-type
epithelium	I-malignancy-type
ACF	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
11819789	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
2002	O
Feb;38(	O
2	O
)	O
:104	O
-	O
8	O
Prognostic	O
impact	O
of	O
molecular	O
genetic	O
alterations	O
in	O
hepatoblastoma	B-malignancy-type
.	O
von	O
Schweinitz	O
D	O
,	O
Kraus	O
JA	O
,	O
Albrecht	O
S,	O
Koch	O
A	O
,	O
Fuchs	O
J,	O
Pietsch	O
T.	O
Department	O
of	O
Pediatric	O
Surgery	O
,	O
University	O
of	O
Basle	O
Childrens	O
'	O
Hospital	O
,	O
Basle	O
,	O
Switzerland	O
.	O
Dietrich	O
.vonSchweinitz@unibas	O
.ch	O
BACKGROUND	O
:	O
During	O
recent	O
years	O
,	O
we	O
identified	O
characteristic	O
genetic	O
alterations	O
in	O
sporadic	B-malignancy-type
hepatoblastoma	I-malignancy-type
(	O
HB	B-malignancy-type
)	O
.	O
These	O
include	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
the	O
chromosomal	O
region	O
11p15.5	O
,	O
LOH	O
on	O
chromosome	O
arms	O
1p	O
and	O
1q	O
,	O
activating	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
as	O
well	O
as	O
overexpression	O
of	O
the	O
c-met	O
oncogene	O
,	O
which	O
encodes	O
the	O
hepatocyte	O
growth	O
factor	O
receptor	O
.	O
We	O
now	O
wanted	O
to	O
evaluate	O
the	O
prognostic	O
relevance	O
of	O
these	O
abnormalities	O
concerning	O
the	O
outcome	O
in	O
a	O
large	O
group	O
of	O
patients	O
.	O
PROCEDURE	O
:	O
All	O
but	O
7	O
of	O
56	O
patients	O
with	O
HB	B-malignancy-type
were	O
treated	O
either	O
with	O
primary	O
resection	O
for	O
small	O
tumors	O
,	O
or	O
neo	O
-	O
adjuvant	O
chemotherapy	O
with	O
ifosfamide	O
,	O
cisplatin	O
and	O
doxorubicin	O
(	O
IPA	O
)	O
before	O
delayed	O
surgery	O
in	O
case	O
of	O
extended	O
disease	O
and	O
additional	O
adjuvant	O
IPA	O
therapy	O
in	O
all	O
cases	O
.	O
Seven	O
tumors	O
were	O
primarily	O
resected	O
and	O
adjuvantly	O
treated	O
with	O
different	O
cytotoxic	O
drugs	O
.	O
LOH	O
11p15.5	O
,	O
LOH	O
1p	O
,	O
and	O
LOH	O
1q	O
were	O
detected	O
in	O
tumor	O
tissue	O
in	O
comparison	O
to	O
normal	O
liver	O
and/or	O
peripheral	O
blood	O
leukocytes	O
by	O
PCR	O
based	O
microsatellite	O
analysis	O
.	O
Beta-catenin	O
mutations	O
were	O
analysed	O
with	O
SSCP	O
,	O
deletion	O
screening	O
and	O
direct	O
sequencing	O
.	O
RT	O
-	O
PCR	O
was	O
used	O
for	O
identification	O
of	O
c-met	O
mRNA	O
overexpression	O
.	O
The	O
results	O
were	O
correlated	O
with	O
the	O
tumors	O
'	O
stage	O
,	O
histological	O
type	O
and	O
epithelial	O
differentiation	O
,	O
as	O
well	O
as	O
with	O
the	O
patients	O
'	O
outcome	O
.	O
RESULTS	O
:	O
Overall	O
disease	O
-	O
free	O
survival	O
after	O
median	O
follow	O
-	O
up	O
of	O
5	O
years	O
was	O
43	O
/	O
56	O
patients	O
(	O
77	O
%	O
)	O
.	O
LOH	O
11p15.5	O
was	O
found	O
in	O
15	O
/	O
56	O
,	O
LOH	O
1p	O
in	O
11	O
/	O
53	O
,	O
LOH	O
1q	O
in	O
7	O
/	O
53	O
and	O
beta-catenin	O
mutations	O
in	O
25	O
/	O
55	O
HB	B-malignancy-type
.	O
13	O
/	O
23	O
HB	B-malignancy-type
had	O
a	O
c-met	O
overexpression	O
.	O
LOH	O
11p15.5	O
and	O
LOH	O
1p	O
were	O
significantly	O
more	O
often	O
found	O
in	O
embryonal	O
HB	B-malignancy-type
,	O
while	O
there	O
was	O
no	O
correlation	O
of	O
other	O
genetic	O
alterations	O
with	O
histological	O
type	O
or	O
differentiation	O
.	O
Furthermore	O
,	O
statistical	O
analysis	O
revealed	O
no	O
correlation	O
of	O
any	O
of	O
these	O
disorders	O
with	O
initial	O
tumor	O
stage	O
,	O
nor	O
with	O
the	O
patients	O
'	O
outcome	O
.	O
CONCLUSION	O
:	O
None	O
of	O
the	O
investigated	O
molecular	O
genetic	O
alterations	O
are	O
suited	O
to	O
serve	O
as	O
a	O
prognostic	O
indicator	O
in	O
HB	B-malignancy-type
.	O
Further	O
investigations	O
,	O
especially	O
genetic	O
screening	O
of	O
tumor	O
tissue	O
may	O
reveal	O
prognostic	O
markers	O
for	O
this	O
neoplasm	B-malignancy-type
.	O
Copyright	O
2002	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11813174	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Nov	O
15;61(	O
22	O
)	O
:8118	O
-	O
21	O
KIT	O
activation	O
is	O
a	O
ubiquitous	O
feature	O
of	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
.	O
Rubin	O
BP	O
,	O
Singer	O
S,	O
Tsao	O
C	O
,	O
Duensing	O
A	O
,	O
Lux	O
ML	O
,	O
Ruiz	O
R,	O
Hibbard	O
MK	O
,	O
Chen	O
CJ	O
,	O
Xiao	O
S,	O
Tuveson	O
DA	O
,	O
Demetri	O
GD	O
,	O
Fletcher	O
CD	O
,	O
Fletcher	O
JA.	O
Department	O
of	O
Pathology	O
,	O
Brigham	O
and	O
Women	O
's	O
Hospital	O
,	O
75	O
Francis	O
Street	O
,	O
Boston	O
,	O
MA	O
02115	O
,	O
USA	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
they	O
are	O
generally	O
resistant	O
to	O
chemotherapy	O
and	O
radiation	O
therapy	O
.	O
Most	O
GISTs	B-malignancy-type
express	O
the	O
KIT	O
receptor	O
tyrosine	O
kinase	O
protein	O
,	O
and	O
a	O
subset	O
of	O
GISTs	B-malignancy-type
contain	O
activating	O
mutations	O
within	O
the	O
KIT	O
juxtamembrane	O
region	O
.	O
We	O
evaluated	O
48	O
GISTs	B-malignancy-type
,	O
including	O
10	O
benign	O
,	O
10	O
borderline	O
,	O
and	O
28	O
malignant	O
cases	O
,	O
to	O
determine	O
whether	O
KIT	O
expression	O
and	O
activation	O
are	O
general	O
properties	O
of	O
these	O
tumors	O
.	O
Immunohistochemical	O
KIT	O
expression	O
was	O
demonstrated	O
in	O
each	O
case	O
.	O
Somatic	O
KIT	O
mutations	O
were	O
found	O
in	O
44	O
tumors	O
(	O
92	O
%	O
)	O
,	O
of	O
which	O
34	O
(	O
71	O
%	O
)	O
had	O
juxtamembrane	O
region	O
mutations	O
.	O
Other	O
GISTs	B-malignancy-type
had	O
KIT	O
mutations	O
in	O
the	O
extracellular	O
region	O
(	O
n	O
=	O
6	O
)	O
and	O
in	O
two	O
different	O
regions	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
(	O
n	O
=	O
4	O
)	O
.	O
Contrary	O
to	O
previous	O
reports	O
,	O
KIT	O
mutations	O
were	O
not	O
identified	O
preferentially	O
in	O
higher	O
-	O
grade	O
tumors	O
:	O
indeed	O
,	O
they	O
were	O
found	O
in	O
each	O
of	O
10	O
histologically	O
benign	O
GISTs	B-malignancy-type
.	O
Notably	O
,	O
mutations	O
in	O
all	O
KIT	O
domains	O
were	O
associated	O
with	O
high	O
-	O
level	O
KIT	O
activation	O
/	O
phosphorylation	O
,	O
and	O
KIT	O
activation	O
was	O
also	O
demonstrated	O
in	O
the	O
four	O
GISTs	B-malignancy-type
that	O
lacked	O
detectable	O
KIT	O
genomic	O
and	O
cDNA	O
mutations	O
.	O
These	O
studies	O
underscore	O
the	O
role	O
of	O
KIT	O
activation	O
in	O
GIST	B-malignancy-type
pathogenesis	O
,	O
and	O
they	O
suggest	O
that	O
activated	O
KIT	O
might	O
represent	O
a	O
universal	O
therapeutic	O
target	O
in	O
GISTs	B-malignancy-type
.	O
PMID	O
:	O
11719439	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
2001	O
Sep;195(	O
2	O
)	O
:222	O
-	O
8	O
beta-catenin	O
nuclear	O
expression	O
correlates	O
with	O
cyclin	O
D1	O
overexpression	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumours	I-malignancy-type
.	O
Saito	O
T	O
,	O
Oda	O
Y	O
,	O
Tanaka	O
K	O
,	O
Matsuda	O
S,	O
Tamiya	O
S,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
The	O
immunohistochemical	O
expression	O
of	O
beta-catenin	O
,	O
cyclin	O
D1	O
,	O
Ki-67	O
and	O
PCNA	O
was	O
Examined	O
in	O
38	O
cases	O
of	O
sporadic	B-malignancy-type
extra	I-malignancy-type
-	I-malignancy-type
abdominal	I-malignancy-type
or	O
abdominal	B-malignancy-type
-	I-malignancy-type
wall	I-malignancy-type
desmoid	I-malignancy-type
tumours	I-malignancy-type
without	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
(	O
FAP	B-malignancy-type
)	O
,	O
to	O
evaluate	O
the	O
hypothesis	O
that	O
the	O
accumulated	O
beta-catenin	O
within	O
the	O
nuclei	O
could	O
affect	O
the	O
regulation	O
of	O
the	O
cyclin	O
D1	O
gene	O
.	O
There	O
was	O
a	O
statistically	O
significant	O
correlation	O
between	O
beta-catenin	O
accumulation	O
and	O
cyclin	O
D1	O
overexpression	O
(	O
p	O
=	O
0.029	O
)	O
.	O
Each	O
group	O
with	O
beta-catenin	O
accumulation	O
or	O
cyclin	O
D1	O
overexpression	O
showed	O
a	O
higher	O
PCNA	O
-	O
LI	O
than	O
those	O
without	O
,	O
the	O
difference	O
being	O
statistically	O
significant	O
(	O
p	O
=	O
0.007	O
,	O
p	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O
Differential	O
PCR	O
was	O
also	O
performed	O
to	O
detect	O
amplification	O
of	O
the	O
cyclin	O
D1	O
gene	O
and	O
mutational	O
analysis	O
was	O
undertaken	O
for	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
.	O
Amplification	O
of	O
the	O
cyclin	O
D1	O
gene	O
was	O
observed	O
in	O
13	O
out	O
of	O
22	O
cases	O
(	O
59.1	O
%	O
)	O
.	O
There	O
were	O
nine	O
-	O
point	O
mutations	O
in	O
7	O
out	O
of	O
18	O
cases	O
(	O
38.9	O
%	O
)	O
.	O
The	O
distribution	O
of	O
beta-catenin	O
mutation	O
fell	O
within	O
a	O
wide	O
range	O
,	O
from	O
codon	O
21	O
to	O
codon	O
67	O
.	O
In	O
conclusion	O
,	O
beta-catenin	O
nuclear	O
expression	O
correlated	O
with	O
cyclin	O
D1	O
overexpression	O
in	O
sporadic	B-malignancy-type
desmoid	I-malignancy-type
tumours	I-malignancy-type
,	O
which	O
could	O
be	O
an	O
in	O
vivo	O
model	O
system	O
for	O
the	O
APC	O
-	O
beta-catenin	O
-	O
Tcf	O
pathway	O
.	O
In	O
addition	O
,	O
beta-catenin	O
mutations	O
in	O
desmoid	B-malignancy-type
tumours	I-malignancy-type
occurred	O
at	O
an	O
unusually	O
wide	O
range	O
of	O
sites	O
within	O
the	O
gene	O
.	O
Copyright	O
2001	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
PMID	O
:	O
11592102	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Endocrinol	O
(	O
Oxf	O
)	O
2001	O
Aug;55(	O
2	O
)	O
:241	O
-	O
8	O
Ras	O
mutations	O
are	O
rare	O
in	O
solitary	O
cold	O
and	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
Krohn	O
K	O
,	O
Reske	O
A	O
,	O
Ackermann	O
F	O
,	O
Muller	O
A	O
,	O
Paschke	O
R.	O
III	O
Medical	O
Department	O
,	O
University	O
of	O
Leipzig	O
,	O
Leipzig	O
,	O
Germany	O
.	O
OBJECTIVE	O
:	O
Activation	O
of	O
ras	O
proto	O
-	O
oncogenes	O
as	O
a	O
result	O
of	O
point	O
mutations	O
is	O
detectable	O
in	O
a	O
significant	O
percentage	O
of	O
most	O
types	O
of	O
tumour	O
.	O
Similar	O
to	O
neoplasms	O
of	O
other	O
organs	O
,	O
mutations	O
of	O
all	O
three	O
ras	O
genes	O
can	O
be	O
found	O
in	O
thyroid	B-malignancy-type
tumours	I-malignancy-type
.	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
mutations	O
have	O
been	O
detected	O
in	O
up	O
to	O
20	O
%	O
of	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
and	O
adenomatous	B-malignancy-type
nodules	I-malignancy-type
which	O
were	O
not	O
functionally	O
characterized	O
.	O
This	O
raises	O
the	O
question	O
as	O
to	O
whether	O
ras	O
mutations	O
are	O
specific	O
for	O
hypofunctional	O
nodules	O
and	O
TSH	O
receptor	O
mutations	O
for	O
hyperfunctioning	O
nodules	O
.	O
DESIGN	O
:	O
To	O
investigate	O
ras	O
and	O
TSH	O
receptor	O
mutations	O
with	O
respect	O
to	O
functional	O
differentiation	O
we	O
studied	O
41	O
scintigraphically	O
cold	O
nodules	B-malignancy-type
and	O
47	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
To	O
address	O
the	O
likelihood	O
of	O
a	O
somatic	O
mutation	O
we	O
also	O
studied	O
the	O
clonal	O
origin	O
of	O
these	O
tumours	O
.	O
MEASUREMENTS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
nodular	O
and	O
surrounding	O
tissue	O
.	O
Mutational	O
hot	O
spots	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
H	O
-	O
and	O
K	O
-	O
ras	O
gene	O
were	O
PCR	O
amplified	O
and	O
sequenced	O
using	O
big	O
dye	O
terminator	O
chemistry	O
.	O
Denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
was	O
used	O
to	O
verify	O
sequencing	O
results	O
for	O
the	O
H-ras	O
gene	O
and	O
to	O
analyse	O
the	O
N-ras	O
gene	O
because	O
its	O
greater	O
sensitivity	O
in	O
detecting	O
somatic	O
mutations	O
.	O
Clonality	O
of	O
nodular	O
thyroid	O
tissue	O
was	O
evaluated	O
using	O
X	O
-	O
Chromosome	O
inactivation	O
based	O
on	O
PCR	O
amplification	O
of	O
the	O
human	O
androgen	O
receptor	O
locus	O
.	O
RESULTS	O
:	O
Monoclonal	O
origin	O
was	O
detectable	O
in	O
14	O
of	O
23	O
informative	O
samples	O
from	O
cold	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
.	O
In	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
the	O
frequency	O
of	O
clonal	O
tissue	O
was	O
20	O
in	O
30	O
informative	O
cases	O
.	O
Only	O
one	O
point	O
mutation	O
could	O
be	O
found	O
in	O
the	O
N-ras	O
gene	O
codon	O
61	O
(	O
Gly	O
to	O
Arg	O
)	O
in	O
a	O
cold	O
adenomatous	B-malignancy-type
nodule	I-malignancy-type
which	O
was	O
monoclonal	O
.	O
In	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
no	O
ras	O
mutation	O
was	O
detectable	O
.	O
CONCLUSION	O
:	O
Our	O
study	O
suggests	O
that	O
ras	O
mutations	O
are	O
rare	O
in	O
solitary	O
cold	O
and	O
toxic	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
and	O
that	O
the	O
frequent	O
monoclonal	O
origin	O
of	O
these	O
tumours	O
implies	O
somatic	O
mutations	O
in	O
genes	O
other	O
than	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
.	O
PMID	O
:	O
11531932	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Gynecol	O
Oncol	O
2001	O
Sep;82(	O
3	O
)	O
:450	O
-	O
5	O
Cytoplasmic	O
/	O
nuclear	O
expression	O
without	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
is	O
frequent	O
in	O
the	O
development	O
of	O
the	O
neoplasm	B-malignancy-type
of	O
the	O
uterine	O
cervix	O
.	O
Shinohara	O
A	O
,	O
Yokoyama	O
Y	O
,	O
Wan	O
X	O
,	O
Takahashi	O
Y	O
,	O
Mori	O
Y	O
,	O
Takami	O
T	O
,	O
Shimokawa	O
K	O
,	O
Tamaya	O
T.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Gifu	O
University	O
School	O
of	O
Medicine	O
,	O
40	O
Tsukasa	O
-	O
machi	O
,	O
Gifu	O
,	O
500	O
-	O
8705	O
,	O
Japan	O
.	O
OBJECTIVE	O
:	O
The	O
dual	O
function	O
of	O
beta-catenin	O
(	O
e.g.	O
,	O
as	O
an	O
intermediate	O
protein	O
between	O
adherence	O
junctions	O
and	O
the	O
microfilaments	O
,	O
and	O
as	O
a	O
mediator	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
)	O
is	O
currently	O
known	O
.	O
Stabilization	O
of	O
beta-catenin	O
and	O
subsequent	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
are	O
involved	O
in	O
the	O
development	O
of	O
some	O
malignancies	O
.	O
We	O
analyzed	O
the	O
immunohistochemical	O
localization	O
of	O
beta-catenin	O
and	O
the	O
somatic	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
the	O
malignant	O
phenotype	O
of	O
the	O
uterine	O
cervix	O
.	O
METHODS	O
:	O
Immunohistochemical	O
localization	O
of	O
beta-catenin	O
and	O
mutation	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
were	O
analyzed	O
in	O
38	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
and	O
43	O
cancerous	B-malignancy-type
lesions	I-malignancy-type
.	O
RESULTS	O
:	O
In	O
normal	O
cervix	O
,	O
beta-catenin	O
was	O
observed	O
around	O
the	O
plasma	O
membrane	O
of	O
the	O
cells	O
in	O
the	O
basal	O
and	O
parabasal	O
layers	O
of	O
the	O
epithelium	O
.	O
The	O
frequency	O
of	O
cytoplasmic	O
/	O
nuclear	O
beta-catenin	O
expression	O
correlated	O
with	O
a	O
high	O
histological	O
grade	O
of	O
cervical	B-malignancy-type
intraepithelial	I-malignancy-type
neoplasia	I-malignancy-type
.	O
Among	O
invasive	O
carcinomas	B-malignancy-type
,	O
11	O
(	O
73	O
%	O
)	O
of	O
15	O
samples	O
showed	O
cytoplasmic	O
/	O
nuclear	O
localization	O
to	O
variable	O
extents	O
.	O
A	O
mutational	O
analysis	O
showed	O
that	O
mutation	O
occurred	O
in	O
7	O
of	O
68	O
specimens	O
.	O
Six	O
cases	O
with	O
mutations	O
revealed	O
cytoplasmic	O
/	O
nuclear	O
beta-catenin	O
expression	O
,	O
though	O
32	O
(	O
84	O
%	O
)	O
of	O
the	O
38	O
samples	O
showing	O
cytoplasmic	O
/	O
nuclear	O
beta-catenin	O
expression	O
were	O
not	O
associated	O
with	O
the	O
mutation	O
.	O
CONCLUSION	O
:	O
These	O
results	O
indicate	O
that	O
cytoplasmic	O
/	O
nuclear	O
expression	O
of	O
beta-catenin	O
is	O
associated	O
with	O
the	O
malignant	O
phenotype	O
of	O
the	O
cervix	O
,	O
but	O
the	O
contribution	O
of	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
is	O
limited	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11520139	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Digestion	O
2001;63(	O
4)	O
:229	O
-	O
33	O
K-ras	O
and	O
p53	O
mutations	O
in	O
colonic	O
lavage	O
fluid	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
neoplasias	I-malignancy-type
.	O
Heinzlmann	O
M,	O
Neynaber	O
S,	O
Heldwein	O
W	O
,	O
Folwaczny	O
C.	O
Department	O
of	O
Gastroenterology	O
,	O
Medizinische	O
Klinik	O
Innenstadt	O
,	O
Ludwig	O
-	O
Maximilians	O
-	O
Universitat	O
,	O
Munchen	O
,	O
Germany	O
.	O
BACKGROUND	O
:	O
The	O
adenoma	B-malignancy-type
-	O
carcinoma	B-malignancy-type
sequence	O
has	O
its	O
molecular	O
basis	O
in	O
several	O
gene	O
mutations	O
of	O
which	O
K-ras	O
and	O
p53	O
are	O
of	O
paramount	O
importance	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
whether	O
these	O
genetic	O
alterations	O
can	O
be	O
detected	O
in	O
colonic	O
lavage	O
fluid	O
from	O
patients	O
with	O
colorectal	B-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
METHODS	O
:	O
In	O
45	O
patients	O
with	O
adenomas	B-malignancy-type
,	O
20	O
patients	O
with	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
and	O
38	O
patients	O
with	O
non	O
-	O
neoplastic	O
and	O
noninflammatory	O
diseases	O
of	O
the	O
colon	O
p53	O
and	O
K-ras	O
mutations	O
were	O
evaluated	O
in	O
colonic	O
lavage	O
fluid	O
employing	O
single	O
-	O
strand	O
confirmation	O
polymorphism	O
analysis	O
and	O
dot	O
-	O
blot	O
hybridization	O
,	O
respectively	O
.	O
RESULTS	O
:	O
Mutations	O
of	O
the	O
K-ras	O
and	O
the	O
p53	O
gene	O
were	O
found	O
in	O
15.6	O
%	O
(	O
p	O
=	O
0.065	O
)	O
of	O
patients	O
with	O
adenomas	B-malignancy-type
,	O
in	O
25.0	O
%	O
(	O
p	O
=	O
0.016	O
)	O
of	O
patients	O
with	O
carcinomas	B-malignancy-type
and	O
in	O
2.6	O
%	O
in	O
the	O
control	O
group	O
.	O
CONCLUSION	O
:	O
Genetic	O
alterations	O
in	O
the	O
colonic	O
lavage	O
fluid	O
could	O
be	O
an	O
additional	O
diagnostic	O
tool	O
for	O
the	O
surveillance	O
of	O
patients	O
with	O
colorectal	B-malignancy-type
neoplasias	I-malignancy-type
.	O
PMID	O
:	O
11435722	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Formos	O
Med	O
Assoc	O
2001	O
May	O
;100(	O
5	O
)	O
:352	O
-	O
4	O
K-ras	O
mutation	O
at	O
codon	O
12	O
in	O
stage	O
I	O
pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
:	O
analysis	O
by	O
laser	O
capture	O
microdissection	O
and	O
direct	O
sequencing	O
.	O
Chang	O
MC	O
,	O
Chang	O
YT	O
,	O
Wu	O
MS	O
,	O
Shun	O
CT	O
,	O
Tien	O
YW	O
,	O
Lin	O
JT.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
7	O
Chung	O
-	O
Shan	O
South	O
Road	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
Pancreatic	B-malignancy-type
ductal	I-malignancy-type
adenocarcinoma	I-malignancy-type
has	O
been	O
reported	O
to	O
carry	O
a	O
rate	O
mutation	O
high	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
.	O
To	O
avoid	O
the	O
pitfalls	O
of	O
conventional	O
methods	O
of	O
tissue	O
dissection	O
that	O
might	O
affect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
detecting	O
K-ras	O
mutation	O
,	O
laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
technique	O
was	O
used	O
.	O
Pancreatic	B-malignancy-type
adenocarcinoma	I-malignancy-type
tissues	O
were	O
obtained	O
from	O
15	O
patients	O
who	O
underwent	O
Whipple	O
's	O
procedure	O
.	O
Selected	O
tissues	O
procured	O
by	O
LCM	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
after	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
K-ras	O
sequences	O
at	O
codon	O
12	O
.	O
K-ras	O
mutation	O
was	O
noted	O
in	O
nine	O
patients	O
.	O
All	O
mutations	O
showed	O
G	O
to	O
A	O
substitution	O
at	O
codon	O
12	O
.	O
The	O
mutational	O
pattern	O
(	O
GGT	O
to	O
GAT	O
)	O
is	O
similar	O
in	O
both	O
western	O
and	O
eastern	O
reports	O
.	O
LCM	O
is	O
a	O
feasible	O
method	O
to	O
effectively	O
obtain	O
pure	O
tumor	O
cells	O
from	O
a	O
surgical	O
specimen	O
.	O
It	O
remains	O
to	O
be	O
determined	O
whether	O
this	O
low	O
mutation	O
rate	O
is	O
a	O
result	O
of	O
relatively	O
early	O
stage	O
of	O
disease	O
or	O
different	O
carcinogenesis	O
in	O
different	O
geographic	O
regions	O
.	O
PMID	O
:	O
11432318	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2001	O
Jul	O
-	O
Aug;8(	O
4)	O
:889	O
-	O
92	O
K-ras	O
gene	O
mutations	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
in	O
Japanese	O
.	O
Noda	O
N	O
,	O
Matsuzoe	O
D	O
,	O
Konno	O
T	O
,	O
Kawahara	O
K	O
,	O
Yamashita	O
Y	O
,	O
Shirakusa	O
T.	O
Second	O
Department	O
of	O
Surgery	O
,	O
Fukuoka	O
University	O
School	O
of	O
Medicine	O
,	O
7	O
-	O
45	O
-	O
1	O
Nanakuma	O
,	O
Johnan	O
-	O
ku	O
,	O
Fukuoka	O
City	O
,	O
Fukuoka	O
814	O
-0180	O
,	O
Japan	O
.	O
n	O
-	O
nao@pop17.odn	O
.ne	O
.jp	O
To	O
evaluate	O
the	O
association	O
of	O
mutations	O
in	O
the	O
K-ras	O
gene	O
with	O
the	O
incidence	O
of	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
in	O
Japanese	O
patients	O
,	O
410	O
patients	O
treated	O
surgically	O
were	O
studied	O
.	O
DNA	O
was	O
extracted	O
from	O
frozen	O
specimens	O
,	O
and	O
polymerase	O
chain	O
reaction	O
-	O
sequence	O
specific	O
oligonucleotide	O
probe	O
(	O
PCR	O
-	O
SSOP	O
)	O
hybridization	O
assay	O
was	O
used	O
to	O
examine	O
K-ras	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
.	O
K-ras	O
mutations	O
were	O
found	O
in	O
33	O
patients	O
(	O
8.0	O
%	O
)	O
,	O
and	O
all	O
were	O
smokers	O
or	O
ex	O
-	O
smokers	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
clinical	O
or	O
pathological	O
stage	O
between	O
wild	O
-	O
type	O
cases	O
and	O
mutant	O
cases	O
.	O
The	O
most	O
frequently	O
identified	O
mutation	O
was	O
a	O
G	O
-->	O
T	O
transversion	O
(	O
25	O
/	O
33	O
,	O
75.8	O
%	O
)	O
that	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
glycine	O
for	O
a	O
cysteine	O
or	O
a	O
valine	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
the	O
majority	O
of	O
K-ras	O
mutations	O
among	O
smokers	O
are	O
G	O
-->	O
T	O
transversion	O
.	O
In	O
our	O
study	O
,	O
K-ras	O
mutations	O
were	O
found	O
only	O
in	O
smokers	O
,	O
and	O
there	O
was	O
a	O
high	O
frequency	O
of	O
G	O
-->	O
T	O
transversions	O
.	O
A	O
clear	O
correlation	O
exists	O
between	O
smoking	O
and	O
K-ras	O
gene	O
mutations	O
.	O
PMID	O
:	O
11410804	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2001	O
Jun	O
1;61(	O
11	O
)	O
:4350	O
-	O
6	O
p53	O
and	O
K-ras	O
mutations	O
in	O
lung	B-malignancy-type
cancers	I-malignancy-type
from	O
former	O
and	O
never	O
-	O
smoking	O
women	O
.	O
Vahakangas	O
KH	O
,	O
Bennett	O
WP	O
,	O
Castren	O
K	O
,	O
Welsh	O
JA	O
,	O
Khan	O
MA	O
,	O
Blomeke	O
B	O
,	O
Alavanja	O
MC	O
,	O
Harris	O
CC.	O
Department	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Oulu	O
,	O
P.	O
O.	O
Box	O
5000	O
,	O
FIN	O
-	O
90014	O
Oulu	O
,	O
Finland	O
.	O
Somatic	O
p53	O
mutations	O
are	O
common	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
Active	O
cigarette	O
smoking	O
is	O
positively	O
correlated	O
with	O
the	O
total	O
frequency	O
of	O
p53	O
mutations	O
and	O
G	O
:	O
C	O
to	O
T	O
:	O
A	O
transversions	O
on	O
the	O
nontranscribed	O
(	O
DNA	O
coding	O
)	O
strand	O
.	O
Mutational	O
hotspots	O
within	O
the	O
p53	O
gene	O
,	O
e.g.	O
,	O
codon	O
157	O
,	O
have	O
been	O
identified	O
for	O
tobacco	O
-	O
related	O
lung	B-malignancy-type
cancer	I-malignancy-type
,	O
whereas	O
these	O
same	O
mutations	O
are	O
found	O
rarely	O
in	O
other	O
cancers	O
.	O
Such	O
data	O
implicate	O
specific	O
p53	O
mutations	O
as	O
molecular	O
markers	O
of	O
smoking	O
.	O
Because	O
limited	O
data	O
exist	O
concerning	O
the	O
p53	O
mutation	O
frequency	O
and	O
spectra	O
in	O
ex	O
-	O
smokers	O
and	O
nonsmokers	O
,	O
we	O
have	O
analyzed	O
p53	O
and	O
K-ras	O
mutations	O
in	O
126	O
lung	B-malignancy-type
cancers	I-malignancy-type
from	O
a	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
of	O
nonsmoking	O
(	O
n	O
=	O
117	O
)	O
or	O
ex	O
-	O
smoking	O
(	O
n	O
=	O
9	O
)	O
women	O
from	O
Missouri	O
with	O
quantitative	O
assessments	O
of	O
exposure	O
to	O
environmental	O
tobacco	O
smoke	O
.	O
Mutations	O
in	O
the	O
p53	O
gene	O
were	O
found	O
in	O
lung	B-malignancy-type
cancers	I-malignancy-type
from	O
lifetime	O
nonsmokers	O
(	O
19	O
%	O
)	O
and	O
ex	O
-	O
smokers	O
(	O
67	O
%	O
;	O
odds	O
ratio	O
,	O
9.08	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
2.06	O
-	O
39.98	O
)	O
.	O
All	O
deletions	O
were	O
found	O
in	O
tumors	O
from	O
patients	O
who	O
were	O
either	O
ex	O
-	O
smokers	O
or	O
nonsmokers	O
exposed	O
to	O
passive	O
smoking	O
.	O
The	O
G	O
:	O
C	O
to	O
A	O
:	O
T	O
transitions	O
(	O
11	O
of	O
28	O
;	O
39	O
%	O
)	O
were	O
the	O
most	O
frequent	O
p53	O
mutations	O
found	O
and	O
clustered	O
in	O
tumors	O
from	O
lifetime	O
nonsmokers	O
without	O
passive	O
smoke	O
exposure	O
.	O
The	O
incidence	O
of	O
K-ras	O
codon	O
12	O
or	O
13	O
mutations	O
was	O
11	O
%	O
(	O
14	O
of	O
115	O
analyzed	O
)	O
with	O
no	O
difference	O
between	O
long	O
-	O
term	O
ex	O
-	O
smokers	O
and	O
nonsmokers	O
.	O
These	O
and	O
other	O
results	O
indicate	O
that	O
p53	O
mutations	O
occur	O
more	O
commonly	O
in	O
smokers	O
and	O
ex	O
-	O
smokers	O
than	O
in	O
never	O
-	O
smokers	O
.	O
Such	O
comparisons	O
provide	O
additional	O
evidence	O
of	O
genetic	O
damage	O
caused	O
by	O
tobacco	O
smoke	O
during	O
lung	O
carcinogenesis	O
.	O
PMID	O
:	O
11389059	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
2001	O
Jul;25(	O
7)	O
:627	O
-	O
34	O
A	O
case	O
of	O
'	B-malignancy-type
smouldering	I-malignancy-type
'	I-malignancy-type
mastocytosis	I-malignancy-type
with	O
high	O
mast	O
cell	O
burden	O
,	O
monoclonal	O
myeloid	O
cells	O
,	O
and	O
C-KIT	O
mutation	O
Asp	O
-	O
816	O
-	O
Val	O
.	O
Jordan	O
JH	O
,	O
Fritsche	O
-	O
Polanz	O
R,	O
Sperr	O
WR	O
,	O
Mitterbauer	O
G	O
,	O
Fodinger	O
M,	O
Schernthaner	O
GH	O
,	O
Christian	O
Bankl	O
H	O
,	O
Gebhart	O
W	O
,	O
Chott	O
A	O
,	O
Lechner	O
K	O
,	O
Valent	O
P.	O
Department	O
of	O
Internal	O
Medicine	O
I	O
,	O
Division	O
of	O
Hematology	O
and	O
Hemostaseology	O
,	O
University	O
of	O
Vienna	O
,	O
Vienna	O
,	O
Austria	O
.	O
Mastocytosis	B-malignancy-type
is	O
a	O
term	O
used	O
for	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
abnormal	O
growth	O
and	O
accumulation	O
of	O
tissue	O
mast	O
cells	O
(	O
MC	O
)	O
in	O
one	O
or	O
more	O
organ	O
systems	O
.	O
In	O
patients	O
with	O
systemic	B-malignancy-type
mastocytosis	I-malignancy-type
(	O
SM	B-malignancy-type
)	O
the	O
clinical	O
course	O
may	O
be	O
indolent	O
or	O
aggressive	O
or	O
even	O
complicated	O
by	O
leukemic	O
progression	O
or	O
an	O
associated	B-malignancy-type
clonal	I-malignancy-type
hematologic	I-malignancy-type
non	I-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
lineage	I-malignancy-type
disease	I-malignancy-type
(	O
AHNMD	B-malignancy-type
)	O
.	O
However	O
,	O
at	O
first	O
presentation	O
(	O
diagnosis	O
)	O
it	O
may	O
be	O
difficult	O
to	O
define	O
the	O
category	O
of	O
disease	O
and	O
the	O
prognosis	O
.	O
We	O
report	O
on	O
a	O
48	O
-	O
year	O
-	O
old	O
female	O
patient	O
with	O
SM	B-malignancy-type
with	O
urticaria	B-malignancy-type
pigmentosa	I-malignancy-type
-	I-malignancy-type
like	I-malignancy-type
skin	I-malignancy-type
lesions	I-malignancy-type
and	O
mediator	O
-	O
related	O
symptoms	O
.	O
She	O
was	O
found	O
to	O
have	O
splenomegaly	O
,	O
a	O
high	O
infiltration	O
grade	O
(	O
MC	O
)	O
in	O
bone	O
marrow	O
biopsies	O
(	O
>	O
30	O
%	O
)	O
,	O
mild	O
anemia	O
,	O
and	O
a	O
high	O
serum	O
tryptase	O
level	O
(	O
>	O
500	O
ng	O
/	O
ml	O
)	O
.	O
In	O
addition	O
,	O
she	O
exhibited	O
discrete	O
histologic	O
signs	O
of	O
myeloproliferation	O
in	O
the	O
'	O
non	O
-	O
affected	O
'	O
marrow	O
and	O
monoclonal	O
blood	O
cells	O
established	O
by	O
C-KIT	O
2468	O
A	O
-->	O
T	O
mutation	O
(	O
Asp	O
-	O
816	O
-	O
Val	O
)	O
-	O
analysis	O
and	O
HUMARA	O
assay	O
.	O
Despite	O
these	O
findings	O
,	O
however	O
,	O
the	O
clinical	O
course	O
was	O
stable	O
over	O
years	O
and	O
no	O
AHNMD	B-malignancy-type
or	O
organ	O
impairment	O
developed	O
.	O
Because	O
of	O
the	O
'	O
intermediate	O
'	O
clinical	O
signs	O
and	O
absence	O
of	O
progression	O
to	O
aggressive	O
disease	O
,	O
we	O
proposed	O
the	O
term	O
'	B-malignancy-type
smouldering	I-malignancy-type
mastocytosis	I-malignancy-type
'	I-malignancy-type
.	O
PMID	O
:	O
11377687	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2001	O
May;92(	O
5	O
)	O
:494	O
-	O
8	O
Mutations	O
in	O
c-kit	O
gene	O
exons	O
9	O
and	O
13	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
among	O
Japanese	O
.	O
Sakurai	O
S,	O
Oguni	O
S,	O
Hironaka	O
M,	O
Fukayama	O
M,	O
Morinaga	O
S,	O
Saito	O
K.	O
Department	O
of	O
Pathology	O
,	O
Jichi	O
Medical	O
School	O
,	O
Minamikawachi	O
-	O
machi	O
,	O
Kawachi	O
-	O
gun	O
,	O
Tochigi	O
329	O
-	O
0498	O
,	O
Japan	O
.	O
ssakurai@jichi	O
.ac.	O
jp	O
Gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
c-kit	O
proto	O
-	O
oncogene	O
exon	O
11	O
has	O
been	O
described	O
in	O
about	O
20	O
--	O
50	O
%	O
of	O
gastrointestinal	B-malignancy-type
stroma	I-malignancy-type
tumor	I-malignancy-type
(	O
GIST	B-malignancy-type
)	O
.	O
Recently	O
,	O
additional	O
mutational	O
hot	O
-	O
spots	O
in	O
exon	O
9	O
and	O
exon	O
13	O
of	O
the	O
c-kit	O
gene	O
have	O
been	O
reported	O
in	O
GISTs	B-malignancy-type
without	O
mutations	O
of	O
exon	O
11	O
,	O
but	O
a	O
subsequent	O
report	O
in	O
a	O
Western	O
population	O
indicated	O
that	O
only	O
a	O
small	O
portion	O
of	O
GISTs	B-malignancy-type
(	O
eight	O
of	O
200	O
GISTs	B-malignancy-type
,	O
4	O
%	O
)	O
showed	O
mutations	O
in	O
these	O
regions	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
mutations	O
in	O
exon	O
9	O
and	O
exon	O
13	O
of	O
the	O
c-kit	O
gene	O
by	O
both	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
in	O
48	O
GISTs	B-malignancy-type
in	O
a	O
Japanese	O
population	O
,	O
for	O
which	O
the	O
clinicopathological	O
and	O
immunohistochemical	O
features	O
and	O
mutations	O
in	O
exon	O
11	O
had	O
previously	O
been	O
reported	O
.	O
C-kit	O
gene	O
mutation	O
in	O
exon	O
9	O
,	O
representing	O
insertion	O
of	O
GCC	O
TAT	O
,	O
was	O
identified	O
in	O
only	O
4	O
of	O
48	O
GISTs	B-malignancy-type
(	O
8	O
%	O
)	O
,	O
and	O
none	O
of	O
the	O
GISTs	B-malignancy-type
had	O
mutations	O
in	O
exon	O
13	O
.	O
All	O
four	O
GISTs	B-malignancy-type
with	O
mutation	O
in	O
exon	O
9	O
were	O
high	O
-	O
risk	O
,	O
and	O
the	O
patients	O
died	O
of	O
multiple	O
tumor	O
metastasis	O
.	O
Mutations	O
in	O
exon	O
9	O
and	O
exon	O
13	O
of	O
the	O
c-kit	O
gene	O
were	O
also	O
rare	O
events	O
in	O
Japanese	O
GISTs	B-malignancy-type
and	O
were	O
related	O
to	O
a	O
poor	O
prognosis	O
.	O
These	O
results	O
in	O
Japanese	O
are	O
consistent	O
with	O
those	O
in	O
Western	O
populations	O
,	O
although	O
a	O
preferential	O
occurrence	O
of	O
GISTs	B-malignancy-type
with	O
exon	O
9	O
mutation	O
in	O
the	O
small	O
intestine	O
,	O
which	O
was	O
suggested	O
in	O
a	O
previous	O
report	O
,	O
was	O
not	O
observed	O
.	O
PMID	O
:	O
11376557	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Nippon	O
Med	O
Sch	O
2001	O
Apr;68(	O
2	O
)	O
:143	O
-	O
8	O
[	O
Abnormalities	O
of	O
the	O
p53	O
,	O
N-ras	O
,	O
DCC	O
and	O
FLT-3	O
genes	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
]	O
[Article	O
in	O
Japanese	O
]	O
Nakamura	O
K	O
,	O
Inokuchi	O
K	O
,	O
Dan	O
K.	O
Department	O
of	O
3rd	O
Internal	O
Medicine	O
,	O
Nippon	O
Medical	O
School	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
molecular	O
mechanism	O
of	O
carcinogenesis	O
is	O
a	O
multistep	O
process	O
that	O
is	O
characterized	O
by	O
both	O
activation	O
of	O
oncogenes	O
and	O
inactivation	O
of	O
tumor	O
suppressor	O
genes	O
.	O
In	O
the	O
present	O
study	O
,	O
mutations	O
of	O
N-ras	O
,	O
p53	O
and	O
FMS	O
-	O
like	O
tyrosine	O
kinase	O
3	O
(	O
FLT-3	O
)	O
genes	O
and	O
loss	O
of	O
expression	O
of	O
the	O
deleted	O
in	O
colorectal	O
carcinoma	O
(	O
DCC	O
)	O
gene	O
were	O
analyzed	O
in	O
59	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
.	O
Mutations	O
of	O
N-ras	O
,	O
p53	O
,	O
and	O
FLT-3	O
genes	O
were	O
detected	O
in	O
7	O
,	O
7	O
,	O
1	O
of	O
the	O
59	O
patients	O
with	O
MDS	B-malignancy-type
,	O
respectively	O
.	O
Loss	O
of	O
DCC	O
expression	O
was	O
detected	O
in	O
16	O
patients	O
.	O
Type	O
of	O
MDS	B-malignancy-type
patients	O
with	O
N-ras	O
mutation	O
were	O
all	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
in	O
transformation	O
(	O
RAEB-T	O
)	O
.	O
Abnormalities	O
of	O
p53	O
and	O
DCC	O
genes	O
were	O
significantly	O
associated	O
with	O
survival	O
time	O
(	O
p	O
<	O
0.02	O
,	O
p	O
<	O
0.004	O
,	O
respectively	O
)	O
.	O
PMID	O
:	O
11301359	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2001	O
Apr;14(	O
4)	O
:343	O
-	O
9	O
H-ras	O
oncogene	O
mutation	O
in	O
dedifferentiated	B-malignancy-type
chondrosarcoma	I-malignancy-type
:	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
.	O
Sakamoto	O
A	O
,	O
Oda	O
Y	O
,	O
Adachi	O
T	O
,	O
Oshiro	O
Y	O
,	O
Tamiya	O
S,	O
Tanaka	O
K	O
,	O
Matsuda	O
S,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Pathological	O
Sciences	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
Dedifferentiated	B-malignancy-type
chondrosarcomas	I-malignancy-type
,	O
which	O
are	O
known	O
for	O
their	O
poor	O
prognosis	O
,	O
are	O
characterized	O
by	O
conventional	B-malignancy-type
chondrosarcoma	I-malignancy-type
with	O
high	O
-	O
grade	O
anaplastic	O
components	O
.	O
Activating	O
mutations	O
in	O
ras	O
genes	O
are	O
a	O
common	O
genetic	O
abnormality	O
in	O
human	O
malignancies	O
.	O
The	O
presence	O
of	O
point	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
H-ras	O
gene	O
was	O
studied	O
in	O
20	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
chondrosarcomas	B-malignancy-type
,	O
comprising	O
11	O
cases	O
of	O
conventional	B-malignancy-type
chondrosarcoma	I-malignancy-type
(	O
six	O
Grade	O
1	O
cases	O
and	O
five	O
Grade	O
2	O
cases	O
)	O
and	O
nine	O
cases	O
of	O
dedifferentiated	B-malignancy-type
chondrosarcoma	I-malignancy-type
,	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
direct	O
sequencing	O
analysis	O
.	O
H-ras	O
mutations	O
were	O
only	O
seen	O
in	O
two	O
out	O
of	O
the	O
nine	O
cases	O
of	O
dedifferentiated	B-malignancy-type
chondrosarcoma	I-malignancy-type
(	O
2	O
/	O
9	O
,	O
22	O
%	O
)	O
and	O
they	O
were	O
not	O
seen	O
in	O
any	O
of	O
the	O
cases	O
of	O
conventional	B-malignancy-type
chondrosarcoma	I-malignancy-type
(	O
0	O
/	O
11	O
,	O
0	O
%	O
)	O
.	O
Dedifferentiated	B-malignancy-type
chondrosarcomas	I-malignancy-type
had	O
a	O
worse	O
prognosis	O
than	O
conventional	B-malignancy-type
chondrosarcomas	I-malignancy-type
(	O
P	O
<	O
.01	O
)	O
;	O
among	O
the	O
patients	O
with	O
dedifferentiated	B-malignancy-type
chondrosarcomas	I-malignancy-type
,	O
those	O
with	O
H-ras	O
mutation	O
(	O
n	O
=	O
2	O
)	O
tended	O
to	O
have	O
a	O
worse	O
prognosis	O
than	O
those	O
without	O
(	O
n	O
=	O
7	O
)	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.068	O
)	O
.	O
Our	O
results	O
would	O
seem	O
to	O
suggest	O
that	O
H-ras	O
mutation	O
may	O
occur	O
during	O
the	O
course	O
of	O
dedifferentiation	O
and	O
may	O
also	O
have	O
some	O
effect	O
on	O
malignant	O
potential	O
.	O
PMID	O
:	O
11301351	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
2001	O
Mar;44(	O
3	O
)	O
:358	O
-	O
63	O
Prognostic	O
significance	O
of	O
K-ras	O
and	O
TP53	O
mutations	O
in	O
the	O
role	O
of	O
adjuvant	O
chemotherapy	O
on	O
survival	O
in	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
.	O
Bleeker	O
WA	O
,	O
Hayes	O
VM	O
,	O
Karrenbeld	O
A	O
,	O
Hofstra	O
RM	O
,	O
Verlind	O
E	O
,	O
Hermans	O
J,	O
Poppema	O
S,	O
Buys	O
CH	O
,	O
Plukker	O
JT.	O
Department	O
of	O
Surgery	O
/	O
Surgical	O
Oncology	O
,	O
University	O
Hospital	O
Groningen	O
,	O
The	O
Netherlands	O
.	O
PURPOSE	O
:	O
Mutations	O
in	O
K-ras	O
and	O
TP53	O
genes	O
are	O
common	O
in	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
They	O
affect	O
biologic	O
behavior	O
and	O
might	O
influence	O
chemotherapy	O
susceptibility	O
in	O
these	O
tumors	O
.	O
We	O
investigated	O
whether	O
the	O
survival	O
of	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
treated	O
with	O
adjuvant	O
chemotherapy	O
is	O
influenced	O
by	O
K-ras	O
and	O
TP53	O
mutations	O
.	O
METHODS	O
:	O
Mutation	O
screening	O
of	O
the	O
hot	O
spots	O
of	O
the	O
K-ras	O
gene	O
and	O
of	O
the	O
evolutionarily	O
conserved	O
regions	O
of	O
the	O
TP53	O
gene	O
was	O
performed	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
technique	O
in	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
specimens	O
of	O
55	O
consecutive	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
treated	O
with	O
adjuvant	O
5-fluorouracil	O
-	O
based	O
chemotherapy	O
.	O
The	O
median	O
follow	O
-	O
up	O
was	O
47	O
(	O
range	O
,	O
32	O
-	O
66	O
)	O
months	O
.	O
RESULTS	O
:	O
Alterations	O
in	O
the	O
mutation	O
hot	O
spots	O
of	O
K-ras	O
were	O
found	O
at	O
codon	O
12	O
(	O
n	O
=	O
11	O
)	O
and	O
13	O
(	O
n	O
=	O
4	O
)	O
in	O
15	O
of	O
the	O
55	O
carcinomas	B-malignancy-type
(	O
27	O
percent	O
)	O
.	O
No	O
mutation	O
was	O
found	O
at	O
codon	O
61	O
.	O
Mutations	O
of	O
a	O
probably	O
causative	O
nature	O
in	O
the	O
evolutionarily	O
conserved	O
regions	O
(	O
exons	O
5	O
-	O
8	O
)	O
of	O
the	O
TP53	O
gene	O
were	O
found	O
in	O
24	O
tumors	O
(	O
44	O
percent	O
)	O
.	O
K-ras	O
and	O
TP53	O
mutations	O
were	O
found	O
equally	O
in	O
the	O
group	O
with	O
recurrent	O
disease	O
(	O
7	O
/	O
26	O
(	O
26	O
percent	O
)	O
and	O
12	O
/	O
27	O
(	O
44	O
percent	O
)	O
,	O
respectively	O
)	O
and	O
in	O
the	O
group	O
without	O
recurrences	O
(	O
8	O
/	O
28	O
(	O
24	O
percent	O
)	O
and	O
12	O
/	O
28	O
(	O
43	O
percent	O
)	O
,	O
respectively	O
)	O
.	O
Cancer	O
-	O
specific	O
survival	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
with	O
K-ras	O
or	O
TP53	O
or	O
both	O
mutated	O
and	O
nonmutated	O
tumors	O
,	O
respectively	O
(	O
log	O
-	O
rank	O
test	O
:	O
K-ras	O
,	O
P	O
=	O
0.72	O
and	O
TP53	O
,	O
P	O
=	O
0.77	O
;	O
K-ras	O
and	O
TP53	O
,	O
P	O
=	O
0.8	O
)	O
.	O
Also	O
,	O
potentially	O
aggressive	O
K-ras	O
codon	O
12	O
and	O
13	O
mutations	O
had	O
the	O
same	O
survival	O
as	O
tumors	O
without	O
these	O
mutations	O
(	O
log	O
-	O
rank	O
test	O
;	O
P	O
=	O
0.73	O
)	O
.	O
CONCLUSIONS	O
:	O
Patients	O
with	O
K-ras	O
or	O
TP53	O
or	O
both	O
mutated	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
tumors	I-malignancy-type
have	O
the	O
same	O
survival	O
as	O
nonmutated	O
tumors	O
when	O
treated	O
with	O
adjuvant	O
chemotherapy	O
.	O
These	O
data	O
suggest	O
that	O
mutations	O
in	O
K-ras	O
or	O
TP53	O
alone	O
are	O
not	O
prognostic	O
indicators	O
in	O
patients	O
with	O
Dukes	B-malignancy-type
C	I-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
receiving	O
adjuvant	O
5-Fluorouracil	O
-	O
based	O
therapy	O
.	O
PMID	O
:	O
11289281	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2001	O
Mar	O
;	O
158	O
(	O
3	O
)	O
:	O
1073	O
-	O
8	O
Frequent	O
beta-catenin	O
mutations	O
in	O
juvenile	O
nasopharyngeal	B-malignancy-type
angiofibromas	I-malignancy-type
.	O
Abraham	O
SC	O
,	O
Montgomery	O
EA	O
,	O
Giardiello	O
FM	O
,	O
Wu	O
TT.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
Gastroenterology	O
,	O
The	O
Johns	O
Hopkins	O
University	O
School	O
of	O
Medicine	O
,	O
720	O
Rutland	O
Ave	O
.	O
,	O
Baltimore	O
,	O
MD	O
21205	O
-	O
2196	O
,	O
USA	O
.	O
Juvenile	O
nasopharyngeal	B-malignancy-type
angiofibromas	I-malignancy-type
(	O
JNAs	B-malignancy-type
)	O
are	O
locally	O
aggressive	O
vascular	B-malignancy-type
tumors	I-malignancy-type
occurring	O
predominantly	O
in	O
adolescent	O
males	O
.	O
The	O
pathogenesis	O
of	O
JNAs	B-malignancy-type
is	O
unknown	O
.	O
Recently	O
,	O
JNAs	B-malignancy-type
have	O
been	O
reported	O
to	O
occur	O
at	O
increased	O
frequency	O
among	O
patients	O
with	O
familial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
,	O
suggesting	O
that	O
alterations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
/	O
beta-catenin	O
pathway	O
might	O
also	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-malignancy-type
JNAs	I-malignancy-type
.	O
We	O
analyzed	O
somatic	O
beta-catenin	O
and	O
APC	O
gene	O
mutations	O
in	O
16	O
sporadic	B-malignancy-type
JNAs	I-malignancy-type
from	O
nonfamilial	B-malignancy-type
adenomatous	I-malignancy-type
polyposis	I-malignancy-type
patients	O
using	O
immunohistochemistry	O
for	O
beta-catenin	O
,	O
and	O
direct	O
DNA	O
sequencing	O
for	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
and	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
.	O
Nuclear	O
accumulation	O
of	O
beta-catenin	O
was	O
diffusely	O
present	O
in	O
the	O
stromal	O
cells	O
but	O
not	O
in	O
the	O
endothelial	O
cells	O
of	O
all	O
16	O
JNAs	B-malignancy-type
.	O
Activating	O
beta-catenin	O
gene	O
mutations	O
were	O
present	O
in	O
75	O
%	O
(	O
12	O
of	O
16	O
)	O
of	O
JNAs	B-malignancy-type
.	O
Six	O
JNA	B-malignancy-type
patients	O
also	O
had	O
recurrent	O
tumors	O
after	O
surgery	O
,	O
and	O
in	O
all	O
cases	O
the	O
beta-catenin	O
gene	O
status	O
of	O
the	O
recurrent	O
JNA	B-malignancy-type
was	O
identical	O
to	O
the	O
initial	O
tumor	O
.	O
No	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
of	O
the	O
APC	O
gene	O
were	O
detected	O
in	O
the	O
four	O
JNAs	B-malignancy-type
without	O
beta-catenin	O
mutations	O
.	O
The	O
high	O
frequency	O
of	O
beta-catenin	O
mutations	O
in	O
sporadic	B-malignancy-type
JNAs	I-malignancy-type
and	O
the	O
presence	O
of	O
identical	O
beta-catenin	O
gene	O
mutations	O
in	O
recurrent	O
tumors	O
indicates	O
that	O
activating	O
beta-catenin	O
gene	O
mutations	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
JNAs	B-malignancy-type
.	O
The	O
immunohistochemical	O
localization	O
of	O
beta-catenin	O
only	O
to	O
the	O
nuclei	O
of	O
stromal	O
cells	O
further	O
suggests	O
that	O
the	O
stromal	O
cells	O
,	O
rather	O
than	O
endothelial	O
cells	O
,	O
are	O
the	O
neoplastic	O
cells	O
of	O
JNAs	B-malignancy-type
.	O
PMID	O
:	O
11238055	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Clin	O
Oncol	O
2001	O
Jan	O
15	O
;	O
2	O
)	O
:	O
299	O
-	O
304	O
Comment	O
in	O
:	O
J	O
Clin	O
Oncol	O
.	O
2001	O
Jan	O
15	O
;	O
19	O
(	O
2	O
)	O
:	O
286	O
-	O
8	O
.	O
K-ras	O
and	O
p16	O
aberrations	O
confer	O
poor	O
prognosis	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Esteller	O
M,	O
Gonzalez	O
S,	O
Risques	O
RA	O
,	O
Marcuello	O
E	O
,	O
Mangues	O
R,	O
Germa	O
JR	O
,	O
Herman	O
JG	O
,	O
Capella	O
G	O
,	O
Peinado	O
MA.	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
Baltimore	O
,	O
MD	O
,	O
USA	O
.	O
PURPOSE	O
:	O
Mutations	O
in	O
the	O
K-ras	O
gene	O
are	O
frequent	O
in	O
human	O
cancer	O
.	O
ras	O
activation	O
in	O
primary	O
cells	O
results	O
in	O
a	O
cellular	O
senescence	O
phenotype	O
that	O
is	O
precluded	O
by	O
inactivation	O
of	O
p16	O
.	O
At	O
the	O
clinical	O
level	O
,	O
this	O
may	O
imply	O
a	O
differential	O
behavior	O
for	O
tumors	O
with	O
alternative	O
or	O
cooperative	O
activation	O
of	O
K-ras	O
function	O
and	O
impairment	O
of	O
p16	O
pathways	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
have	O
determined	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
K-ras	O
gene	O
and	O
the	O
methylation	O
status	O
of	O
p16	O
promoter	O
in	O
a	O
series	O
of	O
119	O
prospectively	O
collected	O
colorectal	B-malignancy-type
carcinomas	I-malignancy-type
.	O
p53	O
mutations	O
and	O
p14	O
alternative	O
reading	O
frame	O
methylation	O
status	O
were	O
also	O
assessed	O
.	O
Associations	O
with	O
survival	O
were	O
investigated	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
present	O
in	O
44	O
(	O
38	O
%	O
)	O
of	O
115	O
cases	O
,	O
and	O
p16	O
methylation	O
was	O
present	O
in	O
42	O
(	O
37	O
%	O
)	O
of	O
113	O
cases	O
.	O
p53	O
mutations	O
were	O
detected	O
in	O
50	O
%	O
(	O
56	O
of	O
115	O
)	O
and	O
p14	O
methylation	O
in	O
29	O
%	O
(	O
32	O
of	O
112	O
)	O
of	O
cases	O
.	O
K-ras	O
and	O
p16	O
alterations	O
were	O
independent	O
genetic	O
events	O
.	O
Presence	O
of	O
K-ras	O
or	O
p16	O
genetic	O
alterations	O
(	O
analyzed	O
independently	O
)	O
was	O
associated	O
with	O
shorter	O
survival	O
,	O
although	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O
Cox	O
analysis	O
of	O
the	O
two	O
variables	O
combined	O
showed	O
a	O
diminished	O
survival	O
as	O
the	O
results	O
of	O
an	O
interaction	O
between	O
p16	O
and	O
K-ras	O
.	O
Alternative	O
alteration	O
of	O
K-ras	O
and	O
p16	O
genes	O
was	O
an	O
independent	O
prognostic	O
factor	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
in	O
univariate	O
and	O
multivariate	O
analysis	O
.	O
Differences	O
were	O
maintained	O
when	O
cases	O
undergoing	O
radical	O
surgery	O
and	O
without	O
distant	O
metastases	O
were	O
considered	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
the	O
combined	O
K-ras	O
and	O
p16	O
analyses	O
may	O
be	O
of	O
prognostic	O
use	O
in	O
human	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
Publication	O
Types	O
:	O
Evaluation	O
Studies	O
PMID	O
:	O
11208819	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncol	O
Rep	O
2001	O
Mar	O
-	O
Apr	O
;	O
(	O
2	O
)	O
:	O
249	O
-	O
55	O
Expression	O
of	O
E-cadherin	O
and	O
beta-catenin	O
in	O
primary	O
and	O
peritoneal	B-malignancy-type
metastatic	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
.	O
Fujioka	O
T	O
,	O
Takebayashi	O
Y	O
,	O
Kihana	O
T	O
,	O
Kusanagi	O
Y	O
,	O
Hamada	O
K	O
,	O
Ochi	O
H	O
,	O
Uchida	O
T	O
,	O
Fukumoto	O
M,	O
Ito	O
M.	O
Department	O
of	O
Pathology	O
,	O
Institute	O
of	O
Development	O
,	O
Aging	O
and	O
Cancer	O
,	O
Tohoku	O
University	O
,	O
Aoba	O
-	O
ku	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
fujioka@idac.tohoku.ac.	O
jp	O
Protein	O
expression	O
levels	O
of	O
E-cadherin	O
and	O
beta-catenin	O
were	O
examined	O
in	O
39	O
primary	O
and	O
10	O
metastatic	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
to	O
elucidate	O
the	O
role	O
of	O
these	O
molecules	O
in	O
the	O
extension	O
of	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
by	O
immunohistochemistry	O
.	O
Twenty-two	O
of	O
39	O
(	O
56	O
%	O
)	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
were	O
preserved	O
type	O
and	O
17	O
of	O
39	O
(	O
44	O
%	O
)	O
were	O
reduced	O
type	O
of	O
E-cadherin	O
.	O
In	O
contrast	O
,	O
36	O
of	O
39	O
(	O
92	O
%	O
)	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
were	O
preserved	O
type	O
and	O
3	O
of	O
39	O
(	O
8	O
%	O
)	O
were	O
reduced	O
type	O
of	O
beta-catenin	O
.	O
E-cadherin	O
expression	O
in	O
well	O
-	B-malignancy-type
differentiated	I-malignancy-type
carcinoma	I-malignancy-type
was	O
higher	O
than	O
that	O
in	O
moderately	O
/	O
poorly	O
-	O
differentiated	O
carcinoma	B-malignancy-type
(	O
p	O
<	O
0.05	O
)	O
.	O
Interestingly	O
,	O
6	O
of	O
10	O
(	O
60	O
%	O
)	O
peritoneal	B-malignancy-type
metastatic	I-malignancy-type
lesions	I-malignancy-type
resulted	O
in	O
the	O
reduced	O
expression	O
of	O
E-cadherin	O
compared	O
with	O
primary	O
lesions	O
.	O
In	O
contrast	O
,	O
only	O
2	O
of	O
10	O
(	O
20	O
%	O
)	O
metastatic	O
lesions	O
showed	O
reduced	O
expression	O
of	O
beta-catenin	O
compared	O
with	O
primary	O
lesions	O
.	O
Mutation	O
of	O
exon	O
3	O
of	O
beta-catenin	O
gene	O
was	O
rare	O
(	O
3	O
%	O
,	O
1	O
/	O
39	O
)	O
in	O
carcinoma	B-malignancy-type
.	O
These	O
results	O
suggested	O
that	O
the	O
cell	O
adhesion	O
molecule	O
E-cadherin	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
of	O
peritoneal	B-malignancy-type
metastasis	I-malignancy-type
.	O
In	O
contrast	O
,	O
beta-catenin	O
is	O
not	O
a	O
good	O
indicator	O
of	O
metastasis	O
in	O
human	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
11182035	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gut	O
2001	O
Mar	O
;	O
48	O
(	O
3	O
)	O
:	O
403	O
-	O
8	O
K-ras	O
mutations	O
in	O
the	O
bile	O
of	O
patients	O
with	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
.	O
Kubicka	O
S,	O
Kuhnel	O
F	O
,	O
Flemming	O
P	O
,	O
Hain	O
B	O
,	O
Kezmic	O
N	O
,	O
Rudolph	O
KL	O
,	O
Manns	O
M,	O
Meier	O
PN.	O
Department	O
of	O
Gastroenterology	O
and	O
Hepatology	O
,	O
Medizinische	O
Hochschule	O
Hannover	O
,	O
Carl	O
Neubergstrasse	O
1	O
,	O
30625	O
Hannover	O
,	O
Germany	O
.	O
BACKGROUND	O
AND	O
AIMS	O
:	O
The	O
development	O
of	O
cholangiocarcinoma	B-malignancy-type
(	O
CCC	B-malignancy-type
)	O
is	O
a	O
complication	O
of	O
primary	O
sclerosing	B-malignancy-type
cholangitis	I-malignancy-type
(	O
PSC	B-malignancy-type
)	O
.	O
To	O
date	O
,	O
no	O
reliable	O
factors	O
have	O
been	O
described	O
which	O
can	O
define	O
those	O
PSC	B-malignancy-type
patients	O
at	O
high	O
risk	O
for	O
the	O
development	O
of	O
CCC	B-malignancy-type
and	O
the	O
clinical	O
diagnosis	O
of	O
CCC	B-malignancy-type
in	O
PSC	B-malignancy-type
patients	O
is	O
difficult	O
.	O
Therefore	O
,	O
molecular	O
markers	O
of	O
cholangiocarcinogenesis	O
,	O
such	O
as	O
K-ras	O
mutations	O
,	O
may	O
improve	O
the	O
early	O
diagnosis	O
of	O
CCC	B-malignancy-type
or	O
the	O
timing	O
of	O
liver	O
transplantation	O
.	O
METHODS	O
:	O
K-ras	O
mutations	O
were	O
analysed	O
by	O
enriched	O
polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	O
in	O
the	O
bile	O
fluid	O
of	O
56	O
PSC	B-malignancy-type
patients	O
and	O
20	O
patients	O
with	O
other	O
cholestatic	O
diseases	O
.	O
To	O
assess	O
the	O
value	O
of	O
K-ras	O
mutations	O
as	O
a	O
risk	O
factor	O
for	O
cholangiocarcinogenesis	O
,	O
patients	O
were	O
prospectively	O
investigated	O
over	O
a	O
mean	O
period	O
of	O
31.5	O
months	O
.	O
RESULTS	O
:	O
In	O
contrast	O
with	O
the	O
control	O
group	O
,	O
17	O
(	O
30	O
%	O
)	O
patients	O
with	O
PSC	B-malignancy-type
revealed	O
K-ras	O
mutations	O
in	O
bile	O
fluid	O
.	O
The	O
mean	O
Mayo	O
score	O
was	O
not	O
significantly	O
different	O
between	O
PSC	B-malignancy-type
patients	O
with	O
(	O
mean	O
score	O
0.70	O
)	O
and	O
without	O
(	O
mean	O
score	O
0.13	O
;	O
p	O
=	O
0.2	O
)	O
K-ras	O
mutations	O
.	O
In	O
contrast	O
with	O
the	O
group	O
of	O
PSC	B-malignancy-type
patients	O
without	O
K-ras	O
mutations	O
,	O
four	O
CCCs	B-malignancy-type
and	O
two	O
dysplasia	O
were	O
diagnosed	O
in	O
the	O
group	O
of	O
patients	O
with	O
K-ras	O
mutations	O
during	O
the	O
follow	O
up	O
investigation	O
(	O
p	O
<	O
0.001	O
)	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
K-ras	O
mutations	O
in	O
bile	O
fluid	O
of	O
PSC	B-malignancy-type
patients	O
represent	O
frequent	O
early	O
events	O
during	O
cholangiocarcinogenesis	O
.	O
However	O
,	O
most	O
of	O
the	O
PSC	B-malignancy-type
patients	O
with	O
K-ras	O
mutations	O
remained	O
tumour	O
free	O
after	O
a	O
long	O
follow	O
up	O
investigation	O
which	O
is	O
in	O
agreement	O
with	O
the	O
fact	O
that	O
these	O
mutations	O
are	O
not	O
specific	O
for	O
malignancy	O
but	O
may	O
also	O
occur	O
in	O
normal	O
bile	O
duct	O
mucosa	O
or	O
in	O
dysplasias	B-malignancy-type
.	O
Therefore	O
,	O
analysis	O
of	O
K-ras	O
mutations	O
in	O
bile	O
should	O
not	O
be	O
used	O
for	O
diagnosis	O
of	O
CCC	B-malignancy-type
in	O
PSC	B-malignancy-type
patients	O
.	O
However	O
,	O
the	O
results	O
of	O
our	O
prospective	O
follow	O
up	O
investigation	O
indicate	O
that	O
K-ras	O
mutations	O
in	O
bile	O
fluid	O
of	O
PSC	B-malignancy-type
patients	O
have	O
to	O
be	O
considered	O
as	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CCC	B-malignancy-type
which	O
may	O
have	O
implications	O
for	O
the	O
timing	O
of	O
liver	O
transplantation	O
.	O
PMID	O
:	O
11171833	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2001	O
Feb	O
163	O
(	O
1	O
)	O
:	O
125	O
-	O
30	O
Somatic	O
beta-catenin	O
mutation	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
--	O
an	O
infrequent	O
event	O
that	O
is	O
not	O
specific	O
for	O
microsatellite	O
instability	O
.	O
Tong	O
JH	O
,	O
To	O
KF	O
,	O
Ng	O
EK	O
,	O
Lau	O
JY	O
,	O
Lee	O
TL	O
,	O
Lo	O
KW	O
,	O
Leung	O
WK	O
,	O
Tang	O
NL	O
,	O
Chan	O
FK	O
,	O
Sung	O
JJ	O
,	O
Chung	O
SC	O
.	O
Department	O
of	O
Anatomical	O
and	O
Cellular	O
Pathology	O
,	O
Prince	O
of	O
Wales	O
Hospital	O
,	O
The	O
Chinese	O
University	O
of	O
Hong	O
Kong	O
,	O
Shatin	O
,	O
Hong	O
Kong	O
SAR	O
,	O
PR	O
China	O
.	O
We	O
screened	O
90	O
cases	O
of	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
(	O
GCA	B-malignancy-type
)	O
samples	O
for	O
beta-catenin	O
exon	O
3	O
mutation	O
and	O
assessed	O
its	O
possible	O
relationship	O
with	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
.	O
Three	O
mutations	O
were	O
detected	O
in	O
two	O
samples	O
,	O
including	O
a	O
single	O
mutation	O
in	O
an	O
intestinal	B-malignancy-type
type	I-malignancy-type
and	O
double	O
mutations	O
in	O
a	O
diffuse	B-malignancy-type
type	I-malignancy-type
GCA	I-malignancy-type
.	O
One	O
of	O
the	O
mutations	O
found	O
in	O
the	O
diffuse	B-malignancy-type
type	I-malignancy-type
GCA	I-malignancy-type
sample	O
was	O
a	O
non	O
-	O
sense	O
mutation	O
at	O
codon	O
68	O
(	O
CAG	O
-->	O
TAG	O
)	O
.	O
This	O
novel	O
mutation	O
was	O
predicted	O
to	O
disrupt	O
the	O
binding	O
of	O
beta-catenin	O
to	O
alpha-catenin	O
and	O
may	O
be	O
related	O
to	O
the	O
diffuse	O
type	O
morphology	O
.	O
The	O
other	O
two	O
mutations	O
were	O
missense	O
mutations	O
involved	O
or	O
related	O
to	O
the	O
GSK-3beta	O
phosphorylation	O
site	O
,	O
which	O
have	O
been	O
reported	O
previously	O
.	O
No	O
MSI	O
can	O
be	O
demonstrated	O
in	O
the	O
two	O
cases	O
with	O
beta-catenin	O
mutation	O
.	O
Our	O
results	O
suggested	O
that	O
beta-catenin	O
mutation	O
was	O
infrequent	O
in	O
GCA	B-malignancy-type
and	O
appeared	O
not	O
specific	O
for	O
MSI	O
.	O
PMID	O
:	O
11163116	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Cancer	O
2001	O
Jan;84(	O
2	O
)	O
:253	O
-	O
62	O
Pancreatic	B-malignancy-type
tumours	I-malignancy-type
:	O
molecular	O
pathways	O
implicated	O
in	O
ductal	B-malignancy-type
cancer	I-malignancy-type
are	O
involved	O
in	O
ampullary	O
but	O
not	O
in	O
exocrine	O
nonductal	O
or	O
endocrine	O
tumorigenesis	O
.	O
Moore	O
PS	O
,	O
Orlandini	O
S,	O
Zamboni	O
G	O
,	O
Capelli	O
P	O
,	O
Rigaud	O
G	O
,	O
Falconi	O
M,	O
Bassi	O
C	O
,	O
Lemoine	O
NR	O
,	O
Scarpa	O
A.	O
Department	O
of	O
Pathology	O
,	O
Universita	O
di	O
Verona	O
,	O
Italy	O
.	O
Alterations	O
of	O
K	O
-	O
ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
/	O
Smad4	O
characterize	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
cancer	I-malignancy-type
(	O
PDC	B-malignancy-type
)	O
.	O
Reports	O
of	O
inactivation	O
of	O
these	O
latter	O
two	O
genes	O
in	O
pancreatic	B-malignancy-type
endocrine	I-malignancy-type
tumours	I-malignancy-type
(	O
PET	B-malignancy-type
)	O
suggest	O
that	O
common	O
molecular	O
pathways	O
are	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
pancreatic	O
exocrine	O
and	O
endocrine	O
epithelia	O
.	O
We	O
characterized	O
112	O
primary	O
pancreatic	B-malignancy-type
tumours	I-malignancy-type
for	O
alterations	O
in	O
p16	O
and	O
DPC4	O
and	O
immunohistochemical	O
expression	O
of	O
DPC4	O
.	O
The	O
cases	O
included	O
34	O
PDC	O
,	O
10	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
-	I-malignancy-type
mucinous	I-malignancy-type
tumours	I-malignancy-type
(	O
IPMT	B-malignancy-type
)	O
,	O
6	O
acinar	B-malignancy-type
carcinomas	I-malignancy-type
(	O
PAC	B-malignancy-type
)	O
,	O
5	O
solid	B-malignancy-type
-	I-malignancy-type
pseudopapillary	I-malignancy-type
tumours	I-malignancy-type
(	O
SPT	B-malignancy-type
)	O
,	O
16	O
ampulla	B-malignancy-type
of	I-malignancy-type
Vater	I-malignancy-type
cancers	I-malignancy-type
(	O
AVC	B-malignancy-type
)	O
and	O
41	O
PET	B-malignancy-type
.	O
All	O
tumours	O
were	O
also	O
presently	O
or	O
previously	O
analysed	O
for	O
K	O
-	O
ras	O
and	O
p53	O
mutations	O
and	O
allelic	O
loss	O
at	O
9p	O
,	O
17p	O
and	O
18q	O
.	O
Alterations	O
in	O
K	O
-	O
ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
were	O
found	O
in	O
82	O
%	O
,	O
53	O
%	O
,	O
38	O
%	O
and	O
9	O
%	O
of	O
PDC	B-malignancy-type
,	O
respectively	O
and	O
in	O
47	O
%	O
,	O
60	O
%	O
,	O
25	O
%	O
and	O
6	O
%	O
of	O
AVC	B-malignancy-type
.	O
Alterations	O
in	O
these	O
genes	O
were	O
virtually	O
absent	O
in	O
PET	B-malignancy-type
,	O
PAC	B-malignancy-type
or	O
SPT	B-malignancy-type
,	O
while	O
in	O
IPMT	B-malignancy-type
only	O
K	O
-	O
ras	O
mutations	O
were	O
present	O
(	O
30	O
%	O
)	O
.	O
Positive	O
immunostaining	O
confirmed	O
the	O
absence	O
of	O
DPC4	O
alterations	O
in	O
all	O
IPMT	B-malignancy-type
,	O
SPT	B-malignancy-type
,	O
PAC	B-malignancy-type
and	O
PET	B-malignancy-type
,	O
while	O
47	O
%	O
of	O
PDC	B-malignancy-type
and	O
38	O
%	O
of	O
AVC	B-malignancy-type
were	O
immunonegative	O
.	O
These	O
data	O
suggest	O
that	O
pancreatic	O
exocrine	O
and	O
endocrine	O
tumourigenesis	O
involves	O
different	O
genetic	O
targets	O
and	O
that	O
among	O
exocrine	B-malignancy-type
pancreatic	I-malignancy-type
neoplasms	I-malignancy-type
,	O
only	O
ductal	B-malignancy-type
and	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
share	O
common	O
molecular	O
events	O
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
PMID	O
:	O
11161385	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Blood	O
2001	O
Feb	O
1	O
97	O
(	O
3	O
)	O
:	O
729	O
-	O
36	O
Comment	O
in	O
:	O
Blood	O
.	O
2001	O
Aug	O
15	O
;	O
98	O
(	O
4	O
)	O
:	O
1271	O
-	O
2	O
.	O
Activated	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
is	O
an	O
oncogene	O
that	O
contributes	O
to	O
tumor	O
progression	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
Chesi	O
M,	O
Brents	O
LA	O
,	O
Ely	O
SA	O
,	O
Bais	O
C	O
,	O
Robbiani	O
DF	O
,	O
Mesri	O
EA	O
,	O
Kuehl	O
WM	O
,	O
Bergsagel	O
PL.	O
Department	O
of	O
Medicine	O
,	O
Division	O
of	O
Hematology	O
-	O
Oncology	O
,	O
New	O
York	O
Presbyterian	O
Hospital	O
-	O
Weill	O
Medical	O
College	O
of	O
Cornell	O
University	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
.	O
The	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	O
occurs	O
frequently	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
and	O
results	O
in	O
the	O
simultaneous	O
dysregulated	O
expression	O
of	O
2	O
potential	O
oncogenes	O
,	O
FGFR3	O
(	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
)	O
from	O
der	O
(	O
14	O
)	O
and	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
SET	O
domain	O
protein	O
/	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
candidate	O
gene	O
1	O
from	O
der	O
(	O
4	O
)	O
.	O
It	O
is	O
now	O
shown	O
that	O
myeloma	B-malignancy-type
cells	O
carrying	O
a	O
t	O
(	O
4	O
;	O
14	O
)	O
translocation	O
express	O
a	O
functional	O
FGFR3	O
that	O
in	O
some	O
cases	O
is	O
constitutively	O
activated	O
by	O
the	O
same	O
mutations	O
that	O
cause	O
thanatophoric	B-malignancy-type
dysplasia	I-malignancy-type
.	O
As	O
with	O
activating	O
mutations	O
of	O
K-ras	O
and	O
N-ras	O
,	O
which	O
are	O
reported	O
in	O
approximately	O
40	O
%	O
of	O
patients	O
with	O
MM	B-malignancy-type
,	O
activating	O
mutations	O
of	O
FGFR3	O
occur	O
during	O
tumor	O
progression	O
.	O
However	O
,	O
the	O
constitutive	O
activation	O
of	O
ras	O
and	O
FGFR3	O
does	O
not	O
occur	O
in	O
the	O
same	O
myeloma	B-malignancy-type
cells	O
.	O
Thus	O
the	O
activated	O
forms	O
of	O
these	O
proteins	O
appear	O
to	O
share	O
an	O
overlapping	O
role	O
in	O
tumor	O
progression	O
,	O
suggesting	O
that	O
they	O
also	O
share	O
the	O
signaling	O
cascade	O
.	O
Consistent	O
with	O
this	O
prediction	O
,	O
it	O
is	O
shown	O
that	O
activated	O
FGFR3	O
-	O
when	O
expressed	O
at	O
levels	O
similar	O
to	O
those	O
seen	O
in	O
t	O
(	O
4	O
;	O
14	O
)	O
myeloma	B-malignancy-type
-	O
is	O
an	O
oncogene	O
that	O
acts	O
through	O
the	O
MAP	O
kinase	O
pathway	O
to	O
transform	O
NIH	O
3T3	O
cells	O
,	O
which	O
can	O
then	O
generate	O
tumors	O
in	O
nude	O
mice	O
.	O
Thus	O
,	O
FGFR3	O
,	O
when	O
overexpressed	O
in	O
MM	B-malignancy-type
,	O
may	O
be	O
not	O
only	O
oncogenic	O
when	O
stimulated	O
by	O
FGF	O
ligands	O
in	O
the	O
bone	O
marrow	O
microenvironment	O
,	O
but	O
is	O
also	O
a	O
target	O
for	O
activating	O
mutations	O
that	O
enable	O
FGFR3	O
to	O
play	O
a	O
ras	O
-	O
like	O
role	O
in	O
tumor	O
progression	O
.	O
PMID	O
:	O
11157491	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Surg	O
Oncol	O
2000	O
Dec	O
;	O
75	O
(	O
4	O
)	O
:	O
246	O
-	O
51	O
K-ras	O
oncogene	O
mutation	O
in	O
cancer	B-malignancy-type
and	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
of	O
the	O
gallbladder	O
.	O
Kim	O
SW	O
,	O
Her	O
KH	O
,	O
Jang	O
JY	O
,	O
Kim	O
WH	O
,	O
Kim	O
YT	O
,	O
Park	O
YH.	O
Department	O
of	O
Surgery	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
determine	O
whether	O
K-ras	O
mutation	O
plays	O
any	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
,	O
or	O
has	O
any	O
clinical	O
or	O
pathological	O
significance	O
in	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
patients	O
,	O
we	O
investigated	O
the	O
presence	O
and	O
incidence	O
of	O
this	O
mutation	O
in	O
the	O
normal	O
mucosa	O
,	O
and	O
precancerous	B-malignancy-type
and	O
cancerous	B-malignancy-type
lesions	I-malignancy-type
of	O
the	O
gallbladder	O
.	O
METHODS	O
:	O
DNA	O
was	O
obtained	O
from	O
normal	O
mucosa	O
,	O
dysplastic	O
mucosa	O
,	O
primary	O
cancer	O
tissues	O
,	O
and	O
metastatic	B-malignancy-type
lymph	I-malignancy-type
nodes	I-malignancy-type
that	O
were	O
identified	O
and	O
microdissected	O
from	O
the	O
paraffin	O
blocks	O
of	O
20	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
cases	O
.	O
K-ras	O
codon	O
12	O
mutations	O
were	O
investigated	O
using	O
a	O
modified	O
two	O
-	O
step	O
polymerase	O
chain	O
reaction	O
and	O
the	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
,	O
and	O
by	O
direct	O
sequencing	O
with	O
an	O
automated	O
sequencer	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
the	O
tissues	O
of	O
10	O
out	O
of	O
the	O
20	O
patients	O
.	O
A	O
mutation	O
was	O
present	O
in	O
the	O
dysplastic	O
epithelium	O
associated	O
with	O
the	O
primary	O
carcinoma	B-malignancy-type
in	O
3	O
out	O
of	O
12	O
specimens	O
,	O
in	O
metastatic	B-malignancy-type
carcinoma	I-malignancy-type
in	O
1	O
out	O
of	O
5	O
patients	O
,	O
and	O
in	O
primary	O
carcinoma	B-malignancy-type
in	O
8	O
out	O
of	O
20	O
patients	O
.	O
Mutation	O
was	O
found	O
only	O
once	O
in	O
the	O
dysplastic	O
,	O
noncancerous	O
epithelium	O
,	O
and	O
only	O
once	O
in	O
a	O
metastatic	B-malignancy-type
tumor	I-malignancy-type
although	O
not	O
detectable	O
in	O
the	O
primary	O
cancer	O
.	O
Direct	O
sequencing	O
showed	O
that	O
the	O
mutations	O
were	O
G	O
to	O
C	O
substitutions	O
(	O
GGT	O
-->	O
CGT	O
)	O
at	O
the	O
first	O
site	O
of	O
codon	O
12	O
,	O
except	O
in	O
two	O
cases	O
(	O
GGT	O
-->	O
TGT	O
)	O
.	O
There	O
were	O
no	O
correlations	O
between	O
K-ras	O
mutations	O
and	O
clinicopathological	O
factors	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
half	O
of	O
the	O
gallbladder	B-malignancy-type
cancer	I-malignancy-type
cases	O
.	O
We	O
suggest	O
that	O
K-ras	O
mutation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
premalignant	B-malignancy-type
lesions	I-malignancy-type
or	O
early	O
carcinogenesis	O
in	O
some	O
gallbladder	B-malignancy-type
cancers	I-malignancy-type
.	O
We	O
were	O
unable	O
to	O
find	O
any	O
evidence	O
that	O
K-ras	O
mutation	O
plays	O
any	O
role	O
in	O
tumor	O
progression	O
or	O
metastasis	O
,	O
or	O
that	O
it	O
has	O
any	O
clinicopathological	O
significance	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11135265	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Prostate	O
2000	O
Dec	O
1;45(	O
4)	O
:323	O
-	O
34	O
Detection	O
and	O
analysis	O
of	O
beta-catenin	O
mutations	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
Chesire	O
DR	O
,	O
Ewing	O
CM	O
,	O
Sauvageot	O
J,	O
Bova	O
GS	O
,	O
Isaacs	O
WB.	O
Brady	O
Urological	O
Institute	O
,	O
Research	O
Laboratories	O
,	O
The	O
Johns	O
Hopkins	O
Medical	O
Institutions	O
,	O
Baltimore	O
,	O
Maryland	O
21287	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
E-cadherin	O
and	O
alpha-catenin	O
are	O
components	O
of	O
adherens	O
junctions	O
which	O
mediate	O
calcium	O
-	O
dependent	O
,	O
cell	O
-	O
cell	O
adhesion	O
in	O
a	O
homotypic	O
manner	O
.	O
Both	O
these	O
molecules	O
have	O
been	O
defined	O
as	O
useful	O
tumor	O
markers	O
as	O
their	O
altered	O
expression	O
correlates	O
with	O
increased	O
tumor	O
aggressiveness	O
and	O
dedifferentiation	O
.	O
More	O
recently	O
,	O
alterations	O
of	O
a	O
third	O
component	O
of	O
adherens	O
junctions	O
,	O
beta-catenin	O
,	O
have	O
been	O
observed	O
to	O
play	O
a	O
role	O
in	O
several	O
human	O
cancers	O
.	O
Dysregulation	O
of	O
beta-catenin	O
,	O
either	O
by	O
direct	O
mutation	O
or	O
by	O
defects	O
in	O
interacting	O
pathways	O
/	O
regulators	O
,	O
can	O
result	O
in	O
its	O
cytoplasmic	O
accumulation	O
and	O
nuclear	O
translocation	O
.	O
In	O
the	O
nucleus	O
,	O
beta-catenin	O
forms	O
a	O
transcriptional	O
complex	O
capable	O
of	O
upregulating	O
target	O
genes	O
,	O
many	O
of	O
which	O
encode	O
proliferative	O
factors	O
.	O
Given	O
its	O
oncogenic	O
activity	O
and	O
connection	O
to	O
human	O
cancer	O
,	O
we	O
examined	O
the	O
beta-catenin	O
gene	O
and	O
its	O
expression	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
.	O
METHODS	O
:	O
By	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
DNA	O
sequencing	O
analyses	O
,	O
we	O
screened	O
exon	O
3	O
of	O
beta-catenin	O
from	O
a	O
panel	O
of	O
81	O
primary	O
tumors	O
obtained	O
at	O
radical	O
prostatectomy	O
,	O
22	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
from	O
untreated	O
patients	O
,	O
and	O
a	O
unique	O
set	O
of	O
61	O
metastatic	O
tissues	O
from	O
19	O
patients	O
who	O
died	O
of	O
hormone	O
-	O
refractory	O
disease	O
.	O
RESULTS	O
:	O
We	O
found	O
putative	O
activating	O
mutations	O
(	O
missense	O
and	O
deletion	O
)	O
at	O
a	O
rate	O
of	O
5	O
%	O
(	O
7	O
/	O
138	O
)	O
.	O
One	O
patient	O
had	O
the	O
same	O
72	O
base	O
pair	O
deletion	O
in	O
each	O
of	O
nine	O
separate	O
metastases	B-malignancy-type
examined	O
,	O
indicating	O
that	O
this	O
change	O
was	O
associated	O
with	O
a	O
clonal	O
population	O
of	O
metastatic	O
cells	O
.	O
CONCLUSIONS	O
:	O
Immunohistological	O
staining	O
of	O
mutation	O
-	O
positive	O
tumors	O
demonstrated	O
beta-catenin	O
accumulation	O
and	O
nuclear	O
localization	O
in	O
a	O
heterogeneous	O
fashion	O
.	O
Consistent	O
with	O
this	O
in	O
vivo	O
finding	O
,	O
our	O
in	O
vitro	O
analyses	O
demonstrate	O
that	O
certain	O
mutations	O
can	O
result	O
in	O
increased	O
beta-catenin	O
nuclear	O
activity	O
in	O
prostate	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
These	O
data	O
implicate	O
the	O
beta-catenin	O
signaling	O
pathway	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
prostate	B-malignancy-type
cancers	I-malignancy-type
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11102958	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2000	O
Nov;9(	O
11	O
)	O
:1223	O
-	O
32	O
K-ras	O
and	O
p53	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
:	O
association	O
with	O
medical	O
history	O
,	O
histopathology	O
,	O
and	O
environmental	O
exposures	O
in	O
a	O
population	O
-	O
based	O
study	O
.	O
Slebos	O
RJ	O
,	O
Hoppin	O
JA	O
,	O
Tolbert	O
PE	O
,	O
Holly	O
EA	O
,	O
Brock	O
JW	O
,	O
Zhang	O
RH	O
,	O
Bracci	O
PM	O
,	O
Foley	O
J,	O
Stockton	O
P	O
,	O
McGregor	O
LM	O
,	O
Flake	O
GP	O
,	O
Taylor	O
JA.	O
Laboratory	O
of	O
Molecular	O
Carcinogenesis	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
,	O
USA	O
.	O
Pancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
a	O
highly	O
fatal	O
cancer	O
with	O
few	O
identified	O
risk	O
factors	O
.	O
Increased	O
risk	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
in	O
tobacco	O
smokers	O
and	O
among	O
diabetic	O
patients	O
is	O
well	O
established	O
,	O
and	O
some	O
reports	O
have	O
suggested	O
associations	O
with	O
coffee	O
consumption	O
and	O
occupational	O
exposure	O
to	O
organochlorines	O
.	O
At	O
present	O
,	O
there	O
is	O
little	O
information	O
regarding	O
the	O
possible	O
association	O
of	O
these	O
risk	O
factors	O
with	O
the	O
known	O
genetic	O
alterations	O
found	O
in	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
such	O
as	O
activation	O
of	O
the	O
K-ras	O
oncogene	O
and	O
inactivation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
.	O
Knowledge	O
of	O
such	O
relationships	O
may	O
help	O
to	O
understand	O
the	O
molecular	O
pathways	O
of	O
pancreatic	O
tumorigenesis	O
.	O
We	O
investigated	O
the	O
association	O
between	O
these	O
molecular	O
defects	O
and	O
risk	O
factors	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
in	O
61	O
newly	O
diagnosed	O
patients	O
identified	O
through	O
an	O
ongoing	O
study	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
in	O
the	O
San	O
Francisco	O
Bay	O
Area	O
.	O
Interview	O
information	O
was	O
obtained	O
regarding	O
environmental	O
exposures	O
,	O
medical	O
history	O
,	O
and	O
demographic	O
factors	O
.	O
Serum	O
levels	O
of	O
dichlorodiphenyltrichloroethylene	O
(	O
DDE	O
)	O
and	O
polychlorinated	O
biphenyls	O
were	O
available	O
on	O
a	O
subset	O
of	O
24	O
patients	O
.	O
Tumor	O
blocks	O
were	O
located	O
from	O
local	O
hospitals	O
and	O
used	O
for	O
K-ras	O
mutational	O
analysis	O
at	O
codon	O
12	O
and	O
for	O
p53	O
protein	O
immunohistochemistry	O
.	O
The	O
molecular	O
analyses	O
were	O
facilitated	O
through	O
the	O
use	O
of	O
laser	O
capture	O
microdissection	O
,	O
which	O
provides	O
a	O
reliable	O
method	O
to	O
obtain	O
almost	O
pure	O
populations	O
of	O
tumor	O
cells	O
.	O
Mutations	O
in	O
K-ras	O
codon	O
12	O
were	O
found	O
in	O
46	O
(	O
75	O
%	O
)	O
of	O
61	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
.	O
A	O
prior	O
diagnosis	O
of	O
diabetes	O
was	O
significantly	O
associated	O
with	O
K-ras	O
negative	O
tumors	O
(	O
P	O
=	O
0.002	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
The	O
absence	O
of	O
this	O
mutation	O
was	O
also	O
associated	O
with	O
increased	O
serum	O
levels	O
of	O
DDE	O
,	O
although	O
this	O
association	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.16	O
,	O
Wilcoxon	O
's	O
test	O
)	O
.	O
There	O
was	O
no	O
difference	O
in	O
polychlorinated	O
biphenyl	O
levels	O
between	O
the	O
K-ras	O
wild	O
-	O
type	O
and	O
mutant	O
groups	O
.	O
Immunohistochemical	O
staining	O
for	O
p53	O
protein	O
did	O
not	O
differ	O
by	O
patient	O
characteristics	O
or	O
clinical	O
history	O
,	O
but	O
significant	O
associations	O
were	O
found	O
with	O
poor	O
glandular	O
differentiation	O
(	O
P	O
=	O
0.002	O
,	O
chi2	O
trend	O
test	O
)	O
,	O
severe	B-malignancy-type
nuclear	I-malignancy-type
atypia	I-malignancy-type
(	O
P	O
=	O
0.0007	O
,	O
chi2	O
trend	O
test	O
)	O
,	O
and	O
high	O
tumor	O
grade	O
(	O
P	O
=	O
0.004	O
,	O
chi2	O
trend	O
test	O
)	O
.	O
Our	O
results	O
are	O
suggestive	O
of	O
the	O
presence	O
of	O
K-ras	O
codon	O
12	O
mutation	O
-	O
independent	O
tumorigenesis	O
pathways	O
in	O
patients	O
with	O
prior	O
diabetes	O
and	O
possibly	O
in	O
patients	O
with	O
higher	O
serum	O
levels	O
of	O
DDE	O
.	O
Our	O
results	O
also	O
support	O
a	O
role	O
for	O
the	O
p53	O
tumor	O
suppressor	O
protein	O
in	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
.	O
PMID	O
:	O
11097231	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Pathol	O
2000	O
Nov;192(	O
3	O
)	O
:342	O
-	O
50	O
Prognostic	O
value	O
of	O
the	O
preserved	O
expression	O
of	O
the	O
E-cadherin	O
and	O
catenin	O
families	O
of	O
adhesion	O
molecules	O
and	O
of	O
beta-catenin	O
mutations	O
in	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
.	O
Saito	O
T	O
,	O
Oda	O
Y	O
,	O
Sakamoto	O
A	O
,	O
Tamiya	O
S,	O
Kinukawa	O
N	O
,	O
Hayashi	O
K	O
,	O
Iwamoto	O
Y	O
,	O
Tsuneyoshi	O
M.	O
Department	O
of	O
Anatomic	O
Pathology	O
,	O
Graduate	O
School	O
of	O
Medical	O
Sciences	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
,	O
Japan	O
.	O
This	O
study	O
addresses	O
the	O
immunohistochemical	O
expression	O
of	O
the	O
E-cadherin	O
and	O
catenin	O
families	O
and	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
detected	O
by	O
PCR	O
-	O
SSCP	O
in	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
.	O
Immunohistochemical	O
analysis	O
was	O
performed	O
for	O
72	O
cases	O
,	O
with	O
follow	O
-	O
up	O
data	O
available	O
on	O
62	O
.	O
The	O
prognostic	O
value	O
of	O
the	O
expression	O
of	O
these	O
proteins	O
was	O
evaluated	O
.	O
Reduced	O
immunoreactivity	O
for	O
E-cadherin	O
and	O
alpha-catenin	O
was	O
significantly	O
correlated	O
with	O
a	O
poor	O
survival	O
rate	O
(	O
p	O
=	O
0.0040	O
and	O
0.0053	O
,	O
respectively	O
)	O
.	O
According	O
to	O
multivariate	O
analysis	O
,	O
low	O
AJC	O
stage	O
(	O
stages	O
I	O
and	O
II	O
:	O
p	O
<	O
0.0001	O
)	O
,	O
the	O
preservation	O
of	O
alpha-catenin	O
expression	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
and	O
a	O
low	O
necrotic	O
rate	O
(	O
<	O
50	O
%	O
:	O
p	O
=	O
0.0139	O
)	O
were	O
independent	O
favourable	O
prognostic	O
factors	O
.	O
Widespread	O
aberrant	O
staining	O
of	O
beta-catenin	O
protein	O
within	O
cytoplasm	O
and/or	O
nuclei	O
was	O
observed	O
in	O
28	O
cases	O
(	O
38.9	O
%	O
)	O
and	O
was	O
significantly	O
correlated	O
with	O
poor	O
survival	O
(	O
p	O
=	O
0.0122	O
)	O
.	O
In	O
addition	O
,	O
there	O
was	O
a	O
trend	O
towards	O
a	O
correlation	O
between	O
widespread	O
aberrant	O
staining	O
of	O
beta-catenin	O
and	O
the	O
MIB-1	O
labelling	O
index	O
(	O
p	O
=	O
0.0535	O
)	O
.	O
Mutational	O
analysis	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
was	O
performed	O
for	O
49	O
cases	O
.	O
Nucleotide	O
sequencing	O
analysis	O
revealed	O
that	O
four	O
(	O
8.2	O
%	O
)	O
contained	O
point	O
mutations	O
(	O
three	O
in	O
codon	O
32	O
,	O
GAC	O
to	O
TAC	O
;	O
one	O
in	O
codon	O
37	O
,	O
TCT	O
to	O
TTT	O
)	O
.	O
Survival	O
data	O
were	O
available	O
for	O
three	O
out	O
of	O
four	O
cases	O
with	O
beta-catenin	O
mutations	O
;	O
two	O
of	O
these	O
patients	O
died	O
within	O
1	O
year	O
(	O
died	O
of	O
disease	O
at	O
6	O
and	O
11	O
months	O
,	O
respectively	O
)	O
.	O
These	O
results	O
suggest	O
that	O
E-cadherin	O
and	O
alpha-catenin	O
undertake	O
important	O
roles	O
as	O
intercellular	O
adhesion	O
molecules	O
;	O
their	O
preserved	O
expression	O
is	O
associated	O
with	O
a	O
better	O
overall	O
survival	O
rate	O
in	O
synovial	O
sarcoma	O
and	O
may	O
have	O
prognostic	O
value	O
.	O
Abnormal	O
levels	O
of	O
beta-catenin	O
,	O
with	O
or	O
without	O
mutation	O
,	O
could	O
contribute	O
to	O
the	O
development	O
and	O
progression	O
of	O
synovial	B-malignancy-type
sarcoma	I-malignancy-type
,	O
through	O
increasing	O
the	O
proliferative	O
activity	O
of	O
the	O
tumour	O
cells	O
.	O
Copyright	O
2000	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
PMID	O
:	O
11054718	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
2000	O
Sep;13(	O
9	O
)	O
:1005	O
-	O
13	O
Beta-catenin	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
:	O
expression	O
is	O
related	O
to	O
proliferative	O
activity	O
in	O
high	O
-	O
grade	O
sarcomas	B-malignancy-type
.	O
Kuhnen	O
C	O
,	O
Herter	O
P	O
,	O
Muller	O
O	O
,	O
Muehlberger	O
T	O
,	O
Krause	O
L,	O
Homann	O
H	O
,	O
Steinau	O
HU	O
,	O
Muller	O
KM	O
.	O
Institute	O
for	O
Pathology	O
,	O
Limb	O
Tumor	O
Registry	O
,	O
University	O
Hospital	O
Bergmannsheil	O
,	O
Bochum	O
,	O
Germany	O
.	O
patho	O
-	O
bhl@ruhr	O
-	O
uni	O
-	O
bochum	O
.de	O
Besides	O
its	O
role	O
in	O
cell	O
adhesion	O
,	O
beta-catenin	O
exerts	O
a	O
function	O
as	O
an	O
oncoprotein	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
characterization	O
of	O
its	O
expression	O
,	O
possible	O
mutation	O
,	O
and	O
the	O
assessment	O
of	O
beta-catenin	O
as	O
a	O
prognostic	O
indicator	O
for	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
A	O
total	O
of	O
115	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
were	O
analyzed	O
using	O
immunohistochemistry	O
,	O
immunogold	O
-	O
electron	O
microscopy	O
,	O
and	O
DNA	O
analysis	O
.	O
Information	O
from	O
56	O
patients	O
was	O
available	O
for	O
follow	O
-	O
up	O
.	O
A	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
intracellular	O
distribution	O
of	O
beta-catenin	O
and	O
the	O
proliferative	O
activity	O
(	O
MIB-1	O
expression	O
)	O
in	O
high	O
-	O
grade	O
sarcomas	B-malignancy-type
(	O
P	O
=	O
.0008	O
)	O
.	O
Beta-catenin	O
was	O
identified	O
with	O
intracytoplasmic	O
and	O
nuclear	O
accumulation	O
,	O
showing	O
additional	O
membranous	O
staining	O
in	O
sarcomas	B-malignancy-type
with	O
epithelioid	O
pattern	O
.	O
Ultrastructurally	O
,	O
a	O
colocalization	O
between	O
beta-catenin	O
and	O
nuclear	O
heterochromatin	O
was	O
demonstrated	O
.	O
In	O
22	O
analyzed	O
tumors	O
,	O
only	O
one	O
(	O
yet	O
undescribed	O
)	O
mutation	O
of	O
the	O
beta-catenin	O
gene	O
(	O
C	O
-	O
A	O
transversion	O
)	O
could	O
be	O
detected	O
.	O
Prognostic	O
validity	O
of	O
the	O
cellular	O
expression	O
of	O
beta-catenin	O
,	O
however	O
,	O
was	O
not	O
proven	O
.	O
Apart	O
from	O
its	O
membranous	O
function	O
as	O
an	O
effective	O
molecule	O
for	O
cell	O
-	O
adhesion	O
in	O
sarcomas	B-malignancy-type
with	O
epithelioid	O
pattern	O
,	O
beta-catenin	O
may	O
act	O
as	O
an	O
oncoprotein	O
in	O
sarcomas	B-malignancy-type
with	O
intracytoplasmic	O
and	O
nuclear	O
localization	O
with	O
binding	O
to	O
nuclear	O
DNA	O
.	O
A	O
previously	O
discussed	O
stimulation	O
of	O
cell	O
proliferation	O
caused	O
by	O
an	O
increased	O
beta-catenin	O
level	O
can	O
also	O
be	O
postulated	O
for	O
high	O
-	O
grade	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
in	O
correlation	O
with	O
the	O
rate	O
of	O
proliferation	O
.	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
are	O
probably	O
of	O
lesser	O
importance	O
for	O
the	O
accumulation	O
of	O
beta-catenin	O
in	O
soft	B-malignancy-type
tissue	I-malignancy-type
sarcomas	I-malignancy-type
.	O
PMID	O
:	O
11007041	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
2000	O
Sep;43(	O
9	O
)	O
:1316	O
-	O
8	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
of	O
the	O
rectum	O
with	O
activating	O
mutation	O
of	O
c-kit	O
:	O
report	O
of	O
a	O
case	O
.	O
Kurokawa	O
Y	O
,	O
Nishisho	O
I	O
,	O
Kawahara	O
K	O
,	O
Mishima	O
H	O
,	O
Hirota	O
S,	O
Kikkawa	O
N.	O
Department	O
of	O
Surgery	O
,	O
Osaka	O
National	O
Hospital	O
,	O
Japan	O
.	O
Nonepithelial	B-malignancy-type
malignancies	I-malignancy-type
of	O
the	O
large	O
bowel	O
are	O
rare	O
.	O
A	O
new	O
disease	O
entity	O
,	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
,	O
has	O
attracted	O
attention	O
among	O
primary	O
mesenchymal	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
gastrointestinal	O
tract	O
.	O
Here	O
we	O
present	O
a	O
case	O
of	O
spindle	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
sarcoma	I-malignancy-type
of	O
the	O
rectum	O
,	O
lacking	O
either	O
smooth	O
muscle	O
cells	O
or	O
neural	O
elements	O
.	O
Immunohistochemical	O
findings	O
and	O
sequencing	O
of	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
diagnosed	O
this	O
tumor	O
as	O
a	O
malignant	B-malignancy-type
gastrointestinal	I-malignancy-type
stromal	I-malignancy-type
tumor	I-malignancy-type
of	O
the	O
rectum	O
.	O
PMID	O
:	O
11005505	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Hepatobiliary	O
Pancreat	O
Surg	O
2000	O
;	O
7	O
(	O
1	O
)	O
:	O
63	O
-	O
71	O
Significance	O
of	O
K-ras	O
mutation	O
and	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
in	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
Futakawa	O
N	O
,	O
Kimura	O
W	O
,	O
Yamagata	O
S,	O
Zhao	O
B	O
,	O
Ilsoo	O
H	O
,	O
Inoue	O
T	O
,	O
Sata	O
N	O
,	O
Kawaguchi	O
Y	O
,	O
Kubota	O
Y	O
,	O
Muto	O
T.	O
Department	O
of	O
Surgical	O
Oncology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Tokyo	O
,	O
Japan	O
.	O
The	O
early	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
is	O
essential	O
for	O
increasing	O
patient	O
survival	O
rates	O
.	O
In	O
this	O
study	O
,	O
52	O
patients	O
with	O
suspected	O
pancreatic	O
diseases	O
were	O
examined	O
to	O
investigate	O
the	O
value	O
of	O
K-ras	O
codon	O
12	O
point	O
mutation	O
,	O
levels	O
of	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
and	O
carbohydrate	O
antigen	O
(	O
CA19-9	O
)	O
,	O
and	O
cytology	O
of	O
pancreatic	O
juice	O
in	O
the	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Pancreatic	O
juice	O
was	O
taken	O
without	O
secretin	O
stimulation	O
.	O
K-ras	O
mutation	O
was	O
detected	O
by	O
enriched	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
.	O
K-ras	O
mutation	O
in	O
pancreatic	O
juice	O
was	O
more	O
frequent	O
in	O
carcinoma	B-malignancy-type
than	O
in	O
benign	O
diseases	O
(	O
P	O
=	O
0.0448	O
)	O
.	O
The	O
positive	O
predictive	O
value	O
of	O
K-ras	O
mutation	O
for	O
the	O
diagnosis	O
of	O
neoplastic	O
disease	O
was	O
83	O
%	O
.	O
The	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
in	O
carcinoma	B-malignancy-type
was	O
significantly	O
greater	O
than	O
that	O
in	O
benign	O
disease	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
When	O
the	O
cutoff	O
level	O
of	O
CEA	O
was	O
set	O
at	O
50	O
ng	O
/	O
ml	O
,	O
its	O
accuracy	O
for	O
the	O
diagnosis	O
of	O
carcinoma	B-malignancy-type
was	O
85	O
%	O
.	O
A	O
multivariate	O
analysis	O
showed	O
that	O
K-ras	O
mutation	O
and	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
,	O
as	O
well	O
as	O
serum	O
CA19-9	O
level	O
and	O
age	O
of	O
the	O
patient	O
were	O
independent	O
variables	O
for	O
the	O
diagnosis	O
of	O
carcinoma	B-malignancy-type
,	O
and	O
the	O
accuracy	O
of	O
diagnosis	O
by	O
this	O
analysis	O
was	O
increased	O
to	O
90	O
%	O
.	O
In	O
conclusion	O
,	O
both	O
K-ras	O
mutation	O
and	O
CEA	O
level	O
in	O
pancreatic	O
juice	O
may	O
be	O
valuable	O
for	O
the	O
diagnosis	O
of	O
carcinoma	B-malignancy-type
.	O
Better	O
discrimination	O
was	O
possible	O
with	O
a	O
multivariate	O
analysis	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10982594	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
2000	O
Sep;157(	O
3	O
)	O
:967	O
-	O
72	O
Mutations	O
and	O
copy	O
number	O
increase	O
of	O
HRAS	O
in	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
with	O
distinctive	O
histopathological	O
features	O
.	O
Bastian	O
BC	O
,	O
LeBoit	O
PE	O
,	O
Pinkel	O
D.	O
Departments	O
of	O
Dermatology	O
and	O
Pathology	O
and	O
UCSF	O
Comprehensive	O
Cancer	O
Center	O
,	O
University	O
of	O
California	O
San	O
Francisco	O
,	O
San	O
Francisco	O
,	O
California	O
94143	O
-	O
0808	O
,	O
USA	O
.	O
bastian@cc.ucsf.edu	O
Spitz	B-malignancy-type
nevus	I-malignancy-type
is	O
a	O
benign	O
melanocytic	B-malignancy-type
neoplasm	I-malignancy-type
that	O
can	O
be	O
difficult	O
or	O
impossible	O
to	O
histologically	O
distinguish	O
from	O
melanoma	B-malignancy-type
.	O
We	O
have	O
recently	O
described	O
copy	O
number	O
increases	O
of	O
chromosome	O
11p	O
in	O
a	O
subset	O
of	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
.	O
To	O
study	O
the	O
molecular	O
and	O
histological	O
features	O
of	O
this	O
group	O
,	O
we	O
studied	O
102	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
for	O
11p	O
copy	O
number	O
increases	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
on	O
tissue	O
arrays	O
.	O
Copy	O
number	O
increases	O
of	O
at	O
least	O
threefold	O
were	O
found	O
in	O
12	O
cases	O
(	O
11.8	O
%	O
)	O
and	O
involved	O
the	O
HRAS	O
gene	O
on	O
chromosome	O
11p	O
.	O
Sequence	O
analysis	O
of	O
HRAS	O
showed	O
frequent	O
oncogenic	O
mutations	O
in	O
cases	O
with	O
copy	O
number	O
increase	O
(	O
8	O
/	O
12	O
or	O
67	O
%	O
)	O
,	O
contrasting	O
with	O
rare	O
HRAS	O
mutations	O
in	O
cases	O
with	O
normal	O
HRAS	O
copy	O
numbers	O
(	O
1	O
/	O
21	O
or	O
5	O
%	O
,	O
P	O
:	O
<	O
0.0001	O
)	O
.	O
Tumors	B-malignancy-type
with	O
11p	O
copy	O
number	O
increases	O
were	O
larger	O
,	O
predominantly	B-malignancy-type
intradermal	I-malignancy-type
,	O
had	O
marked	O
desmoplasia	B-malignancy-type
,	O
characteristic	O
cytological	O
features	O
,	O
and	O
had	O
an	O
infiltrating	O
growth	O
pattern	O
.	O
Proliferation	O
rates	O
in	O
the	O
majority	O
of	O
these	O
cases	O
were	O
low	O
to	O
absent	O
.	O
HRAS	O
activation	O
by	O
either	O
mutation	O
or	O
copy	O
number	O
increase	O
alone	O
could	O
explain	O
several	O
of	O
the	O
histological	O
features	O
that	O
overlap	O
with	O
those	O
of	O
melanoma	B-malignancy-type
.	O
We	O
speculate	O
that	O
HRAS	O
activation	O
in	O
the	O
absence	O
of	O
co	O
-	O
operating	O
additional	O
genetic	O
alterations	O
drives	O
the	O
partially	O
transformed	O
melanocytes	O
of	O
these	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
into	O
senescence	O
or	O
a	O
stable	O
growth	O
arrest	O
.	O
Although	O
there	O
is	O
no	O
data	O
suggesting	O
that	O
Spitz	B-malignancy-type
nevi	I-malignancy-type
with	O
HRAS	O
activation	O
are	O
at	O
risk	O
for	O
progression	O
to	O
melanoma	B-malignancy-type
,	O
future	O
studies	O
are	O
warranted	O
to	O
assess	O
their	O
biological	O
behavior	O
more	O
accurately	O
.	O
PMID	O
:	O
10980135	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pancreas	O
2000	O
Aug;21(	O
2	O
)	O
:152	O
-	O
7	O
Reassessment	O
of	O
K-ras	O
mutations	O
at	O
codon	O
12	O
by	O
direct	O
PCR	O
and	O
sequencing	O
from	O
tissue	O
microdissection	O
in	O
human	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
Aoki	O
Y	O
,	O
Hosaka	O
S,	O
Tachibana	O
N	O
,	O
Karasawa	O
Y	O
,	O
Kawa	O
S,	O
Kiyosawa	O
K.	O
The	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Shinshu	O
University	O
School	O
of	O
Medicine	O
,	O
Matsumoto	O
,	O
Nagono	O
,	O
Japan	O
.	O
yaoki55@hsp.md	O
.shinshu	O
-	O
u.ac.	O
jp	O
K-ras	O
mutations	O
at	O
codon	O
12	O
have	O
been	O
detected	O
in	O
almost	O
all	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
by	O
highly	O
sensitive	O
assays	O
.	O
We	O
reassessed	O
the	O
K-ras	O
mutation	O
status	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
sequencing	O
from	O
tissue	O
microdissection	O
without	O
DNA	O
extraction	O
in	O
10	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
and	O
also	O
assessed	O
the	O
K-ras	O
and	O
DPC4	O
genes	O
in	O
nine	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
.	O
Eight	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
were	O
found	O
to	O
harbor	O
K-ras	O
mutations	O
at	O
codon	O
12	O
of	O
either	O
GTT	O
or	O
GAT	O
,	O
five	O
of	O
which	O
were	O
inferred	O
to	O
harbor	O
amplified	O
mutant	O
alleles	O
.	O
Mutations	O
at	O
the	O
sites	O
other	O
than	O
codon	O
12	O
were	O
found	O
in	O
seven	O
of	O
70	O
clones	O
(	O
seven	O
of	O
9,380	O
bases	O
)	O
by	O
the	O
TA	O
cloning	O
analysis	O
,	O
suggesting	O
that	O
artifactual	O
mutations	O
at	O
the	O
first	O
or	O
second	O
base	O
of	O
codon	O
12	O
before	O
and	O
during	O
PCR	O
could	O
occur	O
at	O
a	O
frequency	O
of	O
approximately	O
10(-3)	O
,	O
enough	O
for	O
highly	O
sensitive	O
assays	O
to	O
detect	O
.	O
Two	O
cell	O
lines	O
without	O
K-ras	O
mutations	O
at	O
codon	O
12	O
were	O
found	O
to	O
have	O
homozygous	O
deletions	O
at	O
the	O
DPC4	O
gene	O
.	O
Thus	O
the	O
K-ras	O
mutation	O
status	O
was	O
demonstrated	O
to	O
be	O
correctly	O
determined	O
by	O
just	O
direct	O
sequencing	O
from	O
tissue	O
microdissection	O
.	O
All	O
possible	O
mutations	O
or	O
multiple	O
mutations	O
at	O
K-ras	O
codon	O
12	O
that	O
have	O
been	O
reported	O
in	O
pancreatic	B-malignancy-type
adenocarcinomas	I-malignancy-type
might	O
include	O
artifacts	O
or	O
mutations	O
without	O
a	O
selective	O
advantage	O
.	O
In	O
addition	O
,	O
we	O
must	O
be	O
very	O
cautious	O
about	O
contamination	O
.	O
PMID	O
:	O
10975709	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Med	O
Res	O
2000	O
Aug	O
18;5(	O
8	O
)	O
:341	O
-	O
6	O
Detection	O
of	O
K-ras	O
and	O
p53	O
mutations	O
in	O
bronchoscopically	O
obtained	O
malignant	O
and	O
non	O
-	O
malignant	O
tissue	O
from	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
Lang	O
SM	O
,	O
Stratakis	O
DF	O
,	O
Freudling	O
A	O
,	O
Ebelt	O
K	O
,	O
Oduncu	O
F	O
,	O
Hautmann	O
H	O
,	O
Huber	O
RM	O
.	O
Medizinische	O
Klinik	O
Innenstadt	O
,	O
Universitat	O
Munchen	O
,	O
Ziemssenstr.1	O
,	O
D-	O
80336	O
Munchen	O
,	O
Germany	O
.	O
slang@medinn	O
.med	O
.uni	O
-	O
muenchen	O
.de	O
Molecular	O
screening	O
may	O
increase	O
the	O
likelihood	O
to	O
identify	O
early	O
malignant	O
lesions	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
.	O
However	O
the	O
presence	O
of	O
gene	O
mutations	O
in	O
non	O
-	O
malignant	O
bronchial	O
tissue	O
has	O
remained	O
controversial	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
systematically	O
the	O
presence	O
of	O
mutations	O
of	O
the	O
K-ras	O
and	O
p53	O
gene	O
in	O
bronchial	O
biopsies	O
taken	O
during	O
routine	O
bronchoscopy	O
of	O
normal	O
as	O
well	O
as	O
tumour	O
tissues	O
from	O
a	O
series	O
of	O
40	O
patients	O
with	O
histologically	O
verified	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancer	I-malignancy-type
(	O
NSCLC	B-malignancy-type
)	O
.	O
K-ras	O
mutations	O
were	O
analysed	O
with	O
specific	O
detection	O
oligonucleotides	O
,	O
p53	O
mutations	O
were	O
examined	O
by	O
SSCP	O
analysis	O
.	O
In	O
all	O
biopsies	O
the	O
wildtype	O
of	O
both	O
K-ras	O
and	O
p53	O
could	O
be	O
detected	O
.	O
The	O
overall	O
frequency	O
of	O
mutations	O
was	O
14	O
(	O
35	O
%	O
)	O
with	O
2	O
K-ras	O
mutations	O
(	O
5	O
%	O
)	O
and	O
12	O
mutations	O
of	O
the	O
p53	O
gene	O
(	O
30	O
%	O
)	O
.	O
In	O
3	O
cases	O
(	O
1	O
ras	O
mutation	O
,	O
2	O
p53	O
mutations	O
)	O
the	O
same	O
mutation	O
could	O
be	O
shown	O
in	O
the	O
tumour	O
biopsy	O
and	O
in	O
the	O
distant	O
normal	O
control	O
.	O
In	O
another	O
case	O
only	O
the	O
normal	O
appearing	O
tissue	O
had	O
a	O
mutation	O
of	O
the	O
p53	O
gene	O
.	O
All	O
other	O
mutations	O
could	O
be	O
detected	O
in	O
the	O
tumour	O
tissue	O
only	O
.	O
Our	O
data	O
confirm	O
that	O
K-ras	O
mutations	O
and	O
p53	O
can	O
be	O
detected	O
not	O
only	O
in	O
malignant	O
but	O
also	O
in	O
non	O
-	O
malignant	O
bioptic	O
samples	O
from	O
patients	O
with	O
NSCLC	B-malignancy-type
.	O
The	O
use	O
of	O
molecular	O
screening	O
for	O
the	O
early	O
detection	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
may	O
be	O
a	O
promising	O
new	O
approach	O
.	O
PMID	O
:	O
10958767	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
2000	O
Jun;95(	O
6)	O
:1576	O
-	O
80	O
Molecular	O
and	O
biological	O
analysis	O
of	O
carcinoma	B-malignancy-type
of	O
the	O
small	O
intestine	O
:	O
beta-catenin	O
gene	O
mutation	O
by	O
interstitial	O
deletion	O
involving	O
exon	O
3	O
and	O
replication	O
error	O
phenotype	O
.	O
Murata	O
M,	O
Iwao	O
K	O
,	O
Miyoshi	O
Y	O
,	O
Nagasawa	O
Y	O
,	O
Ohta	O
T	O
,	O
Shibata	O
K	O
,	O
Oda	O
K	O
,	O
Wada	O
H	O
,	O
Tominaga	O
S,	O
Matsuda	O
Y	O
,	O
Ohsawa	O
M,	O
Nakamura	O
Y	O
,	O
Shimano	O
T.	O
Department	O
of	O
Surgery	O
,	O
Ikeda	O
Municipal	O
Hospital	O
,	O
Osaka	O
,	O
Japan	O
.	O
The	O
genetic	O
mechanisms	O
of	O
carcinomas	B-malignancy-type
of	O
the	O
small	O
intestine	O
are	O
not	O
well	O
understood	O
.	O
We	O
report	O
the	O
results	O
of	O
analysis	O
of	O
genetic	O
alterations	O
in	O
a	O
case	O
of	O
small	B-malignancy-type
intestinal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
A	O
tumor	O
in	O
the	O
terminal	O
ileum	O
was	O
resected	O
in	O
a	O
59	O
-	O
yr	O
-	O
old	O
woman	O
.	O
Histologically	O
,	O
the	O
tumor	O
was	O
classified	O
as	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
We	O
screened	O
for	O
genetic	O
alterations	O
in	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
,	O
beta-catenin	O
,	O
K-ras	O
,	O
and	O
p53	O
genes	O
,	O
as	O
well	O
as	O
microsatellite	O
instability	O
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
colorectal	O
tumorigenesis	O
.	O
The	O
tumor	O
exhibited	O
somatic	O
interstitial	O
deletion	O
of	O
425-bp	O
,	O
which	O
included	O
the	O
entire	O
exon	O
3	O
in	O
beta-catenin	O
gene	O
.	O
Immunohistochemical	O
staining	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
the	O
cytoplasm	O
and	O
nuclei	O
of	O
the	O
malignant	O
tissue	O
.	O
Furthermore	O
,	O
a	O
frameshift	O
mutation	O
in	O
the	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
type	O
II	O
gene	O
with	O
replication	O
error	O
phenotype	O
was	O
detected	O
in	O
the	O
tumor	O
DNA	O
.	O
In	O
contrast	O
,	O
no	O
genetic	O
alterations	O
were	O
found	O
in	O
the	O
APC	O
,	O
K-ras	O
,	O
and	O
p53	O
genes	O
.	O
Our	O
results	O
suggested	O
that	O
both	O
beta-catenin	O
gene	O
mutation	O
and	O
replication	O
error	O
phenotype	O
might	O
contribute	O
to	O
carcinogenesis	O
of	O
the	O
small	B-malignancy-type
intestinal	I-malignancy-type
tumor	I-malignancy-type
in	O
our	O
case	O
.	O
This	O
is	O
the	O
first	O
report	O
that	O
activation	O
of	O
beta-catenin	O
gene	O
by	O
somatic	O
gene	O
mutation	O
is	O
involved	O
in	O
the	O
development	O
of	O
carcinoma	B-malignancy-type
of	O
the	O
small	O
intestine	O
.	O
PMID	O
:	O
10894600	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2000	O
Apr;91(	O
4)	O
:395	O
-	O
8	O
Mutation	O
of	O
the	O
SRC	O
gene	O
in	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Sugimura	O
M,	O
Kobayashi	O
K	O
,	O
Sagae	O
S,	O
Nishioka	O
Y	O
,	O
Ishioka	O
S,	O
Terasawa	O
K	O
,	O
Tokino	O
T	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Chuo	O
-	O
ku	O
,	O
Sapporo	O
060	O
-0061	O
,	O
Japan	O
.	O
Recently	O
,	O
an	O
activating	O
mutation	O
of	O
the	O
SRC	O
gene	O
has	O
been	O
implicated	O
in	O
about	O
one-tenth	O
of	O
advanced	O
colon	B-malignancy-type
cancers	I-malignancy-type
.	O
The	O
SRC	O
531	O
mutation	O
results	O
in	O
truncation	O
of	O
SRC	O
directly	O
C	O
-	O
terminal	O
to	O
the	O
regulatory	O
Tyr	O
530	O
and	O
appears	O
to	O
activate	O
the	O
Tyr	O
530	O
.	O
To	O
investigate	O
whether	O
mutation	O
of	O
SRC	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
gynecological	B-malignancy-type
tumors	I-malignancy-type
,	O
we	O
performed	O
mutational	O
analysis	O
of	O
the	O
entire	O
coding	O
region	O
of	O
SRC	O
in	O
70	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
68	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
and	O
3	O
endometrial	B-malignancy-type
stromal	I-malignancy-type
sarcomas	I-malignancy-type
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
followed	O
by	O
nucleotide	O
sequencing	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
We	O
found	O
one	O
truncated	O
mutation	O
at	O
codon	O
531	O
(	O
Gln	O
to	O
Stop	O
)	O
in	O
an	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
.	O
However	O
,	O
we	O
found	O
no	O
mutation	O
of	O
this	O
gene	O
in	O
ovarian	B-malignancy-type
carcinoma	I-malignancy-type
or	O
endometrial	B-malignancy-type
stromal	I-malignancy-type
sarcoma	I-malignancy-type
.	O
Our	O
results	O
suggest	O
that	O
mutation	O
of	O
SRC	O
may	O
be	O
implicated	O
in	O
a	O
small	O
proportion	O
of	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
10804287	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
2000	O
Mar;108(	O
4)	O
:729	O
-	O
36	O
Mastocytosis	B-malignancy-type
cells	O
bearing	O
a	O
c-kit	O
activating	O
point	O
mutation	O
are	O
characterized	O
by	O
hypersensitivity	O
to	O
stem	O
cell	O
factor	O
and	O
increased	O
apoptosis	O
.	O
Dror	O
Y	O
,	O
Leaker	O
M,	O
Caruana	O
G	O
,	O
Bernstein	O
A	O
,	O
Freedman	O
MH.	O
Division	O
of	O
Hematology	O
/	O
Oncology	O
,	O
Department	O
of	O
Pediatrics	O
,	O
Research	O
Institute	O
,	O
The	O
Hospital	O
for	O
Sick	O
Children	O
and	O
the	O
University	O
of	O
Toronto	O
,	O
Toronto	O
,	O
Canada	O
.	O
yigal	O
.dror@hotmail	O
.com	O
Mastocytosis	B-malignancy-type
is	O
characterized	O
by	O
abnormal	O
infiltration	O
of	O
mast	O
cells	O
into	O
various	O
organs	O
.	O
An	O
activating	O
mutation	O
in	O
c-kit	O
,	O
involving	O
an	O
A	O
-->	O
T	O
substitution	O
at	O
nucleotide	O
2648	O
has	O
recently	O
been	O
described	O
in	O
some	O
patients	O
with	O
mastocytosis	B-malignancy-type
.	O
We	O
describe	O
a	O
12	O
-	O
year	O
-	O
old	O
girl	O
with	O
this	O
mutation	O
in	O
her	O
bone	O
marrow	O
cells	O
at	O
diagnosis	O
with	O
a	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
without	O
evidence	O
of	O
mastocytosis	B-malignancy-type
,	O
and	O
then	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
1	O
year	O
later	O
after	O
the	O
emergence	O
of	O
mastocytosis	B-malignancy-type
.	O
The	O
role	O
of	O
the	O
c-Kit	O
receptor	O
and	O
its	O
ligand	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
was	O
analysed	O
in	O
marrow	O
cell	O
clonogenic	O
assays	O
.	O
We	O
show	O
that	O
the	O
genetic	O
abnormalities	O
in	O
the	O
patient	O
resulted	O
in	O
factor	O
-	O
independent	O
growth	O
and	O
hypersensitivity	O
of	O
primitive	O
progenitors	O
to	O
SCF	O
,	O
with	O
increased	O
production	O
of	O
mast	O
cells	O
.	O
Increased	O
apoptosis	O
and	O
cluster	O
formation	O
,	O
consistent	O
with	O
the	O
myelodysplastic	O
nature	O
of	O
the	O
disorder	O
,	O
accompanied	O
accumulation	O
of	O
abnormal	O
cells	O
with	O
increasing	O
concentrations	O
of	O
SCF	O
.	O
PMID	O
:	O
10792276	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Gastroenterol	O
2000	O
Apr;30(	O
3	O
)	O
:307	O
-	O
10	O
Nonfunctioning	B-malignancy-type
islet	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
the	O
pancreas	O
with	O
high	O
serum	O
CEA	O
&	O
CA19-9	O
,	O
K-ras	O
codon	O
12	O
mutation	O
,	O
and	O
microsatellite	O
instability	O
.	O
Okai	O
T	O
,	O
Kawashima	O
A	O
,	O
Watanabe	O
H	O
,	O
Takahashi	O
Y	O
,	O
Sakai	O
J,	O
Ohtsubo	O
K	O
,	O
Motoo	O
Y	O
,	O
Matsui	O
O	O
,	O
Murakami	O
S,	O
Nakabayashi	O
H	O
,	O
Sawabu	O
N.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
A	O
55	O
-	O
year	O
-	O
old	O
man	O
with	O
nonfunctioning	B-malignancy-type
islet	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
showing	O
elevation	O
of	O
serum	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
and	O
carbohydrate	O
antigen	O
19-9	O
(	O
CA19-9	O
)	O
levels	O
is	O
described	O
with	O
genetic	O
analyses	O
.	O
Pathological	O
examination	O
of	O
the	O
resected	O
specimen	O
revealed	O
two	O
independent	O
islet	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
in	O
the	O
body	O
and	O
the	O
other	O
in	O
the	O
tail	O
of	O
the	O
pancreas	O
.	O
It	O
was	O
proved	O
immunohistochemically	O
that	O
the	O
tumor	O
cells	O
,	O
particularly	O
those	O
in	O
the	O
tail	O
,	O
were	O
immunoreactive	O
to	O
CEA	O
and	O
CA	O
19-9	O
and	O
had	O
the	O
property	O
of	O
duct	O
cells	O
,	O
as	O
well	O
as	O
endocrine	O
cells	O
.	O
Gastrin	O
was	O
demonstrated	O
immunohistochemically	O
in	O
these	O
tumor	O
cells	O
,	O
although	O
its	O
level	O
in	O
serum	O
was	O
not	O
elevated	O
.	O
Genetic	O
analyses	O
of	O
the	O
fresh	O
specimens	O
from	O
the	O
tumor	O
in	O
the	O
body	O
revealed	O
K-ras	O
codon	O
12	O
mutation	O
and	O
microsatellite	O
instability	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
its	O
progressive	O
clinical	O
course	O
and	O
strongly	O
suggest	O
that	O
these	O
tumors	O
originate	O
,	O
not	O
from	O
the	O
islet	O
cells	O
of	O
Langerhans	O
,	O
but	O
from	O
protodifferentiated	O
cells	O
,	O
capable	O
of	O
giving	O
rise	O
to	O
all	O
the	O
pancreatic	O
cell	O
types	O
.	O
PMID	O
:	O
10777194	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Invest	O
2000	O
;18(	O
3	O
)	O
:185	O
-	O
90	O
Prognostic	O
role	O
of	O
K-ras	O
in	O
patients	O
with	O
progressive	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
who	O
received	O
treatment	O
with	O
Marimastat	O
(	O
BB2516	O
)	O
.	O
Nemunaitis	O
J,	O
Cox	O
J,	O
Hays	O
S,	O
Meyer	O
W	O
,	O
Kebart	O
R,	O
Ognoskie	O
N	O
,	O
Courtney	O
A	O
,	O
Yu	O
Y	O
,	O
Rasmussen	O
H	O
,	O
Tong	O
A.	O
PRN	O
Research	O
,	O
Inc.	O
,	O
Dallas	O
,	O
Texas	O
,	O
USA	O
.	O
We	O
determined	O
the	O
prognostic	O
role	O
of	O
K-ras	O
mutation	O
in	O
tumor	O
tissue	O
of	O
patients	O
with	O
refractory	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
who	O
received	O
Marimastat	O
(	O
BB2516	O
)	O
.	O
DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
stored	O
tumor	O
tissue	O
of	O
27	O
patients	O
who	O
previously	O
failed	O
5-fluorouracil	O
and	O
were	O
treated	O
with	O
BB2516	O
.	O
The	O
presence	O
of	O
K-ras	O
mutation	O
was	O
characterized	O
by	O
Polymerase	O
Chain	O
Reaction	O
using	O
ras	O
-	O
and	O
p53	O
-	O
specific	O
primers	O
.	O
ras	O
and	O
p53	O
oncoprotein	O
expression	O
was	O
analyzed	O
by	O
an	O
automated	O
biotin	O
-	O
avidin	O
immunoproxidase	O
technique	O
.	O
Seventeen	O
patients	O
had	O
a	O
normal	O
K-ras	O
sequence	O
and	O
10	O
patients	O
had	O
a	O
K-ras	O
mutation	O
.	O
Median	O
survival	O
of	O
patients	O
with	O
a	O
normal	O
ras	O
sequence	O
was	O
330	O
days	O
from	O
the	O
time	O
of	O
BB2516	O
treatment	O
compared	O
with	O
160	O
days	O
for	O
patients	O
with	O
a	O
K-ras	O
mutation	O
(	O
p	O
=	O
0.0442	O
,	O
Wilcoxon	O
;	O
0.0130	O
Log	O
-	O
Rank	O
)	O
.	O
No	O
differences	O
in	O
age	O
,	O
sex	O
,	O
cancer	O
stage	O
,	O
surgical	O
treatment	O
,	O
or	O
chemotherapy	O
treatment	O
were	O
observed	O
.	O
Abnormalities	O
involving	O
ras	O
expression	O
did	O
not	O
affect	O
survival	O
.	O
By	O
comparison	O
,	O
median	O
survival	O
for	O
patients	O
with	O
p53	O
mutation	O
or	O
p53	O
overexpression	O
was	O
both	O
158	O
days	O
after	O
BB2516	O
treatment	O
.	O
Patients	O
having	O
both	O
K-ras	O
and	O
p53	O
mutations	O
had	O
the	O
poorest	O
median	O
survival	O
of	O
113	O
days	O
(	O
p	O
=	O
0.035	O
)	O
.	O
There	O
is	O
a	O
suggestion	O
by	O
univariate	O
analysis	O
that	O
the	O
presence	O
of	O
a	O
K-ras	O
mutation	O
may	O
predict	O
survival	O
in	O
patients	O
with	O
progressive	B-malignancy-type
colon	I-malignancy-type
cancer	I-malignancy-type
.	O
Further	O
assessment	O
with	O
larger	O
patient	O
numbers	O
and	O
multivariate	O
analysis	O
is	O
indicated	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10754986	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
2000	O
Mar	O
16;19(	O
12	O
)	O
:1547	O
-	O
55	O
Somatic	O
mutations	O
of	O
the	O
MET	O
oncogene	O
are	O
selected	O
during	O
metastatic	O
spread	O
of	O
human	O
HNSC	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Di	O
Renzo	O
MF	O
,	O
Olivero	O
M,	O
Martone	O
T	O
,	O
Maffe	O
A	O
,	O
Maggiora	O
P	O
,	O
Stefani	O
AD	O
,	O
Valente	O
G	O
,	O
Giordano	O
S,	O
Cortesina	O
G	O
,	O
Comoglio	O
PM	O
.	O
Laboratory	O
of	O
Cancer	O
Genetics	O
,	O
Institute	O
for	O
Cancer	O
Research	O
and	O
Treatment	O
(	O
IRCC)	O
,	O
SP	O
142	O
,	O
Km	O
.	O
3.95	O
,	O
10060	O
Candiolo	O
,	O
Torino	O
,	O
Italy	O
.	O
A	O
metastatic	B-malignancy-type
cancer	I-malignancy-type
develops	O
by	O
accumulation	O
of	O
mutations	O
in	O
genes	O
that	O
control	O
growth	O
,	O
survival	O
and	O
spreading	O
.	O
The	O
latter	O
genes	O
have	O
not	O
yet	O
been	O
identified	O
.	O
In	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
of	O
head	B-malignancy-type
and	I-malignancy-type
neck	I-malignancy-type
squamous	I-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
HNSCC	B-malignancy-type
)	O
,	O
we	O
found	O
mutations	O
in	O
the	O
MET	O
oncogene	O
,	O
which	O
encodes	O
the	O
tyrosine	O
kinase	O
receptor	O
for	O
Scatter	O
Factor	O
,	O
a	O
cytokine	O
that	O
stimulates	O
epithelial	O
cell	O
motility	O
and	O
invasiveness	O
during	O
embryogenesis	O
and	O
tissue	O
remodeling	O
.	O
We	O
identified	O
two	O
somatic	O
mutations	O
:	O
the	O
Y	O
1230	O
C	O
,	O
known	O
as	O
a	O
MET	O
germline	O
mutation	O
which	O
predisposes	O
to	O
hereditary	B-malignancy-type
renal	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
the	O
Y	O
1235	O
D	O
that	O
is	O
novel	O
and	O
changes	O
a	O
critical	O
tyrosine	O
,	O
known	O
to	O
regulate	O
MET	O
kinase	O
activity	O
.	O
The	O
mutated	O
MET	O
receptors	O
are	O
constitutively	O
active	O
and	O
confer	O
an	O
invasive	O
phenotype	O
to	O
transfected	O
cells	O
.	O
Interestingly	O
,	O
cells	O
carrying	O
the	O
MET	O
mutations	O
are	O
selected	O
during	O
metastatic	O
spread	O
:	O
transcripts	O
of	O
the	O
mutant	O
alleles	O
are	O
highly	O
represented	O
in	O
metastases	B-malignancy-type
,	O
but	O
barely	O
detectable	O
in	O
primary	O
tumors	O
.	O
These	O
data	O
indicate	O
that	O
cells	O
expressing	O
mutant	O
MET	O
undergo	O
clonal	O
expansion	O
during	O
HNSCC	B-malignancy-type
progression	O
and	O
suggest	O
that	O
MET	O
might	O
be	O
one	O
of	O
the	O
long	O
sought	O
oncogenes	O
controlling	O
progression	O
of	O
primary	O
cancers	O
to	O
metastasis	O
.	O
PMID	O
:	O
10734314	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

5	O
KIT	O
extracellular	O
and	O
kinase	O
domain	O
mutations	O
in	O
gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
JA.	O
.	O
Gastrointestinal	B-malignancy-type
stromal	I-malignancy-type
tumors	I-malignancy-type
(	O
GISTs	B-malignancy-type
)	O
are	O
the	O
most	O
common	O
mesenchymal	B-malignancy-type
neoplasms	I-malignancy-type
arising	O
in	O
the	O
gastrointestinal	O
GISTs	B-malignancy-type
express	O
the	O
KIT	O
receptor	O
tyrosine	O
kinase	O
,	O
and	O
many	O
cases	O
have	O
activating	O
mutations	O
in	O
the	O
KIT	O
juxtamembrane	O
KIT	O
cDNA	O
and	O
genomic	O
sequences	O
in	O
eight	O
GISTs	B-malignancy-type
that	O
lack	O
juxtamembrane	O
region	O
mutations	O
contained	O
heterozygous	O
exon	O
9	O
mutations	O
in	O
which	O
six	O
nucleotides	O
,	O
encoding	O
Ala	O
-	O
Tyr	O
homozygous	O
exon	O
13	O
missense	O
mutations	O
,	O
resulting	O
in	O
substitution	O
of	O
Glu	O
for	O
Lys	O
(	O
642	O
)	O
,	O
that	O
were	O
associated	O
with	O
constitutive	O
KIT	O
tyrosine	O
Sequence	O
analysis	O
of	O
DNAs	O
from	O
nonneoplastic	O
companion	O
tissues	O
revealed	O
that	O
both	O
the	O
exon	O
9	O
and	O
exon	O
13	O
mutations	O
were	O
somatic	O
descriptions	O
,	O
in	O
any	O
tumor	O
,	O
of	O
mutations	O
in	O
KIT	O
exons	O
encoding	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
extracellular	O
domain	O
and	O
the	O
first	O
part	O
of	O
the	O
split	O
kinase	O
domain	O
KIT	O
may	O
be	O
activated	O
by	O
mutations	O
in	O
at	O
least	O
three	O
domains-	O
extracellular	O
,	O
juxtamembrane	O
,	O
and	O
kinase	O
-	O
in	O
GISTs	B-malignancy-type
MEDLINE]	O

Oncol	O
Rep	O
2000	O
Mar	O
-	O
Apr;7(	O
2	O
)	O
:323	O
-	O
6	O
Mutational	O
analysis	O
of	O
the	O
CTNNB1	O
(	O
beta-catenin	O
)	O
gene	O
in	O
human	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
:	O
frequent	O
mutations	O
at	O
codon	O
34	O
that	O
cause	O
nuclear	O
accumulation	O
.	O
Ikeda	O
T	O
,	O
Yoshinaga	O
K	O
,	O
Semba	O
S,	O
Kondo	O
E	O
,	O
Ohmori	O
H	O
,	O
Horii	O
A.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
Recently	O
,	O
CTNNB1	O
(	O
beta-catenin	O
)	O
has	O
been	O
found	O
to	O
function	O
as	O
an	O
oncoprotein	O
that	O
works	O
in	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
and	O
mutation	O
of	O
this	O
gene	O
has	O
been	O
reported	O
in	O
various	O
human	O
cancers	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
44	O
endometrial	B-malignancy-type
cancers	I-malignancy-type
and	O
found	O
somatic	O
missense	O
mutations	O
in	O
five	O
(	O
11	O
%	O
)	O
tumors	O
.	O
Interestingly	O
,	O
four	O
(	O
80	O
%	O
)	O
of	O
the	O
five	O
tumors	O
with	O
mutations	O
would	O
cause	O
amino	O
acid	O
alterations	O
at	O
residues	O
next	O
to	O
Ser	O
33	O
,	O
one	O
of	O
the	O
targets	O
for	O
phosphorylation	O
of	O
glycogen	O
synthase	O
kinase	O
(	O
GSK	O
)	O
-	O
3beta	O
.	O
The	O
tumors	O
with	O
mutations	O
showed	O
accumulation	O
of	O
the	O
CTNNB1	O
protein	O
in	O
cytoplasm	O
and	O
nucleus	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
frequent	O
somatic	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
at	O
codons	O
adjacent	O
to	O
those	O
encoding	O
to	O
Ser	O
/	O
Thr	O
residues	O
in	O
endometrial	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10671680	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2000	O
Feb	O
1;88(	O
3	O
)	O
:518	O
-	O
23	O
H-ras	O
gene	O
mutations	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
mucoepidermoid	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Yoo	O
J,	O
Robinson	O
RA.	O
Department	O
of	O
Pathology	O
,	O
Catholic	O
University	O
,	O
St.	O
Vincent	O
Hospital	O
,	O
Suwon	O
,	O
South	O
Korea	O
.	O
BACKGROUND	O
:	O
The	O
authors	O
'	O
recent	O
investigation	O
of	O
salivary	B-malignancy-type
gland	I-malignancy-type
tumors	I-malignancy-type
in	O
ras	O
gene	O
alteration	O
has	O
suggested	O
that	O
K-ras	O
activation	O
may	O
not	O
play	O
a	O
role	O
in	O
their	O
oncogenesis	O
but	O
H-ras	O
may	O
,	O
especially	O
in	O
mucoepidermoid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
A	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
overall	O
incidence	O
of	O
mutated	O
H-ras	O
genes	O
in	O
mucoepidermoid	B-malignancy-type
carcinomas	I-malignancy-type
and	O
to	O
discover	O
its	O
potential	O
correlation	O
with	O
clinicopathologic	O
parameters	O
.	O
METHODS	O
:	O
Fifty	O
samples	O
from	O
patients	O
with	O
salivary	B-malignancy-type
gland	I-malignancy-type
mucoepidermoid	I-malignancy-type
carcinoma	I-malignancy-type
were	O
analyzed	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
H-ras	O
gene	O
using	O
the	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
automated	O
direct	O
sequencing	O
methodology	O
.	O
RESULTS	O
:	O
Mutated	O
H-ras	O
genes	O
were	O
detected	O
in	O
9	O
patients	O
,	O
for	O
an	O
overall	O
incidence	O
of	O
18	O
%	O
(	O
9	O
of	O
50	O
patients	O
)	O
.	O
All	O
but	O
1	O
of	O
the	O
mutations	O
occurred	O
at	O
codon	O
12	O
:	O
a	O
GGC	O
-	O
to	O
-	O
GTC	O
transversion	O
in	O
8	O
patients	O
and	O
a	O
GGC	O
-	O
to	O
-	O
GAC	O
transition	O
in	O
1	O
patient	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
of	O
valine	O
and	O
aspartic	O
acid	O
,	O
respectively	O
,	O
for	O
glycine	O
.	O
One	O
of	O
the	O
samples	O
showed	O
concurrent	O
mutations	O
at	O
codons	O
12	O
(	O
GGC	O
-	O
to	O
-	O
GTC	O
)	O
and	O
13	O
(	O
GGT	O
-	O
to	O
-	O
GGA	O
)	O
.	O
None	O
of	O
the	O
samples	O
demonstrated	O
mutations	O
involving	O
codon	O
61	O
.	O
The	O
H-ras	O
mutations	O
were	O
observed	O
in	O
5	O
%	O
(	O
1	O
of	O
21	O
)	O
,	O
17	O
%	O
(	O
2	O
of	O
12	O
)	O
,	O
and	O
35	O
%	O
(	O
6	O
of	O
17	O
)	O
of	O
low	O
,	O
intermediate	O
,	O
and	O
high	O
grade	O
lesions	O
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
involvement	O
of	O
H-ras	O
activation	O
in	O
conjunction	O
with	O
other	O
yet	O
-	O
unknown	O
events	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
mucoepidermoid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
It	O
is	O
noteworthy	O
that	O
a	O
stepwise	O
increase	O
in	O
the	O
frequency	O
of	O
H-ras	O
mutations	O
strongly	O
correlates	O
with	O
tumor	O
grade	O
(	O
P	O
=	O
0.017	O
)	O
.	O
Molecular	O
analysis	O
of	O
this	O
gene	O
alteration	O
may	O
provide	O
assistance	O
in	O
the	O
determination	O
of	O
tumor	O
grade	O
and	O
differentiation	O
.	O
Copyright	O
2000	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
10649241	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Nov	O
11	O
;18(	O
47	O
)	O
:6615	O
-	O
20	O
Predominance	O
of	O
beta-catenin	O
mutations	O
and	O
beta-catenin	O
dysregulation	O
in	O
sporadic	B-malignancy-type
aggressive	I-malignancy-type
fibromatosis	I-malignancy-type
(	O
desmoid	B-malignancy-type
tumor	I-malignancy-type
)	O
.	O
Tejpar	O
S,	O
Nollet	O
F	O
,	O
Li	O
C	O
,	O
Wunder	O
JS	O
,	O
Michils	O
G	O
,	O
dal	O
Cin	O
P	O
,	O
Van	O
Cutsem	O
E	O
,	O
Bapat	O
B	O
,	O
van	O
Roy	O
F	O
,	O
Cassiman	O
JJ	O
,	O
Alman	O
BA.	O
Programme	O
in	O
Development	O
Biology	O
,	O
Hospital	O
for	O
Sick	O
Children	O
,	O
Toronto	O
Ontario	O
,	O
Canada	O
.	O
Aggressive	B-malignancy-type
fibromatosis	I-malignancy-type
(	O
also	O
called	O
desmoid	B-malignancy-type
tumor	I-malignancy-type
)	O
occurs	O
as	O
a	O
sporadic	B-malignancy-type
lesion	I-malignancy-type
or	O
as	O
part	O
of	O
Familial	B-malignancy-type
Adenomatous	I-malignancy-type
Polyposis	I-malignancy-type
,	O
which	O
is	O
caused	O
by	O
germ	O
line	O
mutations	O
in	O
the	O
Adenomatous	O
polyposis	O
Coli	O
(	O
APC	O
)	O
gene	O
.	O
APC	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
cellular	O
level	O
of	O
beta-catenin	O
,	O
which	O
is	O
a	O
mediator	O
in	O
Wnt	O
signaling	O
.	O
Mutational	O
analysis	O
of	O
the	O
beta-catenin	O
and	O
APC	O
genes	O
was	O
performed	O
in	O
42	O
sporadic	B-malignancy-type
aggressive	I-malignancy-type
fibromatoses	I-malignancy-type
.	O
Nine	O
tumors	O
had	O
mutations	O
in	O
APC	O
,	O
and	O
22	O
had	O
a	O
point	O
mutation	O
in	O
beta-catenin	O
at	O
either	O
codon	O
45	O
or	O
codon	O
41	O
(	O
producing	O
a	O
stabilized	O
beta-catenin	O
protein	O
product	O
)	O
.	O
Immunohistochemistry	O
showed	O
an	O
elevated	O
beta-catenin	O
protein	O
level	O
in	O
all	O
tumors	O
,	O
regardless	O
of	O
mutational	O
status	O
.	O
Beta-catenin	O
localized	O
to	O
the	O
nucleus	O
,	O
and	O
was	O
not	O
tyrosine	O
phosphorylated	O
in	O
the	O
six	O
tumors	O
in	O
which	O
this	O
was	O
tested	O
.	O
The	O
demonstration	O
of	O
mutations	O
in	O
two	O
mediators	O
in	O
the	O
Wnt	O
-	O
APC	O
-	O
beta-catenin	O
pathway	O
implicates	O
beta-catenin	O
stabilization	O
as	O
the	O
key	O
factor	O
in	O
the	O
pathogenesis	O
of	O
aggressive	B-malignancy-type
fibromatosis	I-malignancy-type
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
somatic	O
beta-catenin	O
mutations	O
in	O
a	O
locally	O
invasive	O
,	O
but	O
non	B-malignancy-type
metastatic	I-malignancy-type
lesion	I-malignancy-type
composed	O
of	O
spindle	O
cells	O
,	O
illustrating	O
the	O
importance	O
of	O
beta-catenin	O
stabilization	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
neoplastic	O
processes	O
.	O
Moreover	O
,	O
this	O
tumor	O
has	O
one	O
of	O
the	O
highest	O
reported	O
frequencies	O
of	O
beta-catenin	O
mutations	O
of	O
any	O
tumor	O
type	O
.	O
PMID	O
:	O
10597266	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Sep	O
15;59(	O
18	O
)	O
:4506	O
-	O
9	O
Frequent	O
mutation	O
of	O
beta-catenin	O
and	O
APC	O
genes	O
in	O
primary	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
from	O
patients	O
with	O
hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
.	I-malignancy-type
Miyaki	O
M,	O
Iijima	O
T	O
,	O
Kimura	O
J,	O
Yasuno	O
M,	O
Mori	O
T	O
,	O
Hayashi	O
Y	O
,	O
Koike	O
M,	O
Shitara	O
N	O
,	O
Iwama	O
T	O
,	O
Kuroki	O
T.	O
Hereditary	O
Tumor	O
Research	O
Project	O
,	O
Tokyo	O
Metropolitan	O
Komagome	O
Hospital	O
,	O
Japan	O
.	O
mmiyaki@opal	O
.	O
famille	O
.ne	O
.jp	O
Hereditary	B-malignancy-type
nonpolyposis	I-malignancy-type
colorectal	I-malignancy-type
cancer	I-malignancy-type
(	O
HNPCC	B-malignancy-type
)	O
is	O
characterized	O
by	O
defective	O
DNA	O
mismatch	O
repair	O
,	O
which	O
results	O
in	O
genetic	O
instability	O
of	O
tumors	O
;	O
however	O
,	O
only	O
a	O
few	O
target	O
genes	O
have	O
been	O
recognized	O
.	O
Our	O
previous	O
study	O
detected	O
a	O
low	O
frequency	O
of	O
APC	O
gene	O
mutation	O
(	O
21	O
%	O
)	O
in	O
colorectal	B-malignancy-type
tumors	I-malignancy-type
from	O
HNPCC	B-malignancy-type
patients	O
,	O
in	O
contrast	O
to	O
a	O
high	O
frequency	O
of	O
APC	O
gene	O
alteration	O
(	O
>	O
70	O
%	O
)	O
in	O
non	B-malignancy-type
-	I-malignancy-type
HNPCC	I-malignancy-type
tumors	I-malignancy-type
.	O
Because	O
both	O
beta-catenin	O
and	O
ACP	O
gene	O
mutations	O
have	O
recently	O
been	O
shown	O
to	O
activate	O
the	O
same	O
signaling	O
pathway	O
,	O
we	O
analyzed	O
beta-catenin	O
mutation	O
in	O
HNPCC	B-malignancy-type
tumors	I-malignancy-type
.	O
A	O
notable	O
frequency	O
of	O
beta-catenin	O
gene	O
mutation	O
(	O
43	O
%	O
,	O
12	O
of	O
28	O
)	O
was	O
found	O
to	O
occur	O
in	O
HNPCC	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Beta-catenin	O
mutations	O
were	O
not	O
detected	O
in	O
tumors	O
with	O
APC	O
mutations	O
.	O
All	O
beta-catenin	O
mutations	O
detected	O
in	O
HNPCC	B-malignancy-type
tumors	I-malignancy-type
existed	O
within	O
the	O
regulatory	O
domain	O
of	O
beta-catenin	O
.	O
Immunohistochemical	O
staining	O
of	O
tumors	O
with	O
this	O
mutation	O
showed	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
nuclei	O
.	O
These	O
and	O
previous	O
data	O
from	O
our	O
laboratory	O
suggest	O
that	O
activation	O
of	O
the	O
beta-catenin	O
-	O
Tcf	O
signaling	O
pathway	O
,	O
through	O
either	O
beta-catenin	O
or	O
APC	O
mutation	O
,	O
contributes	O
to	O
HNPCC	B-malignancy-type
colorectal	O
carcinogenesis	O
in	O
approximately	O
65	O
%	O
of	O
cases	O
.	O
PMID	O
:	O
10493496	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Gastroenterol	O
1999	O
Sep;94(9	O
)	O
:2513	O
-	O
8	O
Diagnosis	O
of	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
by	O
detecting	O
telomerase	O
activity	O
in	O
pancreatic	O
juice	O
:	O
comparison	O
with	O
K-ras	O
mutations	O
.	O
Uehara	O
H	O
,	O
Nakaizumi	O
A	O
,	O
Tatsuta	O
M,	O
Baba	O
M,	O
Takenaka	O
A	O
,	O
Uedo	O
N	O
,	O
Sakai	O
N	O
,	O
Yano	O
H	O
,	O
Iishi	O
H	O
,	O
Ohigashi	O
H	O
,	O
Ishikawa	O
O	O
,	O
Okada	O
S,	O
Kakizoe	O
T.	O
Department	O
of	O
Gastroenterology	O
,	O
Osaka	O
Medical	O
Center	O
for	O
Cancer	O
and	O
Cardiovascular	O
Disease	O
,	O
Higashinari	O
,	O
Japan	O
.	O
OBJECTIVE	O
:	O
Telomerase	O
activity	O
is	O
reported	O
to	O
be	O
specific	O
and	O
very	O
frequent	O
in	O
human	O
malignancy	O
.	O
K-ras	O
mutations	O
are	O
also	O
very	O
frequently	O
detected	O
in	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
their	O
specificity	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
is	O
controversial	O
.	O
We	O
examined	O
the	O
telomerase	O
activity	O
and	O
K-ras	O
mutations	O
in	O
pancreatic	O
juice	O
from	O
patients	O
with	O
pancreatic	B-malignancy-type
disease	I-malignancy-type
.	O
METHODS	O
:	O
Pancreatic	O
juice	O
was	O
obtained	O
endoscopically	O
at	O
endoscopic	O
retrograde	O
pancreatography	O
from	O
10	O
patients	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
three	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
,	O
and	O
three	O
with	O
a	O
normal	O
pancreas	O
.	O
The	O
telomerase	O
activity	O
in	O
pancreatic	O
juice	O
was	O
assayed	O
by	O
telomeric	O
repeat	O
amplification	O
protocol	O
.	O
K-ras	O
mutations	O
in	O
exon	O
1	O
codon	O
12	O
were	O
examined	O
by	O
the	O
two-step	O
polymerase	O
chain	O
reaction	O
combined	O
with	O
restriction	O
enzyme	O
digestion	O
,	O
followed	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
.	O
RESULTS	O
:	O
Telomerase	O
activity	O
of	O
>	O
5.0	O
was	O
detected	O
in	O
eight	O
of	O
10	O
(	O
80	O
%	O
)	O
subjects	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
,	O
but	O
in	O
none	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
or	O
normal	O
pancreas	O
.	O
K-ras	O
mutations	O
were	O
detected	O
not	O
only	O
in	O
eight	O
of	O
10	O
(	O
80	O
%	O
)	O
subjects	O
with	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
but	O
also	O
in	O
two	O
of	O
three	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
in	O
one	O
of	O
three	O
with	O
a	O
normal	O
pancreas	O
.	O
CONCLUSIONS	O
:	O
It	O
was	O
shown	O
that	O
the	O
detection	O
of	O
telomerase	O
activity	O
in	O
pancreatic	O
juice	O
is	O
a	O
more	O
useful	O
diagnostic	O
tool	O
for	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
than	O
that	O
of	O
K-ras	O
mutations	O
.	O
Publication	O
Types	O
:	O
Clinical	O
Trial	O
PMID	O
:	O
10484017	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Histopathology	O
1999	O
Sep;35(	O
3	O
)	O
:230	O
-	O
40	O
Protein	O
expression	O
and	O
genetic	O
alterations	O
of	O
p53	O
and	O
ras	O
in	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
.	O
Furubo	O
S,	O
Harada	O
K	O
,	O
Shimonishi	O
T	O
,	O
Katayanagi	O
K	O
,	O
Tsui	O
W	O
,	O
Nakanuma	O
Y.	O
Department	O
of	O
Pathology	O
(	O
II	O
)	O
,	O
Kanazawa	O
University	O
School	O
of	O
Medicine	O
,	O
Kanazawa	O
,	O
Japan	O
.	O
AIMS	O
:	O
The	O
significance	O
of	O
molecular	O
and	O
genetic	O
alterations	O
of	O
p53	O
and	O
ras	O
in	O
the	O
development	O
and	O
progression	O
as	O
well	O
as	O
the	O
histological	O
differentiation	O
of	O
intrahepatic	B-malignancy-type
cholangiocarcinoma	I-malignancy-type
(	O
ICC	B-malignancy-type
)	O
was	O
evaluated	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
examined	O
immunohistochemically	O
ras	O
p21	O
protein	O
and	O
p53	O
-	O
related	O
products	O
(	O
p53	O
protein	O
,	O
WAF-1	O
and	O
mdm-2	O
)	O
in	O
43	O
cases	O
of	O
ICC	B-malignancy-type
.	O
In	O
addition	O
,	O
point	O
mutations	O
of	O
ras	O
and	O
p53	O
were	O
examined	O
genetically	O
in	O
selected	O
ICC	B-malignancy-type
cases	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
and	O
direct	O
sequence	O
analysis	O
.	O
Point	O
mutation	O
of	O
K-ras	O
gene	O
codon	O
12	O
was	O
detected	O
in	O
three	O
of	O
14	O
cases	O
and	O
one	O
of	O
15	O
cases	O
by	O
PCR	O
-	O
RFLP	O
and	O
direct	O
sequence	O
analysis	O
,	O
respectively	O
.	O
Immunoreactivity	O
of	O
ras	O
p21	O
protein	O
was	O
not	O
detected	O
.	O
Point	O
mutation	O
of	O
p53	O
was	O
detected	O
in	O
three	O
of	O
15	O
cases	O
.	O
p53	O
protein	O
was	O
immunohistochemically	O
detectable	O
in	O
33	O
of	O
43	O
cases	O
.	O
Immunoreactivity	O
of	O
p53	O
was	O
more	O
frequent	O
in	O
well	O
-	O
differentiated	O
and	O
less	O
frequent	O
in	O
poorly	O
differentiated	O
cases	O
.	O
Immunoreactivity	O
of	O
WAF-1	O
and	O
mdm-2	O
was	O
seen	O
in	O
16	O
and	O
eight	O
of	O
43	O
cases	O
,	O
respectively	O
.	O
Both	O
proteins	O
were	O
frequently	O
detected	O
in	O
the	O
cases	O
positive	O
for	O
p53	O
protein	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
dysregulation	O
of	O
ras	O
is	O
involved	O
in	O
at	O
least	O
20	O
%	O
of	O
ICC	B-malignancy-type
and	O
expression	O
of	O
p53	O
protein	O
is	O
more	O
significantly	O
involved	O
in	O
ICC	B-malignancy-type
,	O
particularly	O
in	O
the	O
well	O
and	O
moderately	O
differentiated	O
cases	O
.	O
While	O
some	O
cases	O
of	O
p53	O
expression	O
may	O
be	O
explainable	O
by	O
point	O
mutation	O
of	O
p53	O
,	O
there	O
may	O
be	O
some	O
epigenetic	O
phenomena	O
that	O
stabilize	O
p53	O
protein	O
in	O
ICC	B-malignancy-type
.	O
That	O
is	O
,	O
wild	O
type	O
p53	O
may	O
be	O
stabilized	O
and	O
then	O
detectable	O
by	O
forming	O
complexes	O
with	O
other	O
molecules	O
of	O
p53	O
downstream	O
effector	O
genes	O
,	O
such	O
as	O
WAF-1	O
and	O
mdm-2	O
.	O
PMID	O
:	O
10469215	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Aug;155(	O
2	O
)	O
:527	O
-	O
36	O
beta-catenin	O
expression	O
pattern	O
in	O
stage	O
I	O
and	O
II	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
:	O
relationship	O
with	O
beta-catenin	O
gene	O
mutations	O
,	O
clinicopathological	O
features	O
,	O
and	O
clinical	O
outcome	O
.	O
Gamallo	O
C	O
,	O
Palacios	O
J,	O
Moreno	O
G	O
,	O
Calvo	O
de	O
Mora	O
J,	O
Suarez	O
A	O
,	O
Armas	O
A.	O
Departamento	O
de	O
Anatomia	O
Patologica	O
,	O
Hospital	O
La	O
Paz	O
,	O
Madrid	O
,	O
Spain	O
.	O
cgamallo@hulp.es	O
The	O
immunohistochemical	O
expression	O
pattern	O
of	O
beta-catenin	O
has	O
been	O
correlated	O
with	O
beta-catenin	O
gene	O
mutations	O
,	O
clinicopathological	O
features	O
,	O
and	O
disease	O
outcome	O
in	O
69	O
stage	O
I	O
and	O
II	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
.	O
beta-Catenin	O
expression	O
was	O
localized	O
in	O
the	O
nuclei	O
,	O
in	O
addition	O
to	O
the	O
cytoplasm	O
and	O
membrane	O
,	O
in	O
11	O
tumors	O
(	O
16	O
%	O
)	O
:	O
nine	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
widespread	O
nuclear	O
expression	O
and	O
two	O
serous	B-malignancy-type
carcinomas	I-malignancy-type
with	O
focal	O
nuclear	O
expression	O
.	O
The	O
remaining	O
58	O
carcinomas	B-malignancy-type
(	O
84	O
%	O
)	O
only	O
had	O
membranous	O
beta-catenin	O
expression	O
.	O
All	O
but	O
one	O
of	O
the	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
nuclear	O
beta-catenin	O
expression	O
had	O
considerable	O
squamous	O
metaplasia	O
,	O
and	O
five	O
of	O
these	O
cases	O
had	O
large	O
areas	O
of	O
endometrioid	B-malignancy-type
tumor	I-malignancy-type
of	O
low	O
malignant	O
potential	O
.	O
In	O
addition	O
,	O
beta-catenin	O
nuclear	O
expression	O
was	O
observed	O
in	O
atypical	O
epithelial	O
cells	O
in	O
endometriotic	O
glands	O
adjacent	O
to	O
an	O
endometrioid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Sequencing	O
was	O
performed	O
on	O
25	O
tumors	O
and	O
corresponding	O
normal	O
tissue	O
:	O
all	O
13	O
endometrioid	B-malignancy-type
tumors	I-malignancy-type
as	O
well	O
as	O
12	O
carcinomas	B-malignancy-type
of	O
other	O
histological	O
types	O
(	O
four	O
serous	B-malignancy-type
,	O
two	O
clear	B-malignancy-type
cell	I-malignancy-type
,	O
two	O
mucinous	B-malignancy-type
,	O
and	O
two	O
mixed	B-malignancy-type
)	O
.	O
There	O
were	O
oncogenic	O
mutations	O
in	O
the	O
phosphorylation	O
sequence	O
for	O
GSK-3beta	O
in	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
in	O
seven	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
beta-catenin	O
nuclear	O
expression	O
.	O
Three	O
mutations	O
affected	O
codon	O
32	O
(	O
D	O
32	O
G	O
,	O
D	O
32	O
Y	O
,	O
and	O
D	O
32	O
Y	O
)	O
,	O
one	O
affected	O
codon	O
33	O
(	O
S	O
33	O
C	O
)	O
,	O
two	O
affected	O
codon	O
37	O
(	O
S	O
37	O
C	O
and	O
S	O
37	O
F	O
)	O
,	O
and	O
one	O
affected	O
codon	O
41	O
(	O
T	O
41	O
A	O
)	O
.	O
No	O
mutations	O
were	O
observed	O
in	O
the	O
other	O
18	O
carcinomas	B-malignancy-type
analyzed	O
,	O
comprising	O
two	O
endometrioid	B-malignancy-type
and	O
two	O
serous	B-malignancy-type
carcinomas	I-malignancy-type
with	O
beta-catenin	O
nuclear	O
expression	O
,	O
and	O
14	O
carcinomas	B-malignancy-type
of	O
different	O
histological	O
types	O
with	O
only	O
membranous	O
expression	O
.	O
In	O
the	O
univariate	O
and	O
multivariate	O
survival	O
analyses	O
,	O
beta-catenin	O
nuclear	O
expression	O
was	O
selected	O
as	O
an	O
indicator	O
of	O
good	O
prognosis	O
,	O
because	O
no	O
patient	O
whose	O
tumor	O
expressed	O
beta-catenin	O
in	O
the	O
nuclei	O
showed	O
relapses	O
or	O
died	O
,	O
in	O
contrast	O
to	O
the	O
19	O
relapses	O
and	O
deaths	O
among	O
patients	O
with	O
tumors	O
that	O
only	O
had	O
beta-catenin	O
membranous	O
expression	O
,	O
including	O
three	O
of	O
the	O
four	O
patients	O
with	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Oncogenic	O
beta-catenin	O
mutation	O
is	O
characteristic	O
of	O
a	O
group	O
of	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
a	O
good	O
prognosis	O
,	O
most	O
of	O
which	O
originate	O
from	O
previous	O
benign	O
or	O
borderline	O
lesions	O
.	O
Endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
with	O
exclusively	O
membranous	O
expression	O
of	O
beta-catenin	O
seem	O
to	O
represent	O
a	O
different	O
subgroup	O
of	O
carcinomas	B-malignancy-type
that	O
probably	O
have	O
a	O
worse	O
prognosis	O
.	O
In	O
early-stage	O
ovarian	B-malignancy-type
cancer	I-malignancy-type
,	O
determination	O
of	O
the	O
beta-catenin	O
expression	O
pattern	O
could	O
prove	O
to	O
be	O
a	O
useful	O
marker	O
for	O
selecting	O
low-risk	O
patients	O
.	O
PMID	O
:	O
10433945	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1999	O
Jul	O
15	O
;86(	O
2	O
)	O
:255	O
-	O
64	O
ras	O
gene	O
mutations	O
in	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinoma	I-malignancy-type
:	O
prognostic	O
implications	O
.	O
Perez	O
P	O
,	O
Dominguez	O
O	O
,	O
Gonzalez	O
S,	O
Gonzalez	O
S,	O
Trivino	O
A	O
,	O
Suarez	O
C.	O
Department	O
of	O
ENT	O
,	O
University	O
Hospital	O
Central	O
of	O
Asturias	O
,	O
Oviedo	O
,	O
Spain	O
.	O
BACKGROUND	O
:	O
The	O
presence	O
of	O
mutations	O
of	O
the	O
3	O
ras	O
proto	O
-	O
oncogenes	O
in	O
31	O
cases	O
of	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
an	O
uncommon	O
tumor	O
type	O
epidemiologically	O
related	O
to	O
professional	O
exposure	O
to	O
wood	O
dust	O
,	O
was	O
studied	O
.	O
METHODS	O
:	O
The	O
authors	O
studied	O
31	O
patients	O
with	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinoma	I-malignancy-type
.	O
The	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
amplify	O
ras	O
specific	O
sequences	O
of	O
DNA	O
isolated	O
from	O
paraffin	O
embedded	O
tumor	O
samples	O
.	O
ras	O
point	O
mutations	O
were	O
subsequently	O
detected	O
with	O
mutation	O
specific	O
oligonucleotide	O
probes	O
.	O
RESULTS	O
:	O
H-ras	O
was	O
found	O
to	O
be	O
mutated	O
in	O
5	O
cases	O
(	O
16	O
%	O
)	O
.	O
It	O
is	O
noteworthy	O
that	O
all	O
of	O
these	O
mutations	O
were	O
identical	O
and	O
consisted	O
of	O
a	O
G	O
-	O
for	O
-	O
T	O
transversion	O
at	O
the	O
second	O
base	O
of	O
codon	O
12	O
.	O
H-ras	O
mutations	O
were	O
related	O
to	O
a	O
worse	O
prognosis	O
,	O
with	O
shorter	O
tumor	O
free	O
survival	O
(	O
P	O
=	O
0.04	O
)	O
and	O
overall	O
survival	O
(	O
P	O
=	O
0.008	O
)	O
.	O
T	O
classification	O
was	O
a	O
significant	O
clinical	O
factor	O
related	O
to	O
survival	O
(	O
P	O
=	O
0.01	O
for	O
disease	O
free	O
survival	O
and	O
P	O
=	O
0.006	O
for	O
overall	O
survival	O
)	O
.	O
The	O
prognostic	O
value	O
of	O
H-ras	O
mutation	O
was	O
consistent	O
after	O
adjustment	O
for	O
T	O
classification	O
.	O
H-ras	O
mutations	O
showed	O
no	O
association	O
with	O
patients	O
'	O
previous	O
exposure	O
to	O
wood	O
dust	O
.	O
K-ras	O
was	O
found	O
to	O
be	O
transformed	O
in	O
a	O
single	O
case	O
;	O
this	O
was	O
the	O
only	O
patient	O
in	O
the	O
series	O
to	O
develop	O
lymph	B-malignancy-type
node	I-malignancy-type
metastases	I-malignancy-type
.	O
In	O
this	O
case	O
,	O
both	O
the	O
nasal	B-malignancy-type
tumor	I-malignancy-type
and	O
the	O
lymph	O
nodes	O
showed	O
the	O
GAT	O
-	O
for	O
-	O
GGT	O
mutation	O
at	O
codon	O
12	O
of	O
K-ras	O
.	O
No	O
activation	O
of	O
the	O
N-ras	O
gene	O
was	O
detected	O
.	O
CONCLUSIONS	O
:	O
The	O
presence	O
of	O
H-ras	O
point	O
mutations	O
defines	O
a	O
subgroup	O
of	O
patients	O
with	O
ethmoid	B-malignancy-type
sinus	I-malignancy-type
adenocarcinomas	I-malignancy-type
for	O
whom	O
the	O
prognosis	O
is	O
very	O
poor	O
.	O
The	O
finding	O
that	O
all	O
of	O
these	O
mutations	O
are	O
identical	O
emphasizes	O
the	O
peculiarity	O
of	O
this	O
type	O
of	O
tumor	O
.	O
PMID	O
:	O
10421261	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
Respir	O
J	O
1999	O
May	O
;13(	O
5	O
)	O
:1120	O
-	O
4	O
Additional	O
value	O
of	O
K-ras	O
point	O
mutations	O
in	O
bronchial	O
wash	O
fluids	O
for	O
diagnosis	O
of	O
peripheral	B-malignancy-type
lung	I-malignancy-type
tumours	I-malignancy-type
.	O
Somers	O
VA	O
,	O
van	O
Henten	O
AM	O
,	O
ten	O
Velde	O
GP	O
,	O
Arends	O
JW	O
,	O
Thunnissen	O
FB.	O
Dept	O
of	O
Pathology	O
,	O
Maastricht	O
University	O
,	O
The	O
Netherlands	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
additional	O
diagnostic	O
value	O
of	O
K-ras	O
point	O
mutations	O
in	O
the	O
clinical	O
diagnosis	O
of	O
peripheral	B-malignancy-type
lung	I-malignancy-type
tumours	I-malignancy-type
.	O
To	O
this	O
end	O
,	O
bronchial	O
wash	O
fluids	O
obtained	O
during	O
bronchoscopy	O
from	O
patients	O
suspected	O
of	O
having	O
lung	B-malignancy-type
cancer	I-malignancy-type
were	O
studied	O
.	O
Only	O
those	O
patients	O
were	O
investigated	O
for	O
whom	O
the	O
cytological	O
diagnosis	O
was	O
not	O
conclusive	O
for	O
malignancy	O
.	O
As	O
a	O
control	O
group	O
,	O
patients	O
without	O
lung	B-malignancy-type
cancer	I-malignancy-type
were	O
investigated	O
.	O
The	O
method	O
of	O
"	O
point	O
mutation	O
detection	O
using	O
the	O
exonuclease	O
amplification	O
coupled	O
capture	O
technique	O
"	O
(	O
Point	O
-	O
EXACCT	O
)	O
for	O
analysis	O
of	O
K-ras	O
codon	O
12	O
was	O
performed	O
in	O
bronchial	O
wash	O
fluids	O
and	O
the	O
corresponding	O
tumour	O
tissue	O
,	O
if	O
available	O
.	O
K-ras	O
point	O
mutations	O
were	O
identified	O
in	O
4	O
out	O
of	O
19	O
(	O
21	O
%	O
)	O
bronchial	O
wash	O
fluids	O
from	O
patients	O
without	O
a	O
decisive	O
diagnosis	O
of	O
malignancy	O
.	O
The	O
diagnosis	O
of	O
malignancy	O
was	O
further	O
based	O
on	O
cytological	O
examination	O
of	O
bronchial	O
brush	O
specimens	O
,	O
perthoracic	O
needle	O
aspiration	O
,	O
histological	O
investigation	O
of	O
biopsy	O
and	O
resection	O
specimens	O
,	O
needle	O
aspiration	O
of	O
a	O
lymph	O
node	O
in	O
the	O
neck	O
and	O
pleural	O
fluid	O
examination	O
.	O
Four	O
of	O
the	O
patients	O
who	O
were	O
K-ras	O
-	O
positive	O
yielded	O
positive	O
malignant	O
tissue	O
via	O
bronchoscopy	O
even	O
though	O
the	O
bronchial	O
wash	O
was	O
negative	O
for	O
malignancy	O
.	O
The	O
bronchial	O
wash	O
was	O
positive	O
for	O
K-ras	O
in	O
two	O
of	O
the	O
four	O
patients	O
whose	O
tumour	O
tissue	O
demonstrated	O
the	O
K-ras	O
mutations	O
.	O
Analysis	O
of	O
bronchial	O
wash	O
fluids	O
from	O
11	O
patients	O
without	O
lung	B-malignancy-type
cancer	I-malignancy-type
revealed	O
no	O
K-ras	O
codon	O
12	O
mutations	O
.	O
In	O
conclusion	O
,	O
K-ras	O
point	O
mutations	O
can	O
be	O
identified	O
in	O
bronchial	O
wash	O
fluids	O
obtained	O
during	O
bronchoscopic	O
procedures	O
.	O
K-ras	O
can	O
be	O
used	O
as	O
a	O
biomarker	O
in	O
the	O
clinical	O
diagnosis	O
of	O
lung	B-malignancy-type
cancer	I-malignancy-type
and	O
may	O
serve	O
as	O
an	O
adjunct	O
to	O
cytology	O
in	O
lung	B-malignancy-type
cancer	I-malignancy-type
diagnosis	O
.	O
PMID	O
:	O
10414414	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1999	O
Jun	O
11	O
;81(	O
6)	O
:902	O
-	O
10	O
Establishment	O
and	O
characterization	O
of	O
12	O
human	O
colorectal	B-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
.	O
Oh	O
JH	O
,	O
Ku	O
JL	O
,	O
Yoon	O
KA	O
,	O
Kwon	O
HJ	O
,	O
Kim	O
WH	O
,	O
Park	O
HS	O
,	O
Yeo	O
KS	O
,	O
Song	O
SY	O
,	O
Chung	O
JK	O
,	O
Park	O
JG.	O
Laboratory	O
of	O
Cell	O
Biology	O
,	O
Cancer	O
Research	O
Center	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Korean	O
Cell	O
Line	O
Bank	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Republic	O
of	O
Korea	O
.	O
In	O
this	O
article	O
,	O
we	O
describe	O
the	O
characteristics	O
of	O
12	O
human	O
colorectal	B-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
established	O
from	O
6	O
primary	O
tumors	O
and	O
6	O
metastatic	O
sites	O
of	O
11	O
Korean	O
colorectal	B-malignancy-type
-	I-malignancy-type
carcinoma	I-malignancy-type
patients	O
,	O
including	O
the	O
morphology	O
in	O
vivo	O
and	O
in	O
vitro	O
and	O
mutations	O
of	O
K-ras2	O
,	O
p15	O
,	O
p16	O
,	O
p53	O
,	O
APC	O
,	O
beta-catenin	O
,	O
hMLH1	O
and	O
hMSH2	O
genes	O
in	O
vitro	O
.	O
No	O
lines	O
were	O
contaminated	O
with	O
Mycoplasma	O
or	O
bacteria	O
.	O
All	O
lines	O
were	O
proven	O
to	O
be	O
unique	O
by	O
DNA	O
-	O
fingerprinting	O
analysis	O
.	O
All	O
lines	O
expressed	O
the	O
surface	O
carcino	O
-	O
embryonic	O
antigen	O
and	O
secreted	O
it	O
into	O
the	O
supernatant	O
fluid	O
.	O
The	O
morphological	O
correlation	O
between	O
the	O
original	O
tumors	O
and	O
cultured	O
cells	O
suggested	O
that	O
the	O
original	O
tumors	O
showing	O
mucinous	B-malignancy-type
adenocarcinoma	I-malignancy-type
correlated	O
with	O
floating	O
aggregates	O
in	O
culture	O
,	O
and	O
degree	O
of	O
desmoplasia	B-malignancy-type
in	O
the	O
original	O
tumor	O
correlated	O
with	O
attached	O
growth	O
in	O
culture	O
.	O
Five	O
of	O
the	O
cell	O
lines	O
showed	O
mutations	O
in	O
the	O
K-ras2	O
gene	O
,	O
and	O
6	O
of	O
the	O
cell	O
lines	O
showed	O
mutations	O
in	O
the	O
p53	O
gene	O
.	O
The	O
p15	O
gene	O
was	O
deleted	O
in	O
2	O
cell	O
lines	O
,	O
and	O
the	O
p16	O
gene	O
was	O
hypermethylated	O
in	O
3	O
cell	O
lines	O
.	O
The	O
mutation	O
of	O
mismatch	O
-	O
repair	O
genes	O
(	O
hMLH1	O
and	O
hMSH2	O
)	O
was	O
found	O
in	O
4	O
lines	O
,	O
the	O
APC	O
gene	O
and	O
beta-catenin	O
gene	O
were	O
mutated	O
in	O
9	O
and	O
2	O
lines	O
respectively	O
.	O
These	O
well	O
-	O
characterized	O
colorectal	B-malignancy-type
-	I-malignancy-type
cancer	I-malignancy-type
cell	O
lines	O
should	O
serve	O
as	O
useful	O
tools	O
for	O
investigating	O
the	O
biological	O
characteristics	O
of	O
colorectal	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
10362137	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1999	O
Apr	O
8;18(	O
14	O
)	O
:2343	O
-	O
50	O
Novel	O
mutations	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
papillary	B-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Schmidt	O
L,	O
Junker	O
K	O
,	O
Nakaigawa	O
N	O
,	O
Kinjerski	O
T	O
,	O
Weirich	O
G	O
,	O
Miller	O
M,	O
Lubensky	O
I	O
,	O
Neumann	O
HP	O
,	O
Brauch	O
H	O
,	O
Decker	O
J,	O
Vocke	O
C	O
,	O
Brown	O
JA	O
,	O
Jenkins	O
R,	O
Richard	O
S,	O
Bergerheim	O
U	O
,	O
Gerrard	O
B	O
,	O
Dean	O
M,	O
Linehan	O
WM	O
,	O
Zbar	O
B.	O
Intramural	O
Research	O
Support	O
Program	O
,	O
SAIC	O
Frederick	O
,	O
National	O
Cancer	O
Institute	O
-	O
Frederick	O
Cancer	O
Research	O
and	O
Development	O
Center	O
,	O
Maryland	O
21702	O
,	O
USA	O
.	O
Hereditary	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
(	O
HPRC	B-malignancy-type
)	O
is	O
characterized	O
by	O
multiple	B-malignancy-type
,	I-malignancy-type
bilateral	I-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Previously	O
,	O
we	O
demonstrated	O
missense	O
mutations	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
HPRC	O
and	O
a	O
subset	O
of	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
In	O
this	O
study	O
,	O
we	O
screened	O
a	O
large	O
panel	O
of	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
and	O
various	O
solid	O
tumors	O
for	O
mutations	O
in	O
the	O
MET	O
proto	O
-	O
oncogene	O
.	O
Summarizing	O
these	O
and	O
previous	O
results	O
,	O
mutations	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
were	O
detected	O
in	O
17	O
/	O
129	O
sporadic	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
but	O
not	O
in	O
other	O
solid	O
tumors	O
.	O
We	O
detected	O
five	O
novel	O
missense	O
mutations	O
;	O
three	O
of	O
five	O
mutations	O
were	O
located	O
in	O
the	O
ATP	O
-	O
binding	O
region	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
MET	O
.	O
One	O
novel	O
mutation	O
in	O
MET	O
,	O
V	O
1110	O
I	O
,	O
was	O
located	O
at	O
a	O
codon	O
homologous	O
to	O
an	O
activating	O
mutation	O
in	O
the	O
c-erbB	O
proto	O
-	O
oncogene	O
.	O
These	O
mutations	O
caused	O
constitutive	O
phosphorylation	O
of	O
MET	O
when	O
transfected	O
into	O
NIH3T3	O
cells	O
.	O
Molecular	O
modeling	O
studies	O
suggest	O
that	O
these	O
activating	O
mutations	O
interfere	O
with	O
the	O
intrasteric	O
mechanism	O
of	O
tyrosine	O
kinase	O
autoinhibition	O
and	O
facilitate	O
transition	O
to	O
the	O
active	O
form	O
of	O
the	O
MET	O
kinase	O
.	O
The	O
low	O
frequency	O
of	O
MET	O
mutations	O
in	O
noninherited	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinomas	I-malignancy-type
(	O
PRC	B-malignancy-type
)	O
suggests	O
that	O
noninherited	B-malignancy-type
PRC	I-malignancy-type
may	O
develop	O
by	O
a	O
different	O
mechanism	O
than	O
hereditary	B-malignancy-type
papillary	I-malignancy-type
renal	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
10327054	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1999	O
Apr;13(	O
4)	O
:585	O
-	O
9	O
Lack	O
of	O
constitutive	O
activation	O
of	O
MAP	O
kinase	O
pathway	O
in	O
human	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
cells	O
with	O
N-Ras	O
mutation	O
.	O
Iida	O
M,	O
Towatari	O
M,	O
Nakao	O
A	O
,	O
Iida	O
H	O
,	O
Kiyoi	O
H	O
,	O
Nakano	O
Y	O
,	O
Tanimoto	O
M,	O
Saito	O
H	O
,	O
Naoe	O
T.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nagoya	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
act	O
as	O
transducers	O
of	O
extracellular	O
signaling	O
via	O
tyrosine	O
kinase	O
-	O
growth	O
factor	O
receptors	O
and	O
G-protein	O
-	O
linked	O
receptors	O
to	O
transcription	O
factors	O
.	O
Constitutive	O
activation	O
of	O
MAP	O
kinase	O
has	O
been	O
observed	O
in	O
a	O
variety	O
of	O
solid	O
tumors	O
including	O
renal	B-malignancy-type
cancer	I-malignancy-type
and	O
breast	B-malignancy-type
cancer	I-malignancy-type
.	O
Recently	O
,	O
we	O
have	O
reported	O
that	O
constitutively	O
activated	O
MAP	O
kinase	O
was	O
observed	O
in	O
50	O
%	O
of	O
human	O
primary	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
cells	O
.	O
Ras	O
is	O
one	O
of	O
the	O
components	O
of	O
G-proteins	O
and	O
transduces	O
the	O
signal	O
from	O
cytokine	O
receptors	O
to	O
raf-1	O
theoretically	O
resulting	O
in	O
the	O
activation	O
of	O
MAP	O
kinase	O
pathway	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
examined	O
the	O
correlation	O
of	O
Ras	O
mutations	O
and	O
the	O
activation	O
of	O
MAP	O
kinase	O
pathway	O
in	O
patients	O
with	O
AML	B-malignancy-type
.	O
Twenty	O
out	O
of	O
22	O
AML	B-malignancy-type
cases	O
with	O
activating	O
N-Ras	O
mutations	O
showed	O
no	O
phosphorylated	O
forms	O
of	O
ERK2	O
.	O
ERK2	O
phosphorylation	O
was	O
tightly	O
correlated	O
with	O
ERK1	O
phosphorylation	O
and	O
MAP	O
kinase	O
activity	O
detected	O
by	O
in	O
vitro	O
kinase	O
assay	O
.	O
Three	O
samples	O
with	O
N-Ras	O
mutations	O
were	O
stimulated	O
with	O
IL-3	O
,	O
GM-CSF	O
and	O
G-CSF	O
separately	O
but	O
ERK2	O
activation	O
was	O
induced	O
in	O
none	O
of	O
these	O
samples	O
stimulated	O
with	O
these	O
cytokines	O
.	O
In	O
contrast	O
,	O
ERK2	O
was	O
constitutively	O
activated	O
in	O
all	O
of	O
four	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
cases	O
with	O
K-Ras	O
mutation	O
at	O
codon	O
12	O
.	O
These	O
results	O
suggest	O
that	O
function	O
of	O
the	O
Ras	O
mutations	O
may	O
be	O
different	O
between	O
solid	O
tumors	O
,	O
such	O
as	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
and	O
colorectal	B-malignancy-type
carcinoma	I-malignancy-type
,	O
and	O
AML	B-malignancy-type
.	O
Mutated	O
Ras	O
does	O
not	O
always	O
stimulate	O
MAP	O
kinase	O
pathway	O
constitutively	O
and	O
may	O
rather	O
inhibit	O
classical	O
MAP	O
kinase	O
cascade	O
in	O
AML	B-malignancy-type
blasts	O
from	O
leukemia	B-malignancy-type
patients	O
.	O
PMID	O
:	O
10214865	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreas	O
1999	O
Apr;18(	O
3	O
)	O
:294	O
-	O
9	O
Comment	O
in	O
:	O
Pancreas	O
.	O
2001	O
Jan;22(	O
1	O
)	O
:108	O
-	O
9.	O
Detection	O
of	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
pancreatic	O
juice	O
for	O
the	O
diagnosis	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
.	O
Kaino	O
M,	O
Kondoh	O
S,	O
Okita	O
S,	O
Hatano	O
S,	O
Shiraishi	O
K	O
,	O
Kaino	O
S,	O
Okita	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Yamaguchi	O
University	O
School	O
of	O
Medicine	O
,	O
Ube	O
,	O
Japan	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
mutations	O
of	O
the	O
K-ras	O
oncogene	O
and	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
in	O
pancreatic	O
juice	O
and	O
to	O
evaluate	O
our	O
method	O
for	O
the	O
diagnosis	O
of	O
intraductal	B-malignancy-type
papillary	I-malignancy-type
mucinous	I-malignancy-type
tumors	I-malignancy-type
(	O
IPMT	B-malignancy-type
)	O
.	O
Pancreatic	O
juice	O
was	O
collected	O
endoscopically	O
from	O
12	O
patients	O
with	O
IPMT	B-malignancy-type
who	O
underwent	O
surgical	O
resection	O
(	O
eight	O
carcinomas	B-malignancy-type
and	O
four	O
adenomas	B-malignancy-type
)	O
and	O
eight	O
cases	O
without	O
evident	O
pancreatic	O
diseases	O
.	O
DNA	O
was	O
extracted	O
and	O
both	O
genes	O
were	O
examined	O
by	O
polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
In	O
addition	O
,	O
surgically	O
resected	O
specimens	O
were	O
analyzed	O
for	O
both	O
genes	O
by	O
the	O
same	O
methods	O
,	O
and	O
p53	O
overexpression	O
was	O
investigated	O
immunohistochemically	O
.	O
K-ras	O
point	O
mutations	O
were	O
detected	O
in	O
pancreatic	O
juice	O
from	O
all	O
12	O
patients	O
(	O
100	O
%	O
)	O
and	O
p53	O
mutations	O
were	O
detected	O
in	O
five	O
of	O
12	O
(	O
42	O
%	O
)	O
.	O
They	O
were	O
detected	O
not	O
only	O
in	O
carcinoma	B-malignancy-type
but	O
also	O
in	O
adenoma	B-malignancy-type
and	O
there	O
was	O
no	O
difference	O
between	O
the	O
mutations	O
detected	O
in	O
pancreatic	O
juice	O
and	O
surgical	O
specimens	O
.	O
No	O
mutations	O
were	O
found	O
in	O
any	O
cases	O
without	O
pancreatic	O
diseases	O
.	O
These	O
findings	O
suggest	O
that	O
alterations	O
of	O
K-ras	O
and	O
p53	O
gene	O
are	O
common	O
events	O
in	O
the	O
development	O
of	O
IPMT	B-malignancy-type
and	O
that	O
genetic	O
analysis	O
of	O
them	O
in	O
pancreatic	O
juice	O
can	O
be	O
a	O
useful	O
tool	O
for	O
the	O
clinical	O
diagnosis	O
of	O
IPMT	B-malignancy-type
before	O
surgery	O
.	O
PMID	O
:	O
10206488	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreas	O
1999	O
Mar;18(	O
2	O
)	O
:133	O
-	O
40	O
Analysis	O
of	O
K-ras	O
codon	O
12	O
point	O
mutations	O
using	O
duodenal	O
lavage	O
fluid	O
for	O
diagnosis	O
of	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Nakamura	O
Y	O
,	O
Onda	O
M,	O
Uchida	O
E.	O
First	O
Department	O
of	O
Surgery	O
,	O
Nippon	O
Medical	O
School	O
,	O
Tokyo	O
,	O
Japan	O
.	O
We	O
evaluated	O
the	O
diagnostic	O
significance	O
of	O
the	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
duodenal	O
lavage	O
fluid	O
(	O
DLF	O
)	O
compared	O
with	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
.	O
The	O
DLF	O
was	O
easily	O
and	O
safely	O
collected	O
by	O
injecting	O
distilled	O
water	O
into	O
the	O
duodenum	O
and	O
then	O
aspirating	O
through	O
the	O
working	O
channel	O
of	O
the	O
endoscope	O
during	O
endoscopic	O
retrograde	O
cholangiopancreatography	O
.	O
Two	O
types	O
of	O
DLF	O
are	O
collected	O
this	O
way	O
:	O
DLF	O
1	O
is	O
collected	O
just	O
after	O
insertion	O
of	O
the	O
endoscope	O
into	O
the	O
duodenum	O
and	O
DLF	O
2	O
is	O
collected	O
after	O
cholangiopancreatography	O
and/or	O
collection	O
of	O
the	O
PPJ	O
using	O
secretin	O
.	O
Analysis	O
of	O
K-ras	O
mutations	O
was	O
performed	O
using	O
enriched	O
polymerase	O
chain	O
reaction	O
.	O
In	O
patients	O
with	O
pancreatic	B-malignancy-type
carcinoma	I-malignancy-type
(	O
PC	B-malignancy-type
)	O
,	O
K-ras	O
mutations	O
were	O
detected	O
in	O
14	O
of	O
23	O
(	O
60.9	O
%	O
)	O
in	O
DLF	O
1	O
,	O
16	O
of	O
21	O
(	O
76.2	O
%	O
)	O
in	O
DLF	O
2	O
,	O
14	O
of	O
20	O
(	O
70.0	O
%	O
)	O
in	O
PPJ	O
,	O
and	O
19	O
of	O
21	O
(	O
90.5	O
%	O
)	O
in	O
either	O
DLF	O
1	O
or	O
DLF	O
2	O
.	O
In	O
patients	O
with	O
noncancerous	O
pancreatic	O
diseases	O
consisting	O
of	O
pancreatic	B-malignancy-type
cystic	I-malignancy-type
diseases	I-malignancy-type
and	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
,	O
the	O
incidence	O
of	O
K-ras	O
mutations	O
was	O
2	O
of	O
21	O
(	O
9.5	O
%	O
)	O
in	O
DLF	O
1	O
and	O
7	O
of	O
19	O
(	O
36.8	O
%	O
)	O
in	O
DLF	O
2	O
.	O
These	O
values	O
were	O
lower	O
than	O
that	O
in	O
PPJ	O
,	O
and	O
there	O
was	O
significant	O
difference	O
between	O
the	O
incidence	O
in	O
DLF	O
1	O
and	O
PPJ	O
.	O
These	O
results	O
suggested	O
that	O
DLF	O
may	O
provide	O
a	O
new	O
and	O
useful	O
material	O
for	O
analysis	O
of	O
K-ras	O
codon	O
12	O
point	O
mutations	O
in	O
the	O
diagnosis	O
of	O
PC	B-malignancy-type
.	O
PMID	O
:	O
10090410	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1999	O
Jan;90(	O
1	O
)	O
:55	O
-	O
9	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Kobayashi	O
K	O
,	O
Sagae	O
S,	O
Nishioka	O
Y	O
,	O
Tokino	O
T	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Sapporo	O
Medical	O
University	O
,	O
School	O
of	O
Medicine	O
,	O
Hokkaido	O
.	O
To	O
investigate	O
the	O
contribution	O
of	O
beta-catenin	O
to	O
the	O
development	O
of	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
,	O
we	O
searched	O
for	O
genetic	O
alterations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
primary	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Mutational	O
analysis	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
,	O
encoding	O
the	O
serine	O
/	O
threonine	O
residues	O
for	O
GSK-3	O
beta	O
phosphorylation	O
,	O
was	O
performed	O
for	O
35	O
tumors	O
.	O
Nucleotide	O
sequencing	O
analysis	O
revealed	O
that	O
5	O
tumors	O
(	O
5	O
/	O
35	O
,	O
14	O
%	O
)	O
contained	O
mutations	O
(	O
S	O
33	O
C	O
,	O
S	O
37	O
C	O
,	O
S	O
37	O
F	O
,	O
T	O
41	O
A	O
)	O
that	O
altered	O
potential	O
GSK-3	O
beta	O
phosphorylation	O
sites	O
.	O
Each	O
of	O
the	O
mutations	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	O
/	O
threonine	O
residues	O
that	O
have	O
been	O
implicated	O
in	O
the	O
down-regulation	O
of	O
beta-catenin	O
through	O
phosphorylation	O
by	O
GSK-3	O
beta	O
kinase	O
.	O
Furthermore	O
,	O
the	O
incidence	O
of	O
beta-catenin	O
mutations	O
was	O
significantly	O
higher	O
in	O
early-onset	O
(	O
3	O
of	O
5	O
)	O
than	O
that	O
in	O
late-onset	O
tumors	O
(	O
2	O
of	O
30	O
)	O
(	O
P	O
=	O
0.014	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
Replication	O
error	O
(	O
RER	O
)	O
-	O
positive	O
phenotype	O
was	O
not	O
detected	O
in	O
tumors	O
with	O
the	O
beta-catenin	O
gene	O
mutation	O
,	O
although	O
10	O
of	O
35	O
tumors	O
revealed	O
RER	O
.	O
We	O
performed	O
immunohistochemistry	O
of	O
beta-catenin	O
in	O
17	O
cases	O
for	O
which	O
tissue	O
samples	O
were	O
available	O
.	O
We	O
confirmed	O
accumulation	O
of	O
beta-catenin	O
protein	O
in	O
both	O
the	O
nucleus	O
and	O
cytoplasm	O
in	O
3	O
tumors	O
,	O
including	O
two	O
in	O
which	O
amino	O
acid	O
alterations	O
had	O
occurred	O
at	O
codon	O
33	O
and	O
37	O
.	O
The	O
other	O
case	O
had	O
no	O
mutation	O
in	O
exon	O
3	O
.	O
Our	O
results	O
suggested	O
that	O
mutations	O
at	O
serine	O
/	O
threonine	O
residues	O
involved	O
in	O
phosphorylation	O
by	O
GSK-3	O
beta	O
affected	O
the	O
stability	O
of	O
beta-catenin	O
.	O
Accumulation	O
of	O
mutant	O
beta-catenin	O
could	O
contribute	O
to	O
the	O
development	O
of	O
a	O
subset	O
of	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
,	O
particularly	O
those	O
of	O
the	O
early-onset	O
type	O
.	O
PMID	O
:	O
10076565	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virchows	O
Arch	O
1999	O
Feb;434(	O
2	O
)	O
:117	O
-	O
20	O
In	O
serous	B-malignancy-type
ovarian	I-malignancy-type
neoplasms	I-malignancy-type
the	O
frequency	O
of	O
Ki-ras	O
mutations	O
correlates	O
with	O
their	O
malignant	O
potential	O
.	O
Haas	O
CJ	O
,	O
Diebold	O
J,	O
Hirschmann	O
A	O
,	O
Rohrbach	O
H	O
,	O
Lohrs	O
U.	O
Institute	O
of	O
Pathology	O
,	O
Ludwig	O
-	O
Maximilians	O
-	O
Universitat	O
,	O
Munich	O
,	O
Germany	O
.	O
We	O
analysed	O
44	O
tissue	O
samples	O
from	O
serous	B-malignancy-type
ovarian	I-malignancy-type
neoplasms	I-malignancy-type
of	O
different	O
malignant	O
potential	O
for	O
Ki-ras	O
mutations	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
and	O
direct	O
sequencing	O
after	O
microdissection	O
.	O
Point	O
mutations	O
at	O
codon	O
12	O
were	O
found	O
in	O
7	O
of	O
20	O
tumours	O
of	O
low	O
malignant	O
potential	O
(	O
LMP	O
)	O
(	O
35	O
%	O
)	O
and	O
in	O
2	O
of	O
6	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
carcinomas	I-malignancy-type
(	O
33	O
%	O
)	O
.	O
In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
11	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
samples	O
or	O
in	O
the	O
7	O
serous	B-malignancy-type
cystadenomas	I-malignancy-type
.	O
The	O
frequency	O
of	O
Ki-ras	O
mutations	O
in	O
serous	B-malignancy-type
ovarian	I-malignancy-type
tumours	I-malignancy-type
seems	O
to	O
correlate	O
with	O
the	O
malignant	O
potential	O
of	O
the	O
neoplasms	B-malignancy-type
.	O
The	O
data	O
favour	O
the	O
hypothesis	O
of	O
a	O
de	O
novo	O
development	O
of	O
poorly	B-malignancy-type
differentiated	I-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
and	O
do	O
not	O
support	O
an	O
evolution	O
from	O
LMP	O
tumours	O
or	O
well	B-malignancy-type
-	I-malignancy-type
differentiated	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
10071245	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1998	O
Dec;34(	O
13	O
)	O
:2053	O
-	O
7	O
K-ras	O
mutations	O
in	O
colorectal	B-malignancy-type
adenocarcinomas	I-malignancy-type
and	O
neighbouring	O
transitional	O
mucosa	O
.	O
Zhang	O
H	O
,	O
Nordenskjold	O
B	O
,	O
Dufmats	O
M,	O
Soderkvist	O
P	O
,	O
Sun	O
XF	O
.	O
Division	O
of	O
Cell	O
Biology	O
,	O
Linkoping	O
University	O
,	O
Sweden	O
.	O
The	O
K-ras	O
gene	O
in	O
codons	O
12	O
and	O
13	O
was	O
investigated	O
using	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
in	O
matched	O
normal	O
mucosa	O
(	O
n	O
=	O
106	O
)	O
,	O
transitional	O
mucosa	O
(	O
n	O
=	O
69	O
)	O
and	O
tumours	O
(	O
n	O
=	O
149	O
)	O
from	O
149	O
patients	O
with	O
colorectal	B-malignancy-type
adenocarcinomas	I-malignancy-type
.	O
K-ras	O
mutations	O
in	O
codon	O
12	O
were	O
detected	O
in	O
41	O
/	O
149	O
(	O
28	O
%	O
)	O
of	O
tumours	O
and	O
4	O
/	O
69	O
(	O
6	O
%	O
)	O
of	O
transitional	O
mucosa	O
samples	O
,	O
but	O
not	O
in	O
the	O
normal	O
mucosa	O
.	O
Further	O
,	O
mutation	O
rates	O
were	O
increased	O
in	O
younger	O
patients	O
(	O
P	O
=	O
0.001	O
)	O
and	O
in	O
mucinous	B-malignancy-type
carcinomas	I-malignancy-type
(	O
50	O
%	O
)	O
compared	O
with	O
well	O
differentiated	O
(	O
17	O
%	O
)	O
,	O
moderately	O
differentiated	O
(	O
26	O
%	O
)	O
or	O
poorly	O
differentiated	O
(	O
24	O
%	O
)	O
tumours	O
.	O
Our	O
findings	O
indicate	O
that	O
mucinous	B-malignancy-type
carcinoma	I-malignancy-type
may	O
represent	O
a	O
distinct	O
genetic	O
entity	O
.	O
PMID	O
:	O
10070310	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Anticancer	O
Res	O
1998	O
Jul	O
-	O
Aug;18(	O
4B)	O
:2789	O
-	O
92	O
Mutations	O
of	O
ras	O
genes	O
are	O
relatively	O
frequent	O
in	O
Japanese	O
prostate	B-malignancy-type
cancers	I-malignancy-type
:	O
pointing	O
to	O
genetic	O
differences	O
between	O
populations	O
.	O
Shiraishi	O
T	O
,	O
Muneyuki	O
T	O
,	O
Fukutome	O
K	O
,	O
Ito	O
H	O
,	O
Kotake	O
T	O
,	O
Watanabe	O
M,	O
Yatani	O
R.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Point	O
mutations	O
of	O
the	O
ras	O
gene	O
family	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
a	O
variety	O
of	O
human	O
tumors	O
.	O
However	O
,	O
it	O
remains	O
unknown	O
whether	O
the	O
ras	O
gene	O
might	O
play	O
a	O
key	O
role	O
in	O
prostate	O
carcinogenesis	O
.	O
We	O
therefore	O
analysed	O
Ki	O
-	O
,	O
N	O
-	O
and	O
H	O
-	O
ras	O
gene	O
mutations	O
in	O
a	O
series	O
of	O
81	O
Japanese	O
prostate	B-malignancy-type
cancers	I-malignancy-type
using	O
PCR	O
-	O
SSCP	O
analysis	O
and	O
Mutant	O
-	O
Allele	O
-	O
Specific	O
Amplification	O
(	O
MASA	O
)	O
method	O
.	O
Mutated	O
as	O
genes	O
were	O
detected	O
in	O
20	O
of	O
the	O
81	O
samples	O
(	O
24	O
%	O
)	O
;	O
three	O
of	O
22	O
latent	O
,	O
one	O
of	O
five	O
stage	O
B	O
,	O
four	O
of	O
14	O
stage	O
C	O
and	O
12	O
of	O
40	O
stage	O
D	O
cancers	O
.	O
Of	O
the	O
twenty	O
as	O
gene	O
mutations	O
,	O
13	O
were	O
in	O
Ki-ras	O
(	O
codon	O
12	O
)	O
,	O
five	O
in	O
H-ras	O
codon	O
61	O
and	O
two	O
H-ras	O
codon	O
13	O
.	O
The	O
observed	O
frequency	O
of	O
ras	O
gene	O
mutations	O
was	O
higher	O
than	O
that	O
reported	O
in	O
the	O
literature	O
for	O
some	O
non	O
-	O
Japanese	O
prostate	B-malignancy-type
cancers	I-malignancy-type
,	O
suggesting	O
the	O
possibility	O
of	O
genetic	O
differences	O
between	O
populations	O
.	O
PMID	O
:	O
9713462	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Jun	O
15;58(	O
12	O
)	O
:2524	O
-	O
7	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
in	O
primary	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
by	O
somatic	O
alterations	O
involving	O
exon	O
3	O
.	O
Miyoshi	O
Y	O
,	O
Iwao	O
K	O
,	O
Nagasawa	O
Y	O
,	O
Aihara	O
T	O
,	O
Sasaki	O
Y	O
,	O
Imaoka	O
S,	O
Murata	O
M,	O
Shimano	O
T	O
,	O
Nakamura	O
Y.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Biomedical	O
Research	O
Center	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Japan	O
.	O
We	O
screened	O
75	O
primary	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
for	O
somatic	O
mutations	O
in	O
the	O
entire	O
coding	O
region	O
of	O
the	O
beta-catenin	O
gene	O
.	O
We	O
detected	O
somatic	O
mutations	O
in	O
14	O
tumors	O
;	O
12	O
were	O
considered	O
to	O
cause	O
amino	O
acid	O
substitutions	O
and	O
2	O
were	O
interstitial	O
deletions	O
of	O
51	O
or	O
195	O
nucleotides	O
of	O
genomic	O
DNA	O
,	O
corresponding	O
to	O
exon	O
3	O
.	O
Among	O
the	O
12	O
point	O
mutations	O
,	O
6	O
occurred	O
at	O
potential	O
serine	O
/	O
threonine	O
phosphorylation	O
residues	O
of	O
codons	O
33	O
,	O
41	O
,	O
or	O
45	O
.	O
The	O
remaining	O
six	O
tumors	O
contained	O
a	O
mutation	O
at	O
codon	O
32	O
(	O
aspartic	O
acid	O
)	O
or	O
34	O
(	O
glycine	O
)	O
,	O
flanking	O
to	O
the	O
serine	O
residue	O
at	O
codon	O
33	O
.	O
By	O
Western	O
blot	O
analysis	O
,	O
we	O
confirmed	O
accumulation	O
of	O
beta-catenin	O
in	O
five	O
tumors	O
for	O
which	O
frozen	O
tissues	O
were	O
available	O
;	O
the	O
five	O
included	O
tumors	O
in	O
which	O
amino	O
acid	O
alterations	O
had	O
occurred	O
at	O
codons	O
32	O
,	O
34	O
,	O
or	O
45	O
,	O
and	O
one	O
with	O
a	O
17	O
-	O
amino	O
acid	O
deletion	O
.	O
Our	O
results	O
suggested	O
that	O
accumulation	O
of	O
beta-catenin	O
due	O
to	O
amino	O
acid	O
substitutions	O
at	O
potential	O
serine	O
/	O
threonine	O
phosphorylation	O
residues	O
or	O
at	O
their	O
neighboring	O
codons	O
or	O
interstitial	O
deletions	O
involving	O
exon	O
3	O
could	O
contribute	O
to	O
hepatocellular	O
carcinogenesis	O
.	O
PMID	O
:	O
9635572	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Apr	O
1;58(	O
7)	O
:1344	O
-	O
7	O
Mutations	O
in	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
in	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Palacios	O
J,	O
Gamallo	O
C.	O
Departamento	O
de	O
Anatomia	O
Patologica	O
,	O
Hospital	O
Universitario	O
La	O
Paz	O
(	O
Universidad	O
Autonoma	O
de	O
Madrid	O
)	O
,	O
Spain	O
.	O
Mutations	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
have	O
recently	O
been	O
implicated	O
in	O
the	O
initiation	O
of	O
some	O
colon	B-malignancy-type
carcinomas	I-malignancy-type
and	O
melanomas	B-malignancy-type
.	O
In	O
these	O
tumors	O
,	O
beta-catenin	O
abnormally	O
accumulates	O
in	O
the	O
cell	O
nuclei	O
.	O
In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
the	O
cadherin	O
-	O
catenin	O
complex	O
protein	O
expression	O
in	O
ovarian	B-malignancy-type
carcinomas	I-malignancy-type
,	O
we	O
observed	O
beta-catenin	O
in	O
tumor	O
cell	O
nuclei	O
in	O
some	O
cases	O
;	O
this	O
prompted	O
us	O
to	O
study	O
whether	O
or	O
not	O
this	O
abnormal	O
immunostaining	O
pattern	O
was	O
due	O
to	O
mutation	O
in	O
the	O
beta-catenin	O
gene	O
itself	O
.	O
This	O
study	O
examines	O
beta-catenin	O
immunohistochemical	O
expression	O
in	O
40	O
stage	O
I	O
and	O
II	O
ovarian	B-malignancy-type
borderline	I-malignancy-type
tumors	I-malignancy-type
and	O
carcinomas	B-malignancy-type
of	O
the	O
most	O
common	O
histological	O
types	O
.	O
Membrane	O
expression	O
was	O
heterogeneous	O
in	O
all	O
40	O
cases	O
.	O
However	O
,	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
five	O
(	O
one	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
four	O
carcinomas	B-malignancy-type
)	O
of	O
the	O
six	O
endometrioid	B-malignancy-type
lesions	I-malignancy-type
contained	O
beta-catenin	O
expression	O
.	O
PCR	O
and	O
sequencing	O
analyses	O
of	O
a	O
200	O
-	O
bp	O
fragment	O
of	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
,	O
encompassing	O
the	O
sequence	O
for	O
glycogen	O
synthetase	O
kinase	O
-	O
3beta	O
phosphorylation	O
,	O
were	O
performed	O
in	O
11	O
tumors	O
.	O
Heterozygous	O
substitution	O
mutations	O
at	O
codon	O
37	O
in	O
two	O
cases	O
(	O
S	O
37	O
F	O
and	O
S	O
37	O
C	O
)	O
and	O
at	O
codon	O
41	O
in	O
one	O
case	O
(	O
T	O
41	O
A	O
)	O
were	O
found	O
in	O
three	O
endometrioid	B-malignancy-type
lesions	I-malignancy-type
(	O
one	O
borderline	B-malignancy-type
tumor	I-malignancy-type
and	O
two	O
carcinomas	B-malignancy-type
)	O
with	O
abnormal	O
beta-catenin	O
expression	O
.	O
Three	O
endometrioid	B-malignancy-type
carcinomas	I-malignancy-type
and	O
five	O
tumors	O
of	O
other	O
histological	O
types	O
analyzed	O
showed	O
normal	O
DNA	O
sequences	O
.	O
These	O
results	O
implicate	O
beta-catenin	O
gene	O
mutations	O
in	O
ovarian	O
malignant	O
transformation	O
with	O
a	O
characteristic	O
phenotype	O
:	O
endometrioid	B-malignancy-type
ovarian	I-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9537226	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1998	O
Mar	O
;	O
21	O
(	O
3	O
)	O
:	O
270	O
-	O
5	O
RAS	O
mutations	O
in	O
pediatric	O
leukemias	B-malignancy-type
with	O
MLL	O
gene	O
rearrangements	O
.	O
Mahgoub	O
N	O
,	O
Parker	O
RI	O
,	O
Hosler	O
MR	O
,	O
Close	O
P	O
,	O
Winick	O
NJ	O
,	O
Masterson	O
M	O
,	O
Shannon	O
KM	O
,	O
Felix	O
CA	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
,	O
USA	O
.	O
Translocations	O
of	O
the	O
MLL	O
gene	O
at	O
chromosome	O
band	O
11q23	O
are	O
the	O
most	O
common	O
cytogenetic	O
alterations	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
leukemia	I-malignancy-type
in	O
infants	O
and	O
in	O
leukemia	B-malignancy-type
related	I-malignancy-type
to	I-malignancy-type
chemotherapy	I-malignancy-type
with	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
.	O
Experiments	O
on	O
knock-in	O
mice	O
suggest	O
that	O
additional	O
mutational	O
events	O
may	O
by	O
required	O
for	O
full	O
leukemogenesis	O
.	O
Therefore	O
,	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
an	O
allele	O
-	O
specific	O
restriction	O
enzyme	O
assay	O
to	O
investigate	O
the	O
frequency	O
of	O
KRAS	O
and	O
NRAS	O
mutations	O
in	O
32	O
pediatric	O
leukemias	B-malignancy-type
with	O
translocation	O
of	O
the	O
MLL	O
gene	O
.	O
Of	O
25	O
de	O
novo	O
cases	O
,	O
13	O
were	O
acute	B-malignancy-type
lymphoblastic	I-malignancy-type
leukemia	I-malignancy-type
(	O
ALL	B-malignancy-type
)	O
,	O
10	O
were	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
,	O
and	O
2	O
were	O
biphenotypic	O
.	O
Three	O
secondary	O
leukemias	B-malignancy-type
were	O
AML	B-malignancy-type
,	O
1	O
was	O
biphenotypic	O
,	O
1	O
was	O
ALL	B-malignancy-type
,	O
and	O
2	O
were	O
diagnosed	O
as	O
myelodysplasia	B-malignancy-type
.	O
The	O
frequency	O
of	O
RAS	O
mutations	O
was	O
2	O
of	O
10	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
AML	I-malignancy-type
.	O
Both	O
mutations	O
occurred	O
in	O
infant	O
monoblastic	O
variants	O
.	O
RAS	O
mutations	O
were	O
otherwise	O
absent	O
in	O
this	O
series	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
congenital	B-malignancy-type
leukemias	I-malignancy-type
where	O
translocation	O
of	O
the	O
MLL	O
gene	O
and	O
RAS	O
mutation	O
coexist	O
.	O
The	O
frequency	O
of	O
RAS	O
mutations	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
AMLs	I-malignancy-type
with	O
MLL	O
gene	O
translocations	O
is	O
similar	O
to	O
that	O
in	O
other	O
forms	O
of	O
AML	B-malignancy-type
,	O
but	O
RAS	O
mutations	O
play	O
a	O
limited	O
role	O
in	O
lymphoid	B-malignancy-type
and	O
treatment	B-malignancy-type
-	I-malignancy-type
related	I-malignancy-type
leukemias	I-malignancy-type
with	O
similar	O
translocations	O
.	O
PMID	O
:	O
9523205	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Blood	O
1997	O
Nov	O
15;90(	O
10	O
)	O
:4062	O
-	O
70	O
Comment	O
in	O
:	O
Blood	O
.	O
1998	O
Oct	O
15;92(	O
8	O
)	O
:2987	O
-	O
9.	O
A	O
novel	O
chromosomal	O
translocation	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
involves	O
the	O
fibroblast	O
growth	O
-	O
factor	O
receptor	O
3	O
gene	O
.	O
Richelda	O
R,	O
Ronchetti	O
D	O
,	O
Baldini	O
L,	O
Cro	O
L,	O
Viggiano	O
L,	O
Marzella	O
R,	O
Rocchi	O
M,	O
Otsuki	O
T	O
,	O
Lombardi	O
L,	O
Maiolo	O
AT	O
,	O
Neri	O
A.	O
Laboratorio	O
di	O
Ematologia	O
Sperimentale	O
e	O
Genetica	O
Molecolare	O
,	O
Servizio	O
di	O
Ematologia	O
,	O
Universita	O
degli	O
Studi	O
di	O
Milano	O
,	O
Ospedale	O
Maggiore	O
IRCCS	O
,	O
Milano	O
,	O
Italy	O
.	O
Chromosomal	O
translocations	O
involving	O
the	O
immunoglobulin	O
heavy	O
chain	O
(	O
IGH	O
)	O
locus	O
at	O
chromosome	O
14q32	O
represent	O
a	O
common	O
mechanism	O
of	O
oncogene	O
activation	O
in	O
lymphoid	B-malignancy-type
malignancies	I-malignancy-type
.	O
In	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
,	O
the	O
most	O
consistent	O
chromosomal	O
abnormality	O
is	O
the	O
14q	O
+	O
marker	O
,	O
which	O
originates	O
in	O
one	O
third	O
of	O
cases	O
through	O
a	O
t	O
(	O
11	O
;	O
14	O
)	O
(	O
q13	O
;	O
q32	O
)	O
chromosomal	O
translocation	O
;	O
in	O
the	O
remaining	O
cases	O
,	O
the	O
identity	O
of	O
the	O
partner	O
chromosomes	O
has	O
not	O
been	O
well	O
established	O
.	O
We	O
used	O
a	O
Southern	O
blot	O
approach	O
based	O
on	O
the	O
linkage	O
analysis	O
of	O
the	O
joining	O
(	O
J	O
)	O
and	O
the	O
constant	O
(	O
C	O
)	O
mu	O
,	O
alpha	O
,	O
and	O
gamma	O
regions	O
to	O
detect	O
cases	O
bearing	O
IGH	O
switch	O
-	O
mediated	O
chromosomal	O
translocations	O
.	O
We	O
evaluated	O
DNA	O
of	O
88	O
nonkaryotyped	O
patients	O
with	O
MM	B-malignancy-type
(	O
78	O
cases	O
)	O
or	O
plasma	B-malignancy-type
cell	I-malignancy-type
leukemia	I-malignancy-type
(	O
PCL	B-malignancy-type
)	O
(	O
10	O
cases	O
)	O
and	O
found	O
the	O
presence	O
of	O
"	O
illegitimate	O
"	O
rearranged	O
IGH	O
fragments	O
(	O
no	O
comigration	O
between	O
the	O
J	O
and	O
C	O
regions	O
)	O
in	O
21	O
cases	O
.	O
To	O
confirm	O
this	O
analysis	O
,	O
we	O
cloned	O
the	O
illegitimate	O
rearranged	O
fragments	O
from	O
three	O
samples	O
,	O
and	O
the	O
molecular	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analyses	O
indicated	O
the	O
presence	O
of	O
chromosomal	O
translocations	O
juxtaposing	O
a	O
switch	O
IGH	O
region	O
to	O
sequences	O
from	O
chromosomes	O
11q13	O
(	O
one	O
PCL	B-malignancy-type
case	O
)	O
or	O
4p16.3	O
(	O
two	O
MM	B-malignancy-type
cases	O
)	O
.	O
Interestingly	O
,	O
the	O
breakpoints	O
on	O
4p16.3	O
occurred	O
about	O
14	O
kb	O
apart	O
in	O
a	O
genomic	O
region	O
located	O
approximately	O
50	O
kb	O
centromeric	O
to	O
the	O
fibroblast	O
growth	O
-	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
gene	O
.	O
Moreover	O
,	O
Southern	O
blot	O
analysis	O
using	O
4p16.3	O
genomic	O
probes	O
detected	O
a	O
rearrangement	O
in	O
an	O
additional	O
MM	B-malignancy-type
tumor	O
.	O
FISH	O
analysis	O
of	O
the	O
MM	B-malignancy-type
-	O
derived	O
KMS-11	O
cell	O
line	O
,	O
reported	O
to	O
be	O
associated	O
with	O
a	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
,	O
showed	O
that	O
the	O
FGFR3	O
gene	O
was	O
translocated	O
on	O
14q32	O
.	O
High	O
levels	O
of	O
FGFR3	O
mRNA	O
expression	O
were	O
observed	O
in	O
the	O
cloned	O
MM	B-malignancy-type
tumors	I-malignancy-type
and	O
KMS-11	O
cell	O
line	O
,	O
but	O
not	O
in	O
the	O
cases	O
that	O
were	O
apparently	O
negative	O
for	O
this	O
lesion	B-malignancy-type
.	O
Furthermore	O
,	O
a	O
point	O
mutation	O
at	O
codon	O
373	O
in	O
the	O
transmembrane	O
domain	O
of	O
the	O
FGFR3	O
gene	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
(	O
Tyr	O
-->	O
Cys	O
)	O
was	O
detected	O
in	O
the	O
KMS-11	O
cell	O
line	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
t	O
(	O
4	O
;	O
14	O
)	O
(	O
p16.3	O
;	O
q32	O
)	O
represents	O
a	O
novel	O
,	O
recurrent	O
chromosomal	O
translocation	O
in	O
MM	B-malignancy-type
,	O
and	O
suggest	O
that	O
the	O
FGFR3	O
gene	O
may	O
be	O
the	O
target	O
of	O
this	O
abnormality	O
and	O
thus	O
contribute	O
to	O
tumorigenesis	O
in	O
MM	B-malignancy-type
.	O
PMID	O
:	O
9354676	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Cancer	O
1997	O
May	O
;	O
33	O
(	O
6	O
)	O
:	O
942	O
-	O
9	O
Response	O
to	O
radiotherapy	O
of	O
human	O
uterine	B-malignancy-type
cervix	I-malignancy-type
carcinoma	I-malignancy-type
is	O
not	O
correlated	O
with	O
rearrangements	O
of	O
the	O
Ha-ras-1	O
and/or	O
c-myc	O
genes	O
.	O
Polischouk	O
AG	O
,	O
Scotnikova	O
OI	O
,	O
Sergeeva	O
NS	O
,	O
Zharinov	O
GM	O
,	O
Lewensohn	O
R	O
,	O
Zhivotovsky	O
B	O
.	O
Department	O
of	O
Oncology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
An	O
association	O
between	O
the	O
presence	O
of	O
the	O
activated	O
form	O
of	O
Ha-ras-1	O
and	O
c-myc	O
genes	O
and	O
increased	O
cellular	O
radioresistance	O
has	O
been	O
shown	O
in	O
several	O
cell	O
lines	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
such	O
an	O
association	O
could	O
be	O
observed	O
in	O
clinical	O
tumour	O
biopsies	O
.	O
We	O
examined	O
70	O
tumour	O
specimens	O
and	O
51	O
samples	O
of	O
peripheral	O
blood	O
obtained	O
from	O
untreated	O
patients	O
with	O
carcinoma	B-malignancy-type
of	O
the	O
uterine	O
cervix	O
mainly	O
stage	O
II	O
and	O
III	O
.	O
In	O
addition	O
to	O
initial	O
clinical	O
tumour	O
response	O
to	O
radiotherapy	O
,	O
radiosensitivity	O
was	O
also	O
analysed	O
by	O
the	O
subrenal	O
capsule	O
assay	O
(	O
SRCA	O
)	O
.	O
Mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
Ha-ras-1	O
gene	O
were	O
examined	O
using	O
PCR	O
single-strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
;	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
of	O
the	O
Ha-ras-1	O
gene	O
was	O
analysed	O
using	O
Southern	O
hybridisation	O
.	O
Eight	O
(	O
11	O
%	O
)	O
out	O
of	O
70	O
tumours	O
contained	O
mutations	O
in	O
exons	O
1	O
and	O
2	O
of	O
the	O
Ha-ras-1	O
gene	O
.	O
Eleven	O
(	O
22	O
%	O
)	O
out	O
of	O
the	O
51	O
tumours	O
displayed	O
rearrangements	O
of	O
the	O
Ha-ras-1	O
gene	O
(	O
six	O
tumours	O
(	O
12	O
%	O
)	O
showed	O
alterations	O
of	O
allele	O
length	O
,	O
one	O
amplification	O
and	O
four	O
(	O
8	O
%	O
)	O
loss	O
of	O
one	O
Ha-ras-1	O
allele	O
)	O
.	O
In	O
addition	O
,	O
12	O
(	O
17	O
%	O
)	O
out	O
of	O
70	O
patients	O
demonstrated	O
the	O
presence	O
of	O
rare	O
alleles	O
.	O
Only	O
one	O
of	O
the	O
70	O
tumours	O
contained	O
an	O
amplified	O
c-myc	O
gene	O
.	O
There	O
was	O
no	O
significant	O
correlation	O
between	O
either	O
rearrangements	O
of	O
the	O
structure	O
of	O
the	O
Ha-ras-1	O
and/or	O
c-myc	O
genes	O
or	O
presence	O
of	O
rare	O
alleles	O
in	O
tumours	O
and	O
tumour	O
response	O
to	O
radiotherapy	O
.	O
PMID	O
:	O
9291819	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gastroenterology	O
1997	O
Aug	O
;	O
113	O
(	O
2	O
)	O
:	O
593	O
-	O
8	O
Long-term	O
follow-up	O
of	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
K-ras	O
gene	O
mutation	O
detected	O
in	O
pancreatic	O
juice	O
.	O
Furuya	O
N	O
,	O
Kawa	O
S	O
,	O
Akamatsu	O
T	O
,	O
Furihata	O
K	O
.	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Shinshu	O
University	O
School	O
of	O
Medicine	O
,	O
Matsumoto	O
,	O
Japan	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Conflicting	O
reports	O
have	O
raised	O
the	O
question	O
whether	O
K-ras	O
gene	O
mutations	O
in	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
are	O
related	O
to	O
the	O
development	O
of	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
this	O
issue	O
by	O
surveying	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
and	O
K-ras	O
gene	O
mutation	O
over	O
4	O
years	O
.	O
METHODS	O
:	O
K-ras	O
point	O
mutations	O
at	O
codon	O
12	O
in	O
duodenal	O
juices	O
obtained	O
during	O
exocrine	O
function	O
tests	O
were	O
examined	O
by	O
enriched	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
direct	O
DNA	O
sequence	O
analysis	O
,	O
and	O
long-term	O
follow-up	O
of	O
these	O
patients	O
was	O
performed	O
.	O
RESULTS	O
:	O
K-ras	O
gene	O
mutation	O
was	O
found	O
in	O
20	O
of	O
54	O
patients	O
(	O
37	O
%	O
)	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
.	O
The	O
types	O
of	O
mutation	O
were	O
GAT	O
in	O
7	O
,	O
GTT	O
in	O
11	O
,	O
and	O
TGT	O
in	O
2	O
patients	O
.	O
Pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
occurred	O
in	O
none	O
of	O
the	O
mutation	O
-	O
positive	O
patients	O
over	O
a	O
mean	O
follow-up	O
period	O
of	O
78	O
months	O
.	O
CONCLUSIONS	O
:	O
K-ras	O
gene	O
mutation	O
in	O
patients	O
with	O
chronic	B-malignancy-type
pencreatitis	I-malignancy-type
did	O
not	O
seem	O
to	O
be	O
related	O
to	O
the	O
development	O
of	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
during	O
the	O
follow-up	O
period	O
,	O
and	O
analysis	O
of	O
K-ras	O
gene	O
mutation	O
seems	O
of	O
little	O
use	O
for	O
diagnosing	O
pancreatic	B-malignancy-type
neoplasm	I-malignancy-type
in	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
.	O
PMID	O
:	O
9247481	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Clin	O
Chem	O
1997	O
Jun	O
;	O
43	O
(	O
6	O
Pt	O
1	O
)	O
:	O
936	O
-	O
42	O
Rapid	O
and	O
large-scale	O
method	O
to	O
detect	O
K-ras	O
gene	O
mutations	O
in	O
tumor	O
samples	O
.	O
Lopez	O
-	O
Crapez	O
E	O
,	O
Chypre	O
C	O
,	O
Saavedra	O
J	O
,	O
Marchand	O
J	O
,	O
Grenier	O
J	O
.	O
C.R.L.C.	O
Val	O
d'Aurelle	O
,	O
Laboratoire	O
de	O
Radioanalyse	O
,	O
Montpellier	O
,	O
France	O
.	O
We	O
have	O
developed	O
a	O
rapid	O
and	O
large-scale	O
method	O
for	O
the	O
detection	O
of	O
K-ras	O
gene	O
mutations	O
in	O
tumors	O
.	O
First	O
,	O
DNA	O
is	O
amplified	O
by	O
an	O
asymmetric	O
PCR	O
;	O
second	O
,	O
the	O
single-strand	O
dinitrophenyl	O
(	O
DNP	O
)	O
-	O
labeled	O
amplified	O
DNA	O
is	O
hybridized	O
specifically	O
to	O
oligonucleotide	O
probes	O
affixed	O
on	O
a	O
tube	O
.	O
Finally	O
,	O
perfectly	O
matched	O
duplexes	O
are	O
easily	O
detected	O
by	O
a	O
monoclonal	O
anti	O
-	O
DNP	O
antibody	O
bearing	O
125I	O
.	O
The	O
usefulness	O
of	O
this	O
technique	O
is	O
illustrated	O
by	O
analyzing	O
K-ras	O
codon	O
12	O
mutations	O
in	O
human	O
colorectal	O
samples	O
.	O
This	O
reliable	O
assay	O
procedure	O
can	O
be	O
applied	O
to	O
the	O
rapid	O
screening	O
of	O
virtually	O
any	O
genetic	O
disease	O
caused	O
by	O
previously	O
described	O
point	O
mutations	O
.	O
PMID	O
:	O
9191543	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Gynecol	O
Oncol	O
1997	O
May;65(	O
2	O
)	O
:343	O
-	O
7	O
Identification	O
of	O
H	O
,	O
K	O
,	O
and	O
N	O
-	O
ras	O
point	O
mutations	O
in	O
stage	O
IB	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Grendys	O
EC	O
Jr	O
,	O
Barnes	O
WA	O
,	O
Weitzel	O
J,	O
Sparkowski	O
J,	O
Schlegel	O
R.	O
Division	O
of	O
Gynecologic	O
Oncology	O
,	O
Moffitt	O
Cancer	O
Center	O
,	O
University	O
of	O
South	O
Florida	O
,	O
Tampa	O
33612	O
,	O
USA	O
.	O
OBJECTIVE	O
:	O
The	O
ras	O
oncogenes	O
,	O
Harvey	O
(	O
H	O
)	O
,	O
Kirsten	O
(	O
K	O
)	O
,	O
and	O
neuroblastoma	O
(	O
N	O
)	O
,	O
are	O
a	O
family	O
of	O
genes	O
coding	O
for	O
a	O
membrane	O
-	O
associated	O
protein	O
(	O
p21	O
)	O
which	O
possesses	O
inherent	O
guanine	O
triphosphatase	O
(	O
GTPase	O
)	O
activity	O
.	O
Point	O
mutagenesis	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
has	O
been	O
implicated	O
in	O
ras	O
activation	O
and	O
subsequent	O
cellular	O
transformation	O
.	O
Given	O
the	O
epidemiologic	O
relationship	O
of	O
HPV	O
infection	O
with	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
and	O
the	O
tumorigenic	O
interaction	O
of	O
HPV	O
and	O
mutated	O
ras	O
oncogenes	O
,	O
this	O
study	O
was	O
undertaken	O
to	O
identify	O
if	O
mutated	O
ras	O
oncogenes	O
were	O
present	O
in	O
early	O
invasive	O
cervical	B-malignancy-type
carcinomas	I-malignancy-type
.	O
METHODS	O
:	O
A	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
dot	O
-	O
blot	O
hybridization	O
was	O
used	O
to	O
determine	O
the	O
frequency	O
and	O
types	O
of	O
ras	O
point	O
mutants	O
occurring	O
in	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Thirty-three	O
patients	O
with	O
early	O
-	O
stage	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
were	O
identified	O
.	O
DNA	O
was	O
extracted	O
from	O
archival	O
tumor	O
samples	O
.	O
ras	O
genes	O
were	O
PCR	O
amplified	O
using	O
flanking	O
primers	O
and	O
hybridized	O
with	O
a	O
series	O
of	O
labeled	O
allele	O
-	O
specific	O
oligonucleotides	O
corresponding	O
to	O
wild	O
-	O
type	O
forms	O
of	O
K	O
12	O
,	O
61	O
,	O
N	O
12	O
,	O
13	O
,	O
61	O
,	O
and	O
H	O
12	O
,	O
61	O
,	O
as	O
well	O
as	O
to	O
all	O
combinations	O
of	O
substitution	O
mutations	O
(	O
7	O
wild	O
-	O
type	O
,	O
45	O
mutants	O
)	O
.	O
RESULTS	O
:	O
ras	O
mutations	O
were	O
identified	O
in	O
24.2	O
%	O
of	O
specimens	O
.	O
The	O
detected	O
mutations	O
in	O
H	O
,	O
K	O
,	O
and	O
N	O
-	O
ras	O
all	O
occurred	O
at	O
codon	O
61	O
.	O
This	O
was	O
not	O
the	O
result	O
of	O
PCR	O
or	O
hybridization	O
artifact	O
in	O
that	O
mutations	O
were	O
detected	O
in	O
position	O
12	O
and	O
13	O
in	O
appropriate	O
control	O
samples	O
.	O
CONCLUSIONS	O
:	O
Mutant	O
ras	O
has	O
been	O
shown	O
to	O
convert	O
HPV	O
immortalized	O
keratinocytes	O
to	O
the	O
tumorigenic	O
state	O
.	O
Our	O
results	O
indicate	O
that	O
a	O
significant	O
percentage	O
(	O
24.2	O
%	O
)	O
of	O
these	O
early	O
-	O
stage	O
cervical	B-malignancy-type
cancers	I-malignancy-type
contain	O
activated	O
ras	O
.	O
Additional	O
studies	O
will	O
be	O
needed	O
to	O
evaluate	O
whether	O
codon	O
61	O
represents	O
a	O
characteristic	O
"	O
hot	O
-	O
spot	O
"	O
of	O
ras	O
mutation	O
in	O
a	O
subset	O
of	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
.	O
PMID	O
:	O
9159349	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1997	O
May	O
2	O
;	O
71	O
(	O
3	O
)	O
:	O
364	O
-	O
9	O
A	O
one	O
-	O
step	O
DGGE	O
scanning	O
method	O
for	O
detection	O
of	O
mutations	O
in	O
the	O
K	O
-	O
,	O
N	O
-	O
,	O
and	O
H	O
-	O
ras	O
oncogenes	O
:	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
are	O
rare	O
in	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Nedergaard	O
T	O
,	O
Guldberg	O
P	O
,	O
Ralfkiaer	O
E	O
,	O
Zeuthen	O
J	O
.	O
Department	O
of	O
Tumor	O
Cell	O
Biology	O
,	O
Danish	O
Cancer	O
Society	O
,	O
Copenhagen	O
.	O
Mutations	O
in	O
the	O
N	O
-	O
,	O
K	O
-	O
,	O
and	O
H	O
-	O
ras	O
genes	O
are	O
key	O
events	O
in	O
the	O
process	O
of	O
carcinogenesis	O
of	O
many	O
human	O
cancers	O
and	O
may	O
serve	O
as	O
important	O
targets	O
for	O
therapeutic	O
intervention	O
.	O
We	O
developed	O
a	O
simple	O
diagnostic	O
method	O
that	O
in	O
one	O
step	O
and	O
within	O
5	O
hr	O
determines	O
the	O
mutational	O
status	O
of	O
any	O
of	O
the	O
3	O
ras	O
genes	O
in	O
a	O
given	O
tumor	O
sample	O
.	O
The	O
method	O
combines	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
and	O
allows	O
simultaneous	O
mutation	O
scanning	O
of	O
6	O
regions	O
covering	O
"	O
hot	O
-	O
spot	O
"	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
3	O
ras	O
genes	O
.	O
The	O
sensitivity	O
of	O
the	O
assay	O
was	O
demonstrated	O
by	O
the	O
analysis	O
of	O
control	O
mutations	O
,	O
either	O
naturally	O
occurring	O
or	O
created	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O
We	O
further	O
demonstrate	O
that	O
unambiguous	O
identification	O
of	O
ras	O
mutations	O
can	O
be	O
achieved	O
by	O
heteroduplex	O
analysis	O
in	O
denaturing	O
gradient	O
gels	O
,	O
circumventing	O
sequence	O
analysis	O
.	O
We	O
applied	O
the	O
method	O
to	O
establish	O
the	O
mutational	O
status	O
of	O
all	O
3	O
ras	O
genes	O
in	O
123	O
samples	O
of	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
Altogether	O
,	O
one	O
diffuse	B-malignancy-type
large	I-malignancy-type
B	I-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
lymphoma	I-malignancy-type
and	O
one	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
chronic	I-malignancy-type
lymphocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
B-CLL	B-malignancy-type
)	O
harbored	O
a	O
mutation	O
(	O
G	O
12	O
S	O
and	O
G	O
12	O
A	O
,	O
respectively	O
)	O
in	O
the	O
K-ras	O
gene	O
,	O
and	O
one	O
B-CLL	B-malignancy-type
harbored	O
a	O
mutation	O
(	O
Q	O
61	O
R	O
)	O
in	O
the	O
N-ras	O
gene	O
.	O
We	O
therefore	O
conclude	O
that	O
ras	O
mutations	O
only	O
contribute	O
rarely	O
,	O
if	O
at	O
all	O
,	O
to	O
carcinogenesis	O
in	O
B	B-malignancy-type
-	I-malignancy-type
cell	I-malignancy-type
non	I-malignancy-type
-	I-malignancy-type
Hodgkin	I-malignancy-type
's	I-malignancy-type
lymphoma	I-malignancy-type
.	O
PMID	O
:	O
9139869	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Anticancer	O
Res	O
1997	O
Mar	O
-	O
Apr	O
;	O
17	O
(	O
2B	O
)	O
:	O
1335	O
-	O
9	O
Mutation	O
of	O
ras	O
oncogene	O
in	O
gastric	B-malignancy-type
adenocarcinoma	I-malignancy-type
:	O
association	O
with	O
histological	O
phenotype	O
.	O
Kim	O
TY	O
,	O
Bang	O
YJ	O
,	O
Kim	O
WS	O
,	O
Kang	O
SH	O
,	O
Lee	O
KU	O
,	O
Choe	O
KJ	O
,	O
Kim	O
NK.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Seoul	O
National	O
University	O
College	O
of	O
Medicine	O
,	O
Korea	O
.	O
In	O
order	O
to	O
explore	O
the	O
role	O
of	O
ras	O
oncogene	O
in	O
gastric	B-malignancy-type
carcinomas	I-malignancy-type
from	O
Korean	O
patients	O
,	O
we	O
examined	O
the	O
frequency	O
of	O
point	O
mutations	O
all	O
three	O
ras	O
oncogenes	O
(	O
Ki	O
-	O
,	O
Ha	O
-	O
,	O
and	O
N	O
-	O
ras	O
)	O
.	O
A	O
total	O
of	O
57	O
DNA	O
samples	O
were	O
prepared	O
from	O
3	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
,	O
10	O
malignant	B-malignancy-type
ascites	I-malignancy-type
,	O
and	O
44	O
frozen	O
gastric	B-malignancy-type
tumor	I-malignancy-type
tissues	I-malignancy-type
.	O
Exons	O
1	O
and	O
2	O
of	O
each	O
ras	O
oncogene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and	O
analyzed	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
direct	O
sequencing	O
.	O
Mutated	O
ras	O
genes	O
were	O
detected	O
in	O
6	O
out	O
of	O
57	O
samples	O
(	O
10	O
%	O
)	O
.	O
One	O
cell	O
line	O
and	O
2	O
tumors	O
showed	O
a	O
mutation	O
at	O
exon	O
1	O
of	O
Ki-ras	O
.	O
N-ras	O
mutations	O
were	O
also	O
detected	O
at	O
exon	O
1	O
of	O
3	O
tumors	O
.	O
Histologically	O
,	O
all	O
the	O
ras	O
mutation	O
cases	O
exhibited	O
a	O
diffuse	O
phenotype	O
.	O
In	O
summary	O
,	O
we	O
performed	O
a	O
comprehensive	O
analysis	O
to	O
investigate	O
the	O
mutation	O
of	O
all	O
three	O
ras	O
oncogenes	O
in	O
gastric	B-malignancy-type
carcinoma	I-malignancy-type
.	O
The	O
results	O
demonstrate	O
infrequent	O
mutations	O
of	O
Ki	O
-	O
and	O
N	O
-	O
ras	O
which	O
may	O
favor	O
the	O
development	O
of	O
diffuse	B-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
carcinomas	I-malignancy-type
,	O
implicating	O
a	O
different	O
genetic	O
pathway	O
in	O
diffuse	B-malignancy-type
and	O
intestinal	B-malignancy-type
type	I-malignancy-type
gastric	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
9137494	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Pancreatol	O
1997	O
Feb	O
;	O
21	O
(	O
1	O
)	O
:	O
85	O
-	O
90	O
Sclerosing	B-malignancy-type
pancreatitis	I-malignancy-type
showing	O
rapidly	O
progressive	O
changes	O
with	O
recurrent	O
mass	O
formation	O
.	O
Motoo	O
Y	O
,	O
Minamoto	O
T	O
,	O
Watanabe	O
H	O
,	O
Sakai	O
J	O
,	O
Okai	O
T	O
,	O
Sawabu	O
N	O
.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Kanazawa	O
University	O
,	O
Japan	O
.	O
CONCLUSION	O
:	O
Sclerosing	B-malignancy-type
pancreatitis	I-malignancy-type
might	O
develop	O
repeatedly	O
or	O
might	O
rapidly	O
extend	O
to	O
the	O
whole	O
pancreas	O
with	O
recurrent	O
mass	O
formation	O
.	O
BACKGROUND	O
:	O
Nothing	O
is	O
known	O
concerning	O
course	O
or	O
development	O
of	O
sclerosing	B-malignancy-type
pancreatitis	I-malignancy-type
.	O
METHODS	O
:	O
A	O
63	O
-	O
yr	O
-	O
old	O
male	O
was	O
followed	O
up	O
for	O
2.5	O
yr	O
.	O
RESULTS	O
:	O
The	O
patient	O
was	O
admitted	O
because	O
of	O
a	O
tumor	O
in	O
the	O
body	O
and	O
tail	O
of	O
the	O
pancreas	O
.	O
Serum	O
pancreatic	O
enzymes	O
were	O
transiently	O
elevated	O
,	O
but	O
tumor	O
markers	O
were	O
all	O
negative	O
.	O
Imaging	O
studies	O
showed	O
a	O
tumor	O
7	O
cm	O
in	O
size	O
.	O
The	O
main	O
pancreatic	O
duct	O
was	O
normal	O
in	O
the	O
head	O
and	O
obstructed	O
at	O
the	O
body	O
on	O
endoscopic	O
retrograde	O
pancreatography	O
(	O
ERCP	O
)	O
.	O
The	O
K-ras	O
oncogene	O
mutation	O
was	O
positive	O
in	O
pure	O
pancreatic	O
juice	O
.	O
Distal	O
pancreatectomy	O
was	O
performed	O
because	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
was	O
highly	O
suspected	O
.	O
Pathological	O
findings	O
showed	O
that	O
the	O
tumor	O
was	O
a	O
densely	O
fibrotic	O
mass	O
without	O
malignant	O
cells	O
.	O
Inflammatory	O
cell	O
infiltration	O
was	O
observed	O
in	O
the	O
stroma	O
.	O
One	O
year	O
later	O
,	O
another	O
mass	O
3	O
cm	O
in	O
size	O
was	O
noted	O
in	O
the	O
remnant	O
pancreatic	O
head	O
.	O
ERCP	O
revealed	O
diffuse	O
irregular	O
narrowing	O
of	O
the	O
main	O
pancreatic	O
duct	O
,	O
its	O
branches	O
,	O
and	O
the	O
common	O
bile	O
duct	O
.	O
Liver	O
dysfunction	O
improved	O
and	O
an	O
elevation	O
of	O
serum	O
pancreatic	O
enzymes	O
subsided	O
without	O
any	O
specific	O
treatment	O
,	O
and	O
the	O
mass	O
diminished	O
in	O
size	O
.	O
The	O
patterns	O
of	O
various	O
imaging	O
studies	O
on	O
the	O
second	O
tumor	O
were	O
the	O
same	O
as	O
those	O
of	O
the	O
previous	O
resected	O
mass	O
.	O
Corticosteroid	O
was	O
not	O
administered	O
.	O
PMID	O
:	O
9127178	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Br	O
J	O
Haematol	O
1997	O
Feb	O
;	O
96	O
(	O
2	O
)	O
:	O
374	O
-	O
6	O
A	O
new	O
c-kit	O
mutation	O
in	O
a	O
case	O
of	O
aggressive	B-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
.	O
Pignon	O
JM	O
,	O
Giraudier	O
S	O
,	O
Duquesnoy	O
P	O
,	O
Jouault	O
H	O
,	O
Imbert	O
M	O
,	O
Vainchenker	O
W	O
,	O
Vernant	O
JP	O
,	O
Tulliez	O
M	O
.	O
Service	O
d'Hematologie	O
Biologique	O
,	O
Hopital	O
Henri	O
Mondor	O
,	O
Creteil	O
,	O
France	O
.	O
Systemic	B-malignancy-type
mast	I-malignancy-type
cell	I-malignancy-type
disease	I-malignancy-type
(	O
SMCD	B-malignancy-type
)	O
is	O
a	O
disorder	O
characterized	O
by	O
a	O
mast	O
cell	O
proliferation	O
in	O
various	O
tissues	O
.	O
Mast	O
cells	O
express	O
the	O
c-kit	O
proto	O
-	O
oncogene	O
.	O
A	O
few	O
cases	O
of	O
c-kit	O
mutations	O
have	O
been	O
described	O
in	O
SMCD	B-malignancy-type
.	O
We	O
report	O
an	O
aggressive	B-malignancy-type
SMCD	I-malignancy-type
in	O
a	O
patient	O
who	O
presented	O
with	O
a	O
bone	O
marrow	O
infiltration	O
by	O
abnormal	O
mast	O
cells	O
.	O
Molecular	O
studies	O
of	O
mast	O
cell	O
DNA	O
and	O
RNA	O
revealed	O
a	O
new	O
c-kit	O
heterozygous	O
mutation	O
(	O
Asp	O
820	O
Gly	O
)	O
.	O
This	O
mutation	O
leads	O
to	O
a	O
drastic	O
amino	O
-	O
acid	O
change	O
and	O
is	O
located	O
close	O
to	O
the	O
highly	O
oncogenic	O
Asp	O
816	O
Val	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
Asp	O
820	O
Gly	O
has	O
a	O
potential	O
role	O
in	O
c-kit	O
activation	O
.	O
PMID	O
:	O
9029028	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Scand	O
J	O
Gastroenterol	O
1997	O
Jan;32(	O
1	O
)	O
:62	O
-	O
9	O
K-ras	O
mutations	O
and	O
prognosis	O
in	O
large	B-malignancy-type
-	I-malignancy-type
bowel	I-malignancy-type
carcinomas	I-malignancy-type
.	O
Andersen	O
SN	O
,	O
Lovig	O
T	O
,	O
Breivik	O
J,	O
Lund	O
E	O
,	O
Gaudernack	O
G	O
,	O
Meling	O
GI	O
,	O
Rognum	O
TO	O
.	O
Institute	O
of	O
Forensic	O
Medicine	O
,	O
National	O
Hospital	O
,	O
University	O
of	O
Oslo	O
,	O
Norway	O
.	O
BACKGROUND	O
:	O
Colorectal	O
carcinogenesis	O
is	O
regarded	O
as	O
a	O
multistep	O
process	O
involving	O
several	O
genetic	O
alterations	O
,	O
with	O
mutation	O
in	O
the	O
K-ras	O
gene	O
in	O
about	O
half	O
of	O
the	O
tumours	O
.	O
We	O
aimed	O
at	O
clarifying	O
the	O
role	O
of	O
this	O
genetic	O
alteration	O
related	O
to	O
survival	O
and	O
clinicopathologic	O
variables	O
.	O
METHODS	O
:	O
One	O
hundred	O
large	B-malignancy-type
-	I-malignancy-type
bowel	I-malignancy-type
carcinomas	I-malignancy-type
operated	O
on	O
between	O
1978	O
and	O
1982	O
were	O
studied	O
for	O
the	O
presence	O
of	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
gene	O
,	O
using	O
enriched	O
polymerase	O
chain	O
reaction	O
amplification	O
,	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
and	O
direct	O
sequencing	O
.	O
RESULTS	O
:	O
Forty	O
mutations	O
were	O
found	O
(	O
40	O
%	O
)	O
:	O
31	O
in	O
codon	O
12	O
and	O
9	O
in	O
codon	O
13	O
,	O
7	O
different	O
types	O
.	O
There	O
was	O
no	O
relationship	O
between	O
tumours	O
with	O
and	O
without	O
K-ras	O
mutations	O
with	O
regard	O
to	O
Dukes	O
'	O
stages	O
,	O
age	O
or	O
sex	O
of	O
the	O
patient	O
,	O
tumour	O
localization	O
,	O
histologic	O
grade	O
,	O
DNA	O
ploidy	O
pattern	O
,	O
HLA-DR	O
staining	O
pattern	O
,	O
or	O
survival	O
.	O
Samples	O
from	O
5	O
different	O
localizations	O
in	O
7	O
carcinomas	B-malignancy-type
showed	O
identical	O
K-ras	O
mutation	O
pattern	O
,	O
as	O
did	O
19	O
recurrences	O
/	O
metastases	O
originating	O
from	O
11	O
carcinomas	B-malignancy-type
.	O
CONCLUSIONS	O
:	O
When	O
present	O
,	O
the	O
primary	O
tumour	O
shows	O
homogeneous	O
distribution	O
of	O
K-ras	O
mutation	O
,	O
and	O
the	O
mutation	O
follows	O
the	O
carcinoma	B-malignancy-type
in	O
the	O
secondary	O
deposit	O
,	O
regardless	O
of	O
lymphogenous	O
or	O
hematogenous	O
spread	O
.	O
The	O
presence	O
of	O
K-ras	O
mutation	O
does	O
not	O
seem	O
to	O
have	O
prognostic	O
significance	O
for	O
the	O
patient	O
,	O
and	O
the	O
precise	O
nucleotide	O
change	O
is	O
furthermore	O
not	O
predictive	O
of	O
tumour	O
behaviour	O
.	O
PMID	O
:	O
9018769	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Surgery	O
1997	O
Jan;121(	O
1	O
)	O
:42	O
-	O
9	O
Analysis	O
of	O
K-ras	O
oncogene	O
mutations	O
in	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
with	I-malignancy-type
ductal	I-malignancy-type
hyperplasia	I-malignancy-type
.	O
Rivera	O
JA	O
,	O
Rall	O
CJ	O
,	O
Graeme	O
-	O
Cook	O
F	O
,	O
Fernandez	O
-	O
del	O
Castillo	O
C	O
,	O
Shu	O
P	O
,	O
Lakey	O
N	O
,	O
Tepper	O
R,	O
Rattner	O
DW	O
,	O
Warshaw	O
AL	O
,	O
Rustgi	O
AK.	O
Department	O
of	O
Surgery	O
,	O
Massachusetts	O
General	O
Hospital	O
,	O
Boston	O
02114	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
K-ras	O
oncogene	O
mutations	O
have	O
been	O
identified	O
in	O
up	O
to	O
95	O
%	O
of	O
pancreatic	B-malignancy-type
cancers	I-malignancy-type
,	O
implying	O
their	O
critical	O
role	O
in	O
their	O
molecular	O
pathogenesis	O
.	O
However	O
,	O
the	O
earliest	O
stage	O
in	O
which	O
K-ras	O
mutations	O
can	O
be	O
detected	O
in	O
potential	O
precursor	B-malignancy-type
lesions	I-malignancy-type
of	I-malignancy-type
pancreatic	I-malignancy-type
cancer	I-malignancy-type
remains	O
unclear	O
.	O
This	O
study	O
evaluates	O
pancreatic	B-malignancy-type
ductal	I-malignancy-type
hyperplasia	I-malignancy-type
in	I-malignancy-type
the	I-malignancy-type
setting	I-malignancy-type
of	I-malignancy-type
chronic	I-malignancy-type
pancreatitis	I-malignancy-type
,	O
which	O
predisposes	O
to	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
development	O
,	O
for	O
K-ras	O
codon	O
12	O
and	O
13	O
mutations	O
.	O
METHODS	O
:	O
Paraffin	O
-	O
embedded	O
surgical	O
specimens	O
from	O
42	O
patients	O
with	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
were	O
examined	O
microscopically	O
for	O
the	O
presence	O
of	O
ductal	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
Both	O
hyperplastic	B-malignancy-type
and	O
nonhyperplastic	O
ducts	O
were	O
microdissected	O
from	O
the	O
specimens	O
that	O
contained	O
hyperplasia	B-malignancy-type
(	O
11	O
of	O
42	O
)	O
.	O
Four	O
of	O
the	O
remaining	O
specimens	O
without	O
hyperplasia	B-malignancy-type
served	O
as	O
controls	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
,	O
and	O
polymerase	O
chain	O
reaction	O
and	O
amplification	O
of	O
the	O
K-ras	O
oncogene	O
was	O
performed	O
.	O
Polymerase	O
chain	O
reaction	O
products	O
were	O
evaluated	O
by	O
means	O
of	O
hybridization	O
to	O
mutant	O
specific	O
oligonucleotide	O
probes	O
and	O
by	O
means	O
of	O
automated	O
DNA	O
sequencing	O
.	O
RESULTS	O
:	O
K-ras	O
codon	O
12	O
mutations	O
representing	O
glycine	O
to	O
valine	O
substitutions	O
were	O
present	O
in	O
2	O
of	O
(	O
18	O
%	O
)	O
11	O
patients	O
with	O
ductal	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
No	O
mutations	O
were	O
found	O
in	O
the	O
controls	O
without	O
ductal	B-malignancy-type
hyperplasia	I-malignancy-type
.	O
CONCLUSIONS	O
:	O
Our	O
study	O
supports	O
the	O
premise	O
that	O
K-ras	O
mutations	O
develop	O
in	O
a	O
subset	O
of	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
associated	I-malignancy-type
hyperplasia	I-malignancy-type
and	O
provides	O
a	O
genetic	O
basis	O
for	O
the	O
potential	O
progression	O
of	O
chronic	B-malignancy-type
pancreatitis	I-malignancy-type
to	O
pancreatic	B-malignancy-type
cancer	I-malignancy-type
.	O
PMID	O
:	O
9001550	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Formos	O
Med	O
Assoc	O
1996	O
Oct;95(	O
10	O
)	O
:741	O
-	O
5	O
Detection	O
of	O
k-ras	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
in	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Hsu	O
NY	O
,	O
Chen	O
CY	O
,	O
Wu	O
CH	O
,	O
Liu	O
TJ	O
,	O
Kwan	O
PC	O
,	O
Hsu	O
CP	O
,	O
Hsia	O
JY	O
,	O
Chang	O
WT.	O
Department	O
of	O
Medical	O
Research	O
,	O
Taichung	O
veterans	O
General	O
Hospital	O
,	O
Taiwan	O
,	O
ROC.	O
Point	O
mutations	O
of	O
the	O
K-ras	O
gene	O
have	O
been	O
reported	O
in	O
a	O
wide	O
variety	O
of	O
human	O
tumors	O
.	O
By	O
using	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
,	O
we	O
screened	O
for	O
point	O
mutations	O
at	O
codons	O
12	O
and	O
13	O
of	O
the	O
K-ras	O
gene	O
in	O
specimens	O
obtained	O
from	O
fresh	O
frozen	O
tumors	O
in	O
38	O
patients	O
with	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Point	O
mutations	O
were	O
detected	O
in	O
two	O
of	O
38	O
(	O
5.3	O
%	O
)	O
resected	O
non	B-malignancy-type
-	I-malignancy-type
small	I-malignancy-type
cell	I-malignancy-type
lung	I-malignancy-type
cancers	I-malignancy-type
.	O
Both	O
of	O
them	O
were	O
G	O
to	O
T	O
transversions	O
.	O
One	O
patient	O
was	O
found	O
to	O
have	O
a	O
K-ras	O
codon	O
13	O
point	O
mutation	O
(	O
GGC	O
to	O
TGC	O
,	O
gly	O
to	O
cys	O
)	O
,	O
while	O
the	O
other	O
had	O
a	O
codon	O
12	O
point	O
mutation	O
(	O
GGT	O
to	O
GTT	O
,	O
gly	O
to	O
val	O
)	O
.	O
Based	O
on	O
the	O
limited	O
numbers	O
in	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
frequency	O
of	O
K-ras	O
point	O
mutations	O
in	O
codons	O
12	O
and	O
13	O
among	O
Asian	O
patients	O
with	O
lung	B-malignancy-type
adenocarcinomas	I-malignancy-type
was	O
lower	O
than	O
that	O
detected	O
among	O
Caucasian	O
patients	O
.	O
PMID	O
:	O
8961670	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1996	O
Aug	O
15	O
;13(	O
4)	O
:687	O
-	O
93	O
Prevalence	O
of	O
mutations	O
of	O
ras	O
and	O
p53	O
in	O
benign	B-malignancy-type
and	O
malignant	B-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
from	O
children	O
exposed	O
to	O
radiation	O
after	O
the	O
Chernobyl	O
nuclear	O
accident	O
.	O
Nikiforov	O
YE	O
,	O
Nikiforova	O
MN	O
,	O
Gnepp	O
DR	O
,	O
Fagin	O
JA.	O
Division	O
of	O
Endocrinology	O
,	O
Cedars	O
-	O
Sinai	O
Medical	O
Center	O
,	O
Los	O
Angeles	O
,	O
California	O
,	O
USA	O
.	O
Starting	O
4	O
years	O
after	O
the	O
Chernobyl	O
accident	O
,	O
a	O
dramatic	O
increase	O
in	O
incidence	O
of	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
was	O
noticed	O
in	O
children	O
from	O
contaminated	O
areas	O
.	O
The	O
incidence	O
of	O
benign	B-malignancy-type
thyroid	I-malignancy-type
lesions	I-malignancy-type
in	O
the	O
exposed	O
population	O
was	O
also	O
increased	O
.	O
To	O
study	O
the	O
possible	O
role	O
of	O
ras	O
and	O
p53	O
genes	O
in	O
radiation	O
-	O
induced	O
thyroid	O
tumorigenesis	O
,	O
33	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
,	O
one	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
and	O
22	O
benign	B-malignancy-type
lesions	I-malignancy-type
removed	O
from	O
children	O
aged	O
5	O
-	O
19	O
were	O
screened	O
for	O
point	O
mutations	O
of	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
,	O
as	O
well	O
as	O
of	O
p53	O
(	O
exons	O
5	O
-	O
8	O
)	O
using	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
.	O
Ras	O
point	O
mutations	O
were	O
detected	O
in	O
1	O
/	O
1	O
case	O
of	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
(	O
N-ras	O
codon	O
61	O
CAA	O
gln	O
-->	O
AAA	O
lys	O
)	O
,	O
and	O
in	O
3	O
/	O
7	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
(	O
N-ras	O
codon	O
61	O
CAA	O
gln	O
-->	O
CGA	O
arg	O
x	O
2	O
,	O
CAA	O
gln	O
-->	O
AAA	O
lys	O
)	O
.	O
None	O
of	O
the	O
cases	O
of	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinoma	I-malignancy-type
was	O
positive	O
for	O
ras	O
oncogene	O
abnormalities	O
.	O
The	O
lack	O
of	O
K-ras	O
mutations	O
was	O
confirmed	O
by	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
(	O
ASOH	O
)	O
,	O
and	O
by	O
sequencing	O
in	O
five	O
cases	O
.	O
Somatic	O
point	O
mutations	O
in	O
p53	O
were	O
found	O
by	O
SSCP	O
in	O
2	O
/	O
33	O
papillary	B-malignancy-type
thyroid	I-malignancy-type
carcinomas	I-malignancy-type
,	O
with	O
one	O
missense	O
mutation	O
(	O
exon	O
5	O
,	O
codon	O
160	O
ATG	O
met	O
-->	O
GTG	O
val	O
)	O
and	O
another	O
silent	O
mutation	O
(	O
codon	O
182	O
,	O
TGC	O
cys	O
-->	O
TGT	O
cys	O
)	O
.	O
Immunohisto-chemically	O
,	O
focally	O
positive	O
p53	O
staining	O
was	O
found	O
in	O
four	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
being	O
primarily	O
confined	O
to	O
solid	O
and	O
poorly	O
-	O
differentiated	O
areas	O
in	O
tumors	O
.	O
These	O
data	O
demonstrate	O
that	O
as	O
opposed	O
to	O
the	O
few	O
reports	O
on	O
tumors	O
arising	O
after	O
therapeutic	O
external	O
irradiation	O
,	O
ras	O
mutations	O
are	O
not	O
primary	O
events	O
in	O
the	O
development	O
of	O
post	O
-	O
Chernobyl	O
thyroid	B-malignancy-type
papillary	I-malignancy-type
carcinomas	I-malignancy-type
.	O
p53	O
mutations	O
do	O
not	O
appear	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
these	O
tumors	O
,	O
but	O
may	O
in	O
some	O
cases	O
have	O
a	O
role	O
in	O
progression	O
to	O
a	O
more	O
aggressive	O
phenotype	O
that	O
has	O
not	O
yet	O
fully	O
manifested	O
in	O
these	O
pediatric	O
neoplasms	B-malignancy-type
.	O
PMID	O
:	O
8761289	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1996	O
May	O
;10(	O
5	O
)	O
:844	O
-	O
7	O
Mutation	O
of	O
the	O
ras	O
genes	O
is	O
a	O
rare	O
genetic	O
event	O
in	O
the	O
histologic	O
transformation	O
of	O
follicular	B-malignancy-type
lymphoma	I-malignancy-type
.	O
Clark	O
HM	O
,	O
Yano	O
T	O
,	O
Sander	O
C	O
,	O
Jaffe	O
ES	O
,	O
Raffeld	O
M.	O
Hematopathology	O
Section	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20892	O
,	O
USA	O
.	O
The	O
role	O
of	O
ras	O
gene	O
mutations	O
in	O
the	O
progression	O
of	O
follicular	B-malignancy-type
lymphoma	I-malignancy-type
has	O
been	O
ascertained	O
by	O
SSCP	O
-	O
PCR	O
and	O
sequencing	O
.	O
A	O
total	O
of	O
40	O
transformed	B-malignancy-type
lymphomas	I-malignancy-type
were	O
studied	O
,	O
16	O
of	O
which	O
had	O
a	O
matched	O
preceding	O
low	O
-	O
grade	O
biopsy	O
.	O
Only	O
one	O
transformed	B-malignancy-type
lymphoma	I-malignancy-type
was	O
found	O
to	O
have	O
a	O
missense	O
mutation	O
at	O
codon	O
12	O
of	O
N-ras	O
,	O
resulting	O
in	O
an	O
amino	O
acid	O
change	O
of	O
glycine	O
to	O
serine	O
.	O
We	O
conclude	O
that	O
mutation	O
within	O
the	O
ras	O
gene	O
family	O
is	O
a	O
rare	O
event	O
in	O
the	O
transformation	O
of	O
follicular	B-malignancy-type
lymphoma	I-malignancy-type
.	O
PMID	O
:	O
8656681	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Hematol	O
1995	O
Jun;61(	O
4)	O
:205	O
-	O
13	O
Double	O
mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
a	O
patient	O
with	O
acute	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
.	O
Horiike	O
S,	O
Misawa	O
S,	O
Kaneko	O
H	O
,	O
Nakai	O
H	O
,	O
Ueda	O
Y	O
,	O
Nakao	O
M,	O
Hirakawa	O
K	O
,	O
Taniwaki	O
M,	O
Kashima	O
K.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
report	O
a	O
patient	O
with	O
acute	B-malignancy-type
myelomonocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AMMoL	B-malignancy-type
)	O
who	O
showed	O
two	O
independent	O
point	O
mutations	O
of	O
the	O
N-ras	O
gene	O
at	O
codons	O
12	O
and	O
13	O
.	O
Longitudinal	O
analysis	O
revealed	O
that	O
one	O
mutation	O
at	O
codon	O
13	O
was	O
detectable	O
throughout	O
his	O
disease	O
course	O
and	O
the	O
other	O
at	O
codon	O
12	O
emerged	O
as	O
a	O
second	O
mutation	O
14	O
months	O
after	O
the	O
diagnosis	O
was	O
made	O
,	O
at	O
the	O
refractory	O
stage	O
.	O
Cloning	O
to	O
vector	O
and	O
subsequent	O
sequencing	O
confirmed	O
that	O
these	O
mutations	O
occurred	O
in	O
different	O
alleles	O
.	O
Chromosome	O
findings	O
showed	O
a	O
simple	O
abnormal	O
karyotype	O
at	O
presentation	O
and	O
further	O
karyotypic	O
aberrations	O
during	O
his	O
disease	O
course	O
,	O
concomitantly	O
with	O
the	O
second	O
mutation	O
of	O
the	O
N-ras	O
gene	O
.	O
These	O
findings	O
revealed	O
a	O
close	O
relationship	O
among	O
the	O
disease	O
progression	O
,	O
karyotypic	O
evolution	O
and	O
a	O
newly	O
-	O
appearing	O
N-ras	O
mutation	O
.	O
PMID	O
:	O
8547609	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1995	O
Dec	O
15	O
;86(	O
12	O
)	O
:4579	O
-	O
86	O
Monosomy	O
7	O
and	O
activating	O
RAS	O
mutations	O
accompany	O
malignant	O
transformation	O
in	O
patients	O
with	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
.	O
Kalra	O
R,	O
Dale	O
D	O
,	O
Freedman	O
M,	O
Bonilla	O
MA	O
,	O
Weinblatt	O
M,	O
Ganser	O
A	O
,	O
Bowman	O
P	O
,	O
Abish	O
S,	O
Priest	O
J,	O
Oseas	O
RS	O
,	O
et	O
al	O
.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
-0519	O
,	O
USA	O
.	O
Individuals	O
with	O
severe	O
forms	O
of	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
suffer	O
from	O
recurrent	O
infections	O
.	O
The	O
therapeutic	O
use	O
of	O
recombinant	O
human	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
rhG-CSF	O
)	O
to	O
increase	O
the	O
neutrophil	O
count	O
is	O
associated	O
with	O
fewer	O
infections	O
and	O
an	O
improved	O
quality	O
of	O
life	O
.	O
However	O
,	O
the	O
long-term	O
effects	O
of	O
this	O
new	O
therapy	O
are	O
largely	O
unknown	O
.	O
In	O
particular	O
,	O
it	O
is	O
unclear	O
if	O
myeloid	B-malignancy-type
leukemia	I-malignancy-type
,	O
a	O
known	O
complication	O
of	O
some	O
forms	O
of	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
,	O
will	O
occur	O
with	O
increased	O
frequency	O
among	O
patients	O
who	O
receive	O
long-term	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O
We	O
report	O
13	O
patients	O
with	O
congenital	B-malignancy-type
disorders	I-malignancy-type
of	I-malignancy-type
myelopoiesis	I-malignancy-type
who	O
developed	O
leukemic	O
transformation	O
with	O
either	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	I-malignancy-type
or	O
acute	B-malignancy-type
myelogenous	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
and	O
1	O
who	O
acquired	O
a	O
clonal	O
cytogenetic	O
abnormality	O
without	O
evidence	O
of	O
MDS	B-malignancy-type
or	O
AML	B-malignancy-type
while	O
receiving	O
rhG-CSF	O
.	O
The	O
bone	O
marrows	O
of	O
10	O
patients	O
showed	O
monosomy	O
7	O
and	O
5	O
had	O
activating	O
RAS	O
mutations	O
.	O
These	O
abnormalities	O
were	O
not	O
detected	O
in	O
pretreatment	O
bone	O
marrows	O
and	O
cessation	O
of	O
rhG-CSF	O
was	O
not	O
associated	O
with	O
either	O
clinical	O
improvement	O
or	O
cytogenetic	O
remission	O
.	O
We	O
conclude	O
that	O
patients	O
with	O
severe	O
forms	O
of	O
congenital	B-malignancy-type
neutropenia	I-malignancy-type
are	O
at	O
relatively	O
high	O
risk	O
of	O
developing	O
MDS	B-malignancy-type
and	O
AML	B-malignancy-type
.	O
The	O
occurrence	O
of	O
monosomy	O
7	O
and	O
RAS	O
mutations	O
in	O
these	O
cases	O
suggests	O
that	O
the	O
myeloid	O
progenitors	O
of	O
some	O
patients	O
are	O
genetically	O
predisposed	O
to	O
malignant	O
transformation	O
.	O
The	O
relationship	O
between	O
therapeutic	O
rhG-CSF	O
and	O
leukemogenesis	O
in	O
patients	O
with	O
severe	B-malignancy-type
chronic	I-malignancy-type
neutropenia	I-malignancy-type
is	O
unclear	O
.	O
PMID	O
:	O
8541548	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Urol	O
Int	O
1995	O
;55(	O
2	O
)	O
:63	O
-	O
7	O
Infrequent	O
involvement	O
of	O
mutations	O
on	O
neurofibromatosis	O
type	O
1	O
,	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
in	O
urothelial	B-malignancy-type
tumors	I-malignancy-type
.	O
Uchida	O
T	O
,	O
Wada	O
C	O
,	O
Ishida	O
H	O
,	O
Egawa	O
S,	O
Ao	O
T	O
,	O
Yokoyama	O
E	O
,	O
Koshiba	O
K.	O
Department	O
of	O
Urology	O
and	O
Clinical	O
Pathology	O
,	O
Kitasato	O
University	O
School	O
of	O
Medicine	O
,	O
Kanagawa	O
,	O
Japan	O
.	O
The	O
neurofibromatosis	O
type	O
1	O
(	O
NF1	O
)	O
gene	O
is	O
considered	O
a	O
tumor	O
-	O
suppressor	O
gene	O
whose	O
product	O
acts	O
upstream	O
of	O
ras	O
.	O
The	O
ras	O
gene	O
is	O
an	O
oncogene	O
very	O
commonly	O
detected	O
in	O
human	O
cancers	O
and	O
consists	O
of	O
three	O
families	O
,	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
.	O
These	O
genes	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	O
mutations	O
in	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
Examination	O
was	O
made	O
of	O
the	O
mutations	O
of	O
these	O
genes	O
in	O
39	O
urothelial	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
(	O
31	O
bladder	B-malignancy-type
cancer	I-malignancy-type
,	O
6	O
renal	B-malignancy-type
pelvic	I-malignancy-type
tumor	I-malignancy-type
,	O
and	O
2	O
ureter	O
tumors	O
)	O
using	O
polymerase	O
chain	O
reaction	O
single-stranded	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
methods	O
.	O
Three	O
of	O
39	O
(	O
7.7	O
%	O
)	O
cases	O
showed	O
mobility	O
shifts	O
in	O
the	O
ras	O
family	O
gene	O
but	O
no	O
point	O
mutations	O
in	O
NF1	O
and	O
N-ras	O
genes	O
could	O
be	O
detected	O
.	O
Mutations	O
were	O
found	O
in	O
1	O
case	O
in	O
H-ras	O
at	O
codon	O
13	O
(	O
GGT	O
-	O
GTT	O
/	O
GGT	O
)	O
and	O
K-ras	O
at	O
codon	O
12	O
in	O
2	O
cases	O
(	O
GGT	O
-	O
GCT	O
/	O
GGT	O
,	O
GGT	O
-	O
GTT	O
/	O
GGT	O
)	O
.	O
All	O
3	O
cases	O
had	O
progressed	O
far	O
beyond	O
grade	O
2	O
and	O
stage	O
pT2	O
.	O
It	O
follows	O
from	O
the	O
above	O
that	O
NF1	O
and	O
ras	O
gene	O
mutations	O
are	O
infrequent	O
in	O
the	O
pathogenesis	O
of	O
urothelial	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
8533197	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1993	O
May	O
15	O
;81(	O
10	O
)	O
:2708	O
-	O
13	O
Mutational	O
activation	O
of	O
N	O
-	O
and	O
K	O
-	O
ras	O
oncogenes	O
in	O
plasma	B-malignancy-type
cell	I-malignancy-type
dyscrasias	I-malignancy-type
.	O
Corradini	O
P	O
,	O
Ladetto	O
M,	O
Voena	O
C	O
,	O
Palumbo	O
A	O
,	O
Inghirami	O
G	O
,	O
Knowles	O
DM	O
,	O
Boccadoro	O
M,	O
Pileri	O
A.	O
Department	O
of	O
Medicine	O
and	O
Experimental	O
Oncology	O
,	O
University	O
of	O
Torino	O
,	O
Italy	O
.	O
The	O
frequency	O
of	O
N	O
-	O
and	O
K	O
-	O
ras	O
oncogene	O
mutations	O
was	O
investigated	O
in	O
plasma	B-malignancy-type
cell	I-malignancy-type
dyscrasias	I-malignancy-type
.	O
Genomic	O
DNAs	O
from	O
128	O
patients	O
were	O
selected	O
for	O
this	O
study	O
:	O
30	O
monoclonal	B-malignancy-type
gammopathies	I-malignancy-type
of	O
undetermined	O
significance	O
,	O
8	O
solitary	O
plasmacytomas	O
,	O
77	O
multiple	B-malignancy-type
myelomas	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
,	O
and	O
13	O
plasma	B-malignancy-type
cell	I-malignancy-type
leukemias	I-malignancy-type
(	O
PCL	B-malignancy-type
)	O
.	O
A	O
two	O
-	O
step	O
experimental	O
approach	O
was	O
devised	O
.	O
All	O
samples	O
were	O
screened	O
for	O
mutations	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
.	O
DNA	O
fragments	O
displaying	O
an	O
altered	O
electrophoretic	O
mobility	O
were	O
further	O
studied	O
by	O
direct	O
sequencing	O
to	O
confirm	O
and	O
characterize	O
the	O
nature	O
of	O
the	O
mutations	O
.	O
Ras	O
mutations	O
are	O
not	O
randomly	O
distributed	O
because	O
they	O
are	O
detectable	O
only	O
in	O
MM	B-malignancy-type
(	O
9	O
%	O
)	O
and	O
PCL	B-malignancy-type
(	O
30.7	O
%	O
)	O
.	O
N-ras	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
and	O
K-ras	O
codon	O
12	O
were	O
found	O
to	O
be	O
mutated	O
,	O
but	O
N-ras	O
codon	O
61	O
mutation	O
was	O
the	O
most	O
frequent	O
finding	O
(	O
63.6	O
%	O
)	O
.	O
In	O
conclusion	O
,	O
ras	O
mutations	O
were	O
found	O
in	O
PCL	B-malignancy-type
,	O
and	O
in	O
a	O
subset	O
of	O
MM	B-malignancy-type
characterized	O
by	O
advanced-stage	O
disease	O
and	O
adverse	O
prognostic	O
parameters	O
.	O
Furthermore	O
,	O
based	O
on	O
our	O
findings	O
,	O
it	O
is	O
possible	O
to	O
speculate	O
that	O
ras	O
mutations	O
represent	O
a	O
late	O
molecular	O
lesion	O
in	O
the	O
process	O
of	O
multistep	O
carcinogenesis	O
.	O
PMID	O
:	O
8490179	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1993	O
Jan;6(	O
1	O
)	O
:15	O
-	O
9	O
H-ras-1	O
gene	O
mutations	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
:	O
automated	O
direct	O
sequencing	O
of	O
clinical	O
specimens	O
.	O
Wilke	O
WW	O
,	O
Robinson	O
RA	O
,	O
Kennard	O
CD	O
.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Medicine	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
.	O
Ras	O
oncogenes	O
are	O
activated	O
by	O
point	O
mutations	O
occurring	O
in	O
codons	O
12	O
,	O
13	O
or	O
61	O
and	O
almost	O
any	O
base	O
pair	O
mutation	O
occurring	O
within	O
the	O
first	O
two	O
positions	O
of	O
any	O
of	O
these	O
codons	O
results	O
in	O
activation	O
of	O
the	O
gene	O
.	O
Although	O
ras	O
point	O
mutations	O
have	O
been	O
reported	O
to	O
occur	O
in	O
several	O
skin	B-malignancy-type
neoplasms	I-malignancy-type
including	O
squamous	B-malignancy-type
carcinoma	I-malignancy-type
,	O
keratoacanthoma	B-malignancy-type
and	O
melanoma	B-malignancy-type
,	O
their	O
frequency	O
of	O
occurrence	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
is	O
not	O
known	O
.	O
We	O
examined	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
from	O
13	O
patients	O
for	O
activating	O
mutations	O
in	O
the	O
H-ras-1	O
gene	O
by	O
automated	O
direct	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
assay	O
amplified	O
targets	O
.	O
We	O
amplified	O
sequences	O
in	O
exon	O
1	O
that	O
flanked	O
codons	O
12	O
and	O
13	O
and	O
amplified	O
sequences	O
in	O
exon	O
2	O
that	O
flanked	O
codon	O
61	O
.	O
The	O
PCR	O
products	O
were	O
centrifuged	O
and	O
directly	O
sequenced	O
using	O
antisense	O
primers	O
in	O
an	O
automated	O
sequencer	O
using	O
fluorescent	O
dideoxyterminators	O
.	O
One	O
tumor	O
was	O
found	O
to	O
show	O
an	O
activating	O
G	O
to	O
A	O
transversion	O
in	O
codon	O
13	O
which	O
code	O
for	O
aspartic	O
acid	O
instead	O
of	O
glycine	O
.	O
Although	O
H-ras	O
mutations	O
may	O
be	O
found	O
in	O
some	O
skin	B-malignancy-type
tumors	I-malignancy-type
,	O
they	O
are	O
not	O
frequent	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
From	O
this	O
study	O
we	O
believe	O
that	O
direct	O
sequencing	O
of	O
clinical	O
material	O
is	O
of	O
value	O
and	O
has	O
advantages	O
over	O
other	O
techniques	O
.	O
Additional	O
studies	O
need	O
to	O
be	O
undertaken	O
to	O
understand	O
the	O
true	O
clinical	O
significance	O
of	O
ras	O
mutations	O
in	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
when	O
they	O
occur	O
.	O
PMID	O
:	O
8426854	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1993	O
Jul	O
30	O
;54(	O
6)	O
:978	O
-	O
82	O
Possible	O
role	O
of	O
activated	O
ras	O
genes	O
in	O
human	O
esophageal	O
carcinogenesis	O
.	O
Galiana	O
C	O
,	O
Fusco	O
A	O
,	O
Martel	O
N	O
,	O
Nishihira	O
T	O
,	O
Hirohashi	O
S,	O
Yamasaki	O
H.	O
Unit	O
of	O
Multistage	O
Carcinogenesis	O
,	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
,	O
Lyon	O
,	O
France	O
.	O
Activation	O
by	O
point	O
mutation	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
is	O
found	O
in	O
many	O
tumors	O
.	O
However	O
,	O
no	O
such	O
mutation	O
has	O
yet	O
been	O
found	O
in	O
human	O
esophageal	B-malignancy-type
carcinomas	I-malignancy-type
from	O
various	O
parts	O
of	O
the	O
world	O
.	O
We	O
have	O
confirmed	O
the	O
absence	O
of	O
mutation	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
K	O
-	O
and	O
N	O
-	O
ras	O
and	O
at	O
codons	O
12	O
and	O
61	O
of	O
H-ras	O
in	O
25	O
primary	O
tumors	O
obtained	O
in	O
France	O
.	O
In	O
contrast	O
,	O
among	O
7	O
human	O
esophageal	B-malignancy-type
carcinoma	I-malignancy-type
cell	O
lines	O
(	O
TE1	O
,	O
TE2	O
,	O
TE3	O
,	O
TE8	O
,	O
TE9	O
,	O
TE10	O
,	O
TE13	O
)	O
with	O
different	O
degrees	O
of	O
tumorigenicity	O
in	O
nude	O
mice	O
,	O
3	O
highly	O
tumorigenic	O
lines	O
(	O
TE1	O
,	O
TE2	O
and	O
TE8	O
)	O
exhibited	O
activation	O
of	O
ras	O
oncogenes	O
;	O
2	O
showed	O
a	O
G	O
35	O
to	O
A	O
35	O
transition	O
of	O
K-ras	O
gene	O
and	O
one	O
a	O
H-ras	O
G	O
35	O
to	O
T	O
35	O
transversion	O
.	O
Since	O
these	O
cell	O
lines	O
had	O
been	O
established	O
from	O
tumors	O
of	O
Japanese	O
patients	O
from	O
Sendai	O
,	O
we	O
examined	O
3	O
primary	O
esophageal	B-malignancy-type
tumors	I-malignancy-type
from	O
Tokyo	O
and	O
19	O
from	O
Sendai	O
,	O
including	O
the	O
primary	O
tumors	O
from	O
which	O
the	O
TE	O
cell	O
lines	O
had	O
been	O
derived	O
.	O
No	O
ras	O
mutation	O
was	O
detected	O
,	O
which	O
suggests	O
that	O
the	O
ras	O
gene	O
mutations	O
in	O
the	O
TE	O
cell	O
lines	O
are	O
either	O
due	O
to	O
their	O
long-term	O
culture	O
or	O
that	O
only	O
a	O
small	O
portion	O
of	O
the	O
original	O
tumors	O
contained	O
such	O
mutations	O
.	O
In	O
order	O
to	O
directly	O
examine	O
the	O
effect	O
of	O
ras	O
gene	O
mutation	O
,	O
one	O
of	O
the	O
non	O
-	O
tumorigenic	O
cell	O
lines	O
,	O
TE13	O
,	O
was	O
transfected	O
with	O
a	O
plasmid	O
coding	O
for	O
a	O
mutated	O
H-ras	O
gene	O
(	O
G	O
35	O
to	O
T	O
35	O
)	O
.	O
Transfected	O
clones	O
expressing	O
high	O
levels	O
of	O
mutated	O
ras	O
gene	O
were	O
able	O
to	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O
Thus	O
,	O
although	O
no	O
primary	O
human	O
esophageal	B-malignancy-type
tumor	I-malignancy-type
contained	O
mutated	O
ras	O
genes	O
,	O
our	O
studies	O
do	O
not	O
exclude	O
a	O
significant	O
role	O
of	O
mutated	O
ras	O
genes	O
in	O
cell	O
proliferation	O
and	O
malignant	O
transformation	O
of	O
human	O
esophageal	O
cells	O
.	O
PMID	O
:	O
8335405	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1994	O
Apr;78(	O
4)	O
:842	O
-	O
6	O
H-ras	O
mutations	O
in	O
human	O
pituitary	B-malignancy-type
carcinoma	I-malignancy-type
metastases	I-malignancy-type
.	O
Pei	O
L,	O
Melmed	O
S,	O
Scheithauer	O
B	O
,	O
Kovacs	O
K	O
,	O
Prager	O
D.	O
Department	O
of	O
Medicine	O
,	O
Cedars	O
-	O
Sinai	O
Medical	O
Center	O
-	O
UCLA	O
School	O
of	O
Medicine	O
90048	O
.	O
Molecular	O
mechanisms	O
of	O
pituitary	O
tumorigenesis	O
were	O
studied	O
using	O
Polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
with	O
DNA	O
sequencing	O
to	O
identify	O
potential	O
mutations	O
in	O
the	O
ras	O
protooncogenes	O
and	O
the	O
tumor	O
suppressor	O
gene	O
p53	O
in	O
invasive	B-malignancy-type
pituitary	I-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
Sequencing	O
of	O
exons	O
5	O
through	O
8	O
of	O
the	O
p53	O
gene	O
revealed	O
no	O
mutations	O
,	O
nor	O
were	O
mutations	O
detected	O
in	O
the	O
N	O
-	O
or	O
K	O
-	O
ras	O
protooncogenes	O
in	O
four	O
of	O
the	O
carcinomas	B-malignancy-type
and	O
their	O
respective	O
metastatic	O
deposits	O
.	O
Point	O
mutations	O
of	O
H-ras	O
however	O
,	O
were	O
identified	O
in	O
three	O
distant	O
metastatic	O
pituitary	O
tumor	O
secondaries	O
,	O
but	O
not	O
in	O
their	O
respective	O
primary	O
pituitary	B-malignancy-type
carcinomas	I-malignancy-type
,	O
or	O
in	O
six	O
invasive	B-malignancy-type
adenomas	I-malignancy-type
.	O
Two	O
of	O
the	O
mutations	O
included	O
a	O
G	O
to	O
C	O
substitution	O
at	O
codon	O
12	O
,	O
and	O
a	O
G	O
to	O
A	O
substitution	O
at	O
codon	O
18	O
,	O
resulting	O
in	O
a	O
glycine	O
to	O
arginine	O
,	O
and	O
an	O
alanine	O
to	O
threonine	O
change	O
at	O
these	O
amino	O
acids	O
,	O
respectively	O
.	O
A	O
third	O
mutation	O
involved	O
a	O
single	O
base	O
pair	O
(	O
adenine	O
)	O
deletion	O
in	O
codon	O
3	O
of	O
H-ras	O
which	O
causes	O
a	O
frame	O
shift	O
,	O
resulting	O
in	O
a	O
termination	O
signal	O
at	O
codon	O
19	O
.	O
These	O
results	O
suggest	O
that	O
point	O
mutations	O
in	O
p53	O
and	O
ras	O
are	O
not	O
associated	O
with	O
pituitary	O
tumorigenesis	O
,	O
however	O
,	O
point	O
mutations	O
of	O
the	O
H-ras	O
gene	O
may	O
be	O
important	O
in	O
the	O
formation	O
and	O
or	O
growth	O
of	O
pituitary	B-malignancy-type
metastases	I-malignancy-type
.	O
This	O
observed	O
genomic	O
instability	O
will	O
be	O
of	O
value	O
in	O
predicting	O
the	O
potential	O
metastatic	O
behavior	O
of	O
these	O
aggressive	B-malignancy-type
pituitary	I-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
8157709	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
Apr	O
1	O
;	O
57	O
(	O
1	O
)	O
:51	O
-	O
5	O
Non	O
-	O
involvement	O
of	O
ras	O
mutations	O
in	O
flat	B-malignancy-type
colorectal	I-malignancy-type
adenomas	I-malignancy-type
and	O
carcinomas	B-malignancy-type
.	O
Fujimori	O
T	O
,	O
Satonaka	O
K	O
,	O
Yamamura	O
-	O
Idei	O
Y	O
,	O
Nagasako	O
K	O
,	O
Maeda	O
S.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Kobe	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Ras	O
gene	O
mutations	O
occur	O
relatively	O
early	O
during	O
colorectal	O
tumor	O
development	O
and	O
have	O
been	O
observed	O
in	O
40	O
-	O
50	O
%	O
of	O
malignant	B-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
.	O
Advances	O
in	O
endoscopic	O
techniques	O
have	O
made	O
it	O
possible	O
to	O
detect	O
small	B-malignancy-type
,	I-malignancy-type
flat	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
that	O
could	O
not	O
be	O
detected	O
by	O
standard	O
examinations	O
.	O
To	O
determine	O
whether	O
ras	O
gene	O
mutations	O
are	O
also	O
involved	O
in	O
the	O
genesis	O
of	O
small	B-malignancy-type
,	I-malignancy-type
flat	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
,	O
we	O
examined	O
ras	O
point	O
mutations	O
in	O
34	O
cases	O
of	O
small	B-malignancy-type
polypoid	I-malignancy-type
or	O
flat	B-malignancy-type
elevated	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
(	O
32	O
adenomas	B-malignancy-type
,	O
2	O
carcinomas	B-malignancy-type
)	O
and	O
in	O
26	O
cases	O
of	O
small	B-malignancy-type
,	I-malignancy-type
flat	I-malignancy-type
colorectal	I-malignancy-type
tumors	I-malignancy-type
(	O
13	O
adenomas	B-malignancy-type
,	O
13	O
carcinomas	B-malignancy-type
)	O
by	O
means	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
dot	O
-	O
blot	O
hybridization	O
.	O
Ras	O
gene	O
point	O
mutations	O
were	O
observed	O
in	O
16	O
of	O
the	O
34	O
tumors	O
of	O
the	O
former	O
type	O
(	O
47	O
%	O
)	O
,	O
but	O
in	O
none	O
of	O
the	O
26	O
tumors	O
of	O
the	O
latter	O
type	O
,	O
even	O
though	O
the	O
grade	O
of	O
dysplasia	B-malignancy-type
was	O
severe	O
in	O
the	O
flat	B-malignancy-type
tumors	I-malignancy-type
.	O
Our	O
results	O
suggest	O
that	O
different	O
genetic	O
pathways	O
for	O
tumor	O
progression	O
may	O
exist	O
for	O
polypoid	B-malignancy-type
and	O
for	O
flat	B-malignancy-type
colorectal	I-malignancy-type
carcinomas	I-malignancy-type
.	O
PMID	O
:	O
8150541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Blood	O
1994	O
Mar	O
15	O
;	O
83	O
(	O
6	O
)	O
:	O
1603	O
-	O
11	O
Prognostic	O
importance	O
of	O
mutations	O
in	O
the	O
ras	O
proto	O
-	O
oncogenes	O
in	O
de	B-malignancy-type
novo	I-malignancy-type
acute	I-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
Neubauer	O
A	O
,	O
Dodge	O
RK	O
,	O
George	O
SL	O
,	O
Davey	O
FR	O
,	O
Silver	O
RT	O
,	O
Schiffer	O
CA	O
,	O
Mayer	O
RJ	O
,	O
Ball	O
ED	O
,	O
Wurster	O
-	O
Hill	O
D	O
,	O
Bloomfield	O
CD	O
,	O
et	O
al	O
.	O
Department	O
of	O
Medicine	O
,	O
Lineberger	O
Cancer	O
Research	O
Center	O
,	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
27599	O
-	O
7295	O
.	O
Mutations	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
genes	O
are	O
the	O
most	O
frequent	O
genetic	O
aberrations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
and	O
their	O
detection	O
in	O
preleukemic	O
conditions	O
such	O
as	O
the	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
suggests	O
a	O
role	O
in	O
the	O
earliest	O
phases	O
of	O
leukemogenesis	O
.	O
Despite	O
these	O
observations	O
,	O
little	O
is	O
known	O
about	O
the	O
clinical	O
importance	O
of	O
ras	O
mutations	O
in	O
AML	B-malignancy-type
.	O
We	O
studied	O
the	O
clinical	O
impact	O
of	O
ras	O
mutations	O
in	O
99	O
patients	O
with	O
de	B-malignancy-type
novo	I-malignancy-type
AML	I-malignancy-type
.	O
All	O
patients	O
were	O
treated	O
in	O
two	O
prospective	O
multicenter	O
trials	O
.	O
The	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
amplify	O
areas	O
surrounding	O
the	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
three	O
ras	O
genes	O
N	O
-	O
,	O
K	O
-	O
,	O
and	O
H	O
-	O
ras	O
from	O
DNA	O
from	O
bone	O
marrow	O
cells	O
,	O
ras	O
mutations	O
were	O
detected	O
by	O
an	O
algorithm	O
based	O
on	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
.	O
Eighteen	O
of	O
99	O
(	O
18	O
%	O
)	O
patients	O
harbored	O
mutations	O
in	O
either	O
N	O
-	O
or	O
K	O
-	O
ras	O
.	O
All	O
of	O
the	O
observed	O
mutations	O
occurred	O
in	O
N-ras	O
(	O
N	O
=	O
10	O
)	O
and	O
K-ras	O
(	O
N	O
=	O
5	O
)	O
or	O
concurrently	O
in	O
both	O
N	O
-	O
and	O
K	O
-	O
ras	O
(	O
N	O
=	O
3	O
)	O
.	O
There	O
were	O
no	O
significant	O
differences	O
between	O
ras	O
-	O
negative	O
and	O
ras	O
-	O
positive	O
patients	O
according	O
to	O
age	O
,	O
sex	O
,	O
blood	O
counts	O
,	O
cytogenetic	O
abnormalities	O
,	O
or	O
French	O
-	O
American	O
-	O
British	O
classification	O
.	O
However	O
,	O
univariate	O
analysis	O
suggested	O
a	O
longer	O
survival	O
in	O
ras	O
-	O
positive	O
patients	O
(	O
P	O
=	O
.11	O
)	O
.	O
When	O
adjusted	O
for	O
age	O
,	O
which	O
was	O
the	O
most	O
important	O
factor	O
affecting	O
outcome	O
,	O
the	O
presence	O
of	O
a	O
ras	O
mutation	O
emerged	O
as	O
a	O
significant	O
predictor	O
for	O
improved	O
survival	O
(	O
P	O
=	O
.03	O
)	O
and	O
along	O
with	O
lower	O
bone	O
marrow	O
blast	O
counts	O
(	O
P	O
=	O
.02	O
)	O
and	O
better	O
cytogenetic	O
category	O
(	O
P	O
=	O
.01	O
)	O
.	O
However	O
,	O
the	O
presence	O
of	O
an	O
aberrant	O
ras	O
allele	O
was	O
strongly	O
correlated	O
with	O
lower	O
bone	O
marrow	O
blast	O
counts	O
(	O
P	O
=	O
.007	O
)	O
.	O
Thus	O
,	O
whether	O
a	O
mutation	O
in	O
the	O
N-ras	O
or	O
K-ras	O
proto	O
-	O
oncogenes	O
directly	O
affects	O
treatment	O
outcome	O
or	O
indirectly	O
through	O
an	O
association	O
with	O
lower	O
leukemic	O
burden	O
remains	O
to	O
be	O
determined	O
.	O
Nevertheless	O
,	O
these	O
findings	O
counter	O
the	O
prevailing	O
bias	O
that	O
oncogene	O
mutations	O
lead	O
to	O
more	O
aggressive	O
behavior	O
in	O
human	O
malignancies	O
.	O
PMID	O
:	O
8123851	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Invest	O
Dermatol	O
1994	O
Mar	O
;	O
102	O
(	O
3	O
)	O
:	O
285	O
-	O
90	O
Ras	O
mutations	O
in	O
human	O
melanoma	B-malignancy-type
:	O
a	O
marker	O
of	O
malignant	O
progression	O
.	O
Ball	O
NJ	O
,	O
Yohn	O
JJ	O
,	O
Morelli	O
JG	O
,	O
Norris	O
DA	O
,	O
Golitz	O
LE	O
,	O
Hoeffler	O
JP	O
.	O
Department	O
of	O
Dermatology	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
,	O
Denver	O
80262	O
.	O
In	O
this	O
study	O
we	O
address	O
whether	O
there	O
is	O
an	O
association	O
between	O
ras	O
mutations	O
and	O
disease	O
progression	O
in	O
malignant	B-malignancy-type
melanoma	I-malignancy-type
.	O
DNA	O
was	O
extracted	O
from	O
100	O
paraffin	O
-	O
embedded	O
melanomas	B-malignancy-type
and	O
sequences	O
around	O
the	O
12th	O
,	O
13th	O
and	O
61st	O
codons	O
of	O
N	O
-	O
,	O
H	O
-	O
,	O
and	O
K	O
-	O
ras	O
were	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
probed	O
for	O
single	O
base	O
pair	O
mutations	O
using	O
synthetic	O
oligonucleotide	O
probes	O
.	O
Thirty-six	O
melanomas	B-malignancy-type
contained	O
mutations	O
,	O
which	O
in	O
25	O
cases	O
(	O
69	O
%	O
)	O
occurred	O
at	O
the	O
61st	O
codon	O
of	O
N-ras	O
.	O
The	O
results	O
from	O
dot	O
blot	O
hybridizations	O
were	O
confirmed	O
by	O
subcloning	O
and	O
sequencing	O
the	O
polymerase	O
chain	O
reaction	O
products	O
from	O
two	O
tumors	O
.	O
No	O
ras	O
mutations	O
were	O
found	O
in	O
Clark	O
's	O
level	O
I	O
melanomas	B-malignancy-type
,	O
whereas	O
19	O
%	O
of	O
level	O
II	O
and	O
45	O
%	O
of	O
the	O
more	O
advanced	O
primary	O
tumors	O
contained	O
ras	O
mutations	O
(	O
Chi	O
squared	O
test	O
:	O
p	O
<	O
0.05	O
)	O
.	O
The	O
median	O
Breslow	O
thickness	O
of	O
primary	O
melanomas	B-malignancy-type
with	O
ras	O
mutations	O
was	O
0.72	O
mm	O
,	O
significantly	O
thicker	O
than	O
the	O
0.42	O
mm	O
of	O
melanomas	B-malignancy-type
without	O
mutations	O
(	O
Mann	O
-	O
Whitney	O
U	O
test	O
,	O
p	O
=	O
0.042	O
)	O
.	O
Ras	O
mutations	O
were	O
found	O
more	O
frequently	O
in	O
primary	O
tumors	O
from	O
continuously	O
exposed	O
skin	O
(	O
56	O
%	O
)	O
than	O
tumors	O
from	O
intermittently	O
or	O
non	O
-	O
sun	O
exposed	O
sites	O
(	O
21	O
%	O
)	O
.	O
Fifty	O
percent	O
of	O
locally	O
recurrent	O
and	O
47	O
%	O
of	O
metastatic	B-malignancy-type
melanomas	I-malignancy-type
had	O
ras	O
mutations	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
occur	O
in	O
a	O
subset	O
of	O
melanomas	B-malignancy-type
from	O
sun	O
-	O
exposed	O
skin	O
as	O
a	O
feature	O
of	O
tumor	O
progression	O
.	O
PMID	O
:	O
8120410	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Int	O
J	O
Oral	O
Maxillofac	O
Surg	O
1993	O
Dec	O
;	O
22	O
(	O
6	O
)	O
:	O
359	O
-	O
61	O
H-ras	O
gene	O
mutations	O
in	O
salivary	B-malignancy-type
gland	I-malignancy-type
pleomorphic	I-malignancy-type
adenomas	I-malignancy-type
.	O
Milasin	O
J	O
,	O
Pujic	O
N	O
,	O
Dedovic	O
N	O
,	O
Gavric	O
M	O
,	O
Vranic	O
V	O
,	O
Petrovic	O
V	O
,	O
Minic	O
A	O
.	O
Institute	O
of	O
Biology	O
and	O
Human	O
Genetics	O
,	O
School	O
of	O
Stomatology	O
,	O
Belgrade	O
,	O
Yugoslavia	O
.	O
The	O
DNA	O
from	O
17	O
specimens	O
of	O
pleomorphic	B-malignancy-type
adenoma	I-malignancy-type
of	I-malignancy-type
the	I-malignancy-type
salivary	I-malignancy-type
glands	I-malignancy-type
was	O
screened	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
various	O
human	O
neoplasias	B-malignancy-type
.	O
By	O
a	O
sensitive	O
method	O
of	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
on	O
in	O
vitro	O
amplified	O
tumor	O
DNA	O
,	O
point	O
mutations	O
,	O
mainly	O
in	O
codon	O
12	O
of	O
the	O
H-ras	O
gene	O
,	O
were	O
detected	O
in	O
six	O
tumor	O
specimens	O
(	O
35	O
%	O
)	O
.	O
This	O
high	O
incidence	O
of	O
mutated	O
ras	O
genes	O
suggests	O
that	O
their	O
alteration	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
pleomorphic	B-malignancy-type
adenomas	I-malignancy-type
.	O
PMID	O
:	O
8106812	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Diagn	O
Mol	O
Pathol	O
1994	O
Jun	O
;	O
3	O
(	O
2	O
)	O
:	O
114	O
-	O
21	O
PCR	O
amplification	O
and	O
analysis	O
of	O
ras	O
oncogenes	O
from	O
thyroid	O
cytologic	O
smears	O
.	O
Sciacchitano	O
S	O
,	O
Paliotta	O
DS	O
,	O
Nardi	O
F	O
,	O
Sacchi	O
A	O
,	O
Andreoli	O
M	O
,	O
Pontecorvi	O
A	O
.	O
Department	O
of	O
Experimental	O
Medicine	O
,	O
University	O
La	O
Sapienza	O
,	O
Rome	O
,	O
Italy	O
.	O
Fine	O
needle	O
aspiration	O
(	O
FNA	O
)	O
cytology	O
represents	O
a	O
reliable	O
diagnostic	O
procedure	O
for	O
preoperative	O
identification	O
of	O
thyroid	B-malignancy-type
carcinoma	I-malignancy-type
.	O
For	O
improving	O
its	O
diagnostic	O
accuracy	O
,	O
a	O
technique	O
that	O
allows	O
the	O
analysis	O
of	O
cancer	O
-	O
related	O
gene	O
abnormalities	O
on	O
thyroid	O
FNA	O
smears	O
has	O
been	O
developed	O
.	O
Cells	O
were	O
collected	O
by	O
scraping	O
from	O
thyroid	O
smears	O
,	O
DNA	O
-	O
extracted	O
and	O
ras	O
proto	O
-	O
oncogene	O
sequences	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
Preliminary	O
destaining	O
of	O
cytologic	O
smears	O
was	O
essential	O
for	O
efficient	O
PCR	O
amplification	O
.	O
Twelve	O
thyroid	O
FNA	O
cytologic	O
smears	O
,	O
characterized	O
by	O
the	O
indeterminate	O
pattern	O
of	O
follicular	B-malignancy-type
neoplasia	I-malignancy-type
,	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
known	O
to	O
confer	O
an	O
oncogenic	O
potential	O
.	O
The	O
same	O
nucleotide	O
substitution	O
at	O
codon	O
12	O
of	O
the	O
H-ras	O
proto	O
-	O
oncogene	O
was	O
detected	O
in	O
two	O
different	O
thyroid	B-malignancy-type
nodules	I-malignancy-type
among	O
six	O
cases	O
that	O
,	O
at	O
final	O
histology	O
,	O
were	O
identified	O
as	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
.	O
No	O
ras	O
mutations	O
were	O
observed	O
in	O
the	O
remaining	O
six	O
cases	O
that	O
were	O
diagnosed	O
as	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
at	O
histologic	O
examination	O
.	O
Molecular	O
analysis	O
of	O
FNA	O
smears	O
may	O
provide	O
additional	O
information	O
on	O
the	O
nature	O
of	O
the	O
lesion	B-malignancy-type
underlying	O
thyroid	B-malignancy-type
neoplasia	I-malignancy-type
,	O
thus	O
improving	O
diagnostic	O
accuracy	O
of	O
conventional	O
FNA	O
cytology	O
.	O
PMID	O
:	O
8061889	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Res	O
1994	O
Dec	O
1;54(	O
23	O
)	O
:6282	O
-	O
7	O
A	O
truncated	O
beta-catenin	O
disrupts	O
the	O
interaction	O
between	O
E-cadherin	O
and	O
alpha-catenin	O
:	O
a	O
cause	O
of	O
loss	O
of	O
intercellular	O
adhesiveness	O
in	O
human	O
cancer	O
cell	O
lines	O
.	O
Oyama	O
T	O
,	O
Kanai	O
Y	O
,	O
Ochiai	O
A	O
,	O
Akimoto	O
S,	O
Oda	O
T	O
,	O
Yanagihara	O
K	O
,	O
Nagafuchi	O
A	O
,	O
Tsukita	O
S,	O
Shibamoto	O
S,	O
Ito	O
F	O
,	O
et	O
al	O
.	O
Pathology	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Cadherin	O
cell	O
adhesion	O
molecules	O
play	O
an	O
essential	O
role	O
in	O
creating	O
tight	O
intercellular	O
association	O
and	O
are	O
considered	O
to	O
work	O
as	O
an	O
invasion	O
suppressor	O
system	O
of	O
cancer	O
cells	O
.	O
They	O
form	O
a	O
molecular	O
complex	O
with	O
catenins	O
,	O
a	O
group	O
of	O
cytoplasmic	O
proteins	O
including	O
alpha	O
-	O
and	O
beta	O
-	O
catenins	O
.	O
While	O
alpha-catenin	O
has	O
been	O
demonstrated	O
to	O
be	O
crucial	O
for	O
cadherin	O
function	O
,	O
the	O
role	O
of	O
beta-catenin	O
is	O
not	O
yet	O
fully	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
cadherin	O
-	O
catenin	O
system	O
in	O
two	O
human	O
cell	O
lines	O
,	O
HSC-39	O
and	O
its	O
putative	O
subline	O
HSC-40A	O
,	O
derived	O
from	O
a	O
signet	B-malignancy-type
ring	I-malignancy-type
cell	I-malignancy-type
carcinoma	I-malignancy-type
of	O
stomach	O
.	O
These	O
cells	O
grow	O
as	O
loose	O
aggregates	O
or	O
single	O
cells	O
,	O
suggesting	O
that	O
their	O
cadherin	O
system	O
is	O
not	O
functional	O
.	O
In	O
these	O
cell	O
lines	O
,	O
an	O
identical	O
321	O
-	O
base	O
pair	O
in-frame	O
mRNA	O
deletion	O
of	O
beta-catenin	O
was	O
identified	O
;	O
this	O
led	O
to	O
a	O
107	O
-	O
amino	O
-	O
acid	O
deletion	O
in	O
the	O
NH2	O
-	O
terminal	O
region	O
of	O
the	O
protein	O
.	O
Southern	O
blot	O
analysis	O
disclosed	O
a	O
homozygous	O
deletion	O
in	O
part	O
of	O
the	O
beta-catenin	O
gene	O
.	O
On	O
the	O
other	O
hand	O
,	O
these	O
cells	O
expressed	O
E-cadherin	O
,	O
alpha-catenin	O
,	O
and	O
plakoglobin	O
of	O
normal	O
size	O
.	O
Immunoprecipitation	O
analyses	O
showed	O
that	O
E-cadherin	O
was	O
coprecipitated	O
with	O
the	O
mutated	O
beta-catenin	O
but	O
not	O
with	O
alpha-catenin	O
,	O
and	O
antibodies	O
against	O
beta-catenin	O
did	O
not	O
copurify	O
alpha-catenin	O
.	O
However	O
,	O
the	O
recombinant	O
fusion	O
protein	O
containing	O
wild-type	O
beta-catenin	O
precipitated	O
alpha-catenin	O
from	O
these	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
the	O
dysfunction	O
of	O
E-cadherin	O
in	O
these	O
cell	O
lines	O
is	O
due	O
primarily	O
to	O
its	O
failure	O
to	O
interact	O
with	O
alpha-catenin	O
,	O
and	O
that	O
this	O
defect	O
results	O
from	O
the	O
mutation	O
in	O
beta-catenin	O
.	O
Thus	O
,	O
it	O
is	O
most	O
likely	O
that	O
the	O
association	O
between	O
E-cadherin	O
and	O
alpha-catenin	O
is	O
mediated	O
by	O
beta-catenin	O
,	O
and	O
that	O
this	O
process	O
is	O
blocked	O
by	O
NH2	O
-	O
terminal	O
deletion	O
in	O
beta-catenin	O
.	O
These	O
findings	O
indicate	O
that	O
genetic	O
abnormality	O
of	O
beta-catenin	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
loosening	O
of	O
cell	O
-	O
cell	O
contact	O
,	O
and	O
may	O
be	O
involved	O
in	O
enhancement	O
of	O
tumor	O
invasion	O
in	O
human	O
cancers	O
.	O
PMID	O
:	O
7954478	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Endocr	O
J	O
1994	O
Jun;41(	O
3	O
)	O
:301	O
-	O
8	O
Specific	O
PCR	O
amplification	O
for	O
N-ras	O
mutations	O
in	O
neoplastic	B-malignancy-type
thyroid	I-malignancy-type
diseases	I-malignancy-type
.	O
Kaihara	O
M,	O
Taniyama	O
M,	O
Tadatomo	O
J,	O
Tobe	O
T	O
,	O
Tomita	O
M,	O
Ito	O
K	O
,	O
Ban	O
Y	O
,	O
Katagiri	O
T.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
School	O
of	O
Medicine	O
,	O
Showa	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
We	O
analyzed	O
point	O
mutations	O
of	O
N-ras	O
protooncogene	O
codon	O
61	O
in	O
thyroid	O
neoplasms	O
by	O
means	O
of	O
a	O
mutation	O
-	O
specific	O
PCR	O
method	O
.	O
In	O
this	O
method	O
,	O
one	O
of	O
the	O
paired	O
primers	O
has	O
a	O
base	O
at	O
the	O
3'	O
terminal	O
that	O
is	O
complementary	O
to	O
a	O
mutated	O
base	O
of	O
the	O
DNA	O
sequence	O
to	O
be	O
analyzed	O
.	O
With	O
this	O
primer	O
,	O
only	O
alleles	O
which	O
have	O
the	O
same	O
mutation	O
can	O
be	O
amplified	O
.	O
Among	O
24	O
thyroid	O
tissues	O
,	O
we	O
detected	O
2	O
point	O
mutations	O
out	O
of	O
7	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
(	O
29	O
%	O
)	O
.	O
One	O
tumor	O
had	O
a	O
cytosine	O
to	O
adenine	O
substitution	O
mutation	O
at	O
the	O
first	O
base	O
of	O
codon	O
61	O
,	O
and	O
the	O
other	O
had	O
an	O
adenine	O
to	O
guanine	O
substitution	O
mutation	O
in	O
the	O
second	O
base	O
of	O
the	O
same	O
codon	O
.	O
The	O
same	O
mutations	O
were	O
not	O
detected	O
in	O
7	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
or	O
1	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
.	O
These	O
results	O
were	O
confirmed	O
by	O
both	O
dot	O
blot	O
hybridization	O
and	O
direct	O
sequencing	O
method	O
.	O
Mutation	O
of	O
N-ras	O
codon	O
61	O
may	O
be	O
significant	O
in	O
malignant	O
transformation	O
of	O
follicular	B-malignancy-type
thyroid	I-malignancy-type
tumors	I-malignancy-type
.	O
Because	O
of	O
its	O
easy	O
availability	O
,	O
the	O
mutation	O
-	O
specific	O
PCR	O
method	O
is	O
a	O
useful	O
screening	O
test	O
for	O
N-ras	O
mutations	O
.	O
PMID	O
:	O
7951583	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1994	O
Oct	O
1;59(	O
1	O
)	O
:39	O
-	O
42	O
ras	O
-	O
family	O
gene	O
mutations	O
in	O
neoplasia	B-malignancy-type
of	O
the	O
ampulla	O
of	O
Vater	O
.	O
Scarpa	O
A	O
,	O
Zamboni	O
G	O
,	O
Achille	O
A	O
,	O
Capelli	O
P	O
,	O
Bogina	O
G	O
,	O
Iacono	O
C	O
,	O
Serio	O
G	O
,	O
Accolla	O
RS	O
.	O
Istituti	O
di	O
Anatomia	O
Patologica	O
,	O
Universita	O
di	O
Verona	O
,	O
Italy	O
.	O
Mutations	O
in	O
the	O
first	O
and	O
second	O
exons	O
of	O
Ha	O
-	O
,	O
Ki	O
-	O
and	O
N	O
-	O
ras	O
oncogenes	O
were	O
investigated	O
in	O
17	O
epithelial	B-malignancy-type
tumors	I-malignancy-type
of	O
the	O
ampulla	O
of	O
Vater	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
of	O
DNA	O
fragments	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
The	O
panel	O
included	O
12	O
intestinal	B-malignancy-type
-	I-malignancy-type
type	I-malignancy-type
adenocarcinomas	I-malignancy-type
,	O
3	O
villous	B-malignancy-type
adenomas	I-malignancy-type
,	O
1	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
and	O
1	O
neuroendocrine	B-malignancy-type
carcinoma	I-malignancy-type
.	O
Six	O
cases	O
(	O
35	O
%	O
)	O
contained	O
ras	O
mutations	O
,	O
affecting	O
codon	O
12	O
of	O
Ki-ras	O
in	O
2	O
adenomas	B-malignancy-type
and	O
3	O
carcinomas	B-malignancy-type
,	O
and	O
of	O
N-ras	O
in	O
1	O
adenoma	O
.	O
All	O
mutations	O
were	O
found	O
in	O
adenomas	O
and	O
among	O
cancers	B-malignancy-type
with	I-malignancy-type
adenomatous	I-malignancy-type
areas	I-malignancy-type
,	O
whereas	O
none	O
of	O
the	O
cases	O
lacking	O
adenomatous	O
areas	O
contained	O
mutations	O
.	O
This	O
suggested	O
that	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
represent	O
heterogeneous	O
diseases	O
with	O
respect	O
to	O
the	O
presence	O
or	O
absence	O
of	O
adenomatous	O
areas	O
and	O
,	O
among	O
those	O
with	O
adenomatous	O
areas	O
,	O
with	O
respect	O
to	O
the	O
presence	O
of	O
activated	O
ras	O
genes	O
.	O
Ki-ras	O
mutated	O
cases	O
included	O
3	O
of	O
4	O
tumors	B-malignancy-type
which	I-malignancy-type
mainly	I-malignancy-type
involved	I-malignancy-type
the	I-malignancy-type
intraduodenal	I-malignancy-type
bile	I-malignancy-type
duct	I-malignancy-type
,	O
thus	O
suggesting	O
that	O
a	O
proportion	O
of	O
Ki-ras	O
-	O
mutated	O
ampullary	B-malignancy-type
cancers	I-malignancy-type
might	O
correspond	O
to	O
those	O
originating	O
from	O
the	O
epithelium	O
of	O
the	O
bile	O
duct	O
component	O
of	O
the	O
ampulla	O
.	O
PMID	O
:	O
7927901	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1994	O
Apr;86(	O
4)	O
:774	O
-	O
9	O
Point	O
mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
the	O
blood	O
plasma	O
DNA	O
of	O
patients	O
with	O
myelodysplastic	O
syndrome	O
or	O
acute	O
myelogenous	O
leukaemia	O
.	O
Vasioukhin	O
V	O
,	O
Anker	O
P	O
,	O
Maurice	O
P	O
,	O
Lyautey	O
J,	O
Lederrey	O
C	O
,	O
Stroun	O
M.	O
Department	O
of	O
Plant	O
Physiology	O
,	O
Pavillon	O
des	O
Isotopes	O
,	O
Faculty	O
of	O
Science	O
,	O
University	O
of	O
Geneva	O
,	O
Switzerland	O
.	O
Oncogene	O
mutations	O
are	O
frequently	O
found	O
in	O
several	O
tumour	O
types	O
and	O
,	O
among	O
these	O
,	O
point	O
mutations	O
of	O
the	O
ras	O
gene	O
are	O
particularly	O
significant	O
.	O
A	O
predominance	O
of	O
N-ras	O
mutations	O
has	O
been	O
found	O
in	O
the	O
bone	O
marrow	O
DNA	O
of	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
or	O
acute	O
myelogenous	O
leukaemia	O
(	O
AML	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
increased	O
levels	O
of	O
plasma	O
DNA	O
have	O
previously	O
been	O
observed	O
in	O
patients	O
suffering	O
from	O
various	O
malignant	O
diseases	O
.	O
In	O
the	O
present	O
work	O
we	O
have	O
investigated	O
,	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
point	O
mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
the	O
DNA	O
of	O
plasma	O
,	O
blood	O
cells	O
and	O
bone	O
marrow	O
of	O
10	O
patients	O
suffering	O
from	O
AML	O
or	O
MDS	O
.	O
The	O
different	O
ras	O
mutations	O
detected	O
in	O
five	O
cases	O
were	O
always	O
present	O
in	O
the	O
plasma	O
DNA	O
while	O
sometimes	O
absent	O
in	O
the	O
DNA	O
of	O
peripheral	O
blood	O
cells	O
or	O
bone	O
marrow	O
.	O
This	O
indicates	O
that	O
a	O
bone	O
marrow	O
biopsy	O
or	O
aspiration	O
does	O
not	O
necessarily	O
contain	O
all	O
the	O
malignant	O
clones	O
involved	O
in	O
the	O
disease	O
.	O
Plasma	O
could	O
thus	O
prove	O
to	O
be	O
an	O
easily	O
accessible	O
and	O
useful	O
material	O
for	O
detection	O
and	O
monitoring	O
of	O
myeloid	O
disorders	O
.	O
PMID	O
:	O
7918071	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
1995	O
Mar;15(	O
3	O
)	O
:1175	O
-	O
81	O
Loss	O
of	O
E-cadherin	O
-	O
dependent	O
cell	O
-	O
cell	O
adhesion	O
due	O
to	O
mutation	O
of	O
the	O
beta-catenin	O
-	O
gene	O
in	O
a	O
human	O
cancer	O
cell	O
line	O
,	O
HSC-39	O
.	O
Kawanishi	O
J,	O
Kato	O
J,	O
Sasaki	O
K	O
,	O
Fujii	O
S,	O
Watanabe	O
N	O
,	O
Niitsu	O
Y.	O
Fourth	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Sapporo	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
Detachment	O
of	O
cell	O
-	O
cell	O
adhesion	O
is	O
indispensable	O
for	O
the	O
first	O
step	O
of	O
invasion	O
and	O
metastasis	O
of	O
cancer	O
.	O
This	O
mechanism	O
is	O
frequently	O
associated	O
with	O
the	O
impairment	O
of	O
either	O
E-cadherin	O
expression	O
or	O
function	O
.	O
However	O
,	O
mechanisms	O
of	O
such	O
abnormalities	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
function	O
of	O
E-cadherin	O
was	O
completely	O
abolished	O
in	O
the	O
human	O
gastric	B-malignancy-type
cancer	I-malignancy-type
cell	O
line	O
HSC-39	O
,	O
despite	O
the	O
high	O
expression	O
of	O
E-cadherin	O
,	O
because	O
of	O
mutations	O
in	O
one	O
of	O
the	O
E-cadherin	O
-	O
associated	O
cytoplasmic	O
proteins	O
,	O
beta-catenin	O
.	O
Although	O
immunofluorescence	O
staining	O
of	O
HSC-39	O
cells	O
by	O
using	O
an	O
anti	O
-	O
E-cadherin	O
antibody	O
(	O
HECD-1	O
)	O
revealed	O
the	O
strong	O
and	O
uniform	O
expression	O
of	O
E-cadherin	O
on	O
the	O
cell	O
surface	O
,	O
cell	O
compaction	O
and	O
cell	O
aggregation	O
were	O
not	O
observed	O
in	O
this	O
cell	O
.	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
using	O
HECD-1	O
exhibited	O
a	O
120	O
-	O
kDa	O
band	O
which	O
is	O
equivalent	O
to	O
normal	O
E-cadherin	O
.	O
Northern	O
(	O
RNA	O
)	O
blotting	O
demonstrated	O
a	O
4.7	O
-	O
kb	O
band	O
,	O
the	O
same	O
as	O
mature	O
E-cadherin	O
mRNA	O
.	O
Immunoprecipitation	O
of	O
metabolically	O
labeled	O
proteins	O
with	O
HECD-1	O
revealed	O
three	O
bands	O
corresponding	O
to	O
E-cadherin	O
,	O
alpha-catenin	O
,	O
and	O
gamma-catenin	O
and	O
a	O
79	O
-	O
kDa	O
band	O
which	O
was	O
apparently	O
smaller	O
than	O
that	O
of	O
normal	O
beta-catenin	O
,	O
indicating	O
truncated	O
beta-catenin	O
.	O
The	O
79	O
-	O
kDa	O
band	O
was	O
immunologically	O
identified	O
as	O
beta-catenin	O
by	O
using	O
immunoblotting	O
with	O
anti	O
-	O
beta-catenin	O
antibodies	O
.	O
Examination	O
of	O
beta-catenin	O
mRNA	O
by	O
the	O
reverse	O
transcriptase	O
-	O
PCR	O
method	O
revealed	O
a	O
transcript	O
which	O
was	O
shorter	O
than	O
that	O
of	O
normal	O
beta-catenin	O
.	O
The	O
sequencing	O
of	O
PCR	O
product	O
for	O
beta-catenin	O
confirmed	O
deletion	O
in	O
321	O
bases	O
from	O
nucleotides	O
+82	O
to	O
+402	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
7862112	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1994	O
Oct	O
;	O
88	O
(	O
2	O
)	O
:	O
338	O
-	O
42	O
Sequential	O
acquisition	O
of	O
trisomy	O
8	O
and	O
N-ras	O
mutation	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
demonstrated	O
by	O
analysis	O
of	O
isolated	O
leukaemic	O
colonies	O
.	O
Price	O
CM	O
,	O
Marshall	O
CJ	O
,	O
Bashey	O
A	O
.	O
Centre	O
of	O
Cell	O
and	O
Molecular	O
Biology	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
London	O
.	O
Specific	O
chromosomal	O
aberrations	O
and	O
point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
are	O
characteristic	O
genetic	O
alterations	O
in	O
acute	B-malignancy-type
leukaemias	I-malignancy-type
.	O
However	O
,	O
the	O
relationships	O
between	O
these	O
two	O
different	O
genetic	O
changes	O
are	O
unclear	O
.	O
Here	O
we	O
have	O
determined	O
the	O
order	O
of	O
genetic	O
events	O
in	O
a	O
patient	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukaemia	I-malignancy-type
characterized	O
by	O
trisomy	O
8	O
and	O
a	O
point	O
mutation	O
of	O
N-ras	O
at	O
codon	O
12	O
(	O
N12	O
-	O
cys	O
)	O
and	O
codon	O
61	O
(	O
N61	O
-	O
his	O
)	O
.	O
30	O
colonies	O
obtained	O
by	O
in	O
vitro	O
clonogenic	O
assay	O
of	O
leukaemic	O
cells	O
from	O
a	O
patient	O
with	O
AML	B-malignancy-type
were	O
individually	O
analysed	O
for	O
the	O
presence	O
of	O
trisomy	O
8	O
and	O
each	O
of	O
two	O
different	O
N-ras	O
mutations	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
and	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
Trisomy	O
8	O
was	O
detected	O
in	O
25	O
/	O
26	O
evaluable	O
colonies	O
.	O
19	O
/	O
26	O
colonies	O
contained	O
the	O
N12	O
-	O
cys	O
mutation	O
.	O
The	O
N61	O
-	O
his	O
mutation	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
colonies	O
obtained	O
.	O
All	O
the	O
colonies	O
with	O
the	O
N12	O
cys	O
mutation	O
were	O
also	O
trisomic	O
from	O
chromosome	O
8	O
,	O
whereas	O
6	O
/	O
25	O
colonies	O
with	O
trisomy	O
8	O
had	O
no	O
N-ras	O
mutation	O
.	O
These	O
data	O
suggest	O
that	O
trisomy	O
8	O
was	O
acquired	O
before	O
N12	O
cys	O
mutation	O
in	O
the	O
pathogenesis	O
of	O
this	O
leukaemia	B-malignancy-type
and	O
that	O
two	O
genetic	O
events	O
can	O
co-operate	O
within	O
a	O
single	O
subclone	O
.	O
PMID	O
:	O
7803279	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pathol	O
Int	O
1995	O
Jan;45(	O
1	O
)	O
:45	O
-	O
50	O
N-ras	O
mutation	O
of	O
thyroid	B-malignancy-type
tumor	I-malignancy-type
with	I-malignancy-type
special	I-malignancy-type
reference	I-malignancy-type
to	I-malignancy-type
the	I-malignancy-type
follicular	I-malignancy-type
type	I-malignancy-type
.	O
Oyama	O
T	O
,	O
Suzuki	O
T	O
,	O
Hara	O
F	O
,	O
Iino	O
Y	O
,	O
Ishida	O
T	O
,	O
Sakamoto	O
A	O
,	O
Nakajima	O
T.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Gunma	O
University	O
School	O
of	O
Medicine	O
,	O
Maebashi	O
,	O
Japan	O
.	O
Using	O
the	O
method	O
of	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
,	O
the	O
point	O
mutations	O
of	O
the	O
ras	O
oncogenes	O
in	O
a	O
total	O
of	O
33	O
thyroid	O
tissues	O
,	O
including	O
12	O
follicular	B-malignancy-type
adenomas	I-malignancy-type
,	O
6	O
follicular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
11	O
papillary	B-malignancy-type
carcinomas	I-malignancy-type
,	O
and	O
4	O
undifferentiated	B-malignancy-type
carcinomas	I-malignancy-type
,	O
were	O
examined	O
.	O
The	O
frequency	O
of	O
the	O
mutation	O
was	O
3	O
%	O
(	O
1	O
/	O
33	O
)	O
in	O
codon	O
12	O
,	O
13	O
of	O
Ki-ras	O
and	O
18	O
%	O
(	O
6	O
/	O
33	O
)	O
in	O
codon	O
61	O
of	O
N-ras	O
,	O
including	O
17	O
%	O
(	O
2	O
/	O
12	O
)	O
in	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
50	O
%	O
(	O
3	O
/	O
6	O
)	O
in	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
,	O
0	O
%	O
(	O
0	O
/	O
11	O
)	O
in	O
papillary	B-malignancy-type
carcinoma	I-malignancy-type
and	O
25	O
%	O
(	O
1	O
/	O
4	O
)	O
in	O
undifferentiated	B-malignancy-type
carcinoma	I-malignancy-type
.	O
In	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
positivity	O
was	O
observed	O
in	O
microfollicular	O
or	O
trabecular	O
subtypes	O
.	O
Furthermore	O
,	O
the	O
mutation	O
of	O
ras	O
,	O
was	O
examined	O
in	O
histologically	O
different	O
parts	O
,	O
coexisting	O
in	O
the	O
same	O
tumor	O
in	O
a	O
total	O
of	O
four	O
cases	O
.	O
Both	O
the	O
undifferentiated	B-malignancy-type
carcinoma	I-malignancy-type
and	O
coexisting	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
,	O
and	O
both	O
the	O
microfollicular	B-malignancy-type
adenoma	I-malignancy-type
and	O
trabecular	B-malignancy-type
nodule	I-malignancy-type
growing	O
in	O
the	O
tumor	O
,	O
had	O
the	O
same	O
N-ras	O
(	O
61	O
)	O
mutation	O
.	O
Direct	O
sequencing	O
analysis	O
showed	O
that	O
all	O
mutations	O
were	O
CAA	O
(	O
Gln	O
)	O
to	O
CGA	O
(	O
Arg	O
)	O
transition	O
of	O
codon	O
61	O
,	O
except	O
for	O
CAA	O
to	O
AAA	O
transversion	O
in	O
one	O
case	O
of	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
.	O
A	O
similar	O
genetic	O
abnormality	O
of	O
N-ras	O
genes	O
at	O
codon	O
61	O
between	O
follicular	B-malignancy-type
adenoma	I-malignancy-type
and	O
follicular	B-malignancy-type
carcinoma	I-malignancy-type
suggests	O
that	O
the	O
mutation	O
of	O
N-ras	O
at	O
codon	O
61	O
might	O
play	O
a	O
part	O
in	O
oncogenesis	O
in	O
follicular	B-malignancy-type
tumors	I-malignancy-type
.	O
PMID	O
:	O
7704243	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1993	O
Nov	O
1;82(	O
9	O
)	O
:2829	O
-	O
36	O
p53	O
and	O
N-ras	O
mutations	O
in	O
two	O
new	O
leukemia	B-malignancy-type
cell	O
lines	O
established	O
from	O
a	O
patient	O
with	O
multilineage	O
CD7	O
-	O
positive	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
Abo	O
J,	O
Inokuchi	O
K	O
,	O
Dan	O
K	O
,	O
Nomura	O
T.	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nippon	O
Medical	O
School	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Two	O
new	O
myeloid	O
cell	O
lines	O
(	O
K051	O
and	O
K052	O
)	O
were	O
established	O
from	O
a	O
patient	O
with	O
multilineage	O
CD7	O
-	O
positive	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
The	O
K051	O
and	O
K052	O
were	O
established	O
from	O
the	O
patient	O
's	O
bone	O
marrow	O
cells	O
at	O
diagnosis	O
and	O
at	O
relapse	O
,	O
respectively	O
.	O
The	O
K051	O
cell	O
expressed	O
myeloid	O
-	O
associated	O
antigens	O
(	O
CD13	O
and	O
CD33	O
)	O
,	O
a	O
platelet	O
-	O
associated	O
antigen	O
(	O
CD41	O
)	O
,	O
and	O
an	O
erythroid	O
antigen	O
(	O
glycophorin	O
A	O
)	O
.	O
The	O
K052	O
cell	O
expressed	O
myeloid	O
-	O
associated	O
antigens	O
(	O
CD13	O
,	O
CD14	O
,	O
and	O
CD33	O
)	O
,	O
lymphoid	O
markers	O
(	O
CD2	O
,	O
CD5	O
,	O
and	O
CD7	O
)	O
,	O
and	O
HLA-DR	O
.	O
Chromosome	O
analysis	O
of	O
both	O
cell	O
lines	O
showed	O
a	O
17p	O
-	O
chromosome	O
.	O
Both	O
cell	O
lines	O
were	O
investigated	O
for	O
aberrations	O
of	O
the	O
p53	O
gene	O
and	O
the	O
N-ras	O
gene	O
.	O
A	O
p53	O
mutation	O
detected	O
in	O
both	O
cell	O
lines	O
consisted	O
of	O
a	O
C	O
-->	O
T	O
substitution	O
in	O
codon	O
248	O
.	O
An	O
N-ras	O
mutation	O
detected	O
only	O
in	O
the	O
K052	O
cell	O
consisted	O
of	O
a	O
G	O
-->	O
C	O
substitution	O
in	O
codon	O
13	O
.	O
Expression	O
of	O
the	O
multidrug	O
resistance	O
gene	O
(	O
MDR1	O
)	O
was	O
also	O
investigated	O
by	O
the	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O
MDR1	O
-	O
mRNA	O
was	O
more	O
highly	O
expressed	O
by	O
the	O
K052	O
cell	O
than	O
the	O
K051	O
cell	O
,	O
being	O
equivalent	O
to	O
that	O
in	O
HEL	O
cells	O
.	O
The	O
functional	O
MDR1	O
-	O
protein	O
against	O
vincristine	O
was	O
also	O
observed	O
,	O
and	O
its	O
function	O
was	O
inhibited	O
by	O
verapamile	O
and	O
Cyclosporin	O
A	O
.	O
The	O
K052	O
cells	O
were	O
capable	O
of	O
phenotypic	O
or	O
morphologic	O
differentiation	O
after	O
being	O
incubated	O
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
,	O
interleukin-2	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
or	O
1,25-dihydroxy-vitamin	O
D3	O
.	O
In	O
contrast	O
,	O
the	O
K051	O
cells	O
responded	O
phenotypically	O
to	O
retinoic	O
acid	O
.	O
Thus	O
,	O
the	O
K051	O
and	O
K052	O
cell	O
lines	O
will	O
be	O
useful	O
for	O
investigating	O
the	O
cellular	O
and	O
molecular	O
events	O
in	O
leukemogenesis	O
and	O
differentiation	O
,	O
and	O
the	O
mechanism	O
of	O
expression	O
of	O
the	O
MDR1	O
gene	O
.	O
PMID	O
:	O
7693050	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Apr;8(	O
4)	O
:638	O
-	O
41	O
Mutations	O
in	O
the	O
ras	O
proto	O
-	O
oncogenes	O
in	O
patients	O
with	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
.	O
Neubauer	O
A	O
,	O
Greenberg	O
P	O
,	O
Negrin	O
R,	O
Ginzton	O
N	O
,	O
Liu	O
E.	O
Department	O
of	O
Medicine	O
and	O
Genetics	O
,	O
Lineberger	O
Cancer	O
Research	O
Center	O
,	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
.	O
Activation	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
proto	O
-	O
oncogenes	O
is	O
the	O
most	O
common	O
molecular	O
abnormality	O
in	O
myelodysplastic	B-malignancy-type
syndromes	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
and	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
.	O
In	O
retrospective	O
studies	O
,	O
approximately	O
3	O
-	O
36	O
%	O
of	O
MDS	B-malignancy-type
patients	O
were	O
reported	O
to	O
harbor	O
a	O
mutated	O
ras	O
proto	O
-	O
oncogene	O
,	O
with	O
some	O
series	O
suggesting	O
the	O
presence	O
of	O
ras	O
-	O
mutations	O
are	O
associated	O
with	O
progressive	O
disease	O
and	O
a	O
poor	O
prognosis	O
.	O
Since	O
hematopoietic	O
growth	O
factors	O
such	O
as	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
are	O
currently	O
used	O
for	O
therapy	O
in	O
MDS	B-malignancy-type
but	O
may	O
stimulate	O
the	O
proliferation	O
of	O
leukemic	O
cells	O
,	O
we	O
assessed	O
the	O
frequency	O
and	O
significance	O
of	O
ras	O
mutations	O
in	O
27	O
MDS	B-malignancy-type
patients	O
,	O
15	O
of	O
whom	O
underwent	O
G-CSF	O
therapy	O
.	O
Patients	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
N	O
-	O
and	O
K	O
-	O
ras	O
proto	O
-	O
oncogenes	O
.	O
Only	O
three	O
patients	O
(	O
11	O
%	O
,	O
two	O
refractory	B-malignancy-type
anemia	I-malignancy-type
with	O
excess	O
of	O
blasts	O
(	O
RAEB	B-malignancy-type
)	O
,	O
one	O
RAEB	B-malignancy-type
in	O
transformation	O
(	O
RAEB-T	B-malignancy-type
)	O
)	O
harbored	O
activated	O
ras	O
oncogenes	O
with	O
the	O
mutations	O
localized	O
in	O
N-ras	O
codons	O
12	O
and	O
61	O
.	O
Patients	O
were	O
followed	O
for	O
periods	O
of	O
up	O
to	O
4	O
years	O
or	O
until	O
death	O
supervened	O
.	O
Patients	O
exhibiting	O
ras	O
mutations	O
were	O
no	O
more	O
likely	O
to	O
develop	O
AML	B-malignancy-type
compared	O
to	O
ras	O
-	O
negative	O
patients	O
(	O
1	O
/	O
3	O
vs.	O
10	O
/	O
24	O
)	O
or	O
to	O
have	O
decreased	O
survival	O
(	O
p	O
=	O
0.64	O
)	O
.	O
These	O
data	O
indicate	O
that	O
,	O
in	O
this	O
group	O
of	O
MDS	B-malignancy-type
patients	O
,	O
ras	O
mutations	O
do	O
not	O
appear	O
to	O
correlate	O
with	O
a	O
poor	O
prognosis	O
,	O
and	O
do	O
not	O
adversely	O
interact	O
with	O
exogenously	O
administered	O
G-CSF	O
.	O
PMID	O
:	O
7512175	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nature	O
1987	O
Jun	O
4	O
-	O
10;327(6121	O
)	O
:430	O
-	O
2	O
A	O
point	O
mutation	O
at	O
codon	O
13	O
of	O
the	O
N-ras	O
oncogene	O
in	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
.	O
Hirai	O
H	O
,	O
Kobayashi	O
Y	O
,	O
Mano	O
H	O
,	O
Hagiwara	O
K	O
,	O
Maru	O
Y	O
,	O
Omine	O
M,	O
Mizoguchi	O
H	O
,	O
Nishida	O
J,	O
Takaku	O
F.	O
Patients	O
with	O
a	O
myelodysplastic	B-malignancy-type
syndrome	I-malignancy-type
(	O
MDS	B-malignancy-type
)	O
which	O
has	O
a	O
risk	O
of	O
leukaemic	O
change	O
exhibit	O
a	O
variable	O
clinical	O
course	O
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
development	O
of	O
leukaemia	B-malignancy-type
in	O
patients	O
with	O
MDS	B-malignancy-type
may	O
be	O
related	O
to	O
chromosomal	O
abnormalities	O
or	O
genetic	O
alterations	O
:	O
somatic	O
mutation	O
of	O
the	O
N-ras	O
gene	O
is	O
now	O
considered	O
to	O
be	O
a	O
critical	O
step	O
in	O
the	O
genetic	O
basis	O
of	O
human	O
leukaemogenesis	O
.	O
Here	O
we	O
report	O
that	O
DNAs	O
of	O
bone	O
-	O
marrow	O
cells	O
from	O
three	O
out	O
of	O
eight	O
patients	O
with	O
MDS	B-malignancy-type
contained	O
an	O
activated	O
N-ras	O
oncogene	O
,	O
as	O
detected	O
by	O
an	O
in	O
vivo	O
selection	O
assay	O
in	O
nude	O
mice	O
with	O
transfected	O
NIH	O
3T3	O
cells	O
.	O
Molecular	O
analysis	O
revealed	O
the	O
same	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
13	O
in	O
all	O
three	O
transforming	O
N-ras	O
genes	O
.	O
Each	O
of	O
the	O
three	O
patients	O
showed	O
a	O
progression	O
of	O
the	O
disease	O
and	O
a	O
resulting	O
leukaemic	O
change	O
within	O
the	O
following	O
year	O
.	O
Our	O
observation	O
of	O
the	O
mutation	O
at	O
codon	O
13	O
in	O
leukaemic	O
cell	O
DNAs	O
from	O
all	O
three	O
cases	O
suggests	O
that	O
activation	O
of	O
the	O
N-ras	O
gene	O
is	O
important	O
in	O
the	O
development	O
of	O
leukaemia	B-malignancy-type
in	O
some	O
MDS	B-malignancy-type
cases	O
.	O
PMID	O
:	O
3295562	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
Res	O
1988	O
;3(	O
1	O
)	O
:77	O
-	O
86	O
Preferential	O
and	O
novel	O
activation	O
of	O
H-ras	O
in	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
.	O
Visvanathan	O
KV	O
,	O
Pocock	O
RD	O
,	O
Summerhayes	O
IC	O
.	O
Department	O
of	O
Cell	O
and	O
Molecular	O
Biology	O
,	O
Institute	O
of	O
Cancer	O
Research	O
,	O
Chester	O
Beatty	O
Laboratories	O
,	O
London	O
,	O
UK.	O
In	O
a	O
survey	O
of	O
primary	O
human	O
bladder	B-malignancy-type
carcinomas	I-malignancy-type
from	O
24	O
patients	O
,	O
using	O
the	O
NIH	O
/	O
3T3	O
transfection	O
nude	O
mouse	O
tumor	O
assay	O
,	O
we	O
have	O
detected	O
an	O
activated	O
c-H-ras-1	O
gene	O
in	O
four	O
cases	O
.	O
Two	O
of	O
these	O
scored	O
negative	O
in	O
primary	O
transfections	O
using	O
a	O
NIH	O
/	O
3T3	O
focus	O
assay	O
.	O
Oligonucleotide	O
analysis	O
of	O
genomic	O
and	O
enzymatically	O
amplified	O
DNA	O
revealed	O
substitution	O
of	O
valine	O
at	O
codon	O
12	O
in	O
DNA	O
from	O
three	O
transfectants	O
and	O
their	O
parental	B-malignancy-type
carcinomas	I-malignancy-type
,	O
which	O
was	O
absent	O
from	O
the	O
DNA	O
of	O
normal	O
tissue	O
of	O
each	O
of	O
these	O
patients	O
.	O
The	O
fourth	O
activation	O
was	O
identified	O
as	O
a	O
cysteine	O
substitution	O
at	O
codon	O
13	O
,	O
a	O
novel	O
activation	O
of	O
c-H-ras-1	O
in	O
a	O
solid	B-malignancy-type
tumor	I-malignancy-type
sample	O
.	O
Thus	O
,	O
all	O
seven	O
activated	O
ras	O
genes	O
reported	O
in	O
human	O
urothelial	B-malignancy-type
tumors	I-malignancy-type
(	O
Fujita	O
et	O
al.	O
,	O
Proc.	O
Natl.	O
Acad.	O
Sci.	O
USA	O
82	O
,	O
3849	O
-	O
3853	O
,	O
1985	O
)	O
have	O
been	O
c-H-ras-1	O
genes	O
,	O
strongly	O
suggesting	O
that	O
this	O
member	O
of	O
the	O
ras	O
gene	O
family	O
is	O
preferentially	O
activated	O
in	O
cells	O
of	O
transitional	O
origin	O
.	O
PMID	O
:	O
3144694	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Exp	O
Med	O
1989	O
Nov	O
1;170	O
(	O
5	O
)	O
:	O
171	O
5-25	O
Ras	O
oncogene	O
mutation	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
.	O
Neri	O
A	O
,	O
Murphy	O
JP	O
,	O
Cro	O
L,	O
Ferrero	O
D	O
,	O
Tarella	O
C,	O
Baldini	O
L,	O
Dall	O
a	O
-Favera	O
R.	O
Department	O
of	O
Pathology	O
,	O
College	O
of	O
Physicians	O
and	O
Surgeons	O
,	O
Columbia	O
University	O
,	O
New	O
York	O
,	O
New	O
York	O
10032	O
.	O
The	O
frequency	O
of	O
ras	O
(	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
)	O
and	O
c-myc	O
oncogenes	O
was	O
investigated	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
.	O
By	O
means	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
oligonucleotide	O
hybridization	O
method	O
,	O
DNA	O
from	O
56	O
tumor	O
biopsies	O
was	O
analyzed	O
for	O
the	O
presence	O
of	O
activating	O
mutations	O
involving	O
codons	O
12	O
and	O
61	O
of	O
the	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
and	O
codon	O
13	O
of	O
the	O
N-ras	O
gene	O
.	O
Mutations	O
,	O
involving	O
the	O
N	O
-	O
or	O
K	O
-	O
ras	O
genes	O
,	O
were	O
detected	O
in	O
18	O
of	O
56	O
(	O
32	O
%	O
)	O
cases	O
of	O
which	O
12	O
/	O
43	O
(	O
27	O
%	O
)	O
were	O
at	O
diagnosis	O
and	O
6	O
/	O
13	O
(	O
46	O
%	O
)	O
were	O
after	O
treatment	O
.	O
In	O
some	O
cases	O
,	O
multiple	O
mutations	O
affecting	O
different	O
ras	O
alleles	O
were	O
detected	O
.	O
Direct	O
nucleotide	O
sequence	O
analysis	O
of	O
PCR	O
products	O
indicated	O
that	O
a	O
more	O
heterogeneous	O
nature	O
of	O
the	O
base	O
pair	O
changes	O
than	O
previously	O
shown	O
for	O
other	O
tumors	O
along	O
with	O
a	O
preferential	O
involvement	O
of	O
N-ras	O
codon	O
61	O
.	O
The	O
heterogeneity	O
of	O
MM	B-malignancy-type
cases	O
with	O
respect	O
to	O
the	O
presence	O
of	O
ras	O
oncogenes	O
prompted	O
an	O
analysis	O
of	O
possible	O
correlations	O
with	O
different	O
clinico	O
-	O
pathologic	O
characteristics	O
of	O
MM	B-malignancy-type
from	O
which	O
a	O
correlation	O
between	O
the	O
presence	O
of	O
ras	O
oncogenes	O
and	O
a	O
partial	O
or	O
complete	O
lack	O
of	O
response	O
to	O
therapy	O
emerged	O
.	O
The	O
frequency	O
of	O
activating	O
rearrangements	O
or	O
mutations	O
of	O
the	O
c-myc	O
gene	O
were	O
studied	O
by	O
Southern	O
blot	O
analysis	O
and	O
PCR	O
sequencing	O
,	O
respectively	O
.	O
However	O
,	O
contrary	O
to	O
previous	O
reports	O
involving	O
mostly	O
MM	B-malignancy-type
cell	O
lines	O
,	O
no	O
structural	O
alterations	O
of	O
the	O
c-myc	O
gene	O
were	O
found	O
.	O
These	O
results	O
indicate	O
that	O
ras	O
,	O
but	O
not	O
c-myc	O
,	O
oncogenes	O
are	O
activated	O
in	O
vivo	O
in	O
MM	B-malignancy-type
cells	O
,	O
representing	O
the	O
first	O
oncogene	O
alteration	O
that	O
has	O
been	O
associated	O
at	O
appreciable	O
frequency	O
with	O
this	O
type	O
of	O
malignancy	O
.	O
While	O
the	O
mechanism	O
of	O
occurrence	O
and	O
biological	O
role	O
of	O
ras	O
activation	O
in	O
MM	B-malignancy-type
remains	O
to	O
be	O
elucidated	O
,	O
the	O
preliminary	O
correlations	O
observed	O
in	O
this	O
study	O
between	O
the	O
presence	O
of	O
ras	O
oncogenes	O
and	O
poor	O
therapeutic	O
response	O
suggest	O
that	O
further	O
investigations	O
of	O
the	O
possible	O
prognostic	O
significance	O
of	O
these	O
alterations	O
are	O
necessary	O
.	O
PMID	O
:	O
2681517	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1989	O
Oct	O
15	O
;49(	O
20	O
)	O
:5530	O
-	O
3	O
Activated	O
N-ras	O
oncogenes	O
in	O
human	O
neuroblastoma	B-malignancy-type
.	O
Ireland	O
CM	O
.	O
Children	O
's	O
Leukemia	O
and	O
Cancer	O
Research	O
Unit	O
,	O
Prince	O
of	O
Wales	O
Children	O
's	O
Hospital	O
,	O
New	O
South	O
Wales	O
,	O
Australia	O
.	O
Fifteen	O
primary	O
neuroblastomas	B-malignancy-type
and	O
four	O
bone	O
marrow	O
samples	O
from	O
neuroblastoma	B-malignancy-type
patients	O
,	O
representing	O
clinical	O
Stages	O
I	O
to	O
IV	O
,	O
have	O
been	O
screened	O
for	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
N-ras	O
.	O
Neuroblastoma	B-malignancy-type
DNAs	O
were	O
subjected	O
to	O
the	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
the	O
relevant	O
sequences	O
and	O
were	O
then	O
hybridized	O
with	O
specific	O
oligonucleotides	O
to	O
locate	O
and	O
identify	O
point	O
mutations	O
.	O
The	O
results	O
show	O
that	O
one	O
Stage	O
I	O
tumor	O
contained	O
an	O
N-ras	O
gene	O
that	O
was	O
activated	O
by	O
a	O
GC	O
-	O
CG	O
transversion	O
of	O
the	O
first	O
base	O
of	O
codon	O
61	O
,	O
while	O
in	O
one	O
Stage	O
II	O
tumor	O
,	O
activation	O
of	O
N-ras	O
involved	O
a	O
GC	O
-	O
CG	O
transversion	O
of	O
the	O
first	O
position	O
of	O
codon	O
13	O
.	O
N-ras	O
activations	O
were	O
not	O
detected	O
in	O
the	O
six	O
Stage	O
III	O
tumors	O
and	O
eight	O
Stage	O
IV	O
tumors	O
that	O
were	O
examined	O
.	O
PMID	O
:	O
2676145	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Cell	O
Biol	O
1989	O
Jul;9(	O
7)	O
:3114	O
-	O
6	O
N-ras	O
mutations	O
in	O
human	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
from	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
van	O
't	O
Veer	O
LJ	O
,	O
Burgering	O
BM	O
,	O
Versteeg	O
R,	O
Boot	O
AJ	O
,	O
Ruiter	O
DJ	O
,	O
Osanto	O
S,	O
Schrier	O
PI	O
,	O
Bos	O
JL.	O
Department	O
of	O
Clinical	O
Oncology	O
,	O
Leiden	O
University	O
Hospital	O
,	O
The	O
Netherlands	O
.	O
In	O
7	O
of	O
37	O
patients	O
with	O
cutaneous	B-malignancy-type
melanoma	I-malignancy-type
,	O
mutations	O
in	O
the	O
N-ras	O
gene	O
were	O
found	O
.	O
The	O
primary	O
tumors	O
of	O
these	O
seven	O
patients	O
were	O
exclusively	O
localized	O
on	O
body	O
sites	O
continuously	O
exposed	O
to	O
sunlight	O
.	O
Moreover	O
,	O
the	O
ras	O
mutations	O
were	O
all	O
at	O
or	O
near	O
dipyrimidine	O
sites	O
known	O
to	O
be	O
targets	O
of	O
UV	O
damage	O
.	O
Two	O
primary	O
tumors	O
were	O
biclonal	O
with	O
respect	O
to	O
ras	O
mutation	O
.	O
An	O
active	O
role	O
for	O
UV	O
irradiation	O
in	O
induction	O
of	O
the	O
mutations	O
is	O
suggested	O
.	O
PMID	O
:	O
2674680	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1989	O
Apr;3(	O
4)	O
:247	O
-	O
56	O
Acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
:	O
analysis	O
of	O
ras	O
gene	O
mutations	O
and	O
clonality	O
defined	O
by	O
polymorphic	O
X	O
-	O
linked	O
loci	O
.	O
Bartram	O
CR	O
,	O
Ludwig	O
WD	O
,	O
Hiddemann	O
W	O
,	O
Lyons	O
J,	O
Buschle	O
M,	O
Ritter	O
J,	O
Harbott	O
J,	O
Frohlich	O
A	O
,	O
Janssen	O
JW.	O
Department	O
of	O
Pediatrics	O
II	O
,	O
University	O
of	O
Ulm	O
,	O
F.R.G.	O
In	O
vitro	O
DNA	O
amplification	O
and	O
synthetic	O
oligonucleotide	O
hybridization	O
was	O
used	O
to	O
analyze	O
57	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemias	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
for	O
the	O
presence	O
of	O
ras	O
gene	O
mutations	O
.	O
We	O
demonstrated	O
mutated	O
alleles	O
in	O
19	O
%	O
of	O
primary	B-malignancy-type
AMLs	I-malignancy-type
(	O
10	O
/	O
51	O
)	O
as	O
well	O
as	O
in	O
five	O
of	O
six	O
secondary	B-malignancy-type
leukemias	I-malignancy-type
.	O
Mutations	O
occurred	O
predominantly	O
at	O
N-ras	O
codons	O
12	O
,	O
13	O
,	O
or	O
61	O
(	O
13	O
cases	O
)	O
and	O
twice	O
at	O
Ki-ras	O
codons	O
12	O
and	O
13	O
.	O
Ras	O
gene	O
mutations	O
were	O
preferentially	O
associated	O
with	O
an	O
M4	O
morphology	O
according	O
to	O
the	O
FAB	O
(	O
French	O
-	O
American	O
-	O
British	O
)	O
classification	O
,	O
but	O
no	O
particular	O
correlation	O
was	O
observed	O
with	O
respect	O
to	O
clinical	O
parameter	O
(	O
sex	O
,	O
age	O
,	O
course	O
of	O
disease	O
)	O
or	O
immunophenotype	O
and	O
karyotype	O
.	O
Mutated	O
ras	O
alleles	O
were	O
absent	O
in	O
nine	O
mutation	O
-	O
positive	O
cases	O
analyzed	O
during	O
remission	O
.	O
However	O
,	O
a	O
more	O
complex	O
pattern	O
emerged	O
from	O
the	O
five	O
patients	O
analyzed	O
in	O
relapse	O
exhibiting	O
identical	O
ras	O
mutations	O
in	O
three	O
cases	O
,	O
absence	O
of	O
a	O
mutated	O
allele	O
in	O
one	O
patient	O
,	O
and	O
acquisition	O
of	O
a	O
N-ras	O
mutation	O
in	O
yet	O
another	O
case	O
,	O
in	O
which	O
no	O
mutation	O
had	O
been	O
detected	O
initially	O
.	O
Moreover	O
,	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLP	O
)	O
of	O
the	O
X	O
-	O
chromosome	O
genes	O
hypoxanthine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
)	O
and	O
phosphoglycerate	O
kinase	O
(	O
PGK	O
)	O
were	O
studied	O
in	O
19	O
of	O
the	O
AML	B-malignancy-type
patients	O
.	O
Nine	O
cases	O
(	O
47	O
%	O
)	O
were	O
heterozygous	O
for	O
BglI	O
or	O
BamHI	O
RFLPs	O
at	O
the	O
PGK	O
or	O
HPRT	O
loci	O
,	O
respectively	O
,	O
and	O
therefore	O
suitable	O
for	O
clonal	O
analysis	O
investigating	O
X	O
-	O
chromosome	O
inactivation	O
.	O
All	O
of	O
the	O
patients	O
exhibited	O
a	O
monoclonal	O
leukemic	O
cell	O
population	O
at	O
presentation	O
.	O
In	O
addition	O
,	O
five	O
of	O
seven	O
cases	O
studied	O
in	O
remission	O
showed	O
reemergence	O
of	O
a	O
polyclonal	O
pattern	O
.	O
However	O
,	O
two	O
children	O
exhibited	O
persistence	O
of	O
monoclonal	O
hematopoiesis	O
despite	O
complete	O
clinical	O
/	O
hematological	O
remission	O
and	O
a	O
corresponding	O
loss	O
of	O
a	O
mutated	O
ras	O
allele	O
in	O
one	O
of	O
the	O
patients	O
.	O
These	O
data	O
indicate	O
the	O
value	O
of	O
molecular	O
genetic	O
approaches	O
for	O
evaluation	O
of	O
the	O
heterogeneous	O
nature	O
of	O
remission	O
and	O
relapse	O
in	O
AML	B-malignancy-type
.	O
PMID	O
:	O
2564452	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Feb;4(	O
2	O
)	O
:189	O
-	O
93	O
Activated	O
N-ras	O
gene	O
was	O
found	O
in	O
human	O
hepatoma	B-malignancy-type
tissue	O
but	O
only	O
in	O
a	O
small	O
fraction	O
of	O
the	O
tumor	O
cells	O
.	O
Takada	O
S,	O
Koike	O
K.	O
Department	O
of	O
Gene	O
Research	O
,	O
Cancer	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Activated	O
N-ras	O
gene	O
was	O
isolated	O
from	O
human	O
hepatoma	B-malignancy-type
tissue	O
by	O
DNA	O
transfection	O
assay	O
coupled	O
with	O
the	O
neomycin	O
selection	O
method	O
and	O
molecular	O
cloning	O
and	O
a	O
point	O
mutation	O
in	O
the	O
codon	O
61	O
(	O
CAA	O
----	O
AAA	O
)	O
was	O
noted	O
.	O
However	O
,	O
examination	O
of	O
the	O
proportion	O
of	O
the	O
mutated	O
N-ras	O
gene	O
in	O
the	O
tumor	O
part	O
by	O
molecular	O
cloning	O
and	O
by	O
hybridization	O
using	O
synthetic	O
oligonucleotide	O
probes	O
indicated	O
that	O
the	O
mutated	O
gene	O
occurred	O
with	O
very	O
low	O
frequency	O
.	O
The	O
activated	O
N-ras	O
gene	O
appears	O
located	O
only	O
in	O
a	O
small	O
fraction	O
of	O
the	O
tumor	O
cells	O
.	O
The	O
experimental	O
data	O
indicate	O
activation	O
of	O
this	O
gene	O
as	O
possibly	O
not	O
the	O
major	O
cause	O
of	O
carcinoma	B-malignancy-type
,	O
but	O
rather	O
a	O
manifestation	O
of	O
tumor	O
heterogeneity	O
.	O
PMID	O
:	O
2538792	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1990	O
Jul;	O
5	O
(	O
7	O
)	O
:	O
103	O
7-43	O
Detection	O
of	O
ras	O
gene	O
mutations	O
in	O
human	O
lung	B-malignancy-type
cancers	I-malignancy-type
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
products	O
.	O
Suzuki	O
Y	O
,	O
Orita	O
M,	O
Shiraishi	O
M,	O
Hayashi	O
K,	O
Sekiya	O
T.	O
Oncogene	O
Division	O
,	O
National	O
Cancer	O
Center	O
Research	O
Institute	O
,	O
Tokyo	O
,	O
Japan	O
.	O
A	O
simple	O
,	O
sensitive	O
method	O
of	O
DNA	O
analysis	O
of	O
nucleotide	O
substitutions	O
,	O
namely	O
,	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
products	O
(	O
PCR	O
-	O
SSCP	O
analysis	O
)	O
,	O
was	O
used	O
for	O
detection	O
of	O
mutated	O
ras	O
genes	O
in	O
surgical	O
specimens	O
of	O
human	O
lung	B-malignancy-type
cancer	I-malignancy-type
.	O
Of	O
a	O
total	O
of	O
129	O
tumors	O
analysed	O
,	O
22	O
contained	O
a	O
mutated	O
ras	O
gene	O
.	O
Of	O
the	O
66	O
adenocarcinomas	B-malignancy-type
analysed	O
,	O
14	O
contained	O
an	O
activated	O
c-Ki-ras2	O
gene	O
(	O
the	O
mutations	O
in	O
codon	O
12	O
in	O
6	O
,	O
in	O
codon	O
13	O
in	O
4	O
,	O
in	O
codon	O
18	O
in	O
one	O
,	O
and	O
in	O
codon	O
61	O
in	O
3	O
)	O
,	O
one	O
contained	O
a	O
c-Ha-ras1	O
gene	O
with	O
a	O
mutation	O
in	O
codon	O
61	O
and	O
3	O
contained	O
N-ras	O
genes	O
with	O
mutations	O
(	O
in	O
codon	O
12	O
in	O
one	O
and	O
in	O
codon	O
61	O
in	O
2	O
)	O
.	O
Mutated	O
rats	O
genes	O
were	O
also	O
found	O
in	O
2	O
of	O
36	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
c-Ha-ras1	O
genes	O
with	O
mutations	O
in	O
codon	O
61	O
)	O
and	O
2	O
of	O
14	O
large	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
c-Ki-ras2	O
genes	O
with	O
mutations	O
in	O
codon	O
12	O
)	O
.	O
No	O
mutation	O
of	O
the	O
ras	O
gene	O
was	O
detected	O
in	O
8	O
small	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
and	O
5	O
adenosquamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
.	O
These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
ras	O
gene	O
was	O
not	O
frequent	O
(	O
17	O
%	O
)	O
in	O
human	O
lung	B-malignancy-type
cancers	I-malignancy-type
,	O
that	O
among	O
these	O
lung	B-malignancy-type
cancers	I-malignancy-type
mutation	O
of	O
the	O
ras	O
gene	O
was	O
most	O
frequent	O
in	O
adenocarcinomas	B-malignancy-type
(	O
27	O
%	O
)	O
and	O
73	O
%	O
of	O
the	O
point	O
mutations	O
were	O
in	O
the	O
c-Ki-ras2	O
gene	O
in	O
codon	O
12	O
,	O
13	O
,	O
18	O
or	O
61	O
.	O
PMID	O
:	O
2197591	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1990	O
Feb	O
15	O
;50	O
(	O
4	O
)	O
:	O
112	O
1-4	O
Analysis	O
of	O
ras	O
gene	O
mutations	O
in	O
human	O
hepatic	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Tada	O
M,	O
Omata	O
M,	O
Ohto	O
M.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
The	O
ras	O
gene	O
is	O
one	O
of	O
the	O
oncogenes	O
most	O
commonly	O
detected	O
in	O
human	O
cancers	O
,	O
and	O
it	O
consists	O
of	O
three	O
families	O
(	O
H-ras	O
,	O
K-ras	O
,	O
N-ras	O
)	O
.	O
These	O
genes	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	O
mutations	O
occurring	O
in	O
either	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
.	O
We	O
analyzed	O
mutations	O
of	O
these	O
codons	O
in	O
23	O
primary	O
hepatic	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
(	O
12	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
,	O
nine	O
cholangiocarcinomas	B-malignancy-type
,	O
and	O
two	O
hepatoblastomas	O
)	O
by	O
a	O
method	O
to	O
directly	O
sequence	O
nucleotides	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
a	O
direct	O
sequencing	O
method	O
.	O
Of	O
23	O
hepatic	B-malignancy-type
malignant	I-malignancy-type
tumors	I-malignancy-type
,	O
point	O
mutations	O
at	O
K-ras	O
codon	O
12	O
or	O
K-ras	O
codon	O
61	O
were	O
found	O
in	O
six	O
of	O
nine	O
cholangiocarcinomas	B-malignancy-type
.	O
In	O
contrast	O
,	O
there	O
were	O
no	O
point	O
mutations	O
in	O
any	O
of	O
12	O
hepatocellular	B-malignancy-type
carcinomas	I-malignancy-type
or	O
two	O
hepatoblastomas	B-malignancy-type
around	O
codon	O
12	O
,	O
13	O
,	O
or	O
61	O
of	O
the	O
ras	O
genes	O
.	O
These	O
observations	O
suggest	O
that	O
ras	O
gene	O
mutations	O
are	O
not	O
related	O
to	O
pathogenesis	O
of	O
hepatocellular	B-malignancy-type
carcinoma	I-malignancy-type
,	O
but	O
play	O
an	O
important	O
role	O
in	O
pathogenesis	O
of	O
cholangiocarcinoma	B-malignancy-type
.	O
PMID	O
:	O
2153451	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1990	O
Jan;8	O
1	O
(	O
1	O
)	O
:	O
2	O
2-7	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
in	O
human	O
bladder	B-malignancy-type
cancer	I-malignancy-type
and	O
kidney	B-malignancy-type
cancer	I-malignancy-type
.	O
Nagata	O
Y	O
,	O
Abe	O
M,	O
Kobayashi	O
K,	O
Saiki	O
S	O
,	O
Kotake	O
T	O
,	O
Yoshikawa	O
K,	O
Ueda	O
R	O
,	O
Nakayama	O
E	O
,	O
Shiku	O
H.	O
Department	O
of	O
Oncology	O
,	O
Nagasaki	O
University	O
School	O
of	O
Medicine	O
.	O
Point	O
mutations	O
of	O
c-ras	O
genes	O
at	O
codons	O
12	O
,	O
13	O
and	O
61	O
were	O
analyzed	O
in	O
26	O
cases	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
and	O
16	O
cases	O
of	O
kidney	B-malignancy-type
cancer	I-malignancy-type
.	O
DNA	O
prepared	O
from	O
either	O
frozen	O
tissues	O
or	O
10	O
%	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
were	O
amplified	O
by	O
means	O
of	O
polymerase	O
chain	O
reaction	O
methods	O
,	O
and	O
mutations	O
were	O
analyzed	O
by	O
dot	O
blot	O
hybridization	O
assays	O
with	O
oligonucleotide	O
probes	O
.	O
In	O
three	O
cases	O
of	O
bladder	B-malignancy-type
cancer	I-malignancy-type
c-ras	O
mutations	O
were	O
found	O
,	O
at	O
codons	O
13	O
and	O
61	O
of	O
c-Ha-ras	O
and	O
at	O
codon	O
61	O
of	O
c-Ki-ras	O
,	O
while	O
no	O
mutation	O
was	O
found	O
in	O
kidney	B-malignancy-type
cancer	I-malignancy-type
.	O
No	O
mutation	O
was	O
found	O
in	O
normal	O
bladder	O
epithelial	O
tissues	O
from	O
the	O
same	O
patients	O
.	O
Our	O
findings	O
,	O
taken	O
together	O
,	O
may	O
indicate	O
relative	O
scarcity	O
of	O
c-ras	O
mutations	O
in	O
these	O
types	O
of	O
human	O
cancer	O
.	O
The	O
results	O
of	O
dot	O
blot	O
hybridization	O
assays	O
and	O
DNA	O
sequencing	O
showed	O
a	O
G	O
-	O
to	O
-	O
C	O
transition	O
of	O
the	O
first	O
nucleotide	O
at	O
codon	O
13	O
c-Ha-ras	O
.	O
This	O
is	O
the	O
first	O
time	O
that	O
such	O
a	O
point	O
mutation	O
has	O
been	O
detected	O
in	O
human	O
cancer	O
tissues	O
.	O
PMID	O
:	O
2108944	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Carcinog	O
1991	O
;4(	O
3	O
)	O
:196	O
-	O
202	O
Ras	O
gene	O
mutation	O
and	O
amplification	O
in	O
human	O
nonmelanoma	B-malignancy-type
skin	I-malignancy-type
cancers	I-malignancy-type
.	O
Pierceall	O
WE	O
,	O
Goldberg	O
LH	O
,	O
Tainsky	O
MA	O
,	O
Mukhopadhyay	O
T	O
,	O
Ananthaswamy	O
HN.	O
Department	O
of	O
Immunology	O
,	O
University	O
of	O
Texas	O
M.	O
D.	O
Anderson	O
Cancer	O
Center	O
,	O
Houston	O
77030	O
.	O
Our	O
previous	O
studies	O
have	O
shown	O
that	O
human	O
skin	B-malignancy-type
cancers	I-malignancy-type
occurring	O
on	O
sun	O
-	O
exposed	O
body	O
sites	O
frequently	O
contain	O
activated	O
Ha-ras	O
oncogenes	O
capable	O
of	O
inducing	O
morphologic	O
and	O
tumorigenic	O
transformation	O
of	O
NIH	O
3T3	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
human	O
primary	O
squamous	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
SCCs	B-malignancy-type
)	O
and	O
basal	B-malignancy-type
cell	I-malignancy-type
carcinomas	I-malignancy-type
(	O
BCCs	B-malignancy-type
)	O
occurring	O
on	O
sun	O
-	O
exposed	O
body	O
sites	O
for	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
oncogenes	O
by	O
amplification	O
of	O
genomic	O
tumor	O
DNAs	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
followed	O
by	O
dot	O
-	O
blot	O
hybridization	O
to	O
synthetic	O
oligonucleotide	O
probes	O
designed	O
to	O
detect	O
single	O
base	O
-	O
pair	O
mutations	O
.	O
In	O
addition	O
to	O
the	O
primary	O
human	O
skin	B-malignancy-type
cancers	I-malignancy-type
,	O
we	O
also	O
analyzed	O
Ha-ras	O
-	O
positive	O
NIH	O
3T3	O
transformants	O
for	O
mutations	O
in	O
the	O
Ha-ras	O
oncogene	O
.	O
The	O
results	O
indicated	O
that	O
all	O
three	O
NIH	O
3T3	O
transformants	O
,	O
11	O
of	O
24	O
(	O
46	O
%	O
)	O
SCCs	B-malignancy-type
,	O
and	O
5	O
of	O
16	O
(	O
31	O
%	O
)	O
BCCs	O
contained	O
mutations	O
at	O
the	O
second	O
position	O
of	O
Ha-ras	O
codon	O
12	O
(	O
GGC	O
----	O
GTC	O
)	O
,	O
predicting	O
a	O
glycine	O
-	O
to	O
-	O
valine	O
amino	O
acid	O
substitution	O
,	O
whereas	O
only	O
1	O
of	O
40	O
skin	B-malignancy-type
cancers	I-malignancy-type
(	O
an	O
SCC	B-malignancy-type
)	O
displayed	O
a	O
mutation	O
in	O
the	O
first	O
position	O
of	O
Ki-ras	O
codon	O
12	O
(	O
GGT	O
----	O
AGT	O
)	O
,	O
predicting	O
a	O
glycine	O
-	O
to	O
-	O
serine	O
amino	O
acid	O
change	O
.	O
In	O
addition	O
,	O
three	O
of	O
the	O
SCCs	B-malignancy-type
contained	O
highly	O
amplified	O
copies	O
of	O
the	O
N-ras	O
oncogene	O
in	O
their	O
genomic	O
DNA	O
.	O
Interestingly	O
,	O
two	O
of	O
the	O
SCCs	B-malignancy-type
containing	O
amplified	O
N-ras	O
sequences	O
also	O
had	O
G	O
----	O
T	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
Ha-ras	O
oncogene	O
.	O
These	O
studies	O
demonstrate	O
that	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
Ha-ras	O
oncogene	O
occurred	O
at	O
a	O
high	O
frequency	O
in	O
human	O
skin	B-malignancy-type
cancers	I-malignancy-type
originating	O
on	O
sun	O
-	O
exposed	O
body	O
sites	O
,	O
whereas	O
mutation	O
in	O
codon	O
12	O
of	O
Ki-ras	O
or	O
amplification	O
of	O
N-ras	O
occurred	O
at	O
a	O
low	O
frequency	O
.	O
Since	O
the	O
mutations	O
in	O
the	O
Ha-ras	O
and	O
Ki-ras	O
oncogenes	O
were	O
located	O
opposite	O
potential	O
pyrimidine	O
dimer	O
sites	O
(	O
C	O
-	O
C	O
)	O
,	O
it	O
is	O
likely	O
that	O
these	O
mutations	O
were	O
induced	O
by	O
ultraviolet	O
radiation	O
present	O
in	O
sunlight	O
.	O
PMID	O
:	O
2064725	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mol	O
Carcinog	O
1991	O
;4(	O
3	O
)	O
:189	O
-	O
95	O
Analysis	O
of	O
oncogene	O
alterations	O
in	O
human	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
:	O
prevalence	O
of	O
ras	O
mutations	O
.	O
Boyd	O
J,	O
Risinger	O
JI.	O
Gene	O
Expression	O
Section	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
,	O
Research	O
Triangle	O
Park	O
,	O
North	O
Carolina	O
27709	O
.	O
The	O
molecular	O
genetics	O
of	O
human	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
have	O
yet	O
to	O
be	O
defined	O
to	O
any	O
significant	O
extent	O
.	O
Cell	O
lines	O
from	O
11	O
endometrial	B-malignancy-type
carcinomas	I-malignancy-type
were	O
examined	O
for	O
alterations	O
in	O
proto	O
-	O
oncogenes	O
that	O
might	O
predictably	O
be	O
present	O
,	O
based	O
on	O
existing	O
data	O
from	O
the	O
better	O
-	O
characterized	O
human	O
carcinomas	B-malignancy-type
of	O
the	O
uterine	O
cervix	O
,	O
ovary	O
,	O
and	O
breast	O
.	O
Codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
Ha-ras	O
,	O
Ki-ras	O
,	O
and	O
N-ras	O
genes	O
were	O
examined	O
for	O
possible	O
point	O
mutations	O
,	O
and	O
the	O
c-erbB2	O
/	O
neu	O
,	O
c-myc	O
,	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
genes	O
were	O
examined	O
for	O
amplification	O
or	O
overexpression	O
.	O
Ras	O
mutations	O
were	O
found	O
in	O
seven	O
of	O
11	O
(	O
64	O
%	O
)	O
tumors	O
,	O
including	O
three	O
in	O
codon	O
61	O
of	O
Ha-ras	O
(	O
CAG	O
----	O
CAT	O
)	O
and	O
four	O
in	O
codon	O
12	O
of	O
Ki-ras	O
(	O
GGT	O
----	O
GAT	O
in	O
two	O
and	O
GGT	O
----	O
GTT	O
in	O
two	O
)	O
.	O
No	O
evidence	O
was	O
found	O
for	O
amplification	O
or	O
overexpression	O
of	O
the	O
c-erbB2	O
or	O
EGFR	O
genes	O
in	O
any	O
tumor	O
.	O
One	O
tumor	O
contained	O
amplified	O
c-myc	O
sequences	O
and	O
exhibited	O
relative	O
overexpression	O
of	O
c-myc	O
.	O
These	O
data	O
suggest	O
that	O
the	O
amplification	O
or	O
overexpression	O
of	O
several	O
proto	O
-	O
oncogenes	O
frequently	O
observed	O
in	O
other	O
human	O
gynecologic	B-malignancy-type
and	O
breast	B-malignancy-type
tumors	I-malignancy-type
are	O
not	O
prevalent	O
in	O
endometrial	B-malignancy-type
carcinoma	I-malignancy-type
and	O
that	O
ras	O
gene	O
mutations	O
are	O
relatively	O
common	O
in	O
this	O
tumor	O
type	O
.	O
PMID	O
:	O
2064724	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Pediatr	O
Oncol	O
1991	O
;19(	O
4)	O
:240	O
-	O
5	O
Analysis	O
of	O
N-ras	O
gene	O
mutations	O
in	O
medulloblastomas	B-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
probes	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
.	O
Iolascon	O
A	O
,	O
Lania	O
A	O
,	O
Badiali	O
M,	O
Pession	O
A	O
,	O
Saglio	O
G	O
,	O
Giangaspero	O
F	O
,	O
Miraglia	O
del	O
Giudice	O
E	O
,	O
Perrotta	O
S,	O
Cutillo	O
S.	O
Department	O
of	O
Pediatrics	O
,	O
University	O
of	O
Naples	O
,	O
Italy	O
.	O
Precise	O
data	O
on	O
the	O
incidence	O
of	O
transforming	O
ras	O
oncogenes	O
in	O
pediatric	O
tumors	O
and	O
the	O
correlations	O
with	O
the	O
histopathological	O
properties	O
of	O
the	O
tumors	O
are	O
very	O
limited	O
.	O
Additionally	O
the	O
presence	O
of	O
ras	O
activation	O
in	O
medulloblastomas	B-malignancy-type
has	O
not	O
been	O
investigated	O
so	O
far	O
.	O
Using	O
a	O
combination	O
of	O
techniques	O
including	O
in	O
vitro	O
gene	O
amplification	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
detection	O
of	O
single	O
base	O
mutations	O
by	O
sequence	O
-	O
specific	O
oligonucleotides	O
we	O
studied	O
N-ras	O
activation	O
(	O
mutations	O
at	O
codon	O
12	O
,	O
13	O
,	O
and	O
61	O
)	O
in	O
32	O
medulloblastomas	B-malignancy-type
.	O
DNA	O
was	O
isolated	O
from	O
20	O
microns	O
sections	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
Mutations	O
were	O
found	O
in	O
3	O
out	O
of	O
32	O
examined	O
medulloblastomas	B-malignancy-type
.	O
In	O
all	O
cases	O
only	O
mutations	O
of	O
codon	O
61	O
were	O
found	O
:	O
two	O
of	O
three	O
mutations	O
were	O
C	O
to	O
A	O
mutations	O
at	O
position	O
1	O
of	O
the	O
codon	O
61	O
(	O
leading	O
to	O
a	O
substitution	O
of	O
a	O
glutamine	O
residue	O
for	O
a	O
lysine	O
)	O
and	O
one	O
was	O
A	O
to	O
T	O
mutation	O
at	O
position	O
3	O
in	O
the	O
same	O
codon	O
(	O
glutamine	O
-	O
histidine	O
)	O
.	O
Our	O
results	O
indicate	O
10	O
%	O
incidence	O
N-ras	O
mutation	O
in	O
medulloblastoma	B-malignancy-type
,	O
higher	O
than	O
in	O
other	O
CNS	B-malignancy-type
tumors	I-malignancy-type
studied	O
so	O
far	O
.	O
The	O
main	O
advantages	O
of	O
the	O
procedure	O
described	O
are	O
its	O
greatly	O
improved	O
sensitivity	O
,	O
the	O
increased	O
speed	O
with	O
which	O
tumor	O
samples	O
can	O
be	O
analyzed	O
,	O
and	O
the	O
possibility	O
of	O
using	O
paraffin	O
-	O
embedded	O
sections	O
to	O
analyze	O
various	O
rare	O
tumors	O
in	O
retrospect	O
.	O
PMID	O
:	O
2056968	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Kobe	O
J	O
Med	O
Sci	O
1991	O
Feb;37(	O
1	O
)	O
:35	O
-	O
45	O
RAS	O
gene	O
mutations	O
in	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
and	O
related	O
monoclonal	B-malignancy-type
gammopathies	I-malignancy-type
.	O
Matozaki	O
S,	O
Nakagawa	O
T	O
,	O
Nakao	O
Y	O
,	O
Fujita	O
T.	O
Department	O
of	O
Hematology	O
/	O
Oncology	O
,	O
Hyogo	O
Medical	O
Center	O
for	O
Adult	O
,	O
Akashi	O
.	O
The	O
presence	O
of	O
RAS	O
gene	O
mutations	O
in	O
precancerous	B-malignancy-type
lesions	I-malignancy-type
suggests	O
that	O
they	O
participate	O
in	O
the	O
early	O
stages	O
of	O
neoplastic	O
development	O
.	O
Furthermore	O
,	O
neoplastic	O
progression	O
from	O
monoclonal	B-malignancy-type
gammopathy	I-malignancy-type
of	O
undetermined	O
significance	O
(	O
MGUS	O
)	O
to	O
overt	O
multiple	B-malignancy-type
myeloma	I-malignancy-type
(	O
MM	B-malignancy-type
)	O
have	O
been	O
frequently	O
observed	O
.	O
These	O
observations	O
prompted	O
us	O
to	O
study	O
the	O
pathogenetic	O
role	O
of	O
RAS	O
genes	O
in	O
MM	O
and	O
related	O
monoclonal	B-malignancy-type
gammopathies	I-malignancy-type
.	O
DNA	O
from	O
18	O
patients	O
with	O
monoclonal	B-malignancy-type
gamma-globulinemia	I-malignancy-type
including	O
12	O
MM	B-malignancy-type
were	O
investigated	O
for	O
the	O
presence	O
of	O
N	O
-	O
and	O
K	O
-	O
RAS	O
gene	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
oligonucleotide	O
hybridization	O
.	O
Mutations	O
involving	O
codons	O
12	O
,	O
13	O
or	O
61	O
of	O
N-RAS	O
gene	O
were	O
identified	O
in	O
3	O
of	O
the	O
12	O
MM	B-malignancy-type
patients	O
,	O
1	O
of	O
the	O
solitary	B-malignancy-type
plasmacytoma	I-malignancy-type
patients	O
and	O
none	O
of	O
the	O
3	O
of	O
the	O
MGUS	O
patients	O
.	O
In	O
the	O
case	O
of	O
plasmacytoma	B-malignancy-type
,	O
RAS	O
mutations	O
were	O
detected	O
in	O
his	O
bone	O
marrow	O
specimens	O
.	O
PMID	O
:	O
1921261	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1991	O
Oct	O
1;51(	O
19	O
)	O
:5308	O
-	O
14	O
K-ras	O
activation	O
in	O
premalignant	O
and	O
malignant	O
epithelial	B-malignancy-type
lesions	I-malignancy-type
of	O
the	O
human	O
uterus	O
.	O
Enomoto	O
T	O
,	O
Inoue	O
M,	O
Perantoni	O
AO	O
,	O
Buzard	O
GS	O
,	O
Miki	O
H	O
,	O
Tanizawa	O
O	O
,	O
Rice	O
JM	O
.	O
Laboratory	O
of	O
Comparative	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
Frederick	O
Cancer	O
Research	O
and	O
Development	O
Center	O
,	O
Maryland	O
21702	O
-	O
1201	O
.	O
We	O
previously	O
reported	O
(	O
Cancer	O
Res.	O
,	O
50	O
:	O
6139	O
-	O
6145	O
,	O
1990	O
)	O
a	O
significant	O
frequency	O
of	O
activating	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
the	O
K-ras	O
oncogene	O
in	O
endometrial	B-malignancy-type
adenocarcinomas	I-malignancy-type
of	O
the	O
uterine	O
corpus	O
(	O
series	O
1	O
)	O
.	O
To	O
further	O
define	O
the	O
role	O
of	O
ras	O
activation	O
in	O
the	O
development	O
of	O
endometrial	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
we	O
surveyed	O
cystic	B-malignancy-type
,	O
adenomatous	B-malignancy-type
,	O
and	O
atypical	B-malignancy-type
hyperplasias	I-malignancy-type
of	O
uterine	O
endometrium	O
and	O
additional	O
cases	O
of	O
endometrial	B-malignancy-type
and	O
cervical	B-malignancy-type
carcinoma	I-malignancy-type
(	O
series	O
2	O
)	O
for	O
the	O
presence	O
of	O
activating	O
mutations	O
in	O
cellular	O
protooncogenes	O
of	O
the	O
ras	O
family	O
.	O
Polymerase	O
chain	O
reaction	O
was	O
performed	O
from	O
deparaffinized	O
sections	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
.	O
We	O
screened	O
for	O
point	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
K	O
-	O
,	O
H	O
-	O
,	O
and	O
N	O
-	O
ras	O
genes	O
by	O
dot	O
blot	O
hybridization	O
analysis	O
with	O
mutation	O
-	O
specific	O
oligomers	O
.	O
Mutations	O
in	O
K-ras	O
were	O
also	O
confirmed	O
by	O
direct	O
genomic	O
DNA	O
sequencing	O
.	O
Of	O
19	O
endometrial	B-malignancy-type
adenocarcinomas	I-malignancy-type
in	O
series	O
2	O
,	O
point	O
mutations	O
in	O
ras	O
genes	O
were	O
found	O
in	O
7	O
tumors	O
.	O
Six	O
contained	O
single-base	O
substitutions	O
,	O
five	O
in	O
codon	O
12	O
of	O
K-ras	O
and	O
one	O
in	O
codon	O
12	O
of	O
N-ras	O
.	O
The	O
seventh	O
tumor	O
contained	O
two	O
different	O
point	O
mutations	O
in	O
codon	O
12	O
of	O
K-ras	O
.	O
In	O
one	O
endometrial	B-malignancy-type
adenocarcinoma	I-malignancy-type
,	O
tumor	O
cells	O
with	O
point	O
mutations	O
in	O
K-ras	O
were	O
predominantly	O
localized	O
to	O
a	O
portion	O
that	O
had	O
a	O
more	O
aggressive	O
histological	O
pattern	O
.	O
In	O
endometrial	B-malignancy-type
hyperplasia	I-malignancy-type
,	O
K-ras	O
mutations	O
,	O
one	O
in	O
codon	O
12	O
and	O
one	O
in	O
codon	O
13	O
,	O
were	O
found	O
in	O
2	O
of	O
16	O
hyperplasias	B-malignancy-type
histologically	O
classified	O
as	O
atypical	O
and	O
clinically	O
considered	O
premalignant	O
.	O
None	O
of	O
6	O
adenomatous	B-malignancy-type
hyperplasias	I-malignancy-type
and	O
none	O
of	O
12	O
cystic	B-malignancy-type
hyperplasias	I-malignancy-type
,	O
the	O
latter	O
of	O
which	O
is	O
considered	O
clinically	O
benign	O
,	O
contained	O
any	O
detectable	O
ras	O
mutations	O
.	O
No	O
mutations	O
in	O
H-ras	O
were	O
detected	O
in	O
either	O
carcinomas	B-malignancy-type
or	O
hyperplastic	O
tissue	O
.	O
PMID	O
:	O
1913654	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Formos	O
Med	O
Assoc	O
1991	O
Sep;90(	O
9	O
)	O
:825	O
-	O
30	O
Mutation	O
analysis	O
of	O
the	O
ras	O
gene	O
in	O
myelocytic	B-malignancy-type
leukemia	I-malignancy-type
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
probes	O
.	O
Liu	O
TC	O
,	O
Lin	O
SF	O
,	O
Chen	O
TP	O
,	O
Liu	O
HW	O
,	O
Chang	O
JG.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Kaohsiung	O
Medical	O
College	O
,	O
R.O.C.	O
Twenty-nine	O
patients	O
with	O
acute	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
AML	B-malignancy-type
)	O
and	O
14	O
patients	O
with	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	B-malignancy-type
myelocytic	I-malignancy-type
leukemia	I-malignancy-type
(	O
CML	B-malignancy-type
)	O
were	O
analyzed	O
to	O
detect	O
the	O
presence	O
of	O
mutations	O
in	O
their	O
ras	O
genes	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
methods	O
.	O
Deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
isolated	O
from	O
blood	O
or	O
bone	O
marrow	O
samples	O
was	O
screened	O
for	O
mutations	O
in	O
codons	O
12	O
,	O
13	O
and	O
61	O
of	O
N-ras	O
and	O
in	O
codons	O
12	O
and	O
61	O
of	O
K-ras	O
and	O
H-ras	O
.	O
We	O
detected	O
mutations	O
of	O
the	O
ras	O
gene	O
in	O
7	O
patients	O
with	O
AML	B-malignancy-type
(	O
7	O
/	O
29	O
)	O
,	O
all	O
in	O
N-ras	O
.	O
The	O
mutations	O
were	O
3	O
GGT	O
-_greater_than	O
GAT	O
transitions	O
in	O
codon	O
12	O
,	O
1	O
GGT	O
-_greater_than	O
TGT	O
transition	O
in	O
codon	O
13	O
,	O
and	O
3	O
CAA	O
-_greater_than	O
AAA	O
transitions	O
in	O
codon	O
61	O
.	O
No	O
correlation	O
has	O
been	O
observed	O
between	O
French	O
-	O
American	O
-	O
British	O
subtypes	O
and	O
the	O
incidence	O
of	O
N-ras	O
mutation	O
,	O
nor	O
between	O
cytogenetic	O
changes	O
and	O
the	O
incidence	O
of	O
N-ras	O
mutation	O
.	O
All	O
ras	O
gene	O
mutations	O
detected	O
by	O
the	O
oligonucleotide	O
hybridization	O
method	O
were	O
further	O
confirmed	O
by	O
direct	O
sequencing	O
.	O
No	O
mutations	O
were	O
detected	O
in	O
ras	O
genes	O
in	O
samples	O
from	O
the	O
14	O
Philadelphia	O
chromosome	O
-	O
positive	O
CML	B-malignancy-type
patients	O
(	O
12	O
in	O
chronic	O
phase	O
,	O
2	O
in	O
blastic	O
phase	O
)	O
.	O
These	O
findings	O
are	O
in	O
line	O
with	O
previous	O
results	O
indicating	O
that	O
ras	O
gene	O
mutations	O
in	O
the	O
codons	O
tested	O
play	O
only	O
a	O
small	O
role	O
in	O
the	O
tumorigenesis	O
of	O
CML	B-malignancy-type
.	O
PMID	O
:	O
1683380	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1992	O
Mar	O
12;50(	O
5	O
)	O
:713	O
-	O
8	O
N-ras	O
gene	O
mutations	O
in	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
:	O
accurate	O
detection	O
by	O
solid-phase	O
minisequencing	O
.	O
Syvanen	O
AC	O
,	O
Soderlund	O
H	O
,	O
Laaksonen	O
E	O
,	O
Bengtstrom	O
M,	O
Turunen	O
M,	O
Palotie	O
A.	O
National	O
Public	O
Health	O
Institute	O
,	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O
Helsinki	O
,	O
Finland	O
.	O
Mutations	O
in	O
the	O
N-ras	O
gene	O
are	O
found	O
in	O
one-third	O
of	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
.	O
The	O
N-ras	O
mutations	O
could	O
serve	O
as	O
markers	O
for	O
residual	O
cells	O
,	O
if	O
a	O
highly	O
sensitive	O
method	O
for	O
detecting	O
the	O
mutations	O
was	O
available	O
.	O
We	O
applied	O
a	O
new	O
method	O
,	O
solid-phase	O
minisequencing	O
,	O
to	O
analyze	O
bone	O
-	O
marrow	O
cells	O
from	O
16	O
patients	O
with	O
acute	B-malignancy-type
myeloid	I-malignancy-type
leukemia	I-malignancy-type
for	O
mutations	O
in	O
codon	O
12	O
,	O
13	O
and	O
61	O
of	O
the	O
N-ras	O
gene	O
.	O
In	O
the	O
solid-phase	O
minisequencing	O
technique	O
the	O
mutations	O
are	O
identified	O
by	O
a	O
primer	O
extension	O
reaction	O
,	O
in	O
which	O
a	O
single	O
labelled	O
nucleoside	O
triphosphate	O
is	O
incorporated	O
into	O
an	O
immobilized	O
DNA	O
fragment	O
previously	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
We	O
identified	O
N-ras	O
mutations	O
in	O
5	O
of	O
the	O
patients	O
(	O
30	O
%	O
)	O
.	O
In	O
one	O
patient	O
,	O
we	O
observed	O
2	O
mutations	O
that	O
were	O
shown	O
to	O
be	O
located	O
in	O
different	O
alleles	O
.	O
With	O
the	O
solid-phase	O
minisequencing	O
method	O
,	O
we	O
were	O
able	O
to	O
determine	O
the	O
proportion	O
of	O
mutated	O
cells	O
in	O
the	O
samples	O
.	O
We	O
found	O
that	O
in	O
4	O
of	O
the	O
samples	O
only	O
a	O
fraction	O
(	O
7	O
-	O
64	O
%	O
)	O
of	O
the	O
blasts	O
carried	O
an	O
N-ras	O
mutation	O
,	O
and	O
in	O
one	O
sample	O
practically	O
all	O
blast	O
cells	O
were	O
mutated	O
.	O
The	O
method	O
was	O
highly	O
sensitive	O
,	O
allowing	O
us	O
to	O
identify	O
N-ras	O
mutations	O
even	O
when	O
the	O
sample	O
consisted	O
of	O
99.7	O
%	O
normal	O
cells	O
and	O
only	O
0.3	O
%	O
mutated	O
blasts	O
.	O
PMID	O
:	O
1544704	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1992	O
Mar	O
1;7	O
9	O
(	O
5	O
)	O
:	O
126	O
6-70	O
Longitudinal	O
analysis	O
of	O
point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
in	O
patients	O
with	O
myelodysplasia	B-malignancy-type
using	O
archived	O
blood	O
smears	O
.	O
van	O
Kamp	O
H,	O
de	O
Pijper	O
C,	O
Verlaa	O
n-de	O
Vries	O
M,	O
Bos	O
JL	O
,	O
Leeksma	O
CH,	O
Kerkhofs	O
H,	O
Willemze	O
R	O
,	O
Fibbe	O
WE	O
,	O
Landegent	O
JE.	O
Department	O
of	O
Hematology	O
,	O
University	O
Medical	O
Center	O
,	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
We	O
performed	O
a	O
longitudinal	O
analysis	O
of	O
point	O
mutations	O
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
in	O
patients	O
with	O
myelodysplasia	B-malignancy-type
and	O
a	O
follow-up	O
of	O
at	O
least	O
2.5	O
years	O
after	O
diagnosis	O
.	O
Point	O
mutations	O
at	O
codons	O
12	O
,	O
13	O
,	O
and	O
61	O
of	O
the	O
N-ras	O
oncogene	O
were	O
analyzed	O
after	O
in	O
vitro	O
amplification	O
of	O
N-ras	O
specific	O
sequences	O
followed	O
by	O
dot	O
-	O
blot	O
hybridization	O
.	O
Lysed	O
cells	O
scraped	O
from	O
archived	O
blood	O
and	O
bone	O
marrow	O
smears	O
were	O
used	O
as	O
template	O
for	O
a	O
polymerase	O
chain	O
reaction	O
.	O
In	O
3	O
of	O
90	O
patients	O
tested	O
(	O
3.3	O
%	O
)	O
,	O
a	O
mutation	O
in	O
codon	O
12	O
could	O
be	O
detected	O
in	O
the	O
most	O
recent	O
blood	O
smears	O
.	O
All	O
available	O
blood	O
and	O
bone	O
marrow	O
samples	O
of	O
these	O
patients	O
were	O
subsequently	O
analyzed	O
for	O
the	O
occurrence	O
of	O
that	O
particular	O
mutation	O
.	O
In	O
all	O
three	O
cases	O
the	O
mutation	O
was	O
not	O
detectable	O
at	O
diagnosis	O
,	O
but	O
was	O
acquired	O
later	O
during	O
the	O
course	O
of	O
the	O
disease	O
.	O
In	O
two	O
of	O
these	O
patients	O
this	O
event	O
was	O
associated	O
with	O
rapid	O
deterioration	O
and	O
transformation	O
to	O
acute	B-malignancy-type
leukemia	I-malignancy-type
.	O
However	O
,	O
the	O
third	O
patient	O
showed	O
a	O
protracted	O
course	O
during	O
a	O
period	O
of	O
5	O
years	O
after	O
acquisition	O
of	O
the	O
mutation	O
.	O
These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
N-ras	O
protooncogene	O
in	O
these	O
three	O
patients	O
represents	O
a	O
secondary	O
phenomenon	O
associated	O
with	O
disease	O
progression	O
in	O
some	O
cases	O
,	O
but	O
compatible	O
with	O
stable	O
disease	O
in	O
others	O
.	O
PMID	O
:	O
1536950	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

